



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 137366

**TO: Terra Gibbs
Location: REM/2D10/2C18
Art Unit: 1635
Monday, November 08, 2004**

Case Serial Number: 09/918026

**From: David Schreiber
Location: Biotech-Chem Library
Remsen E01A61
Phone: 272-2526**

david.schreiber@uspto.gov

Search Notes

THIS PAGE BLANK (USE)

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date: _____
 Art Unit: _____ Phone Number 30 _____ Serial Number: _____
 Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>X</u>	NA Sequence (#) <u>15</u>	STN _____
Searcher Phone #: <u>P. Schugbe</u>	AA Sequence (#) <u>Pensacola</u>	Dialog _____
Searcher Location: <u>272-2528</u>	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>P</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>11/8</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>15</u>	Fulltext _____	Sequence Systems <u>Compu</u>
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>83</u>	Other _____	Other (specify) _____

THIS PAGE BLANK (USPTO)

Schreiber, David

137366

From: Gibbs, Terra
Sent: Monday, November 01, 2004 9:14 AM
To: Schreiber, David
Subject: Sequence search request...

Hi David,

I have another request for a score over length search:

I need a length limited nucleotide sequence search of SEQ ID NO:3 in USSN 09/918,026, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched.

*Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
Mailbox 2C18
571-272-0758*

THIS PAGE BLANK (USPTO)



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact **the searcher or contact:**

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

LANE (USPTO)

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



THIS PAGE 1

THIS PAGE BLANK (USPTO)

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75%.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 12:46:08 ; Search time 8 Seconds
(Without alignments)
3.717 Million cell updates/sec

Title: US-09-918-026A-3

Perfect score: 1569

Sequence: 1 atggagcaggcgggggcccg.....cttggctctgccatacctag 1569

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 543 seqs, 9476 residues

Total number of hits satisfying chosen parameters: 1086

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 545 summaries

Database : rge3.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	21.2	1.4	27	1	AR402757
C 2	21.2	1.4	27	1	BD068257
C 3	20	1.3	20	1	AR344230
C 4	20	1.3	20	1	AR344231
C 5	19.6	1.2	26	1	AR344229
C 6	19.2	1.2	24	1	AX548146
C 7	18.2	1.2	24	1	AR344228
C 8	16.8	1.1	21	1	I38900
C 9	16.8	1.1	21	1	I87931
C 10	16.8	1.1	21	1	AR364977
C 11	16.4	1.0	20	1	AR299994
C 12	16.2	1.0	21	1	AX095522
C 13	15.8	1.0	19	1	CQ801047
C 14	15.8	1.0	20	1	AR086279
C 15	15.8	1.0	20	1	AR176845
C 16	15.8	1.0	20	1	BD211221
C 17	15.8	1.0	20	1	AR303015
C 18	15.8	1.0	20	1	AR366451
C 19	15.8	1.0	20	1	AX613601
C 20	15.8	1.0	20	1	BD088361
C 21	15.8	1.0	20	1	AB068400
C 22	15.8	1.0	21	1	AX191814
C 23	15.4	1.0	17	1	CQ621885
C 24	15.4	1.0	17	1	CQ621886
C 25	15.4	1.0	17	1	CQ621887
C 26	15.4	1.0	17	1	CQ621888
C 27	15.4	1.0	17	1	AR188324
C 28	15.4	1.0	17	1	AR285978
C 29	15.4	1.0	17	1	AR324177
C 30	15.4	1.0	17	1	AR328801
C 31	15.4	1.0	17	1	AR397968
C 32	15.4	1.0	17	1	AR462948
C 33	15.4	1.0	17	1	AR462949

34	15.4	1.0	17	1	AR462950
35	15.4	1.0	17	1	AR462951
C 36	15.4	1.0	19	1	AX353169
C 37	15.4	1.0	19	1	AX363014
C 38	15.4	1.0	20	1	AR230366
C 39	15.4	1.0	20	1	AR255958
C 40	15.4	1.0	20	1	AR310061
C 41	15.4	1.0	20	1	AR350473
C 42	15.4	1.0	20	1	AR442660
C 43	15.4	1.0	20	1	AR494207
C 44	15.2	1.0	20	1	AR126680
C 45	15.2	1.0	20	1	AR170934
C 46	15.2	1.0	20	1	BD175122
C 47	15.2	1.0	20	1	BD176245
C 48	15.2	1.0	20	1	E40060
C 49	15.2	1.0	20	1	E40064
C 50	15.2	1.0	20	1	E40868
C 51	15.2	1.0	20	1	E40872
C 52	15.2	1.0	20	1	E43414
C 53	15.2	1.0	20	1	E43418
C 54	15.2	1.0	20	1	I18406
C 55	15.2	1.0	20	1	AR271778
C 56	15.2	1.0	20	1	AR307931
C 57	15.2	1.0	20	1	AR314148
C 58	15.2	1.0	20	1	AX048825
C 59	15.2	1.0	20	1	AX048869
C 60	15.2	1.0	20	1	AX104256
C 61	15.2	1.0	20	1	AX355378
C 62	15.2	1.0	20	1	AX492927
C 63	15.2	1.0	20	1	AX494234
C 64	15.2	1.0	20	1	AX547309
C 65	15.2	1.0	20	1	AX708702
C 66	15.2	1.0	20	1	AX785133
C 67	15.2	1.0	20	1	AX785134
C 68	15.2	1.0	20	1	BD090167
C 69	15.2	1.0	20	1	BD090597
C 70	15.2	1.0	20	1	BD090601
C 71	15.2	1.0	20	1	BD090706
C 72	15.2	1.0	20	1	BD090710
C 73	15	1.0	17	1	AR401804
C 74	15	1.0	17	1	AX750951
C 75	15	1.0	17	1	AX750952
C 76	15	1.0	17	1	AX750953
C 77	15	1.0	17	1	BD067304
C 78	15	1.0	18	1	E25757
C 79	15	1.0	20	1	AR226108
C 80	15	1.0	20	1	AX373782
C 81	15	1.0	20	1	AX418779
C 82	14.8	0.9	18	1	AR257452
C 83	14.8	0.9	19	1	AR300309
C 84	14.8	0.9	19	1	AX010849
C 85	14.8	0.9	19	1	AX131096
C 86	14.8	0.9	19	1	AX804983
C 87	14.8	0.9	19	1	AX804986
C 88	14.4	0.9	17	1	CQ617553
C 89	14.4	0.9	17	1	CQ617554
C 90	14.4	0.9	17	1	CQ617556
C 91	14.4	0.9	17	1	CQ617557
C 92	14.4	0.9	17	1	CQ621884
C 93	14.4	0.9	17	1	CQ621889
C 94	14.4	0.9	17	1	AR188323
C 95	14.4	0.9	17	1	AR324176
C 96	14.4	0.9	17	1	AR328722
C 97	14.4	0.9	17	1	AR458616
C 98	14.4	0.9	17	1	AR458617
C 99	14.4	0.9	17	1	AR458619
C 100	14.4	0.9	17	1	AR458620
C 101	14.4	0.9	17	1	AR462947
C 102	14.4	0.9	17	1	AR462952
C 103	14.4	0.9	17	1	AX217761
C 104	14.4	0.9	17	1	AX217762
C 105	14.4	0.9	17	1	AX729077
C 106	14.4	0.9	18	1	BD175415

ACCESSION:AR462950
ACCESSION:AR462951
ACCESSION:AX353169
ACCESSION:AX363014
ACCESSION:AR230366
ACCESSION:AR255958
ACCESSION:AR310061
ACCESSION:AR350473
ACCESSION:AR442660
ACCESSION:AR494207
ACCESSION:AR126680
ACCESSION:AR170934
ACCESSION:BD175122
ACCESSION:BD176245
ACCESSION:E40060
ACCESSION:E40064
ACCESSION:E40868
ACCESSION:E40872
ACCESSION:E43414
ACCESSION:E43418
ACCESSION:I18406
ACCESSION:AR271778
ACCESSION:AR307931
ACCESSION:AR314148
ACCESSION:AX048825
ACCESSION:AX048869
ACCESSION:AX104256
ACCESSION:AX355378
ACCESSION:AX492927
ACCESSION:AX494234
ACCESSION:AX547309
ACCESSION:AX708702
ACCESSION:AX785133
ACCESSION:AX785134
ACCESSION:BD090167
ACCESSION:BD090597
ACCESSION:BD090601
ACCESSION:BD090706
ACCESSION:BD090710
ACCESSION:AR401804
ACCESSION:AX750951
ACCESSION:AX750952
ACCESSION:AX750953
ACCESSION:BD067304
ACCESSION:E25757
ACCESSION:AR226108
ACCESSION:AX373782
ACCESSION:AX418779
ACCESSION:AR257452
ACCESSION:AR300309
ACCESSION:AX010849
ACCESSION:AX131096
ACCESSION:AX804983
ACCESSION:AX804986
ACCESSION:CQ617553
ACCESSION:CQ617554
ACCESSION:CQ617556
ACCESSION:CQ617557
ACCESSION:CQ621884
ACCESSION:CQ621889
ACCESSION:AR188323
ACCESSION:AR324176
ACCESSION:AR328722
ACCESSION:AR458616
ACCESSION:AR458617
ACCESSION:AR458619
ACCESSION:AR458620
ACCESSION:AR462947
ACCESSION:AR462952
ACCESSION:AX217761
ACCESSION:AX217762
ACCESSION:AX729077
ACCESSION:BD175415

107	14.4	0.9	18	1	BD224907	ACCESSION:BD224907	c 180	13.8	0.9	17	1	AR458622	ACCESSION:AR458622
c 108	14.4	0.9	18	1	BD224994	ACCESSION:BD224994	c 181	13.8	0.9	17	1	AR458623	ACCESSION:AR458623
109	14.4	0.9	18	1	AR188967	ACCESSION:AR188967	c 182	13.8	0.9	17	1	AR463239	ACCESSION:AR463239
110	14.4	0.9	18	1	AR211129	ACCESSION:AR211129	c 183	13.8	0.9	17	1	AR465347	ACCESSION:AR465347
c 111	14.4	0.9	18	1	AR211216	ACCESSION:AR211216	c 184	13.8	0.9	17	1	AR466996	ACCESSION:AR466996
112	14.4	0.9	18	1	AR324766	ACCESSION:AR324766	c 185	13.8	0.9	17	1	AR466997	ACCESSION:AR466997
c 113	14.4	0.9	18	1	AX599746	ACCESSION:AX599746	c 186	13.8	0.9	17	1	AX214637	ACCESSION:AX214637
114	14.4	0.9	18	1	BD075564	ACCESSION:BD075564	c 187	13.8	0.9	17	1	AX215297	ACCESSION:AX215297
115	14.4	0.9	18	1	BD172424	ACCESSION:BD172424	c 188	13.8	0.9	17	1	AX215722	ACCESSION:AX215722
116	14.4	0.9	18	1	BD172743	ACCESSION:BD172743	c 189	13.8	0.9	17	1	AX217699	ACCESSION:AX217699
c 117	14.4	0.9	18	1	BD173062	ACCESSION:BD173062	c 190	13.8	0.9	17	1	AX272675	ACCESSION:AX272675
118	14.4	0.9	18	1	BD173381	ACCESSION:BD173381	c 191	13.8	0.9	17	1	AX273323	ACCESSION:AX273323
c 119	14.4	0.9	19	1	AX132345	ACCESSION:AX132345	c 192	13.8	0.9	17	1	AX422199	ACCESSION:AX422199
120	14	0.9	15	1	AX587022	ACCESSION:AX587022	c 193	13.8	0.9	17	1	AX423454	ACCESSION:AX423454
c 121	14	0.9	17	1	BD200566	ACCESSION:BD200566	c 194	13.8	0.9	17	1	AX530913	ACCESSION:AX530913
122	14	0.9	17	1	AR328723	ACCESSION:AR328723	c 195	13.8	0.9	17	1	AX532013	ACCESSION:AX532013
123	14	0.9	17	1	AR328724	ACCESSION:AR328724	c 196	13.8	0.9	17	1	AX544708	ACCESSION:AX544708
c 124	14	0.9	17	1	AX750950	ACCESSION:AX750950	c 197	13.8	0.9	17	1	AX615330	ACCESSION:AX615330
125	14	0.9	17	1	AX750954	ACCESSION:AX750954	c 198	13.8	0.9	17	1	AX648277	ACCESSION:AX648277
c 126	14	0.9	17	1	169013	ACCESSION:169013	c 199	13.8	0.9	17	1	AX648278	ACCESSION:AX648278
127	14	0.9	18	1	AR253611	ACCESSION:AR253611	c 200	13.8	0.9	17	1	AX692476	ACCESSION:AX692476
c 128	14	0.9	18	1	AX696666	ACCESSION:AX696666	c 201	13.8	0.9	17	1	AX692477	ACCESSION:AX692477
129	13.8	0.9	17	1	AR016864	ACCESSION:AR016864	c 202	13.8	0.9	17	1	AX692478	ACCESSION:AX692478
c 130	13.8	0.9	17	1	AR020890	ACCESSION:AR020890	c 203	13.8	0.9	17	1	AX692479	ACCESSION:AX692479
131	13.8	0.9	17	1	AR027213	ACCESSION:AR027213	c 204	13.8	0.9	17	1	AX722650	ACCESSION:AX722650
c 132	13.8	0.9	17	1	AR038500	ACCESSION:AR038500	c 205	13.8	0.9	17	1	AX724945	ACCESSION:AX724945
133	13.8	0.9	17	1	AR064642	ACCESSION:AR064642	c 206	13.8	0.9	17	1	AX727110	ACCESSION:AX727110
c 134	13.8	0.9	17	1	AR067567	ACCESSION:AR067567	c 207	13.8	0.9	17	1	AX728456	ACCESSION:AX728456
135	13.8	0.9	17	1	BD199056	ACCESSION:BD199056	c 208	13.8	0.9	17	1	AX729352	ACCESSION:AX729352
c 136	13.8	0.9	17	1	BD254698	ACCESSION:BD254698	c 209	13.8	0.9	17	1	AX730435	ACCESSION:AX730435
137	13.8	0.9	17	1	BD254884	ACCESSION:BD254884	c 210	13.8	0.9	17	1	AX730461	ACCESSION:AX730461
c 138	13.8	0.9	17	1	BD259384	ACCESSION:BD259384	c 211	13.8	0.9	17	1	AX730557	ACCESSION:AX730557
139	13.8	0.9	17	1	BD259385	ACCESSION:BD259385	c 212	13.8	0.9	17	1	AX733457	ACCESSION:AX733457
c 140	13.8	0.9	17	1	CQ616191	ACCESSION:CQ616191	c 213	13.8	0.9	17	1	AX736028	ACCESSION:AX736028
141	13.8	0.9	17	1	CQ616796	ACCESSION:CQ616796	c 214	13.8	0.9	17	1	AX736725	ACCESSION:AX736725
c 142	13.8	0.9	17	1	CQ616907	ACCESSION:CQ616907	c 215	13.8	0.9	17	1	AX757242	ACCESSION:AX757242
143	13.8	0.9	17	1	CQ617550	ACCESSION:CQ617550	c 216	13.8	0.9	17	1	AX757362	ACCESSION:AX757362
c 144	13.8	0.9	17	1	CQ617551	ACCESSION:CQ617551	c 217	13.8	0.9	17	1	AX782026	ACCESSION:AX782026
145	13.8	0.9	17	1	CQ617552	ACCESSION:CQ617552	c 218	13.8	0.9	17	1	AX804462	ACCESSION:AX804462
c 146	13.8	0.9	17	1	CQ617555	ACCESSION:CQ617555	c 219	13.8	0.9	18	1	AR069548	ACCESSION:AR069548
147	13.8	0.9	17	1	CQ617558	ACCESSION:CQ617558	c 220	13.8	0.9	18	1	AR069549	ACCESSION:AR069549
c 148	13.8	0.9	17	1	CQ617559	ACCESSION:CQ617559	c 221	13.8	0.9	18	1	CQ830099	ACCESSION:CQ830099
149	13.8	0.9	17	1	CQ617560	ACCESSION:CQ617560	c 222	13.8	0.9	18	1	E15411	ACCESSION:E15411
c 150	13.8	0.9	17	1	CQ622176	ACCESSION:CQ622176	c 223	13.8	0.9	18	1	E16948	ACCESSION:E16948
151	13.8	0.9	17	1	CQ624284	ACCESSION:CQ624284	c 224	13.8	0.9	18	1	E16949	ACCESSION:E16949
c 152	13.8	0.9	17	1	CQ625933	ACCESSION:CQ625933	c 225	13.8	0.9	18	1	AR234685	ACCESSION:AR234685
153	13.8	0.9	17	1	CQ625934	ACCESSION:CQ625934	c 226	13.8	0.9	18	1	AR266198	ACCESSION:AR266198
c 154	13.8	0.9	17	1	114228	ACCESSION:114228	c 227	13.8	0.9	18	1	AR296072	ACCESSION:AR296072
155	13.8	0.9	17	1	122886	ACCESSION:122886	c 228	13.8	0.9	18	1	AR299710	ACCESSION:AR299710
c 156	13.8	0.9	17	1	138519	ACCESSION:138519	c 229	13.8	0.9	18	1	AX235560	ACCESSION:AX235560
157	13.8	0.9	17	1	147511	ACCESSION:147511	c 230	13.8	0.9	18	1	AX353056	ACCESSION:AX353056
c 158	13.8	0.9	17	1	156994	ACCESSION:156994	c 231	13.8	0.9	18	1	AX362901	ACCESSION:AX362901
159	13.8	0.9	17	1	159860	ACCESSION:159860	c 232	13.8	0.9	18	1	AX811434	ACCESSION:AX811434
c 160	13.8	0.9	17	1	175187	ACCESSION:175187	c 233	13.8	0.9	18	1	AX838224	ACCESSION:AX838224
161	13.8	0.9	17	1	AR188690	ACCESSION:AR188690	c 234	13.8	0.9	18	1	BD139690	ACCESSION:BD139690
c 162	13.8	0.9	17	1	AR192186	ACCESSION:AR192186	c 235	13.8	0.9	20	1	AR442660	ACCESSION:AR442660
163	13.8	0.9	17	1	AR221454	ACCESSION:AR221454	c 236	13.6	0.9	17	1	AX724242	ACCESSION:AX724242
c 164	13.8	0.9	17	1	AR286397	ACCESSION:AR286397	c 237	13.4	0.9	15	1	E03871	ACCESSION:E03871
165	13.8	0.9	17	1	AR324543	ACCESSION:AR324543	c 238	13.4	0.9	16	1	AR328259	ACCESSION:AR328259
c 166	13.8	0.9	17	1	AR326057	ACCESSION:AR326057	c 239	13.4	0.9	16	1	AR435794	ACCESSION:AR435794
167	13.8	0.9	17	1	AR362605	ACCESSION:AR362605	c 240	13.4	0.9	17	1	BD200592	ACCESSION:BD200592
c 168	13.8	0.9	17	1	AR398387	ACCESSION:AR398387	c 241	13.4	0.9	17	1	BD241153	ACCESSION:BD241153
169	13.8	0.9	17	1	AR409735	ACCESSION:AR409735	c 242	13.4	0.9	17	1	BD254828	ACCESSION:BD254828
c 170	13.8	0.9	17	1	AR434337	ACCESSION:AR434337	c 243	13.4	0.9	17	1	CQ621883	ACCESSION:CQ621883
171	13.8	0.9	17	1	AR434338	ACCESSION:AR434338	c 244	13.4	0.9	17	1	CQ621890	ACCESSION:CQ621890
c 172	13.8	0.9	17	1	AR457284	ACCESSION:AR457284	c 245	13.4	0.9	17	1	CQ625935	ACCESSION:CQ625935
173	13.8	0.9	17	1	AR457859	ACCESSION:AR457859	c 246	13.4	0.9	17	1	CQ625936	ACCESSION:CQ625936
c 174	13.8	0.9	17	1	AR457970	ACCESSION:AR457970	c 247	13.4	0.9	17	1	AR186916	ACCESSION:AR186916
175	13.8	0.9	17	1	AR458613	ACCESSION:AR458613	c 248	13.4	0.9	17	1	AR188873	ACCESSION:AR188873
c 176	13.8	0.9	17	1	AR458614	ACCESSION:AR458614	c 249	13.4	0.9	17	1	AR188874	ACCESSION:AR188874
177	13.8	0.9	17	1	AR458615	ACCESSION:AR458615	c 250	13.4	0.9	17	1	AR323547	ACCESSION:AR323547
c 178	13.8	0.9	17	1	AR458618	ACCESSION:AR458618	c 251	13.4	0.9	17	1	AR324726	ACCESSION:AR324726
179	13.8	0.9	17	1	AR458621	ACCESSION:AR458621	c 252	13.4	0.9	17	1	AR324727	ACCESSION:AR324727

C 253	13.4	0.9	17	1	AR327261	ACCSSION:AR327261	C 326	12.8	0.8	16	1	AX927967	ACCSSION:AX927967
C 254	13.4	0.9	17	1	AR327909	ACCSSION:AR327909	327	12.8	0.8	16	1	BD106392	ACCSSION:BD106392
C 255	13.4	0.9	17	1	AR402030	ACCSSION:AR402030	328	12.8	0.8	17	1	AI0566	ACCSSION:AI0566
C 256	13.4	0.9	17	1	AR462946	ACCSSION:AR462946	329	12.8	0.8	17	1	A29124	ACCSSION:A29124
C 257	13.4	0.9	17	1	AR462953	ACCSSION:AR462953	330	12.8	0.8	17	1	A57774	ACCSSION:A57774
C 258	13.4	0.9	17	1	AR466998	ACCSSION:AR466998	C 331	12.8	0.8	17	1	A80029	ACCSSION:A80029
C 259	13.4	0.9	17	1	AR466999	ACCSSION:AR466999	C 332	12.8	0.8	17	1	AR009779	ACCSSION:AR009779
C 260	13.4	0.9	17	1	AR482654	ACCSSION:AR482654	C 333	12.8	0.8	17	1	AR051434	ACCSSION:AR051434
C 261	13.4	0.9	17	1	AR214845	ACCSSION:AR214845	C 334	12.8	0.8	17	1	AR057471	ACCSSION:AR057471
C 262	13.4	0.9	17	1	AX217396	ACCSSION:AX217396	C 335	12.8	0.8	17	1	AR057488	ACCSSION:AR057488
C 263	13.4	0.9	17	1	AX218303	ACCSSION:AX218303	C 336	12.8	0.8	17	1	AR057769	ACCSSION:AR057769
C 264	13.4	0.9	17	1	AX218303	ACCSSION:AX218303	C 337	12.8	0.8	17	1	AR068479	ACCSSION:AR068479
C 265	13.4	0.9	17	1	AX284039	ACCSSION:AX284039	C 338	12.8	0.8	17	1	AR097588	ACCSSION:AR097588
C 266	13.4	0.9	17	1	AX324177	ACCSSION:AX324177	C 339	12.8	0.8	17	1	AR115229	ACCSSION:AR115229
C 267	13.4	0.9	17	1	AX324178	ACCSSION:AX324178	C 340	12.8	0.8	17	1	AR115246	ACCSSION:AR115246
C 268	13.4	0.9	17	1	AX326245	ACCSSION:AX326245	C 341	12.8	0.8	17	1	AR115527	ACCSSION:AR115527
C 269	13.4	0.9	17	1	AX326246	ACCSSION:AX326246	C 342	12.8	0.8	17	1	BD203013	ACCSSION:BD203013
C 270	13.4	0.9	17	1	AX615328	ACCSSION:AX615328	C 343	12.8	0.8	17	1	BD203014	ACCSSION:BD203014
C 271	13.4	0.9	17	1	AX615329	ACCSSION:AX615329	C 344	12.8	0.8	17	1	BD254404	ACCSSION:BD254404
C 272	13.4	0.9	17	1	AX648279	ACCSSION:AX648279	C 345	12.8	0.8	17	1	BD254508	ACCSSION:BD254508
C 273	13.4	0.9	17	1	AX648280	ACCSSION:AX648280	C 346	12.8	0.8	17	1	BD257477	ACCSSION:BD257477
C 274	13.4	0.9	17	1	AX671731	ACCSSION:AX671731	C 347	12.8	0.8	17	1	BD258589	ACCSSION:BD258589
C 275	13.4	0.9	17	1	AX691881	ACCSSION:AX691881	C 348	12.8	0.8	17	1	BD259352	ACCSSION:BD259352
C 276	13.4	0.9	17	1	AX691882	ACCSSION:AX691882	C 349	12.8	0.8	17	1	BD259441	ACCSSION:BD259441
C 277	13.4	0.9	17	1	AX691883	ACCSSION:AX691883	C 350	12.8	0.8	17	1	CO615694	ACCSSION:CO615694
C 278	13.4	0.9	17	1	AX722342	ACCSSION:AX722342	C 351	12.8	0.8	17	1	CO615695	ACCSSION:CO615695
C 279	13.4	0.9	17	1	AX725093	ACCSSION:AX725093	C 352	12.8	0.8	17	1	CO616190	ACCSSION:CO616190
C 280	13.4	0.9	17	1	AX726517	ACCSSION:AX726517	C 353	12.8	0.8	17	1	CO616192	ACCSSION:CO616192
C 281	13.4	0.9	17	1	AX729345	ACCSSION:AX729345	C 354	12.8	0.8	17	1	CO616460	ACCSSION:CO616460
C 282	13.4	0.9	17	1	AX739228	ACCSSION:AX739228	C 355	12.8	0.8	17	1	CO616461	ACCSSION:CO616461
C 283	13.4	0.9	17	1	AX757517	ACCSSION:AX757517	C 356	12.8	0.8	17	1	CO616676	ACCSSION:CO616676
C 284	13.4	0.9	17	1	AX760975	ACCSSION:AX760975	C 357	12.8	0.8	17	1	CO616677	ACCSSION:CO616677
C 285	13.4	0.9	17	1	AX783650	ACCSSION:AX783650	C 358	12.8	0.8	17	1	CO616795	ACCSSION:CO616795
C 286	13.4	0.9	17	1	AX783651	ACCSSION:AX783651	C 359	12.8	0.8	17	1	CO616797	ACCSSION:CO616797
C 287	13.4	0.9	17	1	AX783652	ACCSSION:AX783652	C 360	12.8	0.8	17	1	CO616906	ACCSSION:CO616906
C 288	13.4	0.9	17	1	BD067530	ACCSSION:BD067530	C 361	12.8	0.8	17	1	CO616908	ACCSSION:CO616908
C 289	13.4	0.9	20	1	BD067530	ACCSSION:AR126680	C 362	12.8	0.8	17	1	CO617549	ACCSSION:CO617549
C 290	13.2	0.8	17	1	AR148269	ACCSSION:AR148269	C 363	12.8	0.8	17	1	CO617561	ACCSSION:CO617561
C 291	13.2	0.8	17	1	AR237458	ACCSSION:AR237458	C 364	12.8	0.8	17	1	CO621805	ACCSSION:CO621805
C 292	13	0.8	16	1	AX255782	ACCSSION:AX255782	C 365	12.8	0.8	17	1	CO621806	ACCSSION:CO621806
C 293	13	0.8	17	1	AR039205	ACCSSION:AR039205	C 366	12.8	0.8	17	1	CO622175	ACCSSION:CO622175
C 294	13	0.8	17	1	BD226527	ACCSSION:BD226527	C 367	12.8	0.8	17	1	CO622177	ACCSSION:CO622177
C 295	13	0.8	17	1	CO801550	ACCSSION:CO801550	C 368	12.8	0.8	17	1	CO622966	ACCSSION:CO622966
C 296	13	0.8	17	1	AR188253	ACCSSION:AR188253	C 369	12.8	0.8	17	1	CO622967	ACCSSION:CO622967
C 297	13	0.8	17	1	AR286085	ACCSSION:AR286085	C 370	12.8	0.8	17	1	CO623587	ACCSSION:CO623587
C 298	13	0.8	17	1	AR287615	ACCSSION:AR287615	C 371	12.8	0.8	17	1	CO623588	ACCSSION:CO623588
C 299	13	0.8	17	1	AR324106	ACCSSION:AR324106	C 372	12.8	0.8	17	1	CO623611	ACCSSION:CO623611
C 300	13	0.8	17	1	AR398075	ACCSSION:AR398075	C 373	12.8	0.8	17	1	CO623612	ACCSSION:CO623612
C 301	13	0.8	17	1	AX214846	ACCSSION:AX214846	C 374	12.8	0.8	17	1	CO623621	ACCSSION:CO623621
C 302	13	0.8	17	1	AX215723	ACCSSION:AX215723	C 375	12.8	0.8	17	1	CO623622	ACCSSION:CO623622
C 303	13	0.8	17	1	AX265395	ACCSSION:AX265395	C 376	12.8	0.8	17	1	CO624188	ACCSSION:CO624188
C 304	13	0.8	17	1	AX265396	ACCSSION:AX265396	C 377	12.8	0.8	17	1	CO624189	ACCSSION:CO624189
C 305	13	0.8	17	1	AX673472	ACCSSION:AX673472	C 378	12.8	0.8	17	1	CO624280	ACCSSION:CO624280
C 306	13	0.8	17	1	AX674648	ACCSSION:AX674648	C 379	12.8	0.8	17	1	CO624281	ACCSSION:CO624281
C 307	13	0.8	17	1	AX691884	ACCSSION:AX691884	C 380	12.8	0.8	17	1	CO624283	ACCSSION:CO624283
C 308	13	0.8	17	1	AX691885	ACCSSION:AX691885	C 381	12.8	0.8	17	1	CO624285	ACCSSION:CO624285
C 309	13	0.8	17	1	AX723124	ACCSSION:AX723124	C 382	12.8	0.8	17	1	CO625089	ACCSSION:CO625089
C 310	13	0.8	17	1	AX725762	ACCSSION:AX725762	C 383	12.8	0.8	17	1	CO625090	ACCSSION:CO625090
C 311	13	0.8	17	1	AX730681	ACCSSION:AX730681	C 384	12.8	0.8	17	1	CO625932	ACCSSION:CO625932
C 312	13	0.8	17	1	AX737420	ACCSSION:AX737420	C 385	12.8	0.8	17	1	I30846	ACCSSION:I30846
C 313	13	0.8	17	1	AX737926	ACCSSION:AX737926	C 386	12.8	0.8	17	1	I37442	ACCSSION:I37442
C 314	13	0.8	17	1	AX750949	ACCSSION:AX750949	C 387	12.8	0.8	17	1	I46305	ACCSSION:I46305
C 315	13	0.8	17	1	AX750955	ACCSSION:AX750955	C 388	12.8	0.8	17	1	I89918	ACCSSION:I89918
C 316	13	0.8	17	1	AX758682	ACCSSION:AX758682	C 389	12.8	0.8	17	1	I94292	ACCSSION:I94292
C 317	13	0.8	17	1	AX762870	ACCSSION:AX762870	C 390	12.8	0.8	17	1	AR190193	ACCSSION:AR190193
C 318	12.8	0.8	16	1	A97811	ACCSSION:A97811	C 391	12.8	0.8	17	1	AR201825	ACCSSION:AR201825
C 319	12.8	0.8	16	1	I06972	ACCSSION:I06972	C 392	12.8	0.8	17	1	AR201825	ACCSSION:AR201825
C 320	12.8	0.8	16	1	AR254804	ACCSSION:AR254804	C 393	12.8	0.8	17	1	AR286076	ACCSSION:AR286076
C 321	12.8	0.8	16	1	AR305481	ACCSSION:AR305481	C 394	12.8	0.8	17	1	AR325165	ACCSSION:AR325165
C 322	12.8	0.8	16	1	AR309585	ACCSSION:AR309585	C 395	12.8	0.8	17	1	AR327366	ACCSSION:AR327366
C 323	12.8	0.8	16	1	AX255692	ACCSSION:AX255692	C 396	12.8	0.8	17	1	AR327367	ACCSSION:AR327367
C 324	12.8	0.8	16	1	AX428689	ACCSSION:AX428689	C 397	12.8	0.8	17	1	AR327383	ACCSSION:AR327383
C 325	12.8	0.8	16	1	AX927948	ACCSSION:AX927948	C 398	12.8	0.8	17	1	AR327384	ACCSSION:AR327384

C 399	12.8	0.8	17	1	AR329088	ACCESSION:AR329088	472	12.8	0.8	17	1	AX530914	ACCESSION:AX530914
C 400	12.8	0.8	17	1	AR329089	ACCESSION:AR329089	473	12.8	0.8	17	1	AX532012	ACCESSION:AX532012
C 401	12.8	0.8	17	1	AR329284	ACCESSION:AR329284	474	12.8	0.8	17	1	AX532014	ACCESSION:AX532014
C 402	12.8	0.8	17	1	AR365425	ACCESSION:AR365425	C 475	12.8	0.8	17	1	AX544680	ACCESSION:AX544680
C 403	12.8	0.8	17	1	AR381048	ACCESSION:AR381048	C 476	12.8	0.8	17	1	AX544681	ACCESSION:AX544681
C 404	12.8	0.8	17	1	AR398066	ACCESSION:AR398066	C 477	12.8	0.8	17	1	AX544707	ACCESSION:AX544707
C 405	12.8	0.8	17	1	AR434332	ACCESSION:AR434332	C 478	12.8	0.8	17	1	AX544709	ACCESSION:AX544709
C 406	12.8	0.8	17	1	AR434333	ACCESSION:AR434333	C 479	12.8	0.8	17	1	AX578858	ACCESSION:AX578858
C 407	12.8	0.8	17	1	AR434336	ACCESSION:AR434336	C 480	12.8	0.8	17	1	AX579831	ACCESSION:AX579831
C 408	12.8	0.8	17	1	AR434339	ACCESSION:AR434339	C 481	12.8	0.8	17	1	AX580241	ACCESSION:AX580241
C 409	12.8	0.8	17	1	AR456757	ACCESSION:AR456757	C 482	12.8	0.8	17	1	AX600661	ACCESSION:AX600661
C 410	12.8	0.8	17	1	AR456758	ACCESSION:AR456758	C 483	12.8	0.8	17	1	AX615331	ACCESSION:AX615331
C 411	12.8	0.8	17	1	AR457253	ACCESSION:AR457253	C 484	12.8	0.8	17	1	AX615494	ACCESSION:AX615494
C 412	12.8	0.8	17	1	AR457255	ACCESSION:AR457255	C 485	12.8	0.8	17	1	AX615495	ACCESSION:AX615495
C 413	12.8	0.8	17	1	AR457523	ACCESSION:AR457523	C 486	12.8	0.8	17	1	AX634491	ACCESSION:AX634491
C 414	12.8	0.8	17	1	AR457524	ACCESSION:AR457524	C 487	12.8	0.8	17	1	AX634525	ACCESSION:AX634525
C 415	12.8	0.8	17	1	AR457739	ACCESSION:AR457739	C 488	12.8	0.8	17	1	AX634793	ACCESSION:AX634793
C 416	12.8	0.8	17	1	AR457740	ACCESSION:AR457740	C 489	12.8	0.8	17	1	AX648276	ACCESSION:AX648276
C 417	12.8	0.8	17	1	AR457858	ACCESSION:AR457858	C 490	12.8	0.8	17	1	AX672102	ACCESSION:AX672102
C 418	12.8	0.8	17	1	AR457860	ACCESSION:AR457860	C 491	12.8	0.8	17	1	AX672538	ACCESSION:AX672538
C 419	12.8	0.8	17	1	AR457969	ACCESSION:AR457969	C 492	12.8	0.8	17	1	AX672554	ACCESSION:AX672554
C 420	12.8	0.8	17	1	AR457971	ACCESSION:AR457971	C 493	12.8	0.8	17	1	AX674757	ACCESSION:AX674757
C 421	12.8	0.8	17	1	AR458612	ACCESSION:AR458612	C 494	12.8	0.8	17	1	AX690693	ACCESSION:AX690693
C 422	12.8	0.8	17	1	AR458624	ACCESSION:AR458624	C 495	12.8	0.8	17	1	AX690694	ACCESSION:AX690694
C 423	12.8	0.8	17	1	AR462868	ACCESSION:AR462868	C 496	12.8	0.8	17	1	AX691810	ACCESSION:AX691810
C 424	12.8	0.8	17	1	AR462869	ACCESSION:AR462869	C 497	12.8	0.8	17	1	AX691811	ACCESSION:AX691811
C 425	12.8	0.8	17	1	AR463238	ACCESSION:AR463238	C 498	12.8	0.8	17	1	AX692475	ACCESSION:AX692475
C 426	12.8	0.8	17	1	AR463240	ACCESSION:AR463240	C 499	12.8	0.8	17	1	AX692480	ACCESSION:AX692480
C 427	12.8	0.8	17	1	AR464029	ACCESSION:AR464029	C 500	12.8	0.8	17	1	AX693479	ACCESSION:AX693479
C 428	12.8	0.8	17	1	AR464030	ACCESSION:AR464030	C 501	12.8	0.8	17	1	AX693480	ACCESSION:AX693480
C 429	12.8	0.8	17	1	AR464650	ACCESSION:AR464650	C 502	12.8	0.8	17	1	AX693481	ACCESSION:AX693481
C 430	12.8	0.8	17	1	AR464651	ACCESSION:AR464651	C 503	12.8	0.8	17	1	AX693482	ACCESSION:AX693482
C 431	12.8	0.8	17	1	AR464652	ACCESSION:AR464652	C 504	12.8	0.8	17	1	AX722341	ACCESSION:AX722341
C 432	12.8	0.8	17	1	AR464675	ACCESSION:AR464675	C 505	12.8	0.8	17	1	AX722341	ACCESSION:AX722341
C 433	12.8	0.8	17	1	AR464675	ACCESSION:AR464675	C 506	12.8	0.8	17	1	AX722551	ACCESSION:AX722551
C 434	12.8	0.8	17	1	AR464684	ACCESSION:AR464684	C 507	12.8	0.8	17	1	AX722604	ACCESSION:AX722604
C 435	12.8	0.8	17	1	AR464685	ACCESSION:AR464685	C 508	12.8	0.8	17	1	AX722959	ACCESSION:AX722959
C 436	12.8	0.8	17	1	AR465252	ACCESSION:AR465252	C 509	12.8	0.8	17	1	AX723858	ACCESSION:AX723858
C 437	12.8	0.8	17	1	AR465252	ACCESSION:AR465252	C 510	12.8	0.8	17	1	AX724110	ACCESSION:AX724110
C 438	12.8	0.8	17	1	AR465343	ACCESSION:AR465343	C 511	12.8	0.8	17	1	AX724156	ACCESSION:AX724156
C 439	12.8	0.8	17	1	AR465344	ACCESSION:AR465344	C 512	12.8	0.8	17	1	AX724958	ACCESSION:AX724958
C 440	12.8	0.8	17	1	AR465348	ACCESSION:AR465348	C 513	12.8	0.8	17	1	AX725065	ACCESSION:AX725065
C 441	12.8	0.8	17	1	AR466152	ACCESSION:AR466152	C 514	12.8	0.8	17	1	AX725288	ACCESSION:AX725288
C 442	12.8	0.8	17	1	AR466152	ACCESSION:AR466152	C 515	12.8	0.8	17	1	AX725362	ACCESSION:AX725362
C 443	12.8	0.8	17	1	AR466995	ACCESSION:AR466995	C 516	12.8	0.8	17	1	AX726174	ACCESSION:AX726174
C 444	12.8	0.8	17	1	AR466995	ACCESSION:AR466995	C 517	12.8	0.8	17	1	AX726186	ACCESSION:AX726186
C 445	12.8	0.8	17	1	AX026212	ACCESSION:AX026212	C 518	12.8	0.8	17	1	AX730202	ACCESSION:AX730202
C 446	12.8	0.8	17	1	AX027100	ACCESSION:AX027100	C 519	12.8	0.8	17	1	AX731025	ACCESSION:AX731025
C 447	12.8	0.8	17	1	AX119952	ACCESSION:AX119952	C 520	12.8	0.8	17	1	AX734575	ACCESSION:AX734575
C 448	12.8	0.8	17	1	AX214636	ACCESSION:AX214636	C 521	12.8	0.8	17	1	AX735159	ACCESSION:AX735159
C 449	12.8	0.8	17	1	AX215298	ACCESSION:AX215298	C 522	12.8	0.8	17	1	AX735383	ACCESSION:AX735383
C 450	12.8	0.8	17	1	AX215458	ACCESSION:AX215458	C 523	12.8	0.8	17	1	AX735386	ACCESSION:AX735386
C 451	12.8	0.8	17	1	AX215459	ACCESSION:AX215459	C 524	12.8	0.8	17	1	AX735688	ACCESSION:AX735688
C 452	12.8	0.8	17	1	AX215542	ACCESSION:AX215542	C 525	12.8	0.8	17	1	AX735736	ACCESSION:AX735736
C 453	12.8	0.8	17	1	AX217324	ACCESSION:AX217324	C 526	12.8	0.8	17	1	AX736290	ACCESSION:AX736290
C 454	12.8	0.8	17	1	AX217701	ACCESSION:AX217701	C 527	12.8	0.8	17	1	AX736619	ACCESSION:AX736619
C 455	12.8	0.8	17	1	AX217701	ACCESSION:AX217701	C 528	12.8	0.8	17	1	AX744074	ACCESSION:AX744074
C 456	12.8	0.8	17	1	AX217893	ACCESSION:AX217893	C 529	12.8	0.8	17	1	AX744075	ACCESSION:AX744075
C 457	12.8	0.8	17	1	AX264028	ACCESSION:AX264028	C 530	12.8	0.8	17	1	AX757324	ACCESSION:AX757324
C 458	12.8	0.8	17	1	AX264029	ACCESSION:AX264029	C 531	12.8	0.8	17	1	AX757876	ACCESSION:AX757876
C 459	12.8	0.8	17	1	AX272674	ACCESSION:AX272674	C 532	12.8	0.8	17	1	AX759336	ACCESSION:AX759336
C 460	12.8	0.8	17	1	AX272676	ACCESSION:AX272676	C 533	12.8	0.8	17	1	AX759623	ACCESSION:AX759623
C 461	12.8	0.8	17	1	AX273322	ACCESSION:AX273322	C 534	12.8	0.8	17	1	AX760112	ACCESSION:AX760112
C 462	12.8	0.8	17	1	AX273324	ACCESSION:AX273324	C 535	12.8	0.8	17	1	AX760633	ACCESSION:AX760633
C 463	12.8	0.8	17	1	AX422180	ACCESSION:AX422180	C 536	12.8	0.8	17	1	AX761902	ACCESSION:AX761902
C 464	12.8	0.8	17	1	AX422209	ACCESSION:AX422209	C 537	12.8	0.8	17	1	AX781903	ACCESSION:AX781903
C 465	12.8	0.8	17	1	AX422210	ACCESSION:AX422210	C 538	12.8	0.8	17	1	AX781903	ACCESSION:AX781903
C 466	12.8	0.8	17	1	AX422447	ACCESSION:AX422447	C 539	12.8	0.8	17	1	AX782025	ACCESSION:AX782025
C 467	12.8	0.8	17	1	AX423046	ACCESSION:AX423046	C 540	12.8	0.8	17	1	AX782027	ACCESSION:AX782027
C 468	12.8	0.8	17	1	AX499274	ACCESSION:AX499274	C 541	12.8	0.8	17	1	AX783601	ACCESSION:AX783601
C 469	12.8	0.8	17	1	AX499275	ACCESSION:AX499275	C 542	12.8	0.8	17	1	AX784077	ACCESSION:AX784077
C 470	12.8	0.8	17	1	AX530599	ACCESSION:AX530599	C 543	12.8	0.8	17	1	AX784078	ACCESSION:AX784078
C 471	12.8	0.8	17	1	AX530600	ACCESSION:AX530600	C 544	12.8	0.8	17	1	BD104108	ACCESSION:BD104108
					ACCESSION:AX530912								

Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

RESULT 3
 AR344230
 LOCUS
 AR344230
 DEFINITION
 AR344230
 ACCESSION
 AR344230
 VERSION
 AR344230.1
 KEYWORDS
 .
 SOURCE
 Unknown.
 ORGANISM
 Unknown.
 Unclassified.
 1 (bases 1 to 20)
 Cases, S., Parsee, R.V. Jr. and Erickson, S.K.
 Title
 Acyl CoA:cholesterol acyltransferase (ACAT-2)
 Journal
 Patent: US 6579974-A 7 17-JUN-2003;
 Features
 Location/Qualifiers
 1..20
 source
 /organism="unknown"
 /mol_type="genomic DNA"

```

Query Match      1.3%  Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1331 TCTTCTATCCCGTCATGCTG 1350
      .  |||||
Db       1 TCTTCTATCCCGTCATGCTG 20

```

RESULT 4
 AR344231 LOCUS 20 bp DNA linear PAT 17-AUG-2003
 AR344231 Sequence 8 from patent US 6579974.
 AR344231 ACCESSION
 AR344231.1 GI:33740140
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 20)
 Cases, S., Farese, R. V. Jr. and Erickson, S. K.
 Acyl CoA:cholesterol acyltransferase (ACAT-2)
 Patent: US 6579974-A 8 17-JUN-2003;
 Location/Qualifiers
 1..20
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1418 GGACGCTGCTGATGTGGACC 1437
 ||||||||||||||||
 20 GGACGCTGCTGATGTGGACC 1
 Db
 RESULT 5
 AR344229
 LOCUS

LOCUS	AR344229	25 bp	DNA	linear	PAT 17-AUG-2003
DEFINITION	Sequence 6 from patent US 6579974.				
ACCESSION	AR344229				
VERSION	AR344229.1	GI:33740138			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
	Unclassified.				

REFERENCE 1 (bases 1 to 26)
AUTHORS Cases, S., Farese, R.V. Jr. and Erickson, S.K.
TITLE Acyl CoA:cholesterol acyltransferase (ACAT-2)
JOURNAL Patent: US 6579974-A 6 17-JUN-2003;
FEATURES Location/Qualifiers
source
1..26
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.2%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 46;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1253 CCGAGGGGTAGCCATGCTGGGTG 1278
|||||
Db 1 CTCGGGGGTGGCCATGCTGGGAGTG 26

RESULT 6
AX548146/c
LOCUS AX548146 24 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 70 from Patent WO0240716.
ACCESSION AX548146
VERSION AX548146.1 GI:25813180
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Palm, K.
TITLE Profiling tumor specific markers for the diagnosis and treatment of
neoplastic disease
JOURNAL Patent: WO 0240716-A 70 23-MAY-2002;
Cemines, LLC (US)
FEATURES Location/Qualifiers
source
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Probe"

Query Match 1.2%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 45;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1088 TCAACGCCTTTCGCGAGATGCTAC 1111
|||||
Db 24 TCAACGCCTTTCGCGAGCTGCTAC 1

RESULT 7
AR344228
LOCUS AR344228 24 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 5 from patent US 6579974.
ACCESSION AR344228
VERSION AR344228.1 GI:33740137
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Cases, S., Farese, R.V. Jr. and Erickson, S.K.
TITLE Acyl CoA:cholesterol acyltransferase (ACAT-2)
JOURNAL Patent: US 6579974-A 5 17-JUN-2003;
FEATURES Location/Qualifiers
source
1..24
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.2%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 67;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 749 CTGTGCTGGGATCCTTCGTGCC 771
|||||
Db 2 CTGTGCTGGGATCCTTTGTGC 24

RESULT 8
I38900/c
LOCUS I38900 21 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 10 from patent US 5616483.
ACCESSION I38900
VERSION I38900.1 GI:2083378
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 21)
AUTHORS Bjursell, K.G., Carlsson, P.N.I., Enerback, C.S.M., Hansson, S.L.,
Lidberg, U.F.P., Nilsson, J.A. and Tornell, J.B.F.
TITLE Genomic DNA sequences encoding human BSSL/CEL
JOURNAL Patent: US 5616483-A 10 01-APR-1997;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 85;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1050 GCTGCTGTCATCTCTTTG 1069
|||||
Db 21 GCTGCTGCCATCTCTTTG 2

RESULT 9
I87931/c
LOCUS I87931 21 bp DNA linear PAT 10-AUG-1998
DEFINITION Sequence 10 from patent US 5716817.
ACCESSION I87931
VERSION I87931.1 GI:3407871
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 21)
AUTHORS Tornell, J. Birger, Fredrik.
TITLE Transgenic non-human mammals that express human BSSL/CEL
JOURNAL Patent: US 5716817-A 10 10-FEB-1998;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 85;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1050 GCTGCTGTCATCTCTTTG 1069
|||||
Db 21 GCTGCTGCCATCTCTTTG 2

RESULT 10
AR364977/c
LOCUS AR364977 21 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 28 from patent US 5455029.
ACCESSION AR364977
VERSION AR364977.1 GI:34428198
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 21)

AUTHORS Hartman,J.R., Oppenheim,A.B., Gorecki,M., Aviv,H. and Oren,R.
 TITLE Therapeutic compositions comprising a mixture of human CuZn superoxide dismutase analogs
 JOURNAL Patent: US 545029-A 28 03-OCT-1995;
 FEATURES Location/Qualifiers
 source 1..21
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.1%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 85;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1342 GTCATGCTGATCTCTCTCT 1361
 | | | | | | | | | | | | | | | | | | | | | |
 Db 20 GCCATAGTATGATCTCTCTCT 1

RESULT 11
 AR299994
 LOCUS 20 bp DNA linear PAT 12-JUN-2003
 DEFINITION Sequence 11729 from patent US 6537751.
 ACCESSION AR299994
 VERSION AR299994.1 GI:31687278
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
 TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
 JOURNAL Patent: US 6537751-A 11729 25-MAR-2003;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.0%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 89;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 821 TCCTCTTCTGCCCAACAC 838
 | | | | | | | | | | | | | | | | | | | | | |
 Db 3 TCCTCTTCTGCCCAACTC 20

RESULT 12
 AX095522
 LOCUS 21 bp DNA linear PAT 30-MAR-2001
 DEFINITION Sequence 700 from Patent WO0118250.
 ACCESSION AX095522
 VERSION AX095522.1 GI:13511725
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Lander,B.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
 TITLE Single nucleotide polymorphisms in genes
 JOURNAL Patent: WO 0118250-A 700 15-MAR-2001;
 JOURNAL WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..21
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 1.0%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1220 ATCAGATGGCTGGCGTCC 1240
 | | | | | | | | | | | | | | | | | | | | | |
 Db 1 ATCACCATGGYCTGGCGTCC 21

RESULT 13
 CQ801047/c
 LOCUS 19 bp DNA linear PAT 05-MAY-2004
 DEFINITION Sequence 38 from Patent WO2004033728.
 ACCESSION CQ801047
 VERSION CQ801047.1 GI:47057819
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS van Dongen,J.J., Langerak,A.W., Schuurink,E.M., van Miquel,J.F., Garcia Sanz,R., Ferreira,A., Smith,J.L., Lavender,F.L., Morgan,G.J., Evans,P.A., Kneba,M., Hummel,M., Macintyre,E.A. and Bastard,C.
 TITLE Nucleic acid amplification primers for pcr-based clonality studies
 JOURNAL Patent: WO 2004033728-A 38 22-APR-2004;
 ERASMUS Universiteit Rotterdam (NL); Van Dongen, Jacobus, Johannes, Maria (NL)
 FEATURES Location/Qualifiers
 source 1..19
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: DH4 primer"

Query Match 1.0%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1315 TCCTTCGTCCTGGGTCT 1333
 | | | | | | | | | | | | | | | | | | | | | |
 Db 19 TCGTCGTCCTGGGTCT 1

RESULT 14
 AR086279
 LOCUS 20 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 100 from patent US 5985558.
 ACCESSION AR086279
 VERSION AR086279.1 GI:10013045
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Dean,N.M., McKay,R., Miraglia,L. and Baker,B.
 TITLE Antisense oligonucleotide compositions and methods for the inhibition of c-Jun and c-Fos
 JOURNAL Patent: US 5985558-A 100 16-NOV-1999;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 1.0%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTCGCGCTGCCG 645
 | | | | | | | | | | | | | | | | | | | | | |
 Db 2 GATGCTCTCGCGCTGCCG 20

RESULT 15
 AR176845

LOCUS AR176845 20 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 100 from patent US 6312900.
ACCESSION AR176845
VERSION AR176845.1 GI:17919200
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M., McKay,R., Miraglia,L. and Baker,B.
TITLE Antisense oligonucleotide compositions and methods for the
modulation of activating protein 1
JOURNAL Patent: US 6312900-A 100 06-NOV-2001;
FEATURES
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTGGCGCTGCCG 645
DB 2 GATGCTCTGGCGCTGCCG 20

RESULT 16
BD231221/c
LOCUS BD231221 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Interferon-epsilon.
ACCESSION BD231221
VERSION BD231221.1 GI:33040991
KEYWORDS JP 2002526078-A/7.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Conklin,D.C., Grant,F.J., Rixon,M. and Kindsvogel,W.
TITLE Interferon-epsilon
JOURNAL Patent: JP 2002526078-A 7 20-AUG-2002;
ZYMOGENETICS INC
COMMENT OS Artificial Sequence
PN JP 2002526078-A/7
PD 20-AUG-2002
PF 16-SEP-1999 JP 2000574260
PR 18-SEP-1998 US 09/157068, 05-FEB-1999 US 09/245293 PR
08-JUL-1999 US 09/350232
PI DARRELL C CONKLIN, FRANCIS J GRANT, MARK RIXON, WAYNE KINDSVOGEL
PC C12N15/09, A61K38/00, A61K38/21, A61K48/00, A61P9/00, A61P9/10, PC
A61P15/08,
PC A61P25/00, A61P25/16, A61P25/18, A61P25/22, A61P25/24, A61P25/28,
PC A61P29/00,
PC A61P31/12, A61P31/18, A61P35/00, A61P35/02, A61P37/02, A61P37/04,
PC C07K14/555,
PC C07K16/00, C07K16/24, C07K19/00, C12N1/15, C12N1/19, C12N1/21 PC
, C12N5/10, C12N7/00,
PC C12P21/02, C12Q1/02, C12Q1/68, G01N33/53//A61K35/76, C12P21/08, PC
C12N15/00,
PC C12N5/00, A61K37/02, A61K37/66
CC PCR primer
FH Key
FT source 1..20
Location/Qualifiers
/organism='Artificial Sequence'.
FEATURES
1..20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAGTTT 310
DB 19 CTGAGGAGCAGAAAGTTT 1

RESULT 17
AR303015/c
LOCUS AR303015 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 10 from patent US 6544505.
ACCESSION AR303015
VERSION AR303015.1 GI:31691629
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Conklin,D.C., Grant,F.J., Rixon,M.W. and Kindsvogel,W.
TITLE Interferon-epsilon
JOURNAL Patent: US 6544505-A 10 08-APR-2003;
FEATURES
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAGTTT 310
DB 19 CTGAGGAGCAGAAAGTTT 1

RESULT 18
AR366451/c
LOCUS AR366451 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 10 from patent US 6329175.
ACCESSION AR366451
VERSION AR366451.1 GI:34598927
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Conklin,D.C., Grant,F.J., Rixon,M.W. and Kindsvogel,W.
TITLE Interferon-epsilon
JOURNAL Patent: US 6329175-A 10 11-DEC-2001;
FEATURES
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAGTTT 310
DB 19 CTGAGGAGCAGAAAGTTT 1

RESULT 19
AX613601
LOCUS AX613601 20 bp DNA linear PAT 17-FEB-2003
DEFINITION Sequence 4626 from Patent WO02072882.
ACCESSION AX613601
VERSION AX613601.1 GI:28409030
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

	REFERENCE	AUTHORS TITLE JOURNAL	Cullen,P. and Seedorf,U. Coronary chip Patent: WO 02072892-A 4626 19-SEP-2002; OGHAM GmbH (DE)	artificial sequences.
	FEATURES	source	Location/Qualifiers 1..20 /organism='Homo sapiens' /mol_type='unassigned DNA' /db_xref='taxon:9606'	
		Query Match Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;	Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
	QY	363 CACCATCTACCACATGTTTC 381 1 CACCATCTATACATGTTC 19		
	Db			
	RESULT 20	BD088361/c		
	LOCUS	A method of arraying genome clone.	20 bp DNA linear PAT 27-AUG-2002	
	DEFINITION	Accession		
	VERSION	BD088361.1 GI:22633971		
	KEYWORDS	JP 2001321190-A/605.		
	SOURCE	synthetic construct		
	ORGANISM	artificial constructs.		
	REFERENCE	Soeda,E.		
	AUTHORS	A method of arraying genome clone		
	TITLE	Patent: JP 2001321190-A 605 20-NOV-2001;		
	JOURNAL	THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUENKAISHA		
	COMMENT	GENOTECHS OS Artificial Sequence		
		PN JP 2001321190-A/605 PD 20-NOV-2001 PF 12-MAR-2001 JP 2001068285 PI EIICHI SOEDA PC CI2N15/09,CI2N15/09,CI2MI/00.CI2Q1/68.G01N33/53,G01N33/566,PC CI2N15/00, CC Description of Artificial Sequence:Synthetic DNA FH Key FT source Location/Qualifiers		
	FT	source	1..20 /organisms=Artificial Sequence'. Location/Qualifiers	
	FEATURES	source	1..20 /organism='synthetic construct' /mol_type='genomic DNA' /db_xrefs='taxon:32630'	
		Query Match Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;	Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
	QY	936 CTTCATCCTGGCGGCCTC 954 20 CTTCATCCTGGGCTACTC 2		
	Db			
	RESULT 21	AB068400/c		
	LOCUS	Synthetic construct DNA, forward primer for human STS sts-T89426 at 1p36.	20 bp DNA linear SYN 21-MAY-2003	
	DEFINITION	Accession		
	VERSION	AB068400		
	KEYWORDS	AB068400.1 GI:15129204		
	SOURCE	synthetic construct		
	ORGANISM	synthetic construct		
		Query Match Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;	Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
	QY	936 CTTCATCCTGGCGGCCTC 954 20 CTTCATCCTGGGCTACTC 2		
	Db			
	RESULT 22	AX191814/c		
	LOCUS	Sequence 96 from Patent WOO149775.	21 bp DNA linear PAT 15-AUG-2001	
	DEFINITION	Accession		
	VERSION	AX191814 AX191814.1 GI:15209983		
	KEYWORDS	synthetic construct		
	SOURCE	artificial sequences.		
	ORGANISM	Iversen,P.L.		
	REFERENCE	Antisense antibacterial cell division composition and method		
	AUTHORS	Title	Patent: WO 0149775-A 96 12-JUL-2001;	
	TITLE	Journal	Avi Biopharma, Inc. (US) Location/Qualifiers	
	JOURNAL	source	1..21 /organism='synthetic construct' /mol_type='unassigned DNA' /db_xref='taxon:32630' /note='oligonucleotide'	
	FEATURES	source	1..21 /organism='synthetic construct' /mol_type='unassigned DNA' /db_xref='taxon:32630' /note='oligonucleotide'	
		Query Match Best Local Similarity 1.0%; Score 15.8; DB 1; Length 21;	Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
	QY	711 TAGGTTCCCTGATGAAGC 729 19 TAGGCTCATGATAAAAGC 1		
	Db			
	RESULT 23	CQ621885		
	LOCUS	Sequence 6625 from Patent WOO192524.	17 bp DNA linear PAT 02-FEB-2004	
	DEFINITION	Accession		
	VERSION	CQ621885		
	KEYWORDS	CQ621885		
	SOURCE	synthetic construct		
	ORGANISM	synthetic construct		

```

VERSION      CQ621885.1  GI:41672103
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM
REFERENCE    1  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
              Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 6625 06-DEC-2001;
FEATURES     location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      21  TCTGGCTCTGCAGGACA 37
          |||||
          1  TCTGGCTCTGCATAGGA 17

Db

RESULT 24
CQ621886
LOCUS      CQ621886      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 6626 from Patent WO0192524.
ACCESSION CQ621886
VERSION    CQ621886.1  GI:41672104
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 6626 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      22  CTGGCTCTGCAGGAC 38
          |||||
          1  CTGGCTCTGCATAGGAC 17

Db

RESULT 25
CQ621887
LOCUS      CQ621887      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 6627 from Patent WO0192524.
ACCESSION CQ621887
VERSION    CQ621887.1  GI:41672105
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 6627 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      23  TGGCTCTGCAGGACA 39
          |||||
          1  TGGCTCTGCATAGGACA 17

Db

RESULT 26
CQ621888
LOCUS      CQ621888      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 6628 from Patent WO0192524.
ACCESSION CQ621888
VERSION    CQ621888.1  GI:41672106
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 6628 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      24  GCGTCTGCAGGACAG 40
          |||||
          1  GCGTCTGCATAGGACAG 17

Db

RESULT 27
ARI88324/c
LOCUS      ARI88324      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 3812 from patent US 6346398.
ACCESSION ARI88324
VERSION    ARI88324.1  GI:20234289
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unknown.
            Unclassified.
            1 (bases 1 to 17)
REFERENCE  1  Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
            Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
            Patent: US 6346398-A 3812 12-FEB-2002;
            Aeomica, Inc. (US)
FEATURES   location/Qualifiers
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 120 ATGGACCCGACATGG 136
Db 17 ATGGACCCGACATGG 1
RESULT 28
LOCUS AR285978 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 350 from patent US 6528640.
ACCESSION AR285978
VERSION AR285978.1 GI:29723574
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpelsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 350 04-MAR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 668 AGCTCCCGCGGCTCC 684
Db 17 AGCTCCCGCGGCTCC 1
RESULT 29
LOCUS AR324177/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1579 from patent US 6566127.
ACCESSION AR324177
VERSION AR324177.1 GI:33709985
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1579 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 120 ATGGACCCGACATGG 136
Db 17 ATGGACCCGACATGG 1
RESULT 30
LOCUS AR328801/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6203 from patent US 6566127.
ACCESSION AR328801
VERSION AR328801.1 GI:33714609
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6203 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 121 TGGACCCGACATGGA 137
Db 17 TGGACCCGACATGGA 1
RESULT 31
LOCUS AR397968/c 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 349 from patent US 6617438.
ACCESSION AR397968
VERSION AR397968.1 GI:40135394
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpelsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 349 09-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 668 AGCTCCCGCGGCTCC 684
Db 17 AGCTCCCGCGGCTCC 1
RESULT 32
LOCUS AR462948 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6625 from patent US 6686188.
ACCESSION AR462948
VERSION AR462948.1 GI:42698005
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6625 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAGGA 37
Db 1 TCTGCGTCTGCATAGGA 17

RESULT 33
AR462949
LOCUS AR462949 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6626 from patent US 6686188.
ACCESSION AR462949
VERSION AR462949.1 GI:42698006
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6626 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 22 CTGCGTCTGCAGAGGAC 38
Db 1 CTGCGTCTGCATAGGAC 17

RESULT 34
AR462950
LOCUS AR462950 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6627 from patent US 6686188.
ACCESSION AR462950
VERSION AR462950.1 GI:42698007
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6627 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 23 TCGGCTCTGCAGAGGACA 39
Db 1 TCGGCTCTGCATAGGACA 17

RESULT 35
AR462951
LOCUS AR462951 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6628 from patent US 6686188.
ACCESSION AR462951
VERSION AR462951.1 GI:42698008
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6628 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 90;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCGTCTGCAGAGGACAG 40
Db 1 GCGTCTGCATAGGACAG 17

RESULT 36
AX353169/c
LOCUS AX353169 19 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 375 from Patent EP1174518.
ACCESSION AX353169
VERSION AX353169.1 GI:18618251
KEYWORDS
SOURCE
ORGANISM synthetic construct
synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Loukachov, V.V., van Gemen, B. and Goudsmit, J.
TITLE Collection of binding molecules
JOURNAL Patent: EP 1174518-A 375 23-JAN-2002;
Amsterdam Support Diagnostics B.V. (NL)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 151"

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 286 CCATCCCTGGGGAACA 302
Db 17 CCATCCCTGGGGAAGCA 1

RESULT 37
AX363014/c
LOCUS AX363014 19 bp DNA linear PAT 15-FEB-2002
DEFINITION Sequence 375 from Patent WO0208463.
ACCESSION AX363014
VERSION AX363014.1 GI:18695154
KEYWORDS
SOURCE
ORGANISM synthetic construct
synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Loukachov, V.V., Goudsmit, J. and van Gemen, B.
TITLE Collection of binding molecules
JOURNAL Patent: WO 0208463-A 375 31-JAN-2002;
Amsterdam Support Diagnostics B.V. (NL)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"

/db xref="taxon:32630"
/note="position 151"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 286 CCATCCCTGGGGAACA 302
|||||
Db 17 CCATCCCTGGGGAACA 1

RESULT 38
LOCUS AR230366/c
DEFINITION Sequence 99 from patent US 6451578.
ACCESSION AR230366
VERSION AR230366
KEYWORDS GI:27270505
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Simons,J.N., Pilot-Matias,T.J., Dawson,G.J., Schlauder,G.G.,
Desai,S.M., Leary,T.P., Muerthoff,A.S., Erker,J.C., Buijk,S.L. and
Mushahwar,I.K.
TITLE Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods
for their use
JOURNAL Patent: US 6451578-A 99 17-SEP-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGCTACG 1492
|||||
Db 19 CTGCCAGGAGGCTACG 3

RESULT 39
LOCUS AR255958/c
DEFINITION Sequence 17 from patent US 6482644.
ACCESSION AR255958
VERSION AR255958.1 GI:27305217
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowseert,L.W.
TITLE Antisense modulation of dual specific phosphatase 8 expression
JOURNAL Patent: US 6482644-A 17 19-NOV-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1184 ACCTGCTGTCATGAC 1200
|||||
Db 19 ACCTGCTGTCATGAC 3

RESULT 40
LOCUS AR310061/c

LOCUS AR310061
DEFINITION Sequence 99 from patent US 6558898.
ACCESSION AR310061
VERSION AR310061.1 GI:31702339
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Simons,J.N., Pilot-Matias,T.J., Dawson,G.J., Schlauder,G.G.,
Desai,S.M., Leary,T.P., Muerthoff,A.S., Erker,J.C., Buijk,S.L. and
Mushahwar,I.K.
TITLE Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods
for their use
JOURNAL Patent: US 6558898-A 99 06-MAY-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGCTACG 1492
|||||
Db 19 CTGCCAGGAGGCTACG 3

RESULT 41
LOCUS AR350473/c
DEFINITION Sequence 99 from patent US 6586568.
ACCESSION AR350473
VERSION AR350473.1 GI:33751616
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Simons,J.N., Pilot-Matias,T.J., Dawson,G.J., Schlauder,G.G.,
Desai,S.M., Leary,T.P., Muerthoff,A.S., Erker,J.C., Buijk,S.L. and
Mushahwar,I.K.
TITLE Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods
for their use
JOURNAL Patent: US 6586568-A 99 01-JUL-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGCTACG 1492
|||||
Db 19 CTGCCAGGAGGCTACG 3

RESULT 42
LOCUS AR442660/c
DEFINITION Sequence 9 from patent US 6670135.
ACCESSION AR442660
VERSION AR442660.1 GI:42669921
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Spriggs,M.K.
TITLE Semaphorin polypeptides

JOURNAL Patent: US 6670135-A 9 30-DEC-2003;
 FEATURES source
 1. .20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.0%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 GGGCCAGGGGACCTGG 579
 |||
 19 GGTCCAGGGGACCTGG 3

RESULT 43
 AR494207/c
 LOCUS 20 bp DNA linear PAT 15-MAY-2004
 DEFINITION Sequence 99 from patent US 6720166.
 ACCESSION AR494207
 VERSION AR494207.1 GI:47267129
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Simons,J.N., Pilot-Matias,T.J., Dawson,G.J., Schlauder,G.G.,
 Desai,S.M., Leary,T.P., Muenhoff,A.S., Erker,J.C., Buifk,S.H. and
 Mushahwar,I.K.
 TITLE Non-a, non-b, non-c, non-d, non-e hepatitis reagents and
 methods for their use
 JOURNAL Patent: US 6720166-A 99 13-APR-2004;
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.0%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492
 |||
 19 CTGCCAGGAGGCGGTACG 3

RESULT 44
 AR126680/c
 LOCUS 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 109 from patent US 6180353.
 ACCESSION AR126680
 VERSION AR126680.1 GI:14113273
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Dean,N.M. and Cowser,L.M.
 TITLE Antisense modulation of daxx expression
 JOURNAL Patent: US 6180353-A 109 30-JAN-2001;
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 TGTGTTCTGGTCTCCGAG 1294
 |||
 20 TGTGTTTCTGGCCTCTGCAG 1

Db

RESULT 45
 AR170934/c
 LOCUS 20 bp DNA linear PAT 17-DEC-2001
 DEFINITION Sequence 1 from patent US 6297007.
 ACCESSION AR170934
 VERSION AR170934.1 GI:17909884
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Waters,B., Miao,V., Ho,Y.Wai. and Tong,S.Kah.
 TITLE Method for isolation of biosynthesis genes for bioactive molecules
 JOURNAL Patent: US 6297007-A 1 02-OCT-2001;
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 77.8%; Pred. No. 1.4e+02;
 Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 635 GCGCGCTGCGGTCACG 652
 |||
 20 GCGCGCTGCGGTCAYS 3

Db

RESULT 46
 BD175122/c
 LOCUS 20 bp DNA linear PAT 18-MAR-2003
 DEFINITION Androgen receptor complex-associated protein.
 ACCESSION BD175122
 VERSION BD175122.1 GI:29120816
 KEYWORDS JP 2002262871-A/3.
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Chan,T.Z.
 TITLE Androgen receptor complex-associated protein
 JOURNAL Patent: JP 2002262871-A 3 17-SEP-2002;
 COMMENT VETERANS GENERAL HOSPITAL
 OS Artificial Sequence
 PN JP 2002262871-A/3
 PD 17-SEP-2002
 PF 28-FEB-2001 JP 2001055192
 PI TAI ZHAI CHAN
 PC C12N15/09,C07K14/47,C12N1/15,C12N1/19,C12N1/21,C12N5/10 PC
 C12P21/02,C12Q1/68,
 PC G01N33/15,G01N33/50,G01N33/566,C12N15/00,C12N5/00 CC primer
 for PCR
 FH Key Location/Qualifiers
 FT source 1. .20
 /organism='Artificial Sequence'.
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 963 TGTCTTGGCAACATGAGCC 982
 |||
 20 TGTCTTGGCAAAATGTCC 1

Db

RESULT 47
 BD176245/c

JOURNAL Patent: US 6670135-A 9 30-DEC-2003;
 FEATURES source
 1. .20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.0%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 GGGCCAGGGGACCTGG 579
 |||
 19 GGTCCAGGGGACCTGG 3

RESULT 43
 AR494207/c
 LOCUS 20 bp DNA linear PAT 15-MAY-2004
 DEFINITION Sequence 99 from patent US 6720166.
 ACCESSION AR494207
 VERSION AR494207.1 GI:47267129
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Simons,J.N., Pilot-Matias,T.J., Dawson,G.J., Schlauder,G.G.,
 Desai,S.M., Leary,T.P., Muenhoff,A.S., Erker,J.C., Buifk,S.H. and
 Mushahwar,I.K.
 TITLE Non-a, non-b, non-c, non-d, non-e hepatitis reagents and
 methods for their use
 JOURNAL Patent: US 6720166-A 99 13-APR-2004;
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.0%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492
 |||
 19 CTGCCAGGAGGCGGTACG 3

RESULT 44
 AR126680/c
 LOCUS 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 109 from patent US 6180353.
 ACCESSION AR126680
 VERSION AR126680.1 GI:14113273
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Dean,N.M. and Cowser,L.M.
 TITLE Antisense modulation of daxx expression
 JOURNAL Patent: US 6180353-A 109 30-JAN-2001;
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 TGTGTTCTGGTCTCCGAG 1294
 |||
 20 TGTGTTTCTGGCCTCTGCAG 1

Db

RESULT 45
 AR170934/c
 LOCUS 20 bp DNA linear PAT 17-DEC-2001
 DEFINITION Sequence 1 from patent US 6297007.
 ACCESSION AR170934
 VERSION AR170934.1 GI:17909884
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Waters,B., Miao,V., Ho,Y.Wai. and Tong,S.Kah.
 TITLE Method for isolation of biosynthesis genes for bioactive molecules
 JOURNAL Patent: US 6297007-A 1 02-OCT-2001;
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 77.8%; Pred. No. 1.4e+02;
 Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 635 GCGCGCTGCGGTCACG 652
 |||
 20 GCGCGCTGCGGTCAYS 3

Db

RESULT 46
 BD175122/c
 LOCUS 20 bp DNA linear PAT 18-MAR-2003
 DEFINITION Androgen receptor complex-associated protein.
 ACCESSION BD175122
 VERSION BD175122.1 GI:29120816
 KEYWORDS JP 2002262871-A/3.
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Chan,T.Z.
 TITLE Androgen receptor complex-associated protein
 JOURNAL Patent: JP 2002262871-A 3 17-SEP-2002;
 COMMENT VETERANS GENERAL HOSPITAL
 OS Artificial Sequence
 PN JP 2002262871-A/3
 PD 17-SEP-2002
 PF 28-FEB-2001 JP 2001055192
 PI TAI ZHAI CHAN
 PC C12N15/09,C07K14/47,C12N1/15,C12N1/19,C12N1/21,C12N5/10 PC
 C12P21/02,C12Q1/68,
 PC G01N33/15,G01N33/50,G01N33/566,C12N15/00,C12N5/00 CC primer
 for PCR
 FH Key Location/Qualifiers
 FT source 1. .20
 /organism='Artificial Sequence'.
 FEATURES Location/Qualifiers
 source 1. .20
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 963 TGTCTTGGCAACATGAGCC 982
 |||
 20 TGTCTTGGCAAAATGTCC 1

Db

RESULT 47
 BD176245/c

LOCUS BD176245 20 bp DNA linear PAT 18-MAR-2003
DEFINITION A method of arraying genome clone.
ACCESSION BD176245
VERSION BD176245.1 GI:29121951
KEYWORDS WO 02072815-A/45.
SOURCE synthetic construct
ORGANISM artificial construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Soeda,E.
TITLE A method of arraying genome clone
JOURNAL Patent: WO 02072815-A 45 19-SEP-2002;
EIIICHI SOEDA,TAKESHI KUKITA
COMMENT OS Artificial Sequence
PN WO 02072815-A/45
PD 17-SEP-2002
PR 17-MAY-2001 WO 2001JP004139
PI EIIICHI SOEDA
PC C12N15/09,C12Q1/68
CC Description of Artificial Sequence: Synthetic DNA FH Key
Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
1..20
Location/Qualifiers
/organism='Artificial Sequence'.
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 745 GAGGCTGTGCTGGGATCCT 764
DB 20 GAGGATGCTCCCTGAGATCCT 1
|||||
RESULT 48
E40060/C
LOCUS E40060 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Drug containing anti-Fas antibody.
ACCESSION E40060
VERSION E40060.1 GI:18627176
KEYWORDS JP 2000169393-A/57.
SOURCE synthetic construct
ORGANISM artificial construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Takahashi,W., Yoshida,H., Ichikawa,K.,
Okuma,J., Otsuki,M., Shiraishi,A. and Yonehara,S.
TITLE Drug containing anti-Fas antibody
JOURNAL Patent: JP 2000169393-A 57 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000169393-A/57
PD 20-JUN-2000
PF 30-SEP-1999 JP 1999278301
PR NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,WATARU TAKAHASHI, PI
HIROKO YOSHIDA,
PI KIMIHIISA ICHIKAWA, JUN OKUMA, MASAHICO OTSUKI, AKIO SHIRAISHI, PI
SHIN YONEHARA
PC A61K39/395,A61K39/395,A61K39/00,A61P1/16,A61P7/06,A61P9/00, PC
A61P9/10,
PC A61P13/12,A61P31/18,A61P37/06,C12N5/10,C12N15/02,C12N15/09, PC
C12P21/08//
CC C07K16/28,C12N5/00,C12N15/00,C12N15/00
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
/organism='Artificial Sequence'.
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 745 GAGGCTGTGCTGGGATCCT 764
DB 20 GAGGATGCTCCCTGAGATCCT 1
|||||
RESULT 48
E40060/C
LOCUS E40060 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Drug containing anti-Fas antibody.
ACCESSION E40060
VERSION E40060.1 GI:18627176
KEYWORDS JP 2000169393-A/57.
SOURCE synthetic construct
ORGANISM artificial construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Takahashi,W., Yoshida,H., Ichikawa,K.,
Okuma,J., Otsuki,M., Shiraishi,A. and Yonehara,S.
TITLE Drug containing anti-Fas antibody
JOURNAL Patent: JP 2000169393-A 57 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000169393-A/57
PD 20-JUN-2000
PF 30-SEP-1999 JP 1999278301
PR NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,WATARU TAKAHASHI, PI
HIROKO YOSHIDA,
PI KIMIHIISA ICHIKAWA, JUN OKUMA, MASAHICO OTSUKI, AKIO SHIRAISHI, PI
SHIN YONEHARA
PC A61K39/395,A61K39/395,A61K39/00,A61P1/16,A61P7/06,A61P9/00, PC
A61P9/10,
PC A61P13/12,A61P31/18,A61P37/06,C12N5/10,C12N15/02,C12N15/09, PC
C12P21/08//
CC C07K16/28,C12N5/00,C12N15/00,C12N15/00
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
/organism='Artificial Sequence'.
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCCAACAC 838
DB 20 CTTCTCTTCTGCCCCAACAC 1
|||||
RESULT 49
E40064
LOCUS E40064 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Drug containing anti-Fas antibody.
ACCESSION E40064
VERSION E40064.1 GI:18627180
KEYWORDS JP 2000169393-A/61.
SOURCE synthetic construct
ORGANISM artificial construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Takahashi,W., Yoshida,H., Ichikawa,K.,
Okuma,J., Otsuki,M., Shiraishi,A. and Yonehara,S.
TITLE Drug containing anti-Fas antibody
JOURNAL Patent: JP 2000169393-A 61 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000169393-A/61
PD 20-JUN-2000
PF 30-SEP-1999 JP 1999278301
PR NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,WATARU TAKAHASHI, PI
HIROKO YOSHIDA,
PI KIMIHIISA ICHIKAWA, JUN OKUMA, MASAHICO OTSUKI, AKIO SHIRAISHI, PI
SHIN YONEHARA
PC A61K39/395,A61K39/395,A61K39/00,A61P1/16,A61P7/06,A61P9/00, PC
A61P9/10,
PC A61P13/12,A61P31/18,A61P37/06,C12N5/10,C12N15/02,C12N15/09, PC
C12P21/08//
CC C07K16/28,C12N5/00,C12N15/00,C12N15/00
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
/organism='Artificial Sequence'.
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCCAACAC 838
DB 20 CTTCTCTTCTGCCCCAACAC 1
|||||
RESULT 50
E40868/C
LOCUS E40868 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Humanized anti-Fas antibody.
ACCESSION E40868
VERSION E40868.1 GI:18627445
KEYWORDS JP 2000166574-A/57.
SOURCE synthetic construct
ORGANISM synthetic construct

FEATURES
source
1..20
Location/Qualifiers
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCCAACAC 838
DB 20 CTTCTCTTCTGCCCCAACAC 1
|||||
RESULT 49
E40064
LOCUS E40064 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Drug containing anti-Fas antibody.
ACCESSION E40064
VERSION E40064.1 GI:18627180
KEYWORDS JP 2000169393-A/61.
SOURCE synthetic construct
ORGANISM artificial construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Takahashi,W., Yoshida,H., Ichikawa,K.,
Okuma,J., Otsuki,M., Shiraishi,A. and Yonehara,S.
TITLE Drug containing anti-Fas antibody
JOURNAL Patent: JP 2000169393-A 61 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000169393-A/61
PD 20-JUN-2000
PF 30-SEP-1999 JP 1999278301
PR NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,WATARU TAKAHASHI, PI
HIROKO YOSHIDA,
PI KIMIHIISA ICHIKAWA, JUN OKUMA, MASAHICO OTSUKI, AKIO SHIRAISHI, PI
SHIN YONEHARA
PC A61K39/395,A61K39/395,A61K39/00,A61P1/16,A61P7/06,A61P9/00, PC
A61P9/10,
PC A61P13/12,A61P31/18,A61P37/06,C12N5/10,C12N15/02,C12N15/09, PC
C12P21/08//
CC C07K16/28,C12N5/00,C12N15/00,C12N15/00
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
/organism='Artificial Sequence'.
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCCAACAC 838
DB 20 CTTCTCTTCTGCCCCAACAC 1
|||||
RESULT 50
E40868/C
LOCUS E40868 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Humanized anti-Fas antibody.
ACCESSION E40868
VERSION E40868.1 GI:18627445
KEYWORDS JP 2000166574-A/57.
SOURCE synthetic construct
ORGANISM synthetic construct

```
artificial sequences.
1 (bases 1 to 20)
Humanized anti-Fas antibody
TITLE Humanized anti-Fas antibody
JOURNAL Patent: JP 2000166574-A 57 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000166574-A/57
PD 20-JUN-2000
PF 29-SEP-1999 JP 1999275441
PR NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,KAORI NAKAHARA,IKUKO TAMAKI
PI C12N15/09,A61K39/00,A61K39/395,A61K39/395,A61P37/02,A61P43/00,
PC C07K16/18,
PC C12N1/21,C12N5/10,C12P21/08//(C12N1/21,C12R1:19),C12N15/00, PC
C12N5/00
CC
CC Key Location/Qualifiers
FH source 1..20
FT /organism="synthetic construct"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:32630"
FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTCTTCTGCCCAACAC 838
DB 20 CTTCTCTTCTCCCAAAAC 1
FEATURES
LOCUS E40872 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Humanized anti-Fas antibody.
ACCESSION E40872.1 GI:18627449
VERSION JP 2000166574-A/61.
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Nakahara,K. and Tamaki,I.
TITLES Humanized anti-Fas antibody
JOURNAL Patent: JP 2000166574-A 61 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000166574-A/61
PD 20-JUN-2000
PF 29-SEP-1999 JP 1999275441
PR NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,KAORI NAKAHARA,IKUKO TAMAKI
PI C12N15/09,A61K39/00,A61K39/395,A61K39/395,A61P37/02,A61P43/00,
PC C07K16/18,
PC C12N1/21,C12N5/10,C12P21/08//(C12N1/21,C12R1:19),C12N15/00, PC
C12N5/00
CC
CC Key Location/Qualifiers
FH source 1..20
FT /organism="synthetic construct"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:32630"
FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCAACAC 838
DB 20 CTTCTCTTCTCCCAAAAC 1
FEATURES
LOCUS E40872 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Humanized anti-Fas antibody.
ACCESSION E40872.1 GI:18627449
VERSION JP 2000166574-A/61.
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Nakahara,K. and Tamaki,I.
TITLES Humanized anti-Fas antibody
JOURNAL Patent: JP 2000166574-A 61 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000166574-A/61
PD 20-JUN-2000
PF 29-SEP-1999 JP 1999275441
PR NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,KAORI NAKAHARA,IKUKO TAMAKI
PI C12N15/09,A61K39/00,A61K39/395,A61K39/395,A61P37/02,A61P43/00,
PC C07K16/18,
PC C12N1/21,C12N5/10,C12P21/08//(C12N1/21,C12R1:19),C12N15/00, PC
C12N5/00
CC
CC Key Location/Qualifiers
FH source 1..20
FT /organism="synthetic construct"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:32630"
FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
artificial sequences.
1 (bases 1 to 20)
Humanized anti-Fas antibody
TITLE Humanized anti-Fas antibody
JOURNAL Patent: JP 2000166573-A 57 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000166573-A/57
PD 20-JUN-2000
PF 29-SEP-1999 JP 1999275440
PR WATARU TAKAHASHI,HIDEYUKI HARUYAMA,NOBUKI SERIZAWA PC
C12N15/09,A61K38/00,A61K39/00,A61K39/395,A61K39/395,A61P37/00, PC
A61P43/00,
PC C07K16/28,C12N1/21,C12N5/10,C12N15/02,C12P21/08//(C12P21/08,
PC C12R1:91)),
PC C12N15/00,A61K37/02,C12N5/00,C12N15/00
CC
CC Key Location/Qualifiers
FH source 1..20
FT /organism="Artificial Sequence".
FT /organism="synthetic construct"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:32630"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCAACAC 838
DB 20 CTTCTCTTCTCCCAAAAC 1
FEATURES
LOCUS E43418 20 bp DNA linear PAT 31-JAN-2002
DEFINITION Humanized anti-Fas antibody.
ACCESSION E43418.1 GI:18627684
VERSION JP 2000166573-A/61.
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Takahashi,W., Haruyama,H. and Serizawa,N.
TITLES Humanized anti-Fas antibody
JOURNAL Patent: JP 2000166573-A 61 20-JUN-2000;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2000166573-A/61
PD 20-JUN-2000
PF 29-SEP-1999 JP 1999275440
PR WATARU TAKAHASHI,HIDEYUKI HARUYAMA,NOBUKI SERIZAWA PC
C12N15/09,A61K38/00,A61K39/00,A61K39/395,A61K39/395,A61P37/00, PC
```


A61P43/00,
PC C07K16/28, C12N1/21, C12N5/10, C12N15/02, C12P21/08//C12P21/08,
PC C12R1/911,
PC C12N15/00, A61K37/02, C12N5/00, C12N15/00
CC
PH Key Location/Qualifiers
FT source 1..20
FT /organism='Artificial Sequence'.
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCGCAAC 838
Db 1 CTTCTCTTCTGCGCAAC 20
RESULT 54
LOCUS I18406/ 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 20 from patent US 5496699.
ACCESSION I18406
VERSION I18406.1 GI:1598761
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sorenson, G.D.
TITLE Detection of allele - specific mutagens
JOURNAL Patent: US 5496699-A 20 05-MAR-1996;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 361 CGCACCATCTACCATGTT 380
Db 20 CGCTCCAACTACCAAGTT 1
RESULT 55
LOCUS AR271778/c 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 22 from patent US 6503754.
ACCESSION AR271778
VERSION AR271778.1 GI:29703346
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zhang, H. and Wyatt, J.
TITLE Antisense modulation of BH3 interacting domain death agonist
JOURNAL expression
FEATURES Patent: US 6503754-A 22 07-JAN-2003;
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 903 TCCCCAGGCCCTGGGATGTG 922
Db 20 TGCCCGAGGCCATGGACTGTG 1
RESULT 56
LOCUS AR307931 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 142 from patent US 6551826.
ACCESSION AR307931
VERSION AR307931.1 GI:31698687
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Watt, A.T.
TITLE Antisense modulation of raidd expression
JOURNAL Patent: US 6551826-A 142 22-APR-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1466 TCAGCTGTACTGCCAGGAG 1485
Db 1 TCAGCTTCCACTGCCTGGAG 20
RESULT 57
LOCUS AR314148 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 4685 from patent US 6559294.
ACCESSION AR314148
VERSION AR314148.1 GI:31707574
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths, R., Hoieth, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A.,
Sankaran, B., and Fletcher, L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 4685 06-MAY-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 502 GTGACCTGGTGGCCCATGTT 521
Db 1 GAGACCTTGGTGGCCCATGTT 20
RESULT 58
LOCUS AX048825 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 3 from Patent WO0071155.
ACCESSION AX048825
VERSION AX048825.1 GI:12225959
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

```
artificial sequences.
1
REFERENCE
AUTHORS Smith,P.O., Stevenson,D.O., Chana,H.O. and Thraves,P.O.
TITLE New vaccine formulations - 2
JOURNAL Patent: WO 0071155-A 3 30-NOV-2000;
ONYVAX ONYVAX LIMITED (GB)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="PCR primer-PSAINTF Internal forward"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1451 GCCAGGGAATCCAGGTCAGC 1470
Db 1 GCCAGGTAATTCAGGTCAGC 20

RESULT 59
AX048869
LOCUS AX048869 20 bp DNA linear PAT 12-JAN-2001
DEFINITION Sequence 3 from Patent WO0071156.
ACCESSION AX048869
VERSION AX048869.1 GI:12225978
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Sutton,A.O., Smith,P.O., Stevenson,D.O., Chana,H.O. and
Thraves,P.O.
TITLE New vaccine formulations-3
JOURNAL Patent: WO 0071156-A 3 30-NOV-2000;
ONYVAX ONYVAX LIMITED (GB)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="PCR primer-PSAINTF Internal forward"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1451 GCCAGGGAATCCAGGTCAGC 1470
Db 1 GCCAGGTAATTCAGGTCAGC 20

RESULT 60
AX104256/c
LOCUS AX104256/c 20 bp DNA linear PAT 30-APR-2001
DEFINITION Sequence 448 from Patent WO0122972.
ACCESSION AX104256
VERSION AX104256.1 GI:13920453
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Krieg,A.M., Schetter,C. and Vollmer,J.C.
TITLE Immunostimulatory nucleic acids
JOURNAL Patent: WO 0122972-A 448 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
GmbH (DE)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"

artificial sequences.
1
REFERENCE
AUTHORS Smith,P.O., Stevenson,D.O., Chana,H.O. and Thraves,P.O.
TITLE New vaccine formulations - 2
JOURNAL Patent: WO 0071155-A 3 30-NOV-2000;
ONYVAX ONYVAX LIMITED (GB)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="PCR primer-PSAINTF Internal forward"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1451 GCCAGGGAATCCAGGTCAGC 1470
Db 1 GCCAGGTAATTCAGGTCAGC 20

RESULT 61
AX355378/c
LOCUS AX355378/c 20 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 406 from Patent WO0197843.
ACCESSION AX355378
VERSION AX355378.1 GI:18620046
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Weiner,G. and Hartmann,G.
TITLE Methods for enhancing antibody-induced cell lysis and treating
cancer
JOURNAL Patent: WO 0197843-A 406 27-DEC-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Synthetic oligonucleotide"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
Db 20 CCCGGTGAGCCTGTCACTGCC 1

RESULT 62
AX492927/c
LOCUS AX492927/c 20 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 4 from Patent EP12271150.
ACCESSION AX492927
VERSION AX492927.1 GI:23338600
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Tai-Jay,C.
TITLE Androgen receptor complex-associated protein
JOURNAL Patent: EP 1227150-A 4 31-JUL-2002;
Veterans General Hospital (TW)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="primer for PCR"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 963 TGTCTTTGCCCAACATGAGCC 982
Db 20 TGTCTTTGCCCAATGTTC 1
```

```

RESULT 63
AX494234/c
LOCUS AX494234 20 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 10 from Patent WO02059379.
ACCESSION AX494234
VERSION AX494234.1 GI:23339844
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
AUTHORS Shuber,A.P.
TITLE Methods for detecting, grading or monitoring an H. pylori infection
JOURNAL Patent: WO 02059379-A 10 01-AUG-2002;
          EXACT SCIENCES CORP (US)
FEATURES
source
1. .20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="APC forward primer"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 332 TTGATGAGCTGATGAGGTTG 351
Db 20 TTGAGGAGGTGGTGGAGGTG 1

RESULT 64
AX547309/c
LOCUS AX547309 20 bp DNA linear PAT 01-MAR-2003
DEFINITION Sequence 448 from Patent WO02053141.
ACCESSION AX547309
VERSION AX547309.1 GI:25812453
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
AUTHORS Bratzler,R.L.
TITLE Inhibition of angiogenesis by nucleic acids
JOURNAL Patent: WO 02053141-A 448 11-JUL-2002;
          Coley Pharmaceutical Group, Inc. (US)
FEATURES
source
1. .20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic Sequence"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGTTCAGCTCTACTGCC 1480
Db 20 CCGGTGAGCTGCACTGCC 1

RESULT 65
AX708702/c
LOCUS AX708702 20 bp DNA linear PAT 04-APR-2003
DEFINITION Sequence 27 from Patent WO02074991.
ACCESSION AX708702
VERSION AX708702.1 GI:295564432
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.

```

```

artificial sequences.
REFERENCE
AUTHORS Karlsen,F.
TITLE Detection of microorganisms using inducible genes
JOURNAL Patent: WO 02074991-A 27 26-SEP-2002;
          Norchip A/S (NO)
FEATURES
source
1. .20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="probe"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 181 AGGGAGCTGCTGATCGGGC 200
Db 20 AAGGAGGTGCTGGAGCGGC 1

RESULT 66
AX785133
LOCUS AX785133 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 46 from Patent WO03050531.
ACCESSION AX785133
VERSION AX785133.1 GI:32952961
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
AUTHORS Lasters,I., Pletinckx,J., Boutonnet,N., Lauwereys,M. and
          Beirnaert,E.
TITLE Method for displaying loops from immunoglobulin domains in
          different contexts
JOURNAL Patent: WO 03050531-A 46 19-JUN-2003;
          AlgoNomics N.V. (BE) ; Ablynx N.V. (BE)
FEATURES
source
1. .20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="FR4 A primer"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1450 GCCCAGGGAATCCAGGTC 1467
Db 3 GCCCAGGGVACYCAGGTC 20

RESULT 67
AX785134/c
LOCUS AX785134 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 47 from Patent WO03050531.
ACCESSION AX785134
VERSION AX785134.1 GI:32952962
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
AUTHORS Lasters,I., Pletinckx,J., Boutonnet,N., Lauwereys,M. and
          Beirnaert,E.
TITLE Method for displaying loops from immunoglobulin domains in
          different contexts
JOURNAL Patent: WO 03050531-A 47 19-JUN-2003;
          AlgoNomics N.V. (BE) ; Ablynx N.V. (BE)
FEATURES
Location/Qualifiers

```

```
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Exforl primer"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1450 GCCCAGGGGAATCCAGGTC 1467
|||||:|||||
Db 18 GCCCAGGGVACYCAGGTC 1

RESULT 68
BD090167/c
LOCUS BD090167 20 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.
ACCESSION BD090167
VERSION BD090167.1 GI:22635777
KEYWORDS JP 2001321190-A/2411.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE Soeda,E.
AUTHORS A method of arraying genome clone
TITLE Patent: JP 2001321190-A 2411 20-NOV-2001;
JOURNAL THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECHS
COMMENT OS Artificial Sequence
PN JP 2001321190-A/2411
PD 20-NOV-2001
PF 12-MAR-2001 JP 2001068285
PI EIICHI SOEDA
PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
C12N15/00,
PC C12N15/00
CC Description of Artificial Sequence:Synthetic DNA FH Key
CC Location/Qualifiers
FT source 1..20
PAT 27-AUG-2002

FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTTCTCTCTTGTGCCCCAACAC 838
|||||
Db 20 CTTCTCTCTTGTGCCCCAACAC 1

RESULT 70
BD090601
LOCUS BD090601 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Drug containing humanized anti-Fas antibody.
ACCESSION BD090601
VERSION BD090601.1 GI:22636211
KEYWORDS JP 2001342148-A/61.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Nakahara,K. and Tamaki,I.
TITLE Drug containing humanized anti-Fas antibody
JOURNAL Patent: JP 2001342148-A 61 11-DEC-2001;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2001342148-A/61
PD 11-DEC-2001
PF 28-MAR-2001 JP 2001093106
PI NOBUFUSA SERIZAWA,HIDEYUKI HARUYAMA,KAORI NAKAHARA,IKUKO PI
TAMAKI
PC A61K39/395,A61K38/00,A61P1/16,A61P7/06,A61P9/00,A61P9/10, PC
A61P13/12,
PC A61P19/02,A61P29/00,A61P37/00,A61P37/06,A61P37/08,A61P43/00//
PC C12N15/09,
PC C12N15/00
CC Description of Artificial Sequence: Sequencing primer for a
CC the heavy chain of a humanized anti-Fas antibody FH Key
CC Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
FT source 1..20
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTTCTCTCTTGTGCCCCAACAC 838
|||||
Db 20 CTTCTCTCTTGTGCCCCAACAC 1

RESULT 70
BD090601
LOCUS BD090601 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Drug containing humanized anti-Fas antibody.
ACCESSION BD090601
VERSION BD090601.1 GI:22636211
KEYWORDS JP 2001342148-A/61.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Nakahara,K. and Tamaki,I.
TITLE Drug containing humanized anti-Fas antibody
JOURNAL Patent: JP 2001342148-A 61 11-DEC-2001;
SANKYO CO LTD
COMMENT OS Artificial Sequence
PN JP 2001342148-A/61
PD 11-DEC-2001
PF 28-MAR-2001 JP 2001093106
PI NOBUFUSA SERIZAWA,HIDEYUKI HARUYAMA,KAORI NAKAHARA,IKUKO PI
TAMAKI
PC A61K39/395,A61K38/00,A61P1/16,A61P7/06,A61P9/00,A61P9/10, PC
A61P13/12,
PC A61P19/02,A61P29/00,A61P37/00,A61P37/06,A61P37/08,A61P43/00//
PC C12N15/09,
PC C12N15/00
CC Description of Artificial Sequence: Sequencing primer for a
CC the heavy chain of a humanized anti-Fas antibody FH Key
CC Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
FT source 1..20
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 745 GAGGCTGTGCTGGGATCCT 764
|||||
Db 20 GAGGATGCTCCTGAGATCCT 1

RESULT 69
BD090597/c
LOCUS BD090597 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Drug containing humanized anti-Fas antibody.
ACCESSION BD090597
VERSION BD090597.1 GI:22636207
KEYWORDS JP 2001342148-A/57.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Serizawa,N., Haruyama,H., Nakahara,K. and Tamaki,I.
TITLE Drug containing humanized anti-Fas antibody
JOURNAL Patent: JP 2001342148-A 57 11-DEC-2001;
SANKYO CO LTD
```

```
QY 819 CTTCTCTTCTGCCCCAACAC 838
Db 1 CTTCTCTTCTGCCCCAACAC 20

RESULT 71
BD090706/c
LOCUS 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Drug containing humanized anti-Fas antibody.
ACCESSION BD090706
VERSION BD090706.1 GI:22636316
KEYWORDS JP 2001342149-A/57.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Takahashi, W., Haryama, H. and Serizawa, N.
TITLE Drug containing humanized anti-Fas antibody
JOURNAL Patent: JP 2001342149-A 57 11-DEC-2001;
COMMENT SANKYO CO LTD
OS Artificial Sequence
PN JP 2001342149-A/57
PD 11-DEC-2001
PF 28-MAR-2001 JP 2001093243
PI WATARU TAKAHASHI, HIDEYUKI HARYAMA, NOBUFUSA SERIZAWA PC
A61K39/395, A61K39/395, A61P1/16, A61P7/06, A61P9/00, A61P9/10, PC
A61P13/12,
PC A61P17/00, A61P31/14, A61P31/18, A61P31/20, A61P37/00, A61P37/06,
PC A61P37/08,
PC A61P43/00//C12N15/02, C12N15/00
CC Description of Artificial Sequence: Sequencing primer for a
CC DNA encoding
CC the heavy chain of a humanized anti-Fas antibody FH Key
CC Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
/mol_type="synthetic construct"
/db_xref="taxon:32630"

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTGCCCCAACAC 838
Db 1 CTTCTCTTCTGCCCCAACAC 20

RESULT 73
AR401804/c
LOCUS 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 144 from patent US 6623962.
ACCESSION AR401804
VERSION AR401804.1 GI:40149254
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar, S., Fell, P. and McSwiggen, J. A.
TITLE Enzymatic nucleic acid treatment of diseases of conditions related
JOURNAL Patent: US 6623962-A 144 23-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGGAGGTGCAG 354
Db 15 CTGATGGAGGTGCAG 1

RESULT 74
AX750951
LOCUS 17 bp DNA linear PAT 20-JUN-2003
DEFINITION Sequence 167 from Patent WO03033703.
ACCESSION AX750951
VERSION AX750951.1 GI:32133279
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human gtp-activator protein for rab-like gtpase
JOURNAL Patent: WO 03033703-A 167 24-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
source 1..17
/mol_type="unknown"
/mol_type="genomic DNA"

QY 819 CTTCTCTTCTGCCCCAACAC 838
Db 20 CTTCTCTTCTGCCCCAACAC 1

RESULT 72
BD090710
LOCUS 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Drug containing humanized anti-Fas antibody.
ACCESSION BD090710
VERSION BD090710.1 GI:22636320
KEYWORDS JP 2001342149-A/61.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Takahashi, W., Haryama, H. and Serizawa, N.
TITLE Drug containing humanized anti-Fas antibody
JOURNAL Patent: JP 2001342149-A 61 11-DEC-2001;
COMMENT SANKYO CO LTD
OS Artificial Sequence
PN JP 2001342149-A/61
PD 11-DEC-2001
PF 28-MAR-2001 JP 2001093243
PI WATARU TAKAHASHI, HIDEYUKI HARYAMA, NOBUFUSA SERIZAWA PC
A61K39/395, A61K39/395, A61P1/16, A61P7/06, A61P9/00, A61P9/10, PC
```

```

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.0%; Score 15; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 801 TTTCTCCAGCTACCT 815
Db 3 TTTCTCCAGCTACCT 17

RESULT 75
LOCUS AX750952 17 bp DNA linear PAT 20-JUN-2003
DEFINITION Sequence 168 from Patent WO03033703.
ACCESSION AX750952
VERSION AX750952.1 GI:32133280
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Zhang, J.
TITLE Human gtp-activator protein for rab-like gtpase
JOURNAL Patent: WO 03033703-A 168 24-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.0%; Score 15; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 801 TTTCTCCAGCTACCT 815
Db 2 TTTCTCCAGCTACCT 16

RESULT 76
LOCUS AX750953 17 bp DNA linear PAT 20-JUN-2003
DEFINITION Sequence 169 from Patent WO03033703.
ACCESSION AX750953
VERSION AX750953.1 GI:32133281
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Zhang, J.
TITLE Human gtp-activator protein for rab-like gtpase
JOURNAL Patent: WO 03033703-A 169 24-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.0%; Score 15; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 801 TTTCTCCAGCTACCT 815
Db 1 TTTCTCCAGCTACCT 15

```

```

RESULT 77
LOCUS BD067304/c 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067304
VERSION BD067304.1 GI:22612907
KEYWORDS JP 2001511003-A/144.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 144 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/144
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
FH key Location/Qualifiers
FT source 1..17
/organism='Unidentified'.
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.0%; Score 15; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 340 CTGATGGAGGTGCAG 354
Db 15 CTGATGGAGGTGCAG 1

RESULT 78
LOCUS E25757/c 18 bp DNA linear PAT 18-JUN-2001
DEFINITION Method for the type classification of hepatitis B viruses and
primer and probe to be used therein.
ACCESSION E25757
VERSION E25757.1 GI:13024945
KEYWORDS JP 1999103898-A/14.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 18)
AUTHORS Masakazu,M., Kazumasa,H., Kenichi,O. and Masashi,M.
TITLE Method for the type classification of hepatitis B viruses and
primer and probe to be used therein
JOURNAL Patent: JP 1999103898-A 14 20-APR-1999;
SRL INC
COMMENT OS Unidentified
PN JP 1999103898-A/14
PD 20-APR-1999
PF 30-SEP-1997 JP 1997282784
PR MASAKAZU MUKAIDE,KAZUMASA HIKIJI,KENICHI OBA,MASASHI MIZOUE PC
C12Q1/70,C12N15/09,G01N33/576,C12N15/00
CC Strandedness: Single;

```

```
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..18
FT /organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..18
            /organism='unidentified'
            /mol_type='genomic DNA'
            /db_xref='taxon:32644'
Query Match
    Best Local Similarity 1.0%; Score 15; DB 1; Length 18;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 AGGTTCCCTTGAGCAG 275
DB 15 AGGTTCCCTTGAGCAG 1
RESULT 79
LOCUS AR226108 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 171 from patent US 6444465.
ACCESSION AR226108
VERSION AR226108.1 GI:27264262
KEYWORDS
SOURCE
ORGANISM
REFERENCE
    1 (bases 1 to 20)
    Wyatt,J. and Freier,S.M.
    Antisense modulation of Her-1 expression
    Patent: US 6444465-A 171 03-SEP-2002;
JOURNAL
FEATURES
    source
        Location/Qualifiers
            1..20
            /organism='unknown'
            /mol_type='genomic DNA'
Query Match
    Best Local Similarity 1.0%; Score 15; DB 1; Length 20;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CTGATGGAGGTGCAG 354
DB 5 CTGATGGAGGTGCAG 19
RESULT 80
LOCUS AR373782/c 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 174 from patent US 6602857.
ACCESSION AR373782
VERSION AR373782.1 GI:40076193
KEYWORDS
SOURCE
ORGANISM
REFERENCE
    1 (bases 1 to 20)
    Cowser,L.M., Wyatt,J., Monia,B.P., Butler,M.M. and McKay,R.
    Antisense modulation of PTP1B expression
    Patent: US 6602857-A 174 05-AUG-2003;
JOURNAL
FEATURES
    source
        Location/Qualifiers
            1..20
            /organism='unknown'
            /mol_type='genomic DNA'
Query Match
    Best Local Similarity 1.0%; Score 15; DB 1; Length 20;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 245 TGCCCCCACCCTCCCC 259
DB 20 TGCCCCCACCCTCCCC 6
```

```
RESULT 81
LOCUS AX418779/c 20 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 174 from Patent WO0210378.
ACCESSION AX418779
VERSION AX418779.1 GI:21523642
KEYWORDS
SOURCE
ORGANISM
REFERENCE
    1
    Cowser,L.M., Wyatt,J., Freier,S.M., Monia,B.P., Butler,M.M. and
    McKay,R.
    Antisense modulation of ptp1b expression
    Patent: WO 0210378-A 174 07-FEB-2002;
JOURNAL
FEATURES
    source
        Location/Qualifiers
            1..20
            /organism='synthetic construct'
            /mol_type='unassigned DNA'
            /db_xref='taxon:32630'
            /note='Antisense Oligonucleotide'
Query Match
    Best Local Similarity 100.0%; Score 15; DB 1; Length 20;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 245 TGCCCCCACCCTCCCC 259
DB 20 TGCCCCCACCCTCCCC 6
RESULT 82
LOCUS AR257452 18 bp mRNA linear PAT 20-DEC-2002
DEFINITION Sequence 7 from patent US 6486310.
ACCESSION AR257452
VERSION AR257452.1 GI:27307463
KEYWORDS
SOURCE
ORGANISM
REFERENCE
    1 (bases 1 to 18)
    O'Malley,K.L. and Todd,R.D.
    Gene encoding the rat dopamine D4 receptor
    Patent: US 6486310-A 7 26-NOV-2002;
JOURNAL
FEATURES
    source
        Location/Qualifiers
            1..18
            /organism='unknown'
            /mol_type='mRNA'
Query Match
    Best Local Similarity 0.9%; Score 14.8; DB 1; Length 18;
    Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 523 CTGTCCACCCTGTGGCG 540
DB 1 CTGTCCACCCTGTGGCG 18
RESULT 83
LOCUS AR300309 19 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 111 from patent US 6537775.
ACCESSION AR300309
VERSION AR300309.1 GI:31687728
KEYWORDS
SOURCE
ORGANISM
REFERENCE
    1 (bases 1 to 19)
```

AUTHORS Tournier-Lasserre,E., Joutel,A., Bousser,M.-G. and Bach,J.-F.
TITLE Gene involved in cadasil, method of diagnosis and therapeutic application
JOURNAL Patent: US 6537775-A 111 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGGTCTTCGAGCAG 708
Db 1 GTCCTGCTCTTCAAGCAG 18

RESULT 84
AX010849
LOCUS AX010849 19 bp DNA linear PAT 06-SEP-2000
DEFINITION Sequence 18 from Patent WO9958556.
ACCESSION AX010849
VERSION AX010849.1 GI:9997560
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE 1
AUTHORS Ballabio,A. and Casari,G.
TITLE Protein associated to hereditary spastic paraplegia
JOURNAL Patent: WO 9958556-A 18 18-NOV-1999;
FONDAZIONE TELETHON (IT); BALLABIO ANDREA (IT); CASARI GIORGIO (IT)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="oligonucleotide"

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 241 CCTCTGCTCCACCTCCC 258
Db 1 CCTCTGCTCACACTCC 18

RESULT 85
AX131096/c
LOCUS AX131096 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 2314 from Patent WO0130362.
ACCESSION AX131096
VERSION AX131096.1 GI:14137401
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 2314 03-MAY-2001;
IMMUSOL, INC. (US)

FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin E ribozyme binding site"

AUTHORS Tournier-Lasserre,E., Joutel,A., Bousser,M.-G. and Bach,J.-F.
TITLE Gene involved in cadasil, method of diagnosis and therapeutic application
JOURNAL Patent: US 6537775-A 111 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGGTCTTCGAGCAG 708
Db 1 GTCCTGCTCTTCAAGCAG 18

RESULT 84
AX010849
LOCUS AX010849 19 bp DNA linear PAT 06-SEP-2000
DEFINITION Sequence 18 from Patent WO9958556.
ACCESSION AX010849
VERSION AX010849.1 GI:9997560
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE 1
AUTHORS Ballabio,A. and Casari,G.
TITLE Protein associated to hereditary spastic paraplegia
JOURNAL Patent: WO 9958556-A 18 18-NOV-1999;
FONDAZIONE TELETHON (IT); BALLABIO ANDREA (IT); CASARI GIORGIO (IT)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="oligonucleotide"

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 241 CCTCTGCTCCACCTCCC 258
Db 1 CCTCTGCTCACACTCC 18

RESULT 85
AX131096/c
LOCUS AX131096 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 2314 from Patent WO0130362.
ACCESSION AX131096
VERSION AX131096.1 GI:14137401
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 2314 03-MAY-2001;
IMMUSOL, INC. (US)

FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin E ribozyme binding site"

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 110 ACTTGTAACATGGACCC 127
Db 19 ACTTGTAACACGGAGCC 2

RESULT 86
AX804983
LOCUS AX804983 19 bp DNA linear PAT 25-NOV-2003
DEFINITION Sequence 1151 from Patent WO03060160.
ACCESSION AX804983
VERSION AX804983.1 GI:38522124
KEYWORDS Oreochromis niloticus (Nile tilapia)
SOURCE Oreochromis niloticus
ORGANISM Oreochromis niloticus

REFERENCE 1
AUTHORS Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
TITLE Verification of food origin based on nucleic acid pattern recognition
JOURNAL Patent: WO 03060160-A 1151 24-JUL-2003;
Genomar ASA (NO)

FEATURES
source 1..19
/organism="Oreochromis niloticus"
/mol_type="unassigned DNA"
/db_xref="taxon:8128"

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1272 GGGTGTGTTCTCGTCTC 1289
Db 1 GGGTGTCTTCTCGTCTC 18

RESULT 87
AX804986
LOCUS AX804986 19 bp DNA linear PAT 25-NOV-2003
DEFINITION Sequence 1154 from Patent WO03060160.
ACCESSION AX804986
VERSION AX804986.1 GI:38522127
KEYWORDS Oreochromis niloticus (Nile tilapia)
SOURCE Oreochromis niloticus
ORGANISM Oreochromis niloticus

REFERENCE 1
AUTHORS Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
TITLE Verification of food origin based on nucleic acid pattern recognition
JOURNAL Patent: WO 03060160-A 1154 24-JUL-2003;
Genomar ASA (NO)

FEATURES
source 1..19
/organism="Oreochromis niloticus"
/mol_type="unassigned DNA"
/db_xref="taxon:8128"

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1272 GGGTGTGTTCTCGTCTC 1289

[illegible]

TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6624 06-DEC-2001;
Aeomica, Inc. (US)

FEATURES
source 1..17
Location/Qualifiers

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAGG 36
|||||
Db 2 TCTGCGTCTGCATAGG 17
|||||

RESULT 93
LOCUS CQ621889
DEFINITION Sequence 6629 from Patent WO0192524.
ACCESSION CQ621889
VERSION CQ621889.1 GI:41672107
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6629 06-DEC-2001;
Aeomica, Inc. (US)

FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 25 CGTCTGCAGGACAG 40
|||||
Db 1 CGTCTGCATAGGACAG 16
|||||

RESULT 94
ARI88323/c
LOCUS ARI88323
DEFINITION Sequence 3811 from patent US 6346398.
ACCESSION ARI88323
VERSION ARI88323.1 GI:20234288
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 3811 12-FEB-2002;
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 GGACCCGACACATGGA 137
|||||
Db 17 GGACCCGACACATGGA 2
|||||

RESULT 95
ARI324176/c
LOCUS ARI324176
DEFINITION Sequence 1578 from patent US 6566127.
ACCESSION ARI324176
VERSION ARI324176.1 GI:33709984
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1578 20-MAY-2003;
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 GGACCCGACACATGGA 137
|||||
Db 17 GGACCCGACACATGGA 2
|||||

RESULT 96
ARI328722
LOCUS ARI328722
DEFINITION Sequence 6124 from patent US 6566127.
ACCESSION ARI328722
VERSION ARI328722.1 GI:33714530
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6124 20-MAY-2003;
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGGCGCCTCTGT 957
|||||
Db 2 CCGGGCGCCTCTGT 17
|||||

RESULT 97
ARI458616/c
LOCUS ARI458616
DEFINITION Sequence 2293 from patent US 6686188.
ACCESSION ARI458616
VERSION ARI458616.1 GI:42693673
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL
Patent: US 6686188-A 2296 03-FEB-2004;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred.No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CGGCTGTGGGCCAGGG 571
|||||
Db 17 CCGCTGTGGCCATGG 2

RESULT 98
AR458617/c
LOCUS AR458617 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2296 from patent US 6686188.
ACCESSION AR458617
VERSION AR458617.1 GI:42693674
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL
Patent: US 6686188-A 2294 03-FEB-2004;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred.No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CGGCTGTGGGCCAGGG 571
|||||
Db 16 CCGCTGTGGCCATGG 1

RESULT 99
AR458619/c
LOCUS AR458619 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2296 from patent US 6686188.
ACCESSION AR458619
VERSION AR458619.1 GI:42693676
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL
Patent: US 6686188-A 2296 03-FEB-2004;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred.No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CGGCTGTGGGCCAGGG 571
|||||
Db 16 CCGCTGTGGCCATGG 1

Best Local Similarity 93.8%; Pred. No. 1.3e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Qy	553	CTACGGCTGTGGGCCA	568						
Db	17	CTCGGGCTGTGGGCCA	2						
RESULT 100									
AR458620/c									
LOCUS	AR458620	Sequence 2297 from patent US 6686188.		17 bp	DNA	linear	PAT 20-FEB-2004		
DEFINITION	AR458620								
ACCESSION	AR458620								
VERSION	AR458620.1	GI:42693677							
KEYWORDS									
SOURCE	Unknown.								
ORGANISM	Unknown.								
REFERENCE	1 (bases 1 to 17)								
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
JOURNAL	Patent: US 6686188-A 2297 03-FEB-2004;								
FEATURES	Location/Qualifiers								
source	1. .17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match 0.9%; Score 14.4; DB 1; Length 17;									
Best Local Similarity 93.8%; Pred. No. 1.3e+02;									
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Qy	553	CTACGGCTGTGGGCCA	568						
Db	16	CTCGGGCTGTGGGCCA	1						
RESULT 101									
AR462947									
LOCUS	AR462947	Sequence 6624 from patent US 6686188.		17 bp	DNA	linear	PAT 20-FEB-2004		
DEFINITION	AR462947								
ACCESSION	AR462947								
VERSION	AR462947.1	GI:42698004							
KEYWORDS									
SOURCE	Unknown.								
ORGANISM	Unknown.								
REFERENCE	1 (bases 1 to 17)								
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
JOURNAL	Patent: US 6686188-A 6624 03-FEB-2004;								
FEATURES	Location/Qualifiers								
source	1. .17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match 0.9%; Score 14.4; DB 1; Length 17;									
Best Local Similarity 93.8%; Pred. No. 1.3e+02;									
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Qy	21	TCTGCGTCTGCAGAGG	36						
Db	2	TCTGCGTCTGCATAGG	17						
RESULT 102									
AR462952									
LOCUS	AR462952	Sequence 6629 from patent US 6686188.		17 bp	DNA	linear	PAT 20-FEB-2004		
DEFINITION	AR462952								
ACCESSION	AR462952								

VERSION AR462952.1 GI:42698009
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6629 03-FEB-2004;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 25 CGTCTGCAGGACAG 40
Db 1 CGTCTGCATAGGACAG 16
RESULT 103
AX217761
LOCUS AX217761 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3203 from Patent WO0159103.
ACCESSION AX217761
VERSION AX217761.1 GI:15527822
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 3203 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1064 TCTTGCCTTCTCTCCA 1079
Db 2 TCTTGCCTTCTCTCCA 17
RESULT 104
AX217762
LOCUS AX217762 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3204 from Patent WO0159103.
ACCESSION AX217762
VERSION AX217762.1 GI:15527823
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 3204 16-AUG-2001;

RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1064 TCTTGCCTTCTCTCCA 1079
Db 1 TCTTGCCTTCTCTCCA 16
RESULT 105
AX729077
LOCUS AX729077 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 711 from Patent WO03025175.
ACCESSION AX729077
VERSION AX729077.1 GI:30508420
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 711 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 887 ATGTGCCCAAGAACTT 902
Db 2 ATGTGCCCAAGAACTT 17
RESULT 106
BD175415
LOCUS BD175415 18 bp DNA linear PAT 18-MAR-2003
DEFINITION Secretory and transmembrane polypeptide and nucleic acid encoding the same.
ACCESSION BD175415
VERSION BD175415.1 GI:29121111
KEYWORDS JP 2002253280-A/197.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and Yuan, J.
TITLE Secretory and transmembrane polypeptide and nucleic acid encoding the same
JOURNAL Patent: JP 2002253280-A 197 10-SEP-2002;
COMMENT GENENTECH INC
OS Artificial Sequence
PN JP 2002253280-A/197
PD 10-SEP-2002
PF 18-DEC-2001 JP 2001385319

```

PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR
29-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/063735 PR
31-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR
07-NOV-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR
17-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR
21-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR
24-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09, A61K45/00, A61P1/00, A61P13/12, A61P17/00, A61P17/06, PC
A61P25/00,
PC A61P25/16, A61P25/28, A61P31/12, A61P35/00, C07K14/47, C07K16/18,
PC C07K19/00,
PC C12N1/19, C12N1/21, C12N5/10//A61K38/00, A61K39/395, A61K39/395,
PC A61P43/00,
PC C12P21/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19), (C12N5/10,
PC C12R1:91),
PC C12N15/00, C12N5/00, A61K37/02, (C12N5/00, C12R1:91) CC
Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1. .18
/organism='Artificial Sequence'.
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1467 CAGCCCTGTACTGCCAG 1482
|||||
Db 3 CAGCATGTACTGCCAG 18
|||||

RESULT 107
BD224907
LOCUS 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Antisense modulation of expression of tumor necrosis factor
receptor-associated factor (TRAF).
ACCESSION BD224907
VERSION BD224907.1 GI:33034677
KEYWORDS JP 2002526095-A/42.
SOURCE synthetic construct
ORGANISM artificial sequences.
1 (bases 1 to 18)
REFERENCE Baker, B.F., Cowsett, L.M., Monia, B.P. and Xu, X.S.
AUTHORS Antisense modulation of expression of tumor necrosis factor
TITLE receptor-associated factor (TRAF)
JOURNAL Patent: JP 2002526095-A 42 20-AUG-2002;
ISIS PHARMACEUTICALS INC

```

```

COMMENT OS Artificial Sequence
PN JP 2002526095-A/42
PD 20-AUG-2002
PR 05-OCT-1999 JP 2000574546
PR 06-OCT-1998 US 09/167109
PI BRENDA F BAKER, LEX M COWSERT, BRETT P MONIA, XIAOXING S XU PC
C12N15/09, A61K31/7105, A61K48/00, A61P29/00, A61P35/04, C12N15/00 CC
antisense sequence
FH Key Location/Qualifiers
FT source 1. .18
/organism='Artificial Sequence'.
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1269 GCTGGGTGTGCTCTCG 1284
|||||
Db 3 GCTGGGTGTGCTCTCG 18
|||||

RESULT 108
BD224994/c
LOCUS 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Antisense modulation of expression of tumor necrosis factor
receptor-associated factor (TRAF).
ACCESSION BD224994
VERSION BD224994.1 GI:33034764
KEYWORDS JP 2002526095-A/129.
SOURCE synthetic construct
ORGANISM artificial sequences.
1 (bases 1 to 18)
REFERENCE Baker, B.F., Cowsett, L.M., Monia, B.P. and Xu, X.S.
AUTHORS Antisense modulation of expression of tumor necrosis factor
TITLE receptor-associated factor (TRAF)
JOURNAL Patent: JP 2002526095-A 129 20-AUG-2002;
ISIS PHARMACEUTICALS INC
COMMENT OS Artificial Sequence
PN JP 2002526095-A/129
PD 20-AUG-2002
PR 05-OCT-1999 JP 2000574546
PR 06-OCT-1998 US 09/167109
PI BRENDA F BAKER, LEX M COWSERT, BRETT P MONIA, XIAOXING S XU PC
C12N15/09, A61K31/7105, A61K48/00, A61P29/00, A61P35/04, C12N15/00 CC
antisense sequence
FH Key Location/Qualifiers
FT source 1. .18
/organism='Artificial Sequence'.
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 621 CGCCCTGTGCTCTGC 636
|||||
Db 17 CGCCCTGTGCTCTGC 2
|||||

RESULT 109
AR188967
LOCUS 18 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4455 from patent US 6346398.

```

ACCESSION AR189967
VERSION AR189967.1 GI:20234932
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4455 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGGCGGCTCTGTG 958
Db 1 CCGGGCGGCTCTGTG 16

RESULT 110
LOCUS AR211129 18 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 42 from patent US 6399297.
ACCESSION AR211129
VERSION AR211129.1 GI:21514369
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F., Cowsert,L.M., Monia,B.P. and Xu,X.S.
TITLE Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)
JOURNAL Patent: US 6399297-A 42 04-JUN-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1269 GCTGGGTGTCTCTG 1284
Db 3 GCTGGGTGTCTCTG 18

RESULT 111
LOCUS AR211216/c 18 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 129 from patent US 6399297.
ACCESSION AR211216
VERSION AR211216.1 GI:21514479
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F., Cowsert,L.M., Monia,B.P. and Xu,X.S.
TITLE Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)
JOURNAL Patent: US 6399297-A 129 04-JUN-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 621 CGCCGTGGTCTCTGC 636
Db 17 CGCCCTGGTCTCTGC 2

RESULT 112
LOCUS AR324766 18 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2168 from patent US 6566127.
ACCESSION AR324766
VERSION AR324766.1 GI:33710574
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2168 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGGCGGCTCTGTG 958
Db 1 CCGGGCGGCTCTGTG 16

RESULT 113
LOCUS AX599746/c 18 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 1086 from Patent WO2077272.
ACCESSION AX599746
VERSION AX599746.1 GI:28399894
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J., Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E., Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T., Pelet,C. and Ziebarth,H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell proliferative disorders
JOURNAL Patent: WO 02077272-A 1086 03-OCT-2002;
FEATURES Epigenomics AG (DE)
source Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for CSF1"

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 244 CTGCCCCACCTCC 259
Db 17 CTGCCCCACCTCC 2

```
RESULT 114
BD075564
LOCUS
DEFINITION
  BD075564 18 bp DNA linear PAT 27-AUG-2002
  Secretory and transmembrane polypeptide and nucleic acid encoding
  the same.
ACCESSION
BD075564.1 GI:22621167
VERSION
JP 2001516580-A/197.
KEYWORDS
  synthetic construct
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  1 (bases 1 to 18)
REFERENCE
  Wood,W.I., Gurney,A.L., Goddard,A., Penica,D., Chen,J. and Yuan,J.
  Secretory and transmembrane polypeptide and nucleic acid encoding
  the same
  Patent: JP 2001516580-A 197 02-OCT-2001;
  GENENTECH INC
JOURNAL
OS Artificial Sequence
COMMENT
  PN JP 2001516580-A/197
  PD 02-OCT-2001
  PF 16-SEP-1998 JP 2000511867
  PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
  17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
  17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
  18-SEP-1997 US 60/059266,15-OCT-1997 US 60/059263 PR
  18-SEP-1997 US 60/062287,17-OCT-1997 US 60/062125 PR
  21-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
  21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
  24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
  24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
  24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
  27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
  28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
  28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
  28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
  29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
  29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
  29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
  29-OCT-1997 US 60/064103,31-OCT-1997 US 60/063870 PR
  03-NOV-1997 US 60/064248,07-NOV-1997 US 60/064809 PR
  12-NOV-1997 US 60/065186,17-NOV-1997 US 60/065846 PR
  18-NOV-1997 US 60/065933,21-NOV-1997 US 60/066120 PR
  21-NOV-1997 US 60/066364,24-NOV-1997 US 60/066772 PR
  24-NOV-1997 US 60/066466,24-NOV-1997 US 60/066770 PR
  24-NOV-1997 US 60/066511,24-NOV-1997 US 60/066453 PR
  25-NOV-1997 US 60/066840
  PI WILLIAM I WOOD,AUSTIN L GURNEY,AUDLEY GODDARD,DIANE PENICA, PI
  JEAN CHEN,
  PI JEAN YUAN
  PC C12N15/09,C07K14/47,C07K16/18,C07K16/28,C07K19/00,
  PC C12N1/19,
  PC C12N1/21,C12N5/10,C12P21/02,C12P21/08,C12Q1/02/(C12P21/08, PC
  C12R1:91),
  PC C12N15/00,C12N5/00
  CC Description of Artificial Sequence: Synthetic FH Key
  Location/Qualifiers
  FT source 1..18
  FT Location/Qualifiers
  FT /organism='Artificial Sequence'.
  FEATURES
  source
  1..18
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"
  Query Match 0.9%; Score 14.4; DB 1; Length 18;
  Best Local Similarity 93.8%; Pred. No. 1.5e+02;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
  QY 1467 CAGCCTGTACTGCCAG 1482
  |||||
  Db 3 CAGCATGTACTGCCAG 18
```

```
RESULT 115
BD172424
LOCUS
DEFINITION
  BD172424 18 bp DNA linear PAT 18-FEB-2003
  Secreted and transmembrane polypeptides and nucleic acid encoding
  the same.
ACCESSION
BD172424.1 GI:28413724
VERSION
JP 2002223786-A/197.
KEYWORDS
  synthetic construct
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  1 (bases 1 to 18)
REFERENCE
  Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
  Yuan,J.
  Secreted and transmembrane polypeptides and nucleic acids encoding
  the same
  Patent: JP 2002223786-A 197 13-AUG-2002;
  GENENTECH INC
JOURNAL
OS Artificial Sequence
COMMENT
  PN JP 2002223786-A/197
  PD 13-AUG-2002
  PF 18-DEC-2001 JP 2001385135
  PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
  17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
  17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
  18-SEP-1997 US 60/059266,15-OCT-1997 US 60/059263 PR
  18-SEP-1997 US 60/062287,17-OCT-1997 US 60/062125 PR
  21-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
  21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
  24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
  24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
  24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
  27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
  28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
  28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
  28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
  29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
  29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
  29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
  29-OCT-1997 US 60/064103,31-OCT-1997 US 60/063870 PR
  31-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
  31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
  07-NOV-1997 US 60/064809,12-NOV-1997 US 60/065846 PR
  17-NOV-1997 US 60/065933,21-NOV-1997 US 60/066120 PR
  21-NOV-1997 US 60/066364,24-NOV-1997 US 60/066772 PR
  24-NOV-1997 US 60/066466,24-NOV-1997 US 60/066770 PR
  24-NOV-1997 US 60/066511,24-NOV-1997 US 60/066453 PR
  24-NOV-1997 US 60/066840
  PI WILLIAM I WOOD,AUSTIN L GURNEY,AUDLEY GODDARD,DIANE PENNICA, PI
  JIAN ZHENG,
  PI JEAN YUAN
  PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
  C12N5/10,
  PC C12P21/02/(C12P21/08,C12P21/02,C12R1:19), (C12P21/02,C12R1:91), PC
  (C12P21/02,C12R1:645),C12N15/00,C12N5/00
  CC Description of Artificial Sequence: Synthetic FH Key
  Location/Qualifiers
  FT source 1..18
  FT Location/Qualifiers
  FT /organism='Artificial Sequence'.
  FEATURES
  source
  1..18
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"
  Query Match 0.9%; Score 14.4; DB 1; Length 18;
  Best Local Similarity 93.8%; Pred. No. 1.5e+02;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
  QY 1467 CAGCCTGTACTGCCAG 1482
  |||||
  Db 3 CAGCATGTACTGCCAG 18
```

```

RESULT 116
BD172743
LOCUS
DEFINITION
    Secretd and transmembrane polypeptides and nucleic acids encoding
    the same.
ACCESSION
BD172743
VERSION
BD172743.1 GI:28414047
KEYWORDS
JP 2002238586-A/197.
SOURCE
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1 (bases 1 to 18)
AUTHORS
Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J.
TITLE
Secretd and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL
Patent: JP 2002238586-A 197 27-AUG-2002;
COMMENT
OS Artificial Sequence
PN JP 2002238586-A/197
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385205
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059121,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063542 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/064103 PR
29-OCT-1997 US 60/063870,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063732,31-OCT-1997 US 60/064248 PR
17-NOV-1997 US 60/066120,21-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/065693 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02,C12P21/08,(C12N1/19,C12R1/91),(C12N1/21,C12R1/19),
(C12N5/10,C12R1/91),(C12P21/02,C12R1/91),(C12P21/02,C12R1/91), PC
(C12P21/02,C12R1/19),(C12P21/08,C12R1/91),C12N15/00,C12N5/00, PC
(C12N5/00,C12R1/91)
CC Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source
FT source 1..18
Location/Qualifiers
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
|||||
Db 3 CAGCATGTACTGCCAG 18
|||||

RESULT 117
BD173062
LOCUS
DEFINITION
    Secretd and transmembrane polypeptides and nucleic acids encoding
    the same.
ACCESSION
BD173062
VERSION
BD173062.1 GI:28414368
KEYWORDS
JP 2002238587-A/197.
SOURCE
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1 (bases 1 to 18)
AUTHORS
Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J.
TITLE
Secretd and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL
Patent: JP 2002238587-A 197 27-AUG-2002;
COMMENT
OS Artificial Sequence
PN JP 2002238587-A/197
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385248
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059121,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059119,18-SEP-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063542 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/064103 PR
29-OCT-1997 US 60/063870,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063732,31-OCT-1997 US 60/064248 PR
17-NOV-1997 US 60/066120,21-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/065693 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02,C12P21/08,(C12N1/19,C12R1/91),(C12N1/21,C12R1/19),
(C12N5/10,C12R1/91),(C12P21/02,C12R1/91),(C12P21/02,C12R1/91), PC
(C12P21/02,C12R1/19),(C12P21/08,C12R1/91),C12N15/00,C12N5/00, PC
(C12N5/00,C12R1/91)
CC Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source
FT source 1..18
Location/Qualifiers
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```


QY 1467 CAGCCTGTACTGCCAG 1482
Db 3 CAGCATGTACTGCCAG 18

RESULT 118
BD173381
LOCUS
DEFINITION
Secreted and transmembrane polypeptides and nucleic acids encoding the same.
ACCESSION
BD173381.1 GI:28414692
VERSION
JP 2002238588-A/197.
KEYWORDS
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1 (bases 1 to 18)
AUTHORS
Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and Yuan,J.
TITLE
Secreted and transmembrane polypeptides and nucleic acids encoding the same
JOURNAL
Patent: JP 2002238588-A 197 27-AUG-2002;
COMMENT
GENENTECH INC
OS Artificial Sequence
FN JP 2002238588-A/197
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385315
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063124,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 FI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/435,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10
PC C12P21/02//C12P21/08,(C12N1/19,C12R1:645),(C12N1/21,C12R1:19),
PC (C12N5/10,C12R1:91),C12N15/00,C12N5/00,(C12N5/00,C12R1:91) CC
Description of Artificial Sequence: Synthetic Key
Location/Qualifiers
FT source 1. 18
/organism='Artificial Sequence'.
FEATURES
source
1. 18
Location/Qualifiers
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
Db 3 CAGCATGTACTGCCAG 18

RESULT 119
AX132345/C
LOCUS
DEFINITION
Sequence 3563 from Patent WO0130362.
ACCESSION
AX132345
VERSION
AX132345.1 GI:14138650
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
REFERENCE
1
AUTHORS
Robbins,J.M. and Tritz,R.
TITLE
Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL
Patent: WO 0130362-A 3563 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source
1. 19
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'
/note='Cdc25 hs ribozyme binding site'

Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 893 CCAAGAACTTTGCCCA 908
Db 16 CCAAGAAATTTGCCCA 1

RESULT 120
AX587022
LOCUS
DEFINITION
Sequence 44 from Patent WO02072883.
ACCESSION
AX587022
VERSION
AX587022.1 GI:27655897
KEYWORDS
Actinomycetes odontolyticus
SOURCE
Actinomycetes odontolyticus
ORGANISM
Actinomycetes odontolyticus
Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
Actinomycineae; Actinomycetaceae; Actinomycetes.
REFERENCE
1
AUTHORS
Roetger,A.
TITLE
Nucleotide carrier for diagnosing and treating oral diseases
JOURNAL
Patent: WO 02072883-A 44 19-SEP-2002;
ROETGER, Antje (DE)
FEATURES
Location/Qualifiers
source
1. 15
/organism='Actinomycetes odontolyticus'
/mol_type='unassigned DNA'
/db_xref='taxon:1660'

Query Match 0.9%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1493 CACGGCGGCACTGC 1506
Db 1 CACGGCGGCACTGC 14

RESULT 121
BD200566/C
LOCUS
BD200566

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.

ACCESSION BD200566

VERSION BD200566.1 GI:33010336

KEYWORDS JP 2002509721-A/3592.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.

TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response

JOURNAL Patent: JP 2002509721-A 3592 02-APR-2002;

COMMENT RIBOZYME PHARMACEUTICALS INC

OS Homo sapiens (human)

PN JP 2002509721-A/3592

PD 02-APR-2002

PF 27-MAR-1999 JP 2000541291

PR 24-MAR-1998 US 60/079678

PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,

PI JAMES A MCSWIGGEN

PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,

PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00

CC Method and reagent for treating diseases or conditions CC concerning molecule

CC participating in vasculogenic response

FH Key Location/Qualifiers

FT source 1..17

FT /organism='Homo sapiens (human)'. .

FEATURES

source 1..17

/organism="Homo sapiens"

/mol_type="genomic RNA"

/db_xref="taxon:9606"

Query Match 0.9%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 GGGAGGGGAGCGGG 61

|||||

Db 16 GGGAGGGGAGCGGG 3

RESULT 122

AR328723

LOCUS AR328723

DEFINITION Sequence 6125 from patent US 6566127.

ACCESSION AR328723

VERSION AR328723.1 GI:33714531

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 6125 20-MAY-2003;

FEATURES

Location/Qualifiers

source 1..17

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.9%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 GGGAGGGGAGCGGG 61

|||||

Db 16 GGGAGGGGAGCGGG 3

RESULT 122

AR328723

LOCUS AR328723

DEFINITION Sequence 6125 from patent US 6566127.

ACCESSION AR328723

VERSION AR328723.1 GI:33714531

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 6125 20-MAY-2003;

FEATURES

Location/Qualifiers

source 1..17

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.9%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCGCCCTCTGTG 958

Db 2 GGGCGCCCTCTGTG 15

|||||

RESULT 123

AR328724

LOCUS AR328724

DEFINITION Sequence 6126 from patent US 6566127.

ACCESSION AR328724

VERSION AR328724.1 GI:33714532

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 6126 20-MAY-2003;

FEATURES

Location/Qualifiers

source 1..17

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.9%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCGCCCTCTGTG 958

|||||

Db 1 GGGCGCCCTCTGTG 14

RESULT 124

ARX750950

LOCUS ARX750950

DEFINITION Sequence 166 from Patent WO03033703.

ACCESSION ARX750950

VERSION ARX750950.1 GI:32133278

KEYWORDS .

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Zhang,J.

TITLE Human gtp-activator protein for rab-like gtpase

JOURNAL Patent: WO 03033703-A 166 24-APR-2003;

Amersham Biosciences (SV) Corp. (US)

FEATURES

Location/Qualifiers

source 1..17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.9%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 TTTCTCCAGCTACC 814

|||||

Db 4 TTTCTCCAGCTACC 17

RESULT 125

AX750954

LOCUS AX750954

DEFINITION Sequence 170 from Patent WO03033703.

ACCESSION AX750954

VERSION AX750954.1 GI:32133282

KEYWORDS .

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1
Zhang, J.
Human gtp-activator protein for rab-like gtpase
Patent: WO 03033703-A 170 24-APR-2003;
Amersham Biosciences (SV) Corp. (US)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 802 TTCTCCAGCTACT 815
Db 1 TTCTCCAGCTACT 14

RESULT 126
LOCUS I69013 18 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 283 from patent US 5677149.
ACCESSION I69013
VERSION I69013.1 GI:2831135
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE
1 (bases 1 to 18)
AUTHORS Bauer, S.C., Christopher., Abrams, M.Allen., Braford-Goldberg, S.Ruth., Caparon, M.Helena., Easton, A.Michael., Klein, B.Kure., McKearn, J.Patrick., Olin, P., Paik, K., Polazzi, J. and Thomas, J.Warren.
TITLE Interleukin-3 (IL-3) mutant polypeptides and their recombinant production
JOURNAL Patent: US 5677149-A 283 14-OCT-1997;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 ATCTTGGTCTCTGCC 1561
Db 1 ATCTTGGTCTCTGCC 14

RESULT 127
LOCUS AR253611 18 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 283 from patent US 6479261.
ACCESSION AR253611
VERSION AR253611.1 GI:27302039
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE
1 (bases 1 to 18)
AUTHORS Bauer, S.C., Abrams, M.A., Braford-Goldberg, S.R., Caparon, M.H., Easton, A.M., Klein, B.K., McKearn, J.P., Olin, P., Paik, K., Polazzi, J. and Thomas, J.W.
TITLE Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells
JOURNAL Patent: US 6479261-A 283 12-NOV-2002;
FEATURES
source
1. .18
Location/Qualifiers

/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 ATCTTGGTCTCTGCC 1561
Db 1 ATCTTGGTCTCTGCC 14

RESULT 128
LOCUS AX696666 18 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 283 from Patent EPI283264.
ACCESSION AX696666
VERSION AX696666.1 GI:29419776
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE
1
AUTHORS Bauer, S.C., Abrams, M.A., Braford-Goldberg, S.R., Caparon, M.H., Easton, A.M., Klein, B.K., McKearn, J.P., Olin, P., Paik, K., Polazzi, J.O. and Thomas, J.W.
TITLE Interleukin-3 (il-3) mutant polypeptides
JOURNAL Patent: EP 1283264-A 283 12-FEB-2003;
G.D. SEARLE & CO. (US)
FEATURES
source
1. .18
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:33644"

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 ATCTTGGTCTCTGCC 1561
Db 1 ATCTTGGTCTCTGCC 14

RESULT 129
LOCUS AR016864/c 17 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 97 from patent US 5777200.
ACCESSION AR016864
VERSION AR016864.1 GI:3973141
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE
1 (bases 1 to 17)
AUTHORS Ryals, J.A., Alexander, D.C., Goodman, R.M. and Stinson, J.R.
TITLE Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
JOURNAL Patent: US 5777200-A 97 07-JUL-1998;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCTCTGGGTTTC 1332
Db 17 GCTTCGTCTCTGGGTTTC 1

```
RESULT 130
AR020890/c
LOCUS           17 bp      DNA      linear      PAT 05-DEC-1998
DEFINITION      Sequence 97 from patent US 5789214.
ACCESSION       AR020890
VERSION         AR020890.1 GI:3975505
KEYWORDS        .
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Ryals,J.A., Friedrich,L.B., Uknes,S.J. and Ward,E.R.
TITLE          Method of inducing gene transcription in a plant
JOURNAL        Patent: US 5789214-A 97 04-AUG-1998;
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 131
AR027213/c
LOCUS           17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 97 from patent US 5856154.
ACCESSION       AR027213
VERSION         AR027213.1 GI:5938053
KEYWORDS        .
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Ryals,J.A., Alexander,D.C., Goodman,R.M. and Ward,E.R.
TITLE          Method of protecting plants from oomycete pathogens
JOURNAL        Patent: US 5856154-A 97 05-JAN-1999;
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 132
AR038500/c
LOCUS           17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 97 from patent US 5804693.
ACCESSION       AR038500
VERSION         AR038500.1 GI:5957217
KEYWORDS        .
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Gaffney,T.D., Ryals,J.A., Friedrich,L.B., Uknes,S.J., Ward,E.R.,
TITLE          Kessmann,H. and Vernooij,B.T.
JOURNAL        Chemically regulatable and anti-pathogenic DNA sequences and uses
FEATURES       thereof
               Patent: US 5804693-A 97 08-SEP-1998;
               Location/Qualifiers
               source
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 133
AR067567/c
LOCUS           17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 97 from patent US 5851766.
ACCESSION       AR067567
VERSION         AR067567.1 GI:5998789
KEYWORDS        .
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Ryals,J.A. and Harms,C.
TITLE          Process for isolating chemically regulatable DNA sequences
JOURNAL        Patent: US 5851766-A 97 22-DEC-1998;
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 134
AR067567/c
LOCUS           17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 97 from patent US 5851766.
ACCESSION       AR067567
VERSION         AR067567.1 GI:5998789
KEYWORDS        .
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Ryals,J.A. and Harms,C.
TITLE          Process for isolating chemically regulatable DNA sequences
JOURNAL        Patent: US 5851766-A 97 22-DEC-1998;
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 135
BD199056/c
LOCUS           17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION      Method and reagent for treating diseases or conditions concerning
```

```
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 133
AR064642/c
LOCUS           17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 97 from patent US 5847258.
ACCESSION       AR064642
VERSION         AR064642.1 GI:5993950
KEYWORDS        .
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Ryals,J.A., Moyer,M.B., Payne,G.B. and Ward,E.R.
TITLE          DNA encoding .beta.-1,3-glucanases
JOURNAL        Patent: US 5847258-A 97 08-DEC-1998;
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 134
AR067567/c
LOCUS           17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 97 from patent US 5851766.
ACCESSION       AR067567
VERSION         AR067567.1 GI:5998789
KEYWORDS        .
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Ryals,J.A. and Harms,C.
TITLE          Process for isolating chemically regulatable DNA sequences
JOURNAL        Patent: US 5851766-A 97 22-DEC-1998;
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1
RESULT 135
BD199056/c
LOCUS           17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION      Method and reagent for treating diseases or conditions concerning
```

molecule participating in vasculogenic response.

ACCESSION	BD190056
VERSION	BD190056.1
KEYWORDS	GI.33008826
SOURCE	JP 2002509721-A/2082.
ORGANISM	Homo sapiens (human)
REFERENCE	Homo sapiens
AUTHORS	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
TITLE	Mammalia; Euthera; Primates; Catarrhini; Hominiidae; Homo.
JOURNAL	1 (bases 1 to 17)
COMMENT	Pavco, P.A., Roberts, E., Jarvis, T., Coeshott, C. and Mcswiggen, J.A. Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response Patent: JP 2002509721-A 2082 02-APR-2002; RIBOZYME PHARMACEUTICALS INC QS Homo sapiens (human) PN JP 2002509721-A/2082 PD 02-APR-2002 PF 24-MAR-1999 JP 2000541291 PR 27-MAR-1998 US 60/079678 PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT, PI JAMES A MCSWIGGEN PC

PC	C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06,PC
	A61P29/00,
PC	A61P35/00,A61P43/00.C12N5/10,C12N9/00//A61K35/76,C12N15/00,PC
	C12N5/00
CC	Method and reagent for treating diseases or conditions CC
	concerning molecule
CC	participating in vasculogenic response
FH	Key Location/Qualifiers
FT	source 1..17
FT	/organism='Homo sapiens (human)'. Location/Qualifiers
FEATURES	

FEATURES
SOURCE

Query Match	0.98;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 1.7e+02;		
Matches 15;	Conservative	0;	Mismatches 2;	Indels 0; Gaps 0;
QY	176	AACTGAGGGAGCTGCTG	192	
Db	17	AACTGAAGGAGCTGCTG	1	

RESULT	136
LOCUS	BD254698
DEFINITION	BD254698
ACCESSION	Regulation of repressor genes using nucleic acid molecules.
VERSION	BD254698.1 GI:33064468
KEYWORDS	JP 2002541795-A/2491.
SOURCE	unidentified
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Blatt, L., Zwick, M., Pavco, P. and Meswiggen, J.
TITLE	Regulation of repressor genes using nucleic acid molecules
JOURNAL	Patent: JP 2002541795-A 2491 10-DEC-2002;

COMMENT	OS	Eukaryote	ALBIZIMEX PHARMACEUTICALS INC.
	PN	JP 2002541795--A/2491	
	PD	10-DEC-2002	
	PF	11-APR-2000 JP 2000611654	
	PR	12-APR-1999 US 60/123390	
	PI	LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN	PC
		C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC	
		C12P21/02,	
	PC		
		C12P21/02, C12P21/02//A61K31/711, C12N5/10, C12R1:91), C12P21/02, PC	
		C12R1:91),	

PC	(C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
EC	A61K37/02,
PC	(C12N5/00, C12R1:91)
CC	Regulation of repressor genes using nucleic acid molecules FH
Key	Location/Qualifiers
FT	1..17
FT	source
FT	/organism='Eukaryote'.

FEATURES
SOURCE

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15: Conservative 0; Mismatches 2; Indels

Qy 976 ATGAGCCGAGAGCCCCCTT 992
| | | | | | | | | |
Dβ 1 AAGAGCCTAGAGCCCCCTT 17

RESULT 137

AB024113.7	BD254884	17 bp	DNA	linear	PAT 17-JUL-2003			
LOCUS	Regulation of repressor genes using nucleic acid molecules.							
DEFINITION	BD254884							
ACCESSION	BD254884							
VERSION	BD254884.1	GI:33064654						
KEYWORDS	JP 2002541795-A/2677.							
SOURCE	unidentified							
ORGANISM	unidentified							
	unclassified.							

REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				
61				
62				
63				
64				
65				
66				
67				
68				
69				
70				
71				
72				
73				
74				
75				
76				
77				
78				
79				
80				
81				
82				
83				
84				
85				
86				
87				
88				
89				
90				
91				
92				
93				
94				
95				
96				
97				
98				
99				
100				

DN	JP 2002541795-A/2677
PD	10-DEC-2002
PF	11-APR-2000 JP 2000611654
PP	12-APR-1999 US 60/129390
PI	LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWITIGEN PC
C1	C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12	P21/02,
PC	C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
	C12R1:91),
PC	C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC	A61K37/02,
PC	(C12N5/00, C12R1:91)
CC	Regulation of repressor genes using nucleic acid molecules FH
Key	Location/Qualifiers
FT	source
FT	1. .17
FT	/organisms='Eukaryote'.

FEATURES

Query Match 0.9%; Score 13.8; DB 1;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels

Qy 1063 TTCTTTGCCTTCTCTCCA 1079
|||||
Db 17 TTCTTTGCTATCTCTCCA 1

PRECEDENT 138

	BD259384	DNA	linear	PAT	17-JUL-2003
LOCUS	BD259384	17 bp			
RESULT_138					

DEFINITION Regulation of repressor genes using nucleic acid molecules.

ACCESSION BD259384
VERSION BD259384.1 GI:33069154
KEYWORDS JP 2002541795-A/7177.
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A/7177 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/7177
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC

C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
CC Regulation of repressor genes using nucleic acid molecules FH
Key source 1..17
FT Location/Qualifiers
FT source 1..17

FEATURES
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 514 CCATGTTTCTGTCCAC 530
|||||
Db 1 CCAAGCTTCTGTCCAC 17

RESULT 139
BD259385
LOCUS 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD259385
VERSION BD259385.1 GI:33069155
KEYWORDS JP 2002541795-A/7178.
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A/7178 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/7178
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC

C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC

PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key source 1..17
FT Location/Qualifiers
FT source 1..17
/organism="Eukaryote".
FEATURES
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 515 CCATGTTTCTGTCCACC 531
|||||
Db 1 CCAAGCTTCTGTCCACC 17

RESULT 140
CO616191
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 931 from Patent WO0192524.
ACCESSION CO616191
VERSION CO616191.1 GI:41666409
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 931 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGAGAGAGGCTGTGCC 755
|||||
Db 1 CTGAAGAGGCTGTGCC 17

RESULT 141
CO616796
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1536 from Patent WO0192524.
ACCESSION CO616796
VERSION CO616796.1 GI:416667014
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens

REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1536 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

```
/db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGCTGGTGCACCTGG 510
      ||| ||||| ||||| |||||
Db 1 TGGGGCTGTGGCCCTGG 17

RESULT 142
CQ616907/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 1647 from Patent WO0192524.
ACCESSION  CQ616907
VERSION     CQ616907.1 GI:41667125
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 1647 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTTCTTTGCTTCCTCC 1078
      ||| ||||| ||||| |||||
Db 17 CTTCTTTGCTTCCTCC 1

RESULT 143
CQ617550/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 2290 from Patent WO0192524.
ACCESSION  CQ617550
VERSION     CQ617550.1 GI:41667768
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 2290 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 559 CTGTGGGCCAGGGCAC 575
      ||| ||||| ||||| |||||
Db 17 CTGTGGGCCATGGAC 1

RESULT 144
CQ617551/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 2291 from Patent WO0192524.
ACCESSION  CQ617551
VERSION     CQ617551.1 GI:41667769
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 2291 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 GCTGTGGCCAGGGCA 574
      ||| ||||| ||||| |||||
Db 17 GCTGTGGCCATGGACA 1

RESULT 145
CQ617552/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 2292 from Patent WO0192524.
ACCESSION  CQ617552
VERSION     CQ617552.1 GI:41667770
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 2292 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 557 GGCTGTGGCCAGGGGC 573
      ||| ||||| ||||| |||||
Db 17 GGCTGTGGCCATGGAC 1

RESULT 146
CQ617555/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 2295 from Patent WO0192524.
ACCESSION  CQ617555
VERSION     CQ617555.1 GI:41667773
KEYWORDS
```

```
SOURCE      Homo sapiens (human)
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 2295 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 554 TACGGCTGTGGCCAGG 570
Db      |||||
        TCGGCTGTGGCCATG 1

RESULT 147
CQ617558/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 2298 from Patent WO0192524.
ACCESSION  CQ617558
VERSION     CQ617558.1 GI:41667776
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 2298 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 551 CCCTACGGCTGTGGGCC 567
Db      |||||
        CACTGCGGCTGTGGCC 1

RESULT 148
CQ617559/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 2299 from Patent WO0192524.
ACCESSION  CQ617559
VERSION     CQ617559.1 GI:41667777
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 2299 06-DEC-2001;
```

```
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 GCCTACGGCTGTGGGC 566
Db      |||||
        GCACGTGCGGCTGTGGC 1

RESULT 149
CQ617560/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 2300 from Patent WO0192524.
ACCESSION  CQ617560
VERSION     CQ617560.1 GI:41667778
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 2300 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 GCCCTACGGCTGTGGG 565
Db      |||||
        GGCACGTGCGGCTGTGGG 1

RESULT 150
CQ622176/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 6916 from Patent WO0192524.
ACCESSION  CQ622176
VERSION     CQ622176.1 GI:41672394
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 6916 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 GCCCTACGGCTGTGGG 565
Db      |||||
        GGCACGTGCGGCTGTGGG 1
```


Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 CCTGGGAAACAGAAAG 307
|||||
Db 17 CCTGGGAGACAGAAAG 1

RESULT 151
CQ624284/c
LOCUS
DEFINITION
SEQUENCE 9024 from Patent WO0192524.
ACCESSION
VERSION
CQ624284.1 GI:41674502
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM

REFERENCE
AUTHORS
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE
Myosin-like gene expressed in human heart and muscle
JOURNAL
Patent: WO 0192524-A 9024 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 CTCACGTCCTCTCCA 1165
|||||
Db 17 CTCACGTCCTCTCCA 1

RESULT 152
CQ625933/c
LOCUS
DEFINITION
SEQUENCE 10673 from Patent WO0192524.
ACCESSION
VERSION
CQ625933.1 GI:41676151
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM

REFERENCE
AUTHORS
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE
Myosin-like gene expressed in human heart and muscle
JOURNAL
Patent: WO 0192524-A 10673 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 GGTAGCCATGCTGGGTG 1276
|||||
Db 17 GGTAGCCATGCTGGGTG 1

RESULT 153
CQ625934/c

LOCUS
DEFINITION
SEQUENCE 10674 from Patent WO0192524.
ACCESSION
VERSION
CQ625934.1 GI:41676152
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM

REFERENCE
AUTHORS
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE
Myosin-like gene expressed in human heart and muscle
JOURNAL
Patent: WO 0192524-A 10674 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 GGGTAGCCATGCTGGGT 1275
|||||
Db 17 GGGTAGCCATGCTGGGT 1

RESULT 154
I14228/c
LOCUS
DEFINITION
SEQUENCE 25 from patent US 5447839.
ACCESSION
VERSION
I14228.1 GI:997243
KEYWORDS
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
AUTHORS
Manos, M. Michele., Bauer, H.M., Greer, C.E., Resnick, R.M. and Ting, Y.
TITLE
Detection of human papillomavirus by the polymerase chain reaction
JOURNAL
Patent: US 5447839-A 25 05-SEP-1995;
FEATURES
Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 252 ACCTCCCCCAGGTTCTT 268
|||||
Db 17 ACCTCCCCCAGGTTCTT 1

RESULT 155
I22686/c
LOCUS
DEFINITION
SEQUENCE 174 from patent US 5527898.
ACCESSION
VERSION
I22686.1 GI:1603040
KEYWORDS
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
AUTHORS
Bauer, H.M., Gravitt, P.E., Greer, C.E., Manos, M. Michele., Resnick, R.M. and Zhang, T.Y.
TITLE
Detection of human papillomavirus by the polymerase chain reaction
JOURNAL
Patent: US 5527898-A 174 18-JUN-1996;

```
FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 252 ACCTCCCCAGGTTCTCT 268
Db 17 ACCTCCCTCAGGTTCTT 1

RESULT 156
I38519/c
LOCUS      138519          17 bp      DNA      linear      PAT 13-MAY-1997
DEFINITION Sequence 97 from patent US 5614395.
ACCESSION  I38519
VERSION     I38519.1  GI:2084573
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Ryals,J.A., Alexander,D.C., Beck,J.J., Duesing,J.H., Goodman,R.M.,
          Friedrich,L.B., Harms,C., Meins,F. Jr., Montoya,A. deceased,
          Moyer,M.B., Neuhaus,J.-M., Payne,G.B., Sperisen,C., Stinson,J.R.,
          Uknes,S.J., Ward,E.R. and Williams,S.C.
          Chemically regulatable and anti-pathogenic DNA sequences and uses
          thereof
          Patent: US 5614395-A 97 25-MAR-1997;
          Location/Qualifiers
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

TITLE
  Chemically regulatable and anti-pathogenic DNA sequences and uses
  thereof
JOURNAL
  Patent: US 5614395-A 97 25-MAR-1997;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1

RESULT 157
I47511/c
LOCUS      I47511          17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 174 from patent US 5639871.
ACCESSION  I47511
VERSION     I47511.1  GI:2471476
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Bauer,H.M., Gravitt,P.E., Greer,C.E., Impraime,C.C.,
          Manos,M. Michele., Resnick,R.M. and Zhang,T.Yi.
          Detection of human papillomavirus by the polymerase chain reaction
          Patent: US 5639871-A 174 17-JUN-1997;
          Location/Qualifiers
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

TITLE
  Detection of human papillomavirus by the polymerase chain reaction
JOURNAL
  Patent: US 5639871-A 174 17-JUN-1997;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 252 ACCTCCCCAGGTTCTCT 268
Db 17 ACCTCCCTCAGGTTCTT 1
```

```
RESULT 158
I56994/c
LOCUS      I56994          17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 97 from patent US 5650505.
ACCESSION  I56994
VERSION     I56994.1  GI:2477407
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Ryals,J.A., Alexander,D.C., Beck,J.J., Duesing,J.H., Goodman,R.M.,
          Friedrich,L.B., Harms,C., Meins,F. Jr., Montoya,A. deceased,
          Moyer,M.B., Neuhaus,J.-M., Payne,G.B., Sperisen,C., Stinson,J.R.,
          Uknes,S.J., Ward,E.R. and Williams,S.C.
          Chemically regulatable and anti-pathogenic DNA sequences and uses
          thereof
          Patent: US 5650505-A 97 22-JUL-1997;
          Location/Qualifiers
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

TITLE
  Chemically regulatable and anti-pathogenic DNA sequences and uses
  thereof
JOURNAL
  Patent: US 5650505-A 97 22-JUL-1997;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1

RESULT 159
I59860/c
LOCUS      I59860          17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 97 from patent US 5654414.
ACCESSION  I59860
VERSION     I59860.1  GI:2478492
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Ryals,J.A., Beck,J.J. and Friedrich,L.B.
          Chemically inducible promoter of a cucumber chitinase/lysozyme gene
          Patent: US 5654414-A 97 05-AUG-1997;
          Location/Qualifiers
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

TITLE
  Chemically inducible promoter of a cucumber chitinase/lysozyme gene
JOURNAL
  Patent: US 5654414-A 97 05-AUG-1997;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGGTTC 1332
Db 17 GCCTCGTCCTGGAGTTC 1

RESULT 160
I75187/c
LOCUS      I75187          17 bp      DNA      linear      PAT 03-APR-1998
DEFINITION Sequence 97 from patent US 5689044.
ACCESSION  I75187
VERSION     I75187.1  GI:3011328
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
```


JOURNAL Patent: US 6566127-A 1945 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 282 GGAGCCATCCTGGGGA 298
|||||
Db 1 GGAGCAATCCTGTGGA 17

RESULT 166
AR326057/c
LOCUS AR326057 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3459 from patent US 6566127.
ACCESSION AR326057
VERSION AR326057.1 GI:33711865
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3459 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 GGACCCAGGAGCATCC 291
|||||
Db 17 GGATTCAGGAGCATCC 1

RESULT 167
AR362605/c
LOCUS AR362605 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 2 from patent US 5177307.
ACCESSION AR362605
VERSION AR362605.1 GI:34422902
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Houck,C.M., Pear,J.R., Martineau,B.M. and Hiatt,W.
TITLE Compositions and methods for modulation of endogenous cytokinin levels
JOURNAL Patent: US 5177307-A 2 05-JAN-1993;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGTTTC 1332
|||||
Db 17 GCCTCGTCCTGGAGTTC 1

RESULT 170
AR434337
LOCUS AR434337 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 760 from patent US 6656700.
ACCESSION AR434337
VERSION AR434337.1 GI:40197180
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 760 02-DEC-2003;

RESULT 168
AR398387
LOCUS AR398387 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 768 from patent US 6617438.
ACCESSION AR398387
VERSION AR398387.1 GI:40136158
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 768 09-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1178 CTTGGAAGCTGTGGTTC 1194
|||||
Db 1 CTCGGACGTGCTGGTTC 17

RESULT 169
AR409735/c
LOCUS AR409735 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 97 from patent US 6632981.
ACCESSION AR409735
VERSION AR409735.1 GI:40160712
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Meins,F. Jr., Shinshi,H., Wenzler,H.C., Hofsteenge,J., Ryals,J.A. and Sperisen,C.
TITLE DNA sequences encoding polypeptides having beta-1,3-glucanase activity
JOURNAL Patent: US 6632981-A 97 14-OCT-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGTTTC 1332
|||||
Db 17 GCCTCGTCCTGGAGTTC 1

RESULT 170
AR434337
LOCUS AR434337 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 760 from patent US 6656700.
ACCESSION AR434337
VERSION AR434337.1 GI:40197180
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 760 02-DEC-2003;

FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 CTCCTTGTGCCCAACT 839
|||||
Db 1 CTCGCTGCCCACTACT 17

RESULT 171
AR434338
LOCUS 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 761 from patent US 6656700.
ACCESSION AR434338
VERSION AR434338.1 GI:40197181
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 761 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 TCTTGTGCCCAACTC 840
|||||
Db 1 TCGTGTGCCCACTACTC 17

RESULT 172
AR457254
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 931 from patent US 6686188.
ACCESSION AR457254
VERSION AR457254.1 GI:42692311
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 931 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGAGAGAGGCTGTGCC 755
|||||
Db 1 CTGAAGAGGCTGAGCC 17

RESULT 173

AR457859
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1536 from patent US 6686188.
ACCESSION AR457859
VERSION AR457859.1 GI:42692916
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1536 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGCTGCTGACCTGG 510
|||||
Db 1 TGGGCTGCTGCTGCTGG 17

RESULT 174
AR457970/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1647 from patent US 6686188.
ACCESSION AR457970
VERSION AR457970.1 GI:42693027
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1647 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTCCTTTGCTTCCTCC 1078
|||||
Db 1 CTCCTTTGCTTCCTCC 1

RESULT 175
AR458613/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2290 from patent US 6686188.
ACCESSION AR458613
VERSION AR458613.1 GI:42693670
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed

```
predominantly in heart and muscle
Patent: US 6686188-A 2290 03-FEB-2004;
FEATURES
  source
    1. .17
      /organism="unknown"
      /mol_type="genomic DNA"
Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 559 CTGTGGGCCAGGGCCAC 575
Db 17 CTGTGGGCCATGGAC 1

RESULT 176
AR458614/c
LOCUS
DEFINITION
  Sequence 2291 from patent US 6686188.
ACCESSION
  AR458614
VERSION
  AR458614.1 GI:42693671
KEYWORDS
  .
SOURCE
  Unknown.
ORGANISM
  Unclassified.
REFERENCE
  1 (bases 1 to 17)
AUTHORS
  Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
TITLE
  Polynucleotide encoding a human myosin-like polypeptide expressed
  predominantly in heart and muscle
JOURNAL
  Patent: US 6686188-A 2291 03-FEB-2004;
FEATURES
  source
    1. .17
      /organism="unknown"
      /mol_type="genomic DNA"
Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 558 GCTGTGGGCCAGGGCCA 574
Db 17 GCTGTGGGCCATGGACA 1

RESULT 177
AR458615/c
LOCUS
DEFINITION
  Sequence 2292 from patent US 6686188.
ACCESSION
  AR458615
VERSION
  AR458615.1 GI:42693672
KEYWORDS
  .
SOURCE
  Unknown.
ORGANISM
  Unclassified.
REFERENCE
  1 (bases 1 to 17)
AUTHORS
  Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
TITLE
  Polynucleotide encoding a human myosin-like polypeptide expressed
  predominantly in heart and muscle
JOURNAL
  Patent: US 6686188-A 2292 03-FEB-2004;
FEATURES
  source
    1. .17
      /organism="unknown"
      /mol_type="genomic DNA"
Query Match
  Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 557 GCCTGTGGGCCAGGGGC 573
Db 17 GCCTGTGGGCCATGGAC 1

predominantly in heart and muscle
Patent: US 6686188-A 2290 03-FEB-2004;
FEATURES
  source
    1. .17
      /organism="unknown"
      /mol_type="genomic DNA"
Query Match
  Best Local Similarity 88.2%; Pred. No. 1.7e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 554 TACGGCTGTGGCCAGG 570
Db 17 TCGCGCTGTGGCCATG 1

RESULT 179
AR458621/c
LOCUS
DEFINITION
  Sequence 2298 from patent US 6686188.
ACCESSION
  AR458621
VERSION
  AR458621.1 GI:42693678
KEYWORDS
  .
SOURCE
  Unknown.
ORGANISM
  Unclassified.
REFERENCE
  1 (bases 1 to 17)
AUTHORS
  Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
TITLE
  Polynucleotide encoding a human myosin-like polypeptide expressed
  predominantly in heart and muscle
JOURNAL
  Patent: US 6686188-A 2298 03-FEB-2004;
FEATURES
  source
    1. .17
      /organism="unknown"
      /mol_type="genomic DNA"
Query Match
  Best Local Similarity 88.2%; Pred. No. 1.7e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 555 CCCTACCGCGTGTGGCC 567
Db 17 CACTGCGCGTGTGGGCC 1

RESULT 180
AR458622/c
LOCUS
DEFINITION
  Sequence 2299 from patent US 6686188.
ACCESSION
  AR458622
VERSION
  AR458622.1 GI:42693679
KEYWORDS
  .
SOURCE
  Unknown.
ORGANISM
  Unclassified.
```

Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	291	CCTGGGGAACAGAAAG	307						
Db	17	CCTGGCGAGACAGAAAG	1						
RESULT 183									
LOCUS	AR465347/c			17 bp	DNA	linear		PAT 20-FEB-2004	
DEFINITION	Sequence 9024 from patent US 6686188.								
ACCESSION	AR465347								
VERSION	AR465347.1	GI:42700404							
KEYWORDS									
SOURCE	Unknown.								
ORGANISM	Unknown.								
REFERENCE	Unclassified.								
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
JOURNAL	Patent: US 6686188-A 9024 03-FEB-2004;								
FEATURES	Location/Qualifiers								
source	1..17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match	0.9%;	Score 13.8;	DB 1;	Length 17;					
Best Local Similarity	88.2%;	Pred. No. 1.7e+02;							
Matches 15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;	
Qy	1149	CTCAACGTCCTTCTCCA	1165						
Db	17	CTCACGCTACTTCTCCA	1						
RESULT 184									
LOCUS	AR466996/c			17 bp	DNA	linear		PAT 20-FEB-2004	
DEFINITION	Sequence 10673 from patent US 6686188.								
ACCESSION	AR466996								
VERSION	AR466996.1	GI:42702053							
KEYWORDS									
SOURCE	Unknown.								
ORGANISM	Unknown.								
REFERENCE	Unclassified.								
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
JOURNAL	Patent: US 6686188-A 10673 03-FEB-2004;								
FEATURES	Location/Qualifiers								
source	1..17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match	0.9%;	Score 13.8;	DB 1;	Length 17;					
Best Local Similarity	88.2%;	Pred. No. 1.7e+02;							
Matches 15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;	
Qy	1260	GGTAGCCATGCTGGGTG	1276						
Db	17	GGTGGCCATGCTGGCTG	1						
RESULT 185									
LOCUS	AR466997/c			17 bp	DNA	linear		PAT 20-FEB-2004	
DEFINITION	Sequence 10674 from patent US 6686188.								
ACCESSION	AR466997								
VERSION	AR466997.1	GI:42702054							

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10674 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1259 GGCTAGCCATGCTGGGT 1275
Db 17 GGGTGGCCATGCTGGCT 1
RESULT 186
AX214637
LOCUS AX214637 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 79 from Patent WO0159103.
ACCESSION AX214637
VERSION AX214637.1 GI:15524680
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 79 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1346 TGCTGATCTCTTCCTT 1362
Db 1 TGCTGCTCTCTTCCTT 17
RESULT 187
AX215297/c
LOCUS AX215297 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 739 from Patent WO0159103.
ACCESSION AX215297
VERSION AX215297.1 GI:15525340
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 739 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;

McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 739 CTGAGAGGCTGTGCC 755
Db 17 CTGAGAGGCTGTGCC 1
RESULT 188
AX215722
LOCUS AX215722 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1164 from Patent WO0159103.
ACCESSION AX215722
VERSION AX215722.1 GI:15525765
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 1164 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 722 TCAGAGGCTACTCCTTC 738
Db 1 TCAGAGGCTACTCCTTC 17
RESULT 189
AX217699/c
LOCUS AX217699 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3141 from Patent WO0159103.
ACCESSION AX217699
VERSION AX217699.1 GI:15527760
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 3141 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"


```
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 422 11-SEP-2002;
          Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
  Query Match      0.9%; Score 13.8; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 1.7e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 CCTGTCTTTGCCAAT 977
Db 1 CCTGTGTTTCCAAAT 17

RESULT 195
AX532013
LOCUS AX532013 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1522 from Patent EP1239051.
ACCESSION AX532013
VERSION AX532013.1 GI:25255791
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1522 11-SEP-2002;
          Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
  Query Match      0.9%; Score 13.8; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 1.7e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1237 CTCCTTGTGCGCGGC 1253
Db 1 CTCCTTGTGTCACCGGC 17

RESULT 196
AX544708/c
LOCUS AX544708 17 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 221 from Patent EP1243660.
ACCESSION AX544708
VERSION AX544708.1 GI:25809919
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udp-galnac:polypeptide n-acetylgalatasaminyltransferase 10
JOURNAL Patent: EP 1243660-A 221 25-SEP-2002;
          Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
```

```
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
  Query Match      0.9%; Score 13.8; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 1.7e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 626 TGGTGCTCTGCGCGCTG 642
Db 17 TGGCGCTGTGCGCGCTG 1

RESULT 197
AX615330
LOCUS AX615330 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 137 from Patent EP1262488.
ACCESSION AX615330
VERSION AX615330.1 GI:28446229
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu,Y. and Nguyen,C.T.
TITLE Human lcc1-domain containing protein
JOURNAL Patent: EP 1262488-A 137 04-DEC-2002;
          Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
  Query Match      0.9%; Score 13.8; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 1.7e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1291 GCAGTGGGCCCATGAGTA 1307
Db 1 GCAGTGACCATGAGGA 17

RESULT 198
AX648277/c
LOCUS AX648277 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 117 from Patent EP1273660.
ACCESSION AX648277
VERSION AX648277.1 GI:29151095
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 117 08-JAN-2003;
          Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
  Query Match      0.9%; Score 13.8; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 1.7e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1349 TGATACTCTTCCTTGTC 1365
Db 17 TGATACTCATCCTTTC 1
```

RESULT 199
AX648278/c
LOCUS AX648278 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 118 from Patent EP1273660.
ACCESSION AX648278
VERSION AX648278.1 GI:29151096
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 118 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1348 CTGATACTCTTCTCTCT 1364
Db 17 CTGATACTATCTCTTTT 1
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1348 CTGATACTCTTCTCTCT 1364
Db 17 CTGATACTATCTCTTTT 1
RESULT 200
AX692476/c
LOCUS AX692476 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5208 from Patent EP1281758.
ACCESSION AX692476
VERSION AX692476.1 GI:29415434
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5208 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1297 GCCCATGAGTATATCTT 1313
Db 17 GCCCAAGATATATCTT 1
RESULT 201
AX692477/c
LOCUS AX692477 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5209 from Patent EP1281758.
ACCESSION AX692477
VERSION AX692477.1 GI:29415435
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5211 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5209 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1296 GGCCCATGAGTATATCT 1312
Db 17 GGCCCAAGATATATCT 1
RESULT 202
AX692478/c
LOCUS AX692478 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5210 from Patent EP1281758.
ACCESSION AX692478
VERSION AX692478.1 GI:29415436
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5210 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1295 TGGCCCATGAGTATATC 1311
Db 17 TGGCCCAAGATATATC 1
RESULT 203
AX692479/c
LOCUS AX692479 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5211 from Patent EP1281758.
ACCESSION AX692479
VERSION AX692479.1 GI:29415437
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5211 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 GTGGCCCATGAGTATAT 1310
Db 17 GTGGCCCAAGATATAT 1

RESULT 204
AX722650/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Patent: WO 03025176-A 337 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 AGGCTGTGCTGGGATC 762
Db 17 AGGCTGCTCGGGATC 1

RESULT 205
AX724945 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Patent: WO 03025176-A 2632 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 123 GACCCGACACATGGAGG 139
Db 1 GATCCTACACATGGAGG 17

RESULT 206
AX727110/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Patent: WO 03025176-A 4797 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 42 AGGCTGGGAGGGGAGC 58
Db 17 AGGGTGGGAGGGGATC 1

RESULT 207
AX728456 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Patent: WO 03025175-A 90 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1112 GATTGGAGACAGGATG 1128
Db 1 GATCGGAGACAGGATG 17
```

RESULT 208
LOCUS AX729352/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 986 from Patent WO03025175.
ACCESSION AX729352
VERSION AX729352.1 GI:30508695
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 986 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 773 GACGAGTGCAGGATC 789
Db 17 GACGAGTGCAGGATC 1
RESULT 209
LOCUS AX730435 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2069 from Patent WO03025175.
ACCESSION AX730435
VERSION AX730435.1 GI:30509778
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their-use as medicines
JOURNAL Patent: WO 03025175-A 2069 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1350 GATACCTCTTCCTGTCA 1366
Db 1 GATCCTATTCTTGTCA 17
RESULT 210
LOCUS AX730461 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2095 from Patent WO03025175.
ACCESSION AX730461
VERSION AX730461.1 GI:30509804
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 2095 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 334 GATGAGCTGATGGAGCT 350
Db 1 GATCAGCTGATGGAGCT 17
RESULT 211
LOCUS AX730557/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2191 from Patent WO03025175.
ACCESSION AX730557
VERSION AX730557.1 GI:30509900
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 2191 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 773 GACGAGTGCAGGATC 789
Db 17 GCCGAGTGCAGGATC 1
RESULT 212
LOCUS AX733457 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5091 from Patent WO03025175.
ACCESSION AX733457
VERSION AX733457.1 GI:30512800
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour

```
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 5091 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
    1. .17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1419 GAACGTGCTGATGGGA 1435
Db 1 GATCGTGTGATGGGA 17

RESULT 213
AX736028
LOCUS
DEFINITION
Sequence 1618 from Patent WO03025177. linear PAT 08-MAY-2003
ACCESSION
AX736028
VERSION
AX736028.1 GI:30515305
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Amson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL
Patent: WO 03025177-A 1618 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
    1. .17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1547 GATCTTGGTCCTGCCAT 1563
Db 1 GATCATGGTACTGCCAT 17

RESULT 214
AX736725
LOCUS
DEFINITION
Sequence 2315 from Patent WO03025177. linear PAT 08-MAY-2003
ACCESSION
AX736725
VERSION
AX736725.1 GI:30516013
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Amson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL
Patent: WO 03025177-A 2315 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
    1. .17
    /organism="Homo sapiens"
```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 334 GATGAGCTGATGGAGGT 350
Db 1 GATCAGCTGATGGAGCT 17

RESULT 215
AX757242
LOCUS
DEFINITION
Sequence 563 from Patent WO03040369. linear PAT 25-JUN-2003
ACCESSION
AX757242
VERSION
AX757242.1 GI:32251858
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Amson,R. and Tuijnder,M.
TITLE
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL
Patent: WO 03040369-A 563 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
    1. .17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 334 GATGAGCTGATGGAGGT 350
Db 1 GATCAGCTGATGGAGCT 17

RESULT 216
AX757362/c
LOCUS
DEFINITION
Sequence 683 from Patent WO03040369. linear PAT 25-JUN-2003
ACCESSION
AX757362
VERSION
AX757362.1 GI:32251978
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Amson,R. and Tuijnder,M.
TITLE
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL
Patent: WO 03040369-A 683 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
    1. .17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 334 GATGAGCTGATGGAGGT 350
Db 1 GATCAGCTGATGGAGCT 17
```

QY 773 GACGAGGTGAGGGATC 789
Db 17 GCCGAGGTGAGTGGATC 1

RESULT 217
LOCUS AX782026/c
DEFINITION Sequence 357 from Patent WO03050284.
ACCESSION AX782026
VERSION AX782026.1 GI:32949875
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 357 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 587 CGACGGGCTGGCGTGT 603
Db 17 CGACGGGCTCGACTGT 1

RESULT 218
LOCUS AX804462/c
DEFINITION Sequence 630 from Patent WO03060160.
ACCESSION AX804462
VERSION AX804462.1 GI:38521603
KEYWORDS Oreochromis niloticus (Nile tilapia)
SOURCE
ORGANISM Oreochromis niloticus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
Labroidae; Cichlidae; Oreochromis.
REFERENCE 1
AUTHORS Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
TITLE Verification of food origin based on nucleic acid pattern recognition
JOURNAL Patent: WO 03060160-A 630 24-JUL-2003;
Genomar ASA (NO)
FEATURES
Location/Qualifiers
1..17
/organism="Oreochromis niloticus"
/mol_type="unassigned DNA"
/db_xref="taxon:8128"

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 240 ACCTCTGCCCCACCTC 256
Db 17 ACCTCAGCACCCACCTC 1

RESULT 219
LOCUS AR069548
DEFINITION Sequence 22 from patent US 5891671.
ACCESSION AR069548
VERSION AR069548.1 GI:7220436
KEYWORDS Unknown.
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Suzuki,Y., Magota,K. and Masuda,T.
TITLE Method for cleaving chimeric protein using processing enzyme
JOURNAL Patent: US 5891671-A 22 06-APR-1999;
FEATURES
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 402 CATCATCAGCACCTGG 418
Db 1 CACCATCATCACCTGG 17

RESULT 220
LOCUS AR069549/c
DEFINITION Sequence 23 from patent US 5891671.
ACCESSION AR069549
VERSION AR069549.1 GI:7220437
KEYWORDS Unknown.
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Suzuki,Y., Magota,K. and Masuda,T.
TITLE Method for cleaving chimeric protein using processing enzyme
JOURNAL Patent: US 5891671-A 23 06-APR-1999;
FEATURES
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 402 CATCATCAGCACCTGG 418
Db 18 CACCATCATCACCTGG 2

RESULT 221
LOCUS CQ830099/c
DEFINITION Sequence 1 from Patent WO2004055178.
ACCESSION CQ830099
VERSION CQ830099.1 GI:50250631
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Tang,L., Wu,W., Duan,J. and Johannesen,P.F.
TITLE Thermostable alpha-amylases
JOURNAL Patent: WO 2004055178-A 1 01-JUL-2004;
Novozymes A/S (DK)
FEATURES
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

QY 402 CATCATCAGCACCTGG 418
Db 1 CACCATCATCACCTGG 17

RESULT 220
LOCUS AR069549/c
DEFINITION Sequence 23 from patent US 5891671.
ACCESSION AR069549
VERSION AR069549.1 GI:7220437
KEYWORDS Unknown.
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Suzuki,Y., Magota,K. and Masuda,T.
TITLE Method for cleaving chimeric protein using processing enzyme
JOURNAL Patent: US 5891671-A 23 06-APR-1999;
FEATURES
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 402 CATCATCAGCACCTGG 418
Db 18 CACCATCATCACCTGG 2

RESULT 221
LOCUS CQ830099/c
DEFINITION Sequence 1 from Patent WO2004055178.
ACCESSION CQ830099
VERSION CQ830099.1 GI:50250631
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Tang,L., Wu,W., Duan,J. and Johannesen,P.F.
TITLE Thermostable alpha-amylases
JOURNAL Patent: WO 2004055178-A 1 01-JUL-2004;
Novozymes A/S (DK)
FEATURES
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

/note="Primer AM298-CDSF"

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1375 ATGTTGAACCTTCATGAT 1391
||| ||||| ||||| |||||
Db 18 ATGCTGAATTCATGAT 2

RESULT 222
E15411/c 18 bp DNA linear PAT 28-JUL-1999

LOCUS PCR primer.

DEFINITION E15411

ACCESSION E15411

VERSION E15411.1 GI:57110094

KEYWORDS JP 19980665599-A/5.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Okamura,K., Yamashita,M. and Katayama,S.

TITLE ANALYSIS OF SOIL NUCLEIC ACID

JOURNAL Patent: JP 19980665599-A 5 10-MAR-1998;

COMMENT TOYOTA MOTOR CORP

OS None

OC Artificial sequences.

PN JP 19980665599-A/5

PD 10-MAR-1998

PF 27-AUG-1996 JP 1996242503

PI OKAMURA KOJI, YAMASHITA MASAMI, KATAYAMA SHINTA PC

C12Q1/68,G01N1/28,G01N33/24;

CC strandedness: Single;

CC topology: Linear;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

LOCUS E16948

DEFINITION DNA linker.

ACCESSION E16948

VERSION E16948.1 GI:5711631

KEYWORDS JP 1998229884-A/31.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Magota,K., Masuda,T., Suzuki,Y. and Yabuta,M.

TITLE PRODUCTION OF SECRETORY KEX2 DERIVATIVE

JOURNAL Patent: JP 1998229884-A 31 02-SEP-1998;

COMMENT SUNTORY LTD

OS None

OC Artificial sequences.

PN JP 1998229884-A/31

PD 02-SEP-1998

PF 04-MAR-1997 JP 1997063953

PR 04-MAR-1996 JP 96P 73217, 16-DEC-1996 JP 96P 352580 PI

MAGOTA KOJI, MASUDA TOYOFUMI, SUZUKI YUJI, YABUTA MASAYUKI PC

C12N15/09,C07H21/04,C07K14/39,C07K14/40,C12N1/19,C12N9/60, PC

C12P21/02,

PC (C12N1/19,C12R1:78), (C12N1/19,C12R1:72), (C12N1/19,C12R1:84),

PC (C12N9/60,

PC C12R1:78), (C12N9/60,C12R1:72), (C12N9/60,C12R1:84), (C12P21/02,

PC C12R1:78),

CC strandedness: Single;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

LOCUS E16949

DEFINITION DNA linker.

ACCESSION E16949

VERSION E16949.1 GI:5711632

KEYWORDS JP 1998229884-A/32.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Magota,K., Masuda,T., Suzuki,Y. and Yabuta,M.

TITLE PRODUCTION OF SECRETORY KEX2 DERIVATIVE

JOURNAL Patent: JP 1998229884-A 32 02-SEP-1998;

COMMENT SUNTORY LTD

OS None

OC Artificial sequences.

PN JP 1998229884-A/32

PD 02-SEP-1998

PF 04-MAR-1997 JP 1997063953

PR 04-MAR-1996 JP 96P 73217, 16-DEC-1996 JP 96P 352580 PI

MAGOTA KOJI, MASUDA TOYOFUMI, SUZUKI YUJI, YABUTA MASAYUKI PC

C12N15/09,C07H21/04,C07K14/39,C07K14/40,C12N1/19,C12N9/60, PC

C12P21/02,

PC (C12N1/19,C12R1:78), (C12N1/19,C12R1:72), (C12N1/19,C12R1:84),

PC (C12N9/60,

PC C12R1:78), (C12N9/60,C12R1:72), (C12N9/60,C12R1:84), (C12P21/02,

PC C12R1:78),

CC strandedness: Single;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

LOCUS E16949

DEFINITION DNA linker.

ACCESSION E16949

VERSION E16949.1 GI:5711632

KEYWORDS JP 1998229884-A/32.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Magota,K., Masuda,T., Suzuki,Y. and Yabuta,M.

TITLE PRODUCTION OF SECRETORY KEX2 DERIVATIVE

JOURNAL Patent: JP 1998229884-A 32 02-SEP-1998;

COMMENT SUNTORY LTD

OS None

OC Artificial sequences.

PN JP 1998229884-A/32

PD 02-SEP-1998

PF 04-MAR-1997 JP 1997063953

PR 04-MAR-1996 JP 96P 73217, 16-DEC-1996 JP 96P 352580 PI

MAGOTA KOJI, MASUDA TOYOFUMI, SUZUKI YUJI, YABUTA MASAYUKI PC

C12N15/09,C07H21/04,C07K14/39,C07K14/40,C12N1/19,C12N9/60, PC

C12P21/02,

PC (C12N1/19,C12R1:78), (C12N1/19,C12R1:72), (C12N1/19,C12R1:84),

PC (C12N9/60,

PC C12R1:78), (C12N9/60,C12R1:72), (C12N9/60,C12R1:84), (C12P21/02,

PC C12R1:78),

CC strandedness: Single;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

LOCUS E16949

DEFINITION DNA linker.

ACCESSION E16949

VERSION E16949.1 GI:5711632

KEYWORDS JP 1998229884-A/32.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Magota,K., Masuda,T., Suzuki,Y. and Yabuta,M.

TITLE PRODUCTION OF SECRETORY KEX2 DERIVATIVE

JOURNAL Patent: JP 1998229884-A 32 02-SEP-1998;

COMMENT SUNTORY LTD

OS None

OC Artificial sequences.

PN JP 1998229884-A/32

PD 02-SEP-1998

PF 04-MAR-1997 JP 1997063953

PR 04-MAR-1996 JP 96P 73217, 16-DEC-1996 JP 96P 352580 PI

MAGOTA KOJI, MASUDA TOYOFUMI, SUZUKI YUJI, YABUTA MASAYUKI PC

C12N15/09,C07H21/04,C07K14/39,C07K14/40,C12N1/19,C12N9/60, PC

C12P21/02,

PC (C12N1/19,C12R1:78), (C12N1/19,C12R1:72), (C12N1/19,C12R1:84),

PC (C12N9/60,

PC C12R1:78), (C12N9/60,C12R1:72), (C12N9/60,C12R1:84), (C12P21/02,

PC C12R1:78),

CC strandedness: Single;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

LOCUS E16949

DEFINITION DNA linker.

ACCESSION E16949

VERSION E16949.1 GI:5711632

KEYWORDS JP 1998229884-A/32.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Magota,K., Masuda,T., Suzuki,Y. and Yabuta,M.

TITLE PRODUCTION OF SECRETORY KEX2 DERIVATIVE

JOURNAL Patent: JP 1998229884-A 32 02-SEP-1998;

COMMENT SUNTORY LTD

OS None

OC Artificial sequences.

PN JP 1998229884-A/32

PD 02-SEP-1998

PF 04-MAR-1997 JP 1997063953

PR 04-MAR-1996 JP 96P 73217, 16-DEC-1996 JP 96P 352580 PI

MAGOTA KOJI, MASUDA TOYOFUMI, SUZUKI YUJI, YABUTA MASAYUKI PC

C12N15/09,C07H21/04,C07K14/39,C07K14/40,C12N1/19,C12N9/60, PC

C12P21/02,

PC (C12N1/19,C12R1:78), (C12N1/19,C12R1:72), (C12N1/19,C12R1:84),

PC (C12N9/60,

PC C12R1:78), (C12N9/60,C12R1:72), (C12N9/60,C12R1:84), (C12P21/02,

PC C12R1:78),

CC strandedness: Single;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

LOCUS E16949

DEFINITION DNA linker.

ACCESSION E16949

VERSION E16949.1 GI:5711632

KEYWORDS JP 1998229884-A/32.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Magota,K., Masuda,T., Suzuki,Y. and Yabuta,M.

TITLE PRODUCTION OF SECRETORY KEX2 DERIVATIVE

JOURNAL Patent: JP 1998229884-A 32 02-SEP-1998;

COMMENT SUNTORY LTD

OS None

OC Artificial sequences.

PN JP 1998229884-A/32

PD 02-SEP-1998

PF 04-MAR-1997 JP 1997063953

PR 04-MAR-1996 JP 96P 73217, 16-DEC-1996 JP 96P 352580 PI

MAGOTA KOJI, MASUDA TOYOFUMI, SUZUKI YUJI, YABUTA MASAYUKI PC

C12N15/09,C07H21/04,C07K14/39,C07K14/40,C12N1/19,C12N9/60, PC

C12P21/02,

PC (C12N1/19,C12R1:78), (C12N1/19,C12R1:72), (C12N1/19,C12R1:84),

PC (C12N9/60,

PC C12R1:78), (C12N9/60,C12R1:72), (C12N9/60,C12R1:84), (C12P21/02,

PC C12R1:78),

CC strandedness: Single;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

LOCUS E16949

DEFINITION DNA linker.

ACCESSION E16949

VERSION E16949.1 GI:5711632

KEYWORDS JP 1998229884-A/32.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Magota,K., Masuda,T., Suzuki,Y. and Yabuta,M.

TITLE PRODUCTION OF SECRETORY KEX2 DERIVATIVE

JOURNAL Patent: JP 1998229884-A 32 02-SEP-1998;

COMMENT SUNTORY LTD

OS None

OC Artificial sequences.

PN JP 1998229884-A/32

PD 02-SEP-1998

PF 04-MAR-1997 JP 1997063953

PR 04-MAR-1996 JP 96P 73217, 16-DEC-1996 JP 96P 352580 PI

MAGOTA KOJI, MASUDA TOYOFUMI, SUZUKI YUJI, YABUTA MASAYUKI PC

C12N15/09,C07H21/04,C07K14/39,C07K14/40,C12N1/19,C12N9/60, PC

C12P21/02,

PC (C12N1/19,C12R1:78), (C12N1/19,C12R1:72), (C12N1/19,C12R1:84),

PC (C12N9/60,

PC C12R1:78), (C12N9/60,C12R1:72), (C12N9/60,C12R1:84), (C12P21/02,

PC C12R1:78),

CC strandedness: Single;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC Key Location/Qualifiers

PH FT source 1. .18

FT /organism='Artificial sequences'.

[illegible]

KEYWORDS JP 2002504310-A/3.
SOURCE Streptococcus pneumoniae
ORGANISM Bacteria; Firmicutes; Lactobacillales; Streptococcaceae;
Streptococcus.
REFERENCE 1 (bases 1 to 18)
AUTHORS Palmer,L.M., Redon,J.C., Warren,R.L., Kosmatka,A.L., Shilling,L.K.,
Black,M.T., Hodgson,J.E., Nicholas,R.O., Knowles,D.J.C.,
Lonetto,M.A. and Stodola,R.K.
TITLE Riba
JOURNAL Patent: JP 2002504310-A 3 12-FEB-2002;
COMMENT OS SMITHKLINE BEECHAM CORP
PN JP 2002504310-A/3
PD 12-FEB-2002
PF 23-NOV-1998 JP 2000522266
PR 25-NOV-1997 US 08/979616
PI LESLIE M PALMER, JASON C FEDON, RICHARD L
WARREN, ANNS L KOSMATKA,
PI LISA K SHILLING, MICHAEL T BLACK, JOHN E HODGSON, RICHARD O PI
NICHOLAS,
PI DAVID J C KNOWLES, MICHAEL A LONETTO, ROBERT K STODOLA PC
C12N15/09, A61K31/71, A61K38/00, A61K45/00, A61K48/00, A61P31/04, PC
A61P37/04,
PC C07K14/315, C07K16/12, C12N1/21, C12P21/02, G01N33/15, G01N33/50,
PC C12N15/00,
PC A61K37/02
CC Riba
FH Key Location/Qualifiers
FT source 1..18
FT Location/Qualifiers
source
1..18
/organism="Streptococcus pneumoniae"
/mol_type="genomic DNA"
/db_xref="taxon:1313"
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 688 TGTGCTCGTCTTCGA 704
DB 17 TGTGCTCGCTCGCA 1
RESULT 235
AR442660
LOCUS AR442660 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9 from patent US 6670135.
ACCESSION AR442660
VERSION AR442660.1 GI:42669921
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Spriggs,M.K.
TITLE Semaphorin polypeptides
JOURNAL Patent: US 6670135-A 9 30-DEC-2003;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 565 GCCAGGGGACCTGGAC 581
DB 2 GCCAGGTGCCCTGGAC 18

RESULT 236
AX724242
LOCUS AX724242 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1929 from Patent WO03025176.
ACCESSION AX724242
VERSION AX724242.1 GI:30503585
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1929 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.9%; Score 13.6; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1060 ATCTTCTTGCCCTT 1073
DB 2 ATCTTCTWTGCCCTT 15
RESULT 237
E03871
LOCUS E03871 15 bp DNA linear PAT 29-SEP-1997
DEFINITION Oligonucleotide for detecting pectate lyase gene.
ACCESSION E03871
VERSION E03871.1 GI:2172085
KEYWORDS JP 1992229176-A/5.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 15)
AUTHORS Minami,Y.
TITLE OLIGONUCLEOTIDE FOR DETECTING PLANT TRANSFORMANT AND METHOD FOR
DETECTING THE SAME
JOURNAL Patent: JP 1992229176-A 5 18-AUG-1992;
COMMENT SHIMADZU CORP
OS Artificial gene
OC Artificial sequence; Genes.
OS Ervinia carotovora.
PN JP 1992229176-A/5
PD 18-AUG-1992
PF 27-DEC-1990 JP 1990407123
PI MINAMI YOSHIHIRO
PC C12N15/11, C12Q1/68;
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No.
FEATURES Location/Qualifiers
source
1..15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1180 TGGACGTGGTGGTC 1194

```

Db      1  ||||| ||||| ||||| ||||| |||||
      1  TGCAACGTGGTGTC 15

RESULT 238
AR328259 LOCUS          16 bp  RNA  linear  PAT 17-AUG-2003
DEFINITION Sequence 5661 from patent US 6566127.
ACCESSION AR328259
VERSION   AR328259.1 GI:33714067
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unknown.
          Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS  Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE    Method and reagent for the treatment of diseases or conditions
          related to levels of vascular endothelial growth factor receptor
JOURNAL  Patent: US 6566127-A 5661 20-MAY-2003;
FEATURES  Location/Qualifiers
            source          1..16
                        /organism="unknown"
                        /mol_type="unassigned RNA"

Query Match      0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      629  TGCTCTGCGCGCTGC 643
          ||||| ||||| ||||| ||||| |||||
          1  TGCTGTGCGCGCTGC 15

Db

RESULT 239
AR435794/c LOCUS          16 bp  RNA  linear  PAT 18-DEC-2003
DEFINITION Sequence 53 from patent US 6656731.
ACCESSION AR435794
VERSION   AR435794.1 GI:40198878
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unknown.
          Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS  Eckstein,F., Ludwig,J. and Beigelman,I.
TITLE    Nucleic acid catalysts with endonuclease activity
JOURNAL  Patent: US 6656731-A 53 02-DEC-2003;
FEATURES  Location/Qualifiers
            source          1..16
                        /organism="unknown"
                        /mol_type="unassigned RNA"

Query Match      0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      403  ATCATCAGCACCGCTG 417
          ||||| ||||| ||||| ||||| |||||
          16  ATCATCAACACCGCTG 2

Db

RESULT 240
BD200592 LOCUS          17 bp  RNA  linear  PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
          molecule participating in vasculogenic response.
ACCESSION BD200592
VERSION   BD200592.1 GI:33010362
KEYWORDS  JP 2002509721-A/3618.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

Query Match      0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      403  ATCATCAGCACCGCTG 417
          ||||| ||||| ||||| ||||| |||||
          16  ATCATCAACACCGCTG 2

Db

RESULT 241
BD241153/c LOCUS          17 bp  DNA  linear  PAT 17-JUL-2003
DEFINITION Methods and products related to genotyping and DNA analysis.
ACCESSION BD241153
VERSION   BD241153.1 GI:33050923
KEYWORDS  JP 2002525127-A/100.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 17)
AUTHORS  Landers,J.E., Jordan,B., Houseman,D.E. and Charest,A.
TITLE    Methods and products related to genotyping and DNA analysis
JOURNAL  Patent: JP 2002525127-A 100 13-AUG-2002;
          MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT   OS Homo sapiens (human)
          PN JP 2002525127-A/100
          PD 13-AUG-2002
          PF 24-SEP-1999 JP 2000572407
          PR 25-SEP-1998 US 60/101757
          PT JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
          C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
          G01N37/00,
          PC C12N15/00
          CC Methods and products related to genotyping and DNA analysis FH
          Key source          1..17
          Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens (human)".
            Location/Qualifiers
              1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"

```

```

REFERENCE 1 (bases 1 to 17)
AUTHORS  Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE    Method and reagent for treating diseases or conditions concerning
          molecule participating in vasculogenic response
JOURNAL  Patent: JP 2002509721-A 3618 02-APR-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT   OS Homo sapiens (human)
          PN JP 2002509721-A/3618
          PD 02-APR-2002
          PF 24-MAR-1999 JP 2000541291
          PR 27-MAR-1998 US 60/079678
          PT JAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
          PC C12N15/09,A61K31/7089,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
          A61P29/00,
          PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
          C12N5/00
          CC Method and reagent for treating diseases or conditions CC
          concerning molecule
          CC Participating in vasculogenic response
          FH Key Location/Qualifiers
          FT source          1..17
                        /organism="Homo sapiens (human)".
          FT Location/Qualifiers
            1..17
              /organism="Homo sapiens"
              /mol_type="genomic RNA"
              /db_xref="taxon:9606"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1202  GGCTGTACAGCTACG 1216
          ||||| ||||| ||||| ||||| |||||
          3  GGCTGTACAGCTGCG 17

Db

RESULT 241
BD241153/c LOCUS          17 bp  DNA  linear  PAT 17-JUL-2003
DEFINITION Methods and products related to genotyping and DNA analysis.
ACCESSION BD241153
VERSION   BD241153.1 GI:33050923
KEYWORDS  JP 2002525127-A/100.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 17)
AUTHORS  Landers,J.E., Jordan,B., Houseman,D.E. and Charest,A.
TITLE    Methods and products related to genotyping and DNA analysis
JOURNAL  Patent: JP 2002525127-A 100 13-AUG-2002;
          MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT   OS Homo sapiens (human)
          PN JP 2002525127-A/100
          PD 13-AUG-2002
          PF 24-SEP-1999 JP 2000572407
          PR 25-SEP-1998 US 60/101757
          PT JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
          C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
          G01N37/00,
          PC C12N15/00
          CC Methods and products related to genotyping and DNA analysis FH
          Key source          1..17
          Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens (human)".
            Location/Qualifiers
              1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"

```

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 727 AGCTACTGCTTCCTG 741
 DB 15 AGCTACTGCTTCCTG 1

RESULT 242
 LOCUS BD254828 17 bp DNA linear PAT 17-JUL-2003
 DEFINITION Regulation of repressor genes using nucleic acid molecules.
 ACCESSION BD254828
 VERSION BD254828.1 GI:33064598
 KEYWORDS JP 2002541795-A/2621.
 SOURCE unidentified
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 2621 10-DEC-2002;
 COMMENT RIBOZYME PHARMACEUTICALS INC

OS Eukaryote
 PN JP 2002541795-A/2621
 PD 10-DEC-2002
 PF 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC
 C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91),
 PC
 C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 Key source Location/Qualifiers
 FT source 1..17
 FT Location/Qualifiers
 FEATURES source
 1..17
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTG 192
 DB 15 CTGAGGAGCTGCTG 1

RESULT 243
 LOCUS CQ621883 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 6623 from Patent WO0192524.
 ACCESSION CQ621883
 VERSION CQ621883.1 GI:41672101
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
 Shannon, M.E.
 TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 6623 06-DEC-2001;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAG 35
 DB 3 TCTGCGTCTGCATAG 17

RESULT 244
 LOCUS CQ621890 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 6630 from Patent WO0192524.
 ACCESSION CQ621890
 VERSION CQ621890.1 GI:41672108
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
 Shannon, M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 6630 06-DEC-2001;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 GTCTGCAGAGGACAG 40
 DB 1 GTCTGCATAGGACAG 15

RESULT 245
 LOCUS CQ625935 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 10675 from Patent WO0192524.
 ACCESSION CQ625935
 VERSION CQ625935.1 GI:41676153
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
 Shannon, M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 10675 06-DEC-2001;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1259 GGGTAGCCATGCTGG 1273
Db 16 GGGTGGCCATGCTGG 2

RESULT 246
CO625936/c
LOCUS Sequence 10676 from Patent WO0192524.
DEFINITION Sequence 10676 from Patent WO0192524.
ACCESSION CO625936
VERSION CO625936.1 GI:41676154
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
JOURNAL Myosin-like gene expressed in human heart and muscle
PATENT: WO 0192524-A 10676 06-DEC-2001;
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1259 GGGTAGCCATGCTGG 1273
Db 15 GGGTGGCCATGCTGG 1

RESULT 247
AR186916/c
LOCUS Sequence 2404 from patent US 6346398.
DEFINITION Sequence 2404 from patent US 6346398.
ACCESSION AR186916
VERSION AR186916.1 GI:20232881
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2404 12-FEB-2002;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1513 CCCAGGCAACTTC 1527
Db 17 CCCAGGCAAGTTC 3

RESULT 248
AR188873
LOCUS Sequence 4361 from patent US 6346398.
DEFINITION Sequence 4361 from patent US 6346398.

ACCESSION AR188873
VERSION AR188873.1 GI:20234838
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4361 12-FEB-2002;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
Db 2 CCCAGATTCTCCAGC 16

RESULT 249
AR188874
LOCUS Sequence 4362 from patent US 6346398.
DEFINITION Sequence 4362 from patent US 6346398.
ACCESSION AR188874
VERSION AR188874.1 GI:20234839
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4362 12-FEB-2002;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
Db 1 CCCAGATTCTCCAGC 15

RESULT 250
AR323547/c
LOCUS Sequence 949 from patent US 6566127.
DEFINITION Sequence 949 from patent US 6566127.
ACCESSION AR323547
VERSION AR323547.1 GI:33709355
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 949 20-MAY-2003;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1513 CCCAGGCAACTTC 1527
|||||
Db 17 CCCAGGCAAGTTTC 3

RESULT 251
LOCUS AR324726 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2128 from patent US 6566127.
ACCESSION AR324726
VERSION AR324726.1 GI:33710534
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2128 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTCTCCAGC 810
|||||
Db 2 CCCAGATTCCTCCAGC 16

RESULT 252
LOCUS AR324727 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2129 from patent US 6566127.
ACCESSION AR324727
VERSION AR324727.1 GI:33710535
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2129 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTCTCCAGC 810
|||||
Db 1 CCCAGATTCCTCCAGC 15

RESULT 253
LOCUS AR327261 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4663 from patent US 6566127.
ACCESSION AR327261

VERSION AR327261.1 GI:33713069
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4663 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 261 AGGTTCTTGACCAG 275
|||||
Db 17 AGGTTCTTGACCAG 3

RESULT 254
LOCUS AR327909 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5311 from patent US 6566127.
ACCESSION AR327909
VERSION AR327909.1 GI:33713717
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5311 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1512 ACCCAGGCAACTTT 1526
|||||
Db 15 ACCCAGGCAAGTTT 1

RESULT 255
LOCUS AR402030 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 370 from patent US 6623962.
ACCESSION AR402030
VERSION AR402030.1 GI:40149480
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar, S., Fell, P. and McSwiggen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 370 23-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

```
Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCAACTACTACCG 1175
Db 1 CTCCAACTTCTACCG 15

RESULT 256
AR462946
LOCUS AR462946 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6623 from patent US 6686188.
ACCESSION AR462946
VERSION AR462946.1 GI:42698003
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6623 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1259 GGGTAGCCCATGCTGG 1273
Db 16 GGGTGGCCATGCTGG 2

RESULT 259
AR466999/c
LOCUS AR466999 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10676 from patent US 6686188.
ACCESSION AR466999
VERSION AR466999.1 GI:42702056
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10676 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1259 GGGTAGCCCATGCTGG 1273
Db 15 GGGTGGCCATGCTGG 1

RESULT 260
AR482654/c
LOCUS AR482654 17 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 100 from patent US 6703228.
ACCESSION AR482654
VERSION AR482654.1 GI:47245177
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers, J., Jordan, B., Housman, D.E. and Charest, A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 100 09-MAR-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCAACTACTACCG 1175
Db 1 CTCCAACTTCTACCG 15

RESULT 257
AR462953
LOCUS AR462953 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6630 from patent US 6686188.
ACCESSION AR462953
VERSION AR462953.1 GI:42698010
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6630 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 GTCTGCAGAGGACAG 40
Db 1 GTCTGCATAGGACAG 15

RESULT 258
AR466998/c
LOCUS AR466998 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10675 from patent US 6686188.
```



```
/mol_type="genomic DNA"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 727 AGCTACTCCTTCTCTG 741
DB 15 AGCTACTGCTTCTCTG 1

RESULT 261
AX214845
LOCUS AX214845 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 287 from Patent WO0159103.
ACCESSION AX214845
VERSION AX214845.1 GI:15524888
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 287 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 724 AAAAGCTACTCCTTC 738
DB 2 AGAAGCTACTCCTTC 16

RESULT 262
AX217396
LOCUS AX217396 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2838 from Patent WO0159103.
ACCESSION AX217396
VERSION AX217396.1 GI:15527457
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2838 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CTTTGCTTCTCTCCA 1079
```

```
|||||
1 CTTTGCTTCTCTCCA 15

RESULT 263
AX218302/c
LOCUS AX218302/c 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3744 from Patent WO0159103.
ACCESSION AX218302
VERSION AX218302.1 GI:15528363
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3744 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCT 829
DB 17 TCTTCTTCTCTTCT 3

RESULT 264
AX218303/c
LOCUS AX218303 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3745 from Patent WO0159103.
ACCESSION AX218303
VERSION AX218303.1 GI:15528364
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3745 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCT 829
DB 16 TCTTCTTCTCTTCT 2

RESULT 265
AX284039/c
LOCUS AX284039 17 bp DNA linear PAT 20-NOV-2001
```

DEFINITION Sequence 4 from Patent WO0179487.
ACCESSION AX284039
VERSION AX284039.1 GI:17044749
SOURCE synthetic construct
ORGANISM synthetic construct
KEYWORDS artificial sequences.
REFERENCE 1
AUTHORS Degitz,K.K. and Besch,R.
TITLE Polydesoxyribonucleotides for inhibiting the expression of the
JOURNAL icam-1-gene
Patent: WO 0179487-A 4 25-OCT-2001;
DEGITZ, Klaus Karl (DE); BESCH, Robert (DE)
FEATURES
source
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kunstlichen
Sequenz:Polydesoxyribonukleotid"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 GGGAGGGGACGGGA 62
Db 15 GGGAGGGGAGGGGA 1
RESULT 266
AX324177/c
LOCUS AX324177 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 315 from Patent WO0192512.
ACCESSION AX324177
VERSION AX324177.1 GI:18094928
KEYWORDS Spinacia oleracea (spinach)
SOURCE Spinacia oleracea
ORGANISM Spinacia oleracea
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Caryophyllales; Amaranthaceae; Spinacia.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL single stranded oligonucleotides
Patent: WO 0192512-A 315 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Spinacia oleracea"
/mol_type="unassigned DNA"
/db_xref="taxon:3562"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 484 CAGCTGCCATTGGCG 498
Db 17 CAGCTGCCATTGGTG 3
RESULT 267
AX324178
LOCUS AX324178 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 316 from Patent WO0192512.
ACCESSION AX324178
VERSION AX324178.1 GI:18094929
KEYWORDS Spinacia oleracea (spinach)
SOURCE Spinacia oleracea
ORGANISM Spinacia oleracea
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Caryophyllales; Amaranthaceae; Spinacia.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL single stranded oligonucleotides
Patent: WO 0192512-A 316 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Spinacia oleracea"
/mol_type="unassigned DNA"
/db_xref="taxon:3562"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 484 CAGCTGCCATTGGCG 498
Db 1 CAGCTGCCATTGGTG 15
RESULT 268
AX326245/c
LOCUS AX326245 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 2383 from Patent WO0192512.
ACCESSION AX326245
VERSION AX326245.1 GI:18097007
KEYWORDS Oryza sativa
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL single stranded oligonucleotides
Patent: WO 0192512-A 2383 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Oryza sativa"
/mol_type="unassigned DNA"
/db_xref="taxon:4530"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 363 CACCATCTACCACAT 377
Db 17 CACCATCTACCACAT 3
RESULT 269
AX326246
LOCUS AX326246 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 2384 from Patent WO0192512.
ACCESSION AX326246
VERSION AX326246.1 GI:18097008
KEYWORDS Oryza sativa
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL single stranded oligonucleotides
Patent: WO 0192512-A 2384 06-DEC-2001;

[illegible]

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 176 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 322 AAGTCCTCCTGTGAT 336
||||| |||||||
Db 16 AAGTCCTCCTGTGAT 2
RESULT 275
AX691881/c
LOCUS AX691881 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4613 from Patent EP1281758.
ACCESSION AX691881
VERSION AX691881.1 GI:29414822
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 4613 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 741 GAGAGAGGCTGTGCC 755
||||| |||||||
Db 17 GAGAGAGGCTGTGCC 3
RESULT 276
AX691882/c
LOCUS AX691882 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4614 from Patent EP1281758.
ACCESSION AX691882
VERSION AX691882.1 GI:29414823
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

mdz12
JOURNAL Patent: EP 1281758-A 4614 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 741 GAGAGAGGCTGTGCC 755
||||| |||||||
Db 16 GAGAGAGGCTGTGCC 2
RESULT 277
AX691883/c
LOCUS AX691883 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4615 from Patent EP1281758.
ACCESSION AX691883
VERSION AX691883.1 GI:29414824
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 4615 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 741 GAGAGAGGCTGTGCC 755
||||| |||||||
Db 15 GAGAGAGGCTGTGCC 1
RESULT 278
AX722342/c
LOCUS AX722342 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 29 from Patent WO03025176.
ACCESSION AX722342
VERSION AX722342.1 GI:30422843
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 29 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1113 ATTGGAGACAGAT 1127
|||||
Db 16 ATTGGAGAAAGAT 2

RESULT 279
LOCUS AX725093 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2780 from Patent WO03025176.
ACCESSION AX725093
VERSION AX725093.1 GI:30504436
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 2780 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 928 TATGCTGCTTCATC 942
|||||
Db 3 TCTGCTGCTTCATC 17

RESULT 280
LOCUS AX726517/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4204 from Patent WO03025176.
ACCESSION AX726517
VERSION AX726517.1 GI:30505860
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 4204 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 322 AAGTCCCTGCTTGAT 336
|||||

Db 16 AAGGCCCTGCTTGAT 2

RESULT 281
LOCUS AX729345 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 979 from Patent WO03025175.
ACCESSION AX729345
VERSION AX729345.1 GI:30508688
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 979 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 953 TCTGTGTCCTGTCT 967
|||||
Db 3 TCTGTGTCCTGTCT 17

RESULT 282
LOCUS AX739228 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4818 from Patent WO03025177.
ACCESSION AX739228
VERSION AX739228.1 GI:30518525
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 4818 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1018 ATCCTGCATGCCACG 1032
|||||
Db 2 ATCCTGCATGCCACG 16

RESULT 283
LOCUS AX757517/c 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 838 from Patent WO03040369.

ACCESSION AX757517
VERSION AX757517.1 GI:32252133
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 838 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 1; Indels 0; Gaps 0;
QY 322 AAGTCCTGCTTGAT 336
|||||
Db 16 AAGTGCCTGCTTGAT 2
RESULT 284
AX760975/c
LOCUS AX760975 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 4296 from Patent WO03040369.
ACCESSION AX760975
VERSION AX760975.1 GI:32255591
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 4296 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 1; Indels 0; Gaps 0;
QY 70 CCCTGTGGAGATGGA 84
|||||
Db 17 CCCTGTGGAGAGGGA 3
RESULT 285
AX783650/c
LOCUS AX783650 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1981 from Patent WO03050284.
ACCESSION AX783650
VERSION AX783650.1 GI:32951499
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1981 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 1; Indels 0; Gaps 0;
QY 1182 GAACGTGGTGCTCCA 1196
|||||
Db 17 GAACGTGGTGCGCCA 3
RESULT 286
AX783651/c
LOCUS AX783651 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1982 from Patent WO03050284.
ACCESSION AX783651
VERSION AX783651.1 GI:32951500
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1982 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 1; Indels 0; Gaps 0;
QY 1182 GAACGTGGTGCTCCA 1196
|||||
Db 16 GAACGTGGTGCGCCA 2
RESULT 287
AX783652/c
LOCUS AX783652 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1983 from Patent WO03050284.
ACCESSION AX783652
VERSION AX783652.1 GI:32951501
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1983 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```
Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1182 GAACGTGGTGGTCCA 1196
|||||
Db 15 GAACGTGGTGGGCCA 1

RESULT 288
BD067530          17 bp RNA linear PAT 27-AUG-2002
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to levels of epidermal growth factor receptors.
ACCESSION BD067530
VERSION BD067530.1 GI:22613133
KEYWORDS JP 2001511003-A/370.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 370 07-AUG-2001;
COMMENT RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
OS Unidentified
PN JP 2001511003-A/370
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12H9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17
FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCAACTTCTACCG 1175
|||||
Db 1 CTCCAACTTCTACCG 15

RESULT 289
AR126680          20 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 109 from patent US 6180353.
DEFINITION AR126680
ACCESSION AR126680
VERSION AR126680.1 GI:14113273
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowseert,L.M.
TITLE Antisense modulation of daxx expression
JOURNAL Patent: US 6180353-A 109 30-JAN-2001;
COMMENT Location/Qualifiers
source 1..20
/organism="unknown"
```

```
/mol_type="unassigned DNA"

Query Match          0.9%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 CTGCAGAGGACAGAA 42
|||||
Db 1 CTGCAGAGGCCAGAA 15

RESULT 290
AR148269/c        17 bp DNA linear PAT 08-AUG-2001
LOCUS Sequence 17 from patent US 6225081.
DEFINITION AR148269
ACCESSION AR148269
VERSION AR148269.1 GI:15112359
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Shinomura,T., Kawaguchi,T., Kitamura,N. and Miyazawa,K.
TITLE Protein, DNA coding for same and method of producing the protein
JOURNAL Patent: US 6225081-A 17 01-MAY-2001;
COMMENT Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match          0.8%; Score 13.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 876 CAGGTGGAATTATGTGG 892
|||||
Db 17 CAGTNGARTTRTGGG 1

RESULT 291
AR237458/c        17 bp DNA linear PAT 20-DEC-2002
LOCUS Sequence 17 from patent US 6465622.
DEFINITION AR237458
ACCESSION AR237458
VERSION AR237458.1 GI:27282194
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Shinomura,T., Kawaguchi,T., Kitamura,N. and Miyazawa,K.
TITLE Protein, DNA coding for same and method of producing the protein
JOURNAL Patent: US 6465622-A 17 15-OCT-2002;
COMMENT Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match          0.8%; Score 13.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 876 CAGGTGGAATTATGTGG 892
|||||
Db 17 CAGTNGARTTRTGGG 1

RESULT 292
AX255782/c        16 bp DNA linear PAT 10-OCT-2001
LOCUS Sequence 203 from Patent WO0170982.
DEFINITION AX255782
ACCESSION AX255782
VERSION AX255782.1 GI:16074837
```

```

KEYWORDS
SOURCE      synthetic construct
ORGANISM    artificial sequences.

REFERENCE
AUTHORS     Beger, C., Barber, J. and Wong-Staal, F.
TITLE       Brca-1 regulators and methods of use
JOURNAL     Patent: WO 0170982-A 203 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)

FEATURES
source      1..16
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Synthetic oligonucleotide"

Query Match      0.8%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GCCATCGACTTCA 430
Db 14 GCCATCGACTTCA 2

RESULT 293
LOCUS      AR039205/c 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 53 from patent US 5807743.
ACCESSION  AR039205
VERSION     AR039205.1 GI:5958568
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE
AUTHORS     Stinchcomb, D.T. and McSwiggen, J.A.
TITLE       Interleukin-2 receptor gamma-chain ribozymes
JOURNAL     Patent: US 5807743-A 53 15-SEP-1998;
            Location/Qualifiers
FEATURES
source      1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAG 93
Db 13 TGGAAACACTGAG 1

RESULT 294
LOCUS      BD226527 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Method and probes for the detection of chromosome aberrations.
ACCESSION  BD226527
VERSION     BD226527.1 GI:33036297
KEYWORDS    JP 2002513587-A/73.
SOURCE      synthetic construct
            synthetic construct
            artificial construct
            1 (bases 1 to 17)
REFERENCE
AUTHORS     Dongen, J.J.M.V., Pluzek, K.J., Nielsen, K.V. and Adelhorst, K.
TITLE       Method and probes for the detection of chromosome aberrations
JOURNAL     Patent: JP 2002513587-A 73 14-MAY-2002;
            DAKO AS
COMMENT
OS          Artificial Sequence
PN          JP 2002513587-A/73
PD          14-MAY-2002
PP          04-MAY-1999 JP 2000547260
PR          04-MAY-1998 DK 0615/98

PI JACOBS JOHANNES MARIA VAN DONGEN, KARL JOHAN PLUZEK, KIRSTEN PI
VANG NIELSEN,
PI KIM ADELHORST
PC C12N15/09, C07H21/00, C12Q1/68, G01N33/53, G01N33/566, C12N15/00 CC
Description of Artificial Sequence: PNA probe, HER-2, position CC
3115-3099
FH Key      Location/Qualifiers
FT source   1..17
FT          /organism='Artificial Sequence'.
FEATURES
source      1..17
            Location/Qualifiers
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 GGCCATGGGGAG 210
Db 2 GGCCATGGGGAG 14

RESULT 295
LOCUS      CQ801550 17 bp DNA linear PAT 05-MAY-2004
DEFINITION Sequence 60 from Patent WO2004033723.
ACCESSION  CQ801550
VERSION     CQ801550.1 GI:47058140
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS     Mitchell, J. and de Bellerocche, J.
TITLE       Neurodegenerative disease-associated gene
JOURNAL     Patent: WO 2004033723-A 60 22-APR-2004;
            IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
            Location/Qualifiers
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1075 CTCATTGCTGGC 1087
Db 5 CTCATTGCTGGC 17

RESULT 296
LOCUS      AR188253 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3741 from patent US 6346398.
ACCESSION  AR188253
VERSION     AR188253.1 GI:20234218
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE
AUTHORS     Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
            Patent: US 6346398-A 3741 12-FEB-2002;
            Location/Qualifiers
FEATURES
source      1..17
            /organism="unknown"

```



```
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 946 GCGCGCCTCTGTG 958
Db 1 GCGCGCCTCTGTG 13

RESULT 297
AR286085/c
LOCUS AR286085 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 457 from patent US 6528640.
ACCESSION AR286085
VERSION AR286085.1 GI:29723681
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 457 04-MAR-2003;
FEATURES
source
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 GCCCATGCGGGAG 210
Db 16 GCCCATGCGGGAG 4

RESULT 298
AR287615/c
LOCUS AR287615 17 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 17 from patent US 6531281.
ACCESSION AR287615
VERSION AR287615.1 GI:29725370
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Magot,M. and Ravot,G.
TITLE Method of detecting sulphate-reducing bacteria
JOURNAL Patent: US 6531281-A 17 11-MAR-2003;
FEATURES
source
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 AACTTCATGATGC 1393
Db 17 AACTTCATGATGC 5

RESULT 299
AR324106
LOCUS AR324106 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1508 from patent US 6566127.
ACCESSION AR324106

/mol_type="unassigned RNA"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 946 GCGCGCCTCTGTG 958
Db 1 GCGCGCCTCTGTG 13

RESULT 300
AR398075/c
LOCUS AR398075 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 456 from patent US 6617438.
ACCESSION AR398075
VERSION AR398075.1 GI:40135592
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 456 09-SEP-2003;
FEATURES
source
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 GCCCATGCGGGAG 210
Db 16 GCCCATGCGGGAG 4

RESULT 301
AR214846
LOCUS AR214846 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 288 from Patent WO0159103.
ACCESSION AR214846
VERSION AR214846.1 GI:15524889
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 288 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
/mol_type="synthetic construct"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 AACTTCATGATGC 1393
Db 17 AACTTCATGATGC 5

RESULT 299
AR324106
LOCUS AR324106 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1508 from patent US 6566127.
ACCESSION AR324106

/mol_type="unassigned RNA"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 946 GCGCGCCTCTGTG 958
Db 1 GCGCGCCTCTGTG 13

RESULT 300
AR398075/c
LOCUS AR398075 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 456 from patent US 6617438.
ACCESSION AR398075
VERSION AR398075.1 GI:40135592
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 456 09-SEP-2003;
FEATURES
source
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 0.8%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 GCCCATGCGGGAG 210
Db 16 GCCCATGCGGGAG 4

RESULT 301
AR214846
LOCUS AR214846 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 288 from Patent WO0159103.
ACCESSION AR214846
VERSION AR214846.1 GI:15524889
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 288 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
/mol_type="synthetic construct"
```


DEFINITION Sequence 3093 from Patent WO03004526.
ACCESSION AX674648
VERSION AX674648.1 GI:29322996
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3093 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 398 TCTTCATCATCAG 410
Db 3 TCTTCATCATCAG 15
LOCUS AX691884 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4616 from Patent EP1281758.
ACCESSION AX691884
VERSION AX691884.1 GI:29414825
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 4616 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 741 GAGAGAGGCTGTG 753
Db 14 GAGAGAGGCTGTG 2
LOCUS AX691885 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4617 from Patent EP1281758.
ACCESSION AX691885
VERSION AX691885.1 GI:29414826
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 4617 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 741 GAGAGAGGCTGTG 753
Db 13 GAGAGAGGCTGTG 1
LOCUS AX723124 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 811 from Patent WO03025176.
ACCESSION AX723124
VERSION AX723124.1 GI:30423625
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 811 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1547 GATCTTGTCCTG 1559
Db 1 GATCTTGTCCTG 13
LOCUS AX725762 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3449 from Patent WO03025176.
ACCESSION AX725762
VERSION AX725762.1 GI:30505105
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3449 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers

```
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1073 TCTCCATTGCTG 1085
Db 5 TCTCCATTGCTG 17

RESULT 311
AX730681/c
LOCUS AX730681
DEFINITION Sequence 2315 from Patent WO03025175.
ACCESSION AX730681
VERSION AX730681.1 GI:30510024
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2315 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1535 TGGTGACACCTCG 1547
Db 17 TGGTGACACCTCG 5

RESULT 312
AX737420/c
LOCUS AX737420
DEFINITION Sequence 3010 from Patent WO03025177.
ACCESSION AX737420
VERSION AX737420.1 GI:30516708
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3010 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

QY 1199 ACTGCTGTACAG 1211
Db 17 ACTGGCTGTACAG 5

RESULT 313
AX737926
LOCUS AX737926
DEFINITION Sequence 3516 from Patent WO03025177.
ACCESSION AX737926
VERSION AX737926.1 GI:30517214
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3516 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 246 GCCCCACCTCCC 258
Db 5 GCCCCACCTCCC 17

RESULT 314
AX750949
LOCUS AX750949
DEFINITION Sequence 165 from Patent WO03033703.
ACCESSION AX750949
VERSION AX750949.1 GI:32133277
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Zhang,J.
TITLE Human gtp-activator protein for rab-like gtpase
JOURNAL Patent: WO 03033703-A 165 24-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 TTCTCCAGCTAC 813
Db 5 TTCTCCAGCTAC 17

RESULT 315
AX750955
```

LOCUS AX750955 17 bp DNA linear PAT 20-JUN-2003
 DEFINITION Sequence 171 from Patent WO03033703.
 ACCESSION AX750955
 VERSION AX750955.1 GI:32133283
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Zhang, J.
 TITLE Human gtp-activator protein for rab-like gtpase
 JOURNAL Patent: WO 03033703-A 171 24-APR-2003;
 Amersham Biosciences (SV) Corp. (US)
 FEATURES
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 803 TCTCCAGCTACCT 815
 Db 1 TCTCCAGCTACCT 13
 RESULT 316
 AX758682/c
 LOCUS AX758682 17 bp DNA linear PAT 25-JUN-2003
 DEFINITION Sequence 2003 from Patent WO03040369.
 ACCESSION AX758682
 VERSION AX758682.1 GI:32253298
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
 TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
 JOURNAL Patent: WO 03040369-A 2003 15-MAY-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1048 ATGCTGCTGCTCA 1060
 Db 17 ATGCTGCTGCTCA 5
 RESULT 317
 AX762870
 LOCUS AX762870 17 bp DNA linear PAT 25-JUN-2003
 DEFINITION Sequence 6191 from Patent WO03040369.
 ACCESSION AX762870
 VERSION AX762870.1 GI:32257486
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
 TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
 JOURNAL Patent: WO 03040369-A 6191 15-MAY-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 246 GCCCCACCTCCC 258
 Db 5 GCCCCACCTCCC 17
 RESULT 318
 A97811
 LOCUS A97811 16 bp DNA linear PAT 26-JAN-2000
 DEFINITION Sequence 88 from Patent WO9914377.
 ACCESSION A97811
 VERSION A97811.1 GI:6781049
 SOURCE unidentified
 ORGANISM unclassified.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS Quint, W. and Kleter, B.
 TITLE DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND TYPE-SPECIFIC REVERSE HYBRIDIZATION
 JOURNAL Patent: WO 9914377-A 88 25-MAR-1999;
 INNOGENETICS NV (BE); DELFTS DIAGNOSTIC LAB B V (NL)
 FEATURES
 source 1..16
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"
 Query Match 0.8%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 151 CAATTCCTGGAGCAAG 166
 Db 1 CATTTCCTGGGCAAG 16
 RESULT 319
 I06972/c
 LOCUS I06972 16 bp DNA linear PAT 02-DEC-1994
 DEFINITION Sequence 7 from Patent EP 0317511.
 ACCESSION I06972
 VERSION I06972.1 GI:590325
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS Rice, D., Carozzi, N., Lotstein, R., de Framond, A., Anderson, D.M., Rajasekaran, K., Rangan, I.S. and Yenofsky, R.
 TITLE Insecticidal cotton plant cells
 JOURNAL Patent: EP 0317511-A2 7 24-MAY-1989;
 FEATURES
 source 1..16
 /organism="unknown"
 /mol_type="unassigned DNA"

```
Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 189 GCTGGATCGGGCATG 204
DB 16 GCCGGATCGGGCATG 1

RESULT 320
AR254804
LOCUS AR254804 16 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 88 from patent US 6482588.
ACCESSION AR254804
VERSION AR254804.1 GI:27303852
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Van Doorn,L.-J., Quint,W., Kleter,B. and TerSchegget,J.
TITLE Detection and identification of human papillomavirus by PCR and
type-specific reverse hybridization
JOURNAL Patent: US 6482588-A 88 19-NOV-2002;
FEATURES
source
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 151 CAATTGCTGGGCAAG 166
DB 1 CATTTGCTGGGCAAG 16

RESULT 321
AR305481
LOCUS AR305481 16 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 439 from patent US 6545137.
ACCESSION AR305481
VERSION AR305481.1 GI:31694791
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.
TITLE Receptor
JOURNAL Patent: US 6545137-A 439 08-APR-2003;
FEATURES
source
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 151 CAATTGCTGGGCAAG 166
DB 1 CATTTGCTGGGCAAG 16

RESULT 321
AR305481
LOCUS AR305481 16 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 439 from patent US 6545137.
ACCESSION AR305481
VERSION AR305481.1 GI:31694791
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.
TITLE Receptor
JOURNAL Patent: US 6545137-A 439 08-APR-2003;
FEATURES
source
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 CCTCCCCCAGGTTCTCT 268
DB 1 CCTCCCCCAGGTTACCT 16

RESULT 322
AR309585
LOCUS AR309585 16 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 439 from patent US 6555654.
ACCESSION AR309585
VERSION AR309585.1 GI:27303852
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Van Doorn,L.-J., Quint,W., Kleter,B. and TerSchegget,J.
TITLE Detection and identification of human papillomavirus by PCR and
type-specific reverse hybridization
JOURNAL Patent: US 6555654-A 439 29-APR-2003;
FEATURES
source
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 CCTCCCCCAGGTTCTCT 268
DB 1 CCTCCCCCAGGTTACCT 16

RESULT 322
AR309585
LOCUS AR309585 16 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 88 from Patent EP1201771.
ACCESSION AX428689
VERSION AX428689.1 GI:21538600
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Van Doorn,L.J., Kleter,B. and Ter Schegget,J.
TITLE Detection and identification of human papillomavirus by pcr and
type-specific reverse hybridization
JOURNAL Patent: EP 1201771-A 88 02-MAY-2002;
FEATURES
Location/Qualifiers
INNOGENETICS N.V. (BE) ; Delfts Diagnostic laboratory B.V. (NL)
```

```
source
1. .16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 151 CAATTGCTGGACAAG 166
||| ||||| |||||
Db 1 CATTGCTGGACAAG 16

RESULT 325
AX927948/c
LOCUS AX927948 16 bp DNA linear PAT 19-DEC-2003
DEFINITION Sequence 34 from Patent WO03085110.
ACCESSION AX927948
VERSION AX927948.1 GI:40250814
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Thrus, C.A., h G.A.M. and Kristjansen, P.E.
AUTHORS Oligomeric compounds for the modulation hif-lalpha expression
TITLE Patent: WO 03085110-A 34 16-OCT-2003;
JOURNAL Curren A/S (DK)
FEATURES
source
1. .16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence:antisense oligonucleotide to human HIF-1a"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCACCCCTGTTGG 538
||| ||||| |||||
Db 16 CTGCTACCCCTGTTGG 1

RESULT 326
AX927967/c
LOCUS AX927967 16 bp DNA linear PAT 19-DEC-2003
DEFINITION Sequence 53 from Patent WO03085110.
ACCESSION AX927967
VERSION AX927967.1 GI:40250882
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Thrus, C.A., h G.A.M. and Kristjansen, P.E.
AUTHORS Oligomeric compounds for the modulation hif-lalpha expression
TITLE Patent: WO 03085110-A 53 16-OCT-2003;
JOURNAL Curren A/S (DK)
FEATURES
source
1. .16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence:antisense oligonucleotide to human HIF-1a"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1525 TTCTGGGGGCTGGTGA 1540
||||| ||||| |||||
Db 16 TTCTGGATGCTGGTGA 1

RESULT 327
BD106392
LOCUS BD106392 16 bp DNA linear PAT 18-SEP-2002
DEFINITION Novel LDL-receptor.
ACCESSION BD106392
VERSION BD106392.1 GI:23201210
KEYWORDS JP 2002501376-A/407.
SOURCE Chlamydia sp.
ORGANISM Chlamydia sp.
REFERENCE
1 (bases 1 to 16)
AUTHORS Todd, J.A., Hess, J.W., Caskey, C.T., Cox, R.D., Gerhold, D., Hammond, H.
and Hey, P.
TITLE Novel LDL-receptor
JOURNAL Patent: JP 2002501376-A 407 15-JAN-2002;
COMMENT THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO
INC
PN JP 2002501376-A/407
PD 15-JAN-2002
PF 15-APR-1998 JP 1998543635
PR 15-APR-1997 US 60/043553, 05-JUN-1997 US 60/048740 PI
JOHN ANDREW TODD, JOHN WILFRED HESS, CHARLES
THOMAS CASKEY, ROGER
PI DAVID COX,
PI DAVID GERHOLD, HOLLY HAMMOND, PATRICIA HEY
PC C12N15/12, C12N15/11, C12Q1/68, C07K14/705, C07K16/28, A61K38/17,
PC A61K39/395,
PC A61K48/00
CC Strandedness: Double;
CC Topology: Linear;
PH Key Location/Qualifiers.
FEATURES
source
1. .16
/organism="Chlamydia sp."
/mol_type="genomic DNA"
/db_xref="taxon:35827"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 CCTCCCCCAGTTCTCT 268
||||| ||||| |||||
Db 1 CCTCCCGCAGGTACCT 16

RESULT 328
AL0566
LOCUS AL0566 17 bp DNA linear PAT 08-SEP-1993
DEFINITION Nucleotide sequence 22 from patent number EP0229998.
ACCESSION AL0566
VERSION AL0566.1 GI:412123
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 (bases 1 to 17)
AUTHORS Habermann, P.
TITLE Fusion proteins with an eukaryotic ballast sequence
JOURNAL Patent: EP 0229998-A 22 29-JUL-1987;
HOECHST AKTIENGESELLSCHAFT
FEATURES
source
1. .17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
```

```
Best Local Similarity 87.5%; Pred. No. 2.5e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2;

QY 24 GCGTCTGCAGAGGACA 39
Db 2 GCGTCTGCAGATGCCA 17

RESULT 329
LOCUS A29124 17 bp DNA linear PAT 15-JUN-1995
DEFINITION DNA fragment from patent GB2241703.
ACCESSION A29124
VERSION A29124.1 GI:1247182
KEYWORDS synthetic construct
SOURCE artificial sequences.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS
JOURNAL Patent: GB 2241703-A 8 11-SEP-1991;
FEATURES
source
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 397 GTCCTTCATCATCAGCA 412
Db 1 GTCCTTCATCATCA 16

RESULT 330
LOCUS A57774 17 bp DNA linear PAT 03-MAR-1998
DEFINITION Sequence 9 from Patent WO9634100.
ACCESSION A57774
VERSION A57774.1 GI:3713598
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Strosberg,A.D. and Zilberfarb,V.
TITLE IMMORTALISED CELL LINES FROM HUMAN ADIPOSE TISSUE, PROCESS FOR
JOURNAL PREPARING SAME AND APPLICATIONS THEREOF
PATENT: WO 9634100-A 9 31-OCT-1996;
CENTRE NAT RECH SCIENT (FR)
COMMENT Other publication FR 2733513 961031.
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 985 GAGCCCTTCAGCACCC 1000
Db 1 GAGACCTTCACACCC 16

RESULT 331
LOCUS A80029/c 17 bp DNA linear PAT 20-OCT-1999
DEFINITION Sequence 26 from Patent WO9619578.
ACCESSION A80029

Best Local Similarity 87.5%; Pred. No. 2.5e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2;

QY 24 GCGTCTGCAGAGGACA 39
Db 2 GCGTCTGCAGATGCCA 17

RESULT 329
LOCUS A29124 17 bp DNA linear PAT 15-JUN-1995
DEFINITION DNA fragment from patent GB2241703.
ACCESSION A29124
VERSION A29124.1 GI:1247182
KEYWORDS synthetic construct
SOURCE artificial sequences.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS
JOURNAL Patent: GB 2241703-A 8 11-SEP-1991;
FEATURES
source
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 397 GTCCTTCATCATCAGCA 412
Db 1 GTCCTTCATCATCA 16

RESULT 330
LOCUS A57774 17 bp DNA linear PAT 03-MAR-1998
DEFINITION Sequence 9 from Patent WO9634100.
ACCESSION A57774
VERSION A57774.1 GI:3713598
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Strosberg,A.D. and Zilberfarb,V.
TITLE IMMORTALISED CELL LINES FROM HUMAN ADIPOSE TISSUE, PROCESS FOR
JOURNAL PREPARING SAME AND APPLICATIONS THEREOF
PATENT: WO 9634100-A 9 31-OCT-1996;
CENTRE NAT RECH SCIENT (FR)
COMMENT Other publication FR 2733513 961031.
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 985 GAGCCCTTCAGCACCC 1000
Db 1 GAGACCTTCACACCC 16

RESULT 331
LOCUS A80029/c 17 bp DNA linear PAT 20-OCT-1999
DEFINITION Sequence 26 from Patent WO9619578.
ACCESSION A80029

Version A80029/c 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 5 from patent US 5830668.
ACCESSION A8051434
VERSION A8051434.1 GI:5974798
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Mordechai,E. and Vojdani,A.
TITLE Detection of chronic fatigue syndrome
JOURNAL Patent: US 5830668-A 5 03-NOV-1998;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
```


Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAG 307
||| ||||| ||||| |||||
Db 17 CTGCAGAAACAGAAAG 2

RESULT 334
LOCUS AR057471/c 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1675 from patent US 5837542.
ACCESSION AR057471
VERSION AR057471.1 GI:5983048
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1675 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
||| ||||| ||||| |||||
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 335
LOCUS AR057488/c 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1692 from patent US 5837542.
ACCESSION AR057488
VERSION AR057488.1 GI:5983065
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1692 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
||| ||||| ||||| |||||
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 336
LOCUS AR057769/c 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1973 from patent US 5837542.
ACCESSION AR057769

VERSION AR057769.1 GI:5983346
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1973 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
||| ||||| ||||| |||||
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 337
LOCUS AR068479/c 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 5 from patent US 5853996.
ACCESSION AR068479
VERSION AR068479.1 GI:6000686
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Mordechai,E. and Vojdani,A.
TITLE Detection of chronic fatigue syndrome by increased apoptosis and cell cycle arrest of peripheral blood mononuclear cells
JOURNAL Patent: US 5853996-A 5 29-DEC-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAG 307
||| ||||| ||||| |||||
Db 17 CTGCAGAAACAGAAAG 2

RESULT 338
LOCUS AR097588 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 9 from patent US 6071747.
ACCESSION AR097588
VERSION AR097588.1 GI:12806318
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Strosberg,A.Donny. and Zilberfarb,V.
TITLE Immortalized cell lines from human adipose tissue, process for preparing same and applications thereof
JOURNAL Patent: US 6071747-A 9 06-JUN-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 985 GAGCCCTTCAGCACCC 1000
DB 1 GAGACCTTCACACCC 16

RESULT 339
AR115229/c
LOCUS AR115229 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1675 from patent US 6132967.
ACCESSION AR115229
VERSION AR115229.1 GI:14095551
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 1675 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGCCTGGGAGGGGAGC 58
DB 16 GCGCTGGGAGGGGTGC 1

RESULT 340
AR115246/c
LOCUS AR115246 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1692 from patent US 6132967.
ACCESSION AR115246
VERSION AR115246.1 GI:14095568
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 1692 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGCCTGGGAGGGGAGC 58
DB 16 GCGCTGGGAGGGGTGC 1

RESULT 341
AR11527/c
LOCUS AR11527 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1973 from patent US 6132967.

ACCESSION AR11527
VERSION AR11527.1 GI:14095849
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 1973 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGCCTGGGAGGGGAGC 58
DB 16 GCGCTGGGAGGGGTGC 1

RESULT 342
BD203013/c
LOCUS BD203013 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD203013
VERSION BD203013.1 GI:33012783
KEYWORDS JP 2002509721-A/6039.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 6039 02-APR-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/6039
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00, A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'.
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 226 CCATCAAGACAAAC 241


```
QY 1044 CTTTCATGCTGCTGCTC 1059
Db 17 CTTTCATGACTGCTC 2

RESULT 346
BD257477/c
LOCUS 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD257477
VERSION BD257477.1 GI:33067247
KEYWORDS JP 2002541795-A/5270.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 5270 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/5270
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
FEATURES
source
1..17
/organism="Eukaryote".
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 329 TCGTTGATGAGCTGAT 344
Db 17 TCGTAGATGAGCTCAT 2

RESULT 348
BD259352
LOCUS 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD259352
VERSION BD259352.1 GI:33069122
KEYWORDS JP 2002541795-A/7145.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 7145 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/7145
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
FEATURES
source
1..17
/organism="Eukaryote".
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1454 AGGGAATCCAGGTCAG 1469
Db 17 AGGGAATCCAGGTCAG 2

RESULT 347
BD258589/c
LOCUS 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD258589
VERSION BD258589.1 GI:33068359
KEYWORDS JP 2002541795-A/6382.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 6382 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/6382
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
```

Db 2 AGAATCCAGGCCAG 17

RESULT 349
LOCUS BD259441 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD259441
VERSION BD259441.1 GI:33069211
KEYWORDS JP 2002541795-A/7234.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 7234 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/7234
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PI 12-APR-1999 US 60/129390
PR LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA, PAVCO, JAMES, MCSWIGGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
KEY Location/Qualifiers
FT source 1..17
FT /organism='Eukaryote'.
FEATURES
source
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1122 CAGGATGTTCTACCGG 1137
Db 1 CAGGGTGTCTACCCG 16

RESULT 350
LOCUS CQ615694 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 434 from Patent WO0192524.
ACCESSION CQ615694
VERSION CQ615694.1 GI:41665912
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 434 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1122 CAGGATGTTCTACCGG 1137
Db 1 CAGGGTGTCTACCCG 16

RESULT 350
LOCUS CQ615694/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 434 from Patent WO0192524.
ACCESSION CQ615694
VERSION CQ615694.1 GI:41665913
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 434 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTGG 193
Db 16 CTGAGAGATCTGCTGG 1

RESULT 352
LOCUS CQ616190 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 930 from Patent WO0192524.
ACCESSION CQ616190
VERSION CQ616190.1 GI:41666408
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 930 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTGG 193
Db 16 CTGAGAGATCTGCTGG 1

RESULT 352
LOCUS CQ616190 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 930 from Patent WO0192524.
ACCESSION CQ616190
VERSION CQ616190.1 GI:41666408
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 930 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGAGAGAGGCTGTCG 754
Db 2 CTGAAGAGGCTGAGC 17

RESULT 353
CO616192
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 932 from Patent WO0192524.
ACCESSION CO616192
VERSION CO616192.1 GI:41666410
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 932 06-DEC-2001;
Aoemica, Inc. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 740 TGAGAGAGGCTGTGCC 755
||| ||||| ||||| |||||
Db 1 TGAAGAGGCTGAGCC 16
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
LOCUS CO616460/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1200 from Patent WO0192524.
ACCESSION CO616460
VERSION CO616460.1 GI:41666678
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1200 06-DEC-2001;
Aoemica, Inc. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1061 TCTTCTTTCGCTTCT 1076
||||| ||||| ||||| |||||
Db 17 TCTTCTTTCGCTTACT 2
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
LOCUS CO616461/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1201 from Patent WO0192524.
ACCESSION CO616461
VERSION CO616461.1 GI:41666679
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1201 06-DEC-2001;
Aoemica, Inc. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1061 TCTTCTTTCGCTTCT 1076
||||| ||||| ||||| |||||
Db 16 TCTTCTTTCGCTTACT 1
RESULT 356
CO616676
LOCUS CO616676 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1416 from Patent WO0192524.
ACCESSION CO616676
VERSION CO616676.1 GI:41666894
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1416 06-DEC-2001;
Aoemica, Inc. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 138 GGCTGTGAAGCACA 153
||||| ||||| ||||| |||||
Db 2 GGCTGTGAAGCCCCAA 17
RESULT 357
CO616677
LOCUS CO616677 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1417 from Patent WO0192524.
ACCESSION CO616677
VERSION CO616677.1 GI:41666895
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1417 06-DEC-2001;
Aoemica, Inc. (US)

```
FEATURES
source
  Location/Qualifiers
  1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 138 GCGCTGTGAAGGCACAA 153
Db 1 GCGCTGTGAAGCCCA 16

RESULT 358
LOCUS CQ616795 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1535 from Patent WO0192524.
ACCESSION CQ616795
VERSION CQ616795.1 GI:41667013
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1535 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
  Location/Qualifiers
  1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGCTGTGACCTG 509
Db 2 TGGCGCTGTGCGCTG 17

RESULT 359
LOCUS CQ616797 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1537 from Patent WO0192524.
ACCESSION CQ616797
VERSION CQ616797.1 GI:41667015
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1537 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
  Location/Qualifiers
  1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 495 GCGCTGTGACCTGG 510
Db 1 GCGCTGTGTCCTGG 16

RESULT 360
LOCUS CQ616906/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1646 from Patent WO0192524.
ACCESSION CQ616906
VERSION CQ616906.1 GI:41667124
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1646 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
  Location/Qualifiers
  1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1063 TTCTTTGCTCTCTCC 1078
Db 17 TCCTTTGCCCTCTCTCC 2

RESULT 361
LOCUS CQ616908/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1648 from Patent WO0192524.
ACCESSION CQ616908
VERSION CQ616908.1 GI:41667126
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1648 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
  Location/Qualifiers
  1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTCTTTGCTCTCTCC 1077
Db 16 CTCTTTGCCCTCTCTC 1

RESULT 362
LOCUS CQ617549/c 17 bp DNA linear PAT 02-FEB-2004
```

DEFINITION Sequence 2289 from Patent WO0192524.
ACCESSION CQ617549
VERSION CQ617549.1 GI:41667767
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2289 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 560 TGTGGCCCGGCGCAC 575
Db 17 TGTGGCCCGGCGCAC 2
RESULT 363
CQ617561/c
LOCUS CQ617561 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2301 from Patent WO0192524.
ACCESSION CQ617561
VERSION CQ617561.1 GI:41667779
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2301 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 549 GGCCCTACGGCTGTGG 564
Db 16 GGCACTGCGGCTGTGG 1
RESULT 364
CQ621805/c
LOCUS CQ621805 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6545 from Patent WO0192524.
ACCESSION CQ621805
VERSION CQ621805.1 GI:41672023
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6545 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 250 CCACCTCCCCCAGGTT 265
Db 17 CCACCTGCCCGAGGCT 2
RESULT 365
CQ621806/c
LOCUS CQ621806 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6546 from Patent WO0192524.
ACCESSION CQ621806
VERSION CQ621806.1 GI:41672024
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6546 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 250 CCACCTCCCCCAGGTT 265
Db 16 CCACCTGCCCGAGGCT 1
RESULT 366
CQ622175/c
LOCUS CQ622175 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6915 from Patent WO0192524.
ACCESSION CQ622175
VERSION CQ622175.1 GI:41672393
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6915 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAG 307
|||||
Db 17 CTGGGAGACAGAAAG 2

RESULT 367
CQ622177/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6917 from Patent WO0192524.
ACCESSION CQ622177
VERSION CQ622177.1 GI:41672395
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6917 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 CCTGGGGAACAGAAA 306
|||||
Db 16 CTGGGAGACAGAAA 1

RESULT 368
CQ622966
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7706 from Patent WO0192524.
ACCESSION CQ622966
VERSION CQ622966.1 GI:41673184
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7706 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 902 TTGCCAGGCCCTGGG 917
|||||
Db 2 TGCCCCAGGCCCTAGG 17

RESULT 369
CQ622967
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7707 from Patent WO0192524.
ACCESSION CQ622967
VERSION CQ622967.1 GI:41673185
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7707 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 902 TTGCCAGGCCCTGGG 917
|||||
Db 1 TGCCCCAGGCCCTAGG 16

RESULT 370
CQ623587/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8327 from Patent WO0192524.
ACCESSION CQ623587
VERSION CQ623587.1 GI:41673805
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8327 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1067 TTGCCTTCTCCATTG 1082
|||||
Db 17 TTGCCATCTCCATGG 2

RESULT 371
CQ623588/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8328 from Patent WO0192524.
ACCESSION CQ623588
VERSION CQ623588.1 GI:41673806
KEYWORDS

```

SOURCE      Homo sapiens (human)
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8328 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1067 TTGCCTTCTCCATTG 1082
              ||||| ||||| |||||
Db      16 TTGCCATCTCCATGG 1

RESULT 372
CQ623611/c
LOCUS      CQ623611 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8351 from Patent WO0192524.
ACCESSION CQ623611
VERSION   CQ623611.1 GI:41673829
KEYWORDS  .
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8351 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      727 AGCTACTCTCTCTGA 742
              ||||| ||||| |||||
Db      17 AGCTCTCTCTTGTGA 2

RESULT 373
CQ623612/c
LOCUS      CQ623612 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8352 from Patent WO0192524.
ACCESSION CQ623612
VERSION   CQ623612.1 GI:41673830
KEYWORDS  .
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8352 06-DEC-2001;

```

```

              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      727 AGCTACTCTCTCTGA 742
              ||||| ||||| |||||
Db      16 AGCTCTCTCTTGTGA 1

RESULT 374
CQ623621/c
LOCUS      CQ623621 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8361 from Patent WO0192524.
ACCESSION CQ623621
VERSION   CQ623621.1 GI:41673839
KEYWORDS  .
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8361 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      798 CAGTTTCTCCAGCTAC 813
              ||||| ||||| |||||
Db      17 CACTTTCTCCAGCTCC 2

RESULT 375
CQ623622/c
LOCUS      CQ623622 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8362 from Patent WO0192524.
ACCESSION CQ623622
VERSION   CQ623622.1 GI:41673840
KEYWORDS  .
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8362 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      798 CAGTTTCTCCAGCTAC 813
              ||||| ||||| |||||
Db      17 CACTTTCTCCAGCTCC 2

RESULT 375
CQ623622/c
LOCUS      CQ623622 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8362 from Patent WO0192524.
ACCESSION CQ623622
VERSION   CQ623622.1 GI:41673840
KEYWORDS  .
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8362 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;

```



```
REFERENCE
AUTHORS   1  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
           Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 9023 06-DEC-2001;
          Aeomica, Inc. (US)
FEATURES
source    1. .17
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1150 TCAACGTCCTTCTCCA 1165
Db 17 TCCACGCTACTTCTCCA 2

RESULT 381
LOCUS      CQ624285          17 bp      DNA          linear      PAT 02-FEB-2004
DEFINITION Sequence 9025 from Patent WO0192524.
ACCESSION  CQ624285
VERSION     CQ624285.1  GI:41674503
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
           Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 9025 06-DEC-2001;
          Aeomica, Inc. (US)
FEATURES
source    1. .17
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 CTCACGTCCTTCTCC 1164
Db 16 CTCACGCTACTTCTCC 1

RESULT 382
LOCUS      CQ625089          17 bp      DNA          linear      PAT 02-FEB-2004
DEFINITION Sequence 9829 from Patent WO0192524.
ACCESSION  CQ625089
VERSION     CQ625089.1  GI:41675307
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
           Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 9829 06-DEC-2001;
          Aeomica, Inc. (US)
FEATURES
source    1. .17
           /organism="Homo sapiens"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1138 GACTGGTGGAACTCAA 1153
Db 16 GGCTGGTGGACCTCAA 1

RESULT 384
LOCUS      CQ625932          17 bp      DNA          linear      PAT 02-FEB-2004
DEFINITION Sequence 10672 from Patent WO0192524.
ACCESSION  CQ625932
VERSION     CQ625932.1  GI:41676150
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
           Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 10672 06-DEC-2001;
          Aeomica, Inc. (US)
FEATURES
source    1. .17
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 GTAGCATGCTGGTG 1276
Db 11 GTAGCATGCTGGTG 1276
```

Db 17 GTGGCCATGCTGGCTG 2

polynucleotide probes identified based on T.sub.m
Patent: US 5639612-A 284 17-JUN-1997;
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

RESULT 385

LOCUS I30846 17 bp DNA linear PAT 06-FEB-1997

DEFINITION Sequence 284 from patent US 5580971.

ACCESSION I30846

VERSION I30846.1 GI:1821637

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Mitsuhashi,M.

TITLE Fungal detection system based on rRNA probes

JOURNAL Patent: US 5580971-A 284 03-DEC-1996;

FEATURES
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 535 TTGGCGCGCTACCAGG 550
||||| |||||
Db 2 TTGGCGCGCAACCAGG 17

RESULT 386

LOCUS I37442 17 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 455 from patent US 5612215.

ACCESSION I37442

VERSION I37442.1 GI:2085402

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.

TITLE Stromelysin targeted ribozymes

JOURNAL Patent: US 5612215-A 455 18-MAR-1997;

FEATURES
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 535 TTGGCGCGCTACCAGG 550
||||| |||||
Db 2 TTGGCGCGCAACCAGG 17

RESULT 387

LOCUS I46305 17 bp DNA linear PAT 07-OCT-1997

DEFINITION Sequence 284 from patent US 5639612.

ACCESSION I46305

VERSION I46305.1 GI:2470270

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Mitsuhashi,M. and Cooper,A.

TITLE Method for detecting polynucleotides with immobilized

JOURNAL polynucleotide probes identified based on T.sub.m
Patent: US 5639612-A 284 17-JUN-1997;
FEATURES Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 535 TTGGCGCGCTACCAGG 550
||||| |||||
Db 2 TTGGCGCGCAACCAGG 17

RESULT 388

LOCUS I89918 17 bp DNA linear PAT 10-AUG-1998

DEFINITION Sequence 35 from patent US 5723312.

ACCESSION I89918

VERSION I89918.1 GI:3409858

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Noeske-Jungblut,C., Haendler,B., Kraetzschmar,J.Reiner., Schleuning,W.-D., Alagon,A., Possani,L. and Cuevas-Aguirre,D.

TITLE Collagen-induced platelet aggregation inhibitor

JOURNAL Patent: US 5723312-A 35 03-MAR-1998;

FEATURES
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1515 CCAGGCACTTCTGG 1530
||||| |||||
Db 17 CCAGTTAACTTCTGG 2

RESULT 389

LOCUS I94292 17 bp DNA linear PAT 01-DEC-1998

DEFINITION Sequence 455 from patent US 5731295.

ACCESSION I94292

VERSION I94292.1 GI:3938762

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.

TITLE Method of reducing stromelysin RNA via ribozymes

JOURNAL Patent: US 5731295-A 455 24-MAR-1998;

FEATURES
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 38 CAGAGGGCTGGGAGG 53
||||| |||||
Db 1 CTGAGGCTGGGAGG 16

```
RESULT 390
AR190193          17 bp  DNA          linear  PAT 20-APR-2002
LOCUS
DEFINITION      Sequence 5681 from patent US 6346398.
ACCESSION      AR190193
VERSION        AR190193.1  GI:20236158
KEYWORDS
SOURCE
ORGANISM
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6346398-A 5681 12-FEB-2002;
FEATURES
source
Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1354 CTCCTCTTGTGTCATTG 1369
Db 1 CTCCTCTTGTGTCATTG 16

RESULT 391
AR201825/c       17 bp  DNA          linear  PAT 20-APR-2002
LOCUS
DEFINITION      Sequence 40 from patent US 6361941.
ACCESSION      AR201825
VERSION        AR201825.1  GI:20256364
KEYWORDS
SOURCE
ORGANISM
REFERENCE      1 (bases 1 to 17)
AUTHORS      Todd,A.V., Fuery,C.J. and Cairns,M.J.
TITLE        Catalytic nucleic acid-based diagnostic methods
JOURNAL        Patent: US 6361941-A 40 26-MAR-2002;
FEATURES
source
Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 CCTTCTCCAACTACTA 1172
Db 16 CCTTCTCCAACTACTA 1

RESULT 392
AR286076        17 bp  RNA          linear  PAT 10-APR-2003
LOCUS
DEFINITION      Sequence 448 from patent US 6528640.
ACCESSION      AR286076
VERSION        AR286076.1  GI:29723672
KEYWORDS
SOURCE
ORGANISM
REFERENCE      1 (bases 1 to 17)
AUTHORS      Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
              Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE        Synthetic ribonucleic acids with RNase activity
JOURNAL        Patent: US 6528640-A 448 04-MAR-2003;
```

```
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1181 GGAACGTGGTGTCCA 1196
Db 2 GGACGTGCTGTGTCAA 17

RESULT 393
AR325165        17 bp  RNA          linear  PAT 17-AUG-2003
LOCUS
DEFINITION      Sequence 2567 from patent US 6566127.
ACCESSION      AR325165
VERSION        AR325165.1  GI:33710973
KEYWORDS
SOURCE
ORGANISM
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6566127-A 2567 20-MAY-2003;
FEATURES
source
Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1354 CTCCTCTTGTGTCATTG 1369
Db 1 CTCCTCTTGTGTCATTG 16

RESULT 394
AR327366        17 bp  RNA          linear  PAT 17-AUG-2003
LOCUS
DEFINITION      Sequence 4768 from patent US 6566127.
ACCESSION      AR327366
VERSION        AR327366.1  GI:33713174
KEYWORDS
SOURCE
ORGANISM
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6566127-A 4768 20-MAY-2003;
FEATURES
source
Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 801 TTCTCCAGCTACCTC 816
Db 2 TCTCTCCAACTACCTC 17

RESULT 395
```

AR327367
LOCUS AR327367 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4769 from patent US 6566127.
ACCESSION AR327367
VERSION AR327367.1 GI:33713175
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4769 20-MAY-2003;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 803 TCTCCAGCTACTCTTA 818
Db 1 TCTCCAACCTACTCTCA 16
RESULT 396
AR327383
LOCUS AR327383 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4785 from patent US 6566127.
ACCESSION AR327383
VERSION AR327383.1 GI:33713191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4785 20-MAY-2003;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 803 TCTCCAGCTACTCTTA 818
Db 1 TCTCCAACCTACTCTCA 16
RESULT 396
AR327383
LOCUS AR327383 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4785 from patent US 6566127.
ACCESSION AR327383
VERSION AR327383.1 GI:33713191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4785 20-MAY-2003;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 803 TCTCCAGCTACTCTTA 818
Db 1 TCTCCAACCTACTCTCA 16
RESULT 397
AR327384
LOCUS AR327384 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4786 from patent US 6566127.
ACCESSION AR327384
VERSION AR327384.1 GI:33713192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4786 20-MAY-2003;
FEATURES
Location/Qualifiers

source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ATGGAGCCAGCGGGG 16
Db 1 ATGGAGCCAGCGCTGG 16
RESULT 398
AR327973/c
LOCUS AR327973 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5375 from patent US 6566127.
ACCESSION AR327973
VERSION AR327973.1 GI:33713781
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5375 20-MAY-2003;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1416 ATGGAACGTGCTGATG 1431
Db 17 AGGGAATGTGCTGATG 2
RESULT 399
AR329088
LOCUS AR329088 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6490 from patent US 6566127.
ACCESSION AR329088
VERSION AR329088.1 GI:33714896
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6490 20-MAY-2003;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 272 GCAGGACCCAGGAGCC 287
Db 2 GCAGGACCAAGGAGAC 17
RESULT 400
AR329089

```
LOCUS AR329089 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6491 from patent US 6566127.
ACCESSION AR329089
VERSION AR329089.1 GI:33714897
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6491 20-MAY-2003;
FEATURES
source
1..17
/mol_type="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 401
LOCUS AR329284 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6686 from patent US 6566127.
ACCESSION AR329284
VERSION AR329284.1 GI:33715092
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6686 20-MAY-2003;
FEATURES
source
1..17
/mol_type="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 402
LOCUS AR365425 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 10 from patent US 5496924.
ACCESSION AR365425
VERSION AR365425.1 GI:34429067
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Habermann,P. and Wengenmayer,F.
TITLE Fusion protein comprising an interleukin-2 fragment ballast portion
JOURNAL Patent: US 5496924-A 10 05-MAR-1996;
FEATURES
source
1..17
/mol_type="unknown"
```

```
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 24 GCGTCTGCAGAGGACA 39
Db 2 GCGTCTGCAGATGCCA 17

RESULT 403
LOCUS AR381048 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1 from patent US 6607885.
ACCESSION AR381048
VERSION AR381048.1 GI:40088772
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Larossa,R.A. and Wei,Y.
TITLE Method for high-density microarray mediated gene expression
profiling
JOURNAL Patent: US 6607885-A 1 19-AUG-2003;
FEATURES
source
1..17
/mol_type="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1015 TCTATCCTGCGATGCCA 1030
Db 16 TCTGCTCGGTGCCA 1

RESULT 404
LOCUS AR398066 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 447 from patent US 6617438.
ACCESSION AR398066
VERSION AR398066.1 GI:40135577
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 447 09-SEP-2003;
FEATURES
source
1..17
/mol_type="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1181 GGAACGTGGTGGTCCA 1196
Db 2 GGAACGTGCTGTGCAA 17

RESULT 405
LOCUS AR434332 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 755 from patent US 6656700.
```



```
ACCESSION AR434332
VERSION AR434332.1 GI:40197175
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 755 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTGCCCCA 834
Db 2 CTTCTCGTCTGCCCA 17

RESULT 406
AR434333
LOCUS AR434333 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 756 from patent US 6656700.
ACCESSION AR434333
VERSION AR434333.1 GI:40197176
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 756 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTGCCCCA 834
Db 2 CTTCTCGTCTGCCCA 16

RESULT 407
AR434336
LOCUS AR434336 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 759 from patent US 6656700.
ACCESSION AR434336
VERSION AR434336.1 GI:40197179
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 759 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTGCCCCA 834
Db 1 CTTCTCGTCTGCCCA 16

RESULT 408
AR434339
LOCUS AR434339 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 762 from patent US 6656700.
ACCESSION AR434339
VERSION AR434339.1 GI:40197182
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 762 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 825 CTTCTGCCCCAACATC 840
Db 1 CGTCTGCCCATCATC 16

RESULT 409
AR456757/C
LOCUS AR456757 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 434 from patent US 6686188.
ACCESSION AR456757
VERSION AR456757.1 GI:42691814
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 434 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGGAGCTCTGG 193
Db 17 CTGAGAGATCTGCTGG 2

RESULT 410
AR456758/C
LOCUS AR456758 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 435 from patent US 6686188.
ACCESSION AR456758
VERSION AR456758.1 GI:42691815
KEYWORDS
SOURCE Unknown.
```

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 435 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTGG 193
Db 16 CTGAGAGATCTGCTGG 1

RESULT 411
LOCUS AR457253 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 930 from patent US 6686188.
ACCESSION AR457253
VERSION AR457253.1 GI:42692310
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 930 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGAGAGGCTGTGC 754
Db 2 CTGAAGAGGCTGAGC 17

RESULT 412
LOCUS AR457255 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 932 from patent US 6686188.
ACCESSION AR457255
VERSION AR457255.1 GI:42692312
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 932 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 740 TCAGAGAGCTGTGCC 755
Db 1 TGAAGAGGCTGAGCC 16

RESULT 413
LOCUS AR457523/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1200 from patent US 6686188.
ACCESSION AR457523
VERSION AR457523.1 GI:42692580
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1200 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTTGCCCTTCT 1076
Db 17 TCTTCTTCTGCCCTTACT 2

RESULT 414
LOCUS AR457524/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1201 from patent US 6686188.
ACCESSION AR457524
VERSION AR457524.1 GI:42692581
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1201 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTTGCCCTTCT 1076
Db 16 TCTTCTTCTGCCCTTACT 1

RESULT 415
LOCUS AR457739 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1416 from patent US 6686188.

ACCESSION AR457739
VERSION AR457739.1 GI:42692796
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1416 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 138 GGCTGTGAAGGCCAA 153
Db 2 GGCTGTGAAGGCCAA 17
RESULT 416
LOCUS AR457740
DEFINITION Sequence 1417 from patent US 6686188.
ACCESSION AR457740
VERSION AR457740.1 GI:42692797
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1417 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 138 GGCTGTGAAGGCCAA 153
Db 2 GGCTGTGAAGGCCAA 17
RESULT 417
LOCUS AR457858
DEFINITION Sequence 1535 from patent US 6686188.
ACCESSION AR457858
VERSION AR457858.1 GI:42692915
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1535 03-FEB-2004;
FEATURES Location/Qualifiers

source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 494 TGGCGCTGGTGACCTG 509
Db 2 TGGCGCTGGTGACCTG 17
RESULT 418
LOCUS AR457860
DEFINITION Sequence 1537 from patent US 6686188.
ACCESSION AR457860
VERSION AR457860.1 GI:42692917
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1537 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 495 GCGCTGTGGTGACCTG 510
Db 1 GCGCTGTGGTGACCTG 16
RESULT 419
LOCUS AR457969/c
DEFINITION Sequence 1646 from patent US 6686188.
ACCESSION AR457969
VERSION AR457969.1 GI:42693026
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1646 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1063 TTCTTTGCCCTCTCTCC 1078
Db 17 TCCTTTGCCCTCTCTCC 2

RESULT 420
AR457971/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1648 from patent US 6686188.
ACCESSION AR457971
VERSION AR457971.1 GI:42693028
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1648 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1062 CTTCTTTGCTTCCTC 1077
Db 16 CTCCTTGGCCCTCC 1
RESULT 421
AR458612/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2289 from patent US 6686188.
ACCESSION AR458612
VERSION AR458612.1 GI:42693669
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2289 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1062 CTTCTTTGCTTCCTC 1077
Db 16 CTCCTTGGCCCTCC 1
RESULT 422
AR458624/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2301 from patent US 6686188.
ACCESSION AR458624
VERSION AR458624.1 GI:42693681
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2301 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 549 GGCCTACGCTGTGG 564
Db 16 GGCCTACGCTGTGG 1
RESULT 423
AR462868/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6545 from patent US 6686188.
ACCESSION AR462868
VERSION AR462868.1 GI:42697925
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6545 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 250 CCACCTCCCCCAGGTT 265
Db 17 CCACCTCCCCCAGGCT 2
RESULT 424
AR462869/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6546 from patent US 6686188.
ACCESSION AR462869
VERSION AR462869.1 GI:42697926
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6546 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 250 CCACCTCCCCCAGGTT 265
Db 17 CCACCTCCCCCAGGCT 2
RESULT 425
AR462869/c
LOCUS 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6546 from patent US 6686188.
ACCESSION AR462869
VERSION AR462869.1 GI:42697926
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6546 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 250 CCACCTCCCCCAGGTT 265

Unclassified.	
REFERENCE	1 (bases 1 to 17)
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 7706 03-FEB-2004;
FEATURES	Location/Qualifiers
source	1..17
	/organism="unknown"
	/mol_type="genomic DNA"
Query Match	0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 2.5e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy	902 TTGCCCAGGCCCTGGG 917
Db	2 TGGCCACAGGCCCTAGG 17
RESULT 428	
AR464030	
LOCUS	AR464030 17 bp DNA linear PAT 20-FEB-2004
DEFINITION	Sequence 7707 from patent US 6686188.
ACCESSION	AR464030
VERSION	AR464030.1 GI:42699087
KEYWORDS	Unknown.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 7707 03-FEB-2004;
FEATURES	Location/Qualifiers
source	1..17
	/organism="unknown"
	/mol_type="genomic DNA"
Query Match	0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 2.5e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy	902 TTGCCCAGGCCCTGGG 917
Db	1 TGGCCACAGGCCCTAGG 16
RESULT 429	
AR464650/c	
LOCUS	AR464650 17 bp DNA linear PAT 20-FEB-2004
DEFINITION	Sequence 8327 from patent US 6686188.
ACCESSION	AR464650
VERSION	AR464650.1 GI:42699707
KEYWORDS	Unknown.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 8327 03-FEB-2004;
FEATURES	Location/Qualifiers
source	1..17
	/organism="unknown"
	/mol_type="genomic DNA"
Query Match	0.8%; Score 12.8; DB 1; Length 17;

```
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1067 TTGCTTCTCTCCATTG 1082
Db 17 TTGCCATCTCCATGG 2

RESULT 430
AR464651/c
LOCUS AR464651 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8328 from patent US 6686188.
ACCESSION AR464651
VERSION AR464651.1 GI:42699708
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8328 03-FEB-2004;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 727 AGCTACTCTCTCTGCA 742
Db 16 AGCTCTCTCTGCTGA 1

RESULT 433
AR464684/c
LOCUS AR464684 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8361 from patent US 6686188.
ACCESSION AR464684
VERSION AR464684.1 GI:42699741
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8361 03-FEB-2004;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 CAGTTTCTCCAGCTAC 813
Db 17 CACTTCTCCAGCTCC 2

RESULT 434
AR464685/c
LOCUS AR464685 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8362 from patent US 6686188.
ACCESSION AR464685
VERSION AR464685.1 GI:42699742
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8362 03-FEB-2004;
FEATURES
source
Location/Qualifiers
1..17
```

/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 CAGTTTCTCCAGCTAC 813
Db 16 CAGTTTCTCCAGCTCC 1

RESULT 435
AR465251
LOCUS AR465251 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 8928 from patent US 6686188.
ACCESSION AR465251
VERSION AR465251.1 GI:42700308
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8928 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
Db 2 CAGCCAGTACTACCAG 17

RESULT 436
AR465252
LOCUS AR465252 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 8929 from patent US 6686188.
ACCESSION AR465252
VERSION AR465252.1 GI:42700309
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8929 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
Db 1 CAGCCAGTACTACCAG 16

RESULT 437

AR465343/c
LOCUS AR465343 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 9020 from patent US 6686188.
ACCESSION AR465343
VERSION AR465343.1 GI:42700400
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9020 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1153 ACGTCCTTCTCCAACT 1168
Db 17 ACGTACTTCTCCAGCT 2

RESULT 438
AR465344/c
LOCUS AR465344 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 9021 from patent US 6686188.
ACCESSION AR465344
VERSION AR465344.1 GI:42700401
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9021 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1153 ACGTCCTTCTCCAACT 1168
Db 16 ACGTACTTCTCCAGCT 1

RESULT 439
AR465346/c
LOCUS AR465346 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 9023 from patent US 6686188.
ACCESSION AR465346
VERSION AR465346.1 GI:42700403
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed

Db 17 GGCTGGTGGACCTCAA 2

RESULT 442
AR466153/c
LOCUS AR466153 9830 from patent US 6686188. linear PAT 20-FEB-2004
DEFINITION Sequence 9830 from patent US 6686188.
ACCESSION AR466153
VERSION AR466153.1 GI:42701210
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9830 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1138 GACTGGTGGACTCAA 1153
Db 16 GGCTGGTGGACCTCAA 1

RESULT 443
AR466995/c
LOCUS AR466995 10672 from patent US 6686188. linear PAT 20-FEB-2004
DEFINITION Sequence 10672 from patent US 6686188.
ACCESSION AR466995
VERSION AR466995.1 GI:42702052
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10672 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 GTAGCCATGCTGGTG 1276
Db 17 GTGGCCATGCTGGCTG 2

RESULT 444
AX026212
LOCUS AX026212 Sequence 5 from Patent WO0037607. linear PAT 16-SEP-2000
DEFINITION Sequence 5 from Patent WO0037607.
ACCESSION AX026212
VERSION AX026212.1 GI:10187622
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Gros, J., Strosberg, A.D. and Gerhardt, C.
TITLE Method for producing adipocytes from non-differentiated fibroblasts and use of resulting adipocytes
JOURNAL Patent: WO 0037607-A 5 29-JUN-2000;
GROS JEROME (FR); CENTRE NAT RECH SCIENT (FR); STROSBERG ARTHUR DONNY (FR); GERHARDT CINDERELLA (NL)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="amorce"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 985 GAGCCCTTCAGCACCC 1000
||| ||||| |||||
Db 1 GAGACCTTCAACACCC 16

RESULT 445
AX027100/C
LOCUS AX027100 17 bp DNA linear PAT 16-SEP-2000
DEFINITION Sequence 15 from Patent DE19855469.
ACCESSION AX027100
VERSION AX027100.1 GI:10188110
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Esrich, M.
JOURNAL Patent: DE 19855469-A 15 15-JUN-2000;
ESRICH MICHAEL (DE)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer_bind"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 GCGTCGGCTCCTGG 1244
||| ||||| |||||
Db 16 GCCTGCAGCTCCTGG 1

RESULT 446
AX119962/C
LOCUS AX119962 17 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 1 from Patent WO0129261.
ACCESSION AX119962
VERSION AX119962.1 GI:14036701
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Larossa, R. and Wei, L.Y.
TITLE A method for high-density microarray mediated gene expression profiling
JOURNAL Patent: WO 0129261-A 1 26-APR-2001;
E.I. DU PONT DE NEMOURS AND COMPANY (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"

/db_xref="taxon:32630"
/note="PRIMER"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1015 TCTATCCTGCATGCCA 1030
||| ||||| |||||
Db 16 TCTGTCTCTGTCGCCA 1

RESULT 447
AX214636
LOCUS AX214636 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 78 from Patent WO0159103.
ACCESSION AX214636
VERSION AX214636.1 GI:15524679
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 78 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCT 1361
||| ||||| |||||
Db 2 TGCTGCTTCTCTTCCT 17

RESULT 448
AX215298/C
LOCUS AX215298 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 740 from Patent WO0159103.
ACCESSION AX215298
VERSION AX215298.1 GI:15525341
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 740 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
QY 739 CTGAGAGGCTGTGC 754
Db 16 CTGAGAGGCTGGGC 1

LOCUS AX215454 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 984 from Patent WO0159103.
ACCESSION AX215542
VERSION AX215542.1 GI:15525585
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 984 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1347 GCTGATACCTTCCTT 1362
Db 1 GCTGCTTCCTTCCTT 16

LOCUS AX217324 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2766 from Patent WO0159103.
ACCESSION AX217324
VERSION AX217324.1 GI:15527385
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2766 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGATC 1491
Db 16 CTGCCAGGAGTGATCC 1

LOCUS AX217700 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3142 from Patent WO0159103.
ACCESSION AX217700
VERSION AX217700.1 GI:15527761
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 901 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 247 CCCCCACCTCCCCCAG 262
Db 1 CCCCCCTCTCCCCCGG 16

LOCUS AX215458 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 900 from Patent WO0159103.
ACCESSION AX215458
VERSION AX215458.1 GI:15525501
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 900 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 247 CCCCCACCTCCCCCAG 262
Db 2 CCCCCCTCTCCCCCGG 17

LOCUS AX215459 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 901 from Patent WO0159103.
ACCESSION AX215459
VERSION AX215459.1 GI:15525502
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 901 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 247 CCCCCACCTCCCCCAG 262
Db 1 CCCCCCTCTCCCCCGG 16

LOCUS AX215451 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 901 from Patent WO0159103.
ACCESSION AX215451
VERSION AX215451.1 GI:15525502
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 901 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

McSwiggen, James (US) ; Chowrira, Bharat M. (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="synthetic construct"					
/mol_type="unassigned RNA"					
/db_xref="taxon:32630"					
/note="Nucleic Acid"					
Query Match					
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	926	TCTATGCGTCTTCAT	941		
DB	1	TATATGACTGCTTCAT	16		
RESULT 456					
AX264028/c					
LOCUS					
DEFINITION Sequence 1419 from Patent WO0173002.					
ACCESSION AX264028					
VERSION AX264028.1 GI:16512827					
KEYWORDS					
SOURCE					
ORGANISM Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE					
AUTHORS					
TITLE					
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides					
JOURNAL					
Patent: WO 0173002-A 1419 04-OCT-2001; UNIVERSITY OF DELAWARE (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match					
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	1399	CAGCGCACCGGCCGG	1414		
DB	17	CCGGCCCCCGGCCGG	2		
RESULT 457					
AX264029					
LOCUS					
DEFINITION Sequence 1420 from Patent WO0173002.					
ACCESSION AX264029					
VERSION AX264029.1 GI:16512828					
KEYWORDS					
SOURCE					
ORGANISM Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE					
AUTHORS					
TITLE					
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides					
JOURNAL					
Patent: WO 0173002-A 1420 04-OCT-2001; UNIVERSITY OF DELAWARE (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match					
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	1399	CAGCGCACCGGCCGG	1414		
DB	17	CCGGCCCCCGGCCGG	2		
RESULT 457					
AX264029					
LOCUS					
DEFINITION Sequence 1420 from Patent WO0173002.					
ACCESSION AX264029					
VERSION AX264029.1 GI:16512828					
KEYWORDS					
SOURCE					
ORGANISM Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE					
AUTHORS					
TITLE					
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides					
JOURNAL					
Patent: WO 0173002-A 1420 04-OCT-2001; UNIVERSITY OF DELAWARE (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match					
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	1399	CAGCGCACCGGCCGG	1414		
DB	17	CCGGCCCCCGGCCGG	2		
RESULT 457					
AX264029					
LOCUS					
DEFINITION Sequence 1420 from Patent WO0173002.					
ACCESSION AX264029					
VERSION AX264029.1 GI:16512828					
KEYWORDS					
SOURCE					
ORGANISM Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE					
AUTHORS					
TITLE					
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides					
JOURNAL					
Patent: WO 0173002-A 1420 04-OCT-2001; UNIVERSITY OF DELAWARE (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match					
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	1399	CAGCGCACCGGCCGG	1414		
DB	17	CCGGCCCCCGGCCGG	2		
RESULT 457					
AX264029					
LOCUS					
DEFINITION Sequence 1420 from Patent WO0173002.					
ACCESSION AX264029					
VERSION AX264029.1 GI:16512828					
KEYWORDS					
SOURCE					
ORGANISM Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE					
AUTHORS					
TITLE					
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides					
JOURNAL					
Patent: WO 0173002-A 1420 04-OCT-2001; UNIVERSITY OF DELAWARE (US)					

```
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACCGGCCGG 1414
Db 1 CGCGCGCCCGGCCGG 16

RESULT 458
AX272674
LOCUS AX272674
DEFINITION Sequence 243 from Patent WO0162911.
ACCESSION AX272674
VERSION AX272674.1 GI:16545411
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
Ellis,J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 243 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 886 TATGTGGCCCAAGACT 901
Db 2 TATGTGCCCAAGANTT 17

RESULT 459
AX272676
LOCUS AX272676
DEFINITION Sequence 245 from Patent WO0162911.
ACCESSION AX272676
VERSION AX272676.1 GI:16545413
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
Ellis,J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 245 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 887 ATGTGCGCCAAGACTT 902
Db 1 ATGTGCGCCAAGANTT 16

RESULT 460
```

```
AX273322
LOCUS AX273322
DEFINITION Sequence 891 from Patent WO0162911.
ACCESSION AX273322
VERSION AX273322.1 GI:16546059
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
Ellis,J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 891 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 27 TCTGCAGAGGACAGAA 42
Db 2 TCTTCAGGGACAGAA 17

RESULT 461
AX273324
LOCUS AX273324
DEFINITION Sequence 893 from Patent WO0162911.
ACCESSION AX273324
VERSION AX273324.1 GI:16546061
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
Ellis,J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 893 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 CTGCAGAGGACAGAA 43
Db 1 CTCAGGGACAGAA 16

RESULT 462
AX421810/c
LOCUS AX421810
DEFINITION Sequence 146 from Patent WO0188124.
ACCESSION AX421810
VERSION AX421810.1 GI:21525192
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 146 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 446 TGCTGCTGGAGTTTGA 461
|||||
Db 17 TGCAGCTGGAGTTGGA 2

RESULT 463
AX422209/c
LOCUS
AX422209
DEFINITION
Sequence 545 from Patent WO0188124.
ACCESSION
AX422209
VERSION
AX422209.1 GI:21525591
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 545 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 GAGCTGCTGGATCGGG 199
|||||
Db 17 GAGCTGCTGGATCGGG 2

RESULT 464
AX422210/c
LOCUS
AX422210
DEFINITION
Sequence 546 from Patent WO0188124.
ACCESSION
AX422210
VERSION
AX422210.1 GI:21525592
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 546 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 GAGCTGCTGGATCGGG 199
|||||
Db 17 GAGCTGCTGGATCGGG 2

RESULT 465
AX422247/c
LOCUS
AX422247
DEFINITION
Sequence 783 from Patent WO0188124.
ACCESSION
AX422247
VERSION
AX422247.1 GI:21525829
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 783 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 446 TGCTGCTGGAGTTTGA 461
|||||
Db 16 TGCAGCTGGAGTTGGA 1

RESULT 466
AX423046/c
LOCUS
AX423046
DEFINITION
Sequence 1382 from Patent WO0188124.
ACCESSION
AX423046
VERSION
AX423046.1 GI:21526428
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 1382 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 446 TGCTGCTGGAGTTTGA 461
|||||
Db 16 TGCAGCTGGAGTTGGA 1

RESULT 467
AX423046/c
LOCUS
AX423046
DEFINITION
Sequence 1382 from Patent WO0188124.
ACCESSION
AX423046
VERSION
AX423046.1 GI:21526428
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 1382 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 365 CCATCTACCACATGTT 380
|||||
```

```

/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 GAGCTGCTGGATCGGG 199
|||||
Db 16 GAGCTGCTGGATCGGG 1

RESULT 465
AX422247/c
LOCUS
AX422247
DEFINITION
Sequence 783 from Patent WO0188124.
ACCESSION
AX422247
VERSION
AX422247.1 GI:21525829
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 783 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 446 TGCTGCTGGAGTTTGA 461
|||||
Db 16 TGCAGCTGGAGTTGGA 1

RESULT 466
AX423046/c
LOCUS
AX423046
DEFINITION
Sequence 1382 from Patent WO0188124.
ACCESSION
AX423046
VERSION
AX423046.1 GI:21526428
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 1382 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 365 CCATCTACCACATGTT 380
|||||
```

```
Db      16  CCATCTACCAGCTGTT 1
|||||
AX499274      17 bp      DNA      linear      PAT 27-SEP-2002
Sequence 581 from Patent EP1229046.
ACCESSION AX499274
VERSION AX499274.1 GI:23381567
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 581 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1310 TCTTCGCTCGTCCT 1325
|||||
Db 17 TCTTCCTCTTCGTCCT 2

RESULT 468
AX499275/c
LOCUS AX499275 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 582 from Patent EP1229046.
ACCESSION AX499275
VERSION AX499275.1 GI:23381568
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 582 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1310 TCTTCGCTCGTCCT 1325
|||||
Db 16 TCTTCCTCTTCGTCCT 1

RESULT 469
AX530599/c
LOCUS AX530599 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 108 from Patent EP1239051.
ACCESSION AX530599
VERSION AX530599.1 GI:25253005
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 421 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 242 CTCTGCCCCCACCCTCC 257
|||||
Db 17 CTCAGCCCCCTCCTCC 2

RESULT 470
AX530600/c
LOCUS AX530600 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 109 from Patent EP1239051.
ACCESSION AX530600
VERSION AX530600.1 GI:25253007
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 109 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 242 CTCTGCCCCCACCCTCC 257
|||||
Db 16 CTCAGCCCCCTCCTCC 1

RESULT 471
AX530912
LOCUS AX530912 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 421 from Patent EP1239051.
ACCESSION AX530912
VERSION AX530912.1 GI:25253616
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 421 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 242 CTCTGCCCCCACCCTCC 257
|||||
Db 16 CTCAGCCCCCTCCTCC 1

RESULT 471
AX530912
LOCUS AX530912 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 421 from Patent EP1239051.
ACCESSION AX530912
VERSION AX530912.1 GI:25253616
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 421 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 242 CTCTGCCCCCACCCTCC 257
|||||
Db 16 CTCAGCCCCCTCCTCC 1
```

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 CCTGCTCTTGGCCCAACA 976
DB 2 CCTGTGTTTCCCAACA 17

RESULT 472
AX530914
LOCUS AX530914 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 423 from Patent EP1239051.
ACCESSION AX530914
VERSION AX530914.1 GI:25253620
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
Eukaryota; Metazoa; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 423 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 962 CTGCTCTTGGCCCAACAT 977
DB 1 CTGTGTTTCCCAACAT 16

RESULT 473
AX532012
LOCUS AX532012 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1521 from Patent EP1239051.
ACCESSION AX532012
VERSION AX532012.1 GI:25255789
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1521 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1237 CTCCTTGGTCCCGGG 1252
DB 2 CTCCTTGGTCCCGGG 17
```

```
RESULT 474
AX532014
LOCUS AX532014 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1523 from Patent EP1239051.
ACCESSION AX532014
VERSION AX532014.1 GI:25255793
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1523 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1238 TCCTTGGTCCCGGGC 1253
DB 1 TCCTTGGTCCCGGGC 16

RESULT 475
AX544680/c
LOCUS AX544680 17 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 193 from Patent EP1243660.
ACCESSION AX544680
VERSION AX544680.1 GI:25809891
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 193 25-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CTCGCGCGCGTCCGG 646
DB 17 CTCGCGCGCGCGCGG 2

RESULT 476
AX544681/c
LOCUS AX544681 17 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 194 from Patent EP1243660.
ACCESSION AX544681
VERSION AX544681.1 GI:25809892
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
```


QY 1287 CTCCGCGAGTGGCCCAT 1302
Db 17 CTCCACAGTTGCCCAT 2

RESULT 481
AX580241/c
LOCUS AX580241 linear RNA PAT 10-JAN-2003
DEFINITION Sequence 2079 from Patent WO0211674.
ACCESSION AX580241
VERSION AX580241.1 GI:27649443
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 2079 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 515 CCATGTTTCTGTCCAC 530
Db 17 CCTTGCTTCTGTCCAC 2

RESULT 482
AX600661/c
LOCUS AX600661 linear DNA PAT 17-FEB-2003
DEFINITION Sequence 20 from Patent WO02092853.
ACCESSION AX600661
VERSION AX600661.1 GI:28400615
KEYWORDS
SOURCE Geobacillus stearothermophilus
ORGANISM Geobacillus stearothermophilus
Bacteria; Firmicutes; Bacillales; Bacillaceae; Geobacillus.
REFERENCE 1
AUTHORS Breen, A.W. and Singleton, F.L.
TITLE Detection of spore forming bacteria
JOURNAL Patent: WO 02092853-A 20 21-NOV-2002;
HERCULES INCORPORATED (US)
FEATURES
source
1. .17
/organism="Geobacillus stearothermophilus"
/mol_type="unassigned DNA"
/db_xref="taxon:1422"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 CGGCCTCCCGTTGTGT 692
Db 17 CGGCTTGCCGTTGTGT 2

RESULT 483
AX615331
LOCUS AX615331 linear DNA PAT 20-FEB-2003

DEFINITION Sequence 138 from Patent EPI262488.
ACCESSION AX615331
VERSION AX615331.1 GI:28446230
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y. and Nguyen, C.T.
TITLE Human lccl-domain containing protein
JOURNAL Patent: EP 1262488-A 138 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1292 CAGTGGCCCATGAGTA 1307
Db 1 CAGTGGACCATGAGGA 16

RESULT 484
AX615494/c
LOCUS AX615494 linear DNA PAT 20-FEB-2003
DEFINITION Sequence 301 from Patent EPI262488.
ACCESSION AX615494
VERSION AX615494.1 GI:28446540
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y. and Nguyen, C.T.
TITLE Human lccl-domain containing protein
JOURNAL Patent: EP 1262488-A 301 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTTCTTTGCCCTTCCTC 1077
Db 17 CTTCTTTCCCTTCCTC 2

RESULT 485
AX615495/c
LOCUS AX615495 linear DNA PAT 20-FEB-2003
DEFINITION Sequence 302 from Patent EPI262488.
ACCESSION AX615495
VERSION AX615495.1 GI:28446541
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y. and Nguyen, C.T.
TITLE Human lccl-domain containing protein

```
JOURNAL Patent: EP 1262488-A 302 04-DEC-2002;
FEATURES   Aeomica, Inc. (US)
source     1. .17
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTCCTTTGCTTCCTC 1077
Db 16 CTCCTTTGCTTCCTC 1

RESULT 486
AX634491/c
LOCUS AX634491 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1630 from Patent EP1260586.
ACCESSION AX634491
VERSION AX634491.1 GI:28470105
KEYWORDS .
SOURCE .
ORGANISM .
REFERENCE .
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1630 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source 1. .17
       /organism="unidentified"
       /mol_type="unassigned RNA"
       /db_xref="taxon:32644"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 487
AX634525/c
LOCUS AX634525 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1664 from Patent EP1260586.
ACCESSION AX634525
VERSION AX634525.1 GI:28470139
KEYWORDS .
SOURCE .
ORGANISM .
REFERENCE .
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1664 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source 1. .17
       /organism="unidentified"
       /mol_type="unassigned RNA"
       /db_xref="taxon:32644"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 489
AX648276/c
LOCUS AX648276 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 116 from Patent EP1273660.
ACCESSION AX648276
VERSION AX648276.1 GI:29151094
KEYWORDS .
SOURCE .
ORGANISM Homo sapiens (human)
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 116 08-JAN-2003;
FEATURES Aeomica, Inc. (US)
source 1. .17
       /organism="Homo sapiens"
       /mol_type="unassigned DNA"
       /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 488
AX634793/c
LOCUS AX634793 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1932 from Patent EP1260586.
ACCESSION AX634793
VERSION AX634793.1 GI:28470407
KEYWORDS .
SOURCE .
ORGANISM .
REFERENCE .
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1932 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source 1. .17
       /organism="unidentified"
       /mol_type="unassigned RNA"
       /db_xref="taxon:32644"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 489
AX648276/c
LOCUS AX648276 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 116 from Patent EP1273660.
ACCESSION AX648276
VERSION AX648276.1 GI:29151094
KEYWORDS .
SOURCE .
ORGANISM Homo sapiens (human)
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 116 08-JAN-2003;
FEATURES Aeomica, Inc. (US)
source 1. .17
       /organism="Homo sapiens"
       /mol_type="unassigned DNA"
       /db_xref="taxon:9606"

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1350 GATACCTCTTCCTGTC 1365
|||||
Db 17 GATACCTCATCCTTTTC 2

RESULT 490
AX672102
LOCUS AX672102 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 547 from Patent WO03004526.
ACCESSION AX672102
VERSION AX672102.1 GI:29330450
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 547 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 GATCAGCTCATGAGG 349
|||||
Db 1 GATCAGCTCATGAGG 16

RESULT 491
AX672538
LOCUS AX672538 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 983 from Patent WO03004526.
ACCESSION AX672538
VERSION AX672538.1 GI:29330886
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A-983 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1191 GGTCATGACTGGCTG 1206
|||||
Db 1 GATCCAGACTGGCTG 16

RESULT 492
AX672554
LOCUS AX672554 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 999 from Patent WO03004526.
ACCESSION AX672554
VERSION AX672554.1 GI:29330902
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 999 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1459 ATCCAGTCAGCTGT 1474
|||||
Db 2 ATCCAGTCAGCTGT 17

RESULT 493
AX674757
LOCUS AX674757 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 3202 from Patent WO03004526.
ACCESSION AX674757
VERSION AX674757.1 GI:29333105
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3202 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 AACTTTCTGGGGCTG 1536
|||||
Db 2 AACTTTCTGGGGCTG 17

RESULT 494
AX690693
LOCUS AX690693 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3425 from Patent EP1281758.
ACCESSION AX690693
VERSION AX690693.1 GI:294113600
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 3425 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 TGAGGGATCCAGGCC 795
|||||
Db 2 TGAGGAGCTCCAGGCC 17

RESULT 495
AX690694 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 3426 from Patent EP1281758.
DEFINITION AX690694
ACCESSION AX690694
VERSION AX690694.1 GI:29413601
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 3426 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 TGAGGGATCCAGGCC 795
|||||
Db 1 TGAGGAGCTCCAGGCC 16

RESULT 496
AX691810/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 4542 from Patent EP1281758.
DEFINITION AX691810
ACCESSION AX691810
VERSION AX691810.1 GI:29414751
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 4542 05-FEB-2003;

FEATURES Aeomica, Inc. (US)
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 TGTCCTGGTCTTCGAG 705
|||||
Db 17 TGTCAGGGCTTCGAG 2

RESULT 497
AX691811/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 4543 from Patent EP1281758.
DEFINITION AX691811
ACCESSION AX691811
VERSION AX691811.1 GI:29414752
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 4543 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 TGTCCTGGTCTTCGAG 705
|||||
Db 16 TGTCAGGGCTTCGAG 1

RESULT 498
AX692475/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 5207 from Patent EP1281758.
DEFINITION AX692475
ACCESSION AX692475
VERSION AX692475.1 GI:29415428
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 5207 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 TGTCCTGGTCTTCGAG 705
|||||
Db 16 TGTCAGGGCTTCGAG 1

RESULT 499
AX692475/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 5207 from Patent EP1281758.
DEFINITION AX692475
ACCESSION AX692475
VERSION AX692475.1 GI:29415428
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 5207 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1298 CCATGAGTATATCTT 1313
|||||
Db 17 CCCAAGATATATCTT 2

RESULT 499
AX692480/c
LOCUS AX692480 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5212 from Patent EP1281758.
ACCESSION AX692480
VERSION AX692480.1 GI:29415438
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5212 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 GTGCCCATGAGTATA 1309
|||||
Db 16 GTGGCCCAAGATATA 1

RESULT 500
AX693479
LOCUS AX693479 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6211 from Patent EP1281758.
ACCESSION AX693479
VERSION AX693479.1 GI:29416444
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6211 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 CTGCCCAACTCATC 843
|||||
Db 2 CAGCTCAACTCATC 17

RESULT 501
AX693480

LOCUS AX693480 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6212 from Patent EP1281758.
ACCESSION AX693480
VERSION AX693480.1 GI:29416445
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6212 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 CTGCCCAACTCATC 843
|||||
Db 1 CAGCTCAACTCATC 16

RESULT 502
AX693481
LOCUS AX693481 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6213 from Patent EP1281758.
ACCESSION AX693481
VERSION AX693481.1 GI:29416446
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6213 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 830 GCCCAACTCATCTA 845
|||||
Db 2 GCTCAACTCATCTCAA 17

RESULT 503
AX693482
LOCUS AX693482 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6214 from Patent EP1281758.
ACCESSION AX693482
VERSION AX693482.1 GI:29416447
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6214 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

REFERENCE 1
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
 JOURNAL Patent: EP 1281758-A 6214 05-FEB-2003;
 FEATURES Aeomica, Inc. (US)
 source Location/Qualifiers
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 830 GCCCAACACTCATCTA 845 17 bp DNA linear PAT 08-MAY-2003
 Db 1 GCTCAACACTCATCAA 16
 RESULT 504
 AX722341
 LOCUS Sequence 28 from Patent WO03025176.
 DEFINITION
 ACCESSION AX722341
 VERSION AX722341.1 GI:30422842
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 28 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. .17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"
 Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 940 ATCCTGGCGGCTCT 955 17 bp DNA linear PAT 08-MAY-2003
 Db 2 ATCCTGTGCTGCTCT 17
 RESULT 505
 AX722485
 LOCUS Sequence 172 from Patent WO03025176.
 DEFINITION
 ACCESSION AX722485
 VERSION AX722485.1 GI:30422986
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 172 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers

source 1. .17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"
 Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1350 GATACTCTTCCTGTC 1365 17 bp DNA linear PAT 08-MAY-2003
 Db 1 GATCCTCTCCCTGTC 16
 RESULT 506
 AX722551/c
 LOCUS Sequence 238 from Patent WO03025176.
 DEFINITION
 ACCESSION AX722551
 VERSION AX722551.1 GI:30423052
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 238 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. .17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"
 Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 420 CATCGACTTCATTGAT 435 17 bp DNA linear PAT 08-MAY-2003
 Db 17 CATCTATTTCATTGAT 2
 RESULT 507
 AX722604
 LOCUS Sequence 291 from Patent WO03025176.
 DEFINITION
 ACCESSION AX722604
 VERSION AX722604.1 GI:30423105
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 291 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. .17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"
 Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1459 ATCCAGGTCAGCTGT 1474
|||||
Db 2 ATCCAGGTCAGCTGT 17

RESULT 508
AX722959
LOCUS AX722959 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 646 from Patent WO03025176.
ACCESSION AX722959
VERSION AX722959.1 GI:30423460
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 646 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 958 GTTCCTGCTTTGCCA 973
|||||
Db 1 GATCCTGACTTTGCCA 16

RESULT 509
AX723858
LOCUS AX723858 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1545 from Patent WO03025176.
ACCESSION AX723858
VERSION AX723858.1 GI:30503201
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1545 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 786 GATCCAGGTCACAGT 801
|||||
Db 1 GATCCAGGTCACAGT 16

RESULT 510
AX724110
LOCUS AX724110 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1797 from Patent WO03025176.
ACCESSION AX724110
VERSION AX724110.1 GI:30503453
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1797 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 219 ATCCTACCCATCACAA 234
|||||
Db 2 ATCCTACCCATCACAA 17

RESULT 511
AX724156
LOCUS AX724156 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1843 from Patent WO03025176.
ACCESSION AX724156
VERSION AX724156.1 GI:30503499
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1843 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1337 ATCCGTCATGCTGAT 1352
|||||
Db 2 ATCCGTCAGGCTGAT 17

RESULT 512
AX724958
LOCUS AX724958 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2645 from Patent WO03025176.
ACCESSION AX724958
VERSION AX724958.1 GI:30504301
KEYWORDS

SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2645 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1350 GATACCTCTTCCTGTC 1365 17 bp DNA linear PAT 08-MAY-2003
|||||
Db 1 GATCCTCTTCCTGTC 16
RESULT 513
AX725065 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2752 from Patent WO03025176.
DEFINITION AX725065
ACCESSION AX725065.1 GI:30504408
VERSION
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2752 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1267 ATGCTGGGTGTGTTCC 1282 17 bp DNA linear PAT 08-MAY-2003
|||||
Db 2 ATCCTGGGTGTGTTCC 17
RESULT 514
AX725288 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2975 from Patent WO03025176.
DEFINITION AX725288
ACCESSION AX725288.1 GI:30504631
VERSION
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2975 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1376 TGTGAACTTCATGAT 1391 17 bp DNA linear PAT 08-MAY-2003
|||||
Db 17 TGTGAACTTCATGAT 2
RESULT 515
AX725362/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 3049 from Patent WO03025176.
DEFINITION AX725362
ACCESSION AX725362
VERSION AX725362.1 GI:30504705
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3049 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1305 GPATATCTTCGTTC 1320 17 bp DNA linear PAT 08-MAY-2003
|||||
Db 16 GPATATCTTCGTTC 1
RESULT 516
AX726174 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 3861 from Patent WO03025176.
DEFINITION AX726174
ACCESSION AX726174
VERSION AX726174.1 GI:30505517
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3861 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source
1..17
/organism="Mus musculus"

/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 421 ATCGACTTCATTGATG 436
Db 2 ATCAACATCATGATG 17

RESULT 517
AX726186/c
LOCUS AX726186 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3873 from Patent WO03025176.
ACCESSION AX726186
VERSION AX726186.1 GI:30505529
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1293 AGTGGCCCATGAGTAT 1308
Db 17 ATGGGCCCATGAGGAT 2

RESULT 518
AX730202
LOCUS AX730202 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1836 from Patent WO03025175.
ACCESSION AX730202
VERSION AX730202.1 GI:30509545
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 367 ATCTACCACATGTTCA 382
Db 2 ATCAACCACATGCTCA 17

RESULT 519
AX731025
LOCUS AX731025 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2659 from Patent WO03025175.
ACCESSION AX731025
VERSION AX731025.1 GI:30510368
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 958 GTCTCTGTCTTTGCCA 973
Db 1 GATCTGTCTTTTCCA 16

RESULT 520
AX734575/c
LOCUS AX734575 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 165 from Patent WO03025177.
ACCESSION AX734575
VERSION AX734575.1 GI:30513852
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1376 TGTGAACCTTCATGAT 1391
Db 17 TGTGAACCTTAAGGAT 2

RESULT 521
AX735159

REFERENCE	1	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS		Telerman,A., Amson,R. and Tuijnder,M.
TITLE		Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL		Patent: WO 03025177-A 976 27-MAR-2003; Molecular Engines Laboratories (FR)
FEATURES		Location/Qualifiers
source	1..17	/organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match		0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity		87.5%; Pred. No. 2.5e+02;
Matches	14;	Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	181	AGGGAGCTGCTGGATC 196
Db	16	AGGGGGCTGCAGGATC 1
RESULT 524		
AX735688/c		
LOCUS		AX735688 17 bp DNA linear PAT 08-MAY-2003
DEFINITION		Sequence 1278 from Patent WO03025177.
ACCESSION		AX735688
VERSION		AX735688.1 GI:30514965
KEYWORDS		
SOURCE		Homo sapiens (human)
ORGANISM		Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1	Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS		Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
TITLE		Patent: WO 03025177-A 1278 27-MAR-2003; Molecular Engines Laboratories (FR)
JOURNAL		Location/Qualifiers
FEATURES		Location/Qualifiers
source	1..17	/organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match		0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity		87.5%; Pred. No. 2.5e+02;
Matches	14;	Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	1376	TGTTGAACCTTCATGAT 1391
Db	17	TCTTGAATTCATGAT 2
RESULT 525		
AX735736		
LOCUS		AX735736 17 bp DNA linear PAT 08-MAY-2003
DEFINITION		Sequence 1326 from Patent WO03025177.
ACCESSION		AX735736
VERSION		AX735736.1 GI:30515013
KEYWORDS		
SOURCE		Homo sapiens (human)
ORGANISM		Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1	Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS		Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
TITLE		

```
JOURNAL Patent: WO 03025177-A 1326 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
SOURCE Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 219 ATCCTACCCATCACA 234
Db 2 ATCTTAACCATCACA 17
|||||
|||||

RESULT 526
AX736290
LOCUS AX736290 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1880 from Patent WO03025177.
ACCESSION AX736290
VERSION AX736290.1 GI:30515567
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 1880 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 460 GACCTACTGATCTTCA 475
Db 1 GATCTACTTATCTTCA 16
|||||
|||||

RESULT 527
AX736619
LOCUS AX736619 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2209 from Patent WO03025177.
ACCESSION AX736619
VERSION AX736619.1 GI:30515907
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2209 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

JOURNAL Patent: WO 03025177-A 1326 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
SOURCE Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 460 GACCTACTGATCTTCA 475
Db 1 GATCTACTTATCTTCA 16
|||||
|||||

RESULT 527
AX736619
LOCUS AX736619 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 40 from Patent WO03031621.
ACCESSION AX744075
VERSION AX744075.1 GI:30722742
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang,J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 39 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CTCTGCGCGTCCCGG 646
Db 2 CTCTGCGCGTCCCGG 17
|||||
|||||

RESULT 529
AX744075
LOCUS AX744075 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 40 from Patent WO03031621.
ACCESSION AX744075
VERSION AX744075.1 GI:30722742
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang,J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 40 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CTCTGCGCGTCCCGG 646
Db 1 CTCTGCGCGTCCCGG 16
|||||
|||||

RESULT 530

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CTCTGCGCGTCCCGG 646
Db 1 CTCTGCGCGTCCCGG 16
|||||
|||||

RESULT 530
```

AX757324 LOCUS AX757324 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 645 from Patent WO03040369.
ACCESSION AX757324
VERSION AX757324.1 GI:32251940
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in tumoral suppression, tumoral reversion,
TITLE apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 645 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1056 GTCATCTCTTTGTC 1071
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GATCATCTCTTTGTC 16
RESULT 531
AX757876 LOCUS AX757876 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 1197 from Patent WO03040369.
ACCESSION AX757876
VERSION AX757876.1 GI:32252492
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in tumoral suppression, tumoral reversion,
TITLE apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1197 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1419 GAACGTGCTGATGTGG 1434
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GATCGTGGTGTGATGTGG 16
RESULT 532
AX759336 LOCUS AX759336 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 2657 from Patent WO03040369.
ACCESSION AX759336
VERSION AX759336.1 GI:32253952
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in tumoral suppression, tumoral reversion,
TITLE apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 2657 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 420 CATCGACTTCATTGAT 435
| | | | | | | | | | | | | | | | | | | | | |
Db 17 CATCCACCTCATTGAT 2
RESULT 533
AX759623 LOCUS AX759623 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 2944 from Patent WO03040369.
ACCESSION AX759623
VERSION AX759623.1 GI:32254239
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in tumoral suppression, tumoral reversion,
TITLE apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 2944 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 774 ACGAGGTGAGGGGATC 789
| | | | | | | | | | | | | | | | | | | | | |
Db 16 ACGAGGGGAGAGGATC 1
RESULT 534
AX760112 LOCUS AX760112 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3433 from Patent WO03040369.
ACCESSION AX760112
VERSION AX760112.1 GI:32254728
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in tumoral suppression, tumoral reversion,
TITLE apoptosis and/or viral resistance phenomena and their use as
medicines

LOCUS AX782027 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 358 from Patent WO03050284.
ACCESSION AX782027
VERSION AX782027.1 GI:32949876
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 358 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 587 CGACGGCGCTGCGCTG 602
|||||
Db 16 CGACGGCGCTGCGACTG 1
RESULT 540
AX783600/c
LOCUS AX783600 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1931 from Patent WO03050284.
ACCESSION AX783600
VERSION AX783600.1 GI:32951449
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1931 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 594 CCTGGGCTGTGCGCTT 609
|||||
Db 17 CCTGGGCGGTGAGCTT 2
RESULT 541
AX783601/c
LOCUS AX783601 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1932 from Patent WO03050284.
ACCESSION AX783601
VERSION AX783601.1 GI:32951450
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.

TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1932 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 594 CCTGGGCTGTGCGCTT 609
|||||
Db 16 CCTGGGCGGTGAGCTT 1
RESULT 542
AX784077/c
LOCUS AX784077 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2408 from Patent WO03050284.
ACCESSION AX784077
VERSION AX784077.1 GI:32951926
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2408 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 40 GAAGGCGTGGAGGGG 55
|||||
Db 17 GAAGGCGAGGAGGTG 2
RESULT 543
AX784078/c
LOCUS AX784078 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2409 from Patent WO03050284.
ACCESSION AX784078
VERSION AX784078.1 GI:32951927
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2409 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 40 GAAGGCGTGGAGGGG 55
|||||
Db 17 GAAGGCGAGGAGGTG 2
RESULT 543
AX784078/c
LOCUS AX784078 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2409 from Patent WO03050284.
ACCESSION AX784078
VERSION AX784078.1 GI:32951927
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2409 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 40 GAAGGCTGGAGGG 55
Db 16 GAAGGCGAGGAGGTG 1

RESULT 544
BD104108
LOCUS
DEFINITION
Accession
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

OS Artificial Sequence
PN WO 0192572-A/212
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
Nishida,M.
Kit and method for determining HLA type
Patent: WO 0192572-A 212 06-DEC-2001;
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDEOTSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
OS Artificial Sequence
PN WO 0192572-A/212
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
Nishida,M.
Kit and method for determining HLA type
Patent: WO 0192572-A 725 06-DEC-2001;
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDEOTSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
OS Artificial Sequence
PN WO 0192572-A/725

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 157 CTGGAGCAAGCGCAGG 172
Db 1 CTGGAGCAGCGCGGG 16

RESULT 545
BD104621/c
LOCUS
DEFINITION
Accession
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

OS Artificial Sequence
PN WO 0192572-A/725
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
Nishida,M.
Kit and method for determining HLA type
Patent: WO 0192572-A 725 06-DEC-2001;
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDEOTSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
OS Artificial Sequence
PN WO 0192572-A/725

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 172 CTGGAGCAAGCGCAGG 172
Db 1 CTGGAGCAGCGCGGG 16

RESULT 546
BD104621/c
LOCUS
DEFINITION
Accession
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

OS Artificial Sequence
PN WO 0192572-A/725
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
Nishida,M.
Kit and method for determining HLA type
Patent: WO 0192572-A 725 06-DEC-2001;
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDEOTSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
OS Artificial Sequence
PN WO 0192572-A/725

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 172 CAGGATGTTCTTCTCGG 1137
Db 17 CAGGATGTTCTTCTCGG 2

Search completed: November 8, 2004, 12:46:19
Job time : 10 secs

PD 06-DEC-2001 WO 2001JP004662
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
Nishida,M.
Kit and method for determining HLA type
Patent: WO 0192572-A 212 06-DEC-2001;
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDEOTSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
OS Artificial Sequence
PN WO 0192572-A/212
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
Nishida,M.
Kit and method for determining HLA type
Patent: WO 0192572-A 725 06-DEC-2001;
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDEOTSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
OS Artificial Sequence
PN WO 0192572-A/725
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
Nishida,M.
Kit and method for determining HLA type
Patent: WO 0192572-A 725 06-DEC-2001;
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDEOTSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
OS Artificial Sequence
PN WO 0192572-A/725

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1122 CAGGATGTTCTTCTCGG 1137
Db 17 CAGGATGTTCTTCTCGG 2

Search completed: November 8, 2004, 12:46:19
Job time : 10 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 12:52:39 ; Search time 9 Seconds
(without alignments)
3.980 Million cell updates/sec

Title: US-09-918-026A-3

Perfect score: 1569

Sequence: 1 atggagcagcgggggcccg.....cttggtctgcatacctag 1569

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 655 seqs, 11416 residues

Total number of hits satisfying chosen parameters: 1310

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 658 summaries

Database : rnpb3.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	25	1.6	25	1	US-09-918-026A-6
2	21.8	1.4	29	1	US-10-336-638-370
3	21	1.3	21	1	US-09-918-026A-4
4	20	1.3	20	1	US-09-918-026A-14
5	20	1.3	20	1	US-09-918-026A-15
6	20	1.3	20	1	US-09-918-026A-16
7	20	1.3	20	1	US-09-918-026A-17
8	20	1.3	20	1	US-09-918-026A-18
9	20	1.3	20	1	US-09-918-026A-19
10	20	1.3	20	1	US-09-918-026A-20
11	20	1.3	20	1	US-09-918-026A-21
12	20	1.3	20	1	US-09-918-026A-22
13	20	1.3	20	1	US-09-918-026A-23
14	20	1.3	20	1	US-09-918-026A-24
15	20	1.3	20	1	US-09-918-026A-25
16	20	1.3	20	1	US-09-918-026A-26
17	20	1.3	20	1	US-09-918-026A-27
18	20	1.3	20	1	US-09-918-026A-28
19	20	1.3	20	1	US-09-918-026A-29
20	20	1.3	20	1	US-09-918-026A-30
21	20	1.3	20	1	US-09-918-026A-31
22	20	1.3	20	1	US-09-918-026A-32
23	20	1.3	20	1	US-09-918-026A-33
24	20	1.3	20	1	US-09-918-026A-34
25	20	1.3	20	1	US-09-918-026A-35
26	20	1.3	20	1	US-09-918-026A-36
27	20	1.3	20	1	US-09-918-026A-54
28	20	1.3	20	1	US-09-918-026A-65
29	19.2	1.2	24	1	US-09-992-665-70
30	19	1.2	20	1	US-09-918-026A-58
31	18.8	1.2	25	1	US-10-717-597-573
32	18.4	1.2	20	1	US-09-918-026A-52
33	18	1.1	20	1	US-09-918-026A-57
					Sequence 57, Appl
					Sequence 6, Appl
					Sequence 370, Appl
					Sequence 4, Appl
					Sequence 14, Appl
					Sequence 15, Appl
					Sequence 16, Appl
					Sequence 17, Appl
					Sequence 18, Appl
					Sequence 19, Appl
					Sequence 20, Appl
					Sequence 21, Appl
					Sequence 22, Appl
					Sequence 23, Appl
					Sequence 24, Appl
					Sequence 25, Appl
					Sequence 26, Appl
					Sequence 27, Appl
					Sequence 28, Appl
					Sequence 29, Appl
					Sequence 30, Appl
					Sequence 31, Appl
					Sequence 32, Appl
					Sequence 33, Appl
					Sequence 34, Appl
					Sequence 35, Appl
					Sequence 36, Appl
					Sequence 54, Appl
					Sequence 65, Appl
					Sequence 70, Appl
					Sequence 78, Appl
					Sequence 573, Appl
					Sequence 52, Appl

1	1	1	1	1	US-09-918-026A-12	Sequence 12, Appl
17	1	1	1	1	US-09-877-478-846	Sequence 846, App
17	1	1	1	1	US-10-342-902-846	Sequence 846, App
17	1	1	1	1	US-10-669-841-846	Sequence 846, App
17	1	1	1	1	US-09-918-026A-46	Sequence 46, Appl
20	1	1	1	1	US-09-918-026A-47	Sequence 47, Appl
20	1	1	1	1	US-09-918-026A-53	Sequence 53, Appl
20	1	1	1	1	US-09-918-026A-55	Sequence 55, Appl
20	1	1	1	1	US-09-918-026A-61	Sequence 61, Appl
20	1	1	1	1	US-09-918-026A-64	Sequence 64, Appl
20	1	1	1	1	US-10-368-803-11	Sequence 11, Appl
19	1	1	1	1	US-10-251-117-33	Sequence 33, Appl
19	1	1	1	1	US-10-251-117-282	Sequence 282, App
17	1	1	1	1	US-10-349-143-11729	Sequence 11729, A
17	1	1	1	1	US-09-877-478-144	Sequence 144, App
17	1	1	1	1	US-10-342-902-144	Sequence 144, App
17	1	1	1	1	US-10-669-841-144	Sequence 144, App
20	1	1	1	1	US-09-923-517-100	Sequence 100, App
20	1	1	1	1	US-09-971-843-10	Sequence 10, Appl
20	1	1	1	1	US-09-918-026A-56	Sequence 56, Appl
20	1	1	1	1	US-09-954-679-28	Sequence 28, Appl
20	1	1	1	1	US-10-430-196-100	Sequence 100, App
20	1	1	1	1	US-10-187-659A-45	Sequence 45, Appl
20	1	1	1	1	US-10-187-659A-110	Sequence 110, App
20	1	1	1	1	US-10-272-810-49	Sequence 49, Appl
20	1	1	1	1	US-10-273-070-49	Sequence 49, Appl
21	1	1	1	1	US-10-184-085A-1032	Sequence 1032, Ap
21	1	1	1	1	US-10-184-085A-1069	Sequence 1069, Ap
17	1	1	1	1	US-09-866-108-6625	Sequence 6625, Ap
17	1	1	1	1	US-09-866-108-6626	Sequence 6626, Ap
17	1	1	1	1	US-09-866-108-6627	Sequence 6627, Ap
17	1	1	1	1	US-09-866-108-6628	Sequence 6628, Ap
17	1	1	1	1	US-09-825-805-349	Sequence 349, App
17	1	1	1	1	US-10-163-553-134	Sequence 134, App
17	1	1	1	1	US-10-138-674-1579	Sequence 1579, Ap
17	1	1	1	1	US-10-138-674-6203	Sequence 6203, Ap
17	1	1	1	1	US-10-138-674-8446	Sequence 8446, Ap
17	1	1	1	1	US-10-287-949A-1579	Sequence 1579, Ap
17	1	1	1	1	US-10-287-949A-6203	Sequence 6203, Ap
17	1	1	1	1	US-10-287-949A-8446	Sequence 8446, Ap
17	1	1	1	1	US-10-712-723-2333	Sequence 2333, Ap
17	1	1	1	1	US-10-723-361-6625	Sequence 6625, Ap
17	1	1	1	1	US-10-723-361-6626	Sequence 6626, Ap
17	1	1	1	1	US-10-723-361-6627	Sequence 6627, Ap
17	1	1	1	1	US-08-424-550B-99	Sequence 99, Appl
20	1	1	1	1	US-09-918-026A-43	Sequence 43, Appl
20	1	1	1	1	US-10-317-500-89	Sequence 89, Appl
20	1	1	1	1	US-10-740-773-9	Sequence 9, Appl
20	1	1	1	1	US-09-800-631-22	Sequence 22, Appl
20	1	1	1	1	US-09-755-004-10	Sequence 10, Appl
20	1	1	1	1	US-09-924-256A-1	Sequence 1, Appl
20	1	1	1	1	US-09-888-326-406	Sequence 406, App
20	1	1	1	1	US-09-781-693A-4	Sequence 4, Appl
20	1	1	1	1	US-09-776-479-448	Sequence 448, App
20	1	1	1	1	US-09-918-026A-51	Sequence 51, Appl
20	1	1	1	1	US-10-112-653-428	Sequence 428, App
20	1	1	1	1	US-10-017-995-448	Sequence 448, App
20	1	1	1	1	US-10-181-846-109	Sequence 109, App
20	1	1	1	1	US-10-216-484-94	Sequence 94, Appl
20	1	1	1	1	US-10-216-484-98	Sequence 98, Appl
20	1	1	1	1	US-10-293-783-22	Sequence 22, Appl
20	1	1	1	1	US-10-384-933-94	Sequence 94, Appl
20	1	1	1	1	US-10-384-933-98	Sequence 98, Appl
20	1	1	1	1	US-10-314-578-448	Sequence 448, App
20	1	1	1	1	US-10-388-263-670	Sequence 670, App
20	1	1	1	1	US-10-289-762-4685	Sequence 4685, App
20	1	1	1	1	US-10-648-513-84	Sequence 84, Appl
20	1	1	1	1	US-10-671-395-454	Sequence 454, Appl
15	1	1	1	1	US-09-918-026A-5	Sequence 5, Appl
15	1	1	1	1	US-09-877-478-845	Sequence 845, App
17	1	1	1	1	US-09-877-478-2244	Sequence 2244, App

C 107	15	1.0	17	1	US-09-848-754A-144	Sequence 144, App	C 180	13.8	0.9	17	1	US-09-866-108-1647	Sequence 1647, Ap
C 108	15	1.0	17	1	US-09-848-754A-1112	Sequence 1112, Ap	C 181	13.8	0.9	17	1	US-09-866-108-2290	Sequence 2290, Ap
C 109	15	1.0	17	1	US-09-848-754A-1113	Sequence 1113, Ap	C 182	13.8	0.9	17	1	US-09-866-108-2291	Sequence 2291, Ap
C 110	15	1.0	17	1	US-10-342-902-845	Sequence 845, App	C 183	13.8	0.9	17	1	US-09-866-108-2292	Sequence 2292, Ap
C 111	15	1.0	17	1	US-10-342-902-2244	Sequence 2244, Ap	C 184	13.8	0.9	17	1	US-09-866-108-2295	Sequence 2295, Ap
C 112	15	1.0	17	1	US-10-669-841-845	Sequence 845, App	C 185	13.8	0.9	17	1	US-09-866-108-2298	Sequence 2298, Ap
C 113	15	1.0	17	1	US-10-669-841-2047	Sequence 2047, Ap	C 186	13.8	0.9	17	1	US-09-866-108-2299	Sequence 2299, Ap
C 114	15	1.0	20	1	US-09-854-883-174	Sequence 174, App	C 187	13.8	0.9	17	1	US-09-866-108-2300	Sequence 2300, Ap
C 115	15	1.0	20	1	US-10-380-931-171	Sequence 171, App	C 188	13.8	0.9	17	1	US-09-866-108-6916	Sequence 6916, Ap
C 116	15	1.0	20	1	US-10-360-510-174	Sequence 174, App	C 189	13.8	0.9	17	1	US-09-866-108-9024	Sequence 9024, Ap
C 117	14.8	0.9	18	1	US-10-241-313-7	Sequence 7, Appl	C 190	13.8	0.9	17	1	US-09-866-108-10673	Sequence 10673, A
C 118	14.8	0.9	18	1	US-10-404-679-70	Sequence 70, Appl	C 191	13.8	0.9	17	1	US-09-866-108-10674	Sequence 10674, A
C 119	14.8	0.9	18	1	US-10-404-922-11	Sequence 11, Appl	C 192	13.8	0.9	17	1	US-09-827-998-760	Sequence 760, App
C 120	14.8	0.9	18	1	US-10-449-801A-7	Sequence 7, Appl	C 193	13.8	0.9	17	1	US-09-827-998-761	Sequence 761, App
C 121	14.8	0.9	19	1	US-10-251-117-623	Sequence 623, App	C 194	13.8	0.9	17	1	US-09-864-785-345	Sequence 345, App
C 122	14.8	0.9	19	1	US-10-251-117-930	Sequence 930, App	C 195	13.8	0.9	17	1	US-09-864-785-346	Sequence 346, App
C 123	14.8	0.9	19	1	US-10-356-625-111	Sequence 111, App	C 196	13.8	0.9	17	1	US-09-864-785-407	Sequence 407, App
C 124	14.8	0.9	19	1	US-10-244-647-491	Sequence 491, App	C 197	13.8	0.9	17	1	US-09-864-785-1592	Sequence 1592, Ap
C 125	14.8	0.9	19	1	US-10-244-647-511	Sequence 511, App	C 198	13.8	0.9	17	1	US-09-825-805-798	Sequence 798, App
C 126	14.8	0.9	19	1	US-10-244-647-1137	Sequence 1137, App	C 199	13.8	0.9	17	1	US-09-780-533A-739	Sequence 739, App
C 127	14.8	0.9	19	1	US-10-244-647-1157	Sequence 1157, App	C 200	13.8	0.9	17	1	US-09-780-533A-1164	Sequence 1164, Ap
C 128	14.8	0.9	19	1	US-10-262-445-84	Sequence 84, Appl	C 201	13.8	0.9	17	1	US-09-848-754A-1111	Sequence 1111, Ap
C 129	14.4	0.9	17	1	US-09-866-108-2293	Sequence 2293, Ap	C 202	13.8	0.9	17	1	US-09-848-754A-2229	Sequence 2229, Ap
C 130	14.4	0.9	17	1	US-09-866-108-2294	Sequence 2294, Ap	C 203	13.8	0.9	17	1	US-09-848-754A-3192	Sequence 3192, Ap
C 131	14.4	0.9	17	1	US-09-866-108-2296	Sequence 2296, Ap	C 204	13.8	0.9	17	1	US-09-930-423-333	Sequence 333, App
C 132	14.4	0.9	17	1	US-09-866-108-2297	Sequence 2297, Ap	C 205	13.8	0.9	17	1	US-09-930-423-560	Sequence 560, App
C 133	14.4	0.9	17	1	US-09-866-108-6624	Sequence 6624, Ap	C 206	13.8	0.9	17	1	US-09-780-164-440	Sequence 440, App
C 134	14.4	0.9	17	1	US-09-866-108-6629	Sequence 6629, Ap	C 207	13.8	0.9	17	1	US-09-827-395A-215	Sequence 215, App
C 135	14.4	0.9	17	1	US-09-780-164-502	Sequence 502, App	C 208	13.8	0.9	17	1	US-09-827-395A-887	Sequence 887, App
C 136	14.4	0.9	17	1	US-09-780-164-503	Sequence 503, App	C 209	13.8	0.9	17	1	US-09-792-818-244	Sequence 244, App
C 137	14.4	0.9	17	1	US-09-740-332-1413	Sequence 1413, Ap	C 210	13.8	0.9	17	1	US-09-792-818-892	Sequence 892, App
C 138	14.4	0.9	17	1	US-09-740-332-3143	Sequence 3143, Ap	C 211	13.8	0.9	17	1	US-09-745-237A-333	Sequence 333, App
C 139	14.4	0.9	17	1	US-09-817-879-1413	Sequence 1413, Ap	C 212	13.8	0.9	17	1	US-09-745-237A-560	Sequence 560, App
C 140	14.4	0.9	17	1	US-09-817-879-3143	Sequence 3143, Ap	C 213	13.8	0.9	17	1	US-10-060-830-137	Sequence 137, App
C 141	14.4	0.9	17	1	US-10-138-674-1578	Sequence 1578, Ap	C 214	13.8	0.9	17	1	US-10-060-830-137	Sequence 221, App
C 142	14.4	0.9	17	1	US-10-138-674-6134	Sequence 6124, Ap	C 215	13.8	0.9	17	1	US-10-060-895A-221	Sequence 117, App
C 143	14.4	0.9	17	1	US-10-138-674-8044	Sequence 8044, Ap	C 216	13.8	0.9	17	1	US-10-060-998-117	Sequence 118, App
C 144	14.4	0.9	17	1	US-10-287-949A-1578	Sequence 1578, Ap	C 217	13.8	0.9	17	1	US-10-163-553-639	Sequence 639, App
C 145	14.4	0.9	17	1	US-10-287-949A-6124	Sequence 6124, Ap	C 218	13.8	0.9	17	1	US-10-238-700-148	Sequence 148, App
C 146	14.4	0.9	17	1	US-10-287-949A-8044	Sequence 8044, Ap	C 219	13.8	0.9	17	1	US-10-238-700-2807	Sequence 2807, Ap
C 147	14.4	0.9	17	1	US-10-712-672-1852	Sequence 1852, Ap	C 220	13.8	0.9	17	1	Sequence 422, App	Sequence 422, App
C 148	14.4	0.9	17	1	US-10-669-841-4006	Sequence 4006, Ap	C 221	13.8	0.9	17	1	Sequence 1522, Ap	Sequence 1522, Ap
C 149	14.4	0.9	17	1	US-10-669-841-5736	Sequence 5736, Ap	C 222	13.8	0.9	17	1	Sequence 215, App	Sequence 215, App
C 150	14.4	0.9	17	1	US-10-723-361-2293	Sequence 2293, Ap	C 223	13.8	0.9	17	1	Sequence 887, App	Sequence 887, App
C 151	14.4	0.9	17	1	US-10-723-361-2294	Sequence 2294, Ap	C 224	13.8	0.9	17	1	Sequence 52, Appl	Sequence 52, Appl
C 152	14.4	0.9	17	1	US-10-723-361-2296	Sequence 2296, Ap	C 225	13.8	0.9	17	1	Sequence 760, App	Sequence 760, App
C 153	14.4	0.9	17	1	US-10-723-361-2297	Sequence 2297, Ap	C 226	13.8	0.9	17	1	Sequence 1945, Ap	Sequence 1945, Ap
C 154	14.4	0.9	17	1	US-10-723-361-6624	Sequence 6624, Ap	C 227	13.8	0.9	17	1	Sequence 3459, Ap	Sequence 3459, Ap
C 155	14.4	0.9	17	1	US-10-723-361-6629	Sequence 6629, Ap	C 228	13.8	0.9	17	1	Sequence 8362, Ap	Sequence 8362, Ap
C 156	14.4	0.9	18	1	US-10-067-125-42	Sequence 42, Appl	C 229	13.8	0.9	17	1	Sequence 1945, Ap	Sequence 1945, Ap
C 157	14.4	0.9	18	1	US-10-067-125-129	Sequence 129, App	C 230	13.8	0.9	17	1	Sequence 3459, Ap	Sequence 3459, Ap
C 158	14.4	0.9	18	1	US-10-138-674-2168	Sequence 2168, Ap	C 231	13.8	0.9	17	1	Sequence 1647, Ap	Sequence 1647, Ap
C 159	14.4	0.9	18	1	US-10-287-949A-2168	Sequence 2168, Ap	C 232	13.8	0.9	17	1	Sequence 1213, Ap	Sequence 1213, Ap
C 160	14.4	0.9	19	1	US-10-244-647-477	Sequence 477, App	C 233	13.8	0.9	17	1	Sequence 1954, Ap	Sequence 1954, Ap
C 161	14.4	0.9	19	1	US-10-244-647-487	Sequence 487, App	C 234	13.8	0.9	17	1	Sequence 2332, Ap	Sequence 2332, Ap
C 162	14.4	0.9	19	1	US-10-244-647-1123	Sequence 1123, Ap	C 235	13.8	0.9	17	1	Sequence 2720, Ap	Sequence 2720, Ap
C 163	14.4	0.9	19	1	US-10-244-647-1133	Sequence 1133, Ap	C 236	13.8	0.9	17	1	Sequence 931, App	Sequence 931, App
C 164	14.4	0.9	19	1	US-10-444-925-566	Sequence 566, App	C 237	13.8	0.9	17	1	Sequence 1536, Ap	Sequence 1536, Ap
C 165	14	0.9	15	1	US-09-848-754A-9223	Sequence 9223, Ap	C 238	13.8	0.9	17	1	Sequence 1647, Ap	Sequence 1647, Ap
C 166	14	0.9	17	1	US-09-877-478-2245	Sequence 2245, Ap	C 239	13.8	0.9	17	1	Sequence 2290, Ap	Sequence 2290, Ap
C 167	14	0.9	17	1	US-09-848-754A-1114	Sequence 1114, Ap	C 240	13.8	0.9	17	1	Sequence 2291, Ap	Sequence 2291, Ap
C 168	14	0.9	17	1	US-09-740-332-3142	Sequence 3142, Ap	C 241	13.8	0.9	17	1	Sequence 2292, Ap	Sequence 2292, Ap
C 169	14	0.9	17	1	US-09-817-879-3142	Sequence 3142, Ap	C 242	13.8	0.9	17	1	Sequence 2293, Ap	Sequence 2293, Ap
C 170	14	0.9	17	1	US-10-342-902-2245	Sequence 2245, Ap	C 243	13.8	0.9	17	1	Sequence 2298, Ap	Sequence 2298, Ap
C 171	14	0.9	17	1	US-10-138-674-6125	Sequence 6125, Ap	C 244	13.8	0.9	17	1	Sequence 2300, Ap	Sequence 2300, Ap
C 172	14	0.9	17	1	US-10-138-674-6126	Sequence 6126, Ap	C 245	13.8	0.9	17	1	Sequence 6916, Ap	Sequence 6916, Ap
C 173	14	0.9	17	1	US-10-287-949A-6125	Sequence 6125, Ap	C 246	13.8	0.9	17	1	Sequence 10673, A	Sequence 10673, A
C 174	14	0.9	17	1	US-10-287-949A-6126	Sequence 6126, Ap	C 247	13.8	0.9	17	1	Sequence 10674, A	Sequence 10674, A
C 175	14	0.9	17	1	US-10-669-841-2048	Sequence 2048, Ap	C 248	13.8	0.9	17	1	Sequence 95, Appl	Sequence 95, Appl
C 176	14	0.9	17	1	US-10-669-841-5735	Sequence 5735, Ap	C 249	13.8	0.9	17	1		
C 177	14	0.9	17	1	US-10-179-940-283	Sequence 283, App	C 250	13.8	0.9	17	1		
C 178	13.8	0.9	17	1	US-09-866-108-931	Sequence 931, App	C 251	13.8	0.9	17	1		
C 179	13.8	0.9	17	1	US-09-866-108-1536	Sequence 1536, Ap	C 252	13.8	0.9	17	1		

253	13.8	0.9	18	1	US-09-104-654-4	Sequence 4, Appli	C 326	13.4	0.9	17	1	US-10-669-841-4005	Sequence 4005, Ap
c 254	13.8	0.9	18	1	US-09-425-075-3	Sequence 3, Appli	327	13.4	0.9	17	1	US-10-723-361-6623	Sequence 6623, Ap
c 255	13.8	0.9	18	1	US-10-005-956-1236	Sequence 1236, Ap	328	13.4	0.9	17	1	US-10-723-361-6630	Sequence 6630, Ap
c 256	13.8	0.9	18	1	US-10-204-431-6	Sequence 6, Appli	C 329	13.4	0.9	17	1	US-10-723-361-10675	Sequence 10675, A
c 257	13.8	0.9	18	1	US-10-351-951-123	Sequence 123, App	C 330	13.4	0.9	17	1	US-10-723-361-10676	Sequence 10676, A
c 258	13.8	0.9	18	1	US-10-108-260A-5348	Sequence 5348, Ap	331	13.4	0.9	20	1	US-10-181-846-109	Sequence 109, App
c 259	13.8	0.9	18	1	US-10-349-143-7807	Sequence 7807, Ap	C 332	13.2	0.8	17	1	US-09-765-449-17	Sequence 17, Appl
c 260	13.8	0.9	18	1	US-10-349-143-7807	Sequence 7807, Ap	C 333	13	0.8	15	1	US-09-864-783-3767	Sequence 3767, Ap
c 261	13.8	0.9	20	1	US-10-461-790-51	Sequence 51, Appl	C 334	13	0.8	15	1	US-09-740-332-4771	Sequence 4771, Ap
c 262	13.8	0.9	20	1	US-10-740-773-9	Sequence 9, Appli	C 335	13	0.8	15	1	US-09-817-879-4771	Sequence 4771, Ap
c 263	13.4	0.9	15	1	US-10-300-683-118	Sequence 118, App	336	13	0.8	15	1	US-10-287-919-360	Sequence 360, App
c 264	13.4	0.9	15	1	US-10-300-683-291	Sequence 291, App	337	13	0.8	15	1	US-10-287-919-1424	Sequence 1424, App
c 265	13.4	0.9	15	1	US-10-300-683-477	Sequence 477, App	C 338	13	0.8	15	1	US-10-669-841-7368	Sequence 7368, Ap
c 266	13.4	0.9	15	1	US-10-395-031-10	Sequence 10, Appl	C 339	13	0.8	16	1	US-09-740-332-9683	Sequence 9683, Ap
c 267	13.4	0.9	16	1	US-10-210-172-240	Sequence 240, App	C 340	13	0.8	16	1	US-09-817-879-9683	Sequence 9683, Ap
c 268	13.4	0.9	16	1	US-10-138-674-5661	Sequence 5661, Ap	C 341	13	0.8	16	1	US-10-669-841-7427	Sequence 7427, Ap
c 269	13.4	0.9	16	1	US-10-287-949A-5561	Sequence 5561, Ap	C 342	13	0.8	17	1	US-09-864-785-2086	Sequence 2086, Ap
c 270	13.4	0.9	17	1	US-09-866-108-6623	Sequence 6623, Ap	C 343	13	0.8	17	1	US-09-864-785-2838	Sequence 2838, Ap
c 271	13.4	0.9	17	1	US-09-866-108-6630	Sequence 6630, Ap	C 344	13	0.8	17	1	US-09-864-785-2839	Sequence 2839, Ap
c 272	13.4	0.9	17	1	US-09-866-108-10675	Sequence 10675, A	C 345	13	0.8	17	1	US-09-825-805-456	Sequence 456, App
c 273	13.4	0.9	17	1	US-09-866-108-10676	Sequence 10676, A	C 346	13	0.8	17	1	US-09-818-875-2786	Sequence 2786, Ap
c 274	13.4	0.9	17	1	US-09-780-533A-287	Sequence 287, App	347	13	0.8	17	1	US-09-818-875-2787	Sequence 2787, Ap
c 275	13.4	0.9	17	1	US-09-848-754A-370	Sequence 370, App	348	13	0.8	17	1	US-09-780-533A-288	Sequence 288, App
c 276	13.4	0.9	17	1	US-09-848-754A-1340	Sequence 1340, Ap	349	13	0.8	17	1	US-09-780-533A-1165	Sequence 1165, Ap
c 277	13.4	0.9	17	1	US-09-848-754A-1351	Sequence 1351, Ap	C 350	13	0.8	17	1	US-09-877-478-1467	Sequence 1467, Ap
c 278	13.4	0.9	17	1	US-09-848-754A-2408	Sequence 2408, Ap	C 351	13	0.8	17	1	US-09-848-754A-1115	Sequence 1115, Ap
c 279	13.4	0.9	17	1	US-09-930-423-5	Sequence 5, Appli	C 352	13	0.8	17	1	US-09-930-423-335	Sequence 335, App
c 280	13.4	0.9	17	1	US-09-930-423-324	Sequence 324, App	C 353	13	0.8	17	1	US-09-930-423-336	Sequence 336, App
c 281	13.4	0.9	17	1	US-09-930-423-325	Sequence 325, App	C 354	13	0.8	17	1	US-09-745-237A-335	Sequence 335, App
c 282	13.4	0.9	17	1	US-09-930-423-334	Sequence 334, App	C 355	13	0.8	17	1	US-09-745-237A-336	Sequence 336, App
c 283	13.4	0.9	17	1	US-09-780-164-137	Sequence 137, App	C 356	13	0.8	17	1	US-10-163-552-728	Sequence 728, App
c 284	13.4	0.9	17	1	US-09-780-164-1043	Sequence 1043, Ap	C 357	13	0.8	17	1	US-10-156-306-5116	Sequence 5116, Ap
c 285	13.4	0.9	17	1	US-09-780-164-1044	Sequence 1044, Ap	C 358	13	0.8	17	1	US-10-156-306-6360	Sequence 6360, Ap
c 286	13.4	0.9	17	1	US-09-864-636A-2493	Sequence 2493, Ap	C 359	13	0.8	17	1	US-10-156-306-7073	Sequence 7073, Ap
c 287	13.4	0.9	17	1	US-09-740-332-1412	Sequence 1412, Ap	C 360	13	0.8	17	1	US-10-156-306-7074	Sequence 7074, Ap
c 288	13.4	0.9	17	1	US-09-745-237A-5	Sequence 5, Appli	C 361	13	0.8	17	1	US-10-339-782-155	Sequence 155, App
c 289	13.4	0.9	17	1	US-09-745-237A-324	Sequence 324, App	C 362	13	0.8	17	1	US-10-209-787-2786	Sequence 2786, Ap
c 290	13.4	0.9	17	1	US-09-745-237A-325	Sequence 325, App	C 363	13	0.8	17	1	US-10-209-787-2787	Sequence 2787, Ap
c 291	13.4	0.9	17	1	US-09-745-237A-334	Sequence 334, App	C 364	13	0.8	17	1	US-10-261-185-2786	Sequence 2786, Ap
c 292	13.4	0.9	17	1	US-09-817-879-1412	Sequence 1412, Ap	365	13	0.8	17	1	US-10-261-185-2787	Sequence 2787, Ap
c 293	13.4	0.9	17	1	US-09-864-426A-2493	Sequence 2493, Ap	C 366	13	0.8	17	1	US-10-342-902-1467	Sequence 1467, Ap
c 294	13.4	0.9	17	1	US-10-060-830-135	Sequence 135, App	367	13	0.8	17	1	US-10-138-674-1508	Sequence 1508, Ap
c 295	13.4	0.9	17	1	US-10-060-830-136	Sequence 136, App	C 368	13	0.8	17	1	US-10-347-863-17	Sequence 17, Appl
c 296	13.4	0.9	17	1	US-10-060-998-119	Sequence 119, App	C 369	13	0.8	17	1	US-10-287-949A-1508	Sequence 1508, Ap
c 297	13.4	0.9	17	1	US-10-060-998-120	Sequence 120, App	C 370	13	0.8	17	1	US-10-669-841-1467	Sequence 1467, Ap
c 298	13.4	0.9	17	1	US-10-163-552-729	Sequence 729, App	C 371	13	0.8	17	1	US-10-681-074-2786	Sequence 2786, Ap
c 299	13.4	0.9	17	1	US-10-156-306-3771	Sequence 3771, Ap	372	13	0.8	29	1	US-10-681-074-2787	Sequence 2787, Ap
c 300	13.4	0.9	17	1	US-10-339-782-45	Sequence 45, Appl	C 373	13	0.8	29	1	US-10-336-638-370	Sequence 370, App
c 301	13.4	0.9	17	1	US-10-084-839-2493	Sequence 2493, Ap	374	12.8	0.8	16	1	US-10-241-780-88	Sequence 88, Appl
c 302	13.4	0.9	17	1	US-10-307-005-315	Sequence 315, App	375	12.8	0.8	16	1	US-10-331-907-439	Sequence 439, App
c 303	13.4	0.9	17	1	US-10-307-005-316	Sequence 316, App	C 376	12.8	0.8	16	1	US-10-182-230-163	Sequence 163, App
c 304	13.4	0.9	17	1	US-10-307-005-2383	Sequence 2383, Ap	C 377	12.8	0.8	16	1	US-10-407-807-34	Sequence 34, Appl
c 305	13.4	0.9	17	1	US-10-307-005-2384	Sequence 2384, Ap	C 378	12.8	0.8	16	1	US-10-407-807-53	Sequence 53, Appl
c 306	13.4	0.9	17	1	US-10-138-674-949	Sequence 949, App	379	12.8	0.8	16	1	US-10-712-672-1739	Sequence 1739, Ap
c 307	13.4	0.9	17	1	US-10-138-674-2128	Sequence 2128, Ap	C 380	12.8	0.8	16	1	US-10-232-923-2	Sequence 2, Appl1
c 308	13.4	0.9	17	1	US-10-138-674-2129	Sequence 2129, Ap	C 381	12.8	0.8	17	1	US-09-866-108-434	Sequence 434, App
c 309	13.4	0.9	17	1	US-10-138-674-4663	Sequence 4663, Ap	C 382	12.8	0.8	17	1	US-09-866-108-435	Sequence 435, App
c 310	13.4	0.9	17	1	US-10-138-674-5311	Sequence 5311, Ap	383	12.8	0.8	17	1	US-09-866-108-930	Sequence 930, App
c 311	13.4	0.9	17	1	US-10-138-674-7200	Sequence 7200, Ap	384	12.8	0.8	17	1	US-09-866-108-932	Sequence 932, App
c 312	13.4	0.9	17	1	US-10-138-674-7201	Sequence 7201, Ap	C 385	12.8	0.8	17	1	US-09-866-108-1200	Sequence 1200, Ap
c 313	13.4	0.9	17	1	US-10-138-674-8515	Sequence 8515, Ap	C 386	12.8	0.8	17	1	US-09-866-108-1201	Sequence 1201, Ap
c 314	13.4	0.9	17	1	US-10-676-154-100	Sequence 100, App	387	12.8	0.8	17	1	US-09-866-108-1416	Sequence 1416, Ap
c 315	13.4	0.9	17	1	US-10-287-949A-949	Sequence 949, App	388	12.8	0.8	17	1	US-09-866-108-1417	Sequence 1417, Ap
c 316	13.4	0.9	17	1	US-10-287-949A-2128	Sequence 2128, Ap	389	12.8	0.8	17	1	US-09-866-108-1535	Sequence 1535, Ap
c 317	13.4	0.9	17	1	US-10-287-949A-2129	Sequence 2129, Ap	390	12.8	0.8	17	1	US-09-866-108-1537	Sequence 1537, Ap
c 318	13.4	0.9	17	1	US-10-287-949A-4663	Sequence 4663, Ap	C 391	12.8	0.8	17	1	US-09-866-108-1646	Sequence 1646, Ap
c 319	13.4	0.9	17	1	US-10-287-949A-5311	Sequence 5311, Ap	C 392	12.8	0.8	17	1	US-09-866-108-1648	Sequence 1648, Ap
c 320	13.4	0.9	17	1	US-10-287-949A-7200	Sequence 7200, App	C 393	12.8	0.8	17	1	US-09-866-108-2289	Sequence 2289, Ap
c 321	13.4	0.9	17	1	US-10-287-949A-7201	Sequence 7201, Ap	C 394	12.8	0.8	17	1	US-09-866-108-2301	Sequence 2301, Ap
c 322	13.4	0.9	17	1	US-10-287-949A-8515	Sequence 8515, Ap	C 395	12.8	0.8	17	1	US-09-866-108-6545	Sequence 6545, Ap
c 323	13.4	0.9	17	1	US-10-712-672-304	Sequence 304, App	C 396	12.8	0.8	17	1	US-09-866-108-6546	Sequence 6546, Ap
c 324	13.4	0.9	17	1	US-10-712-672-1212	Sequence 1212, Ap	C 397	12.8	0.8	17	1	US-09-866-108-6915	Sequence 6915, Ap
c 325	13.4	0.9	17	1	US-10-712-672-2128	Sequence 2128, Ap	C 398	12.8	0.8	17	1	US-09-866-108-6917	Sequence 6917, Ap

c 545 12.8 0.8 17 1 US-10-297-068-725 Sequence 725, App
c 546 12.8 0.8 17 1 US-10-300-683-95 Sequence 95, Appl
c 547 12.8 0.8 17 1 US-10-300-683-256 Sequence 256, App
c 548 12.8 0.8 17 1 US-10-300-683-446 Sequence 446, App
c 549 12.8 0.8 17 1 US-10-393-075-1 Sequence 1, Appl
c 550 12.8 0.8 17 1 US-10-261-185-1419 Sequence 1419, Ap
c 551 12.8 0.8 17 1 US-10-261-185-1420 Sequence 1420, Ap
c 552 12.8 0.8 17 1 US-10-608-062-20 Sequence 20, Appl
c 553 12.8 0.8 17 1 US-10-342-902-118 Sequence 118, App
c 554 12.8 0.8 17 1 US-10-342-902-808 Sequence 808, App
c 555 12.8 0.8 17 1 US-10-342-902-2178 Sequence 2178, Ap
c 556 12.8 0.8 17 1 US-10-675-685-755 Sequence 755, App
c 557 12.8 0.8 17 1 US-10-675-685-756 Sequence 756, App
c 558 12.8 0.8 17 1 US-10-675-685-759 Sequence 759, App
c 559 12.8 0.8 17 1 US-10-675-685-762 Sequence 762, App
c 560 12.8 0.8 17 1 US-10-138-674-2567 Sequence 2567, Ap
c 561 12.8 0.8 17 1 US-10-138-674-4768 Sequence 4768, Ap
c 562 12.8 0.8 17 1 US-10-138-674-4769 Sequence 4769, Ap
c 563 12.8 0.8 17 1 US-10-138-674-4785 Sequence 4785, Ap
c 564 12.8 0.8 17 1 US-10-138-674-4786 Sequence 4786, Ap
c 565 12.8 0.8 17 1 US-10-138-674-5375 Sequence 5375, Ap
c 566 12.8 0.8 17 1 US-10-138-674-6490 Sequence 6490, Ap
c 567 12.8 0.8 17 1 US-10-138-674-6491 Sequence 6491, Ap
c 568 12.8 0.8 17 1 US-10-138-674-6686 Sequence 6686, Ap
c 569 12.8 0.8 17 1 US-10-138-674-7443 Sequence 7443, Ap
c 570 12.8 0.8 17 1 US-10-138-674-7558 Sequence 7558, Ap
c 571 12.8 0.8 17 1 US-10-138-674-7644 Sequence 7644, Ap
c 572 12.8 0.8 17 1 US-10-138-674-7715 Sequence 7715, Ap
c 573 12.8 0.8 17 1 US-10-138-674-8432 Sequence 8432, Ap
c 574 12.8 0.8 17 1 US-10-138-674-8433 Sequence 8433, Ap
c 575 12.8 0.8 17 1 US-10-138-674-8463 Sequence 8463, Ap
c 576 12.8 0.8 17 1 US-10-287-949A-2567 Sequence 2567, Ap
c 577 12.8 0.8 17 1 US-10-287-949A-4768 Sequence 4768, Ap
c 578 12.8 0.8 17 1 US-10-287-949A-4769 Sequence 4769, Ap
c 579 12.8 0.8 17 1 US-10-287-949A-4785 Sequence 4785, Ap
c 580 12.8 0.8 17 1 US-10-287-949A-4786 Sequence 4786, Ap
c 581 12.8 0.8 17 1 US-10-287-949A-5375 Sequence 5375, Ap
c 582 12.8 0.8 17 1 US-10-287-949A-6490 Sequence 6490, Ap
c 583 12.8 0.8 17 1 US-10-287-949A-6491 Sequence 6491, Ap
c 584 12.8 0.8 17 1 US-10-287-949A-6686 Sequence 6686, Ap
c 585 12.8 0.8 17 1 US-10-287-949A-7443 Sequence 7443, Ap
c 586 12.8 0.8 17 1 US-10-287-949A-7558 Sequence 7558, Ap
c 587 12.8 0.8 17 1 US-10-287-949A-7644 Sequence 7644, Ap
c 588 12.8 0.8 17 1 US-10-287-949A-7715 Sequence 7715, Ap
c 589 12.8 0.8 17 1 US-10-287-949A-8432 Sequence 8432, Ap
c 590 12.8 0.8 17 1 US-10-287-949A-8463 Sequence 8463, Ap
c 591 12.8 0.8 17 1 US-10-287-949A-8716 Sequence 8716, Ap
c 592 12.8 0.8 17 1 US-10-712-672-305 Sequence 305, App
c 593 12.8 0.8 17 1 US-10-712-672-344 Sequence 344, App
c 594 12.8 0.8 17 1 US-10-712-672-345 Sequence 345, App
c 595 12.8 0.8 17 1 US-10-712-672-446 Sequence 446, App
c 596 12.8 0.8 17 1 US-10-712-672-1251 Sequence 1251, Ap
c 597 12.8 0.8 17 1 US-10-712-672-1252 Sequence 1252, Ap
c 598 12.8 0.8 17 1 US-10-712-672-1413 Sequence 1413, Ap
c 599 12.8 0.8 17 1 US-10-712-672-1928 Sequence 1928, Ap
c 600 12.8 0.8 17 1 US-10-712-672-2191 Sequence 2191, Ap
c 601 12.8 0.8 17 1 US-10-712-672-2477 Sequence 2477, Ap
c 602 12.8 0.8 17 1 US-10-712-672-2669 Sequence 2669, Ap
c 603 12.8 0.8 17 1 US-10-376-770-72 Sequence 72, Appl
c 604 12.8 0.8 17 1 US-10-669-841-118 Sequence 118, App
c 605 12.8 0.8 17 1 US-10-669-841-808 Sequence 808, App
c 606 12.8 0.8 17 1 US-10-669-841-1994 Sequence 1994, Ap
c 607 12.8 0.8 17 1 US-10-669-841-3028 Sequence 3028, Ap
c 608 12.8 0.8 17 1 US-10-669-841-3225 Sequence 3225, Ap
c 609 12.8 0.8 17 1 US-10-669-841-3969 Sequence 3969, Ap
c 610 12.8 0.8 17 1 US-10-669-841-4492 Sequence 4492, Ap
c 611 12.8 0.8 17 1 US-10-669-841-4498 Sequence 4498, Ap
c 612 12.8 0.8 17 1 US-10-669-841-4620 Sequence 4620, Ap
c 613 12.8 0.8 17 1 US-10-669-841-4725 Sequence 4725, Ap
c 614 12.8 0.8 17 1 US-10-669-841-5016 Sequence 5016, Ap
c 615 12.8 0.8 17 1 US-10-669-841-5243 Sequence 5243, Ap
c 616 12.8 0.8 17 1 US-10-669-841-5772 Sequence 5772, Ap
c 617 12.8 0.8 17 1 US-10-669-841-6713 Sequence 6713, Ap

c 618 12.8 0.8 17 1 US-10-661-165-72 Sequence 72, Appl
c 619 12.8 0.8 17 1 US-10-723-361-434 Sequence 434, App
c 620 12.8 0.8 17 1 US-10-723-361-435 Sequence 435, App
c 621 12.8 0.8 17 1 US-10-723-361-930 Sequence 930, App
c 622 12.8 0.8 17 1 US-10-723-361-932 Sequence 932, App
c 623 12.8 0.8 17 1 US-10-723-361-1200 Sequence 1200, Ap
c 624 12.8 0.8 17 1 US-10-723-361-1201 Sequence 1201, Ap
c 625 12.8 0.8 17 1 US-10-723-361-1416 Sequence 1416, Ap
c 626 12.8 0.8 17 1 US-10-723-361-1417 Sequence 1417, Ap
c 627 12.8 0.8 17 1 US-10-723-361-1535 Sequence 1535, Ap
c 628 12.8 0.8 17 1 US-10-723-361-1537 Sequence 1537, Ap
c 629 12.8 0.8 17 1 US-10-723-361-1646 Sequence 1646, Ap
c 630 12.8 0.8 17 1 US-10-723-361-1648 Sequence 1648, Ap
c 631 12.8 0.8 17 1 US-10-723-361-2289 Sequence 2289, Ap
c 632 12.8 0.8 17 1 US-10-723-361-2301 Sequence 2301, Ap
c 633 12.8 0.8 17 1 US-10-723-361-6545 Sequence 6545, Ap
c 634 12.8 0.8 17 1 US-10-723-361-6546 Sequence 6546, Ap
c 635 12.8 0.8 17 1 US-10-723-361-6915 Sequence 6915, Ap
c 636 12.8 0.8 17 1 US-10-723-361-6917 Sequence 6917, Ap
c 637 12.8 0.8 17 1 US-10-723-361-7706 Sequence 7706, Ap
c 638 12.8 0.8 17 1 US-10-723-361-7707 Sequence 7707, Ap
c 639 12.8 0.8 17 1 US-10-723-361-8327 Sequence 8327, Ap
c 640 12.8 0.8 17 1 US-10-723-361-8328 Sequence 8328, Ap
c 641 12.8 0.8 17 1 US-10-723-361-8351 Sequence 8351, Ap
c 642 12.8 0.8 17 1 US-10-723-361-8352 Sequence 8352, Ap
c 643 12.8 0.8 17 1 US-10-723-361-8361 Sequence 8361, Ap
c 644 12.8 0.8 17 1 US-10-723-361-8362 Sequence 8362, Ap
c 645 12.8 0.8 17 1 US-10-723-361-8928 Sequence 8928, Ap
c 646 12.8 0.8 17 1 US-10-723-361-8929 Sequence 8929, Ap
c 647 12.8 0.8 17 1 US-10-723-361-9020 Sequence 9020, Ap
c 648 12.8 0.8 17 1 US-10-723-361-9021 Sequence 9021, Ap
c 649 12.8 0.8 17 1 US-10-723-361-9033 Sequence 9033, Ap
c 650 12.8 0.8 17 1 US-10-723-361-9035 Sequence 9035, Ap
c 651 12.8 0.8 17 1 US-10-723-361-9829 Sequence 9829, Ap
c 652 12.8 0.8 17 1 US-10-723-361-9830 Sequence 9830, Ap
c 653 12.8 0.8 17 1 US-10-723-361-10672 Sequence 10672, A
c 654 12.8 0.8 17 1 US-10-741-601-26208 Sequence 26208, A
c 655 12.8 0.8 17 1 US-10-741-601-26250 Sequence 26250, A
c 656 12.8 0.8 17 1 US-10-681-074-1419 Sequence 1419, Ap
c 657 12.8 0.8 17 1 US-10-681-074-1420 Sequence 1420, Ap
c 658 12.8 0.8 17 1 US-10-699-557-23 Sequence 23, Appl

ALIGNMENTS

RESULT 1
US-09-918-026A-6
; Sequence 6, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX1
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 6
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-09-918-026A-6

Query Match 1.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1212 CTACGTGTATCAGGTGGCTCGG 1236
|||||

Db 1 CTACGTGTATCAGTAGGCGCTCGG 25

RESULT 2

US-10-336-638-370
; Sequence 370, Application US/10336638
; Publication No. US20030170699A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian Bing
; APPLICANT: Chakravarti, Aravinda
; APPLICANT: Halushka, Marc Kennech
; APPLICANT: Case Western Reserve University School of Medicine
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Polymorphisms Associated With
; FILE REFERENCE: 018547-034210US
; CURRENT APPLICATION NUMBER: US/10/336,638
; CURRENT FILING DATE: 2003-01-02
; PRIOR APPLICATION NUMBER: US/09/304,232
; PRIOR FILING DATE: 1999-05-03
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/084,641
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-05-07
; NUMBER OF SEQ ID NOS: 909
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 370
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: CYP11B2EX3 138
US-10-336-638-370

Query Match 1.4%; Score 21.8; DB 1; Length 29;
Best Local Similarity 85.2%; Pred. No. 65;
Matches 23; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 889 GTGGCAAGAAGCTTTGCCAGGCCCTG 915
Db 1 GTGGCAGGACTTCTCCAGGCCCTG 27

RESULT 3

US-09-918-026A-4
; Sequence 4, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-918-026A-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1190 TGGTCCATGACTGGCTGTACA 1210
Db 1 TGGTCCATGACTGGCTGTACA 21

RESULT 4

US-09-918-026A-14/c

; Sequence 14, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-918-026A-14

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 CCGTCTGCGTCTGCAGGAGA 37
Db 20 CCGTCTGCGTCTGCAGGAGA 1

RESULT 5

US-09-918-026A-15/c
; Sequence 15, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-918-026A-15

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 GAGCGCCACCCCTGTGGAGA 80
Db 20 GAGCGCCACCCCTGTGGAGA 1

RESULT 6

US-09-918-026A-16/c
; Sequence 16, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 16
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-09-918-026A-16

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAGAGCCACA 100
|||||
DB 20 TGGAAACACTGAGAGCCACA 1

RESULT 7

US-09-918-026A-17/c
; Sequence 17, Application US/09918026A
; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 17

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-17

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 CTTGTACAAATGACCCGAC 130
|||||
DB 20 CTTGTACAAATGACCCGAC 1

RESULT 8

US-09-918-026A-18/c

; Sequence 18, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 18

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-18

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 AGCAAGCGGAGGACACTG 180
|||||
DB 20 AGCAAGCGGAGGACACTG 1

RESULT 9

US-09-918-026A-19/c

; Sequence 19, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 19

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-19

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGGAGAGCTGCTGGATCGGCG 200
|||||
DB 20 AGGAGAGCTGCTGGATCGGCG 1

RESULT 10

US-09-918-026A-20/c

; Sequence 20, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 20

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-20

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 AGGAGCCATCCCTGGGAAA 300
|||||
DB 20 AGGAGCCATCCCTGGGAAA 1

RESULT 11

US-09-918-026A-21/c

; Sequence 21, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30
 ; NUMBER OF SEQ ID NOS: 65
 ; SEQ ID NO 21
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-918-026A-21

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 55;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 431 TTGATGAGGCGAGGTGCTG 450
 DB 20 TTGATGAGGCGAGGTGCTG 1

RESULT 12
 US-09-918-026A-22/c
 ; Sequence 22, Application US/09918026A
 ; Publication No. US20030096772A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rosanne M. Crooke
 ; APPLICANT: Mark J. Graham
 ; APPLICANT: Kristina M. Lemonidis
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
 ; FILE REFERENCE: ISPH-0588
 ; CURRENT APPLICATION NUMBER: US/09/918,026A
 ; CURRENT FILING DATE: 2001-07-30
 ; NUMBER OF SEQ ID NOS: 65
 ; SEQ ID NO 22
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-918-026A-22

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 55;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 CCGTACCGGCGCTACGGCT 560
 DB 20 CCGTACCGGCGCTACGGCT 1

RESULT 13
 US-09-918-026A-23/c
 ; Sequence 23, Application US/09918026A
 ; Publication No. US20030096772A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rosanne M. Crooke
 ; APPLICANT: Mark J. Graham
 ; APPLICANT: Kristina M. Lemonidis
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
 ; FILE REFERENCE: ISPH-0588
 ; CURRENT APPLICATION NUMBER: US/09/918,026A
 ; CURRENT FILING DATE: 2001-07-30
 ; NUMBER OF SEQ ID NOS: 65
 ; SEQ ID NO 23
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-918-026A-23

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 55;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GTGGGCCAGGGCGACCTGGA 580
 DB 20 GTGGGCCAGGGCGACCTGGA 1

RESULT 14
 US-09-918-026A-24/c
 ; Sequence 24, Application US/09918026A
 ; Publication No. US20030096772A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rosanne M. Crooke
 ; APPLICANT: Mark J. Graham
 ; APPLICANT: Kristina M. Lemonidis
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
 ; FILE REFERENCE: ISPH-0588
 ; CURRENT APPLICATION NUMBER: US/09/918,026A
 ; CURRENT FILING DATE: 2001-07-30
 ; NUMBER OF SEQ ID NOS: 65
 ; SEQ ID NO 24
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-918-026A-24

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 55;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 581 CGCAGGCGACGGCGCTGGGC 600
 DB 20 CGCAGGCGACGGCGCTGGGC 1

RESULT 15
 US-09-918-026A-25/c
 ; Sequence 25, Application US/09918026A
 ; Publication No. US20030096772A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rosanne M. Crooke
 ; APPLICANT: Mark J. Graham
 ; APPLICANT: Kristina M. Lemonidis
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
 ; FILE REFERENCE: ISPH-0588
 ; CURRENT APPLICATION NUMBER: US/09/918,026A
 ; CURRENT FILING DATE: 2001-07-30
 ; NUMBER OF SEQ ID NOS: 65
 ; SEQ ID NO 25
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-918-026A-25

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 55;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 GTGCGCTGGGATCCTTCGTGC 770
 DB 20 GTGCGCTGGGATCCTTCGTGC 1

RESULT 16
 US-09-918-026A-26/c
 ; Sequence 26, Application US/09918026A
 ; Publication No. US20030096772A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rosanne M. Crooke
 ; APPLICANT: Mark J. Graham


```

; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-26

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 CAGACGAGGTGAGGGATCC 790
Db 20 CAGACGAGGTGAGGGATCC 1

RESULT 17
US-09-918-026A-27/c
; Sequence 27, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-27

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 881 GGAATTATGTGCCAAGAAC 900
Db 20 GGAATTATGTGCCAAGAAC 1

RESULT 18
US-09-918-026A-28/c
; Sequence 28, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-28
```

```

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCCTGGCGCGCCTCTGTGT 960
Db 20 TCCTGGCGCGCCTCTGTGT 1

RESULT 19
US-09-918-026A-29/c
; Sequence 29, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-29

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1021 CTGCATGCCACGTTGCCAG 1040
Db 20 CTGCATGCCACGTTGCCAG 1

RESULT 20
US-09-918-026A-30/c
; Sequence 30, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-30

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1081 TGCTGGCTCAACGCTTTGC 1100
Db 20 TGCTGGCTCAACGCTTTGC 1

RESULT 21
US-09-918-026A-31/c
; Sequence 31, Application US/09918026A
```

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 31

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-31

Query Match

Best Local Similarity 1.3%; Score 20; DB 1; Length 20;

Mismatches 0; Indels 0; Gaps 0;

Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAACGTGGTGCATGAC 1200

Db 20 GGAACGTGGTGCATGAC 1

RESULT 22

US-09-918-026A-32/c

; Sequence 32, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 32

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-32

Query Match

Best Local Similarity 1.3%; Score 20; DB 1; Length 20;

Mismatches 0; Indels 0; Gaps 0;

Mismatches 0; Indels 0; Gaps 0;

QY 1221 TCAGGATGGCTCGGCTCC 1240

Db 20 TCAGGATGGCTCGGCTCC 1

RESULT 23

US-09-918-026A-33/c

; Sequence 33, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 33

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-33

Query Match

Best Local Similarity 1.3%; Score 20; DB 1; Length 20;

Mismatches 0; Indels 0; Gaps 0;

Mismatches 0; Indels 0; Gaps 0;

QY 1271 TGGGTGTGTTCTCTCTCC 1290

Db 20 TGGGTGTGTTCTCTCTCC 1

RESULT 24

US-09-918-026A-34/c

; Sequence 34, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 34

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-34

Query Match

Best Local Similarity 1.3%; Score 20; DB 1; Length 20;

Mismatches 0; Indels 0; Gaps 0;

Mismatches 0; Indels 0; Gaps 0;

QY 1401 GCGCACCGCGCGCATGGA 1420

Db 20 GCGCACCGCGCGCATGGA 1

RESULT 25

US-09-918-026A-35/c

; Sequence 35, Application US/09918026A

; Publication No. US20030096772A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 35

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-35

Query Match

Best Local Similarity 1.3%; Score 20; DB 1; Length 20;

Mismatches 0; Indels 0; Gaps 0;

Mismatches 0; Indels 0; Gaps 0;

QY 1451 GCCAGGGAATCCAGGTCAGC 1470

Db 20 GCCAGGGAATCCAGGTCAGC 1

```
RESULT 26
US-09-918-026A-36/c
; Sequence 36, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-36

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1541 CACCTCGATCTTGCTCTGC 1560
Db 20 CACCTCGATCTTGCTCTGC 1

RESULT 27
US-09-918-026A-54/c
; Sequence 54, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-54

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1541 CACCTCGATCTTGCTCTGC 1560
Db 20 CACCTCGATCTTGCTCTGC 1

RESULT 28
US-09-918-026A-65/c
; Sequence 65, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-65
```

```
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-65

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 CTTGGTCCTGCCATACCTAG 1569
Db 20 CTTGGTCCTGCCATACCTAG 1

RESULT 29
US-09-992-665-70/c
; Sequence 70, Application US/09992665
; Publication No. US20030092009A1
; GENERAL INFORMATION:
; APPLICANT: Kaia Palm
; TITLE OF INVENTION: PROFILING TUMOR SPECIFIC MARKERS FOR THE
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF NEOPLASTIC DISEASE
; FILE REFERENCE: CEMINES.002A
; CURRENT APPLICATION NUMBER: US/09/992,665
; CURRENT FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: 60/249,508
; PRIOR FILING DATE: 2000-11-16
; NUMBER OF SEQ ID NOS: 380
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe
US-09-992-665-70

Query Match      1.2%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1088 TCAACGCCCTTTCGCGAGATGCTAC 1111
Db 24 TCAACGCCCTTTCGCGAGTGTCTAC 1

RESULT 30
US-09-918-026A-58/c
; Sequence 58, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-58

Query Match      1.2%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 76;
```

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1133 ACCGGGACTGTGGAACTC 1151
|||
Db 20 ACCGGGACTGTGGAACTC 2

RESULT 31

US-10-717-597-573/c
; Sequence 573, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Burczynski, Michael E.

; APPLICANT: Twine, Natalie C.

; APPLICANT: Dörner, Andrew J.

; APPLICANT: Trepicchio, William L.

; APPLICANT: Slonim, Donna K.

; APPLICANT: Stover, Jennifer A.

; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS

; FILE REFERENCE: AM101080L

; CURRENT APPLICATION NUMBER: US/10/717,597

; CURRENT FILING DATE: 2003-11-21

; PRIOR APPLICATION NUMBER: US 60/459,782

; PRIOR FILING DATE: 2003-04-03

; PRIOR APPLICATION NUMBER: US 60/427,982

; PRIOR FILING DATE: 2002-11-21

; NUMBER OF SEQ ID NOS: 4904

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 573

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-717-597-573

Query Match 1.2%; Score 18.8; DB 1; Length 25;

Best Local Similarity 90.9%; Pred. No. 1.3e+02;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 278 CCAGAGCCATCCCTGGGGAA 299

|||
Db 23 CCAAGGAGCCATCTCTGGGGAA 2

RESULT 32

US-09-918-026A-52/c
; Sequence 52, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 52

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-52

Query Match 1.2%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 93;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 743 GAGAGCTGTGCTGGATC 762

|||
Db 20 GAGAGCTGTGCTGGATC 1

RESULT 33

US-09-918-026A-57/c
; Sequence 57, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 57

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-57

Query Match 1.1%; Score 18; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1035 GCCAGGCATCTTCATGCT 1052

|||
Db 18 GCCAGGCATCTTCATGCT 1

RESULT 34

US-09-918-026A-12/c
; Sequence 12, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 12

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: PCR Primer

US-09-918-026A-12

Query Match 1.1%; Score 17.8; DB 1; Length 21;

Best Local Similarity 90.5%; Pred. No. 1.2e+02;

Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 109 GACTTGGTACAATGGACCCGA 129

|||
Db 21 GACTTGGTACAATGGACTCGA 1

RESULT 35

US-09-877-478-846/c
; Sequence 846, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Draper, Kenneth

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Morrissey, Dave

; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

; FILE REFERENCE: MBH00-845-H (400/029)

;; CURRENT APPLICATION NUMBER: US/09/877,478
;; CURRENT FILING DATE: 2001-12-31
;; PRIOR APPLICATION NUMBER: US 07/882,712
;; PRIOR FILING DATE: 1992-05-14
;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 08/433,993
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 08/434,504
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6586
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 846
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-10-342-902-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCCCTTGACGAGGA 277
DB 17 AGGTTCCCTTGACGAGGA 1

RESULT 36
US-10-342-902-846/c
;; Sequence 846, Application US/10342902
;; Publication No. US20040054156A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Draper, Kenneth
;; APPLICANT: Blatt, Larry
;; APPLICANT: McSwiggen, Jim
;; APPLICANT: Morrissey, Dave
;; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;; FILE REFERENCE: 400/075 (MEHB00-845-I)
;; CURRENT APPLICATION NUMBER: US/10/342,902
;; CURRENT FILING DATE: 2003-01-15
;; PRIOR APPLICATION NUMBER: US 09/877,478
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 07/882,712
;; PRIOR FILING DATE: 1992-05-14
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6592
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 846
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-10-342-902-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 AGGTTCCCTTGACGAGGA 277
DB 17 AGGTTCCCTTGACGAGGA 1

RESULT 37
US-10-669-841-846/c
;; Sequence 846, Application US/10669841
;; Publication No. US20040127446A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Lawrence, Blatt
;; APPLICANT: Dennis, Macejak
;; APPLICANT: James, McSwiggen
;; APPLICANT: David, Morrissey
;; APPLICANT: Pamela, Pavco
;; APPLICANT: Patrice, Lee
;; APPLICANT: Kenneth, Draper
;; APPLICANT: Elisabeth, Roberts
;; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
;; FILE REFERENCE: 400/042US (MEHB02-249-E)
;; CURRENT APPLICATION NUMBER: US/10/669,841
;; CURRENT FILING DATE: 2003-09-23
;; PRIOR APPLICATION NUMBER: PCT/US02/09187
;; PRIOR FILING DATE: 2002-03-26
;; PRIOR APPLICATION NUMBER: US 60/296,876
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 60/335,059
;; PRIOR FILING DATE: 2001-10-24
;; PRIOR APPLICATION NUMBER: US 60/337,055
;; PRIOR FILING DATE: 2001-12-05
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 09/817,879
;; PRIOR FILING DATE: 2001-03-26
;; PRIOR APPLICATION NUMBER: US 09/740,332
;; PRIOR FILING DATE: 2000-12-18
;; PRIOR APPLICATION NUMBER: US 09/611,931
;; PRIOR FILING DATE: 2000-07-07
;; PRIOR APPLICATION NUMBER: US 09/504,321
;; PRIOR FILING DATE: 2000-02-15
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 16207
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 846
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B Virus
US-10-669-841-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCCCTTGACGAGGA 277
DB 17 AGGTTCCCTTGACGAGGA 1

RESULT 38
US-09-918-026A-46/c
;; Sequence 46, Application US/09918026A
;; Publication No. US20030096772A1
;; GENERAL INFORMATION:
;; APPLICANT: Rosanne M. Crooke
;; APPLICANT: Mark J. Graham
;; APPLICANT: Kristina M. Lemonidis
;; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXI


```
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lenonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-918-026A-64

Query Match      1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1523 CTTTCTGGGGCTGGTGACA 1542
      |||||
Db 20 CATTCTGGGGATGGTGACA 1

RESULT 44
US-10-368-803-11/c
; Sequence 11, Application US/10368803
; Publication No. US20030219728A1
; GENERAL INFORMATION:
; APPLICANT: Terri H. Finkel
; APPLICANT: Jiayi Yin
; TITLE OF INVENTION: CELLULAR GENES REGULATED BY HIV-1
; TITLE OF INVENTION: INFECTION AND METHODS OF USE THEREOF
; FILE REFERENCE: CHOP-0146
; CURRENT APPLICATION NUMBER: US/10/368,803
; CURRENT FILING DATE: 2003-02-19
; PRIOR APPLICATION NUMBER: 60/358,495
; PRIOR FILING DATE: 2002-02-19
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; US-10-368-803-11

Query Match      1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1368 TCGAGGAGTGTGAACCTTCA 1387
      |||||
Db 20 TTGAGGAGTGTGAACCTTCA 1

RESULT 45
US-10-251-117-33/c
; Sequence 33, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
```

```
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
; US-10-251-117-33

Query Match      1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGCGCTCC 684
      |||||
Db 18 CAGCTCCCGCAGGCTCC 1

RESULT 46
US-10-251-117-282
; Sequence 282, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 282
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; US-10-251-117-282

Query Match      1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGCGCTCC 684
      |||||
Db 2 CAGCUCCCGCAGGCCUCC 19

RESULT 47
US-10-349-143-11729
; Sequence 11729, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
```

APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilva
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/10/349,143
CURRENT FILING DATE: 2003-01-21
PRIOR APPLICATION NUMBER: US/09/422,978
PRIOR FILING DATE: 1999-10-20
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 11729
LENGTH: 20
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..20
OTHER INFORMATION: downstream amplification primer 99-3894 for SEQ 3864, in compleme
US-10-349-143-11729

Query Match 1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 821 TCCTCTTCTGCCAACAC 838
| | | | | | | | | | | | | | | | | | | | | |
Db 3 TCCTCTTCTGCCAACTC 20

RESULT 48
US-09-877-478-144/c
Sequence 144, Application US/09877478
Publication No. US20030068301A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Draper, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
FILE REFERENCE: MEHB00-845-H (400/029)
CURRENT APPLICATION NUMBER: US/09/877,478
CURRENT FILING DATE: 2001-12-31
PRIOR APPLICATION NUMBER: US 07/882,712
PRIOR FILING DATE: 1992-05-14
PRIOR APPLICATION NUMBER: US 09/531,025
PRIOR FILING DATE: 2000-03-20
PRIOR APPLICATION NUMBER: US 09/636,385
PRIOR FILING DATE: 2000-08-09
PRIOR APPLICATION NUMBER: US 09/696,347
PRIOR FILING DATE: 2000-10-24
PRIOR APPLICATION NUMBER: US 08/193,627
PRIOR FILING DATE: 1994-02-07
PRIOR APPLICATION NUMBER: US 08/433,993
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 08/434,504
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 09/436,430
PRIOR FILING DATE: 1999-11-08
NUMBER OF SEQ ID NOS: 6586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 144
LENGTH: 17
TYPE: RNA
ORGANISM: Hepatitis B virus
US-09-877-478-144

Query Match 1.0%; Score 16; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 GGTTCCTTGAGCAGGA 277
| | | | | | | | | | | | | | | | | | | | | |
Db 17 GGTTCCTTGAGCAGGA 2

RESULT 49
US-10-342-902-144/c
Sequence 144, Application US/10342902
Publication No. US20040054156A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Draper, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
FILE REFERENCE: 400/075 (MEHB00-845-I)
CURRENT APPLICATION NUMBER: US/10/342,902
CURRENT FILING DATE: 2003-01-15
PRIOR APPLICATION NUMBER: US 09/877,478
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 09/531,025
PRIOR FILING DATE: 2000-03-20
PRIOR APPLICATION NUMBER: US 09/636,385
PRIOR FILING DATE: 2000-08-09
PRIOR APPLICATION NUMBER: US 09/696,347
PRIOR FILING DATE: 2000-10-24
PRIOR APPLICATION NUMBER: US 08/193,627
PRIOR FILING DATE: 1994-02-07
PRIOR APPLICATION NUMBER: US 07/882,712
PRIOR FILING DATE: 1992-05-14
PRIOR APPLICATION NUMBER: US 09/436,430
PRIOR FILING DATE: 1999-11-08
NUMBER OF SEQ ID NOS: 6592
SOFTWARE: PatentIn version 3.2
SEQ ID NO 144
LENGTH: 17
TYPE: RNA
ORGANISM: Hepatitis B virus
US-10-342-902-144

Query Match 1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 GGTTCCTTGAGCAGGA 277
| | | | | | | | | | | | | | | | | | | | | |
Db 17 GGTTCCTTGAGCAGGA 2

RESULT 50
US-10-669-841-144/c
Sequence 144, Application US/10669841
Publication No. US2004012746A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blatt
APPLICANT: Dennis, Macejak
APPLICANT: James, McSwiggen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Patricia, Lee
APPLICANT: Kenneth, Draper
APPLICANT: Elisabeth, Roberts
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
TITLE OF INVENTION: VIRUS REPLICATION
FILE REFERENCE: 400/042US (MEHB02-249-E)
CURRENT APPLICATION NUMBER: US/10/669,841
CURRENT FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: PCT/US02/09187


```
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-144

Query Match          1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.5e+02; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0;

QY 262 GGTTCCTTGAGCAGGA 277
Db 17 GGTTCCTTGAGCAGGA 2

RESULT 51
US-09-923-517-100
; Sequence 100, Application US/09923517
; Publication No. US20020039741A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; Compositions and Methods for the Modulation of
; Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/923,517
; FILING DATE: 07-Aug-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/364,416
; FILING DATE: 1999-07-30
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
```

```
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 100:
US-09-923-517-100

Query Match          1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

QY 627 GGTGCTCTCGCGCTGCCG 645
Db 2 GATGCTCTCGCGCTGCCG 20

RESULT 52
US-09-971-843-10/c
; Sequence 10, Application US/09971843
; Publication No. US20030013162A1
; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell C.
; APPLICANT: Grant, Francis J.
; APPLICANT: Rixon, Mark W.
; APPLICANT: Kindsvogel, Wayne
; TITLE OF INVENTION: Interferon-epsilon
; FILE REFERENCE: 98-46D1
; CURRENT APPLICATION NUMBER: US/09/971,843
; CURRENT FILING DATE: 2001-10-04
; PRIOR APPLICATION NUMBER: 60/101,012
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/118,578
; PRIOR FILING DATE: 1999-02-05
; PRIOR APPLICATION NUMBER: 60/142,766
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: 09/397,992
; PRIOR FILING DATE: 1999-09-16
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-09-971-843-10

Query Match          1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

QY 292 CTGGGAAACAGAAAGTTT 310
Db 19 CTGAGGAGCAGAAAGTTT 1

RESULT 53
US-09-918-026A-56/c
; Sequence 56, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXI
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
```

```
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-56

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 GAGAGCCCTTCAGCACCCG 1001
Db 20 GGGACCCCTCAGCACCCG 2

RESULT 54
US-09-954-679-28/c
; Sequence 28, Application US/09954679
; Publication No. US2003010052A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RIBONUCLEASE L (2',5'-OLIGOISODENYLATE
; FILE REFERENCE: RTS-0212
; CURRENT APPLICATION NUMBER: US/09/954,679
; CURRENT FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-679-28

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1311 CTTCGCTTCGTCCTGGGG 1329
Db 20 CTTCGCTTCGTCATGGTG 2

RESULT 55
US-10-430-196-100
; Sequence 100, Application US/10430196
; Publication No. US20030194738A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; Compositions and Methods for the Modulation of
; Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/430,196
; FILING DATE: 05-May-2003
```

```
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/923,517A
; FILING DATE: 07-Aug-2001
; APPLICATION NUMBER: 09/364,416
; FILING DATE: 1999-07-30
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 100:
US-10-430-196-100

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTGCGCGCTGCCG 645
Db 2 GATGCTCTGCGCTCTGCCG 20

RESULT 56
US-10-187-659A-45
; Sequence 45, Application US/10187659A
; Publication No. US20040002152A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF P2X4 EXPRESSION
; FILE REFERENCE: RTS-0379
; CURRENT APPLICATION NUMBER: US/10/187,659A
; CURRENT FILING DATE: 2002-07-01
; NUMBER OF SEQ ID NOS: 143
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-187-659A-45

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 501 GTGACCTGGTGCCCATG 519
Db 2 GTTGACCTGGATGCCCATG 20

RESULT 57
US-10-187-659A-110/c
; Sequence 110, Application US/10187659A
; Publication No. US20040002152A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF P2X4 EXPRESSION
; FILE REFERENCE: RTS-0379
; CURRENT APPLICATION NUMBER: US/10/187,659A
; CURRENT FILING DATE: 2002-07-01
; NUMBER OF SEQ ID NOS: 143
; SEQ ID NO 110
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: H. sapiens
US-10-187-659A-110

Query Match      1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 501 GGTGACCTGGTGCCCATG 519
Db 19 GTTGACCTGGATGCCCATG 1

RESULT 58
US-10-272-810-49
; Sequence 49, Application US/10272810
; Publication No. US20040077568A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH (DROSOPHILA) HOMOLOG 4 EXPRESSION
; FILE REFERENCE: RTS-0263
; CURRENT APPLICATION NUMBER: US/10/272,810
; CURRENT FILING DATE: 2002-10-16
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-272-810-49

Query Match      1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 381 CATCGCTGGCCTGTGTGTC 399
Db 1 CACCACTGGCCTGTGTGTC 19

RESULT 59
US-10-273-070-49
; Sequence 49, Application US/10273070
; Publication No. US20040077569A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH (DROSOPHILA) HOMOLOG 4 EXPRESSION
; FILE REFERENCE: RTS-0231
; CURRENT APPLICATION NUMBER: US/10/273,070
; CURRENT FILING DATE: 2002-10-16
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-273-070-49

Query Match      1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 381 CATCGCTGGCCTGTGTGTC 399
Db 1 CACCACTGGCCTGTGTGTC 19

RESULT 60
US-10-184-085A-1032/c
; Sequence 1032, Application US/10184085A
; Publication No. US20030152950A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balog, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1032
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-184-085A-1032

Query Match      1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 TGATGAGGGCAGGCTGCTG 450
Db 21 TGATGAGGGCAGGCTGCTG 3

RESULT 61
US-10-184-085A-1069/c
; Sequence 1069, Application US/10184085A
; Publication No. US20030152950A1
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balog, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1069
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-184-085A-1069

Query Match      1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 TCATGAGGGCAGGCTGCTG 450
Db 20 TCATGAGGGCAGGCTGCTG 2

RESULT 62
US-09-866-108-6625
; Sequence 6625, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
```

FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6625
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6625

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 21 TCTGCGTCTGCAGGGA 37
Db 1 TCTGCGTCTGCATAGGA 17

RESULT 63
US-09-866-108-6626
; Sequence 6626, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6626
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6626

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 22 CTGCGTCTGCAGGAC 38
Db 1 CTGCGTCTGCATAGGAC 17

RESULT 64
US-09-866-108-6627
; Sequence 6627, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6627
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6627

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 23 TCGCTCTGCAGAGGACA 39
|||||
DB 1 TCGCTCTGCATAGGACA 17

RESULT 65
US-09-866-108-6628
; Sequence 6628, Application US/09866108
; Patent No. US20030048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6628
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6628

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCGTCTGCAGAGGACAG 40
|||||
DB 1 GCGTCTGCATAGGACAG 17

RESULT 66
US-09-825-805-349/c
; Sequence 349, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotids
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 349
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-349

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 668 AGCTCCCGCGGCTCC 684
|||||
DB 17 AGCTCCCGCAGGCTCC 1

RESULT 67
US-10-163-552-134/c
; Sequence 134, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE OF INVENTION: HER2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 134
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-134

Query Match          1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 668 AGCTCCCGCGGCCTCC 684
Db 17 AGCTCCCGAGGCTCC 1

RESULT 68
US-10-138-674-1579/c
; Sequence 1579, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1579

Query Match          1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136
Db 17 ATGGACCCGACATGG 1

RESULT 69
US-10-138-674-6203/c
; Sequence 6203, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6203
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6203

Query Match          1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACATGGA 137
Db 17 TGGACCCGACATGGA 1

RESULT 70
US-10-138-674-8446
; Sequence 8446, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8446

Query Match          1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCGCCTCTGTG 958
Db 1 CCCGGCGCCUCUGUG 17

RESULT 71
US-10-287-949A-1579/c
; Sequence 1579, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1579

Query Match          1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 120 ATGGACCCGACATGG 136
DB 17 ATGGACCCGACATGG 1

RESULT 72
US-10-287-949A-6203/c
; Sequence 6203, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6203
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6203

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACATGGA 137
DB 17 TGGACCCGACATGGA 1

RESULT 73
US-10-287-949A-8446
; Sequence 8446, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8446

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCGCCCTCTGTG 958
DB 1 CCGGCGCCGCGCUGUG 17

RESULT 74
US-10-712-672-2333
; Sequence 2333, Application US/10712672
; Publication No. US20040102413A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2333

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 941 TCCTGGCGCCCTCTGT 957
DB 1 UCCUGGCGGCCUCUGU 17

RESULT 75
US-10-723-361-6625
; Sequence 6625, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: Ji, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6625
; LENGTH: 17

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6625

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTCGTCTGCAGAGGA 37
|||||
Db 1 TCTCGTCTGCATAGGA 17

RESULT 76

US-10-723-361-6626
; Sequence 6626, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; SEQ ID NO 6626

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-723-361-6626

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 22 CTGCGTCTGCAGAGGAC 38
|||||
Db 1 CTGCGTCTGCATAGGAC 17

RESULT 77

US-10-723-361-6627

; Sequence 6627, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; SEQ ID NO 6627

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-723-361-6627

Query Match 1.0%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 1.8e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 23 TCGGTCTGCAGAGGACA 39

|||||

Db 1 TCGGTCTGCATAGGACA 17

RESULT 78

US-10-723-361-6628

; Sequence 6628, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666


```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15758
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6628
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6628

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      24 GCGTCTGCAGAGGACAG 40
Db      1 GCGTCTGCATAGGACAG 17

RESULT 79
US-08-424-550B-99/c
; Sequence 99, Application US/08424550B
; Publication No. US2002011947A1
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BUIJUK
; APPLICANT: ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS
; TITLE OF INVENTION: REAGENTS AND METHODS FOR THEIR USE
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,550B
; FILING DATE:
; CLASSIFICATION: 435435
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs

```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-424-550B-99

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1476 CTGCCAGGAGTGCTACG 1492
Db      19 CTGCCAGGAGGGGTACG 3

RESULT 80
US-09-918-026A-43/c
; Sequence 43, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACVL COA CHOLESTEROL ACYLTRANSFERASE-2 EXI
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-43

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      184 GAGCTGCTGGATCGGCG 200
Db      17 GAGCTGTTGGATCGGCG 1

RESULT 81
US-10-317-500-89
; Sequence 89, Application US/10317500
; Publication No. US20040115637A1
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PPAR-ALPHA EXPRESSION
; FILE REFERENCE: RTS-0380
; CURRENT APPLICATION NUMBER: US/10/317,500
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 276
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-500-89

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      935 GCTTCATCCTGGCGCG 951
Db      2 GCTTCAGCTGGCGCG 18

```

RESULT 82
US-10-740-773-9/c
; Sequence 9, Application US/10740773
; Publication No. US20040180825A1
; GENERAL INFORMATION:
; APPLICANT: Spriggs, Melanie K.
; TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
; FILE REFERENCE: 2634-US
; CURRENT APPLICATION NUMBER: US/10/740,773
; CURRENT FILING DATE: 2003-12-19
; PRIOR APPLICATION NUMBER: US/09/689,012
; PRIOR FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: PCT/US99/09831
; PRIOR FILING DATE: 1999-05-05
; PRIOR APPLICATION NUMBER: US 60/085,497
; PRIOR FILING DATE: 1998-05-14
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PRIMER
US-10-740-773-9

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 GGGCCAGGGGCACCTGG 579
||| ||||| ||||| |||||
DB 19 GGTCCAGGGGCACCTGG 3

RESULT 83
US-09-800-631-22/c
; Sequence 22, Application US/09800631
; Patent No. US20020082228A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF BH3 INTERACTING DOMAIN DEATH AGONIST EXPRESSION
; FILE REFERENCE: ISPH-0544
; CURRENT APPLICATION NUMBER: US/09/800,631
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US/09/657,346
; PRIOR FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 175
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-800-631-22

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 903 TGCCAGGCCCTGGGATGG 922
||||| ||||| ||||| |||||
DB 20 TGCCAGGCCCATGGACTGTG 1

RESULT 84
US-09-755-004-10/c
; Sequence 10, Application US/09755004
; Patent No. US20020110810A1
; GENERAL INFORMATION:
; APPLICANT: Shuber, Anthony

; TITLE OF INVENTION: Methods for Detecting, Grading or Monitoring an H. pylori Infection
; FILE REFERENCE: EXT-048
; CURRENT APPLICATION NUMBER: US/09/755,004
; CURRENT FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: APC forward primer
US-09-755-004-10

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 332 TTGATGAGCTGATGGAGGTG 351
||||| ||||| ||||| |||||
DB 20 TTGAGGAGGTGGTGAGGTG 1

RESULT 85
US-09-924-256A-1/c
; Sequence 1, Application US/09924256A
; Patent No. US20020127659A1
; GENERAL INFORMATION:
; APPLICANT: Waters, Barbara
; APPLICANT: Miao, Vivian
; APPLICANT: Ho, Yap
; APPLICANT: Tong, Seow
; TITLE OF INVENTION: METHOD FOR ISOLATION OF BIOSYNTHESIS GENES FOR BIOACTIVE MOLECULES
; FILE REFERENCE: 9993-006
; CURRENT APPLICATION NUMBER: US/09/924,256A
; CURRENT FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 08/861,774
; PRIOR FILING DATE: 2001-04-13
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-924-256A-1

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 77.8%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 635 GCGCGCTGCGGTCCACG 652
||||| ||||| ||||| |||||
DB 20 GCGCGCTGCGGTCSAYS 3

RESULT 86
US-09-888-326-406/c
; Sequence 406, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced Cell Lysis and Treating Cancer
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 406
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-09-888-326-406

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
DB 20 CCCGGTGAGCCTGCACCTGCC 1

RESULT 87
US-09-781-693A-4/c
; Sequence 4, Application US/09781693A
; Publication No. US20030054438A1
; GENERAL INFORMATION:
; APPLICANT: Chang, Tai-Jay
; TITLE OF INVENTION: ANDROGEN RECEPTOR COMPLEX-ASSOCIATED
; FILE REFERENCE: 11709-003001
; CURRENT APPLICATION NUMBER: US/09/781,693A
; CURRENT FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: US 60/262,312
; PRIOR FILING DATE: 2001-01-17
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for PCR
US-09-781-693A-4

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 963 TGCTTTTGGCAACATGAGCC 982
DB 20 TGCTTTTGGCAAAATGTTCC 1

RESULT 88
US-09-776-479-448/c
; Sequence 448, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence

US-09-776-479-448

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
DB 20 CCCGGTGAGCCTGCACCTGCC 1

RESULT 89
US-09-776-479-448/c
; Sequence 448, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-448

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
DB 20 CCCGGTGAGCCTGCACCTGCC 1

RESULT 90
US-09-918-026A-51/c
; Sequence 51, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXI
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-51

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 633 CTGCGCGCTGCGGTCCACG 652
DB 20 CTGCGTCTCTGCGGTGCACG 1

```

; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; FILE REFERENCE: RTSP-0363
; CURRENT APPLICATION NUMBER: US/10/112653
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-109

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
Db 20 CCGGTCAGCCTGTACTGCC 1

RESULT 91
US-10-112-653-428/c
; Sequence 428, Application US/10112653
; Publication No. US20030050288A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Arthur M.
; APPLICANT: Berg, Daniel J.
; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
; FILE REFERENCE: C01039/70060(AWS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 428
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-428

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
Db 20 CCGGTCAGCCTGTACTGCC 1

RESULT 92
US-10-017-995-448/c
; Sequence 448, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/WAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-448

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
Db 20 CCGGTCAGCCTGTACTGCC 1

RESULT 93
US-10-181-846-109/c
; Sequence 109, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
```

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTSP-0363
; CURRENT APPLICATION NUMBER: US/10/181,846
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-109

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 TGTGTTCTCTGGTCTCCGCGAG 1294
Db 20 TGTGTTCTCTGGCCTCTGCAG 1

RESULT 94
US-10-216-484-94/c
; Sequence 94, Application US/10216484
; Publication No. US20030103976A1
; GENERAL INFORMATION:
; APPLICANT: Serizawa, No. US20030103976A1ufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/10/216,484
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: US/09/499,662
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: US 09/053,583
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-10-216-484-94

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTTCTCTCTTCTGCCCAACAC 838
Db 20 CTTCTCTCTTCTGCCCAACAC 1

RESULT 95
US-10-216-484-98
; Sequence 98, Application US/10216484
; Publication No. US20030103976A1
; GENERAL INFORMATION:
; APPLICANT: Serizawa, No. US20030103976A1ufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
```

; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT FILING DATE: 2003-02-05
; PRIOR APPLICATION NUMBER: US/10/216,484
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: US/09/499,662
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: US 09/053,583
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-10-216-484-98

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTCTTCTGCCCAAC 838
Db 1 CTTCTCTCTTCTGCCCAAC 20
|||||

RESULT 96
US-10-293-783-22/c
; Sequence 22, Application US/10293783
; Publication No. US20030130222A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF BH3 INTERACTING DOMAIN DEATH AGONIST EXPRESSION
; FILE REFERENCE: ISPH-0544
; CURRENT APPLICATION NUMBER: US/10/293,783
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US/09/800,631
; PRIOR FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US/09/657,346
; PRIOR FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 175
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-293-783-22

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 903 TGCCAGGCGCTGGATGTG 922
Db 20 TGCCAGGCGCTGGATGTG 1
|||||

RESULT 97
US-10-384-933-94/c
; Sequence 94, Application US/10384933
; Publication No. US20030170817A1
; GENERAL INFORMATION:
; APPLICANT: Serizawa, No. US20030170817A1ufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies

; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/10/384,933
; CURRENT FILING DATE: 2003-02-05
; PRIOR APPLICATION NUMBER: US/09/499,662
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/053,583
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-10-384-933-94

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCAAC 838
Db 20 CTTCTCTTCTGCCCAAC 1
|||||

RESULT 98
US-10-384-933-98
; Sequence 98, Application US/10384933
; Publication No. US20030170817A1
; GENERAL INFORMATION:
; APPLICANT: Serizawa, No. US20030170817A1ufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/10/384,933
; CURRENT FILING DATE: 2003-02-05
; PRIOR APPLICATION NUMBER: US/09/499,662
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/053,583
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-10-384-933-98

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTCTGCCCAAC 838
Db 1 CTTCTCTTCTGCCCAAC 20
|||||

RESULT 99
US-10-314-578-448/c
; Sequence 448, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg

```
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/WAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-448
```

```
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1461 CCAGGTGACGCTGTACTGCC 1480
DB 20 CCGGTGAGCCTGCCTGCTGCC 1
```

RESULT 100

```
US-10-388-263-670/c
; Sequence 670, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowser, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Preter, Susan M.
; APPLICANT: Sasmor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 670
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-670
```

```
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 903 TGCCAGGCGCCTGGGATGTG 922
DB 20 TGCCAGGCGCCTGGGACTGTG 1
```

RESULT 101

```
US-10-289-762-4685
; Sequence 4685, Application US/10289762
; Publication No. US20040006218A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Griffois, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4685
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4685
```

```
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 502 GTGACCTGGTGCCCATGTT 521
DB 1 GAGACCTTGGTCCCATGTT 20
```

RESULT 102

```
US-10-648-512-84/c
; Sequence 84, Application US/10648512
; Publication No. US20040096922A1
; GENERAL INFORMATION:
; APPLICANT: Hildebrandt, Friedhelm
; APPLICANT: Otto, Edgar
; APPLICANT: Hoefele, Julia
; APPLICANT: Ruf, Rainer
; APPLICANT: Mueller, Adelheid M.
; APPLICANT: Hiller, Karl S.
; APPLICANT: Wolf, Matthias T.F.
; APPLICANT: Schuermann, Maria J.
; APPLICANT: Becker, Achim
; TITLE OF INVENTION: NHP Nucleic Acids and Proteins
; FILE REFERENCE: UM-08333
; CURRENT APPLICATION NUMBER: US/10/648,512
; CURRENT FILING DATE: 2003-08-26
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-648-512-84
```

```
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 232 CAAGACAAACCTCTGCCCCC 251
DB 20 CAAGAAACCTCTGTGCCCC 1
```

RESULT 103

```
US-10-671-395-454
; Sequence 454, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
```

; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 454
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-454

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 245 TGCCCCCAGCTCCCCCAGGT 264
Db 1 TGCCCCCAGCTCCCCCAGGT 20

RESULT 104

US-09-918-026A-5/c
; Sequence 5, Application US/09918026A
; Publication No. US20030096772A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lomonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0388
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-918-026A-5

Query Match 1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1238 TCCTTGGTGGCCGGG 1252
Db 15 TCCTTGGTGGCCGGG 1

RESULT 105

US-09-877-478-845/c
; Sequence 845, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH800-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24

; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-845

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 263 GTTCCTTGAGCAGGA 277
Db 17 GTTCCTTGAGCAGGA 3

RESULT 106

US-09-877-478-2244/c
; Sequence 2244, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MEH800-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2244
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2244

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTCCTTGAGCAG 275
Db 15 AGGTCCTTGAGCAG 1

RESULT 107

```
US-09-848-754A-144/c
; Sequence 144, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH800-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-144

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      340 CTGATGGAGGTGCAG 354
Db      15 CTGATGGAGGTGCAG 1

RESULT 108
US-09-848-754A-1112/c
; Sequence 1112, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH800-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1112
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1112

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      340 CTGATGGAGGTGCAG 354
Db      15 CTGATGGAGGTGCAG 1

RESULT 109
US-09-848-754A-1113/c
; Sequence 1113, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH800-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1113
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1113

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      340 CTGATGGAGGTGCAG 354
Db      17 CTGATGGAGGTGCAG 3

RESULT 110
US-10-342-902-845/c
; Sequence 845, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH800-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-845

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      263 GTTCCTTGAGCAGGA 277
Db      17 GTTCCTTGAGCAGGA 3

RESULT 111
US-10-342-902-2244/c
; Sequence 2244, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH800-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
```


;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 07/882,712
;; PRIOR FILING DATE: 1992-05-14
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6592
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 2244
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-10-342-902-2244

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCTTGACGAG 275
Db 15 AGGTTCTTGACGAG 1
|||||

RESULT 112
US-10-669-841-845/c
; Sequence 845, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus

US-10-669-841-845
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 263 GTTCCTTGACGAG 277
Db 17 GTTCCTTGACGAG 3
|||||

RESULT 113
US-10-669-841-2047/c
; Sequence 2047, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2047
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2047

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCTTGACGAG 275
Db 15 AGGTTCTTGACGAG 1
|||||

RESULT 114
US-09-854-883-174/c
; Sequence 174, Application US/09854883
; Patent No. US20020055479A1
; GENERAL INFORMATION:

APPLICANT: Lex M. Cowser
APPLICANT: Jacqueline Wyatt
APPLICANT: Susan M. Freier
APPLICANT: Brett P. Monia
APPLICANT: Madeline M. Butler
APPLICANT: Robert McKay
TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
FILE REFERENCE: ISPH-0576
CURRENT APPLICATION NUMBER: US/09/854,883
CURRENT FILING DATE: 2001-05-14
PRIOR APPLICATION NUMBER: US 09/629,644
PRIOR FILING DATE: 2000-07-31
PRIOR APPLICATION NUMBER: US 09/487,368
PRIOR FILING DATE: 2000-01-18
NUMBER OF SEQ ID NOS: 389
SEQ ID NO 174
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-854-883-174

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 259
|||||
DB 20 TGCCCCCACCCTCCCC 6

RESULT 115
US-10-380-931-171
Sequence 171, Application US/10380931
Publication No. US20030215944A1
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
APPLICANT: Susan M. Freier
TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITION OF HER-1 EXPRESSION
FILE REFERENCE: RTSP-0187
CURRENT APPLICATION NUMBER: US/10/380,931
CURRENT FILING DATE: 2003-03-18
PRIOR APPLICATION NUMBER: 09/676,610
PRIOR FILING DATE: 2000-09-29
NUMBER OF SEQ ID NOS: 182
SEQ ID NO 171
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-931-171

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATCGAGGTGCAG 354
|||||
DB 5 CTGATCGAGGTGCAG 19

RESULT 116
US-10-360-510-174/c
Sequence 174, Application US/10360510
Publication No. US20030220282A1
GENERAL INFORMATION:
APPLICANT: Lex M. Cowser
APPLICANT: Jacqueline Wyatt
APPLICANT: Susan M. Freier

APPLICANT: Brett P. Monia
APPLICANT: Madeline M. Butler
APPLICANT: Robert McKay
TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
FILE REFERENCE: ISPH-0576
CURRENT APPLICATION NUMBER: US/10/360,510
CURRENT FILING DATE: 2003-02-07
PRIOR APPLICATION NUMBER: US/09/854,883
PRIOR FILING DATE: 2001-05-14
PRIOR APPLICATION NUMBER: US 09/629,644
PRIOR FILING DATE: 2000-07-31
PRIOR APPLICATION NUMBER: US 09/487,368
PRIOR FILING DATE: 2000-01-18
NUMBER OF SEQ ID NOS: 389
SEQ ID NO 174
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-174

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 259
|||||
DB 20 TGCCCCCACCCTCCCC 6

RESULT 117
US-10-241-313-7
Sequence 7, Application US/10241313
Publication No. US20030118506A1
GENERAL INFORMATION:
APPLICANT: O'Malley, Karen L
APPLICANT: Todd, Richard D
TITLE OF INVENTION: Gene Encoding the Rat Dopamine D4 Receptor
FILE REFERENCE: WU 102 CON DIV(2)
CURRENT APPLICATION NUMBER: US/10/241,313
CURRENT FILING DATE: 2002-09-11
PRIOR APPLICATION NUMBER: US 08/475,742
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: US 08/261,293
PRIOR FILING DATE: 1994-06-16
PRIOR APPLICATION NUMBER: US 08/014,013
PRIOR FILING DATE: 1993-01-28
NUMBER OF SEQ ID NOS: 16
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 7
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
OTHER INFORMATION: primer-reverse transcribed using ord4-515 and is
OTHER INFORMATION: complementary to nucleotides 2389-2406 in SEQ ID NO:1
PUBLICATION INFORMATION:
TITLE: The rat dopamine D4 receptor: sequence, gene structure
TITLE: and demonstration of expression in the cardiovascular
TITLE: system
JOURNAL: New Biol.
VOLUME: 4
PAGES: 1-9
DATE: 1992
US-10-241-313-7

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCCACCCTGTGGCG 540

```
Db 1 CTTCCACGCTGATGCG 18
|||||
RESULT 118
US-10-404-679-70
; Sequence 70, Application US/10404679
; Publication No. US20030229044A1
; GENERAL INFORMATION:
; APPLICANT: STEINMAN, LAWRENCE
; APPLICANT: GARREN, HIDEK
; TITLE OF INVENTION: USE OF STATINS AND OTHER
; TITLE OF INVENTION: IMMUNOMODULATORY AGENTS IN THE TREATMENT OF AUTOIMMUNE
; TITLE OF INVENTION: DISEASE
; FILE REFERENCE: STAN-262
; CURRENT APPLICATION NUMBER: US/10/404,679
; CURRENT FILING DATE: 2003-03-31
; PRIOR APPLICATION NUMBER: 60/368,803
; PRIOR FILING DATE: 2002-03-29
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-10-404-679-70
Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1320 CGTCTGGGGTCTTCTA 1337
|||||
Db 1 CGACCTGGGGATCTTCTA 18
|||||

RESULT 119
US-10-404-922-11
; Sequence 11, Application US/10404922
; Publication No. US20040002537A1
; GENERAL INFORMATION:
; APPLICANT: ZAMWIL, SCOTT S.
; APPLICANT: STEINMAN, LAWRENCE
; APPLICANT: YOUSSEF, SAWSAN
; APPLICANT: STUVE, OLAF
; TITLE OF INVENTION: USE OF STATINS IN THE TREATMENT OF
; TITLE OF INVENTION: AUTOIMMUNE DISEASE
; FILE REFERENCE: STAN-262US2
; CURRENT APPLICATION NUMBER: US/10/404,922
; CURRENT FILING DATE: 2003-03-31
; PRIOR APPLICATION NUMBER: 60/368,803
; PRIOR FILING DATE: 2002-03-29
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: mouse
US-10-404-922-11
Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1320 CGTCTGGGGTCTTCTA 1337
|||||
Db 1 CGACCTGGGGATCTTCTA 18
|||||

RESULT 120
US-10-449-801A-7
```

```
; Sequence 7, Application US/10449801A
; Publication No. US20040058314A1
; GENERAL INFORMATION:
; APPLICANT: HE, Ming Liang
; APPLICANT: KUNG, Heiang Fu
; APPLICANT: LIN, Marie Chia Mi
; TITLE OF INVENTION: A New Method For the Quantification of HBV cccDNA by Real Time PCR
; FILE REFERENCE: HE et al-1
; CURRENT APPLICATION NUMBER: US/10/449,801A
; CURRENT FILING DATE: 2003-05-29
; PRIOR APPLICATION NUMBER: 60/383,953
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic DNA
US-10-449-801A-7
Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
|||||
Db 1 CCTCTTCATCTGCTGCT 18
|||||

RESULT 121
US-10-251-117-623/c
; Sequence 623, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Re
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 623
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-251-117-623
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGAGGTGCAGCATTT 359
|||||
Db 19 GATGAGGTGCAGTTT 2
|||||

RESULT 122
```

US-10-251-117-930
; Sequence 930, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 930
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-930

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 2.6e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGAGGTGCACATT 359
DB 1 GAUGGAGGUGCAGUUUU 18

RESULT 123
US-10-356-625-111
; Sequence 111, Application US/10356625
; Publication No. US20030186290A1
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserre, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Germaine
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/10/356,625
; CURRENT FILING DATE: 2003-02-03
; PRIOR APPLICATION NUMBER: US/09/230,652
; PRIOR FILING DATE: 1999-05-17
; PRIOR APPLICATION NUMBER: FR 96 09733
; PRIOR FILING DATE: 1996-08-01
; PRIOR APPLICATION NUMBER: FR 97 04680
; PRIOR FILING DATE: 1997-04-16
; PRIOR APPLICATION NUMBER: PCT/FR97/01433
; PRIOR FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-356-625-111

Query Match 0.9%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 691 GTCCTGCTCTTCGACGAG 708
DB 1 GTCCTGCTCTTCAAGCAG 18

RESULT 124
US-10-244-647-491
; Sequence 491, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Ue
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 491
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-244-647-491

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
DB 1 CCUCUUCAUCCUGUGCU 18

RESULT 125
US-10-244-647-511
; Sequence 511, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Ue
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0

```
; SEQ ID NO 511
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-244-647-511

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
Db 2 CCUCUUCACUCCUGCUCU 19

RESULT 126
US-10-244-647-1137/c
; Sequence 1137, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1137
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1137

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
Db 19 CCTCTTCATCCTGCTGCT 2

RESULT 127
US-10-244-647-1157/c
; Sequence 1157, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
```

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1157
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1157

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
Db 18 CCTCTTCATCCTGCTGCT 1

RESULT 128
US-10-262-445-84
; Sequence 84, Application US/10262445
; Publication No. US20040014058A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook II, John
; APPLICANT: Burgess, Catherine
; APPLICANT: Catterton, Elina
; APPLICANT: Chant, John
; APPLICANT: Chaudhuri, Amitabha
; APPLICANT: Edinger, Shlomit
; APPLICANT: Gerlach, Valerie
; APPLICANT: Giot, Loic
; APPLICANT: Gorman, Linda
; APPLICANT: Guo, Xiaojia
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Mezes, Peter
; APPLICANT: Millet, Isabelle
; APPLICANT: Ooi, Chean Eng
; APPLICANT: Patturajan, Meera
; APPLICANT: Rieger, Daniel
; APPLICANT: Spytek, Kimberly
; APPLICANT: Taupier Jr., Raymond J.
; APPLICANT: Zerhusen, Bryan
; APPLICANT: Zhong, Haihong
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF
; FILE REFERENCE: 21402-462D
; CURRENT APPLICATION NUMBER: US/10/262,445
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/327,454
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/329,414
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/330,142
; PRIOR FILING DATE: 2001-10-17
; PRIOR APPLICATION NUMBER: 60/341,058
; PRIOR FILING DATE: 2001-10-22
```

;; PRIOR APPLICATION NUMBER: 60/343,629
;; PRIOR FILING DATE: 2001-10-24
;; PRIOR APPLICATION NUMBER: 60/349,575
;; PRIOR FILING DATE: 2001-10-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 133
;; SOFTWARE: CuraseqList version 0.1
;; SEQ ID NO 84
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-262-445-84

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1044 CTTTCATGCTGCTCAT 1061
Db 2 CTTTCATGCTGCACCTCAT 19
|||||

RESULT 129
US-09-866-108-2293/c
; Sequence 2293, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2293

;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2293

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CGGCTGTGGCCAGG 571
Db 17 CGGCTGTGGCCATGG 2
|||||

RESULT 130
US-09-866-108-2294/c
; Sequence 2294, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2294
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2294

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CGGCTGTGGCCAGG 571

Db 16 CGCGCTGTGGCCATGG 1
|||||

RESULT 131

US-09-866-108-2296/c
; Sequence 2296, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2296
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2296

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 553 CTACGGCTGTGGGCCA 568
Db 17 CTGCGGCTGTGGGCCA 2
|||||

RESULT 132

US-09-866-108-2297/c
; Sequence 2297, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2297
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2297

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 553 CTACGGCTGTGGGCCA 568
Db 16 CTGCGGCTGTGGGCCA 1
|||||

RESULT 133

US-09-866-108-6624
; Sequence 6624, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25

;
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6624
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6624

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGG 36
|||||
Db 2 TCTGCGTCTGCATAGG 17

RESULT 134
US-09-866-108-6629
; Sequence 6629, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

;
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6629
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6629

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 25 CGCTGTCAGGACAG 40
|||||
Db 1 CGCTGTCATAGGACAG 16

RESULT 135
US-09-780-164-502
; Sequence 502, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 502
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-502

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 2.4e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1064 TCTTGGCCTTCTCCA 1079
:|:|:|:|:|:|:|:|:|
Db 2 UCUUUGCCUUCUCCA 17

RESULT 136
US-09-780-164-503
; Sequence 503, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
FILE REFERENCE: 400/010
CURRENT APPLICATION NUMBER: US/09/780,164
CURRENT FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/185,516
PRIOR FILING DATE: 2000-02-28
NUMBER OF SEQ ID NOS: 2603
SOFTWARE: PatentIn version 3.0
SEQ ID NO 503
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-780-164-503

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 2.4e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1064 TCTTTCCTCTCTCCCA 1079
Db 1 UCUUGCCUUCUCCA 16

RESULT 137
US-09-740-332-1413/c
Sequence 1413, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1413
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1413

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGAAG 148
Db 16 ATGGAGGCTGTGAATG 1

RESULT 138
US-09-740-332-3143
Sequence 3143, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3143
LENGTH: 17

TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3143

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 134 TGGAGGCTGTGAAGC 149
Db 1 UGAGGCGUGGAUGC 16

RESULT 139
US-09-817-879-1413/c
Sequence 1413, Application US/09817879
Publication No. US20030171311A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: MBH800-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1413
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1413

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGAAG 148
Db 16 ATGGAGGCTGTGAATG 1

RESULT 140
US-09-817-879-3143
Sequence 3143, Application US/09817879
Publication No. US20030171311A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: MBH800-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3143
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3143

Query Match 0.9%; Score 14.4; DB 1; Length 17;

```
Best Local Similarity 75.0%; Pred. No. 2.4e+02; Indels 0; Gaps 0;
Matches 12; Conservative 3; Mismatches 1;

QY 134 TGGAGGCTGTGAAGGC 149
      :|||||:|:|:|
Db 1 UGGAGGCGUGAAGC 16

RESULT 141
US-10-138-674-1578/c
; Sequence 1578, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1578
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1578

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 GGACCCGACACATGGA 137
      |||||||
Db 17 GGACCCGAGACATGGA 2

RESULT 142
US-10-138-674-6124
; Sequence 6124, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6124

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGGCGCGCTGTGT 957
      |||||||
Db 2 CCCGGGCGCCUCUGU 17

RESULT 143
```

```
US-10-138-674-8044/c
; Sequence 8044, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8044
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8044

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1512 ACCCAGCGCACTTTC 1527
      |||||||
Db 17 ACCCAGCGCAGTTTC 2

RESULT 144
US-10-287-949A-1578/c
; Sequence 1578, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1578
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1578

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 GGACCCGACACATGGA 137
      |||||||
Db 17 GGACCCGAGACATGGA 2

RESULT 145
US-10-287-949A-6124
; Sequence 6124, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
```

```
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6124

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCGGGCCGCTCTGT 957
DB 2 CCGGGCCGCCUCUGU 17

RESULT 146
US-10-287-949A-8044/c
; Sequence 8044, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8044
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8044

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1512 ACCCCAGGCACTTTC 1527
DB 17 ACCCCAGGCAAGTTTC 2

RESULT 147
US-10-712-672-1852/c
; Sequence 1852, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
```

```
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1852
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1852

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1400 AGCGACCGCGCGGC 1415
DB 16 AGCGACCGCGCTCGGC 1

RESULT 148
US-10-669-841-4006/c
; Sequence 4006, Application US/10659841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4006
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4006

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
```

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGAAGG 148
Db 16 ATGGAGGCTGTGAATG 1

RESULT 149

US-10-669-841-5736
; Sequence 5736, Application US/10669841

; Publication No. US20040127446A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Lawrence, Blatt

; APPLICANT: Dennis, Macejak

; APPLICANT: James, McSwiggen

; APPLICANT: David, Morrissey

; APPLICANT: Pamela, Pavco

; APPLICANT: Patrice, Lee

; APPLICANT: Kenneth, Draper

; APPLICANT: Elisabeth, Roberts

; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA

; FILE REFERENCE: 400/042US (MBHB02-249-E)

; CURRENT APPLICATION NUMBER: US/10/669,841

; CURRENT FILING DATE: 2003-09-23

; PRIOR APPLICATION NUMBER: PCT/US02/09187

; PRIOR FILING DATE: 2002-03-26

; PRIOR APPLICATION NUMBER: US 60/296,876

; PRIOR FILING DATE: 2001-06-08

; PRIOR APPLICATION NUMBER: US 60/335,059

; PRIOR FILING DATE: 2001-10-24

; PRIOR APPLICATION NUMBER: US 60/337,055

; PRIOR FILING DATE: 2001-12-05

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 09/817,879

; PRIOR FILING DATE: 2001-03-26

; PRIOR APPLICATION NUMBER: US 09/740,332

; PRIOR FILING DATE: 2000-12-18

; PRIOR APPLICATION NUMBER: US 09/611,931

; PRIOR FILING DATE: 2000-07-07

; PRIOR APPLICATION NUMBER: US 09/504,321

; PRIOR FILING DATE: 2000-02-15

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 16207

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 5736

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate

US-10-669-841-5736

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 2.4e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 134 TGGAGGCTGTGAAGGC 149
Db 1 UGGAGGCGUGAAGUC 16

RESULT 150

US-10-723-361-2293/c

; Sequence 2293, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; SEQ ID NO 2293

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-723-361-2293

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 2.4e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CGGCTGTGGGCCAGGG 571
Db 17 CGGCTGTGGGCCATGG 2

RESULT 151

US-10-723-361-2294/c

; Sequence 2294, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2294
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2294
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 556 CGGCTGTGGCCAGG 571
Db 16 CGGCTGTGGCCATGG 1
```

RESULT 152

```
US-10-723-361-2296/c
; Sequence 2296, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2296
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2296
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 553 CTACGGCTGTGGCCA 568
Db 17 CTGCGGCTGTGGCCA 2
```

RESULT 153

```
US-10-723-361-2297/c
; Sequence 2297, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2297
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2297
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 553 CTACGGCTGTGGCCA 568
Db 16 CTGCGGCTGTGGCCA 1
```

RESULT 154

```
US-10-723-361-6624
; Sequence 6624, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Shaixun G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6624
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6624

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAGG 36
    |||||
Db 2 TCTGCGTCTGCATAGG 17

RESULT 155
US-10-723-361-6629
; Sequence 6629, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Shaixun G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6629
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6629

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 25 CGTCTGCAGAGGACAG 40
    |||||
Db 1 CGTCTGCATAGGACAG 16

RESULT 156
US-10-067-125-42
; Sequence 42, Application US/10067125
; Publication No. US20030055015A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Cowser, Lex M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Xu, Xiaoxing S.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION
; FILE REFERENCE: ISPH-0321
; CURRENT APPLICATION NUMBER: US/10/067,125
; CURRENT FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: 09/167,109
; PRIOR FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 42
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-067-125-42

Query Match      0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1269 GCTGGGTGTGTCTCTG 1284
    |||||
Db 3 GCTGGGTGTGTCTCTG 18

RESULT 157
US-10-067-125-129/c
; Sequence 129, Application US/10067125
; Publication No. US20030055015A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Cowser, Lex M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Xu, Xiaoxing S.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION
; FILE REFERENCE: ISPH-0321

```

; CURRENT APPLICATION NUMBER: US/10/067,125
; CURRENT FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: 09/167,109
; PRIOR FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 129
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-067-125-129

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 621 CGCGGTGGTCTCTGC 636
| | | | | | | | | | | | | | | | | |
Db 17 CGCCTGGTCTCTGC 2

RESULT 158
US-10-138-674-2168
; Sequence 2168, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2168
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2168

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 2.7e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGCGCGCTCTGTG 958
| | | | | | | | | | | | | | | | | |
Db 1 CCGGGCGGCUCUG 16

RESULT 159
US-10-287-949A-2168
; Sequence 2168, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2168
; LENGTH: 18

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2168

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 2.7e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGCGCGCTCTGTG 958
| | | | | | | | | | | | | | | | | |
Db 1 CCGGGCGGCUCUG 16

RESULT 160
US-10-244-647-477
; Sequence 477, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) U_E
; FILE REFERENCE: 400/060 (MEH802-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense se
US-10-244-647-477

Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 3e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TCTTCATGCTGTGCT 1058
| | | | | | | | | | | | | | | | | |
Db 2 UCUCUACUCCUGCUGCU 17

RESULT 161
US-10-244-647-487
; Sequence 487, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) U_E
; FILE REFERENCE: 400/060 (MEH802-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187

```
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 487
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siRNA sense
US-10-244-647-487

Query Match          0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 8; Conservative 7; Mismatches 0;

QY 1043 TCTTCATGCTGCTGCT 1058
      ||::||: ||::||:
Db 1 UCUCUACUCCUGUGCU 16

RESULT 162
US-10-244-647-1123/c
; Sequence 1123, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1123
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-244-647-1123

Query Match          0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

QY 1043 TCTTCATGCTGCTGCT 1058
      ||||| ||||| |||||
Db 18 TCTTCATCTGCTGCT 3

RESULT 163
US-10-244-647-1133/c
; Sequence 1133, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
```

```
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1133
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-244-647-1133

Query Match          0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

QY 1043 TCTTCATGCTGCTGCT 1058
      ||||| ||||| |||||
Db 19 TCTTCATCTGCTGCT 4

RESULT 164
US-10-444-925-566/c
; Sequence 566, Application US/10444925
; Publication No. US2004000946A1
; GENERAL INFORMATION:
; APPLICANT: Lewis, Stephen Patrick
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Wilson, Linda K.
; TITLE OF INVENTION: MODULATION OF PTP1B SIGNAL TRANSDUCTION
; TITLE OF INVENTION: BY RNA INTERFERENCE
; FILE REFERENCE: 200125.441
; CURRENT APPLICATION NUMBER: US/10/444,925
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 599
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 566
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA
US-10-444-925-566

Query Match          0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

QY 386 CTGGCCTGTGTGCTT 401
      ||||| ||||| |||||
Db 16 CTGGCCTGTGTGCTT 1

RESULT 165
US-09-848-754A-9223/c
; Sequence 9223, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
```



```

; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent In version 3.0
; SEQ ID NO 9223
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description
US-08-848-754A-9223

```

Query Match 0.9%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 341 TGATGGAGGTGCAG 354
Db 15 TGATGGAGGTGCAG 2

```

RESULT 166
US-09-877-478-2245/c
; Sequence 2245, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2245
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2245

Query Match 0.9%; SCORE 14;
Best Local Similarity 100.0%; Pred. No.
Matches 14; Conservative 0; Mismatch

QY 261 AGGTTTCCTTGAGCA 274
|||||
Db 14 AGGTTTCCTTGAGCA 1

RESULT 167
US-09-848-754A-1114/c
; Sequence 1114, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848, 754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1114
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1114

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGGAGGTGCA 353
DB 14 CTGATGGAGGTGCA 1
|||||

RESULT 168
US-09-740-332-3142
; Sequence 3142, Application US/09/40332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3142
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3142

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGAA 146
DB 3 AUGGAGGCUGGAA 16
|||||

RESULT 169
US-09-817-879-3142
; Sequence 3142, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3142
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc feature

```

; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3142

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGAA 146
Db 3 AUGGAGGCGUGAA 16
|||||||:|:|

RESULT 170
US-10-342-902-2245/c
; Sequence 2245, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2245
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2245

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTCCTTGAGCA 274
Db 14 AGGTCCTTGAGCA 1
|||||||:|:|

RESULT 171
US-10-138-674-6125
; Sequence 6125, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6125
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6125

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCGCGCTCTGTG 958
Db 2 GGGCGCGCUCUG 15
|||||||:|:|

RESULT 172
US-10-138-674-6126
; Sequence 6126, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6126
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6126

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCGCGCTCTGTG 958
Db 1 GGGCGCGCUCUG 14
|||||||:|:|

RESULT 173
US-10-287-949A-6125
; Sequence 6125, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6125
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6125

Query Match 0.9%; Score 14; DB 1; Length 17;

```
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCGCCCTCTGTG 958
      |||||:|:|
Db 2 GGGCGCCUCUG 15

RESULT 174
US-10-287-949A-6126
; Sequence 6126, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pam
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Dennis, Macejak
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6126
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6126

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCGCCCTCTGTG 958
      |||||:|:|
Db 1 GGGCGCCUCUG 14

RESULT 175
US-10-669-841-2048/c
; Sequence 2048, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5735
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
```

```
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2048
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2048

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCCCTTGAGCA 274
      |||||:|:|
Db 14 AGGTTCCCTTGAGCA 1

RESULT 176
US-10-669-841-5735
; Sequence 5735, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5735
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
```

NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5735

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGAA 146
Db 3 AUGGAGGCGUGAA 16

RESULT 177

US-10-179-940-283
Sequence 283, Application US/10179940
Publication No. US20040018618A1
GENERAL INFORMATION:
APPLICANT: Abrams, Mark A.
Bauer, S. C.
Braford-Goldberg, Sarah R.
Caparon, Maïre H.
Easton, Alan M.
Klein, Barbara K.
McKearn, John P.
Olins, Peter O.
Paik, Kumman
Polazzi, Joseph O.
TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESSES:
ADDRESSER: Carol M. Nielsen, Gardere Wynne Sewell LLP,
STREET: 1601 Elm Street, Suite 3000
CITY: Dallas
STATE: Texas
COUNTRY: USA
ZIP: 75201-4761
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/179,940
FILING DATE: 19-Jun-2002
CLASSIFICATION: Unknown
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/981044
FILING DATE: 24-NOV-1992
APPLICATION NUMBER: PCT/US93/11198
FILING DATE: 22-NOV-1993
APPLICATION NUMBER: US 08/411796
FILING DATE: 09-APR-1995
APPLICATION NUMBER: US 08/559390
FILING DATE: 15-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Carol M. Nielsen
REGISTRATION NUMBER: 37,676
REFERENCE/DOCKET NUMBER: 126181-1056 (C2713/1)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713)276-5383
TELEFAX: (713)276-5555
INFORMATION FOR SEQ ID NO: 283:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
SEQUENCE DESCRIPTION: SEQ ID NO: 283:
US-10-179-940-283

Query Match 0.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 ATCTTGGTCTGCCC 1561
Db 1 ATCTTGGTCTGCCC 14

RESULT 178

US-09-866-108-931
Sequence 931, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 931
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-931

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTCGAGAGGCTGTGCC 755
Db 1 CTGAAAGAGGCTGAGCC 17

RESULT 179

```

1; APPLICANT: SHANNON, Mark
2; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
3; FILE REFERENCE: AEOICA-7
4; CURRENT APPLICATION NUMBER: US/09/866,108
5; CURRENT FILING DATE: 2001-05-25
6; PRIOR APPLICATION NUMBER: US 60/207,456
7; PRIOR FILING DATE: 2000-05-26
8; PRIOR APPLICATION NUMBER: GB 24263.6
9; PRIOR FILING DATE: 2000-10-04
10; PRIOR APPLICATION NUMBER: US 60/236,359
11; PRIOR FILING DATE: 2000-09-27
12; PRIOR APPLICATION NUMBER: PCT/US01/00666
13; PRIOR FILING DATE: 2001-01-30
14; PRIOR APPLICATION NUMBER: PCT/US01/00667
15; PRIOR FILING DATE: 2001-01-30
16; PRIOR APPLICATION NUMBER: PCT/US01/00664
17; PRIOR FILING DATE: 2001-01-30
18; PRIOR APPLICATION NUMBER: PCT/US01/00669
19; PRIOR FILING DATE: 2001-01-30
20; PRIOR APPLICATION NUMBER: PCT/US01/00665
21; PRIOR FILING DATE: 2001-01-30
22; PRIOR APPLICATION NUMBER: PCT/US01/00668
23; PRIOR FILING DATE: 2001-01-30
24; PRIOR APPLICATION NUMBER: PCT/US01/00663
25; PRIOR FILING DATE: 2001-01-30
26; PRIOR APPLICATION NUMBER: PCT/US01/00662
27; PRIOR FILING DATE: 2001-01-30
28; PRIOR APPLICATION NUMBER: PCT/US01/00661
29; PRIOR FILING DATE: 2001-01-30
30; PRIOR APPLICATION NUMBER: PCT/US01/00670
31; PRIOR FILING DATE: 2001-01-30
32; PRIOR APPLICATION NUMBER: US 60/234,687
33; PRIOR FILING DATE: 2000-09-21
34; PRIOR APPLICATION NUMBER: US 60/266,860
35; PRIOR FILING DATE: 2001-02-05
36; NUMBER OF SEQ ID NOS: 15752
37; SOFTWARE: AEOICA Sequence Listing Engine
38; SEQ ID NO 1647
39; LENGTH: 17
40; TYPE: DNA
41; ORGANISM: Homo sapiens
42; US-09-866-108-1647

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTTCTTTGGCTTCCTCC 1078
Db 17 CTCCTTTGGCTTCCTCC 1

RESULT 181
US-09-866-108-2290/c
; Sequence 2290, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

```

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2290
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2290
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 559 CTGTGGCCAGGGCAC 575
DB 17 CTGTGGCCATGGACAC 1
```

```
RESULT 182
US-09-866-108-2291/c
; Sequence 2291, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN. Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2291
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2291
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 GCTGTGGCCAGGGCAC 574
DB 17 GCTGTGGCCATGGACA 1
```

```
RESULT 183
US-09-866-108-2292/c
; Sequence 2292, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN. Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2292
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2292
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 557 GGCTGTGGCCAGGGC 573
Db 17 GGCTGTGGCCATG 1
```

RESULT 184

```
US-09-866-108-2295/c
; Sequence 2295, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2295
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-09-866-108-2295
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 554 TACGGCTGTGGCCAGG 570
Db 17 TCGCGCTGTGGCCATG 1
```

RESULT 185

```
US-09-866-108-2298/c
; Sequence 2298, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2298
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2298
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 551 CCCTACGGCTGTGGCC 567
Db 17 CACTGCGCTGTGGCC 1
```

```

RESULT 186
US-09-866-108-2299/c
; Sequence 2299, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2299
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2299

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      550  GGCCTACGGCTGTGGC 566
          ||| |||||
          17  GCACCTGCGCTGTGGC 1

Db

RESULT 187
US-09-866-108-2300/c
; Sequence 2300, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2299
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2299

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      550  GGCCTACGGCTGTGGC 566
          ||| |||||
          17  GCACCTGCGCTGTGGC 1

Db

RESULT 188
US-09-866-108-6916/c
; Sequence 6916, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2300
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2300

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      549  GGCCTACGGCTGTGGG 565
          ||| |||||
          17  GGCACCTGCGCTGTGGG 1

Db

RESULT 189
US-09-866-108-6916/c
; Sequence 6916, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2300
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2300

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      550  GGCCTACGGCTGTGGC 566
          ||| |||||
          17  GCACCTGCGCTGTGGC 1

Db

```


; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6916
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6916

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 CCTGGGGAAACAGAAAG 307
Db 17 CCTGGCGAGACAGAAAG 1

RESULT 189
US-09-866-108-9024/C
; Sequence 9024, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9024
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9024

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 CTCACGTCCTCTCCA 1165
Db 17 CTCACGTCCTCTCCA 1

RESULT 190
US-09-866-108-10673/C
; Sequence 10673, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30

```
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10673
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10673

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 GGTAGCCATGCTGGTG 1276
Db 17 GGTGGCCATGCTGGTG 1

RESULT 191
US-09-866-108-10674/c
; Sequence 10674, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
```

```
; SEQ ID NO 10674
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10674

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 GGTAGCCATGCTGGGT 1275
Db 17 GGTGGCCATGCTGGGT 1

RESULT 192
US-09-827-998-760
; Sequence 760, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 760
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-760

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 CTCCTTGTGCCCACT 839
Db 1 CTCGTGCCCACACT 17

RESULT 193
US-09-827-998-761
; Sequence 761, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-761

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

DECIU.T 106

```
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 768
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-768

Query Match          0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.9e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1178 CTTGGAAACGTGGTGGTC 1194
      |:|||||:|:|:|
Db 1 CUCGGAACGUGUGGUC 17

RESULT 199
US-09-780-533A-79
; Sequence 79, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00-878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 79
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-79

Query Match          0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 2.9e+02;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCTT 1362
      :|:|:|:|:|:|:|:|
Db 1 UGUGUCUCUCUCCUU 17

RESULT 200
US-09-780-533A-739/c
; Sequence 739, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00-878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 739
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-739

Query Match          0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGAGAGAGGCTGTGCC 755
      |||||:|:|:|
Db 17 CTGAGAGGGGCTGGGCC 1

RESULT 201
US-09-780-533A-1164
; Sequence 1164, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00-878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1164
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1164

Query Match          0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.9e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 722 TGAAGAAGCTACTCCTTC 738
      :|:|:|:|:|:|:|:|
Db 1 UCAGAAGCUCUCCUUC 17

RESULT 202
US-09-848-754A-1111/c
; Sequence 1111, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of Epidermal Growth Factor Receptors
```

FILE REFERENCE: MBH00-958-I (400/018)
CURRENT APPLICATION NUMBER: US/09/848,754A
CURRENT FILING DATE: 2001-05-03
NUMBER OF SEQ ID NOS: 9645
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1111
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-848-754A-1111

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGGAGGTGCAGATT 358
|||||
Db 17 GATGGAGGTGCAGTTT 1

RESULT 203
US-09-848-754A-2229
Sequence 2229, Application US/09848754A
Publication No. US20030073207A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
FILE REFERENCE: MBH00-958-I (400/018)
CURRENT APPLICATION NUMBER: US/09/848,754A
CURRENT FILING DATE: 2001-05-03
NUMBER OF SEQ ID NOS: 9645
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2229
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-848-754A-2229

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.9e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 629 TGCTCTGCGCGTCCG 645
:|:|:|:|:|:|:|
Db 1 UGCUCCGGCGCGUGCCG 17

RESULT 204
US-09-848-754A-3192
Sequence 3192, Application US/09848754A
Publication No. US20030073207A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
FILE REFERENCE: MBH00-958-I (400/018)
CURRENT APPLICATION NUMBER: US/09/848,754A
CURRENT FILING DATE: 2001-05-03
NUMBER OF SEQ ID NOS: 9645
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3192
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-848-754A-3192

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.9e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 628 GTGCTCTGCGCGTCCG 644
:|:|:|:|:|:|:|

Db 1 GUGCUCCGGCGUGCC 17

RESULT 205
US-09-930-423-333/c
Sequence 333, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH00-918-A 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: PatentIn version 3.0
SEQ ID NO 333
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-333

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGCG 59
|||||
Db 17 GGGCTGGGAGGGGCGGG 1

RESULT 206
US-09-930-423-560/c
Sequence 560, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH00-918-A 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: PatentIn version 3.0
SEQ ID NO 560
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-560

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 197 GGGCCATGCGGGAGGCT 213
|||||
Db 17 GGGCCATGCGGGAGTGCT 1

RESULT 207
US-09-780-164-440/c
Sequence 440, Application US/09780164
Publication No. US20030092646A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
FILE REFERENCE: 400/010
CURRENT APPLICATION NUMBER: US/09/780,164
CURRENT FILING DATE: 2001-02-09

;
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 440
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-440

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGCTAGC 1492
Db 17 CTGCCAGGAGTGATCCG 1

RESULT 208
US-09-827-395A-215/c
; Sequence 215, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 215
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-215

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 906 CCAGGCCCTGGGATGTG 922
Db 17 CCAGGCCGTGGAATGTG 1

RESULT 209
US-09-827-395A-887/c
; Sequence 887, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 887

;
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-887

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 904 GCCCAGGCCCTGGGATG 920
Db 17 GCCCAGGCCGTGGAATG 1

RESULT 210
US-09-792-818-244
; Sequence 244, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ita
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 244
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-244

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.9e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 886 TATGTGGCCAGAACTT 902
Db 1 UAUGUGCCCAAGAAUUT 17

RESULT 211
US-09-792-818-892
; Sequence 892, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ita
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-892

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.9e+02;

```
Matches 13; Conservative 2; Mismatches 2; Indels 2; Gaps 0;
QY 27 TCTGCAGAGGACAGAG 43
      :||| |||||
Db 1 UCUUCAGGGGACAGAG 17

RESULT 212
US-09-745-237A-333/c
; Sequence 333, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (WBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-333

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 2; Gaps 0;

QY 43 GGGCTGGGAGGGGAGCG 59
      ||||| |||||
Db 17 GGGCTGGGAGGGGCGG 1

RESULT 213
US-09-745-237A-560/c
; Sequence 560, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (WBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 560
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-560

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 2; Gaps 0;

QY 197 GGGCCATCGGGAGGCT 213
      ||||| |||||
Db 17 GGGCCATCGGGAGTCT 1

RESULT 214
US-10-060-830-137
; Sequence 137, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
```

```
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 137
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-137

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1291 GCAGTGGCCCATGAGTA 1307
      ||||| |||||
Db 1 GCAGTGGCCCATGAGGA 17

RESULT 215
US-10-060-895A-221/c
; Sequence 221, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10
; FILE REFERENCE: PB0158
; CURRENT APPLICATION NUMBER: US/10/060,895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 221
; LENGTH: 17
; TYPE: DNA
```

; ORGANISM: Homo sapiens			
US-10-060-895A-221			
Query Match		0.9%; Score 13.8; DB 1; Length 17;	
Best Local Similarity		88.2%; Pred. No. 2.9e+02;	
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	626	TGGTGCTCTGCGGCGTG 642	
Db	17	TGGCGCTGTGCGGCGTG 1	
RESULT 216			
US-10-060-998-117/c			
; Sequence 117, Application US/10060998			
; Publication No. US20030104530A1			
; GENERAL INFORMATION:			
; APPLICANT: Gu, Yizhong			
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1			
; FILE REFERENCE: PB01108			
; CURRENT APPLICATION NUMBER: US/10/060,998			
; CURRENT FILING DATE: 2002-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/00666			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: US 09/864,761			
; PRIOR FILING DATE: 2001-05-23			
; PRIOR APPLICATION NUMBER: US 60/343,331			
; PRIOR FILING DATE: 2001-12-21			
; NUMBER OF SEQ ID NOS: 3056			
; SOFTWARE: Aecomica Sequence Listing Engine			
; SEQ ID NO 117			
; LENGTH: 17			
; TYPE: DNA			
; ORGANISM: Homo sapiens			
US-10-060-998-117			
Query Match		0.9%; Score 13.8; DB 1; Length 17;	
Best Local Similarity		88.2%; Pred. No. 2.9e+02;	
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1349	TGATACTCTTCCTTGTC 1365	
Db	17	TGATACTCATCTTTTC 1	
RESULT 217			
US-10-060-998-118/c			
; Sequence 118, Application US/10060998			
; Publication No. US20030104530A1			
; GENERAL INFORMATION:			
; APPLICANT: Gu, Yizhong			
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1			
; FILE REFERENCE: PB01108			
; CURRENT APPLICATION NUMBER: US/10/060,998			
; CURRENT FILING DATE: 2002-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/00666			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: US 09/864,761			
; PRIOR FILING DATE: 2001-05-23			
; PRIOR APPLICATION NUMBER: US 60/343,331			
; PRIOR FILING DATE: 2001-12-21			
; NUMBER OF SEQ ID NOS: 3056			
; SOFTWARE: Aecomica Sequence Listing Engine			
; SEQ ID NO 118			
; LENGTH: 17			
; TYPE: DNA			
; ORGANISM: Homo sapiens			
US-10-060-998-118			
Query Match		0.9%; Score 13.8; DB 1; Length 17;	
Best Local Similarity		88.2%; Pred. No. 2.9e+02;	
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1348	CTGATACTCTTCCTTGT 1364	
Db	17	CTGATACTCATCTTTT 1	
RESULT 218			
US-10-163-552-639			
; Sequence 639, Application US/10163552			
; Publication No. US20030105051A1			
; GENERAL INFORMATION:			
; APPLICANT: Ribozyme Pharmaceuticals, Inc.			
; APPLICANT: McSwiggen, Jim			
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels			
; FILE REFERENCE: MBHB01-1653-A (400/014)			
; CURRENT APPLICATION NUMBER: US/10/163,552			
; CURRENT FILING DATE: 2002-06-06			
; NUMBER OF SEQ ID NOS: 1997			
; SOFTWARE: PatentIn version 3.0			
; SEQ ID NO 639			
; LENGTH: 17			
; TYPE: RNA			
; ORGANISM: Homo sapiens			
US-10-163-552-639			
Query Match		0.9%; Score 13.8; DB 1; Length 17;	
Best Local Similarity		64.7%; Pred. No. 2.9e+02;	
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;			
QY	1178	CTTGAACGTGTGTGTC 1194	
Db	1	CUCGGAACGUGCUGGUC 17	
RESULT 219			
US-10-238-700-148/c			
; Sequence 148, Application US/10238700			
; Publication No. US20030153521A1			
; GENERAL INFORMATION:			
; APPLICANT: Ribozyme Pharmaceuticals, Inc.			
; APPLICANT: McSwiggen, James			
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels			
; FILE REFERENCE: 400/057 (MBHB01-1158-A)			
; CURRENT APPLICATION NUMBER: US/10/238,700			
; CURRENT FILING DATE: 2002-09-18			
; PRIOR APPLICATION NUMBER: PCT/US 02/16840			
; PRIOR FILING DATE: 2002-05-29			
; PRIOR APPLICATION NUMBER: US 60/318,471			
; PRIOR FILING DATE: 2001-09-10			
; NUMBER OF SEQ ID NOS: 4666			
; SOFTWARE: PatentIn version 3.0			
; SEQ ID NO 148			
; LENGTH: 17			
; TYPE: RNA			
; ORGANISM: Homo sapiens			
US-10-238-700-148			
Query Match		0.9%; Score 13.8; DB 1; Length 17;	
Best Local Similarity		88.2%; Pred. No. 2.9e+02;	
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	403	ATCATCAGCACCCCTGCC 419	
Db	17	ATCATCAACACCCCTGTC 1	
RESULT 220			
US-10-238-700-2807			
; Sequence 2807, Application US/10238700			
; Publication No. US20030153521A1			
; GENERAL INFORMATION:			
; APPLICANT: Ribozyme Pharmaceuticals, Inc.			
; APPLICANT: McSwiggen, James			


```
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH001-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2807
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2807

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3 GGAGCCAGCGGGGCC 19
Db      1 GGGGCGCGGGGGGCC 17

RESULT 221
US-10-061-201-422
; Sequence 422, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1522
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1522

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1237 CTCCTTGGTCCCGGCC 1253
Db      1 CTCCTTGGTCCCGGCC 17

RESULT 223
US-10-430-882-215/C
; Sequence 215, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 215
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-215

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 906 CCAGGCCCTGGGATG 922
Db 17 CCAGGCCCTGGGATG 1

RESULT 224
US-10-430-882-887/c
; Sequence 887, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MEH800-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 887
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-887

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 904 GCCCAGGCCCTGGGATG 920
Db 17 GCCCAGGCCCTGGGATG 1

RESULT 225
US-10-461-790-52/c
; Sequence 52, Application US/10461790
; Publication No. US2004002911A1
; GENERAL INFORMATION:
; APPLICANT: Linnen, Jeffery M.
; APPLICANT: Kolik, Daniel P.
; APPLICANT: Dockter, Janel M.
; APPLICANT: Getman, Damon K.
; APPLICANT: Yoshimura, Tadashi
; APPLICANT: Ho-Sing-Ioy, Marcy
; APPLICANT: Stringfellow, Leslie A.
; TITLE OF INVENTION: Compositions and Methods for Detecting
; TITLE OF INVENTION: Hepatitis B Virus
; FILE REFERENCE: GPI34-02.UT
; CURRENT APPLICATION NUMBER: US/10/461,790
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: 60/389,393
```

```
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 142
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 52
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Hepatitis B Virus
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(16)
; OTHER INFORMATION: 2'-OME nucleotide analogs
US-10-461-790-52

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGC 1057
Db 17 CCTCTTCATCCTGCTGC 1

RESULT 226
US-10-675-685-760
; Sequence 760, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 760
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-760

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 CTCTTCTGCCCAACACT 839
Db 1 CTCGTCTGCCCATCACT 17

RESULT 227
US-10-675-685-761
; Sequence 761, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 761
; LENGTH: 17
```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-761

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 TCTTCTGCCCAACATC 840
||| ||||| |||||
DB 1 TCGTCTGCCCATCATC 17

RESULT 228

US-10-138-674-1945
; Sequence 1945, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1945

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.9e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 282 GGAGCCATCCCTGGGA 298
||| ||||| |||||
DB 1 GGAGCAAUCCUGUGA 17

RESULT 229

US-10-138-674-3459/c
; Sequence 3459, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3459
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3459

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 GGACCCAGGAGCATCC 291

DB 17 GGATTCAGGAGCATCC 1
||| ||||| |||||

RESULT 230

US-10-138-674-8362/c
; Sequence 8362, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8362

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTTACCGG 1137
||| ||||| |||||
DB 17 ACAGGATGTTTAAACGG 1

RESULT 231

US-10-287-949A-1945
; Sequence 1945, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1945

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.9e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 282 GGAGCCATCCCTGGGA 298
||| ||||| |||||
DB 1 GGAGCAAUCCUGUGA 17

RESULT 232

US-10-287-949A-3459/c
; Sequence 3459, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3459
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3459

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 GGACCCAGGAGCCATCC 291
Db 17 GGATTCAGGAGCCATCC 1

RESULT 233
US-10-287-949A-8362/c
; Sequence 8362, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8362

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTCTACCG 1137
Db 17 ACAGGATGTTTAAACG 1

RESULT 234
US-10-712-672-1213
; Sequence 1213, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
```

```
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1213
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1213

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.9e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 728 GCTACTCTCTCTGAGA 744
Db 1 GCUACUCCUCCUGAAA 17

RESULT 235
US-10-712-672-1954
; Sequence 1954, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1954

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.9e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 435 TGAGGCGAGGCTGCTGC 451
Db 1 UGGGGCGUGGCGUCG 17

RESULT 236
US-10-712-672-2332
; Sequence 2332, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
```


; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1536

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGCTGGTGACCTGG 510
||| ||||| |||||
Db 1 TGGGCTGGTGCCCTGG 17

RESULT 240

US-10-723-361-1647/c
; Sequence 1647, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1647
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1647

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTCCTTTGCTTCCTCC 1078
||| ||||| |||||
Db 17 CTCCTTTGCTTCCTCC 1

RESULT 241

US-10-723-361-2290/c
; Sequence 2290, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2290
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2290

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 559 CTGTGGCCGCGGCAC 575
||| ||||| |||||
Db 17 CTGTGGCCGCGGCAC 1

RESULT 242

US-10-723-361-2291/c
; Sequence 2291, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 6/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2291
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2291
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 558 GCTGTGGCCAGGGGCA 574
      |||||
DB 17 GCTGTGGCCATGGACA 1
```

```
RESULT 243
US-10-723-361-2292/c
; Sequence 2292, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2292
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2292
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 557 GGCTGTGGCCAGGGGC 573
      |||||
DB 17 GGCTGTGGCCATGGAC 1
```

```
RESULT 244
US-10-723-361-2295/c
; Sequence 2295, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2295
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2295
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 554 TACGGCTGTGGCCAGG 570
      |||||
DB 17 TCGGCTGTGGCCATG 1
```

```
RESULT 245
US-10-723-361-2298/c
; Sequence 2298, Application US/10723361
```

/ Publication No. US20040137589A1

/ GENERAL INFORMATION:

/ APPLICANT: GU, Yizhong

/ APPLICANT: JI, Yonggang

/ APPLICANT: PENN, Sharron G.

/ APPLICANT: HANZEL, David K.

/ APPLICANT: RANK, David R.

/ APPLICANT: CHEN, Wensheng

/ APPLICANT: SHANNON, Mark

/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

/ FILE REFERENCE: PB0105

/ CURRENT APPLICATION NUMBER: US/10/723,361

/ CURRENT FILING DATE: 2003-11-26

/ PRIOR APPLICATION NUMBER: US 09/866,108

/ PRIOR FILING DATE: 2001-05-25

/ PRIOR APPLICATION NUMBER: US 60/207,456

/ PRIOR FILING DATE: 2000-05-26

/ PRIOR APPLICATION NUMBER: GB 24263.6

/ PRIOR FILING DATE: 2000-10-04

/ PRIOR APPLICATION NUMBER: US 60/236,359

/ PRIOR FILING DATE: 2000-09-27

/ PRIOR APPLICATION NUMBER: PCT/US01/00666

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00667

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00664

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00669

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00665

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00668

/ PRIOR FILING DATE: 2001-01-30

/ Remaining Prior Application data removed - See File Wrapper or PALM.

/ NUMBER OF SEQ ID NOS: 15755

/ SOFTWARE: Acomica Sequence Listing Engine

/ SEQ ID NO 2298

/ LENGTH: 17

/ TYPE: DNA

/ ORGANISM: Homo sapiens

/ US-10-723-361-2299

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 551 CCTACGGCTGTGGCC 567

DB 17 CACTGGCGCTGTGGCC 1

RESULT 246

US-10-723-361-2299/c

/ Sequence 2299, Application US/10723361

/ Publication No. US20040137589A1

/ GENERAL INFORMATION:

/ APPLICANT: GU, Yizhong

/ APPLICANT: JI, Yonggang

/ APPLICANT: PENN, Sharron G.

/ APPLICANT: HANZEL, David K.

/ APPLICANT: RANK, David R.

/ APPLICANT: CHEN, Wensheng

/ APPLICANT: SHANNON, Mark

/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

/ FILE REFERENCE: PB0105

/ CURRENT APPLICATION NUMBER: US/10/723,361

/ CURRENT FILING DATE: 2003-11-26

/ PRIOR APPLICATION NUMBER: US 09/866,108

/ PRIOR FILING DATE: 2001-05-25

/ PRIOR APPLICATION NUMBER: US 60/207,456

/ PRIOR FILING DATE: 2000-05-26

/ PRIOR APPLICATION NUMBER: GB 24263.6

/ PRIOR FILING DATE: 2000-10-04

TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-2300

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 GGCCTACGGCTGTGG 565
DB 17 GGCACCTGCGCTGTGG 1

RESULT 248

US-10-723-361-6916/c
Sequence 6916, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
PRIOR FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 6916

LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-6916

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 CCTGGGGAACAGAAAG 307
DB 17 CCTGGCGACAGAAAG 1

RESULT 249

US-10-723-361-9024/c
Sequence 9024, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
PRIOR FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 9024

LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-9024

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 CTCACGTCCTCTCCA 1165
DB 17 CTCACGTCCTCTCCA 1

RESULT 250

US-10-723-361-10673/c
Sequence 10673, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
PRIOR FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666

NAME: MacKnight, Kamrin T.
REGISTRATION NUMBER: 38,230
REFERENCE/DOCKET NUMBER: BCM-02973
TELEPHONE: (415) 705-8410
TELEFAX: (415) 397-8338
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-09-104-654-4

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1139 ACTGGTGGAACTCAACG 1155
Db 1 ACTGGTGGAACTCAACG 17

RESULT 254

US-09-425-075-3/c
Sequence 3, Application US/09425075
Patent No. US20010036647A1
GENERAL INFORMATION:
APPLICANT: CHOUDARY, PRABHAKARA V.
APPLICANT: OGUNJIMI, ABIODUN A.
TITLE OF INVENTION: FUNCTIONALLY ASSEMBLED ANTIGEN-SPECIFIC INTACT
TITLE OF INVENTION: RECOMBINANT ANTIBODY AND A METHOD FOR PRODUCTION
TITLE OF INVENTION: THEREOF

FILE REFERENCE: 480.97-1 (HV)
CURRENT APPLICATION NUMBER: US/09/425,075
CURRENT FILING DATE: 1999-10-21
EARLIER APPLICATION NUMBER: 60/105,259
EARLIER FILING DATE: 1998-10-22
NUMBER OF SEQ ID NOS: 6
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 3

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
OTHER INFORMATION: Oligonucleotide primer

US-09-425-075-3

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 448 CTGCTGCAGTTGCACCT 464
Db 18 CTGCTGCAGTTGCACCT 2

RESULT 255

US-10-005-956-1236/c
Sequence 1236, Application US/10005956
Publication No. US20030113726A1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
FILE REFERENCE: D0053NP
CURRENT APPLICATION NUMBER: US/10/005,956
CURRENT FILING DATE: 2001-12-03
PRIOR APPLICATION NUMBER: 60/251,015
PRIOR FILING DATE: 2000-12-04

PRIOR APPLICATION NUMBER: 60/263,678
PRIOR FILING DATE: 2001-01-23
PRIOR APPLICATION NUMBER: 60/273,037
PRIOR FILING DATE: 2001-03-02
NUMBER OF SEQ ID NOS: 1579
SOFTWARE: Patentin version 3.0
SEQ ID NO 1236
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-10-005-956-1236

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 509 GGGTGCCCATGTTCTG 525
Db 18 GGGTGCCCATGATGCTG 2

RESULT 256

US-10-204-431-6
Sequence 6, Application US/10204431
Publication No. US20030153012A1
GENERAL INFORMATION:
APPLICANT: RENARD, Martial
APPLICANT: BELKADI, Laurent
APPLICANT: ENGLAND, Patrick
APPLICANT: BEDOUELLE, Hugues
TITLE OF INVENTION: BIOSENSORS, METHOD FOR OBTAINING THE SAME AND USES THEREOF
FILE REFERENCE: 227391USOXPCT
CURRENT APPLICATION NUMBER: US/10/204,431
CURRENT FILING DATE: 2002-08-30
PRIOR APPLICATION NUMBER: PCT/FR01/00603
PRIOR FILING DATE: 2001-03-01
PRIOR APPLICATION NUMBER: FR 00/02657
PRIOR FILING DATE: 2000-03-01
NUMBER OF SEQ ID NOS: 25
SOFTWARE: Patentin version 3.1
SEQ ID NO 6
LENGTH: 18
TYPE: DNA
ORGANISM: ARTIFICIAL SEQUENCE
FEATURE:
OTHER INFORMATION: SYNTHETIC DNA

US-10-204-431-6

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 76 GGAGATGGAACACTGA 92
Db 1 GGTGATGGAACACAGA 17

RESULT 257

US-10-351-951-123/c
Sequence 123, Application US/10351951
Publication No. US20030203380A1
GENERAL INFORMATION:
APPLICANT: Stefansson, Stefan E.
TITLE OF INVENTION: GENE LINKED TO OSTEOARTHRITIS
FILE REFERENCE: 2345.2043-004
CURRENT APPLICATION NUMBER: US/10/351,951
CURRENT FILING DATE: 2003-01-24
PRIOR APPLICATION NUMBER: 10/057,312
PRIOR FILING DATE: 2002-01-25
PRIOR APPLICATION NUMBER: 60/431,538
PRIOR FILING DATE: 2002-12-05
NUMBER OF SEQ ID NOS: 132
SOFTWARE: FastSeq for Windows Version 4.0

US-10-351-951-123/c

```
; SEQ ID NO 123
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer that hybridizes to the human MATN3 gene
US-10-351-951-123

Query Match          0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1186 GTGGTGGTCCATGACTG 1202
Db 18 GTGGTGGCCATGCCTG 2

RESULT 258
US-10-108-260A-5348
; Sequence 5348, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1e1 full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; PRIOR FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 5348
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized P
US-10-108-260A-5348

Query Match          0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 767 GTGCCAGACGAGGTGAG 783
Db 2 GTGCCTGACTAGGTGAG 18

RESULT 259
US-10-349-143-7807/c
; Sequence 7807, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7807
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6564 for SEQ 3580, in complemer
US-10-349-143-7807
```

```
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-4157 for SEQ 3873,
US-10-349-143-7807

Query Match          0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 CCTGTCTTTGCCACAT 977
Db 18 CCTGTCTCTGCAACAT 2

RESULT 260
US-10-349-143-11445/c
; Sequence 11445, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11445
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6564 for SEQ 3580, in complemer
US-10-349-143-11445

Query Match          0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 391 CTGTGTCTTTCATCAT 407
Db 18 CTGTGTCTTTCACCT 2

RESULT 261
US-10-461-790-51/c
; Sequence 51, Application US/10461790
; Publication No. US2004002911A1
; GENERAL INFORMATION:
; APPLICANT: Linnen, Jeffery M.
; APPLICANT: Kolk, Daniel P.
; APPLICANT: Dockter, Janel M.
; APPLICANT: Getman, Damon K.
; APPLICANT: Yoshimura, Tadashi
; APPLICANT: Ho-Sing-Loy, Marcy
; APPLICANT: Stringfellow, Leslie A.
; TITLE OF INVENTION: Compositions and Methods for Detecting
; FILE REFERENCE: GPI34-02.UT
; CURRENT APPLICATION NUMBER: US/10/461,790
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: 60/389,393
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 142
```

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 51
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(17)
; OTHER INFORMATION: 2'-OME nucleotide analogs
US-10-461-790-51

Query Match          0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGC 1057
Db 17 CCTCTTCATGCTGCTGC 1

RESULT 262
US-10-740-773-9
; Sequence 9, Application US/10740773
; Publication No. US20040180825A1
; GENERAL INFORMATION:
; APPLICANT: Spriggs, Melanie K.
; TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
; FILE REFERENCE: 2634-US
; CURRENT APPLICATION NUMBER: US/10/740,773
; CURRENT FILING DATE: 2003-12-19
; PRIOR APPLICATION NUMBER: US/09/689,012
; PRIOR FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: PCT/US99/09831
; PRIOR FILING DATE: 1999-05-05
; PRIOR APPLICATION NUMBER: US 60/085,497
; PRIOR FILING DATE: 1998-05-14
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 9
; TYPE: DNA
; LENGTH: 20
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PRIMER
US-10-740-773-9

Query Match          0.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 565 GCCAGGGGCACCTGGAC 581
Db 2 GCCAGGTGCCCTGGAC 18

RESULT 263
US-10-300-683-118
; Sequence 118, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
; APPLICANT: Dunlop, Charles L.M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
; FILE REFERENCE: CHARDUN.010A
; CURRENT APPLICATION NUMBER: US/10/300,683
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/333,531
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 554
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; TYPE: DNA

Query Match          0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1230 GCTGGCGCTCCTTGG 1244
Db 1 GCTGTGGCTCCTTGG 15

RESULT 264
US-10-300-683-291
; Sequence 291, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
; APPLICANT: Dunlop, Charles L.M.
; APPLICANT: Weisel, James M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
; FILE REFERENCE: CHARDUN.010A
; CURRENT APPLICATION NUMBER: US/10/300,683
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/333,531
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 554
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 291
; TYPE: DNA
; LENGTH: 15
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-291

Query Match          0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1230 GCTGGCGCTCCTTGG 1244
Db 1 GCTGTGGCTCCTTGG 15

RESULT 265
US-10-300-683-477
; Sequence 477, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
; APPLICANT: Dunlop, Charles L.M.
; APPLICANT: Weisel, James M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
; FILE REFERENCE: CHARDUN.010A
; CURRENT APPLICATION NUMBER: US/10/300,683
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/333,531
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 554
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 477
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-477

Query Match          0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1230 GCTGGCGCTCCTTGG 1244
Db 1 GCTGTGGCTCCTTGG 15

RESULT 265
US-10-300-683-477
; Sequence 477, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
; APPLICANT: Dunlop, Charles L.M.
; APPLICANT: Weisel, James M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
; FILE REFERENCE: CHARDUN.010A
; CURRENT APPLICATION NUMBER: US/10/300,683
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/333,531
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 554
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 477
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-477

Query Match          0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1230 GCTCGGCTCTCTGG 1244
      ||||| ||||| |||||
Db 1 GCTGTGGCTCTCTGG 15

RESULT 266
US-10-395-031-10
; Sequence 10, Application US/10395031
; Publication No. US20030235845A1
; GENERAL INFORMATION:
; APPLICANT: van Ommen, Garrit-Jan Boudewijn
; APPLICANT: van Deutekom, Judith Christina Theodora
; APPLICANT: den Dunnen, Johannes Theodorus
; TITLE OF INVENTION: INDUCTION OF EXON SKIPPING IN EUKARYOTIC CELLS
; FILE REFERENCE: 2183-5910US (REN/P54258US10)
; CURRENT APPLICATION NUMBER: US/10/395,031
; CURRENT FILING DATE: 2003-03-21
; PRIOR APPLICATION NUMBER: PCT/NL01/00697
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: EP 002063283.7
; PRIOR FILING DATE: 2000-09-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Mouse
US-10-395-031-10

Query Match 0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1051 CTGCTGCTCATCTTC 1065
      ||||| ||||| |||||
Db 1 CTGCTGCTCATCTTC 15

RESULT 267
US-10-210-172-240
; Sequence 240, Application US/10210172
; Publication No. US20040043928A1
; GENERAL INFORMATION:
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Miller, Charles
; APPLICANT: Patturajan, Meera
; APPLICANT: Pena, Carol
; APPLICANT: Rieger, Daniel
; APPLICANT: Shimkets, Richard
; APPLICANT: Zerhusen, Bryan
; APPLICANT: Li, Li
; APPLICANT: Ji, Weizhen
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Casman, Stacie
; APPLICANT: Voss, Edward
; APPLICANT: Boldog, Ferenc
; APPLICANT: Gorman, Linda
; APPLICANT: Leite, Mario
; APPLICANT: Vernet, Corine
; APPLICANT: Anderson, David
; APPLICANT: Guo, Xiaojia
; APPLICANT: Zhong, Mei
; APPLICANT: Gerlach, Valerie
; APPLICANT: Hjalt, Tord
; APPLICANT: Rastelli, Luca
; APPLICANT: Spytek, Kimberly
; APPLICANT: Edinger, Shlomit
; APPLICANT: Ellerman, Karen
; APPLICANT: Malyankar, Uriel
; APPLICANT: MacDougall, John
; APPLICANT: Stone, David
; APPLICANT: Alsobrook II, John
; APPLICANT: Lepley, Denise et al.

; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS
; FILE REFERENCE: 21402-416 A
; CURRENT APPLICATION NUMBER: US/10/210,172
; CURRENT FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: 60/309,501
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: 60/323,994
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: 60/373,814
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 60/310,291
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: 60/310,951
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/310,544
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: 60/311,292
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 60/311,979
; PRIOR FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/313,201
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 60/312,892
; PRIOR FILING DATE: 2001-08-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 327
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 240
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-210-172-240

Query Match 0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 TGGCGCTGCTGACCT 508
      ||||| ||||| |||||
Db 2 TGGCGCTGCTGAGCT 16

RESULT 268
US-10-138-674-5661
; Sequence 5661, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5661
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5661

Query Match 0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 629 TGCTCTGGCGCTGC 643
      ||| : ||||| |||
```

Db 1 UGUGUGCGGCGUC 15

RESULT 269

US-10-287-949A-5661
; Sequence 5661, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth of Endothelial Cells
; FILE REFERENCE: MEH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patent version 3.0
; SEQ ID NO 5661
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5661

Query Match 0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 629 TGTCTGTGCGGCTGC 643

Db 1 UGUGUGCGGCGUC 15

RESULT 270

US-09-866-108-6623
; Sequence 6623, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236.359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30

US-09-866-108-6630
; Sequence 6630, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236.359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6623
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6623

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAG 35

Db 3 TCTGCGTCTGCATAG 17

RESULT 271

US-09-866-108-6630
; Sequence 6630, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine


```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MEH000,978-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; NUMBER OF SEQ ID NOS: 60/181,797
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 287
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-287

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 3.3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 724 AAAAGCTACTCCTTC 738
Db 2 AGAAGCUACUCCUUC 16

RESULT 275
US-09-848-754A-370
; Sequence 370, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEH000-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 370
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-370

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCTACTACTACCG 1175
Db 1 CUCCAAACUUCUACCG 15

RESULT 276
US-09-848-754A-1340
; Sequence 1340, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEH000-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1340
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1340

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCTACTACTACCG 1175
Db 1 CUCCAAACUUCUACCG 15

RESULT 277
US-09-848-754A-1551
; Sequence 1551, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEH000-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1551
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1551

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCTACTACTACCG 1175
Db 2 CUCCAAACUUCUACCG 16

RESULT 278
US-09-848-754A-2408
; Sequence 2408, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEH000-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2408
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2408

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 442 AGGCTGCTGCTGGAG 456
Db 1 AGGCTGCTGCTGGAG 15

RESULT 279
US-09-930-423-5/C
; Sequence 5, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
US-09-848-754A-1340

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 442 AGGCTGCTGCTGGAG 456
Db 2 AGGCTGCTGCTGGAG 16

RESULT 277
US-09-848-754A-1551
; Sequence 1551, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEH000-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1551
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1551

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCTACTACTACCG 1175
Db 2 CUCCAAACUUCUACCG 16

RESULT 278
US-09-848-754A-2408
; Sequence 2408, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEH000-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2408
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2408

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 442 AGGCTGCTGCTGGAG 456
Db 1 AGGCTGCTGCTGGAG 15

RESULT 279
US-09-930-423-5/C
; Sequence 5, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```

; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 137
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-137

Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 3.3e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      1065 CTTTGCTTCCTCCA 1079
          |:::|:::|:::|:::|
Db       1 CUUUGCCUUCUCCA 15

RESULT 284
US-09-780-164-1043/c
; Sequence 1043, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:

```

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
FILE REFERENCE: 400/010
CURRENT APPLICATION NUMBER: US/09/780,164
CURRENT FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/185,516
PRIOR FILING DATE: 2000-02-28
NUMBER OF SEQ ID NOS: 2603
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1043
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-780-164-1043

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCT 829
DB 17 TCTTCTCTCTTCT 3

RESULT 285

US-09-780-164-1044/c
Sequence 1044, Application US/09780164
Publication No. US20030092646A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
FILE REFERENCE: 400/010
CURRENT APPLICATION NUMBER: US/09/780,164
CURRENT FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/185,516
PRIOR FILING DATE: 2000-02-28
NUMBER OF SEQ ID NOS: 2603
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1044
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-780-164-1044

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCT 829
DB 16 TCTTCTCTCTTCT 2

RESULT 286

US-09-864-636A-2493/c
Sequence 2493, Application US/09864636A
Publication No. US20030104378A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Allwai, Hatim
APPLICANT: Bartholomay, Christian
APPLICANT: Chehak, LuAnne
TITLE OF INVENTION: Detection of RNA Sequences
FILE REFERENCE: FORS-04944
CURRENT APPLICATION NUMBER: US/09/864,636A
CURRENT FILING DATE: 2002-10-15
NUMBER OF SEQ ID NOS: 2640
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2493

LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-09-864-636A-2493

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 278 CCCAGGAGCCATCCC 292
DB 16 CCCAGGAGCCATCCC 2

RESULT 287

US-09-740-332-1412/c
Sequence 1412, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
TITLE OF INVENTION: Hepatitis C Virus Infection
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1412
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1412

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 135 GGAGGCTGTGAAGGC 149
DB 17 GGAGGCTGTGAATGC 3

RESULT 288

US-09-745-237A-5/c
Sequence 5, Application US/09745237A
Publication No. US20030143708A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: 400/007 (MBH00-918-A)
CURRENT APPLICATION NUMBER: US/09/745,237A
CURRENT FILING DATE: 2002-04-15
NUMBER OF SEQ ID NOS: 4550
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-745-237A-5

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 43 GGCCTGGAGGGGAG 57

Db 16 GGGCTGGAGGGCG 2
|||||

RESULT 289

US-09-745-237A-324
; Sequence 324, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 324
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-324

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1404 CACCGGCCCGCATG 1418
|||||
Db 2 CACCGGCCCGCCAUG 16

RESULT 290

US-09-745-237A-325
; Sequence 325, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 325
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-325

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1404 CACCGGCCCGCATG 1418
|||||
Db 1 CACCGGCCCGCCAUG 15

RESULT 291

US-09-745-237A-334/c
; Sequence 334, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A

; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 334
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-334

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 43 GGGCTGGAGGGGAG 57
|||||
Db 15 GGGCTGGAGGGGCG 1

RESULT 292

US-09-817-879-1412/c
; Sequence 1412, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1412
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1412

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 135 GGAGGCTGTGAAGC 149
|||||
Db 17 GGAGGCTGTGAATGC 3

RESULT 293

US-09-864-426A-2493/c
; Sequence 2493, Application US/09864426A
; Publication No. US20040018489A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Ma, Wu Po
; APPLICANT: Lyamichev, Victor
; APPLICANT: Saiser, Michael
; TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
; FILE REFERENCE: FORS-04946
; CURRENT APPLICATION NUMBER: US/09/864,426A
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2493
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-426A-2493

```
Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 278 CCAGGAGCCATCCC 292
      ||||| |||||
Db 16 CCAGGAGCCATCCC 2

RESULT 294
US-10-060-830-135
; Sequence 135, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 123
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 135
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-135

Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1291 GCAGTGGCCCATGAG 1305
      ||||| |||||
Db 3 GCAGTGGCCCATGAG 17

RESULT 295
US-10-060-830-136
; Sequence 136, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```
Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1291 GCAGTGGCCCATGAG 1305
      ||||| |||||
Db 2 GCAGTGGCCCATGAG 16

RESULT 296
US-10-060-998-119/c
; Sequence 119, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 119
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-119

Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1348 CTGATACCTCTCCTT 1362
      ||||| |||||
Db 16 CTGATACCTCCTT 2

RESULT 297
US-10-060-998-120/c
; Sequence 120, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
```

; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 120
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-120

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1348 CTGATCTCTTCCTT 1362

Db 15 CTGATCTCATCTT 1

RESULT 298

US-10-163-552-729/c

; Sequence 729, Application US/10163552

; Publication No. US20030105051A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, Jim

; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level

; FILE REFERENCE: MBH01-1653-A (400/014)

; CURRENT APPLICATION NUMBER: US/10/163,552

; CURRENT FILING DATE: 2002-06-06

; NUMBER OF SEQ ID NOS: 1997

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 729

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-163-552-729

Query Match

Best Local Similarity 0.9%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 196 CGGCCCATCGCGAG 210

Db 16 CTGCCCATCGCGAG 2

RESULT 299

US-10-156-306-3771

; Sequence 3771, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 3771

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-3771

Query Match

Best Local Similarity 0.9%; Score 13.4; DB 1; Length 17;

Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 297 GAAACAGAAAGTTT 311

Db 3 GAAACAGAAAGGUU 17

RESULT 300

US-10-339-782-45

; Sequence 45, Application US/10339782

; Publication No. US20030166026A1

; GENERAL INFORMATION:

; APPLICANT: Lynx Therapeutics, Inc.

; APPLICANT: Goodman, Laurie J

; APPLICANT: Bowen, Benjamin A

; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells

; FILE REFERENCE: 37-000110US

; CURRENT APPLICATION NUMBER: US/10/339,782

; CURRENT FILING DATE: 2003-01-08

; NUMBER OF SEQ ID NOS: 495

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 45

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-339-782-45

Query Match

Best Local Similarity 0.9%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 786 GATCCAGGCCCCCG 800

Db 1 GATCCAGGCCCCCG 15

RESULT 301

US-10-084-839-2493/c

; Sequence 2493, Application US/10084839

; Publication No. US20030186238A1

; GENERAL INFORMATION:

; APPLICANT: Third Wave Technologies

; APPLICANT: Allawi, Hatim

; APPLICANT: Argue, Brad T.

; APPLICANT: Bartholomay, Christian T.

; APPLICANT: Chehak, LuAnne

; APPLICANT: Curtis, Michelle L.

; APPLICANT: Eis, Peggy S.

; APPLICANT: Hall, Jeff G.

; APPLICANT: Ip, Hon S.

; APPLICANT: Ji, Lin

; APPLICANT: Kaiser, Michael

; APPLICANT: Kwiatkowski, Jr., Robert W.

; APPLICANT: Lukowiak, Andrew A.

; APPLICANT: Lyamichev, Victor

; APPLICANT: Lyamacheva, Natalie E.

; APPLICANT: Ma, WuPo

; APPLICANT: Neri, Bruce P.

; APPLICANT: Olson, Sarah M.

; APPLICANT: Olson-Munoz, Marilyn C.

; APPLICANT: Schaefer, James J.

; APPLICANT: Skrzypczynski, Zbigniew

; APPLICANT: Takova, Tssetska Y.

; APPLICANT: Thompson, Lisa C.

; APPLICANT: Vedvik, Kevin L.

; TITLE OF INVENTION: RNA Detection Assays

; FILE REFERENCE: FORS-06666

; CURRENT APPLICATION NUMBER: US/10/084,839

; CURRENT FILING DATE: 2002-02-26

; NUMBER OF SEQ ID NOS: 4004

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 2493

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic

US-10-084-839-2493

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 278 CCACGAGCCATCCC 292
DB 16 CCACGAGCCATCCC 2

RESULT 302

US-10-307-005-315/c
; Sequence 315, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 315
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Spinacia oleracea
US-10-307-005-315

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 484 CAGCTGCCATTGCG 498
DB 17 CAGCTGCCATTGCG 3

RESULT 303

US-10-307-005-316
; Sequence 316, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27

NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 316
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Spinacia oleracea
US-10-307-005-316

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 484 CAGCTGCCATTGCG 498
DB 1 CAGCTGCCATTGCG 15

RESULT 304

US-10-307-005-2383/c
; Sequence 2383, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2383
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-307-005-2383

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 363 CACCATCTACGACAT 377
DB 17 CACCATCTACGACAT 3

RESULT 305

US-10-307-005-2384
; Sequence 2384, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672

;
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2384
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-307-005-2384

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 363 CACCATCTACCAT 377
DB 1 CACCATCTACGACAT 15

RESULT 306
US-10-138-674-949/c
; Sequence 949, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-949

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1513 CCCAGGCACTTC 1527
DB 17 CCCAGGCAAGTTC 3

RESULT 307
US-10-138-674-2128
; Sequence 2128, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0

;
; SEQ ID NO 2128
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2128

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
DB 2 CCCAGAUUCCAGC 16

RESULT 308
US-10-138-674-2129
; Sequence 2129, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2129
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2129

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
DB 1 CCCAGAUUCCAGC 15

RESULT 309
US-10-138-674-4663/c
; Sequence 4663, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4663
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4663

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 261 AGGTTCTTGACGAC 275
Db 17 AGGTTCTTGAACAG 3

RESULT 310

US-10-138-674-5311/c
; Sequence 5311, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138, 674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5311
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5311

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1512 ACCCAGGCAACTTT 1526
Db 15 ACCCAGGCAAGTTT 1

RESULT 311

US-10-138-674-7200
; Sequence 7200, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138, 674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7200
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7200

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 3.3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 629 TGTCTCTGCGCGTGC 643
Db 3 UGCUGGCGCGCUGC 17

RESULT 312

US-10-138-674-7201
; Sequence 7201, Application US/10138674

; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138, 674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7201
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7201

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 3.3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 629 TGTCTCTGCGCGTGC 643
Db 1 UGCUGGCGCGCUGC 15

RESULT 313

US-10-138-674-8515/c
; Sequence 8515, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138, 674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8515
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8515

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 119 AATGGACCCGACACA 133
Db 15 AATGGACCCGACACA 1

RESULT 314

US-10-676-154-100/c
; Sequence 100, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045 (HCL/MAT)

; CURRENT APPLICATION NUMBER: US/10/676,154
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 100
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-100

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 727 AGCTACTCCTTCCTG 741
||||| :|||
Db 15 AGCTACTGCTCTCTG 1

RESULT 315

US-10-287-949A-949/c
; Sequence 949, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-949

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1513 CCCAGGCAACTTTC 1527
||||| :|||
Db 17 CCCAGGCAAGTTTC 3

RESULT 316

US-10-287-949A-2128
; Sequence 2128, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2128

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2128

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
||||| :|||
Db 2 CCCAGAUUCUCCAGC 16

RESULT 317

US-10-287-949A-2129
; Sequence 2129, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2129
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2129

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 3.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
||||| :|||
Db 1 CCCAGAUUCUCCAGC 15

RESULT 318

US-10-287-949A-4663/c
; Sequence 4663, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4663
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4663

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 261 AGGTTCTTGACGAG 275
DB 17 AGGTTCTTGAACAG 3

RESULT 319

US-10-287-949A-5311/c
; Sequence 5311, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5311
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5311

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1512 ACCCCAGGCACTTT 1526
DB 15 ACCCCAGGCAAGTTT 1

RESULT 320

US-10-287-949A-7200
; Sequence 7200, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7200
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7200

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 3.3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 629 TGCTCTGCGCGTGC 643
DB 3 UGCUGUGCGCGCUGC 17

RESULT 321

US-10-287-949A-7201
; Sequence 7201, Application US/10287949A
; Publication No. US20040102389A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7201
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7201

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 3.3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 629 TGCTCTGCGCGTGC 643
DB 1 UGCUGUGCGCGCUGC 15

RESULT 322

US-10-287-949A-8515/c
; Sequence 8515, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8515
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8515

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 119 AATGGACCCGACACA 133
DB 15 AATGGACCCGACACA 1

RESULT 323

US-10-712-672-304
; Sequence 304, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13

```

/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 4005
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION:

```

OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4005

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 135 GGAGGCTGTGAGGC 149
|||||
DB 17 GGAGGCTGTGAATGC 3

RESULT 327

US-10-723-361-6623
Sequence 6623, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 6623
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-6623

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAG 35
|||||
DB 3 TCTGCGTCTGCATAG 17

RESULT 328

US-10-723-361-6630
Sequence 6630, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 6630
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-6630

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 GTCTGCAGAGGACAG 40
|||||
DB 1 GTCTGCATAGGACAG 15

RESULT 329
US-10-723-361-10675/c
Sequence 10675, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Acomica Sequence Listing Engine
 ; SEQ ID NO 10675
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-10675

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1259 GGGTAGCCATGCTGG 1273
 ||||| ||||| |||||
 Db 16 GGGTGGCCATGCTGG 2

RESULT 330
 US-10-723-361-10676/c
 ; Sequence 10676, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105
 ; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Acomica Sequence Listing Engine
 ; SEQ ID NO 10676
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-10676

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1259 GGGTAGCCATGCTGG 1273
 ||||| ||||| |||||
 Db 15 GGGTGGCCATGCTGG 1

RESULT 331
 US-10-181-846-109
 ; Sequence 109, Application US/10181846
 ; Publication No. US20030083297A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas M. Dean
 ; APPLICANT: Lex M. Coweert
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
 ; FILE REFERENCE: RTSP-0363
 ; CURRENT APPLICATION NUMBER: US/10/181,846
 ; CURRENT FILING DATE: 2002-07-17
 ; PRIOR APPLICATION NUMBER: PCT/US01/01416
 ; PRIOR FILING DATE: 2001-01-16
 ; PRIOR APPLICATION NUMBER: 09/490,692
 ; PRIOR FILING DATE: 2000-01-24
 ; NUMBER OF SEQ ID NOS: 176
 ; SEQ ID NO 109
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-181-846-109

Query Match 0.9%; Score 13.4; DB 1; Length 20;
 Best Local Similarity 93.3%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 28 CTGCAGAGGACAGAA 42
 ||||| ||||| |||||
 Db 1 CTGCAGAGGACAGAA 15

RESULT 332
 US-09-765-449-17/c
 ; Sequence 17, Application US/09765449
 ; Patent No. US20020098537A1
 ; GENERAL INFORMATION:
 ; APPLICANT: SHIMOMURA, Takeshi
 ; KAWAGUCHI, Toshiya
 ; KITAMURA, Naomi
 ; MIYAZAWA, Keiji
 ; TITLE OF INVENTION: NOVEL PROTEIN, DNA CODING FOR SAME
 ; NUMBER OF SEQUENCES: 18
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
 ; STREET: 2100 Pennsylvania Avenue, N.W.
 ; CITY: Washington
 ; STATE: DC
 ; COUNTRY: USA
 ; ZIP: 20037
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy Disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/765,449
 ; FILING DATE: 22-Jan-2001
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/685,558
 ; FILING DATE: <Unknown>
 ; INFORMATION FOR SEQ ID NO: 17

SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthetic DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 17
US-09-765-449-17

Query Match 0.8%; Score 13.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 876 CAGGTGGGAATTATGTGG 892
DB 17 CARGTNGARTTGTGGG 1

RESULT 333

US-09-864-785-3767/c
; Sequence 3767, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3767
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-3767

Query Match 0.8%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 397 GTCCTCATCATCA 409
DB 13 GTCCTCATCATCA 1

RESULT 334

US-09-740-332-4771/c
; Sequence 4771, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4771
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4771

Query Match 0.8%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGA 145
DB 13 ATGGAGGCTGTGA 1

RESULT 335

US-09-817-879-4771/c
; Sequence 4771, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4771
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4771

Query Match 0.8%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGA 145
DB 13 ATGGAGGCTGTGA 1

RESULT 336

US-10-287-919-360
; Sequence 360, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,919
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 360
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (107330)...(107344)
; OTHER INFORMATION: Chromosome = 1 Strand = positive
US-10-287-919-360

Query Match 0.8%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1374 AATGTTGAACCTC 1386
DB 1 AATGTTGAACCTC 13

RESULT 337

US-10-287-919-1424
; Sequence 1424, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,919
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 1424
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (719844)...(719858)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 1780
US-10-287-919-1424

Query Match 0.8%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1374 AATGTTGAACCTTC 1386
|||||
Db 1 AATGTTGAACCTTC 13

RESULT 338
US-10-669-841-7368/c
; Sequence 7368, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (WBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7368
; LENGTH: 15

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-7368

Query Match 0.8%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGA 145
|||||
Db 13 ATGGAGGCTGTGA 1

RESULT 339
US-09-740-332-9683/c
; Sequence 9683, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9683
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)...(16)
; OTHER INFORMATION: n is inverted deoxyabasic
US-09-740-332-9683

Query Match 0.8%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGA 145
|||||
Db 13 ATGGAGGCTGTGA 1

RESULT 340
US-09-817-879-9683/c
; Sequence 9683, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: WBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9683
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)...(16)
; OTHER INFORMATION: n is inverted deoxyabasic
US-09-817-879-9683

Query Match 0.8%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGA 145
|||||
Db 13 ATGGAGGCTGTGA 1

RESULT 341

US-10-669-841-7427/c
; Sequence 7427, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7427
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: n is inverted deoxyabasic

Query Match 0.8%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 ATGGAGGCTGTGA 145
|||||
Db 13 ATGGAGGCTGTGA 1

RESULT 342

US-09-864-785-2086/c
; Sequence 2086, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2086
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid

US-09-864-785-2086

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 397 GTCCTCATCATCA 409
|||||
Db 16 GTCCTCATCATCA 4

RESULT 343

US-09-864-785-2838/c
; Sequence 2838, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid

US-09-864-785-2838

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 397 GTCCTCATCATCA 409
|||||
Db 17 GTCCTCATCATCA 5

RESULT 344

US-09-864-785-2839/c
; Sequence 2839, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan

```
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2839
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2839

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      397 GTCCTCATCATCA 409
Db      14 GTCCTCATCATCA 2

RESULT 345
US-09-825-805-456/c
; Sequence 456, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT FILING DATE: 2001-09-27
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US/09/825,805
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 456
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-456

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      198 GGCATCGCGGAG 210
Db      16 GGCATCGCGGAG 4

RESULT 346
US-09-818-875-2786/c
; Sequence 2786, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT FILING DATE: 2001-03-27
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2786
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-2786

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1508 CCTTACCCGAGC 1520
Db      14 CCTTACCCGAGC 2

RESULT 347
US-09-818-875-2787
; Sequence 2787, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT FILING DATE: 2001-03-27
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2787
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-2787

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1508 CCTTACCCGAGC 1520
Db      14 CCTTACCCGAGC 2
```

```
Db          4 CCTTACCCAGGC 16

RESULT 348
US-09-780-533A-288
; Sequence 288, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 288
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-288

Query Match          0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 3.7e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 726 AAGCTACTCCTTC 738
|||:|:|:|:|
Db 1 AAGCUACUCCUUC 13

RESULT 349
US-09-780-533A-1165
; Sequence 1165, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1165
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1165

Query Match          0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 3.7e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 726 AAGCTACTCCTTC 738
|||:|:|:|:|
Db 2 AAGCUACUCCUUC 14

RESULT 350
US-09-877-478-1467/c
; Sequence 1467, Application US/09877478
; Publication No. US20030068301A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH800-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1467
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1467

Query Match          0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 265 TCCTTGAGCAGGA 277
|||||:|:|:|:|
Db 17 TCCTTGAGCAGGA 5

RESULT 351
US-09-848-754A-1115/c
; Sequence 1115, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH800-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1115
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1115

Query Match          0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGGAGGTGC 352
|||||:|:|:|:|
Db 13 CTGATGGAGGTGC 1

RESULT 352
US-09-930-423-335/c
```

```

; Sequence 335, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00.918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 335
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-335

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGG 55
   |||||
Db 14 GGGCTGGGAGGG 2

RESULT 353
US-09-930-423-336/c
; Sequence 336, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00.918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-336

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGG 55
   |||||
Db 14 GGGCTGGGAGGG 2

RESULT 354
US-09-930-423-336/c
; Sequence 335, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00.918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 335
; LENGTH: 17
; TYPE: RNA

```

```

; ORGANISM: Homo sapiens
US-09-745-237A-335

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGG 55
   |||||
Db 14 GGGCTGGGAGGG 2

RESULT 355
US-09-745-237A-336/c
; Sequence 336, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00.918-A
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-336

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGG 55
   |||||
Db 13 GGGCTGGGAGGG 1

RESULT 356
US-10-163-552-728/c
; Sequence 728, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 728
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-728

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 GGCCATGCGGGAG 210
   |||||
Db 16 GGCCATGCGGGAG 4

RESULT 357
US-10-156-306-5116/c
; Sequence 5116, Application US/10156306

```

```

US-10-156-306-7073

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      936 CTTTCATCCTGGGC 948
DB      16 CTTTCATCCTGGGC 4
|||||
|||||

RESULT 360
US-10-156-306-7074/c
; Sequence 7074, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7074

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      936 CTTTCATCCTGGGC 948
DB      15 CTTTCATCCTGGGC 3
|||||
|||||

RESULT 361
US-10-339-782-155/c
; Sequence 155, Application US/10339782
; Publication No. US2003016602eA1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 155
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-155

Query Match      0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      72 CTGTGGAGATGGA 84
DB      15 CTGTGGAGATGGA 3
|||||
|||||

RESULT 362
US-10-209-787-2786/c
; Sequence 2786, Application US/10209787
; Publication No. US20030217377A1

```

```
/ GENERAL INFORMATION:
/ APPLICANT: Kmiec, Eric B.
/ APPLICANT: Gamper, Howard B.
/ APPLICANT: Rice, Michael C.
/ TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
/ FILE REFERENCE: Napro-4
/ CURRENT APPLICATION NUMBER: US/10/209,787
/ PRIOR FILING DATE: 2002-07-30
/ PRIOR APPLICATION NUMBER: US 09/818,875
/ PRIOR FILING DATE: 2001-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,176
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,179
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/208,538
/ PRIOR FILING DATE: 2000-06-01
/ PRIOR APPLICATION NUMBER: US 60/244,989
/ PRIOR FILING DATE: 2000-10-30
/ NUMBER OF SEQ ID NOS: 4385
/ SOFTWARE: Friedman macro Napro4
/ SEQ ID NO 2786
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-209-787-2786

Query Match          0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CCTTACCCGAGC 1520
DB 14 CCTTACCCGAGC 2

RESULT 363
US-10-209-787-2787
/ Sequence 2787, Application US/10209787
/ Publication No. US20030217377A1
/ GENERAL INFORMATION:
/ APPLICANT: Kmiec, Eric B.
/ APPLICANT: Gamper, Howard B.
/ APPLICANT: Rice, Michael C.
/ TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
/ FILE REFERENCE: Napro-4
/ CURRENT APPLICATION NUMBER: US/10/209,787
/ PRIOR FILING DATE: 2002-07-30
/ PRIOR APPLICATION NUMBER: US 09/818,875
/ PRIOR FILING DATE: 2001-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,176
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,179
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/208,538
/ PRIOR FILING DATE: 2000-06-01
/ PRIOR APPLICATION NUMBER: US 60/244,989
/ PRIOR FILING DATE: 2000-10-30
/ NUMBER OF SEQ ID NOS: 4385
/ SOFTWARE: Friedman macro Napro4
/ SEQ ID NO 2787
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-209-787-2787

Query Match          0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CCTTACCCGAGC 1520
DB 14 CCTTACCCGAGC 2

RESULT 364
US-10-261-185-2786/c
/ Sequence 2786, Application US/10261185
/ Publication No. US20040014057A1
/ GENERAL INFORMATION:
/ APPLICANT: Kmiec, Eric B.
/ APPLICANT: Gamper, Howard B.
/ APPLICANT: Rice, Michael C.
/ TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
/ FILE REFERENCE: Napro-4CON
/ CURRENT APPLICATION NUMBER: US/10/261,185
/ CURRENT FILING DATE: 2002-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/09761
/ PRIOR FILING DATE: 2001-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,176
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,179
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/208,538
/ PRIOR FILING DATE: 2000-06-01
/ PRIOR APPLICATION NUMBER: US 60/244,989
/ PRIOR FILING DATE: 2000-10-30
/ NUMBER OF SEQ ID NOS: 4385
/ SOFTWARE: Friedman macro Napro4
/ SEQ ID NO 2786
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-261-185-2786

Query Match          0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CCTTACCCGAGC 1520
DB 14 CCTTACCCGAGC 2

RESULT 365
US-10-261-185-2787
/ Sequence 2787, Application US/10261185
/ Publication No. US20040014057A1
/ GENERAL INFORMATION:
/ APPLICANT: Kmiec, Eric B.
/ APPLICANT: Gamper, Howard B.
/ APPLICANT: Rice, Michael C.
/ TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
/ FILE REFERENCE: Napro-4CON
/ CURRENT APPLICATION NUMBER: US/10/261,185
/ CURRENT FILING DATE: 2002-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/09761
/ PRIOR FILING DATE: 2001-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,176
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/192,179
/ PRIOR FILING DATE: 2000-03-27
/ PRIOR APPLICATION NUMBER: US 60/208,538
/ PRIOR FILING DATE: 2000-06-01
/ PRIOR APPLICATION NUMBER: US 60/244,989
/ PRIOR FILING DATE: 2000-10-30
/ NUMBER OF SEQ ID NOS: 4385
/ SOFTWARE: Friedman macro Napro4
/ SEQ ID NO 2787
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-261-185-2787
```

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CCTTACCCAGGC 1520
Db 4 CCTTACCCAGGC 16

RESULT 366
US-10-342-902-1467/c
; Sequence 1467, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MEHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1467
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1467

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 265 TCCTTGAGCAGGA 277
Db 17 TCCTTGAGCAGGA 5

RESULT 367
US-10-138-674-1508
; Sequence 1508, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1508

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1508

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 3.7e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 946 GGCCGCCTCTGTG 958
Db 1 GGCCGCCTCTGTG 13

RESULT 368
US-10-347-869-17/c
; Sequence 17, Application US/10347869
; Publication No. US20040091882A1
; GENERAL INFORMATION:
; APPLICANT: Magot, Michel
; APPLICANT: Ravot, Gilles
; TITLE OF INVENTION: METHOD OF DETECTING SULPHATE-REDUCING BACTERIA
; FILE REFERENCE: 111628-00121
; CURRENT APPLICATION NUMBER: US/10/347,869
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: US 09/535,012
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Desulfovibrio vulgaris
US-10-347-869-17

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 AACTTCATGATGC 1393
Db 17 AACTTCATGATGC 5

RESULT 369
US-10-287-949A-1508
; Sequence 1508, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1508
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1508

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 3.7e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 946 GGCCGCCTCTGTG 958
Db 1 GGCCGCCTCTGTG 13

Db 1 GGCCGCCUCUG 13

RESULT 370
US-10-669-841-1467/c
; Sequence 1467, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS AND HEPATITIS B VIRUS
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1467
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1467

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 265 TCCTTCAGCAGGA 277
Db 17 TCCTTCAGCAGGA 5

RESULT 371
US-10-681-074-2786/c
; Sequence 2786, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NApRo-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1467
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-2787

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CCTTACCCCGAGC 1520
Db 4 CCTTACCCCGAGC 16

RESULT 373
US-10-336-638-370/c
; Sequence 370, Application US/10336638
; Publication No. US20030170699A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian Bing
; APPLICANT: Chakravarti, Aravinda
; APPLICANT: Halushka, Marc Kenneth
; APPLICANT: Case Western Reserve University School of Medicine
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Polymorphisms Associated With
; FILE REFERENCE: 018547-034210US
; CURRENT APPLICATION NUMBER: US/10/336,638
; CURRENT FILING DATE: 2003-01-02
; PRIOR APPLICATION NUMBER: US/09/304,232
; PRIOR FILING DATE: 1999-05-03
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/084,641
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-05-07
; NUMBER OF SEQ ID NOS: 909

; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2786
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-2786

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CCTTACCCCGAGC 1520
Db 14 CCTTACCCCGAGC 2

RESULT 372
US-10-681-074-2787
; Sequence 2787, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NApRo-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2787
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-2787

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CCTTACCCCGAGC 1520
Db 4 CCTTACCCCGAGC 16

RESULT 373
US-10-336-638-370/c
; Sequence 370, Application US/10336638
; Publication No. US20030170699A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian Bing
; APPLICANT: Chakravarti, Aravinda
; APPLICANT: Halushka, Marc Kenneth
; APPLICANT: Case Western Reserve University School of Medicine
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Polymorphisms Associated With
; FILE REFERENCE: 018547-034210US
; CURRENT APPLICATION NUMBER: US/10/336,638
; CURRENT FILING DATE: 2003-01-02
; PRIOR APPLICATION NUMBER: US/09/304,232
; PRIOR FILING DATE: 1999-05-03
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/084,641
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-05-07
; NUMBER OF SEQ ID NOS: 909

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY . 44 GGCTGGGAGGGAGCG 59
Db 16 GGCTGGCAGGAGCG 1

RESULT 377
US-10-407-807-34/c
; Sequence 34, Application US/10407807
; Publication No. US20040096848A1
; GENERAL INFORMATION:
; APPLICANT: THRUUE, CHARLOTTE ALBAEK
; APPLICANT: HOG, ANJA MOLHART
; APPLICANT: KRISTJANSEN, PAUL E.G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION HIP-1ALPHA
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 57390 (45120)
; CURRENT APPLICATION NUMBER: US/10/407,807
; CURRENT FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: 60/370,126
; PRIOR FILING DATE: 2002-04-05
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 34
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-407-807-34

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCACCTGTTGG 538
Db 16 CTGCTACCTGTTGG 1

RESULT 378
US-10-407-807-53/c
; Sequence 53, Application US/10407807
; Publication No. US20040096848A1
; GENERAL INFORMATION:
; APPLICANT: THRUUE, CHARLOTTE ALBAEK
; APPLICANT: HOG, ANJA MOLHART
; APPLICANT: KRISTJANSEN, PAUL E.G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION HIP-1ALPHA
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 57390 (45120)
; CURRENT APPLICATION NUMBER: US/10/407,807
; CURRENT FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: 60/370,126
; PRIOR FILING DATE: 2002-04-05
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 53
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-407-807-53

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1525 TTCTGGGGCTGCTGA 1540

Db 16 TTCTGGATGCTGCTGA 1

RESULT 379
US-10-712-672-1739
; Sequence 1739, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1739
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1739

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 3.5e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 440 GCAGGCTGCTGCTGA 455
Db 1 GCGGCGUGGUGGUGGA 16

RESULT 380
US-10-232-923-2/c
; Sequence 2, Application US/10232923
; Publication No. US20040162249A1
; GENERAL INFORMATION:
; APPLICANT: Hong Kong University Science and Technology
; APPLICANT: Liang, Chun
; APPLICANT: Feng, Daorong
; APPLICANT: Yu, Zhiling
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF HYPERPROLIFERATIVE CONDITIONS IN HUMAN
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE INHIBITION OF HUMAN REPLICATION-INITIAL
; FILE REFERENCE: 32144183-14
; CURRENT APPLICATION NUMBER: US/10/232,923
; CURRENT FILING DATE: 2002-08-29
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 16
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-232-923-2

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 458 TTGACCTACTGATCTT 473
Db 16 TTGACCTACCCATCTT 1

RESULT 381

US-09-866-108-434/c
; Sequence 434, Application US/09866108
; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aeo mica Sequence Listing Engine

; SEQ ID NO 434

; TYPE: DNA

; LENGTH: 17

; ORGANISM: Homo sapiens

US-09-866-108-434

Query Match

Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTGG 193

DB 17 CTGAGAGATCTGCTGG 2

RESULT 382

US-09-866-108-435/c
; Sequence 435, Application US/09866108
; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOmica-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aeo mica Sequence Listing Engine

; SEQ ID NO 435

; TYPE: DNA

; LENGTH: 17

; ORGANISM: Homo sapiens

US-09-866-108-435

Query Match

Best Local Similarity 0.8%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTGG 193

DB 16 CTGAGAGATCTGCTGG 1

RESULT 383

US-09-866-108-930

; Sequence 930, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOmica-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

```

RESULT 385
US-09-866-108-1200/c
; Sequence 1200, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRES
; FILE REFERENCE: ASOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006661
; PRIOR FILING DATE: 2001-01-30

```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1200
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1200
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1061 TCTTCTTTCGCTTCCT 1076
Db 17 TCTTCTCTGCTTACT 2
```

RESULT 386

```
US-09-866-108-1201/c
; Sequence 1201, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1201
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1201
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1061 TCTTCTTTCGCTTCCT 1076
Db 16 TCTTCTCTGCTTACT 1
```

RESULT 387

```
US-09-866-108-1416
; Sequence 1416, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1416

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 138 GCCTGTGAAGGCACAA 153
|||||
```

Db 2 GGCTGTGAAGCCCAA 17

RESULT 388

US-09-866-108-1417

; Sequence 1417, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aecomica Sequence Listing Engine

; SEQ ID NO 1417

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-1417

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 138 GGCTGTGAAGCCCAA 153

Db 1 GGCTGTGAAGCCCAA 16

RESULT 389

US-09-866-108-1535

; Sequence 1535, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aecomica Sequence Listing Engine

; SEQ ID NO 1535

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-1535

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGCTGTGTACCTG 509

Db 2 TGGGGCTGTGCCCTG 17

RESULT 390

US-09-866-108-1537

; Sequence 1537, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 1537
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-1537

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity .87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 495 GGGCTGTGGTACCTGG 510
||| ||||| |||||
DB 1 GGGCTGTGGTACCTGG 16

RESULT 391
US-09-866-108-1646/c
; Sequence 1646, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR APPLICATION NUMBER: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662

;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 1646
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-1646

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity .87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1063 TTCTTGGCTTCTCTCC 1078
||| ||||| |||||
DB 17-TCTTGGCTTCTCTCC 2

RESULT 392
US-09-866-108-1648/c
; Sequence 1648, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR APPLICATION NUMBER: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662

```
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeomica Sequence Listing Engine
/ SEQ ID NO 1648
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-1648
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1062 CTCTTTGGCTTCTC 1077
||| ||||| |||||
Db 16 CTCCTTTGGCTTCTC 1
```

```
RESULT 393
US-09-866-108-2289/c
/ Sequence 2289, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
```

```
/ SOFTWARE: Aeomica Sequence Listing Engine
/ SEQ ID NO 2289
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-2289
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 560 TGTGGCCAGGGGCAC 575
||||| ||||| |||
Db 17 TGTGGCCATGGACAC 2
```

```
RESULT 394
US-09-866-108-2301/c
/ Sequence 2301, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeomica Sequence Listing Engine
/ SEQ ID NO 2301
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-2301
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```


QY 549 GGCCCTACGGCTGTGG 564
Db 16 GGCACTGCGGCTGTGG 1

RESULT 395

US-09-866-108-6545/c
; Sequence 6545, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6545
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6545

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 250 CCACCTCCCCCAGGTT 265
Db 17 CCACCTGCCCCAGGCT 2

RESULT 396

US-09-866-108-6546/c
; Sequence 6546, Application US/09866108
; Patent No. US20020048800A1

GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6546
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6546

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 250 CCACCTCCCCCAGGTT 265
Db 16 CCACCTGCCCCAGGCT 1

RESULT 397
US-09-866-108-6915/c
; Sequence 6915, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 6915
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6915

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAG 307
||||| |||||
Db 17 CTGGCGAGACAGAAAG 2

RESULT 398
US-09-866-108-6917/c
; Sequence 6917, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 6917
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6917

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 CCTGGGGAACAGAAA 306
||||| |||||
Db 16 CCTGGCGAGACAGAAA 1

RESULT 399
US-09-866-108-7706
; Sequence 7706, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

```

1  APPLICANT: CHEN, Wensheng
2  APPLICANT: SHANNON, Mark
3  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPR
4  FILE REFERENCE: AEMCMA-7
5  CURRENT APPLICATION NUMBER: US/09/856,108
6  CURRENT FILING DATE: 2001-05-25
7  PRIOR APPLICATION NUMBER: US 60/207,456
8  PRIOR FILING DATE: 2000-05-26
9  PRIOR APPLICATION NUMBER: GB 24263.6
10 PRIOR FILING DATE: 2000-10-04
11 PRIOR APPLICATION NUMBER: US 60/236,359
12 PRIOR FILING DATE: 2000-09-27
13 PRIOR APPLICATION NUMBER: PCT/US01/00666
14 PRIOR FILING DATE: 2001-01-30
15 PRIOR APPLICATION NUMBER: PCT/US01/00667
16 PRIOR FILING DATE: 2001-01-30
17 PRIOR APPLICATION NUMBER: PCT/US01/00664
18 PRIOR FILING DATE: 2001-01-30
19 PRIOR APPLICATION NUMBER: PCT/US01/00669
20 PRIOR FILING DATE: 2001-01-30
21 PRIOR APPLICATION NUMBER: PCT/US01/00665
22 PRIOR FILING DATE: 2001-01-30
23 PRIOR APPLICATION NUMBER: PCT/US01/00668
24 PRIOR FILING DATE: 2001-01-30
25 PRIOR APPLICATION NUMBER: PCT/US01/00663
26 PRIOR FILING DATE: 2001-01-30
27 PRIOR APPLICATION NUMBER: PCT/US01/00662
28 PRIOR FILING DATE: 2001-01-30
29 PRIOR APPLICATION NUMBER: PCT/US01/00661
30 PRIOR FILING DATE: 2001-01-30
31 PRIOR APPLICATION NUMBER: PCT/US01/00670
32 PRIOR FILING DATE: 2001-01-30
33 PRIOR APPLICATION NUMBER: US 60/234,687
34 PRIOR FILING DATE: 2000-09-21
35 PRIOR APPLICATION NUMBER: US 60/266,860
36 PRIOR FILING DATE: 2001-02-05
37 NUMBER OF SEQ ID NOS: 15752
38 SOFTWARE: Aemcoma Sequence Listing Engine
39 SEQ ID NO 8327
40 LENGTH: 17
41 TYPE: DNA
42 ORGANISM: Homo sapiens
43 US-09-866-108-8327

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1067 TTGCTTCTCCATTG 1082
||||| |||||||
Db 17 TTGCCATCTCCATGG 2

RESULT 402

US-09-866-108-8328/c
; Sequence 8328, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 8328
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8328

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1067 TTGCTTCTCCATTG 1082
||||| |||||||
Db 16 TTGCCATCTCCATGG 1

RESULT 403

US-09-866-108-8351/c
; Sequence 8351, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 8351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8351

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 727 AGCTACTCTTCTGGA 742
||||| |||||||
Db 17 AGCTCTCTTCTGGA 2

RESULT 404

US-09-866-108-8352/c
; Sequence 8352, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng

```

RESULT 405
US-09-866-108-8361/c
; Sequence 8361, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359

```

RESULT 406
 US-09-866-108-8362/c
 ; Sequence 8362, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Shaaron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/006666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/006667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/006664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/006669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/006665

```
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Acomica Sequence Listing Engine
/ SEQ ID NO 8362
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-8362
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 798 CAGTTTCTCCAGCTAC 813
Db 16 CACTTTCTCAGCTCC 1
```

RESULT 407

```
US-09-866-108-8928
/ Sequence 8928, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: ACOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Acomica Sequence Listing Engine
/ SEQ ID NO 8928
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-8928
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1467 CAGCCTGTACTGCCAG 1482
Db 2 CAGCCAGTACTACCAG 17
```

RESULT 408

```
US-09-866-108-8929
/ Sequence 8929, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: ACOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Acomica Sequence Listing Engine
/ SEQ ID NO 8929
/ LENGTH: 17
/ TYPE: DNA
```

ORGANISM: Homo sapiens
US-09-866-108-8929

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTCCAG 1482
||||| ||||| |||||
DB 1 CAGCCAGTACTACCAG 16

RESULT 409

US-09-866-108-9020/c
; Sequence 9020, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 9020
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9020

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1153 ACGTCCTTCTCCAACT 1168
||||| ||||| |||||
DB 17 ACGTACTTCTCCAGCT 2

RESULT 410

US-09-866-108-9021/c
; Sequence 9021, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 9021
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9021

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1153 ACGTCCTTCTCCAACT 1168
||||| ||||| |||||
DB 16 ACGTACTTCTCCAGCT 1

RESULT 411

US-09-866-108-9023/c
; Sequence 9023, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

```

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9025
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9025

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 CTCACGTCCTTCTCC 1164
Db 16 CTCACGTCCTTCTCC 1

RESULT 413
US-09-866-108-9829/c
; Sequence 9829 Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

```


; NUMBER OF SEQ IS NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 10672
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10672

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 GTAGCCATGCTGGTG 1276
Db 17 GTGCCATGCTGGCTG 2

RESULT 416
US-09-827-998-755
; Sequence 755, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US 60/207,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 755
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-755

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTGCCCA 834
Db 2 CTTCTCGTCTGCCA 17

RESULT 417
US-09-827-998-756
; Sequence 756, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US 60/207,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 756
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-756

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTGCCCA 834
Db 1 CTTCTCGTCTGCCCA 16

RESULT 418
US-09-827-998-759
; Sequence 759, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US 60/207,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-759

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 CTCCTCTGCCCAACAC 838
Db 2 CTCGTCTGCCCATCAC 17

RESULT 419
US-09-827-998-762
; Sequence 762, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US 60/207,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 762
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-762

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 825 CTTCTGCCCAACACTC 840
Db 1 CGTCTGCCCATCACTC 16

RESULT 420
US-09-864-785-344/c
; Sequence 344, Application US/09864785

```
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; TITLE OF INVENTION: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 344
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-344

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 158 TGGAGCAAGCGCAGG 173
Db 17 TGGAGCAGGCGCAGG 2

RESULT 421
US-09-864-785-385
; Sequence 385, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-385

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 260
Db 2 UGGCCCCCACCUGCCCC 17

RESULT 422
US-09-864-785-1569/c
; Sequence 1569, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
```

```
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1569
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1569

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 156 GCTGGAGCAAGCGCAG 171
Db 16 GCTGGAGCAGGGGCAG 1

RESULT 423
US-09-864-785-2924/c
; Sequence 2924, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2924
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2924

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 799 AGTTTCTCCAGCTACC 814
Db 17 AGTTTCCCGAGCTCCC 2

RESULT 424
US-09-864-785-2925/c
; Sequence 2925, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2925
```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2925

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 799 AGTTTCTCCAGCTACC 814
||||| ||||| ||
Db 16 AGTTTCTCCAGCTCCC 1

RESULT 425
US-09-825-805-447
; Sequence 447, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 447
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-447

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1181 GGAACGTGGTGTCCA 1196
||||| :||| :|||
Db 2 GGACGUGUGUCA 17

RESULT 426
US-09-730-289B-525/c
; Sequence 525, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCE: MBH00-864-A (400/006)

; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 525
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-525

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 339 GCTGATGGAGTGCAG 354
||||| ||||| |||||
Db 17 GCTGATGTAGCTGCAG 2

RESULT 427
US-09-818-875-1419/c
; Sequence 1419, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1419

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1399 CAGCGCACCGGCCGG 1414
||||| ||||| |||||
Db 17 CCGCGCCCGCGGCCGG 2

RESULT 428
US-09-818-875-1420
; Sequence 1420, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176

```
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1420

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACCGGCCCGG 1414
Db 1 CCGCGCCCGGCCCGG 16

RESULT 429
US-09-780-533A-78
; Sequence 78, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 78
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-78

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 3.9e+02;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCT 1361
Db 2 UGCUCGUUCUUCUCCU 17

RESULT 430
US-09-780-533A-740/C
; Sequence 740, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
```

```
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 740
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-740

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGAGAGGGCTGTGC 754
Db 16 CTGAGAGGGCTGGGC 1

RESULT 431
US-09-780-533A-900
; Sequence 900, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 900
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-900

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 247 CCCCACCTCCCCCGG 262
Db 2 CCCCUCUCCUCCCGG 17

RESULT 432
US-09-780-533A-901
; Sequence 901, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 901
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-901
```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 247 CCCCACACTCCCCGAG 262
DB 1 CCCCUCUCCCGCG 16

RESULT 433
US-09-780-533A-984
; Sequence 984, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 984
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-984

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 3.9e+02;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1347 GCTGATACTCTTCCTT 1362
DB 1 GCUGUCUCUCCU 16

RESULT 434
US-09-927-046-696/c
; Sequence 696, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 696
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-696

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1286 TCTCCGACGTGCCCA 1301

DB 16 TCTCCACAGTTGCCA 1

RESULT 435
US-09-927-046-1669/c
; Sequence 1669, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1669
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1669

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1287 CTCGCCAGTGCCCAT 1302
DB 17 CTCACAGTTGCCAT 2

RESULT 436
US-09-927-046-2079/c
; Sequence 2079, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2079
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-2079

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 515 CCATGTTTCTGTCCAC 530
DB 17 CCTTGCTTCTGTCCAC 2

RESULT 437

US-09-877-478-118
; Sequence 118, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH800-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 118
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-118

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TCTTCATGCTGCTGCT 1058
:|: ||: ||: ||: ||:
Db 2 UCUGCAUCCUGCGUCU 17

RESULT 438
US-09-877-478-808
; Sequence 808, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH800-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 118
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-118

US-09-877-478-808
; Sequence 808, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH800-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2178
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2178

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 527 CCACCTGTGGCGCC 542
||||| ||||| |||||
Db 17 CCACCTGTGGCGTC 2

RESULT 440
US-09-848-754A-2292/c
; Sequence 2292, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2292
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2292

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 344 TGGAGGTGCAGCATTTT 359
Db 17 TGGAGGTGCAGTTT 2

RESULT 441
US-09-848-754A-2407
; Sequence 2407, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2407
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2407

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 440 GCAGGCTGCTGCTGGA 455
Db 2 GGAGGCGUGCGCAGGA 17

RESULT 442
US-09-848-754A-3191
; Sequence 3191, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3191
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3191

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 628 GTGCTCTGCGCGCTGC 643
Db 2 GUGCUCGCGGCGCGUC 17

RESULT 443
US-09-930-423-186
; Sequence 186, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 186
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-186

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GGCATCTTCATGCTGC 1054
Db 2 GCCCUCUUAUGCUGC 17

RESULT 444
US-09-930-423-187
; Sequence 187, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 187
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-187

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GGCATCTTCATGCTGC 1054
Db 1 GCCCUCUUAUGCUGC 16

RESULT 445
US-09-930-423-302
; Sequence 302, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
```


; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 302
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-302

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 GCAGGACCCAGGAGCC 287
DB 1 GCAGGAGCCCGGAGCC 16

RESULT 446
US-09-930-423-332/c
; Sequence 332, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 332
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-930-423-332

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 44 GGCTGGGAGGGGCGG 59
DB 17 GGCTGGGAGGGGCGG 2

RESULT 447
US-09-930-423-534/c
; Sequence 534, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 534
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-534

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 481 GGACAGCTGCCATTGG 496
DB 16 GGACAGCTGCCTCTGG 1

RESULT 448
US-09-930-423-559/c
; Sequence 559, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-559

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 198 GCCCATGCGGGAGGCT 213
DB 17 GCCCATGCGGGAGGCT 2

RESULT 449
US-09-930-423-561/c
; Sequence 561, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 561
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-561

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 197 GGCCCATGCGGGAGGC 212
DB 16 GGCCCATGCGGGAGTC 1

RESULT 450
US-09-930-423-803
; Sequence 803, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease

```
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 803
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-803

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1044 CTTTCATGCTGCTGTC 1059
      |||:|:|:|:|:|:|:|:|
Db 1 CUUCAUGCUGCCACUC 16

RESULT 451
US-09-930-423-1077
; Sequence 1077, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1077
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1077

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TCTTCATGCTGCTGCT 1058
      |:|:|:|:|:|:|:|:|
Db 2 UCUCUAGCUGGCCACU 17

RESULT 452
US-09-780-164-65/c
; Sequence 65, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 65
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-65

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
```

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGATC 1491
      |||:|:|:|:|:|:|:|
Db 16 CTGCCAGGAGTGATCC 1

RESULT 453
US-09-780-164-441/c
; Sequence 441, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 441
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-441

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1474 TACTGCCAGGAGTGCT 1489
      |||:|:|:|:|:|:|:|
Db 17 TGCTGCCAGGAGTGAT 2

RESULT 454
US-09-780-164-442/c
; Sequence 442, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 442
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-442

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1474 TACTGCCAGGAGTGCT 1489
      |||:|:~|:~|:~|:~|:~|
Db 16 TGCTGCCAGGAGTGAT 1

RESULT 455
US-09-780-164-634
; Sequence 634, Application US/09780164
; Publication No. US20030092646A1
```

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
FILE REFERENCE: 400/010
CURRENT APPLICATION NUMBER: US/09/780,164
CURRENT FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/185,516
PRIOR FILING DATE: 2000-02-28
NUMBER OF SEQ ID NOS: 2603
SOFTWARE: Patentin version 3.0
SEQ ID NO 634
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-780-164-634

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 3.9e+02;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 926 TCTATGCTGGTTCAT 941
Db 1 UAUAGACUGCUCAU 16

RESULT 456
US-09-827-395A-214/c
Sequence 214, Application US/09827395A
Publication No. US20030113891A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Lawrence Blatt
APPLICANT: James McSwiggen
APPLICANT: Bharat Chowhira
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
FILE REFERENCE: MBH800-878-C (400/017)
CURRENT APPLICATION NUMBER: US/09/827,395A
CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 60/181,797
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/181,797
PRIOR FILING DATE: 2000-02-11
NUMBER OF SEQ ID NOS: 2617
SOFTWARE: Patentin version 3.0
SEQ ID NO 214
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-827-395A-214

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 907 CAGGCCCTGGATGTG 922
Db 17 CAGGCCCTGGATGTG 2

RESULT 457
US-09-827-395A-216/c
Sequence 216, Application US/09827395A
Publication No. US20030113891A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Lawrence Blatt
APPLICANT: James McSwiggen
APPLICANT: Bharat Chowhira
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
FILE REFERENCE: MBH800-878-C (400/017)
CURRENT APPLICATION NUMBER: US/09/827,395A

CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 09/780,533
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/181,797
PRIOR FILING DATE: 2000-02-11
NUMBER OF SEQ ID NOS: 2617
SOFTWARE: Patentin version 3.0
SEQ ID NO 216
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-827-395A-216

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 613 GCGCCACGCGGTGG 628
Db 17 GCGCCACGCGGTGG 2

RESULT 458
US-09-827-395A-217/c
Sequence 217, Application US/09827395A
Publication No. US20030113891A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Lawrence Blatt
APPLICANT: James McSwiggen
APPLICANT: Bharat Chowhira
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
FILE REFERENCE: MBH800-878-C (400/017)
CURRENT APPLICATION NUMBER: US/09/827,395A
CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 09/780,533
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/181,797
PRIOR FILING DATE: 2000-02-11
NUMBER OF SEQ ID NOS: 2617
SOFTWARE: Patentin version 3.0
SEQ ID NO 217
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-827-395A-217

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 613 GCGCCACGCGGTGG 628
Db 16 GCGCCACGCGGTGG 1

RESULT 459
US-09-827-395A-376/c
Sequence 376, Application US/09827395A
Publication No. US20030113891A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Lawrence Blatt
APPLICANT: James McSwiggen
APPLICANT: Bharat Chowhira
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
FILE REFERENCE: MBH800-878-C (400/017)
CURRENT APPLICATION NUMBER: US/09/827,395A
CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 09/780,533
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/181,797
PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-376

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 198 GGCCATGCGGGAGGCT 213
||| |||||
Db 17 GGCGTTGCGGGAGGCT 2

RESULT 460

US-09-827-395A-619/c
; Sequence 619, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 619
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-619

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 904 GCCCAGGCCCTGGGAT 919
||| |||||
Db 16 GCCCAGGCCCTGGGAT 1

RESULT 461

US-09-827-395A-699/c
; Sequence 699, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 699
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Homo sapiens
US-09-827-395A-699

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 198 GGCCATGCGGGAGGCT 213
||| |||||
Db 16 GGCGTTGCGGGAGGCT 1

RESULT 462

US-09-827-395A-825/c
; Sequence 825, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-825

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 CTGCCGGTCCAGGTGG 655
||| |||||
Db 16 CTGCCGGTCCAGGTGG 1

RESULT 463

US-09-827-395A-946/c
; Sequence 946, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 946
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-946

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 640 CTGCCGGTCCACGTGG 655
Db 17 CTGCCGGTCCAGATGG 2

RESULT 464
US-09-740-332-435
; Sequence 435, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 435
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-435

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 1079 ATTGTGGCTCAACGC 1094
Db 2 AUGGCGGCACUACGC 17

RESULT 465
US-09-740-332-632
; Sequence 632, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-632

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 1430 TGTGACCATGCTGTT 1445
Db 1 UGUGGAUGAUGCUGU 16

RESULT 466
US-09-740-332-1376
```

```
; Sequence 1376, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1376

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 437 AGGCGAGGCTGCTGCT 452
Db 2 AGCGAGGCGUGUGCU 17

RESULT 467
US-09-740-332-1899/c
; Sequence 1899, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1899

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1186 GTGGTGTCATGACT 1201
Db 16 GTGGTGTCAGACT 1

RESULT 468
US-09-740-332-1905/c
; Sequence 1905, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
```


Db 2 UCCUUGAGCAGGUCCC 17

RESULT 473

US-09-740-332-3179/c
; Sequence 3179, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3179
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3179

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 437 AGGCGAGGCTGTGCT 452

Db 17 AGCGGAGGCTGTGCT 2

RESULT 474

US-09-740-332-4120/c
; Sequence 4120, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4120
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4120

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1079 ATTGCTGGCTCAACGC 1094

Db 17 ATTGCTGGCTCAACGC 2

RESULT 475

US-09-792-818-243
; Sequence 243, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 243
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-243

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 886 TATGTGCCCAAGAACT 901

Db 2 UAUGGCCCAAGAAUU 17

RESULT 476

US-09-792-818-245
; Sequence 245, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 245
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-245

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 887 ATGTGCCCAAGAACTT 902

Db 1 AUGUGGCCCAAGAAUU 16

RESULT 477

US-09-792-818-891
; Sequence 891, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-891

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

; FILE REFERENCE: MBHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-891

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 27 TCTGCAGAGGACAGAA 42
| : : : : :
Db 2 UCUUCAGGGACAGAA 17

RESULT 478
US-09-792-818-893
; Sequence 893, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insulin
; FILE REFERENCE: MBHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-893

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 28 CTGCAGAGGACAGAG 43
| : : : : :
Db 1 CUUCAGGGACAGAG 16

RESULT 479
US-09-745-237A-186
; Sequence 186, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 186
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-186

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GGCATCTTCATGCTGC 1054
| : : : : :
Db 2 GCCCUCUUAUGCUGC 17

RESULT 480
US-09-745-237A-187
; Sequence 187, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 187
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-187

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GGCATCTTCATGCTGC 1054
| : : : : :
Db 1 GCCCUCUUAUGCUGC 16

RESULT 481
US-09-745-237A-302
; Sequence 302, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 302
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-302

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 GCAGGACCCGAGGCC 287
| : : : : :
Db 1 GCAGGAGCCCGAGGCC 16

RESULT 482
US-09-745-237A-332/c
; Sequence 332, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.


```
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 332
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-332

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 44 GCGTGGGAGGGAGCG 59
    |||||
Db 17 GCGTGGGAGGGCGG 2

RESULT 483
US-09-745-237A-534/c
; Sequence 534, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 534
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-534

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 481 GGACAGCTCCATTGG 496
    |||||
Db 16 GGACAGCTCCCTGG 1

RESULT 484
US-09-745-237A-559/c
; Sequence 559, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-559

Query Match      0.8%; Score 12.8; DB 1; Length 17;
```

```
; Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 198 GGCCATGCGGAGGCT 213
    |||||
Db 17 GGCCATGCGGAGTCT 2

RESULT 485
US-09-745-237A-561/c
; Sequence 561, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 561
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-561

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 197 GGGCCATGCGGAGGC 212
    |||||
Db 16 GGGCCATGCGGAGTGC 1

RESULT 486
US-09-745-237A-803
; Sequence 803, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 803
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-803

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1044 CTTTCATGCTGCTGCTC 1059
    ||::||::||::||
Db 1 CUUCAUGCUGCCACUC 16

RESULT 487
US-09-745-237A-1077
; Sequence 1077, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
```

```
/ APPLICANT: McSwiggen, Jim
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
/ FILE REFERENCE: 400/007 (MBH00-918-A)
/ CURRENT APPLICATION NUMBER: US/09/745,237A
/ CURRENT FILING DATE: 2002-04-15
/ NUMBER OF SEQ ID NOS: 4550
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 1077
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-745-237A-1077

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TCCTCATGCTGCTGCT 1058
Db      :|||:|||:|
        2 UCUCUAGUCGCGCACU 17

RESULT 488
US-09-510-378-241/c
/ Sequence 241, Application US/09510378
/ Publication No. US20030165823A1
/ GENERAL INFORMATION:
/ APPLICANT: Cronin, Maureen T.
/ Miyada, Charles Garrett
/ Hubbell, Earl A.
/ Chee, Mark
/ Fodor, Stephen P.A.
/ Huang, Xiaohua C.
/ Lipshutz, Robert J.
/ Lobban, Peter E.
/ Morris, Macdonald S.
/ Sheldon, Edward L.
/ TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
/ Detecting Cystic Fibrosis
/ NUMBER OF SEQUENCES: 250
/ CORRESPONDENCE ADDRESSES:
/ ADDRESSEE: Townsend and Townsend and Crew LLP
/ STREET: Two Embarcadero Center, 8th Floor
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94111
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/510,378
/ FILING DATE: 22-Feb-2000
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/544,381
/ FILING DATE: <Unknown>
/ APPLICATION NUMBER: US 08/510,521
/ FILING DATE: 02-AUG-1995
/ APPLICATION NUMBER: PCT/US94/12305
/ FILING DATE: 26-OCT-1994
/ APPLICATION NUMBER: US 08/284,064
/ FILING DATE: 02-AUG-1994
/ APPLICATION NUMBER: US 08/143,312
/ FILING DATE: 26-OCT-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Liebeschuetz, Joe
/ REGISTRATION NUMBER: 37,505
/ REFERENCE/DOCKET NUMBER: 018547-004130US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-576-0200
```

```
/ TELEFAX: 415-576-0300
/ INFORMATION FOR SEQ ID NO: 241:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (oligonucleotide)
/ SEQUENCE DESCRIPTION: SEQ ID NO: 241:
US-09-510-378-241

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 CCTTCTCCAACACTA 1172
Db      |||||:|||
        16 CCTTCTCCAAGAACTA 1

RESULT 489
US-09-817-879-435
/ Sequence 435, Application US/09817879
/ Publication No. US2003017131A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals Inc.
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
/ TITLE OF INVENTION: Hepatitis C Virus Infection
/ FILE REFERENCE: MBH00-801-F
/ CURRENT APPLICATION NUMBER: US/09/817,879
/ CURRENT FILING DATE: 2001-03-26
/ NUMBER OF SEQ ID NOS: 9703
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 435
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: artificial sequence
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION:
/ OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-435

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1079 ATTGCTGGCTCAACGC 1094
Db      |:|:|||:|||
        2 AUUGCUGGCACUACGC 17

RESULT 490
US-09-817-879-632
/ Sequence 632, Application US/09817879
/ Publication No. US2003017131A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals Inc.
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
/ TITLE OF INVENTION: Hepatitis C Virus Infection
/ FILE REFERENCE: MBH00-801-F
/ CURRENT APPLICATION NUMBER: US/09/817,879
/ CURRENT FILING DATE: 2001-03-26
/ NUMBER OF SEQ ID NOS: 9703
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 632
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: artificial sequence
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION:
/ OTHER INFORMATION: oligonucleotide substrate
```

US-09-817-879-632

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1430 TGTGACCATGCTGTT 1445
DB 1 UGUGGAUGAUGCUGU 16

RESULT 491

US-09-817-879-1376
; Sequence 1376, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1376

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 437 AGCGCAGGCTGCTGCT 452
DB 2 AGCGGAGGCGUGUCU 17

RESULT 492

US-09-817-879-1899/c
; Sequence 1899, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1899

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1186 GTGGTGCTCCATGACT 1201
DB 16 GTGGTCGTCGAGACT 1

RESULT 493

US-09-817-879-1905/c
; Sequence 1905, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1905

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 265 TCCTTGACGAGGACCC 280
DB 17 TCCTTGACGAGGACCC 2

RESULT 494

US-09-817-879-2027/c
; Sequence 2027, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2027
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2027

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 387 TGGCTGTGTGCTTC 402
DB 16 TGGCTGTGTGCTTC 1

RESULT 495

US-09-817-879-2132
; Sequence 2132, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2132
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2132

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 260
Db 2 UGACCCCAACACCCCC 17

RESULT 496

US-09-817-879-2423/c
; Sequence 2423, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2423
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2423

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 260
Db 17 TGACCCCAACACCCCC 2

RESULT 497

US-09-817-879-2650
; Sequence 2650, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2650
; LENGTH: 17
; TYPE: RNA

; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2650

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 265 TCCTTGAGCAGGACCC 280
Db 2 UCCUUGAGCAGGUCCC 17

RESULT 498

US-09-817-879-3179/c
; Sequence 3179, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3179
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3179

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 437 AGGCGAGGCTGCTGCT 452
Db 17 AGCGAGGCTGCTGCT 2

RESULT 499

US-09-817-879-4120/c
; Sequence 4120, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4120
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4120

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1079 ATTGCTGGCTACGC 1094
|||||
Db 17 ATTGCTGGCTACGC 2

RESULT 500
US-10-060-830-138
; Sequence 138, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 138
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-138

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1292 CAGTGGCCCATGAGTA 1307
|||||
Db 1 CAGTGGACCATGAGGA 16

RESULT 501
US-10-060-830-301/c
; Sequence 301, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

QY 1062 CTCTTTGCTTCCTC 1077
|||||
Db 17 CTCTTTTCTCTCTC 2

RESULT 502
US-10-060-830-302/c
; Sequence 302, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 302
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-302

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTCTTTGCTTCCTC 1077
|||||
Db 16 CTCTTTTCTCTCTC 1

RESULT 503
US-10-060-756A-581/c
; Sequence 581, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN

FILE REFERENCE: PB0177
CURRENT APPLICATION NUMBER: US/10/060,756A
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/327,898
PRIOR FILING DATE: 2001-10-09
NUMBER OF SEQ ID NOS: 4804
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 581
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-756A-581

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1310 TCTTCTGCTTGTCTCT 1325
Db 17 TCTTCTCTTGTCTCT 2

RESULT 504
US-10-060-756A-582/c
Sequence 582, Application US/10060756A
Publication No. US20030046717A1
GENERAL INFORMATION:
APPLICANT: Zhang, Jian
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
FILE REFERENCE: PB0177
CURRENT APPLICATION NUMBER: US/10/060,756A
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/327,898
PRIOR FILING DATE: 2001-10-09
NUMBER OF SEQ ID NOS: 4804
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 582
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-756A-582

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1310 TCTTCTGCTTGTCTCT 1325
Db 16 TCTTCTCTTGTCTCT 1

RESULT 505
US-10-060-895A-193/c
Sequence 193, Application US/10060895A
Publication No. US20030104403A1
GENERAL INFORMATION:
APPLICANT: Zhang, Jian
TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTTRANSFERASE 10
FILE REFERENCE: PB0158
CURRENT APPLICATION NUMBER: US/10/060,895A
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/315,984
PRIOR FILING DATE: 2001-08-30
NUMBER OF SEQ ID NOS: 1682
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 193
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-895A-193

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CTCGCGCGCTGCCGG 646
Db 17 CTCGCGCGCGCGCGG 2

RESULT 506
US-10-060-895A-194/c
Sequence 194, Application US/10060895A
Publication No. US20030104403A1
GENERAL INFORMATION:
APPLICANT: Zhang, Jian
TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTTRANSFERASE 10
FILE REFERENCE: PB0158
CURRENT APPLICATION NUMBER: US/10/060,895A
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/315,984
PRIOR FILING DATE: 2001-08-30
NUMBER OF SEQ ID NOS: 1682
SOFTWARE: Acomica Sequence Listing Engine
SEQ ID NO 194
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-895A-194

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CTCGCGCGTGGCGG 646
||| ||||| |||||
DB 16 CTCGCGCGGCGCGG 1

RESULT 507
US-10-060-895A-220/c
Sequence 220, Application US/10060895A
Publication No. US20030104403A1
GENERAL INFORMATION:
APPLICANT: Zhang, Jian
APPLICANT: Gu, Yizhong
TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE 10
FILE REFERENCE: PB0158
CURRENT APPLICATION NUMBER: US/10/060,895A
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/315,984
PRIOR FILING DATE: 2001-08-30
NUMBER OF SEQ ID NOS: 1682
SOFTWARE: Acomica Sequence Listing Engine
SEQ ID NO 220
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-895A-220

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 627 GGTGCTCTGGCGGCTG 642
||| ||||| |||||
DB 17 GCGGCTGTGCGGCTG 2

RESULT 508
US-10-060-895A-222/c
Sequence 222, Application US/10060895A
Publication No. US20030104403A1
GENERAL INFORMATION:
APPLICANT: Zhang, Jian
APPLICANT: Gu, Yizhong
APPLICANT: Nguyen, Cung-Tuong
TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE 10
FILE REFERENCE: PB0158
CURRENT APPLICATION NUMBER: US/10/060,895A
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/315,984
PRIOR FILING DATE: 2001-08-30
NUMBER OF SEQ ID NOS: 1682
SOFTWARE: Acomica Sequence Listing Engine
SEQ ID NO 222
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-895A-222

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 626 TGTGCTCTGGCGGCT 641
||| ||||| |||||
DB 16 TGGCGCTGTGCGGCT 1

RESULT 509
US-10-060-998-116/c
Sequence 116, Application US/10060998
Publication No. US20030104330A1
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
FILE REFERENCE: PB01108
CURRENT APPLICATION NUMBER: US/10/060,998
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/343,331
PRIOR FILING DATE: 2001-12-21
NUMBER OF SEQ ID NOS: 3056

; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 116
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-116

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1350 GATACCTTCCTTC 1365
Db 17 GATACCTCATCCTTTC 2

RESULT 510
US-10-163-552-640
; Sequence 640, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE OF INVENTION: HPR2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 640
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-640

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1181 GGAACGTGTGTGTC 1196
Db 2 GGAACGUGCUGUCA 17

RESULT 511
US-10-163-552-653
; Sequence 653, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE OF INVENTION: HPR2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 653
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-653

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 447 GCTGCTGGAGTTTGAC 462
Db 1 GCUGCUGGACAUUGAC 16

RESULT 512
US-10-081-646-3
; Sequence 3, Application US/10081646
; Publication No. US20030108884A1
; GENERAL INFORMATION:
; APPLICANT: Rice, Robert No. US20030108884A1man
; APPLICANT: Harrison, Bruce Thomas
; TITLE OF INVENTION: A Method and Kit
; FILE REFERENCE: 37921-2
; CURRENT APPLICATION NUMBER: US/10/081,646
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: US 60/316,308
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Primer
US-10-081-646-3

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 555 ACGCTGTGGCCAGG 570
Db 2 AAGCTGTGGCAAGG 17

RESULT 513
US-10-156-306-67
; Sequence 67, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 67
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-67

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 3.9e+02;
Matches 6; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1066 TTTCCTTCCTCCATT 1081
Db 2 UUUGCCUCCUGGAU 17

RESULT 514
US-10-156-306-68
; Sequence 68, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 68
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-68

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 3.9e+02;
Matches 6; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1066 TTGGCTTCTCCATT 1081
:::||||:|:|:
Db 1 UUUGCCUUCUGGAU 16

RESULT 515
US-10-156-306-2875
; Sequence 2875, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2875

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAG 307
:|:|||||
Db 1 CUGCAGAAACAGAAAG 16

RESULT 516
US-10-156-306-4977
; Sequence 4977, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4977
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4977

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 334 GATGAGCTGATGAGG 349
||:|||||

Db 2 GAUAGCUGAAGGAGG 17

RESULT 517
US-10-156-306-6984
; Sequence 6984, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6984
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6984

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 334 GATGAGCTGATGAGG 349
||:|||||
Db 1 GAUAGCUGAAGGAGG 16

RESULT 518
US-10-238-700-51/c
; Sequence 51, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 51
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-51

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 365 CCATCTACCACATGTT 380
||| |||||
Db 16 CCAACTACCACAGTT 1

RESULT 519
US-10-238-700-2939/c
; Sequence 2939, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: 400/057 (MBH01-1158-A)

; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2939

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGCTGCTGGATCGG 198
Db 16 GAAGCTGCTGGGTCGG 1

RESULT 520
US-10-238-700-3394/c
; Sequence 3394, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3394
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3394

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 893 CCAAGAACTTGCCCA 908
Db 16 CCTAGAACTTGCCCA 1

RESULT 521
US-10-061-201-108/c
; Sequence 108, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 108
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-108

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 242 CTCGCCCCCACCCTCC 257
Db 17 CTCAGCCCCCTCCTCC 2

RESULT 522
US-10-061-201-109/c
; Sequence 109, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 109
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-109

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 242 CTCGCCCCCACCCTCC 257


```
; Sequence 1523, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 1523
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1523

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1238 TCCTTGTCGCCGGC 1253
Db 1 TCCTTGTCACCGGC 16

RESULT 527
US-10-340-192-84/c
; Sequence 84, Application US/10340192
; Publication No. US20030170700A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Shang, Jin
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: SECRETED AND CELL SURFACE POLYPEPTIDES AFFECTED BY CHOLESTEROL AN
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 37-000610US
; CURRENT APPLICATION NUMBER: US/10/340,192
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 88
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 84
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-340-192-84

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 747 GGCTGTGCTGGGATC 762
Db 16 GGCAGTCCCTGGGATC 1

; Sequence 1523, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 1523
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1523

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1238 TCCTTGTCGCCGGC 1253
Db 1 TCCTTGTCACCGGC 16

RESULT 527
US-10-340-192-84/c
; Sequence 84, Application US/10340192
; Publication No. US20030170700A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Shang, Jin
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: SECRETED AND CELL SURFACE POLYPEPTIDES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; FILE REFERENCE: 37-000310US
; CURRENT APPLICATION NUMBER: US/10/339,793
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 443
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-793-11

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1373 GAATCTTGAATTCAT 1388
Db 17 GAATATTGAATTCAT 2

RESULT 530
US-10-230-006-721
; Sequence 721, Application US/10230006
```

```
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 721
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-721

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      637 GCGCTGCGGTCACG 652
Db      2 GCGCUGCUGGCUCCG 17
      |||||:||||:||||
      |||||:||||:||||

RESULT 531
US-10-230-006-814
; Sequence 814, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-814

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      348 GGTGCAGCATTCGCG 363
Db      1 GGUGCAGCAAUUCCAC 16
      |||||:||||:||||
      |||||:||||:||||

RESULT 532
US-10-230-006-2184
; Sequence 2184, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
```

```
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2184
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2184

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      637 GCGCTGCGGTCACG 652
Db      1 GCGCUGCUGGCUCCG 16
      |||||:||||:||||
      |||||:||||:||||

RESULT 533
US-10-230-006-2221/c
; Sequence 2221, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2221
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2221

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      21 TCTGCTTCTGCAGG 36
Db      16 TCTGCTTCTGCAGG 1
      |||||:||||:||||
      |||||:||||:||||

RESULT 534
US-10-430-882-214/c
; Sequence 214, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
; FILE REFERENCE: MBHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
```

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 214
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-214

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 907 CAGGCCCTGGGATGTG 922
||||| ||| |||||
Db 17 CAGGCCCTGGGATGTG 2

RESULT 535

US-10-430-882-216/c
; Sequence 216, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 216
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-216

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 613 GCGGCCCCAGCCGTGG 628
||||| ||| |||||
Db 17 GCGGCCCCAGCCGTGG 2

RESULT 536

US-10-430-882-217/c
; Sequence 217, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05

; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 217
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-217

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 613 GCGGCCCCAGCCGTGG 628
||||| ||| |||||
Db 16 GCGGCCCCAGCCGTGG 1

RESULT 537

US-10-430-882-376/c
; Sequence 376, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-376

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 198 GGCCATGCGGAGGCT 213
||||| ||| |||||
Db 17 GCGGTTGCGGAGGCT 2

RESULT 538

US-10-430-882-619/c
; Sequence 619, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt

```
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH800-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 619
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-619

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 904 GCCACGCCCTGGAT 919
      |||||
Db 16 GCCACGCCGTGGAAT 1

RESULT 539
US-10-430-882-699/c
; Sequence 699, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH800-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 699
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-699

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 198 GCCCATGCCGAGGCT 213
      |||||
Db 16 GCGTTGCGGAGGCT 1
```

```
RESULT 540
US-10-430-882-825/c
; Sequence 825, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH800-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-825

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 CTGCCGGTCCACGTGG 655
      |||||
Db 16 CTGCCGGTCCAGATGG 1

RESULT 541
US-10-430-882-946/c
; Sequence 946, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH800-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 946
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-430-882-946

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 CTGCCGGTCCACGTGG 655

Db 17 CTGCCGGTCCAGATGG 2

RESULT 542

US-10-209-787-1419/c
; Sequence 1419, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1419

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACGCCGCCG 1414

Db 17 CCGCGCCCGGCCCG 2

RESULT 543

US-10-209-787-1420
; Sequence 1420, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989

; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1420

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACGCCGCCG 1414

Db 1 CCGCGCCCGGCCCG 16

RESULT 544

US-10-297-068-212
; Sequence 212, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 1314OP1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 212
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-212

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 157 CTGGAGCAAGCGCAGG 172

Db 1 CTGGAGCAGCGCCGG 16

RESULT 545

US-10-297-068-725/c
; Sequence 725, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 1314OP1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 725
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-725

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1122 CAGGATGTTCTACCG 1137
|||||
Db 17 CAGGATGTTCTCTGG 2

RESULT 546
US-10-300-683-95
; Sequence 95, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
; APPLICANT: Dunlop, Charles L.M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
; FILE REFERENCE: CHARDUN.010A
; CURRENT APPLICATION NUMBER: US/10/300,683
; PRIOR FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/333,531
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 554
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-95

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1157 CCTTCTCCAACACTA 1172
|||||
Db 2 CCTTCTCCAAGACTA 17

RESULT 547
US-10-300-683-256
; Sequence 256, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
; APPLICANT: Dunlop, Charles L.M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
; FILE REFERENCE: CHARDUN.010A
; CURRENT APPLICATION NUMBER: US/10/300,683
; PRIOR FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/333,531
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 554
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 256
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-256

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1157 CCTTCTCCAACACTA 1172
|||||
Db 2 CCTTCTCCAAGACTA 17

RESULT 548
US-10-300-683-446
; Sequence 446, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
; APPLICANT: Dunlop, Charles L.M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
; FILE REFERENCE: CHARDUN.010A
; CURRENT APPLICATION NUMBER: US/10/300,683
; PRIOR FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/333,531
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 554
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 446
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-446

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1157 CCTTCTCCAACACTA 1172
|||||
Db 2 CCTTCTCCAAGACTA 17

RESULT 549
US-10-393-075-1/c
; Sequence 1, Application US/10393075
; Publication No. US2004002094A1
; GENERAL INFORMATION:
; APPLICANT: LAROSSA A. ROBERT
; APPLICANT: WEI, YAN
; TITLE OF INVENTION: A METHOD FOR HIGH-DENSITY MICROARRAY MEDIATED GENE
; FILE REFERENCE: BC1025 US NA
; CURRENT APPLICATION NUMBER: US/10/393,075
; CURRENT FILING DATE: 2003-03-20
; PRIOR APPLICATION NUMBER: US/09/686,383
; PRIOR FILING DATE: 2000-10-11
; PRIOR APPLICATION NUMBER: 60/159,898
; PRIOR FILING DATE: 1999-10-15
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Microsoft Office 97
; SEQ ID NO 1
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:PRIMER
US-10-393-075-1

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1015 TCTATCTCGTCGCA 1030
|||||
Db 16 TCTGTCTCGTGCCA 1

```
RESULT 550
US-10-261-185-1419/c
; Sequence 1419, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1419

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACCGGCCGG 1414
Db 17 CCGCGCCCGGCCGG 2

RESULT 551
US-10-261-185-1420
; Sequence 1420, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1420

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACCGGCCGG 1414
Db 17 CCGCGCCCGGCCGG 2
```

```
Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACCGGCCGG 1414
Db 1 CCGCGCCCGGCCGG 16

RESULT 552
US-10-608-062-20/c
; Sequence 20, Application US/10608062
; Publication No. US20040014122A1
; GENERAL INFORMATION:
; APPLICANT: BREEN, ALEXANDER
; APPLICANT: SINGLETON, FREDDIE
; TITLE OF INVENTION: DETECTION OF SPORE FORMING BACTERIA
; FILE REFERENCE: B1113P
; CURRENT APPLICATION NUMBER: US/10/608,062
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US 09/356,677
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: US 09/085,359
; PRIOR FILING DATE: 1998-05-27
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Bacillus stearothermophilus
US-10-608-062-20

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 CGGCTTGGCGTTGTGT 692
Db 17 CGGCTTGGCGTTGTGT 2

RESULT 553
US-10-342-902-118
; Sequence 118, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH900-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 118
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-118

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TCTTCATGCTGCTGCT 1058
Db      2 UCUGCAUCCUGCUGCU 17

RESULT 554
US-10-342-902-808
; Sequence 808, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 808
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-808

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TCTTCATGCTGCTGCT 1058
Db      1 UCUGCAUCCUGCUGCU 16

RESULT 555
US-10-342-902-2178/c
; Sequence 2178, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
```

```
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 2178
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2178

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 527 CCACCTGTTGGCGCC 542
Db      17 CCACCTGTTGGCGTC 2

RESULT 556
US-10-675-685-755
; Sequence 755, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 755
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-755

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTTTCTGCCCA 834
Db      2 CTTCTCTGTCGCCCA 17

RESULT 557
US-10-675-685-756
; Sequence 756, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
```


Db 2 UCUCUCCAAUACUCC 17

RESULT 562

US-10-138-674-4769
; Sequence 4769, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4769
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4769

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 803 TCTCCAGCTACCTCTA 818

Db 1 UCUCCAACUACCUCAA 16

RESULT 563

US-10-138-674-4785
; Sequence 4785, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4785

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 ATGGAGCCAGGGGGG 16

Db 2 AUGGAGCCAGGCCUGG 17

RESULT 564

US-10-138-674-4786
; Sequence 4786, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4786

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 ATGGAGCCAGGGGGG 16

Db 1 AUGGAGCCAGGCCUGG 16

RESULT 565

US-10-138-674-5375/c
; Sequence 5375, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5375
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5375

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1416 ATGGAGCTGCTGATG 1431

Db 17 AGGGAATGTGCTGATG 2

RESULT 566

US-10-138-674-6490
; Sequence 6490, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03


```

US-10-138-674-7644
; Sequence 7644, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7644
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7644

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      801 TTCTCCAGCTACCTC 816
       : : : : : : : : : :
Db      1 UCUCUCCACUACCUC 16

RESULT 572
US-10-138-674-7715/c
; Sequence 7715, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7715
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7715

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1540 ACACCTCGATCTTGGT 1555
       : : : : : : : : : :
Db      17 ACACGTGCTCTTGGT 2

RESULT 573
US-10-138-674-8432/c
; Sequence 8432, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

```

```

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8432
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8432

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1010 TGCTCTCTATCTGCA 1025
       : : : : : : : : : :
Db      16 TGCTCTGCACTCTGCA 1

RESULT 574
US-10-138-674-8463
; Sequence 8463, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8463
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8463

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      29 TGCAGAGGACAGAAGG 44
       : : : : : : : : : :
Db      1 UGCAGGGGACAGAGGG 16

RESULT 575
US-10-138-674-8716/c
; Sequence 8716, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8716
; LENGTH: 17

```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8716

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1021 CTGCATGCCACGTTGC 1036
Db 16 CTGCATGTCAGGTGC 1

RESULT 576

US-10-287-949A-2567
; Sequence 2567, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2567
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2567

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 3.9e+02;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1354 CTCCTCCTGTGTCATTG 1369
Db 1 CUCCUCUUGUCAUUG 16

RESULT 577

US-10-287-949A-4768
; Sequence 4768, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4768
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4768

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 801 TTTCTCCAGCTACCTC 816

Db 2 UCUCUCCAAACUACCUC 17

RESULT 578

US-10-287-949A-4769
; Sequence 4769, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4769
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4769

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 803 TCTCCAGCTACCTCTA 818
Db 1 UCUCUCCAAACUACCUC 16

RESULT 579

US-10-287-949A-4785
; Sequence 4785, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4785

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 ATGGAGCCAGCGCGG 16
Db 2 AUGGAGCCAGCGCCUGG 17

RESULT 580

US-10-287-949A-4786
; Sequence 4786, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:


```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4786
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4786

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 ATGGAGCCAGCGCGGG 16
Db 1 AUGGAGCCAGCCUGG 16

RESULT 581
US-10-287-949A-5375/c
; Sequence 5375, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5375
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5375

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1416 ATGGAACGTGCTGATG 1431
Db 17 AGGGAATGTCTGATG 2

RESULT 582
US-10-287-949A-6490
; Sequence 6490, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
```

```
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6490
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6490

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 GCAGGACCCAGGAGCC 287
Db 2 GCAGGACCAAGGAGAC 17

RESULT 583
US-10-287-949A-6491
; Sequence 6491, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6491
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6491

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 GCAGGACCCAGGAGCC 287
Db 1 GCAGGACCAAGGAGAC 16

RESULT 584
US-10-287-949A-6686
; Sequence 6686, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6686
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6686
```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels

Qy 283 GAGCCATCCCTGGGA 298
||| : ||| : |||
Db 1 GAGCAAUCCCTUGGA 16

RESULT 585

```

US-10-287-949A-7443/C
; Sequence 7443, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7644
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7644

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 801 TTTCTCCAGCTACCTC 816
:
Dd 1 UCUCUCCAACUACCUC 16

RESULT 588

```

US-10-287-949A-7715/c
; Sequence 7715, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MSHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7715
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-287-949A-7715

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1540 ACACCTCGATCTTGGT 1555
Dy 17 ACACGTCGCTCTTGGT 2

RESULT 589

US-101-287-949A-8432/c
; Sequence 8432, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

```

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+00;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      283 GAGCCATCCCTGGGGA 298
      |||||:||||:||||
Db      1 GAGCAAUCCUGUGGA 16

RESULT 585
US-10-287-949A-7443/c
; Sequence 7443, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

```

REFERENCE: MEH00-070-N (400/043)
CURRENT APPLICATION NUMBER: US/10/287.949A

```

; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0

```

```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7443

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels

QY 512 TGCCCATGTTTCTGTC 527
|||
Db 17 TTCCCATGTTGCTGTC 2

RESULT 586

```

US-10-287-949A-7558/c
; Sequence 7558, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pwco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7558
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7558

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels

Qy 1370 GAGGAATGTTGAAC TT 1385
db 17 GAGGTATGCTGAAC TT 2

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8432
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8432

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1010 TGCTCTCTATCTCTGCA 1025
Db 16 TGCTCTGTCATCTGCA 1

RESULT 590
US-10-287-949A-8463
; Sequence 8463, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Favco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8463
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8463

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 29 TGCAGGAGGACAGAGG 44
Db 1 UGCAGGGGACAGAGGG 16

RESULT 591
US-10-287-949A-8716/c
; Sequence 8716, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Favco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8716
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8716

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1021 CTGCATGCCACGTTGC 1036
Db 16 CTGCATGTCAGGTTGC 1

RESULT 592
US-10-712-672-305
; Sequence 305, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 305
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-305

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 730 TACTCTCTCTGAGAG 745
Db 1 UACUCCAUCCUGAAG 16

RESULT 593
US-10-712-672-344
; Sequence 344, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 344
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-344

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 352 CAGCATTTCCGCACCA 367
      |||| :||| |||||
      |||| :||| |||||
Db 2 CAGCUUUUCUACCA 17

RESULT 594
US-10-712-672-345
; Sequence 345, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH000-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 345
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-345

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 352 CAGCATTTCCGCACCA 367
      |||| :||| |||||
      |||| :||| |||||
Db 1 CAGCUUUUCUACCA 16

RESULT 595
US-10-712-672-446
; Sequence 446, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH000-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
; ORGANISM: Homo sapiens
US-10-712-672-446

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1486 TGGTACGCACGGCGG 1501
      :||| ||||| |||||
      :||| ||||| |||||
Db 1 UGGACGCACGGCGG 16

RESULT 596
US-10-712-672-1251/c
; Sequence 1251, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH000-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1251
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1251

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1479 CCAGGAGTGGTACGCA 1494
      ||||| ||||| |||||
      ||||| ||||| |||||
Db 17 CCAGGAGTGGCACGTA 2

RESULT 597
US-10-712-672-1252/c
; Sequence 1252, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH000-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1252
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-712-672-1252

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1479 CCAGGAGTGTACGCA 1494
|||:|||||
Db 16 CCAGGAGTGCACGTA 1

RESULT 598

US-10-712-672-1413
; Sequence 1413, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1413
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1413

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1063 TTCTTTGCTTCCTCC 1078
:|::|||:
Db 1 UCCUUGCCUCCACC 16

RESULT 599

US-10-712-672-1928
; Sequence 1928, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1928
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1928

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 186 GCTGCTGGATCGGCC 201
||:|||||
Db 1 GCUGCUGGAACGGGC 16

RESULT 600

US-10-712-672-2191
; Sequence 2191, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2191
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2191

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 590 CGGGCTGGCTGTGC 605
|||||:
Db 2 CGGGCCUGCCUGCGC 17

RESULT 601

US-10-712-672-2477
; Sequence 2477, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2477

```
Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 445 CTGCTGCTGGAGTTTG 460
Db 1 CUGCUCCUGCGGUUG 16

RESULT 602
US-10-712-672-2669/c
; Sequence 2669, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2669
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2669

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 592 GGCCTGGCTGTGGCC 607
Db 17 GGCCTGGCTGTGGCC 2

RESULT 603
US-10-376-770-72/c
; Sequence 72, Application US/10376770
; Publication No. US20040106102A1
; GENERAL INFORMATION:
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
; FILE REFERENCE: 543312000320
; CURRENT APPLICATION NUMBER: US/10/376,770
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; NUMBER OF SEQ ID NOS: 262
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 72
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 6, 7
; OTHER INFORMATION: These nucleotides may be absent
US-10-376-770-72
```

```
Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 926 TCTATGCTGCTTCAT 941
Db 17 TCCATGCTGTTCAT 2

RESULT 604
US-10-669-841-118
; Sequence 118, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 118
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-118

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TCTTCATGCTGCTGCT 1058
Db 2 UCUGCAUCCUGUGCU 17

RESULT 605
US-10-669-841-808
; Sequence 808, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
```



```
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4620
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-4620
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 387 TGGCCTGTGTGCTTC 402
Db 16 TGGCCTGTGTGCTTC 1

RESULT 613
US-10-669-841-4725
; Sequence 4725, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
```

```
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4725
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-4725

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 260
Db 2 UGACCCACCACCCCC 17

RESULT 614
US-10-669-841-5016/c
; Sequence 5016, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
```

```
/ PRIOR FILING DATE: 2000-07-07
/ PRIOR APPLICATION NUMBER: US 09/504,321
/ PRIOR FILING DATE: 2000-02-15
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 16207
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 5016
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION:
/ OTHER INFORMATION: oligonucleotide substrate
/ US-10-669-841-5016

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 260
Db 17 TGACCCCCACACCCCC 2

RESULT 615
US-10-669-841-5243
/ Sequence 5243, Application US/10669841
/ Publication No. US20040127446A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Lawrence, Blatt
/ APPLICANT: Dennis, Macejak
/ APPLICANT: James, McSwiggen
/ APPLICANT: David, Morrissey
/ APPLICANT: Pamela, Pavco
/ APPLICANT: Patrice, Lee
/ APPLICANT: Kenneth, Draper
/ APPLICANT: Elisabeth, Roberts
/ TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
/ FILE REFERENCE: 400/042US (MHB02-249-E)
/ CURRENT FILING DATE: 2003-09-23
/ PRIOR APPLICATION NUMBER: US/10/669,841
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: US 60/296,876
/ PRIOR FILING DATE: 2001-06-08
/ PRIOR APPLICATION NUMBER: US 60/335,059
/ PRIOR FILING DATE: 2001-10-24
/ PRIOR APPLICATION NUMBER: US 60/337,055
/ PRIOR FILING DATE: 2001-12-05
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 09/817,879
/ PRIOR FILING DATE: 2001-03-26
/ PRIOR APPLICATION NUMBER: US 09/740,332
/ PRIOR FILING DATE: 2000-12-18
/ PRIOR APPLICATION NUMBER: US 09/611,931
/ PRIOR FILING DATE: 2000-07-07
/ PRIOR APPLICATION NUMBER: US 09/504,321
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 16207
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 5243
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
```

```
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION:
/ OTHER INFORMATION: oligonucleotide substrate
/ US-10-669-841-5243

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 265 TCCTTGAGCAGGACCC 280
Db 2 UCCUGAGCAGGUGCC 17

RESULT 616
US-10-669-841-5772/c
/ Sequence 5772, Application US/10669841
/ Publication No. US20040127446A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Lawrence, Blatt
/ APPLICANT: Dennis, Macejak
/ APPLICANT: James, McSwiggen
/ APPLICANT: David, Morrissey
/ APPLICANT: Pamela, Pavco
/ APPLICANT: Patrice, Lee
/ APPLICANT: Kenneth, Draper
/ APPLICANT: Elisabeth, Roberts
/ TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
/ FILE REFERENCE: 400/042US (MHB02-249-E)
/ CURRENT FILING DATE: 2003-09-23
/ PRIOR APPLICATION NUMBER: US/10/669,841
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: US 60/296,876
/ PRIOR FILING DATE: 2001-06-08
/ PRIOR APPLICATION NUMBER: US 60/335,059
/ PRIOR FILING DATE: 2001-10-24
/ PRIOR APPLICATION NUMBER: US 60/337,055
/ PRIOR FILING DATE: 2001-12-05
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 09/817,879
/ PRIOR FILING DATE: 2001-03-26
/ PRIOR APPLICATION NUMBER: US 09/740,332
/ PRIOR FILING DATE: 2000-12-18
/ PRIOR APPLICATION NUMBER: US 09/611,931
/ PRIOR FILING DATE: 2000-07-07
/ PRIOR APPLICATION NUMBER: US 09/504,321
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 16207
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 5772
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION:
/ OTHER INFORMATION: oligonucleotide substrate
/ US-10-669-841-5772

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
```


;; PRIOR APPLICATION NUMBER: PCT/US01/00665.
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Acomica Sequence Listing Engine
;; SEQ ID NO 434
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-434

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTGG 193
DB 17 CTGAGAGATCTGCTGG 2

RESULT 620
US-10-723-361-435/c
;; Sequence 435, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; CURRENT FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Acomica Sequence Listing Engine
;; SEQ ID NO 435
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-435

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGCTGG 193
DB 17 CTGAGAGATCTGCTGG 2

Db 16 CTGAGAGATCTGCTGG 1

RESULT 621

US-10-723-361-930
;; Sequence 930, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; CURRENT FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Acomica Sequence Listing Engine
;; SEQ ID NO 930
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-930

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGAGAGGGCTGCTGC 754
DB 2 CTGAAGAGGCTGAGC 17

RESULT 622

US-10-723-361-932
;; Sequence 932, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; CURRENT FILING DATE: 2003-11-26

QY 739 CTGAGAGGGCTGCTGC 754
DB 2 CTGAAGAGGCTGAGC 17

;
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 932
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-932

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 740 TGAGAGAGGCTGTGCC 755
Db 1 TGAAGAGGCTGAGCC 16

RESULT 623
US-10-723-361-1200/c
; Sequence 1200, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

;
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1200
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1200

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTTCCTTCT 1076
Db 17 TCTTCTTTCCTTCTACT 2

RESULT 624
US-10-723-361-1201/c
; Sequence 1201, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1201
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1201

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTTCCTTCT 1076
Db 16 TCTTCTTTCCTTCTACT 1

RESULT 625

US-10-723-361-1416
; Sequence 1416, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1416

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 138 GGCTGTGAAGGCACAA 153

Db 2 GGCTGTGAAGGCACAA 17

RESULT 626

US-10-723-361-1417
; Sequence 1417, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1417
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1417

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 138 GGCTGTGAAGGCACAA 153

Db 1 GGCTGTGAAGGCACAA 16

RESULT 627

US-10-723-361-1535
; Sequence 1535, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1535

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGTGTGACCTG 509
||| ||||| |||||
Db 2 TGGGCTGTGGCCCTG 17

RESULT 628

US-10-723-361-1537
; Sequence 1537, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1537

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1537

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 495 GCGCTGTGACCTGG 510
||| ||||| |||||
Db 1 GCGGCTGTGGCCCTG 16

RESULT 629

US-10-723-361-1646/c
; Sequence 1646, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1646

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1646

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1063 TTCTTTGCCCTCCTCC 1078
| ||||| |||||
Db 17 TCCTTTGCCCTCCTCC 2

RESULT 630

US-10-723-361-1648/c

; Sequence 1648, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1648

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2

QY 1062 CTTCTTGGCTTCCCTC 1077
DB 16 CTCCTTGGCTTCCCTC 1

RESULT 631
US-10-723-361-2289/c
; Sequence 2289, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2289
; LENGTH: 17

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2289

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2

QY 560 TGTGGGCCAGGGGCAC 575
DB 17 TGTGGGCATGGACAC 2

RESULT 632
US-10-723-361-2301/c
; Sequence 2301, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2301
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2301

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2

QY 549 GGCCCTACGGCTGTGG 564
DB 16 GGCACTGGGCTGTGG 1

RESULT 633
US-10-723-361-6545/c
; Sequence 6545, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

```
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ PRIOR FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 6545
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-723-361-6545

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      250 CCACCTCCCCAGGTT 265
Db      17 CCACCTGCCCGAGCT 2

RESULT 634
US-10-723-361-6546/c
/ Sequence 6546, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ PRIOR FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 6545
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-723-361-6545
```

```
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 6546
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-723-361-6546

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      250 CCACCTCCCCAGGTT 265
Db      16 CCACCTGCCCGAGCT 1

RESULT 635
US-10-723-361-6915/c
/ Sequence 6915, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 6915
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-723-361-6915
```


Query Match	0.8%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%	Pred. No. 3.9e+02;		

[illegible]

GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

```
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8351

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 727 AGCTACTCTCTCTGTA 742
Db 17 AGCTCTCTCTGCTGA 2

RESULT 642
US-10-723-361-8352/c
; Sequence 8352, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8351

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 727 AGCTACTCTCTCTGTA 742
Db 17 AGCTCTCTCTGCTGA 2

RESULT 642
US-10-723-361-8352/c
; Sequence 8352, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8351

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 CAGTTTCTCCAGCTAC 813
```

```

;
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8928

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CAGCTGTACTGCCAG 1482
DB 2 CAGCCAGTACTACCAG 17

RESULT 646
US-10-723-361-8929
; Sequence 8929, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723.361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8362

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 CAGTTTCTCCAGTAC 813
DB 16 CACTTCTCCAGTCC 1

RESULT 645
US-10-723-361-8928
; Sequence 8928, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723.361
```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8929
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8929

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CAGCGTGTACTGCAG 1482
||||| ||||| |||||
Db 1 CAGCCAGTACTACCAG 16

RESULT 647

US-10-723-361-9020/c
; Sequence 9020, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9020
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9020

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1153 ACGTCCTCTCCAAC 1168
||||| ||||| |||||
Db 17 ACGTACTTCCAGCT 2

RESULT 648

US-10-723-361-9021/c
; Sequence 9021, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9021
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9021

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1153 ACGTCCTCTCCAAC 1168
||||| ||||| |||||
Db 16 ACGTACTTCCAGCT 1

RESULT 649

US-10-723-361-9023/c
; Sequence 9023, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25

```
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9023
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9023
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1150 TCACGCTCTCTCCCA 1165
Db 17 TCACGCTCTCTCTCCCA 2
```

```
RESULT 650
US-10-723-361-9025/c
; Sequence 9025, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9025
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9025
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1149 CTCACGCTCTCTCC 1164
Db 16 CTCACGCTCTCTCC 1
```

```
RESULT 651
US-10-723-361-9829/c
; Sequence 9829, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9829
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9829
```

```
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1138 GACTGTGGAACCTCA 1153
Db 17 GGCTGTGGAACCTCA 2
```

```
RESULT 652
US-10-723-361-9830/c
```


; Sequence 9830, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9830
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9830

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1138 GACTGGTGAACCTCAA 1153
DB 16 GCGTGGTGAACCTCAA 1

RESULT 653
US-10-723-361-10672/c
; Sequence 10672, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10672
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10672

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 GTAGCCATGCTGGGTG 1276
DB 17 GTGGCCATGCTGGGTG 2

RESULT 654
US-10-741-601-26208/c
; Sequence 26208, Application US/10741601
; Publication No. US20040166519A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: STENOSIS, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001500
; CURRENT APPLICATION NUMBER: US/10/741,601
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 26415
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26208
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-601-26208

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1545 TCGATCTTGGTCTGTC 1560
DB 16 TCAATCTTGGGCTGC 1

RESULT 655
US-10-741-601-26250/c
; Sequence 26250, Application US/10741601
; Publication No. US20040166519A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: STENOSIS, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001500
; CURRENT APPLICATION NUMBER: US/10/741,601
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 26415

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26250
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-601-26250

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1545 TCGATCTTGTCCTGC 1560
||| ||||| |||||
Db 16 TCAATCTTGGCCTGC 1

RESULT 656

US-10-681-074-1419/c
; Sequence 1419, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1419
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-1419

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACCGGCCGG 1414
||| ||||| |||||
Db 17 CCGCGCCCGGCCGG 2

RESULT 657

US-10-681-074-1420
; Sequence 1420, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1420
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-1420

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 CAGCGCACCGGCCGG 1414
||| ||||| |||||
Db 1 CCGCGCCCGGCCGG 16

RESULT 658

US-10-699-557-23
; Sequence 23, Application US/10699557
; Publication No. US20040180357A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Enrico Maria Surace
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF HIF-1 ALPHA
; FILE REFERENCE: 43826-0002US1
; CURRENT APPLICATION NUMBER: US/10/699,557
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: US 60/423,262
; PRIOR FILING DATE: 2002-11-01
; NUMBER OF SEQ ID NOS: 299
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-699-557-23

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1525 TTCTGGGGCTGGTGA 1540
||| ||||| |||||
Db 2 TTCTGGATGCTGGTGA 17

Search completed: November 8, 2004, 12:52:52
Job time : 12 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 12:50:41 ; Search time 4 Seconds
(without alignments)
3.740 Million cell updates/sec

Title: US-09-918-026A-3

Perfect score: 1569

Sequence: 1 atggagcagggggcccg.....cttggtctgcatacctag 1569

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 276 seqs, 4768 residues

Total number of hits satisfying chosen parameters: 552

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 279 summaries

Database : rni3.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	1.5	25	1	US-09-165-042-25
2	23	1.5	23	1	US-09-165-042-30
3	21.8	1.4	29	1	US-09-304-232-370
C 4	21.2	1.4	27	1	US-08-985-162-1097
C 5	21.2	1.4	27	1	US-09-401-063-1097
6	20	1.3	20	1	US-09-328-857A-7
C 7	20	1.3	20	1	US-09-328-857A-8
8	19.6	1.2	26	1	US-09-328-857A-6
9	18.2	1.2	24	1	US-09-328-857A-5
C 10	16.8	1.1	21	1	US-08-068-945A-10
C 11	16.8	1.1	21	1	US-08-442-806-10
C 12	16.8	1.1	21	1	5455029-28
13	16.4	1.0	20	1	US-09-422-978-11729
14	16.2	1.0	21	1	US-09-657-472-700
15	16.2	1.0	21	1	US-09-492-361-37
16	15.8	1.0	20	1	US-08-837-201C-100
17	15.8	1.0	20	1	US-09-364-416-100
C 18	15.8	1.0	20	1	US-09-397-992A-10
C 19	15.8	1.0	20	1	US-09-971-843-10
C 20	15.4	1.0	17	1	US-08-584-040-3812
C 21	15.4	1.0	17	1	US-09-474-432B-350
C 22	15.4	1.0	17	1	US-09-371-772B-1579
C 23	15.4	1.0	17	1	US-09-371-772B-6203
C 24	15.4	1.0	17	1	US-09-476-387-349
C 25	15.4	1.0	17	1	US-09-866-108A-6625
26	15.4	1.0	17	1	US-09-866-108A-6626
27	15.4	1.0	17	1	US-09-866-108A-6627
28	15.4	1.0	17	1	US-09-866-108A-6628
C 29	15.4	1.0	20	1	US-08-469-260A-99
C 30	15.4	1.0	20	1	US-09-920-668-17
C 31	15.4	1.0	20	1	US-08-488-446-99
C 32	15.4	1.0	20	1	US-08-467-344A-99
C 33	15.4	1.0	20	1	US-09-689-012-9

C 34	15.4	1.0	20	1	US-08-424-550B-99	Sequence 99, Appl
C 35	15.2	1.0	20	1	US-08-142-845-20	Sequence 20, Appl
C 36	15.2	1.0	20	1	US-08-483-746A-21	Sequence 21, Appl
C 37	15.2	1.0	20	1	US-09-490-692-109	Sequence 109, Appl
C 38	15.2	1.0	20	1	US-08-861-774E-1	Sequence 1, Appl
C 39	15.2	1.0	20	1	US-09-657-346A-22	Sequence 22, Appl
C 40	15.2	1.0	20	1	US-09-705-267A-142	Sequence 142, Appl
C 41	15.2	1.0	20	1	US-09-198-452A-4685	Sequence 4685, Appl
C 42	15	1.0	17	1	US-08-985-162-144	Sequence 144, Appl
C 43	15	1.0	17	1	US-09-401-063-144	Sequence 144, Appl
C 44	15	1.0	20	1	US-09-487-368A-174	Sequence 174, Appl
C 45	15	1.0	20	1	US-09-676-610B-171	Sequence 171, Appl
C 46	15	1.0	20	1	US-09-629-644A-174	Sequence 174, Appl
C 47	14.8	0.9	18	1	US-08-475-742-7	Sequence 7, Appl
48	14.8	0.9	18	1	US-08-261-293-7	Sequence 7, Appl
C 49	14.8	0.9	19	1	US-09-230-652-111	Sequence 111, Appl
C 50	14.8	0.9	19	1	US-09-696-791-2314	Sequence 2314, Appl
C 51	14.4	0.9	17	1	US-08-584-040-3811	Sequence 3811, Appl
C 52	14.4	0.9	17	1	US-09-371-772B-1578	Sequence 1578, Appl
C 53	14.4	0.9	17	1	US-09-371-772B-6124	Sequence 6124, Appl
C 54	14.4	0.9	17	1	US-09-866-108A-2293	Sequence 2293, Appl
C 55	14.4	0.9	17	1	US-09-866-108A-2294	Sequence 2294, Appl
C 56	14.4	0.9	17	1	US-09-866-108A-2296	Sequence 2296, Appl
C 57	14.4	0.9	17	1	US-09-866-108A-2297	Sequence 2297, Appl
C 58	14.4	0.9	17	1	US-09-866-108A-6624	Sequence 6624, Appl
C 59	14.4	0.9	17	1	US-09-866-108A-6629	Sequence 6629, Appl
C 60	14.4	0.9	18	1	US-08-584-040-4455	Sequence 4455, Appl
C 61	14.4	0.9	18	1	US-09-167-109-42	Sequence 42, Appl
C 62	14.4	0.9	18	1	US-09-167-109-129	Sequence 129, Appl
C 63	14.4	0.9	18	1	US-09-371-772B-2168	Sequence 2168, Appl
C 64	14.4	0.9	19	1	US-09-696-791-3563	Sequence 3563, Appl
C 65	14	0.9	17	1	US-09-371-772B-6125	Sequence 6125, Appl
C 66	14	0.9	17	1	US-09-371-772B-6126	Sequence 6126, Appl
C 67	14	0.9	18	1	US-08-411-796-283	Sequence 283, Appl
C 68	14	0.9	18	1	US-08-471-039-283	Sequence 283, Appl
C 69	14	0.9	18	1	US-08-559-390-283	Sequence 283, Appl
C 70	14	0.9	18	1	PCT-US93-11198-293	Sequence 283, Appl
C 71	13.8	0.9	17	1	US-08-050-743-25	Sequence 25, Appl
C 72	13.8	0.9	17	1	US-08-474-542A-174	Sequence 174, Appl
C 73	13.8	0.9	17	1	US-08-181-271A-97	Sequence 97, Appl
C 74	13.8	0.9	17	1	US-08-457-648-174	Sequence 174, Appl
C 75	13.8	0.9	17	1	US-08-449-315-97	Sequence 97, Appl
C 76	13.8	0.9	17	1	US-08-444-803-97	Sequence 97, Appl
C 77	13.8	0.9	17	1	US-08-449-043-97	Sequence 97, Appl
C 78	13.8	0.9	17	1	US-08-452-055-25	Sequence 25, Appl
C 79	13.8	0.9	17	1	US-08-456-265A-97	Sequence 97, Appl
C 80	13.8	0.9	17	1	US-08-455-416-97	Sequence 97, Appl
C 81	13.8	0.9	17	1	US-08-455-244-97	Sequence 97, Appl
C 82	13.8	0.9	17	1	US-08-454-878-97	Sequence 97, Appl
C 83	13.8	0.9	17	1	US-08-457-364-97	Sequence 97, Appl
C 84	13.8	0.9	17	1	US-08-456-262-97	Sequence 97, Appl
C 85	13.8	0.9	17	1	US-08-456-240-97	Sequence 97, Appl
C 86	13.8	0.9	17	1	US-08-455-736-97	Sequence 97, Appl
C 87	13.8	0.9	17	1	US-08-971-217-97	Sequence 97, Appl
C 88	13.8	0.9	17	1	US-09-350-600-97	Sequence 97, Appl
C 89	13.8	0.9	17	1	US-08-584-040-4178	Sequence 4178, Appl
C 90	13.8	0.9	17	1	US-08-584-040-7674	Sequence 7674, Appl
C 91	13.8	0.9	17	1	US-09-920-663-4	Sequence 4, Appl
C 92	13.8	0.9	17	1	US-09-474-432B-769	Sequence 769, Appl
C 93	13.8	0.9	17	1	US-09-371-772B-1945	Sequence 1945, Appl
C 94	13.8	0.9	17	1	US-09-371-772B-3459	Sequence 3459, Appl
C 95	13.8	0.9	17	1	US-09-476-387-768	Sequence 768, Appl
C 96	13.8	0.9	17	1	US-09-906-234-97	Sequence 97, Appl
C 97	13.8	0.9	17	1	US-09-827-998-760	Sequence 760, Appl
C 98	13.8	0.9	17	1	US-09-827-998-761	Sequence 761, Appl
C 99	13.8	0.9	17	1	US-09-866-108A-931	Sequence 931, Appl
C 100	13.8	0.9	17	1	US-09-866-108A-1536	Sequence 1536, Appl
C 101	13.8	0.9	17	1	US-09-866-108A-1647	Sequence 1647, Appl
C 102	13.8	0.9	17	1	US-09-866-108A-2290	Sequence 2290, Appl
C 103	13.8	0.9	17	1	US-09-866-108A-2291	Sequence 2291, Appl
C 104	13.8	0.9	17	1	US-09-866-108A-2292	Sequence 2292, Appl
C 105	13.8	0.9	17	1	US-09-866-108A-2295	Sequence 2295, Appl
C 106	13.8	0.9	17	1	US-09-866-108A-2298	Sequence 2298, Appl

c 107	13.8	0.9	17	1	US-09-866-108A-2299	Sequence 2299, Ap	180	12.8	0.8	17	1	US-09-371-772B-4768	Sequence 4768, Ap
c 108	13.8	0.9	17	1	US-09-866-108A-2300	Sequence 2300, Ap	181	12.8	0.8	17	1	US-09-371-772B-4769	Sequence 4769, Ap
c 109	13.8	0.9	17	1	US-09-866-108A-6916	Sequence 6916, Ap	182	12.8	0.8	17	1	US-09-371-772B-4785	Sequence 4785, Ap
c 110	13.8	0.9	17	1	US-09-866-108A-9024	Sequence 9024, Ap	183	12.8	0.8	17	1	US-09-371-772B-4786	Sequence 4786, Ap
c 111	13.8	0.9	17	1	US-09-866-108A-10673	Sequence 10673, A	c 184	12.8	0.8	17	1	US-09-371-772B-5375	Sequence 5375, Ap
c 112	13.8	0.9	17	1	US-09-866-108A-10674	Sequence 10674, A	185	12.8	0.8	17	1	US-09-371-772B-6490	Sequence 6490, Ap
c 113	13.8	0.9	17	1	PCT-US91-01750-12	Sequence 12, Appl	186	12.8	0.8	17	1	US-09-371-772B-6491	Sequence 6491, Ap
c 114	13.8	0.9	17	1	5177307-2	Patent No. 5177307	187	12.8	0.8	17	1	US-09-371-772B-6686	Sequence 6686, Ap
c 115	13.8	0.9	17	1	US-08-805-918-34	Sequence 34, Appl	c 188	12.8	0.8	17	1	US-09-686-383-1	Sequence 1, Appl
c 116	13.8	0.9	18	1	US-08-805-918-35	Sequence 35, Appl	189	12.8	0.8	17	1	US-09-476-387-447	Sequence 447, App
c 117	13.8	0.9	18	1	US-08-811-028-22	Sequence 22, Appl	190	12.8	0.8	17	1	US-09-827-998-755	Sequence 755, App
c 118	13.8	0.9	18	1	US-08-811-028-23	Sequence 23, Appl	191	12.8	0.8	17	1	US-09-827-998-756	Sequence 756, App
c 119	13.8	0.9	18	1	US-08-978-458-5	Sequence 5, Appl	192	12.8	0.8	17	1	US-09-827-998-759	Sequence 759, App
c 120	13.8	0.9	18	1	US-09-161-443-18	Sequence 18, Appl	193	12.8	0.8	17	1	US-09-827-998-762	Sequence 762, App
c 121	13.8	0.9	18	1	US-09-161-443-19	Sequence 19, Appl	c 194	12.8	0.8	17	1	US-09-866-108A-434	Sequence 434, App
c 122	13.8	0.9	18	1	US-09-792-594-5	Sequence 5, Appl	c 195	12.8	0.8	17	1	US-09-866-108A-435	Sequence 435, App
c 123	13.8	0.9	18	1	US-09-806-254-1	Sequence 1, Appl	196	12.8	0.8	17	1	US-09-866-108A-930	Sequence 930, App
c 124	13.8	0.9	18	1	US-09-920-760-10	Sequence 10, Appl	197	12.8	0.8	17	1	US-09-866-108A-932	Sequence 932, App
c 125	13.8	0.9	18	1	US-09-422-978-7807	Sequence 7807, Ap	c 198	12.8	0.8	17	1	US-09-866-108A-1200	Sequence 1200, Ap
c 126	13.8	0.9	18	1	US-09-422-978-11445	Sequence 11445, A	c 199	12.8	0.8	17	1	US-09-866-108A-1201	Sequence 1201, Ap
c 127	13.8	0.9	20	1	US-09-689-012-9	Sequence 9, Appl	200	12.8	0.8	17	1	US-09-866-108A-1416	Sequence 1416, Ap
c 128	13.4	0.9	15	1	US-08-363-240A-534	Sequence 534, App	201	12.8	0.8	17	1	US-09-866-108A-1417	Sequence 1417, Ap
c 129	13.4	0.9	16	1	US-09-371-772B-5661	Sequence 5661, Ap	202	12.8	0.8	17	1	US-09-866-108A-1535	Sequence 1535, Ap
c 130	13.4	0.9	16	1	US-09-479-005A-53	Sequence 53, Appl	203	12.8	0.8	17	1	US-09-866-108A-1537	Sequence 1537, Ap
c 131	13.4	0.9	17	1	US-08-985-162-370	Sequence 370, App	c 204	12.8	0.8	17	1	US-09-866-108A-1646	Sequence 1646, Ap
c 132	13.4	0.9	17	1	US-08-584-040-2404	Sequence 2404, Ap	c 205	12.8	0.8	17	1	US-09-866-108A-1648	Sequence 1648, Ap
c 133	13.4	0.9	17	1	US-08-584-040-4361	Sequence 4361, Ap	c 206	12.8	0.8	17	1	US-09-866-108A-2289	Sequence 2289, Ap
c 134	13.4	0.9	17	1	US-08-584-040-4362	Sequence 4362, Ap	c 207	12.8	0.8	17	1	US-09-866-108A-2301	Sequence 2301, Ap
c 135	13.4	0.9	17	1	US-09-371-772B-949	Sequence 949, App	c 208	12.8	0.8	17	1	US-09-866-108A-6545	Sequence 6545, Ap
c 136	13.4	0.9	17	1	US-09-371-772B-2128	Sequence 2128, Ap	c 209	12.8	0.8	17	1	US-09-866-108A-6546	Sequence 6546, Ap
c 137	13.4	0.9	17	1	US-09-371-772B-2129	Sequence 2129, Ap	c 210	12.8	0.8	17	1	US-09-866-108A-6915	Sequence 6915, Ap
c 138	13.4	0.9	17	1	US-09-371-772B-4663	Sequence 4663, Ap	c 211	12.8	0.8	17	1	US-09-866-108A-6917	Sequence 6917, Ap
c 139	13.4	0.9	17	1	US-09-371-772B-5311	Sequence 5311, Ap	c 212	12.8	0.8	17	1	US-09-866-108A-7706	Sequence 7706, Ap
c 140	13.4	0.9	17	1	US-09-401-063-370	Sequence 370, App	213	12.8	0.8	17	1	US-09-866-108A-7707	Sequence 7707, Ap
c 141	13.4	0.9	17	1	US-09-866-108A-6623	Sequence 6623, Ap	c 214	12.8	0.8	17	1	US-09-866-108A-8327	Sequence 8327, Ap
c 142	13.4	0.9	17	1	US-09-866-108A-6630	Sequence 6630, Ap	c 215	12.8	0.8	17	1	US-09-866-108A-8328	Sequence 8328, Ap
c 143	13.4	0.9	17	1	US-09-866-108A-10675	Sequence 10675, A	c 216	12.8	0.8	17	1	US-09-866-108A-8351	Sequence 8351, Ap
c 144	13.4	0.9	17	1	US-09-866-108A-10676	Sequence 10676, A	c 217	12.8	0.8	17	1	US-09-866-108A-8352	Sequence 8352, Ap
c 145	13.4	0.9	17	1	US-09-404-912-100	Sequence 100, App	c 218	12.8	0.8	17	1	US-09-866-108A-8361	Sequence 8361, Ap
c 146	13.4	0.9	20	1	US-09-490-692-109	Sequence 109, App	c 219	12.8	0.8	17	1	US-09-866-108A-8362	Sequence 8362, Ap
c 147	13.2	0.8	17	1	US-08-685-558A-17	Sequence 17, Appl	c 220	12.8	0.8	17	1	US-09-866-108A-8928	Sequence 8928, Ap
c 148	13.2	0.8	17	1	US-09-765-449-17	Sequence 17, Appl	c 221	12.8	0.8	17	1	US-09-866-108A-8929	Sequence 8929, Ap
c 149	13	0.8	17	1	US-08-758-306-53	Sequence 53, Appl	c 222	12.8	0.8	17	1	US-09-866-108A-9020	Sequence 9020, Ap
c 150	13	0.8	17	1	US-08-584-040-3741	Sequence 3741, Ap	c 223	12.8	0.8	17	1	US-09-866-108A-9021	Sequence 9021, Ap
c 151	13	0.8	17	1	US-09-474-432B-457	Sequence 457, App	c 224	12.8	0.8	17	1	US-09-866-108A-9023	Sequence 9023, Ap
c 152	13	0.8	17	1	US-09-535-012A-17	Sequence 17, Appl	c 225	12.8	0.8	17	1	US-09-866-108A-9025	Sequence 9025, Ap
c 153	13	0.8	17	1	US-09-371-772B-1508	Sequence 1508, Ap	c 226	12.8	0.8	17	1	US-09-866-108A-9829	Sequence 9829, Ap
c 154	13	0.8	17	1	US-09-476-387-456	Sequence 456, App	c 227	12.8	0.8	17	1	US-09-866-108A-9830	Sequence 9830, Ap
c 155	13	0.8	29	1	US-09-304-232-370	Sequence 370, App	c 228	12.8	0.8	17	1	US-09-866-108A-10672	Sequence 10672, A
c 156	12.8	0.8	16	1	US-09-527-030G-88	Sequence 88, Appl	229	12.8	0.8	17	1	5496924-10	Patent No. 5496924
c 157	12.8	0.8	16	1	US-09-060-299-439	Sequence 439, App	c 230	12.4	0.8	14	1	US-08-985-162-1812	Sequence 1812, Ap
c 158	12.8	0.8	16	1	US-09-402-923A-439	Sequence 439, App	c 231	12.4	0.8	14	1	US-09-504-132-11	Sequence 11, Appl
c 159	12.8	0.8	17	1	US-08-379-081B-284	Sequence 284, App	c 232	12.4	0.8	14	1	US-09-401-063-1812	Sequence 1812, Ap
c 160	12.8	0.8	17	1	US-08-390-850-455	Sequence 455, App	c 233	12.4	0.8	14	1	US-09-874-601-115	Sequence 115, App
c 161	12.8	0.8	17	1	US-08-379-078-284	Sequence 284, App	c 234	12.4	0.8	15	1	US-08-182-968A-139	Sequence 139, App
c 162	12.8	0.8	17	1	US-08-462-89A-35	Sequence 35, Appl	c 235	12.4	0.8	15	1	US-08-774-306A-139	Sequence 139, App
c 163	12.8	0.8	17	1	US-08-435-634-455	Sequence 455, App	c 236	12.4	0.8	15	1	US-08-585-684B-855	Sequence 855, App
c 164	12.8	0.8	17	1	US-08-206-185-35	Sequence 35, Appl	c 237	12.4	0.8	15	1	US-08-585-684B-1398	Sequence 1398, Ap
c 165	12.8	0.8	17	1	US-08-766-677-5	Sequence 5, Appl	c 238	12.4	0.8	15	1	US-08-585-684B-1801	Sequence 1801, Ap
c 166	12.8	0.8	17	1	US-08-292-620A-1675	Sequence 1675, Ap	c 239	12.4	0.8	15	1	US-08-585-684B-1802	Sequence 1802, Ap
c 167	12.8	0.8	17	1	US-08-292-620A-1692	Sequence 1692, Ap	c 240	12.4	0.8	15	1	US-08-585-684B-1803	Sequence 1803, Ap
c 168	12.8	0.8	17	1	US-08-292-620A-1973	Sequence 1973, Ap	c 241	12.4	0.8	15	1	US-08-913-833-60	Sequence 60, Appl
c 169	12.8	0.8	17	1	US-08-843-951-5	Sequence 5, Appl	c 242	12.4	0.8	15	1	US-09-064-156A-139	Sequence 139, App
c 170	12.8	0.8	17	1	US-08-544-381B-241	Sequence 241, App	c 243	12.4	0.8	15	1	US-09-038-073-855	Sequence 855, App
c 171	12.8	0.8	17	1	US-08-945-654-9	Sequence 9, Appl	c 244	12.4	0.8	15	1	US-09-038-073-1398	Sequence 1398, Ap
c 172	12.8	0.8	17	1	US-08-998-099-50	Sequence 50, Appl	c 245	12.4	0.8	15	1	US-09-038-073-1801	Sequence 1801, Ap
c 173	12.8	0.8	17	1	US-09-071-843-1675	Sequence 1675, Ap	c 246	12.4	0.8	15	1	US-09-038-073-1802	Sequence 1802, Ap
c 174	12.8	0.8	17	1	US-09-071-845-1692	Sequence 1692, Ap	c 247	12.4	0.8	15	1	US-09-038-073-1803	Sequence 1803, Ap
c 175	12.8	0.8	17	1	US-09-071-845-1973	Sequence 1973, Ap	c 248	12.4	0.8	15	1	US-09-580-794C-60	Sequence 60, Appl
c 176	12.8	0.8	17	1	US-08-584-040-5681	Sequence 5681, Ap	c 249	12.4	0.8	15	1	US-09-081-646-513	Sequence 513, App
c 177	12.8	0.8	17	1	US-09-270-140A-40	Sequence 40, Appl	c 250	12.4	0.8	15	1	US-09-474-432B-89	Sequence 89, Appl
c 178	12.8	0.8	17	1	US-09-474-432B-448	Sequence 448, App	251	12.4	0.8	15	1	US-09-476-387-89	Sequence 89, Appl
c 179	12.8	0.8	17	1	US-09-371-772B-2567	Sequence 2567, Ap	c 252	12.4	0.8	15	1	US-09-943-983C-60	Sequence 60, Appl

c 253 12.4 0.8 15 1 5312912-5 Patent No. 5312912
c 254 12.4 0.8 15 1 5463025-7 Patent No. 5463025
c 255 12.4 0.8 16 1 US-08-248-357C-11 Sequence 11, Appl
256 12.4 0.8 16 1 US-09-539-191-5 Sequence 5, Appl
257 12.4 0.8 16 1 US-09-371-772B-5660 Sequence 5660, Ap
258 12.4 0.8 16 1 US-09-371-772B-6965 Sequence 6965, Ap
c 259 12.4 0.8 16 1 US-09-479-008A-54 Sequence 54, Appl
260 12 0.8 15 1 US-08-435-350-95 Sequence 95, Appl
261 12 0.8 15 1 US-08-182-968A-66 Sequence 66, Appl
c 262 12 0.8 15 1 US-08-774-306A-66 Sequence 66, Appl
c 263 12 0.8 15 1 US-08-804-227C-15 Sequence 15, Appl
264 12 0.8 15 1 US-08-585-684B-738 Sequence 738, App
265 12 0.8 15 1 US-08-585-684B-739 Sequence 739, App
c 266 12 0.8 15 1 US-08-585-684B-1771 Sequence 1771, Ap
c 267 12 0.8 15 1 US-08-585-684B-1772 Sequence 1772, Ap
c 268 12 0.8 15 1 US-09-064-156A-66 Sequence 66, Appl
269 12 0.8 15 1 US-09-038-073-738 Sequence 738, App
270 12 0.8 15 1 US-09-038-073-739 Sequence 739, App
c 271 12 0.8 15 1 US-09-038-073-1771 Sequence 1771, Ap
c 272 12 0.8 15 1 US-09-038-073-1772 Sequence 1772, Ap
273 12 0.8 15 1 US-09-593-323-6 Sequence 6, Appl
274 12 0.8 15 1 US-09-594-108-6 Sequence 6, Appl
275 12 0.8 15 1 US-09-344-300-6 Sequence 6, Appl
276 12 0.8 15 1 US-09-081-646-397 Sequence 397, App
277 12 0.8 16 1 US-09-593-323-7 Sequence 7, Appl
278 12 0.8 16 1 US-09-594-108-7 Sequence 7, Appl
279 12 0.8 16 1 US-09-344-300-7 Sequence 7, Appl

ALIGNMENTS

RESULT 1
US-09-165-042-25
; Sequence 25, Application US/09165042
; Patent No. 6100077
; GENERAL INFORMATION:
; APPLICANT: Sturley, Stephen L.
; APPLICANT: Oelkers, Peter
; TITLE OF INVENTION: ISOLATION OF A GENE ENCODING DIACYLGLYCEROL
; FILE REFERENCE: 0575/56331
; CURRENT APPLICATION NUMBER: US/09/165,042
; CURRENT FILING DATE: 1998-10-01
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 25
; TYPE: DNA
; ORGANISM: human
US-09-165-042-25

Query Match 1.5%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.6;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1047 CATGCTGCTGCATCTTCTTGC 1070
DB 1 CATGCTGCTGCATCTTCTTGC 24

RESULT 2
US-09-165-042-30
; Sequence 30, Application US/09165042
; Patent No. 6100077
; GENERAL INFORMATION:
; APPLICANT: Sturley, Stephen L.
; APPLICANT: Oelkers, Peter
; TITLE OF INVENTION: ISOLATION OF A GENE ENCODING DIACYLGLYCEROL
; FILE REFERENCE: 0575/56331
; CURRENT APPLICATION NUMBER: US/09/165,042
; CURRENT FILING DATE: 1998-10-01

; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 30
; TYPE: DNA
; ORGANISM: human
US-09-165-042-30
Query Match 1.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1539 GACACTCGATCTTGTCCTGCC 1561
DB 1 GACACTCGATCTTGTCCTGCC 23
RESULT 3
US-09-304-232-370
; Sequence 370, Application US/09304232
; Patent No. 6525185
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian Bing
; APPLICANT: Chakravarti, Aravinda
; APPLICANT: Halushka, Marc Kenneth
; APPLICANT: Case Western Reserve University School of Medicine
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Polymorphisms Associated With
; FILE REFERENCE: 018547-034210US
; CURRENT APPLICATION NUMBER: US/09/304,232
; CURRENT FILING DATE: 1999-05-03
; EARLIER APPLICATION NUMBER: US 60/084,641
; EARLIER FILING DATE: 1998-05-07
; NUMBER OF SEQ ID NOS: 909
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 370
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: CYP11B2EX3 138
US-09-304-232-370

Query Match 1.4%; Score 21.8; DB 1; Length 29;
Best Local Similarity 85.2%; Pred. No. 9.9;
Matches 23; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 889 GTGGCCAGAACTTGGCCAGGCCCTG 915
DB 1 GTGGCCAGGACTTTCAGGCCCTG 27

RESULT 4
US-08-985-162-1097/c
; Sequence 1097, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

```
;
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1097:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; OTHER INFORMATION: The letter "N" stands for the stem
; OTHER INFORMATION: II region of a HH ribozyme.
US-08-985-162-1097
```

```
Query Match 1.4%; Score 21.2; DB 1; Length 27;
Best Local Similarity 85.2%; Pred. No. 11;
Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 302 AGAAAGTTTTCATCATCCGCAAGTCCC 328
Db 27 AGAAAGTTTTCATCATCAGAAATCCC 1
```

```
RESULT 5
US-09-401-063-1097/c
; Sequence 1097, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
```

```
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1097:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; OTHER INFORMATION: The letter "N" stands for the stem
; OTHER INFORMATION: II region of a HH ribozyme.
US-09-401-063-1097
```

```
Query Match 1.4%; Score 21.2; DB 1; Length 27;
Best Local Similarity 85.2%; Pred. No. 11;
Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 302 AGAAAGTTTTCATCATCCGCAAGTCCC 328
Db 27 AGAAAGTTTTCATCATCAGAAATCCC 1
```

```
RESULT 6
US-09-328-857A-7
; Sequence 7, Application US/09328857A
; Patent No. 6579974
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: No. 6579974ak, Sabine
; APPLICANT: Erickson, Sandra
; TITLE OF INVENTION: No. 6579974el Acyl CoA:Cholesterol Acyl
; TITLE OF INVENTION: Transferase (ACAT-2)
; FILE REFERENCE: 6510-104US1
; CURRENT APPLICATION NUMBER: US/09/328,857A
; CURRENT FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-328-857A-7
```

```
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1331 TCTTCTATCCCGTCATGCTG 1350
Db 1 TCTTCTATCCCGTCATGCTG 20
```

```
RESULT 7
US-09-328-857A-8/c
; Sequence 8, Application US/09328857A
; Patent No. 6579974
; GENERAL INFORMATION:
```

APPLICANT: Cases, Sylvaine
APPLICANT: Farese, Robert
APPLICANT: Erickson, Sandra
TITLE OF INVENTION: No. 6579974el Acyl CoA:Cholesterol Acyl
FILE REFERENCE: 6510-104US1
CURRENT APPLICATION NUMBER: US/09/328,857A
PRIOR FILING DATE: 1999-06-08
CURRENT FILING DATE: 1998-06-23
NUMBER OF SEQ ID NOS: 8
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 8
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: primer
US-09-328-857A-8

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1418 GGAACGCTGCTGATGTGGACC 1437
DB 20 GGAACGCTGCTGATGTGGACC 1

RESULT 8
US-09-328-857A-6
Sequence 6, Application US/09328857A
Patent No. 6579974
GENERAL INFORMATION:
APPLICANT: Cases, Sylvaine
APPLICANT: Farese, Robert
APPLICANT: Erickson, Sandra
TITLE OF INVENTION: No. 6579974el Acyl CoA:Cholesterol Acyl
FILE REFERENCE: 6510-104US1
CURRENT APPLICATION NUMBER: US/09/328,857A
PRIOR FILING DATE: 1999-06-08
CURRENT FILING DATE: 1998-06-23
NUMBER OF SEQ ID NOS: 8
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 6
LENGTH: 26
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: primer
US-09-328-857A-6

Query Match 1.2%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 20;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1253 CCGAGGGGTAGCCATGCTGGGTGTG 1278
DB 1 CTCGGGGGTGGCCATGCTGGGAGTG 26

RESULT 9
US-09-328-857A-5
Sequence 5, Application US/09328857A
Patent No. 6579974
GENERAL INFORMATION:
APPLICANT: Cases, Sylvaine
APPLICANT: Farese, Robert
APPLICANT: Erickson, Sandra
TITLE OF INVENTION: No. 6579974el Acyl CoA:Cholesterol Acyl
FILE REFERENCE: 6510-104US1
CURRENT APPLICATION NUMBER: US/09/328,857A
PRIOR FILING DATE: 1999-06-08
CURRENT FILING DATE: 1998-06-23
NUMBER OF SEQ ID NOS: 8
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 5
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: primer
US-09-328-857A-5

Query Match 1.2%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 30;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 749 CTGTGCTGGATCCTTCGTGCC 771
DB 2 CTGTGCTGGATCCTTCGTGTC 24

RESULT 10
US-08-068-945A-10/c
Sequence 10, Application US/08068945A
Patent No. 5616483
GENERAL INFORMATION:
APPLICANT: Bjursell, Gunnar
APPLICANT: Carlsson, Peter
APPLICANT: Emerback, Sven
APPLICANT: Hansson, Lennart
APPLICANT: Lidberg, Ulf
APPLICANT: Nilsson, Jeanette
APPLICANT: Tornell, Jan
TITLE OF INVENTION: New DNA Sequences
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESS:
ADDRESSEE: White & Case
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: United States
ZIP: 10036-2787
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/068,945A
FILING DATE: 27-MAY-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9201809-2
FILING DATE: 11-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9201826-6
FILING DATE: 12-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9202088-2
FILING DATE: 03-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9300902-5
FILING DATE: 19-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Sterner, Richard J.
REGISTRATION NUMBER: 35,372
REFERENCE/DOCKET NUMBER: 1103326-052

TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)819-8783
; TELEFAX: (212)354-8113
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-068-945A-10

Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1050 GCTGCTCATCTCTTTG 1069
| | | | | | | | | | | | | | | | | | | | |
Db 21 GCTGCTGCCATCTTCTTGG 2

RESULT 11
US-08-442-806-10/c
; Sequence 10, Application US/08442806
; Patent No. 5718617
; GENERAL INFORMATION:
; APPLICANT: Bjursell, Gunnar
; APPLICANT: Carlsson, Peter
; APPLICANT: Enerback, Sven
; APPLICANT: Hansson, Lennart
; APPLICANT: Lidberg, Ulf
; APPLICANT: Nilsson, Jeanette
; APPLICANT: Tornell, Jan
; TITLE OF INVENTION: Genomic DNA Sequences
; TITLE OF INVENTION: Encoding Human BSSL/CEL
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: White & Case
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: United States
; ZIP: 10036-2787
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/442,806
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9201809-2
; FILING DATE: 11-JUN-1992
; FILING DATE: 27-MAY-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9201809-2
; FILING DATE: 11-JUN-1992
; FILING DATE: 03-JUL-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9201826-6
; FILING DATE: 12-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9202088-2
; FILING DATE: 03-JUL-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9300902-5
; FILING DATE: 19-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Steiner, Richard J.
; REGISTRATION NUMBER: 35,372
; REFERENCE/DOCKET NUMBER: 1103326-052
; TELECOMMUNICATION INFORMATION:

TELEPHONE: (212)819-8783
TELEFAX: (212)354-8113
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-442-806-10

Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1050 GCTGCTCATCTCTTTG 1069
| | | | | | | | | | | | | | | | | | | | |
Db 21 GCTGCTGCCATCTTCTTGG 2

RESULT 12
5455029-28/c
; Patent No. 5455029
; APPLICANT: HARTMAN, JACOB R.; OPPENHEIM, AMOS B.; GORECKI,
; MARIAN; AVIV, HAIM; OREN, RACHEL
; TITLE OF INVENTION: THERAPEUTIC COMPOSITIONS COMPRISING
; A MIXTURE OF HUMAN CUZN SUPEROXIDE DISMUTASE ANALOGS
; NUMBER OF SEQUENCES: 30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/933,500
; FILING DATE: 21-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 449,125
; FILING DATE: 08-DEC-1989
; APPLICATION NUMBER: 202,238
; FILING DATE: 03JUN-1988
; APPLICATION NUMBER: 897,056
; FILING DATE: 14-AUG-1985
; APPLICATION NUMBER: 767,143
; FILING DATE: 19-AUG-1985
; APPLICATION NUMBER: 644,245
; FILING DATE: 27-AUG-1984
; SEQ ID NO: 28:
; LENGTH: 21
5455029-28

Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1342 GTCATGCTGATCTTCTTCT 1361
| | | | | | | | | | | | | | | | | | | | |
Db 20 GCCATCTGATCTTCTTCT 1

RESULT 13
US-09-422-978-11729
; Sequence 11729, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21


```
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11729
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-3894 for SEQ 3864, in compleme
US-09-422-978-11729

Query Match
Best Local Similarity 1.0%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 821 TCCTCTTCTGCCCAACAC 838
DB 3 TCCTCTTCTGCCCAACTC 20

RESULT 14
US-09-657-472-700
; Sequence 700, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 700
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-700

Query Match
Best Local Similarity 1.0%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1220 ATCAGATGGCTGGGGTCC 1240
DB 1 ATCACCATGGCTGGGGTCC 21

RESULT 15
US-09-492-361-37
; Sequence 37, Application US/09492361
; Patent No. 6794161
; GENERAL INFORMATION:
; APPLICANT: JENTSCH, Thomas J.
; TITLE OF INVENTION: NOVEL POTASSIUM CHANNELS AND GENES ENCODING THESE
; FILE REFERENCE: 2815-127P
; CURRENT APPLICATION NUMBER: US/09/492,361
; CURRENT FILING DATE: 2000-01-27
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 21
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-09-492-361-37

Query Match
Best Local Similarity 1.0%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 434 ATGAGGCGAGGCTGCTGCTGG 454
DB 1 ACGTGGGCGAGGCTGTGCTGG 21

RESULT 16
US-08-837-201C-100
; Sequence 100, Application US/08837201C
; Patent No. 5985558
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia, Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; TITLE OF INVENTION: Compositions and Methods for the Modulation of
; TITLE OF INVENTION: Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/837,201C
; FILING DATE: April 14, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-837-201C-100

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTGGCGCTGCCG 645
DB 2 GATGCTCTGGCGCTGCCG 20

RESULT 17
US-09-364-416-100
; Sequence 100, Application US/09364416
```

```
; Patent No. 6312900
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; TITLE OF INVENTION: Compositions and Methods for the Modulation of
; TITLE OF INVENTION: Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/364,416
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/837,201
; FILING DATE: April 14, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-364-416-100
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 627 GGTGCTCTGGCGCTGCCG 645
Db 2 GATGCTCTGGCTCTGCCG 20
```

```
RESULT 18
US-09-397-992A-10/c
; Sequence 10, Application US/09397992A
; Patent No. 6329175
; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell
; APPLICANT: Grant, Francis J.
; APPLICANT: Rixon, Mark W.
; APPLICANT: Kindsvogel, Wayne
; TITLE OF INVENTION: Interferon-epsilon
; FILE REFERENCE: 98-46
; CURRENT APPLICATION NUMBER: US/09/397,992A
; CURRENT FILING DATE: 1999-09-16
; PRIOR APPLICATION NUMBER: 60/101,012
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/118,578
; PRIOR FILING DATE: 1999-02-05
; PRIOR APPLICATION NUMBER: 60/142,766
; PRIOR FILING DATE: 1999-07-08
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 3.0
```

```
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-09-397-992A-10
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 292 CTGGGGAACAGAAAGTTT 310
Db 19 CTGAGGAGCAGAAAGTTT 1
```

```
RESULT 19
US-09-971-843-10/c
; Sequence 10, Application US/09971843
; Patent No. 6544505
; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell C.
; APPLICANT: Grant, Francis J.
; APPLICANT: Rixon, Mark W.
; APPLICANT: Kindsvogel, Wayne
; TITLE OF INVENTION: Interferon-epsilon
; FILE REFERENCE: 98-46D1
; CURRENT APPLICATION NUMBER: US/09/971,843
; CURRENT FILING DATE: 2001-10-04
; PRIOR APPLICATION NUMBER: 60/101,012
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/118,578
; PRIOR FILING DATE: 1999-02-05
; PRIOR APPLICATION NUMBER: 60/142,766
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: 09/397,992
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-09-971-843-10
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 292 CTGGGGAACAGAAAGTTT 310
Db 19 CTGAGGAGCAGAAAGTTT 1
```

```
RESULT 20
US-08-584-040-3812/c
; Sequence 3812, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
```

ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3812:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-3812

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136
Db 17 ATGGACCCGACATGG 1

RESULT 21
US-09-474-432B-350/c
Sequence 350, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Bursin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
FILE REFERENCE: MBH00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 350

LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-350

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 668 AGCTCCCGCCGCTCC 684
Db 17 AGCTCCCGCCGCTCC 1

RESULT 22
US-09-371-772B-1579/c
Sequence 1579, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1579
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-1579

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136
Db 17 ATGGACCCGACATGG 1

RESULT 23
US-09-371-772B-6203/c
Sequence 6203, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6203
LENGTH: 17

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6203

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. NO. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACACATGGA 137
      |||||
Db 17 TGGACCCGACACATGGA 1

RESULT 24
US-09-476-387-349/c
; Sequence 349, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MEHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 349
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-349

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. NO. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 668 AGCTCCCGCGGCTCC 684
      |||||
Db 17 AGCTCCCGCGGCTCC 1

RESULT 25
US-09-866-108A-6625
; Sequence 6625, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. NO. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAGGA 37
      |||||
Db 1 TCTGCGTCTGCATAGGA 17

RESULT 26
US-09-866-108A-6626
; Sequence 6626, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6626
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6626

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 22 CTGCGTCTGCAGAGGAC 38
|||||
Db 1 CTGCGTCTGCATAGGAC 17

RESULT 27
US-09-866-108A-6627
; Sequence 6627, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6627
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6627

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 23 TCGCTCTGCAGAGGACA 39
|||||
Db 1 TCGCTCTGCATAGGACA 17

RESULT 28
US-09-866-108A-6628
; Sequence 6628, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6628
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6628

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCGTCTGCAGAGGACAG 40
|||||
Db 1 GCGTCTGCATAGGACAG 17

RESULT 29
US-08-469-260A-99/c
; Sequence 99, Application US/08469260A
; Patent No. 6451578
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUERHOFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BULJAK
; APPLICANT: ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS

;; TITLE OF INVENTION: REAGENTS AND METHODS FOR THEIR USE

;; NUMBER OF SEQUENCES: 716

;; CORRESPONDENCE ADDRESS:

;; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D

;; STREET: 100 ABBOTT PARK ROAD

;; CITY: ABBOTT PARK

;; STATE: IL

;; COUNTRY: USA

;; ZIP: 60064-3500

;; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk

;; COMPUTER: IBM PC compatible

;; OPERATING SYSTEM: PC-DOS/MS-DOS

;; SOFTWARE: PatentIn Release #1.0, Version #1.25

;; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/08/469,260A

;; FILING DATE:

;; CLASSIFICATION:

;; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US/08/424,550

;; FILING DATE:

;; ATTORNEY/AGENT INFORMATION:

;; NAME: FOREMSKI, PRISCILLA E.

;; REGISTRATION NUMBER: 33,207

;; REFERENCE/DOCKET NUMBER: 5527.PC.01

;; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: 708-937-6365

;; TELEFAX: 708-938-2623

;; INFORMATION FOR SEQ ID NO: 99:

;; SEQUENCE CHARACTERISTICS:

;; LENGTH: 20 base pairs

;; TYPE: nucleic acid

;; STRANDEDNESS: single

;; TOPOLOGY: linear

;; MOLECULE TYPE: DNA (genomic)

US-08-469-260A-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 66;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1476 CTGCCAGGAGTGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 30

US-09-920-668-17/c

;; Sequence 17, Application US/09920668

;; Patent No. 6482644

;; GENERAL INFORMATION:

;; APPLICANT: Lex M. Cowser

;; APPLICANT: Brett P. Monia

;; TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 8 EXPRESSION

;; FILE REFERENCE: RTS-0246

;; CURRENT APPLICATION NUMBER: US/09/920,668

;; CURRENT FILING DATE: 2001-08-01

;; NUMBER OF SEQ ID NOS: 49

;; SEQ ID NO 17

;; LENGTH: 20

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Antisense Oligonucleotide

US-09-920-668-17

Query Match

Best Local Similarity 1.0%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 66;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1184 ACGTGTGTGTCCATGAC 1200

Db 19 ACGTGTGTGTCTATGAC 3

RESULT 31

US-08-488-446-99/c

;; Sequence 99, Application US/08488446

;; Patent No. 6558898

;; GENERAL INFORMATION:

;; APPLICANT: JOHN N. SIMONS

;; APPLICANT: TAMI J. PILOT-MATIAS

;; APPLICANT: GEORGE J. DAWSON

;; APPLICANT: GEORGE G. SCHLAUDER

;; APPLICANT: SURESH M. DESAI

;; APPLICANT: THOMAS P. LEARY

;; APPLICANT: ANTHONY SCOTT MUEHROFF

;; APPLICANT: JAMES C. ERKER

;; APPLICANT: SHERI L. BUIJK

;; APPLICANT: ISA K. MUSHAWAR

;; TITLE OF INVENTION: NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS

;; TITLE OF INVENTION: REAGENTS AND METHODS FOR THEIR USE

;; NUMBER OF SEQUENCES: 716

;; CORRESPONDENCE ADDRESS:

;; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D

;; STREET: 100 ABBOTT PARK ROAD

;; CITY: ABBOTT PARK

;; STATE: IL

;; COUNTRY: USA

;; ZIP: 60064-3500

;; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk

;; COMPUTER: IBM PC compatible

;; OPERATING SYSTEM: PC-DOS/MS-DOS

;; SOFTWARE: PatentIn Release #1.0, Version #1.25

;; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/08/488,446

;; FILING DATE:

;; CLASSIFICATION:

;; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US/08/424,550

;; FILING DATE:

;; ATTORNEY/AGENT INFORMATION:

;; NAME: FOREMSKI, PRISCILLA E.

;; REGISTRATION NUMBER: 33,207

;; REFERENCE/DOCKET NUMBER: 5527.PC.01

;; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: 708-937-6365

;; TELEFAX: 708-938-2623

;; INFORMATION FOR SEQ ID NO: 99:

;; SEQUENCE CHARACTERISTICS:

;; LENGTH: 20 base pairs

;; TYPE: nucleic acid

;; STRANDEDNESS: single

;; TOPOLOGY: linear

;; MOLECULE TYPE: DNA (genomic)

US-08-488-446-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 66;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1476 CTGCCAGGAGTGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 32

US-08-467-344A-99/c

;; Sequence 99, Application US/08467344A

;; Patent No. 6586568

;; GENERAL INFORMATION:

;; APPLICANT: JOHN N. SIMONS

;; APPLICANT: TAMI J. PILOT-MATIAS

;; APPLICANT: GEORGE J. DAWSON

;; APPLICANT: GEORGE G. SCHLAUDER

```
; SURESH M. DESAI
; THOMAS P. LEARY
; ANTHONY SCOTT MUERHOFF
; JAMES C. ERKER
; SHERI L. BUIJK
; ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS
; REAGENTS AND METHODS FOR THEIR USE
;
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,344A
; FILING DATE: 07-Jun-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION NUMBER: 08/424,550
; APPLICATION NUMBER: 08/424,550
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 99:
US-08-467-344A-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1476 CTGCCAGGAGTGGTACG 1492
Db 19 CTGCCAGGAGGAGTACG 3

RESULT 33
US-09-689-012-9/c
; Sequence 9, Application US/09689012
; Patent No. 6670135
; GENERAL INFORMATION:
; APPLICANT: Springs, Melanie K.
; TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
; FILE REFERENCE: 2634-US
; CURRENT APPLICATION NUMBER: US/09/689,012
; CURRENT FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: PCT/US99/09831
; PRIOR FILING DATE: 1999-05-05
; PRIOR APPLICATION NUMBER: US 60/085,497
; PRIOR FILING DATE: 1998-05-14
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PRIMER
US-09-689-012-9

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 563 GGGCCAGGGGACCTGG 579
Db 19 GGTCCAGGGGACCTGG 3

RESULT 34
US-08-424-550B-99/c
; Sequence 99, Application US/08424550B
; Patent No. 6720166
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUERHOFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BUIJK
; APPLICANT: ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS
; REAGENTS AND METHODS FOR THEIR USE
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,550B
; FILING DATE:
; CLASSIFICATION: 435435
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; MOLECULE TYPE: DNA (genomic)
US-08-424-550B-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1476 CTGCCAGGAGTGGTACG 1492
Db 19 CTGCCAGGAGGAGTACG 3
```

```
RESULT 35
US-08-142-845-20/c
; Sequence 21, Application US/08142845
; Patent No. 5496699
; GENERAL INFORMATION:
; APPLICANT: Sorenson, George D.
; TITLE OF INVENTION: Detection of
; TITLE OF INVENTION: Gene Sequences
; TITLE OF INVENTION: In Biological
; TITLE OF INVENTION: Fluids
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lahive & Cockfield
; STREET: 60 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII Text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/142,845
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/874,845
; FILING DATE: 27-APR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: William C. Geary III
; REGISTRATION NUMBER: 31,357
; REFERENCE/DOCKET NUMBER: DCI-037
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-142-845-20

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 361 CGCACCATCTACCACATGTT 380
Db 20 CGCTCCAACTACCACAGTT 1

RESULT 36
US-08-483-746A-21/c
; Sequence 21, Application US/08483746A
; Patent No. 6020124
; GENERAL INFORMATION:
; APPLICANT: George D. Sorenson
; TITLE OF INVENTION: Detection of Gene Sequences in Biological
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,746A
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/142,845
; FILING DATE: 25-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Jean M. Silveri
; REGISTRATION NUMBER: 39,030
; REFERENCE/DOCKET NUMBER: DCI-037CNCP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-483-746A-21

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 361 CGCACCATCTACCACATGTT 380
Db 20 CGCTCCAACTACCACAGTT 1

RESULT 37
US-09-490-692-109/c
; Sequence 109, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTS-0120
; CURRENT APPLICATION NUMBER: US/09/490,692
; CURRENT FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-109

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 TGTGTTCTCGTCTCCGCGAG 1294
Db 20 TGTGTTCTCGCTCTGCAG 1

RESULT 38
US-08-861-774E-1/c
; Sequence 1, Application US/08861774E
; Patent No. 6297007
; GENERAL INFORMATION:
; APPLICANT: Waters, Barbara
; APPLICANT: Miao, Vivian
; APPLICANT: Ho, Yap
; APPLICANT: Tong, Seow
; TITLE OF INVENTION: METHOD FOR ISOLATION OF BIOSYNTHESIS GENES FOR
; TITLE OF INVENTION: BIOACTIVE MOLECULES
```



```
; FILE REFERENCE: 9993-006
; CURRENT APPLICATION NUMBER: US/08/861,774E
; CURRENT FILING DATE: 1997-05-22
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-861-774E-1

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 77.8%; Pred. No. 71;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 635 GCGCGCTGCGGTCCACG 652
      |||||
Db 20 GCGCGCTGCGGTCCACG 652
      |||||

RESULT 39
US-09-657-346A-22/c
; Sequence 22, Application US/09657346A
; Patent No. 6503754
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; TITLE OF INVENTION: ANTISENSE MODULATION OF BH3 INTERACTING DOMAIN DEATH AGONIST
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0135
; CURRENT APPLICATION NUMBER: US/09/657,346A
; CURRENT FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-657-346A-22

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 903 TGCCAGGCGCTGGATGTG 922
      |||||
Db 20 TGCCAGGCGCTGGATGTG 1
      |||||

RESULT 40
US-09-705-267A-142
; Sequence 142, Application US/09705267A
; Patent No. 6551826
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RAIDD EXPRESSION
; FILE REFERENCE: RTS-0211
; CURRENT APPLICATION NUMBER: US/09/705,267A
; CURRENT FILING DATE: 2000-11-01
; NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-705-267A-142
```

```
Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1466 TCAGCCTGTACTGCCAGGAG 1485
      |||||
Db 1 TCAGCCTGTACTGCCAGGAG 20
      |||||

RESULT 41
US-09-198-452A-4685
; Sequence 4685, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffois, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4685
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4685

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 502 GTGACCTGGTGCCCATGTT 521
      |||||
Db 1 GAGACCTGGTGCCCATGTT 20
      |||||

RESULT 42
US-08-985-162-144/c
; Sequence 144, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMOLOGIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
```

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 144:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-144

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CTGATGGAGGTGCAG 354
Db 15 CTGATGGAGGTGCAG 1

RESULT 43
US-09-401-063-144/c
Sequence 144, Application US/09401063
Patent No. 6623962
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/401,063
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/985,162
FILING DATE: 04 December 1997
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 144:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-401-063-144
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CTGATGGAGGTGCAG 354
Db 15 CTGATGGAGGTGCAG 1
RESULT 44
US-09-487-368A-174/c
Sequence 174, Application US/09487368A
Patent No. 6261840
GENERAL INFORMATION:
APPLICANT: Lex M. Cowsett
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
FILE REFERENCE: RTS-0093
CURRENT APPLICATION NUMBER: US/09/487,368A
CURRENT FILING DATE: 2000-01-18
NUMBER OF SEQ ID NOS: 240
SEQ ID NO 174
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-368A-174

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 245 TGCCCCCACCCTCCCC 259
Db 20 TGCCCCCACCCTCCCC 6
RESULT 45
US-09-676-610B-171
Sequence 171, Application US/09676610B
Patent No. 6444465
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
APPLICANT: Susan M. Freier
TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITION OF HER-1 EXPRESSION
FILE REFERENCE: RTS-0138
CURRENT APPLICATION NUMBER: US/09/676,610B
CURRENT FILING DATE: 2000-09-29
NUMBER OF SEQ ID NOS: 182
SEQ ID NO 171
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-676-610B-171

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CTGATGGAGGTGCAG 354
Db 5 CTGATGGAGGTGCAG 19
RESULT 46
US-09-629-644A-174/c
Sequence 174, Application US/09629644A

Patent No. 6602857
GENERAL INFORMATION:
APPLICANT: Lex M. Cowsett
APPLICANT: Jacqueline Wyatt
APPLICANT: Susan M. Freier
APPLICANT: Brett P. Monia
APPLICANT: Madeline M. Butler
APPLICANT: Robert McKay
TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
FILE REFERENCE: ISPH-0478
CURRENT APPLICATION NUMBER: US/09/629,644A
CURRENT FILING DATE: 2000-07-31
PRIOR APPLICATION NUMBER: US 09/487,368
PRIOR FILING DATE: 2000-01-18
NUMBER OF SEQ ID NOS: 242
SEQ ID NO 174
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-644A-174

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCCTCCCC 259
DB 20 TGCCCCCACCCTCCCC 6

RESULT 47
US-08-475-742-7
Sequence 7, Application US/08475742
Patent No. 6121015
GENERAL INFORMATION:
APPLICANT: O'Malley, Karen L.
APPLICANT: Todd, Richard D.
TITLE OF INVENTION: Gene Encoding the Rat Dopamine D4 Receptor
FILE REFERENCE: WU 102 CON DIV
CURRENT APPLICATION NUMBER: US/08/475,742
CURRENT FILING DATE: 1995-06-07
EARLIER APPLICATION NUMBER: US 08/261,293
EARLIER FILING DATE: 1994-06-16
EARLIER APPLICATION NUMBER: US 08/014,013
EARLIER FILING DATE: 1993-01-28
NUMBER OF SEQ ID NOS: 16
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 7
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
OTHER INFORMATION: primer-reverse transcribed using orD4-515 and is
OTHER INFORMATION: complementary to nucleotides 366-383 in SEQ ID NO:
OTHER INFORMATION: 1
PUBLICATION INFORMATION:
TITLE: The rat dopamine D4 receptor: sequence, gene structure
TITLE: and demonstration of expression in the cardiovascular
TITLE: system
JOURNAL: New Biol.
VOLUME: 4
PAGES: 1-9
DATE: 1992
US-08-475-742-7

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCCACCCTGTGTGCG 540

Db 1 CTGTCCACCCTGTGTGCG 18
RESULT 48
US-08-261-293-7
Sequence 7, Application US/08261293
Patent No. 6486310
GENERAL INFORMATION:
APPLICANT: O'Malley, Karen L.
APPLICANT: Todd, Richard D.
TITLE OF INVENTION: Gene Encoding the Rat Dopamine D4
TITLE OF INVENTION: Receptor
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kilpatrick & Cody
STREET: 1100 Peachtree Street, Suite 2800
CITY: Atlanta
STATE: Georgia
COUNTRY: U.S.
ZIP: 30309-4530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/261,293
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/014,013
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: WU 102
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 815-6524
TELEFAX: (404) 815-6555
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..18
OTHER INFORMATION: /note= "Synthetic oligonucleotide
OTHER INFORMATION: primer - reverse transcribed using orD4-515, and
OTHER INFORMATION: is complementary to nucleotides 366 to 383 in
PUBLICATION INFORMATION:
AUTHORS: O'Malley, K. L.
AUTHORS: Harmon, S.
AUTHORS: Tang, L.
AUTHORS: Todd, R. D.
TITLE: The rat dopamine D4 receptor: sequence, gene
TITLE: structure and demonstration of expression in the
TITLE: cardiovascular system.
JOURNAL: New Biol.
VOLUME: 4
PAGES: 1-9
DATE: 1992
RELEVANT RESIDUES IN SEQ ID NO: 7: FROM 1 TO 18
US-08-261-293-7

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCCACCGCTGTTCGCG 540
|||||
Db 1 CTGTCCACGCTGATGCG 18

RESULT 49

US-09-230-652-111
; Sequence 111, Application US/09230652A
; Patent No. 6537775
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserre, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Francoise
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; TITLE OF INVENTION: THERAPEUTIC APPLICATION
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/09/230,652A
; CURRENT FILING DATE: 1999-05-17
; EARLIER APPLICATION NUMBER: FR 96 09733
; EARLIER FILING DATE: 1996-08-01
; EARLIER APPLICATION NUMBER: FR 97 04680
; EARLIER FILING DATE: 1997-04-16
; EARLIER APPLICATION NUMBER: PCT/FR97/01433
; EARLIER FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-230-652-111

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGCTTCGAGCAG 708
|||||
Db 1 GTCCTGCTTCGAGCAG 18

RESULT 50

US-09-696-791-2314/c
; Sequence 2314, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2314
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-696-791-2314

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 110 ACTTGTAATGGACCC 127
|||||

Db 19 ACTTGTAACGAGCC 2

RESULT 51

US-08-584-040-3811/c
; Sequence 3811, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3811:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3811

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 GGACCCGACATGGA 137
|||||
Db 17 GGACCCGACATGGA 2

RESULT 52

US-09-371-772B-1578/c
; Sequence 1578, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1578
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1578

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 GGACCCGACATGGA 137
Db 17 GGACCCGACATGGA 2

RESULT 53
US-09-371-772B-6124
; Sequence 6124, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 6124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6124

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 70;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCCGCGCTCTGT 957
Db 2 CCGGGCCGCGCCUCUG 17

RESULT 54
US-09-866-108A-2293/c
; Sequence 2293, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
```

```
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2293
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2293

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CGGCTGTGGGCCAGGG 571
Db 17 CGGCTGTGGGCCATGG 2

RESULT 55
US-09-866-108A-2294/c
; Sequence 2294, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Acomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 2294
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-2294

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 CCGCTGTGGCGCCAGG 571
||| ||||| |||
Db 16 CCGCTGTGGCGCATGG 1

RESULT 56
US-09-866-108A-2296/c
;; Sequence 2296, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: ACOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Acomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 2296
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-2296

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 553 CTACGGCTGTGGGCCA 568
||| ||||| |||||
Db 17 CTGCGGCTGTGGGCCA 2

RESULT 57
US-09-866-108A-2297/c
;; Sequence 2297, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: ACOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Acomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 2297
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-2297

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 553 CTACGGCTGTGGGCCA 568
||| ||||| |||||
Db 16 CTGCGGCTGTGGGCCA 1

RESULT 58
US-09-866-108A-6624
;; Sequence 6624, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aemica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6624
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6624

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGG 36
Db 2 TCTGCGTCTGCATAGG 17

RESULT 59
US-09-866-108A-6629
Sequence 6629, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aemica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6629
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6629

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 25 CCTCTGCAGGACAG 40
Db 1 CGTCTGCATAGGACAG 16

RESULT 60
US-08-584-040-4455
Sequence 4455, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4455:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-4455

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGGCGGCTCTGTG 958
Db 1 CCGGGCCGCCUCUG 16

RESULT 61

US-09-167-109-42
; Sequence 42, Application US/09167109
; Patent No. 6399297

; GENERAL INFORMATION:

; APPLICANT: Baker, Brenda F.
; APPLICANT: Cowsett, Lex M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Xu, Xiaoxing S.

; TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION

; FILE REFERENCE: ISPH-0321

; CURRENT APPLICATION NUMBER: US/09/167,109

; CURRENT FILING DATE: 1998-10-06

; NUMBER OF SEQ ID NOS: 228

; SEQ ID NO 42

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: antisense sequence

US-09-167-109-42

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1269 GCTGGGTGTGTCCTG 1284
Db 3 GCTGGGTGTGTCCTG 18

RESULT 62

US-09-167-109-129/c
; Sequence 129, Application US/09167109
; Patent No. 6399297

; GENERAL INFORMATION:

; APPLICANT: Baker, Brenda F.
; APPLICANT: Cowsett, Lex M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Xu, Xiaoxing S.

; TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION

; FILE REFERENCE: ISPH-0321

; CURRENT APPLICATION NUMBER: US/09/167,109

; CURRENT FILING DATE: 1998-10-06

; NUMBER OF SEQ ID NOS: 228

; SEQ ID NO 129

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: antisense sequence

US-09-167-109-129

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 621 CGCCCTGGTCTCTGC 636
Db 17 CGCCCTGGTCTCTGC 2

RESULT 63

US-09-371-772B-2168

; Sequence 2168, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; FILE REFERENCE: MBH00,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 2168

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-371-772B-2168

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGGCGGCTCTGTG 958
Db 1 CCGGGCCGCCUCUG 16

RESULT 64

US-09-696-791-3563/c

; Sequence 3563, Application US/09696791

; Patent No. 6770633

; GENERAL INFORMATION:

; APPLICANT: Robbins, Joan M.

; APPLICANT: Tritz, Richard

; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE

; FILE REFERENCE: 480124.407

; CURRENT APPLICATION NUMBER: US/09/696,791

; CURRENT FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 4523

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3563

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; OTHER INFORMATION: Cdc25 hs ribozyme binding site

US-09-696-791-3563

Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 893 CCAAGAACTTCCCA 908
Db 16 CCAAGAAATTTGCCCA 1

RESULT 65


```
US-09-371-772B-6125
; Sequence 6125, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH900.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6125
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6125
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 82;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCCGCTCTGTG 958
DB 2 GGGCCGCCUCUG 15

RESULT 66
US-09-371-772B-6126
; Sequence 6126, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH900.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6126
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6126
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 82;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 945 GGGCCGCTCTGTG 958
DB 1 GGGCCGCCUCUG 14

RESULT 67
US-08-411-796-283
; Sequence 283, Application US/08411796
; Patent No. 5677149
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Mair H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: McKearn, John P.
; APPLICANT: Olins, Peter O.
; APPLICANT: Paik, Kuman
; APPLICANT: Polazzi, Joseph O.
; APPLICANT: Thomas, John W.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,796
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/981044
; FILING DATE: 24-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/11198
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bennett, Dennis A.
; REGISTRATION NUMBER: 34,547
; REFERENCE/DOCKET NUMBER: C2713/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708)470-6501
; TELEFAX: (708)470-6881
; INFORMATION FOR SEQ ID NO: 283:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-08-411-796-283
Query Match 0.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 ATCTTGGTCTGCTGCC 1561
DB 1 ATCTTGGTCTGCTGCC 14

RESULT 68
US-08-471-039-283
; Sequence 283, Application US/08471039
; Patent No. 6017523
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Mair H.
```

APPLICANT: Easton, Alan M.
APPLICANT: Klein, Barbara K.
APPLICANT: McKearn, John P.
APPLICANT: Olins, Peter O.
APPLICANT: Paik, Kuman
APPLICANT: Polazzi, Joseph O.
APPLICANT: Thomas, John W.
TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
STREET: P. O. Box 5110
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60680
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,039
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/981,044
FILING DATE: 24-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/11198
FILING DATE: 22-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Bennett, Dennis A.
REGISTRATION NUMBER: 34,547
REFERENCE/DOCKET NUMBER: C2713/5
TELEPHONE: (708)470-6501
TELEFAX: (708)470-6881
INFORMATION FOR SEQ ID NO: 283:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-08-471-039-283
Query Match 0.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1548 ATCTTGGTCTGCC 1561
Db 1 ATCTTGGTCTGCC 14
RESULT 69
US-08-559-390-283
Sequence 283, Application US/08559390
Patent No. 6479261
GENERAL INFORMATION:
APPLICANT: Abrams, Mark A.
APPLICANT: Bauer, S. C.
APPLICANT: Braford-Goldberg, Sarah R.
APPLICANT: Caparon, Mair H.
APPLICANT: Easton, Alan M.
APPLICANT: Klein, Barbara K.
APPLICANT: McKearn, John P.
APPLICANT: Olins, Peter O.
APPLICANT: Paik, Kuman
APPLICANT: Thomas, John W.
TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
STREET: P. O. Box 5110

TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
STREET: P. O. Box 5110
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60680
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/559,390
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/411,796
FILING DATE:
APPLICATION NUMBER: US 07/981044
FILING DATE: 24-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/11198
FILING DATE: 22-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Bennett, Dennis A.
REGISTRATION NUMBER: 34,547
REFERENCE/DOCKET NUMBER: C2713/1
TELEPHONE: (708)470-6501
TELEFAX: (708)470-6881
INFORMATION FOR SEQ ID NO: 283:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-08-559-390-283
Query Match 0.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1548 ATCTTGGTCTGCC 1561
Db 1 ATCTTGGTCTGCC 14
RESULT 70
PCT-US93-11198-283
Sequence 283, Application PC/TUS9311198
GENERAL INFORMATION:
APPLICANT: Abrams, Mark A.
APPLICANT: Bauer, S. C.
APPLICANT: Braford-Goldberg, Sarah R.
APPLICANT: Caparon, Mair H.
APPLICANT: Easton, Alan M.
APPLICANT: Klein, Barbara K.
APPLICANT: McKearn, John P.
APPLICANT: Olins, Peter O.
APPLICANT: Paik, Kuman
APPLICANT: Polazzi, Joseph O.
APPLICANT: Thomas, John W.
TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
STREET: P. O. Box 5110

;; CITY: Chicago
;; STATE: Illinois
;; COUNTRY: USA
;; ZIP: 60680
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent in Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US93/11198
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/981044
;; FILING DATE: 24-NOV-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Bennett, Dennis A.
;; REGISTRATION NUMBER: 34,547
;; REFERENCE/DOCKET NUMBER: C2713/1
;; TELEPHONE: (708)470-6501
;; TELEFAX: (708)470-6881
;; INFORMATION FOR SEQ ID NO: 283:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (synthetic)
;; PCT-US93-11198-283
;;
Query Match 0.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1548 ATCTGGTCTGCC 1561
DB 1 ATCTGGTCTGCC 14
;;
RESULT 71
US-08-050-743-25/c
; Sequence 25, Application US/08050743
; Patent No. 5447839
; GENERAL INFORMATION:
; APPLICANT: Bauer, Heidi M.
; APPLICANT: Greer, Catherine E.
; APPLICANT: Manos, Michele
; APPLICANT: Resnick, Robert M.
; APPLICANT: Ting, Yi
; TITLE OF INVENTION: Detection of Human Papillomavirus by the
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/050,743
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sias, Stacey R.
; REGISTRATION NUMBER: 32,630
;;

;; REFERENCE/DOCKET NUMBER: 8793
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (510) 814-2863
;; TELEFAX: (510) 814-2977
;; INFORMATION FOR SEQ ID NO: 25:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; US-08-050-743-25
;;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 252 ACCTCCCCAGGTTCT 268
DB 17 ACCTCCCTCAGGTTCTT 1
;;
RESULT 72
US-08-474-542A-174/c
; Sequence 174, Application US/08474542A
; Patent No. 5527898
; GENERAL INFORMATION:
; APPLICANT: Bauer, Heidi M.
; APPLICANT: Gravitt, Patti B.
; APPLICANT: Greer, Catherine E.
; APPLICANT: Impraam, Chaka C.
; APPLICANT: Manos, M. Michele
; APPLICANT: Resnick, Robert M.
; TITLE OF INVENTION: Detection of Human Papillomavirus by the
; NUMBER OF SEQUENCES: 298
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,542A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry, Douglas A.
; REGISTRATION NUMBER: 35,321
; REFERENCE/DOCKET NUMBER: 9234
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2974
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 174:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-474-542A-174
;;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 252 ACCTCCCCAGGTTCT 268

Db 17 ACCTCGCTCAGGTTCT 1

RESULT 73

US-08-181-271A-97/c

Sequence 97, Application US/08181271A

Patent No. 5614395

GENERAL INFORMATION:

APPLICANT: Rvals, John A.

APPLICANT: Alexander, Danny C.

APPLICANT: Beck, James J.

APPLICANT: Duesing, John H.

APPLICANT: Friedrich, Leslie B.

APPLICANT: Goodman, Robert M.

APPLICANT: Harms, Christian

APPLICANT: Meins, Jr., Frederick

APPLICANT: Montoya, Alice

APPLICANT: Moyer, Mary B.

APPLICANT: Neuhaus, Jean-Marc

APPLICANT: Payne, George B.

APPLICANT: Sperison, Christoph

APPLICANT: Stinson, Jeffrey R.

APPLICANT: Uknes, Scott J.

APPLICANT: Ward, Eric R.

APPLICANT: Williams, Shericca C.

TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC

TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF

NUMBER OF SEQUENCES: 106

CORRESPONDENCE ADDRESS:

ADDRESSEE: CIBA-GEIGY Corporation

STREET: 7 Skyline Drive

CITY: Hawthorne

STATE: New York

COUNTRY: USA

ZIP: 10532

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/181,271A

FILING DATE: 13-JAN-94

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/093,301

FILING DATE: 16-JUL-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/937,197

FILING DATE: 6-NOV-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/678,378

FILING DATE: 1-APR-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/305,566

FILING DATE: 6-FEB-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/165,667

FILING DATE: 8-MAR-1988

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/042,847

FILING DATE: 6-APR-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/632,441

FILING DATE: 21-DEC-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/425,504

FILING DATE: 20-OCT-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/848,506

FILING DATE: 6-MAR-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/768,122

FILING DATE: 27-SEP-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/580,431

FILING DATE: 7-SEP-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/368,672

FILING DATE: 20-JUN-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/329,018

FILING DATE: 24-MAR-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/045,957

FILING DATE: 12-APR-1993

ATTORNEY/AGENT INFORMATION:

NAME: Elmer, James Scott

REGISTRATION NUMBER: 36,129

REFERENCE/DOCKET NUMBER: S-19825/P1/COC 1727

TELECOMMUNICATION INFORMATION:

TELEPHONE: (919)541-8614

TELEFAX: (919)541-8689

INFORMATION FOR SEQ ID NO: 97:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

US-08-181-271A-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 89;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGCTCCTGGGTTTC 1332

Db 17 GCCTCGCTCCTGGAGTTC 1

RESULT 74

US-08-457-648-174/c

Sequence 174, Application US/08457648

Patent No. 5639871

GENERAL INFORMATION:

APPLICANT: Bauer, Heidi M.

APPLICANT: Gravitt, Patti E.

APPLICANT: Greer, Catherine E.

APPLICANT: Impraia, Chaka C.

APPLICANT: Manos, M. Michele

APPLICANT: Resnick, Robert M.

TITLE OF INVENTION: Detection of Human Papillomavirus by the

TITLE OF INVENTION: Polymerase Chain Reaction

NUMBER OF SEQUENCES: 298

CORRESPONDENCE ADDRESS:

ADDRESSEE: Hoffmann-La Roche Inc.

STREET: 340 Kingsland Street

CITY: Nutley

STATE: New Jersey

COUNTRY: U.S.A.

ZIP: 07110

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/457,648

FILING DATE:

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Petry, Douglas A.

REGISTRATION NUMBER: 35,321

REFERENCE/DOCKET NUMBER: 9205

TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 174:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-457-648-174

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 252 ACCTCCCCAGGTTCT 268
DB 17 ACCTCCCTCAGGTTCTT 1

RESULT 75

US-08-449-315-97/c
Sequence 97, Application US/08449315
Patent No. 5650505

GENERAL INFORMATION:

APPLICANT: Ryals, John A.
APPLICANT: Alexander, Danny C.
APPLICANT: Beck, James J.
APPLICANT: Duesing, John H.
APPLICANT: Friedrich, Leslie B.
APPLICANT: Goodman, Robert M.
APPLICANT: Harms, Christian
APPLICANT: Meins, Jr., Frederick
APPLICANT: Montoya, Alice
APPLICANT: Moyer, Mary B.
APPLICANT: Neuhaus, Jean-Marc
APPLICANT: Payne, George B.
APPLICANT: Sperison, Christoph
APPLICANT: Stinson, Jeffrey R.
APPLICANT: Uknes, Scott J.
APPLICANT: Ward, Eric R.
APPLICANT: Williams, Shericca C.
TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/449,315
FILING DATE: 24-MAY-1995
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/181,271
FILING DATE: 13-JAN-94
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/937,197
FILING DATE: 6-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/678,378
FILING DATE: 1-APR-1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/305,566
FILING DATE: 6-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/165,667
FILING DATE: 8-MAR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/042,847
FILING DATE: 6-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/632,441
FILING DATE: 21-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/425,504
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/848,506
FILING DATE: 6-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/768,122
FILING DATE: 27-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/580,431
FILING DATE: 7-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/368,672
FILING DATE: 20-JUN-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/045,957
FILING DATE: 12-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Elmer, James Scott
REGISTRATION NUMBER: 36,129
REFERENCE/DOCKET NUMBER: S-19825/PL/CSG 1727
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919) 541-8614
TELEFAX: (919) 541-8689
INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-449-315-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGCTCTGGGTTTC 1332
DB 17 GCCTCGCTCTGGAGTTC 1

RESULT 76

US-08-444-803-97/c
Sequence 97, Application US/08444803
Patent No. 5654414
GENERAL INFORMATION:
APPLICANT: Ryals, John A.
APPLICANT: Alexander, Danny C.
APPLICANT: Beck, James J.
APPLICANT: Duesing, John H.
APPLICANT: Friedrich, Leslie B.
APPLICANT: Goodman, Robert M.
APPLICANT: Harms, Christian
APPLICANT: Meins, Jr., Frederick
APPLICANT: Montoya, Alice
APPLICANT: Moyer, Mary B.

APPLICANT: Neuhaus, Jean-Marc
APPLICANT: Payne, George B.
APPLICANT: Sperison, Christopher
APPLICANT: Stinson, Jeffrey R.
APPLICANT: Utnes, Scott J.
APPLICANT: Ward, Eric R.
APPLICANT: Williams, Shericca C.
TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/444,803
FILING DATE: 19-MAY-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/181,271
FILING DATE: 13-JAN-94
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/937,197
FILING DATE: 6-NOV-1992
PRIOR APPLICATION DATA: US 07/678,378
FILING DATE: 1-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/305,566
FILING DATE: 6-FEB-1989
PRIOR APPLICATION DATA: US 07/165,667
FILING DATE: 8-MAR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/042,847
FILING DATE: 6-APR-1993
PRIOR APPLICATION DATA: US 07/632,441
FILING DATE: 21-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/425,504
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/848,506
FILING DATE: 6-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/768,122
FILING DATE: 27-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/580,431
FILING DATE: 7-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/368,672
FILING DATE: 20-JUN-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/045,957
FILING DATE: 12-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Elmer, James Scott
REGISTRATION NUMBER: 36,129

REFERENCE/DOCKET NUMBER: S-19825/Pl/CGC 1727
TELEPHONE: (919)541-8614
TELEFAX: (919)541-8689
INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-444-803-97
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCTCGGGTTC 1332
DB 17 GCCTCGTCTCGAGTTC 1
RESULT 77
US-08-449-043-97/c
Sequence 97, Application US/08449043
Patent No. 5689044
GENERAL INFORMATION:
APPLICANT: Ryals, John A.
APPLICANT: Alexander, Danny C.
APPLICANT: Beck, James J.
APPLICANT: Duesing, John H.
APPLICANT: Friedrich, Leslie B.
APPLICANT: Goodman, Robert M.
APPLICANT: Harms, Christian
APPLICANT: Meins, Jr., Frederick
APPLICANT: Montoya, Alice
APPLICANT: Moyer, Mary B.
APPLICANT: Neuhaus, Jean-Marc
APPLICANT: Payne, George B.
APPLICANT: Sperison, Christoph
APPLICANT: Stinson, Jeffrey R.
APPLICANT: Utnes, Scott J.
APPLICANT: Ward, Eric R.
APPLICANT: Williams, Shericca C.
TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/449,043
FILING DATE: 24-MAY-1995
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/181,271
FILING DATE: 13-JAN-94
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/937,197
FILING DATE: 6-NOV-1992
PRIOR APPLICATION DATA: US 07/678,378

;; FILING DATE: 1-APR-1991
;; PRIOR APPLICATION DATA: US 07/305,566
;; FILING DATE: 6-FEB-1989
;; PRIOR APPLICATION DATA: US 07/165,667
;; FILING DATE: 8-MAR-1988
;; PRIOR APPLICATION DATA: US 08/042,847
;; FILING DATE: 6-APR-1993
;; PRIOR APPLICATION DATA: US 07/632,441
;; FILING DATE: 21-DEC-1990
;; PRIOR APPLICATION DATA: US 07/425,504
;; FILING DATE: 20-OCT-1989
;; PRIOR APPLICATION DATA: US 07/848,506
;; FILING DATE: 6-MAR-1992
;; PRIOR APPLICATION DATA: US 07/768,122
;; FILING DATE: 27-SEP-1991
;; PRIOR APPLICATION DATA: US 07/580,431
;; FILING DATE: 7-SEP-1990
;; PRIOR APPLICATION DATA: US 07/368,672
;; FILING DATE: 20-JUN-1989
;; PRIOR APPLICATION DATA: US 07/329,018
;; FILING DATE: 24-MAR-1989
;; PRIOR APPLICATION DATA: US 08/045,957
;; FILING DATE: 12-APR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Elmer, James Scott
;; REGISTRATION NUMBER: 36,129
;; REFERENCE/DOCKET NUMBER: S-19825/Pl/CGC 1727
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (919)541-8614
;; TELEFAX: (919)541-8689
;; INFORMATION FOR SEQ ID NO: 97:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-449-043-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGCTCTGGGGTTC 1332
DB 17 GCCTCGCTCTGGAGTTC 1

RESULT 78
US-08-452-055-25/c
; Sequence 25, Application US/08452055
; Patent No. 5705627
; GENERAL INFORMATION:
; APPLICANT: Bauer, Heidi M.
; APPLICANT: Greer, Catherine E.
; APPLICANT: Manos, Michele
; APPLICANT: Resnick, Robert M.
; APPLICANT: Ting, Yi
; TITLE OF INVENTION: Detection of Human Papillomavirus by the
; TITLE OF INVENTION: Polymerase Chain Reaction
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:

;; ADDRESSEE: Hoffmann-La Roche Inc.
;; STREET: 340 Kingsland Street
;; CITY: Nutley
;; STATE: New Jersey
;; COUNTRY: U.S.A.
;; ZIP: 07110
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/452,055
;; FILING DATE:
;; CLASSIFICATION: 536
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sias, Stacey R.
;; REGISTRATION NUMBER: 32,630
;; REFERENCE/DOCKET NUMBER: 9188
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (510) 814-2863
;; TELEFAX: (510) 814-2977
;; INFORMATION FOR SEQ ID NO: 25:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-452-055-25

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 252 ACCTCCCCCAGGTTCT 268
DB 17 ACCTCCCTCAGGTTCTT 1

RESULT 79
US-08-456-265A-97/c
; Sequence 97, Application US/08456265A
; Patent No. 5767369
; GENERAL INFORMATION:
; APPLICANT: Alexander, Danny C.
; APPLICANT: Ryals, John A.
; APPLICANT: Goodman, Robert M.
; APPLICANT: Stinson, Jeffrey R.
; TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
; TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
; NUMBER OF SEQUENCES: 111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 520 White Plains Road, P.O. Box 2005
; CITY: Tarrytown
; STATE: New York
; COUNTRY: USA
; ZIP: 10591
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/456,265A
;; FILING DATE: 31-MAY-95
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/181,271
;; FILING DATE: 13-JAN-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/093,301

```

; FILING DATE: 16-JUL-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/937,197
; FILING DATE: 6-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/678,378
; FILING DATE: 1-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/305,566
; FILING DATE: 6-FEB-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/165,667
; FILING DATE: 8-MAR-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/042,847
; FILING DATE: 6-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/632,441
; FILING DATE: 21-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/425,504
; FILING DATE: 20-OCT-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/848,506
; FILING DATE: 6-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/768,122
; FILING DATE: 27-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/580,431
; FILING DATE: 7-SEP-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/368,672
; FILING DATE: 20-JUN-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/329,018
; FILING DATE: 24-MAR-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/045,957
; FILING DATE: 12-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Meigs, J. Timothy
; REGISTRATION NUMBER: 38,241
; REFERENCE/DOCKET NUMBER: S-19825/P1/CGC 1727/DIV10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919)541-8587
; TELEFAX: (919)541-8689
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-456-265A-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTCGGGGTTTC 1332
Db 17 GCCTCGTCCTCGGAGTTC 1

RESULT 80
US-08-455-416-97/c
; Sequence 97, Application US/08455416
; Patent No. 5777200
; GENERAL INFORMATION:
; APPLICANT: Ryals, John A.
; APPLICANT: Alexander, Danny C.
; APPLICANT: Beck, James J.
; APPLICANT: Duesing, John H.
; APPLICANT: Friedrich, Leslie B.
; APPLICANT: Goodman, Robert M.
; APPLICANT: Harms, Christian
; APPLICANT: Meins, Jr., Frederick
; APPLICANT: Montoya, Alice
; APPLICANT: Moyer, Mary B.
; APPLICANT: Neuhaus, Jean-Marc
; APPLICANT: Payne, George B.
; APPLICANT: Sperison, Christoph
; APPLICANT: Stinson, Jeffrey R.
; APPLICANT: Unnes, Scott J.
; APPLICANT: Ward, Eric R.
; APPLICANT: Williams, Shericca C.
; TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
; TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: New York
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,416
; FILING DATE: 31-MAY-1995
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/181,271
; FILING DATE: 13-JAN-94
; APPLICATION NUMBER: US 08/093,301
; FILING DATE: 16-JUL-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/937,197
; FILING DATE: 6-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/678,378
; FILING DATE: 1-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/305,566
; FILING DATE: 6-FEB-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/165,667
; FILING DATE: 8-MAR-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/042,847
; FILING DATE: 6-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/632,441
; FILING DATE: 21-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/425,504
; FILING DATE: 20-OCT-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/848,506
; FILING DATE: 6-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/768,122
; FILING DATE: 27-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/580,431
; FILING DATE: 7-SEP-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/368,672
; FILING DATE: 20-JUN-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/329,018
```


;; FILING DATE: 24-MAR-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/045,957
;; FILING DATE: 12-APR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Elmer, James Scott
;; REGISTRATION NUMBER: 36,129
;; REFERENCE/DOCKET NUMBER: S-19825/P1/CGC 1727
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (919)541-8614
;; TELEFAX: (919)541-8689
;; INFORMATION FOR SEQ ID NO: 97:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-455-416-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGCTCTGGGGTTC 1332
|| ||||| |||||
Db 17 GCCTCGCTCTGGAGTTC 1

RESULT 81
US-08-455-244-97/c
; Sequence 97, Application US/08455244
; Patent No. 5789214
; GENERAL INFORMATION:
; APPLICANT: Ryals, John A.
; APPLICANT: Alexander, Danny C.
; APPLICANT: Beck, James J.
; APPLICANT: Duesing, John H.
; APPLICANT: Friedrich, Leslie B.
; APPLICANT: Goodman, Robert M.
; APPLICANT: Harms, Christian
; APPLICANT: Meins, Jr., Frederick
; APPLICANT: Montoya, Alice
; APPLICANT: Moyer, Mary B.
; APPLICANT: Neuhaus, Jean-Marc
; APPLICANT: Payne, George B.
; APPLICANT: Sparison, Christoph
; APPLICANT: Stinson, Jeffrey R.
; APPLICANT: Uknes, Scott J.
; APPLICANT: Ward, Eric R.
; APPLICANT: Williams, Shericca C.
; TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
; TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: New York
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,244
; FILING DATE: 31-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/181,271
; FILING DATE: 13-JAN-94

;; APPLICATION NUMBER: US 08/093,301
;; FILING DATE: 16-JUL-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/937,197
;; FILING DATE: 6-NOV-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/678,378
;; FILING DATE: 1-APR-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/305,566
;; FILING DATE: 6-FEB-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/165,667
;; FILING DATE: 8-MAR-1988
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/042,847
;; FILING DATE: 6-APR-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/632,441
;; FILING DATE: 21-DEC-1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/425,504
;; FILING DATE: 20-OCT 1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/848,506
;; FILING DATE: 6-MAR-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/768,122
;; FILING DATE: 27-SEP-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/580,431
;; FILING DATE: 7-SEP-1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/368,672
;; FILING DATE: 20-JUN-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/329,018
;; FILING DATE: 24-MAR-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/045,957
;; FILING DATE: 12-APR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Elmer, James Scott
;; REGISTRATION NUMBER: 36,129
;; REFERENCE/DOCKET NUMBER: S-19825/P1/CGC 1727
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (919)541-8614
;; TELEFAX: (919)541-8689
;; INFORMATION FOR SEQ ID NO: 97:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-455-244-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGCTCTGGGGTTC 1332
|| ||||| |||||
Db 17 GCCTCGCTCTGGAGTTC 1

RESULT 82
US-08-454-876-97/c
; Sequence 97, Application US/08454876
; Patent No. 5804693
; GENERAL INFORMATION:
; APPLICANT: Ryals, John A.
; APPLICANT: Alexander, Danny C.

APPLICANT: Beck, James J.
APPLICANT: Duesing, John H.
APPLICANT: Friedrich, Leslie B.
APPLICANT: Goodman, Robert M.
APPLICANT: Harms, Christian
APPLICANT: Meins, Jr., Frederick
APPLICANT: Montoya, Alice
APPLICANT: Moyer, Mary B.
APPLICANT: Neuhaus, Jean-Marc
APPLICANT: Payne, George B.
APPLICANT: Sperison, Christoph
APPLICANT: Stinson, Jeffrey R.
APPLICANT: Uknes, Scott J.
APPLICANT: Ward, Eric R.
APPLICANT: Williams, Shericca C.
TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/454,876
FILING DATE: 31-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/181,271
FILING DATE: 13-JAN-94
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/937,197
FILING DATE: 6-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/678,378
FILING DATE: 1-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/305,566
FILING DATE: 6-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/165,667
FILING DATE: 8-MAR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/042,847
FILING DATE: 6-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/632,441
FILING DATE: 21-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/425,504
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/848,506
FILING DATE: 6-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/768,122
FILING DATE: 27-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/580,431
FILING DATE: 7-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/368,672
FILING DATE: 20-JUN-1989
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/045,957
FILING DATE: 12-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Elmer, James Scott
REGISTRATION NUMBER: 36,129
REFERENCE/DOCKET NUMBER: S-19825/Pl/CGC 1727
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919)541-8614
TELEFAX: (919)541-8689
INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-454-876-97
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTCGTCTCTGGGTTTC 1332
||| ||||| ||||| |||||
Db 17 GCCTGCTCTGGAGTTC 1
RESULT 83
US-08-457-364-97/C
Sequence 97, Application US/08457364
Patent No. 5847258
GENERAL INFORMATION:
APPLICANT: Ryals, John A.
APPLICANT: Alexander, Danny C.
APPLICANT: Beck, James J.
APPLICANT: Duesing, John H.
APPLICANT: Friedrich, Leslie B.
APPLICANT: Goodman, Robert M.
APPLICANT: Harms, Christian
APPLICANT: Meins, Jr., Frederick
APPLICANT: Montoya, Alice
APPLICANT: Moyer, Mary B.
APPLICANT: Neuhaus, Jean-Marc
APPLICANT: Payne, George B.
APPLICANT: Sperison, Christoph
APPLICANT: Stinson, Jeffrey R.
APPLICANT: Uknes, Scott J.
APPLICANT: Ward, Eric R.
APPLICANT: Williams, Shericca C.
TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/457,364
FILING DATE: 31-MAY-1995
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/181,271

;; FILING DATE: 13-JAN-94
;; APPLICATION NUMBER: US 08/093,301
;; FILING DATE: 16-JUL-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/937,197
;; FILING DATE: 6-NOV-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/678,378
;; FILING DATE: 1-APR-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/305,566
;; FILING DATE: 6-FEB-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/165,667
;; FILING DATE: 8-MAR-1988
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/042,847
;; FILING DATE: 6-APR-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/632,441
;; FILING DATE: 21-DEC-1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/425,504
;; FILING DATE: 20-OCT-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/368,672
;; FILING DATE: 20-JUN-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/848,506
;; FILING DATE: 6-MAR-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/768,122
;; FILING DATE: 27-SEP-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/580,431
;; FILING DATE: 7-SEP-1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/368,672
;; FILING DATE: 20-JUN-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/329,018
;; FILING DATE: 24-MAR-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/045,957
;; FILING DATE: 12-APR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Elmer, James Scott
;; REGISTRATION NUMBER: 36,129
;; REFERENCE/DOCKET NUMBER: S-19825/P1/CGC 1727
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (919)541-8614
;; TELEFAX: (919)541-8689
;; INFORMATION FOR SEQ ID NO: 97:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-457-364-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGTTTC 1332

Db 17 GCTTCGTCCTGGGTTTC 1

RESULT 84

US-08-456-262-97/c
; Sequence 97, Application US/08456262
; Patent No. 5851766
; GENERAL INFORMATION:
; APPLICANT: Ryals, John A.

;; APPLICANT: Alexander, Danny C.
;; APPLICANT: Beck, James J.
;; APPLICANT: Duesing, John H.
;; APPLICANT: Friedrich, Leslie B.
;; APPLICANT: Goodman, Robert M.
;; APPLICANT: Harms, Christian
;; APPLICANT: Meins, Jr., Frederick
;; APPLICANT: Montoya, Alice
;; APPLICANT: Moyer, Mary B.
;; APPLICANT: Neuhaus, Jean-Marc
;; APPLICANT: Payne, George B.
;; APPLICANT: Sperison, Christoph
;; APPLICANT: Stinson, Jeffrey R.
;; APPLICANT: Uxnes, Scott J.
;; APPLICANT: Ward, Eric R.
;; APPLICANT: Williams, Shericca C.
;; TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
;; TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
;; NUMBER OF SEQUENCES: 106
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: CIBA-GEIGY Corporation
;; STREET: 7 Skyline Drive
;; CITY: Hawthorne
;; STATE: New York
;; COUNTRY: USA
;; ZIP: 10532
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US 08/456,262
;; FILING DATE: 31-MAY-1995
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/181,271
;; FILING DATE: 13-JAN-94
;; APPLICATION NUMBER: US 08/093,301
;; FILING DATE: 16-JUL-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/937,197
;; FILING DATE: 6-NOV-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/678,378
;; FILING DATE: 1-APR-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/305,566
;; FILING DATE: 6-FEB-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/165,667
;; FILING DATE: 8-MAR-1988
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/042,847
;; FILING DATE: 6-APR-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/632,441
;; FILING DATE: 21-DEC-1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/425,504
;; FILING DATE: 20-OCT-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/848,506
;; FILING DATE: 6-MAR-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/768,122
;; FILING DATE: 27-SEP-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/580,431
;; FILING DATE: 7-SEP-1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/368,672
;; FILING DATE: 20-JUN-1989

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA: US 08/045,957
FILING DATE: 12-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Elmer, James Scott
REGISTRATION NUMBER: 36,129
REFERENCE/DOCKET NUMBER: S-19825/P1/CGC 1727
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919)541-8614
TELEFAX: (919)541-8689
INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-456-262-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGGTTC 1332
DB 17 GCCTCGTCCTGGAGTTC 1

RESULT 85
US-08-456-240-97/c
Sequence 97, Application US/08456240
Patent No. 5856154
GENERAL INFORMATION:
APPLICANT: Ryals, John A.
APPLICANT: Alexander, Danny C.
APPLICANT: Beck, James J.
APPLICANT: Duesing, John H.
APPLICANT: Friedrich, Leslie B.
APPLICANT: Goodman, Robert M.
APPLICANT: Harms, Christian
APPLICANT: Meins, Jr., Frederick
APPLICANT: Montoya, Alice
APPLICANT: Moyer, Mary B.
APPLICANT: Neuhaus, Jean-Marc
APPLICANT: Payne, George B.
APPLICANT: Sperison, Christoph
APPLICANT: Stinson, Jeffrey R.
APPLICANT: Uknes, Scott J.
APPLICANT: Ward, Eric R.
APPLICANT: Williams, Shericca C.
TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/456,240
FILING DATE: 31-MAY-1995
CLASSIFICATION: 800
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/181,271
FILING DATE: 13-JAN-94
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA: US 07/937,197
FILING DATE: 6-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/678,378
FILING DATE: 1-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/305,566
FILING DATE: 6-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/165,667
FILING DATE: 8-MAR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/042,847
FILING DATE: 6-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/632,441
FILING DATE: 21-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/425,504
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/848,506
FILING DATE: 6-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/768,122
FILING DATE: 27-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/580,431
FILING DATE: 7-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/368,672
FILING DATE: 20-JUN-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/045,957
FILING DATE: 12-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Elmer, James Scott
REGISTRATION NUMBER: 36,129
REFERENCE/DOCKET NUMBER: S-19825/P1/CGC 1727
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919)541-8614
TELEFAX: (919)541-8689
INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-456-240-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGTCCTGGGGTTC 1332
DB 17 GCCTCGTCCTGGAGTTC 1

RESULT 86
US-08-455-736-97/c
Sequence 97, Application US/08455736
Patent No. 5880328
GENERAL INFORMATION:

APPLICANT: Ryals, John A.
APPLICANT: Alexander, Danny C.
APPLICANT: Beck, James J.
APPLICANT: Duesing, John H.
APPLICANT: Friedrich, Leslie B.
APPLICANT: Goodman, Robert M.
APPLICANT: Harms, Christian
APPLICANT: Meins, Jr., Frederick
APPLICANT: Montoya, Alice
APPLICANT: Moyer, Mary B.
APPLICANT: Neuhaus, Jean-Marc
APPLICANT: Payne, George B.
APPLICANT: Sperison, Christoph
APPLICANT: Stinson, Jeffrey R.
APPLICANT: Uknes, Scott J.
APPLICANT: Ward, Eric R.
APPLICANT: Williams, Shericca C.
TITLE OF INVENTION: CHEMICALLY REGULATABLE AND ANTI-PATHOGENIC
TITLE OF INVENTION: DNA SEQUENCES AND USES THEREOF
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
CITY: 7 Skyline Drive
STATE: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,736
FILING DATE: 31-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/181,271
FILING DATE: 13-JAN-1994
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/937,197
FILING DATE: 6-NOV-1992
APPLICATION NUMBER: US 07/678,378
FILING DATE: 1-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/305,566
FILING DATE: 6-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/165,667
FILING DATE: 8-MAR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/042,847
FILING DATE: 6-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/632,441
FILING DATE: 21-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/425,504
FILING DATE: 20-OCT 1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/848,506
FILING DATE: 6-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/768,122
FILING DATE: 27-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/580,431
FILING DATE: 7-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/368,672

FILING DATE: 20-JUN-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/045,957
FILING DATE: 12-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Elmer, James Scott
REGISTRATION NUMBER: 36,129
REFERENCE/DOCKET NUMBER: S-19825/Pl/CGC 1727
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919)541-8614
TELEFAX: (919)541-8689
INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-455-736-97
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGTTTC 1332
Db 17 GCTTCGTCCTGGGTTTC 1
RESULT 87
US-08-971-217-97/c
Sequence 97, Application US/08971217
Patent No. 5942662
GENERAL INFORMATION:
APPLICANT: Ryals, John A.
APPLICANT: Harms, Christian
APPLICANT: Friedrich, Leslie
APPLICANT: Beck, James
APPLICANT: Uknes, Scott
APPLICANT: Ward, Eric
TITLE OF INVENTION: INDUCIBLE HERBICIDE RESISTANCE
NUMBER OF SEQUENCES: 111
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5942662artis Corporation
STREET: 3054 Cornwallis Road, P.O. Box 12257
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/971,217
FILING DATE:
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/457,364
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/181,271
FILING DATE: 13-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/937,197
FILING DATE: 6-NOV-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/678,378
FILING DATE: 1-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/305,566
FILING DATE: 6-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/165,667
FILING DATE: 8-MAR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/042,847
FILING DATE: 6-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/632,441
FILING DATE: 21-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/425,504
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/848,506
FILING DATE: 6-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/768,122
FILING DATE: 27-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/580,431
FILING DATE: 7-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/368,672
FILING DATE: 20-JUN-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/045,957
FILING DATE: 12-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Meigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: S-19825/P1/CGC 1727/DIV5/CONT
TELEPHONE: (919)541-8587
TELEFAX: (919)541-8689
INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-971-217-97
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGTTTC 1332
DB 17 GCCTCGTCCTGGAGTTC 1
RESULT 88
US-09-350-600-97/C
Sequence 97, Application US/09350600
Patent No. 6262342
GENERAL INFORMATION:
APPLICANT: Meins, Frederick
APPLICANT: Shinsai, Hideaki
APPLICANT: Wenzler, Herman
APPLICANT: Hofsteenge, Jan
APPLICANT: Ryals, John
APPLICANT: Sperisen, Christoph
TITLE OF INVENTION: DNA SEQUENCES ENCODING POLYPEPTIDES

TITLE OF INVENTION: HAVING BETA-1,3-GLUCANASE ACTIVITY
NUMBER OF SEQUENCES: 111
CORRESPONDENCE ADDRESS:
ADDRESSER: No. 6262342artis Corporation
STREET: 3054 Cornwallis Road, P.O. Box 12257
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/350,600
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/971,217
FILING DATE: 14-NOV-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/457,364
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/181,271
FILING DATE: 13-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/093,301
FILING DATE: 16-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/937,197
FILING DATE: 6-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/678,378
FILING DATE: 1-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/305,566
FILING DATE: 6-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/165,667
FILING DATE: 8-MAR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/042,847
FILING DATE: 6-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/632,441
FILING DATE: 21-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/425,504
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/848,506
FILING DATE: 6-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/768,122
FILING DATE: 27-SEP-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/580,431
FILING DATE: 7-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/368,672
FILING DATE: 20-JUN-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/329,018
FILING DATE: 24-MAR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/381,443
FILING DATE: 18-JUL-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/353,312
FILING DATE: 17-MAY-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/226,303

;; FILING DATE: 29-JUL-1988
;; PRIOR APPLICATION DATA: US 08/045,957
;; FILING DATE: 12-APR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Meigs, J. Timothy
;; REGISTRATION NUMBER: 38,241
;; REFERENCE/DOCKET NUMBER: S-198250
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (919)541-8587
;; TELEFAX: (919)541-8689
;; INFORMATION FOR SEQ ID NO: 97:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-09-350-600-97

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCTTCGCTCTGGGTTTC 1332
DB 17 GCCTCGCTCTGGAGTTTC 1

RESULT 89
US-08-584-040-4178
; Sequence 4178, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; COUNTRY: U.S.A.
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

;; INFORMATION FOR SEQ ID NO: 4178:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-584-040-4178

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 89;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 282 GGAGCCATCCCTGGGA 298
DB 1 GGAGCAAUCCUGGA 17

RESULT 90
US-08-584-040-7674/c
; Sequence 7674, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; COUNTRY: U.S.A.
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7674:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7674

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 GGACCCAGGAGCCATCC 291
Db 17 GGATTCAGGAGCCATCC 1

RESULT 91
US-09-920-663-4
; Sequence 4, Application US/09920663
; Patent No. 6426221
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF RIP2 EXPRESSION
; FILE REFERENCE: RTS-0233
; CURRENT APPLICATION NUMBER: US/09/920,663
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-920-663-4

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 649 CACGTGGCCGTGGAGCA 665
Db 1 CAGTGGCCGTGAAGCA 17

RESULT 92
US-09-474-432B-769
; Sequence 769, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 769
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-769

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 89;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1178 CTTGGAACGTGGTGTC 1194
; : |||||:|:|:|

Db 1 CUCGGAACGUGCUGGUC 17

RESULT 93
US-09-371-772B-1945
; Sequence 1945, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1945

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 89;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 282 GGAGCCATCCCTGGGGA 298
Db 1 GGAGCAUCCCGUGGA 17

RESULT 94
US-09-371-772B-3459/C
; Sequence 3459, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3459
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3459

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 GGACCCAGGAGCCATCC 291
Db 17 GGATTCAGGAGCCATCC 1


```
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 760
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-760

Query Match          0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      823 CTCCTTGCCCACT 839
Db      1 CTCGCTGCCCATCACT 17

RESULT 98
US-09-827-998-761
; Sequence 761, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-761

Query Match          0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      824 TCTTCTGCCCACTC 840
Db      1 TCGTCTGCCCATCACTC 17

RESULT 99
US-09-866-108A-931
; Sequence 931, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Ji, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
```

```
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 931
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-931

Query Match          0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      739 CTGAGAGAGGCTGTGCC 755
Db      1 CTGAAGAGGCTGAGCC 17

RESULT 100
US-09-866-108A-1536
; Sequence 1536, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
```

PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 1536
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-1536

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGCTGTGACCTGG 510
||| ||||| |||||
Db 1 TGGGGCTGTGCTCTGG 17

RESULT 101
US-09-866-108A-1647/c
Sequence 1647, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: Aecomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 1647
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-1647

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;

* Matched 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1062 CTCTTTTGCCTTCCTCC 1078
||| ||||| |||||
Db 17 CTCCTTTGCCTTCCTCC 1

RESULT 102
US-09-866-108A-2290/c
Sequence 2290, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: Aecomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 2290
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-2290

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 559 CTGTGGCCCGGCGAC 575
||| ||||| |||||
Db 17 CTGTGGCCCGGCGAC 1

RESULT 103
US-09-866-108A-2291/c
Sequence 2291, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng

```
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2291
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2291
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 558 GCTGTGGCCAGGGGCA 574
|||
Db 17 GCTGTGGCCATGGACA 1
```

```
RESULT 104
US-09-866-108A-2292/c
; Sequence 2292, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2292
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2292
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 557 GGCTGTGGCCAGGGGC 573
|||
Db 17 GGCTGTGGCCATGGAC 1
```

```
RESULT 105
US-09-866-108A-2295/c
; Sequence 2295, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2295
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2295
```

```
Query Match 0.9%; Score 13.8; DB 1; Length 17;
```

```
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 554 TACGGCTGTGGCCAGG 570
Db 17 TCGGCGCTGTGGCCATG 1

RESULT 106
US-09-866-108A-2298/c
; Sequence 2298, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2298
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2299

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 GCCCTACGGCTGTGGGC 566
Db 17 GCACTGCGCTGTGGGC 1

RESULT 108
US-09-866-108A-2300/c
; Sequence 2300, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 551 CCTACGGCTGTGGCC 567
Db 17 CACTGCGCTGTGGCC 1

RESULT 107
US-09-866-108A-2299/c
; Sequence 2299, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 551 CCTACGGCTGTGGCC 567
Db 17 CACTGCGCTGTGGCC 1

RESULT 107
US-09-866-108A-2299/c
; Sequence 2299, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
```

ORGANISM: Homo sapiens
US-09-866-108A-6916

APPLICANT: PENN, Sharron G.

APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEWICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: Aemica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 10673
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-10673

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 GGTAGCCATGCTGGTG 1276
DB 17 GGTGGCCATGCTGGTG 1

RESULT 112
US-09-866-108A-10674/c
Sequence 10674, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: FENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEWICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: Aemica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 10674
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-10674

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 GGTAGCCATGCTGGTG 1275
DB 17 GGTGGCCATGCTGGTG 1

RESULT 113
PCT-US91-01750-12/c
Sequence 12, Application PC/TUS9101750
GENERAL INFORMATION:
APPLICANT: KNAUF, VIC C.
APPLICANT: KRAIDL, JEAN C.
APPLICANT: SCHERER, DONNA E.
TITLE OF INVENTION: Novel Sequences Preferentially
TITLE OF INVENTION: Expressed In Early Seed
TITLE OF INVENTION: Development and Methods
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Calgene, Inc.
STREET: 1920 Fifth Street
CITY: Davis
STATE: CA
COUNTRY: USA
ZIP: 95616
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.0 MB storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0
SOFTWARE: Microsoft Word 4.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/01750
FILING DATE: 19910314
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/494,722
FILING DATE: 16-MAR-1990
ATTORNEY/AGENT INFORMATION:
NAME: Elizabeth Lassen
REGISTRATION NUMBER: 31,845
NAME: Donna E. Scherer
REGISTRATION NUMBER: 34,719
REFERENCE/DOCKET NUMBER: CGNE 68WO
TELECOMMUNICATION INFORMATION:
TELEPHONE: 916-753-6313
TELEFAX: 916-753-1510
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single

```
/
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: synthetic oligonucleotide
PCT-US91-01750-12

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCCTCGCTCTGGGGTTC 1332
Db 17 GCCTCGCTCTGGAGTTC 1

RESULT 114
5177307-2/c
/ Patent No. 5177307
/ APPLICANT: HOUCK, CATHERINE M.; PEAR, JULIE R.; MARTINEAU,
/ BELINDA M.; HIATT, WILLIAM
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
/ MODULATIONS OF ENDOGENOUS CYTOKININ LEVELS
/ NUMBER OF SEQUENCES: 6
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/554,196
/ FILING DATE: 17-JUL-1990
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 382,802
/ FILING DATE: 19-JUL-1989
/ APPLICATION NUMBER: 186,361
/ FILING DATE: 29-APR-1988
/ APPLICATION NUMBER: 168,190
/ FILING DATE: 15-MAR-1988
/ APPLICATION NUMBER: 54,369
/ FILING DATE: 26-MAY-1987
/ SEQ ID NO:2
/ LENGTH: 17
5177307-2

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 89;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCCTCGCTCTGGGGTTC 1332
Db 17 GCCTCGCTCTGGAGTTC 1

RESULT 115
US-08-805-918-34
/ Sequence 34, Application US/08805918
/ Patent No. 5885821
/ GENERAL INFORMATION:
/ APPLICANT: MAGOTA, Koji
/ APPLICANT: MASUDA, Toyofumi
/ APPLICANT: SUZUKI, Yuji
/ APPLICANT: YABUTA, Masayuki
/ TITLE OF INVENTION: PROCESS FOR PRODUCTION OF SECRETORY KEX2
/ TITLE OF INVENTION: DERIVATIVES
/ NUMBER OF SEQUENCES: 45
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
/ STREET: P.O. Box 1404
/ CITY: Alexandria
/ STATE: Virginia
/ COUNTRY: United States
/ ZIP: 22313-1404
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/805,918
/ FILING DATE: 04-MAR-1997
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: JP 8-073217
/ FILING DATE: 04-MAR-1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: JP 8-352580
/ FILING DATE: 16-DEC-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Meuth, Donna M.
/ REGISTRATION NUMBER: 36,607
/ REFERENCE/DOCKET NUMBER: 001560-295
/ TELECOMMUNICATION INFORMATION:

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 402 CATCATCAGCACCTGG 418
Db 1 CACCATCATCACCTGG 17

RESULT 116
US-08-805-918-35/c
/ Sequence 35, Application US/08805918
/ Patent No. 5885821
/ GENERAL INFORMATION:
/ APPLICANT: MAGOTA, Koji
/ APPLICANT: MASUDA, Toyofumi
/ APPLICANT: SUZUKI, Yuji
/ APPLICANT: YABUTA, Masayuki
/ TITLE OF INVENTION: PROCESS FOR PRODUCTION OF SECRETORY KEX2
/ TITLE OF INVENTION: DERIVATIVES
/ NUMBER OF SEQUENCES: 45
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
/ STREET: P.O. Box 1404
/ CITY: Alexandria
/ STATE: Virginia
/ COUNTRY: United States
/ ZIP: 22313-1404
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/805,918
/ FILING DATE: 04-MAR-1997
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: JP 8-073217
/ FILING DATE: 04-MAR-1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: JP 8-352580
/ FILING DATE: 16-DEC-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Meuth, Donna M.
/ REGISTRATION NUMBER: 36,607
/ REFERENCE/DOCKET NUMBER: 001560-295
/ TELECOMMUNICATION INFORMATION:
```


Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels

```
QY 688 TGTGTCCTGCTCTCGA 704
Db 17 TGTGTCCTGCGCTGGCA 1

RESULT 120
US-09-161-443-18/c
; Sequence 18, Application US/09161443A
; Patent No. 6020198
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF RIP-1 EXPRESSION
; FILE REFERENCE: RTS-0011
; CURRENT APPLICATION NUMBER: US/09/161,443A
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-443-18

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 335 ATGAGCTGATGGAGGTG 351
Db 18 ATGAGCTGAGGGAAGTG 2

RESULT 121
US-09-161-443-19/c
; Sequence 19, Application US/09161443A
; Patent No. 6020198
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF RIP-1 EXPRESSION
; FILE REFERENCE: RTS-0011
; CURRENT APPLICATION NUMBER: US/09/161,443A
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 19
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-443-19

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 362 GCACCATCTACCACATG 378
Db 18 GCACCCCTCTACTACATG 2

RESULT 122
US-09-792-594-5
; Sequence 5, Application US/09792594
; Patent No. 6436706
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RECQL4 EXPRESSION
; FILE REFERENCE: RTS-0209

; CURRENT APPLICATION NUMBER: US/09/792,594
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-792-594-5

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 683 CCCGTTGTCTCTGGTC 699
Db 1 CCCGTTGCTTCCTGGTC 17

RESULT 123
US-09-806-254-1/c
; Sequence 1, Application US/09806254
; Patent No. 6458838
; GENERAL INFORMATION:
; APPLICANT: The Johns Hopkins University School of Medicine
; TITLE OF INVENTION: Adrenoleukodystrophy Treatments and
; FILE REFERENCE: 01107.83615
; CURRENT APPLICATION NUMBER: US/09/806,254
; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/102,186
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-806-254-1

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 241 CCTCTGCCCCCACCCTCC 257
Db 17 CCTCTGCCACCAGCTCC 1

RESULT 124
US-09-920-760-10/c
; Sequence 10, Application US/09920760
; Patent No. 6492173
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF CVCLIN D2 EXPRESSION
; FILE REFERENCE: RTS-0275
; CURRENT APPLICATION NUMBER: US/09/920,760
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-920-760-10

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 242 CTCTGCCCCCACCCTCCC 258
DB 17 CTCTGCCCCCACCCTCTC 1

RESULT 125
US-09-422-978-7807/c
; Sequence 7807, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7807
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-4157 for SEQ 3873,
US-09-422-978-7807

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 CCTGTCTTTGCCAACAT 977
DB 18 CCTGTCTGTCAACAT 2

RESULT 126
US-09-422-978-11445/c
; Sequence 11445, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11445
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6564 for SEQ 3580, in complete
US-09-422-978-11445

Query Match 0.9%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 391 CTGTGTCTTCATCAT 407
DB 18 CTGTGTCTTCACCT 2

RESULT 127
US-09-689-012-9
; Sequence 9, Application US/09689012
; Patent No. 6670135
; GENERAL INFORMATION:
; APPLICANT: Spriggs, Melanie K.
; TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
; FILE REFERENCE: 2634-US
; CURRENT APPLICATION NUMBER: US/09/689,012
; CURRENT FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: PCT/US99/09831
; PRIOR FILING DATE: 1999-05-05
; PRIOR APPLICATION NUMBER: US 60/085,497
; PRIOR FILING DATE: 1998-05-14
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PRIMER
US-09-689-012-9

Query Match 0.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 565 GCCAGGGGCACCTGGAC 581
DB 2 GCCAGGTGCCCTGGAC 18

RESULT 128
US-08-363-240A-534/c
; Sequence 534, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:

```
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 210/096
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 534:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-363-240A-534

Query Match          0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 654 GGCGGTGGAGCATCA 668
Db 15 GGCGGAGGAGCATCA 1

RESULT 129
US-09-371-772B-5661
/ Sequence 5661, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00.876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 5661
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-371-772B-5661

Query Match          0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 92;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 629 TGCTCTGCGCGTGC 643
Db 1 UGUGUGCGCGGUGC 15

RESULT 130
US-09-479-005A-53/c
/ Sequence 53, Application US/09479005A
/ Patent No. 6656731
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
/ FILE REFERENCE: MBH00-884-C
/ CURRENT APPLICATION NUMBER: US/09/479,005A
/ CURRENT FILING DATE: 2000-01-07
```

```
/ PRIOR APPLICATION NUMBER: US 09/444,209
/ PRIOR FILING DATE: 1999-11-19
/ PRIOR APPLICATION NUMBER: US 09/159,274
/ PRIOR FILING DATE: 1998-09-22
/ PRIOR APPLICATION NUMBER: US 60/059,473
/ PRIOR FILING DATE: 1997-09-22
/ NUMBER OF SEQ ID NOS: 1208
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 53
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-479-005A-53

Query Match          0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 403 ATCATCAGCACCCCTG 417
Db 16 ATCATCAACACCCCTG 2

RESULT 131
US-08-985-162-370
/ Sequence 370, Application US/08985162
/ Patent No. 6057156
/ GENERAL INFORMATION:
/ APPLICANT: Akhtar, Saghir
/ APPLICANT: Fell, Patricia
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
/ TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
/ TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
/ TITLE OF INVENTION: FACTOR RECEPTORS
/ NUMBER OF SEQUENCES: 1877
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq for Windows 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/985,162
/ FILING DATE: 04 December 1997
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 230/107
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 370:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-985-162-370
```

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCACTACTACCG 1175
DB 1 CUCCAGCUUCCG 15

RESULT 132

US-08-584-040-2404/c
Sequence 2404, Application US/08584040

Patent No. 6346398

GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 2404:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2404

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1513 CCCAGGCAACTTC 1527
DB 17 CCCAGGCAAGTTC 3

RESULT 133

US-08-584-040-4361

Sequence 4361, Application US/08584040

Patent No. 6346398

GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 4361:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4361

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTCTCCAGC 810
DB 2 CCCAGAUUCCAGC 16

RESULT 134

US-08-584-040-4362

Sequence 4362, Application US/08584040

Patent No. 6346398

GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 4362:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-4362

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
||||| :|:|:|
Db 1 CCCAGAUUCCAGC 15

RESULT 135
US-09-371-772B-949/c
; Sequence 949, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-949

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1513 CCCAGGCAACTTTC 1527
||||| :|:|:|
Db 17 CCCAGGCAAGTTTC 3

RESULT 136
US-09-371-772B-2128
; Sequence 2128, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2128
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2128

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
||||| :|:|:|
Db 2 CCCAGAUUCCAGC 16

RESULT 137
US-09-371-772B-2129
; Sequence 2129, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2129
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2129

Query Match 0.9%; Score 13.4; DB 1; Length 17;

Best Local Similarity 73.3%; Pred. No. 1.1e+02; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCAGTTCCTCCAGC 810
| | | | : | | | |
Db 1 CCAGAUUCCAGC 15

RESULT 138

US-09-371-772B-4663/c
; Sequence 4663, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4663
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4663

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 261 AGTTCCTTGAGCAG 275
| | | | | | | | | |
Db 17 AGTTCCTTGAGCAG 3

RESULT 139

US-09-371-772B-5311/c
; Sequence 5311, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5311
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5311

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1512 ACCCAGGCAACTTT 1526
| | | | | | | | | |
Db 15 ACCCAGGCAAGTTT 1

RESULT 140

US-09-401-063-370
; Sequence 370, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 370:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-370

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.1e+02;

Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCCAACTACTACCG 1175
| | | | | | | | | |
Db 1 CUCCAAUCUCCG 15

RESULT 141

US-09-866-108A-6623
; Sequence 6623, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6623
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6623

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAC 35
Db 3 TCTGCGTCTGCATAG 17

RESULT 142
US-09-866-108A-6630
; Sequence 6630, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6623
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6623

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAC 35
Db 3 TCTGCGTCTGCATAG 17

RESULT 142
US-09-866-108A-6630
; Sequence 6630, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6623
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6623

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 GTCTGCAGAGGACAG 40
Db 1 GTCTGCATAGGACAG 15

RESULT 143
US-09-866-108A-10675/c
; Sequence 10675, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10675
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6630
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6630

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 GTCTGCAGAGGACAG 40
Db 1 GTCTGCATAGGACAG 15

RESULT 143
US-09-866-108A-10675/c
; Sequence 10675, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10675
```



```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10675

Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1259 GGGTAGCCATGCTGG 1273
    |||||
DB 16 GGGTGGCCATGCTGG 2

RESULT 144
US-09-866-108A-10676/c
; Sequence 10676, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10676
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10676

Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1259 GGGTAGCCATGCTGG 1273
    |||||
DB 15 GGGTGGCCATGCTGG 1

RESULT 145
US-09-404-912-100/c
; Sequence 100, Application US/09404912
; Patent No. 6703228
```

```
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 100
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-100

Query Match          0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 727 AGCTACTCCTTCCTG 741
    |||||
DB 15 AGCTACTCCTTCCTG 1

RESULT 146
US-09-490-692-109
; Sequence 109, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTS-0120
; CURRENT APPLICATION NUMBER: US/09/490,692
; CURRENT FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-109

Query Match          0.9%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 CTGCAGAGGACAGAA 42
    |||||
DB 1 CTGCAGAGGACAGAA 15

RESULT 147
US-08-685-558A-17/c
; Sequence 17, Application US/08685558A
; Patent No. 6225081
; GENERAL INFORMATION:
; APPLICANT: SHIMOMURA, Takeshi
; APPLICANT: KAWAGUCHI, Toshiya
; APPLICANT: KITAMURA, Naomi
; APPLICANT: MIYAZAWA, Keiji
; TITLE OF INVENTION: NOVEL PROTEIN, DNA CODING FOR SAME
; TITLE OF INVENTION: AND METHOD OF PRODUCING THE PROTEIN
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
STREET: 2100 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20037

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/685,558A
FILING DATE: 24-JUL-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JPA Hei 7-187135

FILING DATE: 24-JUL-1995
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid, synthetic DNA
US-08-685-558A-17

Query Match 0.8%; Score 13.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 876 CAGGTGGAATTATGTGG 892
||:|||||:|||||

Db 17 CARGTNGARTTGTGGG 1

RESULT 148
US-09-765-449-17/c
; Sequence 17, Application US/09765449
; Patent No. 6465622
; GENERAL INFORMATION:
; APPLICANT: SHIMOMURA, Takeshi
; KAWAGUCHI, Toshiya
; KITAMURA, Naomi
; MIYAZAWA, Keiji

TITLE OF INVENTION: NOVEL PROTEIN, DNA CODING FOR SAME
AND METHOD OF PRODUCING THE PROTEIN

NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESSES:
ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
STREET: 2100 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20037

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/765,449
FILING DATE: 22-Jan-2001
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/685,558
FILING DATE: <Unknown>

INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid, synthetic DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 17

Query Match 0.8%; Score 13.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 876 CAGGTGGAATTATGTGG 892
||:|||||:|||||

Db 17 CARGTNGARTTGTGGG 1

RESULT 149
US-08-758-306-53/c
; Sequence 53, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-758-306-53

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAG 93
|||||

Db 13 TGGAAACACTGAG 1

RESULT 150
US-08-584-040-3741
; Sequence 3741, Application US/08584040

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAG 93
|||||

Db 13 TGGAAACACTGAG 1

RESULT 150
US-08-584-040-3741
; Sequence 3741, Application US/08584040

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAG 93
|||||

Db 13 TGGAAACACTGAG 1

Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3741:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-3741

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.2e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 946 GGCCGCGCTCTGTG 958
DB 1 GGCCGCGCUCUG 13

RESULT 151
US-09-474-432B-457/c
Sequence 457, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleo

CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 457
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-457

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 GGCCATGCGGAG 210
DB 16 GGCCATGCGGAG 4

RESULT 152
US-09-535-012A-17/c
Sequence 17, Application US/09535012A
Patent No. 6531281
GENERAL INFORMATION:
APPLICANT: Elf Exploration Production
TITLE OF INVENTION: Method of Detecting Sulphate- Reducing Bacteria
FILE REFERENCE: 111628-00114
CURRENT APPLICATION NUMBER: US/09/535,012A
CURRENT FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: 9903637
PRIOR FILING DATE: 1999-03-24
NUMBER OF SEQ ID NOS: 25
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 17
LENGTH: 17
TYPE: DNA
ORGANISM: Desulfovibrio vulgaris
FEATURE:
OTHER INFORMATION: aspl3 primer
US-09-535-012A-17

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 AACTTCATGATGC 1393
DB 17 AACTTCATGATGC 5

RESULT 153
US-09-371-772B-1508
Sequence 1508, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH900,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1508
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1508

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.2e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 946 GGCGGCTCTGTG 958
Db 1 GGCGGCCUCUG 13

RESULT 154
US-09-476-387-456/c
; Sequence 456, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 456
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-456

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 GGCCATGCGGGAG 210
Db 16 GGCCATGCGGGAG 4

RESULT 155
US-09-304-232-370/c
; Sequence 370, Application US/09304232
; Patent No. 6525185
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian Bing
; APPLICANT: Chakravarti, Aravinda
; APPLICANT: Halushka, Marc Kenneth
; APPLICANT: Case Western Reserve University School of Medicine

; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Polymorphisms Associated With
; FILE REFERENCE: 018547-034210US
; CURRENT APPLICATION NUMBER: US/09/304,232
; CURRENT FILING DATE: 1999-05-03
; EARLIER APPLICATION NUMBER: US 60/084,641
; EARLIER FILING DATE: 1998-05-07
; NUMBER OF SEQ ID NOS: 909
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 370
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: CYP11B2EX3 138
US-09-304-232-370

Query Match 0.8%; Score 13; DB 1; Length 29;
Best Local Similarity 69.6%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 273 CAGGACCCAGGAGCCATCCCTGG 295
Db 27 CAGGGCTGGGARAAGTCCTGG 5

RESULT 156
US-09-527-030G-88
; Sequence 88, Application US/09527030G
; Patent No. 6482588
; GENERAL INFORMATION:
; APPLICANT: VAN DOORN, Leen-Jan et al.
; TITLE OF INVENTION: Detection and Identification of Human Papillomavirus by PCR and ty
; FILE REFERENCE: Specific reverse hybridization.
; CURRENT APPLICATION NUMBER: US/09/527,030G
; CURRENT FILING DATE: 2000-03-16
; NUMBER OF SEQ ID NOS: 497
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 88
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Type specific probe derived from the Human Papillomavirus (HPV)
US-09-527-030G-88

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 151 CAATTGCTGGGCAAG 166
Db 1 CATTGCTGGGCAAG 16

RESULT 157
US-09-060-299-439
; Sequence 439, Application US/09060299
; Patent No. 6545137
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6545137el Receptor


```
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida glabrata
; IMMEDIATE SOURCE:
; CLONE: Y55CRNAS
US-08-379-081B-284

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      535 TTGGCGCGGTACCAGG 550
Db      2 TTGGCGCGGACCAGG 17
      ||||| |||||

RESULT 160
US-08-390-850-455
; Sequence 455, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTIFICIAL CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 455:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-390-850-455

Query Match          0.8%; Score 12.8; DB 1; Length 17;
```

```
; Best Local Similarity 81.2%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      38 CAGAAGCGCTGGAGG 53
Db      1 CUGAAGGUCUGGAGG 16
      ||||| |||||

RESULT 161
US-08-379-078-284
; Sequence 284, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:
; APPLICANT: Mitsuhashi, Masato
; APPLICANT: Cooper, Allan
; TITLE OF INVENTION: Gene Detection System
; NUMBER OF SEQUENCES: 726
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,078
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/974,406
; FILING DATE: 12-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 284:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida glabrata
; IMMEDIATE SOURCE:
; CLONE: Y55CRNAS
US-08-379-078-284

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      535 TTGGCGCGGTACCAGG 550
Db      2 TTGGCGCGGACCAGG 17
      ||||| |||||

RESULT 162
US-08-462-894-35/c
; Sequence 35, Application US/08462894
; Patent No. 5723312
; GENERAL INFORMATION:
; APPLICANT: NOESKE-JUNGBLUT, CHRISTIANE
```

APPLICANT: HAENDLER, BERNHARD
APPLICANT: KRAETZSCHMAR, JOERN
APPLICANT: SCHLEUNING, WOLF-DIETER
APPLICANT: ALAGON, ALEJANDRO
APPLICANT: POSSANI, LOURIVAL
APPLICANT: CURVAS-AGUIRRE, DELIA
TITLE OF INVENTION: COLLAGEN-INDUCED PLATELET AGGREGATION
TITLE OF INVENTION: INHIBITOR
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
STREET: 2200 CLARENDON BLVD., SUITE 1400
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: US
ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,894
FILING DATE: 05-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/206,185
FILING DATE: 07-MAR-1994
APPLICATION NUMBER: US 08/116,889
FILING DATE: 07-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/EP92/02052
FILING DATE: 04-SEP-1992
APPLICATION NUMBER: US 07/914,383
FILING DATE: 17-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/814,884
FILING DATE: 31-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/756,211
FILING DATE: 05-SEP-1991
ATTORNEY/AGENT INFORMATION:
NAME: HAMLET-KING, DIANA
REGISTRATION NUMBER: 33,302
REFERENCE/DOCKET NUMBER: SCH 1359
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-243-6333
TELEFAX: 703-243-6410
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-462-894-35

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1515 CCAGGCAACTTCTCG 1530
Db 17 CCAGTTAACTTCTGG 2

RESULT 163
US-08-435-634-455
Sequence 455, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John T.
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
CITY: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295 September 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 455:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-455

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 38 CAGAGGGCTGGGAGG 53
Db 1 CUGAGGGCUGGGAGG 16

RESULT 164
US-08-206-185-35/c
Sequence 35, Application US/08206185
Patent No. 5756454
GENERAL INFORMATION:
APPLICANT: NOESKE-JUNGBLUT, CHRISTIANE
APPLICANT: HAENDLER, BERNHARD
APPLICANT: KRAETZSCHMAR, JOERN
APPLICANT: SCHLEUNING, WOLF-DIETER
APPLICANT: ALAGON, ALEJANDRO
APPLICANT: POSSANI, LOURIVAL
APPLICANT: CURVAS-AGUIRRE, DELIA
TITLE OF INVENTION: COLLAGEN-INDUCED PLATELET AGGREGATION
TITLE OF INVENTION: INHIBITOR
NUMBER OF SEQUENCES: 36

/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
/ STREET: 2200 CLARENDON BLVD., SUITE 1400
/ CITY: ARLINGTON
/ STATE: VIRGINIA
/ COUNTRY: US
/ ZIP: 22201
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ FILING DATE: 07-MAR-1994
/ APPLICATION NUMBER: US/08/206,185
/ CLASSIFICATION: 530
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/116,889
/ FILING DATE: 07-SEP-1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: WO PCT/EP92/02052
/ FILING DATE: 04-SEP-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/914,383
/ FILING DATE: 17-JUL-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/814,884
/ FILING DATE: 31-DEC-1991
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/756,211
/ FILING DATE: 05-SEP-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: HAMLET-KING, DIANA
/ REGISTRATION NUMBER: 33,302
/ REFERENCE/DOCKET NUMBER: SCH 1359
/ TELEPHONE: 703-243-6333
/ TELEFAX: 703-243-6410
/ INFORMATION FOR SEQ ID NO: 35:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-206-185-35

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1515 CCAGGCAACTTCTGG 1530
||| |||||
Db 17 CCAGTTAACTTCTGG 2

RESULT 165
US-08-766-677-5/c
; Sequence 5, Application US/08766677
; Patent No. 5830668
; GENERAL INFORMATION:
; APPLICANT: Vojdani, Ariosto
; APPLICANT: Mordechai, Eli
; TITLE OF INVENTION: Detection of Chronic Fatigue
; TITLE OF INVENTION: Syndrome
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:

/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/766,677
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Altman, Daniel E
/ REGISTRATION NUMBER: 34,115
/ REFERENCE/DOCKET NUMBER: IMSCI.002A
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 714/760-0404
/ TELEFAX: 714/760-9503
/ TELEX:
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA
/ US-08-766-677-5

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGAAACAGAAAG 307
||| |||||
Db 17 CTGCAGAAACAGAAAG 2

RESULT 166
US-08-292-620A-1675/c
; Sequence 1675, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application

two

;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1675:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-292-620A-1675

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 167

US-08-292-620A-1692/c
; Sequence 1692, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.

two

;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1692:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-292-620A-1692

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 168

US-08-292-620A-1973/c
; Sequence 1973, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1973:

two

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1973

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGCCTGGGAGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 169
US-08-843-951-5/c
; Sequence 5, Application US/08843951
; Patent No. 5853996
; GENERAL INFORMATION:
; APPLICANT: Vojdani, Aristo
; APPLICANT: Mordchai, Eli
; TITLE OF INVENTION: Detection of Chronic Fatigue
; TITLE OF INVENTION: Syndrome
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive Sixteenth Flo
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/843,951
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/766,677
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: IMSCI.002A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714/760-0404
; TELEFAX: 714/760-9503
; TELEX:
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-843-951-5

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACAGAAAG 307
Db 17 CTGCAGAACAGAAAG 2

RESULT 170
US-08-544-381B-241/c
; Sequence 241, Application US/08544381B
; Patent No. 6027880
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbard, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; TITLE OF INVENTION: Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004130US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 241:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
US-08-544-381B-241

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 CCTTCTCCAACTACTA 1172
Db 16 CCTTCTCCAACTACTA 1

RESULT 171
US-08-945-654-9
; Sequence 9, Application US/08945654
; Patent No. 6071747
```

```

; GENERAL INFORMATION:
; APPLICANT: IMMORTALIZED CELL LINES FROM HUMAN
; TITLE OF INVENTION: ADIPOSE TISSUE, PROCESS FOR PREPARING SAME AND APPLICATIONS
; TITLE OF INVENTION: THEREOF.
; NUMBER OF SEQUENCES: 22
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/945,654
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 9504922
; FILING DATE: 25-APR-1995
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "PRIMER"
US-08-945-654-9
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 985 GAGCCCTTCAGCACCC 1000
Db 1 GAGACCTTCACACCC 16

RESULT 172
US-08-998-099-50
; Sequence 50, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-FOS
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 50
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-50
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1285 GTCCTCGCAGTGCC 1300
Db 2 GUCUCCUCUGGCC 17
```

```

RESULT 173
US-09-071-845-1675/c
; Sequence 1675, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (1-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1675:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1675
Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGCCTGGGAGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

-RESULT 174
US-09-071-845-1692/c
; Sequence 1692, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
```

APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1692:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1692

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 175
US-09-071-845-1973/c
Sequence 1973, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1973:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1973

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 GGGCTGGGAGGGGAGC 58
Db 16 GCGCTGGGAGGGGTGC 1

RESULT 176
US-08-584-040-5681
Sequence 5681, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California

COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5681:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5681

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1354 CTCCTCTGTCATTG 1369
|||: |||: |||: |||:
DB 1 CUCCUUCUGUCAUG 16

RESULT 177
US-09-270-140A-40/c
Sequence 40, Application US/09270140A
Patent No. 6361941
GENERAL INFORMATION:
APPLICANT: Todd, Alison
APPLICANT: Fuary, Caroline
APPLICANT: Cairns, Murray
TITLE OF INVENTION: Catalytic Nucleic Acid base Diagnostic Methods
FILE REFERENCE: J&J1799
CURRENT APPLICATION NUMBER: US/09/270,140A
CURRENT FILING DATE: 1999-03-16
PRIOR APPLICATION NUMBER: 60/079,651
PRIOR FILING DATE: 1998-03-27
NUMBER OF SEQ ID NOS: 96
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 40
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:wildtype RNA
OTHER INFORMATION: for codon 542 - wildtype cystic fibrosis
US-09-270-140A-40

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 CCTCTCCCAACTACTA 1172
||||| ||||| |||||
DB 16 CCTTCTCCCAAGAACTA 1

RESULT 178
US-09-474-432B-448
Sequence 448, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
FILE REFERENCE: MBH00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 448
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-448

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1181 GGAACGTGTGTGTCCA 1196
||||| ||||| |||||
DB 2 GGAACGUGCUGGUCAA 17

RESULT 179
US-09-371-772B-2567
Sequence 2567, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2567
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-2567

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Db 1 AUGGAGCCAGGCCUGG 16
|:|||||

RESULT 184
US-09-371-772B-5375/c
; Sequence 5375, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5375
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5375

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1416 ATGGACGTGCTGATG 1431
|:|||||

RESULT 185
US-09-371-772B-6490
; Sequence 6490, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6490
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6490

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 GCAGGACCCAGGAGCC 287
|:|||||

Db 2 GCAGGACCCAGGAGAC 17
|:|||||

RESULT 186
US-09-371-772B-6491
; Sequence 6491, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6491
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6491

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 GCAGGACCCAGGAGCC 287
|:|||||

RESULT 187
US-09-371-772B-6686
; Sequence 6686, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6686
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6686

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 283 GAGCCATCCCTGGGA 298
|:|||||

Db 1 GAGCAUCCUGUGGA 16
|:|||||

RESULT 188
US-09-686-383-1/c
; Sequence 1, Application US/09686383
; Patent No. 6607885
; GENERAL INFORMATION:
; APPLICANT: LAROSSA A, ROBERT
; APPLICANT: WEI, YAN
; TITLE OF INVENTION: A METHOD FOR HIGH-DENSITY MICROARRAY MEDIATED GENE
; TITLE OF INVENTION: EXPRESSION PROFILING
; FILE REFERENCE: BC1025 US NA
; CURRENT APPLICATION NUMBER: US/09/686,383
; CURRENT FILING DATE: 2000-10-11
; PRIOR APPLICATION NUMBER: 60/159,898
; PRIOR FILING DATE: 1999-10-15
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Microsoft Office 97
; SEQ ID NO 1
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:PRIMER
US-09-686-383-1

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1015 TCTATCTGTCATGCCA 1030
Db 16 TCTGTCCTGCGTGCCA 1

RESULT 189
US-09-476-387-447
; Sequence 447, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MEBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 447
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-447

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1181 GGAACGTGCTGTCCA 1196
Db 2 GGAACGUCGUGGCA 17
RESULT 190
US-09-827-998-755
; Sequence 755, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 755
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-755

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTCTCTGCCA 834
Db 2 CTTCTCTCTCTGCCA 17

RESULT 191
US-09-827-998-756
; Sequence 756, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 756
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-756

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTCTCTGCCA 834
Db 1 CTTCTCTCTCTGCCA 16

RESULT 192
US-09-827-998-759


```

; Sequence 759, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF
; FILE REFERENCE: MDHW0F-8
; CURRENT APPLICATION NUMBER: US/09/827998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeonica Sequence Listing Ex
; Patent No. 6656700
; SEQ ID NO 759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-759

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 823 CTCTTCTGCCCAACAC 838
||| ||| ||| ||| ||| ||| ||| |||
Db 2 CTCGTCTGCCCATCAC 17

```

RESULT 193
US-09-827-998-762
Sequence 762, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
APPLICANT: Shanon, Mark
TITLE OF INVENTION: NOVEL ISOFORMS OF
FILE REFERENCE: MDWOPF-8
CURRENT APPLICATION NUMBER: US/09/827
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1981
SOFTWARE: Aeonica Sequence Listing Ex
Patent No. 6656700
SEQ ID NO 762
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-762

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 825 CTTCTGCCCAACACTC 840
| | | | | | | | | |
Db 1 CGTCTGCCCATCACTC 16

RESULT 194
US-09-866-108A-434/c
; Sequence 434, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

```

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; FILE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aewmica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 434
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-434

```

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14: Conservative 0; Mismatches 2; Indels

Qy 178 CTGAGGGAGCTGCTGG 193
|||
Db 17 CTGAGAGATCTGCTGG 2

RESULT 195
US-09-866-108A-435/c
; Sequence 435, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 435
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-435

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 CTGAGGAGCTGTGG 193
||||| ||| |||||
Db 16 CTGAGAGATCTGTGG 1

RESULT 196
US-09-866-108A-930
; Sequence 930, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 930
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-930

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 739 CTGAGAGAGCTGTGC 754
||||| ||| |||||
Db 2 CTGAAAGAGCTGAGC 17

RESULT 197
US-09-866-108A-932
; Sequence 932, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 932
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-932

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 740 TGAGAGAGCTGTGCC 755
||||| ||| |||||
Db 1 TGAAGAGCTGAGCC 16

RESULT 198
US-09-866-108A-1200/c
; Sequence 1200, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1200
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1200

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTGCCTTCT 1076
DB 17 TCTTCTGCTTACT 2

RESULT 199
US-09-866-108A-1201/c
; Sequence 1201, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1200
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1200

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTGCCTTCT 1076
DB 17 TCTTCTGCTTACT 2
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1201
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1201

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTGCCTTCT 1076
DB 16 TCTTCTGCTTACT 1

RESULT 200
US-09-866-108A-1416
; Sequence 1416, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
US-09-866-108A-1416
Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 138 GGCTGTGAAGGCACAA 153
      |||||
Db 2 GGCTGTGAAGCCCAA 17

RESULT 201
US-09-866-108A-1417
; Sequence 1417, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1417
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1417

Query Match          0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 138 GGCTGTGAAGGCACAA 153
      |||||
Db 1 GGCTGTGAAGCCCAA 16

RESULT 202
US-09-866-108A-1535
; Sequence 1535, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1537

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 495 GCGCTGTGACCTGG 510
DB 1 GCGCTGTGACCTGG 16

RESULT 204
US-09-866-108A-1646/c
; Sequence 1646, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1646
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1646

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 495 GCGCTGTGACCTGG 510
DB 1 GCGCTGTGACCTGG 16

RESULT 204
US-09-866-108A-1646/c
; Sequence 1646, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1646
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1646
```

```

; ORGANISM: Homo sapiens
US-09-866-108A-1646

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1063 TTCCTTGCCCTTCCTCC 1078
DB 17 TCCTTTGCCCTCCTCC 2

RESULT 205
US-09-866-108A-1648/c
; Sequence 1648, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1648

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CTCCTTTGCCCTTCCTC 1077
DB 16 CTCCTTTGCCCTTCCTC 1

RESULT 206
US-09-866-108A-2289/c
; Sequence 2289, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2289
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2289

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 560 TGTGGCCAGGGGCAC 575
Db 17 TGTGGCCATGGACAC 2

RESULT 207
US-09-866-108A-2301/c
; Sequence 2301, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2289
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2289
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2301
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2301

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 GGCCTACGGCTGG 564
Db 16 GGCCTACGGCTGG 1

RESULT 208
US-09-866-108A-6545/c
; Sequence 6545, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6545
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6545

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 250 CCACCTCCCCCAGGTT 265
Db 17 CCACCTGCCCCAGGCT 2

RESULT 209
US-09-866-108A-6546/c
; Sequence 6546, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6915
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6915

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGGAACACAGAAAG 307
Db 17 CTGGCGAGACAGAAAG 2

RESULT 211
US-09-866-108A-6917/c
; Sequence 6917, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6546

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 250 CCACCTCCCCCAGGTT 265
Db 16 CCACCTGCCCCAGGCT 1

RESULT 210
US-09-866-108A-6915/c
; Sequence 6915, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

;
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6917
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6917

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 CCTGGGGAACAGAAA 306
Db 16 CCTGGCGAGACAGAAA 1

RESULT 212
US-09-866-108A-7706
; Sequence 7706, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7706

;
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7706

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 902 TTGCCCGAGCCCTGGG 917
Db 2 TGGCCCGAGCCCTAGG 17

RESULT 213
US-09-866-108A-7707
; Sequence 7707, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7707
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7707

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 902 TTGCCCGAGCCCTGGG 917
Db 1 TGGCCCGAGCCCTAGG 16

RESULT 214
US-09-866-108A-8327/c
; Sequence 8327, Application US/09866108A
; Patent No. 6686188


```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8327
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8327

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1067 TTGCTTCTCCATTG 1082
DB 17 TTGCTTCTCCATTG 2

RESULT 215
US-09-866-108A-8328/c
; Sequence 8328, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8327
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8327

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1067 TTGCTTCTCCATTG 1082
DB 17 TTGCTTCTCCATTG 2

RESULT 216
US-09-866-108A-8351/c
; Sequence 8351, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
```

; SEQ ID NO 8351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8351

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 727 AGCTACTCCTTCTGA 742
|||||
Db 17 AGCTCCTCTTGCTGA 2

RESULT 217
US-09-866-108A-8352/c
; Sequence 8352, Application US/09866108A
; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 8352

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-8352

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 727 AGCTACTCCTTCTGA 742
|||||
Db 16 AGCTCCTCTTGCTGA 1

RESULT 218

US-09-866-108A-8361/c

; Sequence 8361, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 8361

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-8361

Query Match 0.8%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.3e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 CAGTTTCTCCAGCTAC 813

|||||

Db 17 CACTTCTCCAGCTCC 2

RESULT 219

US-09-866-108A-8362/c

; Sequence 8362, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8362

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 CAGTTTCTCCAGCTAC 813
||| |||||
DB 16 CACTTTCTCCAGCTCC 1

RESULT 220
US-09-866-108A-8928
; Sequence 8928, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine

; Patent No. 6686188
; SEQ ID NO. 8928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8928

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTCCAG 1482
||||| |||||
DB 2 CAGCCAGTACTACCAG 17

RESULT 221
US-09-866-108A-8929
; Sequence 8929, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8929
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8929

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTCCAG 1482
||||| |||||
DB 1 CAGCCAGTACTACCAG 16

RESULT 222
US-09-866-108A-9020/c

; Sequence 9020, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeonica Sequence Listing Engine
; NUMBER OF SEQ ID NOS: 15755
; Patent No. 6686188
; SEQ ID NO 9020
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9020

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1153 ACGTCCTTCTCCAACT 1168
||| ||||| ||||| |||
Db 17 ACGTACTTCTCCAGCT 2

RESULT 223
US-09-866-108A-9021/c
; Sequence 9021, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeonica Sequence Listing Engine
; NUMBER OF SEQ ID NOS: 15755
; Patent No. 6686188
; SEQ ID NO 9021
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9021

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1153 ACGTCCTTCTCCAACT 1168
||| ||||| ||||| |||
Db 16 ACGTACTTCTCCAGCT 1

RESULT 224
US-09-866-108A-9023/c
; Sequence 9023, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755


```
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9830
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-9830

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1138 GACTGTGGGAACCTCAA 1153
Db 16 GGCTGTGGGACCTCAA 1

RESULT 228
US-09-866-108A-10672/c
; Sequence 10672, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10672
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-10672

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 GTAGCCATGCTGGGTG 1276
Db 17 GTGGCCATGCTGGGTG 2

RESULT 229
5496924-10
; Patent No. 5496924
; APPLICANT: HABERMANN, PAUL; WENGENMAYER, FRIEDRICH
; TITLE OF INVENTION: FUSION PROTEIN COMPRISING AN
; INTERLEUKIN-2 FRAGMENT BALLAST PORTION
; NUMBER OF SEQUENCES: 56
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/194,545
; FILING DATE: 28-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 377,313
; FILING DATE: 10-JUL-1989
; APPLICATION NUMBER: 934,910
; FILING DATE: 25-NOV-1986
; APPLICATION NUMBER: 943,804
; FILING DATE: 19-DEC-1986
; SEQ ID NO: 10;
; LENGTH: 17
5496924-10

Query Match      0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 24 GCGTCTGCAGAGGACA 39
Db 2 GCGTCTGCAGATGCCA 17

RESULT 230
US-08-985-162-1812
; Sequence 1812, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
```

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1812:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-1812

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 442 AGGCTGCTGCTGGA 455
DB 1 AGGCUGCUGCAGGA 14
||||:|||||

RESULT 231
US-09-504-132-11/C
Sequence 11, Application US/09504132
Patent No. 6582899
GENERAL INFORMATION:
APPLICANT: Kamb, Carl Alexander
TITLE OF INVENTION: METHODS FOR IDENTIFYING AGENTS THAT CAUSE A LETHAL
TITLE OF INVENTION: METHODS FOR IDENTIFYING AGENTS THAT CAUSE A LETHAL
FILE REFERENCE: 29345/36169
CURRENT APPLICATION NUMBER: US/09/504,132
CURRENT FILING DATE: 2000-02-15
NUMBER OF SEQ ID NOS: 26
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 11
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: synthetic -
OTHER INFORMATION: Aptamer 5
US-09-504-132-11

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 183 GGAGCTGCTGGATC 196
DB 14 GGAGCTTCTGGATC 1
|||||

RESULT 232
US-09-401-063-1812
Sequence 1812, Application US/09401063
Patent No. 6623962
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia

APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/401,063
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/985,162
FILING DATE: 04 December 1997
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1812:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-401-063-1812

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 442 AGGCTGCTGCTGGA 455
DB 1 AGGCUGCUGCAGGA 14
||||:|||||

RESULT 233
US-09-874-601-115
Sequence 115, Application US/09874601
Patent No. 6632057
GENERAL INFORMATION:
APPLICANT: LEWIN, ALFRED S.
APPLICANT: SHAW, LYNN C.
TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHODS
TITLE OF INVENTION: THE TREATMENT OF RETINAL DISEASES
FILE REFERENCE: 4300.014100
CURRENT APPLICATION NUMBER: US/09/874,601
CURRENT FILING DATE: 2001-05-01
PRIOR APPLICATION NUMBER: 09/063,667
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/046,147
PRIOR FILING DATE: 1997-05-09
PRIOR APPLICATION NUMBER: 60/044,492
PRIOR FILING DATE: 1997-04-21

ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 855:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-855

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 1.2e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 880 TGGATTATGTGCG 893
DB 2 UGUUAUUGUGC 15

RESULT 237
US-08-585-684B-1398
Sequence 1398, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1801:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
FILING DATE: January 16, 1996

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1398:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1398

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 1.2e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1038 AGGCATCTCATGC 1051
DB 2 AGACAUUUGUGC 15

RESULT 238
US-08-585-684B-1801/C
Sequence 1801, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1801:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

```
; TOPOLOGY: linear
; US-08-585-684B-1801

Query Match          0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 77 TGAGTGGAAACT 90
Db 15 GAGATGGAACTCT 2

RESULT 239
US-08-585-684B-1802/c
; Sequence 1802, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1802:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-1802

Query Match          0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 73 TGTGGAGATGGA 86
Db 14 TGAGGAGATGGA 1

RESULT 241
US-08-913-833-60/c
; Sequence 60, Application US/08913833
; Patent No. 6087093
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, JOOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Microsoft Word 6.0 / ASCII text output
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/913,833
;; FILING DATE: 15 Sep 1997
;; PRIOR APPLICATION DATA: PCT/EP97/00211
;; FILING DATE: 17 Jan 1997
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: EP 96870005.4
;; FILING DATE: 26 Jan 1996
;; PRIOR APPLICATION DATA: EP 96870081.5
;; FILING DATE: 25 Jun 1996
;; ATTORNEY/AGENT INFORMATION:
;; NAME: KAMMERER, PATRICIA A.
;; REGISTRATION NUMBER: 29,775
;; REFERENCE/DOCKET NUMBER: INNS:008
;; INFORMATION FOR SEQ ID NO: 60:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; HYPOTHETICAL: NO
;; ANTI-SENSE: NO
;; US-08-913-833-60

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 286 CCATCCCTGGGAA 299
Db 15 CCATCCCTGTGAA 2

RESULT 242
US-09-064-156A-139/c
; Sequence 139, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992

;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 234/083
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 139:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-064-156A-139

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 340 CTGATGGAGGTGCA 353
Db 14 CTGATGGAGGTGCA 1

RESULT 243
US-09-038-073-855
; Sequence 855, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/595,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 855:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-855

```

Query Match          0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 1.2e+02;
Matches 8; Conservative 5; Mismatches 1; Indels

```

RESULT 244
US-09-038-073-1398
Sequence 1398, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ version 1.5
CURRENT APPLICATION DATA: 09/038, 073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684

RESULT 245
US-09-038-073-1801/c
; Sequence 1801, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale

APPLICANT: McSwiggen, James
 TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
 TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
 NUMBER OF SEQUENCES: 2751
 CORRESPONDENCE ADDRESS:
 ADDRESS: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: FastSEQ Version 1.5
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/038,073
 FILING DATE:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/585,684
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 218/078
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 1801:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-09-038-073-1801

```

RESULT 246
US-09-038-073-1802/c
; Sequence 1802, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
;

```

```

RESULT 246
US-09-038-073-1802/c
; Sequence 1802, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
;

```

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1802:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1802

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 73 TGTGGAGATGGAAA 86
DB 14 TGAGGAGATGGAAA 1

RESULT 247
US-09-038-073-1803/c
Sequence 1803, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1803:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1803

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 73 TGTGGAGATGGAAA 86
DB 14 TGAGGAGATGGAAA 1

RESULT 248
US-09-580-794C-60/c
Sequence 60, Application US/09580794C
Patent No. 6331389
GENERAL INFORMATION:
APPLICANT: Stuyver, Lieven
APPLICANT: Louwagie, Joost
APPLICANT: Rossau, Rudi
TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
TRANSCRIPTASE GENE
FILE REFERENCE: INNS008--2
CURRENT APPLICATION NUMBER: US/09/580,794C
CURRENT FILING DATE: 2000-05-30
PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
PRIOR FILING DATE: 1997-09-15
PRIOR APPLICATION NUMBER: PCT/EP 97/00211
PRIOR FILING DATE: 1997-01-17
PRIOR APPLICATION NUMBER: EP 96870005.4
PRIOR FILING DATE: 1996-01-26
PRIOR APPLICATION NUMBER: EP 96870081.5
PRIOR FILING DATE: 1996-06-25
NUMBER OF SEQ ID NOS: 164
SOFTWARE: PatentIn version 3.0
SEQ ID NO 60
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic Primer
US-09-580-794C-60

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 286 CCATCCCTGGGAA 299
DB 15 CCATCCCTGGGAA 2

RESULT 249
US-09-081-646-513/c
Sequence 513, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
Cancer Cells
FILE REFERENCE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352

; EARLIER FILING DATE: 1997-05-21
 ; NUMBER OF SEQ ID NOS: 871
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 513
 ; LENGTH: 15
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-081-646-513

Query Match 0.8%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 647 TCCACGTGGCGGTG 660
 Db 14 TCCACGTGGCCATG 1

RESULT 250
 US-09-474-432B-89
 ; Sequence 89, Application US/09474432B
 ; Patent No. 6528640
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Burgin, Alex
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka
 ; APPLICANT: Sweedler, David
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
 ; FILE REFERENCE: MHB00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: Patent in version 3.0
 ; SEQ ID NO 89
 ; LENGTH: 15
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-474-432B-89

Query Match 0.8%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 71.4%; Pred. No. 1.2e+02;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1230 GCTGCGGCTCCTTG 1243
 Db 2 GCTGCGGCCUCCUG 15

RESULT 251
 US-09-476-387-89
 ; Sequence 89, Application US/09476387
 ; Patent No. 6617438
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka Matulic
 ; APPLICANT: Sweedler, Dave
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot

; FILE REFERENCE: MHB00-831-C (249/073)
 ; CURRENT APPLICATION NUMBER: US/09/476,387
 ; CURRENT FILING DATE: 2001-04-04
 ; PRIOR APPLICATION NUMBER: 09/474,432
 ; PRIOR FILING DATE: 1999-12-29
 ; PRIOR APPLICATION NUMBER: 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; PRIOR APPLICATION NUMBER: 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: 60/083,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; NUMBER OF SEQ ID NOS: 1524
 ; SOFTWARE: Patent in version 3.0
 ; SEQ ID NO 89
 ; LENGTH: 15
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-476-387-89

Query Match 0.8%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 71.4%; Pred. No. 1.2e+02;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1230 GCTGCGGCTCCTTG 1243
 Db 2 GCTGCGGCCUCCUG 15

RESULT 252
 US-09-943-983C-60/c
 ; Sequence 60, Application US/09943983C
 ; Patent No. 6713251
 ; GENERAL INFORMATION:
 ; APPLICANT: Stuyver, Lieven
 ; APPLICANT: Louwagie, Joost
 ; APPLICANT: Rosseau, Rudi
 ; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
 ; TITLE OF INVENTION: TRANSCRIPTASE GENE
 ; FILE REFERENCE: 11362.0008.DUUS02 (INNS008--3)
 ; CURRENT APPLICATION NUMBER: US/09/943,983C
 ; CURRENT FILING DATE: 2001-08-31
 ; PRIOR APPLICATION NUMBER: US 09/580,794
 ; PRIOR FILING DATE: 2000-05-30
 ; PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
 ; PRIOR FILING DATE: 1997-09-15
 ; PRIOR APPLICATION NUMBER: PCT/EP 97/00211
 ; PRIOR FILING DATE: 1997-01-17
 ; PRIOR APPLICATION NUMBER: EP 96870005.4
 ; PRIOR FILING DATE: 1996-01-26
 ; PRIOR APPLICATION NUMBER: EP 96870081.5
 ; PRIOR FILING DATE: 1996-06-25
 ; NUMBER OF SEQ ID NOS: 164
 ; SOFTWARE: Patent in version 3.0
 ; SEQ ID NO 60
 ; LENGTH: 15
 ; TYPE: DNA
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Primer
 US-09-943-983C-60

Query Match 0.8%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 286 CCATCCCTGGGAA 299
 Db 15 CCATCCCTGGGAA 2

RESULT 253

5312912-5/c
; Patent No. 5312912
; APPLICANT: HADWIGER, LEE A.; CHIANG, CHIN C.; HOROVITZ,
; DANIEL A.
; TITLE OF INVENTION: PROCEDURES AND REGULATORY DNA SEQUENCES
; FOR GENETICALLY ENGINEERING DISEASE RESISTANCE AND OTHER
; INDUCIBLE TRAITS IN PLANTS
; NUMBER OF SEQUENCES: 9
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/393,301
; FILING DATE: 13-JUN-1989
; SEQ ID NO: 5:
; LENGTH: 15
5312912-5

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1368 TCGAGGAATGTTGA 1381
||||| |||||||
DB 15 TCGAGGAATGTTGA 2

RESULT 254
5463025-7/c
; Patent No. 5463025
; APPLICANT: Sumi, Yoshihiko; Ichikawa, Yataro; Aoki, Nobuo
; Muramatsu, Masami
; TITLE OF INVENTION: PROTEIN HAVING HUMAN PLASMIN INHIBITING
; ACTIVITY
; NUMBER OF SEQUENCES: 7
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/185,162
; FILING DATE: 24-JAN-1994
; PRIOR APPLICATION NUMBER: 60,691
; APPLICATION NUMBER: 60,691
; FILING DATE: 13-MAY-1993
; APPLICATION NUMBER: 419,913
; FILING DATE: 05-SEP-1989
; SEQ ID NO: 7:
; LENGTH: 15
5463025-7

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 44 GGCTGGGAGGGGAG 57
||||| |||||||
DB 15 GGCTGGGAGGGGAG 2

RESULT 255
US-08-248-357C-11/c
; Sequence 11, Application US/08248357C
; Patent No. 5773225
; GENERAL INFORMATION:
; APPLICANT: Luban, Jeremy
; APPLICANT: Goff, Stephen P.
; TITLE OF INVENTION: Screening Method for the Identification of
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/248,357C
; FILING DATE: 24-MAY-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 44010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-278-0400
; TELEFAX: 212-391-0525
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: N
; ANTI-SENSE: N
; FRAGMENT TYPE: N-terminal
US-08-248-357C-11

Query Match 0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 395 GTGCTTCATCATC 408
||||| |||||||
DB 15 GTATCTTCATCATC 2

RESULT 256
US-09-539-191-5
; Sequence 5, Application US/09539191
; Patent No. 6309839
; GENERAL INFORMATION:
; APPLICANT: Raney, Kevin
; APPLICANT: Morris, Patric
; APPLICANT: Dennis, Regina
; TITLE OF INVENTION: Screening Methods for Compounds that Inhibit
; TITLE OF INVENTION: or Stimulate Helicase Enzyme Activity
; FILE REFERENCE: D6229
; CURRENT APPLICATION NUMBER: US/09/539,191
; CURRENT FILING DATE: 2000-03-30
; EARLIER APPLICATION NUMBER: US 60/126,873
; EARLIER FILING DATE: 1999-03-30
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 5:
; LENGTH: 16
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; LOCATION: 15
; OTHER INFORMATION: 3'-bio-16-mer oligonucleotide sequence used for
; OTHER INFORMATION: streptavidin displacement experiments;
; OTHER INFORMATION: n = unknown at nucleotide 15 is biotinylated
US-09-539-191-5

Query Match 0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 327 CCTGCTTGATGAGCT 341
||||| |||||||
DB 2 CCTGCATGATGAGT 16

RESULT 257
US-09-371-772B-5660
; Sequence 5660, Application US/09371772B

```
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5660
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5660

Query Match      0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 1.4e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 629 TGCTCTGCGCGCTG 642
Db 3 UGCUGGCGCGCUG 16

RESULT 258
US-09-371-772B-6965
; Sequence 6965, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6965
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6965

Query Match      0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 78.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGGCGCGCTCT 955
Db 3 CCCGGGCGCGCCUCU 16

RESULT 259
US-09-479-005A-54/c
; Sequence 54, Application US/09479005A
; Patent No. 6656731
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 54
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-54

Query Match      0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 402 CATCATCAGCACCC 415
Db 14 CATCATCAGCACCC 1

RESULT 260
US-08-435-350-95
; Sequence 95, Application US/08435350
; Patent No. 5599704
; GENERAL INFORMATION:
; APPLICANT: James D. Thompson
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: TREATMENT OF BREAST CANCER
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: Wordperfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,350
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936,531
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 197/245
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-350-95
```


Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 500 TCGTGACCTGGG 511
DB 2 UGGUGACCGUGG 13

RESULT 261

US-08-182-968A-66

; Sequence 66, Application US/08182968A

; Patent No. 5610054

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; TITLE OF INVENTION: METHOD AND REAGENT FOR

; TITLE OF INVENTION: INHIBITING HEPATITIS C

; TITLE OF INVENTION: VIRUS REPLICATION

; NUMBER OF SEQUENCES: 497

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: California

; ZIP: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/182,968A

; FILING DATE: 13-JANUARY-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/882,888

; FILING DATE: 14-MAY-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 205/277

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 66:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-182-968A-66

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 679 GCCTCCCGTGT 690
DB 4 GCUCUCCGUGU 15

RESULT 262

US-08-774-306A-66

; Sequence 66, Application US/08774306A

; Patent No. 5869253

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; TITLE OF INVENTION: METHOD AND REAGENT FOR

; TITLE OF INVENTION: INHIBITING HEPATITIS C

; TITLE OF INVENTION: VIRUS REPLICATION

; NUMBER OF SEQUENCES: 497

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: California

; ZIP: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/774,306A

; FILING DATE: December 26, 1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/182,968

; FILING DATE: January 13, 1994

; APPLICATION NUMBER: 07/882,888

; FILING DATE: May 14, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 223/227

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 66:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-774-306A-66

Query Match 0.8%; Score 12; DB 1; Length 15;

Best Local Similarity 66.7%; Pred. No. 1.4e+02;

Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 679 GCCTCCCGTGT 690
DB 4 GCUCUCCGUGU 15

RESULT 263

US-08-804-227C-15/c

; Sequence 15, Application US/08804227C

; Patent No. 5876991

; GENERAL INFORMATION:

; APPLICANT: DeHoff, Bradley S.

; APPLICANT: Kuhstoss, Stuart A.

; APPLICANT: Rostock, Paul R., Jr.

; APPLICANT: Sutton, Kimberly L.

; TITLE OF INVENTION: POLYKETIDE SYNTHASE GENES

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: THOMAS G. PLANT 1501

; STREET: LILLY CORPORATE CENTER

; CITY: INDIANAPOLIS

; STATE: IN

; COUNTRY: USA

; ZIP: 46285

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: MS-DOS

; SOFTWARE: ASCII(DOS) Text only

; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/804,227C
 FILING DATE: February 21, 1997
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Plant, Thomas, G.
 REGISTRATION NUMBER: 35,784
 REFERENCE/DOCKET NUMBER: X-8231
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 317-276-2459
 INFORMATION FOR SEQ ID NO: 15:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 US-08-804-227C-15

Query Match 0.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 CCGCGCGGCTC 683
 DB 13 CCGCGCGGCTC 2

RESULT 264
 US-08-585-684B-738
 ; Sequence 738, Application US/08585684B
 ; Patent No. 5877021
 ; GENERAL INFORMATION:
 ; APPLICANT: Stinchcomb, Daniel T.
 ; APPLICANT: Jarvis, Thale
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
 ; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
 ; NUMBER OF SEQUENCES: 2751
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq version 1.5
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/585,684B
 ; FILING DATE: January 16, 1996
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/000,951
 ; FILING DATE: July 7, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/078
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 738:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear

US-08-804-227C-15

Query Match 0.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 CCGCGCGGCTC 683
 DB 13 CCGCGCGGCTC 2

RESULT 264
 US-08-585-684B-738
 ; Sequence 738, Application US/08585684B
 ; Patent No. 5877021
 ; GENERAL INFORMATION:
 ; APPLICANT: Stinchcomb, Daniel T.
 ; APPLICANT: Jarvis, Thale
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
 ; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
 ; NUMBER OF SEQUENCES: 2751
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq version 1.5
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/585,684B
 ; FILING DATE: January 16, 1996
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/000,951
 ; FILING DATE: July 7, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/078
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 738:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear

US-08-804-227C-15

Query Match 0.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 CCGCGCGGCTC 683
 DB 13 CCGCGCGGCTC 2

RESULT 264
 US-08-585-684B-738
 ; Sequence 738, Application US/08585684B
 ; Patent No. 5877021
 ; GENERAL INFORMATION:
 ; APPLICANT: Stinchcomb, Daniel T.
 ; APPLICANT: Jarvis, Thale
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
 ; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
 ; NUMBER OF SEQUENCES: 2751
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq version 1.5
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/585,684B
 ; FILING DATE: January 16, 1996
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/000,951
 ; FILING DATE: July 7, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/078
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 738:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear

US-08-804-227C-15

Query Match 0.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 CCGCGCGGCTC 683
 DB 13 CCGCGCGGCTC 2

RESULT 264
 US-08-585-684B-738
 ; Sequence 738, Application US/08585684B
 ; Patent No. 5877021
 ; GENERAL INFORMATION:
 ; APPLICANT: Stinchcomb, Daniel T.
 ; APPLICANT: Jarvis, Thale
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
 ; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
 ; NUMBER OF SEQUENCES: 2751
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq version 1.5
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/585,684B
 ; FILING DATE: January 16, 1996
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/000,951
 ; FILING DATE: July 7, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/078
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 738:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear

US-08-804-227C-15

Query Match 0.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 CCGCGCGGCTC 683
 DB 13 CCGCGCGGCTC 2

RESULT 264
 US-08-585-684B-738
 ; Sequence 738, Application US/08585684B
 ; Patent No. 5877021
 ; GENERAL INFORMATION:
 ; APPLICANT: Stinchcomb, Daniel T.
 ; APPLICANT: Jarvis, Thale
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
 ; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
 ; NUMBER OF SEQUENCES: 2751
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq version 1.5
 ; CURRENT

APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1771:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1771
Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e-02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 741 GAGAGAGGCTGT 752
DB 12 GAGAGAGGCTGT 1
RESULT 267
US-08-585-684B-1772/c
Sequence 1772, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1772:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1772
Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e-02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 741 GAGAGAGGCTGT 752
DB 12 GAGAGAGGCTGT 1
RESULT 268
US-09-064-156A-66
Sequence 66, Application US/09064156A
Patent No. 6132966
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 498
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/064,156A
FILING DATE: April 21, 1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/774,306
FILING DATE: December 26, 1996
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 66:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-66

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 679 GCCTCCGTTGT 690
DB 4 GCCUCCGUUG 15

RESULT 269

US-09-038-073-738
Sequence 738, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 738:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-738

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 938 TCATCCTGGCC 949
DB 4 UCAUCCUGGCC 15

RESULT 270

US-09-038-073-739
Sequence 739, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 739:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-739

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 938 TCATCCTGGCC 949
DB 4 UCAUCCUGGCC 15

RESULT 271

US-09-038-073-1771/c
Sequence 1771, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE

;; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
;; NUMBER OF SEQUENCES: 2751
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: Los Angeles
;; COUNTRY: U.S.A.
;; ZIP: 90071
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSEQ Version 1.5
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/038,073
;; FILING DATE:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/585,684
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/078
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1771:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-038-073-1771

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 GAGAGAGGCTGT 752
Db 12 GAGAGAGGCTGT 1

RESULT 272
US-09-038-073-1772/c
; Sequence 1772, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5

;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/038,073
;; FILING DATE:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/585,684
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/078
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1772:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-038-073-1772

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 GAGAGAGGCTGT 752
Db 12 GAGAGAGGCTGT 1

RESULT 273
US-09-593-323-6
; Sequence 6, Application US/09593323
; Patent No. 6265213
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; APPLICANT: Severini, Alberto
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: OF DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/593,323
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; US-09-593-323-6

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTCT 1132
Db 4 ACAGGATGTTCT 15

RESULT 274
US-09-594-108-6
; Sequence 6, Application US/09594108
; Patent No. 6284468
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; APPLICANT: Severini, Alberto
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity

; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/594,108
; PRIOR FILING DATE: 2000-06-13
; PRIOR FILING DATE: 09/344,300
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-594-108-6

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTCT 1132
Db |||||||

RESULT 275
US-09-344-300-6
; Sequence 6, Application US/09344300B
; Patent No. 6297013
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of

; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/344,300B
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-344-300-6

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTCT 1132
Db |||||||

RESULT 276
US-09-081-646-397
; Sequence 397, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352

; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 397
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-397

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 747 GGCTGTGCTGG 758
Db |||||||

RESULT 277
US-09-593-323-7
; Sequence 7, Application US/09593323
; Patent No. 6265213
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of

; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/593,323
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-593-323-7

Query Match 0.8%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTCT 1132
Db |||||||

RESULT 278
US-09-594-108-7
; Sequence 7, Application US/09594108
; Patent No. 6284468
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; APPLICANT: Severini, Alberto
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/594,108
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-594-108-7

Query Match 0.8%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTCT 1132
|||
Db 5 ACAGGATGTTCT 16

RESULT 279
US-09-344-300-7
; Sequence 7, Application US/09344300B
; Patent No. 6297013
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; APPLICANT: Severini, Alberto
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/344,300B
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-344-300-7

Query Match 0.8%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 ACAGGATGTTCT 1132
|||
Db 5 ACAGGATGTTCT 16

Search completed: November 8, 2004, 12:50:47
Job time : 5 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 12:48:20 ; Search time 7 Seconds
(without alignments)
3.506 Million cell updates/sec

Title: US-09-918-026A-3
Perfect score: 1569
Sequence: 1 atggagccaggcggggcccg.....cttggtcctgcatacctag 1569

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 426 seqs, 7822 residues

Total number of hits satisfying chosen parameters: 852

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 428 summaries

Database : rng3.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	25	1.6	25	1	ACCA23398 Human acyl CoA:cho
2	24	1.5	25	1	AAAT76178 Human ACAT Related
3	23	1.5	23	1	AAAT76183 Human ACAT Related
4	21.8	1.4	29	1	AAA041170 Polymorphic fragment
5	21.2	1.4	27	1	AAV983137 Human EGF-R hammer
6	21	1.3	21	1	ACCA23396 Human acyl CoA:cho
7	20	1.3	20	1	AA257334 Human acyl CoA:cho
8	20	1.3	20	1	AA257334 Human acyl CoA:cho
9	20	1.3	20	1	AA257335 Human acyl CoA:cho
10	20	1.3	20	1	ACCA2413 Acyl CoA:cholester
11	20	1.3	20	1	ACCA2419 Acyl CoA:cholester
12	20	1.3	20	1	ACCA2427 Acyl CoA:cholester
13	20	1.3	20	1	ACCA2411 Acyl CoA:cholester
14	20	1.3	20	1	ACCA2422 Acyl CoA:cholester
15	20	1.3	20	1	ACCA2420 Acyl CoA:cholester
16	20	1.3	20	1	ACCA2428 Acyl CoA:cholester
17	20	1.3	20	1	ACCA2446 Acyl CoA:cholester
18	20	1.3	20	1	ACCA2409 Acyl CoA:cholester
19	20	1.3	20	1	ACCA2418 Acyl CoA:cholester
20	20	1.3	20	1	ACCA2429 Acyl CoA:cholester
21	20	1.3	20	1	ACCA2410 Acyl CoA:cholester
22	20	1.3	20	1	ACCA2425 Acyl CoA:cholester
23	20	1.3	20	1	ACCA2431 Acyl CoA:cholester
24	20	1.3	20	1	ACCA2430 Acyl CoA:cholester
25	20	1.3	20	1	ACCA2426 Acyl CoA:cholester
26	20	1.3	20	1	ACCA2414 Acyl CoA:cholester
27	20	1.3	20	1	ACCA2457 Acyl CoA:cholester
28	20	1.3	20	1	ACCA2414 Acyl CoA:cholester
29	20	1.3	20	1	ACCA2415 Acyl CoA:cholester
30	20	1.3	20	1	ACCA2417 Acyl CoA:cholester
31	20	1.3	20	1	ACCA2412 Acyl CoA:cholester
32	20	1.3	20	1	ACCA2421 Acyl CoA:cholester
33	20	1.3	20	1	ACCA2423 Acyl CoA:cholester

34	19.6	1.2	26	1	AA257362 Mouse acyl CoA:cho
35	19.2	1.2	24	1	ABT03549 Human Ach-1 gene P
36	19	1.2	20	1	ACCA2450 Acyl CoA:cholester
37	18.8	1.2	25	1	ADP13837 Renal cell carcinoma
38	18.4	1.2	20	1	ACCA2444 Acyl CoA:cholester
39	18.2	1.2	24	1	AA257361 Mouse acyl CoA:cho
40	18	1.1	18	1	ADL06682 Human P33 cell con
41	18	1.1	20	1	AB276973 Bovine DGAT PCR pr
42	18	1.1	20	1	ACCA2449 Acyl CoA:cholester
43	17.8	1.1	21	1	ACCA2404 Mouse acyl CoA:cho
44	17.4	1.1	21	1	AA449183 Porcine CD 151 cod
45	17	1.1	17	1	ACD51913 HBV inozyme eubatr
46	17	1.1	17	1	ADMS8712 Hepatitis B virus
47	16.8	1.1	20	1	AA202911 PCR primer used to
48	16.8	1.1	20	1	ADCA4458 Primer #2 used to
49	16.8	1.1	20	1	ACCA2438 Acyl CoA:cholester
50	16.8	1.1	20	1	ACCA2439 Acyl CoA:cholester
51	16.8	1.1	20	1	ACCA2447 Acyl CoA:cholester
52	16.8	1.1	20	1	ACCA2453 Acyl CoA:cholester
53	16.8	1.1	20	1	ACCA2445 Acyl CoA:cholester
54	16.8	1.1	20	1	ACCA2456 Acyl CoA:cholester
55	16.8	1.1	20	1	ADJ24468 Human endothelial
56	16.8	1.1	20	1	ADJ23788 Human endothelial
57	16.8	1.1	21	1	AAQ38666 PSOBetaMAX10 5' e
58	16.8	1.1	21	1	AAQ54227 BSSL/CEL Exon 11 r
59	16.8	1.1	21	1	AA292061 SOD expression vec
60	16.4	1.0	19	1	ADL78868 Human HER2 (EGFR2)
61	16.4	1.0	19	1	ADL79117 Human HER2 (EGFR2)
62	16.4	1.0	20	1	AA277373 Human biallelic ma
63	16.2	1.0	21	1	AA447648 Primer (Mkir) for
64	16.2	1.0	21	1	AA447648 Human gene single
65	16	1.0	21	1	AA447648 HBV hammerhead rib
66	16	1.0	17	1	ACD50543 Hepatitis B virus
67	15.8	1.0	19	1	ADL58010 Human PDGFR-target
68	15.8	1.0	19	1	ADL58010 Human PDGFR-target
69	15.8	1.0	19	1	ADL58010 Human PDGFR-target
70	15.8	1.0	19	1	ADL58010 Human PDGFR-target
71	15.8	1.0	20	1	AAH08761 IGH tube D DH fami
72	15.8	1.0	20	1	AAH08761 Rat c-fos protein
73	15.8	1.0	20	1	AAH08761 Primer 1 to amplif
74	15.8	1.0	20	1	AAH08761 PCR primer for a m
75	15.8	1.0	20	1	AAH08761 Human interferon (
76	15.8	1.0	20	1	AAH08761 Human chromosome 1
77	15.8	1.0	20	1	AAH08761 Human ribonuclease
78	15.8	1.0	20	1	AAH08761 Human oligonucleot
79	15.8	1.0	20	1	AAH08761 Human interfeon-e
80	15.8	1.0	20	1	AAH08761 Acyl CoA:cholester
81	15.8	1.0	20	1	AAH08761 Human myosin x-der
82	15.8	1.0	20	1	AAH08761 Human P2X4 gene-sp
83	15.8	1.0	20	1	AAH08761 Human P2X4 gene-sp
84	15.8	1.0	20	1	AAH08761 Primer of the inve
85	15.8	1.0	20	1	AAH08761 Human endothelial
86	15.8	1.0	20	1	AAH08761 Human endothelial
87	15.8	1.0	20	1	AAH08761 Human Notch (Dro
88	15.8	1.0	21	1	AAH08761 Human edg6 PCR pr
89	15.8	1.0	21	1	AAH08761 Human gene single
90	15.8	1.0	21	1	AAH08761 Human DNA probe us
91	15.4	1.0	17	1	AAH08761 Human KDR VEGF rec
92	15.4	1.0	17	1	AAH08761 Human GDMPL-1 17-m
93	15.4	1.0	17	1	AAH08761 Human GDMPL-1 17-m
94	15.4	1.0	17	1	AAH08761 Human GDMPL-1 17-m
95	15.4	1.0	17	1	AAH08761 Human GDMPL-1 17-m
96	15.4	1.0	17	1	AAH08761 Human HER2 DNazyme
97	15.4	1.0	19	1	AAH08761 HIV-1 related bind
98	15.4	1.0	20	1	AAH08761 Hepatitis GB virus
99	15.4	1.0	20	1	AAH08761 Hepatitis GB virus
100	15.4	1.0	20	1	AAH08761 PCR primer for hum
101	15.4	1.0	20	1	AAH08761 Human TSP1 domain
102	15.4	1.0	20	1	AAH08761 Human dual specif
103	15.4	1.0	20	1	AAH08761 Acyl CoA:cholester
104	15.4	1.0	20	1	AAH08761 Chimeric phosphoro
105	15.4	1.0	20	1	AAH08761 Chimeric phosphoro
106	15.4	1.0	20	1	AAH08761 Chimeric phosphoro

107	15.4	1.0	20	1	ADK73666	Chimeric phosphoro	180	14.8	0.9	19	1	AAZ28917	Reverse primer aal
108	15.4	1.0	20	1	ADP68653	Human PPAR-alpha a	c 181	14.8	0.9	19	1	AA84728	Cyclin E ribozyme
c 109	15.2	1.0	20	1	AAQ50904	K-ras LCR primer.	c 182	14.8	0.9	19	1	AAH59890	Cyclin E ribozyme
c 110	15.2	1.0	20	1	AAT58120	K-ras mutated in t	c 183	14.8	0.9	19	1	ACH90207	Novel human protei
c 111	15.2	1.0	20	1	AAV68513	Type I polyketide	c 184	14.8	0.9	19	1	ADD20516	Oreochromis niloti
c 112	15.2	1.0	20	1	AAV95359	PCR primer used to	c 185	14.8	0.9	19	1	ADD20519	Oreochromis niloti
c 113	15.2	1.0	20	1	AAA72164	Humanised anti-Fas	c 186	14.8	0.9	19	1	ADMO0095	Hepatitis B virus
c 114	15.2	1.0	20	1	AAA72168	Humanised anti-Fas	c 187	14.8	0.9	19	1	ADMO0721	Hepatitis B virus
c 115	15.2	1.0	20	1	AAAL1602	Humanised HPE7A de	c 188	14.8	0.9	19	1	ADMO0741	Hepatitis B virus
c 116	15.2	1.0	20	1	AAAL1606	Humanised HPE7A de	c 189	14.8	0.9	19	1	ADMO0075	Hepatitis B virus
c 117	15.2	1.0	20	1	AAF73008	Human dact inhib	c 190	14.8	0.9	19	1	ADL79404	Hepatitis B virus
c 118	15.2	1.0	20	1	ACF89142	Human prostate-spe	c 191	14.8	0.9	19	1	ADL79711	Human HER1 (EGFR)
c 119	15.2	1.0	20	1	AAF99319	Immunostimulatory	c 192	14.8	0.9	19	1	ADCO9390	Novel human protei
c 120	15.2	1.0	20	1	AAC89563	Tumour antigen PCR	c 193	14.4	0.9	17	1	AAK71061	Human KDR VEGF rec
c 121	15.2	1.0	20	1	ABK99789	Mouse RAIDD antise	c 194	14.4	0.9	17	1	ABK03203	Human CD20 Inozyme
c 122	15.2	1.0	20	1	ABS77964	Angiogenesis inhib	c 195	14.4	0.9	17	1	ABK03204	Human CD20 Inozyme
c 123	15.2	1.0	20	1	ABL39004	Immunostimulatory	c 196	14.4	0.9	17	1	ABNO2304	Human GDMPLP-1 17-m
c 124	15.2	1.0	20	1	ABS93854	Human transferrin	c 197	14.4	0.9	17	1	ABNO6632	Human GDMPLP-1 17-m
c 125	15.2	1.0	20	1	ABS54317	Human ARCAP associ	c 198	14.4	0.9	17	1	ABNO2302	Human GDMPLP-1 17-m
c 126	15.2	1.0	20	1	ABL48724	Humanised anti-Fas	c 199	14.4	0.9	17	1	ABNO2301	Human GDMPLP-1 17-m
c 127	15.2	1.0	20	1	ABL48728	Humanised anti-Fas	c 200	14.4	0.9	17	1	ABNO6637	Human GDMPLP-1 17-m
c 128	15.2	1.0	20	1	ABL45367	Human chromosome 2	c 201	14.4	0.9	17	1	ABNO2305	Human GDMPLP-1 17-m
c 129	15.2	1.0	20	1	ABT12924	Mycobacterium tube	c 202	14.4	0.9	17	1	ABT35074	Tumour suppression
c 130	15.2	1.0	20	1	ABA00084	Human APC primer #	c 203	14.4	0.9	17	1	ADCO9390	HCV DNazyme substr
c 131	15.2	1.0	20	1	AAU38179	Human BH3 interact	c 204	14.4	0.9	17	1	ADCO9390	HCV DNazyme substr
c 132	15.2	1.0	20	1	ABL45981	Humanised anti-Fas	c 205	14.4	0.9	17	1	ADL84167	HCV DNazyme substr
c 133	15.2	1.0	20	1	ABL45985	Humanised anti-Fas	c 206	14.4	0.9	17	1	ADL85897	HCV DNazyme substr
c 134	15.2	1.0	20	1	ACD99742	Immunostimulatory	c 207	14.4	0.9	18	1	AAK71705	Human KDR VEGF rec
c 135	15.2	1.0	20	1	AAU62118	Human HCDR3 amplif	c 208	14.4	0.9	18	1	AAK71705	Forward PCR primer
c 136	15.2	1.0	20	1	ADB36821	Immunostimulatory	c 209	14.4	0.9	18	1	AAK55618	TRAF4 antisense ol
c 137	15.2	1.0	20	1	ADF33079	Variant detecting	c 210	14.4	0.9	18	1	AAK55531	TRAF1 antisense ol
c 138	15.2	1.0	20	1	ADJ33237	Primer sequence mT	c 211	14.4	0.9	18	1	ADC78694	Human PRO protein-
c 139	15.2	1.0	20	1	ABZ85105	Human oligonucleot	c 212	14.4	0.9	18	1	AAK72582	Human PRO polypept
c 140	15.2	1.0	20	1	ABZ86052	Human oligonucleot	c 213	14.4	0.9	18	1	ABZ10946	Haematopoietic cel
c 141	15.2	1.0	20	1	ABZ88990	Human oligonucleot	c 214	14.4	0.9	18	1	ADH59543	Human secreted/tra
c 142	15.2	1.0	20	1	ABZ88917	Human oligonucleot	c 215	14.4	0.9	18	1	ADJ38322	Human secreted/tra
c 143	15.2	1.0	20	1	ACC42443	Acyl CoA cholester	c 216	14.4	0.9	18	1	ADJ26590	Human secreted/tra
c 144	15.2	1.0	20	1	ABD25187	AI041482-derived o	c 217	14.4	0.9	18	1	ADE99693	Human secreted/tra
c 145	15.2	1.0	20	1	ABD22282	Human stanniocalci	c 218	14.4	0.9	18	1	ADE98813	Human secreted/tra
c 146	15.2	1.0	20	1	ABD21335	Human transglutami	c 219	14.4	0.9	18	1	ADE99240	Human secreted/tra
c 147	15.2	1.0	20	1	ABD25220	AI051839-derived o	c 220	14.4	0.9	18	1	ADG40710	Human secreted/tra
c 148	15.2	1.0	20	1	ADK96408	Primer of the inve	c 221	14.4	0.9	18	1	ADG92523	Human secreted/tra
c 149	15.2	1.0	20	1	ADK95418	Primer of the inve	c 222	14.4	0.9	18	1	ADG92950	Human secreted/tra
c 150	15.2	1.0	20	1	ADJ22418	Human endothelial	c 223	14.4	0.9	18	1	ADH20739	Human secreted/tra
c 151	15.2	1.0	20	1	ADL15530	PCR primer 40 used	c 224	14.4	0.9	18	1	ADH07594	Human secreted/tra
c 152	15.2	1.0	20	1	ADML4267	Human mPGES-1 chim	c 225	14.4	0.9	18	1	ADH60139	Human secreted/tra
c 153	15.2	1.0	20	1	ADCO52746	Farnesoid X recept	c 226	14.4	0.9	18	1	ADH07167	Human secreted/tra
c 154	15	1.0	15	1	ADCO52746	Human scyl CoA cho	c 227	14.4	0.9	18	1	ADH07167	Human secreted/tra
c 155	15	1.0	17	1	AAV97354	Human EGF-R target	c 228	14.4	0.9	18	1	ADI18909	Human secreted/tra
c 156	15	1.0	17	1	ACD55428	HBV amberyzyme subs	c 229	14.4	0.9	18	1	ADI37888	Human secreted/tra
c 157	15	1.0	17	1	ACD51912	HBV inozyme subst	c 230	14.4	0.9	18	1	ADI97688	Human secreted/tra
c 158	15	1.0	17	1	ADD20913	Human GAP N DNA 17	c 231	14.4	0.9	18	1	ADI66056	Human secreted/tra
c 159	15	1.0	17	1	ADD20912	Human GAP N DNA 17	c 232	14.4	0.9	18	1	ADM25390	Human secreted/tra
c 160	15	1.0	17	1	ADM20911	Human GAP N DNA 17	c 233	14.4	0.9	18	1	ADM30140	Human secreted/tra
c 161	15	1.0	17	1	ADM60110	Hepatitis B virus	c 234	14.4	0.9	18	1	ADO08462	Cdc 25 hs ribozyme
c 162	15	1.0	17	1	ADM58711	Hepatitis B virus	c 235	14.4	0.9	19	1	AAH61139	Cdc 25 hs ribozyme
c 163	15	1.0	18	1	AAK55895	Hepatitis B virus	c 236	14.4	0.9	19	1	AAH61139	Cdc 25 hs ribozyme
c 164	15	1.0	18	1	AAZ37843	PCR primer #2 from	c 237	14.4	0.9	19	1	ADM00071	Hepatitis B virus
c 165	15	1.0	20	1	AAU12117	Rat PTPIB antisens	c 238	14.4	0.9	19	1	ADM00071	Hepatitis B virus
c 166	15	1.0	20	1	AAU12117	Rat PTPIB antisens	c 239	14.4	0.9	19	1	ADM00061	Hepatitis B virus
c 167	15	1.0	20	1	ABK85192	Rat PTPB1 antisens	c 240	14.4	0.9	19	1	ADM00707	Hepatitis B virus
c 168	15	1.0	20	1	ABK37361	Rat PTPB1 antisens	c 241	14.4	0.9	19	1	ADH01954	Protein tyrosine p
c 169	15	1.0	20	1	ADP75475	Human ADAMTS2 gene	c 242	14.4	0.9	19	1	ADM69775	Plant gene polymor
c 170	15	1.0	20	1	ADL13922	Antisense DNA olig	c 243	14.4	0.9	19	1	ADM69774	Plant gene polymor
c 171	14.8	0.9	18	1	AAA99605	Rat D4 receptor mR	c 244	14	0.9	15	1	ABX03915	A. odontolyticus 1
c 172	14.8	0.9	18	1	ABS54291	Pig beta-actin cDN	c 245	14	0.9	17	1	AAA20366	Integrin alpha 6 s
c 173	14.8	0.9	18	1	ABX12225	Rat dopamine D4 re	c 246	14	0.9	17	1	ACD63058	HCV minus strand D
c 174	14.8	0.9	18	1	ADP38319	Beta-actin PCR pri	c 247	14	0.9	17	1	ACD55429	HBV amberyzyme subs
c 175	14.8	0.9	18	1	ADP38319	3-hydroxy-3-methyl	c 248	14	0.9	17	1	ADD20914	Human GAP N DNA 17
c 176	14.8	0.9	18	1	ADP29053	Rat dopamine D4 re	c 249	14	0.9	17	1	ADD20910	Human GAP N DNA 17
c 177	14.8	0.9	19	1	ADM16806	Hepatitis B virus	c 250	14	0.9	17	1	ADM60111	Hepatitis B virus
c 178	14.8	0.9	19	1	AAT32495	Calpain large subu	c 251	14	0.9	17	1	ADL85896	HCV DNazyme substr
c 179	14.8	0.9	19	1	AAV57110	Human Notch3 mutan	c 252	14	0.9	18	1	ADC02823	Ex vivo stem-cell

253	14	0.9	18	1	AD158498	Human interleukin	C 326	13.8	0.9	17	1	ACC63090	Murine oligonucleo
c 254	13.8	0.9	17	1	AAQ40994	Mutagenic primer.	327	13.8	0.9	17	1	ADB40240	Tumour suppression
c 255	13.8	0.9	17	1	AAQ98599	Human papilloma vi	c 328	13.8	0.9	17	1	ADB40360	Tumour suppressio
c 256	13.8	0.9	17	1	AA744617	Human papillomavir	c 329	13.8	0.9	17	1	ADC03630	Human Na/H exchang
c 257	13.8	0.9	17	1	AA778038	Human papillomavir	c 330	13.8	0.9	17	1	ADC03631	Human Na/H exchang
c 258	13.8	0.9	17	1	AA747924	Mouse flt-1 VEGF r	c 331	13.8	0.9	17	1	ADD11995	Oreochromis niloti
c 259	13.8	0.9	17	1	AA771428	Human KDR VEGF rec	c 332	13.8	0.9	17	1	ADD35392	Identifier tag seq
c 260	13.8	0.9	17	1	AAV11280	Human CYP2A6 gene	c 333	13.8	0.9	17	1	ADF62453	Human PCP1 DNA fr
c 261	13.8	0.9	17	1	AAV95636	Solanidine glucosy	334	13.8	0.9	17	1	ADI49812	Human tumour suppr
c 262	13.8	0.9	17	1	AAV17463	Probe MY110 for hu	335	13.8	0.9	17	1	ADI49115	Human tumour suppr
c 263	13.8	0.9	17	1	AA118856	Human TIE-2 substr	c 336	13.8	0.9	17	1	ADM09492	Human NOGO recepto
c 264	13.8	0.9	17	1	AAV93332	Human B-raf substr	c 337	13.8	0.9	17	1	AD146682	Human NOGO recepto
c 265	13.8	0.9	17	1	AAV93333	Human B-raf substr	c 338	13.8	0.9	17	1	ADM54579	Human GR1D mRNA su
c 266	13.8	0.9	17	1	AAV81678	Oligonucleotide SE	c 339	13.8	0.9	17	1	ADJ53658	HBV probe #3. Hep
c 267	13.8	0.9	17	1	AAFO7186	Hammerhead ribozym	c 340	13.8	0.9	17	1	ADP46272	Extend primer 53 u
c 268	13.8	0.9	17	1	AAFO7187	Hammerhead ribozym	c 341	13.8	0.9	18	1	AX795556	PCR primer for S.
c 269	13.8	0.9	17	1	AAFO2166	Hammerhead ribozym	c 342	13.8	0.9	18	1	AA289760	Human RIP-1 antise
c 270	13.8	0.9	17	1	AAFO2500	Hammerhead ribozym	c 343	13.8	0.9	18	1	AA289759	Human RIP-1 antise
c 271	13.8	0.9	17	1	ABK003141	Human CD20 Inozyme	c 344	13.8	0.9	18	1	AA239259	Anti-mouse monoclo
c 272	13.8	0.9	17	1	ABK00739	Human NOGO Inozyme	c 345	13.8	0.9	18	1	AA273451	Human biallelic ma
c 273	13.8	0.9	17	1	ABK01164	Human NOGO Inozyme	c 346	13.8	0.9	18	1	AA277089	Human biallelic ma
c 274	13.8	0.9	17	1	ABK00079	Human NOGO Hammerh	c 347	13.8	0.9	18	1	AAA15590	Forward PCR primer
c 275	13.8	0.9	17	1	ABL46611	Human GR1D NCH rib	c 348	13.8	0.9	18	1	AAH75401	Chloramphenicol ac
c 276	13.8	0.9	17	1	ABL47259	Human GR1D Ambery	c 349	13.8	0.9	18	1	AAI66128	Human glaucoma-cod
c 277	13.8	0.9	17	1	ABN01544	Human GDMPL-1 17-m	350	13.8	0.9	18	1	AA770537	Human DRD2 fragmen
c 278	13.8	0.9	17	1	ABN02238	Human GDMPL-1 17-m	c 351	13.8	0.9	18	1	ABU89040	Hiv-1 related bind
c 279	13.8	0.9	17	1	ABN02239	Human GDMPL-1 17-m	c 352	13.8	0.9	18	1	AB61018	Human genotyping p
c 280	13.8	0.9	17	1	ABN10682	Human GDMPL-1 17-m	c 353	13.8	0.9	18	1	AB68853	Human RecQ protein
c 281	13.8	0.9	17	1	ABN02300	Human GDMPL-1 17-m	c 354	13.8	0.9	18	1	ADG89548	Human matrilin-3 p
c 282	13.8	0.9	17	1	ABN01655	Human GDMPL-1 17-m	c 355	13.8	0.9	18	1	ACA60572	Antisense inhibiti
c 283	13.8	0.9	17	1	ABN00939	Human GDMPL-1 17-m	c 356	13.8	0.9	18	1	ADN06863	Human PCR primer S
c 284	13.8	0.9	17	1	ABN02239	Human GDMPL-1 17-m	c 357	13.8	0.9	18	1	ADH35262	Primer of the inve
c 285	13.8	0.9	17	1	ABN02307	Human GDMPL-1 17-m	c 358	13.8	0.9	18	1	ADJ53657	HBV probe #2. Hep
c 286	13.8	0.9	17	1	ABN02306	Human GDMPL-1 17-m	c 359	13.8	0.9	18	1	ADQ43211	Vascular endotheli
c 287	13.8	0.9	17	1	ABN02300	Human GDMPL-1 17-m	c 360	13.8	0.9	18	1	ADQ16557	4 synthesis-period
c 288	13.8	0.9	17	1	ABN10681	Human GDMPL-1 17-m	c 361	13.8	0.9	18	1	ADQ26322	Rhizomucor pusillu
c 289	13.8	0.9	17	1	ABN09032	Human GDMPL-1 17-m	c 362	13.8	0.9	20	1	AA240168	PCR primer for hum
c 290	13.8	0.9	17	1	ABN06924	Human GDMPL-1 17-m	c 363	13.6	0.9	15	1	AS988771	Colony stimulating
c 291	13.8	0.9	17	1	ABV85228	Human pp-GaNTase 1	c 364	13.6	0.9	17	1	ACC64682	Murine oligonucleo
c 292	13.8	0.9	17	1	AA448306	Human ribozyme cle	c 365	13.4	0.9	15	1	AAQ28689	pela target oligon
c 293	13.8	0.9	17	1	AA445137	Human RIP2 DNA spe	c 366	13.4	0.9	15	1	AA750174	Rabbit CETP HH rib
c 294	13.8	0.9	17	1	ABK17888	Human ERG hammerhe	c 367	13.4	0.9	15	1	AS02509	Human CHM1 allele
c 295	13.8	0.9	17	1	ABK19143	Human ERG Ambery	c 368	13.4	0.9	15	1	AA467996	IGFBP3 oligonucleo
c 296	13.8	0.9	17	1	ABK75233	Human PAPP-Ea asso	c 369	13.4	0.9	15	1	AA445929	Murine dystrophin-
c 297	13.8	0.9	17	1	ABV75234	Human PAPP-Ea asso	c 370	13.4	0.9	15	1	ADJ82534	FFHVP-encoding nuc
c 298	13.8	0.9	17	1	ABV89709	Human POSHL1 scan	c 371	13.4	0.9	15	1	AD144618	Human cystic fibro
c 299	13.8	0.9	17	1	ABV90809	Human POSHL1 scan	c 372	13.4	0.9	15	1	AD144791	Human cystic fibro
c 300	13.8	0.9	17	1	ACN03715	WNV Zinzyme substr	c 373	13.4	0.9	15	1	AD144977	Human cystic fibro
c 301	13.8	0.9	17	1	ACN11548	WNV minus strand I	c 374	13.4	0.9	16	1	AAV06294	Mouse spleen RNA a
c 302	13.8	0.9	17	1	ACN00235	WNV Hammerhead Rib	c 375	13.4	0.9	16	1	ABS98344	Human multidrug re
c 303	13.8	0.9	17	1	ACN00234	WNV Hammerhead Rib	c 376	13.4	0.9	16	1	AD840334	Reverse Age832 RT-
c 304	13.8	0.9	17	1	ACN04899	WNV DNazyme substr	c 377	13.4	0.9	16	1	ADG38558	Human genomic Cpg
c 305	13.8	0.9	17	1	ACN15125	WNV minus strand A	c 378	13.4	0.9	17	1	AAQ68371	Half mini-zyme Krm
c 306	13.8	0.9	17	1	ABT35349	Tumour suppression	c 379	13.4	0.9	17	1	AA771612	Human KDR VEGF rec
c 307	13.8	0.9	17	1	ABT36458	Tumour suppression	c 380	13.4	0.9	17	1	AA771611	Human KDR VEGF rec
c 308	13.8	0.9	17	1	ABT36554	Tumour suppression	c 381	13.4	0.9	17	1	AA771611	Human fltl VEGF re
c 309	13.8	0.9	17	1	ABT36432	Tumour suppression	c 382	13.4	0.9	17	1	AAV97590	Human EGF-R target
c 310	13.8	0.9	17	1	ABT34453	Tumour suppression	c 383	13.4	0.9	17	1	AAA20392	Integrin alpha 6 s
c 311	13.8	0.9	17	1	ABT39454	Tumour suppression	c 384	13.4	0.9	17	1	AAV93334	Human B-raf substr
c 312	13.8	0.9	17	1	ACN06527	NFKB sub-unit modu	c 385	13.4	0.9	17	1	AAA36043	Human genomic SNP
c 313	13.8	0.9	17	1	ACN06598	NFKB sub-unit modu	c 386	13.4	0.9	17	1	AAV02630	Hammerhead ribozym
c 314	13.8	0.9	17	1	ACA07773	NFKB sub-unit modu	c 387	13.4	0.9	17	1	ABK00287	Human NOGO Hammerh
c 315	13.8	0.9	17	1	ACA06526	NFKB sub-unit modu	c 388	13.4	0.9	17	1	ABK02838	Human CD20 Hammerh
c 316	13.8	0.9	17	1	AD804225	Human MD27 scannin	c 389	13.4	0.9	17	1	ABK03744	Human CD20 Ambery
c 317	13.8	0.9	17	1	AD804222	Human MD27 scannin	c 390	13.4	0.9	17	1	ABK03745	Human CD20 Ambery
c 318	13.8	0.9	17	1	AD804222	Human MD27 scannin	c 391	13.4	0.9	17	1	AAI68602	ICAM-1 triple heli
c 319	13.8	0.9	17	1	AD804223	Human MD27 scannin	c 392	13.4	0.9	17	1	ABN10683	Human GDMPL-1 17-m
c 320	13.8	0.9	17	1	ABQ81024	Plasmid pXL3675-re	c 393	13.4	0.9	17	1	ABN06631	Human GDMPL-1 17-m
c 321	13.8	0.9	17	1	AB260036	Human K-Ras DNazym	c 394	13.4	0.9	17	1	ABN10684	Human GDMPL-1 17-m
c 322	13.8	0.9	17	1	AB265182	Human HER2 DNazyme	c 395	13.4	0.9	17	1	ABN10684	Human GDMPL-1 17-m
c 323	13.8	0.9	17	1	AB261374	Human H-Ras DNazym	c 396	13.4	0.9	17	1	ABK24955	Porphyric herbicid
c 324	13.8	0.9	17	1	ACC67550	Murine oligonucleo	c 397	13.4	0.9	17	1	ABK27023	Increased sterate
c 325	13.8	0.9	17	1	ACC65385	Murine oligonucleo	c 398	13.4	0.9	17	1	ABK24956	Porphyric herbicid

```
399 13.4 0.9 17 1 ABK27024 Increased stearate
400 13.4 0.9 17 1 ABT35342 Tumour suppression
C 401 13.4 0.9 17 1 ADB03627 Human MDZ7 scannin
C 402 13.4 0.9 17 1 ADB03629 Human MDZ7 scannin
C 403 13.4 0.9 17 1 ADB03628 Human MDZ7 scannin
C 404 13.4 0.9 17 1 ABZ65272 Human HER2 DNazyme
C 405 13.4 0.9 17 1 ACD59610 HCV DNazyme substr
406 13.4 0.9 17 1 ACC65533 Murine oligonucleo
C 407 13.4 0.9 17 1 ACC66957 Murine oligonucleo
C 408 13.4 0.9 17 1 ACC62782 Murine oligonucleo
C 409 13.4 0.9 17 1 ADB43973 Tumour suppression
C 410 13.4 0.9 17 1 ADB40615 Tumour suppression
C 411 13.4 0.9 17 1 ADC03633 Human Na/H exchange
C 412 13.4 0.9 17 1 ADC03632 Human Na/H exchange
C 413 13.4 0.9 17 1 ADG64077 Human PCCP1 DNA fr
C 414 13.4 0.9 17 1 ADF64078 Human PCCP1 DNA fr
C 415 13.4 0.9 17 1 ADF64079 Human tumour suppr
416 13.4 0.9 17 1 ADI52315 Human tumour suppr
C 417 13.4 0.9 17 1 ACS51409 Human PKR substrat
418 13.4 0.9 17 1 ADL50726 Human glioma endot
419 13.4 0.9 17 1 ADL13282 Human ER+ breast c
420 13.4 0.9 17 1 ADL82074 HCV DNazyme substr
C 421 13.4 0.9 17 1 ADL84166 Mutant cell identi
422 13.4 0.9 17 1 ADN43647 Mutant cell identi
C 423 13.4 0.9 17 1 ADN45714 Mutant cell identi
C 424 13.4 0.9 17 1 ADN43646 Mutant cell identi
425 13.4 0.9 17 1 ADN45715 Human daxx inhibit
426 13.4 0.9 20 1 AAT73008 17-mer DNA probe f
427 13.2 0.8 17 1 AAT04567 Primer for hepatoc
C 428 13.2 0.8 17 1 AAT90047
```

ALIGNMENTS

```
RESULT 1
ACC42398 ACC42398 standard; DNA; 25 BP.
XX ID ACC42398 standard; DNA; 25 BP.
XX AC ACC42398;
XX DT 26-AUG-2003 (first entry)
XX DE Human acyl CoA cholesterol acyltransferase-2 PCR probe.
XX KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; PCR; probe; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT FT /*mod_base= OTHER
FT FT /note= "Labelled with FAM, fluorescent reporter dye"
FT modified_base 25 /*tag= b
FT FT /*mod_base= OTHER
FT FT /note= "Labelled with TAMRA, quencher dye"
XX WO2003011889-A2.
XX PN 13-FEB-2003.
XX PD 13-FEB-2003.
XX PF 15-JUL-2002; 2002WO-US022746.
XX PR 30-JUL-2001; 2001US-00918026.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Crooke RM, Graham MJ, Lemonidis KM;
```

```
XX WPI; 2003-248145/24.
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX Example 13; Page 85; 112pp; English.
XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease. The present sequence is a PCR probe for human
CC ACAT-2, used in an example from the invention
XX Sequence 25 BP; 4 A; 5 C; 10 G; 6 T; 0 U; 0 Other;
SQ Query Match 1.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.5;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1212 CTACGTGATCAGGATGGGCTGCGG 1236
Db 1 CTACGTGATCAGGATGGGCTGCGG 25
RESULT 2
AAA76178
ID AAA76178 standard; DNA; 25 BP.
XX AC AAA76178;
XX DT 14-DEC-2000 (first entry)
XX DE Human ACAT Related Gene Product 2 ARGP2 PCR primer 206.
XX KW Human; ACAT Related Gene Product 2; ARGP2; enzyme;
KW acyl Coenzyme A-cholesterol acyltransferase 1; ACAT1;
KW sterol esterification; lipid homeostasis; diacylglycerol acyltransferase;
KW DGAT; PCR primer; ss.
XX OS Homo sapiens.
XX PN US6100077-A.
XX PD 08-AUG-2000.
XX PF 01-OCT-1998; 98US-00165042.
XX PR 01-OCT-1998; 98US-00165042.
XX PA (UYCO ) UNIV COLUMBIA NEW YORK.
XX PI Sturley SL, Oelkers P;
XX WPI; 2000-557622/51.
XX New nucleic acid encoding a human diacylglycerol acyltransferase, useful
PT for treating hyperlipidemia, atherosclerosis, heart disease, or other
PT diseases associated with an imbalance of triglyceride levels.
XX Disclosure; Col 17; 32pp; English.
XX The enzyme acyl Coenzyme A-cholesterol acyltransferase 1 (ACAT1) mediates
CC sterol esterification, an important component of intracellular lipid
```

```
CC homeostasis. The present invention relates to human ACAT Related Gene
CC Product 2 (ARGP2). ARGP2 is a diacylglycerol acyltransferase (DGAT).
CC ARGP2 is a tissue specific sterol esterification enzyme. The present
CC sequence is a PCR primer used to isolate ARGP2 coding sequence (see
CC AAA76170)
XX
SQ Sequence 25 BP; 3 A; 8 C; 4 G; 10 T; 0 U; 0 Other;

Query Match      1.5%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1047 CATGCTGCTGCTCATCTTCTTGGC 1070
Db 1 CATGCTGCTGCTCATCTTCTTGGC 24

RESULT 3
AAA76183
ID AAA76183 standard; DNA; 23 BP.
XX
AC AAA76183;
XX
DT 14-DEC-2000 (first entry)
XX
DE Human ACAT Related Gene Product 2 ARGP2 PCR primer 201.
XX
KW Human ACAT Related Gene Product 2; ARGP2; enzyme;
KW acyl Coenzyme A-cholesterol acyltransferase 1; ACAT1;
KW sterol esterification; lipid homeostasis; diacylglycerol acyltransferase;
KW DGAT; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN US6100077-A.
XX
PD 08-AUG-2000.
XX
PF 01-OCT-1998; 98US-00165042.
XX
PR 01-OCT-1998; 98US-00165042.
XX
PA (UYCO ) UNIV COLUMBIA NEW YORK.
XX
PI Sturley SL, Oelkers P;
XX
DR WPI; 2000-557622/51.
XX
PT New nucleic acid encoding a human diacylglycerol acyltransferase, useful
PT for treating hyperlipidemia, atherosclerosis, heart disease, or other
PT diseases associated with an imbalance of triglyceride levels.
XX
PS Disclosure; Col 17; 32pp; English.
XX
CC The enzyme acyl Coenzyme A-cholesterol acyltransferase 1 (ACAT1) mediates
CC sterol esterification, an important component of intracellular lipid
CC homeostasis. The present invention relates to human ACAT Related Gene
CC Product 2 (ARGP2). ARGP2 is a diacylglycerol acyltransferase (DGAT).
CC ARGP2 is a tissue specific sterol esterification enzyme. The present
CC sequence is a PCR primer used to isolate ARGP2 coding sequence (see
CC AAA76170)
XX
SQ Sequence 23 BP; 3 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

Query Match      1.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 5.2;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1539 GACACCTCGATCTTGGTCTGCGC 1561
Db 1 GACACCTCGATCTTGGTCTGCGC 23
```

```
RESULT 4
AAA04170
ID AAA04170 standard; DNA; 29 BP.
XX
AC AAA04170;
XX
DT 22-MAY-2000 (first entry)
XX
DE Polymorphic fragment of hypertension associated gene CYP11B2.
XX
KW Polymorphism; hypertension; agammaglobulinemia; diabetes insipidus;
KW Lesch-Nyhan syndrome; muscular dystrophy; Wiskott-Aldrich syndrome;
KW Fabry's disease; familial hypercholesterolemia; hereditary spherocytosis;
KW polycystic kidney disease; von Willebrand's disease; hereditary osteogenesis imperfecta;
KW tuberosus sclerosis; hereditary hemorrhagica telangiectasia;
KW familial colonic polyposis; osteogenesis imperfecta; porphyria;
KW Ehlers-Danlos syndrome; ss.
XX
OS Homo sapiens.
XX
PN BP955382-A2.
XX
PD 10-NOV-1999.
XX
PF 07-MAY-1999; 99EP-00250150.
XX
PR 07-MAY-1999; 98US-0084641P.
XX
PR 03-MAY-1999; 99US-00304232.
XX
PA (AFPV-) AFFYMETRIX INC.
XX
PA (UYCA-) UNIV CASE WESTERN RESERVE.
XX
PI Fan JB, Chakravarti A, Haluska MK;
XX
DR WPI; 2000-107928/10.
XX
PT Novel nucleic acids containing polymorphisms used in the diagnosis of
PT hypertension.
XX
PS Claim 1; Page 28; 53pp; English.
XX
CC The invention provides polymorphic fragments of genes associated with
CC hypertension. The nucleic acids including the polymorphic sites can be
CC used as probes or primers for expressing variant proteins. Detection of
CC the polymorphisms is useful in designing prophylactic and therapeutic
CC regimes customized to underlying abnormalities. The polymorphisms can be
CC used for association studies for hypertension, and in hypertension
CC diagnostic assays. Where the polymorphisms have strong correlation with
CC hypertension, within a gene, they are likely to have a causative role in
CC hypertension. This information can be used to find the precise role of a
CC polymorphism in the disease, and this can be used to identify potential
CC drugs which combat the disease. The polymorphisms can be tested for
CC association with other diseases e.g. agammaglobulinemia, diabetes
CC insipidus, Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich
CC syndrome, Fabry's disease, familial hypercholesterolemia, polycystic
CC kidney disease, hereditary spherocytosis, von Willebrand's disease,
CC tuberosus sclerosis, hereditary hemorrhagica telangiectasia, familial
CC colonic polyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and
CC acute intermittent porphyria. The polymorphic forms can also be used in
CC forensics to identify individuals
XX
SQ Sequence 29 BP; 5 A; 9 C; 9 G; 5 T; 0 U; 1 Other;

Query Match      1.4%; Score 21.8; DB 1; Length 29;
Best Local Similarity 85.2%; Pred. No. 13;
Matches 23; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 889 GTGGCCAGAACTTTGCCAGGCCCTG 915
Db 1 GTGGCCAGGACTTTCCTCCAGGCCCTG 27
XX
```

RESULT 5

```
AAV98317/c
ID AAV98317 standard; RNA; 27 BP.
XX AC
XX AAV98317;
XX DT
XX 17-MAR-1999 (first entry)
XX DE
XX Human EGF-R hammerhead ribozyme nucleotide position 2401.
XX KW
XX Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
XX hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
XX cancer; genetic drift; detection; mutation; ss.
XX OS
XX Synthetic.
XX OS Homo sapiens.
XX PN
XX WO9833893-A2.
XX XX
XX 06-AUG-1998.
XX XX
XX 14-JAN-1998; 98WO-US000730.
XX PF
XX 31-JAN-1997; 97US-0036476P.
XX PR
XX 04-DEC-1997; 97US-00985162.
XX XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA (UYAS-) UNIV ASTON.
XX PI
XX Akhtar S, Fell P, Mcswiggen JA;
XX XX
XX WPI; 1998-437449/37.
XX DR
XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal
XX PT growth factor receptor, useful for inhibiting cell proliferation and for
XX PT treating cancers.
XX PT
XX Claim 8; Page 73; 109pp; English.
XX PS
XX The present invention describes enzymatic nucleic acid molecules (NAMs)
XX CC which specifically cleave RNA derived from an epidermal growth factor
XX CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
XX CC represent specifically claimed target sequence from human EGF-R. AAV98044
XX CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
XX CC hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
XX CC cleaving EGF-R RNA in the treatment of a condition associated with EGF-R
XX CC expression levels e.g. to inhibit cell proliferation in the prevention or
XX CC treatment of cancers. The NAMs can also be used as diagnostic tools to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of EGF-R RNA in a cell
XX XX
XX Sequence 27 BP; 8 A; 3 C; 6 G; 0 T; 9 U; 1 Other;
XX SQ
Query Match 1.4%; Score 21.2; DB 1; Length 27;
Best Local Similarity 85.2%; Pred. No. 15;
Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 302 AGAAGTTTTCATCATCCCAAGTCCC 328
DB 27 AGAAGTTTTCATCATCAGAAATCCC 1
RESULT 6
ACC42396
ID ACC42396 standard; DNA; 21 BP.
XX AC
XX ACC42396;
XX XX
XX 26-AUG-2003 (first entry)
XX DT
XX Human acyl CoA cholesterol acyltransferase-2 PCR primer #1.
XX DE
XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
XX KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
XX KW
```

```
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; PCR; primer; ss.
XX OS
XX Homo sapiens.
XX PN
XX WO2003011889-A2.
XX XX
XX 13-FEB-2003.
XX XX
XX 15-JUL-2002; 2002WO-US022746.
XX PF
XX 30-JUL-2001; 2001US-00918026.
XX PR
XX (ISIS-) ISIS PHARM INC.
XX PA
XX Crooke RM, Graham MJ, Lemonidis KM;
XX PI
XX WPI; 2003-248145/24.
XX DR
XX
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
XX PT acyltransferase-2, e.g. for preventing or treating diseases associated
XX PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
XX PT cardiovascular disease.
XX PT
XX Example 13; Page 85; 112pp; English.
XX PS
XX The present invention relates to novel antisense oligonucleotides which
XX CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
XX CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
XX CC ACC42457). The antisense oligonucleotides specifically hybridize with and
XX CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
XX CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
XX CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
XX CC useful for treating an animal which has a disease or condition associated
XX CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
XX CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
XX CC cardiovascular disease. The present sequence is a PCR primer for human
XX CC ACAT-2, used in an example from the invention
XX XX
XX Sequence 21 BP; 4 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
XX SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1190 TGGTCCATGACTGGCTGTACA 1210
DB 1 TGGTCCATGACTGGCTGTACA 21
RESULT 7
AAZ57364/c
ID AAZ57364 standard; DNA; 20 BP.
XX AC
XX AAZ57364;
XX XX
XX 05-APR-2000 (first entry)
XX DT
XX Human acyl CoA:cholesterol acyltransferase 2 antisense PCR primer.
XX DE
XX Human; acyl CoA:cholesterol acyltransferase; ACAT-2; diagnosis;
XX KW antilipemic; hypercholesterolaemia; hypertriglyceridaemia;
XX KW hyperlipidaemia; PCR primer; ss.
XX XX
XX Homo sapiens.
XX OS
XX WO9967368-A1.
XX PN
XX 29-DEC-1999.
XX PD
XX 16-JUN-1999; 99WO-US013683.
XX PF
XX 23-JUN-1998; 98US-0090354P.
XX PR
```


PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Claim 3; Page 89; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 161 AGCAAGCGGAGGACAACTG 180
DB 20 AGCAAGCGGAGGACAACTG 1
RESULT 10
ACC42419/c
ID ACC42419 standard; DNA; 20 BP.
XX
AC ACC42419;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140154.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011889-A2.
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.

XX
PS Example 15; Page 89; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 1 A; 10 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 581 CGCAGCGGACGGGCGCTGGGC 600
DB 20 CGCAGCGGACGGGCGCTGGGC 1
RESULT 11
ACC42427/c
ID ACC42427 standard; DNA; 20 BP.
XX
AC ACC42427;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140162.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011889-A2.
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Claim 3; Page 89; 112pp; English.
XX

CC The present invention relates to novel antisense oligonucleotides which
 CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
 CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
 CC ACC42457). The antisense oligonucleotides specifically hybridize with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
 CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
 CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease

SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 TCAGATGGGCTGCGGCTCC 1240
 |||||
 DB 20 TCAGATGGGCTGCGGCTCC 1

RESULT 12
 ACC42411/c
 ID ACC42411 standard; DNA; 20 BP.
 XX
 AC ACC42411;
 XX
 DT 26-AUG-2003 (first entry)
 XX
 DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140146.
 XX
 DE Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
 KW antiatherosclerotic; cardiovascular; ACAT-2; lipid metabolism;
 KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
 KW phosphorothioate; human; ss.
 XX
 OS Synthetic.
 XX

Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Oligonucleotide has phosphorothioate backbone and
 FT all cytidine nucleotides are 5-methylcytidine. Optionally
 FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
 FT modification"

PN WO2003011899-A2.
 XX
 PD 13-FEB-2003.
 XX
 PF 15-JUL-2002; 2002WO-US022746.
 XX
 PR 30-JUL-2001; 2001US-00918026.
 XX
 PR (ISIS-) ISIS PHARM INC.
 XX
 PI Crooke RM, Graham MJ, Lemonidis KM;
 XX
 DR WPI; 2003-248145/24.
 XX
 PT New antisense oligonucleotides for modulating acyl CoA cholesterol
 PT acyltransferase-2, e.g. for preventing or treating diseases associated
 PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
 PT cardiovascular disease.
 XX
 PS Example 15; Page 88; 112pp; English.
 XX
 CC The present invention relates to novel antisense oligonucleotides which
 CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
 CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
 CC ACC42457). The antisense oligonucleotides specifically hybridize with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
 CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
 CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease

CC ACC42457). The antisense oligonucleotides specifically hybridize with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
 CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
 CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease

SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAGACGCACA 100
 |||||
 DB 20 TGGAAACACTGAGACGCACA 1

RESULT 13
 ACC42422/c
 ID ACC42422 standard; DNA; 20 BP.
 XX
 AC ACC42422;
 XX
 DT 26-AUG-2003 (first entry)
 XX
 DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140157.
 XX
 DE Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
 KW antiatherosclerotic; cardiovascular; ACAT-2; lipid metabolism;
 KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
 KW phosphorothioate; human; ss.
 XX
 OS Synthetic.
 XX

Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Oligonucleotide has phosphorothioate backbone and
 FT all cytidine nucleotides are 5-methylcytidine. Optionally
 FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
 FT modification"

PN WO2003011899-A2.
 XX
 PD 13-FEB-2003.
 XX
 PF 15-JUL-2002; 2002WO-US022746.
 XX
 PR 30-JUL-2001; 2001US-00918026.
 XX
 PR (ISIS-) ISIS PHARM INC.
 XX
 PI Crooke RM, Graham MJ, Lemonidis KM;
 XX
 DR WPI; 2003-248145/24.
 XX
 PT New antisense oligonucleotides for modulating acyl CoA cholesterol
 PT acyltransferase-2, e.g. for preventing or treating diseases associated
 PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
 PT cardiovascular disease.
 XX
 PS Claim 3; Page 89; 112pp; English.
 XX
 CC The present invention relates to novel antisense oligonucleotides which
 CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
 CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
 CC ACC42457). The antisense oligonucleotides specifically hybridize with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from

CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
 CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease

SQ Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 881 GGAATTATGTGGCCAAAGAAC 900
 |||||
 Db 20 GGAATTATGTGGCCAAAGAAC 1

RESULT 14
 ACC42420/c
 ID ACC42420 standard; DNA; 20 BP.
 AC ACC42420;
 XX
 DT 26-AUG-2003 (first entry)
 DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140155.
 XX
 KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
 KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
 KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
 KW phosphorothioate; human; ss.
 XX
 OS Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Oligonucleotide has phosphorothioate backbone and
 FT all cytidine nucleotides are 5-methylcytidine. Optionally
 FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
 FT modification"

XX WO2003011889-A2.
 PN
 PD 13-FEB-2003.
 XX
 PF 15-JUL-2002; 2002WO-US022746.
 XX
 PR 30-JUL-2001; 2001US-00918026.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Crooke RM, Graham MJ, Lemonidis KM;

XX WPI; 2003-248145/24.
 DR
 XX New antisense oligonucleotides for modulating acyl CoA cholesterol
 PT acyltransferase-2, e.g. for preventing or treating diseases associated
 PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
 PT cardiovascular disease.

XX Claim 3; Page 89; 112pp; English.
 PS
 XX The present invention relates to novel antisense oligonucleotides which
 CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
 CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
 CC ACC42457). The antisense oligonucleotides specifically hybridize with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
 CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a

CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease
 XX
 SQ Sequence 20 BP; 6 A; 7 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 GTGCTGGGATCCTTCGTGC 770
 |||||
 Db 20 GTGCTGGGATCCTTCGTGC 1

RESULT 15
 ACC42428/c
 ID ACC42428 standard; DNA; 20 BP.
 XX
 AC ACC42428;
 XX
 DT 26-AUG-2003 (first entry)
 DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140163.
 XX
 KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
 KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
 KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
 KW phosphorothioate; human; ss.

XX Synthetic.
 XX
 FH Key Location/Qualifiers
 modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Oligonucleotide has phosphorothioate backbone and
 FT all cytidine nucleotides are 5-methylcytidine. Optionally
 FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
 FT modification"

XX WO2003011889-A2.
 PN
 PD 13-FEB-2003.
 XX
 PF 15-JUL-2002; 2002WO-US022746.
 XX
 PR 30-JUL-2001; 2001US-00918026.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Crooke RM, Graham MJ, Lemonidis KM;

XX WPI; 2003-248145/24.
 DR
 XX New antisense oligonucleotides for modulating acyl CoA cholesterol
 PT acyltransferase-2, e.g. for preventing or treating diseases associated
 PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
 PT cardiovascular disease.

XX Claim 3; Page 89; 112pp; English.
 PS
 XX The present invention relates to novel antisense oligonucleotides which
 CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
 CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
 CC ACC42457). The antisense oligonucleotides specifically hybridize with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
 CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
 CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease

XX

```
SQ Sequence 20 BP; 8 A; 7 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 TGGGTGTGTTCTCTGCTCC 1290
      |||||
DB 20 TGGGTGTGTTCTCTGCTCC 1

RESULT 16
ACC42446/c
ID ACC42446 standard; DNA; 20 BP.
XX
AC ACC42446;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143034.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /mod_base= a
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
FT
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Claim 3; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
Query Match 1.3%; Score 20; DB 1; Length 20;

SQ Sequence 20 BP; 8 A; 7 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CTGCTTCATCTCTGGGCGGCC 952
      |||||
DB 20 CTGCTTCATCTCTGGGCGGCC 1

RESULT 17
ACC42409/c
ID ACC42409 standard; DNA; 20 BP.
XX
AC ACC42409;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140144.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /mod_base= a
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
FT
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Example 15; Page 88; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 18 CCGTCTGCGCTCTGCAGAGGA 37
Db 20 CCGTCTGCGCTCTGCAGAGGA 1

RESULT 18

ACC42418/c
ID ACC42418 standard; DNA; 20 BP.

XX
AC ACC42418;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140153.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"

XX WO2003011889-A2.

XX PD 13-FEB-2003.

XX PF 15-JUL-2002; 2002WO-US022746.

XX PR 30-JUL-2001; 2001US-00918026.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Crooke RM, Graham MJ, Lemonidis KM;

XX WPI; 2003-248145/24.

XX
DR New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.

XX Claim 3; Page 89; 112pp; English.

XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease

XX Sequence 20 BP; 2 A; 10 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GTGGCCAGGGGACCTGGA 580

Db 20 GTGGCCAGGGGACCTGGA 1

RESULT 19

ACC42429/c
ID ACC42429 standard; DNA; 20 BP.

XX
AC ACC42429;

XX
DT 26-AUG-2003 (first entry)

XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140164.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.

XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"

XX WO2003011889-A2.

XX PD 13-FEB-2003.

XX PF 15-JUL-2002; 2002WO-US022746.

XX PR 30-JUL-2001; 2001US-00918026.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Crooke RM, Graham MJ, Lemonidis KM;

XX WPI; 2003-248145/24.

XX
DR New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.

XX Claim 3; Page 89; 112pp; English.

XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease

XX Sequence 20 BP; 1 A; 8 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1401 GCGCACCAGCGCCGCGCATGGA 1420

Db 20 GCGCACCAGCGCCGCGCATGGA 1

RESULT 20

ACC42416/C	ACC42416 standard; DNA; 20 BP.
ID	XX
XX	AC
XX	ACC42416;
XX	26-AUG-2003 (first entry)
DT	XX
DE	Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140151.
XX	XX
XX	Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW	antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW	cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW	phosphorothioate; human; ss.
XX	XX
OS	Synthetic.
XX	XX
XX	XX
Key	Location/Qualifiers
modified_base	1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "Oligonucleotide has phosphorothioate backbone and
FT	all cytidine nucleotides are 5-methylcytidine. Optionally
FT	some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT	modification"
XX	XX
PN	W02003011889-A2.
XX	XX
PD	13-FEB-2003.
XX	XX
PF	15-JUL-2002; 2002WO-US022746.
XX	XX
PR	30-JUL-2001; 2001US-00918026.
XX	XX
PA	(ISIS-) ISIS PHARM INC.
PI	Crooke RM, Graham MJ, Lemonidis KM;
XX	XX
DR	WPI; 2003-248145/24.
PT	New antisense oligonucleotides for modulating acyl CoA cholesterol
PT	acyltransferase-2, e.g. for preventing or treating diseases associated
PT	with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT	cardiovascular disease.
XX	XX
PS	Claim 3; Page 89; 112pp; English.
XX	XX
CC	The present invention relates to novel antisense oligonucleotides which
CC	are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC	nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC	ACC42457). The antisense oligonucleotides specifically hybridise with and
CC	inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC	ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC	free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC	useful for treating an animal which has a disease or condition associated
CC	with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC	condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC	cardiovascular disease
XX	XX
SQ	Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
Query Match	1.3%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred.No. 15;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	431 TTGATGAGGCAGGCTGCTG 450
Db	20 TTGATGAGGCAGGCTGCTG 1
RESULT 21	
ACC42425/c	
ID	ACC42425 standard; DNA; 20 BP.
XX	XX

XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140166.
DE
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
FT
XX WO2003011889-A2.
PN
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX WPI; 2003-248145/24.
DR
XX
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
PT
XX Example 15; Page 89; 112pp; English.
PS
XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
XX Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1541 CACCTCGATCTTGCTCTGC 1560
Db 20 CACCTCGATCTTGCTCTGC 1
RESULT 23
ACC42430/c
ID ACC42430 standard; DNA; 20 BP.
XX
AC ACC42430;
XX
XX 26-AUG-2003 (first entry)
DT
XX
XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140165.
DE
XX

KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
XX phosphorothioate; human; ss.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
FT
XX WO2003011889-A2.
PN
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX WPI; 2003-248145/24.
DR
XX
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
PT
XX Claim 3; Page 89; 112pp; English.
PS
XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1451 GCCAGGGAATCCAGGTCAGC 1470
Db 20 GCCAGGGAATCCAGGTCAGC 1
RESULT 24
ACC42426/c
ID ACC42426 standard; DNA; 20 BP.
XX
AC ACC42426;
XX
XX 26-AUG-2003 (first entry)
DT
XX
XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140161.
DE
XX
XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
XX

```
KW phosphorothioate; human; ss.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
XX WO2003011889-A2.
XX
XX 13-FEB-2003.
XX
XX 15-JUL-2002; 2002WO-US022746.
XX
XX 30-JUL-2001; 2001US-00918026.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ, Lemonidis KM;
XX WPI; 2003-248145/24.
XX
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
XX acyltransferase-2, e.g. for preventing or treating diseases associated
XX with abnormal lipid or cholesterol metabolism, atherosclerosis,
XX cardiovascular disease.
XX
XX Claim 3; Page 89; 112pp; English.
XX
XX The present invention relates to novel antisense oligonucleotides which
XX are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
XX nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
XX ACC42457). The antisense oligonucleotides specifically hybridise with and
XX inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
XX ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
XX free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
XX useful for treating an animal which has a disease or condition associated
XX with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
XX cardiovascular disease
XX
XX Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 15;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1181 GGAACTGCTGCTCCATGAC 1200
XX ||||||||||||||||
XX 20 GGAACGTGCTGCTCCATGAC 1
XX
XX RESULT 25
XX ACC42410/C
XX ID ACC42410 standard; DNA; 20 BP.
XX
XX AC ACC42410;
XX
XX 26-AUG-2003 (first entry)
XX
XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140145.
XX
XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
XX antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
XX cholesterol metabolism; atherosclerosis; cardiovascular disease;
XX phosphorothioate; human; ss.
XX Synthetic.
XX
```

```
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
XX WO2003011889-A2.
XX
XX 13-FEB-2003.
XX
XX 15-JUL-2002; 2002WO-US022746.
XX
XX 30-JUL-2001; 2001US-00918026.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ, Lemonidis KM;
XX WPI; 2003-248145/24.
XX
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
XX acyltransferase-2, e.g. for preventing or treating diseases associated
XX with abnormal lipid or cholesterol metabolism, atherosclerosis,
XX cardiovascular disease.
XX
XX Example 15; Page 88; 112pp; English.
XX
XX The present invention relates to novel antisense oligonucleotides which
XX are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
XX nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
XX ACC42457). The antisense oligonucleotides specifically hybridise with and
XX inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
XX ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
XX free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
XX useful for treating an animal which has a disease or condition associated
XX with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
XX cardiovascular disease
XX
XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 15;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 61 GAGCGCCAAACCTGTGGAGA 80
XX ||||||||||||||||
XX 20 GAGCGCCAAACCTGTGGAGA 1
XX
XX RESULT 26
XX ACC42457/C
XX ID ACC42457 standard; DNA; 20 BP.
XX
XX AC ACC42457;
XX
XX 26-AUG-2003 (first entry)
XX
XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143045.
XX
XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
XX antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
XX cholesterol metabolism; atherosclerosis; cardiovascular disease;
XX phosphorothioate; mouse; ss.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT
```

```

FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "Oligonucleotide has phosphorothioate backbone and
FT FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT FT modification"
XX XX
XX XX WO2003011889-A2.
XX XX
XX XX 13-FEB-2003.
XX XX
XX XX 15-JUL-2002; 2002WO-US022746.
XX XX
XX XX 30-JUL-2001; 2001US-00918026.
XX XX
XX XX (ISIS-) ISIS PHARM INC.
XX XX
XX XX Crooke RM, Graham MJ, Lemonidis KM;
XX XX WPI; 2003-248145/24.
XX XX
XX XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX XX
XX XX Claim 3; Page 90; 112pp; English.
XX XX
XX XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX XX
XX XX Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 CTTGTCCTGCCATACCTAG 1569
Db |||||
20 CTTGTCCTGCCATACCTAG 1

RESULT 27
ACC42414/c
ID ACC42414 standard; DNA; 20 BP.
XX
AC ACC42414;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140149.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT FT modification"
FT FT

```

```

FT FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT FT modification"
XX XX
XX XX WO2003011889-A2.
XX XX
XX XX 13-FEB-2003.
XX XX
XX XX 15-JUL-2002; 2002WO-US022746.
XX XX
XX XX 30-JUL-2001; 2001US-00918026.
XX XX
XX XX (ISIS-) ISIS PHARM INC.
XX XX
XX XX Crooke RM, Graham MJ, Lemonidis KM;
XX XX WPI; 2003-248145/24.
XX XX
XX XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX XX
XX XX Example 15; Page 89; 112pp; English.
XX XX
XX XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX XX
XX XX Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGGGAGCTGCTGGATCGGGC 200
Db |||||
20 AGGGAGCTGCTGGATCGGGC 1

RESULT 28
ACC42415/c
ID ACC42415 standard; DNA; 20 BP.
XX
AC ACC42415;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140150.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT FT modification"
FT FT

```



```

13-FEB-2003.
15-JUL-2002; 2002WO-US022746.
30-JUL-2001; 2001US-00918026.
(ISIS-) ISIS PHARM INC.
Crooke RM, Graham MJ, Lemonidis KM;
WPI; 2003-248145/24.
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX Claim 3; Page 89; 112pp; English.
XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 541 CCGTACCAGGCCCTACGGCT 560
DB 20 CCGTACCAGGCCCTACGGCT 1
|||||
RESULT 30
ACC42424/c
ID ID ACC42424 standard; DNA; 20 BP.
AC ACC42424;
XX
XX 26-AUG-2003 (first entry)
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140159.
XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; human; ss.
XX Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
XX WO2003011889-A2.
PN
XX
XX 13-FEB-2003.
PD 15-JUL-2002; 2002WO-US022746.

```

```
XX 30-JUL-2001; 2001US-00918026.
XX (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ, Lemonidis KM;
XX WPI; 2003-248145/24.
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
XX acyltransferase-2, e.g. for preventing or treating diseases associated
XX with abnormal lipid or cholesterol metabolism, atherosclerosis,
XX cardiovascular disease.
XX Example 15; Page 89; 112pp; English.
XX The present invention relates to novel antisense oligonucleotides which
XX are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
XX nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
XX ACC42457). The antisense oligonucleotides specifically hybridize with and
XX inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
XX ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
XX free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
XX useful for treating an animal which has a disease or condition associated
XX with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
XX condition involving abnormal cholesterol metabolism, atherosclerosis, or
XX cardiovascular disease
XX Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
SQ Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1021 CTGCATGCCACGTTGCCAGG 1040
DB 20 CTGCATGCCACGTTGCCAGG 1

RESULT 31
ACC42412/c
ID ACC42412 standard; DNA; 20 BP.
XX ACC42412;
XX 26-AUG-2003 (first entry)
XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140147.
XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
XX antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
XX cholesterol metabolism; atherosclerosis; cardiovascular disease;
XX phosphorothioate; human; ss.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX WO2003011889-A2.
XX 13-FEB-2003.
XX 15-JUL-2002; 2002WO-US022746.
XX 30-JUL-2001; 2001US-00918026.
XX (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ, Lemonidis KM;
```

```
PA (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ, Lemonidis KM;
XX WPI; 2003-248145/24.
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
XX acyltransferase-2, e.g. for preventing or treating diseases associated
XX with abnormal lipid or cholesterol metabolism, atherosclerosis,
XX cardiovascular disease.
XX Example 15; Page 89; 112pp; English.
XX The present invention relates to novel antisense oligonucleotides which
XX are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
XX nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
XX ACC42457). The antisense oligonucleotides specifically hybridize with and
XX inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
XX ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
XX free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
XX useful for treating an animal which has a disease or condition associated
XX with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
XX condition involving abnormal cholesterol metabolism, atherosclerosis, or
XX cardiovascular disease
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
SQ Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 CTTGGTACAATGGACCCGAC 130
DB 20 CTTGGTACAATGGACCCGAC 1

RESULT 32
ACC42421/c
ID ACC42421 standard; DNA; 20 BP.
XX ACC42421;
XX 26-AUG-2003 (first entry)
XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140156.
XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
XX antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
XX cholesterol metabolism; atherosclerosis; cardiovascular disease;
XX phosphorothioate; human; ss.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX WO2003011889-A2.
XX 13-FEB-2003.
XX 15-JUL-2002; 2002WO-US022746.
XX 30-JUL-2001; 2001US-00918026.
XX (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ, Lemonidis KM;
```

XX DR WPI; 2003-248145/24.

XX PT New antisense oligonucleotides for modulating acyl CoA cholesterol

PT acyltransferase-2, e.g. for preventing or treating diseases associated

PT with abnormal lipid or cholesterol metabolism, atherosclerosis,

PT cardiovascular disease.

XX PS Claim 3; Page 89; 112pp; English.

XX CC The present invention relates to novel antisense oligonucleotides which

CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)

CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-

CC ACC42457). The antisense oligonucleotides specifically hybridise with and

CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and

CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from

CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are

CC useful for treating an animal which has a disease or condition associated

CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a

CC condition involving abnormal cholesterol metabolism, atherosclerosis, or

CC cardiovascular disease

XX SQ Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 CAGACGAGGTGAGGGATCC 790

DB 20 CAGACGAGGTGAGGGATCC 1

RESULT 33

ACC42423/c

ID ACC42423 standard; DNA; 20 BP.

XX AC ACC42423;

XX DT 26-AUG-2003 (first entry)

XX DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #140158.

XX KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;

KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;

KW cholesterol metabolism; atherosclerosis; cardiovascular disease;

KW phosphorothioate; human; ss.

OS Synthetic.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Oligonucleotide has phosphorothioate backbone and

FT all cytidine nucleotides are 5-methylcytidine. Optionally

FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)

FT modification"

XX PN WO2003011889-A2.

XX PD 13-FEB-2003.

XX PF 15-JUL-2002; 2002WO-US022746.

XX PR 30-JUL-2001; 2001US-00918026.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Crooke RM, Graham MJ, Lemonidis KM;

XX DR WPI; 2003-248145/24.

PT New antisense oligonucleotides for modulating acyl CoA cholesterol

PT acyltransferase-2, e.g. for preventing or treating diseases associated

PT with abnormal lipid or cholesterol metabolism, atherosclerosis,

XX cardiovascular disease.

XX PS Claim 3; Page 89; 112pp; English.

XX CC The present invention relates to novel antisense oligonucleotides which

CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)

CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-

CC ACC42457). The antisense oligonucleotides specifically hybridise with and

CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and

CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from

CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are

CC useful for treating an animal which has a disease or condition associated

CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a

CC condition involving abnormal cholesterol metabolism, atherosclerosis, or

CC cardiovascular disease

XX SQ Sequence 20 BP; 7 A; 6 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCCTGGCGCGCTCTGTGTT 960

DB 20 TCCTGGCGCGCTCTGTGTT 1

RESULT 34

AAZ57362

ID AAZ57362 standard; DNA; 26 BP.

XX AC AAZ57362;

XX DT 05-APR-2000 (first entry)

XX DE Mouse acyl CoA:cholesterol acyltransferase 2 antisense PCR primer.

XX KW Mouse; acyl CoA:cholesterol acyltransferase; ACAT-2; diagnosis;

KW antilipemic; hypercholesterolaemia; hypertriglyceridaemia;

KW hyperlipidaemia; PCR primer; ss.

XX OS Mus musculus.

XX PN W09967368-A1.

XX PD 29-DEC-1999.

XX PF 16-JUN-1999; 99WO-US013683.

XX PR 23-JUN-1998; 98US-0090354P.

XX PR 08-JUN-1999; 99US-00328857.

XX PA (REGC) UNIV CALIFORNIA.

XX PI Cases S, Faresse RV, Novak S, Erickson SK;

XX WPI; 2000-106291/09.

XX PT Novel polypeptide, useful to treat conditions associated with elevated

PT cholesterol ester levels e.g. hypercholesterolemia.

XX PS Example; Page 40; 57pp; English.

XX CC The present sequence represents a PCR primer for the mouse acyl

CC CoA:cholesterol acyltransferase designated ACAT-2. ACAT-2 polypeptides

CC can be administered therapeutically, especially by expressing encoding

CC polynucleotides, to treat individuals in need of ACAT-2 polypeptide. They

CC may especially be administered to treat disease conditions associated

CC with elevated cholesterol ester levels e.g. hypercholesterolaemia or

CC hyperlipidaemia (including hypertriglyceridaemia), since ACAT-2 catalyses

CC the esterification of cholesterol with fatty acyl CoA substrates. The
CC polypeptides can also be used to diagnose diseases related to polypeptide
CC expression or activity, by analysing for polypeptide presence or amount
CC in a sample. They are useful to screen for compounds inhibiting or
CC activating the polypeptide, which can be included in pharmaceutical
CC compositions and administered therapeutically to treat conditions
CC associated with ACAT-2; inhibitory agents can especially be used to
CC inhibit ACAT-2 activity, especially therapeutically, and especially
CC agents which selectively inhibit ACAT-2 and not prior art ACAT-1
XX
SQ Sequence 26 BP; 2 A; 6 C; 13 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 28;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1253 CCCGAGGGGTAGCCATGCTGGGTGTG 1278
DB 1 CTCGGGGGTGGCCATGCTGGGAGTG 26

RESULT 35
ABT03549/c
ID ABT03549 standard; DNA; 24 BP.
XX
AC ABT03549;
XX
DT 13-SEP-2002 (first entry)
XX
DE Human Ath-1 gene PCR primer SEQ ID NO: 70.
XX
KW Human; cancer; neoplastic disease; tumour specific marker; cytostatic;
KW transcription factor; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200240716-A2.
XX
PD 23-MAY-2002.
XX
PF 13-NOV-2001; 2001WO-US043461.
XX
PR 16-NOV-2000; 2000US-0249508P.
XX
PA (CEMI-) CEMINES LLC.
XX
PI Palm K;
XX
DR WPI; 2002-537346/57.

XX Determining the presence of neoplastic molecular markers, by identifying
PT the presence of markers in host test sample using array of neoplastic
PT molecular marker specific reagents and analyzing the array of the
PT reagents.
XX
PS Example 1; Page 13; 41pp; English.

XX The present invention relates to a method for determining the presence of
CC neoplastic molecular markers in a host, involving the use of neoplastic
CC molecular marker specific reagents to detect such markers and analysing
CC the array of reagents, allowing the identification of the neoplastic
CC disease present. This can be used to determine the best treatment for
CC cancers, in particular neural cell, lung and prostate tumours. The
CC present sequence is a PCR primer useful for detecting the coding
CC sequences of markers of the invention

XX
SQ Sequence 24 BP; 6 A; 5 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 1.2%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 29;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1088 TCAACGCCTTTCGCGAGATGCTAC 1111

DB 24 TCAACGCCTTTCGCGAGTGTCTAC 1
RESULT 36
ACC42450/c
ID ACC42450 standard; DNA; 20 BP.
XX
AC ACC42450;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143038.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011899-A2.

XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Claim 3; Page 90; 112pp; English.

XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease

XX
SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 1.2%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1133 ACCGGGACTGTGGGAATC 1151
DB 20 ACCGGGACTGTGGGAATC 2

RESULT 37
ADP13837/C
ID ADP13837 standard; DNA; 25 BP.
XX
XX
AC ADP13837;
XX
DT 26-AUG-2004 (first entry)
XX
DE Renal cell carcinoma differentially expressed gene probe #242.
XX
KW ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
OS Homo sapiens.
XX
PN WO2004048933-A2.
XX
PD 10-JUN-2004.
XX
PF 21-NOV-2003; 2003WO-US037481.
XX
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX
(AMHP) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M B.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX
PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX
WPI; 2004-460799/43.
XX
DR Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
PS Disclosure; SEQ ID NO 573; 350pp; English.
XX
CC The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
SQ Sequence 25 BP; 4 A; 8 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 36;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 278 CCAGGAGGCATCCCTGGGAA 299
DB 23 CCAAGGAGGCATCTCTGGGAA 2

RESULT 38
ACC42444/C
ID ACC42444 standard; DNA; 20 BP.
XX
XX
AC ACC42444;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143032.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
WPI; 2003-248145/24.
XX
DR New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2 e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Example 16; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 1.2%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 29;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 743 GAGAGGCTGTGCTGGGATC 762
DB 20 GAGAGACTGTGCTGGGATC 1
RESULT 39
AAZ57361
ID AAZ57361 standard; DNA; 24 BP.

```
XX AAZ57361;
XX AC
XX DT
XX 05-APR-2000 (first entry)
XX DE
XX Mouse acyl CoA:cholesterol acyltransferase 2 sense PCR primer.
XX KW
XX Mouse; acyl CoA:cholesterol acyltransferase; ACAT-2; diagnosis;
XX KW antilipaemic; hypercholesterolaemia; hypertriglyceridaemia;
XX KW hyperlipidaemia; PCR primer; ss.
XX OS
XX Mus musculus.
XX PN
XX WO9967368-A1.
XX PD
XX 29-DEC-1999.
XX PF
XX 16-JUN-1999; 99WO-US013683.
XX PR
XX 23-JUN-1998; 98US-0090354P.
XX PR
XX 08-JUN-1999; 99US-00328857.
XX PA
XX (REGC ) UNIV CALIFORNIA.
XX PI
XX Cases S, Farese RV, Novak S, Erickson SK;
XX PN
XX WPI; 2000-106291/09.
XX DR
XX Novel polypeptide, useful to treat conditions associated with elevated
XX PT cholesterol ester levels e.g. hypercholesterolaemia.
XX PS
XX Example; Page 40; 57pp; English.
XX PS
XX The present sequence represents a PCR primer for the mouse acyl
XX CC CoA:cholesterol acyltransferase designated ACAT-2. ACAT-2 polypeptides
XX CC can be administered therapeutically, especially by expressing encoding
XX CC polynucleotides, to treat individuals in need of ACAT-2 polypeptide. They
XX CC may especially be administered to treat disease conditions associated
XX CC with elevated cholesterol ester levels e.g. hypercholesterolaemia or
XX CC hyperlipidaemia (including hypertriglyceridaemia), since ACAT-2 catalyses
XX CC the esterification of cholesterol with fatty acyl CoA substrates. The
XX CC polypeptides can also be used to diagnose diseases related to polypeptide
XX CC expression or activity, by analysing for polypeptide presence or amount
XX CC in a sample. They are useful to screen for compounds inhibiting or
XX CC activating the polypeptide, which can be included in pharmaceutical
XX CC compositions and administered therapeutically to treat conditions
XX CC associated with ACAT-2; inhibitory agents can especially be used to
XX CC inhibit ACAT-2 activity, especially therapeutically, and especially
XX CC agents which selectively inhibit ACAT-2 and not prior art ACAT-1
XX SQ
XX Sequence 24 BP; 2 A; 5 C; 7 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 1.2%; Score 18.2; DB 1; Length 24;
XX Best Local Similarity 87.0%; Pred. No. 44;
XX Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 749 CTGTGCGCTGGGATCCTTCGTGCC 771
XX Db |||||
XX 2 CTGTGCGCTGGGATCCTTCGTGTC 24
XX
XX RESULT 40
XX ADL06682
XX ID ADL06682 standard; DNA; 18 BP.
XX AC
XX ADL06682;
XX XX
XX 06-MAY-2004 (first entry)
XX DT
XX Human 3T3 cell conversion promoter FP852 PCR primer #1.
XX DE
XX 3T3 cell conversion; promoter; human; ss; PCR; primer.
XX KW
XX
```

```
OS Homo sapiens.
XX CN1403477-A.
XX PN
XX 19-MAR-2003.
XX PD
XX 12-SEP-2001; 2001CN-00126725.
XX PF
XX 12-SEP-2001; 2001CN-00126725.
XX PR
XX (SHAN-) SHANGHAI XINSHIJI GENE TECHN DEV CO LTD.
XX PA
XX Gu J, Yang S;
XX PI
XX WPI; 2003-494226/47.
XX PN
XX Human protein with function of promoting 3T3 cell conversion and its
XX PT coding sequence.
XX PD
XX Example 2; Page 13; 41pp; Chinese.
XX PS
XX This invention describes a novel human protein with 3T3 cell conversion
XX CC promoting function, polynucleotides encoding the polypeptide and the
XX CC recombinant process of producing the polypeptide. The present invention
XX CC also discloses the agonist resisting the polypeptide and its treatment
XX CC effect. The present invention also discloses the application of the
XX CC polynucleotides encoding the human protein with 3T3 cell conversion
XX CC promoting function.
XX SQ
XX Sequence 18 BP; 3 A; 9 C; 1 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.1%; Score 18; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred. No. 29;
XX Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 822 CCTCTTCTGCCCAACT 839
XX Db |||||
XX 1 CCTCTTCTGCCCAACT 18
XX
XX RESULT 41
XX ABZ76973
XX ID ABZ76973 standard; DNA; 20 BP.
XX AC
XX ABZ76973;
XX XX
XX 07-MAY-2003 (first entry)
XX DT
XX Bovine DGAT PCR primer #9.
XX DE
XX
XX KW Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14; bovine;
XX KW milk; meat marbling; low fat; polymorphic; SNP;
XX KW single nucleotide polymorphism; PCR primer; ss.
XX XX
XX Bos taurus.
XX OS
XX Synthetic.
XX PN
XX WO2003004630-A2.
XX PD
XX 16-JAN-2003.
XX XX
XX 05-JUL-2002; 2002WO-EP007520.
XX PF
XX 06-JUL-2001; 2001EP-00116412.
XX PR
XX 13-MAY-2002; 2002US-0379412P.
XX XX
XX (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
XX PA
XX Fries H, Winter A;
XX PI
XX WPI; 2003-239205/23.
XX DR
XX New nucleic acid molecule comprising a sequence of an allele of a
XX PT
```

PT polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
PT testing a mammal for its predisposition for fat content of milk and for
XX meat marbling.
XX
PS Example 1; Page 36; 91pp; English.
XX
CC The present invention describes a nucleic acid molecule (NA) (I) encoding
CC a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
CC indicative for low fat content of milk and to low meat marbling
CC (intramuscular fat content). Human DGAT is located to chromosome 8, and
CC bovine DGAT is located to chromosome 14. (I) is useful for testing a
CC mammal for its predisposition for fat content of milk and/or its
CC predisposition for meat marbling. The method comprises analysing the gene
CC encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
CC polymorphisms (SNPs)) which are connected with the predisposition. The
CC nucleotide polymorphisms are located in the coding region of the DGAT
CC gene and result in substitution, deletion and/or addition of an amino
CC acid sequence of the polypeptide which is encoded by the gene. The
CC nucleic acid molecule has at the position 10433 and 10434 of the DGAT
CC gene a guanine and a cytosine residue, at position 3343 a cytosine or
CC thymine, 11030 a guanine, 11048 a cytosine or thymine and 11093 a
CC thymine, which correlate with a predisposition for low fat content of
CC milk and low meat marbling. The nucleic acid molecule has at the position
CC corresponding to position 10433 and 10434 of the DGAT gene two adenine
CC residues which correlate with a predisposition for high content of milk
CC and high meat marbling. The nucleotide polymorphisms are located in a
CC region which is responsible for the regulation of the expression of the
CC product of the gene encoding DGAT. AB276924 to AB277045 and ABP96035 to
CC ABP96046 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 1.1%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1128 GTTCTACCGGACTGGT 1145
DB 3 GTTCTACCGGACTGGT 20

RESULT 42
ACC42449/c
ID ACC42449 standard; DNA; 20 BP.
XX
AC ACC42449;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143037.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiatherosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.

XX 30-JUL-2001; 2001US-00918026.
PR (ISIS-) ISIS PHARM INC.
XX
PA Crooke RM, Graham MJ, Lemonidis KM;
XX
PI WPI; 2003-248145/24.
XX
DR New antisense oligonucleotides for modulating acyl CoA cholesterol
XX acyltransferase-2, e.g. for preventing or treating diseases associated
XX with abnormal lipid or cholesterol metabolism, atherosclerosis,
XX cardiovascular disease.
XX
PS Claim 3; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.1%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1035 GCCAGGCATCTTCATGCT 1052
DB 18 GCCAGGCATCTTCATGCT 1

RESULT 43
ACC42404/c
ID ACC42404 standard; DNA; 21 BP.
XX
AC ACC42404;
XX
DT 26-AUG-2003 (first entry)
XX
DE Mouse acyl CoA cholesterol acyltransferase-2 PCR primer #2.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiatherosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; PCR; primer; ss.
XX
OS Mus musculus.
XX
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PD New antisense oligonucleotides for modulating acyl CoA cholesterol
PD acyltransferase-2, e.g. for preventing or treating diseases associated
PD with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT

PT cardiovascular disease.
XX Example 13; Page 86; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease. The present sequence is a PCR primer for mouse
CC ACAT-2, used in an example from the invention
XX
XX Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 41;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 109 GACTTGGTACAAATGACCCGA 129
DB 21 GACTTGGTGAATGGACTCGA 1
RESULT 44
ID AAL49183
XX AAL49183 standard; DNA; 21 BP.
XX
AC AAL49183;
XX
XX 30-OCT-2002 (first entry)
XX
XX Porcine CD 151 coding sequence PCR primer #7.
XX
XX CD 151; porcine reproductive and respiratory syndrome virus; PRRSV; pig;
XX selective breeding; xenotransplant; anti-RNA entry protein; anti-REP;
XX anti-viral; vaccine; PCR; primer; ss.
XX
XX Sus scrofa.
XX
XX WO200260924-A2.
XX
XX 08-AUG-2002.
XX
XX 29-JAN-2002; 2002WO-US002869.
XX
XX 29-JAN-2001; 2001US-00772044.
XX
XX 28-JAN-2002; 2002US-00772044.
XX
XX (UNIV) UNIV KANSAS STATE RES FOUND.
XX
XX PA
XX Kapil S, Shanmukhappa K;
XX
XX WPI; 2002-619225/66.
XX
XX Determining susceptibility and resistance to porcine reproductive and
XX respiratory syndrome virus (PRRSV), useful for improving swine breeding,
XX by assaying for CD 151 in a sample of cellular material of known origin
XX from the animal.
XX
XX Example 17; Page 35; 77pp + Sequence Listing; English.
XX
XX The present invention relates to a method of determining the
XX susceptibility or resistance of an animal to porcine reproductive and
XX respiratory syndrome virus (PRRSV). This involves assaying for CD 151 in
XX a sample of cellular material of known origin from the animal. In
XX addition, coding sequences of CD 151 are described, and anti-viral
XX compounds designated anti-RNA entry proteins (anti-REPs). The method is
XX useful for determining susceptibility and resistance to PRRSV in an

CC animal. This is particularly useful for improving swine breeding or for
CC screening different pig breeding lines. The method is also useful for
CC developing non-simian recombinant cell lines for propagating the virus,
CC for producing anti-viral compounds or vaccines for inducing immunity
CC against PRRSV, and for diagnosing PRRSV infection in a swine. The present
CC sequence is a PCR primer used to isolate the porcine CD 151 coding
CC sequence. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 21 BP; 1 A; 8 C; 3 G; 9 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 49;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1046 TCATGCTGCTGCTCATCTT 1064
DB 1 TCCTGCTGCTGCTCATCTT 19
RESULT 45
ID ACD51913/c
XX ACD51913 standard; RNA; 17 BP.
XX
AC ACD51913;
XX
XX 24-SEP-2003 (first entry)
XX
XX HBV inozyme substrate sequence #145.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis B virus.
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX 08-JUN-2001; 2001US-0296876P.
XX
XX 24-OCT-2001; 2001US-0335059P.
XX
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BLAT/) BLATT L.
XX
XX (MACE/) MACEJAK D.
XX
XX (MCSW/) MCSWIGGEN J.
XX
XX (MORR/) MORRISSEY D.
XX
XX (PAVC/) PAVCO P.
XX
XX (LEEP/) LEE P.
XX
XX (DRAP/) DRAPER K.
XX
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.


```
PS Example 1; Page 152; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
CC disclosed in the present invention
XX
XX Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 AGGTTCTTGGACGAGCA 277
DB 17 AGGTTCTTGGACGAGCA 1
RESULT 46
ADM58712/c
ID ADM58712 standard; RNA; 17 BP.
XX
AC ADM58712;
XX
XX 03-JUN-2004 (first entry)
XX
XX Hepatitis B virus (HBV) RNA target sequence #846.
XX
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX 15-JAN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
XX
XX 07-FEB-1994; 94US-00193627.
XX
XX 08-NOV-1999; 99US-00436430.
XX
XX 20-MAR-2000; 2000US-00531025.
XX
XX 09-AUG-2000; 2000US-00636385.
XX
XX 24-OCT-2000; 2000US-00696347.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
XX
XX (BLAT/) BLATT L.
XX
XX (MCSW/) MCSWIGGEN J A.
XX
XX (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
PT
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 846; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 AGGTTCTTGGACGAGCA 277
DB 17 AGGTTCTTGGACGAGCA 1
RESULT 47
AAZ02911/c
ID AAZ02911 standard; DNA; 20 BP.
XX
AC AAZ02911;
XX
XX 07-OCT-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
XX paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
XX Synthetic.
XX
XX Chlamydia trachomatis.
XX
XX WO9928475-A2.
XX
XX 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
XX
XX 28-NOV-1997; 97FR-00015041.
XX
XX 17-DEC-1997; 97FR-00016034.
XX
XX 04-NOV-1998; 98US-0107077P.
XX
XX (GEST ) GENSET.
XX
XX Griffais R;
XX
XX WPI; 1999-371125/31.
XX
XX Genome sequence of Chlamydia trachomatis.
XX
XX Disclosure; Page 1563; 1755pp; English.
XX
XX PCR primers AAZ01426-Z06209 were used to amplify open reading frames
XX (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
XX encode polypeptides (see AAY36754-Y37949) which can be used as vaccine
XX against Chlamydia trachomatis. Antisense and ribozyme sequences can also
```

CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as
CC conventional trachoma, nongonococcal trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis,
CC epidymitis, cervicitis, salpingitis, perihepatitis, Bartholinitis,
CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
XX
SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGGAGTGCAGCATTTCC 361
||||| |||||||
DB 20 GATGGAGTGCAGCATTTGCC 1

RESULT 48
ACC84458/c
ID ADC84458 standard; DNA; 20 BP.
XX
AC ADC84458;
XX
DT 01-JAN-2004 (first entry)
XX
DE Primer #2 used to to generate DA2 cDNA.
XX
KW HALP protein; anti-apoptotic activity; chronic inflammatory disease;
KW leukemia; myocardial infarction; stroke; traumatic brain injury;
KW muscular degenerative diseases; aging; tumor induced-cachexia;
KW rheumatoid arthritis; system lupus erythematosus; hair loss;
KW antinflammatory; cytostatic; cardiant; cerebroprotective;
KW immunomodulator; antirheumatic; antiarthritic; immunosuppressive;
KW dermatological; anti-HIV; ss; primer.
XX
OS Synthetic.
XX
PN WO2003070906-A2.
XX
PD 28-AUG-2003.
XX
PF 19-FEB-2003; 2003WO-US0004945.
XX
PR 19-FEB-2002; 2002US-0358495P.
XX
PA (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI Finkel TH, Yin J;
XX
WPI; 2003-679875/64.
XX
PT New HALP protein and nucleic acids having anti-apoptotic activity in HIV-
PT 1 infected cells, useful for treating HIV infection and AIDS, or
PT disorders associated with inordinate cellular apoptosis, e.g. leukemia,
PT stroke or brain injury.
XX
PS Example 2; Page 28; 92pp; English.
XX
CC A nucleic acid molecule encoding HALP protein having anti-apoptotic
CC activity in HIV-1 infected cells, is new. The agent is selected from
CC HALP, CD4, DF2, DF3, CC8 and molecule selected from those given in the
CC specification. The disorder may be acute and chronic inflammatory
CC disease, leukemia, myocardial infarction, stroke, traumatic brain injury,
CC neural and muscular degenerative diseases, aging, tumor induced-cachexia,
CC rheumatoid arthritis, system lupus erythematosus, or hair loss. The
CC method is considered antinflammatory, cytostatic, cardiant,
CC cerebroprotective, immunomodulator, antirheumatic, antiarthritic,
CC immunosuppressive, dermatological and anti-HIV. HALP, CD4, DF2, DF3, and
CC CC8 are useful for maintaining cell viability in a subject having a
CC disorder characterized by inordinate cellular apoptosis, such as acute

CC and chronic inflammatory disease, leukemia, myocardial infarction,
CC stroke, traumatic brain injury, neural and muscular degenerative
CC diseases, aging, tumor induced-cachexia, rheumatoid arthritis, system
CC lupus erythematosus, or hair loss. The HALP nucleic acids are
CC particularly useful for the development of therapeutic agents for
CC treating HIV infection and AIDS. The present sequence represents a primer
CC used in the method of invention.
XX
SQ Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1368 TGGAGGATGTTGAACCTTCA 1387
||||| |||||||
DB 20 TTGAGGAGTGTGAACCTTCA 1

RESULT 49
ACC42438/c
ID ACC42438 standard; DNA; 20 BP.
XX
AC ACC42438;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143026.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note="Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011899-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Claim 3; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are

CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 5 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 435 TGAGGCGAGCTGCTGCTGG 454
Db 20 TGAGGCGAGCTGATGCTGG 1
RESULT 50
ACC42439/c
ID ACC42439 standard; DNA; 20 BP.
XX
AC ACC42439;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143027.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tags a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Claim 3; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC

CC cardiovascular disease
XX
SQ Sequence 20 BP; 7 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 505 ACTGGGTCCCATGTTCT 524
Db 20 ACTGGGTCCCATGTTCT 1
RESULT 51
ACC42447/c
ID ACC42447 standard; DNA; 20 BP.
XX
AC ACC42447;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143035.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Claim 3; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC
XX
SQ Sequence 20 BP; 1 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 970 GCCACATGAGCGGAGCC 989
DB 20 GCCACATGAGCGGGAACC 1

RESULT 52
ACC42453/c
ID ACC42453 standard; DNA; 20 BP.
XX
AC ACC42453;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143041.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Example 16; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 7 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1324 CTGGGGTTCTTCTATCCCGT 1343
DB 20 CTGGGGTTCTTCTACCCGT 1

RESULT 53
ACC42445/c
ID ACC42445 standard; DNA; 20 BP.
XX
AC ACC42445;
XX
DT 26-AUG-2003 (first entry)
XX
DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143033.
XX
KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methylcytidine. Optionally
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
PN WO2003011889-A2.
XX
PD 13-FEB-2003.
XX
PF 15-JUL-2002; 2002WO-US022746.
XX
PR 30-JUL-2001; 2001US-00918026.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ, Lemonidis KM;
XX
DR WPI; 2003-248145/24.
XX
PT New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
PS Example 16; Page 90; 112pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
SQ Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 913 CTGGATGTGCTCTATGC 932

```
Db      20 CTGGGCTGTTGCTCTATGC 1
RESULT 54
ACC42456/c
ID ACC42456 standard; DNA; 20 BP.
XX
XX
AC ACC42456;
XX
XX 26-AUG-2003 (first entry)
XX
XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143044.
DE
DE Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
XX antihypercholesteric; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /mod_base= OTHER
FT /note= "Oligonucleotide has phosphorothioate backbone and
FT all cytidine nucleotides are 5-methoxyethyl (2'-MOE wings)
FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT modification"
XX
XX WO2003011889-A2.
PN
XX
XX 13-FEB-2003.
PD
XX
XX 15-JUL-2002; 2002WO-US022746.
PF
XX
XX 30-JUL-2001; 2001US-00918026.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Crooke RM, Graham MJ, Lemonidis KM;
PI
XX
XX WPI; 2003-248145/24.
DR
XX
XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.
XX
XX Example 16; Page 90; 112pp; English.
PS
XX
XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridise with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease
XX
XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1523 CTTTCTGGGGCTGGTGACA 1542
Db      20 CATTCTGGGGATGGTGACA 1
```

```
RESULT 55
ADJ24468/c
ID ADJ24468 standard; DNA; 20 BP.
XX
XX
AC ADJ24468;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human endothelial lipase antisense oligonucleotide, SEQ ID 2866.
DE
DE Antilipemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
XX Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW cardiovascular disorder; metabolic syndrome X; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
XX WO2004009541-A2.
PN
XX
XX 29-JAN-2004.
PD
XX
XX 18-JUL-2003; 2003WO-US022410.
PF
XX
XX 19-JUL-2002; 2002US-0397106P.
PR
XX
XX (PHAA ) PHARMACIA CORP.
PA
XX
XX Bhat BG;
PI
XX
XX WPI; 2004-132912/13.
DR
XX
XX New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
PT
XX
XX Claim 3; SEQ ID NO 2866; 1007pp; English.
PS
XX
XX The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
XX Sequence 20 BP; 4 A; 1 C; 10 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 237 CAAACCTCTGCCCCACCTC 256
Db      20 CAAACCTCTGTCCACCTC 1
RESULT 56
ADJ23788/c
ID ADJ23788 standard; DNA; 20 BP.
XX
XX ADJ23788;
```

```
XX DT 20-MAY-2004 (first entry)
XX DE Human endothelial lipase antisense oligonucleotide, SEQ ID 2186.
XX DE
XX DE
XX DE Antilipaseic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
XX KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
XX KW cardiovascular disorder; metabolic syndrome X; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "this oligonucleotide has a phosphorothioate
XX FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
XX FT and 3' ends, which are 4 nucleotides in length. Also all
XX FT cytidine residues are 5-methylcytidines"
XX PN WO2004009541-A2.
XX XX
XX XX
XX PD 29-JAN-2004.
XX PF 18-JUL-2003; 2003WO-US022410.
XX PR 19-JUL-2002; 2002US-0397106P.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Bhat BG;
XX XX
XX XX WPI; 2004-132912/13.
XX XX
XX PT New antisense oligonucleotide for modulating endothelial lipase
XX PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
XX PT high density lipoprotein or cardiovascular disorders.
XX PS Claim 3; SEQ ID NO 2186; 1007pp; English.
XX XX
XX CC The present invention relates to antisense oligonucleotides (ADJ21603-
XX CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
XX CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
XX CC with and inhibits the expression of EL. The antisense oligonucleotides
XX CC are useful for modulating the expression of endothelial lipase in cells
XX CC or tissues to treat diseases associated with EL expression, such as
XX CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
XX CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
XX CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX SQ Sequence 20 BP; 4 A; 1 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 57;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 238 AAACCTCTGCCACCTCC 257
DB 20 AAACCTCTGCCACCTCC 1

RESULT 57
AAQ38666/c
ID AAQ38666 standard; DNA; 21 BP.
XX AC AAQ38666;
XX XX
XX XX 25-MAR-2003 (revised)
XX DT 07-MAY-1993 (first entry)
XX XX
XX DE PSODbetaMAX10 5' end.
XX XX
```

```
KW Superoxide dismutase; beta-lactamase; RBS; initiation codon;
KW PSODbeta111; PSODbetaMA; PSODbetaMAX10; PSODbetaMAX11; PSODbetaMAX12;
XX ss.
XX OS Synthetic.
XX XX
XX PN US5162217-A.
XX XX
XX PD 10-NOV-1992.
XX XX
XX PF 08-DEC-1989; 89US-00449125.
XX XX
XX PR 27-AUG-1984; 84US-00644245.
XX PR 19-AUG-1985; 85US-00767143.
XX PR 14-AUG-1986; 86US-00897056.
XX PR 03-JUN-1988; 88US-00202238.
XX XX
XX PA (BIOT-) BIO-TECHNOLOGY GENERAL CORP.
XX XX
XX PI Hartman JR, Oppenheim AB, Gorecki M, Aviv H, Oren R;
XX XX
XX DR WPI; 1992-398025/48.
XX XX
XX PT Plasmid for prodn. of super:oxide dismutase - using Escherichia coli host
XX PT cell contg. temp. sensitive repressor.
XX PS Example 19; Page 60; 61pp; English.
XX XX
XX CC High level expression of authentic hSOD was achieved by a single base
XX CC change in the beta-lactamase RBS region as compared to the sequence
XX CC present in PSODbeta111 (AAQ38664). The 22 bp long SspI-NdeI fragment of
XX CC PSODbetaMA (AAQ38665) was replaced with 3 different synthetic fragments,
XX CC each having a single base substitution which eliminates the first ATG
XX CC (either C, T or A instead of G in the third position of the initiator
XX CC codon; producing PSODbetaMAX10 (AAQ38666), PSODbetaMAX11 (AAQ38667) and
XX CC PSODbetaMAX12 (AAQ38668) respectively). Only the G to C and G to A
XX CC substitutions resulted in high level hSOD expression upon induction.
XX CC (Updated on 25-MAR-2003 to correct PF field.)
XX SQ Sequence 21 BP; 7 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 62;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1342 GTCATGCTGACTCTCTCCT 1361
DB 20 GCCATGCTGACTCTCTCCT 1

RESULT 58
AAQ54227/c
ID AAQ54227 standard; DNA; 21 BP.
XX AC AAQ54227;
XX XX
XX XX 25-MAR-2003 (revised)
XX DT 27-JUN-1994 (first entry)
XX XX
XX DE BSSL/CEL Exon 11 repetition Primer.
XX XX
XX KW BSSL; biologically functional bile salt stimulated lipase; CEL;
XX KW carboxyl ester lipase; hybridisation; milk protein; transgenic;
XX KW infant milk substitute; oral; specific; lipolysis; vitamin; bile;
XX KW lipid malabsorption; cystic fibrosis; chronic pancreatitis; digestion;
XX KW ss.
XX OS Synthetic.
XX XX
XX PN WO9325669-A1.
XX XX
XX PD 23-DEC-1993.
XX XX
```

```
PF 09-JUN-1993; 93WO-SE000515.
XX
XX 11-JUN-1992; 92SE-00001809.
PR 12-JUN-1992; 92SE-00001826.
PR 03-JUL-1992; 92SE-00002088.
PR 19-MAR-1993; 93SE-00000902.
XX
XX (ASTR ) ASTRA AB.
XX
XX Bjursell KG, Carlsson PNI, Enerback CSM, Hansson SL, Lidberg UFF;
PI Nilsson JA, Toernell JBB;
XX
XX WPI; 1994-007527/01.
XX
XX DNA encoding bile salt-stimulated lipase/carboxyl ester lipase -
PT expressed by transgenic non-human mammals and used as human milk
PT substitute, contains intron sequences.
XX
XX Disclosure; Page 36; 76pp; English.
XX
XX The primers (AAQ54223-28) are used to amplify fragments of the BSSL / CEL
CC gene, (AAQ54222). Which encodes a bile salt-stimulated lipase / carboxyl
CC ester lipase which when expressed by transgenic animals can be used as a
CC human milk substitute. The BSSL is designed to pass through the stomach
CC and is activated in the small intestine. As it has a broad substrate
CC specificity it can mediate the complete digestion of most dietary lipids.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 21 BP; 8 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 62;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1050 GCTGTCCTCATCTCTCTTGG 1069
DB 21 GCTGTCCTCATCTCTTGG 2
RESULT 59
ID AAZ92061/c
XX AAZ92061 standard; DNA; 21 BP.
AC AAZ92061;
XX
XX 09-JUN-2000 (first entry)
XX
XX SOD expression vector fragment betaMAX10.
XX
XX SOD; expression vector; superoxide dismutase; superoxide radical injury;
KW human CuZn SOD; organ transplantation; spinal cord injury reduction;
KW spinal cord ischaemia; therapy; ds.
XX
XX Synthetic.
XX
XX US6030611-A.
XX
XX 29-FEB-2000.
XX
XX 26-MAY-1995; 95US-00451474.
XX
XX 27-AUG-1984; 84US-00644245.
PR 19-AUG-1985; 85US-00767143.
PR 14-AUG-1986; 86US-00897056.
PR 03-JUN-1988; 88US-00202238.
PR 08-DEC-1989; 89US-00449125.
PR 21-AUG-1992; 92US-00993500.
XX
XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
XX Gorecki M, Gonienne A;
XX
XX WPI; 2000-205188/18.
```

```
1.1%
XX
XX Reducing injuries caused by superoxide radicals by administering
PT superoxide dismutase enzymes.
XX
XX Example 19; Col 50; 58pp; English.
XX
XX This sequence represents a fragment of a superoxide dismutase (SOD)
CC expression vector. The invention relates to methods of treating injuries
CC caused by superoxide radicals, comprising administering enzymatically
CC active human CuZn SOD. One method is for reducing injuries caused by
CC superoxide radicals to an organ recipient following an organ
CC transplantation, which comprises administering a composition comprising
CC enzymatically active CuZn SOD (which has the amino acid sequence and
CC enzymatic activity of natural human CuZn SOD) and a carrier. The other
CC method of the invention is for reducing spinal cord injuries caused by
CC superoxide radicals in a patient, which comprises administering, by
CC infusion into the patient's blood, a composition comprising enzymatically
CC active CuZn SOD (which has the amino acid sequence and enzymatic activity
CC of natural human CuZn SOD) and a carrier. The methods are used to treat
CC injuries caused by superoxide radicals, especially injuries to organs
CC following transplantation and spinal cord injuries caused by superoxide
CC radicals in a patient due to reperfusion following spinal cord ischaemia
XX
XX Sequence 21 BP; 7 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 62;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1342 GTCATGCTGATCTCTTCT 1361
DB 20 GCCATGCTGATCTCTTCT 1
RESULT 60
ADL78868/c
ID ADL78868 standard; RNA; 19 BP.
XX
XX ADL78868;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human HER2 (EGFR2) transcript target sequence/siNA upper strand, SEQ:33.
XX
XX RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER2; EGFR2; neu; erbB2; c-erbB-2; target sequence; ss.
XX
XX Homo sapiens.
XX
XX WO2003070912-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005045.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
```

```

PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX
DR WPI; 2003-697612/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 33; 171pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised.
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human HER2 (EGFR2)-targeted double-stranded siNA, which is identical to
CC the HER2 transcript target sequence.
XX
SQ Sequence 19 BP; 2 A; 5 C; 10 G; 0 T; 2 U; 0 Other;

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCTCC 684
Db 18 CAGCTCCCGCGGCTCC 1

RESULT 61
ADL79117
ID ADL79117 standard; RNA; 19 BP.
XX
AC ADL79117;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human HER2 (EGFR2) siNA lower strand, SEQ ID NO:282.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER2; EGFR2; neu; erbB2; c-erb-B-2; ss.
XX
OS Homo sapiens.
XX
PN WO2003070912-A2.
XX
PD 28-AUG-2003.
XX
PP 20-FEB-2003; 2003WO-US005045.
XX

```

```

PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX
DR WPI; 2003-697612/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 282; 171pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised.
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the lower strand of a
CC human HER2 (EGFR2)-targeted double-stranded siNA.
XX
SQ Sequence 19 BP; 2 A; 10 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 62;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCTCC 684
Db 2 CAGCTCCCGCGGCTCC 19

RESULT 62
AAZ77373
ID AAZ77373 standard; DNA; 20 BP.
XX
AC AAZ77373;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:11729.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;

```



```

KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
XX
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST ) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
XX WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 9; Page 2731; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease, as well as other treatment.
CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 20 BP; 2 A; 10 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 821 TCCTCTTCTGCCCAACAC 838
Db |||||
3 TCCTCTTCTGCCCAACTC 20

RESULT 63
AA447648
ID AAA47648 standard; cDNA; 21 BP.
XX
AC AAA47648;
XX
XX 08-NOV-2000 (first entry)
XX
XX Primer (Mk1r) for amplifying murine KCNQ1 potassium channel gene.
XX
KW KCNQ4; potassium channel; cardiac arrhythmia; neonatal epilepsy;
KW deafness; probes; treatment; therapy; transgenic animal; antibody;
KW agonist; antagonist; tinnitus; hearing loss; neonatal deafness;
KW presbycusis; affective disorder; Alzheimer's disease; anxiety; ataxia;
KW cognitive deficits; compulsive behavior; dementia; depression;
KW Huntington's disease; mania; memory impairment; motor disorders;
KW neurodegenerative disease; Parkinson's disease; Pick's disease;
KW psychosis; schizophrenia; spinal cord damage; stroke; tremor; ss.
XX
OS Mus musculus.
XX
PN WO200044786-A1.

03-AUG-2000.
19-JAN-2000; 2000WO-DK000024.
26-JAN-1999; 99DK-00000076.
19-MAY-1999; 99DK-00000693.
(NEUR-) NEUROSEARCH AS.
Jentsch TJ;
WPI; 2000-548913/50.
Nucleic acids encoding the novel KCNQ4 potassium channel subunit, useful
e.g. for treating tinnitus, deafness, Alzheimer's and Parkinson's
diseases.
Example 3; Page 26; 65pp; English.
Mutations in 3 known genes of the KCNQ branch of the potassium channel
gene family underlie inherited cardiac arrhythmia's, neonatal epilepsy
and in some cases associated with deafness. KCNQ4 has been mapped to the
DFNA2 locus for autosomal dominant hearing loss, and a dominant negative
KCNQ4 mutation that causes deafness in a DFNA2 pedigree has been
identified. KCNQ4 is the first potassium channel gene underlying non-
syndromic deafness. KCNQ4 forms heteromeric channels with other KCNQ
channel subunits, especially KCNQ3. Nucleotides encoding the KCNQ4
protein and the protein itself may be used in the prevention, treatment
and diagnosis of diseases associated with inappropriate KCNQ4 expression.
The nucleotides may also be used as DNA probes in diagnostic assays (e.g.
polymerase chain reactions (PCR)) to detect and quantitate the presence
of similar nucleic acid sequences in samples and to identify mutations
within them, and hence which patients may be in need of restorative
therapy. They may also be used to study the expression and function of
KCNQ4 polypeptides and their role in metabolism, for example through the
production of transgenic animals. The KCNQ4 polypeptides may be used as
antigens in the production of antibodies and to identify modulators
(agonists and antagonists) of KCNQ4 expression and activity. The anti-
KCNQ4 antibodies and KCNQ4 antagonists may also be used to down regulate
KCNQ4 expression and activity. They may be used in this way to treat
tinnitus, loss of hearing (especially progressive hearing loss, neonatal
deafness and presbycusis (deafness of the elderly)) and disease or
adverse conditions of the central nervous system (CNS) such as affective
disorder, Alzheimer's disease, anxiety, ataxia, CNS damage caused by
trauma, stroke or neurodegenerative illness, cognitive deficits,
compulsive behavior, dementia, depression, Huntington's disease, mania,
memory impairment, memory disorders and dysfunctions, motion disorders,
motor disorders, neurodegenerative diseases, Parkinson's disease,
Parkinson-like motor disorders, phobias, Pick's disease, psychosis,
schizophrenia, spinal cord damage, stroke and/or tremor. Conversely,
antisense nucleic acid molecules may be administered to down regulate
KCNQ4 expression by binding with the cells own KCNQ4 genes and preventing
their expression. Two primers (AAA47647, AAA47648) were used to amplify
the murine KCNQ1 potassium channel gene
Sequence 21 BP; 2 A; 3 C; 11 G; 5 T; 0 U; 0 Other;

Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 80;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 434 ATGAGGCGAGGCTGCTGTGG 454
Db | | | | | | | | | | | | | | | | | | | |
1 AGGTGGCGAGGCTGTGTGG 21

RESULT 64
AAF95935
ID AAF95935 standard; DNA; 21 BP.
XX
XX AAF95935;
XX
```

DT 06-JUN-2001 (first entry)
XX Human gene single nucleotide polymorphism #696.
XX
XX
KW Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
OS Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT Variation replace(11,T)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX
PD 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JU;
PI WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 96; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
SQ Sequence 21 BP; 3 A; 9 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 80;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1220 ATCAGATGGCTGGCTCC 1240
Db 1 ATCACCATGGCTGGCTCC 21

RESULT 65
ACD50543/C
ID ACD50543 standard; RNA; 17 BP.
XX
AC ACD50543;
XX
XX 23-SEP-2003 (first entry)
XX
XX HBV hammerhead ribozyme substrate sequence #111.

KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNase; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW viricide; antiinflammatory; substrate; ss.
XX
XX Hepatitis B virus.
OS
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 138; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNase, DNase,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNase, or amberzyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 4 A; 7 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 GGTTCCTTGACGAGCA 277
Db 17 GGTTCCTTGACGAGCA 2


```

SQ Sequence 19 BP; 0 A; 6 C; 7 G; 0 T; 6 U; 0 Other;
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 80;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 1314 CTGCTTCGTCCTGGGGTTC 1332
Db 1 CUGGUUCGUCUGGGGUC 19

RESULT 68
ADO14767/c
ID ADO14767 standard; RNA; 19 BP.
XX ADO14767;
XX 01-JUL-2004 (first entry)
XX Human PDGFr-targeted siNA upper strand SEQ ID NO:198.
DE
XX cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human;
KW platelet derived growth factor receptor; PDGFr; ss.
XX
OS Homo sapiens.
XX
XX WO2003072704-A2.
PN
XX 04-SEP-2003.
XX
XX 05-FEB-2003; 2003WO-US003473.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Chowrira B;
PI
XX WPI; 2003-731605/69.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of tumors, downregulates expression of the platelet-derived
PT growth factor receptor gene.
XX
XX Example 3; SEQ ID NO 198; 148pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human platelet-derived growth factor
CC receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA, double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC modulate expression of the PDGFr gene in cells, tissue explants or
CC

CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating leukaemia and solid tumors, restenosis, polycystic kidney
CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC useful for drug screening, diagnosis, therapeutic target identification
CC and validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human PDGFr-
CC targeted double-stranded siNA, which is identical to the PDGFr transcript
CC target sequence.
XX
XX Sequence 19 BP; 6 A; 7 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1314 CTGCTTCGTCCTGGGGTTC 1332
Db 19 CTGGTTCGTCCTGGGGGTC 1

RESULT 69
ADM94080/c
ID ADM94080 standard; DNA; 19 BP.
XX ADM94080;
XX 15-JUL-2004 (first entry)
DT
XX IGH tube D DH family primer DH4.
DE
XX nucleic acid amplification; primer; PCR; detection;
KW chromosomal translocation; clonal rearrangement; chromosome aberration;
KW lymphoproliferative disorder; ss.
XX
XX Synthetic.
XX
XX WO2004033728-A2.
XX
XX 22-APR-2004.
XX
XX 13-OCT-2003; 2003WO-NL000690.
XX
XX 11-OCT-2002; 2002US-0417779P.
XX
XX (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
XX (DAVI/) DAVI F B L.
XX
XX Van Dongen JTM, Langerak AW, Schuurink EMD, San Miquel JF;
PI Garzia Sanz R, Parreira A, Smith JL, Lavender FL, Morgan GJ;
PI Evans PAS, Kneba M, Hummel M, Macintyre EA, Bastard C;
XX
XX WPI; 2004-364878/34.
XX
XX New set of nucleic amplification primers comprising a forward primer and
PT a reverse primer and capable of amplifying a rearrangement, useful in
PT diagnosing lymphoproliferative disorders.
XX
XX Claim 2; Fig 4A; 121pp; English.
XX
XX The present invention describes a set of nucleic amplification primers
CC capable of amplifying a VH-JH or DH-JH IGH, VK-JK or VK/intron-Kde IGH,
CC Lambda-Jlambda IGL, Vbeta-Jbeta TCRB or Dbeta-Jdelta or Vdelta-Ddelta
CC Vdelta-Jdelta, Ddelta-Ddelta or Vdelta-Ddelta TCRD rearrangement
CC comprises a forward primer and a reverse primer. Also described: (1) a
CC nucleic acid amplification assay, preferably a PCR or multiplex PCR
CC assay, using the set of primers; (2) detecting VH-JH or DH-JH IGH, VK-JK
CC or VK/intron-Kde IGH, Vlambda-Jlambda IGL, Vbeta-Jbeta TCRB or Dbeta-
CC Jbeta TCRB, VJ-JY TCRG, Vdelta-Jdelta, Ddelta-Ddelta or Vdelta-Ddelta
CC TCRD rearrangement; (3) detecting chromosomal translocation (11;14) (BCLg-
CC JGZ-1) or t(14;18) (BCL2-IGH); (4) detecting human TbxAS1, recombination
CC activating protein (RAG1), promyelocytic leukaemia zinc finger protein
CC
```

CC (PLZF) or AP4 gene; (5) assessing clonal rearrangements and/or chromosome
 CC aberrations; and (6) a kit for the detecting at least one rearrangement
 CC comprising the set of primers. The new set of nucleic amplification
 CC primers capable of amplifying a VH-JH or DH-JH IGH, VK-JK or VK/Intron-
 CC Kde IGH, Vlambda-Jlambda IGL, Vbeta-Jbeta TCRB or Dbeta-Jbeta TCRB, VY-JY
 CC TCRG, Vdelta-Jdelta, Ddelta-Ddelta or Vdelta-Ddelta TCRD rearrangement
 CC are useful in diagnosing lymphoproliferative disorders. The present
 CC sequence is used in an example from the present invention.

XX SQ Sequence 19 BP; 6 A; 7 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 80;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1315 TGCTCGTCTCGGGTCT 1333
 Db 19 TGCTCGTCTCGGGATCT 1

RESULT 70
 AAV70046
 ID AAV70046 standard; DNA; 20 BP.
 XX AC AAV70046;
 XX DT 04-FEB-1999 (first entry)
 XX DE Rat c-Fos protein antisense oligonucleotide #100.
 XX KW Rat; c-fos; c-jun; activating protein 1; AP-1; diagnosis; metastasis;
 KW antisense oligonucleotide; phosphorothioate; regulation;
 KW malignant tumour; cell cycle expression; hyperproliferative disease; ss.
 XX OS Synthetic.
 XX OS Rattus sp.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate linkages"
 XX WO9846272-A1.
 XX 22-OCT-1998.
 XX 14-APR-1998; 98WO-US007386.
 XX 14-APR-1997; 97US-00837201.
 XX (ISIS-) ISIS PHARM INC.
 XX Dean NM, Mckay R, Miraglia L, Baker B;
 XX WPI; 1998-609906/51.
 XX Antisense oligonucleotides regulating Activating Protein 1 subunits -
 PT hybridise with c-fos and c-jun mRNA, used for regulating metastasis, cell
 PT cycle expression and hyperproliferative disease.
 XX Example 9; Page 57; 120pp; English.

CC AAV70042 to AAV70052 represent antisense oligonucleotides which are
 CC specifically hybridisable with a region of a nucleic acid encoding rat c-
 CC Fos protein. The antisense compound regulates the expression of the c-Fos
 CC protein. The present invention also describes antisense oligonucleotides
 CC which regulate the c-Jun protein. The antisense oligonucleotides are used
 CC for the diagnosis and treatment of diseases or disorders associated with
 CC Activating Protein 1 expression, of which c-Fos and c-Jun are subunits.
 CC The antisense oligonucleotides are used in compositions as c-Fos and/or c-
 CC Jun together with a carrier and a chemotherapeutic agent. They are used
 CC to regulate the expression of c-Fos or c-Jun in cells or tissues,
 CC preferably by inhibiting metastasis. They also regulate cell cycle

XX expression and can be used to treat an animal with, or being prone to, a
 CC hyperproliferative disease

XX SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 87;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTCGCGCTGCCG 645
 Db 2 GATGCTCTCGGCTCTGCCG 20

RESULT 71
 AAA08761/c
 ID AAA08761 standard; DNA; 20 BP.
 XX AC AAA08761;
 XX DT 19-JUL-2000 (first entry)
 XX DE Primer 1 to amplify human interferon epsilon gene probe 2.
 XX KW Interferon-epsilon; IFN-e; antiviral; anticancer; immunomodulatory;
 KW antiproliferative; probe; primer; ss.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX FN WO200017361-A2.
 XX PD 30-MAR-2000.
 XX PF 16-SEP-1999; 99WO-US021279.
 XX PR 18-SEP-1998; 98US-00157068.
 XX PR 05-FEB-1999; 99US-00245293.
 XX PR 08-JUL-1999; 99US-00350232.
 XX PA (ZYMO) ZYMOGENETICS INC.
 XX Conklin DC, Grant FJ, Rixon M, Kindsvogel W;
 XX WPI; 2000-283586/24.
 XX New murine and human interferon-epsilon, useful for treating viral
 PT infection, cancer and other proliferative diseases e.g. multiple
 PT sclerosis or arteriosclerosis.
 XX Example 2; Page 131; 140pp; English.

CC AAA08759-62 are primers used to generate probes to detect cDNA which
 CC encodes a novel human interferon, designated "interferon-epsilon" (IFN-
 CC e). The IFN-e gene has been mapped to chromosome 9p22.2. Variants and
 CC mouse/human chimeric IFN-e proteins are also claimed. IFN-e, its variants
 CC and chimeras are used to inhibit viral infection and proliferation of
 CC cancer cells, particularly of B-cell lymphoma and chronic or acute
 CC lymphatic leukemia, (claimed) and to treat many other proliferative
 CC diseases, e.g. multiple sclerosis or arteriosclerosis, to modulate
 CC neuronal cell growth, e.g. in cases of depression, or neurodegeneration,
 CC to treat myocarditis and to promote growth of, or protect, fetuses. They
 CC may be expressed in vivo from vectors or recombinant viruses containing
 CC the appropriate nucleic acid. IFN-e antibodies and anti-idiotypic
 CC antibodies are used as immunoassay reagents and as antiviral and
 CC antiproliferative agents. IFN-e-derived fusion proteins are used to
 CC identify agonists and antagonists, useful as adjuvants for culture media,
 CC for inducing expression of antigen, as adjuvants in immunotherapy or
 CC immunoscinigraphy and also for characterizing cognate receptors

XX SQ Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.8; DB 1; Length 20;

XX

OS Homo sapiens.
 XX JP2001321190-A.
 XX
 XX 20-NOV-2001.
 XX
 XX 12-MAR-2001; 2001JP-00068285.
 XX
 XX 10-MAR-2000; 2000JP-00066716.
 XX
 XX (RIKA) RIKAGAKU KENKYUSHO.
 XX (GENO-) GENOTEX YG.
 XX WPI; 2002-144136/19.
 XX
 XX Arraying genome clones.
 XX
 XX Claim 4; Page 16; 528pp; Japanese.
 XX
 CC The present invention describes a method of arraying genome clones. The
 CC method comprises: (a) clones of the genomic libraries contained in
 CC multiwell plates numbered for discrimination are mixed in each of the
 CC multiwell plates; (b) a primer designed based on the chromosome marker
 CC sequence is added to the mixture to carry out an amplification reaction;
 CC (c) a signal corresponding to the marker is detected from the resultant
 CC amplified product to specify the discrimination Nos. of the multiwell
 CC plates containing the clones having said marker sequence; (d) the order
 CC of the markers is changed so that the same discrimination Nos. succeed to
 CC the maximum in the specified discrimination Nos. to array the multiwell
 CC plates; (e) the clones in the multiwell plates of the specified
 CC discrimination Nos. are mixed respectively in each wells of longitudinal
 CC and lateral directions; (f) the mixed clones are cultured and the
 CC resultant cultures are amplified by using the above primer; (g) signals
 CC are detected from the amplified products; (h) the clones in the multiwell
 CC plates are specified from the detected result; and (i) the clones are
 CC reconstituted as the positions on the chromosome and arrayed. The
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 CC represent PCR primers for human chromosome 21q22.1, which are
 CC specifically claimed for use in the present invention
 XX
 SQ Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 87;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 936 CTTTCATCTGGCGGCTC 954
 DB 20 CTTTCATCTGGCGTACCTC 2
 RESULT 75
 ACC49211/c
 ID ACC49211 standard; DNA; 20 BP.
 XX
 AC ACC49211;
 XX
 XX 20-JUN-2003 (first entry)
 XX
 DE Human ribonuclease L antisense oligonucleotide SEQ ID NO:28.
 XX
 KW Human; ribonuclease L; antisense modulation; cytostatic; antimicrobial;
 KW antiinflammatory; antitumor; ribonuclease L expression inhibitor;
 KW antisense gene therapy; infection; aberrant apoptosis; cancer; tumour;
 KW inflammation; phosphorothioate; 2'-O-methoxyethyl; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a

FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages"
 FT 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls (2'-MOEs)"
 FT 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls (2'-MOEs)"
 PN WO2003023011-A2.
 XX 20-MAR-2003.
 XX
 XX 09-SEP-2002; 2002WO-US028729.
 XX
 XX 12-SEP-2001; 2001US-00954679.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Ward DT, Watt AT;
 XX
 XX WPI; 2003-313248/30.
 XX
 PT Novel antisense compound which is targeted to nucleic acid encoding
 PT ribonuclease L, and inhibits expression of ribonuclease L protein, useful
 PT for treating diseases or conditions resulting from infections and
 PT aberrant apoptosis.
 XX
 XX Claim 3; Page 77; 106pp; English.
 XX
 CC The present invention describes a compound (I) of 8-50 nucleobases in
 CC length targeted to a nucleic acid molecule (II) encoding ribonuclease L
 CC (III), and which specifically hybridises with (II) and inhibits
 CC expression of (III), where (I) specifically hybridises with at least an 8
 CC -nucleobase portion of an active site on (II). (I) has cytostatic,
 CC antimicrobial, antiinflammatory and antitumour activities, and can be
 CC used as a ribonuclease L expression inhibitor and in antisense gene
 CC therapy. (I) is useful for inhibiting the expression of ribonuclease L in
 CC cells or tissues, and for treating an animal having a disease condition
 CC associated with ribonuclease L, e.g. infection, aberrant apoptosis or
 CC cancer. (I) is also useful for modulating the process of RNA-mediated
 CC interference (RNAi) in a cell or animal. (I) is also useful
 CC prophylactically, e.g. to prevent or delay infection, inflammation or
 CC tumour formation. (I) is useful as a tool in differential and/or
 CC combinatorial analyses to elucidate expression patterns of a portion or
 CC the entire complement of genes expressed within cells and tissues. (I) is
 CC also useful for research, therapeutics and diagnostics. (I) is also
 CC useful for distinguishing functions of various members of a biological
 CC pathway, and in antisense gene therapy. The present sequence represents a
 CC human ribonuclease L chimeric phosphorothioate antisense oligonucleotide,
 CC which is used in an example from the present invention
 XX
 SQ Sequence 20 BP; 8 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 87;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1311 CTTTCGCTTCGTCCTGGGG 1329
 DB 20 CTTTCGCTTCGTCATGGTG 2
 RESULT 76
 ABZ87090/c
 ID ABZ87090 standard; DNA; 20 BP.
 XX
 XX
 AC ABZ87090;
 XX
 XX 17-OCT-2003 (first entry)
 XX
 XX

DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;

XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

OS

XX WO200285308-A2.

PN 31-OCT-2002.

XX

XX 23-APR-2002; 2002WO-US013135.

PF

XX 24-APR-2001; 2001US-0286137P.

PR

XX (EPIG-) EPIGENESIS PHARM INC.

PA

XX Nyce JW, Li Y, Sandraaagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shanabuddin S;

PI WPI; 2003-229219/22.

XX

XX Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubiquinone.

XX

PS Claim 15; SEQ ID NO 2332; 872pp; English.

XX

XX The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, may have a

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 20 BP; 5 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 87;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 CCTTCTCCAACTACTACCG 1175

|||||

Db 19 CCTTCTCCAACTCTCTACGG 1

RESULT 77

ACA63127/c

ID ACA63127 standard; DNA; 20 BP.

XX

XX ACA63127;

XX

XX 28-AUG-2003 (first entry)

XX

XX

DE Human interferon-epsilon (Zifne) probe #3.

XX Human; interferon-epsilon; zifne; cytostatic; antibacterial; virucide;

KW anti-HIV; hepatotropic; neuroprotective; nootropic; antiparkinsonian;

KW gene therapy; viral infection; tumour cell proliferation;

KW autoimmune disease; multiple sclerosis; hepatitis; Parkinson's disease;

KW Alzheimer's disease; cancer; infection; cytokine; probe; ss.

XX

OS Homo sapiens.

XX

XX US2003013162-A1.

PN 16-JAN-2003.

XX

XX 04-OCT-2001; 2001US-00971843.

PF

XX 18-SEP-1998; 98US-0101012P.

PR

XX 05-FEB-1999; 99US-0118578P.

PR

XX 08-JUL-1999; 99US-0142766P.

PR

XX 16-SEP-1999; 99US-00397992.

XX

XX (ZYMO) ZYMOGENETICS INC.

PA

XX Conklin DC, Grant FU, Rixon MW, Kindsvogel W;

PI WPI; 2003-491969/46.

XX

XX New interferon-epsilon polypeptide for diagnosing and treating autoimmune

PT disease, hepatitis, Parkinson's disease, Alzheimer's disease, cancer or

PT infections (e.g. bacterial or viral such as AIDS).

PT

XX

PS Example 2; Page 41; 64pp; English.

XX

XX The invention describes a new isolated polypeptide comprising an amino

CC acid sequence of: (a) residues 22-192 of a sequence having 192 amino

CC acids (S1) given in the specification; (b) S1, that is at least 70%

CC identical to residues 27-183 of S1; or (c) at least 15 contiguous amino

CC acid residues of S1. The composition and methods are useful for

CC inhibiting viral infection of cells, proliferation of tumour cells and in

CC diagnosing and treating a variety of medical conditions, including

CC autoimmune diseases (e.g. multiple sclerosis), hepatitis, Parkinson's

CC disease, Alzheimer's disease, cancers, and infections (e.g. bacterial

CC viral such as AIDS). This sequence represents a probe used to detect DNA

CC encoding the novel human cytokine of the invention, interferon-epsilon

CC (Zifne) during gene expression analysis

XX

SQ Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 87;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 CTGGGAAACAGAAAGTTT 310

|||||

Db 19 CTGAGGACGAGAAAGTTT 1

RESULT 78

ACC42448/c

ID ACC42448 standard; DNA; 20 BP.

XX

XX ACC42448;

XX

XX 26-AUG-2003 (first entry)

DT

XX

XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143036.

DE

XX

XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;

KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;

KW cholesterol metabolism; atherosclerosis; cardiovascular disease;

KW phosphorothioate; mouse; ss.

XX

XX Synthetic.

OS


```

XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "oligonucleotide has phosphorothioate backbone and
XX FT all cytidine nucleotides are 5-methylcytidine. Optionally
XX FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
XX FT modification"
XX PN WO2003011889-A2.
XX PD 13-FEB-2003.
XX PF 15-JUL-2002; 2002WO-US022746.
XX PR 30-JUL-2001; 2001US-00918026.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Crooke RM, Graham MJ, Lemonidis KM;
XX PS WPI; 2003-248145/24.
XX PT New antisense oligonucleotides for modulating acyl CoA cholesterol
XX PT acyltransferase-2, e.g. for preventing or treating diseases associated
XX PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
XX PT cardiovascular disease.
XX PS Claim 3; Page 90; 112pp; English.
XX CC The present invention relates to novel antisense oligonucleotides which
XX CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
XX CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
XX CC ACC42457). The antisense oligonucleotides specifically hybridize with and
XX CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
XX CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
XX CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
XX CC useful for treating an animal which has a disease or condition associated
XX CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
XX CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
XX CC cardiovascular disease
XX SQ Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 87;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 GAGAGCCCTTCAGCACCG 1001
Db 20 GGGACCCCTTCAGCACCG 2

RESULT 79
ABD23320/c
ID ABD23320 standard; DNA; 20 BP.
AC ABD23320;
XX 29-JUL-2004 (first entry)
XX Human myosin X-derived oligonucleotide SEQ ID 2332.
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.

```

```

XX OS Homo sapiens.
XX PN WO200285309-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013143.
XX PR 24-APR-2001; 2001US-0286036P.
XX PA (EPIC-) EPICGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-093058/08.
XX PT Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX PS Claim 15; SEQ ID NO 2332; 763pp; English.
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes a kit, that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC instructions for adding a carrier and for use of the kit. The composition
XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC inflammation, allergies, asthma, impeded respiration, respiratory
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX CC prevent any unwanted effects due to it
XX SQ Sequence 20 BP; 5 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 87;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 CCTTCTCCAACTACTACCG 1175
Db 19 CTTTCTCCAACTCTCTACCG 1

RESULT 80
ADI81478/c
ID ADI81478 standard; DNA; 20 BP.
XX ADI81478;
XX 22-APR-2004 (first entry)

```



```
Best Local Similarity 89.5%; Pred. No. 87;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1270 CTGGGTGTTCTCTGCTCT 1288
    ||| ||||| |||||
Db 20 CTGCATGTTCTCTGCTCT 2

RESULT 83
ADJ23947/c
ID ADJ23947 standard; DNA; 20 BP.
XX
AC ADJ23947;
XX
KW Antilipemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW Cardiovascular disorder; metabolic syndrome X; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
PN WO2004009541-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022410.
XX
PR 19-JUL-2002; 2002US-0397106P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Bhat BG;
XX
DR WPI; 2004-132912/13.
XX
PT New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
XX
PS Claim 3; SEQ ID NO 2345; 1007pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 4 A; 1 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 87;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 237 CAACCTCTGCCCCACCT 255
    ||||| ||||| |||||
Db 19 CAACCTCTGTCCACACCT 1
```

```
RESULT 84
ADJ23665/c
ID ADJ23665 standard; DNA; 20 BP.
XX
AC ADJ23665;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human endothelial lipase antisense oligonucleotide, SEQ ID 2063.
XX
KW Antilipemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW Cardiovascular disorder; metabolic syndrome X; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
PN WO2004009541-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022410.
XX
PR 19-JUL-2002; 2002US-0397106P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Bhat BG;
XX
DR WPI; 2004-132912/13.
XX
PT New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
XX
PS Claim 3; SEQ ID NO 2063; 1007pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 4 A; 1 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 87;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 239 AACCTCTGCCCCACCTCC 257
    ||||| ||||| |||||
Db 20 AACCTCTGTCCACCTCC 2

RESULT 85
ADN48796
ID ADN48796 standard; DNA; 20 BP.
XX
```

AC ADN48796;
XX 15-JUL-2004 (first entry)
XX Human Notch (Drosophila) homologue 4 antisense oligo ISIS 141637.
DE Notch (Drosophila) homologue 4; hyperproliferative disorder; cancer;
XX rheumatoid arthritis; diabetes; prophylactic; infection; inflammation;
KW tumour formation; antisense therapy; human; antisense;
KW phosphorothioate backbone; ss.
XX Homo sapiens.
OS Synthetic.
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /*note= "Phosphorothioate backbone where all cytidines are
FT 5-methyl cytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /*note= "2' -methoxyethyl (2' -MOE) nucleotide"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /*note= "2' -methoxyethyl (2' -MOE) nucleotide"
XX US2004077569-A1.
XX 22-APR-2004.
XX 16-OCT-2002; 2002US-00273070.
XX 16-OCT-2002; 2002US-00273070.
XX (ISIS-) ISIS PHARM INC.
XX Watt AT;
XX WPI; 2004-340034/31.
XX New compound of 8-50 nucleobases in length which specifically hybridizes
PT with and inhibits the expression of Notch (Drosophila) homologue 4, useful
PT for treating cancer, rheumatoid arthritis or diabetes.
XX Example 15; SEQ ID NO 49; 66pp; English.
XX The present invention provides antisense oligonucleotides which are
CC targeted to nucleic acid encoding human Notch (Drosophila) homologue 4
CC and which modulate the expression Notch (Drosophila) homologue 4. The
CC invention is useful for inhibiting the expression of Notch (Drosophila)
CC homologue 4 in cells or tissues, in treating a disease or condition
CC associated with Notch (Drosophila) homologue 4 which includes
CC hyperproliferative disorder such as cancer, rheumatoid arthritis and
CC diabetes and useful prophylactically to prevent or delay infection,
CC inflammation and tumour formation. The invention is also useful in
CC antisense therapy. The present sequence is human Notch (Drosophila)
CC homologue 4 antisense oligonucleotide. This sequence is used in the
CC exemplification of the invention.
XX Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 87;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 381 CATCGCTGGCCGTGTGTC 399
DB 1 CACCACCTGGCCGTGTGTC 19

RESULT 86
AAX09362/c
ID AAX09362 standard; DNA; 21 BP.
XX AC AAX09362;
XX 24-MAR-1999 (first entry)
XX Human biallelic polymorphic marker upstream primer #242.
DE Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW detection; phenotypic typing; characteristic; infection; hereditary;
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW treatment; marker; primer; ss.
XX Synthetic.
OS Homo sapiens.
XX WO9820165-A2.
XX 14-MAY-1998.
XX 05-NOV-1997; 97WO-US020313.
XX 06-NOV-1996; 96US-0030455P.
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX Lander ES, Wang D, Hudson T;
XX WPI; 1998-286974/25.
XX New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
PT testing or phenotypic typing for disease.
XX Claim 15; Page 78; 310pp; English.
XX AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC isolation of various biallelic polymorphic markers found in the human
CC genome (represented in AAX10269-X12937). These primers can be used in a
CC method for determining polymorphic forms in an individual for use in e.g.
CC as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
CC hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC autoimmune diseases, inflammation, cancer, diseases of the nervous
CC system, infection by pathogenic microorganisms, and characteristics such
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC endurance, fertility, and susceptibility or receptivity to particular
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC segments can also be used to produce medicaments for the treatment or
CC prophylaxis of such diseases
XX Sequence 21 BP; 3 A; 8 C; 2 G; 8 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 79 GATGGAAACACTGAGAGCG 97
DB 21 GATGGAAACACTGAGAGCG 3
RESULT 87
AAX82780/c
ID AAX82780 standard; DNA; 21 BP.
XX AC AAX82780;

```
XX 29-JUN-2000 (first entry)
XX Human edg6 PCR primer hgSP1.
XX edg6; human; G-coupled receptor; endothelial differentiation gene;
XX antiinflammatory; immunomodulatory; antimicrobial; antiallergic;
XX cytostatic; gene therapy; inflammation; autoimmune disease; allergy;
XX tumor; leukemia; lymphoma; PCR primer; ss.
XX Homo sapiens.
XX DE19846979-A1.
XX 23-MAR-2000.
XX 13-OCT-1998; 98DE-01046979.
XX 11-SEP-1998; 98DE-01043240.
XX (DELB-) DELBRUECK CENT MOLEKULARE MEDIZIN MAX.
XX Graeler M, Bernhardt G, Lipp M;
XX WPI; 2000-258069/23.
XX New human and murine G-coupled receptor EDG (endothelial differentiation
XX gene) 6, useful for modulating inflammatory and immune reactions and for
XX treatment of allergy or tumors.
XX Example; Page 5; 12pp; German.
XX This invention describes novel human and murine G-coupled receptors EDG
XX (endothelial differentiation gene) 6 (I and II). The products of the
XX invention have antiinflammatory, immunomodulatory, antimicrobial,
XX antiallergic and cytostatic activity. (I) and (II) are involved in signal
XX transduction. (I), (II) and their fragments, variants and mutants or
XX binding partners, are used therapeutically to modulate the function of
XX blood and body cells, particularly for inhibition of acute and chronic
XX inflammation and to raise specific antibodies against them. They are used
XX as a source of diagnostic oligonucleotides and for gene therapy.
XX Antibodies against (I) and (II) are useful for diagnosis and optionally
XX when coupled to therapeutic agents, toxins or other antibodies, to
XX modulate immune and inflammatory responses for example immunological
XX defects such as inflammation, infection, autoimmune diseases, allergy,
XX tumors, leukemia and lymphoma. AAX82777-X82788 represent PCR primers used
XX in the amplification of the human and murine edg6 genes described in the
XX method of the invention
XX Sequence 21 BP; 7 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
XX Query Match 1.0%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 94;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 814 CTCCTACTCTCTCTCTGCC 832
XX 20 CGCTACATCTCTCTCTGCC 2
XX
XX RESULT 88
XX AAF97388/c
XX ID AAF97388 standard; DNA; 21 BP.
XX AC AAF97388;
XX 06-JUN-2001 (first entry)
XX Human gene single nucleotide polymorphism #2149.
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX polymorphism; vascular disease; coronary artery disease; forensics;
XX myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
```

```
XX pulmonary embolism; paternity test; ds.
XX Homo sapiens.
XX Key Location/Qualifiers
XX Variation replace(11,T)
XX /*tag= a
XX /standard_name= "single nucleotide polymorphism"
XX WO200118250-A2.
XX 15-MAR-2001.
XX 07-SEP-2000; 2000WO-US024503.
XX 10-SEP-1999; 99US-0153357P.
XX 26-JUL-2000; 2000US-0220947P.
XX 16-AUG-2000; 2000US-0225724P.
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI; 2001-226749/23.
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX applications such as forensics, paternity testing, medicine, genetic
XX analysis and phenotype correlations to diseases such as diabetes and
XX atherosclerosis.
XX Example; Page 196; 242pp; English.
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
XX polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX genes. The sequences at a number of polymorphic sites are also provided
XX in the specification. In particular, the method can be used in the
XX diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX useful in forensics, paternity testing, genetic analysis and phenotype
XX correlations to diseases. The present sequence is an example of one of
XX the human gene SNPs shown in the specification
XX Sequence 21 BP; 4 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
XX Query Match 1.0%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 94;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 435 TGAGGGCAGGCTGCTGCTG 453
XX 20 TGAGGACACGCTGCTGCTG 2
XX
XX RESULT 89
XX ADJ13905/c
XX ID ADJ13905 standard; DNA; 21 BP.
XX AC ADJ13905;
XX 20-MAY-2004 (first entry)
XX Human DNA probe used to immobilise CpG methylated DNA SeqID 1032.
XX probe; ss; chemical modification; methylation; array; CpG island;
XX tumour suppressor; p16; human; H69; H1618.
XX Homo sapiens.
XX US2003152950-A1.
XX
```

```
PD 14-AUG-2003.
XX
PF 27-JUN-2002; 2002US-00184085.
XX
PR 27-JUN-2001; 2001US-0301370P.
XX
XX (GARN/) GARNER H R.
PA (MINN/) MINNA J D.
PA (LUEB/) LUEBKE K J.
PA (BALO/) BALOG R P.
XX
XX
PI Garner HR, Minna JD, Luebke KJ, Balog RP;
XX WPI; 2003-874843/81.
XX
XX Analysis of chemical modification of DNA involves obtaining sample of DNA
PT to be analyzed, treating DNA with chemical reagents that result in
PT different base sequences, and determining sequence of resulting DNA.
XX
XX Example 1; SEQ ID NO 1032; 210pp; English.
XX
XX This invention relates to a novel method for analysing chemically
CC modified macromolecules. Specifically, it refers to a high throughput
CC method for the parallel analysis of many potential sites of chemical
CC modification (e.g. methylation) in DNA. The present invention describes
CC treating the DNA with one or more chemical reagents that result in
CC different base sequences depending upon the presence or absence of the
CC modification of interest. Accordingly, a device comprising an array of
CC probes is provided to hybridise with and select the altered DNA sequences
CC that comprise the modifications of interest such as a CpG island. In
CC particular, this invention refers to analysing the methylation pattern of
CC a region of the promoter for the tumour suppressor gene p16 from two
CC human lung tumour cell lines H69 and H1618. This oligonucleotide sequence
CC is a human DNA probe used to immobilise CpG methylated DNA of the
CC invention.
XX
XX Sequence 21 BP; 3 A; 12 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 TGATGAGGCGAGGCTGCTG 450
DB 21 TGATGAGGCGAGGCGGCTG 3

RESULT 90
ADJ13942/c
ID ADJ13942 standard; DNA; 21 BP.
XX
AC ADJ13942;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human DNA probe used to immobilise CpG methylated DNA SeqID 1069.
XX
XX probe; ss; chemical modification; methylation; array; CpG island;
XX tumour suppressor; p16; human; H69; H1618.
XX
XX Homo sapiens.
XX
XX US2003152950-A1.
XX
XX 14-AUG-2003.
XX
XX 27-JUN-2002; 2002US-00184085.
XX
XX 27-JUN-2001; 2001US-0301370P.
XX
XX (GARN/) GARNER H R.
PA (MINN/) MINNA J D.
PA (LUEB/) LUEBKE K J.
```

```
PA (BALO/) BALOG R P.
XX
XX Garner HR, Minna JD, Luebke KJ, Balog RP;
XX WPI; 2003-874843/81.
XX
XX Analysis of chemical modification of DNA involves obtaining sample of DNA
PT to be analyzed, treating DNA with chemical reagents that result in
PT different base sequences, and determining sequence of resulting DNA.
XX
XX Example 1; SEQ ID NO 1069; 210pp; English.
XX
XX This invention relates to a novel method for analysing chemically
CC modified macromolecules. Specifically, it refers to a high throughput
CC method for the parallel analysis of many potential sites of chemical
CC modification (e.g. methylation) in DNA. The present invention describes
CC treating the DNA with one or more chemical reagents that result in
CC different base sequences depending upon the presence or absence of the
CC modification of interest. Accordingly, a device comprising an array of
CC probes is provided to hybridise with and select the altered DNA sequences
CC that comprise the modifications of interest such as a CpG island. In
CC particular, this invention refers to analysing the methylation pattern of
CC a region of the promoter for the tumour suppressor gene p16 from two
CC human lung tumour cell lines H69 and H1618. This oligonucleotide sequence
CC is a human DNA probe used to immobilise CpG methylated DNA of the
CC invention.
XX
XX Sequence 21 BP; 3 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 TCATGAGGCGAGGCTGCTG 450
DB 20 TCATGAGGCGCGCGGCTG 2

RESULT 91
AAX71062/c
ID AAX71062 standard; RNA; 17 BP.
XX
AC AAX71062;
XX
XX 28-JUL-1999 (first entry)
XX
XX Human KDR VEGF receptor hammerhead ribozyme substrate #74.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flk-1;
XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX foetal liver kinase 1; ss.
XX
XX Homo sapiens.
XX
XX WO9715662-A2.
XX
XX 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
XX
XX 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT
```

PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 99; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136
Db 17 ATGGACCCGACATGG 1

RESULT 92
ABN06634
ID ABN06634 standard; DNA; 17 BP.
XX
AC ABN06634;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6626.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser

desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 6626; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 22 CTGCGTCTGCAGAGGAC 38
Db 1 CTGCGTCTGCATAGGAC 17

RESULT 93
ABN06635
ID ABN06635 standard; DNA; 17 BP.
XX
AC ABN06635;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6627.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.

```
PR 30-JAN-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001US-0266860P.
PR (AEOM-) AEOMICA INC.
PR Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PR WPI; 2002-179446/23.
PR New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PR or as specific biomolecule capture probes for surface-enhanced laser
PR desorption ionization, comprises human myosin-like protein hGDMLP-1.
PR Disclosure; SEQ ID NO 6627; 214pp; English.
PR
PR The present invention describes a human genome-derived myosin-like
PR protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
PR 1 can be used in gene therapy and vaccine production. The hGDMLP-1
PR nucleic acids can be used as probes to detect, characterise and quantify
PR hGDMLP-1 nucleic acids in samples, as amplification substrates, to
PR provide initial substrates for the recombinant engineering of hGDMLP-1
PR protein variants having desired phenotypic improvements, and for
PR expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
PR used as immunogens to raise antibodies that specifically recognise hGDMLP
PR -1 proteins, as standards in assays used to determine the concentration
PR and/or amount specifically of hGDMLP proteins, as specific biomolecule
PR capture probes for surface-enhanced laser desorption/ionisation, as
PR therapeutic supplement in patients having specific deficiency in hGDMLP-1
PR production, and in vaccines or for replacement therapy. The
PR polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
PR disorder associated with the expression of hGDMLP-1, in particular heart
PR and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
PR The present sequence represents an oligomer used in the screening of the
PR hGDMLP-1 sequence in the exemplification of the present invention. N.B.
PR The sequence data for this patent did not form part of the printed
PR specification, but was obtained in electronic format directly from WIPO
PR at ftp.wipo.int/pub/published_pct_sequence
PR
PR Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
PR
PR Query Match 1.0%; Score 15.4; DB 1; Length 17;
PR Best Local Similarity 94.1%; Pred. No. 78;
PR Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
PR
PR QY 23 TGCCTCTGCAGGACAGCA 39
PR Db 1 TGCCTCTGCATAGGACA 17
PR
PR RESULT 94
PR ABN06636
PR ID ABN06636 standard; DNA; 17 BP.
PR XX AC ABN06636;
PR XX
PR XX 29-MAY-2002 (first entry)
PR DT Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6628.
PR DE Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
PR KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
PR KW skeletal muscle disorder; amplicon; screening; ss.
PR XX Homo sapiens.
PR XX
PR PN WO200192524-A2.
PR XX
PR PD 06-DEC-2001.
PR XX
PR XX 25-MAY-2001; 2001WO-US016981.
PR PF
PR XX 26-MAY-2000; 2000US-0207456P.
PR PR 21-SEP-2000; 2000US-0234687P.
```

```
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US0000661.
PR 30-JAN-2001; 2001WO-US0000662.
PR 30-JAN-2001; 2001WO-US0000663.
PR 30-JAN-2001; 2001WO-US0000664.
PR 30-JAN-2001; 2001WO-US0000665.
PR 30-JAN-2001; 2001WO-US0000666.
PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001US-0266860P.
PR XX (AEOM-) AEOMICA INC.
PR XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PR WPI; 2002-179446/23.
PR New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PR or as specific biomolecule capture probes for surface-enhanced laser
PR desorption ionization, comprises human myosin-like protein hGDMLP-1.
PR Disclosure; SEQ ID NO 6628; 214pp; English.
PR
PR The present invention describes a human genome-derived myosin-like
PR protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
PR 1 can be used in gene therapy and vaccine production. The hGDMLP-1
PR nucleic acids can be used as probes to detect, characterise and quantify
PR hGDMLP-1 nucleic acids in samples, as amplification substrates, to
PR provide initial substrates for the recombinant engineering of hGDMLP-1
PR protein variants having desired phenotypic improvements, and for
PR expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
PR used as immunogens to raise antibodies that specifically recognise hGDMLP
PR -1 proteins, as standards in assays used to determine the concentration
PR and/or amount specifically of hGDMLP proteins, as specific biomolecule
PR capture probes for surface-enhanced laser desorption/ionisation, as
PR therapeutic supplement in patients having specific deficiency in hGDMLP-1
PR production, and in vaccines or for replacement therapy. The
PR polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
PR disorder associated with the expression of hGDMLP-1, in particular heart
PR and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
PR The present sequence represents an oligomer used in the screening of the
PR hGDMLP-1 sequence in the exemplification of the present invention. N.B.
PR The sequence data for this patent did not form part of the printed
PR specification, but was obtained in electronic format directly from WIPO
PR at ftp.wipo.int/pub/published_pct_sequence
PR
PR Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
PR
PR Query Match 1.0%; Score 15.4; DB 1; Length 17;
PR Best Local Similarity 94.1%; Pred. No. 78;
PR Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
PR
PR QY 24 GCGTCTGCAGGACAGCA 40
PR Db 1 GCGTCTGCATAGGACAG 17
PR
PR RESULT 95
PR ABN06633
PR ID ABN06633 standard; DNA; 17 BP.
PR XX AC ABN06633;
PR XX
PR XX 29-MAY-2002 (first entry)
PR DT Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6625.
PR DE Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
PR KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
PR KW skeletal muscle disorder; amplicon; screening; ss.
```



```
XX OS Homo sapiens.
XX AC WO200192524-A2.
XX PN 06-DEC-2001.
XX PD 25-MAY-2001; 2001WO-US016981.
XX PF 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX PI WPI; 2002-179446/23.
XX DR
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PI
XX PS Disclosure, SEQ ID NO 6625; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption/ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 3 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
    Query Match 1.0%; Score 15.4; DB 1; Length 17;
    Best Local Similarity 94.1%; Pred. No. 78;
    Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 21 TCTGCGCTCTGCAGGAGGA 37
    |||||
Db 1 TCTGCGCTCTGCATAGGA 17
    |||||
XX RESULT 96
XX ABZ64677/c
```

```
XX ABZ64677 standard; RNA; 17 BP.
XX AC ABZ64677;
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNase substrate #134.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US016840.
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX PS Claim 4; Page 135; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
XX CC rheumatic activity. The nucleic acid molecules are useful for reducing
XX CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX CC also useful for treating breast, ovarian, colorectal, lung, prostate,
XX CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ65524,
XX CC ABZ66530 - ABZ66595 represent substrate/target sequences for the human
XX CC ribozymes of the invention
XX SQ Sequence 17 BP; 2 A; 4 C; 9 G; 0 T; 2 U; 0 Other;
    Query Match 1.0%; Score 15.4; DB 1; Length 17;
    Best Local Similarity 94.1%; Pred. No. 78;
    Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 668 AGCTCCCGCGCGCTCC 684
    |||||
Db 17 AGCTCCCGCGCGCTCC 1
    |||||
XX RESULT 97
XX ABL89153/c
XX ID ABL89153 standard; DNA; 19 BP.
XX AC ABL89153;
XX DT 22-MAY-2002 (first entry)
XX DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:375.
XX KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
XX KW reverse transcriptase; binding group; ss.
XX XX
```

```
OS Human immunodeficiency virus 1.
XX Synthetic.
PN EP1174518-A1.
XX
XX 23-JAN-2002.
XX
XX 20-JUL-2000; 2000EP-00202611.
XX
XX 20-JUL-2000; 2000EP-00202611.
XX
XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
XX Loukachov VV, Van Gemen B, Goudsmit J;
XX WPI; 2002-156696/21.
XX
XX Collection of binding groups for determining or typing samples,
XX especially clinical samples, has groups capable to identify essentially
XX all members of the family of nucleic acids of relatively high
XX significance.
XX
XX Disclosure; Page 98; 166pp; English.
XX
XX The present invention describes a collection of binding groups for a
XX family of nucleic acids comprising members of relative high and relative
XX low significance, where the binding groups are selected to be capable to
XX identify, alone or in combination, essentially all members of the family
XX of nucleic acids of relatively high significance. The collection of
XX binding groups is useful for typing of nucleic acid in a clinical sample,
XX by contacting the nucleic acid with the collection and determining
XX whether one or more binding groups bound to the nucleic acid of the
XX sample. This method is useful for determining whether the sample
XX comprises at least a part of a member of relatively high significance of
XX a family of nucleic acids. The collection of binding groups is useful for
XX diagnosing the severity of a disease caused by a pathogen containing a
XX member of a family of nucleic acids. ABL89779 to ABL89321 represent
XX oligonucleotide sequences used in the exemplification of the present
XX invention
XX
XX Sequence 19 BP; 4 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 94;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 286 CCATCCCTCGGGAACA 302
XX 17 CCATCCCTCGGGAACA 1
XX
XX
XX RESULT 98
XX AAT00065/c
XX ID AAT00065 standard; DNA; 20 BP.
XX
XX AC
XX AC AAT00065;
XX
XX DT 02-JUL-1996 (first entry)
XX
XX DE Hepatitis GB virus (HGBV) clone 50 PCR primer.
XX
XX KW Hepatitis GB virus; HGBV; diagnosis; treatment; vaccine; reagents; non-A;
XX non-B; non-C; non-D; non-E; clone; tamarin; infected plasma;
XX lambda phage; cDNA library; PCR primer; ss.
XX
XX OS Synthetic.
XX
XX PN WO9521922-A2.
XX
XX PD 17-AUG-1995.
XX
XX PF 14-FEB-1995; 95WO-US002118.
XX
```

```
PR 14-FEB-1994; 94US-00196030.
PR 13-MAY-1994; 94US-00242654.
PR 29-JUL-1994; 94US-00283314.
PR 23-NOV-1994; 94US-00344185.
PR 23-NOV-1994; 94US-00344185.
PR 27-JAN-1995; 94US-00344190.
XX
XX (ABBO ) ABBOTT LAB.
XX
XX Simons JN, Pilot-Matias TJ, Dawson GJ, Schlauder GG, Desai SM;
XX Leary TP, Muerhoff AS, Erker JC, Buijk SL, Mushahwar IK;
XX WPI; 1995-293123/38.
XX
XX Non-A, non-B, non-C, non-D, non-E Hepatitis virus reagents - useful for
XX diagnosis and therapy of hepatitis GB virus.
XX
XX Example 6; Page 268; 661pp; English.
XX
XX Double stranded hepatitis GB virus (HGBV) DNA obtd. from HGBV infected
XX tamarin plasma, using standard procedures, was used to prepare a lambda
XX phage HGBV cDNA library. cDNA clones rescued from the lambda phage and
XX amplified using the PCR primers AAT00053-66, were searched against a
XX sequence database and found to be unique HGBV sequences. Reagents which
XX comprise the HGBV DNA, or its protein prods. can be used for the
XX diagnosis, therapy or in a vaccine to prevent HGBV infection
XX
XX Sequence 20 BP; 2 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 1e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1476 CTGCCAGAGTGTTACG 1492
XX Db 19 CTGCCAGAGGAGGTACG 3
XX
XX RESULT 99
XX AAA55311/c
XX ID AAA55311 standard; DNA; 20 BP.
XX
XX AC AAA55311;
XX
XX DT 06-AUG-2003 (revised)
XX DT 30-AUG-2000 (first entry)
XX
XX DE Hepatitis GB virus PCR primer SEQ ID NO:99.
XX
XX KW Hepatitis GB virus; HGBV; diagnosis; therapeutic; immunogenic; infection;
XX detection; characterisation; hepatitis; PCR primer; ss.
XX
XX OS Hepatitis GB virus.
XX
XX PN US6051374-A.
XX
XX PD 18-APR-2000.
XX
XX PF 07-JUN-1995; 95US-00488445.
XX
XX PR 14-FEB-1994; 94US-00196030.
XX PR 13-MAY-1994; 94US-00242654.
XX PR 29-JUL-1994; 94US-00283314.
XX PR 23-NOV-1994; 94US-00344185.
XX PR 23-NOV-1994; 94US-00344190.
XX PR 30-JAN-1995; 95US-00377557.
XX
XX (ABBO ) ABBOTT LAB.
XX
XX Dawson GJ, Leary TP, Muerhoff AS, Pilot-Matias TJ, Buijk SL;
XX Mushahwar IK, Simons JN, Desai SM, Erker JC, Schlauder GG;
XX WPI; 2000-338307/29.
XX
```

XX Detecting target hepatitis GB virus nucleic acid in a test sample
PT suspected of containing HGBV comprises reacting the test sample the HGBV
PT polynucleotide probe and detecting the complex that contains target HGBV.
XX
XX Example 6; Col 255; 369pp; English.
XX
CC The present invention describe a method for detecting target hepatitis GB
CC virus (HGBV) nucleic acid (THN) in a test sample (T) suspected of
CC containing HGBV. The method involves reacting (T) with a HGBV
CC polynucleotide probe (I) containing 15 contiguous nucleotides, and which
CC selectively hybridises to the HGBV genome or its full complement, and
CC detecting the complex that contains THN, indicating the presence of
CC target HGBV. The method is used for detecting target HGBV nucleic acid in
CC the test sample suspected of containing HGBV and for characterisation of
CC newly ascertained etiological agent of non-A, non-B, non-C, non-D and non
CC -E hepatitis causing agents collectively termed as hepatitis GB virus.
CC AAAS5270 to AAAS5489 and AAB08985 to AAB09480 represent nucleotide and
CC protein sequences used in the exemplification of the present invention.
CC (Updated on 06-AUG-2003 to correct OS field.)
XX
SQ Sequence 20 BP; 2 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1476 CTGCCAGGAGTGGTACG 1492
DB 19 CTGCCAGGAGGGGTACG 3
RESULT 100
AAZ40168/c
ID AAZ40168 standard; DNA; 20 BP.
XX
AC AAZ40168;
XX
DT 18-FEB-2000 (first entry)
XX
DE PCR primer for human semaphorin, DCSema, coding sequence.
XX
KW Semaphorin; DCSema; human; inflammatory disease; VESPR; interleukin-12;
KW IL-12; immune response; aggressive micrometastatising tumour; therapy;
KW immune suppression; autoimmune disorder; semaphorin receptor;
KW immune regulation; viral infection; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9958676-A2.
XX
PD 18-NOV-1999.
XX
PF 05-MAY-1999; 99WO-US009831.
XX
PR 14-MAY-1998; 98US-0085497P.
XX
PA (IMMV) IMMUNEX CORP.
XX
PI Spriggs MK;
XX
DR WPI; 2000-053100/04.
XX
PT Novel neurologic regulator polypeptide for treating inflammatory
PT diseases, autoimmune disorders, etc.,.
XX
PS Example 1; Page 20; 41pp; English.
XX
CC This sequence represents a PCR primer for DNA encoding the human
CC semaphorin protein, designated DCSema. Of the invention. DCSema is used
CC for treating inflammatory diseases. DCSema ligands bind with VESPR to
CC enhance or promote interleukin-12 (IL-12) production which induces an

CC immune response against aggressive micrometastatising tumours. They are
CC associated with immune suppression of mature dendritic cells and
CC therefore can be used for treating autoimmune disorders. They can be
CC employed to measure biological activity of any semaphorin receptor in
CC terms of its binding affinity for semaphorin ligand and also for
CC detecting semaphorin receptor by in vitro assays. DCSema polypeptides are
CC used as reagents in quality assurance studies (to monitor shelf life and
CC stability of semaphorin receptor under different conditions). They are
CC also used as a research tool for studying the role of this ligand and its
CC receptor in immune regulation and are also used as carriers for
CC delivering diagnostic or therapeutic agents to cells expressing
CC semaphorin receptor. They are shown to play a role as immune regulators
CC in viral infection
XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 563 GGGCCAGGGGACCTGG 579
DB 19 GGTCCAGGGGACCTGG 3
RESULT 101
ABK70805/c
ID ABK70805 standard; DNA; 20 BP.
XX
AC ABK70805;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human TSP1 domain containing gene sequencing primer KY01-A16.
XX
KW TSP1; thrombospondin domain; DNA sequencing; primer; ss; FG06969;
KW FG01896; angiogenesis; vasculogenesis.
XX
OS Homo sapiens.
XX
PN JP2002085059-A.
XX
PD 26-MAR-2002.
XX
PF 08-SEP-2000; 2000JP-00273778.
XX
PR 08-SEP-2000; 2000JP-00273778.
XX
XX (KAZU-) ZH KAZUSA DNA KENKYUSHO.
PA (YOSH) YOSHITOMI PHARM IND KK.
XX
DR WPI; 2002-378268/41.
XX
PT TSP1 domain-containing polypeptide useful for drug compositions.
XX
PS Example 2; Page 15; 51pp; Japanese.
XX
CC The invention relates to a TSP1 (thrombospondin 1) domain-containing
CC polypeptide comprising the proteins appearing as AAU80188 and AAU80189,
CC encoded by cDNAs designated FG06969 and FG01896. Also included are
CC proteins that are 50% homologous to the proteins and a polypeptide having
CC at least one deletion, replacement, addition or insertion of amino acid
CC in the proteins and having at least 8 repetitions of the TSP1 domain. The
CC polypeptide can be used in drug compositions particularly for disorders
CC associated with angiogenesis and vasculogenesis. The present sequence is
CC a sequencing primer for the cDNAs of the invention
XX
SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 71 CCTGTGGAGATGGAAC 87
 Db 20 CCTGTGGAGTGGAAAC 4

RESULT 102
 ABX10774/c
 ID ABX10774 standard; DNA; 20 BP.
 XX
 AC ABX10774;
 XX
 DT 10-MAY-2003 (first entry)
 XX
 DE Human dual specific phosphatase 8 DNA antisense oligonucleotide #8.
 XX
 KW Human; dual specific phosphatase 8; antisense; infection; inflammation;
 KW tumour formation; cytostatic; antiinflammatory; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN US6482644-B1.
 XX
 PD 19-NOV-2002.
 XX
 PF 01-AUG-2001; 2001US-00920668.
 XX
 PR 01-AUG-2001; 2001US-00920668.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cowser LM;
 XX
 DR WPI; 2003-298140/29.
 XX
 PT New antisense compound targeted to a nucleic acid encoding human dual
 PT specific phosphatase 8, for modulating gene expression and treating
 PT diseases associated with expression of the phosphatase in humans.
 XX
 PS Example 15; Col 45; 36pp; English.
 XX
 CC The invention relates to a compound targeted to the coding region of a
 CC nucleic acid encoding human dual specific phosphatase 8, where the
 CC compound specifically hybridises with the region and inhibits the
 CC expression of human dual specific phosphatase 8. The compound is useful
 CC for inhibiting the expression of human dual specific phosphatase 8 in
 CC cells or tissues, and for treating an animal, particularly a human,
 CC suspected of having or being prone to a disease or condition associated
 CC with expression of dual specific phosphatase 8. The compound is useful
 CC for diagnostics, therapeutics and as a research reagent, e.g. to prevent
 CC or delay infections, inflammation or tumour formation, and to distinguish
 CC between functions of various members of a biological pathway. This
 CC sequence represents an antisense oligonucleotide which inhibits
 CC expression of human dual specific phosphatase 8 DNA
 XX
 SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1184 ACGTGTGGTCCATGAC 1200
 Db 19 ACGTGTGGTCTATGAC 3

RESULT 103
 ACC42435/c
 ID ACC42435 standard; DNA; 20 BP.
 XX
 AC ACC42435;
 XX
 DT 26-AUG-2003 (first entry)
 XX

XX
 DE Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143023.
 XX
 KW Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
 KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
 KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
 KW phosphorothioate; mouse; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod base= OTHER
 FT /note= "Oligonucleotide has phosphorothioate backbone and
 FT all cytidine nucleotides are 5-methylcytidine. Optionally
 FT some nucleotides with 2'-methoxyethyl (2'-MOE wings)
 FT modification"
 XX
 PN WO2003011889-A2.
 XX
 PD 13-FEB-2003.
 XX
 PF 15-JUL-2002; 2002WO-US022746.
 XX
 PR 30-JUL-2001; 2001US-00918026.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Crooke RM, Graham MJ, Lemonidis KM;
 XX
 DR WPI; 2003-248145/24.
 XX
 PT New antisense oligonucleotides for modulating acyl CoA cholesterol
 PT acyltransferase-2, e.g. for preventing or treating diseases associated
 PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
 PT cardiovascular disease.
 XX
 PS Claim 3; Page 90; 112pp; English.
 XX
 CC The present invention relates to novel antisense oligonucleotides which
 CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
 CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
 CC ACC42457). The antisense oligonucleotides specifically hybridise with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyse the synthesis of cholesterol esters from
 CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
 CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease
 XX
 SQ Sequence 20 BP; 4 A; 9 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GAGCTGCTGGATCGGC 200
 Db 17 GAGCTGTTGGATCGGC 1

RESULT 104
 ADK73915
 ID ADK73915 standard; DNA; 20 BP.
 XX
 AC ADK73915;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #1249.
 XX

KW Navl.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
OS Synthetic.
XX WO2004016754-A2.
XX 26-FEB-2004.
XX 14-AUG-2003; 2003WO-US025465.
XX 14-AUG-2002; 2002US-0403416P.
XX (PHAA) PHARMACIA CORP.
XX Robertds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Navl.3, useful for treating a disease or condition associated
PT with Navl.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 1249; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Navl.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Navl.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Navl.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Navl.3 expression, the oligonucleotides are designed to target
CC different regions of the human Navl.3 RNA.
XX Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
SQ Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 396 TGTCTTCATCATCAGCA 412
DB 3 TGTGTTTCATCATCAGCA 19
RESULT 105
ADK74127
ID ADK74127 standard; DNA; 20 BP.
XX ADK74127;
XX 20-MAY-2004 (first entry)
XX Chimeric phosphorothioate oligonucleotide to target Navl.3 #1461.
XX Navl.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX Synthetic.
XX WO2004016754-A2.
XX 26-FEB-2004.
XX

PF 14-AUG-2003; 2003WO-US025465.
XX 14-AUG-2002; 2002US-0403416P.
XX (PHAA) PHARMACIA CORP.
XX Robertds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Navl.3, useful for treating a disease or condition associated
PT with Navl.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 1461; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Navl.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Navl.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Navl.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Navl.3 expression, the oligonucleotides are designed to target
CC different regions of the human Navl.3 RNA.
XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
SQ Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 396 TGTCTTCATCATCAGCA 412
DB 2 TGTGTTTCATCATCAGCA 18
RESULT 106
ADK74198
ID ADK74198 standard; DNA; 20 BP.
XX ADK74198;
XX 20-MAY-2004 (first entry)
XX Chimeric phosphorothioate oligonucleotide to target Navl.3 #1532.
XX Navl.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX Synthetic.
XX WO2004016754-A2.
XX 26-FEB-2004.
XX 14-AUG-2003; 2003WO-US025465.
XX 14-AUG-2002; 2002US-0403416P.
XX (PHAA) PHARMACIA CORP.
XX Robertds SL;
XX WPI; 2004-203785/19.
XX

PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 1532; 417pp; English.
XX
The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 396 TGTCTTCATCATCAGCA 412
Db 1 TGTGTTTCATCATCAGCA 17

RESULT 107
ADK73666
ID ADK73666 standard; DNA; 20 BP.
XX
AC ADK73666;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #1000.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Robertds SL;
XX
DR WPI; 2004-203785/19.
XX
The present invention relates to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 1000; 417pp; English.
XX
The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The

CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 396 TGTCTTCATCATCAGCA 412
Db 4 TGTGTTTCATCATCAGCA 20

RESULT 108
ADP68653
ID ADP68653 standard; DNA; 20 BP.
XX
AC ADP68653;
XX
DT 09-SEP-2004 (first entry)
XX
DE Human PPAR-alpha antisense oligonucleotide seqid 89.
XX
KW cytostatic; gene therapy; PPAR-alpha;
KW peroxisome proliferator-activated receptor-alpha; PPAR-alpha modulator;
KW PPAR-alpha associated disorder; hyperproliferative disorder; human;
KW antisense oligonucleotide; antisense technology; ss.
XX
OS Homo sapiens.
XX
PN US2004115637-A1.
XX
PD 17-JUN-2004.
XX
PF 11-DEC-2002; 2002US-00317500.
XX
PR 11-DEC-2002; 2002US-00317500.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI McKay R, Dobie KW;
XX
DR WPI; 2004-449378/42.
XX
New oligonucleotide compound that inhibits expression of PPAR-alpha,
PT useful for preparing a composition for treating hyperproliferative
PT disorders, e.g. cancer.
XX
PS Example 15; SEQ ID NO 89; 121pp; English.
XX
The invention describes a compound, having a sequence comprising 8-80 bp
CC targeted to a nucleic acid encoding PPAR-alpha (peroxisome proliferator-
CC activated receptor-alpha), that specifically hybridizes with the nucleic
CC acid encoding PPAR-alpha comprising 86001-bp sequence and inhibits
CC expression of PPAR-alpha in cells or tissues; a method of screening for a
CC modulator of PPAR-alpha; a diagnostic method for identifying a disease
CC state; a kit or assay device comprising the compound; and a method of
CC treating an animal having a disease or condition associated with PPAR-
CC alpha. The oligonucleotide compound is useful for preparing a composition
CC for treating hyperproliferative disorder e.g. cancer. This sequence
CC represents a human peroxisome proliferator-activated receptor-alpha (PPAR-
CC alpha) antisense oligonucleotide.

```
XX SQ Sequence 20 BP; 2 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 935 GCTTCATCTCGGCCGC 951
DB 2 GCTTCAGCCTGGGCCGC 18

RESULT 109
AAQ50904/c
ID AAQ50904 standard; DNA; 20 BP.
XX AC
XX AC AAQ50904;
XX DT 25-MAR-2003 (revised)
XX DT 20-MAY-1994 (first entry)
XX DE K-ras LCR primer.
XX KW Mutation; primer; detection; amplification; k-ras; cancer; oncogene;
XX KW mutation; LCR; ligase chain reaction; ss.
XX OS Synthetic.
XX PN W09322456-A1.
XX PD 11-NOV-1993.
XX PF 14-APR-1993; 93WO-US003561.
XX PR 27-APR-1992; 92US-00874845.
XX PA (DART-) DARTMOUTH COLLEGE.
XX PI Sorenson GD;
XX DR WPI; 1993-368814/46.
XX KW Method for detecting mutated genes or oncogene(s) in samples - by
PT denaturation and polymerase chain reaction amplification.
XX PS Disclosure; Page 15; 44pp; English.
XX CC Primers (AAQ50885-94) are used to amplify position 1 and 2 mutations at
CC codon 12 of the k-ras gene. Primers (AAQ50885-89) are used to amplify
CC position 1 mutation, while primers (AAQ50890-94) are used for the
CC position 2 mutation. Primers (AAQ50895-04) can be used in ligase chain
CC reactions, also used to detect the k-ras gene. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 361 CGCACCATCTACCATGTT 380
DB 20 CGTCCCACTACCAAGTT 1

RESULT 110
AAT58120/c
ID AAT58120 standard; cDNA; 20 BP.
XX AC
XX AC AAT58120;
XX DT 01-SEP-1997 (first entry)
XX DT 01-SEP-1997 (first entry)
XX XX
```

```
DE K-ras mutated in the twelfth codon at position 2 antisense primer.
XX Mutant alleles; cancer; whole blood; plasma; serum; urine; sputum;
XX colonic effluent; endoscopic retrograde cholangiopancreatography;
KW bone marrow; lymph fluid; cerebrospinal fluid; ligase chain reaction;
XX polymerase chain reaction; ss.
XX OS Synthetic.
XX XX W09640995-A1.
XX PN 19-DEC-1996.
XX PD
XX XX
XX PF 03-JUN-1996; 96WO-US008385.
XX PR 07-JUN-1995; 95US-00483746.
XX XX (DART-) DARTMOUTH COLLEGE.
XX PA Sorenson GD;
XX PI WPI; 1997-052366/05.
XX DR
XX KW Detecting and quantifying mutant alleles in soluble DNA, esp. from blood
XX PT - by amplification using peptide nucleic acid primer and allele-specific
XX PT primer sets, useful for detecting e.g. cancer.
XX PS Disclosure; Page 12; 46pp; English.
XX CC A method of detecting a mutant allele has been produced which involves;
XX CC extracting DNA from a biological sample containing soluble DNA including
XX CC a mutant allele of interest; contacting the DNA with a peptide nucleic
XX CC acid (PNA) which is complementary to a segment of the DNA; amplifying the
XX CC mutant allele in an allele-specific manner using at least a first set of
XX CC 4 allele-specific primers containing one primer complementary to a
XX CC mutation-containing fragment of a first strand of the DNA and a first
XX CC common primer for pairing during amplification to each allele-specific
XX CC primer where the common primer is complementary to a segment of a second
XX CC strand of the DNA distant with respect to the position of the first
XX CC primer; and detecting the presence of the mutant allele. The present
XX CC sequence represents an allele-specific oligonucleotide antisense primer,
XX CC for use in the detection of mutated K-ras gene sequences in biological
XX CC fluid where the mutation is present in the twelfth codon at position 2.
XX CC The method is used to detect and also quantify soluble gene sequences
XX CC especially in whole blood, plasma or serum, but also in urine, sputum,
XX CC colonic effluent, fluid from endoscopic retrograde
XX CC cholangiopancreatography, bone marrow, lymph and cerebrospinal fluid. The
XX CC amount of soluble DNA is known to increase markedly in individuals with
XX CC cancer and some other diseases, especially individuals with mutated K-ras
XX CC alleles. Using a PNA complementary to the wild-type DNA blocks access of
XX CC the primers to the wild-type sequences. This results in a significant
XX CC decrease in false positives and allows for detection of mutant alleles in
XX CC the presence of a 100000-fold excess of wild-type DNA
XX SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 361 CGCACCATCTACCATGTT 380
DB 20 CGTCCCACTACCAAGTT 1

RESULT 111
AAV69513/c
ID AAV69513 standard; DNA; 20 BP.
XX AC
XX AC AAV69513;
XX DT 15-MAR-1999 (first entry)
XX DT 15-MAR-1999 (first entry)
XX XX
```

DE Type I polyketide synthase PCR primer #1.
 XX Type I polyketide synthase; soil; lichen; antibiotic biosynthesis; humus;
 KW therapeutic; immunosuppressor; antitumour agent; pathogen;
 KW genetic diversity; PCR primer; ss.
 XX Synthetic.
 OS
 XX WO9853097-A2.
 PN
 XX 26-NOV-1998.
 PD
 XX 21-MAY-1998; 98WO-CA000488.
 PF
 XX 22-MAY-1997; 97US-00861774.
 PR
 XX (TERR-) TERRAGEN DIVERSITY INC.
 PA
 XX Waters B, Miao VPW, Yap WH, Seow KT;
 PI WPI; 1999-070158/06.
 XX
 XX New degenerate primers - used for recovering antibiotic biosynthetic DNA
 PT from soil/lichen material.
 PT
 XX Claim 3; Page 18; 98pp; English.
 PS
 XX This sequence is a PCR primer used to amplify a Type I polyketide
 CC synthase from soil/lichen material. This protein is used in a method for
 CC the recovery of antibiotic biosynthetic DNA from humic materials or
 CC lichen. The PCR products have the potential to be used as therapeutic
 CC molecules including antibiotics, immunosuppressors and antitumour agents.
 CC The method allows access to the reservoir of genetic diversity in soil
 CC pathogenic micro-organisms, in order to find new antibiotics. It also
 CC allows access to novel biosynthetic genes/enzymes that can be used to
 CC produce antibiotics or produce specific compounds, enzymatically, in
 CC vitro
 CC
 XX Sequence 20 BP; 2 A; 8 C; 6 G; 1 T; 0 U; 3 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 77.8%; Pred. No. 1.1e+02;
 Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 635 GCGCGCTGCGGTCCACG 652
 ||||| ||||| ||||| : :
 Db 20 GCGCGCTGCGGTCSAYS 3
 RESULT 112
 AAX95359
 ID AAX95359 standard; DNA; 20 BP.
 AC AAX95359;
 XX
 XX 13-SEP-1999 (first entry)
 DT
 XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
 DE
 XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KW neutralising epitope; PCR primer; ss.
 XX
 XX Synthetic.
 OS Chlamydothila pneumoniae.
 XX
 XX WO9927105-A2.
 PN
 XX 03-JUN-1999.
 PD
 XX 20-NOV-1998; 98WO-IB001890.
 PF
 XX 21-NOV-1997; 97FR-00014673.
 PR

PR 04-NOV-1998; 98US-0107078P.
 XX (GEST) GENSET.
 PA
 XX Griffais R;
 PI
 XX WPI; 1999-357842/30.
 DR
 XX Genome sequence of Chlamydia pneumoniae.
 PT
 XX Page 1742; Disclosure; 1912pp; English.
 PS
 XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAY34584-AAY35879) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotide sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae
 CC
 XX Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 502 GTGACCTGGTGCCCATGTT 521
 ||||| ||||| ||||| |||||
 Db 1 GAGACCTGGTGCCCATGTT 20
 RESULT 113
 AAA72164/c
 ID AAA72164 standard; DNA; 20 BP.
 XX
 XX AAA72164;
 AC
 XX 15-SEP-2003 (revised)
 DT
 XX 24-NOV-2000 (first entry)
 DT
 XX Humanised anti-Fas antibody heavy chain primer, SEQ ID NO:94.
 DE
 XX Anti-Fas antibody; monoclonal antibody HPE7A; FERM-BP-5828; murine;
 KW humanised antibody; complementarity determining region; CDR; human Fas;
 KW Fas ligand; apoptosis modulator; programmed cell death;
 KW autoimmune disease; allergy; atopy; arteriosclerosis; myocarditis;
 KW cardiomyopathy; glomerulonephritis; aplastic anaemia; pancytopenia;
 KW hepatitis; AIDS; graft rejection; heavy chain; sequencing primer; ss.
 XX
 XX Mus musculus.
 OS Homo sapiens.
 OS Chimeric.
 OS
 XX JP2000169393-A.
 PN
 XX 20-JUN-2000.
 PD
 XX 30-SEP-1999; 99JP-00278301.
 PF
 XX 30-SEP-1998; 98JP-00276883.
 PR
 XX (SANY) SANKYO CO LTD.
 PA
 XX WPI; 2000-485645/43.
 XX
 XX Preventive or treating agent for the diseases caused by an abnormality in
 PT the Fas/Fas ligand system e.g. autoimmune diseases, contains anti-Fas
 PT antibody.
 XX

PS Example 15; Page 49; 139pp; Japanese.

XX The invention relates to compositions for the prevention or treatment or diseases caused by an abnormality in the Fas/Fas ligand system containing an anti-Fas antibody as the active component. The anti-Fas antibody is either the murine anti-human Fas monoclonal antibody HFE7A, or a humanised version of HFE7A containing identical CDRs (complementarity determining regions) to antibody HFE7A. Via its interaction with Fas, the antibody of the invention acts as a modulator of apoptosis. The compositions of the invention may therefore be used in the treatment or prevention of conditions such as autoimmune diseases, allergy, atopy, arteriosclerosis, myocarditis, cardiomyopathy, glomerulonephritis, aplastic anaemia (panmyelophthisis), hepatitis, AIDS and organ graft rejection. The present sequence represents a humanised HFE7A-derived anti -Fas antibody heavy chain sequencing primer used in an exemplification of the invention. (Updated on 15-SEP-2003 to standardise OS field)

XX Sequence 20 BP; 5 A; 0 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTCTCTCTCTGCCCCAACAC 838

DB 20 CTCTCTCTCTGCCCCAACAC 1

RESULT 114

AA72168
ID AAA72168 standard; DNA; 20 BP.

XX

AC AAA72168;

DT 15-SEP-2003 (revised)

DT 24-NOV-2000 (first entry)

XX Humanised anti-Fas antibody heavy chain primer, SEQ ID NO:98.

XX Anti-Fas antibody; monoclonal antibody HFE7A; FERM-BP-5828; murine;
KW humanised antibody; complementarity determining region; CDR; human Fas;
KW Fas ligand; apoptosis modulator; programmed cell death;
KW autoimmune disease; allergy; atopy; arteriosclerosis; myocarditis;
KW cardiomyopathy; glomerulonephritis; aplastic anaemia; panmyelophthisis;
KW hepatitis; AIDS; graft rejection; heavy chain; sequencing primer; ss.

XX Mus musculus.

OS Homo sapiens.

OS Chimeric.

XX JP2000169393-A.

XX 20-JUN-2000.

XX 30-SEP-1999; 99JP-00278301.

XX 30-SEP-1998; 98JP-00276883.

XX (SANY) SANKYO CO LTD.

XX WPI; 2000-485645/43.

XX Preventive or treating agent for the diseases caused by an abnormality in the Fas/Fas ligand system e.g. autoimmune diseases, contains anti-Fas antibody.

PS Example 15; Page 49; 139pp; Japanese.

XX The invention relates to compositions for the prevention or treatment or diseases caused by an abnormality in the Fas/Fas ligand system containing an anti-Fas antibody as the active component. The anti-Fas antibody is either the murine anti-human Fas monoclonal antibody HFE7A, or a humanised version of HFE7A containing identical CDRs (complementarity

XX determining regions) to antibody HFE7A. Via its interaction with Fas, the antibody of the invention acts as a modulator of apoptosis. The compositions of the invention may therefore be used in the treatment or prevention of conditions such as autoimmune diseases, allergy, atopy, arteriosclerosis, myocarditis, cardiomyopathy, glomerulonephritis, aplastic anaemia (panmyelophthisis), hepatitis, AIDS and organ graft rejection. The present sequence represents a humanised HFE7A-derived anti -Fas antibody heavy chain sequencing primer used in an exemplification of the invention. (Updated on 15-SEP-2003 to standardise OS field)

XX Sequence 20 BP; 4 A; 11 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTCTCTCTCTGCCCCAACAC 838

DB 1 CTCTCTCTCTGCCCCAACAC 20

RESULT 115

AA11602/c

ID AA11602 standard; DNA; 20 BP.

XX

AC AA11602;

XX

DT 08-AUG-2000 (first entry)

DE Humanised HFE7A designed heavy chain DNA primer #5.

XX Fas; antibody; human; anti-inflammatory; anti-anemic; antidiabetic;
KW anti-allergic; anti-arthritis; antiviral; immunomodulatory; cardiant;
KW dermatological; immunosuppressive; thyromimetic; antirheumatic; anti-Fas;
KW nephrotropic; antiinfertility; neuroprotective; antiarteriosclerotic;
KW hepatotropic; humanized; apoptosis; systemic lupus erythematosus;
KW Hashimoto disease; rheumatoid arthritis; graft versus host disease;
KW Sjogren's syndrome; anemia; Addison's disease; scleroderma; sterility;
KW Goodpasture syndrome; Crohn's disease; myasthenia gravis;
KW multiple sclerosis; Basedow's disease; thrombopenia purpura; allergy;
KW insulin dependent diabetes mellitus; arteriosclerosis; myocarditis;
KW cardiomyopathy; glomerulonephritis; hepatitis; transplant rejection;
KW primer; ss.

XX Synthetic.

XX EP990663-A2.

XX 05-APR-2000.

XX 29-SEP-1999; 99EP-00307711.

XX 30-SEP-1998; 98JP-00276881.

XX 30-SEP-1998; 98JP-00276882.

XX (SANY) SANKYO CO LTD.

XX Serizawa N, Haruyama H, Nakahara K, Tamaki I, Takahashi T;

XX WPI; 2000-258930/23.

XX New humanized anti-Fas antibody, useful for treating or preventing e.g. PT inflammatory or autoimmune disease, induces apoptosis selectively in PT cells with abnormal Fas-Fas ligand systems.

XX Example reference 15; Page 137; 263pp; English.

XX This invention describes a novel humanized anti-Fas antibody-like CC molecule (I) that, induces apoptosis in cells with an abnormal Fas/Fas CC ligand system, by binding to Fas on the cell surface, and prevents CC apoptosis in cells with a normal system, by inhibiting binding between CC Fas and its ligand. The products of the invention have anti-inflammatory, CC anti-anemic, antidiabetic, anti-allergic, anti-arthritis, antiviral,

CC immunomodulatory, dermatological, immunosuppressive, thyromimetic,
CC antirheumatic, nephrotropic, antiinfertility, neuroprotective,
CC antiarteriosclerotic, cardiant and hepatropic activity. (I) induce
CC apoptosis by binding to cell surface Fas or inhibit it by competitive
CC inhibition of ligand binding. (I) are used to treat and/or prevent
CC diseases associated with the Fas/Fas ligand system, especially systemic
CC lupus erythematosus, Hashimoto disease, rheumatoid arthritis, graft
CC versus host disease, Sjorgen's syndrome, pernicious or hypoplastic
CC anemia, Addison's disease, scleroderma, Goodpasture syndrome, Crohn's
CC disease, autoimmune hemolytic anemia, sterility, myasthenia gravis,
CC multiple sclerosis, Basedow's disease, thrombopenia purpura, insulin
CC dependent diabetes mellitus, allergy, arteriosclerosis, myocarditis,
CC cardiomyopathy, glomerulonephritis, hepatitis (fulminant, chronic, viral
CC (B, C or D) or alcoholic), and transplant rejection. (I) selectively
CC inhibit apoptosis in normal cells but selectively induce it in abnormal
CC cells. They bind to both human and murine Fas, so can be evaluated in
CC murine disease models. (I) act on the active site of Fas, i.e. they mimic
CC the native ligand, do not induce liver disease, and have reduced risk of
CC inducing a human anti-murine antibody response. This sequence represents
CC primer used in the construction of a humanised anti-Fas antibody HFE7A
CC designed heavy chain which is used in the method described in the
CC invention
XX
SQ Sequence 20 BP; 5 A; 0 C; 11 G; 4 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTTCGCCCAAC 838
Db 20 CTTCTCTTTCGCCCAAC 1
RESULT 116
AA11606
ID AAA11606 standard; DNA; 20 BP.
AC AAA11606;
XX
XX 08-AUG-2000 (first entry)
XX Humanised HFE7A designed heavy chain DNA primer #9.
XX Fas; antibody; human; anti-inflammatory; anti-anemic; antidiabetic;
KW anti-allergic; anti-arthritis; antiviral; immunomodulatory; cardiant;
KW dermatological; immunosuppressive; thyromimetic; antirheumatic; anti-Fas;
KW nephrotropic; antiinfertility; neuroprotective; antiarteriosclerotic;
KW hepatotropic; apoptosis; systemic lupus erythematosus;
KW Hashimoto disease; rheumatoid arthritis; graft versus host disease;
KW Sjorgen's syndrome; anemia; Addison's disease; scleroderma; sterility;
KW Goodpasture syndrome; Crohn's disease; sterility; myasthenia gravis;
KW multiple sclerosis; Basedow's disease; thrombopenia purpura; allergy;
KW insulin dependent diabetes mellitus; arteriosclerosis; myocarditis;
KW cardiomyopathy; glomerulonephritis; hepatitis; transplant rejection;
KW primer; ss.
XX
XX Synthetic.
OS
XX Fas binding protein; CENP-C binding protein; dap6; EAP; cytostatic;
PN antinflammatory; death associated protein 6; Ets-1 associated protein;
XX infection; inflammation; tumour formation; ss.
XX
XX Homo sapiens.
OS
XX US6180353-B1.
PN
XX 30-JAN-2001.
PD
XX 24-JAN-2000; 2000US-00490692.
PF
XX 24-JAN-2000; 2000US-00490692.
PR
XX (ISIS-) ISIS PHARM INC.
DR

XX New humanized anti-Fas antibody, useful for treating or preventing e.g.
PT inflammatory or autoimmune disease, induces apoptosis selectively in
PT cells with abnormal Fas-Fas ligand systems.
XX
PS Example reference 15; Page 138; 263pp; English.
XX This invention describes a novel humanized anti-Fas antibody-like
CC molecule (I) that, induces apoptosis in cells with an abnormal Fas/Fas
CC ligand system, by binding to Fas on the cell surface, and prevents
CC apoptosis in cells with a normal system, by inhibiting binding between
CC Fas and its ligand. The products of the invention have anti-inflammatory,
CC anti-anemic, antidiabetic, anti-allergic, anti-arthritis, antiviral,
CC immunomodulatory, dermatological, immunosuppressive, thyromimetic,
CC antirheumatic, nephrotropic, antiinfertility, neuroprotective,
CC antiarteriosclerotic, cardiant and hepatropic activity. (I) induce
CC apoptosis by binding to cell surface Fas or inhibit it by competitive
CC inhibition of ligand binding. (I) are used to treat and/or prevent
CC diseases associated with the Fas/Fas ligand system, especially systemic
CC lupus erythematosus, Hashimoto disease, rheumatoid arthritis, graft
CC versus host disease, Sjorgen's syndrome, pernicious or hypoplastic
CC anemia, Addison's disease, scleroderma, Goodpasture syndrome, Crohn's
CC disease, autoimmune hemolytic anemia, sterility, myasthenia gravis,
CC multiple sclerosis, Basedow's disease, thrombopenia purpura, insulin
CC dependent diabetes mellitus, allergy, arteriosclerosis, myocarditis,
CC cardiomyopathy, glomerulonephritis, hepatitis (fulminant, chronic, viral
CC (B, C or D) or alcoholic), and transplant rejection. (I) selectively
CC inhibit apoptosis in normal cells but selectively induce it in abnormal
CC cells. They bind to both human and murine Fas, so can be evaluated in
CC murine disease models. (I) act on the active site of Fas, i.e. they mimic
CC the native ligand, do not induce liver disease, and have reduced risk of
CC inducing a human anti-murine antibody response. This sequence represents
CC primer used in the construction of a humanised anti-Fas antibody HFE7A
CC designed heavy chain which is used in the method described in the
CC invention
XX
SQ Sequence 20 BP; 4 A; 11 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 819 CTTCTCTTTCGCCCAAC 838
Db 1 CTTCTCTTTCGCCCAAC 20
RESULT 117
AAF73008/c
ID AAF73008 standard; DNA; 20 BP.
AC AAF73008;
XX
XX 24-APR-2001 (first entry)
DT Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:109.
XX
DE Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
KW Fas binding protein; CENP-C binding protein; dap6; EAP; cytostatic;
KW antinflammatory; death associated protein 6; Ets-1 associated protein;
KW infection; inflammation; tumour formation; ss.
XX
XX Homo sapiens.
OS
XX US6180353-B1.
PN
XX 30-JAN-2001.
PD
XX 24-JAN-2000; 2000US-00490692.
PF
XX 24-JAN-2000; 2000US-00490692.
PR
XX (ISIS-) ISIS PHARM INC.
PA

XX PI Dean NM, Cowseert LM;
 XX DR WPI; 2001-217744/22.
 XX PT Novel antisense compounds capable of modulating expression of daxx useful
 XX PT for diagnosis, prophylaxis and treatment of diseases associated with
 XX PT expression of daxx.
 XX PS Claim 1; Col 47; 59pp; English.
 XX CC The present invention describes an antisense compound (I) up to 30
 CC nucleobases in length, where (I) inhibits expression of daxx (also known
 CC as Fas binding protein, CENP-C binding protein, daps for death associated
 CC protein 6 and EAP for Ets-1 associated protein). (I) has cytostatic and
 CC antiinflammatory activity, and can be used in antineoplastic therapy and as a
 CC modulator of daxx. (I) is useful for inhibiting the expression of daxx in
 CC cells or tissues in vitro. (I) can be utilised for diagnostics,
 CC therapeutics for the treatment of diseases associated with the expression
 CC of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
 CC tumour formation and as research reagent. The present sequence represents
 CC an inhibitory human daxx antisense phosphorothioate oligonucleotide which
 CC is used in the exemplification of the present invention
 XX CC
 XX SQ Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1275 TGTGTTCTGCTGCTCGGAG 1294
 DB 20 TGTGTTCTGCTGCTCGGAG 1
 RESULT 118
 AAC89142
 ID AAC89142 standard; DNA; 20 BP.
 XX AC AAC89142;
 XX DT 07-MAR-2001 (first entry)
 XX DE Human prostate-specific antigen PSA PCR primer #3.
 XX KW PCR primer; cytostatic; vaccine; cancer; human;
 XX KW prostate-specific antigen; PSA; ss.
 XX OS Homo sapiens.
 XX PN WO200071156-A2.
 XX PD 30-NOV-2000.
 XX PF 19-MAY-2000; 2000WO-GB001921.
 XX PR 21-MAY-1999; 99GB-00011823.
 XX PR 21-MAY-1999; 99GB-00011824.
 XX PR 21-MAY-1999; 99GB-00011825.
 XX PR 01-APR-2000; 2000GB-00008029.
 XX PR 01-APR-2000; 2000GB-00008032.
 XX PA (ONYV-) ONYVAX LTD.
 XX PI Sutton A, Smith P, Stevenson D, Chana H, Thraves P;
 XX DR WPI; 2001-031966/04.
 XX PT Novel vaccine for treating cancer, especially prostate cancer, comprises
 XX PT immunogenic component which includes peptide mixture extracted from
 XX PT malignant cells which have altered immunogenicity.
 XX PS Example; Page 14; 39pp; English.

XX CC The present invention relates to a cancer vaccine. The cancer vaccine has
 CC an immunogenic component which includes a peptide mixture extracted from
 CC malignant cells which have an altered immunogenicity. The cancer vaccine
 CC is useful for treating cancer, preferably prostate cancer. The present
 CC sequence is a PCR primer, which was used to amplify human prostate-
 CC specific antigen (PSA) DNA, for use in the present invention
 XX CC
 XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1451 GCCAGGGAATCCAGGTGAC 1470
 DB 1 GCCAGGTATTTCAGGTGAC 20
 RESULT 119
 AAF99319/c
 ID AAF99319 standard; DNA; 20 BP.
 XX AC AAF99319;
 XX DT 12-JUN-2001 (first entry)
 XX DE Immunostimulatory nucleic acid #435.
 XX KW Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
 KW immunostimulatory; tumour; viral infection; bacterial infection;
 KW fungal infection; parasitic infection; cancer; asthma;
 KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
 XX OS Synthetic.
 XX PN WO200122972-A2.
 XX PD 05-APR-2001.
 XX PF 25-SEP-2000; 2000WO-US026383.
 XX PR 25-SEP-1999; 99US-0156113P.
 XX PR 27-SEP-1999; 99US-0156135P.
 XX PR 23-AUG-2000; 2000US-0227436P.
 XX PA (IOWA) UNIV IOWA RES FOUND.
 XX PA (COLE-) COLEY PHARM GMBH.
 XX PI Krieg AM, Schetter C, Vollmer J;
 XX DR WPI; 2001-273485/28.
 XX PT Vaccinating against tumors, infectious diseases, allergies and asthma
 XX PT using immunostimulatory Py-rich and TG nucleic acids.
 XX PS Claim 101; Page 47; 338pp; English.
 XX CC The present invention relates to a method for stimulating an immune
 CC response. The method comprises administering an immunostimulatory nucleic
 CC acid to a non-rodent subject in sufficient quantity to stimulate an
 CC immune response. The present sequence is one such immunostimulatory
 CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
 CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
 CC against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
 CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
 CC haemophilus, campylobacter, clostridium, Escherichia coli and/or
 CC staphylococcus), fungal antigens and/or parasitic antigens. The method is
 CC also useful for preventing cancer, asthma, infectious disease, allergy or
 CC immune deficiency. The present sequence can also be used to redirect a
 CC Th2 to a Th1 immune response and to activate immune cells. Note: the
 CC present sequence may have a phosphorothioate backbone
 XX CC

DR WPI; 2002-676576/73.
 XX Novel substantially pure androgen receptor (AR) complex-associated
 PT protein which binds to AR and increases ability of AR to transactivate
 PT androgen-responsive gene, useful as drug target for treating liver
 PT cancer.
 XX
 XX Example; Page 10; 26pp; English.
 XX
 XX The invention relates to an androgen receptor complex-associated protein
 CC (ARCAP) sequence and the cDNA encoding it. The protein is useful for
 CC screening a compound that decreases AR-mediated (androgen receptor
 CC mediated) transactivation which involves contacting the ARCAP protein
 CC with a protein complex comprising an AR in the presence of a candidate
 CC compound, measuring the extent of binding between the polypeptide, and
 CC determining if the extent of binding is less than the extent of binding
 CC between the polypeptide and the protein complex in the absence of the
 CC candidate compound. The ARCAP DNA is useful for determining if a sample
 CC contains cancerous cells which involves providing a sample from a human
 CC patient and detecting ARCAP expression in the sample. The sequences are
 CC useful for determining whether a sample contains liver tumour cells. This
 CC sequence represents a human transferrin gene PCR primer used in a test
 CC PCR reaction of the invention
 XX
 XX Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 963 TGTCTTTGCCAATGAGCC 982
 DB 20 TGTCTTTGCCAATGTTCC 1
 RESULT 125
 ABL48724/c
 ID ABL48724 standard; DNA; 20 BP.
 XX
 XX ABL48724;
 XX
 XX 30-APR-2002 (first entry)
 XX
 XX Humanised anti-Fas antibody related PCR primer SEQ ID NO 62.
 XX
 XX Human; mouse; Fas/Fas ligand system; Fas; antibody; light chain;
 KW heavy chain; apoptosis; antiallergic; immunosuppressive; apoptotic;
 KW autoimmune disease; allergy; atopy; PCR primer; ss.
 XX
 XX Synthetic.
 XX
 XX JP2001342149-A.
 XX
 XX 11-DEC-2001.
 XX
 XX 28-MAR-2001; 2001JP-00093243.
 XX
 XX 29-MAR-2000; 2000JP-00091144.
 XX
 XX (SANY) SANKYO CO LTD.
 XX
 XX WPI; 2002-145114/19.
 XX
 XX Drug for preventing or treating e.g. autoimmune disease or allergy,
 PT comprises humanized anti-Fas antibody.
 XX
 XX Example 14 (preparatory); Page 32; 154pp; Japanese.
 XX
 XX The invention relates to a preventive or treating agent for diseases
 CC caused by abnormality in the Fas/Fas ligand system containing, as the
 CC active component, an antibody having a light chain subunit and a heavy
 CC chain subunit and an activity of combining specifically with mammalian
 CC Fas and an activity of inducing apoptosis in a cell expressing Fas. The
 CC agent has antiallergic, immunosuppressive and apoptotic activity and is
 CC used for preventing and treating autoimmune diseases, allergy, atopy and
 CC others. The present sequence is that of a PCR primer useful in the
 CC construction of anti-Fas antibodies of the invention
 XX
 XX Sequence 20 BP; 5 A; 0 C; 11 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 819 CTTCCTCTTCCCAACAC 838
 DB 20 CTTCCTCTTCCCAACAC 1
 RESULT 127

CC the activity of the androgen receptor, transactivating the androgen
 CC responding gene. The invention also describes a vector containing the
 CC ARCAP polynucleotide sequence, and a host cell containing the ARCAP
 CC polynucleotide sequence. The ARCAP polypeptide can be used as a treating
 CC agent. The present sequence represents a PCR primer used in the example
 CC of the present invention
 XX
 XX Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 963 TGTCTTTGCCAATGAGCC 982
 DB 20 TGTCTTTGCCAATGTTCC 1
 RESULT 126
 ABL48724/c
 ID ABL48724 standard; DNA; 20 BP.
 XX
 XX ABL48724;
 XX
 XX 30-APR-2002 (first entry)
 XX
 XX Humanised anti-Fas antibody related PCR primer SEQ ID NO 62.
 XX
 XX Human; mouse; Fas/Fas ligand system; Fas; antibody; light chain;
 KW heavy chain; apoptosis; antiallergic; immunosuppressive; apoptotic;
 KW autoimmune disease; allergy; atopy; PCR primer; ss.
 XX
 XX Synthetic.
 XX
 XX JP2001342149-A.
 XX
 XX 11-DEC-2001.
 XX
 XX 28-MAR-2001; 2001JP-00093243.
 XX
 XX 29-MAR-2000; 2000JP-00091144.
 XX
 XX (SANY) SANKYO CO LTD.
 XX
 XX WPI; 2002-145114/19.
 XX
 XX Drug for preventing or treating e.g. autoimmune disease or allergy,
 PT comprises humanized anti-Fas antibody.
 XX
 XX Example 14 (preparatory); Page 32; 154pp; Japanese.
 XX
 XX The invention relates to a preventive or treating agent for diseases
 CC caused by abnormality in the Fas/Fas ligand system containing, as the
 CC active component, an antibody having a light chain subunit and a heavy
 CC chain subunit and an activity of combining specifically with mammalian
 CC Fas and an activity of inducing apoptosis in a cell expressing Fas. The
 CC agent has antiallergic, immunosuppressive and apoptotic activity and is
 CC used for preventing and treating autoimmune diseases, allergy, atopy and
 CC others. The present sequence is that of a PCR primer useful in the
 CC construction of anti-Fas antibodies of the invention
 XX
 XX Sequence 20 BP; 5 A; 0 C; 11 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 819 CTTCCTCTTCCCAACAC 838
 DB 20 CTTCCTCTTCCCAACAC 1
 RESULT 127

DR WPI; 2002-676576/73.
 XX Novel substantially pure androgen receptor (AR) complex-associated
 PT protein which binds to AR and increases ability of AR to transactivate
 PT androgen-responsive gene, useful as drug target for treating liver
 PT cancer.
 XX
 XX Example; Page 10; 26pp; English.
 XX
 XX The invention relates to an androgen receptor complex-associated protein
 CC (ARCAP) sequence and the cDNA encoding it. The protein is useful for
 CC screening a compound that decreases AR-mediated (androgen receptor
 CC mediated) transactivation which involves contacting the ARCAP protein
 CC with a protein complex comprising an AR in the presence of a candidate
 CC compound, measuring the extent of binding between the polypeptide, and
 CC determining if the extent of binding is less than the extent of binding
 CC between the polypeptide and the protein complex in the absence of the
 CC candidate compound. The ARCAP DNA is useful for determining if a sample
 CC contains cancerous cells which involves providing a sample from a human
 CC patient and detecting ARCAP expression in the sample. The sequences are
 CC useful for determining whether a sample contains liver tumour cells. This
 CC sequence represents a human transferrin gene PCR primer used in a test
 CC PCR reaction of the invention
 XX
 XX Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 963 TGTCTTTGCCAATGAGCC 982
 DB 20 TGTCTTTGCCAATGTTCC 1
 RESULT 125
 ABL48724/c
 ID ABL48724 standard; DNA; 20 BP.
 XX
 XX ABL48724;
 XX
 XX 30-APR-2002 (first entry)
 XX
 XX Humanised anti-Fas antibody related PCR primer Tref8.
 XX
 XX Human; androgen receptor complex-coupled protein; ARCAP; PCR; primer; ss.
 KW Homo sapiens.
 XX
 XX JP2002262871-A.
 XX
 XX 17-SEP-2002.
 XX
 XX 28-FEB-2001; 2001JP-00055192.
 XX
 XX 12-FEB-2001; 2001US-00781693.
 XX
 XX (VETE-) VETERANS GEN HOSPITAL.
 XX
 XX Tai-Jay C;
 XX
 XX WPI; 2002-676576/73.
 XX
 XX Novel substantially pure androgen receptor (AR) complex-associated
 PT protein which binds to AR and increases ability of AR to transactivate
 PT androgen-responsive gene, useful as drug target for treating liver
 PT cancer.
 XX
 XX Example; Page 14; 18pp; Japanese.
 XX
 XX The present invention relates to the isolation of human androgen receptor
 CC complex-coupled protein (ARCAP), and the polynucleotide sequence encoding
 CC it. The ARCAP polypeptide complexes with an androgen receptor to increase

ABL48728
ID ABL48728 standard; DNA; 20 BP.
XX
AC ABL48728;
XX
DT 30-APR-2002 (first entry)
XX
DE Humanised anti-Fas antibody related PCR primer SEQ ID NO 66.
XX
KW Human; mouse; Fas/Fas ligand system; Fas; antibody; light chain;
KW heavy chain; apoptosis; antiallergic; immunosuppressive; apoptotic;
KW autoimmune disease; allergy; atopy; PCR primer; 88.
XX
OS Synthetic.
XX
PN JP2001342149-A.
XX
PD 11-DEC-2001.
XX
PF 28-MAR-2001; 2001JP-00093243.
XX
PR 29-MAR-2000; 2000JP-00091144.
XX
PA (SANY) SANKYO CO LTD.
XX
DR WPI; 2002-145114/19.
XX
PT Drug for preventing or treating e.g. autoimmune disease or allergy,
PT comprises humanized anti-Fas antibody.
XX
PS Example 14 (preparatory); Page 32; 154pp; Japanese.
XX
CC The invention relates to a preventive or treating agent for diseases
CC caused by abnormality in the Fas/Fas ligand system containing, as the
CC active component, an antibody having a light chain subunit and a heavy
CC chain subunit and an activity of combining specifically with mammalian
CC Fas and an activity of inducing apoptosis in a cell expressing Fas. The
CC agent has antiallergic, immunosuppressive and apoptotic activity and is
CC used for preventing and treating autoimmune diseases, allergy, atopy and
CC others. The present sequence is that of a PCR primer useful in the
CC construction of anti-Fas antibodies of the invention
XX
SQ Sequence 20 BP; 4 A; 11 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 819 CTTCTCTTCTGCGCCCAAC 838
Db 1 CTTCTCTTCTGCGCCCAAC 20
RESULT 128
ABL45367/c
ID ABL45367 standard; DNA; 20 BP.
XX
AC ABL45367;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 21q22.1 PCR primer SEQ ID NO:2411.
XX
KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; 88.
XX
OS Homo sapiens.
XX
PN JP2001321190-A.
XX
PD 20-NOV-2001.
XX
PF 12-MAR-2001; 2001JP-00068285.

XX
PR 10-MAR-2000; 2000JP-00066716.
XX
PA (RIKA) RIKAGAKU KENKYUSHO.
XX
DR WPI; 2002-144136/19.
XX
PT Arraying genome clones.
XX
PS Claim 6; Page 52; 528pp; Japanese.
XX
CC The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 745 GAGGCTGTGCTGGGATCCT 764
Db 20 GAGGATGCTCCTGAGATCCT 1
RESULT 129
ABT12924/c
ID ABT12924 standard; DNA; 20 BP.
XX
AC ABT12924;
XX
DT 17-JAN-2003 (first entry)
XX
DE Mycobacterium tuberculosis-specific DNA sequence #27.
XX
KW Mycobacterium detection method; PCR; primer; probe; ss.
XX
OS Mycobacterium tuberculosis.
XX
PN WO200274991-A2.
XX
PD 26-SEP-2002.
XX
PF 20-MAR-2002; 2002WO-GB001308.
XX
PR 20-MAR-2001; 2001GB-00006949.
XX
PA (NORC-) NORCHIP AS.
PA (ALLA/) ALLARD S J.
XX
PI Karlsen F;
XX
DR WPI; 2002-750564/81.

XX Detecting the presence of Mycobacterium tuberculosis in a test sample,
PT comprises inducing mRNA expression of Mycobacterium tuberculosis and
PT detecting the induced mRNA.
XX
PS Claim 17; Page 14; 70pp; English.
XX
CC The invention comprises a method for detecting the presence of a micro-
CC organism (particularly Mycobacterium tuberculosis) in a test sample. The
CC method of the invention comprises exposing the test sample to an inducer
CC that is capable of inducing the expression of at least one gene in the
CC micro-organism and then testing for the presence of mRNA from this gene.
CC The method of the invention is useful for detecting an mRNA that is
CC expressed in a species of Mycobacterium (e.g. Mycobacterium
CC tuberculosis). The present DNA sequence represents a Mycobacterium-
CC specific nucleotide which can be used as a primer or probe in the method
CC of the invention
XX
SQ Sequence 20 BP; 2 A; 11 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 181 AGGAGCTGCTGGATCGGC 200
| | | | | | | | | | | | | | | | | | | |
Db 20 AAGGAGCTGCTGGATCGGC 1
RESULT 130
ID ABA00084/c
AC ABA00084;
XX
XX 25-OCT-2002 (first entry)
DE Human APC primer #1.
XX
XX Primer; probe; detection; Helicobacter pylori; integrity; ss.
XX
XX Homo sapiens.
XX
XX WO200259379-A2.
XX
XX 01-AUG-2002.
XX
XX 04-JAN-2002; 2002WO-US000267.
XX
XX 05-JAN-2001; 2001US-00755004.
XX (EXAC-) EXACT SCI CORP.
XX Shuber AP;
XX
XX WPI; 2002-599807/64.
XX
XX Detecting, grading and/or monitoring a Helicobacter pylori infection by
PT detecting a high-integrity H. pylori nucleic acid in a patient sample.
PT
PS Example 5; Page 27; 28pp; English.
XX
CC The sequences given in ABA00075 and ABA00083-85 are probes and primers
CC which were used in the detection of H. pylori infection pre- and post-
CC treatment in a patient, compared to the presence of human DNA. These
CC sequences may be used in the method of the invention for detecting a H.
CC pylori infection. The method comprises: (a) determining an integrity of a
CC Helicobacter pylori nucleic acid present; or (b) amplifying and detecting
CC a first, second or third Helicobacter pylori nucleic acid at least 200,
CC 400 or 600 in length, respectively, where a patient is identified with an
CC infection if the integrity of the nucleic acid exceeds a predetermined
CC threshold, or if the amplified first, second or third Helicobacter pylori
CC nucleic acids are detected. The method is useful for detecting a

CC Helicobacter pylori infection, determining its status, monitoring
CC progression, evaluating efficacy of a treatment and diagnosing gastric
CC disease by detecting a high-integrity Helicobacter pylori nucleic acid in
CC a patient sample. Prior methods of using polymerase chain reaction (PCR)
CC in assays detecting H. pylori infection usually lack the specificity to
CC distinguish a successfully treated patient from a patient with a
CC continuing H. pylori infection. The present invention of non-invasive
CC method uses more sensitive and more specific assays to test for and to
CC monitor H. pylori infection and course of treatment
XX
SQ Sequence 20 BP; 5 A; 12 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 332 TTGATGAGCTGATGGAGGTG 351
| | | | | | | | | | | | | | | | | | | |
Db 20 TTGAGGAGGTGCTGGAGGTG 1
RESULT 131
ID AAL38179/c
AC AAL38179;
XX
XX 29-AUG-2003 (revised)
DT 15-AUG-2002 (first entry)
XX
XX Human BH3 interacting domain death mRNA agonist inhibitor SEQ ID 22.
XX
XX Hepatotropic; immunomodulatory; cytostatic; antiinflammatory; hepatitis;
KW haematopoietic disorder; developmental disorder; immunological disorder;
KW hyperproliferative disorder; apoptosis; human; chimeric; 2'-methoxyethyl;
KW 2'-MOE; phosphorothioate backbone; ds.
XX
XX Homo sapiens.
XX Chimeric.
XX
XX WO200220547-A1.
XX
XX 14-MAR-2002.
XX
XX 31-AUG-2001; 2001WO-US027316.
XX
XX 07-SEP-2000; 2000US-00657346.
PR 07-MAR-2001; 2001US-00800631.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Zhang H, Wyatt JR;
XX
XX WPI; 2002-393838/42.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding the
PT BH3 interacting domain death agonist, useful for treating animals with
PT diseases associated with BH3 interacting domain death agonist, e.g.
PT hepatitis.
XX
XX Claim 3; Page 86; 171pp; English.
XX
XX The invention relates to a compound 8 to 50 nucleotides in length
CC targeted to a nucleic acid molecule encoding a BH3 interacting domain
CC death agonist, where the compound specifically hybridises with and
CC inhibits the expression of the BH3 interacting domain death agonist. The
CC compound of the invention is useful for inhibiting the expression of the
CC BH3 interacting domain death agonist in cells or tissues. The compound is
CC also useful for treating an animal having a disease or condition
CC associated with the BH3 interacting domain death agonist, e.g.
CC haematopoietic disorder, hyperproliferative disorder, a developmental
CC disorder, immunological disorder, or a disease or condition of the liver

CC e.g., hepatitis, or a condition associated with apoptosis. The compound
CC is useful for diagnostics, therapeutics, prophylaxis and as research
CC reagents and kits. This polynucleotide sequence represents an antisense
CC oligonucleotide inhibitor of the DNA from human BH3 interacting domain
CC death agonist RNA of the invention. NOTE: This sequence is a chimeric
CC oligonucleotide 20 nucleotides in length, which is flanked on both sides
CC by five-nucleotide 'wings'. The wings are composed of 2'-methoxyethyl (2'
CC -MOE) nucleotides. The internucleoside (backbone) linkages are
CC phosphorothioate (P=S) throughout the oligonucleotide. (Updated on 29-AUG
CC -2003 to standardise OS field)
XX
SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 903 TGCCAGGCCCTGGGATG 922
DB 20 TGCCAGGCCCTGGGACTGTG 1

RESULT 132
ABL45981/c
ID ABL45981 standard; DNA; 20 BP.
XX
AC ABL45981;
XX
DT 26-APR-2002 (first entry)
XX
DE Humanised anti-Fas antibody related PCR primer SEQ ID NO 19.
XX
KW Human; mouse; humanised anti-Fas antibody; Fas/Fas ligand;
KW light chain subunit; apoptosis; immunosuppressive; antiallergic;
KW autoimmune disease; allergy; atopic; PCR primer; ss.
XX
OS Synthetic.
XX
PN JP2001342148-A.
XX
PD 11-DEC-2001.
XX
PF 28-MAR-2001; 2001JP-00093106.
XX
PR 29-MAR-2000; 2000JP-00090918.
XX
PA (SANY) SANKYO CO LTD.
XX
DR WPI; 2002-145113/19.
XX
PT Drug containing humanized anti-Fas antibody, used for preventing and
PT treating autoimmune diseases, allergy, and atopy.
XX
PS Example 4 (Preparatory); Page 23; 194pp; Japanese.

The invention relates to a preventive or treating agent for diseases
CC caused by abnormality in Fas/Fas ligand system containing as the active
CC component an antibody having as the light chain subunit a polypeptide
CC containing residues 1-218 of one of 3, 239 residue amino acid sequences,
CC or residues 1-451 of one of 3, 470 residue amino acid sequences, all
CC fully defined in the specification and having an activity of combining
CC specifically with mammalian Fas and an activity of inducing apoptosis in
CC a cell expressing Fas. The agent has immunosuppressive and antiallergic
CC activity and is used for preventing and treating autoimmune diseases,
CC allergy, atopy and others. The present sequence is that of a PCR primer,
CC useful to the invention
XX
SQ Sequence 20 BP; 5 A; 0 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTCCCAACAC 838
DB 20 CTTCTCTTCTCCCAACAC 1

RESULT 133
ABL45985
ID ABL45985 standard; DNA; 20 BP.
XX
AC ABL45985;
XX
DT 26-APR-2002 (first entry)
XX
DE Humanised anti-Fas antibody related PCR primer SEQ ID NO 23.
XX
KW Human; mouse; humanised anti-Fas antibody; Fas/Fas ligand;
KW light chain subunit; apoptosis; immunosuppressive; antiallergic;
KW autoimmune disease; allergy; atopic; PCR primer; ss.
XX
OS Synthetic.
XX
PN JP2001342148-A.
XX
PD 11-DEC-2001.
XX
PF 28-MAR-2001; 2001JP-00093106.
XX
PR 29-MAR-2000; 2000JP-00090918.
XX
PA (SANY) SANKYO CO LTD.
XX
DR WPI; 2002-145113/19.
XX
PT Drug containing humanized anti-Fas antibody, used for preventing and
PT treating autoimmune diseases, allergy, and atopy.
XX
PS Example 5 (Preparatory); Page 25; 194pp; Japanese.

The invention relates to a preventive or treating agent for diseases
CC caused by abnormality in Fas/Fas ligand system containing as the active
CC component an antibody having as the light chain subunit a polypeptide
CC containing residues 1-218 of one of 3, 239 residue amino acid sequences,
CC or residues 1-451 of one of 3, 470 residue amino acid sequences, all
CC fully defined in the specification and having an activity of combining
CC specifically with mammalian Fas and an activity of inducing apoptosis in
CC a cell expressing Fas. The agent has immunosuppressive and antiallergic
CC activity and is used for preventing and treating autoimmune diseases,
CC allergy, atopy and others. The present sequence is that of a PCR primer,
CC useful to the invention
XX
SQ Sequence 20 BP; 4 A; 11 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTCCCAACAC 838
DB 1 CTTCTCTTCTCCCAACAC 20

RESULT 134
ACD99742/c
ID ACD99742 standard; DNA; 20 BP.
XX
AC ACD99742;
XX
DT 25-SEP-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #428.
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;

KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
 KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
 XX Synthetic.
 XX US2003050268-A1.
 XX 13-MAR-2003.
 XX 29-MAR-2002; 2002US-00112653.
 XX 29-MAR-2001; 2001US-0279642P.
 XX (KRIE/) KRIEG A M.
 XX (BERG/) BERG D J.
 XX Krieg AM, Berg DJ;
 XX WPI; 2003-521815/49.
 XX Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
 PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
 PT disease by administering an immunostimulatory nucleic acid.
 XX Disclosure; Page 20; 229pp; English.
 CC The invention describes a method of treating non-allergic inflammatory
 CC disease comprising administering to a subject having or at risk of
 CC developing a non-allergic inflammatory disease an immunostimulatory
 CC nucleic acid for prevention or treatment of the disease. The method is
 CC useful for treating non-allergic inflammatory diseases, such as
 CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
 CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
 CC This sequence represents an immunostimulatory nucleic acid
 XX
 XX Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1461 CCAGGTCAGCCTGTACTGCC 1480
 Db 20 CCCGGTGAGCCTGCACTGCC 1
 RESULT 135
 AAL62118
 ID AAL62118 standard; DNA; 20 BP.
 AC AAL62118;
 XX 22-SEP-2003 (first entry)
 DT Human HCDR3 amplifying forward PCR primer, Exfor1.
 XX Micro-scaffold; immunoglobulin; complementarity determining region; CDR;
 KW human; PCR; primer; ss.
 KW Homo sapiens.
 OS WO2003050531-A2.
 PN 19-JUN-2003.
 XX 11-DEC-2002; 2002WO-BE000189.
 PF 11-DEC-2001; 2001EP-00870274.
 XX (ALGO-) ALGONOMICS NV.
 XX (ABLY-) ABLYNX NV.
 XX Lasters I, Pletinckx J, Boutonnet N, Lauwereys M, Beirnaert E;

XX WPI; 2003-577302/54.
 XX New isolated polypeptide micro-scaffold displaying immunoglobulin
 PT complementarity determining region (CDR) 2 or CDR3 polypeptide sequences,
 PT useful for searching, selecting and screening for immunoglobulin CDR2 or
 XX CDR3 polypeptide sequences.
 XX Example 2; Page 37; 90pp; English.
 XX The invention relates to an isolated polypeptide micro-scaffold
 CC displaying immunoglobulin complementarity determining region (CDR)-2 or
 CC CDR3 polypeptide sequences, comprising a CDR2 or CDR3 polypeptide
 CC sequence interconnecting fragments of the adjacent framework polypeptide
 CC sequences, which are arranged to form two anti-parallel beta-strands. The
 CC polypeptide micro-scaffold and the nucleotide sequences are useful for
 CC searching, selecting and screening for immunoglobulin CDR2 or CDR3
 CC polypeptide sequences. The present sequence is a PCR primer used in the
 CC amplification of human HCDR3 DNA
 XX
 XX Sequence 20 BP; 3 A; 5 C; 9 G; 1 T; 0 U; 2 Other;
 SQ
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 83.3%; Pred. No. 1.1e+02;
 Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1450 GGCCAGGGAATCCAGGTC 1467
 Db 3 GGCCAGGGVACVACAGGTC 20
 RESULT 136
 ADB36821/c
 ID ADB36821 standard; DNA; 20 BP.
 XX ADB36821;
 AC ADB36821;
 XX 04-DEC-2003 (first entry)
 DT Immunostimulatory nucleic acid #435.
 XX ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
 KW hypo-responsive subject; immunostimulatory.
 XX Synthetic.
 XX US2003087848-A1.
 XX 08-MAY-2003.
 PD 02-FEB-2001; 2001US-00776479.
 PF 03-FEB-2000; 2000US-0179991P.
 PR (BRAT/) BRATZLER R L.
 PA (PETE/) PETERSEN D M.
 PA (FOUR/) FOURON Y.
 XX Bratzler RL, Petersen DM, Fouron Y;
 PI WPI; 2003-657977/62.
 DR Treating and/or preventing allergy or asthma using an immunostimulatory
 XX nucleic acid alone or in combination with an asthma/allergy medicament.
 PT Disclosure; Page 11; 221pp; English.
 XX The invention relates to a method of treating or preventing allergy or
 CC asthma which comprises administering to a subject a poly-G nucleic acid
 CC in an aerosol formulation. The methods and compositions of the present
 CC invention are useful for diagnosing and/or treating asthma and allergy
 CC especially in a hypo-responsive subject. The present sequence represents
 CC an immunostimulatory nucleic acid of the invention.

```
XX Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
SQ Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGACTGCC 1480
DB ||||| ||||| ||||| |||||
20 CCCGGTGAGCCTGCACTGCC 1

RESULT 137
ID ADF53079 standard; DNA; 20 BP.
XX AC
XX ADF53079;
XX XX
DT 12-FEB-2004 (first entry)
XX XX
DE Variant detecting primer extension assay extension primer, SEQ ID No 35.
XX variant detection; primer extension assay; mutation; cancer;
XX heterogeneous; sporadic mutation; genotyping; pooled sample; primer; ss.
XX Unidentified.
OS WO2003071252-A2.
XX PN
XX 28-AUG-2003.
XX PD
XX PF 18-FEB-2003; 2003WO-US004827.
XX PR 15-FEB-2002; 2002US-0357585P.
XX PA (EXAC-) EXACT SCI CORP.
XX PI Shuber AP, Kann L, Whitney D;
XX WPI; 2003-697649/66.
XX DR
XX PT Detecting a variant in a primer extension assay, useful for analyzing
XX molecular events for identifying mutations indicative of cancer, by
XX contacting a target nucleic acid primer complementary to a region of the
XX target nucleic acid.
XX Example 5; SEQ ID NO 35; 54pp; English.
XX PS
XX CC The invention relates to a novel method for detecting a variant in a
XX primer extension assay, useful for analyzing molecular events for
XX identifying mutations indicative of cancer, by contacting a target
XX nucleic acid primer complementary to a region of the target nucleic acid.
XX Detecting a variant in a primer extension assay comprises contacting a
XX target nucleic acid primer complementary to a region of the target
XX nucleic acid, and extending the primer in the presence of a first
XX nucleotide that is complementary to a first variant nucleotide suspected
XX to be at a position downstream of the region and a second nucleotide that
XX is complementary to a second variant nucleotide at the position, thus to
XX reduce misincorporation of the first nucleotide on a template comprising
XX the second variant nucleotide. The methods are useful for analysing
XX molecular events for identifying individuals with mutations indicative of
XX cancer. They are particularly useful in detecting a rare mutation in a
XX heterogeneous biological sample (e.g. sporadic mutation in a
XX heterogeneous patient sample), detecting rare genotypes in genotyping
XX reactions (e.g. viral genotyping reactions), or detecting mutant or viral
XX sequences in pooled samples (e.g. detecting polymorphisms or inherited
XX sequence variations in pooled patient samples). This polynucleotide
XX sequence represents a primer used as part of the primer extension assay
XX of the invention.
XX SQ Sequence 20 BP; 5 A; 12 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 332 TTGATGAGCTGATGGAGGTG 351
DB ||||| ||||| ||||| |||||
20 TTGAGGAGGTGCTGGAGGTG 1

RESULT 138
ID ADJ33237 standard; DNA; 20 BP.
XX AC
XX ADJ33237;
XX XX
DT 15-APR-2004 (first entry)
XX XX
DE Primer sequence mTMF, seq id 104.
XX XX
XX Antinflammatory; nephrotropic; hepatotropic; neuroprotective; nootropic;
XX gynaecological; cytostatic; antiallergic; immunosuppressive; antithyroid;
XX antiparkinsonian; antiarthritic; monocarboxylic acid; transport protein;
XX inhibitor; potentiator; organic ion; TCH131; TCH182; TCH120;
XX respiratory disease; asthma; kidney disease; kidney failure;
XX nervous system disease; Alzheimer's disease; muscle disease;
XX muscle wasting; allergic disease; meningitis; autoimmune disease;
XX multiple sclerosis; allergic disease; hayfever; spleen disease;
XX immune deficiency disease; leukopenia; liver disease; hepatitis;
XX digestive disease; Crohn's disease; genital disease;
XX ovarian hypofunction; cancer; PCR; primer; ss.
XX OS
XX Unidentified.
XX PN WO2003040184-A1.
XX PR 15-MAY-2003.
XX PD
XX PF 06-NOV-2002; 2002WO-JP011559.
XX PR 07-NOV-2001; 2001JP-00342139.
XX PR 16-NOV-2001; 2001JP-00351086.
XX PR 20-NOV-2001; 2001JP-00354971.
XX PA (TAKA ) TAKEDA CHEM IND LTD.
XX XX
XX PI Nakanishi A, Sagiya Y, Hikichi Y, Nishimura A;
XX WPI; 2003-441528/41.
XX DR
XX XX
XX Monocarboxylic acid and organic ion transport proteins and compounds
XX modifying their activity or expression for treatment, prevention and
XX diagnosis of respiratory, inflammatory, autoimmune, allergic and kidney
XX diseases and cancer.
XX PS
XX Example 19; SEQ ID NO 104; 209pp; Japanese.
XX CC
XX The invention relates to proteins TCH131 (human, mouse and rat), TCH182
XX (human) and TCH120 (human) and their salts and partial peptides, and
XX similar proteins with equivalent activity. Also disclosed are
XX polynucleotides (including DNA) encoding the proteins. Proteins of the
XX invention are useful in the prevention, treatment and diagnosis of
XX respiratory diseases (including asthma and bronchitis), kidney diseases
XX (including kidney failure and nephritis), nervous system diseases
XX (including Alzheimer's, Parkinson's and schizophrenia), metabolic
XX acidosis, muscle diseases (including muscle wasting), allergic diseases
XX (including pneumonia, meningitis and myocarditis), autoimmune diseases
XX (including muscular dystrophy and multiple sclerosis), allergic diseases
XX (including hayfever), spleen diseases (including spleen hyperfunction),
XX immune deficiency diseases (including leukopenia), liver diseases
XX (including hepatitis), digestive diseases (including Crohn's disease),
XX genital diseases (including ovarian hypofunction) and cancer (including
XX pancreas cancer, lung cancer, non-small cell lung cancer, kidney cancer,
XX liver cancer, ovarian cancer, prostate cancer, stomach cancer, breast
XX cancer, bladder cancer and colon cancer). The sequences given in records
XX CC
```

CC ADJ33134-ADJ33242 include proteins of the invention and those related to
CC the invention, polynucleotides encoding these proteins, and primers and
CC probes for the amplification and detection of DNA encoding them.

XX Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1364 TCATTGGAGGAAATGTTGAAC 1383
|||||||
Db 1 TCATTGGAGGCTGTGTGAAC 20

RESULT 139
ABZ85105/C
ID ABZ85105 standard; DNA; 20 BP.
XX AC ABZ85105;
XX 17-OCT-2003 (first entry)
XX Human oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Claim 15; SEQ ID NO 347; 872pp; English.

The invention relates to a novel pharmaceutical composition, which has a
first active agent comprising an oligonucleotide antisense to the
initiation codon, coding region, 5' or 3' end genomic flanking regions,
5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
junctions of genes encoding a polypeptide associated with lung and/or
nasal airway dysfunction and a second active agent comprising an
antiinflammatory steroid and ubiquinone. A composition of the invention
has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
immunosuppressive, and cytostatic activity. The composition may have a
use in antisense gene therapy. The composition is useful for treating or
preventing a respiratory, lung or malignant disease or condition, also
for enhancing the prophylactic or therapeutic respiratory effect of an
antiinflammatory steroid in a subject, for reducing or depleting levels
of, or reducing sensitivity to adenosine, reducing levels of adenosine
receptor, producing bronchodilation, increasing levels of ubiquinone or
lung surfactant in a subject's tissue, or treating bronchoconstriction,
lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1418 GGAACGTGCTGATGTGGACC 1437
|||||||
Db 20 GGAACGTACTGCTGTGGCCC 1

RESULT 140
ABZ86052
ID ABZ86052 standard; DNA; 20 BP.
XX AC ABZ86052;
XX 17-OCT-2003 (first entry)
XX Human oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Claim 15; SEQ ID NO 1294; 872pp; English.

The invention relates to a novel pharmaceutical composition, which has a
first active agent comprising an oligonucleotide antisense to the
initiation codon, coding region, 5' or 3' end genomic flanking regions,
5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
junctions of genes encoding a polypeptide associated with lung and/or
nasal airway dysfunction and a second active agent comprising an
antiinflammatory steroid and ubiquinone. A composition of the invention
has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
immunosuppressive, and cytostatic activity. The composition may have a
use in antisense gene therapy. The composition is useful for treating or
preventing a respiratory, lung or malignant disease or condition, also
for enhancing the prophylactic or therapeutic respiratory effect of an
antiinflammatory steroid in a subject, for reducing or depleting levels
of, or reducing sensitivity to adenosine, reducing levels of adenosine
receptor, producing bronchodilation, increasing levels of ubiquinone or
lung surfactant in a subject's tissue, or treating bronchoconstriction,
lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 5 A; 3 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 73 TGTGGAGATGGAACACTGA 92

||||| ||||| ||||| ||||| |||||
DB 1 TGTGGATCTGGATACACTGA 20

RESULT 141

ABZ88990/c

ID ABZ88990 standard; DNA; 20 BP.

XX AC ABZ88990;

XX DT 17-OCT-2003 (first entry)

XX DE Human oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EP1G-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 4232; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 433 GATGAGGCGAGGCTGCTGCT 452

||||| ||||| ||||| ||||| |||||
DB 20 GATGAGAGAGGCGGCTGCT 1

RESULT 142

ABZ88917

ID ABZ88917 standard; DNA; 20 BP.

XX AC ABZ88917;

XX DT 17-OCT-2003 (first entry)

XX DE Human oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EP1G-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 4159; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1193 TCCATGACTGGCTGTACAGC 1212
| | | | | | | | | | | | | | | | | | | |
Db 1 TACATGACTGGCAGTGCAGC 20

RESULT 143
ACC42443/C
ID ACC42443 standard; DNA; 20 BP.

XX AC ACC42443;

XX 26-AUG-2003 (first entry)

XX Acyl CoA cholesterol acyltransferase-2 antisense oligo ISIS #143031.

XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW phosphorothioate; mouse; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Oligonucleotide has phosphorothioate backbone and
all cytidine nucleotides are 5-methylcytidine. Optionally
some nucleotides with 2'-methoxyethyl (2'-MOE wings)
modification"

XX WO2003011889-A2.

XX 13-FEB-2003.

XX 15-JUL-2002; 2002WO-US022746.

XX 30-JUL-2001; 2001US-00918026.

XX (ISIS-) ISIS PHARM INC.

XX Crooke RM, Graham MJ, Lemonidis KM;

XX WPI; 2003-248145/24.

XX New antisense oligonucleotides for modulating acyl CoA cholesterol
PT acyltransferase-2, e.g. for preventing or treating diseases associated
PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
PT cardiovascular disease.

XX Example 16; Page 90; 112pp; English.

XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to human ACY CoA cholesterol acyltransferase-2 (ACAT-2)
CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
CC ACC42457). The antisense oligonucleotides specifically hybridize with and
CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
CC useful for treating an animal which has a disease or condition associated
CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
CC cardiovascular disease

XX

SQ Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 633 CTGCGCGTCTGCGGTCCACG 652

Db 20 CTGCGTCTGCGGTGCACG 1

RESULT 144

ABD25147

ID ABD25147 standard; DNA; 20 BP.

XX AC ABD25147;

XX 29-JUL-2004 (first entry)

XX AI041482-derived oligonucleotide SEQ ID 4159.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15; SEQ ID NO 4159; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1193 TCCATGACTGGCTGTACAGC 1212
 Db 1 TACATGACTGGCAGTGCAGC 20
 RESULT 145
 ID ABD22282 standard; DNA; 20 BP.
 AC ABD22282;
 XX
 XX 29-JUL-2004 (first entry)
 DT Human stannocalcin-derived oligo SEQ ID 1294.
 DE Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS WO200285309-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 PF 24-APR-2001; 2001US-0286036P.
 PR (EPITG-) EPITGENESIS PHARM INC.
 PA Nyce JW, Li Y, Sandraseagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR Pharmaceutical composition for treating asthma, has antisense
 XX oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 1294; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposcretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 5 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 73 TGTGGAGATGGAAACACTGA 92
 Db 1 TGTGGATCTGGATACACTGA 20
 RESULT 146
 ID ABD21335/c
 XX ABD21335 standard; DNA; 20 BP.
 AC ABD21335;
 XX
 XX 29-JUL-2004 (first entry)
 DT Human transglutaminase-derived oligo SEQ ID 347.
 DE Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS WO200285309-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 PF 24-APR-2001; 2001US-0286036P.
 PR (EPITG-) EPITGENESIS PHARM INC.
 PA Nyce JW, Li Y, Sandraseagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR Pharmaceutical composition for treating asthma, has antisense
 XX oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.


```
XX PN JP2003259875-A.
XX PD
XX PF 16-SEP-2003.
XX PR 08-MAR-2002; 2002JP-00064373.
XX PA 08-MAR-2002; 2002JP-00064373.
XX DR (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX PT WPI; 2004-093977/10.
XX CC Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX PS Claim 2; SEQ ID NO 5437; 2627pp; Japanese.
XX CC The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 143 TGAAGGCACAAATGCTGGAG 162
Db 1 TGCAGGCACAACACTACTGGAG 20
RESULT 149
ADK95418/c
ID ADK95418 standard; DNA; 20 BP.
XX AC ADK95418;
XX DT 06-MAY-2004 (first entry)
XX DE Primer of the invention #1138.
XX KW human; single nucleotide polymorphism; SNP; ss; primer.
XX OS Synthetic.
XX PN JP2003259875-A.
XX PD 16-SEP-2003.
XX PF 08-MAR-2002; 2002JP-00064373.
XX PR 08-MAR-2002; 2002JP-00064373.
XX PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX DR WPI; 2004-093977/10.
XX CC Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX PS Claim 2; SEQ ID NO 4447; 2627pp; Japanese.
XX CC The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
```

```
XX SQ Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 691 GTCCTGGTCTTCGACGAGT 710
Db 20 GTCCTGGTTCGACGAGT 1
RESULT 150
ADJ22418/c
ID ADJ22418 standard; DNA; 20 BP.
XX AC ADJ22418;
XX DT 20-MAY-2004 (first entry)
XX DE Human endothelial lipase antisense oligonucleotide, SEQ ID 816.
XX KW Antilipemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW Cardiovascular disorder; metabolic syndrome X; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..20 /tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX PN WO2004009541-A2.
XX PD 29-JAN-2004.
XX PF 18-JUL-2003; 2003WO-US022410.
XX PR 19-JUL-2002; 2002US-0397106P.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Bhat BG;
XX DR WPI; 2004-132912/13.
XX PT New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
XX PS Claim 3; SEQ ID NO 816; 1007pp; English.
XX CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX SQ Sequence 20 BP; 3 A; 11 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 197 GGGCCATGGGGAGGCTATA 216
 |||||
 Db 20 GGGGCTGGGGAGGCTATA 1
 |||||
 RESULT 151
 ADL15530/c
 ID ADL15530 standard; DNA; 20 BP.
 XX
 AC ADL15530;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE PCR primer 40 used during mutational analysis of human nephroretinin.
 XX
 KW nephroretinic; nephroretinin; nephroretinin-4; NPHP4; gene therapy;
 KW cystic kidney disease; human; ss; PCR; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO2004018702-A2.
 XX
 PD 04-MAR-2004.
 XX
 PF 26-AUG-2003; 2003WO-US026507.
 XX
 PR 26-AUG-2002; 2002US-0406001P.
 XX
 PA (UNMI) UNIV MICHIGAN.
 XX
 PI Hildebrandt F, Otto E, Hoesfele J, Ruf R, Mueller AM, Hiller KS;
 PI Wolf MTF, Schuermann MJ, Becker A;
 DR WPI; 2004-226861/21.
 XX
 PT New isolated and purified nucleic acid encoding nephroretinin or
 PT nephrocystin-4, useful for treating cystic kidney disease or for drug
 PT screening applications.
 PS Example 1; SEQ ID NO 62; 175pp; English.
 XX
 CC The invention relates to a novel isolated and purified nucleic acid. The
 CC nucleic acid of the invention demonstrates nephrotropic activity and may
 CC be useful for drug screening applications for compounds that alter
 CC signaling within the nephroretinin (nephrocystin-4; NPHP4) pathway, as
 CC well as in yeast two-hybrid screening assays and gene therapy. The
 CC nucleic acid may also be used for treating cystic kidney disease. The
 CC current sequence is that of a PCR primer used during mutational analysis
 CC of human nephroretinin of the invention.
 XX
 SQ Sequence 20 BP; 3 A; 2 C; 9 G; 6 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 232 CAAGACAAACCTCTGCCCC 251
 |||||
 Db 20 CAAGAAACCTCTGTCCCC 1
 |||||
 RESULT 152
 ADM14267
 ID ADM14267 standard; DNA; 20 BP.
 XX
 AC ADM14267;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:454.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;

KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulatory; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 PN WO2004028458-A2.
 XX
 PD 08-APR-2004.
 XX
 PF 25-SEP-2003; 2003WO-US030374.
 XX
 PR 25-SEP-2002; 2002US-0413549P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Gierse JK;
 XX
 DR WPI; 2004-305094/28.
 XX
 PT New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 PS Claim 4; SEQ ID NO 454; 132pp; English.
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nontropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 245 TGGCCCCACCTCCCCAGGT 264
 Db 1 TGGCCCGCAGCTTCCCCAGGT 20

RESULT 153
 ADO52746
 ID ADO52746 standard; DNA; 20 BP.
 AC ADO52746;
 XX
 XX
 XX 15-JUL-2004 (first entry)
 XX
 DE Farnesoid X receptor gene expression antisense inhibitory oligo #119.
 XX ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
 KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
 KW neuroprotective; vasotropic; antisense; gene therapy;
 KW Farnesoid X receptor; diabetes; immunological disorder;
 KW cardiovascular disorder; dyslipidemia; atherosclerosis;
 KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
 KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
 KW ischemia; reperfusion; diagnostics; prophylaxis.
 XX
 XX Homo sapiens.
 OS
 XX WO2004030750-A1.
 PN
 XX 15-APR-2004.
 PD
 XX 25-SEP-2003; 2003WO-US030353.
 PF
 XX 25-SEP-2002; 2002US-0413588P.
 PR
 XX (PHAA) PHARMACIA CORP.
 PA
 XX Kane CD;
 PI
 XX WPI; 2004-347928/32.
 DR
 XX New antisense oligonucleotides useful for modulating expression of
 PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
 PT e.g. diabetes, immunological disorders, cardiovascular disorders,
 PT gallstones or obesity.
 XX
 XX Claim 4; SEQ ID NO 119; 150pp; English.
 PS
 XX The invention relates to an antisense compound 8-30 nucleobases in length
 CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
 CC where the antisense compound specifically hybridizes with and inhibits
 CC the expression of FXR. The composition and methods are useful for
 CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
 CC tissues, or for treating diseases or conditions associated with FXR, such
 CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
 CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
 CC lipoprotein), elevated LDL (low density lipoprotein) or
 CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
 CC neurological disorders, or ischemia/reperfusion injury. In addition, the
 CC composition is used for diagnostics, prophylaxis, or as research reagents
 CC or kits. This sequence corresponds to an antisense oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1042 ATCTTCATGCTGCTGCTCAT 1061
 Db 1 ATCTGCATGCTGCTTCACAT 20

RESULT 154
 ACC42397/c
 ID ACC42397 standard; DNA; 15 BP.
 XX
 XX ACC42397;
 AC
 XX 26-AUG-2003 (first entry)
 DT
 XX Human acyl CoA cholesterol acyltransferase-2 PCR primer #2.
 DE
 XX
 XX Acyl CoA cholesterol acyltransferase-2; antisense therapy; antilipemic;
 KW antiarteriosclerotic; cardiovascular; ACAT-2; lipid metabolism;
 KW cholesterol metabolism; atherosclerosis; cardiovascular disease;
 KW phosphorothioate; human; PCR; primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2003011889-A2.
 PN
 XX 13-FEB-2003.
 PD
 XX 15-JUL-2002; 2002WO-US022746.
 PF
 XX 30-JUL-2001; 2001US-00918026.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Crooke RM, Graham MJ, Lemonidis KM;
 PI
 XX WPI; 2003-248145/24.
 DR
 XX New antisense oligonucleotides for modulating acyl CoA cholesterol
 PT acyltransferase-2, e.g. for preventing or treating diseases associated
 PT with abnormal lipid or cholesterol metabolism, atherosclerosis,
 PT cardiovascular disease.
 XX
 XX Example 13; Page 85; 112pp; English.
 PS
 XX The present invention relates to novel antisense oligonucleotides which
 CC are targeted to human acyl CoA cholesterol acyltransferase-2 (ACAT-2)
 CC nucleotide sequence (ACC42409-ACC42431), and mouse ACAT-2 (ACC42432-
 CC ACC42457). The antisense oligonucleotides specifically hybridize with and
 CC inhibit the expression of ACAT-2 nucleotide sequences (ACC42395 and
 CC ACC42402). ACAT enzymes catalyze the synthesis of cholesterol esters from
 CC free cholesterol and fatty acyl-CoA. The antisense oligonucleotides are
 CC useful for treating an animal which has a disease or condition associated
 CC with ACAT-2, e.g. a condition involving abnormal lipid metabolism, a
 CC condition involving abnormal cholesterol metabolism, atherosclerosis, or
 CC cardiovascular disease. The present sequence is a PCR primer for human
 CC ACAT-2, used in an example from the invention
 XX
 XX Sequence 15 BP; 4 A; 6 C; 5 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 74;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1238 TCCTTGGTCCCGGG 1252
 Db 15 TCCTTGGTCCCGGG 1
 RESULT 155
 AAV97364/c
 ID AAV97364 standard; RNA; 17 BP.
 XX
 XX AAV97364;
 AC
 XX 17-MAR-1999 (first entry)
 DT
 XX Human EGF-R target sequence nucleotide position 1277.
 DE
 XX Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;

KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.
XX Homo sapiens.
XX WO9833893-A2.
XX
XX PD 06-AUG-1998.
XX
XX PF 14-JAN-1998; 98WO-US000730.
XX
XX 31-JAN-1997; 97US-0036476P.
PR 04-DEC-1997; 97US-00985162.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (UYAS-) UNIV ASTON.
XX
XX Akhtar S, Fell P, Mcswiggen JA;
PI WPI; 1998-437449/37.
XX
DR Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT growth factor receptor, useful for inhibiting cell proliferation and for
PT treating cancers.
XX
XX Claim 5; Page 71; 109pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules (NAMS)
CC which specifically cleave RNA derived from an epidermal growth factor
CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAMS are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAMS can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell
XX
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CTGATCGAGGTCGAG 354
DB 15 CTGATCGAGGTCGAG 1
RESULT 156
ACD55428/c
ID ACD55428 standard; RNA; 17 BP.
XX
AC ACD55428;
XX
DT 23-SEP-2003 (first entry)
XX
DE HBV amberzyme substrate sequence #49.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN WO200281494-A1.
XX

PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY J.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
DR Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 203; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 AGGTTCCCTTGAGCAG 275
DB 15 AGGTTCCCTTGAGCAG 1
RESULT 157
ACD51912/c
ID ACD51912 standard; RNA; 17 BP.
XX
AC ACD51912;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV inozyme substrate sequence #144.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;

KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW viricide; antiinflammatory; substrate; ss.
XX Hepatitis B virus.
XX
XX
XX WO200281494-A1.
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX 08-JUN-2001; 2001US-00877478.
XX 08-JUN-2001; 2001US-0296876P.
XX 24-OCT-2001; 2001US-0335059P.
XX 05-DEC-2001; 2001US-0337055P.
XX (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MACE/) MACEJAK D.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (MORR/) MORRISSEY D.
XX PA (PAVC/) PAVCO P.
XX PA (LEEP/) LEE P.
XX PA (DRAP/) DRAPER K.
XX PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.
XX
XX Example 1; Page 152; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX as oligonucleotides that specifically bind the Enhancer I region of HBV
XX DNA. The nucleic acids may be used to modulate the expression of HBV
XX genes and HBV viral replication. Also disclosed is a method for screening
XX compounds and/or potential therapies directed against HBV, and compounds
XX that modulate the expression and/or replication of HCV. The compounds and
XX methods of the invention are useful for the treatment of degenerative and
XX disease states related to HBV and HCV infection, replication and gene
XX expression such as cirrhosis, liver failure, and hepatocellular
XX carcinoma. The present sequence represents a substrate for one of the HBV
XX ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
XX disclosed in the present invention
XX
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 263 GTTCCTTGAGCAGGA 277
Db 17 GTTCCTTGAGCAGGA 3
RESULT 158

ADD20913
ID ADD20913 standard; DNA; 17 BP.
XX
XX ADD20913;
AC
XX 15-JAN-2004 (first entry)
DT
XX
XX Human GAP_N DNA 17-mer oligo #145.
DE
XX
XX Gene therapy; antibody therapy; modulator of GAPN;
KW GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
KW
XX Homo sapiens.
OS
XX WO2003033703-A2.
FN
XX 24-APR-2003.
PD
XX 11-OCT-2002; 2002WO-US032597.
PF
XX 15-OCT-2001; 2001US-0330323P.
PR
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
PA
XX Zhang J;
PI
XX
XX WPI; 2003-403224/38.
DR
XX
XX Novel human GTP-activator protein for Rab-like GTPase and polynucleotide
PT encoding the protein, useful for diagnosing, treating or preventing
PT disorders associated with increased expression or activity of the
PT protein.
PT
XX Example 2; SEQ ID NO 169; 149pp; English.
XX
XX The invention relates to an isolated human GTP-activator protein for Rab-
CC like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to
CC (I), a sequence in which at least 95% of deviations from (I) are
CC conservative substitutions, or a fragment of at least 8 contiguous amino
CC acids of (I). The polypeptide is useful for identifying a specific
CC binding partner for itself, by contacting the polypeptide in vivo to a
CC potential binding partner and determining if the polypeptide binding
CC partner binds to the polypeptide. (I) and a nucleic acid encoding the
CC polypeptide (II) are useful for diagnosing or monitoring a disease caused
CC by altered expression of GAPN, by determining the level of expression of
CC GAPN in a sample of nucleic acids or proteins that derives from a subject
CC suspected to have the disease, alterations from a normal level of
CC expression providing diagnostic and/or monitoring information. (I), (II)
CC or agonist of (I) is useful for treating or preventing a disorder
CC associated with decreased expression or activity of GAPN, and an
CC antagonist of (I) is useful for treating or preventing a disorder
CC associated with increased expression or activity of GAPN (all claimed).
CC (I) is useful as immunogen to raise antibodies that specifically
CC recognize GAPN proteins. (II) is useful to drive in vivo expression of
CC GAPN proteins, and as hybridization probes to detect, characterize and
CC quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both
CC genomic and transcript-derived nucleic acid samples. This sequence
CC represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.
XX
XX Sequence 17 BP; 2 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 801 TTTCCTCAGCTACCT 815
Db 1 TTTCCTCAGCTACCT 15
RESULT 159
ADD20912
ID ADD20912 standard; DNA; 17 BP.

```

XX AC ADD20912;
XX DT 15-JAN-2004 (first entry)
XX DE Human GAP_N DNA 17-mer oligo #144.
XX KW gene therapy; antibody therapy; modulator of GAPN;
XX KW GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
XX OS Homo sapiens.
XX PN WO2003033703-A2.
XX PD 24-APR-2003.
XX PF 11-OCT-2002; 2002WO-US032597.
XX PP 15-OCT-2001; 2001US-0330323P.
XX PR (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX PA Zhang J;
XX PI WPI; 2003-403224/38.
XX DR Novel human GTP-activator protein for Rab-like GTPase and polynucleotide
XX PT encoding the protein, useful for diagnosing, treating or preventing
XX PT disorders associated with increased expression or activity of the
XX PT protein.
XX PS Example 2; SEQ ID NO 168; 149pp; English.
XX CC The invention relates to an isolated human GTP-activator protein for Rab-
XX CC like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to
XX CC (I), a sequence in which at least 95% of deviations from (I) are
XX CC conservative substitutions, or a fragment of at least 8 contiguous amino
XX CC acids of (I). The polypeptide is useful for identifying a specific
XX CC binding partner for itself, by contacting the polypeptide in vivo to a
XX CC potential binding partner and determining if the polypeptide binding
XX CC partner binds to the polypeptide. (I) and a nucleic acid encoding the
XX CC polypeptide (II) are useful for diagnosing or monitoring a disease caused
XX CC by altered expression of GAPN, by determining the level of expression of
XX CC GAPN in a sample of nucleic acids or proteins that derives from a subject
XX CC suspected to have the disease, alterations from a normal level of
XX CC expression providing diagnostic and/or monitoring information. (I), (II)
XX CC or agonist of (I) is useful for treating or preventing a disorder
XX CC associated with decreased expression or activity of GAPN, and an
XX CC antagonist of (I) is useful for treating or preventing a disorder
XX CC associated with increased expression or activity of GAPN, and an
XX CC (I) is useful as immunogen to raise antibodies that specifically
XX CC recognize GAPN proteins. (II) is useful to drive in vivo expression of
XX CC GAPN proteins, and as hybridization probes to detect, characterize and
XX CC quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both
XX CC genomic and transcript-derived nucleic acid samples. This sequence
XX CC represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.
XX SQ Sequence 17 BP; 2 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 TTTCTCCAGCTACCT 815
Db 2 TTTCTCCAGCTACCT 16

RESULT 160
ADD20911
ID ADD20911 standard; DNA; 17 BP.
XX AC ADD20911;

```

```

XX DT 15-JAN-2004 (first entry)
XX DE Human GAP_N DNA 17-mer oligo #143.
XX KW gene therapy; antibody therapy; modulator of GAPN;
XX KW GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
XX OS Homo sapiens.
XX PN WO2003033703-A2.
XX PD 24-APR-2003.
XX PF 11-OCT-2002; 2002WO-US032597.
XX PP 15-OCT-2001; 2001US-0330323P.
XX PR (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX PA Zhang J;
XX PI WPI; 2003-403224/38.
XX DR Novel human GTP-activator protein for Rab-like GTPase and polynucleotide
XX PT encoding the protein, useful for diagnosing, treating or preventing
XX PT disorders associated with increased expression or activity of the
XX PT protein.
XX PS Example 2; SEQ ID NO 167; 149pp; English.
XX CC The invention relates to an isolated human GTP-activator protein for Rab-
XX CC like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to
XX CC (I), a sequence in which at least 95% of deviations from (I) are
XX CC conservative substitutions, or a fragment of at least 8 contiguous amino
XX CC acids of (I). The polypeptide is useful for identifying a specific
XX CC binding partner for itself, by contacting the polypeptide in vivo to a
XX CC potential binding partner and determining if the polypeptide binding
XX CC partner binds to the polypeptide. (I) and a nucleic acid encoding the
XX CC polypeptide (II) are useful for diagnosing or monitoring a disease caused
XX CC by altered expression of GAPN, by determining the level of expression of
XX CC GAPN in a sample of nucleic acids or proteins that derives from a subject
XX CC suspected to have the disease, alterations from a normal level of
XX CC expression providing diagnostic and/or monitoring information. (I), (II)
XX CC or agonist of (I) is useful for treating or preventing a disorder
XX CC associated with decreased expression or activity of GAPN, and an
XX CC antagonist of (I) is useful for treating or preventing a disorder
XX CC associated with increased expression or activity of GAPN (all claimed).
XX CC (I) is useful as immunogen to raise antibodies that specifically
XX CC recognize GAPN proteins. (II) is useful to drive in vivo expression of
XX CC GAPN proteins, and as hybridization probes to detect, characterize and
XX CC quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both
XX CC genomic and transcript-derived nucleic acid samples. This sequence
XX CC represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.
XX SQ Sequence 17 BP; 2 A; 6 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 TTTCTCCAGCTACCT 815
Db 3 TTTCTCCAGCTACCT 17

RESULT 161
ADM60110/c
ID ADM60110 standard; RNA; 17 BP.
XX AC ADM60110;
XX DT 03-JUN-2004 (first entry)

```

```
XX Hepatitis B virus (HBV) RNA target sequence #2244.
DE
XX
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX
XX 15-JAN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 2244; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 AGTTCCTTGAGCAG 275
DB 15 AGTTCCTTGAGCAG 1
RESULT 162
ADM58711/c
ID ADM58711 standard; RNA; 17 BP.
XX
XX ADM58711;
AC
XX 03-JUN-2004 (first entry)
DT
XX
```

```
DE Hepatitis B virus (HBV) RNA target sequence #845.
XX
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX
XX 15-JAN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 845; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 263 GTTCTTGAGCAGGA 277
DB 17 GTTCTTGAGCAGGA 3
RESULT 163
AAK55895/c
ID AAK55895 standard; DNA; 18 BP.
XX
XX AAK55895;
AC
XX 08-JUL-1999 (first entry)
DT
XX Hepatitis B virus classification probe SEQ ID NO:14.
DE
```

```
XX Hepatitis B virus; HBV; classification; probe; S gene; infection;
KW genotyping; gdw1; gdw2; ss.
XX
XX Synthetic.
OS Hepatitis B virus.
XX
XX JP11103898-A.
XX
XX 20-APR-1999.
XX
XX 30-SEP-1997; 97JP-00282784.
XX
XX 30-SEP-1997; 97JP-00282784.
XX (SRLS-) SRL KK.
XX
XX WPI; 1999-305861/26.
XX
XX New primer and probes - useful for classification of the type of
PT hepatitis B virus.
XX
XX Claim 22; Page 12; 17pp; Japanese.
XX
XX The present invention describes classification of the type of hepatitis B
CC virus (HBV) involving checking if the 22nd nucleotide (22nt) in the S
CC gene is cytosine, to distinguish the gdw2 type of HBV from other types.
CC Also described are: (1) a method as above for distinguishing the gdw2
CC type gene, involving checking if the 166nt, 169nt, 176nt and 390nt are
CC adenine, thymine, guanine or cytosine respectively; (2) a method as above
CC for distinguishing the gdw1 type gene, involving checking if the 392nt is
CC adenine; (3) a method as above for distinguishing the gdw type gene
CC involving checking if the 401nt is adenine; and (4) a method as above for
CC distinguishing the gdr type gene involving checking if the 328nt is
CC cytosine and if the 337nt is adenine. The method can classify HBV easily
CC to match with clinical symptoms. The present sequence represents a probe
CC for use in the method of the invention
XX
XX Sequence 18 BP; 5 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 261 AGGTCCTTGAGCAG 275
DB 15 AGGTCCTTGAGCAG 1
RESULT 164
AAZ37843
ID AAZ37843 standard; DNA; 18 BP.
AC AAZ37843;
XX
XX 15-FEB-2000 (first entry)
DT
DE
DE PCR primer #2 from set A for amplification of EGFR gene from tumours.
KW Epidermal growth factor receptor; EGFR; deletion mutant; glioma; tumour;
KW breast cancer; lung cancer; detect; PCR primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX US5981725-A.
XX
XX 09-NOV-1999.
XX
XX 07-JUN-1995; 95US-00479808.
XX
XX 08-SEP-1989; 89US-00404226.
PR 01-JUN-1990; 90US-00531410.
FT
```

```
PR 11-JUN-1992; 92US-00896909.
XX (UYDU-) UNIV DUKE.
XX (UYJO ) UNIV JOHNS HOPKINS.
XX
XX Bigner D, Vogelstein B;
XX
XX WPI; 1999-633374/54.
XX
XX Intron free DNA molecule encoding a mutant epidermal growth factor
PT receptor is useful in the diagnosis of tumors.
XX
XX Example; Col 22; 43pp; English.
XX
XX PCR primers AAZ37842-Z37845 are used in the amplification of epidermal
CC growth factor receptor (EGFR) cDNA from tumour cells. These primers are
CC used to identify EGFR deletion mutant. Deletions in the EGFR gene are
CC found in many gliomas, breast tumours and lung tumours. The nucleotide
CC and amino acid sequence (AAZ37841 and Y5189) of the type II EGFR deletion
CC mutant are used in the invention to create vectors containing the
CC nucleotide sequence, which can be used to transform cells, and to create
CC probes for the type II EGFR mutant. The invention also relates to a kit
CC for detecting type II mutants. A cell sample taken from an individual can
CC be screened for the presence of a tumour, in particular breast cancer,
CC lung cancer or gliomas using probes for type II mutant EGFR. The probes
CC can be radiolabelled or labelled with fluorescent material and
CC hybridization to a deletion-specific probe indicates the presence of the
CC deletion associated with the tumour. Diagnosis could also be carried out
CC using a polymerase chain amplification technique. The sequences can also
CC be used for the generation of antibodies which can be used to treat these
CC tumours
XX
XX Sequence 18 BP; 4 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 340 CTGATGGAGGTGCAG 354
DB 3 CTGATGGAGGTGCAG 17
RESULT 165
AAZ12117/c
ID AAD12117 standard; DNA; 20 BP.
XX
XX AAD12117;
XX
XX 25-SEP-2001 (first entry)
DT
DE Rat PTP1B antisense oligonucleotide (ISIS# 113721).
XX
XX Rat; PTP1B; protein phosphatase 1B inhibitor; antisense; gene therapy;
KW infection; inflammation; tumour; prophylaxis; phosphorothioate; ss.
XX
XX Rattus norvegicus.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Methoxyethyl residues"
FT modified_base 4..5
FT /*tag= d
FT /mod_base= m5c
FT modified_base 16..20
FT /*tag= c
FT
```



```
FT /mod_base= OTHER
FT /note= "Methoxyethyl residues"
FT modified_base
FT 19
FT /tag= e
FT /mod_base= m5c
XX
XX
PN US6261840-B1.
XX
XX 17-JUL-2001.
XX
XX 18-JAN-2000; 2000US-00487368.
XX
XX 18-JAN-2000; 2000US-00487368.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowseert LM, Wyatt J;
XX
XX WPI; 2001-432181/46.
XX
XX New antisense compounds capable of modulating expression of human protein
PT phosphatase 1B, useful for diagnosis, prophylaxis and treatment of
PT diseases associated with expression of protein phosphatase.
XX
XX Example 17; Col 51-52; 71pp; English.
XX
XX The invention is directed to antisense compounds, particularly
CC oligonucleotides which are targeted to a DNA encoding protein
CC phosphatase 1B (PTP1B) to modulate its expression. The antisense
CC compounds are useful for diagnosis, prophylaxis and treatment of diseases
CC associated with the expression of PTP1B, to prevent or delay infection,
CC inflammation and tumour formation and as a research reagent. The PTP1B
CC DNA is useful in gene therapy. The present sequence is an antisense
CC oligonucleotide with a phosphorothioate backbone. This oligo is targeted
CC to rat PTP1B to inhibit its expression
XX
XX Sequence 20 BP; 2 A; 3 C; 13 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 245 TGCCCCCACCTCCCC 259
Db 20 TGCCCCCACCTCCCC 6
RESULT 166
AAD36657
ID AAD36657 standard; DNA; 20 BP.
XX
AC AAD36657;
XX
XX 09-AUG-2002 (first entry)
XX
XX Human Her-1 antisense oligonucleotide ISIS #128531.
XX
XX Human; epidermal growth factor receptor; hyperproliferative disease;
KW Her1; antisense; prophylaxis; psoriasis; phosphorothioate backbone;
KW tumour; cancer; ss.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
```

```
FT modified_base 2
FT /tag= d
FT /mod_base= m5c
FT modified_base 3
FT /tag= e
FT /mod_base= m5c
FT modified_base 5
FT /tag= f
FT /mod_base= m5c
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 17
FT /tag= g
FT /mod_base= m5c
XX
XX WO200226758-A1.
XX
XX 04-APR-2002.
XX
XX 28-SEP-2001; 2001WO-US030551.
XX
XX 29-SEP-2000; 2000US-00676610.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Wyatt JR, Freier SM;
XX
XX WPI; 2002-394234/42.
XX
XX Novel antisense oligonucleotide that specifically hybridizes with and
PT inhibits nucleic acid encoding epidermal growth factor receptor, useful
PT for treating hyperproliferative disease such as cancer or psoriasis.
XX
XX Claim 1; Page 47; 169pp; English.
XX
XX The invention relates to an antisense oligonucleotide targeted to a
CC nucleic acid molecule encoding human epidermal growth factor receptor
CC (Her1) to inhibit its expression. The antisense compounds are useful for
CC treating diseases or conditions associated with Her-1 such as
CC hyperproliferative diseases especially cancer (lung, ovarian, colon or
CC prostate cancer) and psoriasis. They are also useful as research
CC reagents, diagnostics, therapeutics, kits and prophylactically e.g. to
CC prevent or delay tumour formation. The present sequence is an antisense
CC oligonucleotide targeted to human Her-1
XX
XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CTGATGGAGGTGCAG 354
Db 5 CTGATGGAGGTGCAG 19
RESULT 167
ABK85192/c
ID ABK85192 standard; DNA; 20 BP.
XX
XX ABK85192;
XX
XX 13-AUG-2002 (first entry)
XX
XX Rat PTPB1 antisense oligonucleotide ISIS 113721.
XX
XX Antisense; protein phosphatase 1B; PTP1B; ss; probe; rat;
KW type 2 diabetes; obesity; ovarian cancer; chronic myeloid leukaemia;
KW hyperproliferative disease; antidiabetic; anorectic; cytostatic;
KW blood glucose; gene therapy.
XX
```


XX WO2003031594-A2.
XX 17-APR-2003.
XX 11-OCT-2002; 2002WO-US032700.
XX 11-OCT-2001; 2001US-0328424P.
XX (GENO-) GENOME THERAPEUTICS CORP.
XX Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG;
XX Allen K;
XX WPI; 2003-381712/36.
XX New isolated nucleic acid or alternate splice variant, useful for
XX diagnosing and treating a disintegrin and metalloprotease (ADAM) or
XX interactor gene-associated disorder, e.g. asthma, atopy, obesity or
XX inflammatory bowel disease.
XX Claim 2; Page 130; 338pp; English.
XX The invention relates to an isolated nucleic acid or alternate splice
XX variant comprising a nucleotide sequence containing at least one of the
XX single nucleotide polymorphisms given in the specification, a nucleotide
XX sequence having at least 15 contiguous nucleotides of them, or
XX complements of them. The genes are ADAM19 (a disintegrin and
XX metalloprotease 19, also known as gene 845), NRG2 (neuregulin 2, also
XX known as gene 847), endophilin 1 (also known as gene 874), endophilin 2
XX (also known as gene 803) and ADAMTS2 (a disintegrin and metalloprotease
XX with thrombospondin type motif 2, also known as gene 962). Also included
XX are a vector comprising the isolated nucleic acid (or alternate splice
XX variant), a host cell containing the vector, an isolated polypeptide
XX encoded by the novel nucleic acid (or alternate splice variant), an
XX antibody or antibody fragment that binds to the polypeptide, an
XX pharmaceutical compositions (comprising the nucleic acid or alternate
XX splice variant, vector, polypeptide or antibody, and a carrier,
XX excipient or diluent), a kit for detecting a disintegrin and
XX metalloprotease (ADAM) gene nucleotide sequence (comprising the isolated
XX nucleic acid or alternate splice variant, antibody or antibody fragment,
XX and at least one component to detect the hybridisation of the variant or
XX the binding of the antibody to an ADAM gene amino acid sequence), a kit
XX for detecting an interactor gene amino acid sequence (comprising the
XX antibody or antibody fragment, and at least one component to detect the
XX binding of the antibody to the interactor gene amino acid sequence),
XX diagnosing an ADAM or interactor gene-associated disorder or a
XX respiratory disorder in a human subject, determining an ADAM or
XX interactor gene pharmacogenetic profile in a human subject, identifying
XX an orthologue of a human ADAM or interactor gene, treating an ADAM or
XX interactor gene-associated disorder (or a respiratory disorder) by
XX administering the pharmaceutical composition, a transgenic mouse (whose
XX genome comprises an introduced null mutation in an endogenous gene that
XX is orthologous to a human ADAM gene), making a homozygous transgenic
XX knockout mouse, forming a crystal of the isolated polypeptide, a cell
XX line comprising the isolated nucleic acid or alternate splice variant, a
XX biochip comprising the isolated nucleic acid or alternate splice variant,
XX an isolated nucleic acid probe or primer comprising at least 8 contiguous
XX nucleotides of the nucleic acid, an isolated antisense nucleic acid,
XX identifying an ADAM or interactor gene ligand and an isolated nucleic
XX acid variant of Gene 803, 845, 847, 874 or 962. The nucleic acid or
XX alternate splice variants, methods, kits and antibody/antibody fragment
XX are useful for diagnosing and treating an ADAM or interactor gene-
XX associated disorder, e.g. asthma, atopy, obesity or inflammatory bowel
XX disease. The present sequence is a primer used to sequence the regions
XX surrounding polymorphisms in the above genes.

XX Sequence 20 BP; 8 A; 4 C; 7 G; 1 T; 0 U; 0 Other;
XX Query Match 1.0%; Score 15; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 31 CAGAGGACAGAGGG 45
DB 5 CAGAGGACAGAGGG 19
RESULT 170
AD113922/c
ID AD113922 standard; DNA; 20 BP.
XX AC AD113922;
XX 22-APR-2004 (first entry)
XX Antisense DNA oligo to target rat PTP1B DNA SeqID 174.
XX rat; ss; antisense; PTP1B; protein phosphatase 1B; PTPN1;
XX phosphorothioate backbone; hyperproliferative condition; cancer;
XX cytostatic; antidiabetic; anorectic; type 2 diabetes; obesity.
XX OS Rattus norvegicus.
XX Synthetic.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
XX nucleobases are 5' methycytidine."
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
XX nucleobases are 5' methycytidine."
XX US2003220282-A1.
XX 27-NOV-2003.
XX 07-FEB-2003; 2003US-00360510.
XX 18-JAN-2000; 2000US-00487368.
XX 31-JUL-2000; 2000US-00629644.
XX 14-MAY-2001; 2001US-00854883.
XX (ISIS-) ISIS PHARM INC.
XX Bhanot S, Cowser LM, Wyatt JR, Monia BP, Butler MM, McKay R;
XX Freier SM;
XX WPI; 2004-051719/05.
XX New compounds, particularly antisense oligonucleotides targeted to a
XX nucleic acid encoding PTP1B, useful for treating a disease/condition
XX associated with PTP1B, such as cancer, diabetes or obesity.
XX Example 16; SEQ ID NO 174; 143pp; English.
XX This invention relates to novel compositions and methods for modulating
XX the expression of PTP1B (also known as protein phosphatase 1B and PTPN1).
XX Specifically, it refers to antisense compounds that can target and
XX hybridise with a nucleic acid molecule encoding PTP1B, as well as splice
XX variants thereof and inhibit expression accordingly. PTP1B is a tyrosine
XX phosphatase that plays an essential regulatory role in signalling
XX mediated by the insulin receptor and as such is useful for treating
XX diseases such as type 2 diabetes and obesity. Furthermore, PTP1B can
XX suppress transformation of oncogenic genes, such that compositions of
XX this invention can also be used to treat hyperproliferative conditions
XX including cancer. Accordingly, these compounds can be described as having
XX cytostatic, antidiabetic and anorectic activities. This oligonucleotide

CC sequence is an antisense DNA oligo that targets rat PTP1B DNA, and which
CC has a phosphorothioate backbone and 2'-O-methoxyethyl wings, used in an
CC exemplification of the invention.

XX SQ Sequence 20 BP; 2 A; 3 C; 13 G; 2 T; 0 U; 0 Other;
Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCAGCTCC 259
20 TGCCCCCAGCTCC 6

Db RESULT 171
ABS54291/c
ID ABS54291 standard; DNA; 18 BP.
XX AC ABS54291;
XX DT 05-DEC-2002 (first entry)
XX DE Pig beta-actin cDNA, PCR primer #2.
XX KW Pig; tissue repair; progenitor cell; bioresorbable bead; chondrocyte;
KW gel forming substance; embryonic stem cell; bone marrow stromal cell;
KW tissue damage; articular cartilage degeneration; primary osteoarthritis;
KW articular cartilage damage; sporting injury; tissue augmentation; trauma;
KW cosmetic; scar; facial wrinkle; tissue growth; osteopathic;
KW antiarthritic; dermatological; PCR; primer; ss; beta-actin.
XX OS Sus sp.
XX FN WO200262357-A1.
XX PD 15-AUG-2002.
XX PF 04-FEB-2002; 2002WO-AU000106.
XX PR 05-FEB-2001; 2001AU-00002896.
XX PA (CSIR) COMMONWEALTH SCI & IND RES ORG.
XX PA (INTE-) IND TECHNOLOGY RES INST.
XX PI Werkmeister JA, Tsai W, Ramshaw JAM, Thissen HW, Chang K;
XX WPI; 2002-723146/78.
XX DR New device having tissue-like characteristics, useful for treating
XX PT diseased or damaged tissue, e.g. articular cartilage degeneration
XX PT associated with primary osteoarthritis, or for tissue augmentation for
XX PT cosmetic purposes.
XX PS Example 20; Page 18; 52pp; English.
XX CC The present invention relates to methods and devices for tissue repair.
XX CC The devices have tissue-like characteristics for treating diseased or
XX CC damaged tissue or for augmenting tissue in a subject. The device
XX CC comprises cells of type(s) normally found in healthy tissue corresponding
XX CC to the diseased or damaged tissue or in the tissue to be augmented,
XX CC and/or its suitable progenitor cells in association with bioresorbable
XX CC beads or particles, and optionally a gel and/or gel forming substance.
XX CC The cells and/or suitable progenitor cells are chondrocytes, embryonic
XX CC stem cells, and/or bone marrow stromal cells. The devices and methods are
XX CC useful for treating diseased or damaged tissue in a subject, such as
XX CC articular cartilage degeneration associated with primary osteoarthritis,
XX CC or other articular cartilage damage caused by sporting injuries or
XX CC trauma. They are also useful for tissue augmentation for cosmetic
XX CC purposes, e.g. treatment of scars or facial wrinkles. The present devices
XX CC and methods provide treatment that is less traumatic than previous art.
XX CC The use of biodegradable polymers in the device offer advantages over non
XX CC -degradable polymers in that their gradual degradation steadily creates
XX CC room for tissue growth and eliminate the need for surgical removal of the
XX CC scaffolds following restoration of the articular cartilage. Another
XX CC advantage is its ability to be administered by injection if desired. The
XX CC beads or particles provide mechanical and space-filling benefits while
XX CC tissue regeneration is progressing, by offering physical support and
XX CC resistance to compression. The present sequence represents a PCR primer
XX CC used to amplify pig beta-actin cDNA, in the examples of the present
XX CC invention
XX SQ Sequence 18 BP; 3 A; 1 C; 11 G; 3 T; 0 U; 0 Other;

CC sequence is an antisense DNA oligo that targets rat PTP1B DNA, and which
CC has a phosphorothioate backbone and 2'-O-methoxyethyl wings, used in an
CC exemplification of the invention.

XX SQ Sequence 20 BP; 2 A; 3 C; 13 G; 2 T; 0 U; 0 Other;
Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCAGCTCC 259
20 TGCCCCCAGCTCC 6

Db RESULT 171
AAA99605
ID AAA99605 standard; DNA; 18 BP.
XX AC AAA99605;
XX DT 02-FEB-2001 (first entry)
XX DE Rat D4 receptor mRNA reverse transcription primer orD4-515.
XX KW Rat; D4 dopamine receptor; cardiovascular system; retinal tissue;
KW vasoregulator; primer; ss.
XX OS Rattus sp.
XX PN US6121015-A.
XX PD 19-SEP-2000.
XX PF 07-JUN-1995; 95US-00475742.
XX PR 28-JAN-1993; 93US-00014013.
XX PR 16-JUN-1994; 94US-00261293.
XX PA (UNIW) UNIV WASHINGTON.
XX PI Todd RD, O'malley KL;
XX WPI; 2000-655527/63.
XX CC Screening for compounds that selectively bind to a rat D4 dopamine
XX CC receptor (DDR), useful for identifying dopamine (ant)agonists, comprises
XX CC exposing cells transfected with a nucleic acid encoding the DDR to
XX CC candidate compounds.
XX PS Disclosure; Col 6; 29pp; English.
XX CC The present sequence is a primer which was used for reverse transcription
XX CC of rat RNA in order to study the tissue distribution of the rat D4
XX CC dopamine receptor mRNA. A cDNA encoding the rat D4 dopamine receptor was
XX CC expressed in transfected mammalian cells and shown to preferentially bind
XX CC dopamine antagonists such as clozapine. The cDNA is useful for screening
XX CC drugs which specifically bind to the receptor and have selective effects
XX CC on the cardiovascular and retinal tissues through interactions with
XX CC the receptor. Such compounds may act as vasoregulators or may have
XX CC ionotropic effects. The D4 receptor protein may be used for the
XX CC production of polyclonal or monoclonal antibodies which recognise the D4
XX CC receptor sequence but do not recognise other dopaminergic receptors. The
XX CC antibodies may be used in immunocytochemical studies and for
XX CC identification and isolation via flow sorting of D4 expressing cell types
XX SQ Sequence 18 BP; 2 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCCACCCTGTGGCG 540

```

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 989 CCTTACAGCACCCGTGGCC 1006
    ||||| ||||| |||||
Db 18 CCTTACAGCACCCGTGGCC 1

RESULT 173
ABX12225
ID ABX12225 standard; DNA; 18 BP.
XX
AC ABX12225;
XX
DT 16-MAY-2003 (first entry)
XX
DE Rat dopamine D4 receptor tissue distribution RT-PCR primer, orD4-515.
XX
KW Rat; ss; primer; dopamine; D4; D4 receptor; D4 dopamine receptor probe;
KW clozapine; RT-PCR; reverse transcription.
XX
OS Rattus norvegicus.
XX
PN US6486310-B1.
XX
PD 26-NOV-2002.
XX
PF 16-JUN-1994; 94US-00261293.
XX
PR 28-JAN-1993; 93US-00014013.
XX
PA (UNIW ) UNIV WASHINGTON.
XX
PI O'malley KL, Todd RD;
XX
KW WPI; 2003-310438/30.
XX
PT Novel nucleic acid molecule encoding rat D4 dopamine receptor, useful as
PT a probe for related D4 dopamine receptors.
XX
PS Example 1; Col 6; 33pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule encoding rat
CC D4 dopamine receptor. The rat D4 dopamine receptor binds dopamine
CC antagonists such as clozapine. The nucleic acid is useful as a probe for
CC related D4 dopamine receptors. The nucleic acid when expressed in cell
CC lines, is useful as an in vitro screen for drugs which specifically bind
CC to the receptor. Antibodies to the protein are useful in
CC immunocytochemical studies, identification and isolation via flow sorting
CC of D4 expressing cell types and in blocking or modifying the effects of
CC D4 agonists and/or antagonists. The present sequence represents the rat
CC dopamine D4 receptor reverse transcription (RT)-PCR primer. orD4-515,
CC used for tissue distribution studies of the rat dopamine D4 receptor.
XX
SQ Sequence 18 BP; 2 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCCACCCGTGTGGCG 540
    ||||| ||||| |||||
Db 1 CTGTCCACCCGTGTGGCG 18

RESULT 174
ADE38319
ID ADE38319 standard; DNA; 18 BP.
XX
AC ADE38319;
XX
DT 29-JAN-2004 (first entry)

```

```

XX
DE Beta-actin PCR primer SEQ ID NO:70.
XX
KW autoimmune disease; statin; antigen-specific immunomodulatory agent;
KW non-antigen-specific immunomodulatory agent; immunomodulatory;
KW antidiabetic; antiarthritic; vasotropic; gene therapy;
KW multiple sclerosis; insulin dependent diabetes mellitus; IDDM;
KW rheumatoid arthritis; autoimmune uveitis; PCR primer; ss.
XX
OS Synthetic.
XX
PN WO2003082269-A1.
XX
PD 09-OCT-2003.
XX
PF 31-MAR-2003; 2003WO-US009807.
XX
PR 29-MAR-2002; 2002US-0368803P.
XX
PA (STRD ) UNIV LELAND STANFORD JUNIOR.
PA (BAYH-) BAYHILL THERAPEUTICS INC.
XX
PI Garren H, Steinman L;
XX
KW WPI; 2003-803953/75.
XX
PT Treating an autoimmune disease by co-administering to a patient a statin
PT and an antigen-specific non-antigen-specific immunomodulatory agent.
XX
PS Example 1; SEQ ID NO 70; 90pp; English.
XX
CC The present invention describes a method for treating an autoimmune
CC disease comprising co-administering to a patient a statin and an antigen-
CC specific/non-antigen-specific immunomodulatory agent. The
CC immunomodulatory agent has antidiabetic, antiarthritic and vasotropic
CC activities, and can be used in gene therapy. The method is useful for
CC treating autoimmune disease e.g., multiple sclerosis, insulin dependent
CC diabetes mellitus (IDDM), rheumatoid arthritis or autoimmune uveitis. The
CC present sequence is used in the exemplification of the present invention.
XX
SQ Sequence 18 BP; 3 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1320 CGTCCTGGGGTCTTCTTA 1337
    ||||| ||||| |||||
Db 1 CGACCTGGGGATCTTCTTA 18

RESULT 175
ADF13584/c
ID ADF13584 standard; DNA; 18 BP.
XX
AC ADF13584;
XX
DT 12-FEB-2004 (first entry)
XX
DE 3-hydroxy-3-methylglutaryl coenzyme A synthase, BaySNP13191, PCR primer #6.
XX
KW Cardiant; antiarteriosclerotic; vasotropic; cerebroprotective;
KW hypotensive; gene therapy; human;
KW 3-hydroxy-3-methylglutaryl coenzyme A synthase; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003072813-A2.
XX
PD 04-SEP-2003.
XX
PF 14-FEB-2003; 2003WO-EP001514.
XX

```

PR 27-FEB-2002; 2002EP-00004258.
 XX (FARB) BAYER AG.
 XX
 PI Stropp U, Schwes S, Kallabis H;
 XX WPI; 2003-712738/67.
 DR
 XX New isolated polynucleotide encoded by a phenotype-associated gene,
 PT useful for prognosticating statin therapy response, and diagnosing or
 PT treating cardiovascular diseases, such as hypertension, myocardial
 PT infarction and stroke.
 XX
 XX Example 1; Page 72; 182pp; English.
 XX
 CC The present invention relates to human phenotype-associated (PA) genes (I
 CC ; ADF13307-ADFI3386) which contain a Single Nucleotide Polymorphism
 CC (SNP). The SNP is given in the sequence as a variant nucleotide. Also
 CC claimed are methods for screening for agents which regulate the activity
 CC of a PA gene and reagents that modulate the activity of a PA polypeptide
 CC or a polynucleotide where the reagent is identified by the screening
 CC methods. The methods and compositions of the present invention are useful
 CC for prognosticating, diagnosing and treating cardiovascular diseases,
 CC such as atherosclerosis, hypertension, restenosis, arterial inflammation,
 CC myocardial infarction and stroke. The present sequence is a PCR primer,
 CC used in the examples from the invention.
 XX
 SQ Sequence 18 BP; 6 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1065 CTTGCGCTTCCTCCATTG 1082
 DB 18 CATAGCGCTTCCTCCATTG 1
 RESULT 176
 ADF29053
 ID ADF29053 standard; DNA; 18 BP.
 AC ADF29053;
 XX
 XX 12-FEB-2004 (first entry)
 DT
 XX Rat dopamine D4 receptor related primer seq id 7.
 DE
 XX cardiovascular; ophthalmological; rat; D4 dopamine receptor;
 KW cardiovascular tissue; retinal tissue; neuronal morphology disorder;
 KW neuronal connection disorder; PCR; primer; ss.
 XX
 OS Unidentified.
 XX
 XX US2003118506-A1.
 PN
 XX 26-JUN-2003.
 PD
 XX 11-SEP-2002; 2002US-00241313.
 PF
 XX 28-JAN-1993; 93US-00014013.
 PR
 XX 16-JUN-1994; 94US-00261293.
 XX
 XX (UNIW) UNIV WASHINGTON.
 PA
 XX O'malley KL, Todd RD;
 PI
 XX WPI; 2004-009074/01.
 DR
 XX A new nucleic acid encoding a rat D4 dopamine receptor is useful to treat
 PT disorders of the cardiovascular or retinal tissue or prevent or treat
 PT disorders of neuronal morphology or connections.
 XX

PS Example 1; SEQ ID NO 7; 30pp; English.
 XX
 CC The invention describes an isolated nucleic acid encoding a rat D4
 CC dopamine receptor. The invention is useful to treat disorders of the
 CC cardiovascular or retinal tissue or prevent or treat disorders of
 CC neuronal morphology or connections. This sequence represents a primer
 CC used to isolate DNA encoding the rat dopamine D4 receptor.
 XX
 SQ Sequence 18 BP; 2 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 523 CTGTCCACCCCTGTGCG 540
 DB 1 CTGTCCACCGCTGATGCG 18
 RESULT 177
 ADM16806
 ID ADM16806 standard; DNA; 18 BP.
 AC ADM16806;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 XX Hepatitis B virus (HBV) genomic DNA, PCR primer HBV-S-F.
 DE
 XX Hepatitis B virus; HBV; covalently closed circular DNA; cccDNA;
 KW liver cell; anti-HBV therapy; liver biopsy; antiviral therapy; PCR;
 KW primer; ss.
 XX
 OS Hepatitis B virus.
 XX
 XX US2004058314-A1.
 PN
 XX 25-MAR-2004.
 PD
 XX 29-MAY-2003; 2003US-00449801.
 PF
 XX 29-MAY-2002; 2002US-0383953P.
 PR
 XX (HEML/) HE M L.
 PA (KUNG/) KUNG H.
 PA (LINW/) LIN M C M.
 XX
 PI He ML, Kung H, Lin MCW;
 XX
 XX WPI; 2004-338969/31.
 DR
 XX Specific detection of Hepatitis B virus (HBV) covalently closed circular
 PT (ccc) DNA from liver cell biopsies by real-time PCR, useful for guiding
 PT long-term anti-HBV therapy.
 PT
 XX
 XX Claim 15; SEQ ID NO 7; 17pp; English.
 PS
 XX
 CC The present invention relates to a method for detecting Hepatitis B virus
 CC (HBV) covalently closed circular (ccc) DNA. The method comprises
 CC obtaining a sample of liver cells infected with HBV cccDNA virus from a
 CC patient, preparing at least one primer for applying to at least one end
 CC of the HBV cccDNA virus, amplifying the HBV cccDNA virus by PCR using at
 CC least one primer, preparing at least one probe for applying to the HBV
 CC cccDNA virus genome, where the probe comprises a dye and a dye quencher,
 CC and conducting a second PCR to bind at least one primer to at least one
 CC probe so that the dye and the dye quencher in the probe are separated
 CC allowing the HBV cccDNA virus to be detected through the dye. Also
 CC disclosed is a kit for the detection of HBV cccDNA in a patient. The
 CC method of the invention is useful for detecting cccDNA of HBV in the form
 CC of a HBV cccDNA genome from an infected liver cell and for providing
 CC guidance to the patient undergoing long term anti-HBV therapy. The method
 CC is efficient, rapid, economical and highly sensitive in monitoring HBV
 CC cccDNA in infected human liver biopsies. The method is specific for HBV

CC cccDNA as viral genomic DNA is not amplified. The persistence of HBV
CC cccDNA is believed to be the major reason for relapse after HBV antiviral
CC therapy, but prior art methods are poor at quantifying cccDNA in infected
CC liver cells. The present sequence represents a PCR primer used in the
CC method of the invention.
XX
SQ Sequence 18 BP; 1 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1041 CATCTTCATGCTGCTGCT 1058
| | | | | | | | | | | | | | | | | |
DB 1 CCTCTTCATGCTGCTGCT 18

RESULT 178
AAZ2495/C
ID AAT32495 standard; DNA; 19 BP.
XX
AC AAT32495;
XX
DT 02-DEC-1996 (first entry)
XX
DE Calpain large subunit 1 gene exon 17 splice acceptor site.
XX
KW Calpain; subunit; calcium; protease; mutation; treatment; detection;
KW identification; diagnosis; limb girdle muscular dystrophy; LGMD2;
KW calcium activated neutral protease; CANP; ss.
XX
OS Homo sapiens.

XX
FH Key Location/Qualifiers
FT misc_recomb 14..15
FT /*tag= a
FT /label= Splice acceptor site.
FT

XX
PN W09616175-A2.
XX
PD 30-MAY-1996.
XX
PF 21-NOV-1995; 95WO-EP004575.
XX
PR 22-NOV-1994; 94EP-00402668.
XX
PA (ASPR-) ASSOC FR CONTRE MYOPATHIES.
XX
PI Beckmann J, Richard I;
XX
DR WPI; 1996-268611/27.
XX
PT Human novel Calpain large subunit 1 gene encoding a calcium dependent
PT protease - used to develop prods. for the diagnosis and treatment of limb
PT -girdle muscular dystrophy 2 disease.
XX
PS Claim 16; Page 11; 66pp; English.

XX
CC The calpain large subunit 1 gene located on chromosome 15 codes for a
CC calcium activated neutral protease (CANP3) belonging to the calpain
CC family. Mutations in the gene induce limb-girdle muscular dystrophy
CC (LGMD) 2 disease. The gene, and fragments of it, can be used in the
CC prevention, treatment, diagnosis and detection of a predisposition to
CC LGMD2 disease. Fifty sequences (AAZ32464-509) are given in the
CC amplification which correspond to the splice donor and splice acceptor
CC sites of the calpain large subunit 1 gene exons
XX
SQ Sequence 19 BP; 4 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 136 GAGGCTGTGAAGGCACAA 153
| | | | | | | | | | | | | | | | | |
DB 18 GTGGCTGTGGAGGCACAA 1

RESULT 179
AAV57110
ID AAV57110 standard; DNA; 19 BP.
XX
AC AAV57110;
XX
DT 25-MAR-2003 (revised)
DT 21-DEC-1998 (first entry)
XX
DE Human Notch3 mutant gene primer N15BR.

XX
KW Human; Notch3; transmembrane receptor; lateral inhibition; regulation;
KW developmental cascade; neurogenic gene; mutant; neurological disorder;
KW cerebral autosomal dominant arteriopathy; subcortical infarct; CADASIL;
KW leukoencephalopathy; therapy; PCR; primer; amplification; ss.

XX
OS Synthetic.
OS Homo sapiens.
PN FR2751986-A1.
XX
PD 06-FEB-1998.
XX
PF 16-APR-1997; 97FR-00004680.
XX
PR 01-AUG-1996; 96FR-00009733.
XX
PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI Tournier LE, Joutel A, Bousser MG, Bach JF;
XX
DR WPI; 1998-133138/13.

XX
PT Human Notch3 nucleic acids - and methods for identifying pre-disposition
PT to cerebral autosomal dominant arteriopathy with sub-cortical infarcts
PT and leukoencephalopathy.

XX
PS Example 3; Page 24; 45pp; French.

XX
CC Primers AAV57066-V57162 are used to detect mutations in the human Notch3
CC gene (AAV57001). Primers AAV57109-V57110 amplify a 166 bp fragment from
CC the BGF22-24 domain sequences found in exon 17. Notch3 is a transmembrane
CC receptor protein involved in lateral inhibition and regulating
CC developmental cascades of neurogenic genes. Mutated Notch3 proteins are
CC thought to be involved in neurological disorders, especially of the
CC cerebral autosomal dominant arteriopathy with subcortical infarcts and
CC leukoencephalopathy (CADASIL) type. Blocking expression of a mutated
CC Notch3 gene or by substitution therapy with non-mutated Notch3 gene or
CC protein can be used to treat CADASIL or related disorders. (Updated on 25
CC -MAR-2003 to correct PI field.)
XX
SQ Sequence 19 BP; 4 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 691 GTCCTGCTCTTCGAGCAG 708
| | | | | | | | | | | | | | | | | |
DB 1 GTCCTGCTCTTCGAGCAG 18

RESULT 180
AAZ28917
ID AAZ28917 standard; DNA; 19 BP.
XX
AC AAZ28917;
XX

DT 07-FEB-2000 (first entry)
XX Reverse primer aal9 for amplification of paraplegin gene exon.
DE
XX
XX Reverse primer aal9; paraplegin; human; hereditary spastic paraplegia;
KW HSP; mutation; diagnosis; treatment; neurodegenerative condition;
KW Amyotrophic Lateral Sclerosis; ALS; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9958556-A2.
PN
XX
XX 18-NOV-1999.
PD
XX
XX 06-MAY-1999; 99WO-EP003112.
PF
XX
XX 08-MAY-1998; 98IT-MI001003.
PR
XX
XX (TELE-) FOND TELETHON.
PA
XX
XX Ballabio A, Casari G;
PI
XX
XX WPI; 2000-039065/03.
DR
XX
XX A novel protein associated to hereditary spastic paraplegia used for the
PT diagnosis of neurodegenerative conditions.
PT
XX
XX Claim 4; Fig 3; 53pp; English.
PS
XX
XX The present sequence is a reverse primer aal9 used for amplification and
CC detection of mutations in paraplegin gene exon from hereditary spastic
CC paraplegia (HSP) patients. Detection of mutations in paraplegin gene
CC helps in the diagnosis and treatment of various forms of HSP or other
CC neurodegenerative conditions, such as Amyotrophic lateral Sclerosis
XX
XX Sequence 19 BP; 2 A; 11 C; 1 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 241 CCTCTGCCCCCACCCTCCC 258
Db 1 CCTCTGCTCACACCTCCC 18
RESULT 181
AAA84728/C
ID AAA84728 standard; DNA; 19 BP.
XX
XX AAA84728;
AC
XX
XX 04-DEC-2000 (first entry)
DT
XX
XX Cyclin E ribozyme binding site #261.
DE
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
KW
XX
XX Mammalia.
OS
XX
XX WO200032765-A2.
FN
XX
XX 08-JUN-2000.
PD
XX
XX 06-DEC-1999; 99WO-US028772.
PF
XX
XX 04-DEC-1998; 98US-0110954P.
PR
XX
XX (IMMU-) IMMUSOL INC.
PA
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
PI
XX

DR WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
XX Disclosure; Page 81; 109pp; English.
PS
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
XX Sequence 19 BP; 3 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 110 ACTTGCTACATGACCC 127
Db 19 ACTTGCTACACGAGCC 2
RESULT 182
AAH59890/C
ID AAH59890 standard; DNA; 19 BP.
XX
XX AAH59890;
AC
XX
XX 10-SEP-2001 (first entry)
DT
XX
XX Cyclin E ribozyme binding site SEQ ID NO:2314.
DE
XX
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulvarry;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
XX Homo sapiens.
OS
XX
XX Synthetic.
XX
XX WO200130362-A2.
PN
XX
XX 03-MAY-2001.
PD
XX
XX 26-OCT-2000; 2000WO-US029500.
PF
XX
XX 26-OCT-1999; 99US-0161532P.
PR
XX
XX (IMMU-) IMMUSOL INC.
PA
XX
XX Robbins JM, Tritz R;
PI
XX
XX WPI; 2001-300427/31.
DR
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 240; 408pp; English.
PS
XX
XX The present invention describes a method for treating a proliferative
CC

CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antiproliferative,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
 CC ophthalmological, vulvar, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention

XX Sequence 19 BP; 3 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 110 ACTTGCTACAAAGGACCC 127
 DB 19 ACTTGCTACAAAGGACCC 2

RESULT 183

ACA90207
 ID ACA90207 standard; DNA; 19 BP.

AC ACA90207;

XX 10-JUL-2003 (first entry)

XX Novel human protein identification related primer #7.

XX Human: cytostatic; DAPK3-Agonist; DAPK3-Antagonist; cancer; NOV; PCR;
 KW primer; ss.

XX Homo sapiens.

XX WO2003031571-A2.

XX 17-APR-2003.

XX 02-OCT-2002; 2002WO-US031357.

XX 05-OCT-2001; 2001US-0327454P.

XX 09-OCT-2001; 2001US-0327917P.

XX 09-OCT-2001; 2001US-0328029P.

XX 09-OCT-2001; 2001US-0328056P.

XX 12-OCT-2001; 2001US-0328849P.

XX 15-OCT-2001; 2001US-0329414P.

XX 17-OCT-2001; 2001US-0330142P.

XX 22-OCT-2001; 2001US-0341058P.

XX 24-OCT-2001; 2001US-0343629P.

XX 29-OCT-2001; 2001US-0349575P.

XX 01-NOV-2001; 2001US-0346357P.

XX 25-JUN-2002; 2002US-0391342P.

XX 01-OCT-2002; 2002US-00262445.

XX (CURA-) CURAGEN CORP.

XX Alsbrook JP, Burgess CE, Catterton E, Chant JS, Chaudhuri A;

XX Edinger SR, Gerlach VL, Giot L, Gorman L, Guo X, Kekuda R;

XX Mezes PS, Millet I, Ooi CE, Patturajan M, Rieger DK, Spytek KA;

XX Taupler RJ, Zerhusen BD, Zhong H, Zhong M;

XX WPI; 2003-381704/36.

XX

PT New DAPK3 polypeptide, useful for preparing a composition for treating or
 preventing e.g., cancer.

XX Example 20C; Page 192; 253pp; English.

XX The invention describes an isolated polypeptide comprising any of 33 90-
 CC /1273 amino acid sequences (I) given in the specification or its mature
 CC form, a sequence that is at least 95 % identical to (I), or a sequence
 CC comprising one or more conservative substitutions in the amino acid
 CC sequence of (I). The polypeptide is useful for preparing a composition
 CC for treating or preventing e.g. cancer. This sequence represents a primer
 CC used to isolate DNA encoding a novel human NOV protein

XX Sequence 19 BP; 3 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1044 CTTTCATGCTGCTGCAT 1061
 DB 2 CTTTCATGCTGCATCAT 19

RESULT 184

ADD20516
 ID ADD20516 standard; DNA; 19 BP.

XX ADD20516;

XX 15-JAN-2004 (first entry)

XX Oreochromis niloticus microsatellite primer SEQ ID NO:1151.

XX single nucleotide polymorphism; SNP; fish; Salmo salar;

XX Oreochromis niloticus; Atlantic halibut; microsatellite; cod;

XX polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;
 KW detection; primer; ss.

XX Synthetic.

XX Oreochromis niloticus.

XX WO2003060160-A2.

XX 24-JUL-2003.

XX 17-JAN-2003; 2003WO-IB000112.

XX 18-JAN-2002; 2002US-0349950P.

XX 16-AUG-2002; 2002US-0404200P.

XX (GENO-) GENOMAR ASA.

XX Lie O, Slettan A, Hoyum M, Lingaas F;

XX WPI; 2003-627388/59.

XX Novel isolated nucleic acid molecule comprising single nucleotide
 PT polymorphism associated with fish, useful for forming PCR primers which
 PT are used for detecting single nucleotide polymorphisms in fish nucleic
 PT acids.

XX Claim 18; SEQ ID NO 1151; 233pp; English.

XX The present invention describes an isolated nucleic acid (I) comprising a
 CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of
 CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;
 CC and (ii) a nucleic acid having nucleotide sequence that hybridises to
 CC (i), or its complement under highly stringent hybridisation conditions.
 CC Also described: (i) an isolated oligonucleotide (II) comprising at least
 CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.
 CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod

PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002WO-US009187.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX
PI Morrissey D, Mcswiggen JA, Beigelman L;
XX WPI; 2003-901032/82.
XX
XX New short interfering nucleic acid molecules which down-regulates
PT expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for
PT characterizing gene function.
XX
PS Claim 11; Page 48; 72pp; English.
XX
XX The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesising a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises a sense
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterising pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.
XX
SQ Sequence 19 BP; 1 A; 8 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 1041 CATCTTCATGCTGCTCT 1058
Db 2 CCUCUUCACUCCUGUCU 19
RESULT 187
ADM00721/c

ID ADM00721 standard; RNA; 19 BP.
XX
AC ADM00721;
XX
DT 20-MAY-2004 (first entry)
XX
DE Hepatitis B virus short interfering nucleic acid (siNA) #1137.
XX
KW Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
OS Hepatitis B virus.
XX
PN US2003206887-A1.
XX
PD 06-NOV-2003.
XX
PP 16-SEP-2002; 2002US-00244647.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002WO-US009187.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX
PI Morrissey D, Mcswiggen JA, Beigelman L;
XX WPI; 2003-901032/82.
XX
XX New short interfering nucleic acid molecules which down-regulates
PT expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for
PT characterizing gene function.
XX
PS Claim 11; Page 47; 72pp; English.
XX
XX The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesising a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises a sense
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterising pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.
XX

CC The antisense region 3'-terminal overhang is complementary to RNA
 CC encoding HBV. The siNA is useful for treating human hepatitis B virus
 CC infections, and for characterising pathways of gene function, e.g. to
 CC inhibit activity of target genes in a pathway to determine the function
 CC of uncharacterised genes in gene function analysis. The siNA molecules
 CC may also be used in clinical, industrial, environmental, agricultural
 CC and/or research settings. The present sequence represents 1 of 1504 HBV
 CC siNA molecules of the invention.

XX Sequence 19 BP; 7 A; 2 C; 8 G; 0 T; 2 U; 0 Other;
 SQ Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
 Db 19 CCTCTTCATCTGCTGCT 2

RESULT 188
 ADM00741/c
 ID ADM00741 standard; RNA; 19 BP.
 XX ADM00741;
 AC ADM00741;
 XX 20-MAY-2004 (first entry)
 DT Hepatitis B virus short interfering nucleic acid (siNA) #1157.
 DE Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
 KW siNA; hepatitis B virus; HBV; RNA interference.
 XX Hepatitis B virus.
 OS US2003206887-A1.
 XX 06-NOV-2003.
 PD 16-SEP-2002; 2002US-00244647.
 PF 14-MAY-1992; 92US-00882712.
 PR 07-FEB-1994; 94US-00193627.
 PR 08-NOV-1999; 99US-00436430.
 PR 20-MAR-2000; 2000US-00531025.
 PR 09-AUG-2000; 2000US-00636385.
 PR 24-OCT-2000; 2000US-00696347.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0337055P.
 PR 03-DEC-2001; 2001US-0335059P.
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 26-MAR-2002; 2002WO-US009187.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 03-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 XX (MORRISSEY D.
 PA (MCSWIGGEN J A.
 PA (BEIGELMAN L.
 PA Morrissey D, Mcswiggen JA, Beigelman L;
 PI WPI; 2003-901032/82.
 XX New short interfering nucleic acid molecules which down-regulates
 XX expression of a hepatitis B virus (HBV) or which inhibits HBV
 XX replication, useful for treating human HBV infections or for
 XX characterizing gene function.
 PS Claim 11; Page 48; 72pp; English.

XX The invention relates to a short interfering nucleic acid (siNA) molecule
 CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
 CC interference or that inhibits HBV replication. Also disclosed are the
 CC following: (i) a method of modulating the expression of a HBV gene in a
 CC tissue explant; (ii) a method of generating a library of siNA constructs
 CC having predetermined complexity; (iii) a cell containing one or more siNA
 CC molecules; (iv) a kit containing a siNA molecule which can be used to
 CC modulate the expression of a HBV target gene in a cell, tissue or
 CC organism; and (v) a method for synthesising a siNA molecule. The siNA
 CC molecule is adapted for use to treat HBV infection, and comprises a sense
 CC and an antisense region, where the antisense region comprises sequence
 CC complementary to an RNA sequence encoding HBV and the sense region
 CC comprises sequence complementary to the antisense region. The siNA
 CC molecule is assembled from 2 nucleic acid fragments, where one fragment
 CC comprises the sense region and the second fragment comprises the
 CC antisense region of the siNA molecule, where sense region and the
 CC antisense region comprise separate oligonucleotides, and are covalently
 CC connected via a linker molecule. The linker molecule is a polynucleotide
 CC linker or a non-nucleotide linker. The sense region comprises a 3'-
 CC terminal overhang and the antisense region comprises a 3'-terminal
 CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
 CC The antisense region 3'-terminal overhang is complementary to RNA
 CC encoding HBV. The siNA is useful for treating human hepatitis B virus
 CC infections, and for characterising pathways of gene function, e.g. to
 CC inhibit activity of target genes in a pathway to determine the function
 CC of uncharacterised genes in gene function analysis. The siNA molecules
 CC may also be used in clinical, industrial, environmental, agricultural
 CC and/or research settings. The present sequence represents 1 of 1504 HBV
 CC siNA molecules of the invention.

XX Sequence 19 BP; 8 A; 2 C; 8 G; 0 T; 1 U; 0 Other;
 SQ Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
 Db 18 CCTCTTCATCTGCTGCT 1

RESULT 189
 ADM00075
 ID ADM00075 standard; RNA; 19 BP.
 XX ADM00075;
 AC ADM00075;
 XX 20-MAY-2004 (first entry)
 DT Hepatitis B virus short interfering nucleic acid (siNA) #491.
 DE Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
 KW siNA; hepatitis B virus; HBV; RNA interference.
 XX Hepatitis B virus.
 OS US2003206887-A1.
 XX 06-NOV-2003.
 PD 16-SEP-2002; 2002US-00244647.
 PF 14-MAY-1992; 92US-00882712.
 PR 07-FEB-1994; 94US-00193627.
 PR 08-NOV-1999; 99US-00436430.
 PR 20-MAR-2000; 2000US-00531025.
 PR 09-AUG-2000; 2000US-00636385.
 PR 24-OCT-2000; 2000US-00696347.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.

PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002WO-US009187.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX
XX Morrissey D, Mcswiggen JA, Beigelman L;
PI WPI; 2003-901032/82.
XX
XX
XX New short interfering nucleic acid molecules which down-regulates
PT expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for
PT characterizing gene function.
XX
XX Claim 11; Page 47; 72pp; English.
XX
XX The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesizing a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises a sense
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises a sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC linker or a non-nucleotide linker. The sense region comprises a 3'-
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterizing pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.
XX
XX Sequence 19 BP; 2 A; 8 C; 2 G; 0 T; 7 U; 0 Other;
SQ

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 1041 CATCTTCATGCTGCTCT 1058
DB 1 CCUCUUAUCCUGUGCU 18
RESULT 190
ADL79404/C
ID ADL79404 standard; RNA; 19 BP.
XX
AC ADL79404;
XX
DT 20-MAY-2004 (first entry)
XX
XX Human HER1 (EGFR) transcript target sequence/siNA upper strand, SEQ:569.

XX RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER1; c-erb-B-1; target sequence; ss.
XX
XX Homo sapiens.
OS
XX WO2003070912-A2.
PN
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005045.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcswiggen J, Pavco P, Beigelman L, Fossnaugh K, Jamison S;
PI WPI; 2003-697612/66.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 569; 171pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human HER1 (EGFR)-targeted double-stranded siNA, which is identical to
CC the HER1 transcript target sequence.
XX
XX
SQ Sequence 19 BP; 7 A; 8 C; 1 G; 0 T; 3 U; 0 Other;
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 342 GATGAGGTGCGACATTT 359

Db 19 GATGGAGGTGCAGTTT 2
RESULT 191
ADL79711
ID ADL79711 standard; RNA; 19 BP.
AC ADL79711;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human HER1 (EGFR) siNA lower strand, SEQ ID NO:876.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER1; C-erb-B-1; ss.
XX
OS Homo sapiens.
XX
PN WO2003070912-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005045.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX
XX WPI; 2003-697612/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
XX
PS Example 3; SEQ ID NO 876; 171pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target

CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the lower strand of a
CC human HER1 (EGFR)-targeted double-stranded siNA.
XX
SQ Sequence 19 BP; 3 A; 1 C; 8 G; 0 T; 7 U; 0 Other;
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 1.2e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 342 GATGGAGGTGCAGCATT 359
DB 1 GAUGGAGGUGCAGUUUU 18
RESULT 192
AD009390
ID AD009390 standard; DNA; 19 BP.
XX
AC AD009390;
XX
DT 01-JUL-2004 (first entry)
XX
DE Novel human protein Nov9 probe seqid 84.
XX
KW cytotatic; antidiabetic; anorectic; cerebroprotective; neuroprotective;
KW antiinflammatory; thyromimetic; gene therapy; antisense therapy;
KW NOVX polypeptide related disorder; cancer; diabetes; obesity;
KW endocrine disorder; CNS disorder; inflammatory disorder;
KW chromosome mapping; tissue typing; predictive medicine;
KW intracellular protein-like protein; sorting nexin 6-like protein;
KW 2310038H17RIK membrane protein-like protein;
KW 573045109RIK cyclin-like protein; cMeb5 cancer specific protein;
KW LRP16 protein-like protein;
KW phosphatidyethanolamine-binding protein-like protein;
KW immunoglobulin-like LRR-domain containing protein;
KW NUMB binding protein LNXp80-like protein;
KW zinc finger protein-like protein;
KW actin-binding protein alpha-like protein;
KW actin-binding protein frabin-alpha-like protein;
KW actin related protein 2/3 complex subunit 1A-like protein;
KW hepatocellular carcinoma autoantigen-like protein;
KW haematopoietic stem/progenitor cells protein MDS029-like protein;
KW TRAP-delta-like protein;
KW INTSIG-5-like WD-40 repeats containing protein-like protein;
KW ferritin light chain-like protein; leucine-rich protein 130-like protein;
KW tumour protein p53-binding protein 2-like protein; human; probe; ss.
XX
OS Homo sapiens.
XX
PN US2004014058-A1.
XX
PD 22-JAN-2004.
XX
PF 01-OCT-2002; 2002US-00262445.
XX
PR 05-OCT-2001; 2001US-0327454P.
PR 09-OCT-2001; 2001US-0327917P.
PR 09-OCT-2001; 2001US-0328029P.
PR 09-OCT-2001; 2001US-0328056P.
PR 12-OCT-2001; 2001US-0328849P.
PR 15-OCT-2001; 2001US-0329414P.
PR 17-OCT-2001; 2001US-0330142P.
PR 22-OCT-2001; 2001US-0341058P.
PR 24-OCT-2001; 2001US-0343629P.
PR 29-OCT-2001; 2001US-0349575P.
PR 01-NOV-2001; 2001US-0346357P.
PR 25-JUN-2002; 2002US-0391342P.
XX
PA (ALSO/) ALSOBROOK J P.
PA (BURG/) BURGESS C E.
PA (CATT/) CATTERTON E.

KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
XX Claim 30; Page 148; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) pr
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an inozyme of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 1 G; 0 T; 8 U; 0 Other;

Query Match

0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
QY 1064 TCTTTGCCCTTCCTCCA 1079
Db 2 UCUUGGCCUUCUCCA 17
RESULT 195
ABK03204
ID ABK03204 standard; RNA; 17 BP.
XX
XX AC ABK03204;
XX
XX 12-MAR-2002 (first entry)
XX
XX Human CD20 Inozyme #155.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
XX Claim 30; Page 148; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) pr
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an inozyme of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 1 G; 0 T; 8 U; 0 Other;

CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The NQO-
CC targeting nucleic acid is used to cleave RNA of the NQO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NQO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NQO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NQO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NQO expression. The present
CC sequence is an inozyme of the invention
XX
SQ Sequence 17 BP; 1 A; 6 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1064 TCTTTCCTCTCTCCCA 1079
Db 1 UCUUUGCCUUCUCCCA 16

RESULT 196
ABN02304/C
ID ABN02304 standard; DNA; 17 BP.

XX AC ABN02304;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2296.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; Gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 05-FEB-2001; 2001US-0266860P.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 2296; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionization, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 553 CTACGGCTGTGGGCCA 568

Db 17 CTGCGGCTGTGGGCCA 2

RESULT 197

ABN06632
ID ABN06632 standard; DNA; 17 BP.

XX AC ABN06632;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6624.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; Gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 624; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 21 TCTGCGTCTGCACAGG 36
Db |||||
2 TCTGCGTCTGCATAGG 17
RESULT 198
ABN02302/c
ID ABN02302 standard; DNA; 17 BP.
XX
AC ABN02302;
XX
XX 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2294.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US0000661.
PR 30-JAN-2001; 2001WO-US0000662.
PR 30-JAN-2001; 2001WO-US0000663.
PR 30-JAN-2001; 2001WO-US0000664.
PR 30-JAN-2001; 2001WO-US0000665.
PR 30-JAN-2001; 2001WO-US0000666.
PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2294; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 9 C; 4 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 556 CGGCTGTGGCCAGG 571
Db |||||
16 CGGCTGTGGCCATGG 1
RESULT 199
ABN02301/c
ID ABN02301 standard; DNA; 17 BP.
XX
AC ABN02301;
XX
XX 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2293.
XX

KW Human; genome-derived myosin-like protein 1; hGDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 2293; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP-
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 556 CGGCTGTGGCCAGG 571
DB 17 CGGCTGTGGCCATGG 2

RESULT 200
ABN06637
ID ABN06637 standard; DNA; 17 BP.
XX AC ABN06637;
XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6629.
XX Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 6629; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP-
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX

XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 25 CGTCTGCAGGACAG 40
Db 1 CGTCTGCATAGGACAG 16
RESULT 201
ABN02305/c
ID ABN02305 standard; DNA; 17 BP.
XX AC ABN02305;
XX 29-MAY-2002 (first entry)
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2297.
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; ampiclon; screening; ss.
XX Homo sapiens.
OS
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
PI WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX Disclosure; SEQ ID NO 2297; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 553 CTACGGCTGTGGCCA 568
Db 16 CTGCGGCTGTGGCCA 1
RESULT 202
ABT35074
ID ABT35074 standard; DNA; 17 BP.
XX AC ABT35074;
XX 12-JUN-2003 (first entry)
XX Tumour suppression related human fukutin oligo SEQ ID No 711.
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX Homo sapiens.
XX WO2003025175-A2.
XX 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004208.
XX 17-SEP-2001; 2001FR-00011978.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX Disclosure; Page 117; 720pp; French.
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 887 ATGTGGCCCAAGACTT 902
 Db 2 ATGTGGCCCAAGACTT 17
 |||||
 AC ACDS9611;
 24-SEP-2003 (first entry)
 HCV DNazyme substrate sequence #1413.
 Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 RNA stability; RNA expression; RNA synthesis; antisense;
 enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 HBV reverse transcriptase; Enhancer I region; viral replication;
 degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 viricide; antiinflammatory; substrate; ss.
 Hepatitis C virus.
 WO200281494-A1.
 17-OCT-2002.
 26-MAR-2002; 2002WO-US009187.
 26-MAR-2001; 2001US-00817879.
 08-JUN-2001; 2001US-00877478.
 08-JUN-2001; 2001US-0296876P.
 24-OCT-2001; 2001US-0335059P.
 05-DEC-2001; 2001US-0337055P.
 (RIBO-) RIBOZYME PHARM INC.
 (BLAT/) BLATT L.
 (MACE/) MACEJAK D.
 (MCSW/) MCSWIGGEN J.
 (MORR/) MORRISSEY D.
 (PAVC/) PAVCO P.
 (LEEF/) LEE P.
 (DRAP/) DRAPER K.
 (ROBE/) ROBERTS E.
 Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 Draper K, Roberts E;
 WPI; 2003-229207/22.
 Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 infection.
 XX

PS Claim 1; Page 259; 387pp; English.
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 1 G; 0 T; 4 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 133 ATGGAGGCTGTGAAGG 148
 |||||
 Db 16 ATGGAGGCTGTGAATG 1
 RESULT 204
 ACDS63059
 ID ACDS63059 standard; RNA; 17 BP.
 XX ACDS63059;
 AC ACDS63059;
 XX
 DT 24-SEP-2003 (first entry)
 HCV minus strand DNazyme substrate sequence #866.
 Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 RNA stability; RNA expression; RNA synthesis; antisense;
 enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 HBV reverse transcriptase; Enhancer I region; viral replication;
 degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 viricide; antiinflammatory; substrate; ss.
 Hepatitis C virus.
 WO200281494-A1.
 17-OCT-2002.
 26-MAR-2002; 2002WO-US009187.
 26-MAR-2001; 2001US-00817879.
 08-JUN-2001; 2001US-00877478.
 08-JUN-2001; 2001US-0296876P.
 24-OCT-2001; 2001US-0335059P.
 05-DEC-2001; 2001US-0337055P.
 (RIBO-) RIBOZYME PHARM INC.
 (BLAT/) BLATT L.
 (MACE/) MACEJAK D.
 (MCSW/) MCSWIGGEN J.
 (MORR/) MORRISSEY D.
 (PAVC/) PAVCO P.
 (LEEF/) LEE P.
 (DRAP/) DRAPER K.
 Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 Draper K, Roberts E;
 WPI; 2003-229207/22.
 Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 infection.
 XX

PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
DR
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
infection.
XX
XX Claim 1; Page 290; 387pp; English.
PS
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zincymes, amberszymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.8%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 134 TGGAGGCTGTGAAGGC 149
Db 1 UGGAGGCUGGAUGC 16
:::|||||:|||||
RESULT 205
ADI84167/c
ID ADI84167 standard; RNA; 17 BP.
XX
XX AC ADI84167;
XX
XX DT 03-JUN-2004 (first entry)
XX
XX DE HCV DNazyme substrate sequence #1413.
XX
XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX
XX OS Hepatitis C virus.
XX
XX PN US2003125270-A1.
XX
XX PD 03-JUL-2003.
XX
XX PF 18-DEC-2000; 2000US-00740332.
XX
XX PR 18-DEC-2000; 2000US-00740332.
XX
XX PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI
DR WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 3143; 198pp; English.
PS
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.8%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 134 TGGAGGCTGTGAAGGC 149
Db 1 UGGAGGCUGGAUGC 16
:::|||||:|||||

XX
DR WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1413; 198pp; English.
PS
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
SQ Sequence 17 BP; 4 A; 8 C; 1 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 133 ATGGAGGCTGTGAAGG 148
Db 16 ATGGAGGCTGTGAATG 1
|||||:|||||
RESULT 206
ADI85897
ID ADI85897 standard; RNA; 17 BP.
XX
XX AC ADI85897;
XX
XX DT 03-JUN-2004 (first entry)
XX
XX DE HCV DNazyme substrate sequence #3143.
XX
XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX
XX OS Hepatitis C virus.
XX
XX PN US2003125270-A1.
XX
XX PD 03-JUL-2003.
XX
XX PF 18-DEC-2000; 2000US-00740332.
XX
XX PR 18-DEC-2000; 2000US-00740332.
XX
XX PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI
DR WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 3143; 198pp; English.
PS
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC in the specification. The nucleic acid molecule may be administered for

CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNase substrate
CC sequence.

SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 1.2e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 134 TGGAGCGCTGTGAAGC 149

Db 1 UGAGGCGCUGAAGC 16

RESULT 207

AAX71705

ID AAX71705 standard; RNA; 18 BP.

XX AC AAX71705;

XX DT 28-JUL-1999 (first entry)

XX DE Human KDR VEGF receptor hairpin ribozyme substrate #3.

XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammetthead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.

XX OS Homo sapiens.

XX PN WO9715662-A2.

XX PD 01-MAY-1997.

XX PF 25-OCT-1996; 96WO-US017480.

XX PR 26-OCT-1995; 95US-0005974P.

XX PR 11-JAN-1996; 96US-00584040.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (CHIR) CHIRON CORP.

XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.

PS Claim 4; Page 118; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention

XX SQ Sequence 18 BP; 0 A; 7 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;

Best Local Similarity 75.0%; Pred. No. 1.2e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGCGCGCTCTGTG 958

Db 1 CCGGCGCGCGCUCUGUG 16

RESULT 208

AAX52424

ID AAX52424 standard; DNA; 18 BP.

XX AC AAX52424;

XX DT 25-JUN-1999 (first entry)

XX DE Forward PCR primer used to amplify cDNA encoding PRO295.

XX KW Secreted protein; transmembrane protein; human; enterocolitis;
KW Zollinger-Ellison syndrome; gastrointestinal ulceration;
KW congenital microvillus atrophy; skin disease; cell growth;
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy; fibromodulin;
KW dermal scarring; Usher Syndrome; Atrophia areata; anti-thrombotic;
KW wound healing; tissue repair; PCR primer; ss.

XX OS Synthetic.

XX PN WO9914328-A2.

XX PD 25-MAR-1999.

XX PF 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059115P.

XX PR 17-SEP-1997; 97US-0059117P.

XX PR 17-SEP-1997; 97US-0059119P.

XX PR 17-SEP-1997; 97US-0059121P.

XX PR 17-SEP-1997; 97US-0059122P.

XX PR 17-SEP-1997; 97US-0059184P.

XX PR 18-SEP-1997; 97US-0059263P.

XX PR 18-SEP-1997; 97US-0059266P.

XX PR 15-OCT-1997; 97US-0062125P.

XX PR 17-OCT-1997; 97US-0062285P.

XX PR 17-OCT-1997; 97US-0062287P.

XX PR 21-OCT-1997; 97US-0063486P.

XX PR 24-OCT-1997; 97US-0062814P.

XX PR 24-OCT-1997; 97US-0062816P.

XX PR 24-OCT-1997; 97US-0063045P.

XX PR 24-OCT-1997; 97US-0063120P.

XX PR 24-OCT-1997; 97US-0063121P.

XX PR 24-OCT-1997; 97US-0063127P.

XX PR 24-OCT-1997; 97US-0063128P.

XX PR 27-OCT-1997; 97US-0063327P.

XX PR 27-OCT-1997; 97US-0063329P.

XX PR 28-OCT-1997; 97US-0063541P.

XX PR 28-OCT-1997; 97US-0063542P.

XX PR 28-OCT-1997; 97US-0063544P.

XX PR 28-OCT-1997; 97US-0063549P.

XX PR 28-OCT-1997; 97US-0063550P.

XX PR 28-OCT-1997; 97US-0063564P.

XX PR 29-OCT-1997; 97US-0063435P.

XX PR 29-OCT-1997; 97US-0063704P.

XX PR 29-OCT-1997; 97US-0063732P.

XX PR 29-OCT-1997; 97US-0063734P.

XX PR 29-OCT-1997; 97US-0063735P.

XX PR 29-OCT-1997; 97US-0063738P.

XX PR 29-OCT-1997; 97US-0064215P.

XX PR 31-OCT-1997; 97US-0063870P.

XX PR 31-OCT-1997; 97US-0064103P.

XX PR 03-NOV-1997; 97US-0064248P.

XX PR 07-NOV-1997; 97US-0064809P.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 17-NOV-1997; 97US-0065846P.

XX PR 18-NOV-1997; 97US-0065893P.

XX PR 21-NOV-1997; 97US-0066120P.

PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 XX (GETH) GENENTECH INC.
 PA
 PI Wood WI, Gurney AL, Goddard A, Pennica D, Chen J, Yuan J;
 XX WPI; 1999-229533/19.
 XX
 XX New isolated human genes and polypeptides used in, e.g. treatment of
 PT gastrointestinal ulceration.
 PT
 PS Example 38; Page 144; 320pp; English.
 XX
 CC Oligonucleotides AAX52276-532 represent PCR primers and probes used to
 CC isolate and amplify cDNA encoding secreted and transmembrane human
 CC proteins (see AAX52213-74 and AAX13344-403). The cDNA sequences are
 CC obtained from cDNA libraries, prepared from fetal lung, fetal kidney,
 CC fetal brain, fetal liver and fetal retina. The encoded polypeptides have
 CC specific uses based on their homology to known polypeptides, e.g. PRO211
 CC and PRO217 can be used for disorders associated with the preservation and
 CC maintenance of gastrointestinal mucosa and the repair of acute and
 CC chronic mucosal lesions (e.g. enterocolitis, Zollinger-Ellison syndrome,
 CC gastrointestinal ulceration and congenital microvillus atrophy), skin
 CC diseases associated with abnormal keratinocyte differentiation (e.g.
 CC psoriasis, epithelial cancers such as lung squamous cell carcinoma of the
 CC vulva and gliomas), potent effects on cell growth and development,
 CC diseases related to growth or survival of nerve cells including
 CC Parkinson's disease, Alzheimer's disease, ALS, neuropathies or cancer.
 CC PRO265 can be used as for fibromodulin, e.g. for reducing dermal
 CC scarring. PRO264 can be used as a target for anti-tumor drugs. PRO533 may
 CC be used in the treatment of Usher Syndrome or Atrophia areata; PRO269 can
 CC be used as an anti-thrombotic agent; PRO287 polypeptides and portions may
 CC have therapeutic applications in wound healing and tissue repair; PRO317
 CC can be used for treating problems of the kidney, uterus, endometrium,
 CC blood vessels, or related tissue, e.g. in the heart of genital tract
 XX
 SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1467 CAGCCTGTACTGCCAG 1482
 Db 3 CAGCATGTACTGCCAG 18
 RESULT 209
 AAA55618/c
 ID AAA55618 standard; DNA; 18 BP.
 XX
 AC AAA55618;
 XX
 DT 30-AUG-2000 (first entry)
 XX
 DE TRAF4 antisense oligonucleotide ISIS# 26878.
 XX
 KW Tumour necrosis factor receptor-associated factor; TRAF; human;
 KW antisense oligonucleotide; phosphorothioate; antiproliferative;
 KW anti-inflammatory; E-selectin; Jun kinase; ss.
 XX
 OS Synthetic.
 XX
 XX WO200020435-A1.
 PN
 PD 13-APR-2000.
 XX

PF 05-OCT-1999; 99WO-US023171.
 XX
 PR 06-OCT-1998; 98US-00167109.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Baker BF, Cowsett LM, Monia BP, Xu XS;
 XX WPI; 2000-303732/26.
 DR
 XX
 XX Antisense oligonucleotides targeted to nucleic acids encoding human tumor
 PT necrosis factor receptor-associated factor (TRAF), useful for treating
 PT diseases associated with TRAF expression such as inflammatory diseases.
 XX
 PS Example 19; Page 60; 170pp; English.
 XX
 CC The present invention relates to antisense oligonucleotides (see AAA55496
 CC -A55757) which are targeted to nucleic acids encoding a human tumour
 CC necrosis factor receptor-associated factor (TRAF). The antisense
 CC sequences comprise at least one modified internucleotide linkage, which
 CC is a phosphorothioate linkage. The oligonucleotides also include at least
 CC one modified sugar moiety such as a 2'-O-methoxyethyl sugar moiety.
 CC Sequences AAA55490-A55495 represent nucleotide sequences encoding human
 CC TRAF1-6. Included in the invention is a method for treating a human
 CC having a disease associated with the expression of TRAF comprising
 CC administering an antisense oligonucleotide. The reduction of Jun kinase
 CC activation in cells comprises contacting the cells with an antisense
 CC oligonucleotide targeted to TRAF-6. A method for the reduction of E-
 CC selectin expression in cells or tissues comprises contacting the cells or
 CC tissues with an antisense oligonucleotide targeted to TRAF-2 or TRAF-6.
 CC The antisense oligonucleotides have antiproliferative and anti-
 CC inflammatory activity and are useful for treating disorders associated
 CC with cell proliferation and inflammation. The antisense oligonucleotides
 CC may also be used as a diagnostic probe for studying gene function
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 621 CGCCGTGCTGCTGC 636
 Db 17 CGCCCTGCTGCTGCTGC 2
 RESULT 210
 AAA55531
 ID AAA55531 standard; DNA; 18 BP.
 XX
 AC AAA55531;
 XX
 DT 30-AUG-2000 (first entry)
 XX
 DE TRAF1 antisense oligonucleotide ISIS# 26733.
 XX
 KW Tumour necrosis factor receptor-associated factor; TRAF; human;
 KW antisense oligonucleotide; phosphorothioate; antiproliferative;
 KW anti-inflammatory; E-selectin; Jun kinase; ss.
 XX
 OS Synthetic.
 XX
 XX WO200020435-A1.
 PN
 PD 13-APR-2000.
 XX
 PF 05-OCT-1999; 99WO-US023171.
 XX
 PR 06-OCT-1998; 98US-00167109.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Baker BF, Cowsett LM, Monia BP, Xu XS;

XX WPI; 2000-303732/26.
XX
XX Antisense oligonucleotides targeted to nucleic acids encoding human tumor
PT necrosis factor receptor-associated factor (TRAF), useful for treating
PT diseases associated with TRAF expression such as inflammatory diseases.
XX
XX Example 14; Page 47; 170pp; English.
XX
XX The present invention relates to antisense oligonucleotides (see AAA55496
CC -A55757) which are targeted to nucleic acids encoding a human tumour
CC necrosis factor receptor-associated factor (TRAF). The antisense
CC sequences comprise at least one modified internucleotide linkage, which
CC is a phosphorothioate linkage. The oligonucleotides also include at least
CC one modified sugar moiety such as a 2'-O-methoxyethyl sugar moiety.
CC Sequences AAA55490-A55495 represent nucleotide sequences encoding human
CC TRAF-6. Included in the invention is a method for treating a human
CC having a disease associated with the expression of TRAF comprising
CC administering an antisense oligonucleotide. The reduction of jun kinase
CC activation in cells comprises contacting the cells with an antisense
CC oligonucleotide targeted to TRAF-6. A method for the reduction of E-
CC selectin expression in cells or tissues comprises contacting the cells or
CC tissues with an antisense oligonucleotide targeted to TRAF-2 or TRAF-6.
CC The antisense oligonucleotides have antiproliferative and anti-
CC inflammatory activity and are useful for treating disorders associated
CC with cell proliferation and inflammation. The antisense oligonucleotides
CC may also be used as a diagnostic probe for studying gene function
XX
SQ Sequence 18 BP; 0 A; 4 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1269 GCTGGGTGTCCTG 1284
DB 3 GCTGGGTGTCCTG 18

RESULT 211
ADC78694
ID ADC78694 standard; DNA; 18 BP.
XX
XX ADC78694;
XX
XX 01-JAN-2004 (first entry)
XX
XX Human PRO protein-related forward PCR primer SEQ ID 239.
XX
XX antinflammatory; antiulcer; cytostatic; antipsoriatic; antiparkinsonian;
KW neurotrophic; neuroprotective; vasotropic; chemotactic; angiogenic;
KW neurotrophic; osteopathic; antiaesthetic; antiarthritic; antirheumatic;
KW antiarteriosclerotic; cardiant; antidiabetic; cerebroprotective;
KW thrombolytic; immunomodulator; enterocolitis; Zollinger-Ellison syndrome;
KW gastrointestinal ulceration; psoriasis; cancer; Parkinson's disease;
KW Alzheimer's; ALS; neuropathy; dermal scarring; wound healing;
KW nerve repair; thrombosis; bone; cartilage formation; angiogenesis;
KW asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disorder;
KW atherosclerosis; cardiac injury; infertility; premature aging; AIDS;
KW diabetes; stroke; gene therapy; transgenic; PRO; human; ss; primer; PCR.
XX
XX Homo sapiens.
XX
XX WO200015796-A2.
XX
XX 23-MAR-2000.
XX
XX 15-SEP-1999; 99WO-US021090.
XX
XX 16-SEP-1998; 98WO-US019330.
XX
XX (GETH) GENENTECH INC.

Chen J, Goddard A, Gurney AL, Hillan K, Pennica D, Wood WI;
Yuan J;
WPI; 2000-271434/23.
XX
XX Novel nucleic acids encoding secreted and transmembrane polypeptides with
PT homology, e.g. to growth and cancer-associated antigens.
XX
XX Example 38; SEQ ID NO 239; 355pp; English.
XX
XX The invention relates to a novel nucleic acid encoding a PRO polypeptide.
CC The polypeptides and polynucleotides of the invention may be useful as
CC research tools and as therapeutics for treating enterocolitis, Zollinger-
CC Ellison syndrome, gastrointestinal ulceration, psoriasis, cancer,
CC Parkinson's disease, Alzheimer's disease, AIDS, neuropathies, dermal
CC scarring and wound healing, nerve repair, thrombosis, bone and/or
CC cartilage formation, angiogenesis, asthma, rheumatoid arthritis, multiple
CC sclerosis, inflammatory disorders, atherosclerosis, cardiac injury,
CC infertility, premature aging, AIDS, diabetes complications and stroke.
CC The molecules may also be utilised during gene therapy procedures and
CC transgenic animal production. The current sequence is that of the PCR
CC primer of the invention which was used to analyse the human PRO DNA of
CC the invention.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
DB 3 CAGCCTGTACTGCCAG 18

RESULT 212
AAF72582
ID AAF72582 standard; DNA; 18 BP.
XX
XX AAF72582;
XX
XX 24-APR-2001 (first entry)
XX
XX Human PRO polypeptide gene PCR primer SEQ ID NO: 240.
XX
XX Human; PRO; dermatological; antipsoriatic; cytostatic; antinflammatory;
KW antiparkinsonian neurotropic; neuroprotective; vulnery; cardiant;
KW antiangiogenic; vasotropic; antiaesthetic; antirheumatic; cancer;
KW antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW ischaemia; inflammation; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200104311-A1.
XX
XX 18-JAN-2001.
XX
XX 22-FEB-2000; 2000WO-US004414.
XX
XX 07-JUL-1999; 99US-0143048P.
XX 26-JUL-1999; 99US-0145698P.
XX 28-JUL-1999; 99US-0146222P.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.

```

PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
XX (GETH ) GENENTECH INC.
PA
XX Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Klijavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2001-081051/09.
XX
XX Sixty one nucleic acids encoding PRO polypeptides which are useful in the
XX treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous
XX cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's
XX disease).
XX
XX Example 38; Page 182; 393pp; English.
XX
XX The present sequence is a primer which was used in the isolation of one
XX of sixty one nucleic acids encoding novel secreted and transmembrane PRO
XX polypeptides. The PRO polypeptides are useful for treating skin diseases
XX (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma),
XX gastrointestinal disorders (e.g. enterocolitis), neurodegenerative
XX diseases (e.g. Alzheimer's disease, Parkinson's disease), wound repair,
XX cardiovascular disorders (e.g. endometrial bleeding angiogenesis,
XX ischaemias such as coronary ischaemia, atherosclerosis), inflammatory
XX disorders (e.g. asthma, rheumatoid arthritis, multiple sclerosis),
XX infertility, AIDS and diabetes and retinal disorders such as retinitis
XX pigmentosa. The PRO nucleic acids have applications in molecular
XX biology, including use as hybridization probes, and in chromosome and
XX gene mapping
XX
XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1467 CAGCCTGTACTGCCAG 1482
Db 3 CAGCATGTACTGCCAG 18
|||||
|||||
|||||
RESULT 213
ABZ10946/C
ID ABZ10946 standard; DNA; 18 BP.
XX
XX ABZ10946;
XX
XX 16-JAN-2003 (first entry)
XX
XX Haematopoietic cell proliferation disorder related oligonucleotide #1086.
XX
XX Human; haematopoietic cell proliferation disorder; cytostatic;
XX gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
XX cytosine methylation state; probe; primer; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO20027272-A2.
XX
XX 03-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-BF003401.
XX
XX 26-MAR-2001; 2001US-0278333P.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwöpe I, Ziebarth H;
XX
XX WPI; 2003-018942/01.
XX
XX Detecting and differentiating between hematopoietic cell proliferative
XX disorders, comprises contacting a target nucleic acid with a reagent that
XX distinguishes between methylated and non-methylated CpG dinucleotides.
XX
XX Claim 15; Page 71; 117pp; English.
XX
XX The present invention describes a method for detecting and
XX differentiating between haematopoietic cell proliferative disorders
XX associated with at least 1 gene and/or their regulatory regions in a
XX subject. The method comprises contacting a target nucleic acid in a
XX biological sample obtained from the subject with at least 1 reagent,
XX which distinguishes between methylated and non-methylated CpG
XX dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
XX represent specifically claimed nucleotide sequences from the present
XX invention. Oligonucleotides from the present invention can be used: for
XX differentiating between healthy haematopoietic cells and proliferative
XX disorder haematopoietic cells; for differentiating between acute
XX lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
XX determining the cytosine methylation state and/or single nucleotide
XX polymorphisms (SNPs) of haematopoietic cell proliferation disorder
XX related sequences and their complements; and as primers for the
XX amplification of haematopoietic cell proliferation disorder related DNA
XX sequences. The nucleotide sequences from the present invention can also
XX be used for detecting a predisposition to, differentiation between
XX subclasses, diagnosis, prognosis, treatment and/or monitoring of
XX haematopoietic cell proliferative disorders. The present method enables a
XX highly specific classification of haematopoietic cell proliferative
XX disorders allowing for improved and informed treatment of patients
XX
XX Sequence 18 BP; 4 A; 0 C; 13 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 244 CTGCCCCCACCCTCCCC 259
Db 17 CTTCCCCCACCCTCCCC 2
|||||
|||||
|||||
RESULT 214
ADH59543
ID ADH59543 standard; DNA; 18 BP.
XX
XX ADH59543;
XX
XX 25-MAR-2004 (first entry)
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy; proliferation;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
XX hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
XX arthritis; cardiac; vulnary; cytostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.
XX
XX Homo sapiens.
XX
XX US2003039972-A1.
XX
XX 27-FEB-2003.
XX

```

XX 16-JUL-2001; 2001US-00906700.
XX 17-SEP-1997; 97US-00591113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059124P.
PR 18-SEP-1997; 97US-0059266P.
PR 18-SEP-1997; 97US-0059263P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 31-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0080026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US020944.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2003-503393/47.
XX
XX New isolated PRO polypeptides e.g. PRO211, PRO217 and PRO230, useful for
PT treating Parkinson's disease, Alzheimer's disease, amyotrophic lateral
PT sclerosis, cancer, neuropathies and psoriasis.
XX
XX Example 38; Page 106; 476pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are

CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
|||||
Db 3 CAGCATGTACTGCCAG 18

RESULT 215

ADI38322
ID ADI38322 standard; DNA; 18 BP.

XX
AC ADI38322;

XX
DT 22-APR-2004 (first entry)

XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypotension; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnery; cytosolic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.

XX
OS Homo sapiens.

XX
PN US2003054352-A1.

XX
XX 20-MAR-2003.

XX
XX 17-JUL-2001; 2001US-00907925.

XX
PF 17-SEP-1997; 97US-0059113P.

XX
PR 17-SEP-1997; 97US-0059115P.

XX
PR 17-SEP-1997; 97US-0059117P.

XX
PR 17-SEP-1997; 97US-0059119P.

XX
PR 17-SEP-1997; 97US-0059121P.

XX
PR 17-SEP-1997; 97US-0059122P.

XX
PR 17-SEP-1997; 97US-0059184P.

XX
PR 18-SEP-1997; 97US-0059263P.

XX
PR 18-SEP-1997; 97US-0059266P.

XX
PR 15-OCT-1997; 97US-0062125P.

XX
PR 17-OCT-1997; 97US-0062285P.

XX
PR 17-OCT-1997; 97US-0062287P.

XX
PR 21-OCT-1997; 97US-0063486P.

XX
PR 24-OCT-1997; 97US-0062814P.

XX
PR 24-OCT-1997; 97US-0062816P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 29-OCT-1997; 97US-0064215P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.

PR 12-NOV-1997; 97US-0065186P.

PR 17-NOV-1997; 97US-0065846P.

PR 18-NOV-1997; 97US-0065693P.

PR 21-NOV-1997; 97US-0066120P.

PR 21-NOV-1997; 97US-0066364P.

PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066511P.

PR 24-NOV-1997; 97US-0066770P.

PR 24-NOV-1997; 97US-0066772P.

PR 25-NOV-1997; 97US-0066840P.

PR 12-DEC-1997; 97US-0069425P.

PR 04-JUN-1998; 98US-0088026P.

PR 10-SEP-1998; 98US-009803P.

PR 10-SEP-1998; 98US-009803P.

PR 14-SEP-1998; 98US-0100262P.

PR 14-SEP-1998; 98US-0100262P.

PR 16-SEP-1998; 98US-0100262P.

PR 16-SEP-1998; 98US-0100262P.

PR 17-SEP-1998; 98US-0100858P.

PR 17-SEP-1998; 98US-0100858P.

PR 13-OCT-1998; 98US-0104080P.

PR 20-NOV-1998; 98US-0109304P.

PR 01-DEC-1998; 98US-0109304P.

PR 01-DEC-1998; 98US-0109304P.

PR 22-DEC-1998; 98US-0113296P.

PR 07-JUL-1999; 99US-0143048P.

PR 26-JUL-1999; 99US-0145698P.

PR 28-JUL-1999; 99US-0146222P.

PR 08-SEP-1999; 99US-0146222P.

PR 13-SEP-1999; 99US-0146222P.

PR 15-SEP-1999; 99US-0146222P.

PR 15-SEP-1999; 99US-0146222P.

PR 05-OCT-1999; 99US-0146222P.

PR 29-NOV-1999; 99US-0146222P.

PR 30-NOV-1999; 99US-0146222P.

PR 01-DEC-1999; 99US-0146222P.

PR 02-DEC-1999; 99US-0146222P.

PR 02-DEC-1999; 99US-0146222P.

PR 16-DEC-1999; 99US-0146222P.

PR 20-DEC-1999; 99US-0146222P.

PR 20-DEC-1999; 99US-0146222P.

PR 05-JAN-2000; 2000US-0000219.

PR 11-FEB-2000; 2000US-0000219.

PR 22-FEB-2000; 2000US-0000219.

PR 24-FEB-2000; 2000US-0000219.

PR 02-MAR-2000; 2000US-0000219.

PR 20-MAR-2000; 2000US-0000219.

PR 30-MAR-2000; 2000US-0000219.

PR 22-MAY-2000; 2000US-0000219.

PR 02-JUN-2000; 2000US-0000219.

PR 28-JUL-2000; 2000US-0000219.

PR 24-AUG-2000; 2000US-0000219.

PR 18-SEP-2000; 2000US-0000219.

XX (GETH) GENENTECH INC.

PA Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N;

XX PI

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini ID;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
XX Williams PM, Wood WI;
XX WPI; 2003-695899/66.
XX
XX Novel isolated native PRO polypeptide useful for treating Parkinson's
PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal
PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usher
PT syndrome.
XX
XX Example 38; Page 105; 47pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1467 CAGCTGTACTGCCAG 1482
Db 3 CAGCATGTACTGCCAG 18
|||||
|||||
RESULT 216
ADJ26590

ID ADJ26590 standard; DNA; 18 BP.
XX
AC ADJ26590;
XX
DT 20-MAY-2004 (first entry)
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
DE
XX Human; PCR; primer; as; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
PN US2003054349-A1.
XX
PD 20-MAR-2003.
XX
PF 11-JUL-2001; 2001US-00903943.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028569.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
PA (GETH) GENENTECH INC.
XX
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-708341/67.
XX
PT Novel isolated native PRO polypeptide useful for tissue typing,
PT modulating biological activity of cell, as molecular weight markers in
PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison
PT syndrome.
XX
PS Example 38; Page 111; 483pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal

CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1467 CAGCCTGACTGCCAG 1482
Db 3 CAGCATGACTGCCAG 18
|||||
RESULT 217
ADE99693
ID ADE99693 standard; DNA; 18 BP.
XX
AC ADE99693;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy; proliferation;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocytes; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW osteopathic; antiarthritic; cytostatic; ophthalmological;
XX
OS Homo sapiens.
XX
PN US2003211576-A1.
XX
PD 13-NOV-2003.
XX

PF 18-NOV-2002; 2002US-00298993.
XX 22-FEB-2000; 2000WO-US004414.
PR 18-SEP-2000; 2000US-00665350.

XX (GETH) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen KE, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2004-021580/02.

XX New PRO polypeptide for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT inflammatory diseases, cancer or acquired immunodeficiency syndrome.

XX Example 38; Page 106; 476pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in the disclosure of the patent but differs
CC from the sequence represented in the Sequence Listing.

XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGACTGCTCCAG 1482
||| |||||
DB 3 CAGCATGTAAGTCCAG 18

RESULT 218

AD98813
ID ADE98813 standard; DNA; 18 BP.

XX ADE98813;

XX 12-FEB-2004 (first entry)

XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.

XX Human; PCR; primer; as; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

XX US2003211569-A1.

XX 13-NOV-2003.

XX 12-JUL-2001; 2001US-00904938.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 18-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 27-OCT-1997; 97US-0063327P.

PR 27-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 29-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 31-OCT-1997; 97US-0064215P.

PR 31-OCT-1997; 97US-0063870P.

PR 03-NOV-1997; 97US-0064103P.

PR 07-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.

PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 17-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003569.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, KJavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
WPI; 2004-021576/02.
XX
PT New isolated native PRO polypeptide useful for treating Parkinson's
PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal
PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, or Usher
PT syndrome.
XX
PS Example 38; Page 99; 469pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues of serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 36 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1467 CAGCCTGTACTGCCAG 1482
Db 3 CAGCATGTACTGCCAG 18
RESULT 219
ADE99240
ID ADE99240 standard; DNA; 18 BP.
XX
AC ADE99240;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy; proliferation;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabete; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;

osteopathic; antiarthritic; anorectic.

Homo sapiens.

US2003211568-A1.

13-NOV-2003.

12-JUL-2001; 2001US-00904805.

27-OCT-1997; 97US-0063327P.

18-SEP-1998; 2000WO-US015330;
22-FEB-2000; 2000WO-US004414.

000000-000000; 0000-0000

CONFIDENTIAL (UFG)

Filvaroff E, Fong S,

Williams PM, Wood WI;
Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

WPI; 2004-021575/02.

New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

Example 38; Page 99; 473pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a

antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosum), obesity, diabetes, hyperinsulinaemia, hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a DNA probe which was used to detect a PRO polynucleotide of the invention. NOTE: This sequence is described as SEQ ID NO 239 in Example 38 of the disclosure but is different from SEQ ID NO 239 represented in the Sequence Listing.

Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
DB 3 CAGCATGTACTGCCAG 18
|||||

RESULT 221

ADG92523
ID ADG92523 standard; DNA; 18 BP.

XX AC ADG92523;

XX 11-MAR-2004 (first entry)

DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.

KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; obesity; diabetes; tumour; retinal disorder;
KW retinitis pigmentosum; obesity; diabetes; hyperinsulinaemia;
KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;

KW arthritis; cardiant; vulnery; cytostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.

OS Homo sapiens.

PN US2003027145-A1.

XX 06-FEB-2003.

XX 17-JUL-2001; 2001US-00907613.

XX 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 24-OCT-1997; 97US-0063128P.

PR 27-OCT-1997; 97US-0063327P.

PR 27-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 31-OCT-1997; 97US-0064215P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.

PR 12-NOV-1997; 97US-0065186P.

PR 17-NOV-1997; 97US-0065846P.

PR 18-NOV-1997; 97US-0065693P.

PR 21-NOV-1997; 97US-0066120P.

PR 21-NOV-1997; 97US-0066364P.

PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066511P.

PR 24-NOV-1997; 97US-0066770P.

PR 24-NOV-1997; 97US-0066772P.

PR 25-NOV-1997; 97US-0066840P.

PR 12-DEC-1997; 97US-0069425P.

PR 04-JUN-1998; 98US-0088026P.

PR 10-SEP-1998; 98US-0098033P.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98US-0100262P.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100859P.

PR 17-SEP-1998; 98WO-US019437.

PR 13-OCT-1998; 98US-0104080P.

PR 20-NOV-1998; 98US-0109304P.

PR 01-DEC-1998; 98WO-US025108.

24-OCT-1997; 97US-0062814P.
24-OCT-1997; 97US-0062816P.
24-OCT-1997; 97US-0063045P.
24-OCT-1997; 97US-0063120P.
24-OCT-1997; 97US-0063121P.
24-OCT-1997; 97US-0063127P.
24-OCT-1997; 97US-0063128P.
24-OCT-1997; 97US-0063327P.
27-OCT-1997; 97US-0063329P.
28-OCT-1997; 97US-0063541P.
28-OCT-1997; 97US-0063542P.
28-OCT-1997; 97US-0063544P.
28-OCT-1997; 97US-0063549P.
28-OCT-1997; 97US-0063550P.
28-OCT-1997; 97US-0063564P.
29-OCT-1997; 97US-0063435P.
29-OCT-1997; 97US-0063704P.
29-OCT-1997; 97US-0063732P.
29-OCT-1997; 97US-0063734P.
29-OCT-1997; 97US-0063735P.
29-OCT-1997; 97US-0064215P.
31-OCT-1997; 97US-0063870P.
31-OCT-1997; 97US-0064103P.
03-NOV-1997; 97US-0064248P.
07-NOV-1997; 97US-0064809P.
12-NOV-1997; 97US-0065186P.
17-NOV-1997; 97US-0065846P.
18-NOV-1997; 97US-0065693P.
21-NOV-1997; 97US-0066120P.
21-NOV-1997; 97US-0066364P.
24-NOV-1997; 97US-0066453P.
24-NOV-1997; 97US-0066466P.
24-NOV-1997; 97US-0066511P.
24-NOV-1997; 97US-0066770P.
24-NOV-1997; 97US-0066772P.
25-NOV-1997; 97US-0066840P.
12-DEC-1997; 97US-0069425P.
04-JUN-1998; 98US-0080266P.
10-SEP-1998; 98US-0099803P.
10-SEP-1998; 98US-0098082P.
14-SEP-1998; 98US-0100262P.
14-SEP-1998; 98US-0100917P.
16-SEP-1998; 98US-0101933P.
17-SEP-1998; 98US-0100858P.
17-SEP-1998; 98US-0101943P.
13-OCT-1998; 98US-0104080P.
20-NOV-1998; 98US-0109304P.
01-DEC-1998; 98US-0109304P.
22-DEC-1998; 98US-0113296P.
07-JUL-1999; 99US-0143048P.
26-JUL-1999; 99US-0145698P.
28-JUL-1999; 99US-0146222P.
08-SEP-1999; 99US-0200594P.
13-SEP-1999; 99US-0202094P.
15-SEP-1999; 99US-0202109P.
05-OCT-1999; 99US-0202154P.
15-SEP-1999; 99US-0203089P.
29-NOV-1999; 99US-0208214P.
30-NOV-1999; 99US-0208313P.
01-DEC-1999; 99US-0208301P.
02-DEC-1999; 99US-0208564P.
02-DEC-1999; 99US-0208565P.
16-DEC-1999; 99US-02030095P.
20-DEC-1999; 99US-0203091P.
20-DEC-1999; 99US-0203099P.
05-JAN-2000; 2000US-0000219P.
11-FEB-2000; 2000US-0003565P.
22-FEB-2000; 2000US-0004414P.
24-FEB-2000; 2000US-0005004P.
02-MAR-2000; 2000US-0005841P.
20-MAR-2000; 2000US-0007377P.
30-MAR-2000; 2000US-0008433P.

22-MAY-2000; 2000US-00014042.
02-JUN-2000; 2000US-00015264.
28-JUL-2000; 2000US-00020710.
24-AUG-2000; 2000US-00023328.
18-SEP-2000; 2000US-00065350.
XX (GETH) GENENTECH INC.
PA
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2004-106404/11.
DR
XX Isolated nucleic acid encoding a polypeptide useful for various
PT applications e.g. hybridization probes.
PT
XX
PS Example 38; Page 103; 474pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
Db ||||| ||||| ||||| |||||
3 CAGCATGTACTGCCAG 18
RESULT 223
ADH20739
ID ADH20739 standard; DNA; 18 BP.
XX
AC ADH20739;
XX
DT DT
XX 25-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cytosatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
XX US2004005553-A1.
XX
XX 08-JAN-2004.
XX
XX 18-JUL-2001; 2001US-00908576.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.

PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
XX Filvaroff E, Fong S, Gerber H, Gerritsen ME, Goddard A;
XX Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;
XX Mather JP, Pan J, Faoni NF, Roy MA, Stewart TA, Tumas D;
XX Williams PM, Wood WI;
XX WPI; 2004-081703/08.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor, for chromosome mapping or for tissue
XX typing.
XX
XX Example 38; Page 106; 136pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
XX and the nucleic acid encoding them. The polypeptides can be used to raise
XX antibodies that specifically bind to the PRO polypeptide, for linking a
XX bioactive molecule to a cell expressing a PRO protein and for modulating
XX

at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a DNA probe which was used to detect a PRO polynucleotide of the invention. NOTE: This sequence is described as SEQ ID NO 239 in Example 38 of the disclosure but is different from SEQ ID NO 239 represented in the Sequence Listing.

Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1467 CAGCCTGTACTGCCAG 1482
|||||
3 CAGCATGTACTGCCAG 18

Db

RESULT 224
ADH07594
ID ADH07594 standard; DNA; 18 BP.
XX
AC ADH07594;
XX
XX
DT 25-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW protein therapy.
XX
OS Homo sapiens.
XX
PN US2004006211-A1.
XX
XX 08-JAN-2004.
PD

29-MAY-2003; 2003US-00448713.
XX
24-OCT-1997; 97US-0063128P.
PR 16-SEP-1998; 98WO-US019330.
PR 30-NOV-1999; 99WO-US028313.
PR 22-FEB-2000; 2000WO-US004414.
PR 18-SEP-2000; 2000US-00665350.
PR 12-JUL-2001; 2001US-00905125.
XX (DESN/) DESNOYERS L.
PA (GODD/) GODDARD A.
PA (GODD/) GODOWSKI P J.
PA (GURN/) GURNEY A L.
PA (MATH/) MATHER J P.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX
Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP;
PI Williams PM, Wood WI;
XX
WPI; 2004-081748/08.
XX
New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, as molecular weight markers for protein electrophoresis, as hybridization probes or as therapeutic agents.
XX
Example 38; Page 99; 466pp; English.
XX
The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. The PRO sequences can be used in gene and protein therapy. The PRO polypeptide, the agonist or antagonist or the anti-PRO antibody can be used in the preparation of a medicament for the treatment of a condition which is responsive to the PRO polypeptide, the agonist or antagonist or the anti-PRO antibody. The nucleic acids encoding PRO polypeptides are used as hybridisation probes for gene mapping, generating transgenic animals useful in the development and screening of PRO polypeptides, in chromosome identification or for tissue typing. The PRO polypeptides are also useful in gene therapy, may be employed as molecular weight markers for protein electrophoresis or as therapeutic agents. Anti-PRO antibodies are useful in diagnostic assays or for the affinity purification of PRO for recombinant cell culture or natural sources. The sequence presented is a DNA probe which was used to detect a PRO polynucleotide of the invention. NOTE: This sequence is described as SEQ ID NO 239 in Example 38 of the disclosure but is different from SEQ ID NO 239 represented in the Sequence Listing.

Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1467 CAGCCTGTACTGCCAG 1482
|||||
3 CAGCATGTACTGCCAG 18

Db

RESULT 225
ADH60139
ID ADH60139 standard; DNA; 18 BP.
XX
AC ADH60139;
XX
XX 25-MAR-2004 (first entry)
DT

XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
DE Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cycostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
XX US2003215904-A1.
XX
XX 20-NOV-2003.
XX
XX 16-JUL-2001; 2001US-00906722.
XX
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063814P.
XX 24-OCT-1997; 97US-0063816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 24-OCT-1997; 97US-0063127P.
XX 24-OCT-1997; 97US-0063128P.
XX 27-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063542P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063549P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063435P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063732P.
XX 29-OCT-1997; 97US-0063734P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 31-OCT-1997; 97US-0064215P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065846P.
XX 18-NOV-1997; 97US-0065693P.
XX 21-NOV-1997; 97US-0066120P.
XX 21-NOV-1997; 97US-0066364P.
XX 24-NOV-1997; 97US-0066453P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066511P.
XX 24-NOV-1997; 97US-0066770P.
XX 24-NOV-1997; 97US-0066772P.
XX 25-NOV-1997; 97US-0066840P.
XX 12-DEC-1997; 97US-0069425P.

XX 04-JUN-1998; 98US-0088026P.
XX 10-SEP-1998; 98US-0099803P.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98US-0100262P.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US00858P.
XX 17-SEP-1998; 98WO-US019437.
XX 13-OCT-1998; 98US-0104080P.
XX 13-OCT-1998; 98US-0109304P.
XX 01-DEC-1998; 98WO-US025108.
XX 22-DEC-1998; 98US-0113296P.
XX 07-JUL-1999; 98US-0143048P.
XX 26-JUL-1999; 98US-0145698P.
XX 28-JUL-1999; 98US-0146222P.
XX 08-SEP-1999; 98WO-US020594.
XX 13-SEP-1999; 98WO-US020944.
XX 15-SEP-1999; 98WO-US021090.
XX 15-SEP-1999; 98WO-US021547.
XX 05-OCT-1999; 98WO-US023089.
XX 29-NOV-1999; 98WO-US028214.
XX 30-NOV-1999; 98WO-US028313.
XX 01-DEC-1999; 98WO-US028301.
XX 02-DEC-1999; 98WO-US028564.
XX 02-DEC-1999; 98WO-US028565.
XX 16-DEC-1999; 98WO-US030095.
XX 20-DEC-1999; 98WO-US030911.
XX 20-DEC-1999; 98WO-US030999.
XX 05-JAN-2000; 2000WO-US000219.
XX 11-FEB-2000; 2000WO-US003565.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US005004.
XX 02-MAR-2000; 2000WO-US005841.
XX 20-MAR-2000; 2000WO-US007377.
XX 30-MAR-2000; 2000WO-US008439.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 24-AUG-2000; 2000WO-US023328.
XX 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2004-141684/14.

Novel isolated native PRO polypeptide useful for tissue typing, as
molecular weight markers in protein electrophoresis, for treating
enterocolitis, Zollinger-Ellison syndrome, congenital microvillus
atrophy.

Example 38; Page 99; 470pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides
and the nucleic acid encoding them. The polypeptides can be used to raise
antibodies that specifically bind to the PRO polypeptide, for linking a
bioactive molecule to a cell expressing a PRO protein and for modulating
at least one biological activity of a cell. PRO polypeptides are useful
for detecting other PRO polypeptides in a sample and for linking a
bioactive molecule to a cell expressing a PRO polypeptide. The PRO
polypeptide antibodies are useful for modulating the biological activity
of a cell expressing PRO polypeptides. The PRO polypeptides or
polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
bioreactors. These are useful for stimulating hypertrophy of neonatal
heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
proliferation of endothelial cells, modulating the proliferation of
stimulated T-lymphocytes, enhancing the survival or proliferation of
retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial

CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiating of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
|||||
Db 3 CAGCATGTACTGCCAG 18

RESULT 226
ADH07167
ID ADH07167 standard; DNA; 18 BP.
XX
AC ADH07167;
XX
XX 25-MAR-2004 (first entry)
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
DE Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW protein therapy.
XX
XX Homo sapiens.
XX
XX US2004005665-A1.
XX
XX 08-JAN-2004.
XX
XX 29-MAY-2003; 2003US-00449656.
XX
XX 24-OCT-1997; 97US-0063128P.
PR 16-SEP-1998; 98WO-US019330.
PR 30-NOV-1999; 99WO-US028313.
PR 22-FEB-2000; 2000WO-US004414.
PR 18-SEP-2000; 2000US-00665350.
PR 17-JUL-2001; 2001US-00907794.
XX
XX (DESN//) DESNOYERS L.
PA (GODD//) GODDARD A.

PA (GODD//) GODOWSKI P J.
PA (GURN//) GURNEY A L.
PA (MATH//) MATHER J P.
PA (WILL//) WILLIAMS P M.
PA (WOOD//) WOOD W I.
XX
XX Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP;
PI Williams PW, Wood WI;
XX
XX WPI; 2004-081725/08.
XX
XX New PRO polypeptides and nucleic acid molecules, useful in gene therapy,
PT or preparing a medicament for treating a condition that is responsive to
PT the PRO polypeptide or anti-PRO antibody, e.g. inflammatory diseases,
PT cancer or AIDS.
XX
XX Example 38; Page 93; 462pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. The PRO sequences can be used in gene and protein therapy.
CC The PRO polypeptide, the agonist or antagonist or the anti-PRO antibody
CC can be used in the preparation of a medicament for the treatment of a
CC condition which is responsive to the PRO polypeptide, the agonist or
CC antagonist or the anti-PRO antibody. The nucleic acids encoding PRO
CC polypeptides are used as hybridisation probes for gene mapping,
CC generating transgenic animals useful in the development and screening of
CC useful reagents, in chromosome identification or for tissue typing. The
CC PRO polypeptides are also useful in gene therapy, may be employed as
CC molecular weight markers for protein electrophoresis or as therapeutic
CC agents. Anti-PRO antibodies are useful in diagnostic assays or for the
CC affinity purification of PRO for recombinant cell culture or natural
CC sources. The sequence presented is a DNA probe which was used to detect a
CC PRO polynucleotide of the invention. NOTE: This sequence is described as
CC SEQ ID NO 239 in Example 38 of the disclosure but is different from SEQ
CC ID NO 239 represented in the Sequence Listing.
XX
XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
|||||
Db 3 CAGCATGTACTGCCAG 18

RESULT 227
AD118909
ID AD118909 standard; DNA; 18 BP.
XX
AC AD118909;
XX
XX 15-APR-2004 (first entry)
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;

KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
 KW arthritis; cardiac; vulnerary; cycostatic; ophthalmological;
 XX osteopathic; antiarthritic; anorectic.

OS Homo sapiens.

XX US2003152999-A1.

XX PD 14-AUG-2003.

XX PF 12-JUL-2001; 2001US-00904766.

XX PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 24-OCT-1997; 97US-0063128P.

PR 27-OCT-1997; 97US-0063327P.

PR 27-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 29-OCT-1997; 97US-0064215P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.

PR 12-NOV-1997; 97US-0065186P.

PR 17-NOV-1997; 97US-0065846P.

PR 18-NOV-1997; 97US-0065893P.

PR 21-NOV-1997; 97US-0066120P.

PR 21-NOV-1997; 97US-0066364P.

PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066511P.

PR 24-NOV-1997; 97US-0066770P.

PR 24-NOV-1997; 97US-0066772P.

PR 25-NOV-1997; 97US-0066840P.

PR 12-DEC-1997; 97US-0069425P.

PR 04-JUN-1998; 98US-0088026P.

PR 10-SEP-1998; 98US-0099803P.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98US-0100262P.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100858P.

PR 17-SEP-1998; 98WO-US019437.

PR 13-OCT-1998; 98US-0104080P.

PR 20-NOV-1998; 98US-0109304P.

PR 01-DEC-1998; 98WO-US025108.

PR 22-DEC-1998; 98US-0113298P.

PR 07-JUL-1999; 99US-0143048P.

PR 26-JUL-1999; 99US-0145698P.

PR 28-JUL-1999; 99US-0146222P.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 05-JAN-2000; 2000WO-US000219.

PR 11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.

PR 20-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US008439.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00665350.

XX (GETH) GENENTECH INC.

PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX WPI; 2004-020479/02.

DR Sixty two isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245

PT or PRO1868, useful for treating psoriasis and epithelial cancers such as

PT lung squamous cell carcinoma.

XX Example 38; Page 103; 436pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides

CC and the nucleic acid encoding them. The polypeptides can be used to raise

CC antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating

CC at least one biological activity of a cell. PRO polypeptides are useful

CC for detecting other PRO polypeptides in a sample and for linking a

CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO

CC polypeptide antibodies are useful for modulating the biological activity

CC of a cell expressing PRO polypeptides. The PRO polypeptides or

CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or

CC bioreactors. These are useful for stimulating hypertrophy of neonatal

CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated

CC proliferation of endothelial cells, modulating the proliferation of

CC stimulated T-lymphocytes, enhancing the survival or proliferation of

CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial

CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re

CC differentiation of chondrocytes. In particular, these are useful for

CC detecting or treating cardiac insufficiency disorders, wounds, cancerous

CC tumours, retinal disorders or injuries (e.g. loss of sight due to

CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,

CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or

CC arthritis) in mammals. PRO polypeptides and their portions affect the

CC expression of genes which have a role in cell death. The polynucleotides

CC are useful in molecular biology including uses as hybridisation probes

CC for cDNA library to isolate the full-length PRO cDNA or to isolate other

CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA

CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482

Db 3 CAGCATGTACTGCCAG 18

RESULT 228

AD165629

ID AD165629 standard; DNA; 18 BP.

AC AD165629;

DT 22-APR-2004 (first entry)

DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;

KW tissue typing; immunohistochemical staining; gene therapy;

KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;

KW endothelial cell; stimulated T-lymphocyte; retinal neuron;

KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;

KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;

KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;

KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;

KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

OS US2003148419-A1.

PN 07-AUG-2003.

PD 11-JUL-2001; 2001US-00903603.

PF 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0098030P.
PR 10-SEP-1998; 98US-0098033P.
PR 14-SEP-1998; 98US-0098034P.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98US-0101917P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0101943P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99US-0146222P.
PR 13-SEP-1999; 99US-0146222P.
PR 15-SEP-1999; 99US-0146222P.
PR 15-SEP-1999; 99US-0146222P.
PR 15-SEP-1999; 99US-0146222P.
PR 15-SEP-1999; 99US-0146222P.
PR 29-NOV-1999; 99US-0146222P.
PR 30-NOV-1999; 99US-0146222P.
PR 01-DEC-1999; 99US-0146222P.
PR 02-DEC-1999; 99US-0146222P.
PR 02-DEC-1999; 99US-0146222P.
PR 16-DEC-1999; 99US-0146222P.
PR 20-DEC-1999; 99US-0146222P.
PR 20-DEC-1999; 99US-0146222P.
PR 05-JAN-2000; 2000US-0000219.
PR 11-FEB-2000; 2000US-0003565.
PR 22-FEB-2000; 2000US-0004414.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 20-MAR-2000; 2000US-0007377.
PR 30-MAR-2000; 2000US-0008439.

PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
PA (GETH) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, KJjavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-020444/02.

XX New isolated secreted and transmembrane PRO nucleic acids and
PT polypeptides, useful for preventing, diagnosing and treating disorders
PT associated with their aberrant expression and activity.
XX
PS Example 38; Page 106; 476pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGACTGCCAG 1482
||| |||||
Db 3 CAGCATGACTGCCAG 18

RESULT 229

AD137888
ID AD137888 standard; DNA; 18 BP.
XX
AC AD137888;
XX
DT 22-APR-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiant; vulnerable; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
XX US2003096340-A1.
XX
PD 22-MAY-2003.
XX
PF 16-JUL-2001; 2001US-00906760.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-00658146P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066710P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0099803P.
 PR 14-SEP-1998; 98US-00101824.
 PR 14-SEP-1998; 98US-0100262P.
 PR 14-SEP-1998; 98US-001019177.
 PR 16-SEP-1998; 98US-001019330.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98US-001019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98US-00202108.
 PR 07-JUL-1999; 99US-0113296P.
 PR 26-JUL-1999; 99US-0143048P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99US-0020594.
 PR 13-SEP-1999; 99US-0020944.
 PR 15-SEP-1999; 99US-002021090.
 PR 15-SEP-1999; 99US-002021547.
 PR 05-OCT-1999; 99US-00203089.
 PR 29-NOV-1999; 99US-00202814.
 PR 30-NOV-1999; 99US-0028313.
 PR 01-DEC-1999; 99US-0028301.
 PR 02-DEC-1999; 99US-0028564.
 PR 02-DEC-1999; 99US-0028565.
 PR 16-DEC-1999; 99US-0030095.
 PR 20-DEC-1999; 99US-0030911.
 PR 20-DEC-1999; 99US-0030999.
 PR 05-JAN-2000; 2000US-0000219.
 PR 11-FEB-2000; 2000US-00003565.
 PR 22-FEB-2000; 2000US-0004414.
 PR 24-FEB-2000; 2000US-0005004.
 PR 02-MAR-2000; 2000US-0005841.
 PR 20-MAR-2000; 2000US-0007377.
 PR 30-MAR-2000; 2000US-0008439.
 PR 22-MAY-2000; 2000US-0014042.
 PR 02-JUN-2000; 2000US-0015264.
 PR 28-JUL-2000; 2000US-0020710.
 PR 24-AUG-2000; 2000US-0023328.
 PR 18-SEP-2000; 2000US-00665350.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Botstein D, Desnoyers I, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
 PI Mather JP, Pan J, Faoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX
 DR WPI; 2004-008942/01.
 XX
 XX
 PT New PRO nucleic acid, useful for producing a PRO polypeptide,
 PT manufacturing a medicament for diagnosing or treating tumor, or for
 PT tissue typing.
 XX
 PS Example 38; Page 105; 474pp; English.
 XX
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
 CC proliferation of endothelial cells, modulating the proliferation of
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
 CC -differentiation of chondrocytes. In particular, these are useful for
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
 CC arthritis) in mammals. PRO polypeptides and their portions affect the
 CC expression of genes which have a role in cell death. The polynucleotides
 CC are useful in molecular biology including uses as hybridisation probes
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
 CC and DNA, for preparing PRO polypeptides, for generating transgenic
 CC animals or knockout animals which are useful in the development and
 CC screening of therapeutically useful reagents, as probes and for the
 CC genetic analysis of individuals with genetic disorders as well as for
 CC recombinantly expressing the protein and for chromosome identification.
 CC The proteins are useful as molecular marker for protein electrophoresis
 CC purposes, as therapeutic agents, for screening compounds to identify
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
 CC useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequence presented is a DNA probe which was used to
 CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
 CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
 CC different from SEQ ID NO 239 represented in the Sequence Listing.
 XX
 SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1467 CAGCCTGTACTGCCAG 1482
 Db 3 CAGCATGTACTGCCAG 18
 |||||
 |||||
 RESULT 230
 ADH97688
 ID ADH97688 standard; DNA; 18 BP.
 XX
 AC ADH97688;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
 XX
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy; proliferation;
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;

osteopathic; antiarthritic; anorectic.
Homo sapiens.
US2003190610-A1.
09-OCT-2003.
16-JUL-2001; 2001US-00906618.
17-SEP-1997; 97US-0059113P.
17-SEP-1997; 97US-0059115P.
17-SEP-1997; 97US-0059117P.
17-SEP-1997; 97US-0059119P.
17-SEP-1997; 97US-0059121P.
17-SEP-1997; 97US-0059122P.
17-SEP-1997; 97US-0059184P.
18-SEP-1997; 97US-0059263P.
18-SEP-1997; 97US-0059266P.
15-OCT-1997; 97US-0062125P.
17-OCT-1997; 97US-0062285P.
17-OCT-1997; 97US-0062287P.
21-OCT-1997; 97US-0063486P.
24-OCT-1997; 97US-0062814P.
24-OCT-1997; 97US-0062816P.
24-OCT-1997; 97US-0063045P.
24-OCT-1997; 97US-0063120P.
24-OCT-1997; 97US-0063121P.
24-OCT-1997; 97US-0063127P.
24-OCT-1997; 97US-0063128P.
27-OCT-1997; 97US-0063327P.
27-OCT-1997; 97US-0063329P.
28-OCT-1997; 97US-0063541P.
28-OCT-1997; 97US-0063542P.
28-OCT-1997; 97US-0063544P.
28-OCT-1997; 97US-0063549P.
28-OCT-1997; 97US-0063550P.
28-OCT-1997; 97US-0063564P.
29-OCT-1997; 97US-0063435P.
29-OCT-1997; 97US-0063704P.
29-OCT-1997; 97US-0063732P.
29-OCT-1997; 97US-0063734P.
29-OCT-1997; 97US-0063735P.
29-OCT-1997; 97US-0063738P.
31-OCT-1997; 97US-0064215P.
31-OCT-1997; 97US-0063870P.
31-OCT-1997; 97US-0064103P.
03-NOV-1997; 97US-0064248P.
07-NOV-1997; 97US-0064809P.
12-NOV-1997; 97US-0065186P.
17-NOV-1997; 97US-0065846P.
18-NOV-1997; 97US-0065693P.
21-NOV-1997; 97US-0066120P.
21-NOV-1997; 97US-0066364P.
24-NOV-1997; 97US-0066453P.
24-NOV-1997; 97US-0066466P.
24-NOV-1997; 97US-0066511P.
24-NOV-1997; 97US-0066770P.
24-NOV-1997; 97US-0066772P.
25-NOV-1997; 97US-0066840P.
12-DEC-1997; 97US-0069425P.
04-JUN-1998; 98US-0088026P.
10-SEP-1998; 98US-0099803P.
10-SEP-1998; 98WO-US019824.
14-SEP-1998; 98US-0100262P.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98US-0100858P.
17-SEP-1998; 98WO-US019437.
13-OCT-1998; 98US-0104080P.
20-NOV-1998; 98US-0109304P.
01-DEC-1998; 98WO-US025108.
22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX (GETH) GENENTECH INC.
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2004-032142/03.
XX New nucleic acid encoding a PRO polypeptide, useful for producing a
PT recombinant PRO polypeptide and for treating tumors by gene therapy.
PT Example 38; Page 101; 471pp; English.
PS The invention discloses isolated PRO secreted/transmembrane polypeptides.
XX and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and the
CC screening of therapeutically useful reagents, as probes and for the

CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1467 CAGCCTGTACTGCCAG 1482
||| |||||
Db 3 CAGCATGTACTGCCAG 18

RESULT 231

ADI66056

ID ADI66056 standard; DNA; 18 BP.

AC ADI66056;

DT 22-APR-2004 (first entry)

DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.

KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cycostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.

OS Homo sapiens.

PN US2003148371-A1.

PD 07-AUG-2003.

PF 16-JUL-2001; 2001US-0096777.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064803P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003555.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 28-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.

PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.

XX (GETH) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IU;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI: 2004-020441/02.

XX Isolated secreted and transmembrane PRO nucleic acids and the proteins
PT they encode, e.g. PRO245, PRO269 and PRO1868, useful for preventing,
PT diagnosing and treating e.g. disorders relating to blood coagulation.

XX Example 38; Page 102; 478pp; English.

CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiating of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482

||||| |||||||||

Db. 3 CAGCCTGTACTGCCAG 18

RESULT 232

ADM25390

ID ADM25390 standard; DNA; 18 BP.

XX ADM25390;

AC ADM25390;

XX 20-MAY-2004 (first entry)

XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;

KW tissue typing; immunohistochemical staining; gene therapy;

KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;

KW endothelial cell; stimulated T-lymphocyte; retinal neuron;

KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;

KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;

KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;

KW arthritis; cardiac; vulvovaginal; cytostatic; ophthalmological;

KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

OS US2003096233-A1.

PN 22-MAY-2003.

XX 11-JUL-2001; 2001US-00903925.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 18-SEP-1997; 97US-0059263P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063814P.

PR 24-OCT-1997; 97US-0063816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 24-OCT-1997; 97US-0063128P.

PR 27-OCT-1997; 97US-0063327P.

PR 28-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 31-OCT-1997; 97US-0064215P.

PR 31-OCT-1997; 97US-0063870P.

PR 03-NOV-1997; 97US-0064103P.

PR 07-NOV-1997; 97US-0064248P.

PR 12-NOV-1997; 97US-0064809P.

PR 17-NOV-1997; 97US-0065186P.

PR 17-NOV-1997; 97US-0065946P.

```
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066840P.
PR 25-NOV-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100362P.
PR 16-SEP-1998; 98US-0101917P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0101943P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-0025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-0065350.
XX
XX (GETH ) GENENTECH INC.
PA
PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WT;
XX
XX WPI; 2004-096547/10.
XX
XX Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245
PT or PRO1868, useful in chromosome and gene mapping, in generating
PT antisense RNA and DNA, and in treating cancer and Alzheimer's disease.
XX
XX Example 38; Page 112; 483pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
```

```
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention.
XX
XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1467 CAGCCTGTACTGCCAG 1482
Db 3 CAGCATGTACTGCCAG 18
|||||
RESULT 233
ADM30140
ID ADM30140 standard; DNA; 18 BP.
XX
XX ADM30140;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypotension; bone disorder; cartilage disorder; sport injury;
KW osteopathic; antiarthritic; anorectic.
XX
XX Homo sapiens.
XX
XX US2003190611-A1.
PN
```


XX PD 09-OCT-2003.
XX PF 17-JUL-2001; 2001US-00907728.
XX PF 17-SEP-1997; 97US-0059113P.
XX PF 17-SEP-1997; 97US-0059115P.
XX PF 17-SEP-1997; 97US-0059117P.
XX PF 17-SEP-1997; 97US-0059119P.
XX PF 17-SEP-1997; 97US-0059121P.
XX PF 17-SEP-1997; 97US-0059122P.
XX PF 17-SEP-1997; 97US-0059184P.
XX PF 18-SEP-1997; 97US-0059263P.
XX PF 18-SEP-1997; 97US-0059266P.
XX PF 15-OCT-1997; 97US-0062125P.
XX PF 17-OCT-1997; 97US-0062285P.
XX PF 17-OCT-1997; 97US-0062287P.
XX PF 21-OCT-1997; 97US-0063486P.
XX PF 24-OCT-1997; 97US-0062814P.
XX PF 24-OCT-1997; 97US-0062816P.
XX PF 24-OCT-1997; 97US-0063045P.
XX PF 24-OCT-1997; 97US-0063120P.
XX PF 24-OCT-1997; 97US-0063121P.
XX PF 24-OCT-1997; 97US-0063127P.
XX PF 24-OCT-1997; 97US-0063128P.
XX PF 27-OCT-1997; 97US-0063327P.
XX PF 27-OCT-1997; 97US-0063329P.
XX PF 28-OCT-1997; 97US-0063541P.
XX PF 28-OCT-1997; 97US-0063542P.
XX PF 28-OCT-1997; 97US-0063544P.
XX PF 28-OCT-1997; 97US-0063549P.
XX PF 28-OCT-1997; 97US-0063550P.
XX PF 28-OCT-1997; 97US-0063564P.
XX PF 29-OCT-1997; 97US-0063435P.
XX PF 29-OCT-1997; 97US-0063704P.
XX PF 29-OCT-1997; 97US-0063722P.
XX PF 29-OCT-1997; 97US-0063734P.
XX PF 29-OCT-1997; 97US-0063735P.
XX PF 29-OCT-1997; 97US-0063738P.
XX PF 31-OCT-1997; 97US-0064215P.
XX PF 31-OCT-1997; 97US-0063870P.
XX PF 31-OCT-1997; 97US-0064103P.
XX PF 03-NOV-1997; 97US-0064248P.
XX PF 07-NOV-1997; 97US-0064809P.
XX PF 12-NOV-1997; 97US-0065186P.
XX PF 17-NOV-1997; 97US-0065846P.
XX PF 18-NOV-1997; 97US-0065693P.
XX PF 21-NOV-1997; 97US-0066120P.
XX PF 21-NOV-1997; 97US-0066364P.
XX PF 24-NOV-1997; 97US-0066453P.
XX PF 24-NOV-1997; 97US-0066466P.
XX PF 24-NOV-1997; 97US-0066511P.
XX PF 24-NOV-1997; 97US-0066770P.
XX PF 24-NOV-1997; 97US-0066772P.
XX PF 25-NOV-1997; 97US-0066840P.
XX PF 12-DEC-1997; 97US-0069425P.
XX PF 04-JUN-1998; 98US-0088026P.
XX PF 10-SEP-1998; 98US-0098033P.
XX PF 10-SEP-1998; 98WO-US01882A.
XX PF 14-SEP-1998; 98US-0100262P.
XX PF 14-SEP-1998; 98WO-US019177.
XX PF 16-SEP-1998; 98WO-US019330.
XX PF 17-SEP-1998; 98US-0100858P.
XX PF 17-SEP-1998; 98WO-US019437.
XX PF 13-OCT-1998; 98US-0104080P.
XX PF 20-NOV-1998; 98US-0109304P.
XX PF 01-DEC-1998; 98WO-US025108.
XX PF 22-DEC-1998; 98US-0113296P.
XX PF 07-JUL-1999; 99US-0143048P.
XX PF 26-JUL-1999; 99US-0145698P.
XX PF 28-JUL-1999; 99US-0146222P.
XX PF 08-SEP-1999; 99WO-US020594.
XX PF 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-020978/02.
DR
XX
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
XX Example 38; Page 101; 472pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinaemia,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of

CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
||| |||||
Db 3 CAGCATGTACTGCCAG 18

RESULT 234
ADO06462
ID ADO06462 standard; DNA; 18 BP.

AC ADO06462;

XX 01-JUL-2004 (first entry)

XX Human PRO PCR primer #198..

XX Human; PRO; ss; affinity purification; PCR; primer.

XX Homo sapiens.

XX US6686451-B1.

XX 03-FEB-2004.

XX 10-JUL-2001; 2001US-00902775.

XX 24-OCT-1997; 97US-0063128P.

XX 16-SEP-1998; 98WO-US019330.

XX 30-NOV-1999; 99WO-US028313.

XX 22-FEB-2000; 2000WO-US004414.

XX 18-SEP-2000; 2000US-00665350.

XX (GETH) GENENTECH INC.

XX Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP;

XX Williams PW, Wood WI;

XX WPI; 2004-106364/11.

XX New antibodies binding PRO polypeptides, useful in gene therapy, or in

XX diagnostic assays for the PRO polypeptides, or for the affinity

XX purification of PRO polypeptides from recombinant cell culture or natural

XX sources.

XX Example 38; Col 183; 445pp; English.

XX The invention relates to an antibody that binds to a human PRO

XX polypeptide. The invention also relates to human PRO polynucleotides

XX encoding the PRO polypeptides of the invention. The antibody is a

XX monoclonal or humanised antibody, or is an antibody fragment, and is

XX preferably labelled. The anti-PRO antibodies may be used in diagnostic

XX assays for PRO, or for the affinity purification of PRO from recombinant

XX cell culture or natural sources. This sequence represents a PCR primer

XX used in isolation of a human PRO polynucleotide of the invention.

XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1467 CAGCCTGTACTGCCAG 1482
||| |||||
Db 3 CAGCATGTACTGCCAG 18

RESULT 235
AAA85977/c
ID AAA85977 standard; DNA; 19 BP.

XX AAA85977;

XX 04-DEC-2000 (first entry)

XX Cdc 25 hs ribozyme binding site #85.

XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.

XX Mammalia.

XX WO200032765-A2.

XX 08-JUN-2000.

XX 06-DEC-1999; 99WO-US028772.

XX 04-DEC-1998; 98US-0110954P.

XX (IMMU-) IMMUSOL INC.

XX Tritz R, Welch PJ, Barber JR, Robbins JM;

XX WPI; 2000-412314/35.

XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves

XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,

XX PCNA and Cyclin B1.

XX Disclosure; Page 100; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme,

XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase

XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

XX Representative examples of ribozyme recognition sites are given in

XX AAA82415 to AAA86787. The ribozyme of the invention is useful for

XX inhibiting restenosis by introduction of the ribozyme into cells. The

XX ribozyme is resistant to endonuclease activity and hence is efficient in

XX restenosis treatment

XX Sequence 19 BP; 4 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 893 CCAAGAACTTGGCCA 908
||| |||||

Db 16 CCAGAAATTTGCCCA 1

RESULT 236
AAH61139/c
ID AAH61139 standard; DNA; 19 BP.

XX AAH61139;

XX 10-SEP-2001 (first entry)

XX Cdc25 hs ribozyme binding site SEQ ID NO:3563.

XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnery;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytosatic;
KW antipeptidic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200130362-A2.
XX
XX
XX PD 03-MAY-2001.
XX
XX PF 26-OCT-2000; 2000WO-US029500.
XX
XX PR 26-OCT-1999; 99US-0161532P.
XX
XX PA (IMMU-) IMMUSOL INC.
XX
XX PI Robbins JM, Tritz R;
XX
XX WI 2001-300427/31.
XX
XX DR Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 331; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipeptidic,
CC dermatological, cytosatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnery, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 4 A; 2 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 893 CCAAGAACTTGGCCCA 908
Db 16 CCAAGAAATTTGCCCA 1
RESULT 237
ADM00071
ID ADM00071 standard; RNA; 19 BP.
XX
AC ADM00071;
XX
XX 20-MAY-2004 (first entry)

XX Hepatitis B virus short interfering nucleic acid (siNA) #487.
DE
XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
OS Hepatitis B virus.
XX
XX US2003206887-A1.
XX
XX PD 06-NOV-2003.
XX
XX PF 16-SEP-2002; 2002US-00244647.
XX
XX PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002WO-US009187.
PR 29-AUG-2002; 2002US-0386782P.
PR 06-JUN-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX
XX (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX
XX Morrissey D, Mcswiggen JA, Beigelman L;
PI
XX WI 2003-901032/82.
XX
XX New short interfering nucleic acid molecules which down-regulates
PT expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for
PT characterizing gene function.
XX
XX Claim 11; Page 47; 72pp; English.
XX
XX The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesising a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises a sense
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises a sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC linker or a non-nucleotide linker. The sense region comprises a 3'-
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterizing pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules

PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX
PI Morrissey D, Mcswiggen JA, Beigelman L;
XX WPI; 2003-901032/82.
XX
DR New short interfering nucleic acid molecules which down-regulates
XX expression of a hepatitis B virus (HBV) or which inhibits HBV
XX replication, useful for treating human HBV infections or for
XX characterizing gene function.
XX
PS Claim 11; Page 47; 72pp; English.
XX
CC The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesising a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises a sense
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC linker or a non-nucleotide linker. The sense region comprises a 3'-
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA.
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterising pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.
XX
SQ Sequence 19 BP; 2 A; 7 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 1.4e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
Oy 1043 TCTTCATGCTGCTGCT 1058
Db 2 UCUCUACUCCUGCUGCU 17
RESULT 240
ADM00707/c
ID ADM00707 standard; RNA; 19 BP.
XX
XX ADM00707;
AC ADM00707;
XX
DT 20-MAY-2004 (first entry)
XX
XX Hepatitis B virus short interfering nucleic acid (siNA) #1123.
DE
XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
XX Hepatitis B virus.

XX US2003206887-A1.
XX
XX PD 06-NOV-2003.
XX
XX PF 16-SEP-2002; 2002US-00244647.
XX
XX PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00896347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002WO-05009187.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX
PI Morrissey D, Mcswiggen JA, Beigelman L;
XX WPI; 2003-901032/82.
XX
DR New short interfering nucleic acid molecules which down-regulates
XX expression of a hepatitis B virus (HBV) or which inhibits HBV
XX replication, useful for treating human HBV infections or for
XX characterizing gene function.
XX
PS Claim 11; Page 47; 72pp; English.
XX
CC The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesising a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises a sense
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC linker or a non-nucleotide linker. The sense region comprises a 3'-
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA.
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterising pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.
XX
SQ Sequence 19 BP; 8 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 19;

```
Best Local Similarity 93.8%; Pred. No. 1.4e+02; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TCTTCATGCTGCTGCT 1058
DB 18 TCTTCATGCTGCTGCT 3

RESULT 241
ADH01954/c
ID ADH01954 standard; RNA; 19 BP.
XX AC ADH01954;
XX DT 11-MAR-2004 (first entry)
XX DE Protein tyrosine phosphatase siRNA sequence, SEQ ID No 566.
XX small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTP1B;
KW insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;
KW antiinflammatory; neuroprotective; cytosstatic; immunosuppressive;
KW antimicrobial; gene therapy; ss; siRNA.
XX OS Unidentified.
XX WO2003099227-A2.
XX PD 04-DEC-2003.
XX PF 23-MAY-2003; 2003WO-US016651.
XX PR 23-MAY-2002; 2002US-0383249P.
XX PA 14-APR-2003; 2003US-0462942P.
XX (CEPT-) CEPTYR INC.
XX Lewis SP, Klinghoffer R, Wilson LK;
XX WPI; 2004-035036/03.
XX New small interfering polynucleotide that modulates protein tyrosine
PT phosphatase (PTP)1B polypeptide signal transduction, useful for treating
PT disorders associated with altered PTP1B signal transduction, e.g.
PT diabetes or cancer.
XX Example 3; SEQ ID NO 566; 234pp; English.
XX The invention relates to a novel isolated small interfering RNA (siRNA)
CC polynucleotide, comprising at least one nucleotide sequence from any of
CC the 20 fully defined sequences given in the specification. The invention
CC further relates to: a pharmaceutical composition comprising a new siRNA
CC polynucleotide and a physiological carrier; a recombinant nucleic acid
CC construct, comprising a polynucleotide that is capable of directing
CC transcription of an siRNA; a host cell transformed or transfected with
CC the above recombinant nucleic acid construct; a method for interfering
CC with expression of a protein tyrosine phosphatase (PTP)1B polypeptide, or
CC its variant; a method for identifying a component of a PTP1B signal
CC transduction pathway; a method for modulating an insulin receptor protein
CC phosphorylation state in a cell; a method for altering a Jak2 protein
CC phosphorylation state in a cell; and a method for treating a Jak2-
CC associated disorder. The siRNA has the following activities:
CC antidiabetic, anorectic, antiinflammatory, neuroprotective, cytosstatic,
CC immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can
CC be used in gene therapy to treat disorders. The composition and methods
CC are useful in treating disorders associated with PTP1B-mediated signal
CC transduction, such as diabetes, obesity, hyperglycaemia-induced
CC apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune
CC diseases or infection. This polynucleotide sequence represents an siRNA
CC used for modulating the signal transduction of a protein tyrosine
CC phosphatase of the invention.
XX Sequence 19 BP; 6 A; 6 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 929 ATGCCTGCTTCATCCT 944
DB 3 ATGCCTGCTTCATCCT 18

Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Query Match 0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 386 CTGGCCTGTGTCTCTT 401
DB 16 CTGGCCTGTGTCTCTT 1

RESULT 242
ADM69775
ID ADM69775 standard; DNA; 19 BP.
XX AC ADM69775;
XX DT 03-JUN-2004 (first entry)
XX DE Plant gene polymorphism marker related primer, SEQ ID 654.
XX KW Primer; variation mapping; mutation mapping; plant;
KW gene polymorphism marker; ss.
XX OS Synthetic.
XX JP2003289885-A.
XX PD 14-OCT-2003.
XX PF 31-JAN-2003; 2003JP-00024620.
XX PR 01-FEB-2002; 2002JP-00025338.
XX (RIKA) RIKAGAKU KENKYUSHO.
XX (SAIM-) SAI MEDIA KK.
XX (MATS/) MATSUI M.
XX (NAKA/) NAKAZAWA M.
XX WPI; 2004-126231/13.
XX A primer set and method useful for mapping at least the
PT variation/mutation part of a plant gene using a gene polymorphism marker.
XX Claim 7; SEQ ID NO 654; 120pp; Japanese.
XX The present invention relates to a primer set and method for mapping at
CC least the variation/mutation part of a plant gene using a gene
CC polymorphism marker. A mutation site of the plant gene is mapped by
CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is
CC prepared from a plant homozygously having a mutation to be an object of
CC the mapping; (b) A forward primer 1 containing a base corresponding to
CC the gene polymorphic maker of one ecotype plant, a forward primer 2
CC containing a base corresponding to the genetic polymorphism of the other
CC ecotype plant and a reverse primer 3 based on the base sequence common
CC with both the ecotype plants are prepared; (c) two kinds of
CC oligonucleotides emitting fluorescence of different colors when the
CC genetic polymorphism marker is detected are prepared; (d) an
CC amplification reaction of the genomic DNA is carried out in the presence
CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)
CC the fluorescence intensity emitted from the resultant reactional product
CC is detected and (f) the position on the genome of the mutation site is
CC determined from the results of detection. The present sequence is a
CC primer, used to illustrate the invention.
XX Sequence 19 BP; 2 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
```

```
RESULT 243
ADM69774
ID ADM69774 standard; DNA; 19 BP.
XX AC ADM69774;
XX DT 03-JUN-2004 (first entry)
XX DE Plant gene polymorphism marker related primer, SEQ ID 653.
XX KW Primer: variation mapping; mutation mapping; plant;
XX KW gene polymorphism marker; ss.
XX OS Synthetic.
XX PN JP2003289885-A.
XX PD 14-OCT-2003.
XX PF 31-JAN-2003; 2003JP-00024620.
XX PR 01-FEB-2002; 2002JP-00025338.
XX PA (RIKA) RIKAGAKU KENKYUSHO.
XX PA (SAIM-) SAI MEDIA KK.
XX PA (MATSU) MATSUI M.
XX PA (NAKA/) NAKAZAWA M.
XX DR WPI; 2004-126231/13.
XX PT A primer set and method useful for mapping at least the
XX PT variation/mutation part of a plant gene using a gene polymorphism marker.
XX PS Claim 7; SEQ ID NO 653; 120pp; Japanese.
XX CC The present invention relates to a primer set and method for mapping at
XX CC least the variation/mutation part of a plant gene using a gene
XX CC polymorphism marker. A mutation site of the plant gene is mapped by
XX CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is
XX CC prepared from a plant homozygously having a mutation to be an object of
XX CC the mapping; (b) A forward primer 1 containing a base corresponding to
XX CC the gene polymorphic marker of one ecotype plant, a forward primer 2
XX CC containing a base corresponding to the genetic polymorphism of the other
XX CC ecotype plant and a reverse primer 3 based on the base sequence common
XX CC with both the ecotype plants are prepared; (c) two kinds of
XX CC oligonucleotides emitting fluorescence of different colors when the
XX CC genetic polymorphism marker is detected are prepared; (d) an
XX CC amplification reaction of the genomic DNA is carried out in the presence
XX CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)
XX CC the fluorescence intensity emitted from the resultant reaction product
XX CC is detected and (f) the position on the genome of the mutation site is
XX CC determined from the results of detection. The present sequence is a
XX CC primer, used to illustrate the invention.
XX SQ Sequence 19 BP; 3 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
    Query Match 0.9%; Score 14.4; DB 1; Length 19;
    Best Local Similarity 93.8%; Pred. No. 1.4e+02;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 929 ATGCCTGCTTCATCCT 944
DB 3 ATGGCTGCTTCATCCT 18
RESULT 244
ABX03915
ID ABX03915 standard; DNA; 15 BP.
XX AC ABX03915;
XX DT 09-JAN-2003 (first entry)
XX DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:3592.
XX KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
XX KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
XX KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
XX KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX KW age related macular degeneration; inflammation; neovascular glaucoma;
XX KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
XX KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;
XX KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
```

```
XX
DE
XX
XX A. odontolyticus 16S rRNA fragment.
XX Detection; probe; diagnosis; oral disease; parodontitis; caries; therapy;
XX polymorphism; virulence factor; antibiotic resistance gene; prognosis;
XX oral infection; detection; pathogen; coronary heart disease;
XX diabetic symptom; ss.
XX OS Actinomyces odontolyticus.
XX DE20110013-U1.
XX PD 18-OCT-2001.
XX PF 13-MAR-2001; 2001DE-02010013.
XX PR 13-MAR-2001; 2001DE-01012348.
XX PR 13-MAR-2001; 2001DE-02010013.
XX PA (ROET/) ROETGER A.
XX WPI; 2001-65777/76.
XX OLigonucleotide array, useful for diagnosing oral diseases, particularly
XX parodontitis, carries human or microbial reference sequences.
XX Claim 8; Page 19; 58pp; German.
XX CC This invention describes a novel nucleotide carrier with probes used for
XX CC diagnosis of oral diseases, particularly parodontitis, but also caries,
XX CC especially to identify genetic predisposition (as indicated by
XX CC polymorphisms) to disease and to identify causative microorganisms or
XX CC their associated virulence factors and antibiotic resistance genes, e.g.
XX CC for selection of therapy and for prognosis. They are also useful for
XX CC research into oral infections. The carriers allow simultaneous detection
XX CC of both host and pathogen parameters, providing quickly and simply an
XX CC individual's parodontitis profile, including detection of pathogens that
XX CC are associated with increased risk of coronary heart diseases and/or
XX CC aggravation of diabetic symptoms, and of opportunistic pathogens.
XX CC ABX03870-ABX04044 represent DNA fragments used to illustrate the method
XX CC of the invention
XX SQ Sequence 15 BP; 3 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
    Query Match 0.9%; Score 14; DB 1; Length 15;
    Best Local Similarity 100.0%; Pred. No. 1.1e+02;
    Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1493 CACGGCGGCACCTGC 1506
DB 1 CACGGCGGCACCTGC 14
RESULT 245
AAA20366/c
ID AAA20366 standard; RNA; 17 BP.
XX AC AAA20366;
XX DT 19-JUN-2000 (first entry)
XX DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:3592.
XX KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
XX KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
XX KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
XX KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX KW age related macular degeneration; inflammation; neovascular glaucoma;
XX KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
XX KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;
XX KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
```


AC ACD55429;
XX 23-SEP-2003 (first entry)
XX HBV amberzyme substrate sequence #50.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis B virus.
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX 08-JUN-2001; 2001US-00877478.
XX 08-JUN-2001; 2001US-0296876P.
XX 24-OCT-2001; 2001US-0335059P.
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PVC/) PAVCO P.
PA (LESP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
PI
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
PT
XX Example 1; Page 203; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberzyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 5 A; 5 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 AGGTTCCCTTGAGCA 274
DB 14 AGGTTCCCTTGAGCA 1
RESULT 248
ADD20914
ID ADD20914 standard; DNA; 17 BP.
XX
AC ADD20914;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human GAP_N DNA 17-mer oligo #146.
XX
KW Gene therapy; antibody therapy; modulator of GAPN;
KW GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
XX
OS Homo sapiens.
XX
PN WO2003033703-A2.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032597.
XX
PR 15-OCT-2001; 2001US-0330323P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
PA
PI Zhang J;
XX
XX WPI; 2003-403224/38.
XX
XX Novel human GTP-activator protein for Rab-like GTPase and polynucleotide
PT encoding the protein, useful for diagnosing, treating or preventing
PT disorders associated with increased expression or activity of the
PT protein.
XX
XX Example 2; SEQ ID NO 170; 149pp; English.
XX
XX The invention relates to an isolated human GTP-activator protein for Rab-
CC like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to
CC (I), a sequence in which at least 95% of deviations from (I) are
CC conservative substitutions, or a fragment of at least 8 contiguous amino
CC acids of (I). The polypeptide is useful for identifying a specific
CC binding partner for itself, by contacting the polypeptide in vivo to a
CC potential binding partner and determining if the polypeptide binding
CC partner binds to the polypeptide. (I) and a nucleic acid encoding the
CC polypeptide (II) are useful for diagnosing or monitoring a disease caused
CC by altered expression of GAPN, by determining the level of expression of
CC GAPN in a sample of nucleic acids or proteins that derives from a subject
CC suspected to have the disease, alterations from a normal level of
CC expression providing diagnostic and/or monitoring information. (I), (II)
CC or against of (I) is useful for treating or preventing a disorder
CC associated with decreased expression or activity of GAPN, and an
CC antagonist of (I) is useful for treating or preventing a disorder
CC associated with increased expression or activity of GAPN (all claimed).
CC (I) is useful as immunogen to raise antibodies that specifically
CC recognize GAPN proteins. (II) is useful to drive in vivo expression of
CC GAPN proteins, and as hybridization probes to detect, characterize and
CC quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both
CC genomic and transcript-derived nucleic acid samples. This sequence
CC represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 802 TTCTCCAGCTACT 815
1 TTCTCCAGCTACT 14

Db

RESULT 249
ADD20910
ID ADD20910 standard; DNA; 17 BP.
XX
AC ADD20910;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human GAP_N DNA 17-mer oligo #142.
XX
KW gene therapy; antibody therapy; modulator of GAPN;
KW GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
XX
OS Homo sapiens.
XX
PN WO2003033703-A2.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032597.
XX
PR 15-OCT-2001; 2001US-033023P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
DR WPI; 2003-403224/38.

Novel human GTP-activator protein for Rab-like GTPase and polynucleotide encoding the protein, useful for diagnosing, treating or preventing disorders associated with increased expression or activity of the protein.

Example 2; SEQ ID NO 166; 149pp; English.

The invention relates to an isolated human GTP-activator protein for Rab-like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to (I), a sequence in which at least 95% of deviations from (I) are conservative substitutions, or a fragment of at least 8 contiguous amino acids of (I). The polypeptide is useful for identifying a specific binding partner for itself, by contacting the polypeptide in vivo to a potential binding partner and determining if the polypeptide binding partner binds to the polypeptide. (I) and a nucleic acid encoding the polypeptide (II) are useful for diagnosing or monitoring a disease caused by altered expression of GAPN, by determining the level of expression of GAPN in a sample of nucleic acids or proteins that derives from a subject suspected to have the disease, alterations from a normal level of expression providing diagnostic and/or monitoring information. (I), (II) or agonist of (I) is useful for treating or preventing a disorder associated with decreased expression or activity of GAPN, and an antagonist of (I) is useful for treating or preventing a disorder associated with increased expression or activity of GAPN (all claimed). (I) is useful as immunogen to raise antibodies that specifically recognize GAPN proteins. (II) is useful to drive in vivo expression of GAPN proteins, and as hybridization probes to detect, characterize and quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both genomic and transcript-derived nucleic acid samples. This sequence represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.

XX Sequence 17 BP; 2 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 TTCTCCAGCTACT 814
TTTTTTTTTTTTTTTT

Db 4 TTCTCCAGCTACC 17

RESULT 250
ADM60111/c
ID ADM60111 standard; RNA; 17 BP.
XX
AC ADM60111;
XX
DT 03-JUN-2004 (first entry)
XX
DE Hepatitis B virus (HBV) RNA target sequence #2245.
XX
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
PN US2004054156-A1.
XX
PD 18-MAR-2004.
XX
PF 15-JAN-2003; 2003US-00342902.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
PA (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX
DR WPI; 2004-247781/23.

Novel enzymatic nucleic acid molecule such as DNazymes and inozymes specifically cleaving RNA derived from hepatitis B virus and comprising one or more binding arms, useful for treating hepatitis and cirrhosis.

XX Disclosure; SEQ ID NO 2245; 122pp; English.

The invention relates to an enzymatic nucleic acid molecule that specifically cleaves RNA derived from hepatitis B virus (HBV) and comprising one or more binding arms, without requiring the presence of a 2'-OH group within the molecule for activity. The nucleic acids are useful for treating hepatitis B virus infection, hepatitis, hepatocellular carcinoma, cirrhosis and liver failure, either alone or in combination with other therapies such as lamivudine and interferons. The nucleic acids are useful as diagnostic tools to examine genetic drift and mutations within diseased cells, for detecting the presence of HBV RNA in a cell, for the study of RNA and for down-regulating gene expression of target genes in bacterial, fungal, viral, plant or mammalian cells. This sequence represents an HBV RNA target sequence, used in the scope of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 17 BP; 5 A; 5 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTTCCTTGACA 274
|||||

Db 14 AGGTTTCCTTGACA 1

```
RESULT 251
AD185896
ID AD185896 standard; RNA; 17 BP.
XX AC AD185896;
XX DT 03-JUN-2004 (first entry)
XX DE HCV DNzyme substrate sequence #3142.
XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX KW HCV infection; type I interferon; DNzyme.
XX OS Hepatitis C virus.
XX PN US2003125270-A1.
XX PD 03-JUL-2003.
XX PF 18-DEC-2000; 2000US-00740332.
XX PR 18-DEC-2000; 2000US-00740332.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (ROBE/) ROBERTS E.
XX PA (PAVC/) PAVCO P A.
XX PA (MACE/) MACEJACK D.
XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX DR WPI; 2004-031273/03.
XX PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX PT especially in combination with type I interferon therapy.
XX PS Claim 1; SEQ ID NO 3142; 198pp; English.
XX CC The invention relates to an enzymatic nucleic acid molecule which
XX CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX CC the binding arms of the enzymatic nucleic acid molecule comprises
XX CC sequences complementary to any of the defined substrate sequences given
XX CC in the specification. The nucleic acid molecule may be administered for
XX CC the treatment of HCV infections, especially in combination with type I
XX CC interferons. The present sequence represents a HCV DNzyme substrate
XX CC sequence.
XX SQ Sequence 17 BP; 4 A; 1 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 78.8%; Pred. No. 1.4e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 133 ATGAGGCGTGTGAA 146
DB 3 AUGGAGGCGUGAA 16
RESULT 252
ADCO2823
ID ADCO2823 standard; DNA; 18 BP.
XX AC ADCO2823;
XX DT 18-DEC-2003 (first entry)
XX DE Ex vivo stem-cell expansion related polynucleotide #258.
XX KW cytostatic; antianaemic; immunomodulator; immunostimulant;
XX KW immunosuppressive; antiinflammatory; interleukin agonist 3;
```

```
KW interleukin antagonist 3; gene therapy; ex vivo expansion of stem cell;
KW modified human interleukin-3; cell proliferation;
KW acute myelogenous leukaemia cell proliferation; TP-1 cell proliferation;
KW methylcellulose assay; haematopoietic disorder; cancer;
KW acute myelogenous leukaemia; B lymphoid cancer; leukopenia; neutropenia;
KW aplastic anaemia; Chediak-Higashi's syndrome;
KW systemic lupus erythematosus; myelodysplastic syndrome; myelofibrosis;
KW bone marrow; blood cell activation; blood cell growth; ds.
XX OS Synthetic.
XX PN US6479261-B1.
XX PD 12-NOV-2002.
XX PF 15-NOV-1995; 95US-00559390.
XX PR 24-NOV-1992; 92US-00981044.
XX PR 22-NOV-1993; 93WO-US011198.
XX PR 06-APR-1995; 95US-00411796.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Bauer SC, Abrams MA, Braford-Goldberg SR, Caparon MH, Easton AM;
XX PI Klein BK, McKeam JP, Olins P, Paik K, Polazzi J, Thomas JW;
XX DR WPI; 2003-655574/62.
XX PT Selective ex vivo expansion of stem cells, useful for treating a patient
XX PT having hematopoietic disorder, e.g. leukemia, neutropenia or aplastic
XX PT anemia, comprises using recombinant human interleukin-3 variant or mutant
XX PT proteins.
XX PS Example 66; SEQ ID NO 283; 288pp; English.
XX CC The invention describes selective ex vivo expansion of stem cells
XX CC comprising separating stem cells from other cells, culturing the cells
XX CC with modified human interleukin-3 polypeptide with at least 3 times
XX CC greater cell proliferative activity than native human interleukin-3 in at
XX CC least one assay selected from the group of acute myelogenous leukaemia
XX CC cell proliferation, TP-1 cell proliferation, and methylcellulose assay,
XX CC and harvesting the cultured cells. The method is useful for selective ex
XX CC vivo expansion of stem cells. The recombinant human interleukin-3 variant
XX CC or mutant proteins are useful for treating a patient having a
XX CC haematopoietic disorder, such as cancer (e.g. acute myelogenous leukaemia
XX CC or certain types of B lymphoid cancer), leukopenia, neutropenia,
XX CC aplastic anaemia, Chediak-Higashi's syndrome, systemic lupus
XX CC erythematosus, myelodysplastic syndrome, or myelofibrosis. The
XX CC interleukin-3 mutants are also useful as antagonists for producing
XX CC antibodies used in immunoassay and immunotherapy protocols, or for
XX CC stimulating bone marrow and blood cell activation and growth before
XX CC infusion into patients. This sequence represents an ex vivo stem cell
XX CC expansion method associated polynucleotide.
XX SQ Sequence 18 BP; 2 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 0.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1548 ATCTGGTCTGCTGCC 1561
DB 1 ATCTGGTCTGCTGCC 14
RESULT 253
AD158498
ID AD158498 standard; DNA; 18 BP.
XX AC AD158498;
XX DT 22-APR-2004 (first entry)
XX
```

DE Human interleukin 3 expressing vector related DNA seq id 283.
XX immunostimulant; antianemic; immunomodulator; antiinflammatory;
KW dermatological; immunosuppressive; cytostatic; neuroprotective;
KW gene therapy; interleukin-agonist-3; cultured stem cell;
KW ex-vivo cell expansion; interleukin-3 mutant; aplastic anaemia;
KW cyclic neutropenia; idiopathic neutropenia; Chediak-Higashi syndrome;
KW systemic lupus erythematosus; leukaemia; myelodysplastic syndrome;
KW myelofibrosis; interleukin 3; IL-3; mutagenesis; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN US2004018618-A1.
XX
PD 29-JAN-2004.
XX
PF 19-JUN-2002; 2002US-00179940.
XX
PR 24-NOV-1992; 92US-00981044.
PR 22-NOV-1993; 93WO-US011198.
PR 06-APR-1995; 95US-00411796.
PR 15-NOV-1995; 95US-00559390.
XX
PA (BAUE/) BAUER S C.
PA (ABRA/) ABRAMS M A.
PA (BRAP/) BRAFORD-GOLDBERG S R.
PA (CAPA/) CAPARON M H.
PA (EAST/) EASTON A M.
PA (KLEI/) KLEIN B K.
PA (MCKE/) MCKEARN J P.
PA (OLIN/) OLINS P.
PA (PAIK/) PAIK K.
PA (POLA/) POLAZZI J.
PA (THOM/) THOMAS J W.
XX
PI Bauer SC, Abrams MA, Braford-Goldberg SR, Caparon MH, Easton AM;
PI Klein BK, Mckearn JP, Olins P, Paik K, Polazzi J, Thomas JW;
XX
XX WPI; 2004-122043/12.
XX
XX Culturing stem cells using a recombinant human interleukin-3 mutant
PT polypeptide, useful for treating aplastic anemia, neutropenia, Chediak-
PT Higashi syndrome, systemic lupus erythematosus, leukemia and
PT myelodysplastic syndrome.
XX
PS Example 65; SEQ ID NO 283; 328pp; English.
XX
CC The invention describes cultured stem cells obtained by a method for
CC selective ex-vivo expansion of stem cells comprising separating stem
CC cells from other cells, culturing the separated stem cells with a
CC selected media which comprises a human interleukin-3 mutant polypeptide
CC comprising defined amino acid sequences SEQ ID NO 15 or 19 given in the
CC specification, and harvesting the cultured cells. The methods and
CC compositions of the present invention are useful for treating aplastic
CC anaemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi
CC syndrome, systemic lupus erythematosus, leukaemia, myelodysplastic
CC syndrome and myelofibrosis. This sequence represents a DNA used in the
CC construction of human interleukin 3 (IL-3) mutants.
XX
XX Sequence 18 BP; 2 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1548 ATCTTGGTCTGCTGCC 1561
Dn 1 ATCTTGGTCTGCTGCC 14
RESULT 254
AAQ40994/c

ID AAQ40994 standard; DNA; 17 BP.
XX
AC AAQ40994;
XX
DT 18-FEB-1999 (first entry)
XX
DE Mutagenic primer.
XX
KW Mutagenesis; pCGN783; pBSKm; M13KS; pCGN1543; kanamycin; resistance; ss.
XX
OS Synthetic.
XX
PN US5106739-A.
XX
PD 21-APR-1992.
XX
PF 07-FEB-1990; 90US-00477055.
XX
PR 18-APR-1989; 89US-00339755.
XX
PA (CALJ) CALGENE INC.
XX
PI Comai L, Moran PM;
XX
DR WPI; 1992-159370/19.
XX
PT High level expression in plant cell hosts - using the CaMV 35S upstream
PT activating region to enhance the mannopine synthase promoter.
XX
PS Disclosure; Page 14; 29pp; English.
XX
CC pCGN783 ATCC 67868 contg. the 1 ATG-kanamycin resistance gene is cloned
CC into EcoRI-SmaI digested Bluescript M13KS to create pBSKm; this plasmid
CC contains an M13 region allowing generation of single stranded DNA. Single
CC stranded DNA is generated and in vitro mutagenesis is performed using the
CC sequence below, to alter a PstI site with the kanamycin resistance gene
CC and make it undigestable, creating pCGN1534
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCTCTGGGTTTC 1332
Dn 17 GCTTCGTCTCTGGGTTTC 1
RESULT 255
AAQ98599/c
ID AAQ98599 standard; DNA; 17 BP.
AC AAQ98599;
XX
DT 25-MAR-2003 (revised)
DT 10-APR-1996 (first entry)
XX
DE Human papilloma virus 31 specific oligonucleotide probe MY110.
XX
KW Human papilloma virus; probe; detection; diagnosis; genital; oral;
KW carcinomas; research; typing; HPV31; specific; MY110; ss.
OS Synthetic.
XX
PN US5447839-A.
XX
PD 05-SEP-1995.
XX
PF 20-APR-1993; 93US-00050743.
XX
PR 09-SEP-1988; 88US-00243486.
PR 10-MAR-1989; 89US-00322550.

PR 09-SEP-1989; 89WO-US003747.
 PR 14-NOV-1990; 90US-00613142.
 XX (HOFF) HOFFMANN LA ROCHE INC.
 PA Ting Y, Resnick RM, Greer CE, Manos MM, Bauer HM;
 PI WPI; 1995-319884/41.
 DR
 XX
 XX Detection of human papilloma virus DNA by amplification - using specific
 PT consensus primer pairs and pref. detection with generic or type specific
 PT probes for use in research and diagnosis.
 XX
 XX Claim 3; Col 43-44; 36pp; English.
 PS
 XX The human papilloma virus (HPV) specific probes AAQ98584-Q98650 are used
 CC to detect, or type HPV for research or diagnostic purposes, e.g. to
 CC identify HPV that are implicated in genital or oral carcinomas. (Updated
 CC on 25-MAR-2003 to correct PF field.)
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 252 ACCTCCCCCAGGTTCT 268
 Db 17 ACCTCCCTCAGGTTCTT 1
 RESULT 256
 AAT44617/c
 ID AAT44617 standard; DNA; 17 BP.
 XX
 AC AAT44617;
 XX
 DT 25-MAR-2003 (revised)
 DT 28-JAN-1997 (first entry)
 XX
 XX Human papillomavirus detection probe MY110 for HPV type 31.
 DE
 XX Probe; primer; PCR; polymerase chain reaction; amplification;
 KW human papillomavirus; consensus; ss.
 XX
 OS Synthetic.
 XX
 PN US527898-A.
 XX
 PD 18-JUN-1996.
 XX
 PF 07-JUN-1995; 95US-00474542.
 XX
 PR 09-SEP-1988; 88US-00243486.
 PR 10-MAR-1989; 89US-00322550.
 PR 09-SEP-1989; 89WO-US003747.
 PR 14-NOV-1990; 90US-00613142.
 PR 20-APR-1993; 93US-00050743.
 PR 24-SEP-1993; 93US-00126452.
 XX
 XX (HOFF) HOFFMANN LA ROCHE INC.
 PA
 XX Bauer HM, Resnick RM, Greer CE, Manos MM, Zhang TY, Gravitt PE;
 PI WPI; 1996-299903/30.
 XX
 XX Nucleic acid hybridisation probes - specific for selected human papilloma
 PT virus types.
 PT
 XX Claim 1; Col 129; 96pp; English.
 PS
 XX The invention relates to new oligonucleotide probes and primers used for
 CC the detection of human papillomaviruses which are not genital types 6,
 CC

CC 11, 16, 18 or 33. The probes and primers AAT44608-T44693 are esp. used to
 CC detect HPV types 26, 31, 31b, 35, 39, 40, 43, 45, 51-59 and 68. The
 CC primers can be used to detect these HPV types in conjunction with the
 CC consensus primers and typing probes AAT44733-T44906, which are based on
 CC and amplify fragments of the L1, E6, E7 and E1 regions of the HPV
 CC sequences. This primer is targeted to the new HPV type 31. (Updated on 25
 CC -MAR-2003 to correct PF field.)
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 252 ACCTCCCCCAGGTTCT 268
 Db 17 ACCTCCCTCAGGTTCTT 1
 RESULT 257
 AAT78038/c
 ID AAT78038 standard; DNA; 17 BP.
 XX
 AC AAT78038;
 XX
 DT 25-MAR-2003 (revised)
 DT 07-OCT-1997 (first entry)
 XX
 XX Human papillomavirus 31 specific typing probe MY110.
 DE
 XX Human; papillomavirus 31; HPV31; typing probe; detection; ss.
 KW
 XX Synthetic.
 OS
 XX US5639871-A.
 PN
 XX 17-JUN-1997.
 PD
 XX
 PF 01-JUN-1995; 95US-00457648.
 XX
 PR 09-SEP-1988; 88US-00243486.
 PR 10-MAR-1989; 89US-00322550.
 PR 29-AUG-1989; 89WO-US003747.
 PR 14-NOV-1990; 90US-00613142.
 PR 20-APR-1993; 93US-00050743.
 PR 24-SEP-1993; 93US-00126452.
 XX
 XX (HOFF) ROCHE MOLECULAR SYSTEMS INC.
 PA
 XX Imprim CC, Manos MM, Bauer HM, Zhang TY, Greer CE, Resnick RM;
 PI Gravitt PE;
 XX
 XX WPI; 1997-332084/30.
 DR
 XX New oligo:nucleotide probes for human papilloma-virus - used for
 PT detecting and typing HPV and for detecting previously unknown HPV types
 PT and subtypes.
 PT
 XX Disclosure; Col 127-128; 94pp; English.
 PS
 XX The present sequence is a human papillomavirus 31 (HPV31) specific typing
 CC probe. (Updated on 25-MAR-2003 to correct PF field.) (Updated on 25-MAR-
 CC 2003 to correct PR field.)
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 252 ACCTCCCCCAGGTTCT 268
 Db 17 ACCTCCCTCAGGTTCTT 1

```

XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
AC AAX74924;
XX
DT 28-JUL-1999 (first entry)
XX
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #452.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
PN W09715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
XX
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR ) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
WPI; 1997-259017/23.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
XX
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR ) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 168; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 275 GGACCCAGGAGCATCC 291
Db 17 GGATTCCAGGAGCATCC 1
RESULT 259
AAX71428
ID AAX71428 standard; RNA; 17 BP.
XX
AC AAX71428;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human KDR VEGF receptor hammerhead ribozyme substrate #440.
XX
```

```

XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN W09715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
XX
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR ) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 110; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 282 GGAGCCATCCCTGGGGA 298
Db 1 GGAGCAAUCCUGUGGA 17
RESULT 260
AAV11280/c
ID AAV11280 standard; DNA; 17 BP.
XX
AC AAV11280;
XX
DT 15-JUL-1998 (first entry)
XX
DE Human CYP2A6 gene PCR primer 2A6-6S.
XX
KW Cytochrome P4502A6; CYP2A6; diagnosis; metabolic activity; substrate;
KW human; PCR primer; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN JP09187300-A.
XX
PD 22-JUL-1997.
XX
```

PF 06-NOV-1996; 96JP-00311338.
 PR 06-NOV-1995; 95JP-00313610.
 XX (SUMU) SUMITOMO SEIVAKU KK.
 PA XX
 DR WPI; 1998-275091/25.
 XX
 XX Genetic diagnosis using human CYP2A6 gene - useful to distinguish an
 PT abnormality in the metabolic activity of substrate for CYP2A6.
 XX
 XX Example 12; Page 16; 19pp; Japanese.
 XX
 XX Primers AAV11271-V11287 are used to amplify the human cytochrome P4502A6
 CC (CYP2A6) gene for genetic diagnosis by distinguishing the metabolic
 CC activity of a substrate for CYP2A6. The method can distinguish a patient
 CC with an abnormality in a metabolic pathway requiring CYP2A6
 XX
 XX Sequence 17 BP; 8 A; 6 C; 3 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1320 CGTCTGGGGTCTTCT 1336
 DB 17 CGTGTGGGGTCTTCT 1
 RESULT 261
 AAV95636
 ID AAV95636 standard; RNA; 17 BP.
 XX
 AC AAV95636;
 XX
 DT 01-MAR-1999 (first entry)
 XX
 DE Solanidine glucosyltransferase target sequence position 61.
 XX
 XX Solanidine, glucosyltransferase; potato; citrate synthase; target;
 KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
 KW flower formation; cleavage; solanaceous plant; ss.
 XX
 XX Solanum tuberosum.
 OS
 XX
 PN WO9832843-A2.
 XX
 PD 30-JUL-1998.
 XX
 PF 14-JAN-1998; 98NO-US000738.
 XX
 XX 28-JAN-1997; 97US-0036545P.
 PR 28-JAN-1997; 97US-0036599P.
 PR 24-NOV-1997; 97US-00979416.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Zwick MG, Mcswiggen JA;
 PI
 XX WPI; 1998-427939/36.
 DR
 XX New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
 PT biosynthesis or regulating flowering.
 PT
 XX
 XX Claim 13; Page 45; 79pp; English.
 PS
 XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC -cleaving activity (e.g. ribozymes) which are capable of modulating the
 CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or
 CC (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
 CC AAV96354 represent potato solanidine glucosyltransferase hammerhead and
 CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
 CC AAV96734 represent potato solanidine glucosyltransferase target

sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
 CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.
 CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
 CC synthase target sequences. Ribozymes of the present invention can be used
 CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,
 CC particularly potato but also tomato, pepper, aubergine and ditura or to
 CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
 CC arugula, kale, collards, chard, beet, turnip, sweet potato and turf
 CC grass. Also the ribozymes can be used for RNA manipulation in the same
 CC way that restriction endonucleases are for DNA, as well as to examine
 CC genetic drift and mutations in plants and to detect specific RNA. The
 CC ribozymes can be targeted to specific genes or to consensus sequences
 CC within a family of related genes, and being catalytic need to be present
 CC at only very low concentrations
 XX
 SQ Sequence 17 BP; 1 A; 6 C; 1 G; 0 T; 9 U; 0 Other;
 Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 41.2%; Pred. No. 1.5e+02;
 Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
 QY 1059 CATCTTCTTTCCTTCC 1075
 DB 1 CAUGUUCUUCUCC 17
 RESULT 262
 AAV17483/C
 ID AAV17483 standard; DNA; 17 BP.
 XX
 AC AAV17483;
 XX
 DT 25-MAR-2003 (revised)
 DT 04-JUN-1998 (first entry)
 XX
 XX Probe WY110 for human papillomavirus typing.
 XX
 KW Human papillomavirus; HPV; HPV detection; HPV typing;
 KW L1 type-specific probe; ss.
 XX
 OS Synthetic.
 OS Human papillomavirus.
 XX
 XX US5705627-A.
 PN
 XX
 PD 06-JAN-1998.
 XX
 XX 26-MAY-1995; 95US-00452055.
 XX
 PR 09-SEP-1988; 88US-00243486.
 PR 10-MAR-1989; 89US-00322550.
 PR 14-NOV-1990; 90US-00613142.
 PR 20-APR-1993; 93US-00050743.
 XX
 XX (HOFF) ROCHE MOLECULAR SYSTEMS INC.
 PA
 XX
 XX Ting Y, Resnick RM, Greer CE, Bauer HM, Manos MM;
 PI
 XX WPI; 1998-192210/17.
 DR
 XX Human papilloma probes and primers - useful for, e.g. detecting and
 PT typing of human papilloma viruses.
 PT
 XX Disclosure; Col 15-16; 37pp; English.
 PS
 XX This sequence represents a human papillomavirus (HPV) L1 type-specific
 CC probe of the invention. This sequence may be used in conjunction with L1
 CC specific primers for detecting and typing HPV. Identification and typing
 CC of HPV is important as different types of HPV pose different risks for
 CC infected individuals. HPV16 and HPV18 have been more consistently
 CC identified in higher grades of cervical dysplasia and carcinoma than
 CC other HPV types. (Updated on 25-MAR-2003 to correct PR field.)
 CC
 XX

SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 252 ACCTCCCTCAGGTTCT 268
Db 17 ACCTCCCTCAGGTTCT 1

RESULT 263
AAA18856/c
ID AAA18856 standard; RNA; 17 BP.
XX
AC AAA18856;
XX
DT 19-JUN-2000 (first entry)
DE Human TIE-2 substrate sequence SEQ ID NO:2082.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberos sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US0006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
of an mRNA encoding an angiogenic factors.
XX
PS Claim 56; Page 121; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
cleaving activity, which specifically cleave RNA encoded by an aryl
hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA1689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT.
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,

CC angiofibroma of tuberos sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX Sequence 17 BP; 3 A; 7 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 176 AACTGAGGAGCTGCTG 192
Db 17 AAGTGAAGGAGCTGCTG 1

RESULT 264
AAV93332
ID AAV93332 standard; RNA; 17 BP.
XX
AC AAV93332;
XX
DT 18-FEB-1999 (first entry)
DE Human B-raf substrate nucleotide position 426.
XX
KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW screening; identification; synthesis; deprotection; purification; cancer;
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW restenosis; rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN WO9850530-A2.
XX
PD 12-NOV-1998.
XX
PF 05-MAY-1998; 98WO-US009249.
XX
PR 09-MAY-1997; 97US-0046059P.
PR 09-JUN-1997; 97US-0049002P.
PR 03-JUL-1997; 97US-0051718P.
PR 22-AUG-1997; 97US-0056808P.
PR 02-OCT-1997; 97US-0061321P.
PR 02-OCT-1997; 97US-0061324P.
PR 05-NOV-1997; 97US-0064866P.
PR 19-DEC-1997; 97US-0068212P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
PI Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;
PI Thompson J, Workman CT, Beaudry A, Sweedler D;
XX
DR WPI; 1999-009494/01.
XX
PT Identifying new catalytic nucleic acid that modulates selected processes
- especially ribozymes that cleave Raf RNA for treating cancer,
PT restenosis, and also new ribozymes and modified nucleoside triphosphates
PT used as antiviral agents and synthons.
XX
PS Claim 177; Page 166; 259pp; English.
XX
CC A method has been developed for the identification of a nucleic acid
capable of modulating a process in a biological system. The method
comprises: (a) introducing into the system a random library of nucleic
acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence
CC of at least part of the SBDs in such systems. Nucleic acid molecules with
CC endonuclease activity and catalytic activity, from the present invention, to
CC are used to modulate gene expression in plant and mammalian cells and to

CC cleave target nucleic acid, particularly for treating systemic diseases
 CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
 CC ascites and infection. They may also be used to detect genetic drift and
 CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
 CC with RNA-cleaving activity that modulate expression of the Raf gene, are
 CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
 CC generally any condition associated with the level of c-raf. Introduction
 CC of sugar/phosphate modifications increases stability against nuclease and
 CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
 CC method, specifically for modulating the expression of a Raf gene
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 0 G; 0 T; 9 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 41.2%; Pred. NO. 1.5e+02;

Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTCT 827

Db 1 UACAUCUUCUCCUUCU 17

RESULT 265

AAV93333

ID AAV93333 standard; RNA; 17 BP.

XX

AC AAV93333;

XX

XX

18-FEB-1999 (first entry)

DT

XX

Human B-raf substrate nucleotide position 428.

DE

XX

Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
 KW screening; identification; synthesis; deprotection; purification; cancer;
 KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
 KW restenosis; rheumatoid arthritis; ss.

XX

OS Homo sapiens.

XX

WO9850530-A2.

PN

XX

12-NOV-1998.

PD

XX

05-MAY-1998; 98WO-US009249.

PF

XX

09-MAY-1997; 97US-0046059P.

PR

09-JUN-1997; 97US-0049002P.

PR

03-JUL-1997; 97US-0051718P.

PR

22-AUG-1997; 97US-0056808P.

PR

02-OCT-1997; 97US-0061321P.

PR

05-NOV-1997; 97US-0064866P.

PR

19-DEC-1997; 97US-0068212P.

PR

(RIBO-) RIBOZYME PHARM INC.

XX

PA

XX

Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;

PI

Parry T, Beigelman L, Mcswigen JA, Karpeisky A, Burgin A;

PI

Thompson J, Workman CT, Beaudry A, Sweedler D;

XX

XX

WPI; 1999-009494/01.

DR

XX

Identifying new catalytic nucleic acid that modulates selected processes

PT - especially ribozymes that cleave Raf RNA for treating cancer,

PT restenosis, and also new ribozymes and modified nucleoside triphosphates

PT used as antiviral agents and synthons.

XX

Claim 177; Page 166; 259pp; English.

PS

XX

A method has been developed for the identification of a nucleic acid

CC capable of modulating a process in a biological system. The method

CC comprises: (a) introducing into the system a random library of nucleic

CC

CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules with
 CC endonuclease activity and catalytic activity, from the present invention,
 CC are used to modulate gene expression in plant and mammalian cells and to
 CC cleave target nucleic acid, particularly for treating systemic diseases
 CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
 CC ascites and infection. They may also be used to detect genetic drift and
 CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
 CC with RNA-cleaving activity that modulate expression of the Raf gene, are
 CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
 CC generally any condition associated with the level of c-raf. Introduction
 CC of sugar/phosphate modifications increases stability against nuclease and
 CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
 CC method, specifically for modulating the expression of a Raf gene
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 0 G; 0 T; 9 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 41.2%; Pred. NO. 1.5e+02;

Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 813 CCTCTACTTCTCTCTCT 829

Db 1 CAUCUUCUCCUUCU 17

RESULT 266

AAV81678/C

ID AAV81678 standard; DNA; 17 BP.

XX

AC AAV81678;

XX

25-FEB-1999 (first entry)

DT

XX

Oligonucleotide SEQ ID NO:97 used in Example 84.

DE

XX

Regulation; transcription; plant tissue; chimeric construction; PR;

KW pathogenesis-related protein; anti-pathogenic; transgenic plant;

KW beta-1,3-glucanase activity; pest resistance; primer; ss.

XX

OS Synthetic.

XX

US5847258-A.

PN

XX

08-DEC-1998.

PD

XX

31-MAY-1995; 95US-00457364.

PF

XX

08-MAR-1988; 88US-00165667.

PR

06-FEB-1989; 89US-00305566.

PR

24-MAR-1989; 89US-00329018.

PR

20-JUN-1989; 89US-00368672.

PR

20-OCT-1989; 89US-00425504.

PR

07-SEP-1990; 90US-00580431.

PR

21-DEC-1991; 90US-00632441.

PR

27-SEP-1991; 91US-00768122.

PR

06-MAR-1992; 92US-00848506.

PR

06-NOV-1992; 92US-00973197.

PR

06-APR-1993; 93US-00042847.

PR

12-APR-1993; 93US-00045957.

PR

16-JUL-1993; 93US-00093301.

PR

13-JAN-1994; 94US-00181271.

PR

31-MAY-1995; 95US-00457364.

XX

PA

(NOVS) NOVARTIS FINANCE CORP.

XX

Payne GB, Ward ER, Moyer MB, Ryals JA;

PI

XX

WPI; 1999-059180/05.

XX

PT DNA encoding pathogenesis-related glucanase proteins - useful for
PT producing transgenic plants with enhanced disease or pest resistance.
XX
XX Example 84; Col 106; 169pp; English.
XX
CC The present invention describes a DNA molecule encoding a pathogenesis-
CC related (PR) protein having beta-1,3-glucanase activity selected from PR-
CC 2, PR-2', PR-2'', PR-N, PR-O and PR-O'. Also described are: (i) a
CC chimeric gene comprising the above DNA molecule linked to a heterologous
CC promoter; (ii) a vector containing the chimeric gene; (iii) a host cell
CC containing the chimeric gene; (iv) a transgenic plant containing the
CC chimeric gene; and (v) a seed from the transgenic plant. The DNA molecule
CC is used to produce transgenic plants with enhanced disease or pest
CC resistance. The present sequence represents an oligonucleotide from the
CC present invention
XX
XX Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1316 GCTTCGTCCTGGGTTTC 1332
DB 17 GCCTCGTCCTGGAGTTC 1
RESULT 267
AAF07186
ID AAF07186 standard; DNA; 17 BP.
XX
AC AAF07186;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #3443.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
WPI; 2000-647423/62.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 54; Page 135; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 514 CCCATGTTTCTGTCACC 530
DB 1 CCCAAGCTTCTGTCACC 17
RESULT 268
AAF07187
ID AAF07187 standard; DNA; 17 BP.
XX
AC AAF07187;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #3444.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 54; Page 135; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 515 CCATGTTTCTGTCACC 531
DB 1 CCAAGCTTCTGTCACC 17
RESULT 269
AAF02686/c
ID AAF02686 standard; DNA; 17 BP.
XX
AC AAF02686;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #981.

XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 XX WO200061729-A2.
 XX PD 19-OCT-2000.
 XX PF 11-APR-2000; 2000WO-US009721.
 XX PR 12-APR-1999; 99US-0129390P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX Claim 37; Page 78; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX Sequence 17 BP; 8 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 1063 TTCTTTGCTTCCTCCA 1079
 DB 17 TTCTTTGCTATCCTCCA 1
 RESULT 270
 ID AAF02500 standard; DNA; 17 BP.
 XX AAF02500;
 XX 16-FEB-2001 (first entry)
 XX Hammerhead ribozyme substrate #795.
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 XX WO200061729-A2.
 XX PD 19-OCT-2000.
 XX PF 11-APR-2000; 2000WO-US009721.
 XX PR 12-APR-1999; 99US-0129390P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX Claim 37; Page 78; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX Sequence 17 BP; 8 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 1063 TTCTTTGCTTCCTCCA 1079
 DB 17 TTCTTTGCTATCCTCCA 1
 RESULT 270
 ID AAF02500 standard; DNA; 17 BP.
 XX AAF02500;
 XX 16-FEB-2001 (first entry)
 XX Hammerhead ribozyme substrate #795.
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 XX WO200061729-A2.
 XX PD 19-OCT-2000.
 XX PF 11-APR-2000; 2000WO-US009721.
 XX PR 12-APR-1999; 99US-0129390P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX Claim 37; Page 74; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 976 ATGAGCCGAGGCCCTT 992
 DB 1 AAGAGCCTAGAGCCCTT 17
 RESULT 271
 ID ABK03141 standard; RNA; 17 BP.
 XX ABK03141;
 XX 12-MAR-2002 (first entry)
 XX Human CD20 Inozyme #92.
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberszyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW inflammatory arthropathy; immune thrombocytopenia; stroke; dementia;
 KW chemotherapy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX Homo sapiens.
 XX Synthetic.
 XX WO200159103-A2.
 XX 16-AUG-2001.
 XX 09-FEB-2001; 2001WO-US004273.
 XX 11-FEB-2000; 2000US-0181797P.
 XX 28-FEB-2000; 2000US-0185516P.
 XX 06-MAR-2000; 2000US-0187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 XX (MCSW/) MCSWIGGEN J.
 XX (CHOW/) CHOWRIRA B M.
 XX Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX

DR WPI; 2000-647423/62.
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX Claim 37; Page 74; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 976 ATGAGCCGAGGCCCTT 992
 DB 1 AAGAGCCTAGAGCCCTT 17
 RESULT 271
 ID ABK03141 standard; RNA; 17 BP.
 XX ABK03141;
 XX 12-MAR-2002 (first entry)
 XX Human CD20 Inozyme #92.
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberszyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW inflammatory arthropathy; immune thrombocytopenia; stroke; dementia;
 KW chemotherapy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX Homo sapiens.
 XX Synthetic.
 XX WO200159103-A2.
 XX 16-AUG-2001.
 XX 09-FEB-2001; 2001WO-US004273.
 XX 11-FEB-2000; 2000US-0181797P.
 XX 28-FEB-2000; 2000US-0185516P.
 XX 06-MAR-2000; 2000US-0187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 XX (MCSW/) MCSWIGGEN J.
 XX (CHOW/) CHOWRIRA B M.
 XX Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX

PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.

XX Claim 30; Page 147; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an ambenzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an inozyme of the invention

SQ Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGTGACG 1492
Db 17 CTGCCAGGAGTGTGACG 1

RESULT 272

ABK00739/C

ID ABK00739 standard; RNA; 17 BP.

AC ABK00739;

XX 12-MAR-2002 (first entry)

DE Human NOGO Inozyme #9.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; ambenzyme; zynzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.

XX Synthetic.

PN WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US004273.

XX 11-FEB-2000; 2000US-0181797P.

XX 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (CHOW/) CHOWRIRA B M.

XX Blatt L, Mcswiggen J, Chowrira BM;

PI WPI; 2001-607195/69.

XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.

PS Claim 88; Page 78; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an ambenzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an inozyme of the invention

SQ Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 CTGACAGAGGCTGTGCC 755

Db 17 CTGACAGGCGCTGGGCC 1

RESULT 273

ABK01164
ID ABK01164 standard; RNA; 17 BP.
XX
AC ABK01164;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Inozyme #434.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytooma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 84; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNazyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN motif) or
CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytooma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of

CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an inozyme of the invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 722 TGAAGAAGCTACTCCTTC 738
Db 1 UCAGAAGCUACUCCUUC 17
RESULT 274
ABK00079
ID ABK00079 standard; RNA; 17 BP.
XX
AC ABK00079;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Hammerhead Ribozyme #79.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytooma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 67; 200pp; English.

CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOMO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NNN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
CC with a VGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular NHL, lymphocytic
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, mantle-cell
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOMO-
CC targeting nucleic acid is used to cleave RNA of the NOMO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOMO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOMO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOMO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOMO expression. The present
CC sequence is a hammerhead ribozyme of the invention

SQ Sequence 17 BP; 0 A; 6 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 1.5e+02;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCTT 1362
DB 1 UGCGUGUCUUCUUCUUU 17

RESULT 275
ABL46611
ID ABL46611 standard; RNA; 17 BP.
AC ABL46611;
XX 27-JUN-2003 (first entry)
XX Human GRID NCH ribozyme substrate oligonucleotide #65.
XX Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX Homo sapiens.
XX WO200162911-A2.
XX 30-AUG-2001.
XX 23-FEB-2001; 2001WO-US005957.
XX 24-FEB-2000; 2000US-0184594P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (GLAX) GLAXO GROUP LTD.
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.

XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX Claim 4; Page 64; 108pp; English.
XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;
SQ Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 886 TATGTGGCCAGAACTT 902
DB 1 UAUGUGCCCAAGAUUU 17

RESULT 276
ABL47259
ID ABL47259 standard; RNA; 17 BP.
XX ABL47259;
XX 27-JUN-2003 (first entry)
XX Human GRID Amberzyme substrate oligonucleotide #159.
XX Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX Homo sapiens.
XX WO200162911-A2.
XX 30-AUG-2001.
XX 23-FEB-2001; 2001WO-US005957.
XX 24-FEB-2000; 2000US-0184594P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (GLAX) GLAXO GROUP LTD.
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.

XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX Claim 4; Page 89; 108pp; English.
XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;
SQ Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 886 TATGTGGCCAGAACTT 902
DB 1 UAUGUGCCCAAGAUUU 17

RESULT 276
ABL47259
ID ABL47259 standard; RNA; 17 BP.
XX ABL47259;
XX 27-JUN-2003 (first entry)
XX Human GRID Amberzyme substrate oligonucleotide #159.
XX Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX Homo sapiens.
XX WO200162911-A2.
XX 30-AUG-2001.
XX 23-FEB-2001; 2001WO-US005957.
XX 24-FEB-2000; 2000US-0184594P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (GLAX) GLAXO GROUP LTD.
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.

Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 1.5e+02;

Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

27 TCTGACAGGACAGAG 43

1 UCUUCAGGGGACAGAG 17

RESULT 277

ABN01544

ID ABN01544 standard; DNA; 17 BP.

XX AC

XX ABN01544;

29-MAY-2002 (first entry)

Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1536.

Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

skeletal muscle disorder; amplicon; screening; ss.

Homo sapiens.

WO200192524-A2.

06-DEC-2001.

25-MAY-2001; 2001WO-US016981.

26-MAY-2000; 2000US-0207456P.

21-SEP-2000; 2000US-0234687P.

27-SEP-2000; 2000US-0236359P.

04-OCT-2000; 2000GB-00024263.

30-JAN-2001; 2001WO-US000661.

30-JAN-2001; 2001WO-US000662.

30-JAN-2001; 2001WO-US000663.

30-JAN-2001; 2001WO-US000664.

30-JAN-2001; 2001WO-US000665.

30-JAN-2001; 2001WO-US000666.

30-JAN-2001; 2001WO-US000667.

30-JAN-2001; 2001WO-US000668.

30-JAN-2001; 2001WO-US000669.

30-JAN-2001; 2001WO-US000670.

05-FEB-2001; 2001US-0266860P.

(AEOM-) AEOMICA INC.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

WPI; 2002-179446/23.

New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

or as specific biomolecule capture probes for surface-enhanced laser

desorption ionization, comprises human myosin-like protein hGDMPLP-1.

Disclosure; SEQ ID NO 1536; 214pp; English.

The present invention describes a human genome-derived myosin-like

protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

1 can be used in gene therapy and vaccine production. The hGDMPLP-1

nucleic acids can be used as probes to detect, characterise and quantify

hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

provide initial substrates for the recombinant engineering of hGDMPLP-1

protein variants having desired phenotypic improvements, and for

expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

used as immunogens to raise antibodies that specifically recognise hGDMPLP

-1 proteins, as standards in assays used to determine the concentration

and/or amount specifically of hGDMPLP proteins, as specific biomolecule

capture probes for surface-enhanced laser desorption ionisation, as

therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed CC specification, but was obtained in electronic format directly from WIPO CC at ftp.wipo.int/pub/published_pct_sequence

Sequence 17 BP; 0 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

Query Match

Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

494 TGGCGCTGGTGACCTGG 510

1 TGGGGCTGGTGCCCTGG 17

RESULT 278

ABN02298/c

ID ABN02298 standard; DNA; 17 BP.

XX AC

XX ABN02298;

29-MAY-2002 (first entry)

Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2290.

Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

skeletal muscle disorder; amplicon; screening; ss.

Homo sapiens.

WO200192524-A2.

06-DEC-2001.

25-MAY-2001; 2001WO-US016981.

26-MAY-2000; 2000US-0207456P.

21-SEP-2000; 2000US-0234687P.

27-SEP-2000; 2000US-0236359P.

04-OCT-2000; 2000GB-00024263.

30-JAN-2001; 2001WO-US000661.

30-JAN-2001; 2001WO-US000662.

30-JAN-2001; 2001WO-US000663.

30-JAN-2001; 2001WO-US000664.

30-JAN-2001; 2001WO-US000665.

30-JAN-2001; 2001WO-US000666.

30-JAN-2001; 2001WO-US000667.

30-JAN-2001; 2001WO-US000668.

30-JAN-2001; 2001WO-US000669.

30-JAN-2001; 2001WO-US000670.

05-FEB-2001; 2001US-0266860P.

(AEOM-) AEOMICA INC.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

WPI; 2002-179446/23.

New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

or as specific biomolecule capture probes for surface-enhanced laser

desorption ionization, comprises human myosin-like protein hGDMPLP-1.

Disclosure; SEQ ID NO 2290; 214pp; English.

The present invention describes a human genome-derived myosin-like

protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

1 can be used in gene therapy and vaccine production. The hGDMPLP-1

nucleic acids can be used as probes to detect, characterise and quantify

hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

provide initial substrates for the recombinant engineering of hGDMPLP-1

protein variants having desired phenotypic improvements, and for

expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

used as immunogens to raise antibodies that specifically recognise hGDMPLP

-1 proteins, as standards in assays used to determine the concentration

and/or amount specifically of hGDMPLP proteins, as specific biomolecule

capture probes for surface-enhanced laser desorption ionisation, as

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC
CC Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 559 CTGTGGGCCAGGGGCAC 575
Db 17 CTGTGGGCCATGGACAC 1

RESULT 279
ABN02303/c
ID ABN02303 standard; DNA; 17 BP.
XX
AC ABN02303;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2295.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
PA (AEOM-) AEOMICA INC.
XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon WE;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2295; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 554 TACGGCTGTGGCCAGG 570
Db 17 TCGCGCTGTGGCCATG 1

RESULT 280
ABN10682/c
ID ABN10682 standard; DNA; 17 BP.
XX
AC ABN10682;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10674.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-026860P.
XX
PA (AEOM-) AEOMICA INC.
XX

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 10674; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 GGCTAGCCATGCTGGGT 1275
Db 17 GGCTGGCCATGCTGGCT 1
|||||
RESULT 281
ID ABN02300/c
ID ABN02300 standard; DNA; 17 BP.
XX
AC ABN02300;
XX
XX 29-MAY-2002 (first entry)
DT Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2292.
DE Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
PN
XX

PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2292; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX
SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 557 GGCTGTGGCCAGGGGC 573
Db 17 GGCTGTGGCCATGGAC 1
|||||
RESULT 282
ID ABN01655/c
ID ABN01655 standard; DNA; 17 BP.
XX
AC ABN01655;
XX
XX 29-MAY-2002 (first entry)
DT

XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1647.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 1647; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 6 A; 1 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1062 CTCCTTTGCCCTCTCC 1078

Db 17 CTCCTTTGCCCTCTCC 1
RESULT 283
ABN00939
ID ABN00939 standard; DNA; 17 BP.
XX AC ABN00939;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:931.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 931; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 6 A; 1 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1062 CTCCTTTGCCCTCTCC 1078

CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 739 CTGAGAGGCTGTGCC 755
DB 1 CTGAAGAGGCTGAGCC 17
RESULT 284
ABN02299/c
ID ABN02299 standard; DNA; 17 BP.
XX
AC ABN02299;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2291.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 2291; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples; as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 558 GCTGTGGCGCCAGGGCA 574
DB 17 GCTGTGGCGCCATGGACA 1
RESULT 285
ABN02307/c
ID ABN02307 standard; DNA; 17 BP.
XX
AC ABN02307;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2299.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 2291; 214pp; English.

XX PS Disclosure; SEQ ID NO 2299; 214pp; English.

XX CC The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMPLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMPLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMPLP-1, in particular heart

CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 3 A; 8 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 GCCTACGGCTGTGGGC 566

Db 17 GCCTACGGCTGTGGGC 1

RESULT 286

ABN02306/c

ID ABN02306 standard; DNA; 17 BP.

XX AC ABN02306;

XX DT 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2299.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 04-OCT-2000; 2000US-0236359P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 2298; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMPLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMPLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMPLP-1, in particular heart

CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 3 A; 7 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 551 CCCTACGGCTGTGGGC 567

Db 17 CACTGCGCTGTGGGC 1

RESULT 287

ABN02308/c

ID ABN02308 standard; DNA; 17 BP.

XX AC ABN02308;

XX DT 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2300.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

```

PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2300; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 9 C; 4 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 549 GGCCTTACGGCTGTGGG 565
Db 17 GGCACGTGGCTGTGGG 1
XX
RESULT 288
ABN10681/c
ID ABN10681 standard; DNA; 17 BP.
XX
AC ABN10681;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10673.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.

```

```

OS Homo_sapiens.
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 10673; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1260 GGTAGCCATGCTGGGTG 1276
Db 17 GGTGGCCATGCTGGGTG 1
XX
RESULT 289
ABN09032/c
ID ABN09032 standard; DNA; 17 BP.

```


CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX
SQ Sequence 17 BP; 1 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 CCTGGGAAACAGAAAG 307
DB 17 CCTGGCGAGACAGAAAG 1

RESULT 291
ABV85228/c
ID ABV85228 standard; DNA; 17 BP.
XX AC ABV85228;
XX DT 11-DEC-2002 (first entry)
XX DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:221.
XX KW Human; UDP-GalNAC:polypeptide N-acetyl-galactosaminyltransferase 10;
XX KW pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
XX OS Homo sapiens.
XX OS Synthetic.
XX PN EP1243660-A2.
XX PD 25-SEP-2002.
XX PF 25-JAN-2002; 2002EP-00001161.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 30-AUG-2001; 2001US-0315984P.
XX PA (AEOM-) AEOMICA INC.
XX PI Zhang J, Gu Y, Nguyen C;
XX WPI; 2002-724954/79.
XX Nucleic acid encoding human UDP-GalNAC:polypeptide N-
PT cetyl-galactosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX Example 2; SEQ ID NO 221; 59pp; English.

XX The present invention describes an isolated nucleic acid (I) encoding a
CC human UDP-GalNAC:polypeptide N-acetyl-galactosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to

CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office

XX
SQ Sequence 17 BP; 4 A; 8 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 626 TGGTGCTCTGCGCGCTG 642
DB 17 TGGCGCTGTGCGCGCTG 1

RESULT 292
AAL48306
ID AAL48306 standard; DNA; 17 BP.
XX AC AAL48306;
XX DT 03-OCT-2002 (first entry)
XX DE Human ribozyme cleavage site #2.
XX KW Ribozyme; catalytic nucleic acid; infection; PCR; target site; ss.
XX OS Homo sapiens.
XX PN WO200246449-A2.
XX PD 13-JUN-2002.
XX PF 07-DEC-2001; 2001WO-US046178.
XX PR 07-DEC-2000; 2000US-0251810P.
XX PA (UYPE-) UNIV PENNSYLVANIA STATE.
XX PI Clawson G, Pan W;
XX WPI; 2002-519672/55.
XX Identifying cleavage sites of a target RNA, by adding target RNA to
PT library of nucleic acids e.g. ribozyme, which comprise catalytic core
PT flanked by random nucleotides and isolating nucleic acid that cleave
PT target RNA.
XX Example 5; Page 52; 79pp; English.

XX The present invention relates to a method of identifying cleavage sites
CC in a target RNA which are accessible to a ribozyme comprising a catalytic
CC core flanked by random nucleotides. A target RNA is added to the library
CC of nucleic acids and nucleic acids that bind to and/or cleave the target
CC RNA are isolated. The method is useful for identifying ribozyme cleavage
CC sites in sequences and in real time PCR assays. The present sequence is a
CC ribozyme target site described in the exemplification of the invention

XX
SQ Sequence 17 BP; 1 A; 4 C; 3 G; 0 T; 9 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 1.5e+02;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1304 AGTATATCTTCTGCTTC 1320
DB 1 AGUGUUUCUUCUGCUUC 17

RESULT 293
AAD45173
ID AAD45173 standard; DNA; 17 BP.

XX AAD45173;
XX 27-DEC-2002 (first entry)
XX Human RIP2 DNA specific forward PCR primer.
XX Human; receptor interacting protein; RIP2; antisense; gene therapy; PCR;
KW primer; ss.
XX Homo sapiens.
XX US6426221-B1.
XX 30-JUL-2002.
XX 01-AUG-2001; 2001US-00920663.
XX 01-AUG-2001; 2001US-00920663.
XX (ISIS-) ISIS PHARM INC.
XX Ward DT, Cowseert LM;
XX WPI; 2002-673017/72.
XX New antisense oligonucleotide that targets regions of a nucleic acid
PT encoding human receptor interacting protein (RIP)2, for treating diseases
PT associated with RIP2 expression.
XX Example 13; Col 42; 35pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
CC encoding human receptor interacting protein (RIP)2 to inhibit its
CC expression. Antisense compounds are used for treating diseases associated
CC with RIP2 expression. They are also useful in antisense gene therapy. The
CC present sequence is human RIP2 DNA specific PCR primer
XX Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 649 CACGTGCGCGTGAGCA 665
DB 1 CAGGTGCGCGTGAGCA 17
RESULT 294
ABK17888/c
ID ABK17888 standard; RNA; 17 BP.
XX
XX AC ABK17888;
XX
XX 09-APR-2002 (first entry)
XX Human ERG hammerhead ribozyme target sequence, Seq ID No 535.
XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberos scleriosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW amberyne.
XX Homo sapiens.
XX WO200198124-A2.
XX

PD 22-NOV-2001.
XX
XX 16-MAY-2001; 2001WO-US015866.
XX
XX 16-MAY-2000; 2000US-00572021.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (GLAXO) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
XX WPI; 2002-082995/11.
XX
XX Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
XX Claim 4; Page 68; 149pp; English.
XX
XX The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberos scleriosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17394-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
XX Sequence 17 BP; 5 A; 2 C; 6 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 366 CATCTACCACATGTTCA 382
DB 17 CATCTACCACGCTGTCA 1
RESULT 295
ABK19143/c
ID ABK19143 standard; RNA; 17 BP.
XX
XX AC ABK19143;
XX
XX 09-APR-2002 (first entry)
XX Human ERG Amberzyme target sequence Seq ID No 1790.
XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberos scleriosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW

KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 PD 22-NOV-2001.
 XX
 XX 16-MAY-2001; 2001WO-US015866.
 XX
 XX 16-MAY-2000; 2000US-00572021.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAXO) GLAXO GROUP LTD.
 PA
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX
 DR Novel polynucleotide which down regulates expression of Ets-related gene,
 XX useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 PT
 XX
 PS Claim 4; Page 120; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration, and
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 5 A; 2 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 365 CCATCTACCACATGTC 381
 DB 17 CCATCTACCACATGTC 1
 RESULT 296
 ABS75235
 ID ABS75235 standard; DNA; 17 BP.
 XX
 AC ABS75235;
 XX
 XX 24-DEC-2002 (first entry)
 DT
 XX Human PAPP-Ea associated 17-mer SEQ ID 761.
 DE

KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
 KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
 KW dysgenetic pregnancy; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002102252-A1.
 XX
 PD 01-AUG-2002.
 XX
 XX 06-APR-2001; 2001US-00827998.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 XX
 XX (GUY/) GU Y.
 PA (SHAN/) SHANNON M E.
 PA
 PI Gu Y, Shannon ME;
 XX
 XX WPI; 2002-697817/75.
 DR
 XX New isolated nucleic acid encoding an isoform of human pregnancy
 PT associated plasma protein E, for preventing or aborting pregnancy.
 PT
 XX
 PS Example 2; Page 175; 353pp; English.
 XX
 CC This invention describes a novel isolated nucleic acid that encodes one
 CC of three new isoforms of human pregnancy associated plasma protein E,
 CC hPAPP-E. The products of the invention have abortive and contraceptive
 CC activity and can be used for gene therapy or in a vaccine. The nucleic
 CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
 CC used in pharmaceutical compositions or vaccines for preventing or
 CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
 CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
 CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
 CC antibodies can be used to assess the expression levels of PAPP-E isoform
 CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
 CC antenatally. This sequence represents an oligomer used in scanning the
 CC human PAPP-E genes described in the disclosure of the invention
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 824 TCTTCTGCCCAACATC 840
 DB 1 TCGTCTGCCCAACATC 17
 RESULT 297
 ABS75234
 ID ABS75234 standard; DNA; 17 BP.
 XX
 AC ABS75234;
 XX
 XX 24-DEC-2002 (first entry)
 DT
 XX Human PAPP-Ea associated 17-mer SEQ ID 760.
 DE
 KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
 KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
 KW dysgenetic pregnancy; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002102252-A1.
 XX
 PD 01-AUG-2002.
 XX
 XX 06-APR-2001; 2001US-00827998.
 XX

PR 10-OCT-2001; 2001US-032820SP.
XX (AEOM-) AEOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 1522; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, AB883999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1237 CTCCTTGGTCCCGGSC 1253
DB 1 CTCCTTGGTCCCGGSC 17
|||||||

RESULT 300
ACN03715/C
ID ACN03715 standard; RNA; 17 BP.
XX
AC ACN03715;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Zinzyne substrate SEQ ID NO 3718.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus

PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 3718; 495pp; English.
PS
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 4 A; 1 C; 10 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 CTCCTTGGTCCCAACT 839
DB 17 CTCCTTGGTCCCAACT 1
|||||||

RESULT 301
ACN11548
ID ACN11548 standard; RNA; 17 BP.
XX
AC ACN11548;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Inozyme substrate SEQ ID NO 11551.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
XX
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus

PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PS Claim 23; SEQ ID NO 11551; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 8 C; 2 G; 0 T; 2 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 359 TCGGCACCATCTACAC 375
DB 1 UCCGGACCAUCAAACAC 17
RESULT 302
ACN00235
ID ACN00235 standard; RNA; 17 BP.
XX
AC ACN00235;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Hammerhead Ribozyme substrate SEQ ID NO 225.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
CC New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 225; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 283 GAGCCATCCCTGGGAA 299
DB 1 GAGCCAUCCUGGAA 17
RESULT 303
ACN00234
ID ACN00234 standard; RNA; 17 BP.
XX
AC ACN00234;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Hammerhead Ribozyme substrate SEQ ID NO 224.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
CC New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 224; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX
SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 282 GGAGCCATCCCTGGGGA 298
|||||||: ||: |||||
DB 1 GGAGCCAUUCCUGGGA 17

RESULT 304

ACN04899/c

ID ACN04899 standard; RNA; 17 BP.

XX AC

ACN04899;

XX 22-APR-2004 (first entry)

XX WNV DNzyme substrate SEQ ID NO 4902.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 4902; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 1 A; 2 C; 8 G; 0 T; 6 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 360 CCGCACCCTCTACCACA 376
|||||||: |||||
DB 17 CCGGACCATCAACCACA 1

RESULT 305

ACN15125/c

ID ACN15125 standard; RNA; 17 BP.

XX AC

ACN15125;

XX 22-APR-2004 (first entry)

XX WNV minus strand Amberzyme substrate SEQ ID NO 15128.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 15128; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match

Best Local Similarity 0.9%; Score 13.8; DB 1; Length 17;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 283 GAGCCATCCTCGGGA 299

|||||||: |||||

Db 17 GAGCCATTCCTGTGGAA 1

RESULT 306
ABT35349/C
ID ID ABT35349 standard; DNA; 17 BP.
XX AC
XX ABT35349;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 986.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 148; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 773 GACGAGGTGAGGGATC 789
|||||
17 GACGAGGTGAGGAGATC 1

Db

RESULT 307
ABT36458
ID ID ABT36458 standard; DNA; 17 BP.
XX AC
XX ABT36458;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 2095.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 278; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 GATGAGCTGTGAGGAGGT 350
|||||
1 GATCAGCTGTGAGGAGCT 17

Db

```
ABT36554/c
ID  ABT36554 standard; DNA; 17 BP.
XX
XX
AC  ABT36554;
XX
XX
DT  12-JUN-2003 (first entry)
XX
XX
DE  Tumour suppression related human fukutin oligo SEQ ID No 2191.
XX
XX
KW  Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW  antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW  schizophrenia; protein chip; gene therapy; tumour suppression;
KW  human fukutin; ds.
XX
XX
OS  Homo sapiens.
XX
XX
PN  WO2003025175-A2.
XX
XX
PD  27-MAR-2003.
XX
XX
PF  17-SEP-2002; 2002WO-IB004208.
XX
XX
PR  17-SEP-2001; 2001PR-00011978.
XX
XX
PA  (MOLE-) MOLECULAR ENGINES LAB.
XX
PI  Telerman A, Amson R, Tuijnder M;
XX
XX
DR  WPI; 2003-313353/30.
XX
XX
PT  New isolated nucleic acid, useful for treating viral diseases associated
PT  with tumors and cell degeneration, also related polypeptides, antibodies
PT  and transfected cells.
XX
XX
PS  Disclosure; Page 289; 720pp; French.
XX
XX
CC  The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC  given in the specification, a sequence containing at least 15 consecutive
CC  nucleotides from the 17 mer sequence, a sequence with, after optimal
CC  alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC  hybridizes to them under highly stringent conditions, or the complement
CC  of any of them, or the corresponding RNA. The novel isolated nucleic
CC  acids of the invention are useful as probes and primers for detecting,
CC  identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC  component of a gene chip, in vitro as (anti)sense reagents, and for
CC  production of recombinant polypeptides. Any of the nucleic acids,
CC  polypeptides, vectors containing the nucleic acids, cells containing the
CC  vector or antibodies directed against the polypeptides are useful for
CC  preparation of pharmaceuticals for prevention and/or treatment of viral
CC  diseases that are characterised by development of tumours or cell
CC  degeneration, specifically cancer but also Alzheimer's disease and
CC  schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC  patient samples is useful for diagnosis and/or prognosis of these
CC  diseases. The polypeptides can also be used to generate antibodies, and
CC  both the polypeptide and antibodies are useful as components of protein
CC  chips. The nucleic acid sequences of the invention can be used in gene
CC  therapy. This polynucleotide sequence represents a tumour suppression
CC  related human fukutin oligonucleotide of the invention
XX
XX
SQ  Sequence 17 BP; 2 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  773 GACGAGGTGAGGGATC 789
    | | | | | | | | | |
Db  17 GCCGAGGTGAGGGATC 1

RESULT 309
ABT36432
ID  ABT36432 standard; DNA; 17 BP.
```

```
XX
XX
AC  ABT36432;
XX
XX
DT  12-JUN-2003 (first entry)
XX
XX
DE  Tumour suppression related human fukutin oligo SEQ ID No 2069.
XX
XX
KW  Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW  antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW  schizophrenia; protein chip; gene therapy; tumour suppression;
KW  human fukutin; ds.
XX
XX
OS  Homo sapiens.
XX
XX
PN  WO2003025175-A2.
XX
XX
PD  27-MAR-2003.
XX
XX
PF  17-SEP-2002; 2002WO-IB004208.
XX
XX
PR  17-SEP-2001; 2001PR-00011978.
XX
XX
PA  (MOLE-) MOLECULAR ENGINES LAB.
XX
PI  Telerman A, Amson R, Tuijnder M;
XX
XX
DR  WPI; 2003-313353/30.
XX
XX
PT  New isolated nucleic acid, useful for treating viral diseases associated
PT  with tumors and cell degeneration, also related polypeptides, antibodies
PT  and transfected cells.
XX
XX
PS  Disclosure; Page 274; 720pp; French.
XX
XX
CC  The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC  given in the specification, a sequence containing at least 15 consecutive
CC  nucleotides from the 17 mer sequence, a sequence with, after optimal
CC  alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC  hybridizes to them under highly stringent conditions, or the complement
CC  of any of them, or the corresponding RNA. The novel isolated nucleic
CC  acids of the invention are useful as probes and primers for detecting,
CC  identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC  component of a gene chip, in vitro as (anti)sense reagents, and for
CC  production of recombinant polypeptides. Any of the nucleic acids,
CC  polypeptides, vectors containing the nucleic acids, cells containing the
CC  vector or antibodies directed against the polypeptides are useful for
CC  preparation of pharmaceuticals for prevention and/or treatment of viral
CC  diseases that are characterised by development of tumours or cell
CC  degeneration, specifically cancer but also Alzheimer's disease and
CC  schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC  patient samples is useful for diagnosis and/or prognosis of these
CC  diseases. The polypeptides can also be used to generate antibodies, and
CC  both the polypeptide and antibodies are useful as components of protein
CC  chips. The nucleic acid sequences of the invention can be used in gene
CC  therapy. This polynucleotide sequence represents a tumour suppression
CC  related human fukutin oligonucleotide of the invention
XX
XX
SQ  Sequence 17 BP; 3 A; 5 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1350 GATACCTCTTCCTTGTC A 1366
    | | | | | | | | | |
Db  1 GATCCTATTCCTTGTC A 17

RESULT 310
ABT34453
ID  ABT34453 standard; DNA; 17 BP.
XX
XX
AC  ABT34453;
```

```
XX DT 12-JUN-2003 (first entry)
XX DE Tumour suppression related human fukutin oligo SEQ ID No 90.
XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; protein chip; gene therapy; tumour suppression;
XX KW human fukutin; ds.
XX OS Homo sapiens.
XX PN WO2003025175-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004208.
XX PR 17-SEP-2001; 2001FR-00011978.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX DR New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 44; 720pp; French.
XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX CC given in the specification, a sequence containing at least 15 consecutive
XX CC nucleotides from the 17 mer sequence, a sequence with, after optimal
XX CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX CC hybridizes to them under highly stringent conditions, or the complement
XX CC of any of them, or the corresponding RNA. The novel isolated nucleic
XX CC acids of the invention are useful as probes and primers for detecting,
XX CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX CC component of a gene chip, in vitro as (anti)sense reagents, and for
XX CC production of recombinant polypeptides. Any of the nucleic acids,
XX CC vector or antibodies directed against the nucleic acids, cells containing the
XX CC polypeptides, vectors containing the nucleic acids, cells containing the
XX CC vector or antibodies directed against the polypeptides are useful for
XX CC preparation of pharmaceuticals for prevention and/or treatment of viral
XX CC diseases that are characterised by development of tumours or cell
XX CC degeneration, specifically cancer but also Alzheimer's disease and
XX CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX CC patient samples is useful for diagnosis and/or prognosis of these
XX CC diseases. The polypeptides can also be used to generate antibodies, and
XX CC both the polypeptide and antibodies are useful as components of protein
XX CC chips. The nucleic acid sequences of the invention can be used in gene
XX CC therapy. This polynucleotide sequence represents a tumour suppression
XX CC related human fukutin oligonucleotide of the invention
XX SQ Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;
XX Query Match 0.9%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1112 GATTGGGAGACAGGATG 1128
DB 1 GATCGGAGACAGGATG 17
RESULT 311
ABT39454
ID ABT39454 standard; DNA; 17 BP.
XX AC ABT39454;
XX DT 12-JUN-2003 (first entry)
```

```
XX DE Tumour suppression related human fukutin oligo SEQ ID No 5091.
XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; protein chip; gene therapy; tumour suppression;
XX KW human fukutin; ds.
XX OS Homo sapiens.
XX PN WO2003025175-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004208.
XX PR 17-SEP-2001; 2001FR-00011978.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX DR New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 629; 720pp; French.
XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX CC given in the specification, a sequence containing at least 15 consecutive
XX CC nucleotides from the 17 mer sequence, a sequence with, after optimal
XX CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX CC hybridizes to them under highly stringent conditions, or the complement
XX CC of any of them, or the corresponding RNA. The novel isolated nucleic
XX CC acids of the invention are useful as probes and primers for detecting,
XX CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX CC component of a gene chip, in vitro as (anti)sense reagents, and for
XX CC production of recombinant polypeptides. Any of the nucleic acids,
XX CC vector or antibodies directed against the nucleic acids, cells containing the
XX CC polypeptides, vectors containing the nucleic acids, cells containing the
XX CC vector or antibodies directed against the polypeptides are useful for
XX CC preparation of pharmaceuticals for prevention and/or treatment of viral
XX CC diseases that are characterised by development of tumours or cell
XX CC degeneration, specifically cancer but also Alzheimer's disease and
XX CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX CC patient samples is useful for diagnosis and/or prognosis of these
XX CC diseases. The polypeptides can also be used to generate antibodies, and
XX CC both the polypeptide and antibodies are useful as components of protein
XX CC chips. The nucleic acid sequences of the invention can be used in gene
XX CC therapy. This polynucleotide sequence represents a tumour suppression
XX CC related human fukutin oligonucleotide of the invention
XX SQ Sequence 17 BP; 3 A; 1 C; 8 G; 5 T; 0 U; 0 Other;
XX Query Match 0.9%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1419 GAACGTGCTGATGGGA 1435
DB 1 GATCGTGTGATGTGGA 17
RESULT 312
ACA06527/c
ID ACA06527 standard; RNA; 17 BP.
XX AC ACA06527;
XX DT 03-JUN-2003 (first entry)
XX DE NFkB sub-unit modulating inozyme substrate #346.
```


XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme; G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human; lung cancer; prostate cancer; colorectal cancer; brain cancer; oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer; cervical cancer; head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate; gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes; rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia; gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis; transplant/graft rejection; reperfusion injury; glomerulonephritis; allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

OS US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245466.

PR 15-AUG-1994; 94US-00291932.

PR 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHOMB D T.

PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.

PI Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 32; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic, cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or multidrug resistant cancer. The method involves use of other drug therapies such as monoclonal antibodies, REL-A-specific inhibitors or chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate, gemcitabine or radiation therapy. The enzymatic and antisense nucleic acid molecules are also useful for treating inflammatory disease such as rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, gene therapy applications, ischaemia/reperfusion injury (central nervous system (CNS) and myocardial), glomerulonephritis, sepsis, allergic airway inflammation, inflammatory bowel disease or infection. This sequence represents the substrate of a novel enzymatic nucleic acid molecule

XX Sequence 17 BP; 1 A; 10 C; 3 G; 0 T; 3 U; 0 Other;

XX Query Match 0.9%; Score 13.8; DB 1; Length 17;

XX Best Local Similarity 88.2%; Pred. No. 1.5e+02;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 156 GCTGGAGCAGCGCAGG 172

DB ||||| ||||| |||||

17 GCTGGAGCAGCGCAGG 1

RESULT 313

ACA06588

ID ACA06588 standard; RNA; 17 BP.

XX ACA06588;

XX 03-JUN-2003 (first entry)

XX NFkB sub-unit modulating inozyme substrate #407.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme; G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human; lung cancer; prostate cancer; colorectal cancer; brain cancer; oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer; cervical cancer; head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate; gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes; rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia; gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis; transplant/graft rejection; reperfusion injury; glomerulonephritis; allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

XX US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245466.

PR 15-AUG-1994; 94US-00291932.

PR 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHOMB D T.

PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.

PI Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 33; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic, cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or multidrug resistant cancer. The method involves use of other drug therapies such as monoclonal antibodies, REL-A-specific inhibitors or chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate, gemcitabine or radiation therapy. The enzymatic and antisense nucleic acid molecules are also useful for treating inflammatory disease such as

CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, gene therapy applications, ischaemia/reperfusion injury (central nervous system (CNS) and myocardial), glomerulonephritis, sepsis, allergic airway inflammation, inflammatory bowel disease or infection. This sequence represents the substrate of a novel enzymatic nucleic acid molecule

XX Sequence 17 BP; 2 A; 4 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 444 GCTGCTGCTGGAGTTTG 460
||:| ||:| ||:| ||:| ||:|
Db 1 CGUCAGCUGCAGUUUG 17

RESULT 314
ACA07773

ID ACA07773 standard; RNA; 17 BP.

XX ACA07773;

XX 03-JUN-2003 (first entry)

XX NFKB sub-unit modulating zinzyme substrate #172.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme; G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human; lung cancer; prostate cancer; colorectal cancer; brain cancer; oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer; cervical cancer; head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate; gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes; rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia; gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis; transplant/graft rejection; reperfusion injury; glomerulonephritis; allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

OS US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

XX 18-MAY-1994; 94US-00245466.

XX 15-AUG-1994; 94US-00291932.

XX 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHCOMB D T.

PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.

XX Stinchcomb DT, Mcswiggen J, Draper KG;

PI WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 40; 72pp; English.

PS The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme

CC configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic, cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or multidrug resistant cancer. The method involves use of other drug therapies such as monoclonal antibodies, REL-A-specific inhibitors or chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate, gemcitabine or radiation therapy. The enzymatic and antisense nucleic acid molecules are also useful for treating inflammatory disease such as rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, gene therapy applications, ischaemia/reperfusion injury (central nervous system (CNS) and myocardial), glomerulonephritis, sepsis, allergic airway inflammation, inflammatory bowel disease or infection. This sequence represents the substrate of a novel enzymatic nucleic acid molecule

XX Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 445 CTGCTGCTGGAGTTTGA 461
||:| ||:| ||:| ||:| ||:|
Db 1 CUGCAGCUGCAGUUUGA 17

RESULT 315
ACA06526/c

ID ACA06526 standard; RNA; 17 BP.

XX ACA06526;

XX 03-JUN-2003 (first entry)

XX NFKB sub-unit modulating inozyme substrate #345.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme; G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human; lung cancer; prostate cancer; colorectal cancer; brain cancer; oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer; cervical cancer; head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate; gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes; rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia; gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis; transplant/graft rejection; reperfusion injury; glomerulonephritis; allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

OS US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

XX 18-MAY-1994; 94US-00245466.

XX 15-AUG-1994; 94US-00291932.

XX 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHCOMB D T.

PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.

```
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
XX a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 32; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
XX regulates expression of a sequence encoding a subunit of nuclear factor
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
XX configuration. The enzymatic nucleic acid molecule is adapted to treat
XX cancer and is useful for down-regulating REL-A activity in a cell, for
XX treating a patient having a condition associated with the level of REL-A.
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
XX the presence of a divalent cation, especially Mg2+. The enzymatic and
XX antisense nucleic acid molecules are useful for treating breast, lung,
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
XX multidrug resistant cancer. The method involves use of other drug
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
XX cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
XX acid molecules are also useful for treating inflammatory disease such as
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
XX rejection, gene therapy applications, ischaemia/reperfusion injury,
XX (central nervous system (CNS) and myocardial), glomerulonephritis,
XX sepsis, allergic airway inflammation, inflammatory bowel disease or
XX infection. This sequence represents the substrate of a novel enzymatic
XX nucleic acid molecule
XX
XX Sequence 17 BP; 1 A; 10 C; 3 G; 0 T; 3 U; 0 Other;
SQ
```

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 157 CTGGAGCAGCGCAGGG 173

Db 17 CTGGAGCAGCGCAGGG 1

RESULT 316

ADB04224/c

ID ADB04224 standard; DNA; 17 BP.

AC ADB04224;

AD 20-NOV-2003 (first entry)

DE Human MD27 scanning oligonucleotide SEQ ID 5210.

DE Cytostatic; immunostimulant; gene therapy; vaccine; human;

KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;

KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;

KW developmental disorder; ss.

XX Homo sapiens.

XX EP1281758-A2.

XX 05-FEB-2003.

XX 30-JUL-2002; 2002EP-00016874.

XX 02-AUG-2001; 2001US-00922181.

XX (AEOM-) AEOMICA INC.

XX Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in

PT manufacturing a medicament for treating or preventing a disorder

PT associated with decreased or increased expression or activity of MD23,

PT

PT

PT

PT

PT

PT

PT

XX

PI Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PT MD24, MD27 or MD212, e.g. cancer.
PS Example 8; SEQ ID NO 5211; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder,
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 GTGGCCCATGAGTATAT 1310
DB 17 GTGGCCCAAGATATATAT 1
|||||

RESULT 318
ADB04222/c
ID ADB04222 standard; DNA; 17 BP.
XX
AC ADB04222;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MD27 scanning oligonucleotide SEQ ID 5208.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
DR WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
PS Example 8; SEQ ID NO 5208; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome

CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder,
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 GCCCATGAGTATATCTT 1313
DB 17 GCCCAAGATATATCTT 1
|||||

RESULT 319
ADB04223/c
ID ADB04223 standard; DNA; 17 BP.
XX
AC ADB04223;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MD27 scanning oligonucleotide SEQ ID 5209.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
DR WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
PS Example 8; SEQ ID NO 5209; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder,
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are

```
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1296 GGCCCATGAGTATATCT 1312
DB 17 GGCCCAAGATATATCT 1
RESULT 320
ABQ81024/c
ID ABQ81024 standard; DNA; 17 BP.
XX
AC ABQ81024;
XX
DT 10-JAN-2003 (first entry)
XX
DE Plasmid pXL3675-related oligonucleotide #2.
XX
KW Triple helix; pXL3675; ds.
XX
OS Synthetic.
XX
PN WO20027274-A2.
XX
PD 03-OCT-2002.
XX
PF 25-MAR-2002; 2002WO-FR001034.
XX
PR 23-MAR-2001; 2001FR-00003953.
PR 23-APR-2001; 2001US-0285272P.
XX
PA (AVET ) AVENTIS PHARMA SA.
XX
PI Blanche F, Cameron B;
XX
WPI; 2003-018943/01.
XX
PT Purifying double-stranded DNA, useful e.g. for isolating plasmids or
PT therapeutic genes, by triple helix formation with oligonucleotide
PT directed to a specific target sequence.
XX
PS Example 6; Page 23; 49pp; French.
XX
CC The present invention relates to novel double stranded (ds) DNA sequences
CC which can interact with a third strand to form a stable triple helix. The
CC invention also relates to a method for purifying a ds DNA molecule,
CC comprising contact with a third DNA strand that interacts with a target
CC sequence (TS) in the ds DNA to form a triple helix. The present sequence
CC is a oligonucleotide used in the construction of plasmid pXL3675, used in
CC the examples of the invention
XX
SQ Sequence 17 BP; 10 A; 0 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1061 TCCTCTTTCCTTCCTC 1077
DB 17 TCCTCTTTCCTTCCTC 1
RESULT 321
ABZ60036/c
ID ABZ60036 standard; RNA; 17 BP.
XX
```

```
AC ABZ60036;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNazyme substrate #148.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 87; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 4 A; 1 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 403 ATCATCAGCACCTGTC 419
DB 17 ATCATCAGCACCTGTC 1
RESULT 322
ABZ65182
ID ABZ65182 standard; RNA; 17 BP.
XX
AC ABZ65182;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human HER2 DNazyme substrate #639.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
```

```
XX WO200297114-A2.
XX
XX PD 05-DEC-2002.
XX
XX PF 29-MAY-2002; 2002WO-US016840.
XX
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Mcswiggen J;
XX
XX DR WPI; 2003-140484/13.
XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX PS Claim 4; Page 145; 185pp; English.
XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
XX SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 0.9%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 64.7%; Pred. No. 1.5e+02;
XX Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1178 CTTGGAACGTGTGGTC 1194
XX |:|||||:|:|:|
XX Db 1 CUCGGAACGUGUGGUC 17
XX
XX RESULT 323
XX ABZ61374
XX ID ABZ61374 standard; RNA; 17 BP.
XX
XX AC ABZ61374;
XX
XX DT 21-MAR-2003 (first entry)
XX
XX DE Human H-Ras DNAzyme target #165.
XX
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX anti-rheumatic; cancer; AIDS; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200297114-A2.
XX
XX PD 05-DEC-2002.
XX
XX PF 29-MAY-2002; 2002WO-US016840.
XX
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX
```

```
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Mcswiggen J;
XX
XX DR WPI; 2003-140484/13.
XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX PS Claim 58; Page 114; 185pp; English.
XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX acid molecule or an enzymatic nucleic acid molecule, that modulates
XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX acid molecule of the invention has cytostatic, anti-HIV, and anti-
XX rheumatic activity. The nucleic acid molecules are useful for reducing
XX HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX also useful for treating breast, ovarian, colorectal, lung, prostate,
XX bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
XX ABZ66530 - ABZ66585 represent substrate/target sequences for the human
XX ribozymes of the invention
XX
XX SQ Sequence 17 BP; 0 A; 6 C; 11 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 3 GGAGCCAGCGGGGCC 19
XX |||||:|:|:|
XX Db 1 GGGGCCGGCGGGGCC 17
XX
XX RESULT 324
XX ACC67550/c
XX ID ACC67550 standard; DNA; 17 BP.
XX
XX AC ACC67550;
XX
XX DT 01-JUL-2003 (first entry)
XX
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4797.
XX
XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; ss.
XX
XX OS Mus musculus.
XX
XX PN WO2003025176-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004210.
XX
XX PR 17-SEP-2001; 2001FR-00011979.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijinder M;
XX
XX DR WPI; 2003-333167/31.
XX
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX PS Disclosure; Page 591; 738pp; French.
XX
```

CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC68806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 2 A; 11 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 42 AGGCGTGGGAGGAGG 58
 DB 17 AGGCGTGGGAGGAGGATC 1
 ||||| ||||| ||||| ||||| |||||

RESULT 325
 ACC65385
 ID ACC65385 standard; DNA; 17 BP.
 AC ACC65385;
 XX
 DT 01-JUL-2003 (first entry)
 XX
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2632.
 XX
 KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001PR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 XX WPI; 2003-333167/31.
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated
 XX with tumors and cell degeneration, also related polypeptides, antibodies
 XX and transfected cells.
 XX
 XX Disclosure; Page 338; 738pp; French.
 XX
 XX The present invention relates to murine oligonucleotides (ACC62754-
 XX ACC68806), which are associated with tumour suppression, tumour
 XX reversion, apoptosis and virus resistance. The oligonucleotides are
 XX useful as (1) as probes and primers for detecting, identifying,
 XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
 XX gene chip; in vitro as (anti)sense reagents; and (2) for production of a
 XX recombinant polypeptides. The oligonucleotides are useful for preparation
 XX of pharmaceuticals for prevention and/or treatment of viral diseases that
 XX are characterised by development of tumours or cell degeneration,
 XX specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 123 GACCCGACACATGGAGG 139
 DB 1 GATCCTACACATGGAGG 17
 ||||| ||||| ||||| ||||| |||||

RESULT 326
 ACC63090/c
 ID ACC63090 standard; DNA; 17 BP.
 XX
 AC ACC63090;
 XX
 DT 01-JUL-2003 (first entry)
 XX
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 337.
 XX
 KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001PR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 XX WPI; 2003-333167/31.
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated
 XX with tumors and cell degeneration, also related polypeptides, antibodies
 XX and transfected cells.
 XX
 XX Disclosure; Page 70; 738pp; French.
 XX
 XX The present invention relates to murine oligonucleotides (ACC62754-
 XX ACC68806), which are associated with tumour suppression, tumour
 XX reversion, apoptosis and virus resistance. The oligonucleotides are
 XX useful as (1) as probes and primers for detecting, identifying,
 XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
 XX gene chip; in vitro as (anti)sense reagents; and (2) for production of a
 XX recombinant polypeptides. The oligonucleotides are useful for preparation
 XX of pharmaceuticals for prevention and/or treatment of viral diseases that
 XX are characterised by development of tumours or cell degeneration,
 XX specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 AGGCTGTGCTGGGATC 762
 DB 17 AGGCTGTGCTGGGATC 1
 ||||| ||||| ||||| ||||| |||||

RESULT 327
 ADB40240
 ID ADB40240 standard; DNA; 17 BP.
 XX
 XX ADB40240;
 XX

```
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #563.
KW cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
XX 15-MAY-2003.
XX
XX 17-SEP-2002; 2002WO-IB004219.
XX
XX 17-SEP-2001; 2001FR-00011981.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-441574/41.
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
XX useful e.g. for treatment of tumors and viral infection, also related
XX polypeptide and antibodies.
XX
XX Disclosure; Page 97; 771pp; French.
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
XX fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX sequence having at least 80% identity, after optimal alignment, with the
XX nucleotides, a sequence that hybridizes under stringent conditions with
XX the nucleotides, or the complement, or corresponding RNA, of the
XX nucleotides. The nucleotides are used as probes or primers for detecting,
XX identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX sense and antisense sequences, of nucleotides involved in tumour
XX suppression or reversion, apoptosis and or viral resistance, to produce
XX recombinant polypeptides, and to prepare transgenic animals, as
XX experimental models. The nucleotides (also vectors containing them and
XX cells containing the vectors), the encoded polypeptides and antibodies
XX (Ab) against the polypeptide are useful for prevention and/or treatment
XX of viral infections or diseases characterized by development of tumours
XX or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX Analysis of the expression of the nucleotides can be used for diagnosis
XX and/or prognosis of these diseases. The nucleotides and polypeptides can
XX also be used to screen for their specific interactive molecules,
XX potentially useful for treating diseases associated with abnormal
XX expression of the nucleotides.
XX
XX Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 334 GATGAGCTGATGAGGT 350
DB 1 GATCAGCTGATGAGCT 17
RESULT 328
ADB40360/c
ID ADB40360 standard; DNA; 17 BP.
XX
XX ADB40360;
XX
XX 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
```

```
DE Tumour suppression/reversion associated nucleotide #683.
XX
XX cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
XX 15-MAY-2003.
XX
XX 17-SEP-2002; 2002WO-IB004219.
XX
XX 17-SEP-2001; 2001FR-00011981.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-441574/41.
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
XX useful e.g. for treatment of tumors and viral infection, also related
XX polypeptide and antibodies.
XX
XX Disclosure; Page 111; 771pp; French.
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
XX fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX sequence having at least 80% identity, after optimal alignment, with the
XX nucleotides, a sequence that hybridizes under stringent conditions with
XX the nucleotides, or the complement, or corresponding RNA, of the
XX nucleotides. The nucleotides are used as probes or primers for detecting,
XX identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX sense and antisense sequences, of nucleotides involved in tumour
XX suppression or reversion, apoptosis and or viral resistance, to produce
XX recombinant polypeptides, and to prepare transgenic animals, as
XX experimental models. The nucleotides (also vectors containing them and
XX cells containing the vectors), the encoded polypeptides and antibodies
XX (Ab) against the polypeptide are useful for prevention and/or treatment
XX of viral infections or diseases characterized by development of tumours
XX or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX Analysis of the expression of the nucleotides can be used for diagnosis
XX and/or prognosis of these diseases. The nucleotides and polypeptides can
XX also be used to screen for their specific interactive molecules,
XX potentially useful for treating diseases associated with abnormal
XX expression of the nucleotides.
XX
XX Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 773 GACGAGGTGAGGGATC 789
DB 17 GCCGAGGTGAGTGGATC 1
RESULT 329
ADC03630/c
ID ADC03630 standard; DNA; 17 BP.
XX
XX ADC03630;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human Na/H exchanger-like protein 1 gene oligonucleotide #77.
XX
XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHLEP1; passive replacement therapy; vaccine; diagnosis.
KW
```


XX Novel isolated nucleic acid molecule comprising single nucleotide
PT polymorphism associated with fish, useful for forming PCR primers which
PT are used for detecting single nucleotide polymorphisms in fish nucleic
PT acids.
XX
PS Claim 18; SEQ ID NO 630; 233pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) comprising a
CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of
CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;
CC and (ii) a nucleic acid having nucleotide sequence that hybridises to
CC (i), or its complement under highly stringent hybridisation conditions.
CC Also described: (i) an isolated oligonucleotide (II) comprising at least
CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites, or their complement; (2)
CC a primer pair (iii) suitable for use in PCR, comprising two (iii) capable
CC of amplifying a nucleotide sequence chosen from S. salar SNPs and, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites; and determining (Mi) the
CC origin of fish sample comprising providing a parentage genotype database
CC comprising a collection of candidate parent genotypes, where each of the
CC candidate parent genotype represents a distinct origin, and comparing a
CC sample genotype to the parentage genotype database, where a match between
CC the sample genotype and one of the candidate parent genotype identifies
CC to the origin of the sample. (M1) is useful for determining the origin of
CC a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus,
CC rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for
CC detecting nucleic acid molecule comprising SNP in a sample, which
CC involves contacting the sample containing nucleic acids with one or more
CC (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus
CC SNPs, and identifying nucleic acid that hybridises to (II). (II) is
CC useful for detecting nucleic acid molecule comprising a polymorphic
CC sequence in a sample, comprising contacting the sample containing nucleic
CC acids with one or more (II) which is derived from O. niloticus .
CC microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic
CC sites or seabass polymorphic sites, and identifying a nucleic acid that
CC hybridises to (II). (III) is useful for detecting nucleic acid molecule
CC comprising a microsatellite sequence in sample. The present sequence is
CC used in the exemplification of the present invention.
XX
SQ Sequence 17 BP; 2 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 240 ACCTGTGCCCCCACCCTC 256
Db 17 ACCTCAGCACCCACCCTC 1
RESULT 332
ADE35992/C
ID ADE35992 standard; DNA; 17 BP.
XX
AC ADE35992;
XX
DT 29-JAN-2004 (first entry)
XX
DE Identifier tag sequence #6.
XX
KW ss; genome signature tag; library; genome signature tag library;
KW identifier tag.
XX
OS Yersinia pestis.
XX
PN US2003186251-A1.
XX
PD 02-OCT-2003.
XX
PF 01-APR-2002; 2002US-00113916.

XX 01-APR-2002; 2002US-00113916.
PR (BROO-) BROOKHAVEN SCI ASSOC LLC.
XX
PA Dunn JJ, Van Der Lelie D, Krause MK;
XX WPI; 2003-844149/78.
DR
XX
PT Generating a genome signature tag library useful for genetic analysis.
XX
PS Example; Page 7; 12pp; English.
XX
CC The invention relates to a method of generating a genome signature tag
CC library. The method is used for generating a genome signature tag
CC library. The present sequence represents a Y. pestis identifier tag
CC sequence.
XX
SQ Sequence 17 BP; 4 A; 9 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 438 GGGCAGGCTGCTGCTGG 454
Db 17 GGGCTGGCTGATGCTGG 1
RESULT 333
ADF62453/C
ID ADF62453 standard; DNA; 17 BP.
XX
AC ADF62453;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 357.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
DR WPI; 2003-532916/50.
XX
PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS Example 2; SEQ ID NO 357; 164pp; English.
XX
CC The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-

CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.

XX SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02; Mismatches 2; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 587 CGACGGGCTCGGCTGT 603

DB 17 CGACGGGCTCGACTGT 1

RESULT 334

ADI49812

ID ADI49812 standard; DNA; 17 BP.

XX AC ADI49812;

XX DT 15-APR-2004 (first entry)

XX DE Human tumour suppression/reversion-related DNA sequence SeqID2315.

XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;

XX KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;

XX KW primer; PCR; gene chip; antisense; viral disease; tumour;

XX KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX OS Homo sapiens.

XX PN WO2003025177-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004523.

XX PR 17-SEP-2001; 2001PR-00011980.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX DR New isolated nucleic acid, useful for treating viral diseases associated

XX PT with tumors and cell degeneration, also related polypeptides, antibodies

XX PT and transfected cells.

XX PS Disclosure; SEQ ID NO 2315; 30pp; French.

XX CC This invention relates to novel isolated nucleic acid sequences involved

XX CC in the phenomena of tumour suppression, tumour reversion, apoptosis

XX CC and/or resistance to viruses. The invention may be useful for the

XX CC development of compounds with a cytostatic, virucide, neuroprotective,

XX CC nontropic or neuroleptic activity. The DNA sequences may be useful as

XX CC probes and primers for detecting, indentifying, quantifying and/or

XX CC amplifying nucleic acid, for example as one component of a gene chip, in

XX CC vitro as antisense reagents and for production of recombinant

XX CC polypeptides. The invention may therefore be useful for preparation of

XX CC pharmaceuticals for prevention and/or treatment of viral diseases that

XX CC are characterised by development of tumours or cell degeneration.

XX CC specifically cancer but also Alzheimer's disease and schizophrenia. The

XX CC present sequence is that of a nucleic acid sequence of the invention.

XX CC Note: The sequence data for this patent did not form part of the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/publishedpct_sequences

XX SQ Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 587 CGACGGGCTCGGCTGT 603

DB 17 CGACGGGCTCGACTGT 1

RESULT 336

ADI49115

ID ADI49115 standard; DNA; 17 BP.

XX AC ADI49115;

XX DT 15-APR-2004 (first entry)

XX DE Human tumour suppression/reversion-related DNA sequence SeqID1618.

XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;

XX KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;

XX KW primer; PCR; gene chip; antisense; viral disease; tumour;

XX KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX OS Homo sapiens.

XX PN WO2003025177-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004523.

XX PR 17-SEP-2001; 2001PR-00011980.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX DR New isolated nucleic acid, useful for treating viral diseases associated

XX PT with tumors and cell degeneration, also related polypeptides, antibodies

XX PT and transfected cells.

XX PS Disclosure; SEQ ID NO 1618; 30pp; French.

XX CC This invention relates to novel isolated nucleic acid sequences involved

XX CC in the phenomena of tumour suppression, tumour reversion, apoptosis

XX CC and/or resistance to viruses. The invention may be useful for the

XX CC development of compounds with a cytostatic, virucide, neuroprotective,

XX CC nontropic or neuroleptic activity. The DNA sequences may be useful as

XX CC probes and primers for detecting, indentifying, quantifying and/or

XX CC amplifying nucleic acid, for example as one component of a gene chip, in

XX CC vitro as antisense reagents and for production of recombinant

XX CC polypeptides. The invention may therefore be useful for preparation of

XX CC pharmaceuticals for prevention and/or treatment of viral diseases that

XX CC are characterised by development of tumours or cell degeneration.

XX CC specifically cancer but also Alzheimer's disease and schizophrenia. The

XX CC present sequence is that of a nucleic acid sequence of the invention.

XX CC Note: The sequence data for this patent did not form part of the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/publishedpct_sequences

XX SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 587 CGACGGGCTCGGCTGT 603

DB 17 CGACGGGCTCGACTGT 1

ADM09492/c
ID ADM09492 standard; RNA; 17 BP.
XX
AC ADM09492;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor amberzyme substrate sequence #47.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor amberzyme; substrate; ss.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 887; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor amberzyme substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 904 GCCCAGGCCCTGGGATG 920
|||||
DB 17 GCCCAGGCCCTGGGATG 1
RESULT 337

ADL46682/c
ID ADL46682 standard; RNA; 17 BP.
XX
AC ADL46682;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor inozyme substrate sequence #115.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor inozyme; substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 215; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 906 CCAGGCCCTGGGATGTG 922
|||||
DB 17 CCAGGCCCTGGGATGTG 1
RESULT 338

ADMS4579
ID ADM54579 standard; mRNA; 17 BP.
AC
XX
ADMS4579;
XX
XX
03-JUN-2004 (first entry)
XX
DE Human GRID mRNA substrate sequence #889.

XX
KW Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
KW NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNasezyme; amberyzyme; Inozyme;
KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX
OS Homo sapiens.

XX
XX US2003134806-A1.

XX
XX 17-JUL-2003.

XX
XX 23-FEB-2001; 2001US-00792818.

XX
XX 10-FEB-2000; 2000US-0181594P.

XX
XX (JARV/) JARVIS T.

XX
XX (CARL/) CARLOWITZ I V.

XX
XX (MCSW/) MCSWIGGIN J.

XX
XX (HAMB/) HAMBLIN P A.

XX
XX (ELLIS/) ELLIS J H.

XX
XX Jarvis T, Carlowitz IV, Mcswiggin J, Hamblin PA, Ellis JH;

XX
XX WPI; 2003-829646/77.

XX
XX New nucleic acid molecule that down-regulates expression of Grb2-related
XX with insert domain (GRID) gene, useful for treating a condition
XX associated with the level of GRID, e.g. tissue/graft rejection and
XX leukemia.

XX
XX Claim 4; SEQ ID NO 892; 74pp; English.

XX
XX The invention relates to a nucleic acid molecule that down-regulates
XX expression of Grb2-related with insert domain (GRID) gene, e.g. a
XX hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNasezyme,
XX amberyzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell
XX including the novel nucleic acid molecule, reducing GRID activity in a
XX cell by contacting the cell with the novel nucleic acid molecule,
XX treating a patient having a condition associated with the level of GRID
XX (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
XX the novel nucleic acid molecule, cleaving RNA of a GRID gene by
XX contacting the cell with the novel nucleic acid molecule, an expression
XX vector comprising a nucleic acid sequences (encoding at least the novel
XX nucleic acid molecule in a manner that allows its expression), a
XX mammalian cell including the expression vector and an enzymatic nucleic
XX acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
XX molecule is useful for treating a condition associated with the level of
XX GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
XX a target region for the enzymatic nucleic acids of the invention.

XX
XX Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 27 TCTGCAGAGGACAGAG 43

Db 1 UCUCAGAGGACAGAG 17

RESULT 339

ADJ53658/c

ID ADJ53658 standard; DNA; 17 BP.

XX

AC

XX

DT

XX

XX

DE

XX

KW

KW

XX

OS

XX

XX

PN

XX

XX

PD

XX

XX

PF

XX

XX

PR

XX

XX

PA

XX

XX

PI

XX

PI

XX

XX

DR

XX

XX

PT

XX

PT

XX

PT

XX

XX

XX

PS

XX

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

ADJ53658;

06-MAY-2004 (first entry)

HBV probe #3.

ss; capture oligonucleotide; HBV; HIV-1; HCV; donated blood screening;
probe.

Hepatitis B virus.

WO2003106714-A1.

24-DEC-2003.

13-JUN-2003; 2003WO-US018993.

14-JUN-2002; 2002US-0389393P.

(GENP-) GEN-PROBE INC.

Linnen JM, Kolk DP, Dockter JM, Getman DK, Yoshimura T;
Ho-Sing-Loy M, Stringfellow LA;

WPI; 2004-082210/08.

Capture oligonucleotide composition useful for detection of hepatitis B
virus (HBV), comprising polynucleotide having HBV-complementary sequence
which is immobilized on solid support.

Claim 18; SEQ ID NO 52; 112pp; English.

The invention relates to a capture oligonucleotide composition comprising
an hepatitis B virus (HBV)-complementary sequence polynucleotide
immobilised to a solid support. The composition is useful for detecting
nucleic acids of HBV and/of HIV-1 and/or HCV in biological sample such as
blood, serum, plasma or other body fluid or tissue to be tested. The
composition can be used either in diagnostic application or for screening
donated blood and that products or other tissues that may contain
infectious particles. The composition facilitates detection of very low
levels of HBV nucleic acids. The composition allows selective detection
of nucleic acids of HBV and/or HIV and/or HCV. The present sequence is
used in the exemplification of the invention.

Sequence 17 BP; 6 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGC 1057

Db 17 CCTCTTCATCTGCTGC 1

RESULT 340

ADP46272/c

ID ADP46272 standard; DNA; 17 BP.

AC ADP46272;

26-AUG-2004 (first entry)

Extend primer 53 used to genotype human KIAA0861 polymorphism.

breast cancer; cytostatic; gene therapy; human; ss; primer; SNP;
single nucleotide polymorphism;
Rho family guanine-nucleotide exchange factor; KIAA0861;
chromosome 3q27.3; probe.

Homo sapiens.

WO2004047623-A2.

XX 10-JUN-2004.
 XX PD
 XX PF
 XX XX
 XX 25-NOV-2003; 2003WO-US037948.
 XX
 XX 25-NOV-2002; 2002US-0429136P.
 XX 24-JUL-2003; 2003US-0490234P.
 XX (SEQU-) SEQUENOM INC.
 XX
 XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX WPI; 2004-441051/41.
 XX
 XX Identifying a subject at risk of breast cancer by detecting the presence
 XX of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 XX PT regions which are associated with breast cancer in a nucleic acid sample
 XX PT from a subject.
 XX
 XX Example 6; Page 99; 289pp; English.
 XX
 XX The invention relates to a novel method for identifying a subject at risk
 XX of breast cancer comprising detecting the presence or absence of one or
 XX more polymorphic variations associated with breast cancer in a nucleic
 XX acid sample from a subject. The method of the invention has cytostatic
 XX applications and may be useful for identifying a subject at risk of
 XX breast cancer, for early diagnosis, prevention and treatment of breast
 XX cancer, possibly via gene therapy, as well as to analyse and predict a
 XX response to a breast cancer treatment and in clinical drug trials. The
 XX current sequence is that of an extend primer (also described as probe) of
 XX the invention which was used to genotype human Rho family guanine-
 XX nucleotide exchange factor KIAA0861 gDNA which has been mapped to
 XX CC chromosomal position 3q27.3.
 XX
 XX Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 XX
 XX Query Match 0.9%; Score 13.8; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 111 CTTGGTACATGGACCC 127
 XX 17 CTTGGTACATGGACCC 1
 XX DB
 XX
 XX RESULT 341
 XX AAX79556/c
 XX ID AAX79556 standard; DNA; 18 BP.
 XX
 XX AAX79556;
 XX
 XX 11-AUG-1999 (first entry)
 XX
 XX PCR primer for S. pneumoniae riba coding sequence.
 XX
 XX Riba; 3,4-dihydroxy-2-butanone-4 phosphate synthase; antibiotic; cancer;
 XX KW GTP cyclohydrolase II; vaccine; immunological response; gastric ulcer;
 XX KW antimicrobial compound; Helicobacter pylori infection; gastritis;
 XX KW gastrointestinal carcinoma; therapy; PCR primer; ss.
 XX
 XX Synthetic.
 XX OS Streptococcus pneumoniae.
 XX
 XX WO9927125-A1.
 XX
 XX 03-JUN-1999.
 XX
 XX 23-NOV-1998; 98WO-US024953.
 XX
 XX 25-NOV-1997; 97US-00979616.
 XX
 XX (SMIK) SMITHKLINE BEECHAM CORP.
 XX

PI Palmer LM, Fedon JC, Warren RL, Kosmatka AL, Shilling LK;
 PI Black MT, Hodgson JE, Nicholas RO, Knowles DJC, Lonetto MA;
 PI Stodola RK;
 XX WPI; 1999-370907/31.
 XX
 XX Streptococcus pneumoniae 3,4-dihydroxy-2-butanone-4 phosphate synthase
 XX PT and related polynucleotides.
 XX
 XX Disclosure; Page 16; 52pp; English.
 XX
 XX This sequence is a PCR primer for DNA encoding the Streptococcus
 XX pneumoniae 3,4-dihydroxy-2-butanone-4 phosphate synthase (riba) protein
 XX of the invention. Riba is a member of the GTP cyclohydrolase II family.
 XX Diseases related to expression or activity of riba can be determined by
 XX analysing the nucleic acid sequence encoding riba or detecting the riba
 XX polypeptide in a sample. Riba can also be used to identify antagonists or
 XX agonists. Riba, or its related nucleic acid, also has use as a vaccine to
 XX induce an immunological response in an animal. Antimicrobial compounds
 XX (e.g. agonists and antagonists of riba), especially broad-spectrum
 XX antibiotics, may be of use in the treatment of Helicobacter pylori
 XX infection. This should decrease the advent of H. pylori-induced cancers,
 XX such as gastrointestinal carcinoma. The treatment should also cure
 XX gastric ulcers and gastritis
 XX
 XX Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 0.9%; Score 13.8; DB 1; Length 18;
 XX Best Local Similarity 88.2%; Pred. No. 1.6e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 688 TGTGTCTCTGGCTTGGCA 704
 XX 17 TGTGTCTCTGGCTTGGCA 1
 XX DB
 XX
 XX RESULT 342
 XX AAZ89760/c
 XX ID AAZ89760 standard; DNA; 18 BP.
 XX
 XX AAZ89760;
 XX
 XX 05-MAY-2000 (first entry)
 XX
 XX Human RIP-1 antisense oligonucleotide ISIS# 23903.
 XX
 XX RIP-1; RalBP; RLIP; antisense inhibitor; anti-inflammatory; cytostatic;
 XX KW anti-infective; diagnose; prevent; treatment; tumour formation; ss.
 XX
 XX Homo sapiens.
 XX
 XX US6020198-A.
 XX
 XX 01-FEB-2000.
 XX
 XX 25-SEP-1998; 98US-00161443.
 XX
 XX 25-SEP-1998; 98US-00161443.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennett CF, Cowser LM;
 XX WPI; 2000-146889/13.
 XX
 XX Antisense inhibition of human RIP-1 expression, useful for diagnosing,
 XX PT preventing and treating conditions such as inflammation.
 XX
 XX Example 15; Col 27; 26pp; English.
 XX
 XX This sequence represents an antisense oligonucleotide which binds to the
 XX CC coding region of human RIP-1. RIP-1 (also known as RalBP1 and RLIP) is a
 XX GTPase activating protein (GAP) thought to be a downstream target of Ral.

CC The invention relates to antisense phosphorothioate oligonucleotides with
 CC anti-infective, anti-inflammatory and cytostatic activity. The
 CC oligonucleotides are RIP-1 antisense inhibitors and are used in the
 CC diagnosis, prevention and treatment of conditions associated with RIP-1
 CC expression. Conditions associated with RIP-1 expression include various
 CC infections, inflammation and tumour formation

XX Sequence 18 BP; 4 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 362 GCACCATCTACACATG 378
 ||||| ||||| |||||
 Db 18 GCACCATCTACTACATG 2

RESULT 343
 AAZ89759/C
 ID AAZ89759 standard; DNA; 18 BP.
 XX
 AC AAZ89759;
 XX
 DT 05-MAY-2000 (first entry)
 XX
 DE Human RIP-1 antisense oligonucleotide ISIS# 23902.
 XX
 KW RIP-1; RalBP; RLIP; antisense inhibitor; anti-inflammatory; cytostatic;
 KW anti-infective; diagnose; prevent; treatment; tumour formation; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6020198-A.
 XX
 PD 01-FEB-2000.
 XX
 PF 25-SEP-1998; 98US-00161443.
 XX
 PR 25-SEP-1998; 98US-00161443.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Cowsett LM;
 XX
 DR WPI; 2000-146889/13.
 XX
 PT Antisense inhibition of human RIP-1 expression, useful for diagnosing,
 PT preventing and treating conditions such as inflammation.
 XX
 PS Example 15; Col 27; 26pp; English.

XX This sequence represents an antisense oligonucleotide which binds to the
 CC coding region of human RIP-1. RIP-1 (also known as RalBP1 and RLIP) is a
 CC GTPase activating protein (GAP) thought to be a downstream target of Ral.
 CC The invention relates to antisense phosphorothioate oligonucleotides with
 CC anti-infective, anti-inflammatory and cytostatic activity. The
 CC oligonucleotides are RIP-1 antisense inhibitors and are used in the
 CC diagnosis, prevention and treatment of conditions associated with RIP-1
 CC expression. Conditions associated with RIP-1 expression include various
 CC infections, inflammation and tumour formation

XX Sequence 18 BP; 3 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 335 ATGAGCTGATGGAGTG 351
 ||||| ||||| |||||
 Db 18 ATGAGCTGAGGGAATG 2

RESULT 344
 AAA39259/C
 ID AAA39259 standard; DNA; 18 BP.
 XX
 AC AAA39259;
 XX
 DT 08-SEP-2000 (first entry)
 XX
 DE Anti-mouse monoclonal antibody heavy chain gene PCR primer SEQ ID NO:3.
 XX
 KW Mouse; monoclonal antibody; methylotropic yeast; Pichia pastoris;
 KW expression cassette; antigen-specific; transformation; Ig; c-myc;
 KW immunoglobulin; Her2/neu; lymphoma; cloning; immunised; human; humanised;
 KW immunodiagnostic; immunotherapeutic; PCR primer; ss.

XX Pichia pastoris.
 OS Mus sp.
 OS Synthetic.
 XX
 PN WO200023579-A1.
 XX
 PD 27-APR-2000.
 XX
 PF 21-OCT-1999; 99WO-US024677.
 XX
 PR 22-OCT-1998; 98US-0105259P.
 XX
 PA (REGC) UNIV CALIFORNIA.

XX Choudary PV, Ogunjimi AA, Chandler JM;
 PI WPI; 2000-339681/29.
 XX

XX Large scale production of intact antigen-specific recombinant antibodies
 PT comprises transforming Pichia pastoris with mouse or human immunoglobulin
 PT genes encoding heavy and light chains.
 XX
 PS Example 5; Page 29; 50pp; English.

XX The present invention describes a method (I) for producing intact antigen
 CC specific antibodies by transforming Pichia pastoris with mouse,
 CC humanised mouse or human immunoglobulin genes encoding heavy and light
 CC chains. The method is useful for the preparation of any kind of antibody
 CC and is suitable for large-scale production of human and other mammalian
 CC antibodies. The method is also useful for expression of antibody genes
 CC isolated from clinically and industrially important hybridomas producing
 CC antibodies to e.g. c-myc, Her2/neu, or lymphoma, or for cloning and
 CC expression of antibody genes from immunised or non-immunised animals or
 CC humans. The recombinant antibodies produced by the method are useful for
 CC immunodiagnostic and immunotherapeutic purposes. Prior methods that use
 CC prokaryotes in the production of antibodies are incapable of producing
 CC intact antibodies. The present method is capable of producing intact
 CC antibodies using more practical, economical, faster and safer techniques
 CC than the prior systems. The present sequence represents a PCR primer
 CC which is used in an example from the present invention

XX Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 448 CTGCTGGAGTTTGACCT 464
 ||||| ||||| |||||
 Db 18 CTGCTGCAGTTTGACCT 2

RESULT 345
 AAZ73451/C
 ID AAZ73451 standard; DNA; 18 BP.
 XX
 AC AAZ73451;
 XX

XX PA (UYJO) UNIV JOHNS HOPKINS.
XX PI Smith KD;
XX XX WPI; 2000-292995/25.
XX PT Novel method for treating adrenoleukodystrophy comprises administering an
XX agent which causes peroxisome proliferation.
XX PS Example 7; Page 23; 50pp; English.
XX CC This sequence represents a PCR primer used to amplify the
XX adrenoleukodystrophy gene. The PCR product is used in a method for
XX testing the effect of 4-Phenyl butyrate (4-PBA) treatment on cells
XX derived from patients with X-linked adrenoleukodystrophy (X-ALD). The
XX invention relates to a treatment for a patient with adrenoleukodystrophy.
XX The treatment comprises administering an agent which causes peroxisome
XX proliferation (e.g. 4-PBA). Peroxisome proliferation causes a reduction
XX in the level of C24:0 or C26:0 fatty acids in the central nervous system
XX of the patient. Adrenoleukodystrophy is associated with defective
XX peroxisomal beta-oxidation of saturated long chain fatty acids. The
XX methods are useful for treating a patient with adrenoleukodystrophy, and
XX screening for candidate therapeutic agents for treating
XX adrenoleukodystrophy
XX SQ Sequence 18 BP; 4 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 241 CCTCTGCCCCACCTCC 257
DB 17 CCTCTGCCACCTCC 1
RESULT 348
AAH75401
ID AAH75401 standard; DNA; 18 BP.
XX AC AAH75401;
XX DT 05-OCT-2001 (first entry)
XX DE Chloramphenicol acetyltransferase (CAT) PCR primer 2.
XX KW Gene recombination; Cre recombinase; LOXP; post-mitotic target tissue;
XX KW Chloramphenicol acetyltransferase; PCR primer; CAT;
XX KW site-specific recombination; ss.
XX OS Synthetic.
XX PN US2001008026-A1.
XX PD 12-JUL-2001.
XX PF 25-JUN-1998; 98US-00104654.
XX PR 25-JUN-1998; 98US-00104654.
XX XX (SCHN/) SCHNEIDER M D.
XX PA (OVER/) OVERBEEK P.
XX PA (FREN/) FRENKEL P.
XX PI Schneider MD, Overbeek P, Frenkel P;
XX DR WPI; 2001-432338/46.
XX PT Methods for carrying out tissue specific gene recombination using gene
XX transfer systems are used to generate transgenic animals which are used
XX for screening test compounds.

PS Example 3; Page 14; 36pp; English.
XX CC The invention relates to a method for gene recombination in post-mitotic
XX cells comprising using a gene transfer system, comprising a DNA sequence
XX encoding a Cre recombinase and post-mitotic target tissue comprising
XX target nucleic acids which have one or more site-specific recombination
XX target sequences and introducing the gene transfer system to the target
XX tissue where recombination occurs at one or more site-specific
XX recombination target sequences. The method provides tissue specific gene
XX recombination. The present sequence is that of a PCR primer targeted to
XX chloramphenicol acetyltransferase to confirm a Cre-mediated recombination
XX event at inserted loxP sites
XX SQ Sequence 18 BP; 6 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1139 ACTGTGGAACTCAACG 1155
DB 1 ACTGTGGAACTCAACG 17
RESULT 349
AAI66128
ID AAI66128 standard; DNA; 18 BP.
XX AC AAI66128;
XX DT 15-JAN-2002 (first entry)
XX DE Human glaucoma-coding DNA related PCR primer 7.
XX DE Human; glaucoma-coding DNA; glaucoma; PCR primer; ss.
XX OS Homo sapiens.
XX PN KR2001048693-A.
XX PD 15-JUN-2001.
XX PF 29-NOV-1999; 99KR-00053486.
XX PR 29-NOV-1999; 99KR-00053486.
XX PA (EYEG-) EYEGENE INC.
XX PI Ju CG, Kim HS, Kim SJ;
XX DR WPI; 2001-637115/73.
XX PT New glaucoma-coding DNA sequences for studying glaucoma and developing
XX PT diagnostic kits.
XX PS Example 2; Page 3; 7pp; Korean.
XX CC The invention relates to glaucoma-coding DNA sequences (AAI66120 and
XX AAI66121) for understanding better causes and mechanism of glaucoma and
XX to develop more effective diagnosis kits. New sequences of glaucoma-
XX coding DNA substitute thymine for cytosine at the site of 46th arginine
XX of conventional glaucoma-coding DNA sequence to become a stop codon and
XX thymine for cytosine at the site of 35th threonine of conventional
XX glaucoma-coding DNA sequence to express isoleucine. The present sequence
XX is that of a PCR primer, useful to the invention
XX SQ Sequence 18 BP; 1 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 946 GGCCGCCTCTGTTC 962

Db 2 GGCCACCTCTGCTTCC 18

||||| ||||| ||||| |||||

RESULT 350
AAF70537
ID AAF70537 standard; DNA; 18 BP.
AC AAF70537;
XX
DT 20-APR-2001 (first entry)
XX
DE Human DRD2 fragment 14 PCR primer SEQ ID NO:280.
XX
KW Human; dopamine receptor D2; DRD2; polymorphism; allele specific;
KW drug target isogene; detection; single nucleotide polymorphism; SNP;
KW genotype; schizophrenia; Parkinson's disease; myoclonus dystonia; MD;
KW probe; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200105832-A1.
XX
PD 25-JAN-2001.
XX
PF 19-JUL-2000; 2000WO-US019644.
XX
PR 19-JUL-1999; 99US-0144493P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
XX
PS WPI; 2001-091967/10.
XX
PT Polynucleotides comprising single nucleotide polymorphisms in the human
PT dopamine receptor D2, useful for detecting mutations associated with,
PT e.g. schizophrenia, Parkinson's and myoclonus dystonia.
XX
PS Example 1B; Page 43; 135pp; English.
XX
CC The present invention describes polynucleotides comprising single
CC nucleotide polymorphisms (SNPs) in the human dopamine receptor D2 (DRD2).
CC The polynucleotides may be used in assays to detect and characterise
CC polymorphisms in DRD2 that affect its expression and activity and are
CC involved in disorders such as schizophrenia, Parkinson's and myoclonus
CC dystonia (MD). This information would be useful for studying the
CC biological function of DRD2 as well as in identifying drugs targeting
CC this protein for the treatment of disorders related to its abnormal
CC expression or function. Polymorphisms in the DRD2 gene affect the
CC expression of active and functional polypeptides. Therefore it is
CC advantageous to detect polymorphisms in the DRD2 gene and how those
CC polymorphisms are combined in different copies of the gene. AAF70261 to
CC AAF70308 represent human DRD2 allele specific oligonucleotide probes, and
CC AAF70309 to AAF70404 represent human DRD2 allele specific oligonucleotide
CC primers which are used in the detection of DRD2 polymorphisms. AAF70405
CC to AAF70452 represent oligonucleotide primers for the detection of human
CC DRD2 polymorphisms which are given in the exemplification of the present
CC invention. AAF70453 to AAF70538 represent PCR primers for the human DRD2
CC gene which are used in examples from the present invention
XX
SQ Sequence 18 BP; 3 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1073 TCCTCCATTGCTGGCTC 1089
||||| ||||| ||||| |||||

Db 2 TCCTCCACTGCTGACTC 18

RESULT 351

ABL89040/c
ID ABL89040 standard; DNA; 18 BP.
XX
AC ABL89040;
XX
DT 22-MAY-2002 (first entry)
XX
DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:262.
XX
KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
KW reverse transcriptase; binding group; ss.
XX
OS Human immunodeficiency virus 1.
OS Synthetic.
XX
PN EP1174518-A1.
XX
PD 23-JAN-2002.
XX
PF 20-JUL-2000; 2000EP-00202611.
XX
PR 20-JUL-2000; 2000EP-00202611.
XX
PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
PI Loukachov VV, Van Gemen B, Goudamit J;
XX
PS WPI; 2002-156696/21.
XX
PT Collection of binding groups for determining or typing samples,
PT especially clinical samples, has groups capable to identify essentially
PT all members of the family of nucleic acids of relatively high
PT significance.
XX
PS Disclosure; Page 70; 166pp; English.
XX
CC The present invention describes a collection of binding groups for a
CC family of nucleic acids comprising members of relative high and relative
CC low significance, where the binding groups are selected to be capable to
CC identify, alone or in combination, essentially all members of the family
CC of nucleic acids of relatively high significance. The collection of
CC binding groups is useful for typing of nucleic acid in a clinical sample,
CC by contacting the nucleic acid with the collection and determining
CC whether one or more binding groups bound to the nucleic acid of the
CC sample. This method is useful for determining whether the sample
CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 18 BP; 6 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 TAGCCATGCTGGGTGTG 1278
||||| ||||| ||||| |||||

Db 17 TAGCCCTGCTGGATGTG 1

RESULT 352
ABS61018/c
ID ABS61018 standard; DNA; 18 BP.
XX
AC ABS61018;
XX
DT 05-NOV-2002 (first entry)
XX
DE Human genotyping PCR primer #171.
XX

KW Human; ss; aminopeptidase P; XPNEP2; bradykinin receptor B1; primer;
KW BDKRB1; tachykinin receptor B1; TACK1; C1 esterase inhibitor; C1NH;
KW kallikrein 1; KLK1; bradykinin receptor B2; BDKRB2; gene therapy;
KW angiotensin converting enzyme 2; ACE2; protease inhibitor 4; P14;
KW polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
KW cardiovascular disease; angina pectoris; hypertension; heart failure;
KW myocardial infarction; ventricular hypertrophy; vascular disease;
KW aneurysm; embolism; thrombosis; coronary artery disease; angioedema;
KW arteriosclerosis; atherosclerosis; hyperplasticity; sepsis; PCR;
KW autoimmune disease; inflammatory arthritis; cancer; wound; genotyping;
KW viral infection; bacterial infection; fungal infection; COPD;
KW Chronic obstructive pulmonary disease; enterocolitis.
XX
XX Homo sapiens.
XX WO200261131-A2.
XX
XX 08-AUG-2002.
XX
XX 03-DEC-2001; 2001WO-US047235.
XX
XX 04-DEC-2000; 2000US-025101SP.
XX 23-JAN-2001; 2001US-0263678P.
XX 02-MAR-2001; 2001US-0273037P.
XX
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX (TSUC/) TSUCHIHASHI Z.
XX (HUIL/) HUI L.
XX
XX Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH;
XX Swanson BN, Powell JR;
XX WPI; 2002-619265/66.
XX
XX New isolated nucleic acid with at least one polymorphic position, useful
XX for detecting, diagnosing and treating disorders such as angioedema,
XX cancer, viral, bacterial or fungal infection, cardiovascular and
XX autoimmune diseases.
XX
XX Example 3; Page 916; 977pp; English.
XX
XX The invention relates to an isolated nucleic acid from a human gene
XX encoding aminopeptidase P (XPNEP2), bradykinin receptor B1 (BDKRB1),
XX tachykinin receptor B1 (TACK1), C1 esterase inhibitor (C1NH), kallikrein
XX 1 (KLK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
XX 2 (ACE2) or protease inhibitor 4 (P14), comprising at least one
XX polymorphic position. Also included are (1) a probe that hybridises to a
XX polymorphic position as provided in the detailed summary of single
XX nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
XX sequence; (2) analysing (M1) at least one nucleic acid sample comprising
XX the sample from one or more individuals and determining the
XX nucleic acid sequence at one or more polymorphic positions in a gene
XX encoding a protein selected from the group above; (3) constructing (M2)
XX haplotypes using the genes comprising grouping at least two nucleic acids
XX upon administration of an ACE inhibitor and/or vasoconstrictor inhibitor
XX using the polymorphic data; (5) a library of nucleic acids, each of which
XX comprises one or more polymorphic positions within a gene encoding a
XX human protein selected from the group above; and (6) genotyping (M4) an
XX individual comprising obtaining a nucleic acid sample, determining the
XX nucleotide present in at least one polymorphic position, and comparing at
XX least one position with a known data set. The genes, (M1, M2, M3 and M4)
XX and compositions are useful for detecting, diagnosing, treating,
XX preventing various disorders such as angioedema and diseases which
XX involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
XX disease, trachoma, and cardiovascular diseases like angina pectoris,
XX hypertension, heart failure, myocardial infarction, ventricular
XX hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
XX artery disease, arteriosclerosis and/or atherosclerosis, and
XX hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
XX arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
XX obstructive pulmonary disease (COPD) and enterocolitis (many other
XX diseases and disorders are listed in the specification). The

CC polynucleotides are also useful for chromosome identification. Antibodies
CC against the proteins may be utilised for immunophenotyping of cell lines
CC and biological samples. The present sequence is a genotyping PCR primer
CC for the gene encoding one of the proteins listed above
XX
SQ Sequence 18 BP; 4 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 509 GGGTGCCCATGTTTCTG 525
DB 18 GGGTGCCCATGATGCTG 2
RESULT 353
ABS68853
ID ABS68853 standard; DNA; 18 BP.
XX
XX AC ABS68853;
XX 20-NOV-2002 (first entry)
XX
XX Human RecQ protein-like 4 (RECQL4) DNA PCR primer #2.
XX
XX Human; RecQ protein-like 4; RECQL4; PCR; ss; chromosome 8q24; infection;
XX inflammation; tumour formation; cancer; cytostatic; antiinflammatory;
XX antimicrobial; antisense therapy; primer.
XX
XX Homo sapiens.
XX
XX US6436706-B1.
XX
XX 20-AUG-2002.
XX
XX 23-FEB-2001; 2001US-00792594.
XX
XX 23-FEB-2001; 2001US-00792594.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Ward DT, Watt AT;
XX WPI; 2002-689941/74.
XX
XX New antisense compounds targeted to nucleic acids encoding RecQ protein-
XX like 4, useful for modulating expression of the nucleic acid and treating
XX diseases associated with expression of the nucleic acid in humans.
XX
XX Example 13; Col 43; 45pp; English.
XX
XX The invention relates to a compound targeted to specific nucleobases of
XX RecQ protein-like 4 (RECQL4) and which hybridises and inhibits the
XX expression of RECQL4. The compound is useful for inhibiting the
XX expression of RECQL4 in cells or tissues and for treating an animal,
XX particularly a human suspected of having or being prone to a disease or
XX condition associated with expression of RECQL4. The compound is useful
XX for diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. This sequence represents a PCR primer used in analysis of cDNA
XX encoding human RECQL4
XX
SQ Sequence 18 BP; 1 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 683 CCCGTTGTCCTGGTC 699
DB 1 CCCGTTGTCCTGGTC 17

RESULT 354
ADG89548/c
ID ADG89548 standard; DNA; 18 BP.
XX
AC ADG89548;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human matrilin-3 PCR primer REMAT3.7E.F SEQ ID NO:123.
XX
KW human; matrilin-3; osteopathic; gene therapy; osteoarthritis; MATN3; EGF;
KW ss; PCR; primer.
XX
OS Homo sapiens.
XX
PN WO2003062469-A2.
XX
PD 31-JUL-2003.
XX
PF 23-JAN-2003; 2003WO-IB000342.
XX
PR 25-JAN-2002; 2002US-0453705P.
PR 03-DEC-2002; 2002US-0431538P.
XX
PA (DECO-) DECODE GENETICS EHF.
XX
PI Stefansson SE;
XX
DR WPI; 2003-646073/61.
XX
XX New nucleic acid molecule for diagnosing, prognosing or treating
PT osteoarthritis comprises a matrilin-3 gene or its fragment or variant,
PT and at least one polymorphism.
XX
PS Disclosure; SEQ ID NO 123; 190pp; English.
XX
XX The invention relates to a novel nucleic acid molecule comprising a
CC matrilin-3 gene, or its fragment or variant, a sequence of 137870 bp
CC fully defined in the specification, and at least one polymorphism given
CC in the specification. A protein of the invention has osteopathic
CC activity. A polynucleotide of the invention may have a use in gene
CC therapy. The composition and methods of the invention are useful in
CC diagnosing, prognosing or treating osteoarthritis using polymorphisms in
CC the matrilin-3 gene. The present sequence is used in the exemplification
CC of the invention.
XX
SQ Sequence 18 BP; 5 A; 7 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1186 GTGGTGGTCCATCCTG 1202
Db ||||||| ||||| |||
18 GTGGTGGCCCATGCGCTG 2

RESULT 355
ACA60572/c
ID ACA60572 standard; DNA; 18 BP.
XX
AC ACA60572;
XX
DT 11-JUN-2003 (first entry)
XX
DE Antisense inhibition of human cyclin D2 related oligonucleotide #9.
XX
KW Human; cyclin D2; diagnostic; therapeutic; prophylaxis;
KW cyclin 2 inhibition; ss.
XX
OS Homo sapiens.
XX

PN US6492173-B1.
XX
PD 10-DEC-2002.
XX
PF 01-AUG-2001; 2001US-00920760.
XX
PR 01-AUG-2001; 2001US-00920760.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowser LM;
XX
DR WPI; 2003-361492/34.
XX
XX Novel antisense compound useful for treating diseases associated with
PT Cyclin D2 expression, comprises an oligonucleotide comprising up to 50
PT nucleobases in length, which inhibits expression of Cyclin D2 in cells or
PT tissues in vitro.
XX
PS Claim 1; Col 45-46; 40pp; English.
XX
CC The invention describes a compound (I) of up to 50 nucleobases in length,
CC which inhibits the expression of Cyclin D2. (I) is useful for inhibiting
CC the expression of Cyclin D2 in cells or tissues in vitro. (I) is thus
CC useful for treating disease associated with Cyclin D2 expression. (I) is
CC useful for diagnostics, therapeutics, prophylaxis and as research
CC reagents and kits. This sequence represents human cyclin D2 inhibition
CC associated oligonucleotide
XX
SQ Sequence 18 BP; 6 A; 1 C; 10 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 242 CTCTGCCCCACCTCCC 258
Db ||||||| ||||| |||
17 CTCTGCCCTCACCCTC 1

RESULT 356
ADM06663
ID ADM06663 standard; DNA; 18 BP.
XX
AC ADM06663;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PCR primer SEQ ID NO:5348.
XX
KW human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.
XX
OS Homo sapiens.
XX
PN EP1347046-A1.
XX
PD 24-SEP-2003.
XX
PF 12-APR-2002; 2002EP-00008400.
XX
PR 22-MAR-2002; 2002JP-00137785.
XX
PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
XX
DR WPI; 2003-723558/69.
XX
XX New polynucleotides and polypeptides are useful in gene therapy, for
PT developing a diagnostic marker or medicines for regulating their
PT expression and activity, or as a target of gene therapy.

XX Example 8; SEQ ID NO 5348; 305pp; English.

CC The invention relates to a novel human polynucleotide and the encoded

CC polypeptide. A polynucleotide of the invention may have a use in gene

CC therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful

CC as a primer for synthesizing the polynucleotide or as a probe for

CC detecting the polynucleotide. The polynucleotides ADM0316-ADM03758 are

CC useful in gene therapy, for developing a diagnostic marker or medicines

CC for regulating their expression and activity, or as a target of gene

CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides

CC are useful as pharmaceutical agents. The present sequence represents an

CC oligonucleotide used in the invention.

XX

XX Sequence 18 BP; 3 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 767 GTGCCAGACGAGTGAG 783

Db 2 GTGCCTGACTAGGTGAG 18

RESULT 357

ADH35262

ID ADH35262 standard; DNA; 18 BP.

AC ADH35262;

XX

XX 25-MAR-2004 (first entry)

DT

DE Primer of the invention #11.

XX

XX body fat; vascular endothelial growth factor receptor 1; VEGFR 1;

KW Anorectic; Antiangiogenic; angiogenesis; preadipocytes; primer; ss.

KW

XX Synthetic.

OS

XX WO2004002427-A2.

PN

XX 08-JAN-2004.

XX

XX 27-JUN-2003; 2003WO-US020591.

XX

XX 27-JUN-2002; 2002US-0392463P.

PR

XX (GEHO) GEN HOSPITAL CORP.

PA

XX Jain RK, Fukumura D;

PI

XX WPI; 2004-099174/10.

DR

XX Use of anti-vascular endothelial growth factor receptor 1 (VEGFR 1)

PT antibody to treat or prevent obesity.

PT

XX Disclosure; SEQ ID NO 11; 61pp; English.

PS

XX The present invention relates to a screening method for determination of

CC a compound to treat, stabilize or prevent a condition in a mammal having

CC higher than desired total body weight and a higher than desired

CC percentage of body fat comprises measurement of vascular endothelial

CC growth factor receptor 1 (VEGFR 1) activity in a cell or tissue. The

CC method is useful to treat, stabilize or prevent a higher than desired

CC total body weight or a higher than desired percentage of body fat in

CC mammal (humans) and percentage of body fat decrease by at least 10 %.

CC inhibits angiogenesis and inhibits differentiation of preadipocytes. The

CC method has few adverse side-effects, greater efficacy and reduces the

CC body fat for long-term. The present sequence is a primer of the

CC invention.

XX

XX Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1084 TGGCTCAACGCCCTTGC 1100

Db 1 TGGCTCACCCTTGC 17

RESULT 358

ADJ53657/c

ID ADJ53657 standard; RNA; 18 BP.

XX

XX ADJ53657;

XX

XX 06-MAY-2004 (first entry)

DT

XX HBV probe #2.

DE

XX ss; capture oligonucleotide; HBV; HIV-1; HCV; donated blood screening;

KW probe.

KW

XX Hepatitis B virus.

OS

XX WO2003106714-A1.

PN

XX 24-DEC-2003.

PD

XX 13-JUN-2003; 2003WO-US018993.

PF

XX 14-JUN-2002; 2002US-0389393P.

PR

XX (GENP-) GEN-PROBE INC.

PA

XX Linnen JM, Kolk DP, Dockter JM, Getman DK, Yoshimura T;

PI Ho-Sing-Loy M, Stringfellow LA;

PI

XX WPI; 2004-082210/08.

DR

XX Capture oligonucleotide composition useful for detection of hepatitis B

PT virus (HBV), comprising polynucleotide having HBV-complementary sequence

PT which is immobilized on solid support.

PT

XX Claim 18; SEQ ID NO 51; 112pp; English.

PS

XX The invention relates to a capture oligonucleotide composition comprising

CC an hepatitis B virus (HBV)-complementary sequence polynucleotide

CC immobilized to a solid support. The composition is useful for detecting

CC nucleic acids of HBV and/or HIV-1 and/or HCV in biological sample such as

CC blood, serum, plasma or other body fluid or tissue to be tested. The

CC composition can be used either in diagnostic application or for screening

CC donated blood and that products or other tissues that may contain

CC infectious particles. The composition facilitates detection of very low

CC levels of HBV nucleic acids. The composition allows selective detection

CC of nucleic acids of HBV and/or HIV and/or HCV. The present sequence is

CC used in the exemplification of the invention.

XX

XX Sequence 18 BP; 7 A; 2 C; 8 G; 0 T; 1 U; 0 Other;

Query Match 0.9%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGC 1057

Db 17 CCTCTTCATCCTGCTGC 1

RESULT 359

ADO43211

ID ADO43211 standard; DNA; 18 BP.

XX

AC ADO43211;
XX
XX
DT 29-JUL-2004 (first entry)
XX
XX Vascular endothelial growth factor antisense PCR primer.
DE
XX Vascular endothelial growth factor; VEGF; blood vessel; angiogenesis;
KW vasculogenesis; transplant; tissue engineering; mouse; PCR; primer; ss.
XX
XX Mus sp.
OS
XX WO2004039248-A2.
PN
XX 13-MAY-2004.
PD
XX 30-OCT-2003; 2003WO-US034838.
PF
XX 31-OCT-2002; 2002US-0422709P.
PR
XX (GEO) GEN HOSPITAL CORP.
PA
XX Jain RK, Fukumura D;
PI
XX WPI; 2004-376029/35.
DR
XX Inducing or increasing blood vessel formation or engineering blood
PT vessels in tissue or organ of mammal, by administering cells e.g.
PT preadipocyte, adipocyte not having genetic modification, fibroblast to
PT tissue or organ of mammal in need.
XX
XX Disclosure; SEQ ID NO 11; 100pp; English.
PS
XX The present sequence is that of an antisense PCR primer for the murine
CC vascular endothelial growth factor (VEGF) gene. It was used in an
CC examination of the expression of VEGF and other angiogenesis-related
CC genes in the adipose tissue of mice. A complex relationship between
CC adipose tissue formation, angiogenesis and vessel remodelling has been
CC identified. The invention provides methods and compositions for promoting
CC blood vessel formation or engineering blood vessels in damaged, diseased
CC or transplanted organs, and for producing functional microvascular
CC networks useful in tissue engineering. A method is provided for inducing
CC blood vessel formation (e.g. angiogenesis, vasculogenesis, formation of
CC an immature blood vessel network, blood vessel remodeling, stabilisation
CC and differentiation, or establishment of a functional blood vessel
CC network) or engineering blood vessels in a mammal e.g. a human. The
CC method involves administering preadipocytes, adipocytes, perivascular
CC cells, vascular smooth muscle cells, mesenchymal precursor cells,
CC mesenchymal cells and fibroblasts, or stem cells that differentiate into
CC these cell types, to a tissue or organ. The method is useful for treating
CC various diseases or disorders e.g. by transplantation of insulin-
CC producing cells, adipocytes, preadipocytes for treating diabetes,
CC transplantation of oligodendroglial precursor cells, adipocytes,
CC preadipocytes, mesenchymal cells for treating multiple sclerosis,
CC transplantation of organ producing thyroid hormone for treating endocrine
CC related disorders and transplantation of engineered bone for treating
CC arthritis, cancer, congenital defects of bone or cartilage and trauma.
CC The engineered blood vessel, tissue or organ is useful for screening
CC candidate compound that induce or prevent angiogenesis or vasculogenesis.
XX
XX Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1084 TGGCTCAACGCTTGC 1100
Db 1 TGGCTCAGCGCTTGC 17
RESULT 360
ADO16557
ID ADO16557 standard; DNA; 18 BP.

XX ADO16557;
AC
XX 29-JUL-2004 (first entry)
DT
XX
XX 4 synthesis-period of neuroblastoma related primer, SEQ ID 819.
DE
XX Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
KW
XX Synthetic.
OS
XX WO2004039975-A1.
PN
XX 13-MAY-2004.
PD
XX 30-OCT-2003; 2003WO-JP013932.
PF
XX 30-OCT-2002; 2002JP-00316586.
PR
XX (HISM) HISAMITSU PHARM CO LTD.
PA (CHIB-) CHIBA PREFECTURE.
XX
XX Nakagawara A, Ohira M;
PI
XX WPI; 2004-390323/36.
DR
XX Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
PT cells useful for prognosing and determining progress stage of
PT neuroblastomas.
XX
XX Claim 8; SEQ ID NO 819; 455pp; Japanese.
PS
XX The present invention relates to human nucleic acid sequences (I;
CC ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC neuroblastoma cell. (I) is useful for prognosing and determining the
CC progress stage of 4 synthesis-period of neuroblastoma. The present
CC sequence is a primer, used to illustrate the invention.
XX
XX Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 790 CAGGCCCCAGTTTCTC 806
Db 1 CCGGCCACACAGTTTCTC 17
RESULT 361
ADO26322/c
ID ADO26322 standard; DNA; 18 BP.
XX
XX ADO26322;
AC
XX 23-SEP-2004 (first entry)
DT
XX Rhizomucor pusillus alpha-amylase AM782 PCR primer AM298-CDSF.
DE
XX Alpha-amylase; thermostable; enzyme; PCR; primer; ss.
KW
XX Rhizomucor pusillus.
OS
XX WO2004055178-A1.
PN
XX 01-JUL-2004.
PD
XX 16-DEC-2003; 2003WO-DK000882.
PF
XX 17-DEC-2002; 2002DK-00001928.
PR
XX (NOVO) NOVOZYMES AS.
XX

CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders
CC and the haplotypes can be used to validate CSF1R as a candidate target
CC for treating a specific condition or disease predicted to be associated
CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also
CC be used in developing diagnostic tests and therapeutic treatments. (1) is
CC useful in studying the expression and function of CSF1R, and in
CC expressing CSF1R protein for use in screening for candidate drugs to
CC treat diseases related to CSF1R activity and in studying the effect of
CC the variation on the biological activity of CSF1R as well as on the
CC binding affinity of candidate drugs targeting CSF1R. Antibodies are
CC useful in a variety of diagnostic and prognostic formats and therapeutic
CC methods. A transgenic animal is useful in studying expression of the
CC CSF1R isogenes in vivo, for in vivo screening and testing of drugs
CC targeted against CSF1R protein, and for testing the efficacy of
CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
CC are useful as probes and primers, and for assaying a polymorphism in the
CC target region. Without requiring any a priori knowledge of the phenotypic
CC effect of any particular CSF1R or haplotype the invention provides a
CC method for identifying lead compounds that are more likely to show
CC efficacy in clinical trials. This sequence is an allele specific
CC oligonucleotide primer used for detecting CSF1R gene polymorphisms,
CC described in the method of the invention
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 2 T; 0 U; 1 Other;

Query Match 0.9%; Score 13.6; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 969 TGCCACATGAGCC 982

Db 2 TGCCACATGAGYC 15

RESULT 364

ACC64682
ID ACC64682 standard; DNA; 17 BP.

AC ACC64682;

DT 01-JUL-2003 (first entry)

XX Murine oligonucleotide associated with tumour suppression, SEQ ID 1929.
DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.

XX Disclosure; Page 256; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour

CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 1 A; 4 C; 2 G; 9 T; 0 U; 1 Other;

Query Match 0.9%; Score 13.6; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.6e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTGCCCTT 1073

Db 2 ATCTTCTTTGCCCTT 15

RESULT 365

AAQ28689

ID AAQ28689 standard; DNA; 15 BP.

AC AAQ28689;

XX 24-OCT-2003 (revised)

DT 19-FEB-1993 (first entry)

XX pela target oligonucleotide e.

KW Pectinase; pectate lyase; transformed vegetables; ss.

XX Pectobacterium carotovorum.

XX JP04229176-A.

XX 18-AUG-1992.

XX 27-DEC-1990; 90JP-00407123.

XX 27-DEC-1990; 90JP-00407123.

XX (SHIMA) SHIMADZU CORP.

XX WPI; 1992-321179/39.

XX Oligo:nucleotide for detecting transformant of vegetable - coded by
PT Erwinia carotovora, and targets pectinase-prodn. related gene pectate
PT lyase gene.

XX Claim 1; Page 2; 10pp; Japanese.

XX The sequences given in AAQ28685-92 are oligonucleotides derived from
CC Erwinia carotovora which can be used to target the pectinase- production
CC related gene, pela (pectate lyase gene). The oligonucleotides are
CC complementary to the pela gene. These oligonucleotides can be used to
CC detect foreign genes in transformed vegetables. (Updated on 24-OCT-2003
CC to standardise OS field)

XX Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1180 TGGAACGTGGTGGTC 1194

Db 1 TGGAACGTGGTGGTC 15

RESULT 366

AAT50174/c

ID AAT50174 standard; RNA; 15 BP.
 XX AAT50174;
 AC
 DT 07-MAR-1997 (first entry)
 XX
 XX Rabbit CETP HH ribozyme target sequence #156.
 DE
 XX Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
 KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
 KW reverse cholesterol transport; high density lipoprotein; therapy; CETP;
 KW familial hypercholesterolaemia; dvalipidaemia; hypolipoproteinaemia;
 KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
 KW angioelastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
 KW LDL; ss.
 XX
 XX Oryctolagus cuniculus.
 OS
 XX WO9620279-A1.
 PN
 XX
 XX 04-JUL-1996.
 PD
 XX
 XX 11-DEC-1995; 95WO-US016000.
 PF
 XX
 XX 23-DEC-1994; 94US-00363240.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (WARN) WARNER LAMBERT CO.
 PA
 XX Couture L, Stinchcomb D, Mcswiggen J, Bisgaier C, Page M;
 PI WPI; 1996-321852/32.
 XX
 DR New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA -
 XX useful for preventing or treating initial development, progression or
 PT regression of vascular diseases, esp. familial hypercholesterolaemia.
 PT
 XX
 XX Claim 4; Page 40; 72pp; English.
 PS
 CC AAT50138-T50359 represent target sequences for the rabbit cholesterol
 CC ester transfer protein (CETP) hammerhead (HH) ribozymes (see AAT50360-
 CC T50346). CETP is a 74 kD glycoprotein that facilitates neutral lipid
 CC transfer between plasma lipoproteins. The numbering of the targets refers
 CC to the position of the cleavage site in full length CETP. The ribozyme
 CC then binds to 5 nucleotides either side of this site. The ribozymes are
 CC able to cleave mRNA from the gene encoding CETP, thereby blocking
 CC synthesis and/or expression of the mRNA. By inhibiting CETP, the reverse
 CC cholesterol transport (RCT) pathway can be inhibited (or eliminated)
 CC thereby preventing the reduction in size density of the high density
 CC lipoproteins (HDL), prolonging HDL half life, and therefore increasing
 CC HDL levels. The ribozymes can be used to treat conditions associated with
 CC abnormal levels of CETP, specifically atherosclerosis, familial
 CC hypercholesterolaemia, peripheral vascular disease, dvalipidaemia,
 CC hyperbetalipoproteinaemia, hypolipoproteinaemia, vascular
 CC complications of diabetes, transplant, atherectomy and angioplastic
 CC restenosis. By inhibiting CETP, the levels of HDL and low density
 CC lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a
 CC decrease in LDL levels, and a corresponding increase in HDL levels). The
 CC HH ribozymes can also be used diagnostically to study genetic drift and
 CC mutations in diseased cells, and to detect CETP mRNA. As the HH ribozymes
 CC target specific regions of the CETP gene, they have low non-specific
 CC activity
 CC
 XX Sequence 15 BP; 1 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
 SQ
 Query Match 0.9%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 654 GGCCGTGGAGCATCA 668
 DB 15 GGCCGGAGGAGCATCA 1

RESULT 367
 AAS02509/c
 ID AAS02509 standard; DNA; 15 BP.
 XX
 XX AAS02509;
 AC
 DT 29-AUG-2001 (first entry)
 XX
 XX Human CHMR1 allele specific oligonucleotide probe #1.
 DE
 XX Human; m1 acetylcholine receptor; CHRM1; immunogen; antibody;
 KW Alzheimer's disease; dementia with Lewy bodies; DLB;
 KW allele specific oligonucleotide probe; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200127312-A2.
 PN
 XX 19-APR-2001.
 PD
 XX
 XX 12-OCT-2000; 2000WO-US028211.
 PF
 XX
 XX 13-OCT-1999; 99US-0159269P.
 PR
 XX (GENA-) GENAISANCE PHARM INC.
 PA
 XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
 PI WPI; 2001-282046/29.
 XX
 DR New variants of the m1 muscarinic acetylcholine receptor gene, useful to
 XX find treatment for Alzheimer's and dementia, have single nucleotide
 PT variations at one or more of five polymorphic sites.
 PT
 XX
 XX Claim 15; Page 18; 52pp; English.
 PS
 XX The sequence represents an allele specific oligonucleotide probe for
 CC genotyping individuals using the Human gene encoding the m1 muscarinic
 CC acetylcholine receptor, CHMR1. CHMR1 is one subtype of a family of 5
 CC genetically distinct muscarinic acetylcholine receptors, mAChR, that play
 CC important roles in higher brain function such as learning and memory. The
 CC protein is a possible drug target for treatments for Alzheimer's disease
 CC and dementia with Lewy bodies (DLB). The gene, polypeptide, haplotypes
 CC and antibodies raised against the protein are useful for diagnosing and
 CC developing treatments for diseases associated with the abnormal
 CC expression of the gene or activity of the protein, e.g. Alzheimer's
 CC disease and dementia with Lewy bodies
 CC
 XX Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1290 CCACGTGGCCCATGA 1304
 DB 15 CCACGTGGCCCATGA 1
 RESULT 368
 AAF46796
 ID AAF46796 standard; DNA; 15 BP.
 XX
 XX AAF46796;
 AC
 XX 30-MAR-2001 (first entry)
 DT
 XX IGFBP3 oligonucleotide #216.
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;

KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX
 FI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 7; Page 45; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 0 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.9%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 623 CCGTGGTGGCTGCG 637
 Db 1 CCGTGGTGGCTGCG 15
 XX
 RESULT 369
 AAL45929
 ID AAL45929 standard; DNA; 15 BP.
 XX
 AC AAL45929;
 XX
 XX 08-JUL-2002 (first entry)
 DT
 DE Murine dystrophin-specific antisense oligonucleotide mAON#11.
 XX
 XX Antisense oligonucleotide; exon skipping; exon inclusion signal;
 KW disease treatment; splice-modulation; gene therapy; dystrophin;
 KW haemostatic; antithyroid; muscular; mouse; ss.
 XX
 OS Mus sp.
 XX
 PN EP1191097-A1.

XX
 PD 27-MAR-2002.
 XX
 PF 21-SEP-2000; 2000EP-00203283.
 XX
 PR 21-SEP-2000; 2000EP-00203283.
 XX
 XX (UYLE-) UNIV LEIDS MEDISCH CENT.
 PA
 XX Van Ommen GB, Van Deutekom JCT, Den Dunnen JT, Dauwerse JG;
 PI Datsen NA;
 XX
 DR WPI; 2002-354071/39.
 XX
 XX Decreasing the production of an aberrant protein in a cell, for treatment
 PT of inherited diseases such as Duchenne Muscular Dystrophy or Hemophilia,
 PT comprises a splice modulation therapy of exons.
 XX
 PS Example 1; Page 6; 18pp; English.
 XX
 CC The present invention relates to a method of decreasing the production of
 CC an aberrant protein in a cell containing pre-mRNA of exons coding for the
 CC protein, involving providing the cell with an agent capable of
 CC specifically inhibiting an exon inclusion signal of one of the exons, and
 CC allowing translation of mRNA produced from splicing of pre-mRNA. The new
 CC method decreases the production of an aberrant protein in a cell by using
 CC a process known as exon-skipping. The process is carried out by providing
 CC an agent such as a nucleic acid to inhibit the exon inclusion signal. The
 CC nucleic acid agent can therefore be used as a preparation of a medicament
 CC for treatment of inherited diseases such as haemophilia A, clotting
 CC factor VIII deficiency, some forms of congenital hypothyroidism, Duchenne
 CC Muscular Dystrophy, and Becker Muscular Dystrophy. The present sequence
 CC is an antisense oligonucleotide directed at the murine dystrophin pre-
 CC mRNA
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 2 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 0.9%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1051 CTGCTGCTCATCTTC 1065
 Db 1 CTGCTGCTCATCTTC 15
 XX
 RESULT 370
 ADJ82534
 ID ADJ82534 standard; DNA; 15 BP.
 XX
 AC ADJ82534;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX FFHPV-encoding nucleotide #102.
 DE
 XX ss; cytostatic; platelet-derived growth factor receptor; PDGF-R; cancer;
 KW carcinoma; sarcoma; osteosarcoma; glioma; melanoma; myxoma; adenoma;
 KW neuroblastoma; rhabdomyoma-derived cell; fibrotic disorders;
 KW myeloproliferative disease; blood vessel proliferative disease;
 KW angiogenesis.
 XX
 OS Synthetic.
 XX
 XX WO20003045973-A2.
 PN
 XX 05-JUN-2003.
 PD
 XX 30-SEP-2002; 2002WO-US031165.
 PF
 XX 28-NOV-2001; 2001US-0333476P.
 PR
 XX (BECT) BECTON DICKINSON & CO.

PA (HAAL/) HAALAND P D.
XX
PI Dean C, Heidaran M, Spargo CA;
XX
DR WPI; 2003-505179/47.
XX
XX New peptides having growth inhibitory action, useful for inhibiting tumor
PT or cancer cell proliferation, or for treating fibrotic disorders,
PT myeloproliferative diseases, and blood vessel proliferative (angiogenic)
PT disorders.
XX
XX Disclosure; SEQ ID NO 315; 48pp; English.
XX
CC The invention relates to an isolated peptide or polypeptide (I) of no
CC more than about 50 amino acid residues which when contacted with cells in
CC which a platelet-derived growth factor receptor (PDGF-R) is activated in
CC an autocrine manner, inhibits the growth of these cells. The isolated
CC peptides or polypeptides preferably have the sequences: Lys-Lys-Lys-Lys-
CC Lys (P1) Asp-Asp-Glu-Lys (P2) Lys-Leu-Met-Ser-Tyr (P3) Phe-Phe-Phe-
CC Lys-Lys (P4) Phe-Phe-His-Pro-Val (P5). (I) is useful for inhibiting cell
CC proliferation, where the cell is a tumor or cancer cell (e.g. carcinoma,
CC sarcoma, osteosarcoma, glioma, melanoma, myxoma, adenoma, neuroblastoma,
CC or rhabdomyoma-derived cell), lung, breast, colon, prostate, kidney,
CC ovary, testicular, skin, pancreatic, thyroid, adrenal, pituitary, brain,
CC muscle or bone cell. The peptides are also useful for treating fibrotic
CC disorders, myeloproliferative diseases, and blood vessel proliferative
CC (angiogenic) disorders. This sequence represents a possible nucleotide
CC encoding the P5 peptide.
XX
XX Sequence 15 BP; 1 A; 7 C; 1 G; 6 T; 0 U; 0 Other;
SQ

Query Match 0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1330 TTCTCTATCCGTC 1344
DB 1 TTCTTCCATCCCGTC 15

RESULT 371
ADI44618
ID ADI44618 standard; DNA; 15 BP.
XX
XX
AC ADI44618;
XX
DT 22-APR-2004 (first entry)
XX
DE Human cystic fibrosis CFTR 1-related PCR primer SeqID118.
XX
KW Genetic marker;
KW human cystic fibrosis transmembrane conductance regulator; CFTR;
KW PCR assay; cystic fibrosis; PCR; primer; ss.
XX
OS Homo sapiens.
XX
XX US2003235834-A1.
XX
PD 25-DEC-2003.
XX
XX 19-NOV-2002; 2002US-00300683.
XX
XX 12-NOV-1999; 99US-0165301P.
XX 03-NOV-2000; 2000WO-US030493.
XX 08-MAY-2001; 2001US-00851501.
XX 19-NOV-2001; 2001US-0333531P.
XX 08-MAY-2002; 2002US-00142722.
XX
XX (DUNL/) DUNLOP C L M.
XX (WEIS/) WEISEL J M.
XX
XX Dunlop CLM, Weisel JM;
XX
XX WPI; 2004-070574/07.
XX
XX Identifying the presence or absence of a genetic marker in the human
XX cystic fibrosis transmembrane conductance regulator gene of a subject by
XX contacting the DNA and primer set and separating the extension product.
XX

DR WPI; 2004-070574/07.
XX
XX Identifying the presence or absence of a genetic marker in the human
XX cystic fibrosis transmembrane conductance regulator gene of a subject by
XX contacting the DNA and primer set and separating the extension product.
XX
XX Claim 13; SEQ ID NO 118; 154pp; English.
XX
XX This invention relates to a novel method of identifying the presence or
XX absence of a genetic marker in the human cystic fibrosis transmembrane
XX conductance regulator (CFTR) gene of a subject using a PCR assay. The
XX method comprises providing a DNA sample from the subject, providing at
XX least one primer set given in the specification, contacting the DNA and
XX the primer set, generating an extension product from the at least one
XX primer set that comprises a region of DNA that includes the location of
XX the genetic marker, separating the extension product on the basis of
XX melting behaviour and identifying the presence or absence of the genetic
XX marker in the subject by analysing the melting behaviour of the extension
XX product. The present sequence is that of a PCR primer which was used in
XX the exemplification of the invention.
XX
XX Sequence 15 BP; 0 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ

Query Match 0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1230 GCTGGCGCTCCTTGG 1244
DB 1 GCTGGCGCTCCTTGG 15

RESULT 372
ADI44791
ID ADI44791 standard; DNA; 15 BP.
XX
XX
AC ADI44791;
XX
DT 22-APR-2004 (first entry)
XX
DE Human cystic fibrosis CFTR 1-related PCR primer SeqID291.
XX
KW Genetic marker;
KW human cystic fibrosis transmembrane conductance regulator; CFTR;
KW PCR assay; cystic fibrosis; PCR; primer; ss.
XX
OS Homo sapiens.
XX
XX US2003235834-A1.
XX
PD 25-DEC-2003.
XX
XX 19-NOV-2002; 2002US-00300683.
XX
XX 12-NOV-1999; 99US-0165301P.
XX 03-NOV-2000; 2000WO-US030493.
XX 08-MAY-2001; 2001US-00851501.
XX 19-NOV-2001; 2001US-0333531P.
XX 08-MAY-2002; 2002US-00142722.
XX
XX (DUNL/) DUNLOP C L M.
XX (WEIS/) WEISEL J M.
XX
XX Dunlop CLM, Weisel JM;
XX
XX WPI; 2004-070574/07.
XX
XX Identifying the presence or absence of a genetic marker in the human
XX cystic fibrosis transmembrane conductance regulator gene of a subject by
XX contacting the DNA and primer set and separating the extension product.
XX
XX Claim 1; SEQ ID NO 291; 154pp; English.
XX

CC This invention relates to a novel method of identifying the presence or
 CC absence of a genetic marker in the human cystic fibrosis transmembrane
 CC conductance regulator (CFTR) gene of a subject using a PCR assay. The
 CC method comprises providing a DNA sample from the subject, providing at
 CC least one primer set given in the specification, contacting the DNA and
 CC the primer set, generating an extension product from the at least one
 CC primer set that comprises a region of DNA that includes the location of
 CC the genetic marker, separating the extension product on the basis of
 CC melting behaviour and identifying the presence or absence of the genetic
 CC marker in the subject by analysing the melting behaviour of the extension
 CC product. The present sequence is that of a PCR primer which was used in
 CC the exemplification of the invention.

SQ Sequence 15 BP; 0 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1230 GCTGGGCTCCTTGG 1244
 ||||| ||||| |||||
 Db 1 GCTGGGCTCCTTGG 15

RESULT 373

AD144977

ID AD144977 standard; DNA; 15 BP.

XX AC AD144977;

XX XX

DT 22-APR-2004 (first entry)

XX Human cystic fibrosis CFTR 1-related PCR primer SeqID477.

XX genetic marker;

KW human cystic fibrosis transmembrane conductance regulator; CFTR;

KW PCR assay; cystic fibrosis; PCR; primer; ss.

XX Homo sapiens.

XX US2003235834-A1.

XX 25-DEC-2003.

XX 19-NOV-2002; 2002US-00300683.

XX 12-NOV-1999; 99US-0165301P.

PR 03-NOV-2000; 2000WO-US030493.

PR 08-MAY-2001; 2001US-00851501.

PR 19-NOV-2001; 2001US-033531P.

PR 08-MAY-2002; 2002US-00142722.

XX (DUNL/) DUNLOP C L M.

PA (WEIS/) WEISEL J M.

PA Dunlop CLM, Weisel JM;

PI WPI; 2004-070574/07.

XX Identifying the presence or absence of a genetic marker in the human

PT cystic fibrosis transmembrane conductance regulator gene of a subject by

PT contacting the DNA and primer set and separating the extension product.

XX Disclosure; SEQ ID NO 477; 154pp; English.

PS This invention relates to a novel method of identifying the presence or

CC absence of a genetic marker in the human cystic fibrosis transmembrane

CC conductance regulator (CFTR) gene of a subject using a PCR assay. The

CC method comprises providing a DNA sample from the subject, providing at

CC least one primer set given in the specification, contacting the DNA and

CC the primer set, generating an extension product from the at least one

CC primer set that comprises a region of DNA that includes the location of

CC the genetic marker, separating the extension product on the basis of

CC melting behaviour and identifying the presence or absence of the genetic
 CC marker in the subject by analysing the melting behaviour of the extension
 CC product. The present sequence is that of a PCR primer which was used in
 CC the exemplification of the invention.

SQ Sequence 15 BP; 0 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1230 GCTGGGCTCCTTGG 1244
 ||||| ||||| |||||
 Db 1 GCTGGGCTCCTTGG 15

RESULT 374

AAV06294/c

ID AAV06294 standard; DNA; 16 BP.

XX AC AAV06294;

XX XX

DT 06-MAY-1998 (first entry)

XX Mouse spleen RNA amplifying RT-PCR primer.

XX Collagen; mouse; spleen; recombinant; post-translational enzyme;

KW procollagen; RT-PCR; primer; ss.

XX Synthetic.

XX Mus sp.

XX WO9738710-A1.

XX 23-OCT-1997.

XX 11-APR-1997; 97WO-US007300.

XX 12-APR-1996; 96US-00631336.

XX (FIBR-) FIBROGEN INC.

PA (FIFI-) ACAD FINLAND.

XX Kivirikki KI, Pihlajaniemi T;

XX WPI; 1997-526203/48.

XX Recombinant production of (pro)collagen having correct folding - using

XX vectors encoding collagen subunit and collagen post-translational enzyme

XX respectively.

XX Example 10; Page 49; 90pp; English.

CC This primer is used for RT-PCR amplification of the mouse spleen RNA. The

CC RT-PCR products are used as a template for further PCR amplifications.

CC This is used in a novel method for producing a (pro)collagen polypeptide.

CC The (pro)collagen polypeptide is selected from collagen types IV, V, VI,

CC VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, and XIX. The

CC method comprises culturing a host cell, where the host cell has been

CC infected, transfected or transformed with a first expression vector

CC comprising a polynucleotide molecule having a nucleic acid sequence which

CC encodes a (pro)collagen subunit and a second expression vector comprising

CC a polynucleotide molecule having a nucleic acid sequence which encodes at

CC least one (pro)collagen post-translational enzyme or enzyme subunit. The

CC (pro)collagen polypeptide is then purified from the cultured cell. The

CC methods can be used for the production of collagens such as human

CC collagens which can be used in therapeutic applications. The method

CC provides for the synthesis of correctly folded proteins so that they

CC exhibit the normal triple-helical conformation characteristic of

CC procollagens and collagens. Purification of the collagens is greatly

XX facilitated

XX Sequence 16 BP; 6 A; 6 C; 3 G; 1 T; 0 U; 0 Other;

Query Match	0.9%;	Score 13.4;	DB 1;	Length 16;
Best Local Similarity	93.3%;	Pred. No. 1.6e+02;		
Matches 14;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
OY	386	CTGGCCCTGTGCTCT	400	
DB	15	CTGGCCCTGTGCTGT	1	
RESULT 375				
ABS98344/C				
ID	ABS98344	standard; DNA; 16 BP.		
XX	AC			
XX	ABS98344;			
DT	23-DEC-2002	(first entry)		
XX				
DE	Human multidrug resistance associated protein 3 PCR primer #10.			
XX				
KW	Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;			
KW	cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;			
KW	adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;			
KW	aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;			
KW	cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;			
KW	epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;			
KW	glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;			
KW	HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;			
KW	NADPH quinone oxidoreductase 2; NQO2; sulfortransferase thermolabile; STM;			
KW	UDP-glucuronosyl transferase 284; UDP-glucuronosyl transferase 2B7; UPA;			
KW	UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;			
KW	multidrug resistance 1; lactotransferrin; orphan nuclear receptor;			
KW	multidrug resistance associated protein 3; cancer; prostate;			
KW	acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;			
KW	altered drug metabolism; cardiovascular function; colorectal tumour;			
KW	central nervous system; pulmonary; immunological.			
XX				
OS	Homo sapiens.			
XX				
PN	WO200257410-A2.			
XX				
PD	25-JUL-2002.			
XX				
PF	28-NOV-2001; 2001WO-US044838.			
XX				
PR	28-NOV-2000; 2000US-00724389.			
XX				
PA	(DNAS-) DNA SCI LAB INC.			
XX				
PI	Guida M, Hall J;			
XX				
DR	WPI; 2002-698522/75.			
XX				
PT	Isolated nucleic acid molecules having polymorphisms in known human genes			
PT	e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers			
PT	for locating, identifying and characterizing the genes responsible for			
PT	disorder-related traits.			
XX				
PS	Example 24; Page 150; 71app; English.			
XX				
CC	This invention relates to the sequence of an isolated nucleic acid			
CC	molecule comprising at least one base variation from that of a known			
CC	human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),			
CC	cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),			
CC	aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator			
CC	(ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding			
CC	inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating			
CC	protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl			
CC	transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl			
CC	transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),			
CC	sulfortransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4			
CC	(UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl			
CC	transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1			

PR 21-AUG-2001; 2001US-0314031P.
 PR 23-AUG-2001; 2001US-0314466P.
 PR 28-AUG-2001; 2001US-0315403P.
 PR 29-AUG-2001; 2001US-0315853P.
 PR 17-SEP-2001; 2001US-0322716P.
 PR 21-SEP-2001; 2001US-0323994P.
 PR 14-DEC-2001; 2001US-0340233P.
 PR 05-FEB-2002; 2002US-0354591P.
 PR 19-MAR-2002; 2002US-0365478P.
 PR 19-APR-2002; 2002US-0373814P.
 PR 19-APR-2002; 2002US-0373825P.
 PR 19-APR-2002; 2002US-0373989P.
 PR 23-APR-2002; 2002US-0374632P.
 PR 07-JUN-2002; 2002US-0386971P.
 PR 01-AUG-2002; 2002US-00210172.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Kekuda R, Miller CE, Patturajan M, Pena CEA, Rieger DK;
 PI Shimkets RA, Zerhusen BD, Li L, Ji W, Padigaru M, Casman SJ;
 PI Voss EZ, Boldog FL, Gorman L, Leite MW, Vernet CAM, Anderson DW;
 PI Guo X, Zhong M, Gerlach VL, Hjal T, Rastelli L, Spytek KA;
 PI Edinger SK, Ellerman K, Malyankar UM, Macdougall JR, Stone DU;
 PI Alsobrook JP, Lepley DM, Burgess CE, Majumder K, Wolenc AR;
 PI Smithson G;
 XX
 DR WPI; 2003-663472/62.
 XX
 XX New NOVX polypeptides and nucleic acids, useful for preventing or
 PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy,
 FT atherosclerosis or diabetes, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX
 XX Example C; SEQ ID NO 240; 560pp; English.
 PS
 XX The invention relates to a novel NOVX polypeptide. The polypeptide of the
 CC invention demonstrates cardiant, antiarteriosclerotic, hypotensive,
 CC cytotatic, anorectic, antidiabetic, immunosuppressive, anti-HIV,
 CC neuroprotective, nootropic, antiparkinsonian, antiasthmatic and
 CC preventing NOVX-associated disorders including cardiomyopathy,
 CC atherosclerosis, hypertension, cancer, obesity, diabetes, AIDS, multiple
 CC sclerosis, graft-versus-host disease, Alzheimer's disease, Parkinson's
 CC disease, asthma or fertility disorders. Furthermore, the polypeptides may
 CC be utilised as vaccines whilst the nucleic acids may be used as
 CC hybridisation probes, in gene therapy, chromosome mapping, tissue typing,
 CC preventive medicine and pharmacogenomics. The current sequence is that of
 CC the RT-PCR primer of the invention which was used to amplify human NOV
 CC RNA.
 XX
 SQ Sequence 16 BP; 1 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 494 TGGCGCTGGTGACCT 508
 |||||
 Db 2 TGGCGCTGGTGACCT 16
 RESULT 377
 ADG38558
 ID ADG38558 standard; DNA; 16 BP.
 XX
 AC ADG38558;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 XX Human genomic CpG methylation assessment method-related PCR primer #99.
 DE high throughput; CpG methylation; genomic sequence expression;
 KW microarray; methylation-silenced gene; demethylation action; cancer cell;
 KW

KW PCR; primer; ss; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2003087774-A2.
 XX
 PD 23-OCT-2003.
 XX
 XX 14-APR-2003; 2003WO-US011598.
 PF
 XX 12-APR-2002; 2002US-0372140P.
 PR
 XX (UMOR) UNIV MISSOURI.
 PA
 XX Huang TH, Shi H;
 PI
 XX WPI; 2003-845373/78.
 DR
 XX Microarray with affixed CpG-rich genomic probe fragments each comprising
 PT (a portion of) an exon sequence of an expressible gene, useful in a
 PT method for dual assessment of genomic CpG methylation and expression of
 PT genomic sequences.
 XX
 PS Example 13; SEQ ID NO 190; 100pp; English.
 XX
 CC The invention comprises a high throughput method for assessing genomic
 CC CpG methylation and expression of genomic sequences of a tissue sample.
 CC The method involves the use of a microarray that has affixed CpG-rich
 CC genomic probe fragments each comprising an exon sequence (or portion
 CC thereof) of an expressible gene. The method and microarray of the
 CC invention are useful for assessing genomic CpG methylation and expression
 CC of genomic sequences of a tissue sample. The method is useful for the
 CC identification of novel methylation-silenced genes that are reactivated
 CC upon methylation and in determining the efficacy and mechanisms of
 CC demethylation action in cancer cells. The present DNA sequence represents
 CC a PCR primer that was used in the exemplification of the invention.
 XX
 SQ Sequence 16 BP; 0 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1232 TGGCGCTCCTTGGTG 1246
 |||||
 Db 2 TGGCGCTCCGTGGTG 16
 RESULT 378
 AAQ68371/c
 ID AAQ68371 standard; RNA; 17 BP.
 XX
 AC AAQ68371;
 XX
 DT 25-MAR-2003 (revised)
 DT 17-FEB-1995 (first entry)
 XX
 XX Half mini-zyme Krm1/2A.
 DE
 XX
 KW Ribozyme; minizyme; cleavage; substrate; hammerhead; DNA arms; helix; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 11..17
 FT /*tag= a
 FT /note= "conserved oligonucleotides"
 XX
 PN WO9413688-A1.
 XX
 PD 23-JUN-1994.
 XX
 XX 08-DEC-1993; 93WO-AU000630.
 PF

XX 08-DEC-1992; 92US-00986776.
 XX (GENE-) GENE SHEARS PTY LTD.
 XX JENNINGS PA, McCall MJ, Hendry P;
 XX WPI; 1994-217795/26.
 XX
 XX New mini-zyme(s) and DNA-armed ribozyme(s) - capable of cleaving nucleic
 XX acid polymers in vivo and in vitro, useful for treating e.g. viral
 XX infection.
 XX
 XX Disclosure; Fig 16A; 113pp; English.
 XX
 XX The target for two half-minizymes KrM1/2A and KrM1/2B is Krs21
 XX (AUUUGCAGUCCACACUGGAG). The target for minizymes M(n)pd, Meg, M(n)t,
 XX Mt(6x2) and MUUCG is S13 (GCGGUGCAUGAAG). The minizymes have helix II
 XX replaced by linkers contg. various numbers of neutral ethyleneglycol (eg)
 XX units, charged phosphopropanediol (pd) units, or charged
 XX deoxyribothymidine units. A comparison of the cleavage activities of
 XX these minizymes against the same substrate allows the optimal number of
 XX atoms in the chain linking the two stretches of conserved nucleotides to
 XX be determined, and gives some insight into the chemical properties
 XX required by the linker. The two half-minizymes together are able to
 XX cleave their substrate at the same place as does a hammerhead ribozyme,
 XX however, the active structure is very unstable. This indicates that the
 XX role of the helix II is to stabilise the active structure. (Updated on 25-
 XX MAR-2003 to correct PN field.)
 XX
 XX Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
 XX
 XX Query Match 0.9%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 93.3%; Pred. NO. 1.7e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 404 TCATCAGCACCTGG 418
 XX 17 TCATCAGCACCTGG 3
 XX
 XX RESULT 379
 XX AAX71612
 XX ID AAX71612 standard; RNA; 17 BP.
 XX AC AAX71612;
 XX
 XX 28-JUL-1999 (first entry)
 XX
 XX Human KDR VEGF receptor hammerhead ribozyme substrate #624.
 XX
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 XX foetal liver kinase 1; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO9715662-A2.
 XX
 XX 01-MAY-1997.
 XX
 XX 25-OCT-1996; 96WO-US017480.
 XX
 XX 26-OCT-1995; 95US-0005974P.
 XX
 XX 11-JAN-1996; 96US-00584040.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (CHIR) CHIRON CORP.
 XX
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX
 XX WPI; 1997-259017/23.
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.
 XX
 XX Claim 4; Page 116; 218pp; English.
 XX
 XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient
 XX (preferably human) having a condition associated with the level of the
 XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 XX treated by administering the nucleic acid molecule or the expression
 XX vector to the patient. AAX67275 to AAX75752 represent specific examples
 XX of nucleic acid molecules from the present invention
 XX
 XX Sequence 17 BP; 3 A; 8 C; 2 G; 0 T; 4 U; 0 Other;
 XX
 XX Query Match 0.9%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 73.3%; Pred. NO. 1.7e+02;
 XX Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 796 CCCAGTTTCTCCAGC 810
 XX 1 CCCAGAUUCCAGC 15
 XX
 XX RESULT 380
 XX AAX71611
 XX ID AAX71611 standard; RNA; 17 BP.
 XX AC AAX71611;
 XX
 XX 28-JUL-1999 (first entry)
 XX
 XX Human KDR VEGF receptor hammerhead ribozyme substrate #623.
 XX
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 XX foetal liver kinase 1; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO9715662-A2.
 XX
 XX 01-MAY-1997.
 XX
 XX 25-OCT-1996; 96WO-US017480.
 XX
 XX 26-OCT-1995; 95US-0005974P.
 XX
 XX 11-JAN-1996; 96US-00584040.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (CHIR) CHIRON CORP.
 XX
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX
 XX WPI; 1997-259017/23.
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.
 XX
 XX Claim 4; Page 116; 218pp; English.
 XX
 XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient

DR WPI; 1997-259017/23.
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.
 XX
 XX Claim 4; Page 116; 218pp; English.
 XX
 XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient
 XX (preferably human) having a condition associated with the level of the
 XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 XX treated by administering the nucleic acid molecule or the expression
 XX vector to the patient. AAX67275 to AAX75752 represent specific examples
 XX of nucleic acid molecules from the present invention
 XX
 XX Sequence 17 BP; 3 A; 8 C; 2 G; 0 T; 4 U; 0 Other;
 XX
 XX Query Match 0.9%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 73.3%; Pred. NO. 1.7e+02;
 XX Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 796 CCCAGTTTCTCCAGC 810
 XX 1 CCCAGAUUCCAGC 15
 XX
 XX RESULT 380
 XX AAX71611
 XX ID AAX71611 standard; RNA; 17 BP.
 XX AC AAX71611;
 XX
 XX 28-JUL-1999 (first entry)
 XX
 XX Human KDR VEGF receptor hammerhead ribozyme substrate #623.
 XX
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 XX foetal liver kinase 1; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO9715662-A2.
 XX
 XX 01-MAY-1997.
 XX
 XX 25-OCT-1996; 96WO-US017480.
 XX
 XX 26-OCT-1995; 95US-0005974P.
 XX
 XX 11-JAN-1996; 96US-00584040.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (CHIR) CHIRON CORP.
 XX
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX
 XX WPI; 1997-259017/23.
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.
 XX
 XX Claim 4; Page 116; 218pp; English.
 XX
 XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 3 A; 8 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 796 CCCAGTTTCTCCAGC 810
||||| :|:|:|
DB 2 CCCAGAUUCCAGC 16

RESULT 381
AAX69654/c
ID AAX69654 standard; RNA; 17 BP.

XX AAX69654;

28-JUL-1999 (first entry)

Human flt1 VEGF receptor hammerhead ribozyme substrate #949.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.

XX Homo sapiens.

XX WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US017480.

XX 26-OCT-1995; 95US-0005974P.

XX 11-JAN-1996; 96US-00584040.

XX (RIBO-) RIBOZYME PHARM INC.

XX (CHIR) CHIRON CORP.

XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.

XX Claim 4; Page 75; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX

SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1513 CCCAGGCAACTTTC 1527
||||| :|:|:|
DB 17 CCCAGGCAAGTTTC 3

RESULT 382

AAV97590

ID AAV97590 standard; RNA; 17 BP.

XX AAV97590;

XX 17-MAR-1999 (first entry)

XX Human EGF-R target sequence nucleotide position 3176.

XX Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.

XX Homo sapiens.

XX WO9833893-A2.

XX 06-AUG-1998.

XX 14-JAN-1998; 98WO-US0000730.

XX 31-JAN-1997; 97US-0036476P.

XX 04-DEC-1997; 97US-00985162.

XX (RIBO-) RIBOZYME PHARM INC.

XX (UYAS-) UNIV ASTON.

XX Akhtar S, Fell P, Mcswiggen JA;

XX WPI; 1998-437449/37.

XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT growth factor receptor, useful for inhibiting cell proliferation and for
PT treating cancers.

XX Claim 5; Page 75; 109pp; English.

XX The present invention describes enzymatic nucleic acid molecules (NAMS)
CC which specifically cleave RNA derived from an epidermal growth factor
CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAMS are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAMS can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell
XX

SQ Sequence 17 BP; 3 A; 7 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;

Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1161 CTCGCACTACTACCG 1175
|:|:|:|:|:|:|:|:|
DB 1 CUCCAACUUCUACCG 15

RESULT 383

AAA20392

ID AAA20392 standard; RNA; 17 BP.

XX

AC AAA20392;
XX 19-JUN-2000 (first entry)
XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:3618.
DE
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW Integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
XX WO9950403-A2.
XX 07-OCT-1999.
XX
XX 24-MAR-1999; 99WO-US006507.
XX
XX 27-MAR-1998; 98US-0079678P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX WPI; 1999-591315/S0.
XX
XX Novel ribozymes for modulating the synthesis, expression and/or stability
XX of an mRNA encoding an angiogenic factors.
XX
XX Claim 55; Page 142; 305pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA223263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberos scleriosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1202 GCGTGTACAGCTACG 1216
DB 3 GCGUGUACAGCUGCG 17

RESULT 384
AAV93334
ID AAV93334 standard; RNA; 17 BP.
XX
XX AAV93334;
XX
XX 18-FEB-1999 (first entry)
XX Human B-raf substrate nucleotide position 429.
DE
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW screening; identification; synthesis; deprotection; purification; cancer;
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW restenosis; rheumatoid arthritis; ss.
XX
XX Homo sapiens.
XX
XX WO9850530-A2.
XX 12-NOV-1998.
XX
XX 05-MAY-1998; 98WO-US009249.
XX
XX 09-MAY-1997; 97US-0046059P.
XX 09-JUN-1997; 97US-0049002P.
XX 03-JUL-1997; 97US-0051718P.
XX 22-AUG-1997; 97US-0056808P.
XX 02-OCT-1997; 97US-0061321P.
XX 02-OCT-1997; 97US-0061324P.
XX 05-NOV-1997; 97US-0064866P.
XX 19-DEC-1997; 97US-0068212P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
XX Parry T, Beigelman L, Mcswiggen JA, Karpelsky A, Burgin A;
XX Thompson J, Workman CT, Beaudry A, Sweedler D;
XX WPI; 1999-009494/01.
XX
XX Identifying new catalytic nucleic acid that modulates selected processes
XX - especially ribozymes that cleave Raf RNA for treating cancer,
XX restenosis, and also new ribozymes and modified nucleoside triphosphates
XX used as antiviral agents and synthons.
XX
XX Claim 177; Page 166; 259pp; English.
XX
XX A method has been developed for the identification of a nucleic acid
XX capable of modulating a process in a biological system. The method
XX comprises: (a) introducing into the system a random library of nucleic
XX acid catalysts (NAC) having a substrate binding domain (SBD), comprising
XX a random sequence, and a catalytic domain (CD); and (b) identifying NAC
XX in systems where modulation has occurred and/or determining the sequence
XX of at least part of the SBDs in such systems. Nucleic acid molecules with
XX endonuclease activity and catalytic activity, from the present invention,
XX are used to modulate gene expression in plant and mammalian cells and to
XX cleave target nucleic acid, particularly for treating systemic diseases
XX caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
XX ascites and infection. They may also be used to detect genetic drift and
XX mutations in diseased cells and to determine c-raf RNA. Specifically NACs
XX with RNA-cleaving activity that modulate expression of the Raf gene, are
XX used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
XX generally any condition associated with the level of c-raf. Introduction
XX of sugar/phosphate modifications increases stability against nuclease and
XX activity. AAV90922 to AAV93877 represent NACs that can be used in the
XX method, specifically for modulating the expression of a Raf gene
XX
XX Sequence 17 BP; 2 A; 6 C; 0 G; 0 T; 9 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 40.0%; Pred. No. 1.7e+02;


```
OS Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
XX Claim 88; Page 70; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO). The
XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNAzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX of CD20 in the presence of a divalent cation that is preferably Mg2+.
XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX the cell and treat a patient having a condition associated with the level
XX of CD20. The treatment may further comprise the use of one or more
XX therapies. In particular, the CD20 targeting nucleic acid may be used to
XX treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
XX targeting nucleic acid is used to cleave RNA of the NOGO gene in the
XX presence of a divalent cation that is preferably Mg2+. Furthermore, the
XX nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX cell and treat a patient having a condition associated with the level of
XX NOGO. The treatment may further comprise the use of one or more
XX therapies. In particular, the NOGO-targeting nucleic acid may be used to
XX treat central nervous system (CNS) injury and cerebrovascular accident
XX (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOGO expression. The present
XX sequence is a hammerhead ribozyme of the invention
XX
XX Sequence 17 BP; 5 A; 6 C; 2 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 0.9%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 66.7%; Pred. No. 1.7e+02;
XX Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 724 AAAAGCTACTCTTC 738
XX |::|::|::|::|
XX 2 AGAGGCUACUCCUUC 16
XX
XX RESULT 388
```

```
ABK02838
ID ABK02838 standard; RNA; 17 BP.
XX
XX AC ABK02838;
XX
XX 12-MAR-2002 (first entry)
XX
XX Human CD20 Hammerhead ribozyme #137.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNAzyme; inozyme; G-cleaver; amberzyme; zynzyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
XX Claim 30; Page 142; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO). The
XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNAzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX of CD20 in the presence of a divalent cation that is preferably Mg2+.
XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX the cell and treat a patient having a condition associated with the level
XX of CD20. The treatment may further comprise the use of one or more
XX therapies. In particular, the CD20 targeting nucleic acid may be used to
XX treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
XX targeting nucleic acid is used to cleave RNA of the NOGO gene in the
XX presence of a divalent cation that is preferably Mg2+. Furthermore, the
XX nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX cell and treat a patient having a condition associated with the level of
XX NOGO. The treatment may further comprise the use of one or more
XX therapies. In particular, the NOGO-targeting nucleic acid may be used to
XX treat central nervous system (CNS) injury and cerebrovascular accident
XX (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOGO expression. The present
XX sequence is a hammerhead ribozyme of the invention
XX
```

CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 CC
 CC Sequence 17 BP; 1 A; 6 C; 3 G; 0 T; 7 U; 0 Other;
 SQ

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 53.3%; Pred. No. 1.7e+02;
 Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CTTTGGCTTCCTCCA 1079
 DB 1 CUUUGCCUUCUCCA 15

RESULT 389
 ABK03744/c
 ID ABK03744 standard; RNA; 17 BP.
 XX
 AC ABK03744;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CD20 Amberyze #93.
 XX

Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW musclar; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberyze; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocyto; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX

OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200159103-A2.
 PD 16-AUG-2001.
 XX

09-FEB-2001; 2001WO-US004273.
 XX
 XX 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 XX Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX

Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX Claim 30; Page 168; 200pp; English.
 PS
 XX

CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberyze (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocyto (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an amberyze molecule of the invention
 CC
 CC Sequence 17 BP; 10 A; 1 C; 6 G; 0 T; 0 U; 0 Other;
 SQ

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTCTCT 829
 DB 17 TCTTCTTCTCTCTCT 3

RESULT 390
 ABK03745/c
 ID ABK03745 standard; RNA; 17 BP.
 XX
 AC ABK03745;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CD20 Amberyze #94.
 XX

Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW musclar; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberyze; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocyto; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX

OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200159103-A2.
 PD 16-AUG-2001.
 XX

09-FEB-2001; 2001WO-US004273.
11-FEB-2000; 2000US-0181797P.
28-FEB-2000; 2000US-0185516P.
06-MAR-2000; 2000US-0187128P.
(RIBO-) RIBOZYME PHARM INC.
(BLAT/) BLATT L.
(MCSW/) MCSWIGGEN J.
(CHOW/) CHOWRIRA B M.
Blatt L, Mcswiggen J, Chowrira BM;
WPI; 2001-607195/69.
Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.
Claim 30; Page 168; 200pp; English.
The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NIGO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNzyme) an Inzyme (an endolytic nucleic acid cleaving a an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA with a YGf motif). The CD20-targetting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targetting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopaenia, and inflammatory arthropathy. The NIGO-targetting nucleic acid is used to cleave RNA of the NIGO gene in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid may be contacted with a cell to reduce NIGO activity of the cell and treat a patient having a condition associated with the level of NIGO. The treatment may further comprise the use of one or more therapies. In particular, the NIGO-targetting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NIGO expression. The present sequence is an amberzyme molecule of the invention
Sequence 17 BP; 11 A; 0 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0
QY 815 TCTACTTCCTCTCTCT 829
Db 16 TCTTCTTCCTCTCTCT 2
RESULT 391
AAI68602/C
ID AAI68602 standard; DNA; 17 BP.
XX AAI68602;
AC AAI68602;
XX 14-JAN-2002 (first entry)
XX

ICAM-1 triple helix associated oligonucleotide SEQ ID 4.

ICAM-1; triple helix; transcription inhibition; antipsoriatic; intracellular adhesion molecule; dermatological; antiasthmatic; antiinflammatory; immunosuppressive; gastrointestinal; psoriasis; neurodermatitis; allergic asthma; Crohn's disease; autoimmune disease; transplant rejection; psoralen; photo-ultra-violet therapy; ds.

Unidentified.

W0200179487-A2.

25-OCT-2001.

18-APR-2001; 2001WO-DE0001509.

18-APR-2000; 2000DE-01019252.

(DEGI/) DEGITZ K K.

(BESC/) BESCH R.

Degitz KK, Besch R;

WPI; 2002-017614/02.

Triple-helix forming polydeoxyribonucleotides, useful for treating intracellular adhesion molecule-1 related diseases, e.g. psoriasis, are directed against transcribed or promoter regions of the ICAM-1 gene.

Claim 5; Page 2; 61pp; German.

This invention describes novel polydeoxyribonucleotides (A), for use as triple-helix forming oligonucleotides, having at least 3 sequential purine and/or pyrimidine bases, capable of inhibiting transcription of ICAM-1. (A) has a sequence specific for the transcribed or promoter regions of the ICAM-1 (intracellular adhesion molecule) gene. The products of the invention have antipsoriatic, dermatological, antiasthmatic, antiinflammatory, immunosuppressive and gastrointestinal activity. (A) are used for treatment or prevention of ICAM-1-associated diseases, specifically psoriasis, neurodermatitis, allergic asthma, Crohn's disease, autoimmune diseases and transplant rejection. Compared with antisense oligonucleotides, (A) provide a longer-lasting effect (they bind directly to the gene, so a compensatory increase in transcription is not possible). (A) may be coupled to psoralen to provide light-regulatable, sequence-specific downregulation of genes; this should make photo-ultra-violet therapy more specific, with reduced side effects. AA168599-AA168673 represent oligonucleotides used to illustrate the method of the invention

Sequence 17 BP; 0 A; 13 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 48 GGGAGGGGAGCGGGA 62
Db 15 GCGAGGGGAGGGGGA 1
|||||
|||||

RESULT 392
ABN10683/C
ID ID ABN10683 standard; DNA; 17 BP.
AC ABN10683;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10675.
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart; muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; ampicillin; screening; ss.

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGAC 35
|||||
3 TCTGCGTCTGCATAG 17

DB

RESULT 394
ABN06638
ID ABN06638 standard; DNA; 17 BP.
XX
AC ABN06638;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6630.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
or as specific biomolecule capture probes for surface-enhanced laser
desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 6630; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
1 can be used in gene therapy and vaccine production. The hGDMPLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMPLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMPLP-
1 proteins, as standards in assays used to determine the concentration
and/or amount specifically of hGDMPLP proteins, as specific biomolecule
capture probes for surface-enhanced laser desorption/ionization, as
therapeutic supplement in patients having specific deficiency in hGDMPLP-1
production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
disorder associated with the expression of hGDMPLP-1, in particular heart
and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format directly from WIPO
at ftp.wipo.int/pub/published_pct_sequence

XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 GTCTGCAGAGGACAG 40
|||||
1 GTCTGCATAGGACAG 15

DB

RESULT 395
ABN10684/C
ID ABN10684 standard; DNA; 17 BP.
XX
AC ABN10684;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10676.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
or as specific biomolecule capture probes for surface-enhanced laser
desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 10676; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
1 can be used in gene therapy and vaccine production. The hGDMPLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMPLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMPLP-
1 proteins, as standards in assays used to determine the concentration
and/or amount specifically of hGDMPLP proteins, as specific biomolecule
capture probes for surface-enhanced laser desorption/ionization, as
therapeutic supplement in patients having specific deficiency in hGDMPLP-1
production, and in vaccines or for replacement therapy. The

CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 3 A; 9 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1259 GGGTAGCCATGCTGG 1273
 Db |||||
 15 GGGTGCCATGCTGG 1

RESULT 396
 ABK24955/c
 ID ABK24955 standard; DNA; 17 BP.
 XX
 AC ABK24955;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Porphyric herbicide resistance genome altering oligonucleotide #15.
 XX
 KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyric herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

XX Spinacia oleracea.
 OS Synthetic.
 XX
 PN WO200192512-A2.
 XX
 PD 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-US017672.
 XX
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 PR 27-MAR-2001; 2001US-00818875.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC, Kim J;
 PI
 XX WPI; 2002-106307/14.
 DR
 XX

PT New oligonucleotides with modified nuclease-resistant termini, useful for
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved
 PT nutritional value, herbicide or disease resistance, or modified oil
 PT production.
 XX
 XX Claim 7; Page 63; 220pp; English.
 XX
 XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyric herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 484 CAGCTGCCATTGGCG 498
 Db |||||
 17 CAGCTGCCATTGGTG 3

RESULT 397
 ABK27023/c
 ID ABK27023 standard; DNA; 17 BP.
 XX
 AC ABK27023;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Increased stearate production genome altering oligonucleotide #159.
 XX
 KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyric herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

XX Oryza sativa.
 OS Synthetic.
 XX
 PN WO200192512-A2.
 XX
 PD 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-US017672.
 PF
 XX


```
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
PA (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX
XX Claim 7; Page 185; 220pp; English.
PS
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 3 A; 1 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 363 CACCATCTACCAT 377
DB 17 CACCATCTACGACAT 3
RESULT 398
ABK24956
ID ABK24956 standard; DNA; 17 BP.
XX
AC ABK24956;
XX
XX 09-APR-2002 (first entry)
XX
XX Porphyrin herbicide resistance genome altering oligonucleotide #16.
XX
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine herbicide resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX
XX Spinacia oleracea.
OS Synthetic.
XX
XX WO200192512-A2.
XX
XX 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-US017672.
XX
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX
XX Claim 7; Page 63; 220pp; English.
PS
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 484 CAGCTGCCATTGGCG 498
DB 1 CAGCTGCCATTGGTG 15
RESULT 399
ABK27024
ID ABK27024 standard; DNA; 17 BP.
XX
AC ABK27024;
XX
XX 09-APR-2002 (first entry)
XX
XX Increased stearate production genome altering oligonucleotide #160.
XX
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
```

KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX
OS Oryza sativa.
OS Synthetic.
XX
XX
PN WO200192512-A2.
XX
XX
PD 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-US017672.
XX
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX
XX (UYDE) UNIV DELAWARE.
PA
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
XX
XX WPI; 2002-106307/14.
DR
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX
XX Claim 7; Page 185; 220pp; English.
XX
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 363 CACCATCTACCAT 377
Db 1 CACCATCTACCAT 15
RESULT 400
ABT35342

ID ABT35342 standard; DNA; 17 BP.
XX
AC ABT35342;
XX
DT 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 979.
DE
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
XX
XX 17-SEP-2001; 2001FR-00011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
DR
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; Page 147; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 1 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 953 TCTGTGTTCTCTCTCT 967
Db 3 TCTGTGTTCTCTCTCT 17
RESULT 401
ADB03627/c
ID ADB03627 standard; DNA; 17 BP.
XX

```
AC ADB03627;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ7 scanning oligonucleotide SEQ ID 4613.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MD24; MDZ7; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
PS WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS Example 8; SEQ ID NO 4613; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MD24, MDZ7, MD212. MDZ3 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MD24, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MD24, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MD24, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 2 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 741 GAGAGAGGCTGTGCC 755
DB 17 GAGAGAGGCTGTGCC 3
RESULT 402
ADB03629/c
ID ADB03629 standard; DNA; 17 BP.
XX
AC ADB03629;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ7 scanning oligonucleotide SEQ ID 4615.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MD24; MDZ7; MD212; chromosome 7q22.1;
```

```
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
PS WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS Example 8; SEQ ID NO 4615; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MD24, MDZ7, MD212. MDZ3 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MD24, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MD24, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MD24, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 2 A; 9 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 741 GAGAGAGGCTGTGCC 755
DB 15 GAGAGAGGCTGTGCC 1
RESULT 403
ADB03628/c
ID ADB03628 standard; DNA; 17 BP.
XX
AC ADB03628;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ7 scanning oligonucleotide SEQ ID 4614.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MD24; MDZ7; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
```

```
XX PF 30-JUL-2002; 2002EP-00016874.
XX PF 02-AUG-2001; 2001US-00922181.
XX PA (AEOM-) AEOMICA INC.
XX PI Shannon M, Gu Y, Nguyen C;
XX DR WPI; 2003-423107/40.
XX XX
XX PT New zinc finger-containing proteins and nucleic acids, useful in
XX PT manufacturing a medicament for treating or preventing a disorder
XX PT associated with decreased or increased expression or activity of MDZ3,
XX PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX XX
XX PS Example 8; SEQ ID NO 4614; 103pp; English.
XX XX
XX CC The present invention relates to novel human zinc finger-containing
XX CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
XX CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
XX CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
XX CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
XX CC or in manufacturing a medicament for treating or preventing a disorder,
XX CC associated with decreased or increased expression or activity of MDZ3,
XX CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
XX CC acids and proteins are also useful for diagnosing or monitoring a disease
XX CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
XX CC acids can also be used as probes to detect and characterize gross
XX CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
XX CC useful in constructing microarrays for measuring gene expression. The
XX CC proteins are useful as therapeutic agents for gene therapy or as
XX CC vaccines. The present sequence was used to illustrate the invention.
XX XX
XX SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 741 GAGAGAGGCTGTGCC 755
DB 16 GAGAGAGGCTGTGCC 2

RESULT 404
ABZ65272/c
ID ABZ65272 standard; RNA; 17 BP.
XX AC ABZ65272;
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNAzyme substrate #729.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PF
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US016840.
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX XX

Mcswiggen J;
WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX XX
XX PS Claim 4; Page 147; 185pp; English.
XX XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
XX CC rheumatic activity. The nucleic acid molecules are useful for reducing
XX CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX CC also useful for treating breast, ovarian, colorectal, lung, prostate,
XX CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX CC shown in ABZ5989 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ66524,
XX CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
XX CC ribozymes of the invention
XX SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 196 CGGCGCATGCGGAG 210
DB 16 CTGGCATGCGGAG 2

RESULT 405
ACD59610/c
ID ACD59610 standard; RNA; 17 BP.
XX AC ACD59610;
XX DT 24-SEP-2003 (first entry)
XX DE HCV DNAzyme substrate sequence #1412.
XX KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX KW RNA stability; RNA expression; RNA synthesis; antisense;
XX KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
XX KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX KW HBV reverse transcriptase; Enhancer I region; viral replication;
XX KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX KW virucide; antiinflammatory; substrate; ss.
XX OS Hepatitis C virus.
XX PN WO200281494-A1.
XX PD 17-OCT-2002.
XX PF 26-MAR-2002; 2002WO-US009187.
XX PR 26-MAR-2001; 2001US-00817879.
XX PR 08-JUN-2001; 2001US-00877478.
XX PR 08-JUN-2001; 2001US-0296876P.
XX PR 24-OCT-2001; 2001US-0335059P.
XX PR 05-DEC-2001; 2001US-0337055P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MACE/) MACEJAK D.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (MORR/) MORRISSEY D.
XX PA (PAVC/) PAVCO P.
```

PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
XX (ROBE/) ROBERTS E.
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 259; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, kinzymes, ambrzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 135 GGAGGCTGTGAGGC 149
Db 17 GGAGGCTGTGATGC 3
|||||

RESULT 406
ACC65533
ID ACC65533 standard; DNA; 17 BP.
XX
AC ACC65533;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2780.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Anson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 522; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration.
CC CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 2 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 928 TATGCTGCTTCATC 942
Db 3 TCTGCTGCTTCATC 17
|||||

RESULT 407
ACC66957/C
ID ACC66957 standard; DNA; 17 BP.
XX
AC ACC66957;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4204.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Anson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 522; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

XX WPI; 2003-333167/31.
DR
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 356; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration.
CC CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 2 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 928 TATGCTGCTTCATC 942
Db 3 TCTGCTGCTTCATC 17
|||||

RESULT 407
ACC66957/C
ID ACC66957 standard; DNA; 17 BP.
XX
AC ACC66957;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4204.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Anson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 522; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 322 AAGTCCTGCTTGAT 336
||| |||||
Db 16 AAGCCCTGCTTGAT 2

RESULT 408
ACC62782/c
ID ACC62782 standard; DNA; 17 BP.

XX ACC62782;

XX 01-JUL-2003 (first entry)

XX Murine oligonucleotide associated with tumour suppression, SEQ ID 29.

XX Cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.

XX Disclosure; Page 34; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX

SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1113 ATTGGAGACAGAT 1127
||| ||||| |||||

Db 16 ATTGGAGAAAGAT 2

RESULT 409

ADB43973/c

XX ADB43973 standard; DNA; 17 BP.

XX ADB43973;

XX 18-DEC-2003 (revised)

XX 04-DEC-2003 (first entry)

XX Tumour suppression/reversion associated nucleotide #4296.

XX cytostatic; antiviral; neuroprotective; neurotropic; neuroleptic; ss;

XX primer; probe; tumour suppression; tumour reversion; apoptosis;

XX virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;

XX diagnosis.

XX Homo sapiens.

XX WO2003040369-A2.

XX 15-MAY-2003.

XX 17-SEP-2002; 2002WO-IB004219.

XX 17-SEP-2001; 2001FR-00011981.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-441574/41.

XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.

XX Disclosure; Page 534; 771pp; French.

XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.

SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 70 CCCTGTGGAGATGGA 84

Db 17 CCCTGTGGAGAGGGA 3

RESULT 410
ADB40515/c
ID ADB40515 standard; DNA; 17 BP.
XX AC
XX AC ADB40515;
XX XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX XX
DE Tumour suppression/reversion associated nucleotide #838.
XX XX
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX XX
XX Homo sapiens.
XX OS
XX WO2003040369-A2.
PN
XX PD
XX PD 15-MAY-2003.
XX PF
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR
XX PR 17-SEP-2001; 2001FR-00011981.
XX XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX PA
XX PI Telerman A, Amson R, Tuijnder M;
XX XX
XX WPI; 2003-441574/41.
XX DR
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX PT
XX Disclosure; Page 130; 771pp; French.
XX PS
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX XX
SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 322 AAGTCCCTGCTTGAT 336
||| |||||
DB 16 AAGTGCCTGCTTGAT 2
RESULT 411
ADC03633/c
ID ADC03633 standard; DNA; 17 BP.

XX ADC03633;
XX 18-DEC-2003 (first entry)
XX DT
XX DE Human Na/H exchanger-like protein 1 gene oligonucleotide #80.
XX XX
XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHEPL1; passive replacement therapy; vaccine; diagnosis.
XX KW
XX OS Homo sapiens.
XX XX
XX EP1273660-A2.
PN
XX PD
XX PD 08-JAN-2003.
XX XX
XX PF
XX PF 25-JAN-2002; 2002EP-00001160.
XX XX
XX PR
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 21-DEC-2001; 2001US-0343331P.
XX XX
XX PA (AEOM-) AEOMICA INC.
XX XX
XX PI Gu Y;
XX DR
XX DR WPI; 2003-302724/30.
XX XX
XX New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHEPL1.
XX PT
XX Example 2; SEQ ID NO 120; 468pp; English.
XX PS
XX CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHEPL1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHEPL1 gene (ADC03514).
XX XX
SQ Sequence 17 BP; 6 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1348 CTGATACCTCTTCCTT 1362
|||||
DB 15 CTGATACCTCTTCCTT 1
RESULT 412
ADC03632/c
ID ADC03632 standard; DNA; 17 BP.
XX AC
XX AC ADC03632;
XX XX
XX 19-DEC-2003 (first entry)
XX DT
XX DE Human Na/H exchanger-like protein 1 gene oligonucleotide #79.
XX XX
XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHEPL1; passive replacement therapy; vaccine; diagnosis.
XX KW
XX ID ADC03633 standard; DNA; 17 BP.

OS Homo sapiens.
 XX EPI273660-A2.
 XX
 XX 08-JAN-2003.
 PD
 XX 25-JAN-2002; 2002EP-00001160.
 PF
 XX 30-JAN-2001; 2001WO-US000666.
 PR
 XX 23-MAY-2001; 2001US-00864761.
 PR
 XX 21-DEC-2001; 2001US-0343331P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 XX Gu Y;
 PI
 XX WPI; 2003-302724/30.
 DR
 XX New human sodium-hydrogen exchanger like protein 1 (NHEP1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHEP1.
 XX
 XX Example 2; SEQ ID NO 119; 468pp; English.
 XX
 XX The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHEP1). The NHEP1 nucleic acid molecule, NHEP1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHEP1 nucleic acid molecule, NHEP1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHEP1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHEP1. The NHEP1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHEP1 gene (ADC03514).
 XX
 XX Sequence 17 BP; 7 A; 1 C; 5 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1348 CTGATCTCTTCCTT 1362
 Db |||||
 16 CTGATCTCTTCCTT 2

RESULT 413
 ADF64077/c
 ID ADF64077 standard; DNA; 17 BP.
 XX
 XX ADF64077;
 AC
 XX 12-FEB-2004 (first entry)
 DT
 XX Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1981.
 DE
 XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX
 XX Homo sapiens.
 OS
 XX WO2003050284-A1.
 PN
 XX 19-JUN-2003.
 PD
 XX 22-NOV-2002; 2002WO-US037506.
 PF
 XX 10-DEC-2001; 2001US-0339764P.
 PR
 XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 PA
 XX Guo J;
 PI
 XX WPI; 2003-532916/50.
 DR
 XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX
 XX Example 2; SEQ ID NO 1981; 164pp; English.
 PS
 XX The invention relates to a novel isolated nucleic acid that encodes a

XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 XX Guo J;
 PI
 XX WPI; 2003-532916/50.
 DR
 XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX
 XX Example 2; SEQ ID NO 1981; 164pp; English.
 PS
 XX The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the Wipoweb
 CC database.
 XX
 XX Sequence 17 BP; 2 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1182 GAACGTGGTGGTCCA 1196
 Db |||||
 17 GAACGTGGTGGCCA 3

RESULT 414
 ADF64078/c
 ID ADF64078 standard; DNA; 17 BP.
 XX
 XX ADF64078;
 AC
 XX 12-FEB-2004 (first entry)
 DT
 XX Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1982.
 DE
 XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX
 XX Homo sapiens.
 OS
 XX WO2003050284-A1.
 PN
 XX 19-JUN-2003.
 PD
 XX 22-NOV-2002; 2002WO-US037506.
 PF
 XX 10-DEC-2001; 2001US-0339764P.
 PR
 XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 PA
 XX Guo J;
 PI
 XX WPI; 2003-532916/50.
 DR
 XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX
 XX Example 2; SEQ ID NO 1982; 164pp; English.
 PS
 XX The invention relates to a novel isolated nucleic acid that encodes a

CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytoskeletal activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1182 GAACGTGGTGGTCCA 1196
Db |||||||||
16 GAACGTGGTGGGCCA 2

RESULT 415
ADP64079/c
ID ADF64079 standard; DNA; 17 BP.
XX AC
XX ADF64079;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1983.
XX
XX Chromatin organisation modifier; CHROMO domain; cytoskeletal; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
XX Homo sapiens.
OS
XX
XX WO2003050284-A1.
PN
XX
XX 19-JUN-2003.
PD
XX
XX 22-NOV-2002; 2002WO-US037506.
PF
XX
XX 10-DEC-2001; 2001US-0339764P.
PR
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
PA
XX
XX Guo J;
PI
XX
XX WPI; 2003-532916/50.
DR
XX
PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 1983; 164pp; English.
PS
XX
CC The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytoskeletal activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1182 GAACGTGGTGGTCCA 1196
Db |||||||||
16 GAACGTGGTGGGCCA 2

RESULT 416
ADI52315
ID ADI52315 standard; DNA; 17 BP.
XX AC
XX ADI52315;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID4818.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX Homo sapiens.
OS
XX
XX WO2003025177-A2.
PN
XX
XX 27-MAR-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004523.
PF
XX
XX 17-SEP-2001; 2001PR-00011980.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX
XX Telerman A, Amson R, Tuijnder M;
PI
XX
XX WPI; 2003-313354/30.
DR
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; SEQ ID NO 4818; 30pp; French.
PS
XX
CC This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1018 ATCCTGCATGCCACG 1032
Db |||||||||
2 ATCCTGCATGCCACG 16

Query Match 0.9%; Score 13.4; DB 1; Length 17;

```
RESULT 417
ACC51409/c
ID ACC51409 standard; DNA; 17 BP.
XX
XX ACC51409;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #176.
XX
XX ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
XX Homo sapiens.
OS
XX FR2826373-A1.
PN
XX 27-DEC-2002.
PD
XX
XX 20-JUN-2001; 2001FR-00008139.
PF
XX 20-JUN-2001; 2001FR-00008139.
PR
XX (MOLE-) MOLECULAR ENGINES LAB SA.
PA
XX Tuijnder M, Telerman A, Anson R;
PI
XX WPI; 2003-250498/25.
DR
XX
XX New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
PT
XX
XX Claim 1; Page 81; 798pp; French.
PS
XX
XX This sequence represents an isolated nucleic acid sequence associated
XX with tumour suppression or regression, apoptosis or virus resistance. The
XX invention relates to these sequences or sequences having at least 80%
XX identity to them, and polypeptides encoded by the sequences or
XX polypeptides having 80% identity to the polypeptide sequences. The
XX invention is used to diagnose or treat viral disease or disease
XX characterized by development of tumour cells or cellular degeneration
XX
XX Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 322 AAGTCCCTGCTTGAT 336
Db ||||| ||||| |||||
16 AAGTGCGCTGCTTGAT 2
RESULT 418
ADL50726
ID ADL50726 standard; RNA; 17 BP.
XX
XX ADL50726;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Human PKR substrate sequence #1840.
DE
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW
```

```
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 4259; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/perfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
XX Sequence 17 BP; 8 A; 2 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 297 GAAACAGAAAGTTT 311
Db ||||| ||||| |||||
3 GAAACAGAAAGGUU 17
RESULT 419
ADK13282
ID ADK13282 standard; DNA; 17 BP.
XX
XX ADK13282;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Human glioma endothelial marker (GEM) long tag SEQ ID NO:460.
DE
XX
XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
KW anticancer; antiglioma; immune response; cytostatic;
KW multi-drug sensitive glioma; human; long tag; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO2004016758-A2.
PN
```

XX 26-FEB-2004.
XX 15-AUG-2003; 2003WO-US025614.
XX 15-AUG-2002; 2002US-0403390P.
XX 01-APR-2003; 2003US-0458978P.
XX (GENZ) GENZYME CORP.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Madden SI, Wang CJ, Cook BP, Lattera J, Walter K;
XX WPI; 2004-247973/23.
XX
XX Diagnosing glioma by detecting expression product of any one of 255
XX genes, glioma endothelial markers, in brain tissue sample suspected of
XX being neoplastic, and comparing the expression with expression in normal
XX brain tissue sample.
XX Example 2; SEQ ID NO 460; 114pp; English.
XX
XX The present invention describes a method (M1) for aiding in the diagnosis
XX of glioma. (M1) involves detecting an expression product of at least one
XX gene (I) in a first brain tissue sample (T) suspected of being
XX neoplastic, where (I) is chosen from any one of 255 genes (Glioma
XX endothelial markers (GEMs)) as given in specification, and comparing the
XX expression of (I) in (T) with expression of (I) in a second normal brain
XX tissue sample (R), where increased expression of (I) in (T) relative to
XX (R), identifies (T) as likely to be neoplastic. Also described: (1)
XX treating (M2) glioma involves contacting cells of the glioma with an
XX antibody that specifically binds to a extracellular epitope; (2)
XX identifying (M3) a test compound as potential anticancer or antglioma
XX drug involves contacting a test compound with the cell which expresses
XX (I), monitoring an expression product of the at least one gene and
XX identifying test compound as a potential anticancer drug if it decreases
XX the expression of at least one gene; (3) identifying (M4) a test compound
XX as potential anticancer or antglioma drug involves contacting a test
XX compound with the cell which expresses mRNA of at least one gene
XX identified by a tag as described above, monitoring mRNA of the gene, and
XX identifying the test compound as a potential anticancer drug if it
XX decreases the expression of at least one gene; and (4) inducing (M5) an
XX immune response to glioma involves administering to a mammal, a protein
XX or (I). (I) have cytostatic activities, and can be used to trigger immune
XX destruction of glioma cells, and as immune response inducers. (M1) is
XX useful for aiding in diagnosing glioma. (M2) is useful for treating multi
XX -drug sensitive glioma in a human. (M5) is useful for inducing an immune
XX response to a glioma in a mammal having glioma or in a mammal who has had
XX a glioma surgically removed. The present sequence represents a human GEM
XX long tag oligonucleotide, which is used in the exemplification of the
XX present invention.
XX
XX Sequence 17 BP; 1 A; 4 C; 10 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 557 GGCTGTGGGCCAGGG 571
Db 1 GGCTGTGGGCCAGGG 15
RESULT 420
ADL82074
ID ADL82074 standard; DNA; 17 BP.
XX
XX ADL82074;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human ER+ breast cancer differentially expressed sequence #44.
XX

XX gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX Homo sapiens.
XX US2003166026-A1.
XX 04-SEP-2003.
XX
XX 08-JAN-2003; 2003US-00339782.
XX 09-JAN-2002; 2002US-0348053P.
XX (LYNX-) LYNX THERAPEUTICS INC.
XX Goodman LJ, Bowen BA;
XX WPI; 2004-069003/07.
XX
XX Vector containing nucleic acid associated with breast cancer, useful for
XX treating, diagnosing and characterizing breast cancer, also related
XX polypeptides and antibodies.
XX
XX Claim 1; SEQ ID NO 45; 61pp; English.
XX
XX The invention relates to a composition which contains at least one vector
XX (B) containing a nucleic acid (I) associated with breast cancer. The
XX vector (B), also polypeptides (II) encoded by (I), are used for treatment
XX of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
XX -specific antibodies (Ab) are used to predict characteristics (e.g.
XX invasiveness or stage) of breast cancer, and (I), or its fragments, are
XX used to modulate characteristics of such cells; to identify breast cancer
XX genes and to detect breast cancer (by detecting polymorphic nucleic acid
XX or its products). The present sequence represents a human ER+ breast
XX cancer differentially expressed sequence.
XX
XX Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 786 GATCCAGGCCCCAG 800
Db 1 GATCCAGGCCCCAG 15
RESULT 421
AD184166/c
ID AD184166 standard; RNA; 17 BP.
XX
XX AD184166;
XX
XX 03-JUN-2004 (first entry)
XX
XX HCV DNzyme substrate sequence #1412.
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.

PA (MACE/) MACEJACK D.
 XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
 XX WPI; 2004-031273/03.
 DR Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX Claim 1; SEQ ID NO 1412; 198pp; English.
 XX The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNazyme substrate
 CC sequence.
 XX Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 SQ Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 135 GGAGGCTGTGAAGGC 149
 DB 17 GGAGGCTGTGAATGC 3
 RESULT 422
 ADN43647
 ID ADN43647 standard; DNA; 17 BP.
 XX AC
 AC ADN43647;
 XX DT 15-JUL-2004 (first entry)
 DE Mutant cell identification-related mutagenic oligonucleotide SeqID316.
 XX cell identification; oligonucleotide-directed sequence alteration;
 KW selectable phenotype; transgenic plant; herbicide resistance;
 KW sterile plant; abiotic stress tolerance; albino plant;
 KW amino acid production; ss.
 XX Spinacia oleracea.
 OS Synthetic.
 XX WO2004033708-A2.
 PN 22-APR-2004.
 XX 07-OCT-2003; 2003WO-US031862.
 PF 07-OCT-2002; 2002US-0416983P.
 PR 07-MAR-2003; 2003US-0453360P.
 XX (UYDE) UNIV DELAWARE.
 PA (NAPRO-) NAPRO BIO THERAPEUTICS INC.
 PA Kmiec EB, Van Brabant A;
 PI WPI; 2004-340941/31.
 DR Identifying a cell with a desired oligonucleotide-directed sequence
 XX alteration at a nucleic acid target site within the cell by identifying
 PT the desired sequence alteration in cells selected for the presence of a
 PT selectable phenotype.
 XX Example 23; SEQ ID NO 316; 303pp; English.

CC This invention relates to a novel method of identifying a cell having a
 CC desired oligonucleotide-directed sequence alteration at a first nucleic
 CC acid target site within the cell. The method comprises identifying the
 CC desired sequence alteration in cells that have been selected for the
 CC presence of a selectable phenotype conferred by a concurrent
 CC oligonucleotide-directed sequence alteration at a second nucleic acid
 CC target site within the cells. The method is useful in identifying a cell
 CC having a desired oligonucleotide-directed sequence alteration at a first
 CC nucleic acid target site within the cell. The method may be useful for
 CC the production of plants with herbicide resistance, male or female
 CC sterile plants, abiotic stress tolerance, albino plants or plants with
 CC altered amino acid production as well as for use in mammalian cell lines.
 CC The present sequence is that of a mutagenic oligonucleotide which was
 CC used in the exemplification of the invention.
 XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.9%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 484 CAGCTGCCATTGGCG 498
 DB 1 CAGCTGCCATTGGTG 15
 RESULT 423
 ADN45714/c
 ID ADN45714 standard; DNA; 17 BP.
 XX AC
 AC ADN45714;
 XX DT 15-JUL-2004 (first entry)
 DE Mutant cell identification-related mutagenic oligonucleotide SeqID2383.
 XX cell identification; oligonucleotide-directed sequence alteration;
 KW selectable phenotype; transgenic plant; herbicide resistance;
 KW sterile plant; abiotic stress tolerance; albino plant;
 KW amino acid production; ss.
 XX Oryza sativa.
 OS Synthetic.
 XX WO2004033708-A2.
 PN 22-APR-2004.
 PD 07-OCT-2003; 2003WO-US031862.
 PF 07-OCT-2002; 2002US-0416983P.
 PR 07-MAR-2003; 2003US-0453360P.
 XX (UYDE) UNIV DELAWARE.
 PA (NAPRO-) NAPRO BIO THERAPEUTICS INC.
 PA Kmiec EB, Van Brabant A;
 PI WPI; 2004-340941/31.
 DR Identifying a cell with a desired oligonucleotide-directed sequence
 XX alteration at a nucleic acid target site within the cell by identifying
 PT the desired sequence alteration in cells selected for the presence of a
 PT selectable phenotype.
 XX Example 29; SEQ ID NO 2383; 303pp; English.
 XX This invention relates to a novel method of identifying a cell having a
 CC desired oligonucleotide-directed sequence alteration at a first nucleic
 CC acid target site within the cell. The method comprises identifying the
 CC desired sequence alteration in cells that have been selected for the
 CC presence of a selectable phenotype conferred by a concurrent
 CC oligonucleotide-directed sequence alteration at a second nucleic acid

CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.

SQ Sequence 17 BP; 3 A; 1 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 363 CACCATCTACCACAT 377
DB 17 CACCATCTACGACAT 3

RESULT 424
ADN43646/c
ID ADN43646 standard; DNA; 17 BP.
XX
AC ADN43646;
XX
DT 15-JUL-2004 (first entry)
XX
DE Mutant cell identification-related mutagenic oligonucleotide SeqID315.
XX
KW cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
OS Spinacia oleracea.
OS Synthetic.
XX
PN WO2004033708-A2.
XX
PD 22-APR-2004.
XX
PF 07-OCT-2003; 2003WO-US031862.
XX
PR 07-OCT-2002; 2002US-0416983P.
PR 07-MAR-2003; 2003US-0453360P.
XX
PA (UYDE) UNIV DELAWARE.
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
PI Kmiec EB, Van Brabant A;
XX
DR WPI; 2004-340941/31.
XX
PS Example 23; SEQ ID NO 315; 303pp; English.
XX
PT This invention relates to a novel method of identifying a cell having a
PT desired oligonucleotide-directed sequence alteration at a first nucleic
PT acid target site within the cell. The method comprises identifying the
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.

CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.

CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.

SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 484 CAGCTGCCATTGGCG 498
DB 17 CAGCTGCCATTGGTG 3

RESULT 425
ADN45715
ID ADN45715 standard; DNA; 17 BP.
XX
AC ADN45715;
XX
DT 15-JUL-2004 (first entry)
XX
DE Mutant cell identification-related mutagenic oligonucleotide SeqID2384.
XX
KW cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
OS Oryza sativa.
OS Synthetic.
XX
PN WO2004033708-A2.
XX
PD 22-APR-2004.
XX
PF 07-OCT-2003; 2003WO-US031862.
XX
PR 07-OCT-2002; 2002US-0416983P.
PR 07-MAR-2003; 2003US-0453360P.
XX
PA (UYDE) UNIV DELAWARE.
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
PI Kmiec EB, Van Brabant A;
XX
DR WPI; 2004-340941/31.
XX
PS Example 29; SEQ ID NO 2384; 303pp; English.
XX
PT This invention relates to a novel method of identifying a cell having a
PT desired oligonucleotide-directed sequence alteration at a first nucleic
PT acid target site within the cell. The method comprises identifying the
PT desired sequence alteration in cells that have been selected for the
PT presence of a selectable phenotype conferred by a concurrent
PT oligonucleotide-directed sequence alteration at a second nucleic acid
PT target site within the cells. The method is useful in identifying a cell
PT having a desired oligonucleotide-directed sequence alteration at a first
PT nucleic acid target site within the cell. The method may be useful for
PT the production of plants with herbicide resistance, male or female
PT sterile plants, abiotic stress tolerance, albino plants or plants with
PT altered amino acid production as well as for use in mammalian cell lines.
PT The present sequence is that of a mutagenic oligonucleotide which was
PT used in the exemplification of the invention.

SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 13.4; DB 1; Length 17;
Query Match

```
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 363 CACCATCTACCACAT 377
   |||||
Db 1 CACCATCTAGGACAT 15

RESULT 426
AAF73008
ID AAF73008 standard; DNA; 20 BP.
XX
AC AAF73008;
XX
DT 24-APR-2001 (first entry)
XX
DE Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:109.
XX
KW Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
KW Fas binding protein; CENP-C binding protein; dap6; EAP; cytostatic;
KW antiinflammatory; death associated protein 6; Ets-1 associated protein;
KW infection; inflammation; tumour formation; ss.
XX
OS Homo sapiens.
XX
PN US6180353-B1.
XX
PD 30-JAN-2001.
XX
PF 24-JAN-2000; 2000US-00490692.
XX
PR 24-JAN-2000; 2000US-00490692.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Dean NM, Cowser LM;
XX
WPI; 2001-217744/22.
XX
PT Novel antisense compounds capable of modulating expression of daxx useful
PT for diagnosis, prophylaxis and treatment of diseases associated with
PT expression of daxx.
XX
PS Claim 1; Col 47; 59pp; English.
XX
CC The present invention describes an antisense compound (I) up to 30
CC nucleobases in length, where (I) inhibits expression of daxx (also known
CC as Fas binding protein, CENP-C binding protein, dap6 for death associated
CC protein 6 and EAP for Ets-1 associated protein). (I) has cytostatic and
CC antiinflammatory activity, and can be used in antisense therapy and as a
CC modulator of daxx. (I) is useful for inhibiting the expression of daxx in
CC cells or tissues in vitro. (I) can be utilised for diagnostics,
CC therapeutics for the treatment of diseases associated with the expression
CC of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
CC tumour formation and as research reagent. The present sequence represents
CC an inhibitory human daxx antisense phosphorothioate oligonucleotide which
CC is used in the exemplification of the present invention
XX
SQ Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 CTGCAGAGGACAGAA 42
   |||||
Db 1 CTGCAGAGGCCAGAA 15

RESULT 427
AAT04567
ID AAT04567 standard; DNA; 17 BP.
XX
```

```
AC AAT04567;
XX
DT 26-APR-1996 (first entry)
XX
DE 17-mer DNA probe for S-adenosylmethionine synthetase DNA.
XX
KW Coryneform bacteria; S-adenosylmethionine synthetase; production; probe;
KW identification; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 6 /*tag= a
FT /*mod_base= i
XX
PN JP07227287-A.
XX
PD 29-AUG-1995.
XX
PF 18-FEB-1994; 94JP-00020809.
XX
PR 18-FEB-1994; 94JP-00020809.
XX
PA (MITU ) MITSUBISHI CHEM CORP.
XX
WPI; 1995-331524/43.
XX
P-PSDB; AAR80061.
XX
PT DNA encoding S-adenosylmethionine synthetase - useful for the efficient
PT production of the enzyme.
XX
PS Example; Page 4; 7pp; Japanese.
XX
CC AAT04567-68 are degenerate probes designed based on AAR80061-62 resp. .
CC The probes are used to identify DNA encoding S-adenosylmethionine
CC synthetase. The DNA is used to transform bacteria to efficiently produce
CC the enzyme. A 5.5 kb SalI DNA fragment contg. this DNA gives fragments of
CC 2.4, 1.7 and 1.4 kb when cleaved with BamHI and fragments of 3.3, 1.0,
CC 0.7 and 0.5 kb when cleaved with PstI
XX
SQ Sequence 17 BP; 2 A; 2 C; 9 G; 0 T; 0 U; 4 Other;

Query Match 0.8%; Score 13.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.9e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 495 GCGCGTGTGTGACCTGGG 511
   |||||
Db 1 GGYGCGNGGYGAYCAGGG 17

RESULT 428
AAT90047/C
ID AAT90047 standard; DNA; 17 BP.
XX
AC AAT90047;
XX
DT 21-NOV-1997 (first entry)
XX
DE Primer for hepatocyte growth factor activator inhibitor DNA.
XX
KW Inhibition; inhibitor; protease; hepatocyte; growth factor; activation;
KW activator; human; cancer; cell line; MKW45; primer; regulation;
KW regulator; antibody; kinetic study; assay standard;
KW polymerase chain reaction; amplification; PCR; ss.
XX
OS Synthetic.
XX
PN EP759467-A2.
XX
PD 26-FEB-1997.
XX
```

PF 23-JUL-1996; 96EP-00111870.
 XX
 PR 24-JUL-1995; 95JP-00187135.
 XX
 PA (MITU) MITSUBISHI CHEM CORP.
 XX
 PI Shimomura T, Kawaguchi T, Kitamura N, Miyazawa K;
 XX WPI; 1997-147516/14.
 DR
 XX New hepatocyte growth factor activator inhibitor and DNA - regulates
 PT hepatocyte growth factor and/or HGF activator in vivo or in vitro, and
 PT are used in kinetic studies.
 XX
 PS Example 6; Page 34; 38pp; English.
 XX
 CC The present sequence is a primer for the PCR amplification of a nucleic
 CC acid sequence encoding an inhibitor of the protease activity of
 CC hepatocyte growth factor (HGF) activator (HGFA) which has a molecular
 CC weight of about 40 kD when determined by SDS-PAGE. The inhibitor, which
 CC was isolated from the human cancer cell line MKN45, can be used as an in
 CC vivo or in vitro regulatory factor for HGF or HGFA. It can also be used
 CC to raise antibodies, useful in kinetic studies of the inhibitor, or as
 CC assay standards
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 1 G; 2 T; 0 U; 4 Other;
 Query Match 0.8%; Score 13.2; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 1.9e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 OY 876 CAGGTGGGAATTATGTGG 892
 ||:|:|:|:|:|:|
 Db 17 CAGTNGARTTRTGGGG 1

Search completed: November 8, 2004, 12:48:30
 Job time : 10 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 12:55:13 ; Search time 17 Seconds
(without alignments)
3.612 Million cell updates/sec

Title: US-09-918-026A-3

Perfect score: 1569

Sequence: 1 atggagccagcgggggcccg.....cttggtcctgcatacctag 1569

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 994 seqs, 19570 residues

Total number of hits satisfying chosen parameters: 1988

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 994 summaries

Database : rnpsm3.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	ID	Description
1	25	1.6	25	1 PCT-US02-22746-6
2	25	1.6	25	1 US-09-918-026A-6
3	25	1.6	25	1 US-10-484-441-6
4	24	1.5	25	1 US-09-630-892-25
5	24	1.5	25	1 US-09-630-892A-25
6	23.4	1.5	25	1 US-09-956-584A-191617
7	23.4	1.5	25	1 US-09-956-584A-191623
8	23	1.5	23	1 US-09-630-892-30
9	23	1.5	23	1 US-09-630-892A-30
10	21.8	1.4	25	1 US-09-605-166-6
11	21.8	1.4	25	1 US-09-605-166-7
12	21.8	1.4	25	1 US-09-605-166A-6
13	21.8	1.4	25	1 US-09-605-166A-7
14	21.8	1.4	25	1 US-09-956-584A-191612
15	21.8	1.4	25	1 US-09-956-584A-191616
16	21.8	1.4	25	1 US-09-956-584A-191620
17	21.8	1.4	25	1 US-09-956-584A-191625
18	21.8	1.4	25	1 US-09-956-584A-191627
19	21.8	1.4	25	1 US-10-355-577-567125
20	21.8	1.4	25	1 US-10-779-251-6
21	21.8	1.4	25	1 US-60-353-987-567125
22	21.8	1.4	29	1 US-10-336-638-370
23	21.4	1.4	25	1 US-10-719-956-196282
24	21.4	1.4	25	1 US-60-427-836-196282
25	21	1.3	21	1 PCT-US02-22746-4
26	21	1.3	21	1 US-09-918-026A-4
27	21	1.3	21	1 US-10-484-441-4
28	20.8	1.3	24	1 US-09-605-166-8
29	20.8	1.3	24	1 US-10-779-251-8
30	20.8	1.3	25	1 US-09-956-584A-191618
31	20.8	1.3	25	1 US-09-956-584A-191621
32	20.8	1.3	25	1 US-09-954-427A-131432
33	20.4	1.3	25	1

34	20.4	1.3	25	1	US-09-954-427A-270002	Sequence 270002,
35	20.4	1.3	25	1	US-09-956-584A-146347	Sequence 146347,
36	20.2	1.3	25	1	US-09-954-427A-358884	Sequence 358884,
37	20.2	1.3	25	1	US-09-956-584A-191614	Sequence 191614,
38	20.2	1.3	25	1	US-09-956-584A-191626	Sequence 191626,
39	20.2	1.3	25	1	US-09-956-584A-330489	Sequence 330489,
40	20.2	1.3	25	1	US-10-355-577-567125	Sequence 567126,
41	20.2	1.3	25	1	US-10-719-900-716377	Sequence 716377,
42	20.2	1.3	25	1	US-10-719-956-626166	Sequence 626166,
43	20.2	1.3	25	1	US-60-353-987-567126	Sequence 567126,
44	20.2	1.3	25	1	US-60-427-808-716377	Sequence 716377,
45	20.2	1.3	25	1	US-60-427-836-626166	Sequence 626166,
46	20	1.3	20	1	PCT-US02-22746-14	Sequence 14, Appl
47	20	1.3	20	1	PCT-US02-22746-15	Sequence 15, Appl
48	20	1.3	20	1	PCT-US02-22746-16	Sequence 16, Appl
49	20	1.3	20	1	PCT-US02-22746-17	Sequence 17, Appl
50	20	1.3	20	1	PCT-US02-22746-18	Sequence 18, Appl
51	20	1.3	20	1	PCT-US02-22746-19	Sequence 19, Appl
52	20	1.3	20	1	PCT-US02-22746-20	Sequence 20, Appl
53	20	1.3	20	1	PCT-US02-22746-21	Sequence 21, Appl
54	20	1.3	20	1	PCT-US02-22746-22	Sequence 22, Appl
55	20	1.3	20	1	PCT-US02-22746-23	Sequence 23, Appl
56	20	1.3	20	1	PCT-US02-22746-24	Sequence 24, Appl
57	20	1.3	20	1	PCT-US02-22746-25	Sequence 25, Appl
58	20	1.3	20	1	PCT-US02-22746-26	Sequence 26, Appl
59	20	1.3	20	1	PCT-US02-22746-27	Sequence 27, Appl
60	20	1.3	20	1	PCT-US02-22746-28	Sequence 28, Appl
61	20	1.3	20	1	PCT-US02-22746-29	Sequence 29, Appl
62	20	1.3	20	1	PCT-US02-22746-30	Sequence 30, Appl
63	20	1.3	20	1	PCT-US02-22746-31	Sequence 31, Appl
64	20	1.3	20	1	PCT-US02-22746-32	Sequence 32, Appl
65	20	1.3	20	1	PCT-US02-22746-33	Sequence 33, Appl
66	20	1.3	20	1	PCT-US02-22746-34	Sequence 34, Appl
67	20	1.3	20	1	PCT-US02-22746-35	Sequence 35, Appl
68	20	1.3	20	1	PCT-US02-22746-36	Sequence 36, Appl
69	20	1.3	20	1	PCT-US02-22746-37	Sequence 37, Appl
70	20	1.3	20	1	PCT-US02-22746-38	Sequence 38, Appl
71	20	1.3	20	1	US-09-605-166A-16	Sequence 16, Appl
72	20	1.3	20	1	US-09-605-166A-17	Sequence 17, Appl
73	20	1.3	20	1	US-09-918-026A-14	Sequence 14, Appl
74	20	1.3	20	1	US-09-918-026A-15	Sequence 15, Appl
75	20	1.3	20	1	US-09-918-026A-16	Sequence 16, Appl
76	20	1.3	20	1	US-09-918-026A-17	Sequence 17, Appl
77	20	1.3	20	1	US-09-918-026A-18	Sequence 18, Appl
78	20	1.3	20	1	US-09-918-026A-19	Sequence 19, Appl
79	20	1.3	20	1	US-09-918-026A-20	Sequence 20, Appl
80	20	1.3	20	1	US-09-918-026A-21	Sequence 21, Appl
81	20	1.3	20	1	US-09-918-026A-22	Sequence 22, Appl
82	20	1.3	20	1	US-09-918-026A-23	Sequence 23, Appl
83	20	1.3	20	1	US-09-918-026A-24	Sequence 24, Appl
84	20	1.3	20	1	US-09-918-026A-25	Sequence 25, Appl
85	20	1.3	20	1	US-09-918-026A-26	Sequence 26, Appl
86	20	1.3	20	1	US-09-918-026A-27	Sequence 27, Appl
87	20	1.3	20	1	US-09-918-026A-28	Sequence 28, Appl
88	20	1.3	20	1	US-09-918-026A-29	Sequence 29, Appl
89	20	1.3	20	1	US-09-918-026A-30	Sequence 30, Appl
90	20	1.3	20	1	US-09-918-026A-31	Sequence 31, Appl
91	20	1.3	20	1	US-09-918-026A-32	Sequence 32, Appl
92	20	1.3	20	1	US-09-918-026A-33	Sequence 33, Appl
93	20	1.3	20	1	US-09-918-026A-34	Sequence 34, Appl
94	20	1.3	20	1	US-09-918-026A-35	Sequence 35, Appl
95	20	1.3	20	1	US-09-918-026A-36	Sequence 36, Appl
96	20	1.3	20	1	US-09-918-026A-54	Sequence 54, Appl
97	20	1.3	20	1	US-09-918-026A-65	Sequence 65, Appl
98	20	1.3	20	1	US-10-484-441-14	Sequence 14, Appl
99	20	1.3	20	1	US-10-484-441-15	Sequence 15, Appl
100	20	1.3	20	1	US-10-484-441-16	Sequence 16, Appl
101	20	1.3	20	1	US-10-484-441-17	Sequence 17, Appl
102	20	1.3	20	1	US-10-484-441-18	Sequence 18, Appl
103	20	1.3	20	1	US-10-484-441-19	Sequence 19, Appl
104	20	1.3	20	1	US-10-484-441-20	Sequence 20, Appl
105	20	1.3	20	1	US-10-484-441-21	Sequence 21, Appl
106	20	1.3	20	1	US-10-484-441-22	Sequence 22, Appl

C 253	17.4	1.1	19	1	US-10-714-333A-763971	Sequence 763971,	326	16.2	1.0	21	1	PCT-US04-00035-9047	Sequence 9047, Ap
C 254	17.4	1.1	19	1	US-10-714-333A-950089	Sequence 950089,	327	16.2	1.0	21	1	PCT-US04-00035-9047	Sequence 95040, A
C 255	17.4	1.1	19	1	US-10-714-333A-1245563	Sequence 1245563,	328	16.2	1.0	21	1	US-10-287-820-1589	Sequence 1589, Ap
C 256	17.4	1.1	19	1	US-10-714-333A-1336210	Sequence 1336210,	329	16.2	1.0	21	1	US-10-751-736-8626	Sequence 8626, Ap
C 257	17	1.1	17	1	US-09-531-022A-846	Sequence 846, App	330	16.2	1.0	21	1	US-10-751-736-9047	Sequence 9047, Ap
C 258	17	1.1	17	1	US-09-636-385-846	Sequence 846, App	331	16.2	1.0	21	1	US-10-751-736-39540	Sequence 39540, A
C 259	17	1.1	17	1	US-09-696-347-846	Sequence 846, App	332	16.2	1.0	21	1	US-10-770-726-7037	Sequence 7037, Ap
C 260	17	1.1	17	1	US-09-877-478-846	Sequence 846, App	333	16.2	1.0	21	1	US-10-770-726-12530	Sequence 12530, A
C 261	17	1.1	17	1	US-10-342-902-846	Sequence 846, App	334	16.2	1.0	21	1	US-10-770-726-22694	Sequence 22694, A
C 262	17	1.1	17	1	US-10-669-841-846	Sequence 846, App	335	16.2	1.0	21	1	US-10-770-726-40565	Sequence 40565, A
C 263	16.8	1.1	20	1	PCT-US02-22746-46	Sequence 46, App	336	16.2	1.0	21	1	US-10-831-997-700	Sequence 700, App
C 264	16.8	1.1	20	1	PCT-US02-22746-47	Sequence 47, App	337	16.2	1.0	21	1	US-10-850-928-37	Sequence 37, Appl
C 265	16.8	1.1	20	1	PCT-US02-22746-53	Sequence 53, Appl	338	16	1.0	17	1	US-09-531-025A-144	Sequence 144, App
C 266	16.8	1.1	20	1	PCT-US02-22746-55	Sequence 55, Appl	339	16	1.0	17	1	US-09-636-385-144	Sequence 144, App
C 267	16.8	1.1	20	1	PCT-US02-22746-61	Sequence 61, Appl	340	16	1.0	17	1	US-09-696-347-144	Sequence 144, App
C 268	16.8	1.1	20	1	PCT-US02-22746-64	Sequence 64, Appl	341	16	1.0	17	1	US-09-877-478-144	Sequence 144, App
C 269	16.8	1.1	20	1	PCT-US03-04945-11	Sequence 11, Appl	342	16	1.0	17	1	US-10-342-902-144	Sequence 144, App
C 270	16.8	1.1	20	1	US-09-201-228A-2683	Sequence 2683, Ap	343	16	1.0	17	1	US-10-669-841-144	Sequence 144, App
C 271	16.8	1.1	20	1	US-09-703-708-18206	Sequence 18206, A	344	16	1.0	17	1	US-10-714-333A-253299	Sequence 253299,
C 272	16.8	1.1	20	1	US-09-918-026A-46	Sequence 46, Appl	345	16	1.0	19	1	US-10-714-333A-814227	Sequence 814227,
C 273	16.8	1.1	20	1	US-09-918-026A-47	Sequence 47, Appl	346	16	1.0	20	1	PCT-US04-04452-1067	Sequence 1067, Ap
C 274	16.8	1.1	20	1	US-09-918-026A-53	Sequence 53, Appl	347	16	1.0	20	1	PCT-US04-04452-1068	Sequence 1068, Ap
C 275	16.8	1.1	20	1	US-09-918-026A-55	Sequence 55, Appl	348	15.8	1.0	19	1	PCT-US03-03473-198	Sequence 198, App
C 276	16.8	1.1	20	1	US-09-918-026A-61	Sequence 61, Appl	349	15.8	1.0	19	1	PCT-US03-03473-509	Sequence 509, App
C 277	16.8	1.1	20	1	US-09-918-026A-64	Sequence 64, Appl	350	15.8	1.0	19	1	US-10-714-333A-29001	Sequence 29001, A
C 278	16.8	1.1	20	1	US-10-310-188-50018	Sequence 50018, A	351	15.8	1.0	19	1	US-10-714-333A-29083	Sequence 29083, A
C 279	16.8	1.1	20	1	US-10-368-803-11	Sequence 11, Appl	352	15.8	1.0	19	1	US-10-714-333A-29157	Sequence 29157, A
C 280	16.8	1.1	20	1	US-10-484-441-46	Sequence 46, Appl	353	15.8	1.0	19	1	US-10-714-333A-63628	Sequence 63628, A
C 281	16.8	1.1	20	1	US-10-484-441-47	Sequence 47, Appl	354	15.8	1.0	19	1	US-10-714-333A-63629	Sequence 63629, A
C 282	16.8	1.1	20	1	US-10-484-441-53	Sequence 53, Appl	355	15.8	1.0	19	1	US-10-714-333A-99008	Sequence 99008, A
C 283	16.8	1.1	20	1	US-10-484-441-55	Sequence 55, Appl	356	15.8	1.0	19	1	US-10-714-333A-12482	Sequence 12482,
C 284	16.8	1.1	20	1	US-10-484-441-61	Sequence 61, Appl	357	15.8	1.0	19	1	US-10-714-333A-143055	Sequence 143055,
C 285	16.8	1.1	20	1	US-10-484-441-64	Sequence 64, Appl	358	15.8	1.0	19	1	US-10-714-333A-143239	Sequence 143239,
C 286	16.8	1.1	20	1	US-10-486-090-4	Sequence 4, Appl	359	15.8	1.0	19	1	US-10-714-333A-147470	Sequence 147470,
C 287	16.8	1.1	20	1	US-60-164-320-18206	Sequence 18206, A	360	15.8	1.0	19	1	US-10-714-333A-150408	Sequence 150408,
C 288	16.8	1.1	20	1	US-60-183-791-18206	Sequence 18206, A	361	15.8	1.0	19	1	US-10-714-333A-182227	Sequence 182227,
C 289	16.8	1.1	21	1	PCT-US04-00035-8627	Sequence 8627, Ap	362	15.8	1.0	19	1	US-10-714-333A-265610	Sequence 265610,
C 290	16.8	1.1	21	1	US-10-310-188-78605	Sequence 78605, A	363	15.8	1.0	19	1	US-10-714-333A-372190	Sequence 372190,
C 291	16.8	1.1	21	1	US-10-751-736-8627	Sequence 8627, Ap	364	15.8	1.0	19	1	US-10-714-333A-375661	Sequence 375661,
C 292	16.4	1.0	18	1	US-10-303-778-1826	Sequence 1826, Ap	365	15.8	1.0	19	1	US-10-714-333A-375742	Sequence 375742,
C 293	16.4	1.0	18	1	US-10-310-188-2618	Sequence 2618, Ap	366	15.8	1.0	19	1	US-10-714-333A-391694	Sequence 391694,
C 294	16.4	1.0	19	1	PCT-US03-05045-33	Sequence 33, Appl	367	15.8	1.0	19	1	US-10-714-333A-393089	Sequence 393089,
C 295	16.4	1.0	19	1	PCT-US03-05045-282	Sequence 282, App	368	15.8	1.0	19	1	US-10-714-333A-396174	Sequence 396174,
C 296	16.4	1.0	19	1	PCT-US03-05045A-33	Sequence 33, Appl	369	15.8	1.0	19	1	US-10-714-333A-425463	Sequence 425463,
C 297	16.4	1.0	19	1	PCT-US03-05045A-282	Sequence 282, App	370	15.8	1.0	19	1	US-10-714-333A-433550	Sequence 433550,
C 298	16.4	1.0	19	1	US-10-251-117-33	Sequence 33, Appl	371	15.8	1.0	19	1	US-10-714-333A-486813	Sequence 486813,
C 299	16.4	1.0	19	1	US-10-251-117-282	Sequence 282, App	372	15.8	1.0	19	1	US-10-714-333A-496998	Sequence 496998,
C 300	16.4	1.0	19	1	US-10-714-333A-242202	Sequence 242202,	373	15.8	1.0	19	1	US-10-714-333A-508050	Sequence 508050,
C 301	16.4	1.0	19	1	US-10-714-333A-444807	Sequence 444807,	374	15.8	1.0	19	1	US-10-714-333A-520328	Sequence 520328,
C 302	16.4	1.0	19	1	US-10-714-333A-588275	Sequence 588275,	375	15.8	1.0	19	1	US-10-714-333A-613102	Sequence 613102,
C 303	16.4	1.0	19	1	US-10-714-333A-624592	Sequence 624592,	376	15.8	1.0	19	1	US-10-714-333A-624778	Sequence 624778,
C 304	16.4	1.0	19	1	US-10-714-333A-666149	Sequence 666149,	377	15.8	1.0	19	1	US-10-714-333A-675642	Sequence 675642,
C 305	16.4	1.0	19	1	US-10-714-333A-950074	Sequence 950074,	378	15.8	1.0	19	1	US-10-714-333A-713692	Sequence 713692,
C 306	16.4	1.0	19	1	US-10-714-333A-110583	Sequence 110583,	379	15.8	1.0	19	1	US-10-714-333A-744522	Sequence 744522,
C 307	16.4	1.0	19	1	US-10-714-333A-1245589	Sequence 1245589,	380	15.8	1.0	19	1	US-10-714-333A-751835	Sequence 751835,
C 308	16.4	1.0	19	1	US-10-714-333A-1245608	Sequence 1245608,	381	15.8	1.0	19	1	US-10-714-333A-759661	Sequence 759661,
C 309	16.4	1.0	19	1	US-10-714-333A-1336213	Sequence 1336213,	382	15.8	1.0	19	1	US-10-714-333A-766215	Sequence 766215,
C 310	16.4	1.0	19	1	US-10-714-333A-1353443	Sequence 1353443,	383	15.8	1.0	19	1	US-10-714-333A-787901	Sequence 787901,
C 311	16.4	1.0	19	1	US-10-714-333A-1493677	Sequence 1493677,	384	15.8	1.0	19	1	US-10-714-333A-794260	Sequence 794260,
C 312	16.4	1.0	19	1	US-10-714-333A-1499330	Sequence 1499330,	385	15.8	1.0	19	1	US-10-714-333A-799168	Sequence 799168,
C 313	16.4	1.0	19	1	US-10-714-333A-1499720	Sequence 1499720,	386	15.8	1.0	19	1	US-10-714-333A-804931	Sequence 804931,
C 314	16.4	1.0	20	1	US-09-703-708-12513	Sequence 12513, A	387	15.8	1.0	19	1	US-10-714-333A-814427	Sequence 814427,
C 315	16.4	1.0	20	1	US-09-703-708-12587	Sequence 12587, A	388	15.8	1.0	19	1	US-10-714-333A-828864	Sequence 828864,
C 316	16.4	1.0	20	1	US-09-703-708-16154	Sequence 16154, A	389	15.8	1.0	19	1	US-10-714-333A-841815	Sequence 841815,
C 317	16.4	1.0	20	1	US-10-349-143-11729	Sequence 11729, A	390	15.8	1.0	19	1	US-10-714-333A-842553	Sequence 842553,
C 318	16.4	1.0	20	1	US-60-082-614-2283	Sequence 2283, Ap	391	15.8	1.0	19	1	US-10-714-333A-895382	Sequence 895382,
C 319	16.4	1.0	20	1	US-60-164-320-12513	Sequence 12513, A	392	15.8	1.0	19	1	US-10-714-333A-900276	Sequence 900276,
C 320	16.4	1.0	20	1	US-60-164-320-12587	Sequence 12587, A	393	15.8	1.0	19	1	US-10-714-333A-900364	Sequence 900364,
C 321	16.4	1.0	20	1	US-60-164-320-16154	Sequence 16154, A	394	15.8	1.0	19	1	US-10-714-333A-911300	Sequence 911300,
C 322	16.4	1.0	20	1	US-60-183-791-12513	Sequence 12513, A	395	15.8	1.0	19	1	US-10-714-333A-986535	Sequence 986535,
C 323	16.4	1.0	20	1	US-60-183-791-12587	Sequence 12587, A	396	15.8	1.0	19	1	US-10-714-333A-1008230	Sequence 1008230,
C 324	16.4	1.0	20	1	US-60-183-791-16154	Sequence 16154, A	397	15.8	1.0	19	1	US-10-714-333A-1010596	Sequence 1010596,
C 325	16.2	1.0	21	1	PCT-US04-00035-8626	Sequence 8626, Ap	398	15.8	1.0	19	1	US-10-714-333A-1051939	Sequence 1051939,

c 399	15.8	1.0	19	1	US-10-714-333A-1086368	Sequence 1086368,	c 472	15.4	1.0	17	1	US-09-870-161-1579	Sequence 1579, Ap
c 400	15.8	1.0	19	1	US-10-714-333A-1119042	Sequence 1119042,	c 473	15.4	1.0	17	1	US-09-870-161-6203	Sequence 6203, Ap
c 401	15.8	1.0	19	1	US-10-714-333A-1119105	Sequence 1119105,	c 474	15.4	1.0	17	1	US-09-870-161-8446	Sequence 8446, Ap
c 402	15.8	1.0	19	1	US-10-714-333A-1150262	Sequence 1150262,	c 475	15.4	1.0	17	1	US-10-138-674-1579	Sequence 1579, Ap
c 403	15.8	1.0	19	1	US-10-714-333A-1160483	Sequence 1160483,	c 476	15.4	1.0	17	1	US-10-138-674-6203	Sequence 6203, Ap
c 404	15.8	1.0	19	1	US-10-714-333A-1160589	Sequence 1160589,	c 477	15.4	1.0	17	1	US-10-138-674-8446	Sequence 8446, Ap
c 405	15.8	1.0	19	1	US-10-714-333A-1160688	Sequence 1160688,	c 478	15.4	1.0	17	1	US-10-138-674A-1579	Sequence 1579, Ap
c 406	15.8	1.0	19	1	US-10-714-333A-1160787	Sequence 1160787,	c 479	15.4	1.0	17	1	US-10-138-674A-6203	Sequence 6203, Ap
c 407	15.8	1.0	19	1	US-10-714-333A-1209330	Sequence 1209330,	c 480	15.4	1.0	17	1	US-10-138-674A-8446	Sequence 8446, Ap
c 408	15.8	1.0	19	1	US-10-714-333A-1274666	Sequence 1274666,	c 481	15.4	1.0	17	1	US-10-138-674B-6203	Sequence 6203, Ap
c 409	15.8	1.0	19	1	US-10-714-333A-1285653	Sequence 1285653,	c 482	15.4	1.0	17	1	US-10-138-674B-8446	Sequence 8446, Ap
c 410	15.8	1.0	19	1	US-10-714-333A-1289597	Sequence 1289597,	c 483	15.4	1.0	17	1	US-10-163-552-134	Sequence 134, App
c 411	15.8	1.0	19	1	US-10-714-333A-1320738	Sequence 1320738,	c 484	15.4	1.0	17	1	US-10-287-949A-1579	Sequence 1579, Ap
c 412	15.8	1.0	19	1	US-10-714-333A-1320738	Sequence 1320738,	c 485	15.4	1.0	17	1	US-10-287-949A-6203	Sequence 6203, Ap
c 413	15.8	1.0	19	1	US-10-714-333A-1334204	Sequence 1334204,	c 486	15.4	1.0	17	1	US-10-287-949A-8446	Sequence 8446, Ap
c 414	15.8	1.0	19	1	US-10-714-333A-1353268	Sequence 1353268,	c 487	15.4	1.0	17	1	US-10-287-949A-8446	Sequence 8446, Ap
c 415	15.8	1.0	19	1	US-10-714-333A-1363311	Sequence 1363311,	c 488	15.4	1.0	17	1	US-10-712-633-3487	Sequence 3487, Ap
c 416	15.8	1.0	19	1	US-10-714-333A-1452775	Sequence 1452775,	c 489	15.4	1.0	17	1	US-10-712-633-3487	Sequence 3487, Ap
c 417	15.8	1.0	19	1	US-10-714-333A-1500378	Sequence 1500378,	c 490	15.4	1.0	17	1	US-10-712-633-3487	Sequence 3487, Ap
c 418	15.8	1.0	19	1	US-10-714-333A-1514938	Sequence 1514938,	c 491	15.4	1.0	17	1	US-10-723-361-6626	Sequence 6626, Ap
c 419	15.8	1.0	19	1	US-10-714-333A-1515093	Sequence 1515093,	c 492	15.4	1.0	17	1	US-10-723-361-6626	Sequence 6626, Ap
c 420	15.8	1.0	19	1	US-10-714-333A-1533573	Sequence 1533573,	c 493	15.4	1.0	17	1	US-10-723-361-6626	Sequence 6626, Ap
c 421	15.8	1.0	20	1	PCT-US98-07386-100	Sequence 100, App	c 494	15.4	1.0	17	1	US-10-724-270-4789	Sequence 4789, Ap
c 422	15.8	1.0	20	1	PCT-US02-22746-56	Sequence 56, Appl	c 495	15.4	1.0	18	1	US-10-310-188-30951	Sequence 30951, A
c 423	15.8	1.0	20	1	PCT-US02-28729-28	Sequence 28, Appl	c 496	15.4	1.0	18	1	US-10-310-188-83364	Sequence 83364, A
c 424	15.8	1.0	20	1	PCT-US03-32713-49	Sequence 49, Appl	c 497	15.4	1.0	19	1	US-09-291-838-21	Sequence 21, Appl
c 425	15.8	1.0	20	1	US-08-786-984-9	Sequence 9, Appl	c 498	15.4	1.0	19	1	US-10-310-188-64492	Sequence 64492, A
c 426	15.8	1.0	20	1	US-08-837-201A-100	Sequence 100, App	c 499	15.4	1.0	19	1	US-10-310-188-64684	Sequence 64684, A
c 427	15.8	1.0	20	1	US-08-837-201B-100	Sequence 100, App	c 500	15.4	1.0	19	1	US-10-310-188-64684	Sequence 64684, A
c 428	15.8	1.0	20	1	US-09-157-068-10	Sequence 10, Appl	c 501	15.4	1.0	19	1	US-10-714-333A-28984	Sequence 28984, A
c 429	15.8	1.0	20	1	US-09-245-293-10	Sequence 10, Appl	c 502	15.4	1.0	19	1	US-10-714-333A-29003	Sequence 29003, A
c 430	15.8	1.0	20	1	US-09-918-026A-56	Sequence 56, Appl	c 503	15.4	1.0	19	1	US-10-714-333A-29063	Sequence 29063, A
c 431	15.8	1.0	20	1	US-09-923-517-100	Sequence 100, App	c 504	15.4	1.0	19	1	US-10-714-333A-29070	Sequence 29070, A
c 432	15.8	1.0	20	1	US-09-923-517A-100	Sequence 100, App	c 505	15.4	1.0	19	1	US-10-714-333A-29085	Sequence 29085, A
c 433	15.8	1.0	20	1	US-09-954-679-28	Sequence 28, Appl	c 506	15.4	1.0	19	1	US-10-714-333A-29138	Sequence 29138, A
c 434	15.8	1.0	20	1	US-10-187-659A-45	Sequence 45, Appl	c 507	15.4	1.0	19	1	US-10-714-333A-29144	Sequence 29144, A
c 435	15.8	1.0	20	1	US-10-187-659A-110	Sequence 110, App	c 508	15.4	1.0	19	1	US-10-714-333A-29210	Sequence 29210, A
c 436	15.8	1.0	20	1	US-10-266-090-43749	Sequence 43749, A	c 509	15.4	1.0	19	1	US-10-714-333A-67733	Sequence 67733, A
c 437	15.8	1.0	20	1	US-10-266-090-43958	Sequence 43958, A	c 510	15.4	1.0	19	1	US-10-714-333A-67833	Sequence 67833, A
c 438	15.8	1.0	20	1	US-10-266-090-44137	Sequence 44137, A	c 511	15.4	1.0	19	1	US-10-714-333A-67933	Sequence 67933, A
c 439	15.8	1.0	20	1	US-10-272-810-49	Sequence 49, Appl	c 512	15.4	1.0	19	1	US-10-714-333A-68033	Sequence 68033, A
c 440	15.8	1.0	20	1	US-10-273-070-49	Sequence 49, Appl	c 513	15.4	1.0	19	1	US-10-714-333A-68133	Sequence 68133, A
c 441	15.8	1.0	20	1	US-10-303-778-8812	Sequence 8812, Ap	c 514	15.4	1.0	19	1	US-10-714-333A-68233	Sequence 68233, A
c 442	15.8	1.0	20	1	US-10-430-196-100	Sequence 100, App	c 515	15.4	1.0	19	1	US-10-714-333A-81388	Sequence 81388, A
c 443	15.8	1.0	21	1	US-10-484-441-56	Sequence 56, Appl	c 516	15.4	1.0	19	1	US-10-714-333A-157693	Sequence 157693, A
c 444	15.8	1.0	21	1	PCT-US04-00035-9046	Sequence 9046, Ap	c 517	15.4	1.0	19	1	US-10-714-333A-163815	Sequence 163815, A
c 445	15.8	1.0	21	1	PCT-US04-00035-50130	Sequence 50130, A	c 518	15.4	1.0	19	1	US-10-714-333A-182262	Sequence 182262, A
c 446	15.8	1.0	21	1	PCT-US04-00035-50133	Sequence 50133, A	c 519	15.4	1.0	19	1	US-10-714-333A-190474	Sequence 190474, A
c 447	15.8	1.0	21	1	US-08-965-620-242	Sequence 242, App	c 520	15.4	1.0	19	1	US-10-714-333A-266592	Sequence 266592, A
c 448	15.8	1.0	21	1	US-09-754-468-96	Sequence 96, Appl	c 521	15.4	1.0	19	1	US-10-714-333A-266667	Sequence 266667, A
c 449	15.8	1.0	21	1	US-09-786-926B-8	Sequence 8, Appl	c 522	15.4	1.0	19	1	US-10-714-333A-266688	Sequence 266688, A
c 450	15.8	1.0	21	1	US-10-184-085A-1032	Sequence 1032, Ap	c 523	15.4	1.0	19	1	US-10-714-333A-266761	Sequence 266761, A
c 451	15.8	1.0	21	1	US-10-184-085A-1069	Sequence 1069, Ap	c 524	15.4	1.0	19	1	US-10-714-333A-284094	Sequence 284094, A
c 452	15.8	1.0	21	1	US-10-310-188-60936	Sequence 60936, A	c 525	15.4	1.0	19	1	US-10-714-333A-287934	Sequence 287934, A
c 453	15.8	1.0	21	1	US-10-739-904-29	Sequence 29, Appl	c 526	15.4	1.0	19	1	US-10-714-333A-465235	Sequence 465235, A
c 454	15.8	1.0	21	1	US-10-751-736-9046	Sequence 9046, Ap	c 527	15.4	1.0	19	1	US-10-714-333A-465335	Sequence 465335, A
c 455	15.8	1.0	21	1	US-10-751-736-50130	Sequence 50130, A	c 528	15.4	1.0	19	1	US-10-714-333A-468955	Sequence 468955, A
c 456	15.8	1.0	21	1	US-10-751-736-50133	Sequence 50133, A	c 529	15.4	1.0	19	1	US-10-714-333A-468974	Sequence 468974, A
c 457	15.8	1.0	21	1	US-10-770-726-5072	Sequence 5072, Ap	c 530	15.4	1.0	19	1	US-10-714-333A-474898	Sequence 474898, A
c 458	15.8	1.0	21	1	US-10-770-726-11585	Sequence 11585, A	c 531	15.4	1.0	19	1	US-10-714-333A-474945	Sequence 474945, A
c 459	15.8	1.0	21	1	US-10-770-726-40526	Sequence 40526, A	c 532	15.4	1.0	19	1	US-10-714-333A-474959	Sequence 474959, A
c 460	15.8	1.0	21	1	US-10-861-108-16	Sequence 16, Appl	c 533	15.4	1.0	19	1	US-10-714-333A-560766	Sequence 560766, A
c 461	15.8	1.0	17	1	US-10-897-648-8	Sequence 8, Appl	c 534	15.4	1.0	19	1	US-10-714-333A-581586	Sequence 581586, A
c 462	15.4	1.0	17	1	PCT-US02-16840-4789	Sequence 4789, Ap	c 535	15.4	1.0	19	1	US-10-714-333A-606457	Sequence 606457, A
c 463	15.4	1.0	17	1	PCT-US02-16840A-4789	Sequence 4789, Ap	c 536	15.4	1.0	19	1	US-10-714-333A-606557	Sequence 606557, A
c 464	15.4	1.0	17	1	PCT-US02-17674-3487	Sequence 3487, Ap	c 537	15.4	1.0	19	1	US-10-714-333A-606657	Sequence 606657, A
c 465	15.4	1.0	17	1	US-09-532-537B-378	Sequence 378, App	c 538	15.4	1.0	19	1	US-10-714-333A-624598	Sequence 624598, A
c 466	15.4	1.0	17	1	US-09-532-537B-676	Sequence 676, App	c 539	15.4	1.0	19	1	US-10-714-333A-651411	Sequence 651411, A
c 467	15.4	1.0	17	1	US-09-532-537B-2233	Sequence 2233, Ap	c 540	15.4	1.0	19	1	US-10-714-333A-651460	Sequence 651460, A
c 468	15.4	1.0	17	1	US-09-685-664B-1579	Sequence 1579, Ap	c 541	15.4	1.0	19	1	US-10-714-333A-940279	Sequence 940279, A
c 469	15.4	1.0	17	1	US-09-708-690-1579	Sequence 1579, Ap	c 542	15.4	1.0	19	1	US-10-714-333A-978865	Sequence 978865, A
c 470	15.4	1.0	17	1	US-09-708-690-6203	Sequence 6203, Ap	c 543	15.4	1.0	19	1	US-10-714-333A-1017411	Sequence 1017411, A
c 471	15.4	1.0	17	1	US-09-708-690-8446	Sequence 8446, Ap	c 544	15.4	1.0	19	1	US-10-714-333A-1017411	Sequence 1017411, A
					Sequence 349, App							US-10-714-333A-1147332	Sequence 1147332, A

545	15.4	1.0	19	1	US-10-714-333A-1188581	Sequence 1188581,	618	15.2	1.0	20	1	US-10-293-338-14153	Sequence 4193, Ap
546	15.4	1.0	19	1	US-10-714-333A-1218998	Sequence 1218998,	c 619	15.2	1.0	20	1	US-10-293-778-22	Sequence 22, Appl
547	15.4	1.0	19	1	US-10-714-333A-1274878	Sequence 1274878,	c 620	15.2	1.0	20	1	US-10-303-783-5528	Sequence 5528, Ap
548	15.4	1.0	19	1	US-10-714-333A-1274909	Sequence 1274909,	c 621	15.2	1.0	20	1	US-10-310-188-10900	Sequence 10900, A
549	15.4	1.0	19	1	US-10-714-333A-1345571	Sequence 1345571,	c 622	15.2	1.0	20	1	US-10-310-188-26108	Sequence 26108, A
550	15.4	1.0	19	1	US-10-714-333A-1353450	Sequence 1353450,	c 623	15.2	1.0	20	1	US-10-310-188-40229	Sequence 40229, A
551	15.4	1.0	19	1	US-10-714-333A-1365530	Sequence 1365530,	c 624	15.2	1.0	20	1	US-10-310-188-60181	Sequence 60181, A
552	15.4	1.0	19	1	US-10-714-333A-1366443	Sequence 1436443,	c 625	15.2	1.0	20	1	US-10-314-578-448	Sequence 448, App
553	15.4	1.0	19	1	US-10-714-333A-1473441	Sequence 1473441,	c 626	15.2	1.0	20	1	US-10-367-832A-13308	Sequence 13308, A
554	15.4	1.0	19	1	US-10-714-333A-1499396	Sequence 1499396,	c 627	15.2	1.0	20	1	US-10-384-933-94	Sequence 94, Appl
555	15.4	1.0	19	1	PCT-US02-22746-43	Sequence 1552767,	c 628	15.2	1.0	20	1	US-10-384-933-98	Sequence 98, Appl
556	15.4	1.0	20	1	PCT-US02-34143-17	Sequence 17, Appl	c 629	15.2	1.0	20	1	US-10-388-263-670	Sequence 670, App
557	15.4	1.0	20	1	PCT-US03-39423-89	Sequence 89, Appl	c 630	15.2	1.0	20	1	US-10-484-441-51	Sequence 51, Appl
558	15.4	1.0	20	1	PCT-US04-04452-1653	Sequence 1653, Ap	c 631	15.2	1.0	20	1	US-10-648-512-84	Sequence 84, Appl
559	15.4	1.0	20	1	US-08-196-030C-68	Sequence 68, Appl	c 632	15.2	1.0	20	1	US-10-670-984-119	Sequence 119, App
560	15.4	1.0	20	1	US-08-242-654A-68	Sequence 68, Appl	c 633	15.2	1.0	20	1	US-10-671-395-454	Sequence 454, App
561	15.4	1.0	20	1	US-08-486-749-99	Sequence 99, Appl	c 634	15.2	1.0	20	1	US-10-690-276-175	Sequence 175, App
562	15.4	1.0	20	1	US-08-488-445A-99	Sequence 99, Appl	c 635	15.2	1.0	20	1	US-10-719-370A-219	Sequence 219, App
563	15.4	1.0	20	1	US-09-092-330-24	Sequence 24, Appl	c 636	15.2	1.0	20	1	US-10-719-370A-337	Sequence 337, App
564	15.4	1.0	20	1	US-09-703-708-16738	Sequence 16738, A	c 637	15.2	1.0	20	1	US-10-831-778-448	Sequence 448, App
565	15.4	1.0	20	1	US-09-918-026A-43	Sequence 43, Appl	c 638	15.2	1.0	20	1	US-10-831-901A-29355	Sequence 29355, A
566	15.4	1.0	20	1	US-10-310-188-25216	Sequence 25216, A	c 639	15.2	1.0	20	1	US-10-849-438-43	Sequence 43, Appl
567	15.4	1.0	20	1	US-10-317-500-89	Sequence 89, Appl	c 640	15.2	1.0	20	1	US-10-884-866-448	Sequence 448, App
568	15.4	1.0	20	1	US-10-325-899-9922	Sequence 9922, Ap	c 641	15.2	1.0	20	1	US-10-888-803-448	Sequence 448, App
569	15.4	1.0	20	1	US-10-484-441-43	Sequence 43, Appl	c 642	15.2	1.0	20	1	US-60-164-320-15885	Sequence 15885, A
570	15.4	1.0	20	1	US-10-740-773-9	Sequence 9, Appl	c 643	15.2	1.0	20	1	US-60-183-791-15885	Sequence 15885, A
571	15.4	1.0	20	1	US-60-164-320-16738	Sequence 37, Appl	c 644	15	1.0	15	1	PCT-US02-22746-5	Sequence 5, Appl
572	15.4	1.0	20	1	US-60-183-791-16738	Sequence 16738, A	c 645	15	1.0	15	1	PCT-US02-25943-36411	Sequence 36411, A
573	15.4	1.0	20	1	PCT-US01-01416A-109	Sequence 109, App	c 646	15	1.0	15	1	US-09-918-026A-5	Sequence 5, Appl
574	15.2	1.0	20	1	PCT-US01-27310-22	Sequence 22, Appl	c 647	15	1.0	15	1	US-10-227-565-36411	Sequence 36411, A
575	15.2	1.0	20	1	PCT-US01-50914-142	Sequence 142, App	c 648	15	1.0	15	1	US-10-287-787-8739	Sequence 8739, Ap
576	15.2	1.0	20	1	PCT-US02-22746-51	Sequence 51, Appl	c 649	15	1.0	15	1	US-10-287-787-17784	Sequence 17784, A
577	15.2	1.0	20	1	PCT-US02-25943-13308	Sequence 13308, A	c 650	15	1.0	15	1	US-10-367-832A-36411	Sequence 36411, A
578	15.2	1.0	20	1	PCT-US03-30374-454	Sequence 454, App	c 651	15	1.0	15	1	US-10-484-441-5	Sequence 5, Appl
579	15.2	1.0	20	1	PCT-US03-30378-219	Sequence 219, App	c 652	15	1.0	16	1	PCT-US02-25943-36410	Sequence 36410, A
580	15.2	1.0	20	1	PCT-US03-37383-337	Sequence 337, App	c 653	15	1.0	16	1	US-10-227-565-36410	Sequence 36410, A
581	15.2	1.0	20	1	PCT-US04-04452-810	Sequence 810, App	c 654	15	1.0	16	1	US-10-310-188-49189	Sequence 49189, A
582	15.2	1.0	20	1	PCT-US04-06133-11	Sequence 11, Appl	c 655	15	1.0	16	1	US-10-367-832A-36410	Sequence 36410, A
583	15.2	1.0	20	1	US-09-053-583-94	Sequence 94, Appl	c 656	15	1.0	17	1	US-09-531-025A-845	Sequence 845, App
584	15.2	1.0	20	1	US-09-053-583-94	Sequence 94, Appl	c 657	15	1.0	17	1	US-09-531-025A-2047	Sequence 2047, Ap
585	15.2	1.0	20	1	US-09-408-646-94	Sequence 94, Appl	c 658	15	1.0	17	1	US-09-636-385-845	Sequence 845, App
586	15.2	1.0	20	1	US-09-408-646-94	Sequence 94, Appl	c 659	15	1.0	17	1	US-09-636-385-2047	Sequence 2047, Ap
587	15.2	1.0	20	1	US-09-499-662-94	Sequence 94, Appl	c 660	15	1.0	17	1	US-09-696-347-845	Sequence 845, App
588	15.2	1.0	20	1	US-09-499-662-94	Sequence 94, Appl	c 661	15	1.0	17	1	US-09-696-347-2047	Sequence 2047, Ap
589	15.2	1.0	20	1	US-09-514-000-13143	Sequence 13143, A	c 662	15	1.0	17	1	US-09-848-754A-144	Sequence 144, App
590	15.2	1.0	20	1	US-09-514-000-13384	Sequence 13384, A	c 663	15	1.0	17	1	US-09-848-754A-1112	Sequence 1112, Ap
591	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 664	15	1.0	17	1	US-09-848-754A-1113	Sequence 1113, Ap
592	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 665	15	1.0	17	1	US-09-877-478-845	Sequence 845, App
593	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 666	15	1.0	17	1	US-09-877-478-2244	Sequence 2244, Ap
594	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 667	15	1.0	17	1	US-10-342-902-845	Sequence 845, App
595	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 668	15	1.0	17	1	US-10-342-902-845	Sequence 2244, Ap
596	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 669	15	1.0	17	1	US-10-669-841-845	Sequence 845, App
597	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 670	15	1.0	17	1	US-10-669-841-2047	Sequence 2047, Ap
598	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 671	15	1.0	17	1	US-60-330-323-167	Sequence 167, App
599	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 672	15	1.0	17	1	US-60-330-323-168	Sequence 168, App
600	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 673	15	1.0	17	1	US-60-330-323-169	Sequence 169, App
601	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 674	15	1.0	18	1	US-10-310-188-71964	Sequence 71964, A
602	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 675	15	1.0	19	1	US-10-310-188-71964	Sequence 15688, A
603	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 676	15	1.0	19	1	US-10-714-333A-15788	Sequence 15788, A
604	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 677	15	1.0	19	1	US-10-714-333A-62937	Sequence 62937, A
605	15.2	1.0	20	1	US-09-514-000-13937	Sequence 13937, A	c 678	15	1.0	19	1	US-10-714-333A-89683	Sequence 89683, A
606	15.2	1.0	20	1	US-10-112-653-428	Sequence 428, App	c 679	15	1.0	19	1	US-10-714-333A-140460	Sequence 140460,
607	15.2	1.0	20	1	US-10-181-846-109	Sequence 109, App	c 680	15	1.0	19	1	US-10-714-333A-172875	Sequence 172875,
608	15.2	1.0	20	1	US-10-216-484-94	Sequence 94, Appl	c 681	15	1.0	19	1	US-10-714-333A-246623	Sequence 246623,
609	15.2	1.0	20	1	US-10-216-484-94	Sequence 94, Appl	c 682	15	1.0	19	1	US-10-714-333A-372173	Sequence 372173,
610	15.2	1.0	20	1	US-10-227-565-13308	Sequence 13308, A	c 683	15	1.0	19	1	US-10-714-333A-616176	Sequence 616176,
611	15.2	1.0	20	1	US-10-266-090-39771	Sequence 39771, A	c 684	15	1.0	19	1	US-10-714-333A-616247	Sequence 616247,
612	15.2	1.0	20	1	US-10-266-090-41589	Sequence 41589, A	c 685	15	1.0	19	1	US-10-714-333A-616270	Sequence 616270,
613	15.2	1.0	20	1	US-10-266-090-42307	Sequence 42307, A	c 686	15	1.0	19	1	US-10-714-333A-616337	Sequence 616337,
614	15.2	1.0	20	1	US-10-266-090-42307	Sequence 42307, A	c 687	15	1.0	19	1	US-10-714-333A-730619	Sequence 730619,
615	15.2	1.0	20	1	US-10-266-090-45481	Sequence 45481, A	c 688	15	1.0	19	1	US-10-714-333A-1058176	Sequence 1058176,
616	15.2	1.0	20	1	US-10-289-762-4685	Sequence 4685, Ap	c 689	15	1.0	19	1	US-10-714-333A-1338802	Sequence 1338802,
617	15.2	1.0	20	1	US-10-289-762-4685	Sequence 4685, Ap	c 690	15	1.0	19	1	US-10-714-333A-1415480	Sequence 1415480,

691	15	1.0	19	1	US-10-714-333A-1507089	Sequence 1507089,	c 764	14.8	0.9	19	1	US-10-714-333A-215711	Sequence 215711,
692	15	1.0	20	1	PCT-US01-00109-171	Sequence 174, App	c 765	14.8	0.9	19	1	US-10-714-333A-239980	Sequence 239980,
693	15	1.0	20	1	PCT-US01-30551-171	Sequence 171, App	c 766	14.8	0.9	19	1	US-10-714-333A-256403	Sequence 256403,
694	15	1.0	20	1	PCT-US02-15301-174	Sequence 174, App	c 767	14.8	0.9	19	1	US-10-714-333A-265654	Sequence 265654,
695	15	1.0	20	1	PCT-US04-02003-174	Sequence 174, App	c 768	14.8	0.9	19	1	US-10-714-333A-269745	Sequence 269745,
696	15	1.0	20	1	US-09-854-883-174	Sequence 174, App	c 769	14.8	0.9	19	1	US-10-714-333A-283836	Sequence 283836,
697	15	1.0	20	1	US-10-360-510-174	Sequence 174, App	c 770	14.8	0.9	19	1	US-10-714-333A-283942	Sequence 283942,
698	15	1.0	20	1	US-10-380-931-171	Sequence 171, App	c 771	14.8	0.9	19	1	US-10-714-333A-285391	Sequence 285391,
699	14.8	0.9	18	1	PCT-US03-41761-15621	Sequence 15621, A	c 772	14.8	0.9	19	1	US-10-714-333A-287841	Sequence 287841,
700	14.8	0.9	18	1	PCT-US03-41766A-15621	Sequence 15621, A	c 773	14.8	0.9	19	1	US-10-714-333A-290915	Sequence 290915,
701	14.8	0.9	18	1	US-10-241-313-7	Sequence 7, Appl	c 774	14.8	0.9	19	1	US-10-714-333A-290958	Sequence 290958,
702	14.8	0.9	18	1	US-10-310-188-26628	Sequence 26628, A	c 775	14.8	0.9	19	1	US-10-714-333A-292501	Sequence 292501,
703	14.8	0.9	18	1	US-10-310-188-42100	Sequence 42100, A	c 776	14.8	0.9	19	1	US-10-714-333A-302975	Sequence 302975,
704	14.8	0.9	18	1	US-10-310-188-61795	Sequence 61795, A	c 777	14.8	0.9	19	1	US-10-714-333A-308401	Sequence 308401,
705	14.8	0.9	18	1	US-10-404-679-70	Sequence 70, Appl	c 778	14.8	0.9	19	1	US-10-714-333A-32333	Sequence 32333,
706	14.8	0.9	18	1	US-10-404-922-11	Sequence 11, Appl	c 779	14.8	0.9	19	1	US-10-714-333A-337343	Sequence 337343,
707	14.8	0.9	18	1	US-10-449-801A-7	Sequence 7, Appl	c 780	14.8	0.9	19	1	US-10-714-333A-351775	Sequence 351775,
708	14.8	0.9	18	1	US-10-750-622-15621	Sequence 15621, A	c 781	14.8	0.9	19	1	US-10-714-333A-351873	Sequence 351873,
709	14.8	0.9	18	1	US-10-755-966-105	Sequence 105, App	c 782	14.8	0.9	19	1	US-10-714-333A-351959	Sequence 351959,
710	14.8	0.9	19	1	PCT-US02-31357-84	Sequence 84, Appl	c 783	14.8	0.9	19	1	US-10-714-333A-352632	Sequence 352632,
711	14.8	0.9	19	1	PCT-US03-05045-569	Sequence 569, App	c 784	14.8	0.9	19	1	US-10-714-333A-354098	Sequence 354098,
712	14.8	0.9	19	1	PCT-US03-05045-876	Sequence 876, App	c 785	14.8	0.9	19	1	US-10-714-333A-354563	Sequence 354563,
713	14.8	0.9	19	1	PCT-US03-05045A-569	Sequence 569, App	c 786	14.8	0.9	19	1	US-10-714-333A-354586	Sequence 354586,
714	14.8	0.9	19	1	PCT-US03-05045A-876	Sequence 876, App	c 787	14.8	0.9	19	1	US-10-714-333A-354829	Sequence 354829,
715	14.8	0.9	19	1	US-08-836-734E-107	Sequence 107, App	c 788	14.8	0.9	19	1	US-10-714-333A-357994	Sequence 357994,
716	14.8	0.9	19	1	US-09-453-607A-2314	Sequence 2314, Ap	c 789	14.8	0.9	19	1	US-10-714-333A-362298	Sequence 362298,
717	14.8	0.9	19	1	US-09-453-607C-2314	Sequence 2314, Ap	c 790	14.8	0.9	19	1	US-10-714-333A-364234	Sequence 364234,
718	14.8	0.9	19	1	US-09-612-226-111	Sequence 111, App	c 791	14.8	0.9	19	1	US-10-714-333A-371166	Sequence 371166,
719	14.8	0.9	19	1	US-09-612-226B-111	Sequence 111, App	c 792	14.8	0.9	19	1	US-10-714-333A-372178	Sequence 372178,
720	14.8	0.9	19	1	US-10-244-647-491	Sequence 491, App	c 793	14.8	0.9	19	1	US-10-714-333A-372367	Sequence 372367,
721	14.8	0.9	19	1	US-10-244-647-511	Sequence 511, App	c 794	14.8	0.9	19	1	US-10-714-333A-372453	Sequence 372453,
722	14.8	0.9	19	1	US-10-244-647-1137	Sequence 1137, Ap	c 795	14.8	0.9	19	1	US-10-714-333A-372546	Sequence 372546,
723	14.8	0.9	19	1	US-10-244-647-1157	Sequence 1157, Ap	c 796	14.8	0.9	19	1	US-10-714-333A-395054	Sequence 395054,
724	14.8	0.9	19	1	US-10-251-117-623	Sequence 623, App	c 797	14.8	0.9	19	1	US-10-714-333A-396135	Sequence 396135,
725	14.8	0.9	19	1	US-10-251-117-930	Sequence 930, App	c 798	14.8	0.9	19	1	US-10-714-333A-405763	Sequence 405763,
726	14.8	0.9	19	1	US-10-262-445-84	Sequence 84, Appl	c 799	14.8	0.9	19	1	US-10-714-333A-418870	Sequence 418870,
727	14.8	0.9	19	1	US-10-287-787-205	Sequence 205, App	c 800	14.8	0.9	19	1	US-10-714-333A-425391	Sequence 425391,
728	14.8	0.9	19	1	US-10-293-338-1504	Sequence 1504, Ap	c 801	14.8	0.9	19	1	US-10-714-333A-436531	Sequence 436531,
729	14.8	0.9	19	1	US-10-310-188-24871	Sequence 24871, A	c 802	14.8	0.9	19	1	US-10-714-333A-441375	Sequence 441375,
730	14.8	0.9	19	1	US-10-310-188-85407	Sequence 85407, A	c 803	14.8	0.9	19	1	US-10-714-333A-441375	Sequence 441375,
731	14.8	0.9	19	1	US-10-356-625-111	Sequence 111, App	c 804	14.8	0.9	19	1	US-10-714-333A-442803	Sequence 442803,
732	14.8	0.9	19	1	US-10-643-775-1151	Sequence 1151, Ap	c 805	14.8	0.9	19	1	US-10-714-333A-445044	Sequence 445044,
733	14.8	0.9	19	1	US-10-643-775-1154	Sequence 1154, Ap	c 806	14.8	0.9	19	1	US-10-714-333A-463228	Sequence 463228,
734	14.8	0.9	19	1	US-10-714-333A-7924	Sequence 7924, Ap	c 807	14.8	0.9	19	1	US-10-714-333A-463318	Sequence 463318,
735	14.8	0.9	19	1	US-10-714-333A-29547	Sequence 29547, A	c 808	14.8	0.9	19	1	US-10-714-333A-463409	Sequence 463409,
736	14.8	0.9	19	1	US-10-714-333A-29646	Sequence 29646, A	c 809	14.8	0.9	19	1	US-10-714-333A-464736	Sequence 464736,
737	14.8	0.9	19	1	US-10-714-333A-29646	Sequence 29646, A	c 810	14.8	0.9	19	1	US-10-714-333A-465655	Sequence 465655,
738	14.8	0.9	19	1	US-10-714-333A-40403	Sequence 40403, A	c 811	14.8	0.9	19	1	US-10-714-333A-469027	Sequence 469027,
739	14.8	0.9	19	1	US-10-714-333A-73640	Sequence 73640, A	c 812	14.8	0.9	19	1	US-10-714-333A-473542	Sequence 473542,
740	14.8	0.9	19	1	US-10-714-333A-77161	Sequence 77161, A	c 813	14.8	0.9	19	1	US-10-714-333A-473572	Sequence 473572,
741	14.8	0.9	19	1	US-10-714-333A-77261	Sequence 77261, A	c 814	14.8	0.9	19	1	US-10-714-333A-486856	Sequence 486856,
742	14.8	0.9	19	1	US-10-714-333A-98961	Sequence 98961, A	c 815	14.8	0.9	19	1	US-10-714-333A-493249	Sequence 493249,
743	14.8	0.9	19	1	US-10-714-333A-99062	Sequence 99062, A	c 816	14.8	0.9	19	1	US-10-714-333A-496471	Sequence 496471,
744	14.8	0.9	19	1	US-10-714-333A-99104	Sequence 99104, A	c 817	14.8	0.9	19	1	US-10-714-333A-496830	Sequence 496830,
745	14.8	0.9	19	1	US-10-714-333A-101026	Sequence 101026,	c 818	14.8	0.9	19	1	US-10-714-333A-501486	Sequence 501486,
746	14.8	0.9	19	1	US-10-714-333A-119081	Sequence 119081,	c 819	14.8	0.9	19	1	US-10-714-333A-501869	Sequence 501869,
747	14.8	0.9	19	1	US-10-714-333A-119734	Sequence 119734,	c 820	14.8	0.9	19	1	US-10-714-333A-512570	Sequence 512570,
748	14.8	0.9	19	1	US-10-714-333A-129390	Sequence 129390,	c 821	14.8	0.9	19	1	US-10-714-333A-518052	Sequence 518052,
749	14.8	0.9	19	1	US-10-714-333A-139439	Sequence 139439,	c 822	14.8	0.9	19	1	US-10-714-333A-521556	Sequence 521556,
750	14.8	0.9	19	1	US-10-714-333A-139443	Sequence 139443,	c 823	14.8	0.9	19	1	US-10-714-333A-524286	Sequence 524286,
751	14.8	0.9	19	1	US-10-714-333A-146874	Sequence 146874,	c 824	14.8	0.9	19	1	US-10-714-333A-524390	Sequence 524390,
752	14.8	0.9	19	1	US-10-714-333A-147447	Sequence 147447,	c 825	14.8	0.9	19	1	US-10-714-333A-541621	Sequence 541621,
753	14.8	0.9	19	1	US-10-714-333A-162601	Sequence 162601,	c 826	14.8	0.9	19	1	US-10-714-333A-541621	Sequence 541621,
754	14.8	0.9	19	1	US-10-714-333A-162617	Sequence 162617,	c 827	14.8	0.9	19	1	US-10-714-333A-554319	Sequence 554319,
755	14.8	0.9	19	1	US-10-714-333A-168086	Sequence 168086,	c 828	14.8	0.9	19	1	US-10-714-333A-554319	Sequence 554319,
756	14.8	0.9	19	1	US-10-714-333A-182299	Sequence 182299,	c 829	14.8	0.9	19	1	US-10-714-333A-557566	Sequence 557566,
757	14.8	0.9	19	1	US-10-714-333A-190043	Sequence 190043,	c 830	14.8	0.9	19	1	US-10-714-333A-563121	Sequence 563121,
758	14.8	0.9	19	1	US-10-714-333A-195561	Sequence 195561,	c 831	14.8	0.9	19	1	US-10-714-333A-575698	Sequence 575698,
759	14.8	0.9	19	1	US-10-714-333A-195593	Sequence 195593,	c 832	14.8	0.9	19	1	US-10-714-333A-586923	Sequence 586923,
760	14.8	0.9	19	1	US-10-714-333A-197309	Sequence 197309,	c 833	14.8	0.9	19	1	US-10-714-333A-589132	Sequence 589132,
761	14.8	0.9	19	1	US-10-714-333A-209643	Sequence 209643,	c 834	14.8	0.9	19	1	US-10-714-333A-590892	Sequence 590892,
762	14.8	0.9	19	1	US-10-714-333A-211427	Sequence 211427,	c 835	14.8	0.9	19	1	US-10-714-333A-591241	Sequence 591241,
763	14.8	0.9	19	1	US-10-714-333A-215552	Sequence 215552,	c 836	14.8	0.9	19	1	US-10-714-333A-597268	Sequence 597268,

C 837	14.8	0.9	1	US-10-714-333A-607801	Sequence 607801,	910	14.8	0.9	1	US-10-714-333A-1020858	Sequence 1020858,
C 838	14.8	0.9	1	US-10-714-333A-616091	Sequence 616091,	C 911	14.8	0.9	1	US-10-714-333A-1026435	Sequence 1026435,
C 839	14.8	0.9	1	US-10-714-333A-616166	Sequence 616166,	912	14.8	0.9	1	US-10-714-333A-1037156	Sequence 1037156,
C 840	14.8	0.9	1	US-10-714-333A-616261	Sequence 616261,	913	14.8	0.9	1	US-10-714-333A-1045681	Sequence 1045681,
C 841	14.8	0.9	1	US-10-714-333A-621423	Sequence 621423,	914	14.8	0.9	1	US-10-714-333A-1056677	Sequence 1056677,
C 842	14.8	0.9	1	US-10-714-333A-624796	Sequence 624796,	C 915	14.8	0.9	1	US-10-714-333A-1069406	Sequence 1069406,
C 843	14.8	0.9	1	US-10-714-333A-628455	Sequence 628455,	916	14.8	0.9	1	US-10-714-333A-1076437	Sequence 1076437,
C 844	14.8	0.9	1	US-10-714-333A-638478	Sequence 638478,	917	14.8	0.9	1	US-10-714-333A-1077879	Sequence 1077879,
C 845	14.8	0.9	1	US-10-714-333A-638536	Sequence 638536,	C 918	14.8	0.9	1	US-10-714-333A-1086381	Sequence 1086381,
C 846	14.8	0.9	1	US-10-714-333A-647154	Sequence 647154,	C 919	14.8	0.9	1	US-10-714-333A-1089963	Sequence 1089963,
C 847	14.8	0.9	1	US-10-714-333A-652638	Sequence 652638,	920	14.8	0.9	1	US-10-714-333A-1091236	Sequence 1091236,
C 848	14.8	0.9	1	US-10-714-333A-652653	Sequence 652653,	921	14.8	0.9	1	US-10-714-333A-1097289	Sequence 1097289,
C 849	14.8	0.9	1	US-10-714-333A-666159	Sequence 666159,	C 922	14.8	0.9	1	US-10-714-333A-1099840	Sequence 1099840,
C 850	14.8	0.9	1	US-10-714-333A-666353	Sequence 666353,	923	14.8	0.9	1	US-10-714-333A-1102957	Sequence 1102957,
C 851	14.8	0.9	1	US-10-714-333A-668146	Sequence 668146,	C 924	14.8	0.9	1	US-10-714-333A-1139322	Sequence 1139322,
C 852	14.8	0.9	1	US-10-714-333A-675649	Sequence 675649,	C 925	14.8	0.9	1	US-10-714-333A-1145472	Sequence 1145472,
C 853	14.8	0.9	1	US-10-714-333A-677440	Sequence 677440,	C 926	14.8	0.9	1	US-10-714-333A-1145849	Sequence 1145849,
C 854	14.8	0.9	1	US-10-714-333A-679033	Sequence 679033,	C 927	14.8	0.9	1	US-10-714-333A-1145968	Sequence 1145968,
C 855	14.8	0.9	1	US-10-714-333A-679053	Sequence 679053,	928	14.8	0.9	1	US-10-714-333A-1150268	Sequence 1150268,
C 856	14.8	0.9	1	US-10-714-333A-700954	Sequence 700954,	C 929	14.8	0.9	1	US-10-714-333A-1157018	Sequence 1157018,
C 857	14.8	0.9	1	US-10-714-333A-706981	Sequence 706981,	C 930	14.8	0.9	1	US-10-714-333A-1157077	Sequence 1157077,
C 858	14.8	0.9	1	US-10-714-333A-707106	Sequence 707106,	C 931	14.8	0.9	1	US-10-714-333A-1160091	Sequence 1160091,
C 859	14.8	0.9	1	US-10-714-333A-709630	Sequence 709630,	932	14.8	0.9	1	US-10-714-333A-1160582	Sequence 1160582,
C 860	14.8	0.9	1	US-10-714-333A-717530	Sequence 717530,	933	14.8	0.9	1	US-10-714-333A-1160681	Sequence 1160681,
C 861	14.8	0.9	1	US-10-714-333A-731509	Sequence 731509,	934	14.8	0.9	1	US-10-714-333A-1160780	Sequence 1160780,
C 862	14.8	0.9	1	US-10-714-333A-731565	Sequence 731565,	C 935	14.8	0.9	1	US-10-714-333A-1169305	Sequence 1169305,
C 863	14.8	0.9	1	US-10-714-333A-734141	Sequence 734141,	C 936	14.8	0.9	1	US-10-714-333A-119874	Sequence 119874,
C 864	14.8	0.9	1	US-10-714-333A-764989	Sequence 764989,	C 937	14.8	0.9	1	US-10-714-333A-1185320	Sequence 1185320,
C 865	14.8	0.9	1	US-10-714-333A-766741	Sequence 766741,	938	14.8	0.9	1	US-10-714-333A-1207965	Sequence 1207965,
C 866	14.8	0.9	1	US-10-714-333A-766814	Sequence 766814,	C 939	14.8	0.9	1	US-10-714-333A-1214827	Sequence 1214827,
C 867	14.8	0.9	1	US-10-714-333A-766916	Sequence 766916,	C 940	14.8	0.9	1	US-10-714-333A-1215296	Sequence 1215296,
C 868	14.8	0.9	1	US-10-714-333A-772034	Sequence 772034,	941	14.8	0.9	1	US-10-714-333A-1217017	Sequence 1217017,
C 869	14.8	0.9	1	US-10-714-333A-772055	Sequence 772055,	C 942	14.8	0.9	1	US-10-714-333A-1225105	Sequence 1225105,
C 870	14.8	0.9	1	US-10-714-333A-774996	Sequence 774996,	C 943	14.8	0.9	1	US-10-714-333A-1225133	Sequence 1225133,
C 871	14.8	0.9	1	US-10-714-333A-781370	Sequence 781370,	944	14.8	0.9	1	US-10-714-333A-1233049	Sequence 1233049,
C 872	14.8	0.9	1	US-10-714-333A-782978	Sequence 782978,	945	14.8	0.9	1	US-10-714-333A-1243877	Sequence 1243877,
C 873	14.8	0.9	1	US-10-714-333A-782990	Sequence 782990,	946	14.8	0.9	1	US-10-714-333A-1263871	Sequence 1263871,
C 874	14.8	0.9	1	US-10-714-333A-783816	Sequence 783816,	C 947	14.8	0.9	1	US-10-714-333A-1264196	Sequence 1264196,
C 875	14.8	0.9	1	US-10-714-333A-784439	Sequence 784439,	948	14.8	0.9	1	US-10-714-333A-1265040	Sequence 1265040,
C 876	14.8	0.9	1	US-10-714-333A-788773	Sequence 788773,	C 949	14.8	0.9	1	US-10-714-333A-1266936	Sequence 1266936,
C 877	14.8	0.9	1	US-10-714-333A-794601	Sequence 794601,	C 950	14.8	0.9	1	US-10-714-333A-1274603	Sequence 1274603,
C 878	14.8	0.9	1	US-10-714-333A-800639	Sequence 800639,	C 951	14.8	0.9	1	US-10-714-333A-1274651	Sequence 1274651,
C 879	14.8	0.9	1	US-10-714-333A-801255	Sequence 801255,	952	14.8	0.9	1	US-10-714-333A-1276927	Sequence 1276927,
C 880	14.8	0.9	1	US-10-714-333A-801578	Sequence 801578,	C 953	14.8	0.9	1	US-10-714-333A-1289584	Sequence 1289584,
C 881	14.8	0.9	1	US-10-714-333A-805008	Sequence 805008,	954	14.8	0.9	1	US-10-714-333A-1307426	Sequence 1307426,
C 882	14.8	0.9	1	US-10-714-333A-836678	Sequence 836678,	C 955	14.8	0.9	1	US-10-714-333A-1308952	Sequence 1308952,
C 883	14.8	0.9	1	US-10-714-333A-841744	Sequence 841744,	C 956	14.8	0.9	1	US-10-714-333A-1316185	Sequence 1316185,
C 884	14.8	0.9	1	US-10-714-333A-841816	Sequence 841816,	C 957	14.8	0.9	1	US-10-714-333A-1361062	Sequence 1361062,
C 885	14.8	0.9	1	US-10-714-333A-863225	Sequence 863225,	C 958	14.8	0.9	1	US-10-714-333A-1361160	Sequence 1361160,
C 886	14.8	0.9	1	US-10-714-333A-874982	Sequence 874982,	959	14.8	0.9	1	US-10-714-333A-1363256	Sequence 1363256,
C 887	14.8	0.9	1	US-10-714-333A-883118	Sequence 883118,	960	14.8	0.9	1	US-10-714-333A-1363280	Sequence 1363280,
C 888	14.8	0.9	1	US-10-714-333A-886411	Sequence 886411,	961	14.8	0.9	1	US-10-714-333A-1372643	Sequence 1372643,
C 889	14.8	0.9	1	US-10-714-333A-889009	Sequence 889009,	C 962	14.8	0.9	1	US-10-714-333A-1374565	Sequence 1374565,
C 890	14.8	0.9	1	US-10-714-333A-892117	Sequence 892117,	C 963	14.8	0.9	1	US-10-714-333A-1374574	Sequence 1374574,
C 891	14.8	0.9	1	US-10-714-333A-895383	Sequence 895383,	C 964	14.8	0.9	1	US-10-714-333A-1391199	Sequence 1391199,
C 892	14.8	0.9	1	US-10-714-333A-899079	Sequence 899079,	C 965	14.8	0.9	1	US-10-714-333A-1391222	Sequence 1391222,
C 893	14.8	0.9	1	US-10-714-333A-899180	Sequence 899180,	C 966	14.8	0.9	1	US-10-714-333A-1392126	Sequence 1392126,
C 894	14.8	0.9	1	US-10-714-333A-905395	Sequence 905395,	C 967	14.8	0.9	1	US-10-714-333A-1392327	Sequence 1392327,
C 895	14.8	0.9	1	US-10-714-333A-920823	Sequence 920823,	968	14.8	0.9	1	US-10-714-333A-1394653	Sequence 1394653,
C 896	14.8	0.9	1	US-10-714-333A-920859	Sequence 920859,	C 969	14.8	0.9	1	US-10-714-333A-1408908	Sequence 1408908,
C 897	14.8	0.9	1	US-10-714-333A-933752	Sequence 933752,	C 970	14.8	0.9	1	US-10-714-333A-1408959	Sequence 1408959,
C 898	14.8	0.9	1	US-10-714-333A-935752	Sequence 935752,	971	14.8	0.9	1	US-10-714-333A-1414040	Sequence 1414040,
C 899	14.8	0.9	1	US-10-714-333A-935675	Sequence 935675,	C 972	14.8	0.9	1	US-10-714-333A-1414087	Sequence 1414087,
C 900	14.8	0.9	1	US-10-714-333A-950052	Sequence 950052,	C 973	14.8	0.9	1	US-10-714-333A-1417073	Sequence 1417073,
C 901	14.8	0.9	1	US-10-714-333A-968163	Sequence 968163,	C 974	14.8	0.9	1	US-10-714-333A-1421876	Sequence 1421876,
C 902	14.8	0.9	1	US-10-714-333A-968558	Sequence 968558,	C 975	14.8	0.9	1	US-10-714-333A-1423069	Sequence 1423069,
C 903	14.8	0.9	1	US-10-714-333A-969655	Sequence 969655,	C 976	14.8	0.9	1	US-10-714-333A-1461394	Sequence 1461394,
C 904	14.8	0.9	1	US-10-714-333A-971604	Sequence 971604,	977	14.8	0.9	1	US-10-714-333A-1464324	Sequence 1464324,
C 905	14.8	0.9	1	US-10-714-333A-971139	Sequence 971139,	C 978	14.8	0.9	1	US-10-714-333A-1519627	Sequence 1519627,
C 906	14.8	0.9	1	US-10-714-333A-1009712	Sequence 1009712,	C 979	14.8	0.9	1	US-10-714-333A-1521139	Sequence 1521139,
C 907	14.8	0.9	1	US-10-714-333A-1010570	Sequence 1010570,	C 980	14.8	0.9	1	US-10-714-333A-1525271	Sequence 1525271,
C 908	14.8	0.9	1	US-10-714-333A-1012452	Sequence 1012452,	981	14.8	0.9	1	US-10-714-333A-1540338	Sequence 1540338,
C 909	14.8	0.9	1	US-10-714-333A-1014454	Sequence 1014454,	C 982	14.8	0.9	1	US-10-714-333A-1540797	Sequence 1540797,

983 14.8 0.9 19 1 US-10-714-333A-1544504 Sequence 1544504,
c 984 14.8 0.9 19 1 US-10-714-333A-1544594 Sequence 1545594,
c 985 14.8 0.9 19 1 US-10-714-333A-1545601 Sequence 1545601,
c 986 14.8 0.9 19 1 US-10-714-333A-1550492 Sequence 1550492,
c 987 14.8 0.9 19 1 US-10-714-333A-1550559 Sequence 1550559,
c 988 14.8 0.9 19 1 US-10-714-333A-1556457 Sequence 1556457,
c 989 14.8 0.9 19 1 US-10-714-333A-1562901 Sequence 1562901,
c 990 14.8 0.9 19 1 US-10-714-333A-1570342 Sequence 1570342,
c 991 14.8 0.9 19 1 US-10-714-333A-1572059 Sequence 1572059,
c 992 14.8 0.9 19 1 US-10-714-333A-1574748 Sequence 1574748,
c 993 14.8 0.9 19 1 US-10-714-333A-1585972 Sequence 1585972,
c 994 14.8 0.9 19 1 US-60-216-745-5787 Sequence 5787, Ap

ALIGNMENTS

RESULT 1
PCT-US02-22746-6
; Sequence 6, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Eis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 6
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
PCT-US02-22746-6

Query Match 1.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1212 CTACGTGTATCAGGATGGGCTCGG 1236
|||||
Db 1 CTACGTGTATCAGGATGGGCTCGG 25

RESULT 2
US-09-918-026A-6
; Sequence 6, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 6
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-09-918-026A-6

Query Match 1.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1212 CTACGTGTATCAGGATGGGCTCGG 1236
|||||
Db 1 CTACGTGTATCAGGATGGGCTCGG 25

RESULT 3
US-10-484-441-6
; Sequence 6, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 6
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-484-441-6

Query Match 1.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1212 CTACGTGTATCAGGATGGGCTCGG 1236
|||||
Db 1 CTACGTGTATCAGGATGGGCTCGG 25

RESULT 4
US-09-630-892-25
; Sequence 25, Application US/09630892
; GENERAL INFORMATION:
; APPLICANT: Sturley, Stephen L.
; APPLICANT: Oelkers, Peter
; TITLE OF INVENTION: ISOLATION OF A GENE ENCODING DIACYLGLYCEROL
; FILE REFERENCE: 0575/56331-A
; CURRENT APPLICATION NUMBER: US/09/630,892
; CURRENT FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 25
; LENGTH: 25
; TYPE: DNA
; ORGANISM: human
US-09-630-892-25

Query Match 1.5%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1047 CATGCTGCTCATCTTTCTTTC 1070
|||||
Db 1 CATGCTGCTCATCTTTCTTTC 24

RESULT 5
US-09-630-892A-25
; Sequence 25, Application US/09630892A
; GENERAL INFORMATION:
; APPLICANT: Sturley, Stephen L.
; APPLICANT: Oelkers, Peter
; TITLE OF INVENTION: ISOLATION OF A GENE ENCODING DIACYLGLYCEROL
; FILE REFERENCE: 0575/56331-A
; CURRENT APPLICATION NUMBER: US/09/630,892
; CURRENT FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 25
; LENGTH: 25
; TYPE: DNA
; ORGANISM: human
US-09-630-892A-25


```
; FILE REFERENCE: 0575/56331-A
; CURRENT APPLICATION NUMBER: US/09/630,892A
; CURRENT FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 25
; TYPE: DNA
; ORGANISM: human
US-09-630-892A-25

Query Match 1.5%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1047 CATGCTGCTCATCTTCTTTGC 1070
DB 1 CATGCTGCTCATCTTCTTTGC 24

RESULT 6
US-09-956-584A-191617
; Sequence 191617, Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 191617
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-191617

Query Match 1.5%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 62;
Matches 24; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 1039 GGCATCTTCATGCTGCTGCTCATCT 1063
DB 1 GGCATCTTCATGCTGCTGCTCATCT 25

RESULT 7
US-09-956-584A-191623
; Sequence 191623, Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 191623
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-191623

Query Match 1.5%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 62;
Matches 24; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 1084 TGGCTCAACGCCCTTCCGAGATGC 1108
DB 1 TGGCTCAACGCCCTTCCGAGATGC 25

RESULT 8
US-09-630-892-30
; Sequence 30, Application US/09630892
; GENERAL INFORMATION:
; APPLICANT: Sturley, Stephen L.
; APPLICANT: Oelkers, Peter
; TITLE OF INVENTION: ISOLATION OF A GENE ENCODING DIACYLGLYCEROL
; FILE REFERENCE: 0575/56331-A
; CURRENT APPLICATION NUMBER: US/09/630,892
; CURRENT FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 30
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-09-630-892-30

Query Match 1.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 64;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1539 GACACCTCGATCTTGCTCTGCC 1561
DB 1 GACACCTCGATCTTGCTCTGCC 23

RESULT 9
US-09-630-892A-30
; Sequence 30, Application US/09630892A
; GENERAL INFORMATION:
; APPLICANT: Sturley, Stephen L.
; APPLICANT: Oelkers, Peter
; TITLE OF INVENTION: ISOLATION OF A GENE ENCODING DIACYLGLYCEROL
; FILE REFERENCE: 0575/56331-A
; CURRENT APPLICATION NUMBER: US/09/630,892A
; CURRENT FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-09-630-892A-30

Query Match 1.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 64;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1539 GACACCTCGATCTTGCTCTGCC 1561
DB 1 GACACCTCGATCTTGCTCTGCC 23

RESULT 10
US-09-605-166-6/c
; Sequence 6, Application US/09605166
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: 6510-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166
; CURRENT FILING DATE: 2000-06-27
; NUMBER OF SEQ ID NOS: 9
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166-6

Query Match          1.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 99;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1176 CACTTGGAAACGTGGTGTCATGAC 1200
Db 25 CACTTGGAAACGTGGTGTCATGAC 1

RESULT 11
US-09-605-166-7/c
; Sequence 7, Application US/09605166
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166
; PRIOR FILING DATE: 2003-07-22
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166-7

Query Match          1.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 99;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1176 CACTTGGAAACGTGGTGTCATGAC 1200
Db 25 CACTTGGAAACGTGGTGTCATGAC 1

RESULT 12
US-09-605-166A-6/c
; Sequence 6, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166A
; PRIOR FILING DATE: 2003-07-22
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166-6

Query Match          1.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 99;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1176 CACTTGGAAACGTGGTGTCATGAC 1200
Db 25 CACTTGGAAACGTGGTGTCATGAC 1

RESULT 13
US-09-605-166A-7/c
; Sequence 7, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166A
; PRIOR FILING DATE: 2003-07-22
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166A-7

Query Match          1.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 99;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1176 CACTTGGAAACGTGGTGTCATGAC 1200
Db 25 CACTTGGAAACGTGGTGTCATGAC 1

RESULT 14
US-09-956-584A-191612
; Sequence 191612, Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 191612
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-191612

Query Match          1.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 99;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1108 CTACGATTTGGAGACAGGATGTTCT 1132
```



```

Query Match      1.4%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      916 GGATGTGTGCTCTATGCGCTGCTT 938
      |||||
Db      3 GGATGTGTGCTCTATGCGCTGCTT 25

RESULT 24
US-60-427-836-196282
; Sequence 196282, Application US/60427836
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527
; CURRENT APPLICATION NUMBER: US/60/427,836
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 196282
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-60-427-836-196282

Query Match      1.4%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 916 GGATGTGCTCTATCGCTGCTT 938
DB 3 GGATGTGCTCTATCGCTGCTT 25

RESULT 25

PCT-US02-22746-4
; Sequence 4, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
PCT-US02-22746-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1e+02; 0; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0;

QY 1190 TGGTCCATGACTGGCTGTACA 1210
DB 1 TGGTCCATGACTGGCTGTACA 21

RESULT 26

US-09-918-026A-4
; Sequence 4, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0598
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-918-026A-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1e+02; 0; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0;

QY 1190 TGGTCCATGACTGGCTGTACA 1210
DB 1 TGGTCCATGACTGGCTGTACA 21

RESULT 27

US-10-484-441-4
; Sequence 4, Application US/1048441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE2 EXI
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-484-441-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1e+02; 0; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0;

QY 1190 TGGTCCATGACTGGCTGTACA 1210
DB 1 TGGTCCATGACTGGCTGTACA 21

RESULT 28

US-09-605-166-8
; Sequence 8, Application US/09605166
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Faresse, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: 6510-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166
; CURRENT FILING DATE: 2000-06-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166-8

Query Match 1.3%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1202 GGCTGTACAGTACGTGTATCAGG 1225
DB 1 GGCTGTACAGTACGTGTATCAGG 24

RESULT 29

US-09-605-166A-8
; Sequence 8, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Faresse, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166A
; CURRENT FILING DATE: 2003-07-22
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08

```
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-603-166A-8
```

```
Query Match 1.3%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1202 GGCTGTACAGCTACGTGTATCAGG 1225
Db 1 GGCTGTACAGCTATGTGTATCAAG 24
```

```
RESULT 30
US-10-779-251-8
; Sequence 8, Application US/10779251
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farsse, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; APPLICANT: Accad, Michel
; TITLE OF INVENTION: Novel acyl CoA:cholesterol
; FILE REFERENCE: UCAL-104CON
; CURRENT APPLICATION NUMBER: US/10/779,251
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 09/605,166
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-779-251-8
```

```
Query Match 1.3%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1202 GGCTGTACAGCTACGTGTATCAGG 1225
Db 1 GGCTGTACAGCTATGTGTATCAAG 24
```

```
RESULT 31
US-09-556-584A-191618
; Sequence 191618, Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
```

```
; SEQ ID NO 191618
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-191618
```

```
Query Match 1.3%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1266 CATGCTGGGTGTTCCTGGTCTC 1289
Db 1 CATGCTGGAGTGTTCCTGGTGTCT 24
```

```
RESULT 32
US-09-956-584A-191621
; Sequence 191621, Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 191621
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-191621
```

```
Query Match 1.3%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1216 GTGTATCAGGATGGGCTGGGCTC 1239
Db 2 GTGTATCAAGATGGGCTGTGGCTC 25
```

```
RESULT 33
US-09-954-427A-131432
; Sequence 131432, Application US/09954427A
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat Genome
; FILE REFERENCE: 3112.1
; CURRENT APPLICATION NUMBER: US/09/954,427A
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 60/233,166
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 131432
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus Norvegicus
US-09-954-427A-131432
```

```
Query Match 1.3%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 446 TGCTGCTGGAGTTTGACCTACT 467
Db 4 TGCTGCTGGACTTTGACCTACT 25
```

```
RESULT 34
US-09-954-427A-270002
```

; Sequence 270002; Application US/09954427A
; GENERAL INFORMATION:
; APPLICANT: Michael Mitmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat Genome
; FILE REFERENCE: 3112.1
; CURRENT APPLICATION NUMBER: US/09/954,427A
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 60/233,166
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 270002
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus Norvegicus
US-09-954-427A-270002

Query Match 1.3%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1423 GTGCTGATGTGACCATCTGT 1444
DB 3 GTGCTGATGTGACCATCTGT 24

RESULT 35
US-09-956-584A-146347
; Sequence 146347; Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mitmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 146347
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-146347

Query Match 1.3%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 446 TGCTGCTGGAGTTGACCTACT 467
DB 4 TGCTGCTGGAGTTGACCTACT 25

RESULT 36
US-09-954-427A-358884
; Sequence 358884; Application US/09954427A
; GENERAL INFORMATION:
; APPLICANT: Michael Mitmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat Genome
; FILE REFERENCE: 3112.1
; CURRENT APPLICATION NUMBER: US/09/954,427A
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 60/233,166
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 358884
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus Norvegicus
US-09-954-427A-358884

Query Match 1.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1078 CATTGCTGGCTCAAGCCCTTTGCCG 1102
DB 1 CATTGCTGGCTCAAGCCCTTTGCTG 25

RESULT 37
US-09-956-584A-191614
; Sequence 191614; Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mitmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 191614
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-191614

Query Match 1.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1095 CTTGCCGAGATGCTACGATTTGGA 1119
DB 1 CTTGCCGAGATGCTACGATTTGGA 25

RESULT 38
US-09-956-584A-191626
; Sequence 191626; Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mitmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 191626
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-191626

Query Match 1.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1018 ATCTGTCATGCCACGTTGCCAGCA 1042
DB 1 ATCTGTCATGCCACGTTGCCAGCA 25

RESULT 39
US-09-956-584A-330489
; Sequence 330489; Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mitmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A

Query Match
1.3%; Score 20.2; DB 1; Length 25;


```
Best Local Similarity 88.0%; Pred. No. 1.6e+02; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 689 GTGCTGCTCTTCGAGCAGGTAG 713
Db 1 GTGCTGCTCTTCGAGCAGGTAG 25

RESULT 45
US-60-427-836-626166
; Sequence 626166, Application US/60427836
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527
; CURRENT APPLICATION NUMBER: US/60/427,836
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 626166
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-60-427-836-626166

Query Match 1.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1081 TCGTGGCTCAAGCCTTTCGCCGAGA 1105
Db 1 TCGTGGCTCAAGCCTTTCGCCGAGA 25

RESULT 46
PCT-US02-22746-14/c
; Sequence 14, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
PCT-US02-22746-14

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 CGCTCTGCTCTTCGAGCAGGA 37
Db 20 CGCTCTGCTCTTCGAGCAGGA 1

RESULT 47
PCT-US02-22746-15/c
; Sequence 15, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
```

```
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
PCT-US02-22746-15

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 GAGCGCCCAACCTGTGGAGA 80
Db 20 GAGCGCCCAACCTGTGGAGA 1

RESULT 48
PCT-US02-22746-16/c
; Sequence 16, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
PCT-US02-22746-16

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAGAGCACA 100
Db 20 TGGAAACACTGAGAGCACA 1

RESULT 49
PCT-US02-22746-17/c
; Sequence 17, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
```

; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-17

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 CTTGGTACAATGGACCCGAC 130
Db 20 CTTGGTACAATGGACCCGAC 1

RESULT 50
PCT-US02-22746-18/c
; Sequence 18, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-18

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 AGCAAGCGCAGGACAACGTG 180
Db 20 AGCAAGCGCAGGACAACGTG 1

RESULT 51
PCT-US02-22746-19/c
; Sequence 19, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-19

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGGAGAGCTGCTGGATCGGCG 200
Db 20 AGGAGAGCTGCTGGATCGGCG 1

RESULT 52
PCT-US02-22746-20/c
; Sequence 20, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-20

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 AGGAGCCATCCCTGGGGAAA 300
Db 20 AGGAGCCATCCCTGGGGAAA 1

RESULT 53
PCT-US02-22746-21/c
; Sequence 21, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-21

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 431 TTGATCAGGCGAGCTGCTG 450
Db 20 TTGATCAGGCGAGCTGCTG 1

RESULT 54
PCT-US02-22746-22/c
; Sequence 22, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-22

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 CCGTACGAGCGCTACGGCT 560
Db 20 CCGTACGAGCGCTACGGCT 1

RESULT 55
PCT-US02-22746-23/c
; Sequence 23, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-23

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GTGGGCGAGGCGACCTGGA 580
Db 20 GTGGGCGAGGCGACCTGGA 1

RESULT 56
PCT-US02-22746-24/c
; Sequence 24, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-24

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 581 CGCAGCGGAGCGGCTGGGC 600
Db 20 CGCAGCGGAGCGGCTGGGC 1

RESULT 57
PCT-US02-22746-25/c
; Sequence 25, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-25

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 GTGCCTGGGATCCTTCGTGC 770
Db 20 GTGCCTGGGATCCTTCGTGC 1

RESULT 58
PCT-US02-22746-26/c
; Sequence 26, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
```

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-26

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 CAGACGAGGTGAGGGATCC 790
Db 20 CAGACGAGGTGAGGGATCC 1

RESULT 59
PCT-US02-22746-27/c
; Sequence 27, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-27

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 881 GGAATTATGTGCCAAGAAC 900
Db 20 GGAATTATGTGCCAAGAAC 1

RESULT 60
PCT-US02-22746-28/c
; Sequence 28, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
```

```
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-28

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCCTGGCGCCTCTGTGTT 960
Db 20 TCCTGGCGCCTCTGTGTT 1

RESULT 61
PCT-US02-22746-29/c
; Sequence 29, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-29

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1021 CTGCATGCCAGTTGCCAGG 1040
Db 20 CTGCATGCCAGTTGCCAGG 1

RESULT 62
PCT-US02-22746-30/c
; Sequence 30, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

PCT-US02-22746-30

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1081 TGCTGGCTCAAGCCCTTGC 1100
|||||
Db 20 TGCTGGCTCAAGCCCTTGC 1

RESULT 63

PCT-US02-22746-31/c
; Sequence 31, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-31

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAACGTGGTGCTCCATGAC 1200
|||||
Db 20 GGAACGTGGTGCTCCATGAC 1

RESULT 64

PCT-US02-22746-32/c
; Sequence 32, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-32

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 TCAGGATGGCTGCGGCTCC 1240

Db 20 TCAGGATGGCTGCGGCTCC 1
|||||

RESULT 65

PCT-US02-22746-33/c
; Sequence 33, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-33

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 TGGGTGTGTCTCTGGTCTCC 1290
|||||
Db 20 TGGGTGTGTCTCTGGTCTCC 1

RESULT 66

PCT-US02-22746-34/c
; Sequence 34, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-34

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1401 GCGACCCGCGCGCATGGA 1420
|||||
Db 20 GCGACCCGCGCGCATGGA 1

RESULT 67

PCT-US02-22746-35/c
; Sequence 35, Application PC/TUS0222746

```
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-35

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1451 GCAGGGAATCCAGGTGACG 1470
Db 20 GCAGGGAATCCAGGTGACG 1

RESULT 68
PCT-US02-22746-36/c
; Sequence 36, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-36

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1541 CACCTCGATCTTGGTCTCTGC 1560
Db 20 CACCTCGATCTTGGTCTCTGC 1

RESULT 69
PCT-US02-22746-54/c
; Sequence 54, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
```

```
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-54

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CTGCTTCATCTGGCGCGCC 952
Db 20 CTGCTTCATCTGGCGCGCC 1

RESULT 70
PCT-US02-22746-65/c
; Sequence 65, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-65

Query Match          1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 CTTGGTCCTGCCATACCTAG 1569
Db 20 CTTGGTCCTGCCATACCTAG 1

RESULT 71
US-09-605-166A-16
; Sequence 16, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; TITLE OF INVENTION: ACYLTRANSFERASE (ACAT-2)
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166A
; CURRENT FILING DATE: 2003-07-22
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
```

; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166A-16

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1331 TCTTCTATCCGTCATGCTG 1350
| | | | | | | | | | | | | | | | | | | | | |
DB 1 TCTTCTATCCGTCATGCTG 20

RESULT 72

US-09-605-166A-17/c
; Sequence 17, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166A
; CURRENT FILING DATE: 2003-07-22
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166A-17

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1418 GGAACGTGCTGATGTGGACC 1437
| | | | | | | | | | | | | | | | | | | | | |
DB 20 GGAACGTGCTGATGTGGACC 1

RESULT 73

US-09-918-026A-14/c
; Sequence 14, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer

US-09-918-026A-14

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 CCGTCTGCGTCTGCAGGCA 37
| | | | | | | | | | | | | | | | | | | | | |
DB 20 CCGTCTGCGTCTGCAGGCA 1

RESULT 74

US-09-918-026A-15/c
; Sequence 15, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-918-026A-15

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 GAGCGCCAAACCTGTGGAGA 80
| | | | | | | | | | | | | | | | | | | | | |
DB 20 GAGCGCCAAACCTGTGGAGA 1

RESULT 75

US-09-918-026A-16/c
; Sequence 16, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-09-918-026A-16

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAACTGAGACGACCA 100
| | | | | | | | | | | | | | | | | | | | | |
DB 20 TGGAACTGAGACGACCA 1

RESULT 76

US-09-918-026A-17/c
; Sequence 17, Application US/09918026A
; GENERAL INFORMATION:

```
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-17

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 CTTGGTACAAATGACCCGAC 130
      |||||
Db 20 CTTGGTACAAATGACCCGAC 1

RESULT 77
US-09-918-026A-18/c
; Sequence 18, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-18

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 AGCAAGCGCAGGACAACATG 180
      |||||
Db 20 AGCAAGCGCAGGACAACATG 1

RESULT 78
US-09-918-026A-19/c
; Sequence 19, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-19
```

```
Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGGAGAGCTGCTGGATCGGC 200
      |||||
Db 20 AGGAGAGCTGCTGGATCGGC 1

RESULT 79
US-09-918-026A-20/c
; Sequence 20, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-20

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 AGGAGCCATCCCTGGGGAAA 300
      |||||
Db 20 AGGAGCCATCCCTGGGGAAA 1

RESULT 80
US-09-918-026A-21/c
; Sequence 21, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-21

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 431 TTGATGAGGCGAGGCTGCTG 450
      |||||
Db 20 TTGATGAGGCGAGGCTGCTG 1

RESULT 81
US-09-918-026A-22/c
; Sequence 22, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
```


APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lomonidis
FILE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
FILE REFERENCE: ISPH-0588
CURRENT APPLICATION NUMBER: US/09/918,026A
CURRENT FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 22
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-22

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 CCGTACCGGCGCTACGGCT 560
|||||
DB 20 CCGTACCGGCGCTACGGCT 1

RESULT 82
US-09-918-026A-23/c
Sequence 23, Application US/09918026A
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lomonidis
FILE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
FILE REFERENCE: ISPH-0588
CURRENT APPLICATION NUMBER: US/09/918,026A
CURRENT FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 23
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-23

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GTGGGCGGCGGCGCTGGA 580
|||||
DB 20 GTGGGCGGCGGCGCTGGA 1

RESULT 83
US-09-918-026A-24/c
Sequence 24, Application US/09918026A
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lomonidis
FILE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
FILE REFERENCE: ISPH-0588
CURRENT APPLICATION NUMBER: US/09/918,026A
CURRENT FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 24
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-24

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 581 CGCAGCGGCGGCGCTGGGC 600
|||||
DB 20 CGCAGCGGCGGCGCTGGGC 1

RESULT 84
US-09-918-026A-25/c
Sequence 25, Application US/09918026A
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lomonidis
FILE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
FILE REFERENCE: ISPH-0588
CURRENT APPLICATION NUMBER: US/09/918,026A
CURRENT FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 25
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-25

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 GTGCGTGGGATCCTTCGTGC 770
|||||
DB 20 GTGCGTGGGATCCTTCGTGC 1

RESULT 85
US-09-918-026A-26/c
Sequence 26, Application US/09918026A
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lomonidis
FILE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
FILE REFERENCE: ISPH-0588
CURRENT APPLICATION NUMBER: US/09/918,026A
CURRENT FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 26
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-26

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 CAGACGAGGTGAGGGATCC 790
|||||
DB 20 CAGACGAGGTGAGGGATCC 1

RESULT 86
US-09-918-026A-27/c
Sequence 27, Application US/09918026A
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham

```
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-27

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 881 GGAATTATGTGGCCAAGAAC 900
      |||||
Db 20 GGAATTATGTGGCCAAGAAC 1

RESULT 87
US-09-918-026A-28/c
; Sequence 28, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-28

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCCTGGCGCGCTCTGTGTT 960
      |||||
Db 20 TCCTGGCGCGCTCTGTGTT 1

RESULT 88
US-09-918-026A-29/c
; Sequence 29, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-29

Query Match      1.3%; Score 20; DB 1; Length 20;
```

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1021 CTGCATGCCACGTTGCCAGG 1040
      |||||
Db 20 CTGCATGCCACGTTGCCAGG 1

RESULT 89
US-09-918-026A-30/c
; Sequence 30, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-30

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1081 TGCTGGCTCAACGCCCTTTGC 1100
      |||||
Db 20 TGCTGGCTCAACGCCCTTTGC 1

RESULT 90
US-09-918-026A-31/c
; Sequence 31, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-31

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAACGTGGTGGTCCATGAC 1200
      |||||
Db 20 GGAACGTGGTGGTCCATGAC 1

RESULT 91
US-09-918-026A-32/c
; Sequence 32, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
```

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-32

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 TCAGGATGGCTCGGCTCC 1240
Db 20 TCAGGATGGCTCGGCTCC 1

RESULT 92
US-09-918-026A-33/c
; Sequence 33, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-33

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 TGGGTGTCTCTGGTCTCC 1290
Db 20 TGGGTGTCTCTGGTCTCC 1

RESULT 93
US-09-918-026A-34/c
; Sequence 34, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-34

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1401 GCGCACCGCCCGGCATGGA 1420
Db 20 GCGCACCGCCCGGCATGGA 1

RESULT 94
US-09-918-026A-35/c
; Sequence 35, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-35

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1451 GCCAGGGAATCCAGGTCAGC 1470
Db 20 GCCAGGGAATCCAGGTCAGC 1

RESULT 95
US-09-918-026A-36/c
; Sequence 36, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-36

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1541 CACCTCGATCTTGGTCCTGC 1560
Db 20 CACCTCGATCTTGGTCCTGC 1

RESULT 96
US-09-918-026A-54/c
; Sequence 54, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
```

; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-54

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CTGCTTCATCTGGGCGGCC 952
Db 20 CTGCTTCATCTGGGCGGCC 1

RESULT 97
US-09-918-026A-65/c
; Sequence 65, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-65

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 CTGTGCTCGCCATACCTAG 1569
Db 20 CTGTGCTCGCCATACCTAG 1

RESULT 98
US-10-484-441-14/c
; Sequence 14, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE??2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-484-441-14

Query Match 1.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 CCGTCTGCGCTGCGAGGA 37
Db 20 CCGTCTGCGCTGCGAGGA 1

RESULT 99
US-10-484-441-15/c
; Sequence 15, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE??2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-484-441-15

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 GAGCGCCCAACCTGTGGAGA 80
Db 20 GAGCGCCCAACCTGTGGAGA 1

RESULT 100
US-10-484-441-16/c
; Sequence 16, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE??2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-484-441-16

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGGAAACACTGAGCGCACA 100
Db 20 TGGAAACACTGAGCGCACA 1

RESULT 101
US-10-484-441-17/c
; Sequence 17, Application US/10484441

```

; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-17

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 CTTGTACAATGACCCGAC 130
DB 20 CTTGTACAATGACCCGAC 1

RESULT 102
US-10-484-441-18/c
; Sequence 18, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-18

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 AGCAAGCGCAGGACAACTG 180
DB 20 AGCAAGCGCAGGACAACTG 1

RESULT 103
US-10-484-441-19/c
; Sequence 19, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
```

```

; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-19

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGGAGCTGCTGGATCGGC 200
DB 20 AGGAGCTGCTGGATCGGC 1

RESULT 104
US-10-484-441-20/c
; Sequence 20, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-20

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 AGGAGCCATCCCTGGGAAA 300
DB 20 AGGAGCCATCCCTGGGAAA 1

RESULT 105
US-10-484-441-21/c
; Sequence 21, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-21

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 431 TTGATGAGGCGAGCTGCTG 450
|||||
Db 20 TTGATGAGGCGAGCTGCTG 1

RESULT 106
US-10-484-441-22/c
; Sequence 22, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-22

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 CCGTACCGGCGCTACGGCT 560
|||||
Db 20 CCGTACCGGCGCTACGGCT 1

RESULT 107
US-10-484-441-23/c
; Sequence 23, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-23

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GTGGCCGAGGCGCACTGGA 580
|||||
Db 20 GTGGCCGAGGCGCACTGGA 1

RESULT 108
US-10-484-441-24/c
; Sequence 24, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-24

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 581 CGCAGCGAGCGGCTGGGC 600
|||||
Db 20 CGCAGCGAGCGGCTGGGC 1

RESULT 109
US-10-484-441-25/c
; Sequence 25, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-25

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 GTGCCTGGGATCCTTCGTGC 770
|||||
Db 20 GTGCCTGGGATCCTTCGTGC 1

RESULT 110
US-10-484-441-26/c
; Sequence 26, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 26
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-26

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 CAGACGAGGTGAGGGGATCC 790
Db 20 CAGACGAGGTGAGGGGATCC 1

RESULT 111

US-10-484-441-27/c
; Sequence 27, Application US/10484441
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX

; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441

; CURRENT FILING DATE: 2004-01-29

; PRIOR APPLICATION NUMBER: 09/918,026

; PRIOR FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 27

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-484-441-27

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 881 GGAATTATGTGCGCCAGAAC 900
Db 20 GGAATTATGTGCGCCAGAAC 1

RESULT 112

US-10-484-441-28/c
; Sequence 28, Application US/10484441
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX

; FILE REFERENCE: ISPH20694

; CURRENT APPLICATION NUMBER: US/10/484,441

; CURRENT FILING DATE: 2004-01-29

; PRIOR APPLICATION NUMBER: 09/918,026

; PRIOR FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 28

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-484-441-28

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCCTGGCGCCCTCTGTGTT 960

Db 20 TCCTGGCGCCCTCTGTGTT 1

RESULT 113

US-10-484-441-29/c
; Sequence 29, Application US/10484441
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX

; FILE REFERENCE: ISPH20694

; CURRENT APPLICATION NUMBER: US/10/484,441

; CURRENT FILING DATE: 2004-01-29

; PRIOR APPLICATION NUMBER: 09/918,026

; PRIOR FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 29

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-484-441-29

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1021 CTGCATGCCACGTGCCAGG 1040
Db 20 CTGCATGCCACGTGCCAGG 1

RESULT 114

US-10-484-441-30/c
; Sequence 30, Application US/10484441
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX

; FILE REFERENCE: ISPH20694

; CURRENT APPLICATION NUMBER: US/10/484,441

; CURRENT FILING DATE: 2004-01-29

; PRIOR APPLICATION NUMBER: 09/918,026

; PRIOR FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 30

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-484-441-30

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1081 TCCTGGCTCAACGCTTTGC 1100
Db 20 TCCTGGCTCAACGCTTTGC 1

RESULT 115

US-10-484-441-31/c
; Sequence 31, Application US/10484441
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-31

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAACGTGGTGCATGAC 1200
Db 20 GGAACGTGGTGCATGAC 1

RESULT 116
US-10-484-441-32/c
; Sequence 32, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-32

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 TCAGGATGGCTGCGCTCC 1240
Db 20 TCAGGATGGCTGCGCTCC 1

RESULT 117
US-10-484-441-33/c
; Sequence 33, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-33

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 TGGGTGTGTTCTCTGCTCC 1290
Db 20 TGGGTGTGTTCTCTGCTCC 1

RESULT 118
US-10-484-441-34/c
; Sequence 34, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-34

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1401 GCGCACCGCGCGCATGGA 1420
Db 20 GCGCACCGCGCGCATGGA 1

RESULT 119
US-10-484-441-35/c
; Sequence 35, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH?0694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-35

Query Match      1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1451 GCCAGGGAATCCAGTCAGC 1470
Db 20 GCCAGGGAATCCAGTCAGC 1
```



```
RESULT 120
US-10-484-441-36/c
; Sequence 36, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-36

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1541 CACCTCGATCTGGTCTGC 1560
Db 20 CACCTCGATCTGGTCTGC 1

RESULT 121
US-10-484-441-54/c
; Sequence 54, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-54

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CTGCTTCATCTGGGCGCC 952
Db 20 CTGCTTCATCTGGGCGCC 1

RESULT 122
US-10-484-441-65/c
; Sequence 65, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH20694
```

```
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-65

Query Match 1.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 CTTGGTCTGCCATACCTAG 1569
Db 20 CTTGGTCTGCCATACCTAG 1

RESULT 123
US-60-507-481-28158
; Sequence 28158, Application US/60507481
; GENERAL INFORMATION:
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION IN ANIMAL
; TITLE OF INVENTION: MODLES OF INFLAMMATORY DISEASES
; FILE REFERENCE: AM101084
; CURRENT APPLICATION NUMBER: US/60/507,481
; CURRENT FILING DATE: 2003-10-02
; NUMBER OF SEQ ID NOS: 210107
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28158
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Canis familiaris
US-60-507-481-28158

Query Match 1.3%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 GAGCCATCCCTGGGGAACA 302
Db 2 GAGCCATCCCTGGGGAACA 21

RESULT 124
US-09-953-115A-28045
; Sequence 28045, Application US/09953115A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Analysis of Human Genes
; FILE REFERENCE: 3111.1
; CURRENT APPLICATION NUMBER: US/09/953,115A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: 60/232,597
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 33029
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 28045
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-953-115A-28045

Query Match 1.3%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 417 GGCCATCGACTTCATTGATGAGG 439
Db 2 GGCCATTGAGTTCAATTGATGAGG 24

RESULT 125
US-10-719-956-196281
; Sequence 196281, Application US/10719956
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 196281
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-196281

Query Match 1.3%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 916 GGATGTGCTCTATGCTGCTT 938
Db 3 GGATGTGCTCATGCTGCTT 25

RESULT 126
US-60-427-836-196281
; Sequence 196281, Application US/60427836
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527
; CURRENT APPLICATION NUMBER: US/60/427,836
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 196281
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-60-427-836-196281

Query Match 1.3%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 916 GGATGTGCTCTATGCTGCTT 938
Db 3 GGATGTGCTCATGCTGCTT 25

RESULT 127
US-09-605-166A-15
; Sequence 15, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; TITLE OF INVENTION: ACYLTRANSFERASE (ACAT-2)
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166A
; CURRENT FILING DATE: 2003-07-22
; PRIOR APPLICATION NUMBER: 09/328,857

QY 417 GGCCATCGACTTCATTGATGAGG 439
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166A-15

Query Match 1.2%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 1.9e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1253 CCCGAGGGGTAGCCATGCTGGTG 1278
Db 1 CTCGCGGGGTGGCCATGCTGGAGTG 26

RESULT 128
US-09-396-196F-56288/c
; Sequence 56288, Application US/09396196F
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196F
; CURRENT FILING DATE: 2001-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56288
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196F-56288

Query Match 1.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 631 CTCGTGCGGCTGCCGTCCAC 651
Db 22 CTCGTGCGGCTGCCAGTCCAC 2

RESULT 129
US-09-396-196G-56288/c
; Sequence 56288, Application US/09396196G
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56288
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
```

US-09-396-196G-56288

Query Match 1.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 631 CTCGCGCGCTCGGTCAC 651
Db 22 CTCGCGCGCTCAGGTCAC 2

RESULT 130

US-09-954-427A-131448
; Sequence 131448, Application US/09954427A
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat Genome
; FILE REFERENCE: 3112.1
; CURRENT APPLICATION NUMBER: US/09/954,427A
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 60/233,166
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 131448
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus Norvegicus
US-09-954-427A-131448

Query Match 1.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 447 GCTGCTGGAGTTGACCTACT 467
Db 1 GCTGCTGGAGTTGACCTACT 21

RESULT 131

US-10-809-189-56288/c
; Sequence 56288, Application US/10809189
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56288
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-56288

Query Match 1.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 631 CTCGCGCGCTCGGTCAC 651
Db 22 CTCGCGCGCTCAGGTCAC 2

RESULT 132

US-60-507-511-33003

; Sequence 33003, Application US/60507511
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: AM 101081
; CURRENT APPLICATION NUMBER: US/60/507,511
; CURRENT FILING DATE: 2003-10-02
; NUMBER OF SEQ ID NOS: 203623
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33003
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-60-507-511-33003

Query Match 1.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 906 CCAGGCCCTGGGATGTGCT 926
Db 4 CCAGGCCCTGGGATGTGCT 24

RESULT 133

US-09-992-665-70/c
; Sequence 70, Application US/09992665
; GENERAL INFORMATION:
; APPLICANT: Kaia Palm
; TITLE OF INVENTION: PROFILING TUMOR SPECIFIC MARKERS FOR THE
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF NEOPLASTIC DISEASE
; FILE REFERENCE: CEMINES, 002A
; CURRENT APPLICATION NUMBER: US/09/992,665
; CURRENT FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: 60/249,508
; PRIOR FILING DATE: 2000-11-16
; NUMBER OF SEQ ID NOS: 380
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe
US-09-992-665-70

Query Match 1.2%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1088 TCACGCGCTTCCGAGATGCTAC 1111
Db 24 TCACGCGCTTCCGAGATGCTAC 1

RESULT 134

US-09-953-115A-16549/c
; Sequence 16549, Application US/09953115A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Analysis of Human Genes
; FILE REFERENCE: 3111.1
; CURRENT APPLICATION NUMBER: US/09/953,115A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: 60/232,597
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 33029
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 16549
; LENGTH: 25

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-953-115A-16549

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 859 CCTAGGACGCCCTATGTCAGGTGG 882
    |||||
Db 25 CCTGGGACCCCTATGTCAGGTGG 2

RESULT 135
US-09-954-427-8860/c
; Sequence 8860, Application US/09954427
; GENERAL INFORMATION:
; APPLICANT: Mittmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat
; FILE REFERENCE: 3112
; CURRENT APPLICATION NUMBER: US/09/954,427
; CURRENT FILING DATE: 2001-09-17
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8860
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
; PUBLICATION INFORMATION:
; DATABASE ACCESSION NUMBER: GenBank AA817796
US-09-954-427-8860

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1357 TTCCTGTGTCATTGGAGGATGTTG 1380
    |||||
Db 25 TTGTTGTCATTGGAGTATGTTG 2

RESULT 136
US-09-954-427-319630/c
; Sequence 319630, Application US/09954427
; GENERAL INFORMATION:
; APPLICANT: Mittmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat
; FILE REFERENCE: 3112
; CURRENT APPLICATION NUMBER: US/09/954,427
; CURRENT FILING DATE: 2001-09-17
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 319630
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
; PUBLICATION INFORMATION:
; DATABASE ACCESSION NUMBER: GenBank L03382
US-09-954-427-319630

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1293 ACTGGCCCATGATATATCTTCTG 1316
    |||||
Db 24 ACTGACCCAGGAGTATATCTGCTG 1

RESULT 137
US-09-954-427A-353418
; Sequence 353418, Application US/09954427A
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat Genome
; FILE REFERENCE: 3112.1
; CURRENT APPLICATION NUMBER: US/09/954,427A
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 60/233,166
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 353418
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus Norvegicus
US-09-954-427A-353418

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1033 TTGCCAGGATCTTCATGCTGCTG 1056
    |||||
Db 2 TAGCCAGGATCTGCATGCTGCTG 25

RESULT 138
US-09-954-427A-358883
; Sequence 358883, Application US/09954427A
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat Genome
; FILE REFERENCE: 3112.1
; CURRENT APPLICATION NUMBER: US/09/954,427A
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 60/233,166
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 358883
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus Norvegicus
US-09-954-427A-358883

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1110 ACGATTTGGACAGGAGTGTCTA 1133
    |||||
Db 1 ACGCTTTGGTGCACAGGATGTTTA 24

RESULT 139
US-09-954-427A-358886
; Sequence 358886, Application US/09954427A
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat Genome
; FILE REFERENCE: 3112.1
; CURRENT APPLICATION NUMBER: US/09/954,427A
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 60/233,166
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 358886
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus Norvegicus
```

US-09-954-427A-358886

Query Match 1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1161 CTCACACTACTACCGACCTGGAA 1184
DB 2 CTCACACTACTACGAGCCTGGAA 25

RESULT 140

US-10-355-577-231345/c
; Sequence 331345, Application US/10355577
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Genetic Analysis of Probes: HG-U133
; CURRENT APPLICATION NUMBER: US/10/355,577
; FILE REFERENCE: 3121
; CURRENT FILING DATE: 2003-01-31
; NUMBER OF SEQ ID NOS: 997516
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 231345
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien

US-10-355-577-231345

Query Match 1.2%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1368 TCGAGGAATGTTGAACCTCATGAT 1391
DB 24 TTGAGGACTGGTGAACCTCATGAT 1

RESULT 141

US-10-719-900-708096/c
; Sequence 708096, Application US/10719900
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 708096
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus

US-10-719-900-708096

Query Match 1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 507 CTGGGTGCCCATGTTCTCTCCAC 530
DB 24 CTAGGTTCCAATGTTCTCTCCAC 1

RESULT 142

US-10-719-900-922481
; Sequence 922481, Application US/10719900
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 922481
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus

US-10-719-900-922481

Query Match 1.2%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 269 TGAGCAGGACCCAGGAGCCATCCC 292
DB 1 TTAGCAGGACTCAGGAGCCATGCC 24

RESULT 143

US-10-933-982-4119/c
; Sequence 4119, Application US/10933982
; GENERAL INFORMATION:
; APPLICANT: Barts, Jennifer
; TITLE OF INVENTION: Methods of Genetic Analysis of E. coli
; FILE REFERENCE: 3700
; CURRENT APPLICATION NUMBER: US/10/933,982
; CURRENT FILING DATE: 2004-09-03
; NUMBER OF SEQ ID NOS: 224976
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 4119
; LENGTH: 25
; TYPE: DNA
; ORGANISM: E. coli

US-10-933-982-4119

Query Match 1.2%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1342 GTCATGCTGATCTTCTCTGTGC 1365
DB 25 GGCATCTGATCTTCTCTGTGC 2

RESULT 144

US-60-233-166-8860/c
; Sequence 8860, Application US/60233166
; GENERAL INFORMATION:
; APPLICANT: Mittmann
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat
; TITLE OF INVENTION: Genome
; FILE REFERENCE: 3112
; CURRENT APPLICATION NUMBER: US/60/233,166
; CURRENT FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8860
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus

US-60-233-166-8860

Query Match 1.2%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1357 TTCCTTGTCATTCGAGGAATGTTG 1380

```
Db 25 TTGGTTGTCTATGGAGTAATGTTG 2
; ORGANISM: Mus musculus
US-60-427-808-708096
Query Match 1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

RESULT 145
US-60-233-166-319630/c
; Sequence 319630, Application US/60233166
; GENERAL INFORMATION:
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis of the Rat
; FILE REFERENCE: 3112
; CURRENT APPLICATION NUMBER: US/60/233,166
; CURRENT FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 420907
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 319630
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
; PUBLICATION INFORMATION:
; DATABASE ACCESSION NUMBER: GenBank L03382
US-60-233-166-319630
Query Match 1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1293 ACTGCCCATGAGTATATCTCTG 1316
DB 24 ACTGACCCAGGAGTATATCTGCTG 1

RESULT 146
US-60-353-987-231345/c
; Sequence 231345, Application US/60353987
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Genetic Analysis of Probes: HG-U133
; FILE REFERENCE: 3121
; CURRENT APPLICATION NUMBER: US/60/353,987
; CURRENT FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 997516
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 231345
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-60-353-987-231345
Query Match 1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1368 TGGAGGAATGTGAACCTCATGAT 1391
DB 24 TTGAGGACTGGTGAACCTCATGAT 1

RESULT 147
US-60-427-808-708096/c
; Sequence 708096, Application US/60427808
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528
; CURRENT APPLICATION NUMBER: US/60/427,808
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 708096
; LENGTH: 25
; TYPE: DNA
US-60-427-808-708096
Query Match 1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 507 CTGGGTGCCCATGTTTCTGTCCAC 530
DB 24 CTAGTTCCATGTTTCTGTCCAC 1

RESULT 148
US-60-427-808-922481
; Sequence 922481, Application US/60427808
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528
; CURRENT APPLICATION NUMBER: US/60/427,808
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 922481
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-60-427-808-922481
Query Match 1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 269 TGACGAGACCCAGGAGCCATCCC 292
DB 1 TTAGCAGGACTCAGGAGCCATGCC 24

RESULT 149
US-10-714-333A-572077
; Sequence 572077, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572077
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572077
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 881 GGAATATGTGCCCAAGAA 899
DB 1 GGAUAUUGUGCCCAAGAA 19
```



```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572089
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572089

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      206 GGGAGGCTATACAACTCCTA 224
DB      1 GGGAGGCUAUACAUCCUA 19

RESULT 155
US-10-714-333A-572090
; Sequence 572090, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572090
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572090

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      871 TATGTCAGGTGGAATTATG 889
DB      1 UAUGUCAGGUGGAUUAUG 19

RESULT 156
US-10-714-333A-572091
; Sequence 572091, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572091
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572091

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      76 GGAGATGGAACACTGACA 94
DB      1 GGAGAUGGAACACUGAGA 19

RESULT 157
US-10-714-333A-572093
; Sequence 572093, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572093
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572093

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.7e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1329 GTCTCTCTATCCGTCATG 1347
DB      1 GUUCUUCUUAUCCUGCAUG 19

RESULT 158
US-10-714-333A-572094
; Sequence 572094, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```


; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572094
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572094

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 830 GCCCAACTCATCTACAG 848
DB 1 GCCCAACACUACUACAG 19

RESULT 159
US-10-714-333A-572095
; Sequence 572095, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsing, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572095
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572095

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1414 GCATGACGCTGCTGATG 1432
DB 1 GCAUGGACGUGUGAUG 19

RESULT 160
US-10-714-333A-572096
; Sequence 572096, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsing, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572096
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572096

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.7e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1348 CTGATCTCTCTGTCTCA 1366
DB 1 CUGAUCUCCUUGUCA 19

RESULT 161
US-10-714-333A-572098
; Sequence 572098, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsing, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572098
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572098

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1089 CAACGCTTTGCCGAGATG 1107
DB 1 CAACGCCUUGCCGAGAUG 19

RESULT 162
US-10-714-333A-572099
; Sequence 572099, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsing, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572099
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572099

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 1.7e+02;
Matches 9; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY 951 CCTCTGTGTCTCTGCTTT 969
|||:|||||:|||||:|:|:|
Db 1 CCUCUGUGUCCUGUCUUU 19

RESULT 163
US-10-714-333A-572100
; Sequence 572100, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572100
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572100

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1415 CATGGAACGCTGCTGATGTG 1433
|||:|||||:|||||:|:|:|
Db 1 CAUGGAACGUGUGAUGUG 19

RESULT 164
US-10-714-333A-572101
; Sequence 572101, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572101

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572099
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572101

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1291 GCAGTGGCCCATGAGTATA 1309
|||:|||||:|||||:|:|:|
Db 1 GCAGUGGCCCAUGAGUAUA 19

RESULT 165
US-10-714-333A-572104
; Sequence 572104, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572104

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1099 GCCGAGATGCTACGATTGTG 1117
|||:|||||:|||||:|:|:|
Db 1 GCCGAGAGUCCUACGAUUG 19

RESULT 166
US-10-714-333A-572105
; Sequence 572105, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572105
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572105
```

```
US-10-714-333A-572105
Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. NO. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 213 TATACATCTCTACCATCA 231
   |||:|||||:|||||:|||||:
Db 1 UAUAACAACUCCUACCAUCA 19

RESULT 167
US-10-714-333A-572107
; Sequence 572107, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572107

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. NO. 1.7e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1350 GATACCTCTCTCTGTCATT 1368
   |||:|||||:|||||:|||||:
Db 1 GAUACUCUCCUUGUCAU 19

RESULT 168
US-10-714-333A-572109
; Sequence 572109, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572109
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572109

Query Match      1.2%; Score 19; DB 1; Length 19;

US-10-714-333A-572110
; Sequence 572110, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572110
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572110

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. NO. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 453 GGAGTTTGACCTACTGATC 471
   |||:|||||:|||||:|||||:
Db 1 GGAGUUGACCUACUGAUC 19

RESULT 170
US-10-714-333A-572112
; Sequence 572112, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572112
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572112

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. NO. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

US-10-714-333A-572112
; Sequence 572112, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572112
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572112

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. NO. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

US-10-714-333A-572112
; Sequence 572112, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572112
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572112

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. NO. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

US-10-714-333A-572110
; Sequence 572110, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572110
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572110

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. NO. 1.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1428 GATGTGGACCATGCTGTTT 1446
   |||:|||||:|||||:|||||:
Db 1 GAUGUGGACCAUGUGUUU 19
```

```
QY 1546 CGATCTTGGTCTCGCAT 1564
Db 1 CGAUCUUGGCUCCGCAUA 19

RESULT 171
US-10-714-333A-572113
; Sequence 572113, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572113
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572113

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1192 GTCCATGACTGGCTGTACA 1210
Db 1 GUCCAUGACUGGCGUACA 19

RESULT 172
US-10-714-333A-572115
; Sequence 572115, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572115
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572115

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 117 ACAATGGACCCGACATG 135
Db 1 ACAATGGACCCGACATG 19

RESULT 173
US-10-714-333A-572116
; Sequence 572116, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572116
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572116

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 924 GCTCTATGCTGCTTCATC 942
Db 1 GCUCUAGCCUGCUCAUC 19

RESULT 174
US-10-714-333A-572117
; Sequence 572117, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572117
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572117

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 728 GCTACTCCTTCCTGAGAGA 746
Db 1 GCUACUCCUCCUGAGAGA 19

RESULT 175
```

```
US-10-714-333A-572118
; Sequence 572118, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572118
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572118

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 839 TCATCTACAGGGAGACTTA 857
Db 1 UCAUCUACAGGGAGACUUA 19

RESULT 176
US-10-714-333A-572120
; Sequence 572120, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572120
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572120

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 204 GCGGGAGGCTATCAATCC 222
Db 1 GCGGGAGGCUAACAAUCC 19

RESULT 177
US-10-714-333A-572121
; Sequence 572121, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572121
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572121

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1097 TTGCCGAGATGCTACGATT 1115
Db 1 UTGCCGAGAUCCUACGAU 19

RESULT 178
US-10-714-333A-572122
; Sequence 572122, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572122
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572122

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1097 TTGCCGAGATGCTACGATT 1115
Db 1 UTGCCGAGAUCCUACGAU 19

RESULT 179
US-10-714-333A-572125
; Sequence 572125, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572125
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572125

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 222 CTACCCATCACAGACAA 240
Db 1 CUACCAUACACAGACAA 19

RESULT 180
US-10-714-333A-572126
; Sequence 572126, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572126
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572126

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 159 GGAGCAAGCGCAGGACAA 177
Db 1 GGAGCAAGCGCAGGACAA 19

RESULT 181
US-10-714-333A-572129
; Sequence 572129, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572129
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572129

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 63 GCGCAACCCCTGTGGAGAT 81
Db 1 GCGCAACCCUGUGAGAU 19

RESULT 182
US-10-714-333A-572130
; Sequence 572130, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572130
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572130

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 115 GTACAATGACCCGACACA 133
Db 1 GUACAAUGGACCCGACACA 19

RESULT 183
US-10-714-333A-572131
; Sequence 572131, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
```

```

:
: CURRENT FILING DATE: 2003-11-14
: PRIOR APPLICATION NUMBER: 60/502,050
:
: PRIOR FILING DATE: 2003-09-10
: PRIOR APPLICATION NUMBER: 60/426,137
:
: PRIOR FILING DATE: 2002-11-14
: NUMBER OF SEQ ID NOS: 1591911
:
: SOFTWARE: Proprietary
:
: SEQ ID NO 52131
:
:   LENGTH: 19
:   TYPE: RNA
:
:   ORGANISM: Homo sapiens
US-10-714-333A-572131

```

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 1.7e+02;
Matches 10; Conservative 9; Mismatches 0; Indels

Qy 1301 ATGAGTATATCTTCTGCTT 1319
|:|:|:|:|:|:|:|:|:|:
Db 1 AUGAGUAUAUCUUCUGCUU 19

```

RESULT 184
US-10-714-333A-572132
; Sequence 572132, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyper
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572132
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572132

```

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels

Qy 1290 CGCAGTGGCCCATGAGTAT 1308
Dy 1 CGCAGUGGGCCCAUGAGUAA 19

```

RESULT 185
US-10-714-333A-572133
; Sequence 572133, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Khvortova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfu
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

```

```

; PRIOR APPLICATION NUMBER: 60/426,137
;
; PRIOR FILING DATE: 2002-11-14
;
; NUMBER OF SEQ ID NOS: 1591911
;
; SOFTWARE: PROPRIETARY
;
; SEQ ID NO 572133
;
; LENGTH: 19
;
; TYPE: RNA
;
; ORGANISM: Homo sapiens
US-10-714-333A-572133

```

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels

Qy 1289 CCGCAGTGGCCCATGAGTA 1307
|||:|:|:|:|:|:
Db 1 CCGCAGUGGCCCAUGAGUA 19

```

RESULT 186
US-10-714-333A-572134
; Sequence 572134, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572134

```

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels

Qy 912 CCTGGGATGTGTGCTCTAT 930
||:||||:|:|:|:|:|:|:|:
Db 1 CCUGGGAUGUGUGCUCUAU 19

```

RESULT 187
US-10-714-333A-572135
; Sequence 572135, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1591911

```

```
; SOFTWARE: Proprietary
; SEQ ID NO 572135
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572135

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 726 AAGTACTCCTCTCTGAGA 744
DB 1 AAGCUACUCCUUCUGAGA 19

RESULT 188
US-10-714-333A-572136
; Sequence 572136, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572136
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572136

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 454 GAGTTTGACCTACTGATCT 472
DB 1 GAGUUUGACCUAGUACU 19

RESULT 189
US-10-714-333A-572137
; Sequence 572137, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572137
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572137

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 450 GCTGGAGTTTGACCTACTG 468
DB 1 GCUGGAGUUGACCUACUG 19

RESULT 190
US-10-714-333A-572140
; Sequence 572140, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572140
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572140

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1367 TTGAGGAGTGTGAACTT 1385
DB 1 UUGGAGGAUUGUUGAACUU 19

RESULT 191
US-10-714-333A-572141
; Sequence 572141, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572141
```


Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1297 GCCCATGAGTATATCTTCT 1315
|||||:||||:||||:||||:
Db 1 GCCCAUGAUUAUCUUCU 19

RESULT 192

US-10-714-333A-572142
; Sequence 572142, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572142
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572142

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 363 CACCATCTACCACATGTC 381
|||||:||||:||||:||||:
Db 1 CACCAUCUACCACAGUUC 19

RESULT 193

US-10-714-333A-572143
; Sequence 572143, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572143
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572143

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.7e+02;

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 64 CGCCAACCTGTGGAGATG 82
|||||:||||:||||:||||:
Db 1 CGCCAACCCUGUGGAGAUG 19

RESULT 194

US-10-714-333A-572144
; Sequence 572144, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572144
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572144

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 66 CCAACCTGTGGAGATGGA 84
|||||:||||:||||:||||:
Db 1 CCAACCCUGGAGAUGGA 19

RESULT 195

US-10-714-333A-572145
; Sequence 572145, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 572145
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-572145

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 443 GGCTGCTGTGGAGTTGA 461

		: : : :			
Db	1	GGCUGCUGCGAGUUUGA 19			
RESULT 196					
US-10-714-333A-572146					
; Sequence 572146, Application US/10714333A					
; GENERAL INFORMATION:					
; APPLICANT: Dharmacon, Inc.					
; APPLICANT: Khvorova, Anastasia					
; APPLICANT: Reynolds, Angela					
; APPLICANT: Leake, Devin					
; APPLICANT: Marshall, William					
; APPLICANT: Scaringe, Stephen					
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA					
; FILE REFERENCE: 13499US					
; CURRENT APPLICATION NUMBER: US/10/714,333A					
; CURRENT FILING DATE: 2003-11-14					
; PRIOR APPLICATION NUMBER: 60/502,050					
; PRIOR FILING DATE: 2003-09-10					
; PRIOR APPLICATION NUMBER: 60/426,137					
; PRIOR FILING DATE: 2002-11-14					
; NUMBER OF SEQ ID NOS: 1591911					
; SOFTWARE: Proprietary					
; SEQ ID NO 572146					
; LENGTH: 19					
; TYPE: RNA					
; ORGANISM: Homo sapiens					
US-10-714-333A-572146					
Query Match					
Best Local Similarity 1.2%; Score 19; DB 1; Length 19;					
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;					
Qy	74	GTGGAGATGCAACACTGA 92	: : : :		
Db	1	GUGGAGUGGCAACACUGA 19	: : : :		
RESULT 197					
US-10-714-333A-572148					
; Sequence 572148, Application US/10714333A					
; GENERAL INFORMATION:					
; APPLICANT: Dharmacon, Inc.					
; APPLICANT: Khvorova, Anastasia					
; APPLICANT: Reynolds, Angela					
; APPLICANT: Leake, Devin					
; APPLICANT: Marshall, William					
; APPLICANT: Scaringe, Stephen					
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA					
; FILE REFERENCE: 13499US					
; CURRENT APPLICATION NUMBER: US/10/714,333A					
; CURRENT FILING DATE: 2003-11-14					
; PRIOR APPLICATION NUMBER: 60/502,050					
; PRIOR FILING DATE: 2003-09-10					
; PRIOR APPLICATION NUMBER: 60/426,137					
; PRIOR FILING DATE: 2002-11-14					
; NUMBER OF SEQ ID NOS: 1591911					
; SOFTWARE: Proprietary					
; SEQ ID NO 572148					
; LENGTH: 19					
; TYPE: RNA					
; ORGANISM: Homo sapiens					
US-10-714-333A-572148					
Query Match					
Best Local Similarity 1.2%; Score 19; DB 1; Length 19;					
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;					
Qy	806	CCAGCTACCTCTACTTCT 824	: : : :		
Db	1	CCAGCUACCUACUCCU 19	: : : :		

		: : : :			
Db	1	GGCUGCUGCGAGUUUGA 19			
RESULT 198					
US-10-714-333A-572149					
; Sequence 572149, Application US/10714333A					
; GENERAL INFORMATION:					
; APPLICANT: Dharmacon, Inc.					
; APPLICANT: Khvorova, Anastasia					
; APPLICANT: Reynolds, Angela					
; APPLICANT: Leake, Devin					
; APPLICANT: Marshall, William					
; APPLICANT: Scaringe, Stephen					
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA					
; FILE REFERENCE: 13499US					
; CURRENT APPLICATION NUMBER: US/10/714,333A					
; CURRENT FILING DATE: 2003-11-14					
; PRIOR APPLICATION NUMBER: 60/502,050					
; PRIOR FILING DATE: 2003-09-10					
; PRIOR APPLICATION NUMBER: 60/426,137					
; PRIOR FILING DATE: 2002-11-14					
; NUMBER OF SEQ ID NOS: 1591911					
; SOFTWARE: Proprietary					
; SEQ ID NO 572149					
; LENGTH: 19					
; TYPE: RNA					
; ORGANISM: Homo sapiens					
US-10-714-333A-572149					
Query Match					
Best Local Similarity 1.2%; Score 19; DB 1; Length 19;					
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;					
Qy	1182	GAACGTGGTGTCCTCATGAC 1200	: : : :		
Db	1	GAACGUGGUGGUCAUGAC 19	: : : :		
RESULT 199					
US-10-714-333A-572150					
; Sequence 572150, Application US/10714333A					
; GENERAL INFORMATION:					
; APPLICANT: Dharmacon, Inc.					
; APPLICANT: Khvorova, Anastasia					
; APPLICANT: Reynolds, Angela					
; APPLICANT: Leake, Devin					
; APPLICANT: Marshall, William					
; APPLICANT: Scaringe, Stephen					
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA					
; FILE REFERENCE: 13499US					
; CURRENT APPLICATION NUMBER: US/10/714,333A					
; CURRENT FILING DATE: 2003-11-14					
; PRIOR APPLICATION NUMBER: 60/502,050					
; PRIOR FILING DATE: 2003-09-10					
; PRIOR APPLICATION NUMBER: 60/426,137					
; PRIOR FILING DATE: 2002-11-14					
; NUMBER OF SEQ ID NOS: 1591911					
; SOFTWARE: Proprietary					
; SEQ ID NO 572150					
; LENGTH: 19					
; TYPE: RNA					
; ORGANISM: Homo sapiens					
US-10-714-333A-572150					
Query Match					
Best Local Similarity 1.2%; Score 19; DB 1; Length 19;					
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;					
Qy	391	CTGTGTCTTCATCATCA 409	: : : : : : : : :		
Db	1	CUGUGUGUCUCAUCA 19	: : : : : : : : :		
RESULT 200					
US-10-714-333A-572151					


```
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/10/714,333A
/ CURRENT FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 572158
/ TYPE: RNA
/ LENGTH: 19
/ ORGANISM: Homo sapiens
US-10-714-333A-572158

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1292 CAGTGGCCCATGAGTATAT 1310
      |||:|||||:|||||:|:|:
Db 1 CAGUGGCCCAUGAGUAU 19

RESULT 205
US-10-714-333A-572159
/ Sequence 572159, Application US/10714333A
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/10/714,333A
/ CURRENT FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 572159
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-714-333A-572159

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1286 TCTCCGCACTGGCCCATGA 1304
      :|:|||||:|||||:|:|:
Db 1 UCUCGCGCAGUGGCCCAUGA 19

RESULT 206
US-10-714-333A-572160
/ Sequence 572160, Application US/10714333A
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/10/714,333A
/ CURRENT FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 572160
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-714-333A-572160

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 407 TCAGCACCTGGCCCATCGA 425
      :|||||:|||||:|:|:
Db 1 UCAGCACCCUGGCCCAUGA 19

RESULT 207
PCT-US02-22746-58/c
/ Sequence 58, Application PC/TUS0222746
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Rosanne M. Crooke
/ APPLICANT: Mark J. Graham
/ APPLICANT: Kristina M. Lemonidis
/ TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
/ TITLE OF INVENTION: EXPRESSION
/ FILE REFERENCE: ISPH-0694
/ CURRENT APPLICATION NUMBER: PCT/US02/22746
/ CURRENT FILING DATE: 2002-07-15
/ PRIOR APPLICATION NUMBER: 09/918,026
/ PRIOR FILING DATE: 2001-07-30
/ NUMBER OF SEQ ID NOS: 65
/ SEQ ID NO 58
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-58

Query Match      1.2%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1133 ACCGGGACTGGTGGAACTC 1151
      |||||:|||||:|||||:|:|:
Db 20 ACCGGGACTGGTGGAACTC 2

RESULT 208
US-09-918-026A-58/c
/ Sequence 58, Application US/09918026A
/ GENERAL INFORMATION:
/ APPLICANT: Rosanne M. Crooke
/ APPLICANT: Mark J. Graham
/ APPLICANT: Kristina M. Lemonidis
/ TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXI
/ FILE REFERENCE: ISPH-0588
/ CURRENT APPLICATION NUMBER: US/09/918,026A
/ CURRENT FILING DATE: 2001-07-30
/ NUMBER OF SEQ ID NOS: 65
/ SEQ ID NO 58
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
```

```
;
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-58

Query Match      1.2%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1133 ACCGGGACTGGTGGAACTC 1151
    |||||
Db 20 ACCGGGACTGGTGGAACTC 2

RESULT 209
US-10-484-441-58/c
; Sequence 58, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemondis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE2 EX
; FILE REFERENCE: ISPH70694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-58

Query Match      1.2%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1133 ACCGGGACTGGTGGAACTC 1151
    |||||
Db 20 ACCGGGACTGGTGGAACTC 2

RESULT 210
US-09-956-584A-196181/c
; Sequence 196181, Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 196181
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-196181

Query Match      1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 789 CCAGGCCCCCAGTTCTCCAGC 810
    |||||
Db 24 CCAGGCCCCCAGTTCTCCAGC 3

RESULT 211
```

```
US-09-956-584A-401061/c
; Sequence 401061, Application US/09956584A
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Genetic Analysis of Mouse
; FILE REFERENCE: 3115.1
; CURRENT APPLICATION NUMBER: US/09/956,584A
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/234,017
; PRIOR FILING DATE: 2000-09-20
; NUMBER OF SEQ ID NOS: 605887
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 401061
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-956-584A-401061

Query Match      1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAGCAGGACCCAGGAGCCATCC 291
    |||||
Db 24 GAGCAGGACCCAGGAGCCATCC 3

RESULT 212
US-10-355-577-248204/c
; Sequence 248204, Application US/10355577
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Genetic Analysis of Probes: HG-UI33
; FILE REFERENCE: 3121
; CURRENT APPLICATION NUMBER: US/10/355,577
; CURRENT FILING DATE: 2003-01-31
; NUMBER OF SEQ ID NOS: 997516
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248204
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-355-577-248204

Query Match      1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1189 GTGGTCCATGACTGGCTGTACA 1210
    |||||
Db 23 GTGGTCCATGACTGGCTGTACA 2

RESULT 213
US-10-355-577-611341/c
; Sequence 611341, Application US/10355577
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Genetic Analysis of Probes: HG-UI33
; FILE REFERENCE: 3121
; CURRENT APPLICATION NUMBER: US/10/355,577
; CURRENT FILING DATE: 2003-01-31
; NUMBER OF SEQ ID NOS: 997516
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 611341
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-355-577-611341

Query Match      1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 236 ACAAACTCTGCCCCCACTCC 257
Db 22 AGAACTCTGCCCTTACTCC 1

RESULT 214
US-10-717-597-573/c
; Sequence 573, Application US/10717597
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 573
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-573

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 278 CCAGGAGGCATCCCTGGGAA 299
Db 23 CCAGGAGGCATCTCGGGAA 2

RESULT 215
US-10-719-900-368436
; Sequence 368436, Application US/10719900
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 368436
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-368436

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 729 CTACTCTTCCTGAGAGGCT 750
Db 4 CTACTCTTCCTGAGAGGCT 25

RESULT 216
US-10-719-900-922643
; Sequence 922643, Application US/10719900
```

```
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 922643
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-922643

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 TAGCCATGCTGGTGTGTTCT 1283
Db 2 TAGCCATGCTGAGTGTCTTCT 23

RESULT 217
US-10-719-900-922644
; Sequence 922644, Application US/10719900
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 922644
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-922644

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 TAGCCATGCTGGTGTGTTCT 1283
Db 2 TAGCCATGCTGAGTGTCTTCT 23

RESULT 218
US-60-353-987-248204/c
; Sequence 248204, Application US/60353987
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Genetic Analysis of Probes: HG-U133
; FILE REFERENCE: 3121
; CURRENT APPLICATION NUMBER: US/60/353,987
; CURRENT FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 997516
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248204
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-60-353-987-248204

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 1189 GTGGTCCATGACGTGGCTGTACA 1210
Db 23 GGGGTCCATGACGTGGCTGTACA 2

RESULT 219
US-60-353-987-611341/c
; Sequence 611341, Application US/60353987
; GENERAL INFORMATION:
; APPLICANT: Mittmann, Michael
; TITLE OF INVENTION: Methods of Genetic Analysis of Probes: HG-UI133
; FILE REFERENCE: 3121
; CURRENT APPLICATION NUMBER: US/60/353,987
; CURRENT FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 997516
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 611341
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-60-353-987-611341

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 236 ACAAACTCTGCCCCACCTCC 257
Db 22 AGAACCTCTGCCCTACCTCC 1

RESULT 220
US-60-427-808-368436
; Sequence 368436, Application US/60427808
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528
; CURRENT APPLICATION NUMBER: US/60/427,808
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 368436
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-60-427-808-368436

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 729 CTACTCTTCTCTGAGAGGCT 750
Db 4 CTACTCTTCTCTGAGAGGCT 25

RESULT 221
US-60-427-808-922643
; Sequence 922643, Application US/60427808
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528
; CURRENT APPLICATION NUMBER: US/60/427,808
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 922643
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus

US-60-427-808-922643

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 TAGCCATGCTGGGTGTTCTT 1283
Db 2 TAGCCATGCTGAGTGTCTTCTT 23

RESULT 222
US-60-427-808-922644
; Sequence 922644, Application US/60427808
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528
; CURRENT APPLICATION NUMBER: US/60/427,808
; CURRENT FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 922644
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-60-427-808-922644

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 TAGCCATGCTGGGTGTTCTT 1283
Db 2 TAGCCATGCTGAGTGTCTTCTT 23

RESULT 223
US-60-507-511-77492
; Sequence 77492, Application US/60507511
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: AM 101081
; CURRENT APPLICATION NUMBER: US/60/507,511
; CURRENT FILING DATE: 2003-10-02
; NUMBER OF SEQ ID NOS: 203623
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77492
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-60-507-511-77492

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 277 ACCCAGGAGCCATCCCTGGGGA 298
Db 4 ACCCAGGAGCCAGCACTGGGGA 25

RESULT 224
US-60-545-213-186753
; Sequence 186753, Application US/60545213
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TARGET GENES

FILE REFERENCE: AM101083 (031896-042099)
CURRENT FILING DATE: 2004-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 186753
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-60-545-213-186753

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 277 ACCCAGGAGCCATCCCTGGGA 298
|||||
DB 4 ACCCAGGAGCCACTGGGA 25

RESULT 225
US-60-545-213-186754
Sequence 186754, Application US/60545213
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042099)
CURRENT FILING DATE: 2004-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 186754
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-60-545-213-186754

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 277 ACCCAGGAGCCATCCCTGGGA 298
|||||
DB 4 ACCCAGGAGCCACTGGGA 25

RESULT 226
PCT-US02-22746-52/c
Sequence 52, Application PC/TUS0222746
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
FILE REFERENCE: ISPH-0694
CURRENT FILING DATE: 2002-07-15
PRIOR FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 09/918,026
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 52
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-52

Query Match 1.2%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 743 GAGAGGCTGTGCTGGGATC 762
|||||
DB 20 GAGAGACTGTGCTGGGATC 1

RESULT 227
US-09-918-026A-52/c
Sequence 52, Application US/09918026A
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXI
FILE REFERENCE: ISPH-0588
CURRENT FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 52
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-52

Query Match 1.2%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 743 GAGAGGCTGTGCTGGGATC 762
|||||
DB 20 GAGAGACTGTGCTGGGATC 1

RESULT 228
US-10-484-441-52/c
Sequence 52, Application US/10484441
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXI
FILE REFERENCE: ISPH-0694
CURRENT FILING DATE: 2004-01-29
PRIOR FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 52
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-52

Query Match 1.2%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 743 GAGAGGCTGTGCTGGGATC 762
|||||
DB 20 GAGAGACTGTGCTGGGATC 1

RESULT 229
US-09-605-166-9/c
Sequence 9, Application US/09605166
GENERAL INFORMATION:
APPLICANT: Cases, Sylvaine


```
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: ACYLTRANSFERASE (ACAT-2)
; CURRENT FILING DATE: 2000-06-27
; PRIOR FILING DATE: 2000-06-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166-9

Query Match      1.2%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 2.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1549 TCTTGGTCTCGCCATACCTA 1568
Db 21 TCTTGGTCTCGCCATCCCTA 2

RESULT 230
US-09-605-166A-9/c
; Sequence 9, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: ACYLTRANSFERASE (ACAT-2)
; CURRENT FILING DATE: 2003-07-22
; PRIOR FILING DATE: 2000-06-08
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166A-9

Query Match      1.2%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 2.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1549 TCTTGGTCTCGCCATACCTA 1568
Db 21 TCTTGGTCTCGCCATCCCTA 2

RESULT 231
US-10-779-251-9/c
; Sequence 9, Application US/10779251
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; APPLICANT: Accad, Michel
; TITLE OF INVENTION: Novel acyl CoA:cholesterol
```

```
; TITLE OF INVENTION: acyltransferase (ACAT-2)
; FILE REFERENCE: UCAL-104CON
; CURRENT APPLICATION NUMBER: US/10/779,251
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 09/605,166
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-779-251-9

Query Match      1.2%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 2.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1549 TCTTGGTCTCGCCATACCTA 1568
Db 21 TCTTGGTCTCGCCATCCCTA 2

RESULT 232
US-09-605-166-4/c
; Sequence 4, Application US/09605166
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: ACYLTRANSFERASE (ACAT-2)
; CURRENT FILING DATE: 2000-06-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166-4

Query Match      1.2%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 2.5e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 749 CTGTGCTGGATCCTTCGTGCC 771
Db 23 CTGTGCTGGATCTTTGTGTC 1

RESULT 233
US-09-605-166A-4/c
; Sequence 4, Application US/09605166A
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
; FILE REFERENCE: UCAL-104CIP
; CURRENT APPLICATION NUMBER: US/09/605,166A
```

```
/ FILE REFERENCE: 6510-104CIP
/ CURRENT APPLICATION NUMBER: US/09/605,166
/ CURRENT FILING DATE: 2000-06-27
/ NUMBER OF SEQ ID NOS: 9
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 3
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: primer
US-09-605-166-3
```

```
Query Match 1.2%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 2.5e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 749 CTGTGCTGGGATCCTTCGTGCC 771
Db 23 CTGTGCTGGGATCCTTCGTGTC 1
```

```
RESULT 234
US-10-779-251-4/c
/ Sequence 4, Application US/10779251
/ GENERAL INFORMATION:
/ APPLICANT: Cases, Sylvaine
/ APPLICANT: Farese, Robert
/ APPLICANT: Erickson, Sandra
/ APPLICANT: Novak, Sabine
/ APPLICANT: Accad, Michel
/ TITLE OF INVENTION: Novel acyl CoA:cholesterol
/ FILE REFERENCE: UCAL-104CON
/ CURRENT APPLICATION NUMBER: US/10/779,251
/ CURRENT FILING DATE: 2004-02-12
/ PRIOR APPLICATION NUMBER: 09/605,166
/ PRIOR FILING DATE: 2000-06-27
/ PRIOR APPLICATION NUMBER: 09/328,857
/ PRIOR FILING DATE: 1999-06-08
/ PRIOR APPLICATION NUMBER: 60/090,354
/ PRIOR FILING DATE: 1998-06-23
/ NUMBER OF SEQ ID NOS: 9
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 4
/ LENGTH: 23
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: primer
US-10-779-251-4
```

```
Query Match 1.2%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 2.5e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 749 CTGTGCTGGGATCCTTCGTGCC 771
Db 23 CTGTGCTGGGATCCTTCGTGTC 1
```

```
RESULT 235
US-09-605-166-3
/ Sequence 3, Application US/09605166
/ GENERAL INFORMATION:
/ APPLICANT: Cases, Sylvaine
/ APPLICANT: Farese, Robert
/ APPLICANT: Erickson, Sandra
/ APPLICANT: Novak, Sabine
/ TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
/ FILE REFERENCE: ACYLTRANSFERASE (ACAT-2)
```

```
/ FILE REFERENCE: 6510-104CIP
/ CURRENT APPLICATION NUMBER: US/09/605,166
/ CURRENT FILING DATE: 2000-06-27
/ NUMBER OF SEQ ID NOS: 9
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 3
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: primer
US-09-605-166-3
```

```
Query Match 1.2%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 611 TAGCCGCCACGCCGTGTGCTC 633
Db 2 TGGCTGCCACGCTGTGTGCTC 24
```

```
RESULT 236
US-09-605-166A-3
/ Sequence 3, Application US/09605166A
/ GENERAL INFORMATION:
/ APPLICANT: Cases, Sylvaine
/ APPLICANT: Farese, Robert
/ APPLICANT: Erickson, Sandra
/ APPLICANT: Novak, Sabine
/ TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
/ FILE REFERENCE: UCAL-104CIP
/ CURRENT APPLICATION NUMBER: US/09/605,166A
/ CURRENT FILING DATE: 2003-07-22
/ PRIOR APPLICATION NUMBER: 09/328,857
/ PRIOR FILING DATE: 1999-06-08
/ PRIOR APPLICATION NUMBER: 60/090,354
/ PRIOR FILING DATE: 1998-06-23
/ NUMBER OF SEQ ID NOS: 17
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 3
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: primer
US-09-605-166A-3
```

```
Query Match 1.2%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 611 TAGCCGCCACGCCGTGTGCTC 633
Db 2 TGGCTGCCACGCTGTGTGCTC 24
```

```
RESULT 237
US-09-605-166A-14
/ Sequence 14, Application US/09605166A
/ GENERAL INFORMATION:
/ APPLICANT: Cases, Sylvaine
/ APPLICANT: Farese, Robert
/ APPLICANT: Erickson, Sandra
/ APPLICANT: Novak, Sabine
/ TITLE OF INVENTION: NOVEL ACYL COA: CHOLESTEROL
/ FILE REFERENCE: ACYLTRANSFERASE (ACAT-2)
/ CURRENT APPLICATION NUMBER: US/09/605,166A
/ CURRENT FILING DATE: 2003-07-22
/ PRIOR APPLICATION NUMBER: 09/328,857
/ PRIOR FILING DATE: 1999-06-08
```

; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-605-166A-14

Query Match 1.2%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 749 CTGTGCTGGGATCCTTCGTGCC 771
|||||
DB 2 CTGTGCTGGGATCCTTCGTGCC 24

RESULT 238
US-10-779-251-3
; Sequence 3, Application US/10779251
; GENERAL INFORMATION:
; APPLICANT: Cases, Sylvaine
; APPLICANT: Farese, Robert
; APPLICANT: Erickson, Sandra
; APPLICANT: Novak, Sabine
; APPLICANT: Accad, Michel
; TITLE OF INVENTION: Novel acyl CoA:cholesterol
; FILE REFERENCE: acyltransferase (ACAT-2)
; CURRENT APPLICATION NUMBER: US/10/779,251
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 09/605,166
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 09/328,857
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/090,354
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-779-251-3

Query Match 1.2%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 611 TAGCCGCCACCGCGTGGTCTC 633
|||||
DB 2 TGGCTGCCACCGTGGTGGTCTC 24

RESULT 239
PCT-US02-22746-57/c
; Sequence 57, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15

; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-57

Query Match 1.1%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1035 GCCAGGCATCTTCATGCT 1052
|||||
DB 18 GCCAGGCATCTTCATGCT 1

RESULT 240
US-09-918-026A-57/c
; Sequence 57, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-57

Query Match 1.1%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1035 GCCAGGCATCTTCATGCT 1052
|||||
DB 18 GCCAGGCATCTTCATGCT 1

RESULT 241
US-10-484-441-57/c
; Sequence 57, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-57

Query Match 1.1%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

	Matches	18;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1035	GCCAGGCATCTTCATGCT	1052							
Dd	18	GCCAGGCATCTTCATGCT	1							

```

RESULT 242
PCT-US02-25943-38342/c
; Sequence 38342, Application PC/TUS0225943
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: PCT/US02/25943
; CURRENT FILING DATE: 2002-08-27
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 38342
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (3752231)...(3752251)
; OTHER INFORMATION: Chromosome = 1 Strand = negative
PCT-US02-25943-38342
ConnectronObjectNumber = 41087

```

Query Match	1.1%;	Score 18;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 2.5e+02;		
Matches 18;	Conservative	0;	Mismatches 0;	Indels 0;
				Gaps 0;

Qy 537 GCGCCGTACAGGCCCT 554
|||||
Db 21 GCGCCGTACAGGCCCT 4

```

RESULT 243
US-10-227-565-38342/c
; Sequence 38342, Application US/10227565
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegger Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/227,565
; CURRENT FILING DATE: 2002-08-26
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 38342
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (3752231)...(3752251)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectorObjectNumber = 41087
US-10-227-565-38342

```

```
Query Match      1.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      537 GGC GCCGTAC CAGGCCCT 554
          |||||
Db      21 GGC GCCGTAC CAGGCCCT 4

RESULT 244
US - 367-832A-38342/c
; Sequence 38342, Application US/10367832A
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
CURRENT APPLICATION NUMBER: US/10/367,832A

```

```
; CURRENT FILING DATE: 2002-08-26
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 38342
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (3752231)...(3752251)
; OTHER INFORMATION: Chromosome = 1 Strand = negative
US-10-367-832A-18342
ConnectronObjectNumber = 41087
```

Query Match	1.1%	Score 18;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 2.5e+02;		
Matches	18;	Conservative	0;	Mismatches 0;
			0;	Indels 0;
				Gaps 0;

Qy 537 GGCGCGGTACGAGCCCT 554
|||
pb 21 GGCGCGGTACGAGCCCT 4

```

RESULT 245
PCT-US02-22746-12/c
; Sequence 12, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
PCT-US02-22746-12

```

Query Match	1.1%;	Score 17.8;	DB 1;	Length 21;
Best Local Similarity	90.5%;	Pred. No. 2.6e+02;		
Matches	19;	Conservative	0;	Mismatches 2;
				Indels 0;
				Gaps 0;

QY 109 GACTTGGTACAATGGACCCGA 129
 |||||
 Db 21 GACTTGGTGAATGGACTCGA 1

```

RESULT 246
US-09-918-026A-12/c
; Sequence 12, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXON
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-918-026A-12

```

```
Query Match          1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 109 GACTTGGTACAAATGGACCCGA 129
DB 21 GACTTGGTCAATGGACTCGA 1

RESULT 247
US-10-484-441-12/c
; Sequence 12, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-484-441-12

Query Match          1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 109 GACTTGGTACAAATGGACCCGA 129
DB 21 GACTTGGTCAATGGACTCGA 1

RESULT 248
US-10-310-188-40082/c
; Sequence 40082, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GEN
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40082
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-40082

Query Match          1.1%; Score 17.8; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 391 CTGTGTGTCTTCATCATCAGC 411
DB 23 CTGAGTGTCTTCATCATCTGC 3

RESULT 249
US-10-714-333A-474874
; Sequence 474874, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 474874
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-474874

Query Match          1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1181 GGAACGTGTGTTCATGA 1199
DB 1 GGAAUGUGUGGUCCAUGA 19

RESULT 250
US-10-714-333A-666176/c
; Sequence 666176, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 666176
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-666176

Query Match          1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTGCTTCCTCC 1078
DB 19 ATCTTCTGTGCTTCCTCC 1

RESULT 251
US-10-714-333A-672962/c
; Sequence 672962, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 672962
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-672962
```

```
Query Match 1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1051 CTGCTGCTCATCTCTTTG 1069
||| ||||| ||||| |||||
DB 19 CTTCTGCTCATCTCTTTG 1
```

```
RESULT 252
US-10-714-333A-707046
; Sequence 707046, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 707046
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-707046
```

```
Query Match 1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 833 CAACACTCATCTACAGGA 851
||| ||||| ||||| |||||
DB 1 CAACACUACUACAGAGA 19
```

```
RESULT 253
US-10-714-333A-763971/c
; Sequence 763971, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 763971
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-763971
```

```
Query Match 1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1309 ATCTTCTGCTTCTGCTGG 1327
||| ||||| ||||| |||||
DB 19 ATCTTCTGCTTCTTCTGG 1
```

```
RESULT 254
US-10-714-333A-950069/c
; Sequence 950069, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 950069
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-950069
```

```
Query Match 1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1060 ATCTTCTTTCCTTCTCC 1078
||| ||||| ||||| |||||
DB 19 AACTTCTTTCCTTCTCC 1
```

```
RESULT 255
US-10-714-333A-1245563/c
; Sequence 1245563, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
```

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1245563
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1245563

Query Match 1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1509 CTTACCCAGGCACTTC 1527
Db 19 CTTACACAGGCACTTC 1

RESULT 256

US-10-714-333A-1336210/c
; Sequence 1336210, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1336210
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1336210

Query Match 1.1%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 ATCTCTTTGCTTCCTCC 1078
Db 19 AACTCTTTGCTTCCTCC 1

RESULT 257

US-09-531-025A-846/c
; Sequence 846, Application US/09531025A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH800-845-B (247/277)
; CURRENT APPLICATION NUMBER: US/09/531,025A
; CURRENT FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07

; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6341
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-531-025A-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGTTCCTTGACGAGCA 277
Db 17 AGTTCCTTGACGAGCA 1

RESULT 258

US-09-636-385-846/c
; Sequence 846, Application US/09636385
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH800-845-F (250/125)
; CURRENT APPLICATION NUMBER: US/09/636,385
; CURRENT FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6341
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-636-385-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGTTCCTTGACGAGCA 277
Db 17 AGTTCCTTGACGAGCA 1

RESULT 259

US-09-696-347-846/c
; Sequence 846, Application US/09696347
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/001
; CURRENT APPLICATION NUMBER: US/09/696,347

; CURRENT FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6389
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-09-696-347-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCTTGAGCAGGA 277
Db 17 AGGTTCTTGAGCAGGA 1

RESULT 260

US-09-877-478-846/c
; Sequence 846, Application US/09877478
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MH800-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCTTGAGCAGGA 277
Db 17 AGGTTCTTGAGCAGGA 1

RESULT 261

US-10-342-902-846/c
; Sequence 846, Application US/10342902
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MH800-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGGTTCTTGAGCAGGA 277
Db 17 AGGTTCTTGAGCAGGA 1

RESULT 262

US-10-669-841-846/c
; Sequence 846, Application US/10669841
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MH802-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24

PRIOR APPLICATION NUMBER: US 60/337,055
PRIOR FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 09/817,879
PRIOR FILING DATE: 2001-03-26
PRIOR APPLICATION NUMBER: US 09/740,332
PRIOR FILING DATE: 2000-12-18
PRIOR APPLICATION NUMBER: US 09/611,931
PRIOR FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: US 09/504,321
PRIOR FILING DATE: 2000-02-15
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 16207
SOFTWARE: PatentIn version 3.0
SEQ ID NO 846
LENGTH: 17
TYPE: RNA
ORGANISM: Hepatitis B Virus
US-10-669-841-846

Query Match 1.1%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGTTCCTTGAGCAGGA 277
Db 17 AGTTCCTTGAGCAGGA 1

RESULT 263
PCT-US02-22746-46/c
Sequence 46, Application PC/TUS0222746
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
FILE REFERENCE: ISPH-0694
CURRENT APPLICATION NUMBER: PCT/US02/22746
CURRENT FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 09/918,026
PRIOR FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 46
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-46

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 435 TGAGGCGAGGCTGCTGG 454
Db 20 TGAGGCGAGGCTGCTGG 1

RESULT 264
PCT-US02-22746-47/c
Sequence 47, Application PC/TUS0222746
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis

TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
TITLE OF INVENTION: EXPRESSION
FILE REFERENCE: ISPH-0694
CURRENT APPLICATION NUMBER: PCT/US02/22746
CURRENT FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 09/918,026
PRIOR FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 47
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-47

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 505 ACCTGGTGCCCATGTTCT 524
Db 20 ACCTGGTGCCCATGTTCT 1

RESULT 265
PCT-US02-22746-53/c
Sequence 53, Application PC/TUS0222746
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
FILE REFERENCE: ISPH-0694
CURRENT APPLICATION NUMBER: PCT/US02/22746
CURRENT FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 09/918,026
PRIOR FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 65
SEQ ID NO 53
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-53

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 913 CTGGGATGTGCTCTATGC 932
Db 20 CTGGGATGTGCTCTATGC 1

RESULT 266
PCT-US02-22746-55/c
Sequence 55, Application PC/TUS0222746
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
APPLICANT: Kristina M. Lemonidis
TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
FILE REFERENCE: ISPH-0694
CURRENT APPLICATION NUMBER: PCT/US02/22746
CURRENT FILING DATE: 2002-07-15
PRIOR APPLICATION NUMBER: 09/918,026
PRIOR FILING DATE: 2001-07-30

```
/ NUMBER OF SEQ ID NOS: 65
/ SEQ ID NO 55
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-55

Query Match      1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 970 GCCAACATGAGCGGAGCC 989
Db 20 GCCAACATGAGCGGAGCC 1

RESULT 267
PCT-US02-22746-61/c
; Sequence 61, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-61

Query Match      1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1324 CTGGGGTTCTTATCCCGT 1343
Db 20 CTGGGGTTCTTATCCCGT 1

RESULT 268
PCT-US02-22746-64/c
; Sequence 64, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

```
PCT-US02-22746-64

Query Match      1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1523 CTTTCTGGGGCTGTGACA 1542
Db 20 CATTCTGGGGATGGTGACA 1

RESULT 269
PCT-US03-04945-11/c
; Sequence 11, Application PC/TUS0304945
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: Finkel, Terri
; APPLICANT: Yin, Jiyl
; TITLE OF INVENTION: Cellular genes regulated by HIV-1
; TITLE OF INVENTION: Infection and method of use thereof
; FILE REFERENCE: CHOP.0146PCT
; CURRENT APPLICATION NUMBER: PCT/US03/04945
; CURRENT FILING DATE: 2003-02-19
; PRIOR APPLICATION NUMBER: 60/358,495
; PRIOR FILING DATE: 2002-02-19
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
PCT-US03-04945-11

Query Match      1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1368 TCGAGGATGTTGAACCTCA 1387
Db 20 TTGAGGAGTGTGAACCTCA 1

RESULT 270
US-09-201-228A-2683/c
; Sequence 2683, Application US/09201228A
; GENERAL INFORMATION:
; APPLICANT: Grifais, Remy
; APPLICANT: Hoiseth, Susan K.
; APPLICANT: Zagursky, Robert John
; APPLICANT: Metcalf, Benjamin J.
; APPLICANT: Peek, Joel A.
; APPLICANT: Sankaran, Banumathi
; APPLICANT: Fletcher, Leah Diane
; TITLE OF INVENTION: CHLAMYDIA TRACHOMATIS GENOMIC SEQUENCE
; TITLE OF INVENTION: AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN
; TITLE OF INVENTION: PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF
; TITLE OF INVENTION: INFECTION
; FILE REFERENCE: 9710-0004-999
; CURRENT APPLICATION NUMBER: US/09/201,228A
; CURRENT FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/107,077
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: FR 97-16034
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: FR 97-15041
; PRIOR FILING DATE: 1997-11-28
; NUMBER OF SEQ ID NOS: 5981
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2683
; LENGTH: 20
; TYPE: DNA
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-201-228A-2683

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGGAGTGCAGCATTTCC 361
||||| ||||||| |||||
DB 20 GATGGAGTGCAGCATTTCC 1

RESULT 271

US-09-703-708-18206
; Sequence 18206, Application US/09703708
; GENERAL INFORMATION:

; APPLICANT: Hinkle, Stanley G.

; APPLICANT: Hinkle, Gregory J.

; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof

; FILE REFERENCE: 38-10(15804)C

; CURRENT APPLICATION NUMBER: US/09/703,708

; CURRENT FILING DATE: 2000-11-02 US 60/164,320

; PRIOR APPLICATION NUMBER: 1999-11-10

; PRIOR FILING DATE: US 60/183,791

; PRIOR FILING DATE: 2000-02-22

; NUMBER OF SEQ ID NOS: 18992

; SEQ ID NO 18206

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Xanthomonas campestris

US-09-703-708-18206

Query Match 1.1%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCTGGTCTTCGAGCAGT 710
||||| ||||||| |||||
DB 1 GTCTGGTCTTCGAGCAGT 20

RESULT 272

US-09-918-026A-46/c
; Sequence 46, Application US/09918026A
; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; APPLICANT: Kristina M. Lemonidis

; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX

; FILE REFERENCE: ISPH-0588

; CURRENT APPLICATION NUMBER: US/09/918,026A

; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 46

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-026A-46

Query Match 1.1%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 435 TGAGGCGAGGCTGCTCTGG 454
||||| ||||||| |||||
DB 20 TGAGGCGAGGCTGCTCTGG 1

RESULT 278

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-46

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 435 TGAGGCGAGCTGCTGCTG 454
Db 20 TGAGGCGAGCTGCTGCTG 1

RESULT 281

US-10-484-441-47/c
; Sequence 47, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX
; FILE REFERENCE: ISPH70694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-47

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 505 ACCTGGTGCCATGTTCT 524
Db 20 ACCTGGTGCCATGTTCT 1

RESULT 282

US-10-484-441-53/c
; Sequence 53, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX
; FILE REFERENCE: ISPH70694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-53

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 435 TGAGGCGAGCTGCTGCTG 454
Db 20 TGAGGCGAGCTGCTGCTG 1

QY 913 CTGGGATGTGCTCTATGC 932
Db 20 CTGGGCTGTTGCTCTATGC 1

RESULT 283

US-10-484-441-55/c
; Sequence 55, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX
; FILE REFERENCE: ISPH70694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-55

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 970 GCCACATGAGCGAGGCC 989
Db 20 GCCACATGAGCGGAGCC 1

RESULT 284

US-10-484-441-61/c
; Sequence 61, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE72 EX
; FILE REFERENCE: ISPH70694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-61

Query Match 1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1324 CTGGGTTCTTCTATCCCGT 1343
Db 20 CTGGGTTCTTCTATCCCGT 1

RESULT 285

US-10-484-441-64/c
; Sequence 64, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham

```
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE22 EX
; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-64

Query Match          1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1523 CTTTCTGGGGCTGTGACA 1542
      ||||| ||||| ||||| |||||
Db 20 CATTCTGGGGATGGTGACA 1

RESULT 286
US-10-486-090-4/c
; Sequence 4, Application US/10486090
; GENERAL INFORMATION:
; APPLICANT: Berdel, Wolfgang E.
; APPLICANT: Oelmann, Elisabeth
; TITLE OF INVENTION: Use of TIMP-1 as an Immunosuppressant
; FILE REFERENCE: 19235.002
; CURRENT APPLICATION NUMBER: US/10/486,090
; CURRENT FILING DATE: 2004-02-06
; PRIOR APPLICATION NUMBER: PCT/EP02/08733
; PRIOR FILING DATE: 2002-08-05
; PRIOR APPLICATION NUMBER: DE 101 38 550.1
; PRIOR FILING DATE: 2001-08-06
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-486-090-4

Query Match          1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 GCTGTGGCGCAGGGGACCT 577
      ||||| ||||| ||||| |||||
Db 20 GCTGTGGCGCAGGGGACCT 1

RESULT 287
US-60-164-320-18206
; Sequence 18206, Application US/60164320
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)A
; CURRENT APPLICATION NUMBER: US/60/164,320
; CURRENT FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 18206
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
```

```
US-60-164-320-18206

Query Match          1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGGTCTTCGAGCAGGT 710
      ||||| ||||| ||||| |||||
Db 1 GTCCAGGTCCTTCGAGCATGT 20

RESULT 288
US-60-183-791-18206
; Sequence 18206, Application US/60183791
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)B
; CURRENT APPLICATION NUMBER: US/60/183,791
; CURRENT FILING DATE: 2000-02-22
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 18206
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
US-60-183-791-18206

Query Match          1.1%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGGTCTTCGAGCAGGT 710
      ||||| ||||| ||||| |||||
Db 1 GTCCAGGTCCTTCGAGCATGT 20

RESULT 289
PCT-US04-00035-8627
; Sequence 8627, Application PC/TUS0400035
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: PCT/US04/00035
; CURRENT FILING DATE: 2004-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 8627
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
PCT-US04-00035-8627

Query Match          1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 3.4e+02;
Matches 14; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1423 GTGCTGATGTGGACCATGCT 1442
      ||||| ||||| ||||| |||||
Db 1 GAGCAGAUGUGGACCAUGCU 20

RESULT 290
US-10-310-188-78605/c
; Sequence 78605, Application US/10310188
; GENERAL INFORMATION:
```

```
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 78605
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-78605

Query Match      1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 241 CCTCTGCCCCCACCCTCCCC 260
DB 21 CCTCTCCCCACCCTCCCC 2

RESULT 291
US-10-751-736-8627
; Sequence 8627, Application US/10751736
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8627
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-8627

Query Match      1.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 3.4e+02;
Matches 14; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1423 GTGCTGATGTGGACCATGCT 1442
DB 1 GAGCAGAUGGACCAUGCU 20

RESULT 292
US-10-303-778-1826
; Sequence 1826, Application US/10303778
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL
; FILE REFERENCE: 47416
; CURRENT APPLICATION NUMBER: US/10/303,778
; CURRENT FILING DATE: 2002-11-26
; NUMBER OF SEQ ID NOS: 17608
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1826
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-303-778-1826
```

```
Query Match      1.0%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 310 TTCATCATCCGCAAGTCC 327
DB 1 TTCATCATCCGCAAGTGC 18

RESULT 293
US-10-310-188-2618
; Sequence 2618, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2618
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-2618

Query Match      1.0%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 310 TTCATCATCCGCAAGTCC 327
DB 1 TTCATCATCCGCAAGTGC 18

RESULT 294
PCT-US03-05045-33/c
; Sequence 33, Application PC/TUS0305045
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor
; FILE REFERENCE: 400/081 (MBHB 02-468-B)
; CURRENT APPLICATION NUMBER: PCT/US03/05045
; CURRENT FILING DATE: 2003-05-07
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/251,117
; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/277,494
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1263
```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
PCT-US03-05045-33

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCTCC 684
|||||
Db 18 CAGCTCCCGAGGCTCC 1

RESULT 295
PCT-US03-05045-282
; Sequence 282, Application PC/TUS0305045
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor
; FILE REFERENCE: 400/081 (MBHB 02-468-B)
; CURRENT APPLICATION NUMBER: PCT/US03/05045
; CURRENT FILING DATE: 2003-05-07
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/251,117
; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/277,494
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 282
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
PCT-US03-05045-282

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 3.5e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCTCC 684
|||||
Db 2 CAGCTCCCGAGGCTCC 19

RESULT 296
PCT-US03-05045A-33/c
; Sequence 33, Application PC/TUS0305045A
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor
; FILE REFERENCE: 400/081 (MBHB 02-468-B)
; CURRENT APPLICATION NUMBER: PCT/US03/05045A
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/251,117
; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/277,494
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
PCT-US03-05045A-33

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCTCC 684
|||||
Db 18 CAGCTCCCGAGGCTCC 1

RESULT 297
PCT-US03-05045A-282
; Sequence 282, Application PC/TUS0305045A
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor
; FILE REFERENCE: 400/081 (MBHB 02-468-B)
; CURRENT APPLICATION NUMBER: PCT/US03/05045A
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/251,117


```

; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/277,494
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1263
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 282
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
PCT-US03-05045A-282

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 3.5e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCGCTCC 684
DB 2 CAGCUCCCGCAGGCGCUCC 19

RESULT 298
US-10-251-117-33/c
; Sequence 33, Application US/10251117
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-251-117-33

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCGCTCC 684

```

```

DB 18 CAGCTCCCGCAGGCGCTCC 1

RESULT 299
US-10-251-117-282
; Sequence 282, Application US/10251117
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 282
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-282

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 3.5e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 667 CAGCTCCCGCGGCGCTCC 684
DB 2 CAGCUCCCGCAGGCGCUCC 19

RESULT 300
US-10-714-333A-242202
; Sequence 242202, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmachandran, Inc.
; APPLICANT: Khvorov, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 242202
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-242202

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 3.5e+02;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

```

```
QY 951 CCTCTGTCTCTCTCTT 968
Db 1 CCUCUCUGUCCUGUCUU 18

US-10-714-333A-444807
; Sequence 444807, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 444807
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-444807

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 3.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 179 TGAGGAGCTGCTGGATC 196
Db 1 UGAGGAGCUGCUGGAUC 18

US-10-714-333A-588275
; Sequence 588275, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 588275
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-588275

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 3.5e+02;
Matches 9; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTC 828
Db 1 TACCTCTACTTCTCTTC 828

US-10-714-333A-624582/c
; Sequence 624582, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 624582
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-624582

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCTCTTG 1363
Db 18 TGCTGATCTCTTCTCTTG 1

US-10-714-333A-666149/c
; Sequence 666149, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 666149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-666149

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTTGCCTTCTC 1077
Db 18 ATCTTCTGTGCTTCTCTC 1
```

```
RESULT 305
US-10-714-333A-950074/c
; Sequence 950074, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 950074
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-950074

Query Match      1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 AYTCTCTTTGCGTCTCTC 1077
DB 18 AACTCTTTGCGTCTCTC 1

RESULT 306
US-10-714-333A-1110583
; Sequence 1110583, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1110583
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1110583

Query Match      1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 3.5e+02;
Matches 10; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 391 CTGTGTCTTCATCATC 408
DB 1 CUGAGUGUCUCAUCAUC 18

RESULT 307
US-10-714-333A-1245589/c
; Sequence 1245589, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1245589
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1245589

Query Match      1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1511 TACCCCGAGCACTTCT 1528
DB 19 TACCACAGGCACTTCT 2

RESULT 308
US-10-714-333A-1245608/c
; Sequence 1245608, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1245608
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1245608

Query Match      1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1509 CTTACCCCGAGCACTT 1526
DB 18 CTTACCCAGGCACTT 1

RESULT 309
US-10-714-333A-1336213/c
; Sequence 1336213, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
```

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1336213
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1336213

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTGCCTTCCTC 1077
| | | | | | | | | | | | | | | | | | | | |
Db 18 AACTTCTTTGCCTTCCTC 1

RESULT 310
US-10-714-333A-1353443/c
; Sequence 1499330, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1353443
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1353443

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 953 TCTGTGTTCTGCTCTTTG 970
| | | | | | | | | | | | | | | | | | | | |
Db 19 TCTGTGTTCTGCTCTTTG 2

RESULT 311
US-10-714-333A-1493677/c
; Sequence 1499720, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1493677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1493677

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1052 TGCTGCTCATCTTCTTTG 1069
| | | | | | | | | | | | | | | | | | | | |
Db 18 TGCTGCTCATCTTCTTTG 1

RESULT 312
US-10-714-333A-1499330/c
; Sequence 1499330, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1499330
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1499330

Query Match 1.0%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCTGTC 832
| | | | | | | | | | | | | | | | | | | | |
Db 18 TCTACTTCTCTTCTTCTCC 1

RESULT 313
US-10-714-333A-1499720/c
; Sequence 1499720, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US

Qy 821 TCCTCTTCTGCCCAACAC 838
Db 3 TCCTCTTCTGCCCAACTC 20

RESULT 318
US-60-082-614-2283
; Sequence 2283, Application US/60082614
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Chumakov, Ilya
; APPLICANT: Blumenfeld, Marta
; TITLE OF INVENTION: Biallelic markers for use in constructing a
; TITLE OF INVENTION: high density disequilibrium
; NUMBER OF SEQUENCES: 2730
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 501 West Broadway
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92101-3505
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Win95
; SOFTWARE: Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/60/082,614
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Israelsen, Ned A.
; REGISTRATION NUMBER: 29,655
; REFERENCE/DOCKET NUMBER: GENSET.020PR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 235-8550
; TELEFAX: (619) 235-0176
; INFORMATION FOR SEQ ID NO: 2283:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; MOLECULE TYPE: DNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: downstream amplification primer for SEQ ID124 and SEQ ID977
; LOCATION: 1..20
; US-60-082-614-2283

Query Match 1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 821 TCCTCTTCTGCCCAACAC 838
Db 3 TCCTCTTCTGCCCAACTC 20

RESULT 319
US-60-164-320-12513
; Sequence 12513, Application US/60164320
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)A
; CURRENT APPLICATION NUMBER: US/60/164,320
; CURRENT FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 18992

; SEQ ID NO 12513
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
US-60-164-320-12513

Query Match 1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1043 TCTTCATGCTGCTGCTCA 1060
Db 3 TCTTCTTGTGCTGCTCA 20

RESULT 320
US-60-164-320-12587
; Sequence 12587, Application US/60164320
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)A
; CURRENT APPLICATION NUMBER: US/60/164,320
; CURRENT FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 12587
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
US-60-164-320-12587

Query Match 1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 75 TGGAGATGGAACACTGA 92
Db 1 TGGAGATGGAACCTGA 18

RESULT 321
US-60-164-320-16154
; Sequence 16154, Application US/60164320
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)A
; CURRENT APPLICATION NUMBER: US/60/164,320
; CURRENT FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 16154
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
US-60-164-320-16154

Query Match 1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 446 TGCTGCTGGAGTTTGACC 463
Db 1 TGCTGCTGAAGTTTGACC 18

RESULT 322
US-60-183-791-12513
; Sequence 12513, Application US/60183791
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.

```

; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)B
; CURRENT APPLICATION NUMBER: US/60/183,791
; CURRENT FILING DATE: 2000-02-22
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 12513
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
US-60-183-791-12513

Query Match      1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred.No.3.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1043 TCTTCATGCTGCTGCTCA 1060
          ||||| ||||| |||||
DB       3 TCTTCCTGCTGCTGCTCA 20

RESULT 323
US-60-183-791-12587
; Sequence 12587, Application US/60183791
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)B
; CURRENT APPLICATION NUMBER: US/60/183,791
; CURRENT FILING DATE: 2000-02-22
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 12587
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
US-60-183-791-12587

Query Match      1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred.No.3.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      75 TGGAGATGGAAACACTGA 92
          ||||| ||||| |||||
DB       1 TGGAGATGGAAACCCCTGA 18

RESULT 324
US-60-183-791-16154
; Sequence 16154, Application US/60183791
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)B
; CURRENT APPLICATION NUMBER: US/60/183,791
; CURRENT FILING DATE: 2000-02-22
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 16154
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
US-60-183-791-16154

Query Match      1.0%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred.No.3.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      446 TGCTGCTGGAGTTTGACC 463
          ||||| ||||| |||||
DB       1 TGCTGCTGAAGTTTGACC 18

RESULT 325

```

```
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: PCT/US04/00035
; PRIOR FILING DATE: 2004-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39540
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
PCT-US04-00035-39540
```

```
Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 4e+02;
Matches 10; Conservative 8; Mismatches 0; Gaps 0;
```

```
QY 811 TACCTCTACTTCTCTTCTGC 831
      :||:||||:||||:
Db 1 UUCCUGUACUCCUUCGCGC 21
```

RESULT 328

```
US-10-287-820-1589
; Sequence 1589, Application US/10287820
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Mycoplasma pneumoniae M129 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,820
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2066
; SOFTWARE: Proprietary
; SEQ ID NO 1589
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Mycoplasma pneumoniae M129 complete genome.
; FEATURE:
; LOCATION: (582985)...(583005)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 1755
US-10-287-820-1589
```

```
Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 0; Gaps 0;
```

```
QY 731 ACTCCTTCTTGAGAGAGGCTG 751
      ||||| ||||| ||||| ||
Db 1 ACTCCTTCTTGAAAGAGGTTG 21
```

RESULT 329

```
US-10-751-736-8626
; Sequence 8626, Application US/10751736
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8626
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8626
```

```
Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 0; Gaps 0;
```

```
QY 1421 ACCTGCTGATGTGGACCATGC 1441
      ||||| ||||| ||||| ||
Db 1 AAGAGCAGATGTGGACCATGC 21
```

RESULT 330

```
US-10-751-736-9047
; Sequence 9047, Application US/10751736
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9047
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-9047
```

```
Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 4e+02;
Matches 13; Conservative 5; Mismatches 0; Gaps 0;
```

```
QY 1425 GCTGATGTGGACATGCTGTT 1445
      ||||| ||||| ||||| ||
Db 1 GCAGAGUGGACCAUGCCAUAU 21
```

RESULT 331

```
US-10-751-736-39540
; Sequence 39540, Application US/10751736
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39540
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-39540
```

```
Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 4e+02;
Matches 10; Conservative 8; Mismatches 0; Gaps 0;
```

```
QY 811 TACCTCTACTTCTCTTCTGC 831
      :||:||||:||||:
Db 1 UUCCUGUACUCCUUCGCGC 21
```



```
RESULT 332
US-10-770-726-7037/c
; Sequence 7037, Application US/10770726
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7037
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-7037

Query Match      1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1069 GCCTTCCTCCATTCCTGGCTC 1089
      ||| |||| |||| |||| |||| ||||
Db 21 GCCATCCTGCATTCCTGGCTC 1

RESULT 333
US-10-770-726-12530
; Sequence 12530, Application US/10770726
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12530
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-12530

Query Match      1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1109 TACGATTGGAGACAGGATCT 1129
      ||| |||| |||| |||| |||| ||||
Db 1 TACTATTGGAGCTAGGATCT 21

RESULT 334
US-10-770-726-22694/c
; Sequence 22694, Application US/10770726
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 22694
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-22694

Query Match      1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 338 AGCTGATGGAGGTGCAGCATT 358
      ||| |||| |||| |||| |||| ||||
Db 21 AGCTGATGCAGAGCAGCATT 1

RESULT 335
US-10-770-726-40565
; Sequence 40565, Application US/10770726
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40565
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-40565

Query Match      1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTCTCTCTGC 831
      ||| |||| |||| |||| |||| ||||
Db 1 TACCTCTACTCTCCACTCTCTGC 21

RESULT 336
US-10-831-997-700
; Sequence 700, Application US/10831997
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George O.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/10/831,997
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: US/09/657,472
; PRIOR FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 700
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-831-997-700
```

Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02; 3; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1220 ATCAGGATGGCTGGCTCC 1240
||||| ||||| ||||| ||||| |||||
Db 1 ATCACCATGGYCTGGCTCC 21

RESULT 337
US-10-850-928-37
; Sequence 37, Application US/10850928
; GENERAL INFORMATION:
; APPLICANT: JENTSCH, Thomas J.
; TITLE OF INVENTION: POTASSIUM CHANNELS AND GENES ENCODING THESE
; TITLE OF INVENTION: POTASSIUM CHANNELS
; FILE REFERENCE: 2815-127PUS2
; CURRENT APPLICATION NUMBER: US/10/850,928
; CURRENT FILING DATE: 2004-05-20
; PRIOR APPLICATION NUMBER: 09/492,361
; PRIOR FILING DATE: 2000-01-27
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-10-850-928-37

Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4e+02; 3; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 434 ATCAGGCGAGGCTGCTGCTG 454
||| ||||| ||||| ||||| |||||
Db 1 AGTGGCGAGGCTGTTGCTG 21

RESULT 338
US-09-531-025A-144/c
; Sequence 144, Application US/09531025A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-E (247/277)
; CURRENT APPLICATION NUMBER: US/09/531,025A
; CURRENT FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; NUMBER OF SEQ ID NOS: 6341
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-531-025A-144

Query Match 1.0%; Score 16; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 262 GGTTCCTTGAGCAGGA 277
||||| ||||| ||||| ||||| |||||
Db 17 GGTTCCTTGAGCAGGA 2

RESULT 339
US-09-636-385-144/c
; Sequence 144, Application US/09636385
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-F (250/125)
; CURRENT APPLICATION NUMBER: US/09/636,385
; CURRENT FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6341
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-09-636-385-144

Query Match 1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 262 GGTTCCTTGAGCAGGA 277
||||| ||||| ||||| ||||| |||||
Db 17 GGTTCCTTGAGCAGGA 2

RESULT 340
US-09-696-347-144/c
; Sequence 144, Application US/09696347
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/001
; CURRENT APPLICATION NUMBER: US/09/696,347
; CURRENT FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08

NUMBER OF SEQ ID NOS: 6389
SOFTWARE: PatentIn version 3.0
SEQ ID NO 144
LENGTH: 17
TYPE: RNA
ORGANISM: Hepatitis B Virus
US-09-696-347-144

Query Match 1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 GGTTCCTTGAGCAGGA 277
DB 17 GGTTCCTTGAGCAGGA 2

RESULT 341

US-09-877-478-144/c
Sequence 144, Application US/09877478
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Draper, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
FILE REFERENCE: MBH00-845-H (400/029)
CURRENT APPLICATION NUMBER: US/09/877,478
CURRENT FILING DATE: 2001-12-31
PRIOR APPLICATION NUMBER: US 07/882,712
PRIOR FILING DATE: 1992-05-14
PRIOR APPLICATION NUMBER: US 09/531,025
PRIOR FILING DATE: 2000-03-20
PRIOR APPLICATION NUMBER: US 09/636,385
PRIOR FILING DATE: 2000-08-09
PRIOR APPLICATION NUMBER: US 09/696,347
PRIOR FILING DATE: 2000-10-24
PRIOR APPLICATION NUMBER: US 08/193,627
PRIOR FILING DATE: 1994-02-07
PRIOR APPLICATION NUMBER: US 08/433,993
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 08/434,504
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 09/436,430
PRIOR FILING DATE: 1999-11-08
NUMBER OF SEQ ID NOS: 6586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 144
LENGTH: 17
TYPE: RNA
ORGANISM: Hepatitis B virus
US-09-877-478-144

Query Match 1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 GGTTCCTTGAGCAGGA 277
DB 17 GGTTCCTTGAGCAGGA 2

RESULT 342

US-10-342-902-144/c
Sequence 144, Application US/10342902
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Draper, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

FILE REFERENCE: 400/075 (MBH00-845-I)
CURRENT APPLICATION NUMBER: US/10/342,902
CURRENT FILING DATE: 2003-01-15
PRIOR APPLICATION NUMBER: US 09/877,478
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 09/531,025
PRIOR FILING DATE: 2000-03-20
PRIOR APPLICATION NUMBER: US 09/636,385
PRIOR FILING DATE: 2000-08-09
PRIOR APPLICATION NUMBER: US 09/696,347
PRIOR FILING DATE: 2000-10-24
PRIOR APPLICATION NUMBER: US 08/193,627
PRIOR FILING DATE: 1994-02-07
PRIOR APPLICATION NUMBER: US 07/882,712
PRIOR FILING DATE: 1992-05-14
PRIOR APPLICATION NUMBER: US 09/436,430
PRIOR FILING DATE: 1999-11-08
NUMBER OF SEQ ID NOS: 6592
SOFTWARE: PatentIn version 3.2
SEQ ID NO 144
LENGTH: 17
TYPE: RNA
ORGANISM: Hepatitis B virus
US-10-342-902-144

Query Match 1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 GGTTCCTTGAGCAGGA 277
DB 17 GGTTCCTTGAGCAGGA 2

RESULT 343

US-10-669-841-144/c
Sequence 144, Application US/10669841
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blatt
APPLICANT: Dennis, Macejak
APPLICANT: James, McSwiggen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Patricia, Lee
APPLICANT: Kenneth, Draper
APPLICANT: Elisabeth, Roberts
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT

FILE REFERENCE: 400/042US (MBH02-249-E)
CURRENT APPLICATION NUMBER: US/10/669,841
CURRENT FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: PCT/US02/09187
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/296,876
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 60/335,059
PRIOR FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: US 60/337,055
PRIOR FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 09/817,879
PRIOR FILING DATE: 2001-03-26
PRIOR APPLICATION NUMBER: US 09/740,332
PRIOR FILING DATE: 2000-12-18
PRIOR APPLICATION NUMBER: US 09/611,931
PRIOR FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: US 09/504,321
PRIOR FILING DATE: 2000-02-15
Remaining Prior Application data removed - See File Wrapper or PALM.

```
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-144

Query Match
  1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 GGTTCCTTGACGAGGA 277
Db 17 GGTTCCTTGACGAGGA 2

RESULT 344
US-10-714-333A-253299
; Sequence 253299, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 253299
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-253299

Query Match
  1.0%; Score 16; DB 1; Length 19;
Best Local Similarity 43.8%; Pred. No. 3.9e+02;
Matches 7; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1058 TCATCTCTTTGCTT 1073
Db 3 UCAUCUUCUUGCCU 18

RESULT 345
US-10-714-333A-814227
; Sequence 814227, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 814227
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-814227

Query Match
  1.0%; Score 16; DB 1; Length 19;
Best Local Similarity 68.8%; Pred. No. 3.9e+02;
Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1047 CATGCTGCTCATC 1062
Db 2 CAUGCGUGUCUAC 17

RESULT 346
PCT-US04-04452-1067/C
; Sequence 1067, Application PC/TUS0404452
; GENERAL INFORMATION:
; APPLICANT: Bardelli, Alberto
; APPLICANT: Parsons, Will
; APPLICANT: Velculescu, Victor
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: TYROSINE KINASES IMPLICATED IN CANCERS
; FILE REFERENCE: 001107.00327
; CURRENT APPLICATION NUMBER: PCT/US04/04452
; CURRENT FILING DATE: 2004-02-18
; NUMBER OF SEQ ID NOS: 2191
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1067
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
PCT-US04-04452-1067

Query Match
  1.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 818 ACTCTCTCTTGCCC 833
Db 19 ACTCTCTCTTGCCC 4

RESULT 347
PCT-US04-04452-1068/C
; Sequence 1068, Application PC/TUS0404452
; GENERAL INFORMATION:
; APPLICANT: Bardelli, Alberto
; APPLICANT: Parsons, Will
; APPLICANT: Velculescu, Victor
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: TYROSINE KINASES IMPLICATED IN CANCERS
; FILE REFERENCE: 001107.00327
; CURRENT APPLICATION NUMBER: PCT/US04/04452
; CURRENT FILING DATE: 2004-02-18
; NUMBER OF SEQ ID NOS: 2191
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1068
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
PCT-US04-04452-1068

Query Match
  1.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 818 ACTCTCTCTTGCCC 833
Db 19 ACTCTCTCTTGCCC 4
```

```

; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 672
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 509
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
PCT-US03-03473-509

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1314 CTGCTTCGTCCTGGGGTTC 1332
Db 1 CUGGUUCGUCUGGGGCUC 19

RESULT 350
US-10-714-333A-29001/c
; Sequence 29001, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29001
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29001

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 928 TATGCCTGCTTCCTCTGG 946
Db 19 TATGCCTGCTTCCTCTGG 1

RESULT 351
US-10-714-333A-29083/c
; Sequence 29083, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29083
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29083

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy  928  TATGCTGCTTCATCCTGG 946
      |||||
Db  19  TATGCTGCTTCCTCTGG 1

RESULT 352
US-10-714-333A-29157/c
; Sequence 29157, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29157
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29157

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy  928  TATGCTGCTTCATCCTGG 946
      |||||
Db  19  TATGCTGCTTCCTCTGG 1

RESULT 353
US-10-714-333A-63628/c
; Sequence 63628, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 63628
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-63628

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy  814  CTCCTCTCTCTCTCTGCC 832
      |||||
Db  19  CTCCTCTCTCTCTCTTCC 1

RESULT 354
US-10-714-333A-63629/c
; Sequence 63629, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 63629
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-63629

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy  814  CTCCTCTCTCTCTCTGCC 832
      |||||
Db  19  CTCCTCTCTCTCTCTTCC 1

RESULT 355
US-10-714-333A-99008/c
; Sequence 99008, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 99008
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-99008

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AAACAGAAAGTTTCATCA 316
   |||||
Db 19 AAACAGAAAGTGGTCATCA 1

RESULT 356
US-10-714-333A-112482/c
; Sequence 112482, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; PRIOR FILING DATE: 2002-11-14
; SOFTWARE: Proprietary
; NUMBER OF SEQ ID NOS: 1591911
; SEQ ID NO 112482
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-112482

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCTC 1059
   |||||
Db 19 CATCTTGAAGCTGCTGCTC 1

RESULT 357
US-10-714-333A-143055
; Sequence 143055, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; PRIOR FILING DATE: 2002-11-14
; SOFTWARE: Proprietary
; NUMBER OF SEQ ID NOS: 1591911
; SEQ ID NO 143055
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-143055
```

```
Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 411 CACCCCTGGCATCGACTTC 429
   |||||
Db 1 CAUCCUGGCCAUCGUCUUC 19

RESULT 358
US-10-714-333A-143239
; Sequence 143239, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 143239
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-143239

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 411 CACCCCTGGCATCGACTTC 429
   |||||
Db 1 CAUCCUGGCCAUCGUCUUC 19

RESULT 359
US-10-714-333A-147470
; Sequence 147470, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 147470
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-147470

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.1e+02;
```

Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 418 GCCATCGATTCATTGATG 436
||||:||||:||||:|

Db 1 GCCAUGAGUUAUG 19

RESULT 360
US-10-714-333A-150408
; Sequence 150408, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 150408
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-150408

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1291 GCAGTGCCCATGATGAT 1309
||||:||||:|

Db 1 GCAGUGCCCAUAGUGUA 19

RESULT 361
US-10-714-333A-182227/c
; Sequence 182227, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 182227
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-182227

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 176 AACTGAGGAGCTGCTGGA 194

Db 19 AACTGAGGAGCTGCTGTA 1
||||:||||:||||:|

RESULT 362
US-10-714-333A-265610
; Sequence 265610, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 265610
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-265610

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 42.1%; Pred. No. 4.1e+02;
Matches 8; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 1056 GTCATCTCTTTGCTTC 1074
||||:||||:|

Db 1 GCTCAUCUCUCUCUCUC 19

RESULT 363
US-10-714-333A-372190/c
; Sequence 372190, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 372190
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-372190

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 811 TACCTCTACTCTCTCTCT 829
||||:||||:||||:|

Db 19 TATTCTACTCTCTCTCTCT 1

RESULT 364
US-10-714-333A-375661/c
; Sequence 375661, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 375661
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-375661

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 TCACGCTACCTCTACTTCC 823
||| ||||| ||||| |||||
DB 19 TCACATCTACCTCTACTTCC 1

RESULT 365
US-10-714-333A-375742/c
; Sequence 375742, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 375742
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-375742

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 TCACGCTACCTCTACTTCC 823
||| ||||| ||||| |||||
DB 19 TCACATCTACCTCTACTTCC 1

RESULT 366
US-10-714-333A-391694/c

; Sequence 391694, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 391694
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-391694

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 433 GATGAGGCGAGGCTGCTGC 451
||| ||||| ||||| |||||
DB 19 GATGAGGCGAGGCTGCTTC 1

RESULT 367
US-10-714-333A-393089/c
; Sequence 393089, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 393089
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-393089

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 799 AGTTTCTCCAGCTACCTCT 817
||| ||||| ||||| |||||
DB 19 AGTTTCTCCAGCACCTCT 1

RESULT-368,
US-10-714-333A-396174
; Sequence 396174, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 496998
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-496998

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 665 ATCAGCTCCGCGGCTC 683
|||||
DB 19 ATCAGCTCCGCGGCTC 1

RESULT 373

US-10-714-333A-508050/c
Sequence 508050, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 508050
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-508050

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 520 TTCTCTCCACCTGTGG 538
|||||
DB 19 TTCTCTCCACCTGTGG 1

RESULT 374

US-10-714-333A-520328/c
Sequence 520328, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14

PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 520328
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-520328

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 975 CATGAGCCGAGGCTTC 993
|||||
DB 19 CATGAGCCGAGGCTTC 1

RESULT 375

US-10-714-333A-613102/c
Sequence 613102, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 613102
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-613102

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTCT 829
|||||
DB 19 TACCTCTCTCTCTCTCT 1

RESULT 376

US-10-714-333A-624778/c
Sequence 624778, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 624778
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-624778

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1374 AATGTTGAACCTTCATGATG 1392
| | | | | | | | | | | | | | | | | | |
Db 19 AATGTTGGATTTCATGATG 1

RESULT 377

US-10-714-333A-675642/c
; Sequence 75642, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 675642
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-675642

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 815 TCTACTTCCTCTCTGCCC 833
| | | | | | | | | | | | | | | | | | |
Db 19 TCTTCTCTCTCTGCCC 1

RESULT 378

US-10-714-333A-713692/c
; Sequence 713692, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary

; SEQ ID NO 713692
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-713692

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 400 TTCATCATCAGACCCCTGG 418
| | | | | | | | | | | | | | | | | | |
Db 19 TTCATCATCAGAACCTGG 1

RESULT 379

US-10-714-333A-744522
; Sequence 744522, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 744522
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-744522

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 793 GCCCCAGTTTCTCCAGCT 811
| | | | | | | | | | | | | | | | | | |
Db 1 GCCCAGUUUCCAGUU 19

RESULT 380

US-10-714-333A-751835/c
; Sequence 751835, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 751835
; LENGTH: 19
; TYPE: RNA

```

; ORGANISM: Homo sapiens
US-10-714-333A-751835

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 717 CTGATGAAGCTACTCC 735
DB 19 CATGATGAAGCTACTCC 1

RESULT 381
US-10-714-333A-759661/c
; Sequence 759661, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 759661
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-759661

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTCTTGGCTCTCTCC 1078
DB 19 ATCTCTTGGCTCTCTCC 1

RESULT 382
US-10-714-333A-766215
; Sequence 766215, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 766215
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-766215

; ORGANISM: Homo sapiens
US-10-714-333A-751835

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 103 GCCCGGACTTGTACAAT 121
DB 1 GCCCUGACUUGGUACAGU 19

RESULT 383
US-10-714-333A-787901/c
; Sequence 787901, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 787901
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-787901

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTCTCTCTCTCTGCC 832
DB 19 CTCCTCTCTCTCTCTCTCC 1

RESULT 384
US-10-714-333A-794260/c
; Sequence 794260, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 794260
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-794260

; ORGANISM: Homo sapiens
US-10-714-333A-751835

Query Match
Best Local Similarity 1.0%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 799 AGTTTCTCCAGCTACCTCT 817
Db 19 AGTTTCTCCAGCTTCTTCT 1

RESULT 385
US-10-714-333A-799168
; Sequence 799168, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 799168
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-799168

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 4.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1046 TCATGCTGCTGCTCATCTT 1064
Db 1 UCAAGCUGCUGCUGCUGUU 19

RESULT 386
US-10-714-333A-804931/c
; Sequence 804931, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 804931
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-804931

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 953 TCTGTGTTCTCTCTTTGC 971
Db 1 TCTGTGTTCTCTCTTTGC 19

RESULT 387
US-10-714-333A-814427/c
; Sequence 814427, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 814427
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-814427

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTACTCTCTCTTCTGCC 832
Db 19 CTCCTACTCTCTCTTCTTC 1

RESULT 388
US-10-714-333A-828864
; Sequence 828864, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 828864
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-828864

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 868 CCCTATGTCAGGTGAATT 886
Db 1 CCCTAUGACUGUGGAUU 19
```

```
RESULT 389
US-10-714-333A-841815/c
; Sequence 841815, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 841815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-841815

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTCTCTCTCTCTGCC 832
DB 19 CTCCTCTCTCTCTCTCTCC 1

RESULT 390
US-10-714-333A-842553/c
; Sequence 842553, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 842553
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-842553

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 469 ATCTTCAGTTCGACGACG 487
DB 19 ATCTTCAGTTCCTTACAGC 1

RESULT 391
US-10-714-333A-895382/c
; Sequence 895382, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 895382
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-895382

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTCTCTCTCTCT 829
DB 19 TTCCCTCTCTCTCTCTCTCT 1

RESULT 392
US-10-714-333A-900276
; Sequence 900276, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 900276
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-900276

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 411 CACCTCTGGCCATCGACTTC 429
DB 1 CACCGUGGCCAUGACUUC 19

RESULT 393
US-10-714-333A-900364
; Sequence 900364, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 900364
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-900364
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 411 CACCTGGCCATCGACTTC 429
||||:||||:||||:
Db 1 CACGUGGCCAUGACUUC 19
```

```
RESULT 394
US-10-714-333A-911300
; Sequence 911300, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 911300
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-911300
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 4.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 810 CTACCTCTACTTCCTCTTC 828
|||:|:|:|:|:|:|
Db 1 CUACGUCUCUCCUCCUUC 19
```

```
RESULT 395
US-10-714-333A-986535
; Sequence 986535, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 986535
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-986535
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 42.1%; Pred. No. 4.1e+02;
Matches 8; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 951 CTTCTGTGTTCTCTGCTTT 969
|||:|:|:|:|:|:|
Db 1 CCUCUCUGCUCGUCUUCUU 19
```

```
RESULT 396
US-10-714-333A-1008230
; Sequence 1008230, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1008230
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1008230
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 363 CACCATCTACCACATGTC 381
||||:||||:|:|
Db 1 CACCAUCUACCACAAUCUUC 19
```

```
RESULT 397
US-10-714-333A-1010596/c
; Sequence 1010596, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```



```
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1010596
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1010596

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTCCTTCCTCC 1078
DB 19 ATCTCTATGCTTCCTCC 1

RESULT 398
US-10-714-333A-1051939
; Sequence 1051939, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1051939
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1051939

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 74 GTCGAGATGGAAACACTGA 92
DB 1 GUGGAGAUUUAAACACUGA 19

RESULT 399
US-10-714-333A-1086368/c
; Sequence 1086368, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1086368
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1086368

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1059 CATCTTCTTTCCTTCCTCC 1077
DB 19 CATCTTCTGAGCCTTCCTC 1

RESULT 400
US-10-714-333A-1119042
; Sequence 1119042, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1119042
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1119042

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 592 GGCCTGGGCTGTGCGCTTT 610
DB 1 GGCCUUGGGUGUGCGCUU 19

RESULT 401
US-10-714-333A-1119105
; Sequence 1119105, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
```


US-10-714-333A-1160688

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 4.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 378 GTTCATCGTGGCCTGTGT 396
DB 1 GUUCUUGGUGGCCUGUGU 19

RESULT 406

US-10-714-333A-1160787
; Sequence 1160787, Application US/10714333A
; GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1160787
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-714-333A-1160787

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 4.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 378 GTTCATCGTGGCCTGTGT 396
DB 1 GUUCUUGGUGGCCUGUGU 19

RESULT 407

US-10-714-333A-1209330/c
; Sequence 1209330, Application US/10714333A
; GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1209330
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-714-333A-1209330

Query Match 1.0%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 TTCTCCAGCTACCTTACT 820
DB 19 TTCTCCAGCTTCTCTTCT 1

RESULT 408

US-10-714-333A-1274666/c
; Sequence 1274666, Application US/10714333A
; GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1274666
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1274666

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 314 TCATCCGCAAGTCCCTGCT 332
DB 19 TCATCTGTAAGTCCCTGCT 1

RESULT 409

US-10-714-333A-1285653/c
; Sequence 1285653, Application US/10714333A
; GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1285653
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1285653

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCTACTTCTCTCTCTGCC 832
||| ||||| ||||| ||
Db 19 CTCTTCTCTCTCTCTCC 1

RESULT 410
US-10-714-333A-1289597/c
; Sequence 1289597, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1289597
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1289597

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 955 TGTGTTCTCTCTCTTGTGCCA 973
||| ||||| ||||| ||
Db 19 TATCTTCTCTCTCTTGTGCCA 1

RESULT 411
US-10-714-333A-1320738/c
; Sequence 1320738, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1320738
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1320738

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1046 TCATGCTGCTCTCATCTT 1064
||| ||||| ||||| ||
Db 19 TCATGCTGCTCTCATCTT 1

RESULT 412
US-10-714-333A-1334204/c
; Sequence 1334204, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1334204
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1334204

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTGCCTTCTCTCCA 1079
||| ||||| ||||| ||
Db 19 TCTTCTTGCCTTCTCTCCA 1

RESULT 413
US-10-714-333A-1353268/c
; Sequence 1353268, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1353268
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1353268

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCTACTTCTCTCTCTGCC 832
||| ||||| ||||| ||
Db 19 CTCTACTTCTCTCTCTGCC 1

RESULT 414

```
US-10-714-333A-1363311
; Sequence 1363311, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1363311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1363311

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 707 AGTTAGGTTCTCTGATGAA 725
Db 1 AGGUUGGUUCCUGAUUA 19

RESULT 415
US-10-714-333A-1452775/c
; Sequence 1452775, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1452775
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1452775

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCTACTTCTCTCTGCCC 832
Db 19 CTCTCTCTCTCTCTCTCC 1

RESULT 416
US-10-714-333A-1500378
; Sequence 1500378, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1500378
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1500378

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 410 GCACCTCGCCATCGACTT 428
Db 1 GCACCCUGGCCAACACUU 19

RESULT 417
US-10-714-333A-1514938
; Sequence 1514938, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1514938
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1514938

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 179 TGAGGGAGCTGCTGGATCG 197
Db 1 UGAGGGAGCGUGUGGAUAG 19

RESULT 418
US-10-714-333A-1515093/c
; Sequence 1515093, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1515093
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1515093

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1548 ATCTGGTCTCGCATACC 1566
||||| ||||| ||||| ||||| |||||
Db 19 ATCTGGTCTCGCATACC 1

RESULT 419
US-10-714-333A-1533573/c
; Sequence 1533573, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1533573
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1533573

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTCTCTCTCTCTGCC 832
||||| ||||| ||||| ||||| |||||
Db 19 CTCCTCTCTCTCTCTGCC 1

RESULT 420
PCT-US98-07386-100
; Sequence 100, Application PC/TUS9807386
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; TITLE OF INVENTION: Compositions and Methods for the Modulation of
; TITLE OF INVENTION: Activating Protein 1
; NUMBER OF SEQUENCES: 138

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US98/07386
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/837,201
; FILING DATE: April 14, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0305
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US98-07386-100

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTCGCGCTGCGG 645
||||| ||||| ||||| ||||| |||||
Db 2 GATGCTCTGCGCTGCGG 20

RESULT 421
PCT-US02-22746-56/c
; Sequence 56, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-56

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 GAGAGCCCTTCAGCACCG 1001

```

; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish and Richardson
; STREET: 2200 Sand Hill Road
; CITY: Menlo Park
; STATE: CA
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION NUMBER:
; APPLICATION NUMBER: US/08/786,984
; FILING DATE: 23-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Sherwood, Pamela J
; REGISTRATION NUMBER: 36677
; REFERENCE/DOCKET NUMBER: 06037/008001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 322 5070
; TELEFAX: 322 854-0875
; TELEX:
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other
; US-08-786-984-9

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 TCTACTTCCTCTCTGCCC 833
Db 2 TCTACTTCCTCTCTGCCC 20

RESULT 425
US-08-837-201A-100
; Sequence 100, Application US/08837201A
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; TITLE OF INVENTION: Compositions and Methods for the Modulation of
; TITLE OF INVENTION: Activating Protein 1
; NUMBER OF SEQUENCES: 130
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/837,201A
; FILING DATE: April 14, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:

```

Best Local Similarity	89.5%;	Pred. No. 4.3e+02;			
Matches	17;	Conservative	0;	Mismatches	2;
				Indels	0;
				Gaps	0;
QY	627	GGTGCTCTGGCGCTGCCG	645		
Db	2	GATGCTCTGGCTCTGCCG	20		
RESULT 427					
US-09-157-068-10/c					
; Sequence 10, Application US/09157068					
; GENERAL INFORMATION:					
; APPLICANT: Darrell C. Conklin					
; APPLICANT: Francis J. Grant					
; APPLICANT: Mark W. Rixon					
; APPLICANT: Wayne Kindsvogel					
; TITLE OF INVENTION: Interferon-epsilon					
; FILE REFERENCE: 98-46					
; CURRENT APPLICATION NUMBER: US/09/157,068					
; CURRENT FILING DATE: 1998-09-18					
; NUMBER OF SEQ ID NOS: 17					
; SOFTWARE: FastSEQ for Windows Version 3.0					
; SEQ ID NO 10					
; LENGTH: 20					
; TYPE: DNA					
; ORGANISM: Artificial Sequence					
; FEATURE:					
; OTHER INFORMATION: PCR primer					
US-09-157-068-10					
Query Match		1.0%;	Score 15.8;	DB 1;	Length 20;
Best Local Similarity		89.5%;	Pred. No. 4.3e+02;		
Matches	17;	Conservative	0;	Mismatches	2;
				Indels	0;
				Gaps	0;
QY	292	CTGGGGAAACAGAAAGTTT	310		
Db	19	CTGAGGAAGCAGAAAGTTT	1		
RESULT 428					
US-09-245-293-10/c					
; Sequence 10, Application US/09245293					
; GENERAL INFORMATION:					
; APPLICANT: Conklin, Darrell					
; APPLICANT: Grant, Francis J.					
; APPLICANT: Rixon, Mark W.					
; APPLICANT: Kindsvogel, Wayne					
; TITLE OF INVENTION: INTERFERON-EPSILON					
; FILE REFERENCE: 98-46X2					
; CURRENT APPLICATION NUMBER: US/09/245,293					
; CURRENT FILING DATE: 1999-02-05					
; NUMBER OF SEQ ID NOS: 25					
; SOFTWARE: FastSEQ for Windows Version 3.0					
; SEQ ID NO 10					
; LENGTH: 20					
; TYPE: DNA					
; ORGANISM: Artificial Sequence					
; FEATURE:					
; OTHER INFORMATION: PCR primer					
US-09-245-293-10					
Query Match		1.0%;	Score 15.8;	DB 1;	Length 20;
Best Local Similarity		89.5%;	Pred. No. 4.3e+02;		
Matches	17;	Conservative	0;	Mismatches	2;
				Indels	0;
				Gaps	0;
QY	292	CTGGGGAAACAGAAAGTTT	310		
Db	19	CTGAGGAAGCAGAAAGTTT	1		
RESULT 429					
US-09-918-026A-56/c					
; Sequence 56, Application US/09918026A					


```
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-026A-56

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 GAGAGCCCTTCAGCACCG 1001
| | | | | | | | | | | | | | | | | |
DB 20 GGGACCCCTTCAGCACCG 2

RESULT 430
US-09-923-517-100
; Sequence 100, Application US/09923517
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; Compositions and Methods for the Modulation of
; Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/923,517A
; FILING DATE: 07-Aug-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/364,416
; FILING DATE: 1999-07-30
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 100:
US-09-923-517-100

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 GAGAGCCCTTCAGCACCG 1001
| | | | | | | | | | | | | | | | | |
DB 20 GGGACCCCTTCAGCACCG 2

RESULT 430
US-09-923-517-100
; Sequence 100, Application US/09923517
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; Compositions and Methods for the Modulation of
; Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/923,517
; FILING DATE: 07-Aug-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/364,416
; FILING DATE: 1999-07-30
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 100:
US-09-923-517-100

Query Match 1.0%; Score 15.8; DB 1; Length 20;
```

```
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTGCGCTGCGC 645
| | | | | | | | | | | | | | | | | |
DB 2 GATGCTCTGCGCTGCGC 20

RESULT 431
US-09-923-517A-100
; Sequence 100, Application US/09923517A
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; APPLICANT: Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; Compositions and Methods for the Modulation of
; Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/923,517A
; FILING DATE: 07-Aug-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/364,416
; FILING DATE: 1999-07-30
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 100:
US-09-923-517A-100

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTGCGCTGCGC 645
| | | | | | | | | | | | | | | | | |
DB 2 GATGCTCTGCGCTGCGC 20

RESULT 432
US-09-954-679-28/c
; Sequence 28, Application US/09954679
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RIBONUCLEASE L (2',5'-OLIGOISODENYLATE
; FILE REFERENCE: RTS-0212
; CURRENT APPLICATION NUMBER: US/09/954,679
```

```
; CURRENT FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-679-28

Query Match          1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1311 CTTCTGCTTCGTCCTGGG 1329
Db 20 CTTCTGCTTCGTCATGGTG 2

RESULT 433
US-10-187-659A-45
; Sequence 45, Application US/10187659A
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF P2X4 EXPRESSION
; FILE REFERENCE: RTS-0379
; CURRENT APPLICATION NUMBER: US/10/187,659A
; CURRENT FILING DATE: 2002-07-01
; NUMBER OF SEQ ID NOS: 143
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-187-659A-45

Query Match          1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 501 GGTGACCTGGTGCCCATG 519
Db 2 GTTGACCTGGATGCCCATG 20

RESULT 434
US-10-187-659A-110/c
; Sequence 110, Application US/10187659A
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF P2X4 EXPRESSION
; FILE REFERENCE: RTS-0379
; CURRENT APPLICATION NUMBER: US/10/187,659A
; CURRENT FILING DATE: 2002-07-01
; NUMBER OF SEQ ID NOS: 143
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
US-10-187-659A-110

Query Match          1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 501 GGTGACCTGGTGCCCATG 519
Db 19 GTTGACCTGGATGCCCATG 1

RESULT 435
US-10-266-090-43749/c

; Sequence 437, Application US/10266090
; GENERAL INFORMATION:
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; APPLICANT: WANG, RONG-LIN
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; CURRENT FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 43749
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-43749

Query Match          1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 422 TCGACTTCATTGATGAGG 440
Db 19 TCCACTTCATTGAGGAGG 1

RESULT 436
US-10-266-090-43958
; Sequence 43958, Application US/10266090
; GENERAL INFORMATION:
; APPLICANT: GOFF, STEPHEN
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; CURRENT FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 43958
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-43958

Query Match          1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1046 TCATGCTGCTGCTCATCTT 1064
Db 1 TCAACCTGCTGCTCATCTT 19

RESULT 437
US-10-266-090-44137
; Sequence 44137, Application US/10266090
```

; GENERAL INFORMATION:
; APPLICANT: GOFF, STEPHEN
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; APPLICANT: WANG, RONG-LIN
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; TITLE OF INVENTION: REPEAT MARKERS AND THEIR USES
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; CURRENT FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 44137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-44137

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTCTCTCTCTCTGCC 832
|||
Db 1 CTCCTCTCTCTCTCTGCC 19

RESULT 438
US-10-272-810-49
; Sequence 49, Application US/10272810
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH (DROSOPHILA) HOMOLOG 4 EXPRESSION
; FILE REFERENCE: RTS-0263
; CURRENT APPLICATION NUMBER: US/10/272,810
; CURRENT FILING DATE: 2002-10-16
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-272-810-49

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 381 CATCGCTGGCCTGTGTGTC 399
|||
Db 1 CACCACTGGCCTGTGTGTC 19

RESULT 439
US-10-273-070-49
; Sequence 49, Application US/10273070
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH (DROSOPHILA) HOMOLOG 4 EXPRESSION
; FILE REFERENCE: RTS-0231
; CURRENT APPLICATION NUMBER: US/10/273,070
; CURRENT FILING DATE: 2002-10-16
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-273-070-49

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 381 CATCGCTGGCCTGTGTGTC 399
|||
Db 1 CACCACTGGCCTGTGTGTC 19

RESULT 440
US-10-303-778-8812
; Sequence 8812, Application US/10303778
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL VIRAL
; FILE REFERENCE: 47416
; CURRENT APPLICATION NUMBER: US/10/303,778
; CURRENT FILING DATE: 2002-11-26
; NUMBER OF SEQ ID NOS: 17608
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8812
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-303-778-8812

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 GGAGCTGCTGGATCGGCC 201
|||
Db 1 GCAGCTGCTGGATCGGCC 19

RESULT 441
US-10-430-196-100
; Sequence 100, Application US/10430196
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean; Robert A. McKay; Loren J.
; Miraglia; Brenda F. Baker
; TITLE OF INVENTION: Antisense Oligonucleotide
; Compositions and Methods for the Modulation of
; Activating Protein 1
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/430,196
; FILING DATE: 05-May-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/923,517A
; FILING DATE: 07-Aug-2001
; APPLICATION NUMBER: 09/364,416
; FILING DATE: 1999-07-30
; ATTORNEY/AGENT INFORMATION:

```
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 100:
US-10-430-196-100

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 GGTGCTCTGGCGGTGCGG 645
Db 2 GATGCTCTGGCTCTGCGG 20

RESULT 442
US-10-484-441-56/c
; Sequence 56, Application US/1048441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE?2 EX
; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-484-441-56

Query Match 1.0%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 GAGAGCCCTTCAGCACCCG 1001
Db 20 GGGACCCCTTCAGCACCCG 2

RESULT 443
PCT-US04-00035-9046
; Sequence 9046, Application PC/TUS0400035
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: PCT/US04/00035
; CURRENT FILING DATE: 2004-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 54873
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
PCT-US04-00035-9046

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
; SEQ ID NO 9046
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
PCT-US04-00035-9046

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1423 GTGCTGATGTGGACCATGC 1441
Db 1 GAGCAGATGTGGACCATGC 19

RESULT 444
PCT-US04-00035-50130
; Sequence 50130, Application PC/TUS0400035
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: PCT/US04/00035
; CURRENT FILING DATE: 2004-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50130
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
PCT-US04-00035-50130

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 4.5e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTCT 829
Db 2 UUCCUCUACUUCACUUCU 20

RESULT 445
PCT-US04-00035-50133
; Sequence 50133, Application PC/TUS0400035
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: PCT/US04/00035
; CURRENT FILING DATE: 2004-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50133
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
PCT-US04-00035-50133

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 4.5e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
```

```

; SEQ ID NO 96
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-09-754-468-96

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 711 TAGGTCCTCATGAAAAGC 729
DB 19 TAGGTCATGATGAAAAGC 1

RESULT 448
US-09-786-926B-8/c
; Sequence 8, Application US/09786926B
; GENERAL INFORMATION:
; APPLICANT: Max-Delbruck-Centrum fur Molekulare Medizin
; TITLE OF INVENTION: Human and murine G-protein coupled EDG6 receptor
; FILE OF INVENTION: (endothelial differentiation gene) and use of same
; FILE REFERENCE: 103130-3
; CURRENT APPLICATION NUMBER: US/09/786,926B
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: DE 198 43 240.2
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: DE 198 46 979.9
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: PCT/DE 99/02871
; PRIOR FILING DATE: 1999-09-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence of PCR Primer 5'hGSF1
US-09-786-926B-8

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTACTCTCTCTCTGCG 832
DB 20 CGCTACATCTCTCTCTGCG 2

RESULT 449
US-10-184-085A-1032/c
; Sequence 1032, Application US/10184085A
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balog, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1032
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-184-085A-1032

; SEQ ID NO 96
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-09-754-468-96

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 711 TAGGTCCTCATGAAAAGC 729
DB 19 TAGGTCATGATGAAAAGC 1

RESULT 448
US-09-786-926B-8/c
; Sequence 8, Application US/09786926B
; GENERAL INFORMATION:
; APPLICANT: Max-Delbruck-Centrum fur Molekulare Medizin
; TITLE OF INVENTION: Human and murine G-protein coupled EDG6 receptor
; FILE OF INVENTION: (endothelial differentiation gene) and use of same
; FILE REFERENCE: 103130-3
; CURRENT APPLICATION NUMBER: US/09/786,926B
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: DE 198 43 240.2
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: DE 198 46 979.9
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: PCT/DE 99/02871
; PRIOR FILING DATE: 1999-09-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence of PCR Primer 5'hGSF1
US-09-786-926B-8

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTACTCTCTCTCTGCG 832
DB 20 CGCTACATCTCTCTCTGCG 2

RESULT 449
US-10-184-085A-1032/c
; Sequence 1032, Application US/10184085A
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balog, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1032
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-184-085A-1032

; SEQ ID NO 96
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-09-754-468-96

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 711 TAGGTCCTCATGAAAAGC 729
DB 19 TAGGTCATGATGAAAAGC 1

RESULT 448
US-09-786-926B-8/c
; Sequence 8, Application US/09786926B
; GENERAL INFORMATION:
; APPLICANT: Max-Delbruck-Centrum fur Molekulare Medizin
; TITLE OF INVENTION: Human and murine G-protein coupled EDG6 receptor
; FILE OF INVENTION: (endothelial differentiation gene) and use of same
; FILE REFERENCE: 103130-3
; CURRENT APPLICATION NUMBER: US/09/786,926B
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: DE 198 43 240.2
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: DE 198 46 979.9
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: PCT/DE 99/02871
; PRIOR FILING DATE: 1999-09-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence of PCR Primer 5'hGSF1
US-09-786-926B-8

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTACTCTCTCTCTGCG 832
DB 20 CGCTACATCTCTCTCTGCG 2

RESULT 449
US-10-184-085A-1032/c
; Sequence 1032, Application US/10184085A
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balog, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1032
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-184-085A-1032

; SEQ ID NO 96
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-09-754-468-96

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 711 TAGGTCCTCATGAAAAGC 729
DB 19 TAGGTCATGATGAAAAGC 1

RESULT 448
US-09-786-926B-8/c
; Sequence 8, Application US/09786926B
; GENERAL INFORMATION:
; APPLICANT: Max-Delbruck-Centrum fur Molekulare Medizin
; TITLE OF INVENTION: Human and murine G-protein coupled EDG6 receptor
; FILE OF INVENTION: (endothelial differentiation gene) and use of same
; FILE REFERENCE: 103130-3
; CURRENT APPLICATION NUMBER: US/09/786,926B
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: DE 198 43 240.2
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: DE 198 46 979.9
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: PCT/DE 99/02871
; PRIOR FILING DATE: 1999-09-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence of PCR Primer 5'hGSF1
US-09-786-926B-8

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTACTCTCTCTCTGCG 832
DB 20 CGCTACATCTCTCTCTGCG 2

RESULT 449
US-10-184-085A-1032/c
; Sequence 1032, Application US/10184085A
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balog, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1032
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-184-085A-1032

; SEQ ID NO 96
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-09-754-468-96

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 711 TAGGTCCTCATGAAAAGC 729
DB 19 TAGGTCATGATGAAAAGC 1

RESULT 448
US-09-786-926B-8/c
; Sequence 8, Application US/09786926B
; GENERAL INFORMATION:
; APPLICANT: Max-Delbruck-Centrum fur Molekulare Medizin
; TITLE OF INVENTION: Human and murine G-protein coupled EDG6 receptor
; FILE OF INVENTION: (endothelial differentiation gene) and use of same
; FILE REFERENCE: 103130-3
; CURRENT APPLICATION NUMBER: US/09/786,926B
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: DE 198 43 240.2
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: DE 198 46 979.9
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: P
```

```
Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 TGATGAGGGCAGCTGCTG 450
|||||
Db 21 TGATGAGGGGAGCGCGCTG 3

RESULT 450
US-10-184-085A-1069/c
; Sequence 1069, Application US/10184085A
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balog, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1069
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-184-085A-1069

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 TGATGAGGGCAGCTGCTG 450
|||||
Db 20 TGATGAGGGCGCGCGCTG 2

RESULT 451
US-10-310-188-60936/c
; Sequence 60936, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 60936
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-60936

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 241 CCTCTGCCCCCAGCTCC 259
|||||
Db 19 CCTCTGCCCCCAGCTCC 1

RESULT 452
US-10-739-904-29/c
; Sequence 29, Application US/10739904
; GENERAL INFORMATION:
; APPLICANT: SMITH, Timothy P.
```

```
; APPLICANT: CASAS, Eduardo
; TITLE OF INVENTION: Single Nucleotide Polymorphism Markers in the Bovine
; FILE REFERENCE: CAPN1 Gene to Identify Meat Tenderness
; CURRENT APPLICATION NUMBER: US/10/739,904
; CURRENT FILING DATE: 2003-12-18
; NUMBER OF SEQ ID NOS: 98
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Bos taurus
US-10-739-904-29

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 312 CATCATCCCAAGTCCCTG 330
|||||
Db 19 CATCATCCTCAAGGCGCTG 1

RESULT 453
US-10-751-736-9046
; Sequence 9046, Application US/10751736
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9046
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9046

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1423 GTGCTGATGTGACCATGC 1441
|||||
Db 1 GAGCAGATGTGACCATGC 19

RESULT 454
US-10-751-736-50130
; Sequence 50130, Application US/10751736
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50130
```

```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-50130

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 4.5e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTCTCT 829
Db 2 UUCCUCUACUCCACUUCU 20

RESULT 455
US-10-751-736-50133
; Sequence 50133, Application US/10751736
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50133
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-50133

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 4.5e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTCTCT 829
Db 1 UUCCUCUACUCCACUUCU 19

RESULT 456
US-10-770-726-5072
; Sequence 5072, Application US/10770726
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5072
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-5072

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 363 CACCATCTACCACATGTTTC 381
Db 1 CACCACCTACCGCATGTTTC 19

RESULT 457
US-10-770-726-11585/c
; Sequence 11585, Application US/10770726
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11585
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-11585

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 415 CTGGCCATCGACTTCATTG 433
Db 19 CTGGTCATCGACATCATTTG 1

RESULT 458
US-10-770-726-40526
; Sequence 40526, Application US/10770726
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40526
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-40526

Query Match 1.0%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 808 AGCTACCTCTACTTCTCTCT 826
Db 2 AGCTACCTCTACTCTCCACT 20

RESULT 459
US-10-861-108-16/c
; Sequence 16, Application US/10861108
; GENERAL INFORMATION:
; APPLICANT: Kay, Mark A.
; APPLICANT: Yant, Stephen
; TITLE OF INVENTION: Enhanced Sleeping Beauty Transposon
; FILE REFERENCE: STAN-307
; CURRENT APPLICATION NUMBER: US/10/861,108
; CURRENT FILING DATE: 2004-06-03
; PRIOR APPLICATION NUMBER: 60/476,266
; PRIOR FILING DATE: 2003-06-04
```



```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
PCT-US02-17674-3487

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 4.1e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCGCCGCTCTGTG 958
|||:|||||:|:|
Db 1 CCCGGCGCCGCGCUCUG 17

RESULT 464
US-09-532-537B-378
; Sequence 378, Application US/09532537B
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Mediated Inhibition of Protein Kinase C-
; FILE OF INVENTION: Gene Expression
; FILE REFERENCE: MBH00-945-A (249/004)
; CURRENT APPLICATION NUMBER: US/09/532.537B
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US 09/071,845
; PRIOR FILING DATE: 1998-05-01
; PRIOR APPLICATION NUMBER: US 09/498,824
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 08/292,620
; PRIOR FILING DATE: 1994-08-17
; PRIOR APPLICATION NUMBER: US 08/008,895
; PRIOR FILING DATE: 1993-01-19
; PRIOR APPLICATION NUMBER: US 07/989,849
; PRIOR FILING DATE: 1992-12-07
; PRIOR APPLICATION NUMBER: US 09/406,643
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 08/878,640
; PRIOR FILING DATE: 1997-06-19
; PRIOR APPLICATION NUMBER: US 08/879,078
; NUMBER OF SEQ ID NOS: 2897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 378
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-532-537B-378

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 712 AGTTCCTGATGAAAG 728
|||:|:|:|:|
Db 1 AGGUUCUGAUGAAAG 17

RESULT 465
US-09-532-537B-676
; Sequence 676, Application US/09532537B
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Mediated Inhibition of Protein Kinase C-
; FILE OF INVENTION: Gene Expression
; FILE REFERENCE: MBH00-945-A (249/004)
; CURRENT APPLICATION NUMBER: US/09/532.537B
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US 09/071,845
; PRIOR FILING DATE: 1998-05-01
; PRIOR APPLICATION NUMBER: US 09/498,824
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 08/292,620
; PRIOR FILING DATE: 1994-08-17
```

```
; PRIOR APPLICATION NUMBER: US 08/008,895
; PRIOR FILING DATE: 1993-01-19
; PRIOR APPLICATION NUMBER: US 07/989,849
; PRIOR FILING DATE: 1992-12-07
; PRIOR APPLICATION NUMBER: US 09/406,643
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 08/878,640
; PRIOR FILING DATE: 1997-06-19
; PRIOR APPLICATION NUMBER: US 08/879,078
; PRIOR FILING DATE: 1997-06-19
; NUMBER OF SEQ ID NOS: 2897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 676
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-532-537B-676

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 713 GGTTCCTGATGAAAGC 729
|||:|:|:|:|
Db 1 GGUUCUGAUGAAAGC 17

RESULT 466
US-09-653-225-2333
; Sequence 2333, Application US/09653225
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/09/653,225
; CURRENT FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-653-225-2333

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 4.1e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 941 TCCTGGCGCGCTCTGT 957
|||:|:|:|:|
Db 1 UCCUGGCGCGCUCUGU 17

RESULT 467
US-09-685-664B-1579/c
; Sequence 1579, Application US/09685664B
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
```

RESULT 471
US-09-825-805-349/c
: Sequence 349, Application US/09825805

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Beigelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave

APPLICANT: Zinnen, Shawn

TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides

FILE REFERENCE: MBH800-831-F (400/009)

CURRENT APPLICATION NUMBER: US/09/825,805

CURRENT FILING DATE: 2001-09-27

PRIOR APPLICATION NUMBER: 09/578,223

PRIOR FILING DATE: 2000-05-23

PRIOR APPLICATION NUMBER: 09/476,387

PRIOR FILING DATE: 1999-12-30

PRIOR APPLICATION NUMBER: 09/474,432

PRIOR FILING DATE: 1999-12-29

PRIOR APPLICATION NUMBER: 09/301,511

PRIOR FILING DATE: 1999-04-28

PRIOR APPLICATION NUMBER: 09/186,675

PRIOR FILING DATE: 1998-11-04

PRIOR APPLICATION NUMBER: 60/083,727

PRIOR FILING DATE: 1998-04-29

PRIOR APPLICATION NUMBER: 60/064,866

PRIOR FILING DATE: 1997-11-05

NUMBER OF SEQ ID NOS: 1558

SOFTWARE: PatentIn version 3.0

SEQ ID NO 349

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-825-805-349

Query Match 1.0%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 4.1e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 668 AGCTCCCGCGGCTCC 684

DB 17 AGCTCCCGCGGCTCC 1

RESULT 472

US-09-870-161-1579/c

Sequence 1579, Application US/09870161

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MBH800-876-M (400/026)

CURRENT APPLICATION NUMBER: US/09/870,161

CURRENT FILING DATE: 2001-08-27

NUMBER OF SEQ ID NOS: 20821

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1579

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-870-161-1579

Query Match 1.0%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 4.1e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136

DB 17 ATGGACCCGACATGG 1

RESULT 473

US-09-870-161-6203/c

Sequence 6203, Application US/09870161

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MBH800-876-M (400/026)

CURRENT APPLICATION NUMBER: US/09/870,161

CURRENT FILING DATE: 2001-08-27

NUMBER OF SEQ ID NOS: 20821

SOFTWARE: PatentIn version 3.0

SEQ ID NO 6203

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-870-161-6203

Query Match 1.0%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 4.1e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACATGG 137

DB 17 TGGACCCGACATGG 1

RESULT 474

US-09-870-161-8446

Sequence 8446, Application US/09870161

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MBH800-876-M (400/026)

CURRENT APPLICATION NUMBER: US/09/870,161

CURRENT FILING DATE: 2001-08-27

NUMBER OF SEQ ID NOS: 20821

SOFTWARE: PatentIn version 3.0

SEQ ID NO 8446

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-870-161-8446

Query Match 1.0%; Score 15.4; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 4.1e+02;

Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCGCGCTCTGTG 958

DB 1 CCTGGCGCGCTCTGTG 17

RESULT 475

US-10-138-674-1579/c

Sequence 1579, Application US/10138674

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

;
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1579

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136
||| ||||| |||||
DB 17 ATGGACCCGACATGG 1

RESULT 476
US-10-138-674-6203/c
; Sequence 6203, Application US/10138674
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6203
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6203

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACATGGA 137
||| ||||| |||||
DB 17 TGGACCCGACATGGA 1

RESULT 477
US-10-138-674-8446
; Sequence 8446, Application US/10138674
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8446

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 4.1e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGGCGCCTCTGTG 958
||| ||||| |||||
DB 1 CCGGGCGCCUCUGUG 17

RESULT 478
US-10-138-674A-1579/c
; Sequence 1579, Application US/10138674A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674A
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20826
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674A-1579

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136
||| ||||| |||||
DB 17 ATGGACCCGACATGG 1

RESULT 479
US-10-138-674A-6203/c
; Sequence 6203, Application US/10138674A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674A
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20826
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6203
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674A-6203

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACATGGA 137
||| ||||| |||||
DB 17 TGGACCCGACATGGA 1

RESULT 480

```

; CURRENT APPLICATION NUMBER: US/10/138,674B
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20829
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6203
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674B-6203

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACACATGGA 137
Db 17 TGGACCCGAGACATGGA 1

RESULT 483
US-10-138-674B-8446
; Sequence 8446, Application US/10138674B
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674B
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20829
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674B-8446

Query Match
Best Local Similarity 76.5%; Score 15.4; DB 1; Length 17;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCGCCCTCTGTG 958
Db 1 CCGGGCGCCUCUGUG 17

RESULT 484
US-10-163-552-134/C
; Sequence 134, Application US/10163552
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MEB01-1853-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 134
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-134

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 668 AGCTCCCGCGCCCTCC 684
|||||
Db 17 AGCTCCCGCGCCCTCC 1

RESULT 485

US-10-287-949A-1579/c
; Sequence 1579, Application US/10287949A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1579

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGGACCCGACATGG 136
|||||
Db 17 ATGGACCCGACATGG 1

RESULT 486

US-10-287-949A-6203/c
; Sequence 6203, Application US/10287949A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6203
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6203

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 121 TGGACCCGACATGGA 137
|||||
Db 17 TGGACCCGACATGGA 1

RESULT 487

US-10-287-949A-8446
; Sequence 8446, Application US/10287949A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8446

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 4.1e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCGCGCCCTCTGTG 958
|||||
Db 1 CCTGGCGCGCCCTCTGTG 17

RESULT 488

US-10-712-633-3487
; Sequence 3487, Application US/10712633
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3487
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-3487

Query Match 1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 4.1e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 942 CCTGGCGCGCCCTCTGTG 958
|||||
Db 1 CCTGGCGCGCCCTCTGTG 17

RESULT 489

US-10-712-672-2333

```
; Sequence 3333, Application US/10712672
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowhira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH900-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-712-672-2333

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 4.1e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 941 TCCTGGCGGCTCTGT 957
Db 1 UCCUGGGCGGCCUCUGU 17

RESULT 490
US-10-723-361-6625
; Sequence 6625, Application US/10723361
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6625
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-6626

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 22 CTGCGTCTGCAGGAC 38
Db 1 CTGCGTCTGCATAGGAC 17

RESULT 492
US-10-723-361-6627
; Sequence 6627, Application US/10723361
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-6625

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 21 TCTGCGTCTGCAGGAC 37
Db 1 TCTGCGTCTGCATAGGA 17

RESULT 491
US-10-723-361-6626
; Sequence 6626, Application US/10723361
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6626
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-6626

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 22 CTGCGTCTGCAGGAC 38
Db 1 CTGCGTCTGCATAGGAC 17

RESULT 492
US-10-723-361-6627
; Sequence 6627, Application US/10723361
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
```

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6627
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6627

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      23 TCGGCTGCGAGGACA 39
Db      1 TCGGCTGCGATAGGACA 17

RESULT 493
US-10-723-361-6628
; Sequence 6628, Application US/10723361
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6627
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6627

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      23 TCGGCTGCGAGGACA 39
Db      1 TCGGCTGCGATAGGACA 17

RESULT 493
US-10-723-361-6628
; Sequence 6628, Application US/10723361
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6628
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6628

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      24 GCGTCTGCAGGACAG 40
Db      1 GCGTCTGCATAGGACAG 17

RESULT 494
US-10-724-270-4789/c
; Sequence 4789, Application US/10724270
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MEHR02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-4789

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      668 AGCTCCCGCGCGCTCC 684
Db      17 AGCTCCCGCAGGCTCC 1
```



```

; LENGTH: 19
; TYPE: DNA
; ORGANISM: synthetic construct
US-09-291-838-21

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1469 GCCTGTACTGCCAGGAG 1485
Db 19 GCCGGTACTGCCAGGAG 3

RESULT 498
US-10-310-188-64492
; Sequence 64492, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 64492
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-64492

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 244 CTGCCCCCACCCTCCCCC 260
Db 2 CTACCCCCACCCTCCCCC 18

RESULT 499
US-10-310-188-64684
; Sequence 64684, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 64684
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-64684

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 244 CTGCCCCCACCCTCCCCC 260
Db 2 CAGCCCCCACCCTCCCCC 18

RESULT 500
US-10-714-333A-28984
; Sequence 28984, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 28984
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-28984
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 883 AATTATGTGCCCAAGAA 899
||:|:|:|:|:|:|
Db 3 AAUUAUGUGGCCAGGAA 19
```

```
RESULT 501
US-10-714-333A-29003/c
; Sequence 29003, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29003
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29003
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 926 TCTATGCGCTGCTTCATC 942
|||||:|:|:|:|:|:|
Db 18 TCTATGCGCTGCTTCCTC 2
```

```
RESULT 502
US-10-714-333A-29063/c
; Sequence 29063, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29063
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29063
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 926 TCTATGCGCTGCTTCATC 942
|||||:|:|:|:|:|:|
Db 17 TCTATGCGCTGCTTCCTC 1
```

```
RESULT 503
US-10-714-333A-29070
; Sequence 29070, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29070
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29070
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 883 AATTATGTGCCCAAGAA 899
||:|:|:|:|:|:|
Db 3 AAUUAUGUGGCCAGGAA 19
```

```
RESULT 504
US-10-714-333A-29085/c
; Sequence 29085, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29085
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29085

Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 926 TCTATGCTGCTTCATC 942
Db 18 TCTATGCTGCTTCCTC 2

RESULT 505
US-10-714-333A-29138/c
; Sequence 29138, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29138
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29138

Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 926 TCTATGCTGCTTCATC 942
Db 17 TCTATGCTGCTTCCTC 1

RESULT 506
US-10-714-333A-29144
; Sequence 29144, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29144
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29144

Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.8%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 883 AATTATGTGCCCAAGAA 899
Db 3 AAUUAUGUGGCCAGGAA 19

RESULT 507
US-10-714-333A-29159/c
; Sequence 29159, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29159
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29159

Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 926 TCTATGCTGCTTCATC 942
Db 18 TCTATGCTGCTTCCTC 2

RESULT 508
US-10-714-333A-29210/c
; Sequence 29210, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 29210
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-29210
```

```
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY  926 TCTATGCTGCTTCATC 942
      |||||
Db   17 TCTATGCTGCTTCCTC 1
```

RESULT 509

```
US-10-714-333A-67733
; Sequence 67733, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 67733
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-67733
```

```
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 4.5e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
QY  1423 GTGCTGATGTGGACCAT 1439
      |||||
Db   1 GUGCUGAUCUGGACCAU 17
```

RESULT 510

```
US-10-714-333A-67833
; Sequence 67833, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 67833
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-67833
```

```
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 4.5e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
QY  1423 GTGCTGATGTGGACCAT 1439
      |||||
Db   1 GUGCUGAUCUGGACCAU 17
```

RESULT 511

```
US-10-714-333A-67933
; Sequence 67933, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 67933
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-67933
```

```
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 4.5e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
QY  1423 GTGCTGATGTGGACCAT 1439
      |||||
Db   1 GUGCUGAUCUGGACCAU 17
```

RESULT 512

```
US-10-714-333A-68033
; Sequence 68033, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 68033
; LENGTH: 19
; TYPE: RNA
```

[illegible]

QY 1062 CTTCTTTGCTTCTCC 1078
|||||
Db 17 CTTCTTTGCTTCTCC 1

RESULT 517
US-10-714-333A-163815
; Sequence 163815, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 163815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-163815

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 4.5e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 180 GAGGAGCTGCTGATC 196
|||||
Db 2 GAGGAGCTGCTGATC 18

RESULT 518
US-10-714-333A-182262/c
; Sequence 182262, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 182262
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-182262

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 176 AACTGAGGAGCTGCTG 192
|||||

Db 18 AACTGAGGAAGCTGCTG 2

RESULT 519
US-10-714-333A-190474/c
; Sequence 190474, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 190474
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-190474

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 329 TCGTTGATGAGCTGATG 345
|||||
Db 17 TCGTTGATGATCTGATG 1

RESULT 520
US-10-714-333A-266592/c
; Sequence 266592, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 266592
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-266592

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 898 AACTTTGCCAGGCCCT 914
|||||
Db 19 AACTTTGCCAGGCCCT 3

RESULT 521
US-10-714-333A-266667/c
; Sequence 266667, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 266667
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-266667

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 898 AACTTTGCCCGCCCT 914
| | | | | | | | | | | | | | | | | | | | |
Db 18 AACTTTGCCCGCCCT 2

RESULT 522
US-10-714-333A-266688/c
; Sequence 266688, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 266688
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-266688

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 898 AACTTTGCCCGCCCT 914
| | | | | | | | | | | | | | | | | | | | |
Db 19 AACTTTGCCCGCCCT 3

RESULT 523
US-10-714-333A-266761/c
; Sequence 266761, Application US/10714333A

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 266761
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-266761

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 898 AACTTTGCCCGCCCT 914
| | | | | | | | | | | | | | | | | | | | |
Db 18 AACTTTGCCCGCCCT 2

RESULT 524
US-10-714-333A-284094
; Sequence 284094, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 284094
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-284094

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 4.5e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1519 GCAACUUCUGGGGCT 1535
| | | | | | | | | | | | | | | | | | | | |
Db 1 GCAACUUCUGGGGCT 17

RESULT 525
US-10-714-333A-287934/c
; Sequence 287934, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 287934
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-287934
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 177 ACTGAGGAGCTCTCTG 193
|:|||||:|||||
Db 19 ACTGAGGAGTGTCTGG 3
```

```
RESULT 526
US-10-714-333A-465235
; Sequence 465235, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 465235
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-465235
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 4.5e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1065 CTTTGCTTCTCCTCATT 1081
|:|||||:|||||
Db 2 CUCUGCCUCCUCCAUU 18
```

```
RESULT 527
US-10-714-333A-465335
; Sequence 465335, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 465335
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-465335
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 4.5e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1065 CTTTGCTTCTCCTCATT 1081
|:|||||:|||||
Db 2 CUCUGCCUCCUCCAUU 18
```

```
RESULT 528
US-10-714-333A-468955/c
; Sequence 468955, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 468955
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-468955
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1061 TCTTCTTCTCCTTCTC 1077
|:|||||:|||||
Db 18 TCTTCTTCTTACCTTCTC 2
```

```
RESULT 529
US-10-714-333A-468974/c
; Sequence 468974, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```


; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 468974
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-474959

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1061 TCTTCTTGGCTTCCTC 1077
DB 19 TCTTCTTACCTTCCTC 3

RESULT 530
US-10-714-333A-474898
; Sequence 474898, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 474898
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-474898

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 4.5e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1192 GTCCATGACTGGCTGTA 1208
DB 1 GUCCAUAGCUGGCUAUA 17

RESULT 531
US-10-714-333A-474945
; Sequence 474945, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 474945
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-474945

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.8%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1117 GGAGACAGGATGTTCTA 1133
DB 1 GGUGACAGGAUGUUCUA 17

RESULT 532
US-10-714-333A-474959
; Sequence 474959, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 474959
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-474959

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 4.5e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCTT 1362
DB 2 UGCUGAUUCUUCUUCUU 18

RESULT 533
US-10-714-333A-560766/c
; Sequence 560766, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 560766
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-560766

Query Match          1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1061 TCTTCTTTGCTTCCTC 1077
      ||||| |||||
Db 18 TCTTCTTTGCTTCCTC 2

RESULT 534
US-10-714-333A-581586
; Sequence 581586, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 581586
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-581586

Query Match          1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 179 TGAGGAGCTGCTGGAT 195
      :||| ||||| |||||
Db 1 UGAGAGAGCGUGGAU 17

RESULT 535
US-10-714-333A-606457
; Sequence 606457, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 606457
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-606457

Query Match          1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1229 GGCTGGGCTCTTGGT 1245
      ||| ||||| |||||
Db 1 GGCAGCGGCUCCUUGGU 17

RESULT 536
US-10-714-333A-606657
; Sequence 606657, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 606657
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-606657

Query Match          1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1229 GGCTGGGCTCTTGGT 1245
      ||| ||||| |||||
Db 1 GGCAGCGGCUCCUUGGU 17

RESULT 537
US-10-714-333A-624598/c
; Sequence 624598, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 624598
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-624598/c
```

US-10-714-333A-624598

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCTT 1362

DB 17 TGCTGATCTCTTCCTT 1

RESULT 538

US-10-714-333A-651411/c

; Sequence 651411, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 651411
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-714-333A-651411

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 520 TTCTGTCCACCTGTT 536

DB 19 TTCTGTCCACCTGTT 3

RESULT 539

US-10-714-333A-651460/c

; Sequence 651460, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 651460
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-714-333A-651460

Query Match 1.0%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 520 TTCTGTCCACCTGTT 536

DB 18 TTCTGTCCACCTGTT 2

RESULT 540

US-10-714-333A-667461/c

; Sequence 667461, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 667461
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-714-333A-667461

Query Match 1.0%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 158 TGGAGCAAGTCAGGGA 174

DB 17 TGGAGCAAGTCAGGGA 1

RESULT 541

US-10-714-333A-940279

; Sequence 940279, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 940279
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-714-333A-940279

Query Match 1.0%; Score 15.4; DB 1; Length 19;

Best Local Similarity 82.4%; Pred. No. 4.5e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 402 CATCATCAGCACCCCTGG 418
||:|||||:|
Db 1 CAACAUCAGCACCCUGG 17

RESULT 542

US-10-714-333A-978865/c
; Sequence 978865, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 978865
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-978865

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGGACAGAGGGCTGGG 50
|||||
Db 18 AGGACAGAGAGCTGGG 2

RESULT 543

US-10-714-333A-1017411/c
; Sequence 1017411, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1017411
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1017411

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 177 ACTGAGGAGCTGCTGG 193
|||||
Db 18 ACTGAGCGAGCTGCTGG 2

RESULT 544

US-10-714-333A-1147332/C
; Sequence 1147332, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1147332
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1147332

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1054 CTGCTCATCTCTTTC 1070
|||||
Db 17 CTGCTCATCTTCATTGC 1

RESULT 545

US-10-714-333A-1188581
; Sequence 1188581, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1188581
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1188581

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 4.5e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 444 GCTGCTGCTGGAGTTTG 460
||:||||:|
Db 3 GCUGCUGCGGACUUG 19

RESULT 546

```
US-10-714-333A-1218898
; Sequence 1218898, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1218898
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1218898
;
;
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTT 827
Db 2 UACAUCUACUCCUUCU 18

RESULT 547
US-10-714-333A-1274878/c
; Sequence 1274878, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1274878
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1274878
;
;
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 827 TCTGCCCAACACTCATC 843
Db 17 TCTGACCAACACTCATC 1

RESULT 548
US-10-714-333A-1274909/c
; Sequence 1274909, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1274909
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1274909
;
;
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 827 TCTGCCCAACACTCATC 843
Db 18 TCTGACCAACACTCATC 2

RESULT 549
US-10-714-333A-1345571
; Sequence 1345571, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1345571
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1345571
;
;
Query Match      1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 4.5e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTTGCCTTCT 1076
Db 2 AUCUUCUUGCCAUCCU 18

RESULT 550
US-10-714-333A-1353450/c
; Sequence 1353450, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1353450
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1353450
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 953 TCTGTCTCTCTGCTTT 969
Db 17 TCTGTCTCTCTGCTTT 1
```

RESULT 551

```
US-10-714-333A-1365530/c
; Sequence 1365530, Application US/10714333A
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1365530
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1365530
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 31 CAGAGGACAGAGGGCT 47
Db 18 CAGAGGACAGAGGGCT 2
```

RESULT 552

```
US-10-714-333A-1436443/c
; Sequence 1436443, Application US/10714333A
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1436443
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1436443
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1062 CTTCTTTGCTTCTCTCC 1078
Db 17 CTTCTTTGCTTCTCTCC 1
```

RESULT 553

```
US-10-714-333A-1473441
; Sequence 1473441, Application US/10714333A
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1473441
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1473441
```

```
Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 179 TGAGGAGCTGTGGAT 195
Db 1 UGAGCGAGCGUGGAU 17
```

RESULT 554

```
US-10-714-333A-1499396/c
; Sequence 1499396, Application US/10714333A
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
```

; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1499396
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1499396

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 CCTCTACTCTCTCTCT 829
DB 18 CATCTACTCTCTCTCT 2

RESULT 555
US-10-714-333A-1552767
; Sequence 1552767, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349905
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1552767
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1552767

Query Match 1.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 4.5e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 369 CTACACATGTTTCATCG 385
DB 2 CUACUACAUUGUACUG 18

RESULT 556
PCT-US02-22746-43/C
; Sequence 43, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: PCT/US02/22746
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 65

; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-43

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GAGCTGCTGGATCGGC 200
DB 17 GAGCTGCTGGATCGGC 1

RESULT 557
PCT-US02-24143-17/C
; Sequence 17, Application PC/TUS0224143
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Lex M. Cowart
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 8 EXPRESSION
; FILE REFERENCE: RTSP-0402
; CURRENT APPLICATION NUMBER: PCT/US02/24143
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: 09/920,668
; PRIOR FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-24143-17

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1184 ACGTGTGTCTCATGAC 1200
DB 19 ACGTGTGTCTCATGAC 3

RESULT 558
PCT-US03-39429-89
; Sequence 89, Application PC/TUS0339429
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PPAR-ALPHA EXPRESSION
; FILE REFERENCE: RTS-0380
; CURRENT APPLICATION NUMBER: PCT/US03/39429
; CURRENT FILING DATE: 2003-12-11
; NUMBER OF SEQ ID NOS: 276
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US03-39429-89

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 935 GCTTCATCTCTGGCGGC 951
|||||

```
Db      2  GCTTCAGCCTGGGCGCG 18

RESULT 559
PCT-US04-04452-1653/c
; Sequence 1653, Application PC/TUS0404452
; GENERAL INFORMATION:
; APPLICANT: Bardelli, Alberto
; APPLICANT: Parsons, Will
; APPLICANT: Velculescu, Victor
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: TYROSINE KINASES IMPLICATED IN CANCERS
; FILE REFERENCE: 001107.00327
; CURRENT APPLICATION NUMBER: PCT/US04/04452
; CURRENT FILING DATE: 2004-02-18
; NUMBER OF SEQ ID NOS: 2191
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1653
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
PCT-US04-04452-1653

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      151  CAAATGCTGGAGGAGC 167
          |||||
Db      17  CAAATGCTGGAGGAGC 1

RESULT 560
US-08-196-030C-68/c
; Sequence 68, Application US/08196030C
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: SHERI L. BUIJK
; APPLICANT: ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: ONE ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/196,030C
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.US.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-196-030C-68

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1476  CTGCCAGGAGTGGTACG 1492
          |||||
Db      19  CTGCCAGGAGGAGGTACG 3

RESULT 561
US-08-242-654A-68/c
; Sequence 68, Application US/08242654A
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: SHERI L. BUIJK
; APPLICANT: ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: ONE ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/242,654A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.US.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-242-654A-68

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1476  CTGCCAGGAGTGGTACG 1492
          |||||
Db      19  CTGCCAGGAGGAGGTACG 3
```


RESULT 562

US-08-486-749-99/c
; Sequence 99, Application US/08486749
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BUIJK
; APPLICANT: ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,550
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-486-749-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 563

US-08-488-445A-99/c
; Sequence 99, Application US/08488445A
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BUIJK
; TITLE OF INVENTION: NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,550
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-486-749-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 564

US-09-092-330-24/c
; Sequence 24, Application US/09092330
; GENERAL INFORMATION:
; APPLICANT: BILLING-MEDEL, PATRICIA
; APPLICANT: COHEN, MAURICE
; APPLICANT: COLPITTS, TRACEY L.
; APPLICANT: FRIEDMAN, PAULA N.
; APPLICANT: KLASS, MICHAEL R.
; APPLICANT: RUSSELL, JOHN C.
; APPLICANT: STROUPE, STEPHEN D.
; TITLE OF INVENTION: REAGENTS AND METHODS USEFUL
; FOR DETECTING DISEASES OF THE LUNG
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/092,330

RESULT 565

US-08-488-445A-99/c
; Sequence 99, Application US/08488445A
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BUIJK
; TITLE OF INVENTION: NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,550
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-486-749-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 566

US-08-488-445A-99/c
; Sequence 99, Application US/08488445A
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BUIJK
; TITLE OF INVENTION: NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,550
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-486-749-99

APPLICANT: ISA K. MUSHAWAR
; TITLE OF INVENTION: NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,445A
; FILING DATE:
; CLASSIFICATION: 436
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-488-445A-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 567

US-09-092-330-24/c
; Sequence 24, Application US/09092330
; GENERAL INFORMATION:
; APPLICANT: BILLING-MEDEL, PATRICIA
; APPLICANT: COHEN, MAURICE
; APPLICANT: COLPITTS, TRACEY L.
; APPLICANT: FRIEDMAN, PAULA N.
; APPLICANT: KLASS, MICHAEL R.
; APPLICANT: RUSSELL, JOHN C.
; APPLICANT: STROUPE, STEPHEN D.
; TITLE OF INVENTION: REAGENTS AND METHODS USEFUL
; FOR DETECTING DISEASES OF THE LUNG
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/092,330

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 568

US-09-092-330-24/c
; Sequence 24, Application US/09092330
; GENERAL INFORMATION:
; APPLICANT: BILLING-MEDEL, PATRICIA
; APPLICANT: COHEN, MAURICE
; APPLICANT: COLPITTS, TRACEY L.
; APPLICANT: FRIEDMAN, PAULA N.
; APPLICANT: KLASS, MICHAEL R.
; APPLICANT: RUSSELL, JOHN C.
; APPLICANT: STROUPE, STEPHEN D.
; TITLE OF INVENTION: REAGENTS AND METHODS USEFUL
; FOR DETECTING DISEASES OF THE LUNG
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/092,330

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

RESULT 569

US-08-488-445A-99/c
; Sequence 99, Application US/08488445A
; GENERAL INFORMATION:
; APPLICANT: JOHN N. SIMONS
; APPLICANT: TAMI J. PILOT-MATIAS
; APPLICANT: GEORGE J. DAWSON
; APPLICANT: GEORGE G. SCHLAUDER
; APPLICANT: SURESH M. DESAI
; APPLICANT: THOMAS P. LEARY
; APPLICANT: ANTHONY SCOTT MUEHROFF
; APPLICANT: JAMES C. ERKER
; APPLICANT: SHERI L. BUIJK
; TITLE OF INVENTION: NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
; NUMBER OF SEQUENCES: 716
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES D377/AP6D
; STREET: 100 ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,550
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5527.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-938-2623
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-486-749-99

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1476 CTGCCAGGAGTGGTACG 1492

Db 19 CTGCCAGGAGGGGTACG 3

/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA: 60/048,838
/ APPLICATION NUMBER: 60/048,838
/ FILING DATE: 06-JUN-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Becker, Cheryl L.
/ REGISTRATION NUMBER: 35,441
/ REFERENCE/DOCKET NUMBER: 6108.US.01
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 847/935-1729
/ TELEFAX: 847/938-2623
/ TELEX:
/ INFORMATION FOR SEQ ID NO: 24:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-092-330-24

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 451 CTGGAGTTTGACCTACT 467
Db 17 CTGGAGTTTGACCTTCT 1

RESULT 565
US-09-703-708-16738
/ Sequence 16738, Application US/09703708
/ GENERAL INFORMATION:
/ APPLICANT: Bower, Stanley G.
/ APPLICANT: Hinkle, Gregory J.
/ TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
/ FILE REFERENCE: 38-10(15804)C
/ CURRENT APPLICATION NUMBER: US/09/703,708
/ CURRENT FILING DATE: 2000-11-02 US 60/164,320
/ PRIOR APPLICATION NUMBER: 1999-11-10
/ PRIOR FILING DATE: US 60/183,791
/ PRIOR FILING DATE: 2000-02-22
/ NUMBER OF SEQ ID NOS: 18992
/ SEQ ID NO 16738
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Xanthomonas campestris
/ US-09-703-708-16738

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 327 CCTGCTTGATGACTGA 343
Db 4 CCTGCTTGATGACTGA 20

RESULT 566
US-09-918-026A-43/c
/ Sequence 43, Application US/09918026A
/ GENERAL INFORMATION:
/ APPLICANT: Rosanne M. Crooke
/ APPLICANT: Mark J. Graham
/ APPLICANT: Kristina M. Lemonidis
/ TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
/ FILE REFERENCE: ISPH-0588
/ CURRENT APPLICATION NUMBER: US/09/918,026A
/ CURRENT FILING DATE: 2001-07-30
/ NUMBER OF SEQ ID NOS: 65
/ SEQ ID NO 43

/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
/ US-09-918-026A-43

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GAGCTGCTGGATCGGC 200
Db 17 GAGCTGCTGGATCGGC 1

RESULT 567
US-10-310-188-25216
/ Sequence 25216, Application US/10310188
/ GENERAL INFORMATION:
/ APPLICANT: RosettaGenomics
/ TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
/ TITLE OF INVENTION: USES THEREOF
/ FILE REFERENCE: 47487
/ CURRENT APPLICATION NUMBER: US/10/310,188
/ CURRENT FILING DATE: 2002-12-19
/ NUMBER OF SEQ ID NOS: 86841
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 25216
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-310-188-25216

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 CATCAAGACAAACCT 243
Db 2 CATCAAGACAAACCT 18

RESULT 568
US-10-317-500-89
/ Sequence 89, Application US/10317500
/ GENERAL INFORMATION:
/ APPLICANT: Robert McKay
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF PPAR-ALPHA EXPRESSION
/ FILE REFERENCE: RTS-0380
/ CURRENT APPLICATION NUMBER: US/10/317,500
/ CURRENT FILING DATE: 2002-12-11
/ NUMBER OF SEQ ID NOS: 276
/ SEQ ID NO 89
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
/ US-10-317-500-89

Query Match 1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 935 GCTTCATCTGGCGGC 951
Db 2 GCTTCATCTGGCGGC 18

RESULT 569
US-10-325-899-9922/c

```
; Sequence 9922, Application US/10325899
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Lv, Ngoc
; APPLICANT: Woodward, Robert
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT
; FILE REFERENCE: 506612000122
; CURRENT APPLICATION NUMBER: US/10/325,899
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 10/131,831
; PRIOR FILING DATE: 2002-04-24
; NUMBER OF SEQ ID NOS: 9966
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9922
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-325-899-9922

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 572 GCACCTGGAGCGGCG 588
DB 17 GCACCTGGAGCGGCG 1

RESULT 570
US-10-484-441-43/c
; Sequence 43, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE22 EX
; FILE REFERENCE: ISPH70694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-484-441-43

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GAGCTGCTGGATCGGCG 200
DB 17 GAGCTGTTGGATCGGCG 1

RESULT 571
US-10-740-773-9/c
; Sequence 9, Application US/10740773
; GENERAL INFORMATION:
; APPLICANT: Spriggs, Melanie K.
; TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
; FILE REFERENCE: 2634-US
; CURRENT APPLICATION NUMBER: US/10/740,773
```

```
; CURRENT FILING DATE: 2003-12-19
; PRIOR APPLICATION NUMBER: US/09/689,012
; PRIOR FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: PCT/US99/09831
; PRIOR FILING DATE: 1999-05-05
; PRIOR APPLICATION NUMBER: US 60/085,497
; PRIOR FILING DATE: 1998-05-14
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PRIMER
; US-10-740-773-9

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 GGGCCAGGGGCGACCTGG 579
DB 19 GGTCCAGGGGCGACCTGG 3

RESULT 572
US-60-164-320-16738
; Sequence 16738, Application US/60164320
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)A
; CURRENT APPLICATION NUMBER: US/60/164,320
; CURRENT FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 16738
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
; US-60-164-320-16738

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 327 CCTGCTTGATGAGCTCA 343
DB 4 CCTGCTTGATGATCTGA 20

RESULT 573
US-60-183-791-16738
; Sequence 16738, Application US/60183791
; GENERAL INFORMATION:
; APPLICANT: Bower, Stanley G.
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Xanthomonas campestris Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15804)B
; CURRENT APPLICATION NUMBER: US/60/183,791
; CURRENT FILING DATE: 2000-02-22
; NUMBER OF SEQ ID NOS: 18992
; SEQ ID NO 16738
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Xanthomonas campestris
; US-60-183-791-16738

Query Match      1.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 327 CCTGCTTGATGAGCTGA 343
Db 4 CCTGCTTGATGATCTGA 20

RESULT 574
PCT-US01-01416A-109/c
; Sequence 109, Application PC/TUS0101416A
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTSP-0099
; CURRENT APPLICATION NUMBER: PCT/US01/01416A
; CURRENT FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-24-01
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US01-01416A-109

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 TGTGTTCTCTGCTCCGAG 1294
Db 20 TGTGTTCTCTGCTCTGAG 1

RESULT 575
PCT-US01-27316-22/c
; Sequence 22, Application PC/TUS0127316
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Hong Zhang
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF BH3 INTERACTING DOMAIN DEATH AGONIST EXPRESSION
; FILE REFERENCE: ISPH-0605
; CURRENT APPLICATION NUMBER: PCT/US01/27316
; CURRENT FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: 09/657,346
; PRIOR FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: 09/800,631
; PRIOR FILING DATE: 2001-03-07
; NUMBER OF SEQ ID NOS: 175
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US01-27316-22

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 903 TGCCAGGCGCTGGATGTG 922
Db 20 TGCCAGGCGCATGACTGTG 1

RESULT 576
PCT-US01-50914-142
; Sequence 142, Application PC/TUS0150914
; GENERAL INFORMATION:

; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Hong Zhang
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RAIDD EXPRESSION
; FILE REFERENCE: RTSP-0195
; CURRENT APPLICATION NUMBER: PCT/US01/50914
; CURRENT FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/705,267
; PRIOR FILING DATE: 2000-11-01
; NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US01-50914-142

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1466 TCAGCTGTACTGCCAGGAG 1485
Db 1 TCAGCTCCACTGCCTGGAG 20

RESULT 577
PCT-US02-22746-51/c
; Sequence 51, Application PC/TUS0222746
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2
; FILE REFERENCE: ISPH-0694
; CURRENT APPLICATION NUMBER: PCT/US02/22746
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-22746-51

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 633 CTGCGCTGCGGTCCACG 652
Db 20 CTGCGTCTGCGGTGCACG 1

RESULT 578
PCT-US02-25943-13308/c
; Sequence 13308, Application PC/TUS0225943
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: PCT/US02/25943
; CURRENT FILING DATE: 2002-08-27
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 13308

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (1341916)...(1341935)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectonObjectNumber = 14346
PCT-US02-25943-13308

Query Match
Best Local Similarity 1.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 638 CGCTGCGGTCACGCGGCC 657
Db 20 CGCTGCGGATCAACGCGGCC 1

RESULT 579
PCT-US03-30353-119
; Sequence 119, Application PC/TUS0330353
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Kane, Christopher D
; TITLE OF INVENTION: ANTISENSE MODULATION OF FARNESOID X RECEPTOR EXPRESSION
; FILE REFERENCE: 01290/1/PCT
; CURRENT APPLICATION NUMBER: PCT/US03/30353
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 2146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human FXR antisense
PCT-US03-30353-119

Query Match
Best Local Similarity 1.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1042 ATCTTCATGCTGCTGCTCAT 1061
Db 1 ATCTGCATGCTGCTTCCAT 20

RESULT 580
PCT-US03-30374-454
; Sequence 454, Application PC/TUS0330374
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/PCT
; CURRENT APPLICATION NUMBER: PCT/US03/30374
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 454
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human Gfat antisense
PCT-US03-30374-454

Query Match
Best Local Similarity 1.0%; Score 15.2; DB 1; Length 20;
```

```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 245 TGCCCCCACCTCCCCCAGGT 264
Db 1 TGCCCCGAGCTTCCCCAGGT 20

RESULT 581
PCT-US03-37383-219
; Sequence 219, Application PC/TUS0337383
; GENERAL INFORMATION:
; APPLICANT: ISIS Pharmaceuticals, Inc.
; APPLICANT: Ward, Donna T.
; APPLICANT: Marcussen, Eric G.
; APPLICANT: Freier, Susan W.
; APPLICANT: Dobie, Kenneth W.
; TITLE OF INVENTION: MODULATION OF HYPOXIA-INDUCIBLE FACTOR 1 ALPHA EXPRESSION
; FILE REFERENCE: ISPT-1009
; CURRENT APPLICATION NUMBER: PCT/US03/37383
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 454
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 219
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide Primer
PCT-US03-37383-219

Query Match
Best Local Similarity 1.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 482 GACAGCTGCCATTGGCGCTG 501
Db 1 GTCAGCTGTCATTGTCGCTG 20

RESULT 582
PCT-US03-37383-337/c
; Sequence 337, Application PC/TUS0337383
; GENERAL INFORMATION:
; APPLICANT: ISIS Pharmaceuticals, Inc.
; APPLICANT: Ward, Donna T.
; APPLICANT: Marcussen, Eric G.
; APPLICANT: Freier, Susan W.
; APPLICANT: Dobie, Kenneth W.
; TITLE OF INVENTION: MODULATION OF HYPOXIA-INDUCIBLE FACTOR 1 ALPHA EXPRESSION
; FILE REFERENCE: ISPT-1009
; CURRENT APPLICATION NUMBER: PCT/US03/37383
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 454
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 337
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; OTHER INFORMATION:
PCT-US03-37383-337

Query Match
Best Local Similarity 1.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 482 GACAGCTGCCATTGGCGCTG 501
Db 20 GTCAGCTGTCATTGTCGCTG 1
```

US-09-053-583-94/c
; Sequence 94, Application US/09053583A
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Ichikawa, Kimihisa

```
Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      819 CTTCTCTCTCTGCGCCCAAC 838
Db      1 CTTCTCTCTCTCTGCGCCCAAC 20

RESULT 587
US-09-408-646-94/c
; Sequence 94, Application US/09408646A
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 990540/HG
; CURRENT APPLICATION NUMBER: US/09/408,646A
; CURRENT FILING DATE: 1999-09-30
; EARLIER APPLICATION NUMBER: JP 10-276881
; EARLIER FILING DATE: 1998-09-30
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-09-408-646-94

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      819 CTTCTCTCTCTGCGCCCAAC 838
Db      20 CTTCTCTCTCTCTGCGCCCAAC 1

RESULT 588
US-09-408-646-98
; Sequence 98, Application US/09408646A
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 990540/HG
; CURRENT APPLICATION NUMBER: US/09/408,646A
; CURRENT FILING DATE: 1999-09-30
; EARLIER APPLICATION NUMBER: JP 10-276881
; EARLIER FILING DATE: 1998-09-30
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-09-408-646-98

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      819 CTTCTCTCTCTGCGCCCAAC 838
Db      1 CTTCTCTCTCTCTGCGCCCAAC 20

RESULT 589
US-09-499-662-94/c
; Sequence 94, Application US/09499662
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/09/499,662
; CURRENT FILING DATE: 2000-02-09
; EARLIER APPLICATION NUMBER: US 09/053,583
; EARLIER FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-09-499-662-94

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      819 CTTCTCTCTCTGCGCCCAAC 838
Db      20 CTTCTCTCTCTCTGCGCCCAAC 1

RESULT 590
US-09-499-662-98
; Sequence 98, Application US/09499662
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/09/499,662
; CURRENT FILING DATE: 2000-02-09
; EARLIER APPLICATION NUMBER: US 09/053,583
; EARLIER FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-09-499-662-98

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```



```
RESULT 596
US-09-755-004-10/c
; Sequence 10, Application US/09755004
; GENERAL INFORMATION:
; APPLICANT: Shuber, Anthony
; TITLE OF INVENTION: Methods for Detecting, Grading or Monitoring an H. pylori Infection
; FILE REFERENCE: EXT-048
; CURRENT APPLICATION NUMBER: US/09/755,004
; CURRENT FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: APC forward primer
US-09-755-004-10

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 332 TTGATGAGCTGATGAGGTG 351
Db 20 TTGAGGAGGTGGTGGAGGTG 1

RESULT 597
US-09-776-479-448/c
; Sequence 448, Application US/09776479
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-448

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1461 CCAGGTCAGGCTGTACGTGCC 1480
Db 20 CCCGGTGAGCTGTCACTGCC 1

RESULT 598
US-09-781-693A-4/c
; Sequence 4, Application US/09781693A
; GENERAL INFORMATION:
; APPLICANT: Chang, Tai-Jay
; TITLE OF INVENTION: ANDROGEN RECEPTOR COMPLEX-ASSOCIATED PROTEIN
; FILE REFERENCE: 11709-003001
; CURRENT APPLICATION NUMBER: US/09/781,693A
; CURRENT FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: US 60/262,312
```

```
; PRIOR FILING DATE: 2001-01-17
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for PCR
US-09-781-693A-4

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 963 TGTCTTTGCCAACATGAGCC 982
Db 20 TGTCTTTGCCAAATGTTC 1

RESULT 599
US-09-800-631-22/c
; Sequence 22, Application US/09800631
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF BH3 INTERACTING DOMAIN DEATH AGONIST EXPRESSION
; FILE REFERENCE: ISPH-0544
; CURRENT APPLICATION NUMBER: US/09/800,631
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US/09/657,346
; PRIOR FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 175
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-800-631-22

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 903 TGCCAGGCCCTGGGATGTG 922
Db 20 TGCCAGGCCATGCACTGTG 1

RESULT 600
US-09-888-326-406/c
; Sequence 406, Application US/09888326
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced Cell Lysis and Treating Cancer
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 406
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-09-888-326-406
```

```
Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTCTACTGCC 1480
DB 20 CCCGGTGAGCCTGCATGCC 1

RESULT 601
US-09-888-326A-406/c
; Sequence 406, Application US/09888326A
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; TITLE OF INVENTION: Cell Lysis and Treating Cancer
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 850
; SOFTWARE: Fast-Seq for Windows Version 3.0
; SEQ ID NO 406
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-09-888-326A-406

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTCAGCCTGTACTGCC 1480
DB 20 CCCGGTGAGCCTGCATGCC 1

RESULT 602
US-09-918-026A-51/c
; Sequence 51, Application US/09918026A
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EX
; FILE REFERENCE: ISPH-0588
; CURRENT APPLICATION NUMBER: US/09/918,026A
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-918-026A-51

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 633 CTGCGCGCTGCGGTCACG 652
DB 20 CTGGCTCTGCGGTCGACG 1

RESULT 603
US-09-924-256A-1/c
; Sequence 1, Application US/09924256A
```

```
; GENERAL INFORMATION:
; APPLICANT: Waters, Barbara
; APPLICANT: Miao, Vivian
; APPLICANT: Ho, Yap
; APPLICANT: Tong, Seow
; TITLE OF INVENTION: METHOD FOR ISOLATION OF BIOSYNTHESIS GENES FOR
; TITLE OF INVENTION: BIOACTIVE MOLECULES
; FILE REFERENCE: 9993-006
; CURRENT APPLICATION NUMBER: US/09/924,256A
; CURRENT FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 08/861,774
; PRIOR FILING DATE: 2001-04-13
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-924-256A-1

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 77.8%; Pred. No. 5e+02; 3; Mismatches 0; Indels 0; Gaps 0;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 635 GCGCGCTGCGGTCACG 652
DB 20 GCGCGCTGCGGTCGAYS 3

RESULT 604
US-09-979-128-3
; Sequence 3, Application US/09979128
; GENERAL INFORMATION:
; APPLICANT: SUTTON, Andrew
; APPLICANT: SMITH, Peter
; APPLICANT: STEVENSON, Darren
; APPLICANT: CHANA, Haj
; APPLICANT: THRAVES, Peter
; TITLE OF INVENTION: NEW VACCINE FORMULATIONS-2
; FILE REFERENCE: 37945-0034
; CURRENT APPLICATION NUMBER: US/09/979,128
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: PCT/GB00/01918
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: 0008032.5
; PRIOR FILING DATE: 2000-04-01
; PRIOR APPLICATION NUMBER: 0008029.1
; PRIOR FILING DATE: 2000-04-01
; PRIOR APPLICATION NUMBER: 9911824.2
; PRIOR FILING DATE: 1999-05-21
; PRIOR APPLICATION NUMBER: 9911823.4
; PRIOR FILING DATE: 1999-05-21
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
; NAME/KEY: misc feature
; OTHER INFORMATION: PSAINTF internal forward
US-09-979-128-3

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1451 GCCAGGGGATCCAGGTCAGC 1470
```

```

; CURRENT APPLICATION NUMBER: US/10/181,846
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-109

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1275 TGTGTTCTCGTCTCCGCAG 1294
          ||||| ||||| |||||
Db      20  TGTGTTCTCGCCTCTGCAG 1

RESULT 608
US-10-216-484-94/c
; Sequence 94, Application US/10216484
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/10/216,484
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: US/09/499,662
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: US 09/053,583
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-10-216-484-94

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      819 CTTCCCTCTTCGCCCAACAC 838
          ||||| ||||| |||||
Db      20  CTTCCCTTCCTCCCAAAAC 1

RESULT 609
US-10-216-484-98
; Sequence 98, Application US/10216484
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Tamaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/10/216,484

```

; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: US/09/499,662
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: US 09/053,583
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody
US-10-216-484-98

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTTCTCTCTCTGCCCAAC 838
Db 1 CTTCTCTCTCTGCCCAAC 20
|||||

RESULT 610
US-10-227-565-13308/c
; Sequence 13308, Application US/10227565
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zeigler Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/227,565
; CURRENT FILING DATE: 2002-08-26
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 13308
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (1341916)...(1341935)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 14346
US-10-227-565-13308

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 638 CGCTGCGGTCCACGTGGCC 657
Db 20 CGCTGCGGTCCACGTGGCC 1
|||||

RESULT 611
US-10-266-090-39771/c
; Sequence 39771, Application US/10266090
; GENERAL INFORMATION:
; APPLICANT: GOFF, STEPHEN
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; APPLICANT: WANG, RONG-LIN
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; TITLE OF INVENTION: REPEAT MARKERS AND THEIR USES
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; CURRENT FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 39771
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-39771

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 745 GAGGCTGCTGGGATCCT 764
Db 20 GAGGATATGCTGGGATCCT 1
|||||

RESULT 612
US-10-266-090-41589
; Sequence 41589, Application US/10266090
; GENERAL INFORMATION:
; APPLICANT: GOFF, STEPHEN
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; APPLICANT: WANG, RONG-LIN
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; TITLE OF INVENTION: REPEAT MARKERS AND THEIR USES
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; CURRENT FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 41589
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-41589

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1059 CATCTCTTTGGCTTCCTCC 1078
Db 1 CCTCTTCTCTCCCTTCCTCC 20
|||||

RESULT 613
US-10-266-090-42307/c
; Sequence 42307, Application US/10266090
; GENERAL INFORMATION:
; APPLICANT: GOFF, STEPHEN
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; APPLICANT: WANG, RONG-LIN
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; TITLE OF INVENTION: REPEAT MARKERS AND THEIR USES
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; CURRENT FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 42307

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-42307

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1314 CTCGTCGTCCTGGGTCT 1333
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CTCGCTCGTCATGGAGTCT 1

RESULT 614
US-10-266-090-44824/c
; Sequence 44824, Application US/10266090
; GENERAL INFORMATION:
; APPLICANT: GOFF, STEPHEN
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; APPLICANT: WANG, RONG-LIN
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; PRIOR FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 44824
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-44824

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1120 GACAGGATGTTTACCGGA 1139
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCCAGGATGTTTCCGGTA 1

RESULT 615
US-10-266-090-45481
; Sequence 45481, Application US/10266090
; GENERAL INFORMATION:
; APPLICANT: GOFF, STEPHEN
; APPLICANT: BONAN, CAROLINE
; APPLICANT: COLBERT, MICHELLE
; APPLICANT: WANG, RONG-LIN
; TITLE OF INVENTION: CEREAL TRINUCLEOTIDE SIMPLE SEQUENCE
; FILE REFERENCE: NADII.058C1
; CURRENT APPLICATION NUMBER: US/10/266,090
; PRIOR FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: US 10/260,703
; PRIOR FILING DATE: 2002-09-26
; PRIOR APPLICATION NUMBER: US 60/326,117
; PRIOR FILING DATE: 2001-09-26
; NUMBER OF SEQ ID NOS: 51812
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 45481
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR PRIMER FOR SEQUENCE FROM ORYZA SATIVA
US-10-266-090-45481

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1059 CATCTTCTTTCCTTCCTCC 1078
| | | | | | | | | | | | | | | | | | | | | |
Db 1 CCTCTTCTTTCCTTCCTCC 20

RESULT 616
US-10-287-820-936/c
; Sequence 936, Application US/10287820
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Mycoplasma pneumoniae M129 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,820
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2066
; SOFTWARE: Proprietary
; SEQ ID NO 936
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mycoplasma pneumoniae M129 complete genome.
; FEATURE:
; LOCATION: (409466)...(409485)
; OTHER INFORMATION: Chromosome = 1 Strand = negative
US-10-287-820-936

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 732 CTCCTTCTGAGAGGCTG 751
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CTCCTTCTGAAAGAGGTTG 1

RESULT 617
US-10-289-762-4685
; Sequence 4685, Application US/10289762
; GENERAL INFORMATION:
; APPLICANT: Grifais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4685
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4685

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 502 GTGACCTGGTGCCCATGTT 521
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GAGACCTTGGTCCCATGTT 20

RESULT 618
US-10-293-338-4193

```
; Sequence 4193, Application US/10293338
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY GENES AND
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 45282
; CURRENT APPLICATION NUMBER: US/10/293,338
; CURRENT FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 8785
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-293-338-4193

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 43 GGGCTGGGGAGCGGGA 62
      ||||| ||||| |||||
Db 1 GGGCAGGGAGGGAAGGGA 20

RESULT 619
US-10-293-783-22/c
; Sequence 22, Application US/10293783
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; TITLE OF INVENTION: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF BH3 INTERACTING DOMAIN DEATH AGONIST EXPRESSION
; FILE REFERENCE: ISPH-0544
; CURRENT APPLICATION NUMBER: US/10/293,783
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US/09/800,631
; PRIOR FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US/09/657,346
; PRIOR FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 175
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-293-783-22

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 903 TGCCAGGCCCTGGGATGTG 922
      ||||| ||||| |||||
Db 20 TGCCAGGCCATGACTGTG 1

RESULT 620
US-10-303-778-5528
; Sequence 5528, Application US/10303778
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL
; TITLE OF INVENTION: REGULATORY GENES AND USES THEREOF
; FILE REFERENCE: 47416
; CURRENT APPLICATION NUMBER: US/10/303,778
; CURRENT FILING DATE: 2002-11-26
; NUMBER OF SEQ ID NOS: 17608
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5528
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GCTGCCGGTCCACGTGGCGG 658
      ||||| ||||| |||||
Db 1 GCTGCCGGCCACCTGGCGG 20

RESULT 621
US-10-310-188-10900
; Sequence 10900, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10900
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-10900

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GCTGCCGGTCCACGTGGCGG 658
      ||||| ||||| |||||
Db 1 GCTGCCGGCCACCTGGCGG 20

RESULT 622
US-10-310-188-26108
; Sequence 26108, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-26108

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 42 AGGGCTGGGAGGGAGCGGG 61
      ||||| ||||| |||||
Db 1 AGTGCTGGGGCGGGAGCGGG 20

RESULT 623
US-10-310-188-40229/c
; Sequence 40229, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 47487
```


RESULT 628
US-10-384-933-98

; Sequence 98, Application US/10384933
; GENERAL INFORMATION:
; APPLICANT: Serizawa, Nobufusa
; APPLICANT: Haruyama, Hideyuki
; APPLICANT: Nakahara, Kaori
; APPLICANT: Takaki, Ikuko
; APPLICANT: Takahashi, Tohru
; TITLE OF INVENTION: Anti-Fas Antibodies
; FILE REFERENCE: 980126CIP/HG
; CURRENT APPLICATION NUMBER: US/10/384,933
; CURRENT FILING DATE: 2003-02-05
; PRIOR APPLICATION NUMBER: US/09/499,662
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/053,583
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequencing
; OTHER INFORMATION: primer for a DNA encoding the heavy chain of a
; OTHER INFORMATION: humanized anti-Fas antibody

US-10-384-933-98

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 CTTCCTCTTCTGCCCAAC 838

Db 1 CTTCCTCTTCTGCCCAAC 20

RESULT 629

US-10-388-263-670/c
; Sequence 670, Application US/10388263
; GENERAL INFORMATION:
; APPLICANT: Cowser, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Freiler, Susan M.
; APPLICANT: Sasmor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 670
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-388-263-670

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 903 TCCCCAGCCCTGGGATGTG 922
Db 20 TCCCCAGCCATGGACTGTG 1

RESULT 630

US-10-484-441-51/c
; Sequence 51, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE2 EXI
; FILE REFERENCE: ISPH20694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-484-441-51

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 633 CTGCGGTCTGCGGTCCACG 652

Db 20 CTGCGTCTGCGGTGCACG 1

RESULT 631

US-10-648-512-84/c
; Sequence 84, Application US/10648512
; GENERAL INFORMATION:
; APPLICANT: Hildebrandt, Friedhelm
; APPLICANT: Otto, Edgar
; APPLICANT: Hoeft, Julia
; APPLICANT: Ruf, Rainer
; APPLICANT: Mueller, Adelheid M.
; APPLICANT: Hiller, Karl S.
; APPLICANT: Wolf, Matthias T.F.
; APPLICANT: Schuermann, Maria J.
; APPLICANT: Becker, Achim
; TITLE OF INVENTION: NPHP Nucleic Acids and Proteins
; FILE REFERENCE: UM-08333
; CURRENT APPLICATION NUMBER: US/10/648,512
; CURRENT FILING DATE: 2003-08-26
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: Patent version 3.2
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic

US-10-648-512-84

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02; 3; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 232 CAAGACAAACCTGTGCCCC 251

Db 20 CAAGAAACCTGTGTCCC 1

RESULT 632


```
US-10-670-984-119
; Sequence 119, Application US/10670984
; GENERAL INFORMATION:
; APPLICANT: Kane, Christopher D
; TITLE OF INVENTION: ANTISENSE MODULATION OF FARNESOID X RECEPTOR EXPRESSION
; FILE REFERENCE: 01290/1/US
; CURRENT APPLICATION NUMBER: US/10/670,984
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 2146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human FXR antisense
US-10-670-984-119

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1042 ATCTCATGCTGCTGCTCAT 1061
      |||||
Db 1 ATCTCATGCTGCTGCTCAT 20

RESULT 633
US-10-671-395-454
; Sequence 454, Application US/10671395
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 454
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-454

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 245 TGCCCCCAGCTCCCGAGGT 264
      |||||
Db 1 TGCCCCGAGCTTCCCGAGGT 20

RESULT 634
US-10-690-276-175
; Sequence 175, Application US/10690276
; GENERAL INFORMATION:
; APPLICANT: Myriad Genetics, Incorporated
; APPLICANT: Cimbara, Daniel
; APPLICANT: Heichman, Karen
; APPLICANT: Bartel, Paul
; APPLICANT: Mauck, Kimberly
; APPLICANT: Bush, Angie
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS
```

```
FILE REFERENCE: 1834.01
; CURRENT APPLICATION NUMBER: US/10/690,276
; CURRENT FILING DATE: 2003-10-20
; PRIOR APPLICATION NUMBER: 09/727,384
; PRIOR FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: 60/168,377
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: 60/168,379
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: 60/185,056
; PRIOR FILING DATE: 2000-02-25
; PRIOR APPLICATION NUMBER: 10/035,344
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,571
; PRIOR FILING DATE: 2001-01-04
; PRIOR APPLICATION NUMBER: 10/035,343
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,572
; PRIOR FILING DATE: 2001-01-04
; PRIOR APPLICATION NUMBER: 10/099,924
; PRIOR FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: 60/276,179
; PRIOR FILING DATE: 2001-03-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 728
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-690-276-175

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1048 ATGCTGCTGCTATCTTCTT 1067
      |||||
Db 1 ATGCTGCTGCTCAGCTGCAT 20

RESULT 635
US-10-719-370A-219
; Sequence 219, Application US/10719370A
; GENERAL INFORMATION:
; APPLICANT: Ward, Donna T.
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Marcussen, Eric G.
; APPLICANT: Freier, Susan M.
; TITLE OF INVENTION: MODULATION OF HIF1a AND HIF2a EXPRESSION
; FILE REFERENCE: ISPT-1010
; CURRENT APPLICATION NUMBER: US/10/719,370A
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 219
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-719-370A-219

Query Match      1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 482 GACAGCTGCCATTGGCGCTG 501
      |||||
Db 1 GTCAGCTGTCATTGTCGCTG 20
```

RESULT 636
US-10-719-370A-337/c
; Sequence 337, Application US/10719370A
; GENERAL INFORMATION:
; APPLICANT: Ward, Donna T.
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Marcusson, Eric G.
; APPLICANT: Freier, Susan M.
; TITLE OF INVENTION: MODULATION OF HIF1a AND HIF2a EXPRESSION
; FILE REFERENCE: ISPT-1010
; CURRENT APPLICATION NUMBER: US/10/719,370A
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 337
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-719-370A-337

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 482 GACAGTGCATTTGGCGTG 501
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GTCAGTGTCAATTTGGCGTG 1

RESULT 637
US-10-831-778-448/c
; Sequence 448, Application US/10831778
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-448

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1461 CCAGGTGAGCTGTACTGCC 1480
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CCAGGTGAGCTGTACTGCC 1

RESULT 638
US-10-831-901A-29355/c
; Sequence 29355, Application US/10831901A
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.

; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29355
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29355

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1299 CCATGAGTATATCTTCTGCT 1318
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CCATGAGTGGAGCTTCTGCT 1

RESULT 639
US-10-849-438-43
; Sequence 43, Application US/10849438
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Bridget Lollo
; TITLE OF INVENTION: MODULATION OF PUMILIO 1 EXPRESSION
; FILE REFERENCE: RTS-0715US
; CURRENT APPLICATION NUMBER: US/10/849,438
; CURRENT FILING DATE: 2004-05-18
; NUMBER OF SEQ ID NOS: 123
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Compound
US-10-849-438-43

Query Match 1.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 491 CATTGCGCTGCTGACCTGG 510
| | | | | | | | | | | | | | | | | | | | | |
Db 1 CATTGCTGCTGCTGACCTGG 20

RESULT 640
US-10-884-866-448/c
; Sequence 448, Application US/10884866


```
; OTHER INFORMATION: PCR Primer
PCT-US02-22746-5

Query Match      1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1238 TCCTTGGTGCCCGG 1252
      |||||
Db 15 TCCTTGGTGCCCGG 1

RESULT 645
PCT-US02-25943-36411/c
; Sequence 36411, Application PC/TUS0225943
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: PCT/US02/25943
; CURRENT FILING DATE: 2002-08-27
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 36411
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (3572615)...(3572629)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 39022
PCT-US02-25943-36411

Query Match      1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 902 TTGCCCAGGCCCTGG 916
      |||||
Db 15 TTGCCCAGGCCCTGG 1

RESULT 648
US-10-287-787-8739
; Sequence 8739, Application US/10287787
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Caulobacter crescentus complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,787
; CURRENT FILING DATE: 2003-03-03
; NUMBER OF SEQ ID NOS: 27958
; SOFTWARE: Proprietary
; SEQ ID NO 8739
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Caulobacter crescentus complete genome.
; FEATURE:
; LOCATION: (1185034)...(1185049)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 9576
US-10-287-787-8739

Query Match      1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 615 CGCCACGCCGTGGT 629
      |||||
Db 1 CGCCACGCCGTGGT 15

RESULT 649
US-10-287-787-17784
; Sequence 17784, Application US/10287787
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Caulobacter crescentus complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,787
; CURRENT FILING DATE: 2003-03-03
; NUMBER OF SEQ ID NOS: 27958
; SOFTWARE: Proprietary
; SEQ ID NO 17784
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Caulobacter crescentus complete genome.
; FEATURE:
; LOCATION: (2701137)...(2701151)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 19712
US-10-287-787-17784
```

US-10-287-787-17784

Query Match 1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 615 CGCCACGCCGTGT 629
| | | | | | | | | | | | | | | | |
DB 1 CGCCACGCCGTGT 15

RESULT 650

US-10-367-832A-36411/c

; Sequence 36411, Application US/10367832A
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/367,832A
; CURRENT FILING DATE: 2002-08-26
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 36411
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (3572615)...(3572629)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 39022

US-10-367-832A-36411

Query Match 1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 902 TTGCCAGGCCCTGG 916
| | | | | | | | | | | | | | | | |
DB 15 TTGCCAGGCCCTGG 1

RESULT 651

US-10-484-441-5/c

; Sequence 5, Application US/10484441
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Kristina M. Lemonidis
; TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE22 EX
; FILE REFERENCE: ISPH70694
; CURRENT APPLICATION NUMBER: US/10/484,441
; CURRENT FILING DATE: 2004-01-29
; PRIOR APPLICATION NUMBER: 09/918,026
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 65
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-484-441-5

Query Match 1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1238 TCCTTGTGCCCCGG 1252
| | | | | | | | | | | | | | | | |
DB 15 TCCTTGTGCCCCGG 1

RESULT 652

PCT-US02-25943-36410

US-10-310-188-49189

; Sequence 36410, Application PC/TUS0225943

; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: PCT/US02/25943
; CURRENT FILING DATE: 2002-08-27
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 36410
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (3572614)...(3572629)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 39021

PCT-US02-25943-36410

Query Match 1.0%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 902 TTGCCAGGCCCTGG 916
| | | | | | | | | | | | | | | | |
DB 2 TTGCCAGGCCCTGG 16

RESULT 653

US-10-227-565-36410

; Sequence 36410, Application US/10227565
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/227,565
; CURRENT FILING DATE: 2002-08-26
; NUMBER OF SEQ ID NOS: 64158
; SOFTWARE: Proprietary
; SEQ ID NO 36410
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
; FEATURE:
; LOCATION: (3572614)...(3572629)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 39021

US-10-227-565-36410

Query Match 1.0%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 902 TTGCCAGGCCCTGG 916
| | | | | | | | | | | | | | | | |
DB 2 TTGCCAGGCCCTGG 16

RESULT 654

US-10-310-188-49189/c

; Sequence 49189, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 49189
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-49189

US-10-310-188-49189

Query Match 1.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1238 TCCTTGTGCCCCGG 1252
| | | | | | | | | | | | | | | | |
DB 15 TCCTTGTGCCCCGG 1

Query Match 1.0%; Score 15; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 834 AACACTCATCTACAG 848
 Db 16 AACACTCATCTACAG 2

RESULT 655
 US-10-367-832A-36410
 ; Sequence 36410, Application US/10367832A
 ; GENERAL INFORMATION:
 ; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
 ; TITLE OF INVENTION: Pseudomonas aeruginosa PA01, complete genome.
 ; FILE REFERENCE: Jim Zeger Law Offices - 703-684-8333
 ; CURRENT APPLICATION NUMBER: US/10/367,832A
 ; CURRENT FILING DATE: 2002-08-26
 ; NUMBER OF SEQ ID NOS: 64158
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 36410
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Pseudomonas aeruginosa PA01, complete genome.
 ; FEATURE:
 ; LOCATION: (3572614) ... (3572629)
 ; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 39021
 US-10-367-832A-36410

Query Match 1.0%; Score 15; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 902 TTGCCAGGCCCTGG 916
 Db 2 TTGCCAGGCCCTGG 16

RESULT 656
 US-09-531-025A-845/c
 ; Sequence 845, Application US/09531025A
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Draper, Ken
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Morrissey, Dave
 ; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
 ; FILE REFERENCE: MBH00-845-E (247/277)
 ; CURRENT APPLICATION NUMBER: US/09/531,025A
 ; CURRENT FILING DATE: 2000-03-20
 ; PRIOR APPLICATION NUMBER: US 07/882,712
 ; PRIOR FILING DATE: 1992-05-14
 ; PRIOR APPLICATION NUMBER: US 08/193,627
 ; PRIOR FILING DATE: 1994-02-07
 ; PRIOR APPLICATION NUMBER: US 08/433,993
 ; PRIOR FILING DATE: 1995-05-04
 ; PRIOR APPLICATION NUMBER: US 08/434,504
 ; PRIOR FILING DATE: 1995-05-04
 ; PRIOR APPLICATION NUMBER: US 09/436,430
 ; PRIOR FILING DATE: 1999-11-08
 ; NUMBER OF SEQ ID NOS: 6341
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 845
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Hepatitis B virus
 US-09-531-025A-845

Query Match 1.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 4.6e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 263 GTTCCTTGAGCAGGA 277
 Db 17 GTTCCTTGAGCAGGA 3

RESULT 657
 US-09-531-025A-2047/c
 ; Sequence 2047, Application US/09531025A
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Draper, Ken
 ; APPLICANT: Blatt, Larry
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Morrissey, Dave
 ; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
 ; FILE REFERENCE: MBH00-845-E (247/277)
 ; CURRENT APPLICATION NUMBER: US/09/531,025A
 ; CURRENT FILING DATE: 2000-03-20
 ; PRIOR APPLICATION NUMBER: US 07/882,712
 ; PRIOR FILING DATE: 1992-05-14
 ; PRIOR APPLICATION NUMBER: US 08/193,627
 ; PRIOR FILING DATE: 1994-02-07
 ; PRIOR APPLICATION NUMBER: US 08/433,993
 ; PRIOR FILING DATE: 1995-05-04
 ; PRIOR APPLICATION NUMBER: US 08/434,504
 ; PRIOR FILING DATE: 1995-05-04
 ; PRIOR APPLICATION NUMBER: US 09/436,430
 ; PRIOR FILING DATE: 1999-11-08
 ; NUMBER OF SEQ ID NOS: 6341
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2047
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Hepatitis B virus
 US-09-531-025A-2047

Query Match 1.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 4.6e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 261 AGTTCTTGAGCAG 275
 Db 15 AGTTCTTGAGCAG 1

RESULT 658
 US-09-636-385-845/c
 ; Sequence 845, Application US/09636385
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Draper, Kenneth
 ; APPLICANT: Blatt, Larry
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Morrissey, Dave
 ; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
 ; FILE REFERENCE: MBH00-845-F (250/125)
 ; CURRENT APPLICATION NUMBER: US/09/636,385
 ; CURRENT FILING DATE: 2000-08-09
 ; PRIOR APPLICATION NUMBER: US 07/882,712
 ; PRIOR FILING DATE: 1992-05-14
 ; PRIOR APPLICATION NUMBER: US 09/531,025
 ; PRIOR FILING DATE: 2000-03-20
 ; PRIOR APPLICATION NUMBER: US 08/193,627
 ; PRIOR FILING DATE: 1994-02-07
 ; PRIOR APPLICATION NUMBER: US 09/436,430
 ; PRIOR FILING DATE: 1999-11-08
 ; NUMBER OF SEQ ID NOS: 6341
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 845
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Hepatitis B Virus
 US-09-636-385-845

US-09-636-385-845

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels

Qy 263 GTTCCTTGAGCAGGA 277
Db 17 GTTCCTTGAGCAGGA 3

RESULT 659

```

US-09-636-385-2047/C
; Sequence 2047, Application US/09636385
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-F (250/125)
; CURRENT APPLICATION NUMBER: US/09/636,385
; CURRENT FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6341
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2047
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-09-636-385-2047

```

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels

Qy 261 AGGTTCTTGAGCAG 275
|||
pb 15 AGGTTCTTGAGCAG 1

RESULT 660

US-09-696-347-845/c
; Sequence 845, Application US/09696347
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/001
; CURRENT APPLICATION NUMBER: US/09/696,347
; CURRENT FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504

```

; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6389
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-09-696-147-845

```

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels

Qy 263 GTTCCTTGAGCAGGA 277
|||
Db 17 GTTCCTTGAGCAGGA 3

RESULT 661

```

US-09-696-347-2047/c
; Sequence 2047, Application US/09696347
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/001
; CURRENT APPLICATION NUMBER: US/09/696,347
; CURRENT FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6389
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2047
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
; US-09-696-347-2047

```

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15: Conservative 0; Mismatches 0; Indels

Qy 261 AGGTTCCCTGAGCAG 275
Db 15 AGGTTCCCTGAGCAG 1

RESIT.T 662

RES001 862
 US-09-848-754A-144/c
 ; Sequence.144, Application US/09848754A
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
 ; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
 ; FILE REFERENCE: MBH00-958-I (400/018)
 ; CURRENT APPLICATION NUMBER: US/09/848.754A

; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-144

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGAGGTGCAG 354
|||
DB 15 CTGATGAGGTGCAG 1

RESULT 663

US-09-848-754A-1112/c
; Sequence 1112, Application US/09848754A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1112
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1112

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGAGGTGCAG 354
|||
DB 17 CTGATGAGGTGCAG 3

RESULT 664

US-09-848-754A-1113/c
; Sequence 1113, Application US/09848754A
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1113
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1113

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGAGGTGCAG 354
|||
DB 16 CTGATGAGGTGCAG 2

RESULT 665

US-09-877-478-845/c
; Sequence 845, Application US/09877478
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-845

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 263 GTTCTTGAGCAGGA 277
|||
DB 17 GTTCTTGAGCAGGA 3

RESULT 666

US-09-877-478-2244/c
; Sequence 2244, Application US/09877478
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430

; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2244
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2244

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 261 AGGTTCTTGAGCAG 275
Db 15 AGGTTCTTGAGCAG 1

RESULT 667

US-10-342-902-845/c

; Sequence 845, Application US/10342902

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Draper, Kenneth

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Morrissey, Dave

; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

; FILE REFERENCE: 400/075 (MBH00-845-I)

; CURRENT APPLICATION NUMBER: US/10/342,902

; CURRENT FILING DATE: 2003-01-15

; PRIOR APPLICATION NUMBER: US 09/877,478

; PRIOR FILING DATE: 2001-06-08

; PRIOR APPLICATION NUMBER: US 09/531,025

; PRIOR FILING DATE: 2000-03-20

; PRIOR APPLICATION NUMBER: US 09/636,385

; PRIOR FILING DATE: 2000-08-09

; PRIOR APPLICATION NUMBER: US 09/696,347

; PRIOR FILING DATE: 2000-10-24

; PRIOR APPLICATION NUMBER: US 08/193,627

; PRIOR FILING DATE: 1994-02-07

; PRIOR APPLICATION NUMBER: US 07/882,712

; PRIOR FILING DATE: 1992-05-14

; PRIOR APPLICATION NUMBER: US 09/436,430

; PRIOR FILING DATE: 1999-11-08

; NUMBER OF SEQ ID NOS: 6592

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 845

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Hepatitis B virus

US-10-342-902-845

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 263 GTTCTTGAGCAG 277
Db 17 GTTCTTGAGCAG 3

RESULT 668

US-10-342-902-2244/c

; Sequence 2244, Application US/10342902

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Draper, Kenneth

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Morrissey, Dave

; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

; FILE REFERENCE: 400/075 (MBH00-845-I)

; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2244
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2244

Query Match 1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 261 AGGTTCTTGAGCAG 275
Db 15 AGGTTCTTGAGCAG 1

RESULT 669

US-10-669-841-845/c

; Sequence 845, Application US/10669841

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Lawrence, Blatt

; APPLICANT: Dennis, Macejak

; APPLICANT: James, McSwiggen

; APPLICANT: David, Morrissey

; APPLICANT: Pamela, Pavco

; APPLICANT: Patricia, Lee

; APPLICANT: Kenneth, Draper

; APPLICANT: Elisabeth, Roberts

; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT

; TITLE OF INVENTION: VIRUS REPLICATION

; FILE REFERENCE: 400/042US (MBH02-249-E)

; CURRENT APPLICATION NUMBER: US/10/669,841

; CURRENT FILING DATE: 2003-09-23

; PRIOR APPLICATION NUMBER: PCT/US02/09187

; PRIOR FILING DATE: 2002-03-26

; PRIOR APPLICATION NUMBER: US 60/296,876

; PRIOR FILING DATE: 2001-06-08

; PRIOR APPLICATION NUMBER: US 60/335,059

; PRIOR FILING DATE: 2001-10-24

; PRIOR APPLICATION NUMBER: US 60/337,055

; PRIOR FILING DATE: 2001-12-05

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 09/817,879

; PRIOR FILING DATE: 2001-03-26

; PRIOR APPLICATION NUMBER: US 09/740,332

; PRIOR FILING DATE: 2000-12-18

; PRIOR APPLICATION NUMBER: US 09/611,931

; PRIOR FILING DATE: 2000-07-07

; PRIOR APPLICATION NUMBER: US 09/504,321

; PRIOR FILING DATE: 2000-02-15

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 16207

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-845

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      263 GTTCCTTGAGCAGGA 277
Db      17 GTTCCTTGAGCAGGA 3

RESULT 670
US-10-669-841-2047/c
; Sequence 2047, Application US/10669841
; GENERAL INFORMATION:
; APPLICANT: Sinna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MRHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2047
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2047

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      261 AGGTTCTTGAGCAG 275
Db      15 AGGTTCTTGAGCAG 1

RESULT 671
```

```
US-60-330-323-167
; Sequence 167, Application US/60330323
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN GTP-ACTIVATOR PROTEIN FOR RAB-LIKE GTPASE
; FILE REFERENCE: AEOMICA-20
; CURRENT APPLICATION NUMBER: US/60/330,323
; CURRENT FILING DATE: 2001-10-15
; NUMBER OF SEQ ID NOS: 612
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 167
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-60-330-323-167

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      801 TTCTCCAGCTACCT 815
Db      3 TTCTCCAGCTACCT 17

RESULT 672
US-60-330-323-168
; Sequence 168, Application US/60330323
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN GTP-ACTIVATOR PROTEIN FOR RAB-LIKE GTPASE
; FILE REFERENCE: AEOMICA-20
; CURRENT APPLICATION NUMBER: US/60/330,323
; CURRENT FILING DATE: 2001-10-15
; NUMBER OF SEQ ID NOS: 612
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 168
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-60-330-323-168

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      801 TTCTCCAGCTACCT 815
Db      2 TTCTCCAGCTACCT 16

RESULT 673
US-60-330-323-169
; Sequence 169, Application US/60330323
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN GTP-ACTIVATOR PROTEIN FOR RAB-LIKE GTPASE
; FILE REFERENCE: AEOMICA-20
; CURRENT APPLICATION NUMBER: US/60/330,323
; CURRENT FILING DATE: 2001-10-15
; NUMBER OF SEQ ID NOS: 612
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 169
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-60-330-323-169

Query Match      1.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      801 TTCTCCAGCTACCT 815
```

```
Db 1 TTCTCAGCTACCT 15
|||||
RESULT 674
US-10-310-188-71964/c
; Sequence 71964, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICAALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 71964
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-71964
Query Match 1.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 277 ACCGAGGAGCCATCC 291
|||||
Db 16 ACCGAGGAGCCATCC 2
|||||

RESULT 675
US-10-714-333A-15688
; Sequence 15688, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 15688
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-15688
Query Match 1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 80.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 132 CATGGAGGCTGTGAA 146
|||||
Db 1 CAUGGAGGCGUGA 15
|||||

RESULT 676
US-10-714-333A-15788
; Sequence 15788, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 15788
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-15788
Query Match 1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 80.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 68 AACCTGTGGAGATG 82
|||||
Db 5 AACCCUGGAGAG 19
|||||

RESULT 678
US-10-714-333A-89683/c
; Sequence 89683, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 82937
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-89683/c
Query Match 1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 80.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 68 AACCTGTGGAGATG 82
|||||
Db 5 AACCCUGGAGAG 19
|||||
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 89683
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-89683

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1355 TCTTCCTTGTGCATTG 1369
Db      16 TCTTCCTTGTGCATTG 2

RESULT 679
US-10-714-333A-140460/c
; Sequence 140460, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 140460
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-140460

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1013 TCTCTATCTCTGCATG 1027
Db      18 TCTCTATCTCTGCATG 4

RESULT 680
US-10-714-333A-172875/c
; Sequence 172875, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
```

```
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 172875
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-172875

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 959 TTCCTGTCTTTGCCA 973
Db      15 TTCCTGTCTTTGCCA 1

RESULT 681
US-10-714-333A-246623/c
; Sequence 246623, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 246623
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-246623

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 CTTCTCTCTCTGCC 833
Db      15 CTTCTCTCTCTGCC 1

RESULT 682
US-10-714-333A-372173/c
; Sequence 372173, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 372173
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-372173

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      815 TCTACTTCTCTTCT 829
Db      18 TCTACTTCTCTTCT 4

RESULT 683
US-10-714-333A-616176
; Sequence 616176, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 616176
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-616176

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 86.7%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1223 AGGATGGCTGCGGC 1237
Db      2 AGGAUGGGCUGCGGC 16

RESULT 684
US-10-714-333A-616247
; Sequence 616247, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 616247
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-616247

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 86.7%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1223 AGGATGGCTGCGGC 1237
Db      1 AGGAUGGGCUGCGGC 15

RESULT 685
US-10-714-333A-616270
; Sequence 616270, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 616270
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-616270

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 86.7%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1223 AGGATGGCTGCGGC 1237
Db      2 AGGAUGGGCUGCGGC 16

RESULT 686
US-10-714-333A-616337
; Sequence 616337, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 616337
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-616337

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 86.7%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1223 AGGATGGGCTGCGGC 1237
      |||||:||||:|||||
Db 1 AGGAUGGCGUGCGGC 15

RESULT 687
US-10-714-333A-730619/c
; Sequence 730619, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 730619
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-730619

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 304 AAAGTTTTCATCATC 318
      |||||:|||||
Db 19 AAAGTTTTCATCATC 5

RESULT 688
US-10-714-333A-1058176
; Sequence 1058176, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1058176
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1058176
```

```
Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 53.3%; Pred. No. 5.1e+02;
Matches 8; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 387 TGGCCTGTGTGCTT 401
      :|||:|:|:|:|:|
Db 5 UGGCCUGUGUGUCUU 19

RESULT 689
US-10-714-333A-1338802
; Sequence 133802, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1338802
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1338802

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 53.3%; Pred. No. 5.1e+02;
Matches 8; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1053 GCTGCTCATCTTCTT 1067
      |||:|:|:|:|:|
Db 5 GCTGCTCAUCUCUU 19

RESULT 690
US-10-714-333A-1415480/c
; Sequence 1415480, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1415480
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1415480

Query Match      1.0%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
```

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 818 ACTTCCTCTTCTGCC 832
| | | | | | | | | |
Db 15 ACTTCCTCTTCTGCC 1

RESULT 691

US-10-714-333A-1507089
; Sequence 1507089, Application US/10714333A

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 1507089

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-1507089

Query Match 1.0%; Score 15; DB 1; Length 19;

Best Local Similarity 73.3%; Pred. No. 5.1e+02;

Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1515 CCAGGCAACTTCTG 1529
| | | | | | | | | |
Db 1 CCAGGCAACUUCUG 15

RESULT 692

PCT-US01-00109-174/c

; Sequence 174, Application PC/TUS0100109

; GENERAL INFORMATION:

; APPLICANT: Isis Pharmaceuticals, Inc.

; APPLICANT: Lex M. Cowsett

; APPLICANT: Jacqueline Wyatt

; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPIB EXPRESSION

; FILE REFERENCE: RTSP-0086

; CURRENT APPLICATION NUMBER: PCT/US01/00109

; CURRENT FILING DATE: 2001-01-04

; PRIOR APPLICATION NUMBER: 09/487,368

; PRIOR FILING DATE: 2000-01-18

; NUMBER OF SEQ ID NOS: 240

; SEQ ID NO 174

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

PCT-US01-00109-174

Query Match 1.0%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.3e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCTCCCC 259
| | | | | | | | | |
Db 20 TGCCCCCACCTCCCC 6

RESULT 695

PCT-US04-02003-174/c

; Sequence 174, Application PC/TUS0402003

; GENERAL INFORMATION:

; APPLICANT: Isis Pharmaceuticals, Inc.

; APPLICANT: Sanjay Bhanot

RESULT 693

PCT-US01-30551-171

; Sequence 171, Application PC/TUS0130551

; GENERAL INFORMATION:

; APPLICANT: Isis Pharmaceuticals, Inc.

; APPLICANT: C. Frank Bennett

; APPLICANT: Jacqueline Wyatt

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF HER-1 EXPRESSION

; FILE REFERENCE: RTSP-0187

; CURRENT APPLICATION NUMBER: PCT/US01/30551

; CURRENT FILING DATE: 2001-09-28

; PRIOR APPLICATION NUMBER: 09/676,610

; PRIOR FILING DATE: 2000-09-29

; NUMBER OF SEQ ID NOS: 182

; SEQ ID NO 171

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

PCT-US01-30551-171

Query Match 1.0%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.3e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGGAGGTGCAG 354
| | | | | | | | | |
Db 5 CTGATGGAGGTGCAG 19

RESULT 694

PCT-US02-15301-174/c

; Sequence 174, Application PC/TUS0215301

; GENERAL INFORMATION:

; APPLICANT: Isis Pharmaceuticals, Inc.

; APPLICANT: Lex M. Cowsett

; APPLICANT: Jacqueline Wyatt

; APPLICANT: Susan M. Freier

; APPLICANT: Brett P. Monia

; APPLICANT: Madeline M. Butler

; APPLICANT: Robert McKay

; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPIB EXPRESSION

; FILE REFERENCE: ISPH-0576

; CURRENT APPLICATION NUMBER: PCT/US02/15301

; CURRENT FILING DATE: 2002-05-13

; PRIOR APPLICATION NUMBER: US 09/854,883

; PRIOR FILING DATE: 2001-05-14

; NUMBER OF SEQ ID NOS: 389

; SEQ ID NO 174

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

PCT-US02-15301-174

Query Match 1.0%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.3e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCTCCCC 259
| | | | | | | | | |
Db 20 TGCCCCCACCTCCCC 6

; APPLICANT: Lex M. Cowsett
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
; FILE REFERENCE: BIOL001WO.4
; CURRENT APPLICATION NUMBER: PCT/US04/02003
; CURRENT FILING DATE: 2004-02-06
; NUMBER OF SEQ ID NOS: 415
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
PCT-US04-02003-174

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCTCCCC 259
|||||
Db 20 TGCCCCCACCTCCCC 6

RESULT 696

US-09-854-883-174/c
; Sequence 174, Application US/09854883
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
; FILE REFERENCE: ISPH-0576
; CURRENT APPLICATION NUMBER: US/09/854,883
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 09/629,644
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-854-883-174

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCTCCCC 259
|||||
Db 20 TGCCCCCACCTCCCC 6

RESULT 697

US-10-360-510-174/c
; Sequence 174, Application US/10360510
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia

; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
; FILE REFERENCE: ISPH-0576
; CURRENT APPLICATION NUMBER: US/10/360,510
; CURRENT FILING DATE: 2003-02-07
; PRIOR APPLICATION NUMBER: US/09/854,883
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 09/629,644
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-174

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 TGCCCCCACCTCCCC 259
|||||
Db 20 TGCCCCCACCTCCCC 6

RESULT 698

US-10-380-931-171
; Sequence 171, Application US/10380931
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITION OF HER-1 EXPRESSION
; FILE REFERENCE: RTSP-0187
; CURRENT APPLICATION NUMBER: US/10/380,931
; CURRENT FILING DATE: 2003-03-18
; PRIOR APPLICATION NUMBER: 09/676,610
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 182
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-931-171

Query Match 1.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CTGATGGAGGTGCAG 354
|||||
Db 5 CTGATGGAGGTGCAG 19

RESULT 699

PCT-US03-41761-15621/c
; Sequence 15621, Application PC/TUS0341761
; GENERAL INFORMATION:
; APPLICANT: MMI GENOMICS, INC.
; APPLICANT: Denise, Sue K.
; APPLICANT: CHARTERIS, Paul
; APPLICANT: ROSENFELD, David
; APPLICANT: HOLM, Tom
; APPLICANT: BATES, Stephen
; TITLE OF INVENTION: COMPOSITIONS, METHODS, AND SYSTEMS FOR INFERRING BOVINE BREED

; FILE REFERENCE: MM1150W0
; CURRENT APPLICATION NUMBER: PCT/US03/41761
; PRIOR FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US 60/437,482
; PRIOR FILING DATE: 2002-12-31
; NUMBER OF SEQ ID NOS: 64922
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15621
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Forward Primer
PCT-US03-41761-15621

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1035 GCCAGGCATCTTCATGCT 1052
||| ||||| ||||| |||||
Db 18 GCGAGGCATCTTCATGCT 1

RESULT 700

PCT-US03-41766A-15621/c
; Sequence 15621, Application PC/TUS0341766A
; GENERAL INFORMATION:

; APPLICANT: MMI GENOMICS, INC.
; APPLICANT: DENISE, Sue K.
; APPLICANT: KERR, Richard
; APPLICANT: ROSENFELD, David
; APPLICANT: HOLM, Tom
; APPLICANT: BATES, Stephen
; APPLICANT: FANTIN, Dennis
; TITLE OF INVENTION: COMPOSITIONS, METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS
; FILE REFERENCE: MM1100W0
; CURRENT APPLICATION NUMBER: PCT/US03/41766A
; CURRENT FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US 60/437,482
; PRIOR FILING DATE: 2002-12-31
; NUMBER OF SEQ ID NOS: 64922
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15621
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Forward Primer
PCT-US03-41766A-15621

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1035 GCCAGGCATCTTCATGCT 1052
||| ||||| ||||| |||||
Db 18 GCGAGGCATCTTCATGCT 1

RESULT 701

US-10-241-313-7
; Sequence 7, Application US/10241313
; GENERAL INFORMATION:

; APPLICANT: O'Malley, Karen L
; APPLICANT: Todd, Richard D
; TITLE OF INVENTION: Gene Encoding the Rat Dopamine D4 Receptor
; FILE REFERENCE: WU 102 CON DIV(2)
; CURRENT APPLICATION NUMBER: US/10/241,313
; CURRENT FILING DATE: 2002-09-11
; PRIOR APPLICATION NUMBER: US 08/475,742
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: US 08/261,293

; PRIOR FILING DATE: 1994-06-16
; PRIOR APPLICATION NUMBER: US 08/014,013
; PRIOR FILING DATE: 1993-01-28
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: primer-reverse transcribed using orD4-515 and is
; OTHER INFORMATION: complementary to nucleotides 2389-2406 in SEQ ID NO:1
; PUBLICATION INFORMATION:
; TITLE: The rat dopamine D4 receptor: sequence, gene structure
; TITLE: and demonstration of expression in the cardiovascular
; TITLE: system
; JOURNAL: New Biol.
; VOLUME: 4
; PAGES: 1-9
; DATE: 1992
; US-10-241-313-7

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 CTGTCCACCTCTGTGGCG 540
||||| ||||| |||||
Db 1 CTGTCCACCTCTGTGGCG 18

RESULT 702

US-10-310-188-26628
; Sequence 26628, Application US/10310188
; GENERAL INFORMATION:

; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26628
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-310-188-26628

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 249 CCCACCTCCCCAGGTC 266
||||| ||||| |||||
Db 1 CCCACCTCCCTCCAGGTC 18

RESULT 703

US-10-310-188-42100
; Sequence 42100, Application US/10310188
; GENERAL INFORMATION:

; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 42100
; LENGTH: 18

```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-42100

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 43 GGGCTGGAGGGGAGCGG 60
      ||||| ||||| |||||
Db 1 GGGCCGGAGGGGACCGG 18

RESULT 704
US-10-310-188-61795/c
; Sequence 61795, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICAALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 61795
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-61795

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 TTCTTTGCCCTTCCTCCAT 1080
      ||||| ||||| |||||
Db 18 TTCTTTCCCTTCCTCCGT 1

RESULT 705
US-10-404-679-70
; Sequence 70, Application US/10404679
; GENERAL INFORMATION:
; APPLICANT: STEINMAN, LAWRENCE
; TITLE OF INVENTION: USE OF STATINS AND OTHER
; TITLE OF INVENTION: IMMUNOMODULATORY AGENTS IN THE TREATMENT OF AUTOIMMUNE
; TITLE OF INVENTION: DISEASE
; FILE REFERENCE: STAN-262
; CURRENT APPLICATION NUMBER: US/10/404,679
; CURRENT FILING DATE: 2003-03-31
; PRIOR APPLICATION NUMBER: 60/368,803
; PRIOR FILING DATE: 2002-03-29
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-10-404-679-70

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1320 CGTCTGGGGTTCCTCTA 1337
      || ||||| |||||
Db 1 CGACCTGGGGATCTCTTA 18

```

```
; APPLICANT: BATES, Stephen
; TITLE OF INVENTION: COMPOSITIONS, METHODS, AND SYSTEMS FOR INFERRING BOVINE BREED
; FILE REFERENCE: MM1150
; CURRENT APPLICATION NUMBER: US/10/750,622
; CURRENT FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US 60/437,482
; PRIOR FILING DATE: 2002-12-31
; NUMBER OF SEQ ID NOS: 64922
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15621
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Forward Primer
US-10-750-622-15621

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1035 GCCAGGCATCTTCATGCT 1052
   |||||
Db 18 GCAGGCGATCTTCATGCT 1

RESULT 709
US-10-755-966-105/c
; Sequence 105, Application US/10755966
; GENERAL INFORMATION:
; APPLICANT: Helgeson, John P.
; APPLICANT: Austin-Phillips, Sandra
; APPLICANT: Naese, Sara Kristine
; APPLICANT: Song, Junqi
; APPLICANT: Jiang, Jiming
; APPLICANT: Bradeen, James Mathew
; APPLICANT: Buell, C. Robin
; TITLE OF INVENTION: POTATO GENES FOR RESISTANCE TO LATE BLIGHT
; FILE REFERENCE: WARF-0235
; CURRENT APPLICATION NUMBER: US/10/755,966
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 60/439,376
; PRIOR FILING DATE: 2003-01-10
; NUMBER OF SEQ ID NOS: 125
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 105
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-755-966-105

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 CTTCTCTTCTGCCCCAAC 836
   |||||
Db 18 CTAGCTCTTCTGCCCCAAC 1

RESULT 710
PCT-US02-31357-84
; Sequence 84, Application PC/TUS0231357
; GENERAL INFORMATION:
; APPLICANT: Curagen Corporation, et al
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS
; FILE REFERENCE: 21402-462D-061
; CURRENT APPLICATION NUMBER: PCT/US02/31357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: 60/327,454
```

```
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/329,414
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/330,142
; PRIOR FILING DATE: 2001-10-17
; PRIOR APPLICATION NUMBER: 60/341,058
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: 60/343,629
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: 60/349,575
; PRIOR FILING DATE: 2001-10-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 133
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 84
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
PCT-US02-31357-84

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1044 CTTCTGCTGCTGCTCAT 1061
   |||||
Db 2 CTTCTGCTGCTGCTCAT 19

RESULT 711
PCT-US03-05045-569/c
; Sequence 569, Application PC/TUS0305045
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor
; FILE REFERENCE: 400/081 (MBHB 02-468-B)
; CURRENT APPLICATION NUMBER: PCT/US03/05045
; CURRENT FILING DATE: 2003-05-07
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/251,117
; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/277,494
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
```

; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 1263
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 569
; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense region

PCT-US03-05045-876

Query Match 0.9%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 5.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGGAGGTGCAGCATTT 359

|||||

Db 19 GATGGAGGTGCAGTTT 2

RESULT 712

PCT-US03-05045-876

; Sequence 876, Application PC/TUS0305045

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; APPLICANT: Fosnaugh, Kathy

; APPLICANT: Jamison, Sharon

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor

; FILE REFERENCE: 400/081 (MEHB 02-468-B)

; CURRENT APPLICATION NUMBER: PCT/US03/05045

; CURRENT FILING DATE: 2003-05-07

; PRIOR APPLICATION NUMBER: US 60/393,924

; PRIOR FILING DATE: 2002-07-03

; PRIOR APPLICATION NUMBER: US 10/251,117

; PRIOR FILING DATE: 2002-09-19

; PRIOR APPLICATION NUMBER: US 10/163,552

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 10/277,494

; PRIOR FILING DATE: 2002-10-21

; PRIOR APPLICATION NUMBER: US 09/916,466

; PRIOR FILING DATE: 2001-07-25

; PRIOR APPLICATION NUMBER: PCT/US 02/16840

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 1263

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 876

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region

PCT-US03-05045-876

Query Match 0.9%; Score 14.8; DB 1; Length 19;

Best Local Similarity 61.1%; Pred. No. 5.3e+02;

Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGGAGGTGCAGCATTT 359

|||||

Db 19 GATGGAGGTGCAGTTT 2

Db 1 GAUGGAGGUGCAGUUUU 18

RESULT 713

PCT-US03-05045A-569/c

; Sequence 569, Application PC/TUS0305045A

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; APPLICANT: Fosnaugh, Kathy

; APPLICANT: Jamison, Sharon

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor

; FILE REFERENCE: 400/081 (MEHB 02-468-B)

; CURRENT APPLICATION NUMBER: PCT/US03/05045A

; CURRENT FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/393,924

; PRIOR FILING DATE: 2002-07-03

; PRIOR APPLICATION NUMBER: US 10/251,117

; PRIOR FILING DATE: 2002-09-19

; PRIOR APPLICATION NUMBER: US 10/163,552

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 10/277,494

; PRIOR FILING DATE: 2002-10-21

; PRIOR APPLICATION NUMBER: US 09/916,466

; PRIOR FILING DATE: 2001-07-25

; PRIOR APPLICATION NUMBER: PCT/US 02/16840

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 1263

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 569

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense region

PCT-US03-05045A-569

Query Match 0.9%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 5.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGGAGGTGCAGCATTT 359

|||||

Db 19 GATGGAGGTGCAGTTT 2

RESULT 714

PCT-US03-05045A-876

; Sequence 876, Application PC/TUS0305045A

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; APPLICANT: Fosnaugh, Kathy

; APPLICANT: Jamison, Sharon

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor

; FILE REFERENCE: 400/081 (MEHB 02-468-B)

; CURRENT APPLICATION NUMBER: PCT/US03/05045A

; CURRENT FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/393,924
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 10/251,117
PRIOR FILING DATE: 2002-09-19
PRIOR APPLICATION NUMBER: US 10/163,552
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 10/277,494
PRIOR FILING DATE: 2002-10-21
PRIOR APPLICATION NUMBER: US 09/916,466
PRIOR FILING DATE: 2001-07-25
PRIOR APPLICATION NUMBER: PCT/US 02/16840
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 1263
SOFTWARE: PatentIn version 3.2
SEQ ID NO 876
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
PCT-US03-05045A-876

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 342 GATGGAGGTGCACATT 359
DB 1 GAUGGAGGUGCAGUUUU 18

RESULT 715
US-08-836-734E-107/c
Sequence 107, Application US/08836734E
GENERAL INFORMATION:
APPLICANT: BECKMANN, ISABELLE
TITLE OF INVENTION: LGMD GENE CODING FOR A CALCIUM DEPENDENT PROTEASE
FILE REFERENCE: 960-29 AFM26268AD/FL/SDU
CURRENT APPLICATION NUMBER: US/08/836,734E
PRIOR FILING DATE: 1997-07-02
PRIOR APPLICATION NUMBER: PCT/EP95/04575
PRIOR FILING DATE: 1995-11-21
PRIOR APPLICATION NUMBER: EP 94402668.1
PRIOR FILING DATE: 1994-11-22
NUMBER OF SEQ ID NOS: 116
SOFTWARE: MS Word
SEQ ID NO 107
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)-(19)
OTHER INFORMATION: /label= Table 2
US-08-836-734E-107

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 136 GAGGCTGTGAGGCACAA 153
DB 18 GTGGCTGTGAGGCACAA 1

RESULT 716
US-09-453-607A-2314/c
Sequence 2314, Application US/09453607A
GENERAL INFORMATION:
APPLICANT: Immusol, Inc. et al.
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT AND/OR PREVENTION OF RESTENOSIS
FILE REFERENCE: 480124.406
CURRENT APPLICATION NUMBER: US/09/453,607A
CURRENT FILING DATE: 1999-12-06
NUMBER OF SEQ ID NOS: 4388
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 2314
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-453-607A-2314

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 110 ACTTGGTACAATGGACCC 127
DB 19 ACTTGGTACAACGGAGCC 2

RESULT 717
US-09-453-607C-2314/c
Sequence 2314, Application US/09453607C
GENERAL INFORMATION:
APPLICANT: Immusol, Inc. et al.
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT AND/OR PREVENTION OF RESTENOSIS
FILE REFERENCE: 480124.406
CURRENT APPLICATION NUMBER: US/09/453,607C
CURRENT FILING DATE: 1999-12-07
NUMBER OF SEQ ID NOS: 4389
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 2314
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-453-607C-2314

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 110 ACTTGGTACAATGGACCC 127
DB 19 ACTTGGTACAACGGAGCC 2

RESULT 718
US-09-612-226-111
Sequence 111, Application US/09612226
GENERAL INFORMATION:
APPLICANT: Tournier-Lasserre, Elisabeth
APPLICANT: Joutel, Anne
APPLICANT: Bousser, Marie-Germaine
APPLICANT: Bach, Jean-Francois
TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND THERAPEUTIC APPLICATION
FILE REFERENCE: 03715.0048-00000
CURRENT APPLICATION NUMBER: US/09/612,226
CURRENT FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: FR 96 09733

; PRIOR FILING DATE: 1996-08-01
; PRIOR APPLICATION NUMBER: FR 97 04680
; PRIOR FILING DATE: 1997-04-16
; PRIOR APPLICATION NUMBER: PCT/FR97/01433
; PRIOR FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-612-226B-111

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGCTCTTCGAGCAG 708
| | | | | | | | | | | | | | | | | | | | |
Db 1 GTCCTGCTCTTCGAGCAG 18

RESULT 719
US-09-612-226B-111
; Sequence 111, Application US/09612226B
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserre, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Germaine
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; TITLE OF INVENTION: THERAPEUTIC APPLICATION
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/09/612,226B
; CURRENT FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: FR 96 09733
; PRIOR FILING DATE: 1996-08-01
; PRIOR APPLICATION NUMBER: FR 97 04680
; PRIOR FILING DATE: 1997-04-16
; PRIOR APPLICATION NUMBER: PCT/FR97/01433
; PRIOR FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-612-226B-111

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGCTCTTCGAGCAG 708
| | | | | | | | | | | | | | | | | | | | |
Db 1 GTCCTGCTCTTCGAGCAG 18

RESULT 720
US-10-244-647-491
; Sequence 491, Application US/10244647
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)

; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 491
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siRNA sense re
US-10-244-647-491

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
| | | | | | | | | | | | | | | | | | | | |
Db 1 CCUCUUCUCCUGUGCU 18

RESULT 721
US-10-244-647-511
; Sequence 511, Application US/10244647
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, Leonid
; APPLICANT: Beigelman, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 511
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-244-647-511

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1041 CATCTTCATGCTGCTGCT 1058
| | | | | | | | | | | | | | | | | | | | |
Db 2 CCUCUUCUCCUGUGCU 19

RESULT 722
US-10-244-647-1137/c
; Sequence 1137, Application US/10244647
; GENERAL INFORMATION:

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 342 GATGGAGGTGCAGCATTT 359
|:|||||:|
Db 1 GAUGGAGGUCGAGUUUU 18

RESULT 726
US-10-262-445-84
; Sequence 84, Application US/10262445
; GENERAL INFORMATION:
; APPLICANT: Alsbrook II, John
; APPLICANT: Burgess, Catherine
; APPLICANT: Catterton, Elina
; APPLICANT: Chant, John
; APPLICANT: Chaudhuri, Amitabha
; APPLICANT: Edinger, Shlomit
; APPLICANT: Gerlach, Valerie
; APPLICANT: Giot, Loic
; APPLICANT: Gorman, Linda
; APPLICANT: Guo, Xiaojia
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Mezes, Peter
; APPLICANT: Millet, Isabelle
; APPLICANT: Ooi, Chean Eng
; APPLICANT: Patturajan, Meera
; APPLICANT: Rieger, Daniel
; APPLICANT: Spytek, Kimberly
; APPLICANT: Taupier Jr., Raymond J.
; APPLICANT: Zerhusen, Bryan
; APPLICANT: Zhong, Haihong
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS
; FILE REFERENCE: 21402-462D
; CURRENT APPLICATION NUMBER: US/10/262,445
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/327,454
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/329,414
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/330,142
; PRIOR FILING DATE: 2001-10-17
; PRIOR APPLICATION NUMBER: 60/341,058
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: 60/343,629
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: 60/349,575
; PRIOR FILING DATE: 2001-10-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 133
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 84
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-262-445-84

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1044 CTTTCATGCTGCTGCTCAT 1061
|:|||||:|
Db 2 CTTTCATGCTGCTGCTCAT 19

RESULT 727
US-10-287-787-205
; Sequence 205, Application US/10287787
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Caulobacter crescentus complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,787
; CURRENT FILING DATE: 2003-03-03
; NUMBER OF SEQ ID NOS: 27959
; SOFTWARE: Proprietary
; SEQ ID NO 205
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Caulobacter crescentus complete genome.
; FEATURE:
; LOCATION: (36145)...(36163)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 235
US-10-287-787-205

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 535 TTGGGCGCGTACCAGGCC 552
|:|||||:|
Db 2 TTGGGCGCGTACCAGGCC 19

RESULT 728
US-10-293-338-1504/c
; Sequence 1504, Application US/10293338
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY GENES AND
; FILE REFERENCE: 45282
; CURRENT APPLICATION NUMBER: US/10/293,338
; CURRENT FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 8785
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 1504
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-293-338-1504

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 732 CTCCTTCCTGAGAGGCC 749
|:|||||:|
Db 18 CCCCTTCCTGGGAGGCC 1

RESULT 729
US-10-310-188-24871/c
; Sequence 24871, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENES
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19


```
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24871
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-24871

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1004 CCTCTGGTCTCTCTATCC 1021
Db 18 CCTCTGGTCTCTCTGCCG 1

RESULT 730
US-10-310-188-85407
; Sequence 85407, Application US/10310188
; GENERAL INFORMATION:
; APPLICANT: RosettaGenomics
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL VIRAL REGULATORY GENE
; FILE REFERENCE: 47487
; CURRENT APPLICATION NUMBER: US/10/310,188
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 86841
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 85407
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-310-188-85407

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 669 GCTCCCGCGCGCTCCCG 686
Db 2 GCTCCCGCGCGCTCCCG 19

RESULT 731
US-10-356-625-111
; Sequence 111, Application US/10356625
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserre, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Germaine
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; TITLE OF INVENTION: THERAPEUTIC APPLICATION
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/10/356,625
; CURRENT FILING DATE: 2003-02-03
; PRIOR APPLICATION NUMBER: US/09/230,652
; PRIOR FILING DATE: 1999-05-17
; PRIOR APPLICATION NUMBER: FR 96 09733
; PRIOR FILING DATE: 1996-08-01
; PRIOR APPLICATION NUMBER: FR 97 04680
; PRIOR FILING DATE: 1997-04-16
; PRIOR APPLICATION NUMBER: PCT/FR97/01433
; PRIOR FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
```

```
US-10-356-625-111

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 GTCCTGGTCTTCGAGCAG 708
Db 1 GTCCTGGTCTTCGAGCAG 18

RESULT 732
US-10-643-775-1151
; Sequence 1151, Application US/10643775
; GENERAL INFORMATION:
; APPLICANT: Lie, Oystein
; APPLICANT: Slettan, Audun
; APPLICANT: Hoyum, Morten
; APPLICANT: Lingaas, Frode
; TITLE OF INVENTION: Verification of Food Origin Based on
; TITLE OF INVENTION: Nucleic Acid Pattern Recognition
; FILE REFERENCE: 66849-019
; CURRENT APPLICATION NUMBER: US/10/643,775
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US 60/404,200
; PRIOR FILING DATE: 2002-08-16
; NUMBER OF SEQ ID NOS: 1377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1151
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Oreochromis niloticus
US-10-643-775-1151

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1272 GGGTGTCTTCCTGGTCTC 1289
Db 1 GGGTGTCTTCCTGGTCTC 18

RESULT 733
US-10-643-775-1154
; Sequence 1154, Application US/10643775
; GENERAL INFORMATION:
; APPLICANT: Lie, Oystein
; APPLICANT: Slettan, Audun
; APPLICANT: Hoyum, Morten
; APPLICANT: Lingaas, Frode
; TITLE OF INVENTION: Verification of Food Origin Based on
; TITLE OF INVENTION: Nucleic Acid Pattern Recognition
; FILE REFERENCE: 66849-019
; CURRENT APPLICATION NUMBER: US/10/643,775
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US 60/404,200
; PRIOR FILING DATE: 2002-08-16
; NUMBER OF SEQ ID NOS: 1377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1154
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Oreochromis niloticus
US-10-643-775-1154

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1272 GGGTGTCTTCCTGGTCTC 1289
Db 1 GGGTGTCTTCCTGGTCTC 18
```

RESULT 734

US-10-714-333A-7924

; Sequence 7924, Application US/10714333A

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 7924

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-7924

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 872 ATGTCAGGTGGAAATTATG 889

|:|:| |:|:|:|:|:|

Db 2 AUGUCCUGGGAUUAUG 19

RESULT 735

US-10-714-333A-29547/c

; Sequence 29547, Application US/10714333A

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 29547

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-29547

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 398 TCTTCATCATCAGCACCC 415

|||||

Db 18 TCTTCATCATCATCC 1

RESULT 736

US-10-714-333A-73640

; Sequence 73640, Application US/10714333A

; GENERAL INFORMATION:

US-10-714-333A-29646/c

; Sequence 29646, Application US/10714333A

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 29646

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-29646

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 398 TCTTCATCATCAGCACCC 415

|||||

Db 18 TCTTCATCATCATCC 1

RESULT 737

US-10-714-333A-40403/c

; Sequence 40403, Application US/10714333A

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 40403

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-40403

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1445 TTCTAGGCCAGGGAATCC 1462

|||||

Db 19 TCCTTGGCCAGGGAATCC 2

RESULT 738

US-10-714-333A-73640

; Sequence 73640, Application US/10714333A

; GENERAL INFORMATION:

```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134980US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 73640
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-73640

```

```
Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 38.9%; Pred. No. 5.3e+02;
Matches 7; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
```

Qy 1351 ATACTCTTCCCTTGTCATT 1368
|:|:|:|:|:|:|:|:|:|:
Db 2 AAACUCUUCUUGUGAUU 19

```

RESULT 739
US-10-714-333A-77161/c
; Sequence 77161, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349SUS
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 77161
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-77161

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. NO. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 110 ACTTGGTACAAATGGACCC 127
db 19 ACTTGGTACAAACGGAGCC 2

RESULT 740
US-10-714-333A-77261/c
; Sequence 77261, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela

```

: APPLICANT: Leake, Devin
: APPLICANT: Marshall, William
: APPLICANT: Scarsange, Stephen
: TITLE OF INVENTION: Functional and Hyperfunctional siRNA
: FILE REFERENCE: 134990US
: CURRENT APPLICATION NUMBER: US/10/714,333A
: CURRENT FILING DATE: 2003-11-14
: PRIOR APPLICATION NUMBER: 60/502,050
: PRIOR FILING DATE: 2003-09-10
: PRIOR APPLICATION NUMBER: 60/426,137
: PRIOR FILING DATE: 2002-11-14
: NUMBER OF SEQ ID NOS: 1591911
: SOFTWARE: Proprietary
: SEQ ID NO 77261
: LENGTH: 19
: TYPE: RNA
: ORGANISM: Homo sapiens
: US-10-714-333A-77261

```

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%;	Pred. No. 5.3e+02;		
Matches 16;	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0;

Qy
110 ACTTGGTACAATGGACCC 127
|||
Dp
19 ACTTGGTACAACGGAGCC 2

```

RESULT 741
US-10-714-333A-98961/c
; Sequence 98961, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 98961
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-98961

```

Query Match	0.9*	Score 14.8	DB 1	Length 19
Best Local Similarity	88.9*	Pred. No. 5.3e+02		
Matches 16	Conservative	0	Mismatches 2	Indels 0
				Gaps 0

Qy 298 AACAGAAAGTTTTCATC 315
p6 18 AACAGAAAGTGGTCATC 1

RESULT 742
US-10-714-333A-99062/c
; Sequence 99062, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 99062
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-99062

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AAACAGAAAGTTTTCATC 315
Db 18 AAACAGAAAGTGGTCATC 1

RESULT 743
US-10-714-333A-99104/c
; Sequence 99104, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 99104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-99104

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AAACAGAAAGTTTTCATC 315
Db 19 AAACAGAAAGTGGTCATC 2

RESULT 744
US-10-714-333A-101026
; Sequence 101026, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
```

```
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 101026
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-101026

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 38.9%; Pred. No. 5.3e+02;
Matches 7; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTGGCTTCTC 1077
Db 2 AUCUUCUUGGCUCAUC 19

RESULT 745
US-10-714-333A-119081/c
; Sequence 119081, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 119081
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-119081

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1084 TGGCTCAAGCCTTTGCC 1101
Db 19 TGACTCAAGCCTTTGCC 2

RESULT 746
US-10-714-333A-119734/c
; Sequence 119734, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 119734
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-119734

Query Match      0.9%   Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 477 CTTGGGACAGCTGCCATT 494
    |||||
Db 18 CTTGGGACAGCTGTATT 1

RESULT 747
US-10-714-333A-129390/c
; Sequence 129390, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 129390
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-129390

Query Match      0.9%   Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTGCTTCCTC 1077
    |||||
Db 19 ATCTTCTTTGCTTCCTC 2

RESULT 748
US-10-714-333A-139439/c
; Sequence 139439, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 139439
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-139439

Query Match      0.9%   Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1183 AACGTGGTGTCCTCATGAC 1200
    |||||
Db 18 AACGTGGTGCCCTTGAC 1

RESULT 749
US-10-714-333A-139443/c
; Sequence 139443, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 139443
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-139443

Query Match      0.9%   Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1183 AACGTGGTGTCCTCATGAC 1200
    |||||
Db 19 AACGTGGTGCCCTTGAC 2

RESULT 750
US-10-714-333A-146874
; Sequence 146874, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 146874
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-146874

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 417 GGCCATCGACTTCATTGA 434
Db 1 GGCCAUAGGCCUUAUGA 18

RESULT 751
US-10-714-333A-147447
; Sequence 147447, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 147447
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-147447

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1182 GAACGTGGTGGTCATGA 1199
Db 2 GGACGUGGUGGUCUAUGA 19

RESULT 752
US-10-714-333A-162601/c
; Sequence 162601, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 162601
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-162601
```

```
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 380 TCATCGCTGGCCTGTGTG 397
Db 19 TCATCGATGGCCTGTGTG 2

RESULT 753
US-10-714-333A-162617/c
; Sequence 162617, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 162617
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-162617

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 380 TCATCGCTGGCCTGTGTG 397
Db 18 TCATCGATGGCCTGTGTG 1

RESULT 754
US-10-714-333A-168086
; Sequence 168086, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 168086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-168086

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
```

Matches	9	Conservative	7	Mismatches	2	Indels	0	Gaps	0
---------	---	--------------	---	------------	---	--------	---	------	---

Qy 951 CCTCTGTGTTCTCTGTCCTT 968
||:|:|:|:|:|:|:|:
Db 1 CCUCUGCGUUCUGUCAU 18

```

RESULT 755
US-10-714-333A-182299/c
; Sequence 182299, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 182299
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-182299

```

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%	Pred. No. 5.3e+02;		
Matches 16: Conservative	0;	Mismatches 2	Indels	

Qy 177 ACTGAGGAGCTGCTGGA 194
|||
Db 19 ACTGAGGAAGCTGCTGTA 2

```

RESULT 756
US-10-714-333A-190043/c
; Sequence 190043, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 190043
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-190043

```

Query Match 0.9%; Score 14.8; DB 1;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16: Conservative 0; Mismatches 2; Indels

QY 401 TCATCATCAGCACCCCTGG 418

Db ... 18 TCATCGTCAGCACCGTG 1

```

RESULT 757
US-10-714-333A-195561
; Sequence 195561, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 195561
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-195561

```

Query Match	0.9%	Score 14.8	DB 1	Length 19
Best Local Similarity	72.2%	Pred. No. 5.3e+02		
Matches 13	Conservative	3	Mismatches 2	Indels 0
			Gaps	0

Qy 294 GGGAAACAGAAAGTTT 311
 |||
 Db 2 GGAGAAACAGAAAGCTUU 19
 :::

```

RESULT 750
US-10-714-333A-195593
; Sequence 195593, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCES: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 195593
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-195593

```

Query Match	0.98	Score 14.8	DB 1	Length 19
Best Local Similarity	72.2%	Pred. No. 5.3e+02		
Matches + 13: Conservative		3: Mismatches	2: Indels	0: Gaps

Qy 294 GGGAAACAGAAAGTTT 311
||| ||| ||| ||| ||| :::
Db 1 GGAGAAACAGAAAGCTTT 18

RESULT 759
 US-10-714-333A-197309/c
 ; Sequence 197309, Application US/10714333A
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/10/714,333A
 ; CURRENT FILING DATE: 2003-11-14
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 197309
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-714-333A-197309

Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 5.3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1310 TCCTTCGCTTCGCTCTGG 1327
 Db 18 TCCTTCGCTTCCTCTGG 1

RESULT 760
 US-10-714-333A-209643
 ; Sequence 209643, Application US/10714333A
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/10/714,333A
 ; CURRENT FILING DATE: 2003-11-14
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 209643
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-714-333A-209643

Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 61.1%; Pred. No. 5.3e+02;
 Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 QY 887 ATGTGGCCAGAACTTTG 904
 Db 2 AUGUGGCCUGAACUUG 19

RESULT 761
 US-10-714-333A-211427/c

; Sequence 211427, Application US/10714333A
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/10/714,333A
 ; CURRENT FILING DATE: 2003-11-14
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 211427
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-714-333A-211427

Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 5.3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1060 AACTTCCTTTGCTTCCTC 1077
 Db 18 ATCTCCTTTGCTTCCTC 1

RESULT 762
 US-10-714-333A-215552/c
 ; Sequence 215552, Application US/10714333A
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/10/714,333A
 ; CURRENT FILING DATE: 2003-11-14
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 215552
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-714-333A-215552

Query Match 0.9%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 5.3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1031 CGTTGCCAGCATCTTCA 1048
 Db 18 CGTTCCAGGCTCTTCA 1

RESULT 763
 US-10-714-333A-215637/c
 ; Sequence 215637, Application US/10714333A
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 215637
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-215637

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1031 CGTTGCCAGGCACTTCA 1048
||| ||||| |||||
Db 18 CGTTTCCAGGCTCTTCA 1

RESULT 764

US-10-714-333A-215711/c
; Sequence 215711, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 215711
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-215711

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1031 CGTTGCCAGGCACTTCA 1048
||| ||||| |||||
Db 18 CGTTTCCAGGCTCTTCA 1

RESULT 765

US-10-714-333A-239980/c
; Sequence 239980, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 239980
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-239980

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1345 ATGCTGATCTCTTCTT 1362
||| ||||| |||||
Db 19 ATGCTCATCTCTCTCTT 2

RESULT 766

US-10-714-333A-256403/c
; Sequence 256403, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 256403
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-256403

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 412 ACCCTGGCCATCGACTTC 429
||| ||||| |||||
Db 18 ATCTGGCCTTCGACTTC 1

RESULT 767

US-10-714-333A-265654
; Sequence 265654, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

```

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 283836
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-283836

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1052 TGCTGCTCATCTTCTTTG 1069
Db       18 TGCTGCTCATCTTCTTTG 1

RESULT 770
US-10-714-333A-283942/c
; Sequence 283942, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 283942
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-283942

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1052 TGCTGCTCATCTTCTTTG 1069
Db       18 TGCTGCTCATCTTCTTTG 1

RESULT 771
US-10-714-333A-285391
; Sequence 285391, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137

```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 285391
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-285391

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 5.3e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1059 CATCTTCTTTCCTTCTCT 1076
DB 1 CACCUCUUGUCUUCU 18

RESULT 772
US-10-714-333A-287841
; Sequence 287841, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 287841
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-287841

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 389 GCCTGTGTCTTCATCA 406
DB 1 GCCAGUGUGUCUCA 18

RESULT 773
US-10-714-333A-290915/c
; Sequence 290915, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 290915
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-290915/c

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 TTCTCCAGCTTACCTCTAC 819
DB 18 TTCTCCAGCTGCTCTTC 1

RESULT 775
US-10-714-333A-292501/c
; Sequence 292501, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 292501
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-292501/c
```

```
; ORGANISM: Homo sapiens
US-10-714-333A-292501

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1459 ATCCAGTCAGCCTGTAC 1476
      ||||| ||||| ||||| ||||| |||||
Db 19 ATCTGCTCAGCCTGTCC 2

RESULT 776
US-10-714-333A-302975
; Sequence 302975, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 302975
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-302975

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5.3e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 150 ACAATTGCTGGAGCAAGC 167
      ||||| ||||| ||||| |||||
Db 2 ACAUGGCUAGGACUAGC 19

RESULT 777
US-10-714-333A-308401/c
; Sequence 308401, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 308401
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-308401

; ORGANISM: Homo sapiens
US-10-714-333A-292501

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1046 TCATGCTGCTGCATCT 1063
      ||||| ||||| ||||| ||||| |||||
Db 19 TCTTGCTGCTGCTCTCT 2

RESULT 778
US-10-714-333A-332333
; Sequence 332333, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 332333
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-332333

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1184 ACGTGCTGCTCCATGACT 1201
      ||||| ||||| ||||| |||||
Db 2 AAGUGGUGUCCAUAGCU 19

RESULT 779
US-10-714-333A-337343
; Sequence 337343, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 337343
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-337343

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1054 CTGCTCATCTTTTGGC 1071
Db 1 CUGCUCAUCUCCUGUC 18

RESULT 780
US-10-714-333A-351775/c
; Sequence 351775, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351775
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-351775

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTC 828
Db 19 TACCTCTCTCTCTCTC 2

RESULT 781
US-10-714-333A-351873/c
; Sequence 351873, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351873
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-351873

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTC 828
Db 19 TACCTCTCTCTCTCTC 2

RESULT 782
US-10-714-333A-351959/c
; Sequence 351959, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351959
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-351959

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTC 828
Db 19 TACCTCTCTCTCTCTC 2

RESULT 783
US-10-714-333A-352632/c
; Sequence 352632, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 352632
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-352632

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1071 CTCTCTCCATTGCTGGCT 1088
Db 18 CTCTCTCCATTGCTGGCT 1
```

RESULT 784
US-10-714-333A-354098/c
; Sequence 354098, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; CURRENT APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 354098
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-354098

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 TGCAGAGGACAGAGGCG 46
||||| ||||| ||||| |||||
Db 18 TGCAGAGGACAGAGAGC 1

RESULT 785
US-10-714-333A-354563/c
; Sequence 354563, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; CURRENT APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 354563
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-354563

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTC 828
||||| ||||| ||||| |||||
Db 18 TACCTCAACTTCATCTTC 1

RESULT 786
US-10-714-333A-354586/c
; Sequence 354586, Application US/10714333A

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; CURRENT APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 354586
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-354586

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTC 828
||||| ||||| ||||| |||||
Db 19 TACCTCAACTTCATCTTC 2

RESULT 787
US-10-714-333A-354929/c
; Sequence 354929, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; CURRENT APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 354929
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-354929

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1150 TCAAGCTCTCTTCTCCAAC 1167
||||| ||||| ||||| |||||
Db 19 TCAATTTCTCTTCTCCAAC 2

RESULT 788
US-10-714-333A-357994/c
; Sequence 357994, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia

```

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 357994
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-357994

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	1427	TGATGTGGACCATGCTGT	1444
D_b	18	TGATGTGGACCTTGTTGT	1

RESULT 789
US-10-714-333A-362298
; Sequence 362298, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 362298
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-362298

```
Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

Qy 1292 CAGTGGCCCATGAGTATA 1309
 |||:|||||:| :|:
 Db 1 CAGUGGCCCAUGCCUAUA 18

RESULT 790
US-10-714-333A-364234/C
; Sequence 364234, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William

```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 159191
; SOFTWARE: Proprietary
; SEQ ID NO 364234
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-364234

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 434 ATGAGGCAGGCTGCTGC 451
Db 18 ATCAGGGCTGGCTGCTGC 1

```

RESULT 791
US-10-714-333A-371166/c
; Sequence 371166, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: J34990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 371166
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-371166

```

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%	Pred. No. 5.3e+02;		
Matches 16: Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy 400 TTTCATCATCAGCACCCCTG 417
|||
Db 19 TTTCATCAGCAGCACCCAG 2

RESULT 792
US-10-714-333A-372178/c
; Sequence 372178, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyper
; FILE REFERENCE: 134599US

; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 372178
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-372178

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTCTACTTCTCTTC 828
|||:|||||
Db 18 TATTCTACTTCTCTTC 1

RESULT 793
US-10-714-333A-372367
; Sequence 372367, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 372367
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-372367

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 260 CAGGTTCCCTTGACGAGA 277
||||:|||||
Db 2 CAGGUUCCUUGAGUAGA 19

RESULT 794
US-10-714-333A-372453
; Sequence 372453, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 372453
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-372453

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 260 CAGGTTCCCTTGACGAGA 277
||||:|||||
Db 2 CAGGUUCCUUGAGUAGA 19

RESULT 795
US-10-714-333A-372546
; Sequence 372546, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 372546
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-372546

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 260 CAGGTTCCCTTGACGAGA 277
||||:|||||
Db 2 CAGGUUCCUUGAGUAGA 19

RESULT 796
US-10-714-333A-395054/c
; Sequence 395054, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14


```
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 395054
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-714-333A-395054

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TGGAACTCAACGTCCTTC 1161
      ||||| ||||| |||||
Db 18 TGGATCACACGTCCTTC 1

RESULT 797
US-10-714-333A-396135
; Sequence 396135, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 396135
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-396135

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 448 CTGCTGGAGTTTGACCTA 465
      ||||| ||||| :|||:|
Db 1 CUGCAGGACUUGAGCCUA 18

RESULT 798
US-10-714-333A-405763/c
; Sequence 405763, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 405763

/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 395054
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-714-333A-405763

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCTTG 1363
      ||||| ||||| |||||
Db 18 TGCAGACACTCTTCCTTG 1

RESULT 799
US-10-714-333A-413526/c
; Sequence 413526, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 413526
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-413526

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATCTCTTCCTTG 1363
      ||||| ||||| |||||
Db 18 TGCTCACACTCTTCCTTG 1

RESULT 800
US-10-714-333A-418870
; Sequence 418870, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 418870
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-714-333A-418870

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5.3e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 179 TGAGGGAGCTGCTGGATC 196
|:|||||:|:|:|
Db 1 UGAGGGAGCUGCAGGAC 18

RESULT 801

US-10-714-333A-425391/c
; Sequence 425391, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 425391
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-425391

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCTGCC 832
||| ||||| ||||| ||
Db 18 TCTGCTTCTCTTCTTCC 1

RESULT 802

US-10-714-333A-436531
; Sequence 436531, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 436531
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-436531

Query Match 0.9%; Score 14.8; DB 1; Length 19;

Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1309 ATCTTCTGCTTCTGCTCG 1326
|:|:|:|:|:|:|:|
Db 2 AACUUCUGCUGUCAUG 19

RESULT 803

US-10-714-333A-441375/c
; Sequence 441375, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 441375
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-441375

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 367 ATCTACCACATGTTTCATC 384
||||| ||||| ||||| ||
Db 18 ATCTATCACTTGTTCATC 1

RESULT 804

US-10-714-333A-442803/c
; Sequence 442803, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 442803
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-442803

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 CATGAGTATATCTCTGC 1317
DB 19 CATGAGCATATCTCTGC 2

RESULT 805
US-10-714-333A-445044/c
; Sequence 445044, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 445044
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-445044

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 398 TCTTCATCATCAGCACC 415
DB 18 TCTTCATCATCAGCTCC 1

RESULT 806
US-10-714-333A-463228/c
; Sequence 463228, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 463228
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-463228

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1052 TGCTGCTCATCTCTTTG 1069
DB 18 TGCTGCCCATCTCTTTG 1

RESULT 807
US-10-714-333A-463318/c
; Sequence 463318, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 463318
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-463318

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1052 TGCTGCTCATCTCTTTG 1069
DB 18 TGCTGCCCATCTCTTTG 1

RESULT 808
US-10-714-333A-463409/c
; Sequence 463409, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 463409
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-463409

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1052 TGCTGCTCATCTCTTTG 1069
DB 18 TGCTGCCCATCTCTTTG 1

RESULT 809

```

US-10-714-333A-464736
; Sequence 464736, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 464736
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-464736

```

Query Match	0.9%;	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	50.0%;	Pred. No. 5.3e+02;		
Matches	9;	Conservative	7;	Mismatches 2;
				Indels 0;
				Gaps 0;

Oy 810 CTACCTCTACTTCCCTCTT 827
| : | | | : | | : | | : | :
Db 1 CUACCUCGUCUUCUCCUCUU 18

```

RESULT 810
US-10-714-3333A-465655
; Sequence 465655, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfu
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 465655
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-3333A-465655

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13: Conservative 3; Mismatches 2; Indels

Qy 239 AACCTCTGCCCCACCTC 256
|||||:|||||:
Db 2 AACCTCUGCCUCCACTUC 19

RESULT 811
US-10-714-333A-469027/c
; Sequence 469027, Application US/10714333A
; GENERAL INFORMATION:

```

: APPLICANT: Dharmacon, Inc.
: APPLICANT: Kivorova, Anastasia
: APPLICANT: Reynolds, Angela
: APPLICANT: Leake, Devin
: APPLICANT: Marshall, William
: APPLICANT: Scaringe, Stephen
: TITLE OF INVENTION: Functional and Hyperfunctional siRNA
: FILE REFERENCE: 13498US
: CURRENT APPLICATION NUMBER: US/10/714,333A
: CURRENT FILING DATE: 2003-11-14
: PRIOR APPLICATION NUMBER: 60/502,050
: PRIOR FILING DATE: 2003-09-10
: PRIOR APPLICATION NUMBER: 60/426,137
: PRIOR FILING DATE: 2002-11-14
: NUMBER OF SEQ ID NOS: 1591911
: SOFTWARE: Proprietary
: SEQ ID NO 469027
: LENGTH: 19
: TYPE: RNA
: ORGANISM: Homo sapiens
: US-10-714-333A-469027

```

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%	Pred. No. 5.3e+02;		
Matches 16;	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0;

QY 1057 CTCATCTTCTTTGCCCTTC 1074
Db 18 CTCCTCTTCTTTACCTTC 1

```

RESULT 812
US-10-7114-333A-473542/c
; Sequence 473542, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 473542
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-7114-333A-473542

```

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%;	Pred. No. 5.3e+02;		
Matches 16:	Conservative	0;	Mismatches 2;	Indels 0;
	Gaps	0;		

Qy

815 TCTACTTCCCTCTCTGCG 832

Db

18 TCCTTCCTCCTCTCTTCC 1

RESULT 813
US-10-774-333A-473572/c
; Sequence 473572, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Pharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Revnolds, Angela

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 473572
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-473572

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      815 TCTACTTCTCTCTCTGCC 832
Db      19 TCTTCTCTCTCTCTCTCC 2

RESULT 814
US-10-714-333A-486856
; Sequence 486856, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 486856
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-486856

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      319 CGCAAGTCCCTCTGTGAT 336
Db      2 CGCAAGUCCCUUUGAU 19

RESULT 815
US-10-714-333A-493249/c
; Sequence 493249, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 493249
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-493249

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      815 TCTACTTCTCTCTCTGCC 832
Db      19 TCTTCTCTCTCTCTCTCC 2

RESULT 816
US-10-714-333A-496471/c
; Sequence 496471, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 496471
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-496471

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      354 GCATTTCCGACCATCTA 371
Db      18 GCATTTCCACCATCTTA 1

RESULT 817
US-10-714-333A-496830
; Sequence 496830, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
```

; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 496830
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-496830

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 333 TGATGAGCTGTGAGGT 350
Db 2 UGAUGAGCUGAGGAGAU 19
:|||||:|||||:

RESULT 818
US-10-714-333A-501486
; Sequence 501486, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 501486
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-501486

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 728 GCTACTCTTCTCTGAGAG 745
Db 1 GCUACUCCAUCCUGAAG 18
||:||||:|||||

RESULT 819
US-10-714-333A-501869/c
; Sequence 501869, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 501869
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-501869

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 722 TGAAGAGCTACTCCTTCC 739
Db 18 TGAACAGCTTCTCCTTCC 1
|||||:|||||:

RESULT 820
US-10-714-333A-512570/c
; Sequence 512570, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 512570
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-512570

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 143 TGAAGGCACAAATTGCTGG 160
Db 18 TGAAGGCACGCTTGCTGG 1
|||||:|||||:

RESULT 821
US-10-714-333A-518052
; Sequence 518052, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911

```
; SOFTWARE: Proprietary
; SEQ ID NO 518052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-518052

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 5.3e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 164 AAGCGAGGAGCAACTGA 181
||| ||||| ||||| |||
Db 2 AAGGAGGAGCAACUGA 19

RESULT 822
US-10-714-333A-521556
; Sequence 521556, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 521556
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-521556

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 924 GCTCTATGCTGCTTCAT 941
||| ||| ||| ||| |||
Db 1 GCUCUAUCCUCUUCU 18

RESULT 823
US-10-714-333A-521656
; Sequence 521656, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 521656
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-521656
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-521656

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 924 GCTCTATGCTGCTTCAT 941
||| ||| ||| ||| |||
Db 1 GCUCUAUCCUCUUCU 18

RESULT 824
US-10-714-333A-524286
; Sequence 524286, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 524286
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-524286

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1415 CATGGAACGCTGCTGATG 1432
||| ||| ||| ||| |||
Db 1 CCUGGAACGUGUGUGAU 18

RESULT 825
US-10-714-333A-524390
; Sequence 524390, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 524390
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-524390
```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1415 CATGGAACGTGCTGATGT 1432
|:|||||:|:|:|:
Db 1 CCUGGAACGUGGUGAUGU 18

RESULT 826
US-10-714-333A-541621
; Sequence 541621, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; SOFTWARE: Proprietary
; SEQ ID NO 541621
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-541621

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 442 AGGCTGCTGCTGGAGTTT 459
|||||:|:|:|:|:
Db 2 AGGCUGUUCUGGAGUUTU 19

RESULT 827
US-10-714-333A-554219/c
; Sequence 554219, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 554219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-554219

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1072 TTCTCCATTGCTGGCTC 1089
|:|||||:|:|:|:
Db 19 TACCTCCATTGCTGGCTC 2

RESULT 828
US-10-714-333A-554319/c
; Sequence 554319, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 554319
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-554319

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1072 TTCTCCATTGCTGGCTC 1089
|:|||||:|:|:|:
Db 19 TACCTCCATTGCTGGCTC 2

RESULT 829
US-10-714-333A-557566
; Sequence 557566, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 557566
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-557566

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 351 GCAGCATTTCCGCACCAT 368

Db 1 GCAGUUUUCCGACACAU 18
||||| |:::||||| ||:

RESULT 830
US-10-714-333A-563121/c
; Sequence 563121, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 563121
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-563121

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 400 TTCATCATCAGCACCTCG 417
||||| |:::||||| ||:

Db 19 TTCATCATCCTCCCTCG 2

RESULT 831
US-10-714-333A-575698/c
; Sequence 575698, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 575698
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-575698

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTTCCTTCCTCC 1078
||||| |:::||||| ||:

Db 18 TCTTCTTTCCTTCCTCC 1

RESULT 832
US-10-714-333A-586923/c
; Sequence 586923, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 586923
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-586923

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1345 ATCCTGATCTCTTCCTT 1362
||||| |:::||||| ||:

Db 19 ATCCTGACACGCTCTTCCTT 2

RESULT 833
US-10-714-333A-589132/c
; Sequence 589132, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 589132
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-589132

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 TTCTGCCCACTCATC 843
||||| |:::||||| ||:

Db 18 TTCTGCCCACTCATC 1

RESULT 834
US-10-714-333A-590892/c

```
; Sequence 590892, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 590892
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-590892
```

```
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 815 TCTACTTCCTCTCTGCC 832
Db 18 TCTTCTCTCTCTCTTCC 1
```

```
RESULT 835
US-10-714-333A-591241/c
; Sequence 591241, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 591241
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-591241
```

```
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1033 TTGCCAGGCATCTTCATG 1050
Db 19 TTGCAAGGGATCTTCATG 2
```

```
RESULT 836
US-10-714-333A-597268/c
; Sequence 597268, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 597268
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-597268
```

```
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 240 ACCTCTGCCCCACCTCC 257
Db 18 ACCTCTGCCCCACCTCC 1
```

```
RESULT 837
US-10-714-333A-607801/c
; Sequence 607801, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 607801
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-714-333A-607801
```

```
Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1306 TATATCTCTGCTTCGTC 1323
Db 19 TATTTCTCTGCTTCATC 2
```

```
RESULT 838
US-10-714-333A-616091
; Sequence 616091, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 616091
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-616091

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 86 ACACGAGGAGGAGCTGC 103
DB 1 ACACGAGGAGGAGCTGC 18

RESULT 839

US-10-714-333A-616166/c
Sequence 616166, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 616166
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-616166

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 173 GACAACTGAGGAGCTGC 190
DB 18 GAGAACTGAGGAGCTGC 1

RESULT 840

US-10-714-333A-616261/c
Sequence 616261, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA

FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 616261
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-616261

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 173 GACAACTGAGGAGCTGC 190
DB 18 GAGAACTGAGGAGCTGC 1

RESULT 841

US-10-714-333A-621423/c
Sequence 621423, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 621423
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-714-333A-621423

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 396 TGCTTCATCATCAGCAC 413
DB 18 TGCTTCATCATCCTC 1

RESULT 842

US-10-714-333A-624796/c
Sequence 624796, Application US/10714333A
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/10/714,333A
CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 624796
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-624796

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.3%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1374 AATGTTGAACCTTCATGAT 1391
|||||
Db 18 AATGTTGGATTCATGAT 1

RESULT 843
US-10-714-333A-628455
; Sequence 628455, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 628455
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-628455

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1097 TTGCCGAGATGCTACGAT 1114
:|||||
Db 1 UUGCCGAGAUCCUGAGAU 18

RESULT 844
US-10-714-333A-638478
; Sequence 638478, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 638478
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-638478

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 308 TTTTCATCATCGCAAGT 325
:::|||||
Db 1 UUUACAUCUCCUCAAAGU 18

RESULT 845
US-10-714-333A-638536
; Sequence 638536, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 638536
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-638536

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 308 TTTTCATCATCGCAAGT 325
:::|||||
Db 1 UUUACAUCUCCUCAAAGU 18

RESULT 846
US-10-714-333A-647154
; Sequence 647154, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary

```
; SEQ ID NO 647154
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-647154

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 5.3e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1056 GCTCATCTCTTTCCTT 1073
Db 1 GCUCUUCUUAUUGCCUU 18

RESULT 847
US-10-714-333A-652638/c
; Sequence 652638, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 652638
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-652638

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1017 TATCTGTCATGCCACGTT 1034
Db 19 TATCTGTCATGCCACGTT 2

RESULT 848
US-10-714-333A-652653/c
; Sequence 652653, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 652653
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-652653

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1058 TCATCTCTTTCCTTCC 1075
Db 18 TTATCTCTTTCCTTCC 1

RESULT 850
US-10-714-333A-666353/c
; Sequence 666353, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 666353
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-666353

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1017 TATCTGTCATGCCACGTT 1034
Db 19 TATCTGTCATGCCACGTT 2

RESULT 849
US-10-714-333A-666159/c
; Sequence 666159, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 666159
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-666159

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1058 TCATCTCTTTCCTTCC 1075
Db 18 TTATCTCTTTCCTTCC 1

RESULT 850
US-10-714-333A-666353/c
; Sequence 666353, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 666353
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-666353
```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCTGCC 832
||| ||||| ||||| ||
DB 18 TCTTCTTCTCTTCTGCC 1

RESULT 851
US-10-714-333A-668146/c
; Sequence 668146, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 668146
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-668146

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 926 TCTATGCTGCTTCATCC 943
||| ||||| ||||| ||
DB 18 TCAATGCCAGCTTCATCC 1

RESULT 852
US-10-714-333A-675649/c
; Sequence 675649, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 675649
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-675649

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTTCTGCC 832
||| ||||| ||||| ||
DB 18 TCTTCTTCTCTTCTGCC 1

RESULT 853
US-10-714-333A-677440
; Sequence 677440, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 677440
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-677440

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1509 CTTACCCCGCACTTT 1526
|::| ||||| ||||| ::
DB 2 CUUAAACCAAGCAACUU 19

RESULT 854
US-10-714-333A-679033
; Sequence 679033, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 679033
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-679033

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1107 GCTACGATTTGAGACAG 1124
||:||||: ||||| |||||

Db 1 GCUACGAUGGAAACAG 18

RESULT 855

US-10-714-333A-700954/c
; Sequence 700954, Application US/10714333A

GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 700954

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-700954

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTTCTTGCCTTCTC 1077

Db 18 ATCTTCTTGCCTTCTC 1

RESULT 856

US-10-714-333A-706981/c

; Sequence 706981, Application US/10714333A

GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 706981

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-706981

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1051 CTGCTGCTCATCTCTTT 1068

Db 19 CTGCTGCTCATCTCTTT 2

RESULT 857

US-10-714-333A-707106/c

; Sequence 707106, Application US/10714333A

GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 707106

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-707106

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACCTTCTTCTCTCTTC 828

Db 19 TTCCTCTTCTCTCTTC 2

RESULT 858

US-10-714-333A-709630

; Sequence 709630, Application US/10714333A

GENERAL INFORMATION:

; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/10/714,333A

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 709630

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-714-333A-709630

Query Match

Best Local Similarity 0.9%; Score 14.8; DB 1; Length 19;

Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1056 GCTCATCTTCTTGCCTT 1073

Db 1 GCUCAUCUUCUGCCAU 18

RESULT 859

US-10-714-333A-717530

; Sequence 717530, Application US/10714333A

```

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional sirNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714.333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 717530
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-717530

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 38.9%; Pred. NO. 5.3e+02;
Matches 7; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy . 952 CTCTGTGTTCCCTGTCTTT 969
| : | : | : } : : | : | : :
pb 2 CUCUGUGUUUCUGUCUAU 19

```

RESULT 860
US-10-714-333A-731509/c
; Sequence 731509, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyper
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 731509
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-731509

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 329 TGCTTGATGAGCTGATGG 346
|||
db 19 TCCTTGATGAGCTGTTGG 2

RESULT 861
US-10-714-333A-731565/c
; Sequence 731565, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Dharmacon, Anastasia

```

, APPLICANT: Reynolds, Angela
, APPLICANT: Leake, Devin
, APPLICANT: Marshall, William
, APPLICANT: Scaringe, Stephen
, TITLE OF INVENTION: Functional and Hyperfunctional siRNA
, FILE REFERENCE: 13499US
, CURRENT APPLICATION NUMBER: US/10/714,333A
, CURRENT FILING DATE: 2003-11-14
, PRIOR APPLICATION NUMBER: 60/502,050
, PRIOR FILING DATE: 2003-09-10
, PRIOR APPLICATION NUMBER: 60/426,137
, PRIOR FILING DATE: 2002-11-14
, NUMBER OF SEQ ID NOS: 159191
, SOFTWARE: Proprietary
, SEQ ID NO 731565
, LENGTH: 19
, TYPE: RNA
, ORGANISM: Homo sapiens
US-10-714-333A-731565

```

```

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 421 ATCGACTTCATTGATGAG 438
      ||| ||||| ||||| |||||
Db 19 ATCGACTTCCTTGATGAG 2

```

```

RESULT 862
US-10-714-333A-734141/c
; Sequence 734141, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 734141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-734141

```

Query Match	0.9%	Score 14.8	DB 1	Length 19
Best Local Similarity	88.9%	Pred. No. 5.3e+02		
Matches 16	Conservative	0	Mismatches 2	Indels 0
Gaps 0				
Qy	724	AAAAGCTACTCTTCCTG	741	
Db	19	AAAAGCTGCACCTTCCTG	2	

RESULT 863
US-10-714-333A-764989/c
; Sequence 764989, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William


```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 766741
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-766741

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1548 ATCTGCTCCTGCATAC 1565
      ||||| ||||| |||||
Db 19 ATCTGCTCATGTCATAC 2

RESULT 864
US-10-714-333A-766741/c
; Sequence 766741, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 766741
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-766741

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 152 AATTGCTGGAGCAAGCGC 169
      ||||| ||||| |||||
Db 19 AATTCTGGAGCAATCGC 2

RESULT 865
US-10-714-333A-766814/c
; Sequence 766814, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 766814
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-766814

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 152 AATTGCTGGAGCAAGCGC 169
      ||||| ||||| |||||
Db 18 AATTCTGGAGCAATCGC 1

RESULT 866
US-10-714-333A-766841/c
; Sequence 766841, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 766841
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-766841

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 152 AATTGCTGGAGCAAGCGC 169
      ||||| ||||| |||||
Db 19 AATTCTGGAGCAATCGC 2

RESULT 867
US-10-714-333A-766916/c
; Sequence 766916, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 766916
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-766916

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 152 AATTGCTGGAGCAAGCGC 169
Db 18 AATTCTGGAGCAATGCG 1

RESULT 868
US-10-714-333A-772034/c
; Sequence 772034, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 772034
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-772034

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1374 AATGTTGAACCTTCATGAT 1391
Db 18 AATGTTGAACCTTCATGAT 1

RESULT 869
US-10-714-333A-772055/c
; Sequence 772055, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
```

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 772055
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-772055

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1374 AATGTTGAACCTTCATGAT 1391
Db 19 AATGTTGAACCTTCATGAT 2

RESULT 870
US-10-714-333A-774996
; Sequence 774996, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 774996
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-774996

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 821 TCCTCTTCTGCCCAACAC 838
Db 2 UACUCCUCUGCCCAACAC 19

RESULT 871
US-10-714-333A-781370/c
; Sequence 781370, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 781370
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-781370

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1322 TCCTGGGTTCTTCTATC 1339
      ||||| ||||| ||||| ||
Db 18 TCCTGAGGTTCTTCTTTC 1

RESULT 872
US-10-714-333A-782978/c
; Sequence 782978, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 782978
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-782978

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 812 ACCTCTACTTCTCTTCT 829
      ||||| ||||| ||||| ||
Db 18 ATCTCTTCTCTCTTCT 1

RESULT 873
US-10-714-333A-782990
; Sequence 782990, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 782990
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-10-714-333A-782990

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1185 CGTGGTGGTCCATGACTG 1202
      ||:||||: ||: ||: ||
Db 1 CGUGGUGGUCAUGUCUG 18

RESULT 874
US-10-714-333A-783816
; Sequence 783816, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 783816
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-783816

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1182 GAACGTGGTGGTCCATGA 1199
      ||||| ||||| ||||| ||
Db 2 GAACGUGGUGGUGAUGA 19

RESULT 875
US-10-714-333A-784439
; Sequence 784439, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 784439
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-784439

Query Match      0.9%; Score 14.8; DB 1; Length 19;
```

```
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1009 GTGCTCTCTATCTGTCAT 1026
Db 2 GUGUUCUUAUCCUGCUU 19

RESULT 876
US-10-714-333A-788773
; Sequence 788773, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 788773
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-788773

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 806 CCAGCTACTCTACTTCC 823
Db 1 CCAGCAUCCUUAUCC 18

RESULT 877
US-10-714-333A-794601/c
; Sequence 794601, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 794601
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-794601

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1064 TCTTTGCCCTTCTCCATT 1081
Db 2 UCAUUGCCUUCUUAU 19

RESULT 878
US-10-714-333A-800639
; Sequence 800639, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 800639
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-800639

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 809 GCTACTCTACTTCTCT 826
Db 1 GCUACCAUUCUUCU 18

RESULT 879
US-10-714-333A-801255
; Sequence 801255, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 801255
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-801255

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 5.3e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1064 TCTTTGCCCTTCTCCATT 1081
Db 2 UCAUUGCCUUCUUAU 19
```

```

RESULT 880
US-10-714-333A-801578/c
; Sequence 801578, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmascon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIORITY APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 801578
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-801578

```

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%;	Pred. No. 5.3e+02;		
Matches 16;	Conservative	0;	Mismatches	2;
Indels				
Qy	925	CTCTATGCGCTGCTTCATC	942	
Db	18	CTCTATTACTGCTTCATC	1	

RESULT 881
US-10-714-333A-805008/c
; Sequence 805008, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIORITY APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 805008
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-805008

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%;	Pred. No. 5.3e+02;		
Matches 16;	Conservative	0;	Mismatches 2;	Indels
Qy	953	TCTGTGTTCCCTGCTTTC	970	
Db	18	TCTGTGTTGCTGTATTTC	1	

RESULT 882

```

US-10-714-333A-836678
; Sequence 836678, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714.333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 836678
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-836678

```

```

Query Match      0.98; . Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1; Pred. No. 5.3e+00;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      1036  CCAGGCATCTTCATGCTG 1053
          |||||
Db      1    CCAGGCATCTTCATGCTG 18

```

```

RESULT 883
US-10-714-333A-841744/c
; Sequence 841744, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIORITY APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 841744
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-841744

```

```

Query Match      0.98;   Score 14.8;  DB 1;   Length 19;
Best Local Similarity 88.94;   Pred. No. 5.3e+02;
Matches 16;  Conservative 0;  Mismatches 2;  Indels 0;  Gaps 0;

Qy      815  TCTACTTCCTCTCTCTGCC 832
          ||| ||||| |||
Db      18  TCTCTCTCTCTCTCTGCC 1
          ||| ||||| |||

```

RESULT 884
US-10-714-333A-841816/c
; Sequence 841816, Application US/10714333A
; GENERAL INFORMATION:

```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 841816
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-841816

```

```

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 811 TACCTCTACTCTCTCTTC 828
Db 19 TTCTCTCTCTCTCTCTTC 2

```

```

RESULT 885
US-10-714-333A-863225/c
; Sequence 863225, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 863225
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-863225

```

```

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 400 TTCTCTCTCTCTCTCTTC 417
Db 19 TTCTCTCTCTCTCTCTTC 2

```

```

RESULT 886
US-10-714-333A-874982/c
; Sequence 874982, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela

```

```

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 874982
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-874982

```

```

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1147 AACTCAACGTCCTCTTC 1164
Db 18 AACTCAGCATCTCTTC 1

```

```

RESULT 887
US-10-714-333A-883118
; Sequence 883118, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 883118
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-883118

```

```

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1047 CATGCTGCTCATCTT 1064
Db 2 CAUGCUGCUGCUGCUU 19

```

```

RESULT 888
US-10-714-333A-886411/c
; Sequence 886411, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349909
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 886411
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-886411

Query Match      0.9%  Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 787 ATCCAGGCCCGCCAGTTTC 804
      ||||| ||||| |||||
Db 19 ATCCAGGCCCGCCAGTTTC 2

RESULT 889
US-10-714-333A-889009
; Sequence 889009, Application US/10/714,333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349909
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 889009
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-889009

Query Match      0.9%  Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 5.3e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 392 TGTGTGTCTTCATCATCA 409
      : : : : : : : : :
Db 2 UCUAUGUCUUCAUCAUCA 19

RESULT 890
US-10-714-333A-892117/c
; Sequence 892117, Application US/10/714,333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349909
; CURRENT APPLICATION NUMBER: US/10/714,333A
```

```
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; CURRENT FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 892117
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-892117

Query Match      0.9%  Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTCTCTTCCTCTCTC 1077
      ||||| ||||| |||||
Db 19 ATCTCTCTTCCTCTCTC 2

RESULT 891
US-10-714-333A-895383/c
; Sequence 895383, Application US/10/714,333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349909
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 895383
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-895383

Query Match      0.9%  Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCTACTTCTCTCTCTGC 831
      ||||| ||||| |||||
Db 19 CTCTCTCTCTCTCTCTC 2

RESULT 892
US-10-714-333A-899079
; Sequence 899079, Application US/10/714,333A
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349909
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 899079
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-899079

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5.3e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 74 GTGGAGATGGAAACACTG 91
| | | | | : | | | | | : | |
Db 1 GAGGAGGAUGGAACAAG 18

RESULT 893

US-10-714-333A-899180
; Sequence 899180, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 899180
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-899180

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5.3e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 74 GTGGAGATGGAAACACTG 91
| | | | | : | | | | | : | |
Db 1 GAGGAGGAUGGAACAAG 18

RESULT 894

US-10-714-333A-905395/c
; Sequence 905395, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary
; SEQ ID NO 905395
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-905395

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 CCTTCTCCAACTACTACC 1174
| | | | | : | | | | | : | |
Db 18 CCTTCTCCAACTAATATC 1

RESULT 895

US-10-714-333A-920823/c
; Sequence 920823, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 920823
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-920823

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTTGCTTCTCTCC 1078
| | | | | : | | | | | : | |
Db 18 TCTTCTTTGCTTCTCTCC 1

RESULT 896

US-10-714-333A-920859/c
; Sequence 920859, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 920859
; LENGTH: 19


```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-920859

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1064 TCTTGGCTTCTCCTCATT 1081
      |||||
Db 19 TCTTGGCTTCTCCTTT 2

RESULT 897
US-10-714-333A-933752
; Sequence 933752, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 933752
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-933752

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 440 GCAGGCTGCTGCTGAGT 457
      |||||
Db 1 GCAGGCTGCTGCTGAGT 18

RESULT 898
US-10-714-333A-935675
; Sequence 935675, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 935675
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-935675
```

```
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 872 ATGTCAGGTGAATTATG 889
      ||:|||||:|:|:|
Db 2 AUGCAGGUGGUAUCUAUG 19

RESULT 899
US-10-714-333A-950052/c
; Sequence 950052, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 950052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-950052

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1030 ACCTTCCAGGCATCTTC 1047
      |||||
Db 18 ACCTTCCAGGCATCTTC 1

RESULT 900
US-10-714-333A-957315/c
; Sequence 957315, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 957315
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-957315

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1030 ACCTTCCAGGCATCTTC 1047
      |||||
Db 18 ACCTTCCAGGCATCTTC 1
```

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTGGCTTCTCTCC 1078
||||||| |||||
Db 18 TCTTCTTATCTTCTCTCC 1

RESULT 901
US-10-714-333A-968163/c
; Sequence 968163, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 968163
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-968163

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 152 AATTGCTGGAGCAAGCGC 169
||||||| |||||
Db 18 AATTGCTGGACAGCTC 1

RESULT 902
US-10-714-333A-968558/c
; Sequence 968558, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 968558
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-968558

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 952 CTCTGTGTTCTCTCTTTT 969

Db 18 CTCTTGTCTATCTTT 1
||||| ||||| |||||

RESULT 903
US-10-714-333A-969655
; Sequence 969655, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 969655
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-969655

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 5.3e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTTCTTGGCTTCTCTC 1077
|:|:|:|:|:|:|:|
Db 2 AUGGUCUUUGCCUUCUUC 19

RESULT 904
US-10-714-333A-971604/c
; Sequence 971604, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 971604
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-971604

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 344 TGGAGGTGCGAGCATTTCC 361
||||| ||||| |||||
Db 19 TGGATGTGCGAGCATTTAC 2

```
RESULT 905
US-10-714-333A-977139/c
; Sequence 977139, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 977139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-977139

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1310 TCTTCTGCTTCGCTCTCG 1327
      ||| ||||| ||||| |||
Db 18 TCTACTGCTTCGCTCTCG 1

RESULT 906
US-10-714-333A-1009712/c
; Sequence 1009712, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1009712
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1009712

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 TCTTCTTTCCTTCCTCC 1078
      ||| ||||| ||||| |||
Db 18 TCTTCTTGAATTCCTCC 1

RESULT 907
US-10-714-333A-1010570/c
; Sequence 1010570, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1010570
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1010570

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1060 ATCTTCTTTCCTTCCTC 1077
      ||| ||||| ||||| |||
Db 18 ATCTCTATGCTTCCTC 1
```

```
RESULT 908
US-10-714-333A-1012452/c
; Sequence 1012452, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1012452
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1012452

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 TACTCTTACTTCTTCCTC 828
      ||| ||||| ||||| |||
Db 19 TACTTCTTCTTCCTTC 2

RESULT 909
US-10-714-333A-1014454/c
; Sequence 1014454, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1014454
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1014454

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 435 TGAGGCGAGGCTGCTGCT 452
||| |||||
DB 19 TGATGTCAGGCTGCTGCT 2

RESULT 910
US-10-714-333A-1020858
; Sequence 1020858, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1020858
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1020858

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 390 CCTGTGTGCTTCATCAT 407
||| ||| :|||
DB 1 CCUGUGGUUCAUCAU 18

RESULT 911
US-10-714-333A-1026435/c
; Sequence 1026435, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1026435
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1026435

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 932 CCTGCTTCATCTCGGCC 949
||| |||||
DB 18 CCTTCTTCACGAGGCC 1

RESULT 912
US-10-714-333A-1037156
; Sequence 1037156, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1037156
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1037156

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1527 CTGGGGGCTGTGACACC 1544
|:|:|:|:|:|:|:|:|
DB 2 CUGGGGCGUGGAGCAUC 19

RESULT 913
US-10-714-333A-1045681
; Sequence 1045681, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714.333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1045681
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1045681

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 363 CACCATCTACCACATGTT 380
    |||:|||||:|:
Db. 1 CAGCAUCUACACGUGUU 18

RESULT 914
US-10-714-333A-1056677
; Sequence 1056677, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714.333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1056677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1056677

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 321 CAAGTCCTCTGATGATGA 338
    |||:|||||:|:
Db. 2 CAAGUCCUUGAUGAUGA 19

RESULT 915
US-10-714-333A-1069406/c
; Sequence 1069406, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714.333A
; CURRENT FILING DATE: 2003-11-14
```

```
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1069406
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1069406

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 34 AGGACAGAGGGCTGGGA 51
    |||:|||||:|:
Db. 18 AGAACAGAGGGCTGGTA 1

RESULT 916
US-10-714-333A-1076437
; Sequence 1076437, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714.333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1076437
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1076437

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 65 GCCAACCCCTGTGGAGATG 82
    |||:|||||:|:
Db. 2 GCCUACACUGGAGGAG 19

RESULT 917
US-10-714-333A-1077879
; Sequence 1077879, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714.333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1077879
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1077879

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 516 CATGTTTCTGTCCACCCT 533
Db 2 CAUGUCUCUGCCACUCU 19

RESULT 918
US-10-714-333A-1086381/c
; Sequence 1086381, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; CURRENT FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1086381
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1086381

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1058 TCATCTTCTTTGCTTCC 1075
Db 18 TCATCTTCTGAGCTTCC 1

RESULT 919
US-10-714-333A-1089963/c
; Sequence 1089963, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 1089963
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1089963

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1299 CCATGAGTATATCTCTG 1316
Db 18 CAATGGGTATATCTCTG 1

RESULT 920
US-10-714-333A-1091236
; Sequence 1091236, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1091236
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1091236

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 5.3e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 30 GCAGAGGACAGAGGGGCT 47
Db 1 GCAGUGGACAGAGGGGAU 18

RESULT 921
US-10-714-333A-1097289
; Sequence 1097289, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1097289
; LENGTH: 19
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-10-714-333A-1097289

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 379 TTCATCGCTGCGCTGTCT 396
      :|||:|:|||||:|:
Db 2 UUCAUCUCUGCGCGUUVU 19

RESULT 922
US-10-714-333A-1099840/c
; Sequence 1099840, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1099840
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1099840

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1306 TATATCTCTGCTTCGTC 1323
      ||| ||||| ||||| |||
Db 19 TATCTCTCTGCTTCGTC 2

RESULT 923
US-10-714-333A-1102957
; Sequence 1102957, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1102957
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1102957

; ORGANISM: Homo sapiens
US-10-714-333A-1097289

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 379 TTCATCGCTGCGCTGTCT 396
      :|||:|:|||||:|:
Db 2 UUCAUCUCUGCGCGUUVU 19

RESULT 922
US-10-714-333A-1099840/c
; Sequence 1099840, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1099840
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1099840

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1306 TATATCTCTGCTTCGTC 1323
      ||| ||||| ||||| |||
Db 19 TATCTCTCTGCTTCGTC 2

RESULT 923
US-10-714-333A-1102957
; Sequence 1102957, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1102957
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1102957

; ORGANISM: Homo sapiens
US-10-714-333A-1097289

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 379 TTCATCGCTGCGCTGTCT 396
      :|||:|:|||||:|:
Db 2 UUCAUCUCUGCGCGUUVU 19

RESULT 922
US-10-714-333A-1139322/c
; Sequence 1139322, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1139322
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1139322

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 883 AATTATGTGGCCCAAGAAC 900
      ||| ||||| ||||| |||
Db 18 AACATGTGCCCAAGAAC 1

RESULT 925
US-10-714-333A-1145472/c
; Sequence 1145472, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1145472
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1145472

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 419 CCATCGACTTCATTGATG 436
Db 18 CCATAGACTTCATTGTTG 1

RESULT 926
US-10-714-333A-1145849/c
; Sequence 1145849, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1145849
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1145849

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 ACATCGAGGCTGTGAA 146
Db 18 ACATCGAGGCTGTGAA 1

RESULT 927
US-10-714-333A-1145868/c
; Sequence 1145868, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1145868
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1145868

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 ACATCGAGGCTGTGAA 146
Db 18 ACATCGAGGCTGTGAA 1

RESULT 928
US-10-714-333A-1150268
; Sequence 1150268, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1150268
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1150268

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 436 GAGGCGAGGCTGTGCTG 453
Db 2 GAGGGAAGGCGUCGUGU 19

RESULT 929
US-10-714-333A-1157018/c
; Sequence 1157018, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1157018
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1157018

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 815 TCTACTTCTCTTCTGCC 832
Db 18 TCTTCTTCTCTTCTTCC 1
```


RESULT 930
US-10-714-333A-1157077/c
; Sequence 1157077, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1157077
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1157077

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 811 TACCTCTACTCTCTCTTC 828
| | | | | | | | | | | | | | | | | | | | |
Db 19 TTCCTCTCTCTCTCTCTTC 2

RESULT 931
US-10-714-333A-1160091/c
; Sequence 1160091, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1160091
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1160091

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1157 CCTTCTCACTACTACTAC 1174
| | | | | | | | | | | | | | | | | | | | |
Db 18 CCTTCACTCACTACTACTAC 1

RESULT 932
US-10-714-333A-1160582
; Sequence 1160582, Application US/10714333A

; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1160582
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1160582

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 333 TGATGAGCTGATGAGGT 350
| | | | | | | | | | | | | | | | | | | | |
Db 2 UCAUGAGCUGAUGAUGU 19

RESULT 933
US-10-714-333A-1160681
; Sequence 1160681, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1160681
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1160681

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 333 TGATGAGCTGATGAGGT 350
| | | | | | | | | | | | | | | | | | | | |
Db 2 UCAUGAGCUGAUGAUGU 19

RESULT 934
US-10-714-333A-1160780
; Sequence 1160780, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia

; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1207965
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1207965

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 TTGACGAGGACCCGAGG 285
DB 19 TTGTACGAGGACCCGAGG 2

RESULT 939
US-10-714-333A-1214827/c
; Sequence 1214827, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1214827
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1214827

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1071 CTTCTCCATGCTGGCT 1088
DB 18 CTTCTCCATGCTGGCT 1

RESULT 940
US-10-714-333A-1215296/c
; Sequence 1215296, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1215296
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1215296

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1428 GATGTGGACCATCTGTT 1445
DB 19 GATGTGGACCATCTGTT 2

RESULT 941
US-10-714-333A-1217017
; Sequence 1217017, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1217017
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1217017

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5.3e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 229 TCACAGACAACTCTG 246
DB 1 UCACAGACAGACCUCAG 18

RESULT 942
US-10-714-333A-1225105/c
; Sequence 1225105, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1225105
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1225105

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1349 TGATACCTCTTCCTTGTC 1366
    ||| ||||| ||||| |||||
Db 18 TAACTCTCTTCCTTGTC 1

RESULT 943
US-10-714-333A-1225133/c
; Sequence 1225133, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1225133
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1225133

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1349 TGATACCTCTTCCTTGTC 1366
    ||| ||||| ||||| |||||
Db 19 TAACTCTCTTCCTTGTC 2

RESULT 944
US-10-714-333A-1233049
; Sequence 1233049, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1233049
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1233049

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 5.3e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 978 GAGCCGAGAGCCCTTCAG 995
    ||| ||||| ||||| |||||
Db 1 GAGCAGAGAGCCCAUCAG 18

RESULT 945
US-10-714-333A-1242877
; Sequence 1242877, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1242877
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1242877

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 807 CAGCTACCTCTCTTCCT 824
    ||| ||||| ||||| |||||
Db 2 CAACAACCCUACUCCU 19

RESULT 946
US-10-714-333A-1263871
; Sequence 1263871, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1263871
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-714-333A-1263871

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 379 TTATCGCTGGCTGTGT 396
 :|||:|||:|||:|||:
DB 2 UUCACCCGUGACCUGUGU 19

RESULT 947
US-10-714-333A-1264196/c
; Sequence 1264196, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1264196
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1264196

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTACTTCTCTTCGC 831
 |||||||:|||:
DB 19 CTCCTACTTCACTTCTCC 2

RESULT 948
US-10-714-333A-1265040
; Sequence 1265040, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1265040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1265040

Query Match 0.9%; Score 14.8; DB 1; Length 19;

US-10-714-333A-1263871

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 379 TTATCGCTGGCTGTGT 396
 :|||:|||:|||:|||:
DB 2 UUCACCCGUGACCUGUGU 19

RESULT 947
US-10-714-333A-1264196/c
; Sequence 1264196, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1264196
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1264196

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 CTCCTACTTCTCTTCGC 831
 |||||||:|||:
DB 19 CTCCTACTTCACTTCTCC 2

RESULT 948
US-10-714-333A-1265040
; Sequence 1265040, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1265040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1265040

Query Match 0.9%; Score 14.8; DB 1; Length 19;

Qy 314 TCATCCGCAAGTCCCTGC 331
|||||
Db 18 TCATCTGTAAGTCCCTGC 1

RESULT 951
US-10-714-333A-1274651/c
; Sequence 1274651, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1274651
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1274651

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 315 CATCCGCAAGTCCCTGCT 332
|||||
Db 19 CATCTGTAAGTCCCTGCT 2

RESULT 952
US-10-714-333A-1276927
; Sequence 1276927, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1276927
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1276927

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 1329 GTTCTTCTATCCCGTCAT 1346
|:::|
Db 1 GAUCUUUUUCCCGUCAU 18

RESULT 953
US-10-714-333A-1289584/c
; Sequence 1289584, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1289584
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1289584

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 955 TGTGTTCTCTGCTTGGCC 972
|
Db 18 TATCTTCTGCTTGGCC 1

RESULT 954
US-10-714-333A-1307426
; Sequence 1307426, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1307426
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1307426

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5.3e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 96 GCACAGAGCCCGGACTT 113
|
Db 1 GCACAGAGACCCCGACU 18

RESULT 955

```
US-10-714-333A-1308952/c
; Sequence 1308952, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1308952
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1308952

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1048 ATGCTGCTGCTCATCTTC 1065
Db      18 ATGCTCTGTTTCATCTTC 1

RESULT 956
US-10-714-333A-1336185/c
; Sequence 1336185, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1336185
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1336185

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1030 ACCTTCCAGGCATCTTC 1047
Db      18 ACCTTCCAGGCATCTTC 1

RESULT 957
US-10-714-333A-1361062/c
; Sequence 1361062, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1361062
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1361062

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      335 ATGAGCTGATGGAGGTGC 352
Db      18 AAGAGCTGATGGAGGAGC 1

RESULT 958
US-10-714-333A-1361160/c
; Sequence 1361160, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1361160
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1361160

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      335 ATGAGCTGATGGAGGTGC 352
Db      18 AAGAGCTGATGGAGGAGC 1

RESULT 959
US-10-714-333A-1363256
; Sequence 1363256, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```



```
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; SOFTWARE: Proprietary
; SEQ ID NO 1391191
; TYPE: RNA
; ORGANISM: Homo sapiens
; LENGTH: 19
;
US-10-714-333A-1374574
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 176 AACTGAGGAGCTGCTGG 193
Db 18 AATTGAGGAGCTGCTGG 1

RESULT 964
US-10-714-333A-1391199/c
; Sequence 1391199, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1391199
; TYPE: RNA
; ORGANISM: Homo sapiens
; LENGTH: 19
;
US-10-714-333A-1391199
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTCTCTGCC 832
Db 18 TATACCTCTCTCTCTGCC 1

RESULT 965
US-10-714-333A-1391222/c
; Sequence 1391222, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1391199
; TYPE: RNA
; ORGANISM: Homo sapiens
; LENGTH: 19
;
US-10-714-333A-1391199
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1391222
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; LENGTH: 19
;
US-10-714-333A-1391222
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 TCTACTTCTCTCTCTGCC 832
Db 19 TATACCTCTCTCTCTGCC 2

RESULT 966
US-10-714-333A-1392126/c
; Sequence 1392126, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1392126
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; LENGTH: 19
;
US-10-714-333A-1392126
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 925 CTCTATGCGCTGCTCATC 942
Db 18 CTCTTTCCTCTCTCATC 1

RESULT 967
US-10-714-333A-1392227/c
; Sequence 1392227, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1392126
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; LENGTH: 19
;
US-10-714-333A-1392126
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 1392227
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1392227

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1052 TGCTGCTCATCTTCTTTG 1069
    ||| ||| ||| ||| |||
Db 19 TGCTTCTCTCTTCTTTG 2

RESULT 968
US-10-714-333A-1394653
; Sequence 1394653, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1394653
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1394653

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 5.3e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1056 GCTCATCTTCTTTGCCCTT 1073
    ||| ||| ||| ||| |||
Db 1 GCUCAUCCUCUGCCU 18

RESULT 969
US-10-714-333A-1408908/c
; Sequence 1408908, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1408908
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1408908
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1408908

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 812 ACCTCTACTTCTCTTCTTCT 829
    ||| ||| ||| ||| |||
Db 19 ATCTCTACTTCTTCTTCT 2

RESULT 970
US-10-714-333A-1408959/c
; Sequence 1408959, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1408959
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1408959

Query Match          0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 812 ACCTCTACTTCTCTTCTTCT 829
    ||| ||| ||| ||| |||
Db 18 ATCTCTACTTCTTCTTCT 1

RESULT 971
US-10-714-333A-1412087
; Sequence 1412087, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1412087
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1412087
```

```
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11: Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

Qy 1046 TCATGCTGCTGCTCATCT 1063
:|:|:|:|:|:|:|:
db 1 UCACGCAGCUGCUCACUCU 18

```

RESULT 972
US-10-714-333A-1414040/c
; Sequence 1414040, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1414040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1414040

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1307 ATATCTTCTGCTTCGTCC 1324
Dy 18 ATCTCTTCTGCTTCATCC 1

```

RESULT 973
US-10-714-333A-1417073/c
; Sequence 1417073, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: J3499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1417073
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1417073

```

Query Match	0.9%	Score 14.8; DB 1; Length 19;
Best Local Similarity	88.9%	Pred. No. 5.3e+02;

	Matches	16;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	875	TCAGGTGGAAATTATGTTGG	892							
Dd	18	TCAGATCGAAATATGTGG	1							

```

RESULT 974
US-10-714-333A-1421876/c
; Sequence 1421876, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1421876
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1421876

```

Query Match	0.9%	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%	Pred. No. 5.3e+02;		
Matches 16;	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0;

QY 1220 ATCAGGATGGGCTGCGGC 1237
Db 19 ATCAGGATGAGCTGCTGC 2

```

RESULT 975
US-10-714-333A-1423069/c
; Sequence 1423069, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO.1423069
; .LENGTH: 19
; .TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1423069

```

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16: Conservative 0; Mismatches 2; Indels

Qy 1428 GATGTGGACCATGCTGTT 1445

```
Db      19  GATGTAGACCATGATGTT 2
||||| ||||| ||||| |||||
RESULT 976
US-10-714-333A-1461394/c
; Sequence 1461394, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1461394
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1461394
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      688  TGTGTCCTGCTCTTCGAG 705
||||| ||||| ||||| |||||
Db      19  TGTGTCATGCTCTTTGAG 2

RESULT 977
US-10-714-333A-1464324
; Sequence 1464324, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1464324
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1464324
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      593  GCCTGGGCTGCGCTTT 610
||||| ||||| ||||| |||||
Db      2  GCCUUCGUGGCGCUUU 19

RESULT 978
US-10-714-333A-1519627
; Sequence 1519627, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1519627
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1519627
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      65  GCCAACCCCTGTGGAGATG 82
||||| ||||| ||||| |||||
Db      2  GUCAACACUGUGGAGAG 19

RESULT 979
US-10-714-333A-1521339/c
; Sequence 1521339, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1521339
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1521339
Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1306  TATATCTCTGCTTCCTC 1323
||||| ||||| ||||| |||||
Db      19  TATATCTCTCTCTCTTC 2

RESULT 980
US-10-714-333A-1525271/c
```

; Sequence 1525271, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1525271
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1525271

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 AACTTCTGGGGCTGCT 1538
Db 19 AACTTCTGGGTGCTGT 2

RESULT 981
US-10-714-333A-1540338
; Sequence 1540338, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1540338
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1540338

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 297 GAAACAGAAAGTTTTCAT 314
Db 1 GAAACAGAAAGUACCAU 18

RESULT 982
US-10-714-333A-1540797/c
; Sequence 1540797, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1540797
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1540797

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1343 TCATGCTGACTCTTCC 1360
Db 18 TCATGCTGACACTCTCC 1

RESULT 983
US-10-714-333A-1544504
; Sequence 1544504, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1544504
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1544504

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.3e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 723 GAAAGCTACTCTTCT 740
Db 1 GAAAGCGUAGUCCUCCU 18

RESULT 984
US-10-714-333A-1545594/c
; Sequence 1545594, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1545594
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1545594

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATACCTCTCTCTTG 1363
| | | | | | | | | | | | | | | | | |
Db 18 TTCTGATACCTCTCTCTTG 1

RESULT 985
US-10-714-333A-1545601/c
; Sequence 1545601, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1545601
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1545601

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 TGCTGATACCTCTCTCTTG 1363
| | | | | | | | | | | | | | | | | |
Db 19 TTCTGATACCTCTCTCTTG 2

RESULT 986
US-10-714-333A-1550492/c
; Sequence 1550492, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1550492
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1550492

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 398 TCTTCATCATCAGCACCC 415
| | | | | | | | | | | | | | | | | |
Db 18 TCTTCATCATCAGCACCC 1

RESULT 987
US-10-714-333A-1550559/c
; Sequence 1550559, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1550559
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1550559

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 391 CTGTGTCTCTTCATCATC 408
| | | | | | | | | | | | | | | | | |
Db 18 CTGTGTCTCTTCATCATC 1

RESULT 988
US-10-714-333A-1556457/c
; Sequence 1556457, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1556457
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1556457

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1310 TCTTCTGCTCTGCTG 1327
Db 18 TCTTCTGCTCTGCTG 1

RESULT 989

US-10-714-333A-1562901/c
; Sequence 1562901, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1562901
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1562901

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1523 CTTTCTGGGGCTGGTGA 1540
Db 18 CATTCTGGGCTGGTGA 1

RESULT 990

US-10-714-333A-1570342/c
; Sequence 1570342, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1570342
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1570342

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 520 TTCTGTCCACCTGTG 537
Db 19 TTCTGTCCACCTATTG 2

RESULT 991

US-10-714-333A-1572059
; Sequence 1572059, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1572059
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1572059

Query Match 0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5.3e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 980 GCGAGAGCCCTTCAGCA 997
Db 1 GACGAGAGCUCUCAGCA 18

RESULT 992

US-10-714-333A-1574748
; Sequence 1574748, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary

```
; SEQ ID NO 1574748
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1574748

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 441 CAGGCTGCTGCTGGAGTT 458
      ||||| ||||| ||||| |||||
Db 2 CAGGAGCUGCUGGAGUU 19

RESULT 993
US-10-714-333A-1585972
; Sequence 1585972, Application US/10714333A
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333A
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1585972
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-714-333A-1585972

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 5.3e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 379 TTGATCGCTGCGCTGTGT 396
      :||| ||||| ||||| |||||
Db 2 UUCACCGCUGACCGUGUGU 19

RESULT 994
US-60-216-745-5787/c
; Sequence 5787, Application US/60216745
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Abderrahim, Hadi
; APPLICANT: Dufreure-Gare, Isabelle
; TITLE OF INVENTION: BIALLELIC MARKER MAPS FOR USE IN CONSTRUCTING A HIGH DENSITY...
; FILE REFERENCE: 84.US1.PRO
; CURRENT APPLICATION NUMBER: US/60/216,745
; CURRENT FILING DATE: 2000-06-30
; NUMBER OF SEQ ID NOS: 13665
; SOFTWARE: Patent.pm
; SEQ ID NO 5787
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-22790 for SEQ 1256,
```

```
US-60-216-745-5787

Query Match      0.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1348 CTGATACTCTTCCTTGTTC 1365
      ||||| ||||| ||||| |||||
Db 19 CTGATACTCTTCCTTGTTC 2

Search completed: November 8, 2004, 12:55:34
Job time : 21 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 12:59:58 ; Search time 1 Seconds
(without alignments)
4.334 Million cell updates/sec

Title: US-09-918-026A-3

Perfect score: 1569

Sequence: 1 atggagccagcggggcccg.....cttggtcctgccatacctag 1569

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 83 seqs, 1381 residues

Total number of hits satisfying chosen parameters: 166

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 85 summaries

Database : rnnp3.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20.2	1.3	25	1	US-10-956-157-37782
2	20	1.3	25	1	US-10-956-160-28158
3	19.4	1.2	25	1	US-10-956-157-149185
4	19.2	1.2	25	1	US-10-956-157-37778
5	19.2	1.2	25	1	US-10-956-157-37781
6	19.2	1.2	25	1	US-10-956-157-51378
7	18.8	1.2	25	1	US-10-956-157-193674
8	16.2	1.0	21	1	US-60-522-459-5323
9	15.8	1.0	19	1	US-10-832-522-170
10	15.8	1.0	19	1	US-10-832-522-477
11	15.8	1.0	19	1	US-10-830-569-170
12	15.8	1.0	19	1	US-10-830-569-477
13	15.8	1.0	19	1	US-10-825-485-170
14	15.8	1.0	19	1	US-10-825-485-477
15	15.4	1.0	17	1	US-10-951-303-1579
16	15	1.0	18	1	US-60-522-459-3468
17	14.4	0.9	17	1	US-10-951-303-1578
18	14.4	0.9	17	1	US-60-522-459-13860
19	14.4	0.9	18	1	US-10-951-303-2168
20	14.4	0.9	19	1	US-60-522-459-11672
21	13.8	0.9	17	1	PCT-US04-16942-225
22	13.8	0.9	17	1	US-10-951-303-1945
23	13.8	0.9	17	1	US-10-951-303-3459
24	13.8	0.9	17	1	US-60-522-459-11110
25	13.4	0.9	15	1	US-60-522-459-5757
26	13.4	0.9	15	1	US-60-522-459-9257
27	13.4	0.9	15	1	US-60-522-459-13953
28	13.4	0.9	16	1	US-60-522-459-4865
29	13.4	0.9	16	1	US-60-522-459-6393
30	13.4	0.9	17	1	US-10-951-303-949
31	13.4	0.9	17	1	US-10-951-303-2128
32	13.4	0.9	17	1	US-10-951-303-2129
33	13	0.8	13	1	US-60-522-459-14042

ALIGNMENTS

RESULT 1

US-10-956-157-37782
; Sequence 37782, Application US/10956157
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 37782

; LENGTH: 25

; TYPE: DNA

C	34	13	0.8	14	1	US-60-522-459-2715	Sequence 2715, Ap
	35	13	0.8	17	1	US-10-951-303-1508	Sequence 1508, Ap
	36	12.8	0.8	16	1	US-60-522-459-4058	Sequence 4058, Ap
	37	12.8	0.8	16	1	US-60-522-459-6025	Sequence 6025, Ap
	38	12.8	0.8	17	1	US-10-951-303-2567	Sequence 2567, Ap
	39	12.8	0.8	17	1	US-60-522-459-2801	Sequence 2801, Ap
	40	12.8	0.8	17	1	US-60-522-459-4873	Sequence 4873, Ap
	41	12.8	0.8	17	1	US-60-522-459-6518	Sequence 6518, Ap
	42	12.8	0.8	17	1	US-60-522-459-10001	Sequence 10001, A
	43	12.4	0.8	14	1	US-60-522-459-1665	Sequence 1665, Ap
	44	12.4	0.8	14	1	US-60-522-459-4478	Sequence 4478, Ap
	45	12.4	0.8	14	1	US-60-522-459-5756	Sequence 5756, Ap
	46	12.4	0.8	14	1	US-60-522-459-6702	Sequence 6702, Ap
	47	12.4	0.8	14	1	US-60-522-459-10772	Sequence 10772, A
	48	12.4	0.8	14	1	US-60-522-459-12398	Sequence 12398, A
	49	12.4	0.8	14	1	US-60-522-459-12857	Sequence 12857, A
	50	12.4	0.8	15	1	US-60-522-459-6913	Sequence 6913, Ap
	51	12.4	0.8	15	1	US-60-522-459-13510	Sequence 13510, A
	52	12.4	0.8	15	1	US-60-522-459-14055	Sequence 14055, A
	53	12.4	0.8	15	1	US-60-522-459-14457	Sequence 14457, A
	54	12.4	0.8	16	1	US-60-522-459-1388	Sequence 1388, Ap
	55	12.4	0.8	16	1	US-60-522-459-2625	Sequence 2625, Ap
	56	12.4	0.8	16	1	US-60-522-459-5665	Sequence 5665, Ap
	57	12.4	0.8	16	1	US-60-522-459-12854	Sequence 12854, A
	58	12	0.8	12	1	US-60-522-459-6785	Sequence 6785, Ap
	59	12	0.8	14	1	US-60-522-459-8382	Sequence 8382, Ap
	60	12	0.8	14	1	US-60-522-459-12990	Sequence 12990, A
	61	12	0.8	14	1	US-60-522-459-14443	Sequence 14443, A
	62	12	0.8	15	1	US-60-522-459-11017	Sequence 11017, A
	63	12	0.8	16	1	US-10-852-943-17	Sequence 17, Appl
	64	12	0.8	16	1	US-60-522-459-6700	Sequence 6700, Ap
	65	11.8	0.8	15	1	US-60-522-459-2579	Sequence 2579, Ap
	66	11.8	0.8	15	1	US-60-522-459-3450	Sequence 3450, Ap
	67	11.8	0.8	15	1	US-60-522-459-3670	Sequence 3670, Ap
	68	11.8	0.8	15	1	US-60-522-459-4538	Sequence 4538, Ap
	69	11.8	0.8	15	1	US-60-522-459-5213	Sequence 5213, Ap
	70	11.8	0.8	15	1	US-60-522-459-6091	Sequence 6091, Ap
	71	11.8	0.8	15	1	US-60-522-459-6725	Sequence 6725, Ap
	72	11.8	0.8	15	1	US-60-522-459-6764	Sequence 6764, Ap
	73	11.8	0.8	15	1	US-60-522-459-7375	Sequence 7375, Ap
	74	11.8	0.8	15	1	US-60-522-459-7664	Sequence 7664, Ap
	75	11.8	0.8	15	1	US-60-522-459-8798	Sequence 8798, Ap
	76	11.8	0.8	15	1	US-60-522-459-9304	Sequence 9304, Ap
	77	11.8	0.8	15	1	US-60-522-459-9349	Sequence 9349, Ap
	78	11.8	0.8	15	1	US-60-522-459-9996	Sequence 9996, Ap
	79	11.8	0.8	15	1	US-60-522-459-10676	Sequence 10676, A
	80	11.8	0.8	15	1	US-60-522-459-10983	Sequence 10983, A
	81	11.8	0.8	15	1	US-60-522-459-13126	Sequence 13126, A
	82	11.8	0.8	15	1	US-60-522-459-13406	Sequence 13406, A
	83	11.8	0.8	15	1	US-60-522-459-14041	Sequence 14041, A
	84	11.8	0.8	25	1	US-10-956-157-193674	Sequence 193674, A
	85	11.4	0.7	14	1	US-60-522-459-8382	Sequence 8382, Ap

```
; ORGANISM: Probe Sequence
US-10-956-157-37782

Query Match      1.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.3;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1044 CTTTCATGCTGCTGCTCATCTCTTT 1068
      ||||| ||||| ||||| ||||| |||||
Db 1 CTTTCATGCTGCTGCTCATCTCTTT 25

RESULT 2
US-10-956-160-28158
; Sequence 28158, Application US/10956160
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION IN ANIMAL
; FILE REFERENCE: 031896-044000 (AM101084)
; CURRENT APPLICATION NUMBER: US/10/956,160
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 222274
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28158
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Canis familiaris
US-10-956-160-28158

Query Match      1.3%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.7;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 283 GAGCCATCCCTGGGGAACA 302
      ||||| ||||| ||||| ||||| |||||
Db 2 GAGCCATCCCTGGGGAACA 21

RESULT 3
US-10-956-157-149185
; Sequence 149185, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149185
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-149185

Query Match      1.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 4.9;
Matches 20; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

Qy 906 CCAGGCCCTGGGATGTGCT 926
      ||||| ||||| ||||| ||||| |||||
Db 4 CCAGGCCCTGGGATGTGGCT 24

RESULT 4
US-10-956-157-37778
; Sequence 37778, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37778
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-37778

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 5.4;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1044 CTTTCATGCTGCTGCTCATCTCTTT 1067
      ||||| ||||| ||||| ||||| |||||
Db 2 CTTTCATGCTGCTGCTCATCTCTTT 25

RESULT 5
US-10-956-157-37781
; Sequence 37781, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37781
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-37781

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 5.4;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1045 TTCATGCTGCTGCTCATCTCTTT 1068
      ||||| ||||| ||||| ||||| |||||
Db 1 TTCATGCTGCTGCTCATCTCTTT 24

RESULT 6
US-10-956-157-51378
; Sequence 51378, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 51378
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-51378

Query Match      1.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 5.4;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy 951 CCTCTGTGTTCTCTCTTTGCGCAA 974
Db 1 CCTCTGTGTTCTCTCTATAGCAA 24

RESULT 7

US-10-956-157-193674
; Sequence 193674, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193674
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193674

Query Match 1.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 6.5;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 277 ACCGAGGCGCCATCCCTGGGA 298
Db 4 ACCGAGGCGCCACTGGGA 25

RESULT 8

US-60-522-459-5323/c
; Sequence 5323, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522.459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5323
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-5323

Query Match 1.0%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 14;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 482 GACAGCTGCCATTCGCGCTGG 502
Db 21 GGCAGCTGCCATTCGCGCTGG 1

RESULT 9

US-10-932-522-170
; Sequence 170, Application US/10832522
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/154 (MBHB04-378-B)
; CURRENT APPLICATION NUMBER: US/10/832.522
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: US 10/830,569

; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 825
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 170
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense re

US-10-932-522-170

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 12;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 46 CTGGAGGGGAGCGGAGC 64
Db 1 CUGGAGGGGAGCGGAGC 19

RESULT 10

US-10-832-522-477/c
; Sequence 477, Application US/10832522
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/154 (MBHB04-378-B)
; CURRENT APPLICATION NUMBER: US/10/832.522
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: US 10/830,569
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 825
; SOFTWARE: PatentIn version 3.3

```
; SEQ ID NO 477
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-832-522-477

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 12;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 46 CTGGGAGGGGAGCGGAGC 64
      ||| ||||| ||| |||
Db 19 CTGGGAGGGAGCTGCAGC 1

RESULT 11
US-10-830-569-170
; Sequence 170, Application US/10830569
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 170
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-830-569-477

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 12;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 46 CTGGGAGGGGAGCGGAGC 64
      ||| ||||| ||| |||
Db 19 CTGGGAGGGAGCTGCAGC 1

RESULT 13
US-10-825-485-170
; Sequence 170, Application US/10825485
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/150 (MBHB04-378)
; CURRENT APPLICATION NUMBER: US/10/825,485
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-830-569-477

Query Match          1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 12;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 46 CTGGGAGGGGAGCGGAGC 64
      ||| ||||| ||| |||
Db 19 CTGGGAGGGAGCTGCAGC 1

RESULT 13
US-10-825-485-170
; Sequence 170, Application US/10825485
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/150 (MBHB04-378)
; CURRENT APPLICATION NUMBER: US/10/825,485
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
```

```

; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM..
; NUMBER OF SEQ ID NOS: 724
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 170
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense x
US-10-825-485-170

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 12;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 46 CTGGAGGGGAGCGGGAGC 64
   |||||
Db 1 CUGGAGGGGAGCGGAGC 19

RESULT 14
US-10-825-485-477/c
; Sequence 477, Application US/10825485
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/150 (MBH04-378)
; CURRENT APPLICATION NUMBER: US/10/825,485
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM..
; NUMBER OF SEQ ID NOS: 724
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-825-485-477

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 12;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 CTGGAGGGGAGCGGGAGC 64
   |||||
Db 19 CTGGAGGGGAGCGTGCAGC 1

```

```

RESULT 15
US-10-951-303-1579/c
; Sequence 1579, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951,303
; CURRENT FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-1579

Query Match      1.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 11;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 120 ATGACCCGACATGG 136
   |||||
Db 17 ATGACCCGACATGG 1

RESULT 16
US-60-522-459-3468/c
; Sequence 3468, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3468
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-3468

Query Match      1.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 302 AGAAGTTTTCATCA 316
   |||||
Db 16 AGAAGTTTTCATCA 2

RESULT 17
US-10-951-303-1578/c
; Sequence 1578, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951,303
; CURRENT FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1578
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-1578

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 GGACCCGACACATGGA 137
Db 17 GGACCCGACACATGGA 2

RESULT 18
US-60-522-459-13860
; Sequence 13860, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13860
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13860

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 17;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 963 TGCTTTGCCACATG 978
Db 1 UGUCUUGCCACACUG 16

RESULT 19
US-10-951-303-2168
; Sequence 2168, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB00-876-K (400/021)
```

```
; CURRENT APPLICATION NUMBER: US/10/951,303
; CURRENT FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2168
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-2168

Query Match      0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 20;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 943 CTGGCGGCTCTGTG 958
Db 1 CCGGCGGCTCTGTG 16

RESULT 20
US-60-522-459-11672/c
; Sequence 11672, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11672
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human herpesvirus 1
US-60-522-459-11672

Query Match      0.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1011 GCTCTCTATCTGCTGAT 1026
Db 17 GCTCTCTATCTGCTGAT 2

RESULT 21
PCT-US04-16942-225/c
; Sequence 225, Application PC/TUS0416942
; GENERAL INFORMATION:
; APPLICANT: SEQUENOM, INC.
; APPLICANT: ROTH, Richard B.
; APPLICANT: RENELAND, Rikard
; APPLICANT: ROSETTE, Caridad
; APPLICANT: HOVAL-WRIGHTSON, Carolyn R.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING RISK OF BREAST
; FILE REFERENCE: 524592006641
; CURRENT APPLICATION NUMBER: PCT/US04/16942
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: US 10/722,832
; PRIOR FILING DATE: 2003-11-25
; NUMBER OF SEQ ID NOS: 275
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
PCT-US04-16942-225

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 111 CTTGGTACAAATGGACCC 127
Db 17 CTTGGTACAAATGGACCC 1

RESULT 22
US-10-951-303-1945
; Sequence 1945, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951.303
; CURRENT FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-1945

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 23;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 282 GGAGCCATCCCTGGGA 298
Db 1 GGAGCAUCCUGGA 17

RESULT 23
US-10-951-303-3459/c
; Sequence 3459, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951.303
; CURRENT FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
```

```
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3459
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-951-303-3459

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 GGACCCAGGAGCCATCC 291
Db 17 GGATTCAGGAGCCATCC 1

RESULT 24
US-60-522-459-11110
; Sequence 11110, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11110
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-11110

Query Match      0.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 23;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 261 AGGTTCTTCAGCAGGA 277
Db 1 AGAUTCUCGAGCAGGA 17

RESULT 25
US-60-522-459-5757/c
; Sequence 5757, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5757
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-5757

Query Match      0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 19;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1325 TGGGGTTCTTCTATC 1339
Db 15 TGGGGTTCTTCTGTC 1
```

```

RESULT 26
US-60-522-459-9257
; Sequence 9257, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9257
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-9257

Query Match      0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 19;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      353 AGCATTTCCGCACCA 367
Db      1 AGCAUUCACACCA 15
|||||:|||||
|||||:|||||

RESULT 27
US-60-522-459-13953
; Sequence 13953, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13953
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13953

Query Match      0.9%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 19;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      39 AGAAGGCTGGGAGG 53
Db      1 AGAAGUCGGGAGG 15
|||||:|||||
|||||:|||||

RESULT 28
US-60-522-459-4865/c
; Sequence 4865, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4865
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-4865

```

```

Query Match      0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 23;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      770 CCAGACGAGGTGAGG 784
Db      15 CCAGACGGGTGAGG 1
|||||:|||||
|||||:|||||

RESULT 29
US-60-522-459-6393/c
; Sequence 6393, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6393
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6393

Query Match      0.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 23;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1064 TCCTTGCTCTCTCC 1078
Db      16 TCCTTGCCATCTCTCC 2
|||||:|||||
|||||:|||||

RESULT 30
US-10-951-303-949/c
; Sequence 949, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951,303
; CURRENT FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-949

Query Match      0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 27;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1513 CCCAGGCACTTTC 1527
Db      1513 CCCAGGCACTTTC 1527
|||||:|||||
|||||:|||||

```


Db 17 CCCAGGCAAGTTTC 3

RESULT 31
US-10-951-303-2128
; Sequence 2128, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951.303
; PRIOR FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2128
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-2128

Query Match 0.9%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 27;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 796 CCCAGTTTCTCCAGC 810
||||| :|||
Db 2 CCCAGAUUCCUCCAGC 16

RESULT 32
US-10-951-303-2129
; Sequence 2129, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951.303
; PRIOR FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2129
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-2129

Query Match 0.9%; Score 13.4; DB 1; Length 17;

Best Local Similarity 73.3%; Pred. No. 27;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 796 CCCAGTTTCTCCAGC 810
||||| :|||
Db 1 CCCAGAUUCCUCCAGC 15

RESULT 33
US-60-522-459-14042
; Sequence 14042, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522.459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14042
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 (Epstein-Barr virus)
US-60-522-459-14042

Query Match 0.8%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 53 GGGAGCGGGAGCG 65
|||||
Db 1 GGGAGCGGGAGCG 13

RESULT 34
US-60-522-459-2715/c
; Sequence 2715, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522.459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2715
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2715

Query Match 0.8%; Score 13; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 241 CCTCTGCCCCAC 253
|||||
Db 14 CCTCTGCCCCAC 2

RESULT 35
US-10-951-303-1508
; Sequence 1508, Application US/10951303
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/10/951.303
; PRIOR FILING DATE: 2004-09-27
; PRIOR APPLICATION NUMBER: US/09/685,664
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2129
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-2129

Query Match 0.9%; Score 13.4; DB 1; Length 17;

FILE REFERENCE: MBHB00-876-K (400/021)
CURRENT APPLICATION NUMBER: US/10/951.303
CURRENT FILING DATE: 2004-09-27
PRIOR APPLICATION NUMBER: US/09/685,664
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1508
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-951-303-1508

Query Match 0.8%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 33;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 946 GCGCGCCTCTGTG 958
Db 1 GCGCGCCUCUG 13

RESULT 36
US-60-522-459-4058
Sequence 4058, Application US/60522459
GENERAL INFORMATION:
APPLICANT: ROSETTA GENOMICS LTD
TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
FILE REFERENCE: 52904
CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 4058
LENGTH: 16
TYPE: RNA
ORGANISM: Human
US-60-522-459-4058

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 30;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 733 TCCTTCCTGAGAGG 748
Db 1 UCCUGGCUAGAGG 16

RESULT 37
US-60-522-459-6025
Sequence 6025, Application US/60522459
GENERAL INFORMATION:
APPLICANT: ROSETTA GENOMICS LTD
TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
FILE REFERENCE: 52904
CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 6025
LENGTH: 16
TYPE: RNA
ORGANISM: Human
US-60-522-459-6025

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 30;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1361 TTGTCAATTGAGGAAT 1376
Db 1 UGGUCAUUGCAGGAU 16

RESULT 38
US-10-951-303-2567
Sequence 2567, Application US/10951303
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
FILE REFERENCE: MBHB00-876-K (400/021)
CURRENT APPLICATION NUMBER: US/10/951,303
CURRENT FILING DATE: 2004-09-27
PRIOR APPLICATION NUMBER: US/09/685,664
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2567
LENGTH: 17
TYPE: RNA
ORGANISM: Mus musculus
US-10-951-303-2567

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 36;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 1354 CTCCTCTGTCAATTG 1369
Db 1 CUCCUUCUGCAUG 16

RESULT 39
US-60-522-459-2801/c
Sequence 2801, Application US/60522459
GENERAL INFORMATION:
APPLICANT: ROSETTA GENOMICS LTD
TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
FILE REFERENCE: 52904
CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 2801
LENGTH: 17
TYPE: RNA
ORGANISM: Human
US-60-522-459-2801

Query Match 0.8%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 977 TGAGCCGAGGCCCTT 992
Db 16 TGAGCTGAGAGCCCT 1

RESULT 40
 US-60-522-459-4873
 ; Sequence 4873, Application US/60522459
 ; GENERAL INFORMATION:
 ; APPLICANT: ROSETTA GENOMICS LTD
 ; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
 ; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
 ; FILE REFERENCE: 52904
 ; CURRENT APPLICATION NUMBER: US/60/522,459
 ; CURRENT FILING DATE: 2004-10-04
 ; NUMBER OF SEQ ID NOS: 15575
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 4873
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Human
 US-60-522-459-4873

Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 36;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 244 CTGCCCCCAGCTCCCC 259
 |:|||||:|||||
 Db 2 CUGCCCCCGCAUCCCC 17

RESULT 41
 US-60-522-459-6518
 ; Sequence 6518, Application US/60522459
 ; GENERAL INFORMATION:
 ; APPLICANT: ROSETTA GENOMICS LTD
 ; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
 ; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
 ; FILE REFERENCE: 52904
 ; CURRENT APPLICATION NUMBER: US/60/522,459
 ; CURRENT FILING DATE: 2004-10-04
 ; NUMBER OF SEQ ID NOS: 15575
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 6518
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Human
 US-60-522-459-6518

Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 36;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 26 GTCTGCAGAGCAGACA 41
 |:|||||:|||||
 Db 1 GCGUGCAGAGCCACA 16

RESULT 42
 US-60-522-459-10001
 ; Sequence 10001, Application US/60522459
 ; GENERAL INFORMATION:
 ; APPLICANT: ROSETTA GENOMICS LTD
 ; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
 ; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
 ; FILE REFERENCE: 52904
 ; CURRENT APPLICATION NUMBER: US/60/522,459
 ; CURRENT FILING DATE: 2004-10-04
 ; NUMBER OF SEQ ID NOS: 15575
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 10001
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Human
 US-60-522-459-10001

Query Match 0.8%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 36;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 566 CCAGGGCAGCTGGAC 581
 |:|||||:|||||
 Db 1 CCAGGGAGACCCUGAC 16
 RESULT 43
 US-60-522-459-1665
 ; Sequence 1665, Application US/60522459
 ; GENERAL INFORMATION:
 ; APPLICANT: ROSETTA GENOMICS LTD
 ; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
 ; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
 ; FILE REFERENCE: 52904
 ; CURRENT APPLICATION NUMBER: US/60/522,459
 ; CURRENT FILING DATE: 2004-10-04
 ; NUMBER OF SEQ ID NOS: 15575
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 1665
 ; LENGTH: 14
 ; TYPE: RNA
 ; ORGANISM: Human
 US-60-522-459-1665

Query Match 0.8%; Score 12.4; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 26;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 904 GCCCAGCGCCTGGG 917
 |:|||||:|||||
 Db 1 GCCCGCGCCUGGG 14

RESULT 44
 US-60-522-459-4478/c
 ; Sequence 4478, Application US/60522459
 ; GENERAL INFORMATION:
 ; APPLICANT: ROSETTA GENOMICS LTD
 ; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
 ; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
 ; FILE REFERENCE: 52904
 ; CURRENT APPLICATION NUMBER: US/60/522,459
 ; CURRENT FILING DATE: 2004-10-04
 ; NUMBER OF SEQ ID NOS: 15575
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 4478
 ; LENGTH: 14
 ; TYPE: RNA
 ; ORGANISM: Human
 US-60-522-459-4478

Query Match 0.8%; Score 12.4; DB 1; Length 14;
 Best Local Similarity 92.9%; Pred. No. 26;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 443 GGCTGCTGCTGGAG 456
 |:|||||:|||||
 Db 14 GGCTGCTGCTGGAG 1

RESULT 45
 US-60-522-459-5756/c
 ; Sequence 5756, Application US/60522459
 ; GENERAL INFORMATION:
 ; APPLICANT: ROSETTA GENOMICS LTD
 ; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
 ; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
 ; FILE REFERENCE: 52904
 ; CURRENT APPLICATION NUMBER: US/60/522,459

; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5756
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-5756

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 26;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1326 GGGGTTCTTCTATC 1339
Db 14 GGGGTTCTTCTGTC 1

RESULT 46
US-60-522-459-6702/c
; Sequence 6702, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6702
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6702

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 26;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 244 CTGCCCCCAGCTCC 257
Db 14 CTGCTCCAGCTCC 1

RESULT 47
US-60-522-459-10772/c
; Sequence 10772, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10772
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-10772

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 26;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 907 CAGGCCCTGGGATG 920
Db 14 CAGGCCCTGGGGTG 1

RESULT 48

US-60-522-459-12398
; Sequence 12398, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12398
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human herpesvirus 2
US-60-522-459-12398

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 26;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 635 GCGGCTGGCGGTC 648
Db 1 GCGGCTGGCGGAC 14

RESULT 49
US-60-522-459-12857/c
; Sequence 12857, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12857
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-12857

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 26;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1506 CCGCTTACCCGAG 1519
Db 14 CACCTTACCCGAG 1

RESULT 50
US-60-522-459-6913
; Sequence 6913, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6913
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6913

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 31;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 42 AGGCTGGGAGGG 55
||:|||||
Db 2 AGAGCUGGAGGG 15

RESULT 51
US-60-522-459-13510
; Sequence 13510, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 13510
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13510

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 31;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 523 CTGTCACCTGTT 536
||:|||||
Db 2 CUGUCCACCCUGG 15

RESULT 52
US-60-522-459-14055
; Sequence 14055, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 14055
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-14055

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 31;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 498 GCTGGTGACCTGG 511
||:|||||
Db 2 GCUGGUGCCUGG 15

RESULT 53
US-60-522-459-14457/c
; Sequence 14457, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patent in version 3.2

; SEQ ID NO 14457
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-14457

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 31;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 244 CTGCCCCCACCTCC 257
||:|||||
Db 14 CAGCCCCCACCTCC 1

RESULT 54
US-60-522-459-1388/c
; Sequence 1388, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 1388
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-1388

Query Match 0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 244 CTGCCCCCACCTCC 257
||:|||||
Db 15 CTGCTCCACCTCC 2

RESULT 55
US-60-522-459-2625/c
; Sequence 2625, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 2625
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2625

Query Match 0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 CCTCTACTTCCTCT 826
||:|||||
Db 15 CCTCTCTTCCTCT 2

RESULT 56
US-60-522-459-5665/c
; Sequence 5665, Application US/60522459
; GENERAL INFORMATION:

; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF

; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5665
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-5665

Query Match 0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 926 TCTATGCTGCTTC 939
| | | | | | | | | |
Db 16 TCTATGCTGCTTC 3

RESULT 57
US-60-522-459-12854/c
; Sequence 12854, Application US/60522459
; GENERAL INFORMATION:

; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12854
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-12854

Query Match 0.8%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 441 CAGGCTGCTGCTGG 454
| | | | | | | | | |
Db 15 CCGGCTGCTGCTGG 2

RESULT 58
US-60-522-459-6785/c
; Sequence 6785, Application US/60522459
; GENERAL INFORMATION:

; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6785
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6785

Query Match 0.8%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1325 TGGGGTTCTTCT 1336

Db 12 TGGGGTTCTTCT 1
| | | | | | | | | |

RESULT 59
US-60-522-459-8382/c
; Sequence 8382, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8382
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-8382

Query Match 0.8%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1320 CGTCCTGGGGTT 1331
| | | | | | | | | |
Db 12 CGTCCTGGGGTT 1

RESULT 60
US-60-522-459-12990/c
; Sequence 12990, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12990
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-12990

Query Match 0.8%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 388 GGCCTGTGTGTC 399
| | | | | | | | | |
Db 14 GGCCTGTGTGTC 3

RESULT 61
US-60-522-459-14443
; Sequence 14443, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14443
; LENGTH: 14
; TYPE: RNA

ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-14443

Query Match 0.8%; Score 12; DB 1; Length 14;
Best Local Similarity 75.0%; Pred. No. 31;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 523 CTGTCACCCCTG 534
|:|:|:|:|:|:|:
DB 2 CUGUCCACCCUG 13

RESULT 62

US-60-522-459-11017/c
; Sequence 11017, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11017
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-11017

Query Match 0.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1067 TTGCTTCCTCC 1078
|:|:|:|:|:|:|:
DB 13 TTGCTTCCTCC 2

RESULT 63

US-10-852-943-17/c
; Sequence 17, Application US/10852943
; GENERAL INFORMATION:
; APPLICANT: University of Geneva
; APPLICANT: Stylianos, Antonarakis
; APPLICANT: Deutsch, Samuel
; TITLE OF INVENTION: METHOD FOR DETECTING DISEASES CAUSED BY CHROMOSOMAL IMBALANCES
; FILE REFERENCE: 27067/2005
; CURRENT APPLICATION NUMBER: US/10/852,943
; CURRENT FILING DATE: 2004-05-25
; PRIOR APPLICATION NUMBER: US 60/300,266
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 10/177,063
; PRIOR FILING DATE: 2002-06-21
; NUMBER OF SEQ ID NOS: 98
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 17
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: primer
US-10-852-943-17

Query Match 0.8%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1076 TCCATTGCTGGC 1087
|:|:|:|:|:|:|:
DB 13 TCCATTGCTGGC 2

RESULT 64

US-60-522-459-6700/c
; Sequence 6700, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6700
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6700

Query Match 0.8%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 249 CCCACCTCCCCC 260
|:|:|:|:|:|:|:
DB 16 CCCACCTCCCCC 5

RESULT 65

US-60-522-459-2579
; Sequence 2579, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2579
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2579

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 40;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 242 CTCTGCCCCCCTC 256
|:|:|:|:|:|:|:
DB 1 CACUGCCCCCAGCUC 15

RESULT 66

US-60-522-459-3450
; Sequence 3450, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3450
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-3450

Query Match 0.8%; Score 11.8; DB 1; Length 15;

```
Best Local Similarity 60.0%; Pred. No. 40;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 494 TGGCGCTGGTGACCT 508
Db 1 UAGCUCUGGAGGCU 15

RESULT 67
US-60-522-459-3670
; Sequence 3670, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3670
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-3670

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 40;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1224 GGATGGCTGGCGCT 1238
Db 1 GGCUGGCGUGGGGCU 15

RESULT 68
US-60-522-459-4538
; Sequence 4538, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4538
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-4538

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 40;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 22 CTGCGTCTGCAGAGG 36
Db 1 CUGCGCUGGAGGGG 15

RESULT 69
US-60-522-459-5213/c
; Sequence 5213, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5213
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-5213

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1230 GCTGGCGCTCCTTGG 1244
Db 15 GCTGGCGCTCCATGG 1

RESULT 70
US-60-522-459-6091
; Sequence 6091, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6091
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6091

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 40;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 910 GCCTGGGATGTGTG 924
Db 1 GCCUGGACUGUGUG 15

RESULT 71
US-60-522-459-6725/c
; Sequence 6725, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6725
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6725

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 244 CTGCCCCCACCCTCC 258
Db 15 CTGCCCCCACCCTCC 1

RESULT 72
US-60-522-459-6764/c
; Sequence 6764, Application US/60522459
```


; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; NUMBER OF SEQ ID NOS: 2004-10-04
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6764
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6764

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1061 TCTTCTTTGCTTCC 1075
Db 15 TCTCCTTTGCTTCC 1

RESULT 73
US-60-522-459-7375
; Sequence 7375, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7375
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-7375

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 40;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 945 GGGCGGCTCTGTCT 959
Db 1 GGGCCUCCUGUGU 15

RESULT 74
US-60-522-459-7664/c
; Sequence 7664, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7664
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-7664

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 998 CCCGTGCCCTGGTGC 1012
Db 15 CCCCTCCCTGGTGC 1

RESULT 75
US-60-522-459-8798/c
; Sequence 8798, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8798
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-8798

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1084 TGGCTCAACGCTTT 1098
Db 15 TTGCTACCGCCTTT 1

RESULT 76
US-60-522-459-9304
; Sequence 9304, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9304
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-9304

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 40;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 744 AGAGCGTGTGCTGG 758
Db 1 AGAGCGUGAGGCGUG 15

RESULT 77
US-60-522-459-9349/c
; Sequence 9349, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9349
; LENGTH: 15

```
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-9349

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1514 CCCAGGCACTTCT 1528
Db 15 CCCAGGCGCTGCT 1

RESULT 78
US-60-522-459-9996/c
; Sequence 9996, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9996
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-9996

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1523 CTTTCTGGGGCTGG 1537
Db 15 CTTCTGGGGCTGG 1

RESULT 79
US-60-522-459-10676
; Sequence 10676, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10676
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-10676

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 40;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 335 ATGAGCTGATGAGG 349
Db 1 AUGAGCUGAGGGGG 15

RESULT 80
US-60-522-459-10983/c
; Sequence 10983, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
```

```
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10983
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-10983

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 993 CAGCAGCCGTGCCCT 1007
Db 15 CAGCAGCAGTGCCCT 1

RESULT 81
US-60-522-459-13126/c
; Sequence 13126, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13126
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13126

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 530 CCCTGTGGGCGCTG 544
Db 15 CCCTGTGGGCGCTG 1

RESULT 82
US-60-522-459-13406/c
; Sequence 13406, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13406
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13406

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 519 GTTTCTGTCCACCT 533
Db 15 GCTGCTGTCCACCT 1
```

US-60-522-459-8382

Query Match 0.7%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 857 ACCCTAGGACGCC 869
DB 2 ACCCCAGGACGCC 14
Search completed: November 8, 2004, 13:00:00
Job time: 1 secs

RESULT 83
US-60-522-459-14041
; Sequence 14041, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14041
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-14041

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 40;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 1136 GGGACTGCTGGAAC 1150
DB 1 GGGACUGCGGCACU 15

RESULT 84
US-10-956-157-193674/c
; Sequence 193674, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193674
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193674

Query Match 0.8%; Score 11.8; DB 1; Length 25;
Best Local Similarity 86.7%; Pred. No. 94;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1075 CTCATTGCTGGCTC 1089
DB 24 CCCAGTCTGGCTC 10

RESULT 85
US-60-522-459-8382
; Sequence 8382, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8382
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human

THIS PAGE BLANK (USPTO)

RESULT 1	AA878744	LOCUS	19 bp	mrna	linear	EST 25-MAR-1998
DEFINITION	AA878744	cf585a08.s1	NCI_CGAP L15 Homo sapiens cDNA clone IMAGE:1437110 3', similar to TR:Q67633 Q67633 ECO Q PROTEIN. [1] ; contains TAR1.t2 TAR1 repetitive element ; , mRNA sequence.			
ACCESSION	AA878744	AA878744.1	GI:2987709			
VERSION	EST.					
KEYWORDS	Homo sapiens (human)					
SOURCE	Homo sapiens					
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE	1 (bases 1 to 19)					
AUTHORS	NCI-CGAP					
TITLE	http://www.ncbi.nlm.nih.gov/ncicgap . National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index					
JOURNAL	Unpublished (1997)					
COMMENT	Contact: Robert Strausberg, Ph.D.					

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 1.0%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 0.57; Mismatches 0; Indels 1; Gaps 0;

QY 1258 GGGTAGCCATGCTGGG 1274

Db 17 GGGTAGCCATGCTGGG 1

RESULT 3

AA968729/c

LOCUS

DEFINITION

AA968729 16 bp mRNA linear EST 27-AUG-1998 or69h11.s1 NCI CGAP GC3 Homo sapiens CDNA clone IMAGE:1601157 3' similar to SW:PEPPE_HUMAN P02811 BASIC PROLINE-RICH PEPTIDE P-E ;contains element MSRI repetitive element ;, mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 16)

NCI-CCGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.

National Cancer Institute, Cancer Genome Anatomy Project (CGAP),

Tumor Gene Index

Unpublished (1997)

Contact: Robert Strausberg, Ph.D.

Email: cgaps@mail.nih.gov

Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael

Emmert-Buck, M.D., Ph.D.

CDNA Library Preparation: M. Bento Soares, Ph.D.

CDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center

Clone distribution: NCI-CGAP clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality

Insert Length: 514 Std Error: 0.00

Seq primer: -40m13 fwd. RT from Amersham

High quality sequence stop: 1.

Location/Qualifiers

1. .16

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:1601157"

/tissue_type="pooled germ cell tumors"

/lab_host="DH10B"

/clone_lib="NCI CGAP GC3"

/notes="Vector: pT73D-Pac (Pharmacia) with a modified

polylinker; 1st strand cDNA was prepared from 3 pooled

germ cell tumors, and was then primed with a Not I -

oligo(dT) primer. Double-stranded cDNA was ligated to Eco

RI adaptors (Pharmacia), digested with Not I and cloned

into the Not I and Eco RI sites of the modified pT73 vector. Library is not normalized. Library was constructed by Bento Soares and M. Fatima Bonaldo. "

Query Match 0.8%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.6; Mismatches 14; Conservative 0; Indels 2; Gaps 0;

QY 247 CCCCCACCTCCCCAG 262

Db 16 CCCCCCTCTCCCCCG 1

RESULT 4

AJ595030

LOCUS

DEFINITION

16 bp DNA linear GSS 15-JAN-2004

Arabidopsis thaliana T-DNA flanking sequence, left border, clone

410A08, genomic survey sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

1

Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,

Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,

Lepiniec, L., Caboche, M. and Lecharny, A.

T-DNA integration into the Arabidopsis genome depends on sequences

of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

2363535

PUBMED

12446565

2 (bases 1 to 16)

Balzergue, S.

Direct Submission

Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue

Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana

plants from INRA (Versailles). The DNA fragment(s) resulting from

the PCR were directly sequenced from the left or the right border

to determine the genomic sequence flanking the insertion. T-DNA

derived sequences were removed. Information to order the

corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at

<http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has

been generated in the framework of the French plant genomics

program 'Genoplante' (<http://www.genoplante.com> and

<http://genoplante-info.infobiogen.fr>).

Location/Qualifiers

1. .16

/organism="Arabidopsis thaliana"

/mol_type="genomic DNA"

/cultivar="Wassiljewskija"

/db_xref="taxon:3702"

/clone="410A08"

/clone_lib="Arabidopsis thaliana T-DNA insertion lines"

1. .16

/note="T-DNA flanking sequence

left border"

Query Match 0.8%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.6;

Mismatches 14; Conservative 0; Indels 2; Gaps 0;

QY 814 CTCTACTTCTCTCTCT 829

Db 1 CTCTACTTCTCTCTCT 16

RESULT 5

CF340244/c
LOCUS CF340244 15 bp mRNA linear EST 18-AUG-2003
DEFINITION RCL1--07-G18.g1 Regenerated callus lambda phage cDNA library (RCL1)
 Oryza sativa (japonica cultivar-group) cDNA clone RCL1--07-G18,
 mRNA sequence.

ACCESSION CF340244.1 GI:33828846
VERSION EST.
KEYWORDS Oryza sativa (japonica cultivar-group)
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE 1. (bases 1 to 15)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
 Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
 source
 1..15
 Location/Qualifiers
 /organism="Oryza sativa (japonica cultivar-group)"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:39947"
 /clone="RCL1--07-G18"
 /tissue_type="callus"
 /dev_stage="proliferated callus on 2N6 media for 30 days"
 /lab_host="E.coli SOLR"
 /clone_lib="Regenerated callus lambda phage cDNA library
 (RCL1)"
 /notes="Vector: pBluescript SK(+); Site 1: SstI; Site 2:
 XhoI; cDNA was inserted into lambda Uni-ZAP XR vector at
 end with SstI and 3' end with XhoI site. Callus was
 induced on 2N6 media for 30 days and cultured for 36hrs on
 regenerated media"

Query Match 0.8%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 3.4;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 331 CTTGATGAGCTGAT 344
 ||| |||||
DB 15 CTTGATGAGCTGAT 2

RESULT 6
LOCUS AJ598266 15 bp DNA linear GSS 15-JAN-2004
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
 465A02, genomic survey sequence.

ACCESSION AJ598266
VERSION AJ598266.1 GI:37947894
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eutrosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1
AUTHORS Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
 Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pellatier,G.,
 Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
 of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535

12445565
REFERENCE 2 (bases 1 to 15)
AUTHORS Balzerque,S.
TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
 Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
 plants from INRA (Versailles). The DNA fragment(s) resulting from
 the PCR were directly sequenced from the left or the right border
 to determine the genomic sequence flanking the insertion. T-DNA
 derived sequences were removed. Information to order the
 corresponding mutant line and a link to a database providing a
 graphical display of the insertion site are available at
 http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
 been generated in the framework of the French plant genomics
 program 'Genoplante' (http://www.genoplante.com and
 http://genoplante-info.infobiogen.fr).

FEATURES
 source
 1..15
 Location/Qualifiers
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Wassillewskija"
 /db_xref="taxon:3702"
 /clone="465A02"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"

misc_feature
 1..15
 /notes="T-DNA flanking sequence
 left border"

Query Match 0.8%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 4.5;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 720 GATGAAAAGCTACTC 734
 ||| |||||
DB 1 GAGGAAAAGCTGCTC 15

RESULT 7
LOCUS BM400830 15 bp mRNA linear EST 17-JAN-2002
DEFINITION Tetrahymena thermophila cDNA, mRNA sequence.
 Tetrahymena thermophila
 EST.
ACCESSION BM400830.1 GI:18200883
VERSION BM400830.1
KEYWORDS EST.
SOURCE Tetrahymena thermophila
ORGANISM Tetrahymena thermophila
 Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
 Hymenostomatida; Tetrahymenina; Tetrahymena.
REFERENCE 1 (bases 1 to 15)
AUTHORS Turkewitz,A.P., Karrer,K.M., Jahn,C., Orlas,E., Kirk,K.E.,
 Frankel,J. and Klobutcher,L.
TITLE EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
 Molecular Genetics and Cell Biology
 University of Chicago
 920 E. 58th Street, Chicago, IL 60637, USA
 Tel: 773 702 4374
 Fax: 773 702 3172
 Email: apturkew@midway.uchicago.edu
 Seq primer: T3.

FEATURES
 source
 1..15
 Location/Qualifiers
 /organism="Tetrahymena thermophila"
 /mol_type="mRNA"
 /strain="CU428.1"
 /db_xref="taxon:5911"
 /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
 /note="Vector: Bluescript2 SK+; Details on library
 preparation can be found in Chilcoat and Turkewitz (2001)
 Proc. Natl. Acad. Sci USA, 98: 8709-8713."

```

Query Match          0.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 5.4;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 619 CACGCCGTGGTGC 631
      ||||| |||||
Db 3 CACGCCGTGGTGC 15

RESULT 8
BQ593114/c
LOCUS
DEFINITION E012797-024-027-N23-SP6 MP12-ADIS-024-developing root Beta vulgaris
ACCESSION BQ593114
VERSION BQ593114.1 GI:26122697
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 14)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide
fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
MEDLINE 22362189
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MP12
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaar@mpiz-koeln.mpg.de
Insert Length: 14 Std Error: 0.00
Plate: 27 row: N column: 23
Seq primer: SP6; CATACGATTAGTGACACTATAG.

FEATURES
source
1..14
Location/Qualifiers
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding
line)"
/db_xref="GABI:193738"
/db_xref="taxon:161934"
/clone="024-027-N23"
/tissue_type="developing root"
/lab_host="EMDH10B"
/clone_lib="MP12-ADIS-024-developing root"
/notes="Vector: pCMVSPORT6; Site 1: SalI; Site 2: NotI;
cDNA library from sugar beet, library provided by KWS
Kleinwanzlebener Saatzzucht AG Einbeck, Germany, contact:
b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
orientation:
SP6-Sali-CCACGCTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
Sequencing granted in the context of the GABI-Beet
project, local PI: Dr. Katharina Schneider, coordinator:
Prof. Christian Jung; Sequence submission managed by
RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match          0.7%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 7.6;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 247 CCCCCACCTCCCC 260
      ||||| |||||
Db 14 CCCCCCCCCCCCCC 1

Query Match          0.7%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 7.6;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

RESULT 9
AJ588060/c
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
526B05, genomic survey sequence.
ACCESSION AJ588060
VERSION AJ588060.1 GI:37937684
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE 1
AUTHORS Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., Deroose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 14)
AUTHORS Balzerque,S.
TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES
source
1..14
Location/Qualifiers
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskaja"
/db_xref="taxon:3702"
/clone="526B05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..14
note="T-DNA flanking sequence
left border"

Query Match          0.7%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 7.6;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1249 CGGGCCCCGAGGGGT 1262
      ||||| |||||
Db 14 CCGGCCGAGGGGT 1

Search completed: November 8, 2004, 13:01:15
Job time : 0.001 secs

```